"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04223804","A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With HIV-1",,"Not yet recruiting","No Results Available","Human Immunodeficiency Virus (HIV)|HIV Infection|HIV-1","Drug: ABBV-181|Drug: Placebo","Number of Participants with Study Drug-Related Adverse Events Grade 3 or Higher|Number of Participants with Study Drug-Related Immune-Related Adverse Events (IRAE)|Number of Participants with Adverse Events (AEs) Corresponding to Retroviral Rebound Syndrome|Maximum Observed Concentration (Cmax)|Time to Cmax (Tmax)|Observed Concentration (Ctrough)|Area Under the Curve (AUCtau)|Half-life (t1/2)|Peripheral PD-1 Receptor Saturation","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M19-939","January 17, 2020","November 20, 2021","December 28, 2021","January 10, 2020",,"January 10, 2020","University of Alabama at Birmingham - Main /ID# 216568, Birmingham, Alabama, United States|Felizarta /ID# 215721, Bakersfield, California, United States|Quest Clinical Research /ID# 215796, San Francisco, California, United States|Univ California, San Francisco /ID# 215577, San Francisco, California, United States|George Washington University Medical Faculty Associates /ID# 213893, Washington, District of Columbia, United States|Midway Immunology and Research /ID# 215587, Fort Pierce, Florida, United States|University of Miami, Miller School of Medicine /ID# 213833, Miami, Florida, United States|Northwestern University Feinberg School of Medicine /ID# 215589, Chicago, Illinois, United States|University of Cincinnati /ID# 215615, Cincinnati, Ohio, United States|Prism Health North Texas /ID# 214036, Dallas, Texas, United States|St. Vincent's Hospital, Darlinghurst /ID# 215354, Darlinghurst, New South Wales, Australia|Holdsworth House Medical Practice /ID# 215352, Sydney, New South Wales, Australia|Royal Adelaide Hospital /ID# 217077, Adelaide, South Australia, Australia|Royal Melbourne Hospital /ID# 215351, Parkville, Victoria, Australia|Puerto Rico AIDS Clinical Trials Unit CRS /ID# 213761, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04223804"
2,"NCT04214028","A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus",,"Recruiting","No Results Available","Hepatitis C Virus (HCV)",,"Number of Participants with Adverse Drug Reactions (ADRs)|Percentage of Participants with Adverse Drug Reactions (ADRs)|Number of Participants with Serious Adverse Events (SAEs)|Percentage of Participants with Serious Adverse Events (SAEs)|Percentage of participants achieving Sustained Virologic Response 12 (SVR12)|Percentage of participants achieving Sustained Virologic Response (SVR)|Percentage of Participants with On-Treatment Virologic Failure (Breakthrough)|Percentage of Participants with After-Treatment Virologic Failure (Relapse)","AbbVie","All","12 Years to 17 Years   (Child)",,"50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-620","December 26, 2019","December 30, 2024","December 30, 2024","December 30, 2019",,"January 18, 2020","Gifu Prefectural General Medical Center /ID# 00018, Gifu city, Gifu, Japan",,"https://ClinicalTrials.gov/show/NCT04214028"
3,"NCT04198415","A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)",,"Not yet recruiting","No Results Available","Cancer|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Leukemia (SLL)",,"Number of Participants With Adverse Events|Overall Incidence of Averse Drug Reactions (ADRs) of Tumor Lysis Syndrome (TLS), Bone Marrow Suppression, and Infections|Incidence of Adverse Drug Reactions (ADR)|Incidence of TLS According to Physician Assessment|Incidence of TLS According to Howard Criteria|Incidence of Bone Marrow Suppression|Incidence of Infections|Incidence of ADRs When Venetoclax is Used Concomitantly with CYP3A Inhibitors|Number of Prophylactic Measures Used for TLS|Number of Monitoring Measures Used for TLS|Number of Participants with Dose Modifications|Number of Participants with Dose Interruptions|Number of Participants Who Discontinued Venetoclax|Best Overall Response Rate (ORR)|Time to Best Response","AbbVie","All","Child, Adult, Older Adult",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-830","December 16, 2019","May 30, 2023","May 30, 2023","December 13, 2019",,"December 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04198415"
4,"NCT04196283","A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",,"Recruiting","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-368|Drug: Tilsotolimod|Drug: Nab-paclitaxel|Drug: ABBV-181","Maximum Observed Serum Concentration (Cmax) of ABBV-368|Time to Maximum Serum Concentration (Tmax) of ABBV-368|Area Under Serum Concentration-Time Curve of ABBV-368 From Time 0 to the Time of Last Measurable Concentration (AUCt)|Terminal-Phase Elimination Rate Constant (β) of ABBV-368|Terminal Half-Life (t1/2) of ABBV-368|Maximum Plasma Concentration (Cmax) of Tilsotolimod|Time to Maximum Plasma Concentration (Tmax) of Tilsotolimod|Area Under Plasma Concentration-Time Curve of Tilsotolimod From Time 0 to the Time of Last Measurable Concentration (AUCt)|Terminal-Phase Elimination Rate Constant (β) of Tilsotolimod|Terminal Half-Life (t1/2) of Tilsotolimod|Maximum Observed Serum Concentration (Cmax) of ABBV-181 (Arm 3 Only)|Time to Maximum Serum Concentration (Tmax) of ABBV-181 (Arm 3 Only)|Area Under Serum Concentration-Time Curve of ABBV-181 From Time 0 to the Time of Last Measurable Concentration (AUCt) (Arm 3 Only)|Terminal-Phase Elimination Rate Constant (β) of ABBV-181 (Arm 3 Only)|Terminal Half-Life (t1/2) of ABBV-181 (Arm 3 Only)|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Time to Response (TTR)|Progression Free Survival (PFS)|Duration of Response (DOR)","AbbVie|Idera Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-894|2019-003167-22","January 9, 2020","April 17, 2022","May 26, 2022","December 12, 2019",,"January 21, 2020","UCSD Moores Cancer Center - LaJolla /ID# 216181, La Jolla, California, United States|University of Chicago /ID# 217196, Chicago, Illinois, United States|Norton Cancer Institute /ID# 216179, Louisville, Kentucky, United States|Karmanos Cancer Institute /ID# 214050, Detroit, Michigan, United States|Nebraska Methodist Hospital /ID# 215786, Omaha, Nebraska, United States|Atlantic Health System /ID# 216159, Morristown, New Jersey, United States|Roswell Park Comprehensive Cancer Center /ID# 215882, Buffalo, New York, United States|University of Oklahoma, Stephenson Cancer Center /ID# 215880, Oklahoma City, Oklahoma, United States|Medical University of South Carolina /ID# 216254, Charleston, South Carolina, United States|Vanderbilt University Med Ctr /ID# 214040, Nashville, Tennessee, United States|MD Anderson Cancer Center /ID# 214041, Houston, Texas, United States|Inova Schar Cancer Institute -Fairfax /ID# 215878, Fairfax, Virginia, United States|Institut Curie /ID# 215653, Paris CEDEX 05, Ile-de-France, France|Gustave Roussy /ID# 215865, Villejuif, Ile-de-France, France|Hopital Saint Andre /ID# 215702, Bordeaux, France|Centre Antoine Lacassagne /ID# 215706, Nice, France|Universitaetsklinikum Erlangen /ID# 214196, Erlangen, Bayern, Germany|Universitaetsklinikum Leipzig /ID# 214200, Leipzig, Sachsen, Germany|Charite-Univ. Berlin, Benjamin-Franklin /ID# 214197, Berlin, Germany|Rabin Medical Center /ID# 215230, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 215231, Haifa, Israel|Hadassah University Hospital /ID# 215862, Jerusalem, Israel|Sheba Medical Center /ID# 215229, Ramat Gan, Israel|Antoni van Leeuwenhoek /ID# 215291, Amsterdam, Noord-Holland, Netherlands|Hospital Clinic de Barcelona /ID# 214264, Barcelona, Spain|Hospital Univ de Fuenlabrada /ID# 214263, Fuenlabrada, Spain|Hosp Univ 12 de Octubre /ID# 214198, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 214110, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 214109, Malaga, Spain",,"https://ClinicalTrials.gov/show/NCT04196283"
5,"NCT04195698","Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis",,"Recruiting","No Results Available","Atopic Dermatitis","Drug: Upadacitinib","Number of Participants With Adverse Events","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-850|2019-001227-12","January 2, 2020","July 27, 2021","July 27, 2021","December 12, 2019",,"January 9, 2020","Fakultni nemocnice Ostrava /ID# 214177, Ostrava, Praha 5, Czechia|Fakultni Nemocnice v Motole /ID# 214179, Prague 5, Praha 5, Czechia|Fakultni Nemocnice Brno /ID# 214181, Brno, Czechia|FN Hradec Kralove /ID# 214176, Hradec Kralove, Czechia|Nemocnice Jihlava /ID# 214178, Jihlava, Czechia|Keski-pohjanmaa Central Hospital /ID# 214630, Kokkola, Keski-Pohjanmaa, Finland|Oulu University Hospital /ID# 214628, Oulu, Pohjois-Pohjanmaa, Finland|Mikkeli Central Hospital /ID# 214629, Mikkeli, Finland|Pihlajalinna Turku /ID# 214631, Turku, Finland|Universitatsklinikum Munster /ID# 214222, Munster, Niedersachsen, Germany|Gemeinschaftspraxis /ID# 214225, Blankenfeld-mahlow, Germany|Hautklinik Klinikum Darmstadt /ID# 214224, Darmstadt, Germany|Universitaetsklinikum Frankfurt /ID# 214223, Frankfurt, Germany|Med Hochschule Hanover /ID# 214226, Hannover, Germany|TU Uniklinik Munchen /ID# 214221, Munich, Germany|Oroshazi Korhaz /ID# 214986, Orosháza, Bekes, Hungary|Pecsi Tudomanyegyetem /ID# 214988, Pécs, Pecs, Hungary|Uno Medical Trials Kft /ID# 214987, Budapest XIII, Hungary|Debreceni Egyetem Klinikai Központ /ID# 214985, Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 214984, Kaposvár, Hungary|St Vincent's University Hosp /ID# 213558, Dublin, Ireland|University Hospital Waterford /ID# 213559, Waterford, Ireland|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 214095, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 215727, Rozzano, Milano, Italy|A.O. Policlinico Sant'Orsola Malpighi /ID# 214094, Bologna, Italy|A.O.U. di Brescia /ID# 214097, Brescia, Italy|Ospedale San Giovanni di Dio /ID# 214098, Cagliari, Italy|AO Univ di Modena /ID# 214096, Modena, Italy|Policlinico Univ Tor Vergata /ID# 214093, Rome, Italy|St. Olavs Hospital HF /ID# 214636, Trondheim, Sor-Trondelag, Norway|Universitetssykehuset N-Norge, Harstad /ID# 214637, Harstad, Troms, Norway|Universitetssykehuset N-Norge, Tromso /ID# 214634, Tromso, Troms, Norway|Pratia MCM Krakow /ID# 214303, Krakow, Malopolskie, Poland|Klinika Ambroziak Sp. z o.o. /ID# 214301, Warsaw, Mazowieckie, Poland|ClinicMed Daniluk, Nowak Sp.j. /ID# 214299, Białystok, Podlaskie, Poland|Dermoklinika Medical Center /ID# 214300, Lodz, Poland|Royalderm Agnieszka Nawrocka /ID# 214302, Warsaw, Poland|Hospital Bellvitge /ID# 214257, Barcelona, Spain|Hospital Univ Dr. Negrin /ID# 214256, Las Palmas de Gran Canaria, Spain|Hospital de Manises /ID# 214258, Manises, Spain|Complejo Hosp Pontevedra /ID# 214255, Pontevedra, Spain|Hospital Univ Arnau Vilanova /ID# 214254, Valencia, Spain|Hosp Univ Politecnico la Fe /ID# 214252, Valencia, Spain|Skanes Universitetssjukhus /ID# 214711, Malmö, Skane Lan, Sweden|Sahlgrenska universitetssjukhuset /ID# 217561, Göteborg, Vastra Gotalands Lan, Sweden|Karolinska Univ Sjukhuset /ID# 214712, Solna, Sweden|Royal Alex Childrens County Hospital /ID# 213562, Brighton, Brighton And Hove, United Kingdom|Victoria Hospital /ID# 213564, Kirkcaldy, Fife, United Kingdom|Royal Hospital for Children /ID# 213561, Glasgow, Glasgow City, United Kingdom|The Royal Free Hospital /ID# 213560, London, London, City Of, United Kingdom|Cardiff & Vale University Health Board /ID# 213563, Cardiff, Wales, United Kingdom|Guy's and St Thomas NHS Founda /ID# 216206, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04195698"
6,"NCT04189627","A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation","DETI-2","Not yet recruiting","No Results Available","Hepatitis C Virus (HCV)",,"Overall Percentage of Participants Achieving Sustained Viral Response 12 (SVR12)|Percentage of Participants Achieving Sustained Viral Response 12 (SVR12) With a Sensitive Polymerase Chain Reaction (PCR) Available in the Clinical Site|Number of Participants With Co-morbidities|Percentage of Participants With Co-morbidities|Number of Participants Taking Concomitant Medications|Percentage of Participants Taking Concomitant Medications|Percentage of GLE/PIB dose taken by patient in relation to the prescribed target dose|Number of Participants with Adverse Events|Percentage of Participants with Adverse Events|Average Number of Health Care Resource Utilization (HCRU)","AbbVie","All","12 Years to 17 Years   (Child)",,"99","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P20-105","December 16, 2019","August 16, 2020","December 6, 2020","December 6, 2019",,"December 6, 2019",,,"https://ClinicalTrials.gov/show/NCT04189627"
7,"NCT04189614","An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","Cancer|Non-small Cell Lung Cancer (NSCLC)","Drug: Cofetuzumab Pelidotin","Objective Response Rate (ORR)|Duration of Response (DOR)|Progression Free Survival (PFS)|Overall Survival (OS)","AbbVie|Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-611|2019-003472-39","January 6, 2020","August 15, 2022","August 15, 2022","December 6, 2019",,"January 9, 2020","University of Alabama at Birmingham - Main /ID# 213605, Birmingham, Alabama, United States|Highlands Oncology Group /ID# 215383, Fayetteville, Arkansas, United States|Stanford Univ School Medicine /ID# 213450, Stanford, California, United States|Univ of Colorado Cancer Center /ID# 215295, Aurora, Colorado, United States|Moffitt Cancer Center /ID# 215101, Tampa, Florida, United States|Washington University-School of Medicine /ID# 213453, Saint Louis, Missouri, United States|Tennessee Oncology, PLLC /ID# 215326, Nashville, Tennessee, United States|Oncology Consultants /ID# 215932, Houston, Texas, United States|University of Virginia Cancer Center - West Complex /ID# 216039, Charlottesville, Virginia, United States|Virginia Cancer Specialists /ID# 216427, Fairfax, Virginia, United States|Rabin Medical Center /ID# 217537, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 217536, Haifa, Israel|Sheba Medical Center /ID# 217538, Ramat Gan, Israel|Hospital Universitario Fundacion Jimenez Diaz /ID# 215110, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 215102, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04189614"
8,"NCT04178902","A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory Multiple Myeloma",,"Not yet recruiting","No Results Available","Multiple Myeloma (MM)|Cancer","Drug: ABBV-467","Number of Participants with Adverse Events|Maximum Observed Plasma Concentration (Cmax)|Terminal Phase Elimination Half-life (t1/2)|Area Under the Plasma Concentration-Time Curve (AUCt)|Area Under the Plasma Concentration-Time Curve (AUC0-∞)|Clearance of ABBV-467|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Duration of Response (DOR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-025|2018-003744-24","November 26, 2019","March 28, 2023","March 28, 2023","November 26, 2019",,"November 26, 2019","City of Hope /ID# 209786, Duarte, California, United States|UCSD Moores Cancer Center - LaJolla /ID# 210075, La Jolla, California, United States|Sylvester Comprehensive Cancer /ID# 209398, Miami, Florida, United States|Northwestern University Feinberg School of Medicine /ID# 209621, Chicago, Illinois, United States|Univ Kansas Med Ctr /ID# 209734, Kansas City, Kansas, United States|Lifespan Cancer Institute /ID# 215418, Providence, Rhode Island, United States|Alfred Hospital /ID# 214665, Melbourne, Victoria, Australia|CHU Henri Mondor /ID# 214588, Creteil, France|CHU de Nantes, Hotel Dieu -HME /ID# 215480, Nantes, France|Sheba Medical Center /ID# 214065, Ramat Gan, Israel|Nagoya City University Hospital /ID# 214696, Nagoya-shi, Aichi, Japan|National Cancer Center Hospital East /ID# 214697, Kashiwa-shi, Chiba, Japan|Osaka University Hospital /ID# 214708, Suita-shi, Osaka, Japan|China Medical University Hosp /ID# 209323, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 209322, Taipei City, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT04178902"
9,"NCT04178317","A Study of the Safety and Efficacy of Venetoclax for Patients With Chronic Lymphocytic Leukemia (CLL) Used in Routine Clinical Practice",,"Recruiting","No Results Available","Cancer|Chronic Lymphocytic Leukemia (CLL)",,"Number of Participants With Adverse Events|Overall Response","AbbVie","All","19 Years and older   (Adult, Older Adult)",,"600","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-942","November 30, 2019","November 30, 2023","November 30, 2023","November 26, 2019",,"November 26, 2019","Severance Hospital /ID# 215348, Seoul, Seoul Teugbyeolsi, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04178317"
10,"NCT04169373","A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis",,"Recruiting","No Results Available","Spondyloarthritis","Drug: Upadacitinib|Drug: Placebo","Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) 40 Response|Study 2: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) 40 Response|Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)|Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score (Spine)|Study 1: Percentage of Participants With ASAS Partial Remission (PR)|Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response|Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)|Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL)|Study 1: Change From Baseline in ASAS Health Index (HI)|Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)|Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)|Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) 20 Response|Study 1: Change From Baseline in MRI SPARCC Score (SI Joints)|Study 2: Change From Baseline in ASDAS|Study 2: Change From Baseline in MRI SPARCC Score (SI Joints)|Study 2: Percentage of Participants With BASDAI 50 Response|Study 2: Percentage of Participants With ASAS PR|Study 2: Change From Baseline in BASFI|Study 2: Change From Baseline in ASQoL|Study 2: Change From Baseline in ASAS HI|Study 2: Change From Baseline in MASES|Study 2: Change From Baseline in BASMIlin|Study 2: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) 20 Response|Study 2: Percentage of Participants Rescued Between Week 24 and Week 52|Study 2: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score (Spine)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","690","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M19-944|2019-003229-12","November 26, 2019","June 6, 2022","March 26, 2024","November 19, 2019",,"December 30, 2019","Arizona Arthritis & Rheumatology Associates, P.C. /ID# 215282, Flagstaff, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 215113, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC /ID# 214731, Tucson, Arizona, United States|Newport Huntington Medical Group /ID# 216281, Huntington Beach, California, United States|Inland Rheum & Osteo Med Grp /ID# 215807, Upland, California, United States|Denver Arthritis Clinic /ID# 215346, Denver, Colorado, United States|Tekton Research /ID# 215054, Fort Collins, Colorado, United States|AARDS Research, Inc. /ID# 215306, Aventura, Florida, United States|Sweet Hope Research Specialty Inc /ID# 215931, Hialeah, Florida, United States|Innovation Medical Research Center /ID# 216068, Palmetto Bay, Florida, United States|Conquest Research /ID# 215804, Winter Park, Florida, United States|Great Lakes Clinical Trials /ID# 215790, Chicago, Illinois, United States|Greater Chicago Specialty Physicians /ID# 216213, Schaumburg, Illinois, United States|Clinical Investigation Special /ID# 215055, Skokie, Illinois, United States|Klein & Associates, M.D., P.A. /ID# 214767, Cumberland, Maryland, United States|Tufts Medical Center /ID# 215925, Boston, Massachusetts, United States|Clinical Pharmacology Study Gr /ID# 215293, Worcester, Massachusetts, United States|Wayne State University Health Center /ID# 215930, Detroit, Michigan, United States|Advanced Rheumatology, PC /ID# 214973, Lansing, Michigan, United States|Saint Paul Rheumatology /ID# 215537, Eagan, Minnesota, United States|CenterPointe Institute of Research /ID# 215793, Saint Louis, Missouri, United States|Clinvest Research LLC /ID# 215785, Springfield, Missouri, United States|NYU Langone Medical Center /ID# 215594, New York, New York, United States|St. Lawrence Health System /ID# 215844, Potsdam, New York, United States|Cape Fear Arthritis Care /ID# 215927, Leland, North Carolina, United States|Marietta Memorial Hospital /ID# 215929, Marietta, Ohio, United States|STAT Research, Inc. /ID# 215264, Springboro, Ohio, United States|Health Research Oklahoma /ID# 215117, Oklahoma City, Oklahoma, United States|Oregon Health and Science University /ID# 216446, Portland, Oregon, United States|Altoona Ctr Clinical Res /ID# 214770, Duncansville, Pennsylvania, United States|Tekton Research, Inc. /ID# 214923, Austin, Texas, United States|Trinity Universal Res Assoc /ID# 214948, Carrollton, Texas, United States|Arth and Osteo Clin Brazo Valley /ID# 215805, College Station, Texas, United States|JPS Health Network /ID# 215962, Fort Worth, Texas, United States|Biopharma Informatic, LLC /ID# 215885, Houston, Texas, United States|Biopharma Informatic Research /ID# 215907, Houston, Texas, United States|West Texas Clinical Research /ID# 215928, Lubbock, Texas, United States|Trinity Universal Research Association /ID# 215189, Plano, Texas, United States|Rheumatology and Pulmonary cli /ID# 214946, Beckley, West Virginia, United States|West Virginia Research Inst /ID# 214921, South Charleston, West Virginia, United States|Org Medica de Investigacion /ID# 214557, Buenos Aires, Argentina|Hospital Cordoba /ID# 215846, Cordoba, Argentina|Inst. Rheumatologic Strusberg /ID# 215239, Cordoba, Argentina|Instituto CAICI SRL /ID# 215242, Rosario, Santa FE, Argentina|Centro Medico Privado/Reuma /ID# 214559, San Miguel de Tucuman, Argentina|Cimer /Id# 215240, San Miguel de Tucuman, Argentina|Centro de Enfermedades /ID# 214556, Santa Fe, Argentina|Optimus Clinical Research Pty. /ID# 215507, Kogarah, New South Wales, Australia|BJC Health /ID# 215510, Paramatta, New South Wales, Australia|Emeritus Research /ID# 215506, Camberwell, Victoria, Australia|Monash Health /ID# 215509, Clayton, Victoria, Australia|Barwon Rheumatology /ID# 215508, Geelong, Victoria, Australia|UZ Gent /ID# 215004, Gent, Oost-Vlaanderen, Belgium|ReumaClinic Genk /ID# 215005, Genk, Belgium|UZ Leuven /ID# 215006, Leuven, Belgium|CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 215277, Juiz de Fora, Minas Gerais, Brazil|EDUMED Educacao em Saude S/S L /ID# 215111, Curitiba, Parana, Brazil|LMK Sevicos Medicos S/S /ID# 215112, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 215176, Sao Jose Do Rio Preto, Sao Paulo, Brazil|CPCLIN - Centro de Pesquisas Clínicas /ID# 215175, Sao Paulo, Brazil|Unimed Medical Center /ID# 214816, Plovdiv, Bulgaria|MHAT Kaspela /ID# 214803, Plovdiv, Bulgaria|MHAT-Plovdiv AD /ID# 214815, Plovdiv, Bulgaria|Medical Center - Teodora EOOD /ID# 214813, Russe, Bulgaria|Excelsior Medical Center /ID# 214805, Sofia, Bulgaria|Diag Consult Ctr 17 Sofia EOOD /ID# 214808, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 214804, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 214806, Sofia, Bulgaria|University of Alberta - Division of Rheumatology /ID# 216360, Edmonton, Alberta, Canada|Percuro Clinical Research, Ltd /ID# 215302, Victoria, British Columbia, Canada|Toronto Western Hospital /ID# 215041, Toronto, Ontario, Canada|Applied Medical Informatics Research Inc. (AMIR) /ID# 215303, Montréal, Quebec, Canada|Ctr. de Recherche Musculo-Sque /ID# 215096, Trois-rivières, Quebec, Canada|Centre de recherche du CHUQ /ID# 215038, Quebec, Canada|1st Aff Hosp of Bengbu Med Col /ID# 216609, Bengbu, Anhui, China|Anhui Provincial Hospital /ID# 216631, Hefei, Anhui, China|Guangdong Provincial People's Hospital /ID# 216645, Guangzhou, Guangdong, China|Zhuzhou Central Hospital /ID# 216644, Zhuzhou, Hunan, China|Peking Union Med College Hosp /ID# 216545, Beijing, China|The First Affiliated Hospital /ID# 216607, Soochow, China|People's Hospital of Xinjiang /ID# 216630, Urumqi, China|Revmatologicky ustav Praha /ID# 215154, Prague 2, Praha 2, Czechia|Revmatologická ambulance /ID# 215652, Prague 4, Praha 4, Czechia|Thomayerova nemocnice /ID# 215118, Prague, Praha 4, Czechia|Fakultni Nemocnice v Motole /ID# 215160, Prague 5, Praha 5, Czechia|PV MEDICAL Services s.r.o. /ID# 215119, Zlín 1, Zlin, Czechia|REVMACLINIC s.r.o. /ID# 215153, Brno, Czechia|Revmacentrum MUDr. Mostera /ID# 215161, Brno, Czechia|Revmatologie, s.r.o. /ID# 215309, Brno, Czechia|CCR Ostrava s.r.o. /ID# 215226, Ostrava 2, Czechia|ARTHROHELP, s.r.o. /ID# 215224, Pardubice, Czechia|FN Plzen /ID# 215162, Plzen, Czechia|Medical Plus, s.r.o. /ID# 215324, Uherské Hradište, Czechia|CHU Toulouse /ID# 214780, Toulouse CEDEX 3, Occitanie, France|CHU Bordeaux-Hopital Pellegrin /ID# 214784, Bordeaux, France|Hopital Ambroise Pare /ID# 214783, Boulogne Billancourt, France|Groupe Hospitalier Cochin /ID# 214782, Paris, France|Universitaetsklinikum Erlangen /ID# 214281, Erlangen, Bayern, Germany|Rheumatologische Schwerpunktpraxis Brandt-Juergens /ID# 214282, Berlin, Germany|Charite-Univ. Berlin, Benjamin-Franklin /ID# 214211, Berlin, Germany|Rheuma Research Lausitz, Dr. Mario Sutowicz /ID# 214218, Cottbus, Germany|Universitaetklinikum Dresden /ID# 214207, Dresden, Germany|Praxisgemeinschaft Rheumatolog /ID# 214212, Erlangen, Germany|Rheumaforschungszentrum II /ID# 214208, Hamburg, Germany|Praxis für Rheumatologie /ID# 214219, Hamburg, Germany|Med Hochschule Hanover /ID# 214209, Hannover, Germany|MVZ Planegg /ID# 214261, Planegg, Germany|Aranyklinika /ID# 215185, Szeged, Csongrad, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház /ID# 215180, Nyíregyháza, Szabolcs-Szatmar-Bereg, Hungary|Vital Medical Center Orvosi es /ID# 215182, Veszprém, Veszprem, Hungary|Integrity Maganklinika /ID# 215188, Zalaegerszeg, Zala, Hungary|Betegapolo Irgalmas Rend - Bud /ID# 215183, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 215187, Debrecen, Hungary|Bekes Megyei Pandy Kalman Korh /ID# 215186, Gyula, Hungary|Hevizgyogyfurdo es Szent Andra /ID# 215184, Heviz, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 214501, Kistarcsa, Hungary|C-MED/CMED Rehabilitációsközpont /ID# 215181, Szekesfehervar, Hungary|Tel Aviv Sourasky Medical Ctr /ID# 216956, Tel Aviv-Yafo, Tel-Aviv, Israel|Bnai Zion Medical Center /ID# 215856, Haifa, Israel|Meir Medical Center /ID# 217255, Kfar Saba, Israel|Sheba Medical Center /ID# 215854, Ramat Gan, Israel|A.O.U. Consorziale Policlinico di Bari /ID# 215072, Bari, Italy|Università Vita-Salute San Raffaele /ID# 215071, Milan, Italy|Azienda Ospedaliera Regionale San Carlo /ID# 215067, Potenza, Italy|A.O. Ordine Mauriziano /ID# 215073, Turin, Italy|ASST Sette Laghi /ID# 215069, Varese, Italy|Daido Clinic /ID# 214735, Nagoya-shi, Aichi, Japan|Matsuyama Red Cross Hospital /ID# 216021, Matsuyama-shi, Ehime, Japan|National Hospital Organization Asahikawa Medical Center /ID# 214930, Asahikawa, Hokkaido, Japan|Kobe University Hospital /ID# 214598, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 215638, Nishinomiya-shi, Hyogo, Japan|Kuwana city medical center /ID# 215196, Kuwana City, Mie, Japan|Nagasaki University Hospital /ID# 215947, Nagasaki-shi, Nagasaki, Japan|Sasebo Chuo Hospital /ID# 214703, Sasebo-city, Nagasaki, Japan|Japanese Red Cross Okayama Hospital /ID# 214732, Okayama-shi, Okayama, Japan|NHO Osaka Minami Med Ctr /ID# 214205, Kawachinagano-shi, Osaka, Japan|Juntendo University Hospital /ID# 214929, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 215414, Chuo-ku, Tokyo, Japan|Kita-harima Medical Center /ID# 216069, ONO, Japan|Osaka City General Hospital /ID# 215640, Osaka, Japan|Hokkaido University Hospital /ID# 215221, Sapporo, Japan|Okinawa Prefectural Chubu Hospital /ID# 215575, Uruma-shi, Japan|Ajou University Hospital /ID# 214533, Suwon-si, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center /ID# 214534, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Hanyang University Seoul Hospi /ID# 214297, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 214295, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 214532, Seoul, Korea, Republic of|Kyung Hee University Hospital at Gangdong /ID# 214296, Seoul, Korea, Republic of|Asan Medical Center /ID# 214294, Seoul, Korea, Republic of|Hospital de Especialidades CMN SigloXXI /ID# 216012, Ciudad de México, Ciudad De Mexico, Mexico|CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 215217, Mexico City, Ciudad De Mexico, Mexico|Centro Integral en Reumatología S.A de C.V /ID# 215218, Guadalajara, Jalisco, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 215257, Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigación Básica y Clínica, S.C. /ID# 215258, Guadalajara, Jalisco, Mexico|Centro de investigación de Tratamientos Innovadores de Sinaloa, S.C. /ID# 215256, Culiacán Rosales, Sinaloa, Mexico|Waikato Hospital /ID# 215503, Hamilton, Waikato, New Zealand|Middlemore Clinical Trials /ID# 215502, Auckland, New Zealand|WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 215093, Wrocław, Dolnoslaskie, Poland|NZOZ Nasz Lekarz /ID# 214352, Toruń, Kujawsko-pomorskie, Poland|Osteo-Medic S.C. /ID# 214351, Białystok, Podlaskie, Poland|ETYKA-Osrodek Badan Klinicznyc /ID# 215572, Olsztyn, Warminsko-mazurskie, Poland|Reumed Sp. z o.o. Filia nr 1 /ID# 214353, Lublin, Poland|AI Centrum Medyczne Sp. z o.o. /ID# 214354, Poznań, Poland|NW State Medical Univ na Mechn /ID# 214454, St. Petersburg, Leningradskaya Oblast, Russian Federation|Family Outpatient clinic#4,LLC /ID# 214455, Korolev, Moskva, Russian Federation|FSFSI SRI of Rheumatology n.a.V.A.Nasonova /ID# 214459, Moscow, Moskva, Russian Federation|Nizhniy Novgorod Region clinical hospital named N. A. Semashko /ID# 214461, Nizhniy Novgorod, Nizhegorodskaya Oblast, Russian Federation|LLC Medical Center /ID# 214410, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Family Clinic LLC /ID# 214737, Yekaterinburg, Sverdlovskaya Oblast, Russian Federation|Alliance Biomedical Ural Group /ID# 214457, Izhevsk, Udmurtskaya Respublika, Russian Federation|Chelabinsk Regional Clinical H /ID# 214463, Chelyabinsk, Russian Federation|Kazan State University /ID# 214421, Kazan, Russian Federation|Llc Olla-Med /Id# 214460, Moscow, Russian Federation|City Clinical Hospital #15 /ID# 214486, Moscow, Russian Federation|Moscow RRCI M.F. Vladimirski /ID# 215887, Moscow, Russian Federation|Omsk Clinical Regional Hospita /ID# 214464, Omsk, Russian Federation|Orenburg State Medical Academy /ID# 214408, Orenburg, Russian Federation|LLC Novaya Clinica /ID# 214420, Pyatigorsk, Russian Federation|Ryazan State Medical Universit /ID# 214418, Ryazan, Russian Federation|Clinical Rheumatologic Hospital No 25 /ID# 214488, Sankt-Peterburg, Russian Federation|NIH Road clinical hospital on Saratov II station OJSC RZD /ID# 214465, Saratov, Russian Federation|Reg Clin Hosp n.a. Kuvatova G. /ID# 215886, UFA, Russian Federation|Ulyanovsk Regional Clinical Ho /ID# 214458, Ulyanovsk, Russian Federation|FN s poliklinikou F.D. Rooseve /ID# 215222, Banska Bystrica, Slovakia|UNB, Nemocnica Stare Mesto /ID# 214675, Bratislava, Slovakia|Narodny ustav reumatickych chorob Piestany /ID# 214674, Pieštany, Slovakia|MUDr. Zuzana Cizmarikova s.r.o. /ID# 215220, Poprad, Slovakia|ALBAMED s.r.o. /ID# 215248, Zvolen, Slovakia|Hospital Marina Baixa /ID# 215970, Villajoyosa, Alicante, Spain|Corporac Sanitaria Parc Tauli /ID# 214967, Sabadell, Barcelona, Spain|H. Un. Marques de Valdecilla /ID# 214965, Santander, Cantabria, Spain|Hospital Universitario Reina S /ID# 214968, Cordoba, Spain|Hospital Universitario La Paz /ID# 216032, Madrid, Spain|Hospital Universitario La Fe /ID# 214966, Valencia, Spain|Hospital Xeral Cies (CHUVI) /ID# 214969, Vigo, Spain|Kaohsiung Veterans General Hos /ID# 214332, Kaohsiung, Taichung, Taiwan|China Medical University Hosp /ID# 214019, Taichung City, Taichung, Taiwan|Far Eastern Memorial Hospital /ID# 215384, New Taipei City, Taiwan|Chung Shan Medical University /ID# 214018, Taichung City, Taiwan|Cathay General Hospital /ID# 214183, Taipei City, Taiwan|Hacettepe Universitesi Tip Fak /ID# 214898, Sihhiye, Ankara, Turkey|Istanbul Universitesi Cerrahpa /ID# 214895, Cerrahpasa, Turkey|Mugla Sitki Kocman University Medical Faculty /ID# 215358, Mugla, Turkey|SI Inst of Therapy AMS of UA /ID# 214155, Kharkiv, Kharkivska Oblast, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 214147, Vinnytsia, Vinnytska Oblast, Ukraine|Scientific Research Institute of Invalid Rehabilitation /ID# 214148, Vinnytsia, Vinnytska Oblast, Ukraine|Municipal health care institution Chernihiv Regional Hospital /ID# 214145, Chernihiv, Ukraine|PNE ""City Multifunctional Hospital #18"" /ID# 214154, Kharkiv, Ukraine|Kharkiv Regional Council Regional Clinical Hospital /ID# 214158, Kharkiv, Ukraine|Khmelnitskyi Regional Clinical Hospital /ID# 214153, Khmelnitskyi, Ukraine|Medical centre of CONSILIUM MEDICAL LLC /ID# 216234, Kiev, Ukraine|Municipal Institution of Kyiv Region Council Kyiv Regional Clinical Hospital /ID# 214156, Kiev, Ukraine|ME Kryvyi Rih City Clinical Hospital #2 /ID# 214152, Kryvyi Rih, Ukraine|Kyiv Railway Clinical Hosp №2 /ID# 214779, Kyiv, Ukraine|LLC Revmocentr /ID# 214146, Kyiv, Ukraine|Odessa Regional Clinical Hosp /ID# 214159, Odesa, Ukraine|Odessa National Medical Univ /ID# 214149, Odesa, Ukraine|Poltava Reg Clin Hosp Sklifoso /ID# 214151, Poltava, Ukraine|Ternopil University Hospital /ID# 214705, Ternopil, Ukraine|Norfolk and Norwich Univ Hosp /ID# 214865, Norwich, Norfolk, United Kingdom|Royal United Hospitals Bath /ID# 214864, Bath, United Kingdom|West Suffolk Hospital /ID# 215529, Bury St Edmunds, United Kingdom|Doncaster Royal Infirmary /ID# 214971, Doncaster, United Kingdom|Queen Alexandra Hospital /ID# 216624, Portsmouth, United Kingdom|Lancashire Care NHS Foundation /ID# 216226, Preston, United Kingdom|Haywood Hospital /Id# 214860, Stoke on Trent, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 214876, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04169373"
11,"NCT04161898","A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK)","SELECT-TAK","Recruiting","No Results Available","Takayasu Arteritis (TAK)","Drug: Upadacitinib|Drug: Placebo for Upadacitinib|Drug: Prednisolone","Time to First Relapse of Takayasu Arteritis (TAK) From Baseline|Time to First Relapse of Takayasu Arteritis (TAK) by Kerr Criteria From Baseline|Time to Worsening of Imaging Assessment Due to Takayasu Arteritis (TAK) From Baseline","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M19-052","December 26, 2019","July 8, 2022","July 9, 2023","November 13, 2019",,"December 30, 2019","St. Marianna University Hospital /ID# 214535, Kawasaki, Kanagawa, Japan|Yokohama City University Hospital /ID# 214345, Yokohama-shi, Kanagawa, Japan|Tohoku University Hospital /ID# 214066, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 215683, Nagasaki-shi, Nagasaki, Japan|Okayama University Hospital /ID# 214499, Okayama-shi, Okayama, Japan|Kindai University Hospital /ID# 216491, Osaka-sayama, Osaka, Japan|National Cerebral and Cardiovascular Center /ID# 214061, Suita, Osaka, Japan|Juntendo University Hospital /ID# 214292, Bunkyo-ku, Tokyo, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 214138, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 214067, Chuo-ku, Tokyo, Japan|Keio University Hospital /ID# 214905, Shinjuku-ku, Tokyo, Japan|Center hospital of the National Center for Global Health and Medicine /ID# 214931, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 215129, Shinjuku-ku, Tokyo, Japan|Chiba University Hospital /ID# 214932, Chiba, Japan|Kagawa University Hospital /ID# 214776, Kyoto, Japan|Nagano Red Cross Hospital /ID# 214537, Nagano, Japan|Kyoto University Hospital /ID# 215128, Sakyo-ku, Japan|Hokkaido University Hospital /ID# 215066, Sapporo, Japan|Ehime University Hospital /ID# 215424, Toon, Japan|University of Tsukuba Hospital /ID# 215318, Tsukuba-shi, Japan|Hanyang University Seoul Hospi /ID# 213842, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 215643, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 214566, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 213844, Seoul, Korea, Republic of|Asan Medical Center /ID# 213843, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04161898"
12,"NCT04161885","A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)","VIALE-T","Not yet recruiting","No Results Available","Acute Myeloid Leukemia (AML)|Cancer","Drug: Venetoclax|Drug: Azacitidine|Other: Best Supportive Care (BSC)","Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)|Relapse-Free Survival (RFS) (Part 2)|Overall Survival (OS) (Part 2)|Graft-versus-Host Disease (GvHD)-free, Relapse Free Survival (GRFS) (Part 2)|Time to Deterioration in Global Health Status (GHS)/Quality of Life (QoL) in Adult Participants (Part 2)|Graft-versus-Host Disease (GvHD) rate (Part 2)|Change From Randomization in Fatigue in Adult Participants (Part 2)|Minimal Residual Disease (MRD) Response Rate in Participants With MRD >= 10^-3 at Randomization (Part 2)","AbbVie","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","424","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-063|2019-002621-30","February 17, 2020","June 29, 2024","August 5, 2024","November 13, 2019",,"January 21, 2020","University of Alabama at Birmingham - Main /ID# 214524, Birmingham, Alabama, United States|City of Hope /ID# 213681, Duarte, California, United States|AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 213985, Orlando, Florida, United States|University of Chicago /ID# 215616, Chicago, Illinois, United States|Loyola University Medical Ctr /ID# 215617, Maywood, Illinois, United States|Indiana Blood & Marrow Transpl /ID# 215842, Indianapolis, Indiana, United States|University of Kentucky Chandler Medical Center /ID# 214791, Lexington, Kentucky, United States|Ochsner Clinic Foundation-New Orleans /ID# 213834, New Orleans, Louisiana, United States|Greenebaum Comprehensive Cancer Center - UM /ID# 213855, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 215765, Boston, Massachusetts, United States|Karmanos Cancer Institute - Dresner Clinic /ID# 214581, Detroit, Michigan, United States|Mayo Clinic - Rochester /ID# 214685, Rochester, Minnesota, United States|Weill Cornell Medical College /ID# 214887, New York, New York, United States|Univ Rochester Med Ctr /ID# 215877, Rochester, New York, United States|Duke Univ Med Ctr /ID# 213714, Durham, North Carolina, United States|Oregon Health Science Universi /ID# 215874, Portland, Oregon, United States|Thomas Jefferson University /ID# 213917, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Ctr /ID# 213715, Pittsburgh, Pennsylvania, United States|St. Jude Childrens Res Hosp /ID# 214074, Memphis, Tennessee, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 213735, Dallas, Texas, United States|UTSW Dallas /ID# 216013, Dallas, Texas, United States|Fred Hutchinson Cancer Research /ID# 214436, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 216096, Madison, Wisconsin, United States|St. Vincent's Hospital, Darlinghurst /ID# 214660, Darlinghurst, New South Wales, Australia|Royal Adelaide Hospital /ID# 215678, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre /ID# 214653, Parkville, Victoria, Australia|Hospital de Clinicas de Porto Alegre /ID# 215042, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Amaral Carvalho /ID# 215145, Sao Paulo, Brazil|Vancouver Coastal Health Authority /ID# 215363, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre /ID# 215344, Toronto, Ontario, Canada|Anhui Provincial Hospital /ID# 216408, Hefei, Anhui, China|Peking Univ Peoples Hospital /ID# 215551, Beijing, Beijing, China|Fujian Medical Univ Union Hosp /ID# 215555, Fuzhou, Fujian, China|Nanfang Hospital of Southern Medical University /ID# 215553, Guangzhou, Guangdong, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 215552, Wuhan, Hubei, Hubei, China|Shanghai general hospital /ID# 216410, Shanghai, Shanghai, China|Shanghai Changhai Hospital /ID# 216334, Shanghai, Shanghai, China|Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 215546, Tianjin, Tianjin, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 215550, Hangzhou, Zhejiang, China|The General hospital of people's Liberation Amy(301 hospital) /ID# 216287, Beijing, China|The First Affiliated Hospital /ID# 216605, Soochow, China|Henan Cancer Hospital /ID# 215554, Zhengzhou, Henan, China|Fakultni Nemocnice Brno /ID# 214811, Brno, Czechia|Fakultni nemocnice Hradec Kral /ID# 214814, Hradec Kralove, Czechia|UHKT Prague 2 /ID# 215133, Prague, Czechia|Hopital Haut-Lévêque /ID# 214055, Pessac CEDEX, Gironde, France|CHU de Nantes, Hotel Dieu -HME /ID# 214060, Nantes, France|CHU de Nice /ID# 214056, Nice, France|Universitaetklinikum Dresden /ID# 214244, Dresden, Germany|Med Hochschule Hanover /ID# 214243, Hannover, Germany|Universitatsklinikum Munster /ID# 215213, Muenster, Germany|Univ-Klinikum Wuerzburg /ID# 215212, Wuerzburg, Germany|Rabin Medical Center /ID# 214509, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 214507, Haifa, Israel|Sheba Medical Center /ID# 214305, Ramat Gan, Israel|Tel Aviv Medical Center /ID# 214508, Tel Aviv, Israel|Fondazione Policlinico Universitario Agostino Gemelli /ID# 214910, Rome, Lazio, Italy|AOU Citta della Salute Scienza /ID# 216148, Turin, Piemonte, Italy|A.O. Spedali Civili Brescia /ID# 215997, Brescia, Italy|Ospedale San Raffaele IRCCS /ID# 214311, Milan, Italy|Kyushu University Hospital /ID# 215285, Fukuoka-shi, Fukuoka, Japan|Kobe City Medical Center General Hospital /ID# 215388, Kobe-shi, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 215389, Nishinomiya-shi, Hyogo, Japan|Imamura General Hospital /ID# 215688, Kagoshima-shi, Kagoshima, Japan|Tohoku University Hospital /ID# 214670, Sendai-shi, Miyagi, Japan|Okayama University Hospital /ID# 214842, Okayama-shi, Okayama, Japan|Kindai University Hospital /ID# 214917, Osaka-sayama, Osaka, Japan|Osaka City University Hospital /ID# 215227, Osaka-shi, Osaka, Japan|Jichi Medical University Hospital /ID# 216091, Shimotsuke-shi, Tochigi, Japan|Tokyo Metropolitan Komagome Hospital /ID# 215939, Bunkyo-ku, Tokyo, Japan|Anjo Kosei Hospital /ID# 215857, Anjo, Japan|JP Red Cross Nagoya Daiichi /ID# 215679, Nagoya, Japan|Hokkaido University Hospital /ID# 215937, Sapporo, Japan|Kanagawa Cancer Center /ID# 215029, Yokohama, Japan|The Catholic Univ. of Korea /ID# 214892, Seocho-gu, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 214891, Seoul, Korea, Republic of|Asan Medical Center /ID# 214893, Seoul, Korea, Republic of|FSBI Rogachev National Med. Research center of Pediatric Hematology, Oncology /ID# 216538, Moscow, Moskva, Russian Federation|Research Institute of Hematology & Blood Transfusion /ID# 216591, Kirov, Russian Federation|Federal State Budget Inst. /ID# 214355, Moscow, Russian Federation|St. Petersburg state medical University. Acad. I.P. Pavlova /ID# 214609, Sankt-Peterburg, Russian Federation|Federal Almazov N-W Med Res /ID# 214357, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 216691, St. Petersburg, Russian Federation|Hospital Clinic de Barcelona /ID# 215108, Barcelona, Spain|Hosp Univ Gregorio Marañon /ID# 215107, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 215463, Sevilla, Spain|Hosp Clin Univ de Valencia /ID# 215106, Valencia, Spain|University Hospital Zurich /ID# 215891, Zurich, Zuerich, Switzerland|Universitaetsspital Basel /ID# 215892, Basel, Switzerland|China Medical University Hosp /ID# 215198, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 215245, Taipei City, Taipei, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 215197, Kaohsiung, Taiwan|Linkou Chang Gung Memorial Ho /ID# 215319, Taoyuan City, Taiwan|Univ Hospitals Birmingham NHS Foundation trust /ID# 215120, Birmingham, United Kingdom|UCLH, University College Hospi /ID# 215662, London, United Kingdom|King's College Hospital NHS /ID# 215338, London, United Kingdom|Imperial College Healthcare NHS Trust /ID# 215665, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 215121, Manchester, United Kingdom|Royal Marsden Hospital /ID# 215124, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04161885"
13,"NCT04159779","A Study of Clinical Outcomes in Relapse/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)",,"Overall Response Rate (ORR)|Complete Response (CR)|Complete Response with Incomplete Bone Marrow Recovery (CRi) Rate|Nodule Partial Response (nPR) Rate|Partial Response (PR) Rate|Percentage of Participants With Disease Progression or Death|Progression Free Survival (PFS)|Overall Survival (OS)|Treatment Duration|Time to Progression (TTP)|Change in Patient Reported Outcomes|Percentage of Participants with Undetectable Minimal Residual Disease (uMRD)|Percentage of Participants with Dose Modifications|Percentage of Participants with Adverse Drug Reactions (ADR)|Number of Lines of Prior Therapy","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-568","November 12, 2019","November 12, 2023","November 12, 2023","November 12, 2019",,"December 11, 2019","Metropolitan General Hospital /ID# 212934, Cholargos, Attiki, Greece|University General Hospital of Ioannina /ID# 212936, Ioannina, Greece",,"https://ClinicalTrials.gov/show/NCT04159779"
14,"NCT04159597","Expanded Access to Upadacitinib",,"Available","No Results Available","Atopic Dermatitis (AD)","Drug: Upadacitinib",,"AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"C20-082",,,,"November 12, 2019",,"November 12, 2019",,,"https://ClinicalTrials.gov/show/NCT04159597"
15,"NCT04140175","A Study of Women Receiving Standard of Care (SOC) for the Treatment of Pelvic Pain Due to Suspected or Confirmed Endometriosis and the Impact on the Disease or Symptom Progression.",,"Not yet recruiting","No Results Available","Endometriosis|Chronic Pelvic Pain|Dysmenorrhea",,"Percentage of participants using specific medications for the treatment of chronic pelvic pain (CPP) and/or dysmenorrhea (DYS)|Percentage of participants who underwent surgical interventions for the treatment of CPP and/or DYS|Number of surgical interventions for the treatment of CPP and/or DYS|Percentage of participants undergoing hysterectomy|Percentage of participants undergoing infertility treatment|Percentage of participants undergoing surgery|Percentage of participants with complications associated with surgery|Percentage of participants receiving specific treatment sequences for the treatment of CPP and/or DYS","AbbVie","Female","12 Years and older   (Child, Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-836","November 27, 2019","November 20, 2023","November 20, 2023","October 25, 2019",,"October 25, 2019","Brown, Pearson, Guepet Gynecology /ID# 215500, Fairhope, Alabama, United States|Infertility, Gynecology & Obst /ID# 213734, San Diego, California, United States|Agile Clinical Research Trials /ID# 213746, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04140175"
16,"NCT04138199","A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation","COPI","Recruiting","No Results Available","HIV-1 Infection",,"Percentage of Participants Who Meet HIV-1- RNA Viral Load >50 Copies/mL, OR CD4+ T-Cell Counts < 200 Cells/mm^3|Indicator of Participants Who Have a Development of New or Recurrent Opportunistic Infections or HIV-Associated Malignancies OR Median Monthly Rate of AEs per Patient OR SAE Associated With HIV Treatment|Change in HIV-1- RNA Viral Load Compared To The Last Measure On Kaletra Treatment|Change in CD4+ T-cell Counts Compared To The Last Measure On Kaletra Treatment|Percentage of Participants With Reasons For Switching From Generic LPV/r To Other Antiretroviral Therapy (ART) For HIV Therapy OR Change In The Dosing Regimen|Percentage of Participants Who Develop HIV Drug Resistance Of Generic LPV/r Treatment","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"239","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","P20-097","November 1, 2019","April 28, 2021","April 28, 2021","October 24, 2019",,"November 12, 2019","Rep. Cen. of AIDS Profilactis /ID# 216292, Kazan, Tatarstan, Respublika, Russian Federation|Reg Ctr for AIDS /ID# 216288, Chelyabinsk, Russian Federation|GBUZ Regional Center for the P /ID# 216293, Ekaterinburg, Russian Federation|Reg Ctr for AIDS /ID# 216295, Krasnoyarsk, Russian Federation|Moscow Municipal Hospital /ID# 216294, Moscow, Russian Federation|Ctr for AIDS - Rostov /ID# 216289, Rostov on Don, Russian Federation|Samara region HIV/AIDS Center /ID# 216290, Samara, Russian Federation|Mordovian Republican Center for the Prevention and Control of AIDS /ID# 216480, Saransk, Russian Federation|GBUZ ""Sakhalin Regional Center for the Prevention and Control of AIDS"" /ID# 216478, Yuzhno-Sakhalinsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04138199"
17,"NCT04127695","A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease",,"Not yet recruiting","No Results Available","Parkinson's Disease","Drug: ABBV-0805|Drug: Placebo ABBV-0805","Number of Participants with Adverse Events|Maximum Observed Serum Concentration (Cmax)|Time to Cmax (peak time, Tmax)|Area under the Serum Concentration Time curve (AUC)|Apparent Terminal Phase Elimination Rate Constant (Beta)|Ratio of ABBV-0805 concentration in cerebrospinal fluid (CSF)|Terminal Phase Elimination half-life (t1/2)|Serum Concentration (Ctrough)|Total clearance (CL)","AbbVie","All","up to 85 Years   (Child, Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M19-304","October 31, 2019","July 15, 2021","July 15, 2021","October 15, 2019",,"October 15, 2019","Glendale Adventist Medical Ctr /ID# 212548, Glendale, California, United States|University of Florida /ID# 212823, Gainesville, Florida, United States|Weill Cornell Medicine /ID# 212826, New York, New York, United States|Duke University Medical Center /ID# 214435, Durham, North Carolina, United States|UT Health Science Ctr-Houston /ID# 213029, Houston, Texas, United States|Evergreen Neuroscience Institute /ID# 212827, Kirkland, Washington, United States|Inland Northwest Research /ID# 212119, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04127695"
18,"NCT04102020","A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival","VIALE-M","Not yet recruiting","No Results Available","Acute Myeloid Leukemia (AML)","Drug: Venetoclax|Drug: Azacitidine|Other: Best Supportive Care (BSC)","Relapse-Free Survival (RFS)|Overall Survival (OS)|Percentage of Participants Who Achieve Minimal Minimal Residual Disease (MRD)|Time to Deterioration in Global Health Status (GHS)/Quality-of Life (QoL) Score Based on European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30-Item (EORTC QLQ-C30) Scoring Manual.|Change From Baseline in Patient Reported Outcomes (PRO) Fatigue Score Based on Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form (SF) 7a","AbbVie|Roche-Genentech","All","18 Years and older   (Adult, Older Adult)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-708|2019-002217-19","January 18, 2020","September 10, 2024","May 17, 2025","September 25, 2019",,"November 14, 2019","City of Hope /ID# 215672, Duarte, California, United States|UCSD Moores Cancer Center - LaJolla /ID# 216065, La Jolla, California, United States|University of Kentucky Markey Cancer Center /ID# 215048, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 216401, Louisville, Kentucky, United States|Ochsner Clinic Foundation-New Orleans /ID# 214583, New Orleans, Louisiana, United States|Tufts Medical Center /ID# 216110, Boston, Massachusetts, United States|Univ Michigan Med Ctr /ID# 216524, Ann Arbor, Michigan, United States|Weill Cornell Medical College /ID# 214847, New York, New York, United States|Univ Rochester Med Ctr /ID# 215881, Rochester, New York, United States|Thomas Jefferson University /ID# 214393, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Ctr /ID# 214051, Pittsburgh, Pennsylvania, United States|St George Hospital /ID# 215416, Kogarah, New South Wales, Australia|Wollongong Hospital /ID# 216071, Wollongong, New South Wales, Australia|Gold Coast University Hospital /ID# 214650, Southport, Queensland, Australia|Royal Hobart Hospital /ID# 215829, Hobart, Tasmania, Australia|Tom Baker Cancer Centre /ID# 214625, Calgary, Alberta, Canada|University of Alberta Hospital /ID# 215656, Edmonton, Alberta, Canada|Juravinski Hosp & Cancer Cntr /ID# 214623, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre /ID# 214624, Toronto, Ontario, Canada|Fakultni nemocnice Plzen /ID# 214810, Plzeň 1, Plzen-jih, Czechia|Fakultni nemocnice Ostrava /ID# 214809, Ostrava, Praha 5, Czechia|Fakultni Nemocnice Brno /ID# 214807, Brno, Czechia|Ustav Hematologie a krevni transfuze /ID# 215137, Prague 28, Czechia|Centre Hospitalier Le Mans /ID# 215148, Le Mans CEDEX 9, Sarthe, France|CHU d'Angers /ID# 215151, Angers, France|Hopital Andre Mignot /ID# 215157, Le Chesnay, France|CHU Bordeaux /ID# 215150, Pessac, France|Universitaetsklinikum Leipzig /ID# 214440, Leipzig, Sachsen, Germany|Universitaetsklinikum Schleswig-Holstein /ID# 215173, Lübeck, Germany|Uniklinikum Giessen-Marburg Gm /ID# 214734, Marburg, Germany|General Hospital of Athens Laiko /ID# 213869, Athens, Attiki, Greece|University General Hospital Attikon /ID# 214298, Athens, Attiki, Greece|Gen Univ Hosp Alexandroupolis /ID# 213870, Alexandroupolis, Greece|Duplicate_General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens P /ID# 213872, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 214075, Heraklion, Greece|Patras University General Hosp /ID# 213871, Rion, Patras, Achaia, Greece|Markusovszky Egyetemi Oktatokorhaz /ID# 215644, Szombathely, Vas, Hungary|Semmelweis Egyeteme III /ID# 214423, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 214422, Debrecen, Hungary|Kaposi Mor Oktato Korhaz /ID# 214426, Kaposvar, Hungary|Szabolcs-Szatmar-Beregi /ID# 214425, Nyíregyhaza, Hungary|AOU Federico II /ID# 214278, Naples, Campania, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 213946, Milano, Lombardia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 214826, Milan, Lombardia, Italy|AOU Ospedali Riuniti di Ancona - G.M. Lancisi, G. Salesi /ID# 213944, Ancona, Marche, Italy|AOU Citta della Salute Scienza /ID# 214505, Turin, Piemonte, Italy|Azienda Ospedaliero-Universitaria di Bologna, Policlinico S.Orsola-Malpighi /ID# 213948, Bologna, Italy|A.O. Spedali Civili Brescia /ID# 214580, Brescia, Italy|Azienda Ospedaliero Universita /ID# 214802, Catania, Italy|AORN A. Cardarelli /ID# 213947, Napoli, Italy|Ospedale S.Eugenio /ID# 214277, Rome, Italy|Aichi Cancer Center Hospital /ID# 215284, Nagoya-shi, Aichi, Japan|University of Fukui Hospital /ID# 215283, Yoshida-gun, Fukui, Japan|National Hospital Organization Kyushu Cancer Center /ID# 214841, Fukuoka-shi, Fukuoka, Japan|Kyushu University Hospital /ID# 215286, Fukuoka-shi, Fukuoka, Japan|National Hospital Organization Mito Medical Center /ID# 214699, Higashi Ibaraki-gun, Ibaraki, Japan|Hitachi General Hospital /ID# 214707, Hitachi-shi, Ibaraki, Japan|Tohoku University Hospital /ID# 214669, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 214916, Nagasaki-shi, Nagasaki, Japan|Okayama University Hospital /ID# 214840, Okayama-shi, Okayama, Japan|Kindai University Hospital /ID# 214915, Osaka-sayama, Osaka, Japan|Osaka City University Hospital /ID# 215225, Osaka-shi, Osaka, Japan|Saitama Medical University International Medical Center /ID# 214823, Hidaka-shi, Saitama, Japan|NTT Medical Center Tokyo /ID# 214959, Shinagawa-ku, Tokyo, Japan|Yamagata University Hospital /ID# 214698, Yamagata-shi, Yamagata, Japan|JP Red Cross Nagoya Daiichi /ID# 215680, Nagoya, Japan|Hokkaido University Hospital /ID# 215938, Sapporo, Japan|Pusan National University Hosp /ID# 213941, Busan, Busan Gwang Yeogsi, Korea, Republic of|Seoul National Univ Bundang ho /ID# 215549, Seongnam, Gyeonggido, Korea, Republic of|Samsung Medical Center /ID# 213940, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 213943, Seoul, Korea, Republic of|Pan American Center for Oncology Trials, LLC /ID# 214953, Rio Piedras, Puerto Rico|Moscow State budget healthcare /ID# 214312, Moscow, Moskva, Russian Federation|Nizhniy Novgorod regional clinical hospital named N. A. Semashko /ID# 214309, Nizhnij Novgorod, Nizhegorodskaya Oblast, Russian Federation|Saratov State Medical University n.a. V.I. Razumovskiy /ID# 214315, Saratov, Saratovskaya Oblast, Russian Federation|City Clinical Hospital №40 /ID# 215223, Moscow, Russian Federation|Russian Scientific and Research Institute of Hematology and Transfusiology /ID# 215007, Sankt-Peterburg, Russian Federation|Almazov North-West Federal Med /ID# 214306, Sankt-peterburg, Russian Federation|Yaroslavl Regional Clinic Hosp /ID# 214318, Yaroslavl, Russian Federation|Hospital Santa Creu i Sant Pau /ID# 214714, Barcelona, Spain|ICO l´Hosp- Hosp Duran Reynals /ID# 214715, Barcelona, Spain|Hospital Reina Sofia de Cordob /ID# 214786, Cordoba, Spain|Hospital Infanta Leonor /ID# 214843, Madrid, Spain|MD Anderson CC Madrid /ID# 214477, Madrid, Spain|Hospital Ramon y Cajal /ID# 214684, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 214933, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 214713, Malaga, Spain|Complejo Hospitalario de Navar /ID# 214788, Pamplona, Spain|China Medical University Hosp /ID# 213952, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 213939, Taipei City, Taipei, Taiwan|Kaohsiung Medical University /ID# 213953, Kaohsiung, Taiwan|Linkou Chang Gung Memorial Ho /ID# 213951, Taoyuan City, Taiwan|Erciyes University Medical Fac /ID# 214240, Melikgazi, Kayseri, Turkey|Gulhane Askeri Tip Academy /ID# 214242, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 214239, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 215525, Istanbul, Turkey|Karadeniz University /ID# 214241, Trabzon, Turkey|Belfast City Hospital /ID# 215923, Belfast, United Kingdom|Heartlands Hospital /ID# 215910, Birmingham, United Kingdom|Bristol Haematology and Onc Ct /ID# 215911, Bristol, United Kingdom|University Hospital of Wales /ID# 215906, Cardiff, United Kingdom|St. James University Hospital /ID# 215922, Leeds, United Kingdom|St Bartholomew's Hospital, Bar /ID# 215909, London, United Kingdom|UCLH, University College Hospi /ID# 215921, London, United Kingdom|Guy's Hospital /ID# 215908, London, United Kingdom|Christie NHS Foundation Trust /ID# 215905, Manchester, United Kingdom|Nottingham Univ Hospitals NHS /ID# 215904, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04102020"
19,"NCT04102007","A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab","aimm","Recruiting","No Results Available","Plaque Psoriasis","Drug: Risankizumab","Percentage of participants achieving Static Physician Global Assessment (sPGA) 0/1|Percentage of participants achieving a sPGA clear response|Percentage of participants achieving a Psoriasis Symptoms Scale (PSS) 0|Time to achieve sPGA 0|Percentage of participants achieving a Dermatology Life Quality Index (DLQI) 0 or 1|Percentage of participants achieving sPGA 0/1|Percentage of participants achieving a sPGA 0|Percentage of participants achieving a DLQI 0/1|Percentage of participants achieving a PSS 0|Time to achieve sPGA 0/1","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","250","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-164|2019-000904-14","November 12, 2019","December 13, 2020","November 9, 2021","September 25, 2019",,"January 18, 2020","Bakersfield Derma & Skin Cance /ID# 213480, Bakersfield, California, United States|Central Connecticut Dermatology /ID# 216062, Cromwell, Connecticut, United States|Advanced Medical Research /ID# 213484, Sandy Springs, Georgia, United States|Arlington Dermatology /ID# 216000, Rolling Meadows, Illinois, United States|Dawes Fretzin, LLC /ID# 216004, Indianapolis, Indiana, United States|DermAssociates /ID# 213837, Rockville, Maryland, United States|Central Dermatology, PC /ID# 213479, Saint Louis, Missouri, United States|University Hospitals Case Medical Center /ID# 214795, Cleveland, Ohio, United States|Clinical Partners, LLC /ID# 213836, Johnston, Rhode Island, United States|Modern Research Associates, PL /ID# 213835, Dallas, Texas, United States|Menter Dermatology Res Inst /ID# 214002, Dallas, Texas, United States|St George Dermatology & Skin Cancer Centre /ID# 213888, Kogarah, New South Wales, Australia|Veracity Clinical Research /ID# 213889, Woolloongabba, Queensland, Australia|Skin Health Institute Inc /ID# 213886, Carlton, Victoria, Australia|Fremantle Dermatology /ID# 213887, Fremantle, Western Australia, Australia|CHU d'Angers /ID# 214430, Angers, France|Hopital Saint Joseph /ID# 214429, Marseille, France|Chr Metz Thionville /Id# 214432, Metz, France|Hopital Begin /ID# 214431, Saint Mande, France|Hopital Nord /ID# 214618, Saint Priest En Jarez, France|Universitaetsklinikum Erlangen /ID# 214228, Erlangen, Bayern, Germany|Universitatsklinikum Frankfurt /ID# 215889, Frankfurt, Hessen, Germany|Charité Universitätsmedizin Campus Mitte /ID# 215691, Berlin, Germany|Univ Hosp Schleswig-Holstein /ID# 214469, Kiel, Germany|TU Uniklinik Munchen /ID# 214506, Munich, Germany|Rabin Medical Center /ID# 213813, Petakh Tikva, Tel-Aviv, Israel|Ha'Emek Medical Center /ID# 214059, Afula, Israel|Sheba Medical Center /ID# 213815, Ramat Gan, Israel|Ichilov Medical Center /ID# 213812, Tel Aviv, Israel|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 214750, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 214749, Rozzano, Milano, Italy|A.O. Policlinico Sant'Orsola Malpighi /ID# 214745, Bologna, Italy|Ospedale San Giovanni di Dio /ID# 214748, Cagliari, Italy|AO Univ di Modena /ID# 214751, Modena, Italy|University of Naples Federico /ID# 214752, Naples, Italy|Hosp Univ Fundacion Alcorcon /ID# 214033, Alcorcon, Spain|Hospital Parc de Salut del Mar /ID# 214034, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 214031, Barcelona, Spain|Hospital Puerta del Mar /ID# 214428, Cadiz, Spain|Hospital Universitario La Paz /ID# 214341, Madrid, Spain|Hosp Univ Politecnico la Fe /ID# 214032, Valencia, Spain|National Taiwan Univ Hosp /ID# 213630, Taipei City, Taipei, Taiwan|Chung Shan Medical University /ID# 213634, Taichung City, Taiwan|MacKay Memorial Hospital /ID# 213845, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 213631, Taoyuan City, Taiwan|NHS Fife /ID# 213881, Dunfermline, Fife, United Kingdom|Russells Hall Hospital, Dudley /ID# 213878, Dudley, United Kingdom|Chapel Allerton Hospital /ID# 213880, Leeds, United Kingdom|Newcastle upon Tyne Hospitals /ID# 213877, Newcastle Upon Tyne, United Kingdom|The University of Manchester /ID# 213873, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04102007"
20,"NCT04080856","Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada","GRACE","Recruiting","No Results Available","Endometriosis",,"Change in Dysmenorrhea Score|Percentage of Participants With Patient Global Impression of Change (PGIC) Response|Percentage of Participants With Clinician's Global Impression of Change (CGIC) Response|Change From Baseline in Non-Menstrual Pelvic Pain (NMPP)|Change From Baseline in Dyspareunia Score|Change From Baseline in Pelvic Pain During Periods|Change from Baseline in Bleeding and Menstrual Cycle|Percentage of Participants With Change in Dosing Schedule|Change from Baseline in Morisky Medication Adherence Scale (MMAS)|Percentage of Participants Using Concomitant Medications/Treatments|Percentage of Participants Using Other Medications/Treatments|Percentage of Participants Using Pain/Rescue Medications|Percentage of Participants Using Add-Back|Change from Baseline in Endometrial Health Profile (EHP)-30|Change from Baseline in Endometrial Health Profile (EHP)-5|Change from Baseline in Work Productivity and Activity Impairment (WPAI)","AbbVie","Female","18 Years to 50 Years   (Adult)",,"400","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-933","December 9, 2019","May 26, 2023","May 26, 2023","September 6, 2019",,"December 5, 2019","University of Calgary /ID# 212942, Calgary, Alberta, Canada|South Health Campus /ID# 213065, Calgary, Alberta, Canada|Aubrey D. Uretsky Professional Corporation /ID# 214753, Edmonton, Alberta, Canada|BC Women's Hospital /ID# 214561, Vancouver, British Columbia, Canada|Strand Clinic /ID# 213567, St. John's, Newfoundland and Labrador, Canada|IWK Health Center /ID# 213066, Halifax, Nova Scotia, Canada|McMaster University Med Cent /ID# 213496, Hamilton, Ontario, Canada|Dr. George A. Vilos Medicine Professional Corporation /Id# 214497, London, Ontario, Canada|The Ottawa Hospital /ID# 213608, Ottawa, Ontario, Canada|Medicor Research Inc. /ID# 213467, Sudbury, Ontario, Canada|Sunnybrook Health Sciences Cen /ID# 214330, Toronto, Ontario, Canada|Unity Health Toronto /ID# 213590, Toronto, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 214023, Toronto, Ontario, Canada|Hopital Gatineau CISSSO /ID# 212944, Gatineau, Quebec, Canada|Centre de Gyn-écologie et Maternité /ID# 212943, Lasalle, Quebec, Canada|Clinique de Gynecologie-Obstetrique Pierre Boucher /ID# 213064, Longueuil, Quebec, Canada|Jewish General Hospital /ID# 215728, Montreal, Quebec, Canada|CIUSSS de l'Est de l'Ile de Montréal /ID# 213439, Montréal, Quebec, Canada|Brunswick Medical /ID# 214743, Montréal, Quebec, Canada|CHU de Quebec-Université Laval /ID# 213677, Québec, Quebec, Canada|Dr. John A. Thiel Medecine Professional Corporation /ID# 213766, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT04080856"
21,"NCT04064827","A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)",,"Not yet recruiting","No Results Available","Chronic Kidney Disease (CKD)|Secondary Hyperparathyroidism (SHPT)","Drug: Paricalcitol","Percentage of Participants Who Achieve Positive Response During Dosing Period 1|Incidence of Hypercalcemia During Dosing Period 1|Percentage of Participants Who Achieve a Positive Response During Dosing Period 2|Percentage of Participants Who Achieve a Positive Response During Dosing Periods 1 and 2 Combined|Percentage of Participants Who Achieve Two Consecutive >= 30% Reductions in iPTH From Baseline During Dosing Period 1|Percentage of Participants Who Achieve Two Consecutive >= 30% Reductions in iPTH From Baseline During Dosing Period 2|Percentage of Participants Who Achieve Two Consecutive >= 30% Reductions in iPTH From Baseline During Dosing Periods 1 and 2 Combined|Percentage of Participants Who Achieve Two Consecutive iPTH Values Between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) During Dosing Period 1|Percentage of Participants Who Achieve Two Consecutive iPTH Values Between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) During Dosing Period 2|Percentage of Participants Who Achieve Two Consecutive iPTH Values Between 150 pg/mL to 300 pg/mL (16.5 - 33.0 pmol/L) During Dosing Periods 1 and 2 Combined|Incidence of Hypercalcemia During Dosing Period 2|Incidence of Hypercalcemia During Dosing Periods 1 and 2 Combined","AbbVie","All","up to 9 Years   (Child)","Phase 3","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-617","February 15, 2020","March 9, 2024","August 1, 2024","August 22, 2019",,"December 13, 2019","University of California, Los Angeles /ID# 140668, Los Angeles, California, United States|Colorado Children's Hospital /ID# 162862, Aurora, Colorado, United States|Nicklaus Children's Hospital /ID# 210517, Miami, Florida, United States|Emory University Hospital /ID# 140665, Atlanta, Georgia, United States|Boston Childrens Hospital /ID# 162863, Boston, Massachusetts, United States|UT Southwestern Medical Center /ID# 210495, Dallas, Texas, United States|Seattle Children's Hospital /ID# 162861, Seattle, Washington, United States|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 140663, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT04064827"
22,"NCT04041050","A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Alone and in Combination With Ruxolitinib in Asian Adult Participants With Myeloproliferative Neoplasm",,"Recruiting","No Results Available","Myeloproliferative Neoplasm","Drug: Navitoclax|Drug: Ruxolitinib","Number of Participants with Dose Limiting Toxicities (DLT)|Maximum Observed Plasma Concentration (Cmax)|Time to Cmax (peak time, Tmax)|Area Under the Plasma Concentration-time Curve from time 0 to the time of the last measurable concentration (AUCt)|Number of Participants with Adverse Events|Overall Response Rate (ORR)","AbbVie","All","20 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-753","October 3, 2019","July 21, 2022","July 21, 2022","August 1, 2019",,"October 29, 2019","Kindai University Hospital /ID# 213241, Osaka-sayama, Osaka, Japan|Osaka University Hospital /ID# 213235, Suita-shi, Osaka, Japan|Juntendo University Hospital /ID# 213255, Bunkyo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04041050"
23,"NCT03987958","A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)","REVIVE","Recruiting","No Results Available","Acute Myeloid Leukemia",,"Overall Survival|Percentage of participants achieving composite complete remission (CR or CRi)|Time to transfusion independence|Change in patient reported outcomes for the Euro Quality of Life 5 Dimensions 5 Levels Questionnaire (EQ-5D-5L)|Percentage of participants treated with venetoclax as compared to participants treated with other approved biologics|Change in patient reported outcomes for the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire CORE (EORTC QLQ-C30)|Percentage of participants achieving transfusion independence","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-831","August 8, 2019","July 1, 2023","July 1, 2023","June 17, 2019",,"December 20, 2019","Soroka Medical Center /ID# 213369, Be'er Sheva, HaDarom, Israel|Assuta Medical Centers /ID# 213371, Tel Aviv, HaMerkaz, Israel|Rabin Medical Center /ID# 213343, Petakh Tikva, Tel-Aviv, Israel|Ha'Emek Medical Center /ID# 213370, Afula, Israel|Bnai Zion Medical Center /ID# 213344, Haifa, Israel|Meir Medical Center /ID# 213352, Kfar Saba, Israel|Sheba Medical Center /ID# 213353, Ramat Gan, Israel|Sourasky Medical Center /ID# 213354, Tel-aviv, Israel",,"https://ClinicalTrials.gov/show/NCT03987958"
24,"NCT03982394","Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis","VALUE","Recruiting","No Results Available","Chronic Plaque Psoriasis",,"Percentage of participants who achieved Psoriasis Area and Severity Index (PASI) 90|Time to first treatment change|Time to first treatment change rate|Percentage of participants who achieved Static Physicians Global Assessment (sPGA) 0/1 or sPGA 0|Percentage of participants who achieved Psoriasis Area and Severity Index (PASI) 75, 90, or 100|Percentage of participants who achieved Absolute PASI<=5, <=3 or <=1|Time to achieve sPGA 0/1 or sPGA 0|Time to achieve PASI 75, 90,or 100|Percentage of participants who achieve sPGA 0/1 or sPGA 0 at 4 Months and maintained the response status at 1 Year, 2 Years and 3 Years without increasing the dose or shortening the dose interval|Percentage of participants who achieved PASI 90 or PASI 100 at 4 Months and maintained the response status at 1 Year, 2 Years, and 3 Years without changing the indicated dose or dosing interval|Change in PASI|Change in Body Surface Area (BSA)|Change in Dermatology Quality of Life Index (DLQI) Score|Percentage of participants who achieve DLQI 0/1|Change in Treatment Satisfaction Questionnaire for Medication (TSQM) score","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"751","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-377","July 1, 2019","June 30, 2025","June 30, 2025","June 11, 2019",,"December 16, 2019","Instituto de Neumonología y Dermatología /ID# 217429, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Psoriahue Med Interdisciplinar /ID# 217182, Buenos Aires, Argentina|Hospital Italiano /ID# 217000, Caba, Argentina|Hospital Universitario Austral /ID# 217540, Pilar, Argentina|Krankenanstalt Rudolfstiftung /ID# 217684, Vienna, Wien, Austria|Medizinische Universität Wien /ID# 216138, Vienna, Wien, Austria|Landeskrankenhaus Feldkirch /ID# 216139, Feldkirch, Austria|Klinikum Wels - Grieskirchen /ID# 216140, Wels, Austria|Institute for Skin Advancement /ID# 213524, Calgary, Alberta, Canada|Stratica Medical /ID# 213526, Edmonton, Alberta, Canada|Univ British Columbia /ID# 213507, Vancouver, British Columbia, Canada|Jason Ronald Sneath Medical Co /ID# 213082, Brandon, Manitoba, Canada|Winnipeg Clinic, Manitoba, CA /ID# 212134, Winnipeg, Manitoba, Canada|Dr. Irina Turchin PC Inc. /ID# 212128, Fredericton, New Brunswick, Canada|Karma Clinical Trials /ID# 213522, St. John's, Newfoundland and Labrador, Canada|NewLab Clinical Research Inc. /ID# 213521, St. John's, Newfoundland and Labrador, Canada|Dr. Brown-Maher PMC INC. /ID# 212136, St. John's, Newfoundland and Labrador, Canada|CCA Medical Research /ID# 214446, Ajax, Ontario, Canada|SimcoDerm Medical and Surgical /ID# 213081, Barrie, Ontario, Canada|Hamilton Health Sciences Corporation /ID# 214053, Hamilton, Ontario, Canada|Dermatrials Research /ID# 213523, Hamilton, Ontario, Canada|Lynderm Research Inc. /ID# 212124, Markham, Ontario, Canada|Al-Mohammedi Medicine Professional Corporation /ID# 215408, Mississauga, Ontario, Canada|DermEdge Research Inc. /ID# 213525, Mississauga, Ontario, Canada|JRB Research /ID# 213615, Ottawa, Ontario, Canada|Dr Melinda Gooderham Medicine Professional Corporation /ID# 212133, Peterborough, Ontario, Canada|Farheen Mussani Medicine Professional Corporation /ID# 213811, Stoney Creek, Ontario, Canada|Niakosari Medicine Professional Corporation /ID# 213486, Toronto, Ontario, Canada|K. Papp Clinical Research /ID# 212130, Waterloo, Ontario, Canada|Dr Maksym Breslavets Medicine Professional Corporation /ID# 213338, Whitby, Ontario, Canada|Clinique D /ID# 212126, Laval, Quebec, Canada|Universitatsklinikum Mannheim /ID# 214569, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 213669, Erlangen, Bayern, Germany|CMS3 Company for Medical Study /ID# 213676, Selters (Westerwald), Rheinland-Pfalz, Germany|Univ Hosp Schleswig-Holstein /ID# 213670, Kiel, Schleswig-Holstein, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH /ID# 213977, Kiel, Schleswig-Holstein, Germany|Bell, Andernach, DE /ID# 214545, Andernach, Germany|Praxis Dr. Mihaescu /ID# 213483, Augsburg, Germany|Hautmedizin Bad Soden /ID# 213956, Bad Soden am Taunus, Germany|Timmel/Timm/Vorwerk, Bergen /ID# 214552, Bergen, Germany|Hasert & Hasert, Berlin, DE /ID# 213641, Berlin, Germany|Hautzentrum Friedrichshain /ID# 213981, Berlin, Germany|Weihe/Stavermann, Berlin, DE /ID# 214550, Berlin, Germany|Hautarztzentrum Tegel /ID# 214849, Berlin, Germany|Klinikum Rosenhoehe /ID# 215520, Bielefeld, Germany|Praxis fuer Innere Medizin/Rhe /ID# 213653, Blaubeuren, Germany|Praxis T. Schadeck /ID# 213957, Bogen, Germany|Barth, Borna, DE /ID# 213643, Borna, Germany|Dres. Thiem/Weyergraf/Wörheide /ID# 214466, Bramsche, Germany|Schwichtenberg, Bremen, DE /ID# 213650, Bremen, Germany|Elbe Klinikum Buxtehude /ID# 213366, Buxtehude, Germany|Praxis Dr. Sbornik /ID# 213668, Deggendorf, Germany|Heidlas, Dessau-Rosslau, DE /ID# 217691, Dessau-rosslau, Germany|Richter-Huhn, Dresden, DE /ID# 213659, Dresden, Germany|Korge, Dueren, DE /ID# 213475, Dueren, Germany|Dres. Cesko u. Körber /ID# 214850, Essen, Germany|Kurzen, Freising, DE /ID# 214567, Freising, Germany|Praxis J. Teichmann & Partner /ID# 213482, Gelsenkirchen, Germany|Praxis Dr. Lange /ID# 213984, Gera, Germany|Loth, Gernsbach, DE /ID# 214848, Gernsbach, Germany|Gross/Braeu, Giessen, DE /ID# 213367, Giessen, Germany|Hautarztpraxis Dr. Viehmann /ID# 213675, Gießen, Germany|Brinkmann & Partner, Gladbeck, /ID# 214247, Gladbeck, Germany|Dermatologikum Hamburg /ID# 213978, Hamburg, Germany|Goldbek Medical /ID# 214570, Hamburg, Germany|Praxis Dres. Kaspari /Schenck /ID# 213649, Hannover, Germany|Hautarztpraxis Haßberge /ID# 213644, Haßfurt, Germany|Pawlak, Heilbad Heiligenstadt, /ID# 213113, Heilbad Heiligenstadt, Germany|Reinecke, Holzminden, DE /ID# 215081, Holzminden, Germany|Universitaetsklinikum Jena /ID# 214259, Jena, Germany|Derma Sana /ID# 214544, Karlsruhe, Germany|Grossmann, Koblenz, DE /ID# 214245, Koblenz, Germany|Praxis Dres. Bornemann/Reinerth /ID# 213368, Krefeld, Germany|Dres. Jacobs & Kollegen /ID# 213652, Kulmbach, Germany|Praxis Dr. Schwarz /ID# 213651, Langenau, Germany|Noack-Wiemers, Leipzig, DE /ID# 213654, Leipzig, Germany|Neubauer, Leipzig, DE /ID# 214548, Leipzig, Germany|Hagemeier, Loehne, DE /ID# 214845, Loehne, Germany|Bruecher, Magdeburg, DE /ID# 213476, Magdeburg, Germany|Universitätsklinikum Magdeburg Klinik /ID# 215080, Magdeburg, Germany|Dres. Quist u. Quist /ID# 214249, Mainz, Germany|Hautarztpraxis Schwinn /ID# 213958, Memmingen, Germany|ZENTderma /ID# 213959, Mönchengladbach, Germany|Praxis Dres. Kloss/Peterburgskiy /ID# 213960, Neuwied, Germany|Praxis Dr. Konstantin Ertner /ID# 213640, Nuremberg, Germany|Voelkel, Nuremberg, DE /ID# 213671, Nuremberg, Germany|Breitsprecher, Osnabrueck, DE /ID# 213672, Osnabrueck, Germany|Kramer/Mortazawi, Remscheid /ID# 213477, Remscheid, Germany|Fraenken/Leksa, Schwelm, DE /ID# 214546, Schwelm, Germany|Praxis Dr. Langhoff /ID# 214253, Schwerin, Germany|Karl, Soest, DE /ID# 214547, Soest, Germany|Praxis Dres. Ziegler & Partner /ID# 213647, Stuttgart, Germany|Braun, Ueberlingen, DE /ID# 213646, Ueberlingen, Germany|Barnikol, Waltershausen, DE /ID# 213219, Waltershausen, Germany|Pfennig, Werdau, DE /ID# 213657, Werdau, Germany|Moeller, Wiesbaden, DE /ID# 213955, Wiesbaden, Germany|Hoffmann, Witten, DE /ID# 213444, Witten, Germany|Franz, Wolfenbuettel, DE /ID# 215355, Wolfenbuettel, Germany|Pecsi Tudomanyegyetem /ID# 212960, Pécs, Pecs, Hungary|Markusovszky Egyetemi Oktatókórház /ID# 212961, Szombathely, Vas, Hungary|Debreceni Egyetem Klinikai Központ /ID# 212959, Debrecen, Hungary|Szegedi Tudomanyegyetem /ID# 212958, Szeged, Hungary|Takagi Dermatological Clinic /ID# 213407, Obihiro-shi, Hokkaido, Japan|Tokyo Yamate Medical Center /ID# 213389, Tokyo, Japan|Radboud Universitair Medisch Centrum /ID# 213592, Nijmegen, Gelderland, Netherlands|Meander Medisch Centrum /ID# 215784, Amersfoort, Netherlands|Academisch Medisch Centrum /ID# 213593, Amsterdam, Netherlands|Medisch Centrum Leeuwarden /ID# 215779, Leeuwarden, Netherlands|Kantonsspital St. Gallen /ID# 215488, St. Gallen, Sankt Gallen, Switzerland|Universitaetsspital Basel /ID# 212744, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 212741, Bern, Switzerland|Buergenstock Medical Center /ID# 212743, Obbuergen, Switzerland|Haut. Venen. Allergie.   Zentrum Brunnehof /ID# 212742, Uster, Switzerland|Universitatsspital Zurich /ID# 216539, Zurich, Switzerland|Kingston Hosp NHS Foundation /ID# 215973, Kingston upon Thames, England, United Kingdom|NHS Lanakshire (Monklands) /ID# 215478, Airdire, United Kingdom|Ulster Hospital /ID# 215477, Belfast, United Kingdom|Princess of Wales Hospital /ID# 215974, Bridgend, United Kingdom|Russells Hall Hospital, Dudley /ID# 215839, Dudley, United Kingdom|Imperial College Healthcare NHS Trust /ID# 215978, London, United Kingdom|Newcastle upon Tyne Hospitals /ID# 215479, Newcastle Upon Tyne, United Kingdom|Queen Elizabeth Hospital Kings /ID# 215476, Norfolk, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03982394"
25,"NCT03978520","A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus",,"Recruiting","No Results Available","Systemic Lupus Erythematosus (SLE)","Drug: ABBV-105|Drug: Placebo for ABBV-105|Drug: Upadacitinib|Drug: Placebo for upadacitinib","SLE Responder Index (SRI)-4 and steroid dose <= 10 mg prednisone equivalent QD|SLE Responder Index (SRI)-4|SLE Responder Index (SRI)-5|SLE Responder Index (SRI)-6|SLE Responder Index (SRI)-7|SLE Responder Index (SRI)-8|British Isles Lupus Assessment Group (BILAG) Based Combined Lupus Assessment (BICLA)|Lupus Low Disease Activity State (LLDAS)|Change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2000 (2K) from Baseline|Change in Steroid Burden from Baseline|Number of flares by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLEDAI flare index|Time to first flare by SELENA SLEDAI flare index after first study drug administration|Percentage of Participants Who Achieve 50% Reduction of Number of Tender or Swollen Lupus joints (Among Those Starting With Total >=6 Affected Joints)|Percentage of Participants Who Achieve 50% Reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score (Of Those Starting With CLASI >=10)|Change in British Isles Lupus Assessment Group (BILAG) from Baseline|Change in Physician's Global Assessment from Baseline|Change in Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-F) from Baseline|Change in Short Form (SF)-36 from Baseline|Change Lupus Quality of Life (LupusQoL) from Baseline|Change in Pain Numerical Rating Scale (NRS) from Baseline","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","325","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M19-130|2019-000638-20","July 25, 2019","September 16, 2021","March 18, 2022","June 7, 2019",,"January 9, 2020","Arizona Arthritis & Rheumatology Research, PLLC /ID# 214522, Mesa, Arizona, United States|Arizona Arthritis & Rheumatolo /ID# 211329, Phoenix, Arizona, United States|AZ Arthritis & Rheuma Research /ID# 214267, Phoenix, Arizona, United States|Arthritis and Rheumatism Associates /ID# 211411, Jonesboro, Arkansas, United States|Wallace Rheumatic Studies Ctr /ID# 211600, Beverly Hills, California, United States|Valerius Medical Group /ID# 211599, Los Alamitos, California, United States|UCLA Division of Rheumatology /ID# 213546, Los Angeles, California, United States|East Bay Rheumatology Medical /ID# 211638, San Leandro, California, United States|The Lundquist Institute at Harbor-UCLA Medical Center /ID# 213402, Torrance, California, United States|Medvin Clinical Research /ID# 211996, Tujunga, California, United States|Inland Rheum Clin Trials Inc. /ID# 213617, Upland, California, United States|University of Colorado Hospita /ID# 211314, Denver, Colorado, United States|Yale University /ID# 211546, New Haven, Connecticut, United States|Yale University /ID# 212824, New Haven, Connecticut, United States|Medstar Health Research Institute /ID# 213335, Washington, District of Columbia, United States|LeJenue Research Associates /ID# 212327, Miami, Florida, United States|Ctr Arthritis & Rheumatic Dise /ID# 212326, Miami, Florida, United States|Integral Rheumatology & Immunology Specialists /ID# 213053, Plantation, Florida, United States|W. Broward Rheum Assoc Inc. /ID# 211881, Tamarac, Florida, United States|Affinity Health /ID# 211496, Oak Brook, Illinois, United States|Deerbrook Medical Associates /ID# 212251, Vernon Hills, Illinois, United States|Rheumatology, Arthritis & Immunology Clinic /ID# 214765, Evansville, Indiana, United States|LSUHSC - Shreveport /ID# 211412, Shreveport, Louisiana, United States|The Center for Rheumatology and Bone Research /ID# 211610, Wheaton, Maryland, United States|Beth Israel Deaconess Medical Center /ID# 212321, Boston, Massachusetts, United States|Henry Ford Health System /ID# 211676, Detroit, Michigan, United States|June DO, PC /ID# 211674, Lansing, Michigan, United States|NYU Langone Ambulatory Care Brooklyn Heights /ID# 211548, Brooklyn, New York, United States|NYU Langone Health/NYU School of Medicine /ID# 213620, New York, New York, United States|Ohio State Outpatient Care East /ID# 211636, Columbus, Ohio, United States|STAT Research, Inc. /ID# 211404, Vandalia, Ohio, United States|Premier Rheumatology of Oklahoma - Tulsa /ID# 213850, Tulsa, Oklahoma, United States|Allegheny Health Network /ID# 211607, Pittsburgh, Pennsylvania, United States|Univ TN Health Sciences Ctr /ID# 212177, Memphis, Tennessee, United States|Dr. Ramesh Gupta /ID# 213381, Memphis, Tennessee, United States|Tekton Research, Inc. /ID# 211521, Austin, Texas, United States|Tekton Research, Inc. /ID# 214182, Austin, Texas, United States|Trinity Universal Res Assoc /ID# 211527, Carrollton, Texas, United States|Accurate Clinical Management /ID# 213571, Houston, Texas, United States|SW Rheumatology Res. LLC /ID# 211520, Mesquite, Texas, United States|Carilion Clinic /ID# 213500, Roanoke, Virginia, United States|Virginia Mason Medical Center /ID# 211457, Seattle, Washington, United States|Rheumatology and Pulmonary cli /ID# 211398, Beckley, West Virginia, United States|Aprillus Asistencia e Investig /ID# 211630, Capital Federal, Buenos Aires, Argentina|Hospital Interzonal Gral Agudos San Martin /ID# 211679, La Plata, Buenos Aires, Argentina|Hospital General de Agudos Ram /ID# 212801, Buenos Aires, Argentina|Hospital Cordoba /ID# 212200, Cordoba, Argentina|Instituto CAICI /ID# 211633, Rosario, Santa FE, Argentina|Centro Medico Privado/Reuma /ID# 212714, San Miguel de Tucuman, Argentina|Investigaciones Clin Tucuman /ID# 211942, San Miguel de Tucuman, Argentina|Centro de Enfermedades /ID# 211634, Santa Fe, Argentina|Royal Brisbane and Women's Hospital /ID# 212667, Herston, Queensland, Australia|Rheumatology Research Unit /ID# 211902, Maroochydore, Queensland, Australia|The Queen Elizabeth Hospital /ID# 211901, Woodville, South Australia, Australia|Monash Health /ID# 212313, Clayton, Victoria, Australia|St. Vincents Hosp Melbourne /ID# 212311, Fitzroy, Victoria, Australia|McMaster University Med Cent /ID# 212662, Hamilton, Ontario, Canada|St. Josephs Health Care Centre /ID# 212331, London, Ontario, Canada|Toronto Western Hospital /ID# 213336, Toronto, Ontario, Canada|Guangdong Provincial People's Hospital /ID# 211811, Guangzhou, Guangdong, China|Xiangya Hospital Central South University /ID# 212919, Changsha, Hunan, China|Shanghai Changhai Hospital /ID# 211819, Shanghai, Shanghai, China|Peking Union Med College Hosp /ID# 211614, Beijing, China|Jiangsu Province Hospital /ID# 211818, Nanjing, China|Huashan Hospital of Fudan University /ID# 213976, Shanghai, China|People's Hospital of Xinjiang /ID# 211821, Urumqi, China|Centro de Investigaciòn en Reumatologia CIREEM /ID# 211895, Bogota, Cundinamarca, Colombia|Ctr Int de Reum del Caribe SAS /ID# 211894, Barranquilla, Colombia|Preventive Care Sas /Id# 211896, Chia, Colombia|Clinica Universitaria Bolivari /ID# 211897, Medellin, Colombia|Healthy Medical Center SAS /ID# 211899, Zipaquira, Colombia|CHRU Lille - Hôpital Claude Huriez /ID# 211829, Lille CEDEX, Hauts-de-France, France|CHU Bordeaux-Hopital Pellegrin /ID# 211832, Bordeaux, France|CHU Bicetre /ID# 211968, Le Kremlin Bicetre, France|CHU Paris-GH La Pitie Salpetri /ID# 211831, Paris, France|Hôpital Civil /ID# 211981, Strasbourg CEDEX, France|Univ Klinikum Duesseldorf /ID# 212408, Dusseldorf, Nordrhein-Westfalen, Germany|Charité - Med Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie /ID# 211988, Berlin, Germany|Universitaetklinikum Dresden /ID# 212770, Dresden, Germany|Universitätsklinikum Freiburg /ID# 211990, Freiburg, Germany|Univ Hosp Schleswig-Holstein /ID# 212674, Kiel, Germany|Vital Medical Center Orvosi es /ID# 212796, Veszprém, Veszprem, Hungary|Orszagos Reumatologiai es Fizi /ID# 211827, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 212042, Debrecen, Hungary|Bekes Megyei Pandy Kalman Korh /ID# 216971, Gyula, Hungary|AOU Policlinico Umberto I /ID# 212195, Rome, Lazio, Italy|AOU Arcispedale Sant Anna di /ID# 211861, Cona, Italy|Azienda Istituto Gaetano Pini /ID# 215063, Milan, Italy|AOU Pisana /ID# 211862, Pisa, Italy|Azienda Sanitaria Universitaria Integrata di Udine /ID# 211858, Udine, Italy|Hamanomachi Hospital /ID# 213696, Fukuoka-shi, Fukuoka, Japan|Hospital of the University of Occupational and Environmental Health /ID# 217548, Kitakyushu-shi, Fukuoka, Japan|Fukushima Medical University Hospital /ID# 213913, Fukushima-shi, Fukushima, Japan|National Hospital Organization Asahikawa Medical Center /ID# 213846, Asahikawa, Hokkaido, Japan|EIRAKU Internal Medicine Clinic /ID# 215419, Kagishima, Kagoshima, Japan|Yokohama Rosai Hospital /ID# 213690, Yokohama, Kanagawa, Japan|Kumamoto Shinto General Hospital /ID# 215347, Kumamoto-shi, Kumamoto, Japan|Tohoku University Hospital /ID# 213693, Sendai-shi, Miyagi, Japan|Shinshu University Hospital /ID# 213853, Matsumoto-shi, Nagano, Japan|Sakai City Medical Center /ID# 213689, Sakai-shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 213687, Kawagoe-shi, Saitama, Japan|Keio University Hospital /ID# 216347, Shinjuku-ku, Tokyo, Japan|Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital /ID# 213694, Hiroshima, Japan|Nagano Red Cross Hospital /ID# 214572, Nagano, Japan|NHO Nagoya Medical Center /ID# 213974, Nagoya, Japan|Kita-harima Medical Center /ID# 215474, ONO, Japan|Tomakomai City Hospital /ID# 214234, Tomakomai, Japan|Ajou University Hospital /ID# 211692, Suwon-si, Gyeonggido, Korea, Republic of|Inha University Hospital /ID# 211691, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 211695, Gwangju, Jeonranamdo, Korea, Republic of|Konkuk University Medical Ctr /ID# 213410, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 211740, Seoul, Korea, Republic of|CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 211875, Mexico City, Ciudad De Mexico, Mexico|Centro Integral en Reumatología S.A de C.V /ID# 211876, Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigación Básica y Clínica, S.C. /ID# 212532, Guadalajara, Jalisco, Mexico|Medical Care & Research SA de CV /ID# 212682, Mérida, Yucatan, Mexico|RM Pharma Specialists, S.A de C.V /ID# 211879, Mexico City, Mexico|Vrije Universiteit Medisch Centrum /ID# 214424, Amsterdam, Netherlands|Leids Universitair Medisch Centrum /ID# 214413, Leiden, Netherlands|Universitair Medisch Centrum Utrecht /ID# 214415, Utrecht, Netherlands|Waikato Hospital /ID# 213505, Hamilton, Waikato, New Zealand|North Shore Hospital /ID# 213506, Auckland, New Zealand|Middlemore Clinical Trials /ID# 213504, Auckland, New Zealand|WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 212482, Wrocław, Dolnoslaskie, Poland|SCM Sp.z o.o. /ID# 212146, Cracow, Malopolskie, Poland|Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi /ID# 212483, Poznań, Poland|GCM Medical Group /ID# 211251, San Juan, Puerto Rico|Mindful Medical Research /ID# 213384, San Juan, Puerto Rico|Corporac Sanitaria Parc Tauli /ID# 212145, Sabadell, Barcelona, Spain|Comple Hosp Univ de A Coruna /ID# 211719, A Coruna, Spain|Hospital Universitario Basurto /ID# 212722, Bilbao, Spain|Hospital Universitario Galdakao /Id# 212803, Galdakao, Spain|Hosp Univ 12 de Octubre /ID# 211757, Madrid, Spain|Hospital Universitario de Valm /ID# 212721, Sevilla, Spain|Hospital Universitario La Fe /ID# 211720, Valencia, Spain|Hospital de Alava /ID# 212520, Vitoria, Spain|China Medical University Hosp /ID# 212179, Taichung City, Taichung, Taiwan|National Taiwan University Hospital /ID# 211752, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 211957, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 212216, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 211751, Taoyuan City, Taiwan|Addenbrookes Hospital /ID# 213189, Cambridge, United Kingdom|Guy's Hospital /ID# 211931, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 211838, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03978520"
26,"NCT03969888","A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222",,"Recruiting","No Results Available","Cystic Fibrosis","Drug: ABBV-3067|Drug: Placebo ABBV-3067|Drug: ABBV-2222|Drug: Placebo ABBV-2222","Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Absolute change in sweat chloride (SwCl)|Absolute change in forced vital capacity (FVC)|Absolute change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in percent predicted forced expiratory volume in 1 second (ppFEV1)|Relative change in forced expiratory flow at mid-lung capacity (FEF25-75)|Relative change in forced vital capacity (FVC)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M19-530|2019-000750-63","December 11, 2019","February 19, 2021","July 20, 2021","May 31, 2019",,"January 6, 2020","University of Arkansas /ID# 212541, Little Rock, Arkansas, United States|Tampa General Hospital /ID# 212342, Tampa, Florida, United States|University of Iowa Hospitals and Clinics /ID# 212351, Iowa City, Iowa, United States|St. Louis University /ID# 212349, Saint Louis, Missouri, United States|Washington University-School of Medicine /ID# 212352, Saint Louis, Missouri, United States|Medical University of South Carolina /ID# 212187, Charleston, South Carolina, United States|Vanderbilt University Med Ctr /ID# 212353, Nashville, Tennessee, United States|University of Utah /ID# 212350, Salt Lake City, Utah, United States|Uza /Id# 213412, Edegem, Antwerpen, Belgium|UZ Brussel /ID# 212812, Jette, Bruxelles-Capitale, Belgium|UZ Gent /ID# 213411, Gent, Oost-Vlaanderen, Belgium|ULB Erasme /ID# 213413, Brussels, Belgium|University Hospital Leuven /ID# 213050, Leuven, Belgium|University of Calgary /ID# 212555, Calgary, Alberta, Canada|University of Alberta Hospital /ID# 213874, Edmonton, Alberta, Canada|St. Paul's Hospital /ID# 212554, Vancouver, British Columbia, Canada|Qeii /Id# 212656, Halifax, Nova Scotia, Canada|St. Michael's Hospital /ID# 212552, Toronto, Ontario, Canada|McGill University Health Center Research Institute /ID# 212553, Montreal, Quebec, Canada|Iucpq-Ul /Id# 212655, Québec, Quebec, Canada|Fakultni Nemocnice v Motole /ID# 212966, Prague 5, Praha 5, Czechia|Fakultni Nemocnice Brno /ID# 213437, Brno, Czechia|CHU de Montpellier - Hôpital S /ID# 212856, Montpellier Cedex 5, France|CHU Nantes - Hopital Laennec /ID# 212897, Nantes, France|CHU de Nice /ID# 212862, Nice, France|Hospitaux de Paris - Assistance Publique /ID# 212864, Paris, France|Hospitalier Necker /ID# 212906, Paris, France|CHU Bordeaux /ID# 212898, Pessac, France|Chu Lyon Sud /Id# 212899, Pierre Benite, France|CHU de Reims /ID# 212910, Reims, France|Fondation ILDYS /ID# 212857, Roscoff, France|Orszagos Koranyi Pulmonologiai Intezet /ID# 213494, Budapest XII, Budapest, Hungary|HagaZiekenhuis /ID# 212926, Den Haag, Netherlands|Universitair Medisch Centrum Utrecht /ID# 212935, Utrecht, Netherlands|Institut za zdravstvenu zaštitu majke i deteta Srbije ""Dr Vukan Čupić"" /ID# 212820, Beograd, Serbia|Specializovana geriatricka nemocnica Poddunajske Biskupice-UNB /ID# 213596, Bratislava, Slovakia|UNB Nemocnica Ruzinov /ID# 213146, Bratislava, Slovakia|Vall d'Hebron University Hospi /ID# 213014, Barcelona, Spain|Hospital Universitario La Paz /ID# 213513, Madrid, Spain|NHS Lothian /ID# 212506, Edinburgh, Midlothian, United Kingdom|Cardiff & Vale University Health Board /ID# 212504, Cardiff, Wales, United Kingdom|Belfast Health and Social Health Care /ID# 212502, Belfast, United Kingdom|Heart of England NHS Foundation Trust /ID# 212294, Birmingham, United Kingdom|University Hospitals Bristol /ID# 212494, Bristol, United Kingdom|Papworth Hospital NHS /ID# 212507, Cambridge, United Kingdom|Royal Devon and Exeter NHS Fou /ID# 212289, Exeter, United Kingdom|Leeds Teaching Hospitals /ID# 212491, Leeds, United Kingdom|Liverpool Heart and Chest Hospital NHS Foundation Trust /ID# 212291, Liverpool, United Kingdom|Barts and the London NHS Trust /ID# 213016, London, United Kingdom|King's College Hospital NHS /ID# 212489, London, United Kingdom|Royal Brompton Hospital /ID# 212490, London, United Kingdom|Wythenshawe Hospital /ID# 213058, Manchester, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 212665, Newcastle Upon Tyne, United Kingdom|Nottingham University /ID# 212531, Nottingham, United Kingdom|Univ Hosp Southampton NHS /ID# 212493, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03969888"
27,"NCT03951077","Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary Syndrome",,"Recruiting","No Results Available","Polycystic Ovary Syndrome","Drug: Elagolix|Drug: Placebo","Percentage of Menstrual Cycle Responders|Change in Area Under the Luteinizing Hormone (LH) Serum Concentration-time Curve (AUC)","AbbVie","Female","18 Years to 35 Years   (Adult)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M16-837","August 12, 2019","March 15, 2021","April 14, 2021","May 15, 2019",,"December 23, 2019","Alabama Clinical Therapeutics, LLC /ID# 211498, Birmingham, Alabama, United States|Mobile, Ob-Gyn, P.C. /ID# 205574, Mobile, Alabama, United States|Medical Ctr for Clin Research /ID# 205694, San Diego, California, United States|West Coast Medical Research, I /ID# 205613, San Diego, California, United States|UCSF Center for Reproductive Health /ID# 210836, San Francisco, California, United States|Avail Clinical Research /ID# 210873, DeLand, Florida, United States|University of FL Southside Women's Specialists /ID# 210872, Jacksonville, Florida, United States|Segal Institute for Clinical Research /ID# 205490, North Miami, Florida, United States|A Premier Clinical Research of Florida, LLC /ID# 215659, Orange City, Florida, United States|Virtus Research Consultant,LLC /ID# 205475, Wellington, Florida, United States|Comprehensive Clinical Trials /ID# 205458, West Palm Beach, Florida, United States|Mount Vernon Clinical Res, LLC /ID# 205695, Atlanta, Georgia, United States|Bingham Memorial Hospital /ID# 205606, Blackfoot, Idaho, United States|Leavitt Womens Healthcare /ID# 205571, Idaho Falls, Idaho, United States|Womens Healthcare Assoc, DBA /ID# 211528, Idaho Falls, Idaho, United States|Sonora Clinical Research /ID# 205623, Meridian, Idaho, United States|Asr, Llc /Id# 207037, Nampa, Idaho, United States|PRN Professional Research Network of Kansas, LLC /ID# 205875, Wichita, Kansas, United States|Clinical Trials Management, LLC - Covington /ID# 211219, Covington, Louisiana, United States|Clinical Trials Management, LLC - Metairie /ID# 205494, Metairie, Louisiana, United States|Louisiana State University in /ID# 204958, Shreveport, Louisiana, United States|Baltimore Suburban Health /ID# 205619, Baltimore, Maryland, United States|Johns Hopkins University /ID# 205617, Baltimore, Maryland, United States|Capital Women's Care - Frederi /ID# 210276, Frederick, Maryland, United States|NECCR Fall River LLC /ID# 205567, Fall River, Massachusetts, United States|Wayne State University Physician Group - Southfield /ID# 210245, Southfield, Michigan, United States|R. Garn Mabey Jr, MD /ID# 211149, Las Vegas, Nevada, United States|Dr. Nader and Associates M.D. P.C. /ID# 211150, North Las Vegas, Nevada, United States|Cooper University Hospital/Sheridan Pavilion /ID# 205576, Marlton, New Jersey, United States|University of New Mexico /ID# 212594, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center /ID# 211180, Brooklyn, New York, United States|University of Rochester - Strong Fertility Center - Rochester /ID# 210328, Rochester, New York, United States|OB.GYN Associates of WNY /ID# 210765, West Seneca, New York, United States|Upstate Clinical Research Associates /ID# 205717, Williamsville, New York, United States|Carolina Institute for Clinical Research /ID# 211319, Fayetteville, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 211473, Winston-Salem, North Carolina, United States|Rapid Medical Research, INC /ID# 205643, Cleveland, Ohio, United States|Aventiv Research, Inc. /ID# 205460, Columbus, Ohio, United States|Univ Hosp Landerbrook /ID# 205558, Mayfield Heights, Ohio, United States|AC Clinical Research /ID# 205492, Tiffin, Ohio, United States|Penn State University and Milton S. Hershey Medical Center /ID# 205555, Hershey, Pennsylvania, United States|Thomas Jefferson University /ID# 205614, Philadelphia, Pennsylvania, United States|Reading Hosp Clncl Trials Ofc /ID# 211322, West Reading, Pennsylvania, United States|Chattanooga Medical Research /ID# 215190, Chattanooga, Tennessee, United States|Adams Patterson Gyn & Obs /ID# 205636, Memphis, Tennessee, United States|The University of Texas Southwestern Medical Center /ID# 210804, Dallas, Texas, United States|Advances in Health, Inc. /ID# 211249, Houston, Texas, United States|Diagnostic Clinic of Longview /ID# 211019, Longview, Texas, United States|Center of Reproductive Medicin /ID# 211250, Webster, Texas, United States|Virginia Mason Medical Center /ID# 205586, Seattle, Washington, United States|Seattle Women's Health, Research, Gynecology /ID# 205569, Seattle, Washington, United States|North Spokane Women's Health /ID# 205585, Spokane, Washington, United States|Puerto Rico Medical Research /ID# 211104, Ponce, Puerto Rico|University of Puerto Rico, Medical Sciences Campus /ID# 212320, Rio Piedras, Puerto Rico|Rodriguez-Ginorio, San Juan /ID# 211105, San Juan, Puerto Rico|Mindful Medical Research /ID# 212323, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03951077"
28,"NCT03941964","A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy",,"Recruiting","No Results Available","Acute Myeloid Leukemia (AML)|Cancer","Drug: venetoclax|Drug: azacytidine|Drug: decitabine","Composite Complete Remission Rate (CR + CRi)|Overall Response Rates (CR, CRi)|Percent of Participants who Achieve Transfusion Independence","AbbVie","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-072","August 15, 2019","November 11, 2020","January 30, 2021","May 8, 2019",,"December 9, 2019","Arizona Oncology Associates, PC-HOPE /ID# 211509, Tucson, Arizona, United States|Colorado Blood Cancer Institute /ID# 212800, Denver, Colorado, United States|Rocky Mountain Cancer Centers /ID# 211508, Lone Tree, Colorado, United States|Minnesota Oncology Hematology, /ID# 212837, Minneapolis, Minnesota, United States|Oncology Hematology Care, Inc - Kenwood /ID# 212779, Cincinnati, Ohio, United States|Willamette Valley Cancer Institute /ID# 211504, Eugene, Oregon, United States|Charleston Hematology Oncology Associates, PA /ID# 211471, Charleston, South Carolina, United States|Greenville Health System - Int'l Dr /ID# 211466, Greenville, South Carolina, United States|Tennessee Oncology - Chattanooga / McCallie /ID# 212717, Chattanooga, Tennessee, United States|Tennessee Oncology-Nashville Centennial /ID# 210944, Nashville, Tennessee, United States|Texas Oncology - Austin Midtown /ID# 212780, Austin, Texas, United States|Texas Oncology - Dallas /ID# 211503, Dallas, Texas, United States|Texas Transplant Institute /ID# 213311, San Antonio, Texas, United States|Texas Oncology - San Antonio Medical Center /ID# 211510, San Antonio, Texas, United States|Texas Oncology - Tyler /ID# 213908, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03941964"
29,"NCT03926169","A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa",,"Recruiting","No Results Available","Hidradenitis Suppurativa","Drug: Risankizumab|Drug: Placebo for risankizumab","Percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR)|Percentage of participants achieving at least 30% reduction from Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of Skin Pain (PGA Skin Pain) at Week 8 among participants with Baseline Numerical Rating Scale (NRS) >= 3|Percentage of participants achieving at least 30% reduction from Baseline in Numerical Rating Scale (NRS30) in Patient's Global Assessment of Skin Pain (PGA Skin Pain) at Week 16 among participants with Baseline Numerical Rating Scale (NRS) >= 3|Percentage of participants who experience at least 25% increase in AN counts with a minimum increase of 2 relative to Baseline|Change from Baseline in Dermatology Life Quality Index (DLQI)|Change from Baseline in HS-related swelling assessed based on the Hidradenitis Suppurativa Symptom Assessment (HSSA)|Change from Baseline in HS-related odor assessed based on the HSSA|Change from Baseline in HS-related worst drainage assessed based on the HSSA","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","190","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-833|2019-000122-21","June 3, 2019","October 2, 2020","January 24, 2022","April 24, 2019",,"January 13, 2020","Burke Pharmaceutical Research /ID# 211671, Hot Springs, Arkansas, United States|Bakersfield Derma & Skin Cance /ID# 211684, Bakersfield, California, United States|Wallace Medical Group, Inc. /ID# 215958, Beverly Hills, California, United States|Integrative Skin Science and Research /ID# 212550, Sacramento, California, United States|UC Davis, Dermatology /ID# 211436, Sacramento, California, United States|California Dermatology Institute /ID# 211786, Thousand Oaks, California, United States|Central Connecticut Dermatology /ID# 214479, Cromwell, Connecticut, United States|Advanced Medical Research /ID# 215203, Sandy Springs, Georgia, United States|Tufts Medical Center /ID# 212680, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 211794, Boston, Massachusetts, United States|Hamzavi Dermatology /ID# 212318, Fort Gratiot, Michigan, United States|Minnesota Clinical Study Center /ID# 211979, Fridley, Minnesota, United States|University of Minnesota /ID# 212319, Minneapolis, Minnesota, United States|Skin Specialists, PC /ID# 211675, Omaha, Nebraska, United States|Montefiore Medical Center /ID# 211800, Bronx, New York, United States|Oregon Medical Res Center PC /ID# 211796, Portland, Oregon, United States|Penn State Hershey Medical Ctr /ID# 211659, Hershey, Pennsylvania, United States|Rhode Island Hospital /ID# 211807, Providence, Rhode Island, United States|Modern Research Associates, PL /ID# 215202, Dallas, Texas, United States|Virginia Clinical Research /ID# 215959, Norfolk, Virginia, United States|Premier Clinical Research /ID# 211799, Spokane, Washington, United States|Woden Dermatology /ID# 212437, Phillip, Australian Capital Territory, Australia|Westmead Hospital /ID# 212438, Westmead, New South Wales, Australia|Veracity Clinical Research /ID# 212432, Woolloongabba, Queensland, Australia|Skin Health Institute Inc /ID# 212433, Carlton, Victoria, Australia|Sinclair Dermatology /ID# 215548, East Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 212436, Parkville, Victoria, Australia|Fremantle Dermatology /ID# 212434, Fremantle, Western Australia, Australia|Dermadvances Research, CA /ID# 212243, Winnipeg, Manitoba, Canada|Dr. Irina Turchin PC Inc. /ID# 212248, Fredericton, New Brunswick, Canada|McMaster University Med Cent /ID# 212164, Hamilton, Ontario, Canada|K. Papp Clinical Research /ID# 212166, Waterloo, Ontario, Canada|Dre. Angelique Gagne-Henley /ID# 212249, St-Jerome, Quebec, Canada|Hopital Prive d'Antony /ID# 212566, Antony, Ile-de-France, France|CHU de Nice /ID# 212563, Nice, France|Polyclinique Courlancy /ID# 212567, Reims, France|Hopital Nord /ID# 212564, Saint Priest En Jarez, France|Hopital Larrey - CHU de Toulouse /ID# 213581, Toulouse, France|Universitatsklinikum Frankfurt /ID# 211913, Frankfurt, Hessen, Germany|Charite-Univ. Berlin, Benjamin-Franklin /ID# 211960, Berlin, Germany|Klinikum Ruhr Univ Bochum /ID# 211910, Bochum, Germany|Staedtisches Klinikum Dessau /ID# 211914, Dessau, Germany|Univ Klinik Eppendorf Hamburg /ID# 211912, Hamburg, Germany|Nagoya City University Hospital /ID# 211155, Nagoya-shi, Aichi, Japan|Fukuoka University Hospital /ID# 211303, Fukuoka-shi, Fukuoka, Japan|Tohoku University Hospital /ID# 212214, Sendai-shi, Miyagi, Japan|University of the Ryukyus Hospital /ID# 211373, Nakagami-gun, Okinawa, Japan|Toranomon Hospital /ID# 211742, Minato-ku, Tokyo, Japan|Bravis Ziekenhuis /ID# 212536, Bergen op Zoom, Noord-Brabant, Netherlands|Amphia Ziekenhuis /ID# 212538, Breda, Netherlands|Erasmus Medisch Centrum /ID# 212535, Rotterdam, Netherlands|Hospital General Univ Alicante /ID# 212010, Alicante, Spain|Hospital Santa Creu i Sant Pau /ID# 212009, Barcelona, Spain|Hospital Parc Tauli /ID# 212015, Barcelona, Spain|Hospital Virgen de las Nieves /ID# 212014, Granada, Spain|Hospital Gregorio Maranon /ID# 212011, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 212013, Malaga, Spain|Hospital de Manises /ID# 211541, Manises, Spain",,"https://ClinicalTrials.gov/show/NCT03926169"
30,"NCT03925441","Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea","ped PsO rPMS","Completed","No Results Available","Psoriasis",,"Percentage of Participants Who Reported Any Treatment Emergent Serious Adverse Events (TESAE) OR Drug Reactions|Percentage of Participants Who Reported Any Unexpected Treatment Emergent Adverse Events OR Drug Reactions|Percentage of Participants Who Reported Any Treatment Emergent Non-Serious Adverse Event OR Drug Reaction|Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 75 From Baseline|Percentage of Participants Achieving PASI 90 From Baseline|Percentage of Participants Achieving PASI 100 From Baseline|Change in Body Surface Area (BSA) from Baseline","AbbVie","All","4 Years to 17 Years   (Child)",,"2","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P18-839","June 25, 2019","August 6, 2019","August 6, 2019","April 24, 2019",,"October 16, 2019","Ajou University Hospital /ID# 207843, Suwon-si, Gyeonggido, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03925441"
31,"NCT03924947","A Study to Compare US Marketed Pancrelipase Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis.",,"Recruiting","No Results Available","Cystic Fibrosis","Drug: Pancrelipase","Coefficient of Fat Absorption (CFA)|Stool fat|Coefficient of Nitrogen Absorption (CNA)|Stool weight","AbbVie","All","12 Years and older   (Child, Adult, Older Adult)","Phase 4","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-111|2017-000578-12","October 23, 2019","July 18, 2020","February 22, 2021","April 23, 2019",,"January 6, 2020","Usc /Id# 164571, Los Angeles, California, United States|Landon Pediatric Foundation /ID# 215411, Ventura, California, United States|Nemours Childrens Specialty Ca /ID# 164553, Jacksonville, Florida, United States|Central FL Pulmonary Orlando /ID# 164558, Orlando, Florida, United States|Children's Healthcare of Atlanta - Ferry Rd /ID# 213433, Atlanta, Georgia, United States|Chicago Pulmonary Specialists /ID# 210757, Glenview, Illinois, United States|University of Iowa Hospitals and Clinics /ID# 164551, Iowa City, Iowa, United States|Via Christi Research /ID# 214266, Wichita, Kansas, United States|Cleveland Clinic Main Campus /ID# 212853, Cleveland, Ohio, United States|Children's Hosp of PA (CHOP) /ID# 208114, Philadelphia, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 213434, Nashville, Tennessee, United States|Virginia Commonwealth Univ /ID# 164574, Richmond, Virginia, United States|Hospital Univ Vall d'Hebron /ID# 165112, Barcelona, Spain|Hosp Infantil Univ Nino Jesus /ID# 213460, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03924947"
32,"NCT03922607","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis",,"Recruiting","No Results Available","Psoriasis","Drug: ABBV-157|Drug: Placebo for ABBV-157","Substudy 1: Cmax of ABBV-157|Substudy 1: Tmax of ABBV-157|Substudy 1: AUC0-24 Post-dose of ABBV-157|Substudy 1: Trough Concentration (Ctrough) of ABBV-157|Substudy 1: AUCtau of ABBV-157|Substudy 1: Apparent Oral Clearance (CL/F)|Substudy 1: Volume of Distribution (Vβ/F)|Substudy 1: Apparent Terminal Phase Elimination Constant (β)|Substudy 1: Elimination Half-Life (t1/2)|Substudy 1: Fraction Excreted Unchanged in Urine (fe)|Substudy 1: Apparent Renal Clearance (CLR)|Substudy 1: Accumulation ratio for Cmax|Substudy 1: Accumulation Ratio for AUCtau|Substudy 2: Cmax of ABBV-157|Substudy 2: Tmax of ABBV-157|Substudy 2: AUC0-24 Post-dose of ABBV-157|Substudy 2: AUCtau of ABBV-157|Substudy 2: Apparent Oral Clearance (CL/F)|Substudy 2: Volume of Distribution (Vβ/F)|Substudy 2: Apparent Terminal Phase Elimination Constant (β)|Substudy 2: Elimination Half-Life (t1/2)|Substudy 2: Accumulation ratio for Cmax|Substudy 2: Accumulation Ratio for AUCtau|Substudy 2: Trough Concentration (Ctrough) of ABBV-157|Substudy 2: Percent Change in Psoriasis Area and Severity Index (PASI) score from Baseline|Substudy 2: Change in Self-Assessment of Psoriasis Symptoms (SAPS) Score from Baseline","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M17-238","June 11, 2019","September 15, 2020","October 13, 2020","April 22, 2019",,"November 21, 2019","Anaheim Clinical Trials LLC /ID# 213645, Anaheim, California, United States|Providence Clinical Research /ID# 213339, North Hollywood, California, United States|Acpru /Id# 213639, Grayslake, Illinois, United States|PPD PH I Clinical Unit /ID# 213062, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03922607"
33,"NCT03914261","Expanded Access to Risankizumab",,"Available","No Results Available","Crohn's Disease","Drug: Risankizumab",,"AbbVie",,"18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"C19-882",,,,"April 16, 2019",,"April 16, 2019",,,"https://ClinicalTrials.gov/show/NCT03914261"
34,"NCT03894956","Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa",,"Recruiting","No Results Available","Hidradenitis Suppurativa (HS)",,"Percentage of participants who reported any serious infections during the study|Percentage of participants who reported any adverse drug reactions (ADRs) during the study|Percentage of participants who reported any infections during the study|Percentage of participants achieving ""Improved"" of overall improvement by physician|Percentage of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR)|Change in C-Reactive Protein (CRP)|Change in Patient's global assessment of skin pain|Change in Dermatology Life Quality Index (DLQI)","AbbVie","All","up to 99 Years   (Child, Adult, Older Adult)",,"80","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P18-835","May 2, 2019","April 30, 2023","April 30, 2023","March 29, 2019",,"May 30, 2019","JA Hiroshima General Hospital /ID# 213472, Hiroshima, Japan",,"https://ClinicalTrials.gov/show/NCT03894956"
35,"NCT03893955","A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",,"Recruiting","No Results Available","Cancer|Advanced Solid Tumors|Triple-Negative Breast Cancer (TNBC)|Non-small-cell-lung-cancer (NSCLC)|Head and Neck Squamous Cell Carcinoma (HNSCC)|Metastatic Solid Tumors","Drug: ABBV-927|Drug: ABBV-368|Drug: ABBV-181|Drug: Docetaxel","Dose Expansion: Objective Response Rate (ORR)|Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368|Dose-Escalation Phase: Recommended Phase 2 Dose (RP2D) of ABBV-927 + ABBV-368 + ABBV-181|Dose-Expansion Phase: Progression-free Survival (PFS)|Dose-Expansion Phase: Duration of Response (DOR)|Maximum Serum Concentration (Cmax)|Time to Maximum Observed Serum Concentration (Tmax)|Area Under the Serum Concentration Versus Time Curve from Time 0 to the Time of the Last Measurable Concentration (AUCτ)|Terminal Phase Elimination Half-life (t1/2)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-037|2019-000478-45","May 21, 2019","May 11, 2023","November 26, 2023","March 28, 2019",,"September 30, 2019","University of Alabama at Birmingham - Main /ID# 210679, Birmingham, Alabama, United States|St Jude Hospital dba St Joseph /ID# 211130, Santa Rosa, California, United States|Yale University /ID# 210678, New Haven, Connecticut, United States|Carolina BioOncology Institute /ID# 210664, Huntersville, North Carolina, United States|Mary Crowley Cancer Research /ID# 210716, Dallas, Texas, United States|Duplicate Next Oncology /ID# 210717, San Antonio, Texas, United States|Virginia Cancer Specialists /ID# 210671, Fairfax, Virginia, United States|Gustave Roussy /ID# 213052, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 212880, Angers, France|Hopital Bichat-Claude Bernard /ID# 212869, Paris, France|Sheba Medical Center /ID# 211699, Ramat Gan, Israel|Hospital Vall d'Hebron /ID# 212804, Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 212806, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 212805, Madrid, Spain|National Cheng Kung University Hospital /ID# 210994, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 210993, Taipei City, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03893955"
36,"NCT03886220","A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women",,"Recruiting","No Results Available","Uterine Fibroids","Drug: Elagolix|Drug: Placebo","Percentage of Participants with Menstrual Blood Loss (MBL) volume < 80 mL at Final Month and >= 50% Reduction in MBL Volume from Baseline to the Final Month|Change from Baseline in MBL volume","AbbVie","Female","18 Years to 51 Years   (Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-824|2018-004357-25","April 12, 2019","August 3, 2022","September 16, 2023","March 22, 2019",,"December 19, 2019","University of Alabama at Birmingham - Women's and Infant's Center /ID# 209581, Birmingham, Alabama, United States|Unity Health- Searcy Medical Center /ID# 210905, Searcy, Arkansas, United States|Grossmont Ctr Clin Research /ID# 217690, La Mesa, California, United States|West Coast Medical Research, I /ID# 210253, San Diego, California, United States|Women's Health Care Research /ID# 211472, San Diego, California, United States|Stanford University School of Med /ID# 210594, Stanford, California, United States|CU Rocky Mountain OB-GYN /ID# 210190, Denver, Colorado, United States|ACCEL Research Sites /ID# 209714, DeLand, Florida, United States|Clinical Physiology Associates /ID# 213764, Fort Myers, Florida, United States|Caceres Specialized Gynecology /ID# 214956, Kissimmee, Florida, United States|LCC Medical Research Institute /ID# 213765, Miami, Florida, United States|University of Miami - Gynecology /ID# 213744, Miami, Florida, United States|Genoma Research Group, Inc /ID# 213771, Miami, Florida, United States|A Premier Clinical Research of Florida, LLC /ID# 214947, Orange City, Florida, United States|Comprehensive Clinical Trials /ID# 217177, West Palm Beach, Florida, United States|Georgia Research for Women /ID# 211321, Atlanta, Georgia, United States|Women's Health of Augusta /ID# 214995, Augusta, Georgia, United States|Midtown OBGYN North /ID# 209391, Columbus, Georgia, United States|Affinity Clinical Research /ID# 215252, Oak Brook, Illinois, United States|Clinical Trials Management, LLC - Covington /ID# 215020, Covington, Louisiana, United States|Southern Clinical Research A /ID# 213732, Metairie, Louisiana, United States|Johns Hopkins University /ID# 211135, Baltimore, Maryland, United States|Women's Care of Tufts Medical Center /ID# 209540, Boston, Massachusetts, United States|NECCR Fall River LLC /ID# 215009, Fall River, Massachusetts, United States|Center for Reproductive Medicine, University of Michigan /ID# 209672, Ann Arbor, Michigan, United States|Henry Ford Hospital - West Bloomfield /ID# 209652, West Bloomfield, Michigan, United States|Univ of Mississippi Med Ctr,US /ID# 213755, Jackson, Mississippi, United States|Excel Clinical Research /ID# 215936, Las Vegas, Nevada, United States|Manhattan Medical Research /ID# 213753, New York, New York, United States|Upstate Clinical Research Associates /ID# 215156, Williamsville, New York, United States|M3 Wake Research Inc. /ID# 215166, Raleigh, North Carolina, United States|Carolina Medical Trials - Winston-Salem /ID# 215027, Winston-Salem, North Carolina, United States|Wake Forest Health Sciences /ID# 210738, Winston-Salem, North Carolina, United States|Legacy Medical Group-Gynecologic Oncology /ID# 211016, Portland, Oregon, United States|Penn State Hershey Medical Ctr /ID# 209305, Hershey, Pennsylvania, United States|Clinical Research of Philadelphia, LLC /ID# 213741, Philadelphia, Pennsylvania, United States|Reading Hosp Clncl Trials Ofc /ID# 213763, West Reading, Pennsylvania, United States|Clinical Trials of SC /ID# 210204, Charleston, South Carolina, United States|Chattanooga Medical Research /ID# 215294, Chattanooga, Tennessee, United States|Adams Patterson Gyn & Obs /ID# 213756, Memphis, Tennessee, United States|Access Clinical Trials, Inc. /ID# 215357, Nashville, Tennessee, United States|ARC Clinical Research at Wilson Parke /ID# 211163, Austin, Texas, United States|Signature Gyn Services /ID# 213883, Fort Worth, Texas, United States|University of Texas (UT) Physicians Gynecological Research /ID# 215193, Houston, Texas, United States|Advances in Health, Inc. /ID# 215847, Houston, Texas, United States|FMC Science /ID# 211164, Lampasas, Texas, United States|Clinical Trials of Texas,Inc. /ID# 213768, San Antonio, Texas, United States|Discovery Clinical Trials-San Antonio /ID# 214996, San Antonio, Texas, United States|Storks Research, LLC /ID# 211146, Sugar Land, Texas, United States|Houston Ctr for Clin Research /ID# 215138, Sugar Land, Texas, United States|Seattle Women's Health, Research, Gynecology /ID# 210853, Seattle, Washington, United States|North Spokane Women's Health /ID# 209889, Spokane, Washington, United States|Emanuelli Research & Development Center LLC /ID# 212715, Arecibo, Puerto Rico|Puerto Rico Medical Research /ID# 212841, Ponce, Puerto Rico|Mindful Medical Research /ID# 212496, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03886220"
37,"NCT03875508","A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis",,"Active, not recruiting","No Results Available","Psoriasis","Drug: Risankizumab|Device: Autoinjector","Percentage of participants with an Observer rating of successful participant self-administration|Percentage of participants achieving Psoriasis Area Severity Index (PASI) 90|Percentage of participants achieving static physician global assessment (sPGA) of clear or almost clear|Percentage of participants achieving PASI 100|Percentage of participants achieving PASI 75|Percentage of participants who had no potential hazards|Participant rating of acceptability by the Self-Injection Assessment Questionnaire (SIAQ)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","108","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-005","June 4, 2019","March 2, 2020","July 5, 2020","March 14, 2019",,"October 24, 2019","UAB Department of Dermatology /ID# 210384, Birmingham, Alabama, United States|Advanced Research Associates /ID# 210634, Glendale, Arizona, United States|Cognitive Clinical Trials /ID# 210770, Scottsdale, Arizona, United States|Burke Pharmaceutical Research /ID# 211386, Hot Springs, Arkansas, United States|Bakersfield Derma & Skin Cance /ID# 210773, Bakersfield, California, United States|Encino Research Center / T. Jo /ID# 211735, Encino, California, United States|Tien Q Nguyen MD, Inc /ID# 210775, Fountain Valley, California, United States|University of California Irvine /ID# 210776, Irvine, California, United States|UC Davis, Dermatology /ID# 210411, Sacramento, California, United States|Dermatology Physicians of CT /ID# 210637, Shelton, Connecticut, United States|Florida Academic Centers Research /ID# 210337, Coral Gables, Florida, United States|Medallion Clinical Research Institute, LLC /ID# 210329, Naples, Florida, United States|Renstar Medical Research /ID# 210878, Ocala, Florida, United States|Kansas City Dermatology PA /ID# 211493, Overland Park, Kansas, United States|DermAssociates /ID# 210838, Rockville, Maryland, United States|Tufts Medical Center /ID# 210640, Boston, Massachusetts, United States|Great Lakes Research Group,Inc /ID# 210192, Bay City, Michigan, United States|Somerset Skin Centre /ID# 211596, Troy, Michigan, United States|Central Dermatology, PC /ID# 210301, Saint Louis, Missouri, United States|Northeast Dermatology Associates /ID# 211429, Dover, New Hampshire, United States|Medication Management, LLC /ID# 213217, Greensboro, North Carolina, United States|Rapid Medical Research, INC /ID# 210207, Cleveland, Ohio, United States|Oregon Medical Res Center PC /ID# 210334, Portland, Oregon, United States|University of Pittsburgh MC /ID# 210839, Pittsburgh, Pennsylvania, United States|Center for Clinical Studies /ID# 211565, Cypress, Texas, United States|Center for Clinical Studies /ID# 210362, Houston, Texas, United States|Suzanne Bruce and Associates /ID# 212210, Houston, Texas, United States|Austin Center for Clinical Research /ID# 212203, Pflugerville, Texas, United States|Premier Clinical Research /ID# 212209, Spokane, Washington, United States|Froedtert Mem Lutheran Hosp /ID# 210194, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03875508"
38,"NCT03875482","A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis",,"Active, not recruiting","No Results Available","Psoriasis","Drug: Risankizumab|Drug: Placebo","Percentage of participants achieving Psoriasis Area Severity Index (PASI) 90|Percentage of participants achieving static physician global assessment (sPGA) of clear or almost clear|Percentage of participants achieving PASI 100|Percentage of participants achieving PASI 75","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-999","May 13, 2019","April 12, 2020","April 12, 2020","March 14, 2019",,"November 29, 2019","Total Skin and Beauty Derm Ctr /ID# 210366, Birmingham, Alabama, United States|Alliance Dermatology and MOHs /ID# 210645, Phoenix, Arizona, United States|Hull Dermatology, PA /ID# 210305, Rogers, Arkansas, United States|Anaheim Clinical Trials LLC /ID# 212559, Anaheim, California, United States|Wallace Medical Group, Inc. /ID# 210403, Beverly Hills, California, United States|Dermatology Res. Assoc., CA /ID# 210402, Los Angeles, California, United States|Integrative Skin Science and Research /ID# 212551, Sacramento, California, United States|Mosaic Dermatology /ID# 210780, Santa Monica, California, United States|Skin Care Research, LLC /ID# 210514, Boca Raton, Florida, United States|ACCEL Research Sites /ID# 212709, DeLand, Florida, United States|Multi-Speciality Research Associates /ID# 211625, Lake City, Florida, United States|GSI Clinical Research, LLC /ID# 210330, Margate, Florida, United States|Suncoast Clinical Research /ID# 210874, New Port Richey, Florida, United States|Ormond Medical Arts Pharmaceutical Research Center /ID# 212781, Ormond Beach, Florida, United States|Progressive Medical Research /ID# 210877, Port Orange, Florida, United States|Precision Clinical Research /ID# 212921, Sunrise, Florida, United States|Lenus Research & Medical Group /ID# 212584, Sweetwater, Florida, United States|Treasure Valley Dermatology /ID# 212707, Boise, Idaho, United States|Sneeze, Wheeze, & Itch Associates, LLC /ID# 212562, Normal, Illinois, United States|The Indiana Clinical Trials Center /ID# 210205, Plainfield, Indiana, United States|Forefront Dermatology /ID# 210520, Louisville, Kentucky, United States|DS Research /ID# 210272, Louisville, Kentucky, United States|David Fivenson, MD, PLC /ID# 210193, Ann Arbor, Michigan, United States|Clarkston Skin Research /ID# 210197, Clarkston, Michigan, United States|Henry Ford Medical Center /ID# 211598, Detroit, Michigan, United States|Cleaver Dermatology /ID# 210300, Kirksville, Missouri, United States|Advanced Dermatology of the Midlands /ID# 212763, Omaha, Nebraska, United States|Skin Specialists, PC /ID# 211490, Omaha, Nebraska, United States|Psoriasis Treatment Ctr NJ /ID# 210837, East Windsor, New Jersey, United States|Skin Laser and Surgery Specialists /ID# 210208, Hackensack, New Jersey, United States|DermResearchCenter of NY, Inc. /ID# 210652, Stony Brook, New York, United States|Wilmington Dermatology Center /ID# 210372, Wilmington, North Carolina, United States|Lynn Health Science Institute (LHSI) /ID# 213216, Oklahoma City, Oklahoma, United States|Clinical Partners, LLC /ID# 210642, Johnston, Rhode Island, United States|Palmetto Clinical Trial Services /ID# 210368, Fountain Inn, South Carolina, United States|Coastal Carolina Research Ctr /ID# 213069, Mount Pleasant, South Carolina, United States|Arlington Research Center, Inc /ID# 210344, Arlington, Texas, United States|Center for Clinical Studies - Houston (Binz) /ID# 210361, Houston, Texas, United States|Progressive Clinical Research /ID# 210359, San Antonio, Texas, United States|Acclaim Dermatology /ID# 212252, Sugar Land, Texas, United States|Dr. Samuel Sanchez, PSC /ID# 211142, Caguas, Puerto Rico|Pan American Center for Oncology Trials, LLC /ID# 212445, Rio Piedras, Puerto Rico|Clinical Research Puerto Rico /ID# 211144, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03875482"
39,"NCT03873857","A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)|Cancer","Drug: Venetoclax","Objective Response Rate (ORR) 12 Months after Treatment Initiation|Objective Response Rate (ORR) 24 Months after Treatment Initiation|Time to First Response to Treatment|Time to Best Response to Treatment|Duration of Response (DoR)|Time To Next Treatment|Percentage of Patients with Undetectable Minimal Residual Disease (MRD)|Overall Survival (OS) Rate|Progression-free Survival (PFS)|Change from Baseline in RAND Short Form (SF)-36 Questionnaire","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"50","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-569","February 25, 2019","December 3, 2022","December 3, 2022","March 14, 2019",,"September 18, 2019","Moscow State budget healthcare institution City Clinical Hospital n.a. Botkin /ID# 212875, Moscow, Moskva, Russian Federation|Volgograd Regional Clinical Oncology Dispensary /ID# 212366, Volgograd, Volgogradskaya Oblast, Russian Federation|KGBUZ Regional Clinical Hospital № 1 named. Professor S.I. Sergeev /ID# 212367, Khabarovsk, Russian Federation|BUZ of the Oryol region ""Polyclinic № 2"" /ID# 214778, Oryol, Russian Federation|State Budgetary Health Institution ""Clinical Medical Sanitary Unit No. 1"" /ID# 212364, Perm, Russian Federation|Russian Research Institute of Hematology and Transfusiology /ID# 212372, Sankt-Peterburg, Russian Federation|St. Petersburg state medical University. Acad. I.P. Pavlova /ID# 212368, Sankt-Peterburg, Russian Federation|FGBU ""NMIC them. V.A. Almazov ""of the Ministry of Health of the Russian Federati /ID# 212365, Sankt-Peterburg, Russian Federation|Komi Republican Oncologic Dispensary /ID# 212370, Syktyvkar, Russian Federation|GBUZ City Clinical Hospital № 5 /ID# 212369, Vladimir, Russian Federation|BUZ IN ""Vologda Regional Clinical Hospital"" /ID# 212471, Vologda, Russian Federation|GAU of the Republic of Sakha (Yakutia) ""Republican hospital №1-national center o /ID# 212371, Yakutsk, Russian Federation|Sverdlovsk Regional Clinical Hospital №1 /ID# 214777, Yekaterinburg, Russian Federation|Central City Hospital №7 /ID# 212373, Yekaterinburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03873857"
40,"NCT03873493","A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia",,"Recruiting","No Results Available","Leukemia|T-cell Prolymphocytic Leukemia (T-PLL)|Cancer","Drug: Venetoclax|Drug: Ibrutinib","Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Duration of Response (DOR)|Overall Survival (OS) Rate|Number of Participants Reaching Autologous or Allogeneic Transplantation|Event-free Survival (EFS)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M18-803|2018-002179-17","November 1, 2019","September 21, 2022","January 3, 2024","March 13, 2019",,"November 6, 2019","Dana-Farber Cancer Institute /ID# 207728, Boston, Massachusetts, United States|Mayo Clinic - Rochester /ID# 207692, Rochester, Minnesota, United States|University of Texas MD Anderson Cancer Center /ID# 207746, Houston, Texas, United States|Peter MacCallum Cancer Ctr /ID# 209554, Melbourne, Victoria, Australia|Medizinische Universität Wien /ID# 208497, Vienna, Wien, Austria|Helsinki University Hospital /ID# 208108, Helsinki, Uusimaa, Finland|Centre Hospitalier Lyon Sud /ID# 208731, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHRU Lille - Hôpital Claude Huriez /ID# 208726, Lille CEDEX, Hauts-de-France, France|Hopital Pitie Salpetriere /ID# 208730, Paris, France|University Hospital Cologne /ID# 208834, Cologne, Germany|Azienda Policlinico Umberto I /ID# 212254, Roma, Italy|Azienda Sanitaria Universitaria Integrata di Trieste Ospedale Maggiore /ID# 211487, Trieste, Italy|Maxima Medisch Centrum /ID# 207989, Eindhoven, Netherlands|Universitair Medisch Centrum Groningen /ID# 207990, Groningen, Netherlands|St. James University Hospital /ID# 211265, Leeds, United Kingdom|Royal Marsden Hospital /ID# 211263, London, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 211264, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03873493"
41,"NCT03868163","Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation","EVEREST","Recruiting","No Results Available","Chronic Hepatitis C (CHC)",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants Achieving SVR12 by Mono HCV or co-infected HCV/HIV Status|Percentage of Participants Achieving SVR12 by CHC Genotype|Percentage of Participants Achieving SVR12 by Cirrhosis Status|Percentage of Participants Achieving SVR12 by Previous Treatment Experience|Percentage of Participants Achieving SVR12 by Patients Who Use Drugs|Percentage of Elderly Participants Achieving SVR12|Percentage of Patients with Commodities|Percentage of Participants Taking Concomitant Medications|Percentage of GLE/PIB Dose Taken|Number of Health Care Resource Utilization (HCRU)","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"161","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-454","February 28, 2019","March 15, 2020","March 15, 2020","March 8, 2019",,"June 28, 2019","South Ural State Medical univ /ID# 212020, Chelyabinsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03868163"
42,"NCT03859869","A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)",,"Not yet recruiting","No Results Available","Exocrine Pancreatic Insufficiency (EPI)","Drug: Pancrelipase|Drug: Placebo","Change in stool fat for Resected Dose A and Resected Dose B|Difference between Resected Dose A and Resected Dose B in change from baseline in stool fat|Stool frequency from baseline for Resected Dose A and Resected Dose B|Difference between Resected Dose A and Resected Dose B in change from baseline in stool frequency|Stool consistency from baseline for Resected Dose A and Resected Dose B|Difference between Resected Dose A and Resected Dose B in change from baseline in stool consistency|Exocrine pancreatic insufficiency (EPI) symptoms from baseline for Resected Dose A and Resected Dose B|Difference between Resected Dose A and Resected Dose B in change from baseline in EPI symptoms|European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) questionnaire from baseline for Resected Dose A and Resected Dose B|Difference between Resected Dose A and Resected Dose B in change in EORTC QOL questionnaire|Body weight from baseline for Resected Dose A and Resected Dose B|Body mass index (BMI) from baseline for Resected Dose A and Resected Dose B|Chemotherapy tolerability|Serum albumin from baseline for Resected Dose A and Resected Dose B|Serum pre-albumin from baseline for Resected Dose A and Resected Dose B","AbbVie","All","21 Years and older   (Adult, Older Adult)","Phase 4","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-142","February 13, 2020","February 20, 2020","July 24, 2022","March 1, 2019",,"December 19, 2019","Alabama Oncology /ID# 207770, Mountain Brook, Alabama, United States|Banner University MC Phoenix /ID# 208402, Phoenix, Arizona, United States|University of Arizona Arthritis Center /ID# 204333, Tucson, Arizona, United States|UCSD Moores Cancer Center - LaJolla /ID# 202678, La Jolla, California, United States|Stanford University School of Med /ID# 208821, Stanford, California, United States|MedStar Georgetown University Hospital /ID# 203363, Washington, District of Columbia, United States|University of Florida - Archer /ID# 202679, Gainesville, Florida, United States|IACT Health /ID# 211394, Columbus, Georgia, United States|Northwest Community Hospital /ID# 202270, Arlington Heights, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 209026, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 203962, Harvey, Illinois, United States|Advocate Christ Medical Center /ID# 203132, Oak Lawn, Illinois, United States|University of Michigan Hospitals /ID# 204407, Ann Arbor, Michigan, United States|Ascension Providence Hospital /ID# 203449, Southfield, Michigan, United States|Saint Louis University School of Medicine /ID# 205769, Saint Louis, Missouri, United States|NYU Langone Winthrop Hospital /ID# 207513, Mineola, New York, United States|Northwell-Long Island Jewish Medical Ctr /ID# 207321, New Hyde Park, New York, United States|New York University Langone Me /ID# 202290, New York, New York, United States|Columbia University Medical Center /ID# 204165, New York, New York, United States|East Carolina University /ID# 206661, Greenville, North Carolina, United States|Gabrail Cancer Center Research /ID# 208030, Canton, Ohio, United States|Ohio State Cancer Center /ID# 203131, Columbus, Ohio, United States|Fox Chase Cancer Center /ID# 202288, Philadelphia, Pennsylvania, United States|Allegheny Center Digestive Health /ID# 202291, Pittsburgh, Pennsylvania, United States|Reading Hospital /ID# 206869, Reading, Pennsylvania, United States|Musc /Id# 210727, Charleston, South Carolina, United States|Tennessee Cancer Specialists /ID# 208235, Knoxville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 204231, Nashville, Tennessee, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 206156, Dallas, Texas, United States|UT MD Anderson Cancer Center /ID# 202271, Houston, Texas, United States|WI Center for Advanced Res /ID# 205746, Milwaukee, Wisconsin, United States|Medical College of Wisconsin /ID# 205714, Milwaukee, Wisconsin, United States|Emanuelli Research & Development Center LLC /ID# 207097, Arecibo, Puerto Rico|Auxilio Mutuo Cancer Center /ID# 203129, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03859869"
43,"NCT03844048","An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial",,"Enrolling by invitation","No Results Available","Chronic Lymphocytic Leukemia|Acute Myeloid Leukemia|Multiple Myeloma|Non-Hodgkin's Lymphoma|Acute Lymphoblastic Leukemia|Cancer","Drug: Venetoclax","Number of Participants With Adverse Events","AbbVie","All","Child, Adult, Older Adult","Phase 3","550","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-388","August 29, 2019","December 21, 2024","May 27, 2025","February 18, 2019",,"October 31, 2019","University of Arizona Cancer Center - North Campus /ID# 210548, Tucson, Arizona, United States|UCLA Santa Monica Hematology Oncology /ID# 210551, Los Angeles, California, United States|Ingalls Memorial Hosp /ID# 210553, Harvey, Illinois, United States|Dana-Farber Cancer Institute /ID# 215360, Boston, Massachusetts, United States|Henry Ford Health System /ID# 210557, Detroit, Michigan, United States|Dartmouth-Hitchock Med Ctr /ID# 210555, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Cancer Center /ID# 210549, New York, New York, United States|Clinical Research Trials (CRT) /ID# 212061, Canton, Ohio, United States|Swedish Cancer Institute /ID# 213120, Seattle, Washington, United States|Peter MacCallum Cancer Ctr /ID# 210559, Melbourne, Victoria, Australia|Centre Hospitalier Lyon Sud /ID# 213508, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHRU Lille - Hôpital Claude Huriez /ID# 213509, Lille CEDEX, Hauts-de-France, France",,"https://ClinicalTrials.gov/show/NCT03844048"
44,"NCT03823391","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis",,"Recruiting","No Results Available","Rheumatoid Arthritis (RA)","Drug: ABBV-3373|Drug: Placebo for ABBV-3373|Drug: Adalimumab|Drug: Placebo for adalimumab","Change in disease activity score (DAS) 28 (C-reactive protein [CRP]) from Baseline (BL) for ABBV-3373 and adalimumab|Change in clinical disease activity index (CDAI) from BL for ABBV-3373 and adalimumab|Change in simplified disease activity index (SDAI) from BL for ABBV-3373 and adalimumab|Change in DAS (28 joints) (DAS28) erythrocyte sedimentation rate (ESR) from BL for ABBV-3373 and adalimumab|Percentage of participants achieving a low disease activity (LDA) for ABBV-3373 and adalimumab|Percentage of participants achieving American College of Rheumatology (ACR) 50 for ABBV-3373 and adalimumab","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-560|2018-003053-21","March 27, 2019","December 29, 2020","June 2, 2021","January 30, 2019",,"December 11, 2019","Rheum Assoc of North Alabama /ID# 213626, Huntsville, Alabama, United States|AZ Arthritis and Rheum Researc /ID# 208515, Phoenix, Arizona, United States|C.V. Mehta MD, Med Corporation /ID# 213068, Hemet, California, United States|Robin K. Dore MD, Inc /ID# 213045, Tustin, California, United States|Inland Rheum & Osteo Med Grp /ID# 213044, Upland, California, United States|Suncoast Clinical Research /ID# 213973, New Port Richey, Florida, United States|Arthritis Center, Inc. /ID# 213972, Palm Harbor, Florida, United States|W. Broward Rheum Assoc Inc. /ID# 211017, Tamarac, Florida, United States|BayCare Medical Group, Inc. /ID# 213935, Tampa, Florida, United States|Institute of Arthritis Researc /ID# 213043, Idaho Falls, Idaho, United States|Captain James A. Lovell Federal Health Care Center /ID# 214701, North Chicago, Illinois, United States|OrthoIllinois /ID# 215448, Rockford, Illinois, United States|PRN Professional Research Network of Kansas, LLC /ID# 213046, Wichita, Kansas, United States|The Center for Rheumatology and Bone Research /ID# 213921, Wheaton, Maryland, United States|Clinvest Research LLC /ID# 215451, Springfield, Missouri, United States|Joint & Muscle Research Instit /ID# 215453, Charlotte, North Carolina, United States|Duke Early Phase Research Unit (DCRI) /ID# 213212, Durham, North Carolina, United States|STAT Research, Inc. /ID# 213933, Dayton, Ohio, United States|Paramount Medical Research Con /ID# 209042, Middleburg Heights, Ohio, United States|West Tennessee Research Inst /ID# 208838, Jackson, Tennessee, United States|PCCR Solution /ID# 215457, Colleyville, Texas, United States|Trinity Universal Research Association /ID# 209167, Plano, Texas, United States|Charite Research Organisation GmbH /ID# 210216, Berlin, Germany|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 210055, Miskolc, Borsod-Abauj-Zemplen, Hungary|DRC Gyogyszervizsgalo Kozpont Kft. /ID# 210159, Balatonfüred, Veszprem, Hungary|Budai Irgalmasrendi Korhaz /ID# 208877, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 210164, Debrecen, Hungary|Rambam Health Care Campus /ID# 212747, Haifa, Israel|Sheba Medical Center /ID# 211339, Ramat Gan, Israel|Academisch Medisch Centrum /ID# 209303, Amsterdam, Noord-Holland, Netherlands|SANUS Szpital Specjalistyczny /ID# 209022, Stalowa Wola, Poland|Reumatika - Centrum Reumatologii NZOZ /ID# 209220, Warsaw, Poland|GCM Medical Group, PSC /ID# 208154, San Juan, Puerto Rico|Mindful Medical Research /ID# 208403, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03823391"
45,"NCT03823378","A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib.",,"Enrolling by invitation","No Results Available","Rheumatoid Arthritis (RA)","Drug: Upadacitinib|Drug: Upadacitinib placebo|Drug: ABBV-105 placebo|Drug: ABBV-105","Change in Disease Activity Score (DAS) 28 (C-reactive protein (CRP)) from baseline of Study M16-063|Percentage of participants achieving DAS Low Disease Activity (LDA)|Percentage of participants achieving DAS Clinical Remission (CR)|American College of Rheumatology (ACR) 20 response rate|American College of Rheumatology (ACR) 50 response rate|American College of Rheumatology (ACR) 70 response rate|Change in swollen joint count (SJC) from baseline of Study M16-063|Change in morning fitness from baseline of Study M16-063|Adverse Events (AEs)|Change in tender joint count (TJC) from baseline of Study M16-063|Change in Patient's Assessment of Pain from baseline of Study M16-063|Change in Patient Global Assessment of Disease Activity (PtGA) from baseline of Study M16-063|Change in Physician Global Assessment of Disease Activity (PhGA) from baseline of Study M16-063|Change in Health Assessment Questionnaire Disability Index (HAQ-DI) from baseline of Study M16-063|Change in high-sensitivity C-reactive protein (hs-CRP) from baseline of Study M16-063","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-763|2018-002306-31","May 13, 2019","December 15, 2020","December 15, 2020","January 30, 2019",,"May 21, 2019","CUB Hospital Erasme /ID# 207720, Brussels, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 207719, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 207721, Gent, Oost-Vlaanderen, Belgium|ReumaClinic Genk /ID# 212833, Genk, Belgium|UZ Leuven /ID# 207722, Leuven, Belgium|Rheumatology Research Assoc /ID# 207769, Edmonton, Alberta, Canada|Manitoba Clinic /ID# 206852, Winnipeg, Manitoba, Canada|CIADS Research Co Ltd /ID# 206853, Winnipeg, Manitoba, Canada|Mount Sinai Hosp.-Toronto /ID# 206851, Toronto, Ontario, Canada|Revmatolog s.r.o. /ID# 209941, Jihlava 1, Jihlava, Czechia|Revmatologicky ustav Praha /ID# 209943, Prague 2, Praha 2, Czechia|Revmatologie MUDr. Klara Sirov /ID# 209944, Ostrava, Czechia|CCR Czech a.s /ID# 209942, Pardubice, Czechia|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 208186, Miskolc, Borsod-Abauj-Zemplen, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház /ID# 208184, Nyíregyháza, Szabolcs-Szatmar-Bereg, Hungary|Vital Medical Center Orvosi es /ID# 208185, Veszprém, Veszprem, Hungary|Revita Reumatologiai Rendelo /ID# 208187, Budapest, Hungary|C-MED/CMED Rehabilitációsközpont /ID# 208188, Szekesfehervar, Hungary|Malopolskie Centrum Kliniczne /ID# 209902, Cracow, Malopolskie, Poland|NBR Polska /ID# 209904, Warsaw, Mazowieckie, Poland|Reumatika - Centrum Reumatologii NZOZ /ID# 209903, Warsaw, Poland|H. Un. Marques de Valdecilla /ID# 207729, Santander, Cantabria, Spain|H.U. Clinico San Carlos /ID# 207738, Madrid, Madrid, Comunidad De, Spain|Hospital Regional de Malaga /ID# 207735, Málaga, Malaga, Spain|Comple Hosp Univ de A Coruna /ID# 207732, A Coruna, Spain|Hospital Santa Creu i Sant Pau /ID# 207734, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 207740, Barcelona, Spain|Hospital Universitario Basurto /ID# 207737, Bilbao, Spain|Hospital Virgen Nieves /ID# 209975, Granada, Spain|Hospital Universitario La Fe /ID# 207739, Valencia, Spain|Royal Victoria Infirmary, Newc /ID# 210572, Newcastle Upon Tyne, United Kingdom|University of Oxford /ID# 210571, Oxford, United Kingdom|Warrington + Halton Hosp NHS /ID# 210570, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03823378"
46,"NCT03821935","Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-151|Drug: ABBV-181","Dose Escalation: Recommended Phase 2 Dose (RP2D) ABBV-151 Monotherapy|Dose Escalation: RP2D ABBV-151 + ABBV-181 Combination Therapy|Dose Expansion: Objective Response Rate (ORR)|Dose Expansion: Duration of Response (DOR)|Dose Expansion: Progression-free Survival (PFS)|Maximum Observed Serum Concentration (Cmax)|Time to Maximum Observed Serum Concentration (Tmax)|Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ)|Terminal-phase Elimination Rate Constant (β)|Terminal Phase Elimination Half-life (t1/2)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","184","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-345|2018-004303-40","February 21, 2019","July 14, 2022","July 14, 2022","January 30, 2019",,"November 13, 2019","Yale University /ID# 208356, New Haven, Connecticut, United States|Indiana Univ School Medicine /ID# 208384, Indianapolis, Indiana, United States|Carolina BioOncology Institute /ID# 208358, Huntersville, North Carolina, United States|NEXT Oncology /ID# 208930, San Antonio, Texas, United States|Chris O'Brien Lifehouse /ID# 213236, Camperdown, New South Wales, Australia|Princess Margaret Cancer Centre /ID# 209423, Toronto, Ontario, Canada|Sheba Medical Center /ID# 209037, Ramat Gan, Israel|National Cancer Center Hospital /ID# 209421, Chuo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03821935"
47,"NCT03818542","A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma",,"Recruiting","No Results Available","Head and Neck Cancer","Drug: ABBV-181|Drug: ABBV-368|Drug: ABBV-927","Changes in Gene Expression|Maximum Serum Concentration (Cmax) of Study Drug|Time to Maximum Plasma Concentration (Tmax) of Study Drug|Area Under the Plasma Concentration-time Curve of Study Drug in Plasma","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","104","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M19-228","October 25, 2019","March 1, 2021","April 14, 2021","January 28, 2019",,"November 1, 2019","AdventHealth Research Institute at Celebration /ID# 213926, Celebration, Florida, United States|Massachusetts General Hospital /ID# 207392, Boston, Massachusetts, United States|University of Michigan /ID# 210181, Ann Arbor, Michigan, United States|Oregon Health and Science University /ID# 207531, Portland, Oregon, United States|MD Anderson Cancer Center /ID# 208749, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03818542"
48,"NCT03797261","A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies",,"Suspended","No Results Available","Acute Myeloid Leukemia|Non-Hodgkin's Lymphoma|Diffuse Large B-cell Lymphoma","Drug: Venetoclax|Drug: AMG 176","Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RPTD) for Venetoclax + AMG 176|Number of Participants With Adverse Events|Composite Complete Remission Rate (CRc) for Participants with AML|Objective Response Rate (ORR) for Participants with AML|ORR for Participants with NHL|Maximum Plasma Concentration (Cmax) of Venetoclax|Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax|AUC of Venetoclax|Maximum Plasma Concentration (Cmax) of AMG 176|Half-life (t1/2) of AMG 176|AUC of AMG 176|Clearance (CL) of AMG 176","AbbVie|Genentech, Inc.|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 1","86","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-785|2018-003314-41","March 15, 2019","September 2, 2022","September 2, 2022","January 9, 2019",,"October 1, 2019","City of Hope /ID# 207393, Duarte, California, United States|USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States|Miami Cancer Institute - Baptist Health South Florida /ID# 209825, Miami, Florida, United States|University of Iowa Hospitals and Clinics /ID# 207459, Iowa City, Iowa, United States|Univ Kansas Med Ctr /ID# 207480, Kansas City, Kansas, United States|Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 206995, Saint Louis, Missouri, United States|NYU Langone Medical Center /ID# 207390, New York, New York, United States|Unc /Id# 207388, Chapel Hill, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208482, Pittsburgh, Pennsylvania, United States|Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia|Royal Adelaide Hospital /ID# 210602, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210601, Fitzroy, Victoria, Australia|Alfred Hospital /ID# 210350, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 210599, Melbourne, Victoria, Australia|Universitaetsklinikum Leipzig /ID# 209824, Leipzig, Sachsen, Germany|Charite Universitatsmedizin B- /ID# 207987, Berlin, Germany|Universitaetklinikum Dresden /ID# 207803, Dresden, Germany|Universitaetsklinikum Frankfurt /ID# 207984, Frankfurt, Germany|Univ Klinik Eppendorf Hamburg /ID# 207788, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT03797261"
49,"NCT03785184","A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy",,"Withdrawn","No Results Available","Multiple Myeloma","Drug: venetoclax|Drug: lenalidomide|Drug: dexamethasone","Percentage of Participates Who Achieve CR|Percent of Participants Who Achieve MRD Negativity|Percent of Participants Who Achieve VGPR or Better|Overall Response Rate (ORR)|Time to Response (TTR)|Duration of response (DOR)|Progression-free Survival (PFS)|Minimal Residual Disease (MRD) Negativity Rate at 12 Months|Time to Disease Progression (TTP)|Time to Next Treatment (TTNT)|Overall Survival (OS) Rate","AbbVie|Genentech, Inc.|Celgene Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-104","April 29, 2019","August 22, 2019","August 22, 2019","December 24, 2018",,"August 28, 2019","City of Hope /ID# 212211, Duarte, California, United States|Marin Cancer Care /ID# 208476, Greenbrae, California, United States|University of California, Los Angeles /ID# 208516, Los Angeles, California, United States|Karmanos Cancer Institute /ID# 208805, Detroit, Michigan, United States|Henry Ford Hospital /ID# 208481, Detroit, Michigan, United States|Duke University Hospital /ID# 208306, Durham, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208121, Pittsburgh, Pennsylvania, United States|Westmead Hospital /ID# 210267, Westmead, New South Wales, Australia|Flinders Centre for Innovation /ID# 210697, Bedford Park, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia|Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia|Monash Medical Centre /ID# 210269, Melbourne, Victoria, Australia|Tom Baker Cancer Centre /ID# 208549, Calgary, Alberta, Canada|Princess Margaret Cancer Centr /ID# 208923, Toronto, Ontario, Canada|Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada|McGill Univ HC /ID# 208486, Montreal, Quebec, Canada|Clinica Universitar de Navarra - Pamplona /ID# 209883, Pamplona, Navarra, Comunidad, Spain|Hospital Clinic de Barcelona /ID# 209888, Barcelona, Spain|Hspital Universitario Gregorio Maranon /ID# 209926, Madrid, Spain|Clinica Universitar de Navarra - Madrid /ID# 210131, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 209887, Madrid, Spain|Hospital Univ Dr. Peset /ID# 209884, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03785184"
50,"NCT03781167","A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)",,"Recruiting","No Results Available","Parkinson's Disease (PD)","Drug: ABBV-951","Adverse Events|Adverse Events of Special Interest|Percentage of subjects with numeric grade equal to or higher than 5 and with letter grade equal to or higher than D on the Infusion Site Evaluation Scale|Hematocrit (Hematology): Change from Baseline to end of study|Hemoglobin (Hematology): Change from Baseline to end of study|Red Blood Cell (RBC) Count (Hematology): Change from Baseline to end of study|White blood cell (WBC) count (Hematology): Change from Baseline to end of study|Neutrophils (Hematology): Change from Baseline to end of study|Lymphocytes (Hematology): Change from Baseline to end of study|Monocytes (Hematology): Change from Baseline to end of study|Absolute platelet count (Hematology): Change from Baseline to end of study|Mean corpuscular hemoglobin (Hematology): Change from Baseline to end of study|Mean corpuscular volume concentration (MCHC) (Hematology): Change from Baseline to end of study|Prothrombin time (PT) (Hematology): Change from Baseline to end of study|Activated partial thromboplastin time (Hematology): Change from Baseline to end of study|Blood urea nitrogen (BUN) (Clinical Chemistry): Change from Baseline to end of study|Creatinine (Clinical Chemistry): Change from Baseline to end of study|Creatine phosphokinase (Clinical Chemistry): Change from Baseline to end of study|Total bilirubin (Clinical Chemistry): Change from Baseline to end of study|Serum glutamic pyruvic transaminase (Clinical Chemistry): Change from Baseline to end of study|Serum glutamic-oxaloacetic transaminase (Clinical Chemistry): Change from Baseline to end of study|Lactate dehydrogenase (LDH) (Clinical Chemistry): Change from Baseline to end of study|Gamma-glutamyl transpeptidase (Clinical Chemistry): Change from Baseline to end of study|Alkaline phosphatase (Clinical Chemistry): Change from Baseline to end of study|Sodium (Clinical Chemistry): Change from Baseline to end of study|Potassium (Clinical Chemistry): Change from Baseline to end of study|Calcium (Clinical Chemistry): Change from Baseline to end of study|Inorganic phosphorus (Clinical Chemistry): Change from Baseline to end of study|Uric acid (Clinical Chemistry): Change from Baseline to end of study|Cholesterol (Clinical Chemistry): Change from Baseline to end of study|Albumin (Clinical Chemistry): Change from Baseline to end of study|Glucose (Clinical Chemistry): Change from Baseline to end of study|Sodium bicarbonate/CO2 (Clinical Chemistry): Change from Baseline to end of study|Magnesium (Clinical Chemistry): Change from Baseline to end of study|Creatinine clearance (Clinical Chemistry): Change from Baseline to end of study|Vitamin B6 (Clinical Chemistry): Change from Baseline to end of study|Vitamin B12 (Clinical Chemistry): Change from Baseline to end of study|Homocysteine (Clinical Chemistry): Change from Baseline to end of study|Specific gravity (Urinalysis): Change from Baseline to end of study|Ketones (Urinalysis): Change from Baseline to end of study|pH (Urinalysis): Change from Baseline to end of study|Protein (Urinalysis): Change from Baseline to end of study|Glucose (Urinalysis): Change from Baseline to end of study|Blood (Urinalysis): Change from Baseline to end of study|Bilirubin (Urinalysis): Change from Baseline to end of study|Blood pressure (Vital Signs): Change from Baseline to end of study|Pulse rate (Vital Signs): Change from Baseline to end of study|Percentage of Participants with Abnormal Electrocardiogram (ECG) Results|Average normalized daily ""Off"" time and ""On"" times: Change from Baseline to end of study|Parkinson's Disease (PD) symptoms: Change from Baseline to end of study|Quality of Life Assessed by the Parkinson's Disease Questionnaire-39 Items (PDQ-39): Change from Baseline to end of study|Sleep symptoms as assessed by the Parkinson's Disease Sleep Scale-2 (PDSS-2): Change from Baseline to end of study|Quality of Life Assessed by EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Index Score: Change from Baseline to End of Study","AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","130","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-741|2018-002144-85","April 29, 2019","March 1, 2021","March 1, 2021","December 19, 2018",,"December 27, 2019","University of Alabama at Birmingham - Main /ID# 207996, Birmingham, Alabama, United States|Banner Sun Health Res Inst /ID# 208811, Sun City, Arizona, United States|Parkinson's and Movement /ID# 216126, Fountain Valley, California, United States|University of Colorado Hosp /ID# 207968, Aurora, Colorado, United States|Parkinson's Disease and Moveme /ID# 207677, Boca Raton, Florida, United States|Renstar Medical Research /ID# 216602, Ocala, Florida, United States|Northwestern University Feinberg School of Medicine /ID# 208812, Chicago, Illinois, United States|Indiana Clinical Research Cent /ID# 207952, Indianapolis, Indiana, United States|Univ Kansas Med Ctr /ID# 208963, Kansas City, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 207603, Lexington, Kentucky, United States|Massachusetts General Hospital /ID# 207993, Boston, Massachusetts, United States|Health Partners /ID# 207950, Saint Paul, Minnesota, United States|University of Missouri /ID# 209043, Columbia, Missouri, United States|Washington University-School of Medicine /ID# 207525, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Med Ctr /ID# 207972, Lebanon, New Hampshire, United States|Wake Research Associates, LLC /ID# 209784, Raleigh, North Carolina, United States|Legacy Research Institute /ID# 208031, Portland, Oregon, United States|Greenville Health System /ID# 207650, Greenville, South Carolina, United States|Neurology Consultants of Dallas - LBJ Fwy /ID# 207619, Dallas, Texas, United States|Baylor College of Medicine /ID# 207620, Houston, Texas, United States|Central Texas Neurology Consul /ID# 216918, Round Rock, Texas, United States|Univ Texas HSC San Antonio /ID# 208958, San Antonio, Texas, United States|Evergreen Neuroscience Institute /ID# 208026, Kirkland, Washington, United States|Inland Northwest Research /ID# 208122, Spokane, Washington, United States|Medical College of Wisconsin /ID# 207999, Milwaukee, Wisconsin, United States|Concord Repatriation & Gen Hos /ID# 207628, Concord, New South Wales, Australia|Westmead Hospital /ID# 207633, Westmead, New South Wales, Australia|Royal Adelaide Hospital /ID# 207634, Adelaide, South Australia, Australia|Alfred Hospital /ID# 207632, Melbourne, Victoria, Australia|Perron Institute /ID# 207627, Nedlands, Western Australia, Australia|AZ Sint Jan Brugge /ID# 208178, Brugge, Belgium|UZ Leuven /ID# 209058, Leuven, Belgium|CHC Liege /ID# 208177, Liege, Belgium|University of Calgary /ID# 207342, Calgary, Alberta, Canada|True North Clinical Research /ID# 212850, Halifax, Nova Scotia, Canada|Toronto Western Hospital /ID# 207337, Toronto, Ontario, Canada|Crchum /Id# 209390, Montreal, Quebec, Canada|Ctr Hosp Enfant Jesus /ID# 207343, Quebec City, Quebec, Canada|Centre de Recherche St-Louis /ID# 207344, Quebec, Canada|Bispebjerg Hospital /ID# 207669, Copenhagen NV, Hovedstaden, Denmark|Aarhus University Hospital /ID# 207668, Aarhus N, Midtjylland, Denmark|Odense University Hospital /ID# 207871, Odense C, Syddanmark, Denmark|Universitaetsklinikum Ulm /ID# 208602, Ulm, Thueringen, Germany|Kliniken Beelitz GmbH /ID# 208600, Beelitz-heilstaetten, Germany|Klinik Haag /ID# 208601, Haag, Germany|IRCCS Centro Neurolesi Bonino Pulejo /ID# 207975, Messina, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 207955, Milan, Italy|Azienda Ospedaliera di Padova /ID# 208077, Padua, Italy|National Hospital Organization Asahikawa Medical Center /ID# 210914, Asahikawa, Hokkaido, Japan|National Hospital Organization Utano National Hospital /ID# 210912, Kyoto City, Kyoto, Japan|Osaka University Hospital /ID# 210913, Suita-shi, Osaka, Japan|Juntendo University Hospital /ID# 210915, Bunkyo-ku, Tokyo, Japan|National Center of Neurology and Psychiatry /ID# 210911, Kodaira, Tokyo, Japan|St. Antonius Ziekenhuis /ID# 208529, Nieuwegein, Netherlands|Erasmus Medisch Centrum /ID# 208168, Rotterdam, Netherlands|State Inst Neurology RAMS /ID# 216299, Moscow, Russian Federation|St. Petersburg State Medical U /ID# 216303, St. Petersburg, Russian Federation|City Clinical Hospital #40 /ID# 216301, St. Petersburg, Russian Federation|Hospital Universitario de Bellvitge /ID# 209539, L'Hospitalet de Llobregat, Barcelona, Spain|Comple Hosp Univ de A Coruna /ID# 212147, A Coruna, Spain|Hospital Santa Creu i Sant Pau /ID# 208240, Barcelona, Spain|Hospital General Univ de Elche /ID# 209777, Elche, Spain|Hospital Virgen Nieves /ID# 208242, Granada, Spain|Hospital Univ Ramon y Cajal /ID# 208241, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 208239, Sevilla, Spain|Skane University Hospital Lund /ID# 207811, Lund, Skane Lan, Sweden|Sahlgrenska universitetssjukhuset /ID# 207718, Göteborg, Vastra Gotalands Lan, Sweden|Centrum for neurologi /ID# 207716, Stockholm, Sweden|NHS Tayside /ID# 209242, Dundee, Scotland, United Kingdom|King's College Hospital NHS /ID# 208413, London, United Kingdom|Plymouth Hospitals NHS Trust /ID# 208447, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03781167"
51,"NCT03744546","Expanded Access to ABBV-8E12",,"No longer available","No Results Available","Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)","Drug: ABBV-8E12",,"AbbVie",,"40 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"C19-364|C19-921",,,,"November 16, 2018",,"August 20, 2019",,,"https://ClinicalTrials.gov/show/NCT03744546"
52,"NCT03740230","An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs","Maviret PMS","Recruiting","No Results Available","Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","12 Years and older   (Child, Adult, Older Adult)",,"2790","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-423","September 26, 2018","September 30, 2021","September 30, 2021","November 14, 2018",,"November 13, 2019","Dong-A University Hospital /ID# 209450, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 209813, Busan, Busan Gwang Yeogsi, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital /ID# 209996, Cheonan, Chungcheongnamdo, Korea, Republic of|Kyungpook National Univ Hosp /ID# 209294, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 209293, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Chungnam National University Hospital /ID# 209637, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Hallym University Sacred Heart Hospital /ID# 210809, Anyang-si, Gyeonggi-do, Gyeonggido, Korea, Republic of|Soon Chun Hyang University Hospital Bucheon /ID# 210618, Buncheon, Gyeonggido, Korea, Republic of|National health insurance cooperation ilsan hospital /ID# 209997, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 210616, Seongnam, Gyeonggido, Korea, Republic of|Ajou University Hospital /ID# 209995, Suwon-si, Gyeonggido, Korea, Republic of|Inje University Busan Paik Hospital /ID# 209992, Busan, Gyeongsangbugdo, Korea, Republic of|Pusan Nat Univ Yangsan Hosp /ID# 214960, Yangsan-si,, Gyeongsangnamdo, Korea, Republic of|Gachon University Gil Medical Center /ID# 212513, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Inha University Hospital /ID# 210617, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Wonkwang University Hospital /ID# 210620, Iksan, Jeonrabugdo, Korea, Republic of|Kwangju Christian Hospital /ID# 210623, Gwangju, Jeonranamdo, Korea, Republic of|Kyungpook National University Chilgok Hospital /ID# 209988, Daegu, Seoul Teugbyeolsi, Korea, Republic of|SMG-SNU Boramae Medical Center /ID# 210610, Dongjak-gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 209636, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Gangnam Severance Hospital /ID# 212512, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 209296, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 209635, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Guro Hospital /ID# 209989, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Ewha Womans University Seoul Hospital /Id# 214961, 강서구, Seoul Teugbyeolsi, Korea, Republic of|Bucheon St. Mary's hospital /ID# 216869, Bucheon, Korea, Republic of|Dongnam Institute of Radiologi /ID# 209991, Busan, Korea, Republic of|Good Samsun Hospital /ID# 209291, Busan, Korea, Republic of|Haeundae Paik Hospital /ID# 209993, Busan, Korea, Republic of|Maryknoll Medical Center /ID# 210957, Busan, Korea, Republic of|Kosin University Gospel Hosp /ID# 210608, Busan, Korea, Republic of|Samsung Changwon Hospital /ID# 211507, Changwon, Korea, Republic of|Samsung Changwon Hospital /ID# 211743, Changwon, Korea, Republic of|Dankook University Hospital /ID# 209297, Cheonan, Korea, Republic of|Chuncheon Sacred Heart Hosp /ID# 210612, Chuncheon, Korea, Republic of|Kim Jun Hwan Sok Internal Medi /ID# 209292, Daegu, Korea, Republic of|Keimyung Univ Dongsan medical /ID# 212144, Daegu, Korea, Republic of|Keimyung Univ Dongsan medical /ID# 212514, Daegu, Korea, Republic of|Dongguk University Ilsan Hosp /ID# 210609, Goyang, Korea, Republic of|Myongji Hospital /ID# 215595, Goyang, Korea, Republic of|CHA Gumi Medical Center /ID# 209994, Gumi, Korea, Republic of|Chosun University Hospital /ID# 210607, Gwangju, Korea, Republic of|Jeju National University Hospi /ID# 214700, Jeju, Korea, Republic of|Chonnam National University Hwasun Hospital /ID# 209990, Jeonnam, Korea, Republic of|Korea University Anam Hospital /ID# 210958, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 210959, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 211365, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 211369, Seoul, Korea, Republic of|Asan Medical Center /ID# 210622, Seoul, Korea, Republic of|Chung-Ang University Hostipal /ID# 209295, Seoul, Korea, Republic of|Ewha Womans University Mokdong /ID# 216412, Seoul, Korea, Republic of|National Medical Center /ID# 209911, Seoul, Korea, Republic of|Hallym Univ Kangdong Sacred /ID# 210621, Seoul, Korea, Republic of|Inje University Sanggye Paik H /ID# 210811, Seoul, Korea, Republic of|St. Carollo General Hospital /ID# 210619, Suncheon, Korea, Republic of|Ulsan University Hospital /ID# 210810, Ulsan, Korea, Republic of|Wonju Severance Christian Hosp /ID# 210611, Wonju, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03740230"
53,"NCT03738397","A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis","Heads Up","Recruiting","No Results Available","Atopic Dermatitis","Drug: Upadacitinib (ABT-494)|Drug: Dupilumab|Drug: Placebo","Percentage of participants achieving a 75% reduction in Eczema Area and Severity Index (EASI) (EASI 75) from Baseline|Percent change in worst pruritus numerical rating scale (NRS)|Percentage of participants achieving a 100% reduction in EASI (EASI 100)|Percentage of participants achieving a 90% reduction in EASI (EASI 90)","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","650","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-046|2018-002264-57","February 21, 2019","January 22, 2021","January 22, 2021","November 13, 2018",,"January 6, 2020","Clinical Research Center AL /ID# 210277, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences /ID# 211688, Little Rock, Arkansas, United States|Wallace Medical Group, Inc. /ID# 208524, Beverly Hills, California, United States|Tien Q Nguyen MD, Inc /ID# 208934, Fountain Valley, California, United States|UCSF Fresno Center for Medical Education and Research /ID# 213253, Fresno, California, United States|Jonathan Corren, MD. INC /ID# 208987, Los Angeles, California, United States|California Allergy and Asthma Medical Group /ID# 213680, Los Angeles, California, United States|Dermatology Res. Assoc., CA /ID# 209097, Los Angeles, California, United States|Dermatology Clinical Trials /ID# 214622, Newport Beach, California, United States|UC Davis, Dermatology /ID# 209285, Sacramento, California, United States|Ucsd /Id# 208990, San Diego, California, United States|Clinical Science Institute /ID# 211022, Santa Monica, California, United States|The Community Research of South Florida /ID# 211145, Hialeah, Florida, United States|Miami Dermatology and Laser Institute /ID# 212938, Miami, Florida, United States|Florida International Rsrch cr /ID# 211562, Miami, Florida, United States|Progressive Medical Research /ID# 211994, Port Orange, Florida, United States|GCP Research /ID# 216020, Saint Petersburg, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 210751, Tampa, Florida, United States|Integrated Clinical Research LLC /ID# 208831, West Palm Beach, Florida, United States|Georgia Pollens Clinical Research Centers, Inc /ID# 211092, Albany, Georgia, United States|Meridian Clinical Research Dermatology /ID# 213251, Savannah, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 208680, Chicago, Illinois, United States|Medical Dermatology Associates of Chicago /ID# 210265, Chicago, Illinois, United States|Sneeze, Wheeze, & Itch Associates, LLC /ID# 212058, Normal, Illinois, United States|Dawes Fretzin, LLC /ID# 209187, Indianapolis, Indiana, United States|Beacon Clinical Research, LLC /ID# 209280, Quincy, Massachusetts, United States|Clarkston Skin Research /ID# 208739, Clarkston, Michigan, United States|Henry Ford Health System /ID# 208741, Detroit, Michigan, United States|Clinical Research Institute, Inc /ID# 210852, Minneapolis, Minnesota, United States|Allergy, Asthma & Immunology Associates, PC /ID# 213481, Lincoln, Nebraska, United States|Skin Specialists, PC /ID# 208843, Omaha, Nebraska, United States|Dartmouth-Hitchcock Med Ctr /ID# 213727, Lebanon, New Hampshire, United States|Montefiore Medical Center - Moses Campus /ID# 209647, Bronx, New York, United States|Forest Hills Dermatology Group /ID# 209249, Forest Hills, New York, United States|Wake Forest Univ HS /ID# 208892, Winston-Salem, North Carolina, United States|Univ Hosp Cleveland /ID# 208852, Cleveland, Ohio, United States|The Ohio State University /ID# 209254, Columbus, Ohio, United States|Southside Dermatology /ID# 212004, Tulsa, Oklahoma, United States|Oregon Medical Res Center PC /ID# 208807, Portland, Oregon, United States|Oregon Health and Science University /ID# 208809, Portland, Oregon, United States|Medical University of South Carolina /ID# 211054, Charleston, South Carolina, United States|Clinical Research Solutions, LLC /ID# 212542, Jackson, Tennessee, United States|Orion Clinical Research /ID# 208765, Austin, Texas, United States|DiscoveResearch, Inc. /ID# 213171, Bryan, Texas, United States|Epiphany Dermatology /ID# 211187, Fort Worth, Texas, United States|Sante Clinical Research /ID# 212970, Kerrville, Texas, United States|Stephen Miller, MD PA /ID# 210071, San Antonio, Texas, United States|Sugar Land Allergy, Asthma, and Immunology Center /ID# 211153, Sugar Land, Texas, United States|University of Utah /ID# 209001, Salt Lake City, Utah, United States|Clinical Research Partners, LLC /ID# 212262, Richmond, Virginia, United States|Premier Clinical Research /ID# 212142, Spokane, Washington, United States|West Virginia Research Inst /ID# 212730, South Charleston, West Virginia, United States|The Skin Hospital /ID# 214401, Darlinghurst, New South Wales, Australia|Holdsworth House Medical Practice /ID# 214565, Sydney, New South Wales, Australia|Veracity Clinical Research /ID# 211134, Woolloongabba, Queensland, Australia|Sinclair Dermatology /ID# 209395, East Melbourne, Victoria, Australia|Burswood Dermatology /ID# 214875, Victoria Park, Western Australia, Australia|Dermatology Research Institute Inc. /ID# 210942, Calgary, Alberta, Canada|Kirk Barber Research, CA /ID# 209504, Calgary, Alberta, Canada|Dr. Chih-ho Hong Medical Inc. /ID# 211032, Surrey, British Columbia, Canada|Enverus Medical Research /ID# 209503, Surrey, British Columbia, Canada|Dr. Wei Jing Loo Medicine Prof /ID# 211400, London, Ontario, Canada|Lynderm Research Inc. /ID# 209505, Markham, Ontario, Canada|DermEdge Research Inc. /ID# 211122, Mississauga, Ontario, Canada|Niakosari Medicine Professional Corporation /ID# 211401, Toronto, Ontario, Canada|K. Papp Clinical Research /ID# 209509, Waterloo, Ontario, Canada|Dre. Angelique Gagne-Henley /ID# 209498, St-Jerome, Quebec, Canada|DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 209935, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 209976, Zagreb, Grad Zagreb, Croatia|Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 209937, Ivanić-Grad, Zagrebacka Zupanija, Croatia|Djecja bolnica Srebrnjak /ID# 209939, Zagreb, Croatia|Fakultni nemocnice Ostrava /ID# 209117, Ostrava, Praha 5, Czechia|Fakultni Nemocnice v Motole /ID# 209209, Prague 5, Praha 5, Czechia|Fakultni Nemocnice Brno /ID# 212968, Brno, Czechia|FN Hradec Kralove /ID# 209116, Hradec Kralove, Czechia|Nemocnice Jihlava /ID# 209131, Jihlava, Czechia|Keski-pohjanmaa Central Hospital /ID# 209534, Kokkola, Keski-Pohjanmaa, Finland|Oulu University Hospital /ID# 208961, Oulu, Pohjois-Pohjanmaa, Finland|Mikkeli Central Hospital /ID# 210125, Mikkeli, Finland|Pihlajalinna Turku /ID# 209599, Turku, Finland|CHRU Lille - Hôpital Claude Huriez /ID# 209317, Lille CEDEX, Hauts-de-France, France|CHU Hotel Dieu /ID# 208974, Nantes CEDEX 1, Pays-de-la-Loire, France|Charles Nicolle CHU Rouen /ID# 208973, Rouen CEDEX, Seine-Maritime, France|Hopital de la Timone /ID# 211245, Marseille, France|Hopital de L'archet 2 /ID# 213374, Nice, France|Polyclinique Courlancy /ID# 208975, Reims, France|Hopital Larrey - CHU de Toulouse /ID# 208976, Toulouse, France|Universitatsklinikum Munster /ID# 210935, Munster, Niedersachsen, Germany|Gemeinschaftspraxis /ID# 211174, Blankenfeld-mahlow, Germany|Hautklinik Klinikum Darmstadt /ID# 210938, Darmstadt, Germany|Universitaetsklinikum Frankfurt /ID# 210934, Frankfurt, Germany|Med Hochschule Hanover /ID# 210939, Hannover, Germany|TU Uniklinik Munchen /ID# 210937, Munich, Germany|Oroshazi Korhaz /ID# 210150, Orosháza, Bekes, Hungary|Pecsi Tudomanyegyetem /ID# 210892, Pécs, Pecs, Hungary|Uno Medical Trials Kft /ID# 211177, Budapest XIII, Hungary|Debreceni Egyetem Klinikai Központ /ID# 210893, Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 210149, Kaposvár, Hungary|St Vincent's University Hosp /ID# 208441, Dublin, Ireland|University Hospital Waterford /ID# 208442, Waterford, Ireland|Rabin Medical Center /ID# 210012, Petakh Tikva, Tel-Aviv, Israel|HaEmek Medical Center /ID# 210153, Afula, Israel|Sheba Medical Center /ID# 210013, Ramat Gan, Israel|Ichilov Medical Center /ID# 210014, Tel Aviv, Israel|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 210632, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 215726, Rozzano, Milano, Italy|A.O. Policlinico Sant'Orsola Malpighi /ID# 209111, Bologna, Italy|A.O.U. di Brescia /ID# 209115, Brescia, Italy|Ospedale San Giovanni di Dio /ID# 209109, Cagliari, Italy|AO Univ di Modena /ID# 209110, Modena, Italy|Policlinico Univ Tor Vergata /ID# 209112, Rome, Italy|Hospital Sultan Ismail /ID# 211037, Johor Bahru, Johor, Malaysia|Hospital Pakar Sultanah Fatimah /ID# 210185, Muar, Johor, Malaysia|UKM Medical Centre /ID# 209178, Kuala Lumpur, Selangor, Malaysia|University Malaya Med Ctr /ID# 208861, Kuala Lumpur, Malaysia|Hospital Pulau Pinang /ID# 210212, Penang, Malaysia|Hospital Putrajaya /ID# 209177, Putrajaya, Malaysia|Bravis Ziekenhuis /ID# 208584, Bergen op Zoom, Noord-Brabant, Netherlands|Centrum Oosterwal /ID# 209641, Alkmaar, Netherlands|Academisch Medisch Centrum /ID# 208578, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 208583, Groningen, Netherlands|Erasmus Medisch Centrum /ID# 208582, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 208579, Utrecht, Netherlands|Optimal Clinical Trials Ltd /ID# 209475, Auckland, New Zealand|Clinical Trials NZ /ID# 215590, Hamilton, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 215001, Wellington, New Zealand|St. Olavs Hospital HF /ID# 209137, Trondheim, Sor-Trondelag, Norway|Universitetssykehuset N-Norge, Harstad /ID# 209105, Harstad, Troms, Norway|Universitetssykehuset N-Norge, Tromso /ID# 209103, Tromso, Troms, Norway|Pratia MCM Krakow /ID# 207444, Krakow, Malopolskie, Poland|Klinika Ambroziak Sp. z o.o. /ID# 207443, Warsaw, Mazowieckie, Poland|ClinicMed Daniluk, Nowak Sp.j. /ID# 211112, Białystok, Podlaskie, Poland|Szpital Uniwersytecki nr 1 im. dr. A. Jurasza w Bydgoszczy /ID# 211103, Bydgoszcz, Poland|Dermoklinika Medical Center /ID# 211026, Lodz, Poland|Royalderm Agnieszka Nawrocka /ID# 211015, Warsaw, Poland|National Skin Centre /ID# 208775, Singapore, Central Singapore, Singapore|National University Hospital /ID# 208774, Singapore, Singapore|Singapore General Hospital /ID# 208776, Singapore, Singapore|KK Women's & Children Hospital /ID# 208777, Singapore, Singapore|Hospital Bellvitge /ID# 207063, Barcelona, Spain|Hospital Univ Dr. Negrin /ID# 208969, Las Palmas de Gran Canaria, Spain|Hospital de Manises /ID# 207062, Manises, Spain|Complejo Hosp Pontevedra /ID# 207139, Pontevedra, Spain|Hospital Univ Arnau Vilanova /ID# 207065, Valencia, Spain|Hosp Univ Politecnico la Fe /ID# 207064, Valencia, Spain|Skanes Universitetssjukhus /ID# 206783, Malmö, Skane Lan, Sweden|Sahlgrenska universitetssjukhuset /ID# 217560, Göteborg, Vastra Gotalands Lan, Sweden|Karolinska University Hospital /ID# 207909, Stockholm, Sweden|China Medical University Hosp /ID# 209770, Taichung City, Taichung, Taiwan|National Taiwan University Hospital /ID# 208309, Taipei City, Taipei, Taiwan|Chung Shan Medical University /ID# 208311, Taichung City, Taiwan|Taipei Municipal Wan Fang Hospital /ID# 209987, Taipei, Taiwan|CI Zaporizhzhya Regional Skin and Venereal Clinical Dispensary /ID# 210435, Zaporizhzhya, Zaporizka Oblast, Ukraine|Municipal Institution Regional Skin and Venereal Dispensary /ID# 210289, Dnipro, Ukraine|Kyiv City Clinical Skin and Venereal Hospital /ID# 210755, Kyiv, Ukraine|ME ""Rivne Regional Dermatology and Venereology Dispensary"" of RRC /ID# 210434, Rivne, Ukraine|Royal Alex Childrens County Hospital /ID# 209709, Brighton, Brighton And Hove, United Kingdom|Victoria Hospital /ID# 209853, Kirkcaldy, Fife, United Kingdom|Royal Hospital for Children /ID# 210451, Glasgow, Glasgow City, United Kingdom|The Royal Free Hospital /ID# 208659, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 208881, London, London, City Of, United Kingdom|Cardiff & Vale University Health Board /ID# 209745, Cardiff, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03738397"
54,"NCT03737851","A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis",,"Active, not recruiting","No Results Available","Multiple Sclerosis (MS)","Drug: elezanumab|Drug: placebo","Overall Response Score (ORS) at Week 52|12-week confirmed disability improvement response rate on the Expanded Disability Status Scale Plus (EDSS+)|12-week confirmed disability improvement response rate on Timed 25 Foot Walk (T25FW)|12-week confirmed disability improvement response rate on 9-Hole Peg Test in either hand (9HPT)|12-week confirmed disability improvement response rate on Expanded Disability Status Scale (EDSS)|24-week confirmed disability improvement response rate on the Expanded Disability Status Scale Plus (EDSS+)|24-week confirmed disability improvement response rate on Timed 25 Foot Walk (T25FW)|24-week confirmed disability improvement response rate on 9-Hole Peg Test in either hand (9HPT)|24-week confirmed disability improvement response rate on Expanded Disability Status Scale (EDSS)|Overall Response Score (ORS) at Week 12|Overall Response Score (ORS) at Week 24|Overall Response Score (ORS) at Week 36|Time to first improvement on 12-week confirmed Expanded Disability Status Scale Plus (EDSS+)","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M18-918","December 11, 2018","December 3, 2020","October 4, 2021","November 13, 2018",,"January 21, 2020","University of Alabama at Birmingham - Main /ID# 204618, Birmingham, Alabama, United States|St. Josephs Hosp and Med Ctr /ID# 204197, Phoenix, Arizona, United States|Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 204249, Berkeley, California, United States|The Research Ctr Southern CA /ID# 204269, Carlsbad, California, United States|Vladimir Royter MD /ID# 204392, Hanford, California, United States|UC Irvine Health /ID# 205728, Irvine, California, United States|Stanford MS Center /ID# 204283, Palo Alto, California, United States|UC Davis - Neurology /ID# 204188, Sacramento, California, United States|UCSF School of Medicine - Neurology /ID# 204251, San Francisco, California, United States|University of Colorado School of Medicine, Dept of Neurology /ID# 204250, Aurora, Colorado, United States|Advanced Neurosciences Research, LLC /ID# 204289, Fort Collins, Colorado, United States|University of Chicago /ID# 205319, Chicago, Illinois, United States|Indiana Univ School Medicine /ID# 204891, Indianapolis, Indiana, United States|Rowe Neurology Institute /ID# 204391, Lenexa, Kansas, United States|The NeuroMedical Center /ID# 204253, Baton Rouge, Louisiana, United States|Ochsner Medical Center /ID# 204189, New Orleans, Louisiana, United States|Parexel International /ID# 204273, Baltimore, Maryland, United States|International Neurorehabilitation Institute /ID# 213332, Lutherville, Maryland, United States|Mass General Hospital /ID# 204279, Boston, Massachusetts, United States|Michigan Institute for Neurological Disorders (MIND) /ID# 204194, Farmington Hills, Michigan, United States|Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206328, Owosso, Michigan, United States|Ridgeview Specialty Clinic Chaska - Neurology /ID# 204383, Chaska, Minnesota, United States|Washington University - School of Medicine /ID# 204388, Saint Louis, Missouri, United States|The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205433, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Cent /ID# 204745, Las Vegas, Nevada, United States|Oklahoma Med Res. Foundation /ID# 204389, Oklahoma City, Oklahoma, United States|Providence Neurological Specialties - West /ID# 204248, Portland, Oregon, United States|Thomas Jefferson University /ID# 204281, Philadelphia, Pennsylvania, United States|Advanced Neurosciences Institu /ID# 204557, Franklin, Tennessee, United States|KCA Neurology - Franklin /ID# 204208, Franklin, Tennessee, United States|Tri-State Mountain Neurology /ID# 204252, Johnson City, Tennessee, United States|Neurology Consultants of Dallas - Merit Dr /ID# 204398, Dallas, Texas, United States|UT HSC Multiple Sclerosis Research Group - Houston /ID# 206418, Houston, Texas, United States|Dr. Bhupesh Dihenia, MD, PA /ID# 207839, Lubbock, Texas, United States|Central Texas Neurology Consul /ID# 204268, Round Rock, Texas, United States|Integrated Neurology Services /ID# 204261, Alexandria, Virginia, United States|Evergreen Neuroscience Institute /ID# 204203, Kirkland, Washington, United States|Virginia Mason Medical Center /ID# 205440, Seattle, Washington, United States|Swedish MS Center /ID# 204198, Seattle, Washington, United States|University of Washington Medicine MS Center /ID# 205852, Seattle, Washington, United States|West Virginia Univ School Med /ID# 204292, Morgantown, West Virginia, United States|Froedtert & the Medical College of Wisconsin /ID# 204202, Milwaukee, Wisconsin, United States|University of British Columbia /ID# 204841, Vancouver, British Columbia, Canada|Hamilton Health Sciences /ID# 204847, Hamilton, Ontario, Canada|London Health Sciences Centre /ID# 204848, London, Ontario, Canada|The Ottawa Hospital /ID# 204842, Ottawa, Ontario, Canada|St. Michael's Hospital /ID# 206214, Toronto, Ontario, Canada|Crchum /Id# 204844, Montreal, Quebec, Canada|Montreal Neurological Institut /ID# 204843, Montreal, Quebec, Canada|Recherche Sepmus Inc. /ID# 212851, Greenfield Park, Canada",,"https://ClinicalTrials.gov/show/NCT03737851"
55,"NCT03737812","A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis",,"Active, not recruiting","No Results Available","Multiple Sclerosis (MS)","Drug: elezanumab|Drug: placebo","Overall Response Score (ORS) at Week 52|12-week confirmed disability improvement response rate on the Expanded Disability Status Scale Plus (EDSS+)|12-week confirmed disability improvement response rate on Timed 25 Foot Walk (T25FW)|12-week confirmed disability improvement response rate on 9-Hole Peg Test in either hand (9HPT)|12-week confirmed disability improvement response rate on Expanded Disability Status Scale (EDSS)|24-week confirmed disability improvement response rate on the Expanded Disability Status Scale Plus (EDSS+)|24-week confirmed disability improvement response rate on Timed 25 Foot Walk (T25FW)|24-week confirmed disability improvement response rate on 9-Hole Peg Test in either hand (9HPT)|24-week confirmed disability improvement response rate on Expanded Disability Status Scale (EDSS)|Overall Response Score (ORS) at Week 12|Overall Response Score (ORS) at Week 24|Overall Response Score (ORS) at Week 36|Time to first improvement on 12-week confirmed Expanded Disability Status Scale Plus (EDSS+)","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M14-397","February 27, 2019","September 17, 2020","October 1, 2021","November 13, 2018",,"January 21, 2020","St. Josephs Hosp and Med Ctr /ID# 202809, Phoenix, Arizona, United States|Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 202448, Berkeley, California, United States|The Research Center of Southern California /ID# 202802, Carlsbad, California, United States|Vladimir Royter MD /ID# 202483, Hanford, California, United States|Stanford MS Center /ID# 202445, Palo Alto, California, United States|UC Davis - Neurology /ID# 202485, Sacramento, California, United States|UCSF School of Medicine - Neurology /ID# 203194, San Francisco, California, United States|University of Colorado School of Medicine, Dept of Neurology /ID# 202807, Aurora, Colorado, United States|Advanced Neurosciences Research, LLC /ID# 203072, Fort Collins, Colorado, United States|Rowe Neurology Institute /ID# 202744, Lenexa, Kansas, United States|Parexel International /ID# 202747, Baltimore, Maryland, United States|International Neurorehabilitation Institute /ID# 213333, Lutherville, Maryland, United States|Michigan Institute for Neurological Disorders (MIND) /ID# 202470, Farmington Hills, Michigan, United States|Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206327, Owosso, Michigan, United States|Ridgeview Specialty Clinic Chaska - Neurology /ID# 204384, Chaska, Minnesota, United States|Washington University - School of Medicine /ID# 202899, Saint Louis, Missouri, United States|The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205432, Saint Louis, Missouri, United States|Cleveland Clinic Lou Ruvo Cent /ID# 204744, Las Vegas, Nevada, United States|Oklahoma Med Res. Foundation /ID# 203442, Oklahoma City, Oklahoma, United States|Providence Neurological Specialties - West /ID# 203193, Portland, Oregon, United States|Advanced Neurosciences Institu /ID# 204555, Franklin, Tennessee, United States|KCA Neurology - Franklin /ID# 202912, Franklin, Tennessee, United States|Neurology Consultants of Dallas - Merit Dr /ID# 203102, Dallas, Texas, United States|Central Texas Neurology Consul /ID# 203108, Round Rock, Texas, United States|Integrated Neurology Services /ID# 202743, Alexandria, Virginia, United States|Evergreen Neuroscience Institute /ID# 204205, Kirkland, Washington, United States|Virginia Mason Medical Center /ID# 205439, Seattle, Washington, United States|Swedish MS Center /ID# 202904, Seattle, Washington, United States|West Virginia Univ School Med /ID# 202849, Morgantown, West Virginia, United States|Froedtert & the Medical College of Wisconsin /ID# 202618, Milwaukee, Wisconsin, United States|University of British Columbia /ID# 203536, Vancouver, British Columbia, Canada|Hamilton Health Sciences /ID# 203877, Hamilton, Ontario, Canada|London Health Sciences Centre /ID# 203538, London, Ontario, Canada|The Ottawa Hospital /ID# 203058, Ottawa, Ontario, Canada|St. Michael's Hospital /ID# 206213, Toronto, Ontario, Canada|Crchum /Id# 203869, Montreal, Quebec, Canada|Montreal Neurological Institut /ID# 203868, Montreal, Quebec, Canada|Recherche Sepmus Inc. /ID# 212852, Greenfield Park, Canada",,"https://ClinicalTrials.gov/show/NCT03737812"
56,"NCT03725202","A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis","SELECT-GCA","Recruiting","No Results Available","Giant Cell Arteritis (GCA)","Drug: Upadacitinib|Drug: Corticosteroid (CS)|Other: Placebo","Percentage of participants achieving sustained remission|Percentage of participants achieving sustained complete remission|Cumulative CS exposure|Time to disease flare|Percentage of participants who experience at least 1 disease flare|Percentage of participants in complete remission|Change from Baseline in the 36-item Short Form Quality of Life Questionnaire (SF-36) Physical Component Score (PCS)|Number of disease flares per participant during Period 1|Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)|Assessment of Treatment Satisfaction Questionnaire for Medication (TSQM) Patient Global Satisfaction Subscale|Rate of CS-related Adverse Events","AbbVie","All","50 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-852|2017-003978-13","January 24, 2019","March 25, 2022","May 14, 2023","October 30, 2018",,"January 7, 2020","Rheum Assoc of North Alabama /ID# 168668, Huntsville, Alabama, United States|Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 204702, Glendale, Arizona, United States|VA Long Beach Healthcare System /ID# 203833, Long Beach, California, United States|Robin K. Dore MD, Inc /ID# 201950, Tustin, California, United States|Denver Arthritis Clinic /ID# 171552, Denver, Colorado, United States|Western Connecticut Health Network- Germantown Rd /ID# 205071, Danbury, Connecticut, United States|RASF - Clinical Research /ID# 169040, Boca Raton, Florida, United States|Clinical Res of West FL, Inc. /ID# 201901, Clearwater, Florida, United States|Lakes Research, LLC /ID# 210442, Miami, Florida, United States|Ctr Arthritis & Rheumatic Dise /ID# 168667, Miami, Florida, United States|Medallion Clinical Research Institute, LLC /ID# 168666, Naples, Florida, United States|Omega Research Consultants /ID# 201903, Orlando, Florida, United States|Integral Rheumatology & Immunology Specialists /ID# 169406, Plantation, Florida, United States|Clinical Research West FL /ID# 201899, Tampa, Florida, United States|USF Health /ID# 207077, Tampa, Florida, United States|Lovelace Scientific Resources /ID# 169041, Venice, Florida, United States|Arthritis and Rheumatology /ID# 170295, Atlanta, Georgia, United States|Institute of Arthritis Researc /ID# 168490, Idaho Falls, Idaho, United States|Ochsner Clinic Foundation /ID# 200723, Baton Rouge, Louisiana, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 171199, Monroe, Louisiana, United States|Ochsner Clinic Foundation-New Orleans /ID# 171200, New Orleans, Louisiana, United States|LSUHSC - Shreveport /ID# 202646, Shreveport, Louisiana, United States|The Center for Rheumatology and Bone Research /ID# 168652, Wheaton, Maryland, United States|University of Michigan Hospitals /ID# 168645, Ann Arbor, Michigan, United States|Wayne State University Health Center /ID# 212755, Detroit, Michigan, United States|Henry Ford Medical Center /ID# 207456, Detroit, Michigan, United States|Aa Mrc Llc /Id# 201854, Grand Blanc, Michigan, United States|West Michigan Rheumatology /ID# 168647, Grand Rapids, Michigan, United States|Clinvest Research LLC /ID# 208182, Springfield, Missouri, United States|Physician Res. Collaboration /ID# 168610, Lincoln, Nebraska, United States|University Clinical Research Center /ID# 202504, Somerset, New Jersey, United States|Univ Rochester Med Ctr /ID# 213527, Rochester, New York, United States|Marietta Memorial Hospital /ID# 210834, Marietta, Ohio, United States|STAT Research, Inc. /ID# 200436, Vandalia, Ohio, United States|University of Pennsylvania /ID# 168655, Philadelphia, Pennsylvania, United States|Piedmont Arthritis Clinic, PA /ID# 212431, Greenville, South Carolina, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 212761, Summerville, South Carolina, United States|West Tennessee Research Inst /ID# 209256, Jackson, Tennessee, United States|Arthritis Associates, PLLC /ID# 212756, Kingsport, Tennessee, United States|Tekton Research, Inc. /ID# 201801, Austin, Texas, United States|PCCR Solution /ID# 201798, Colleyville, Texas, United States|West Texas Clinical Research /ID# 204834, Lubbock, Texas, United States|Baylor Scott & White Health - Temple /ID# 213529, Temple, Texas, United States|University of Vermont Medical Center /ID# 211179, Burlington, Vermont, United States|Carilion Clinic /ID# 212928, Roanoke, Virginia, United States|Kadlec Clinic Rheumatology /ID# 201618, Kennewick, Washington, United States|University of Washington /ID# 201619, Seattle, Washington, United States|Aurora Rheumatology and Immunotherapy Center /ID# 201853, Franklin, Wisconsin, United States|Optimus Clinical Research Pty. /ID# 201937, Kogarah, New South Wales, Australia|The Prince of Wales Hospital /ID# 210995, Randwick, New South Wales, Australia|The Queen Elizabeth Hospital /ID# 201939, Woodville, South Australia, Australia|Emeritus Research /ID# 201938, Camberwell, Victoria, Australia|Fiona Stanley Hospital /ID# 201941, Murdoch, Western Australia, Australia|Medizinische Universität Innsbruck /ID# 201786, Innsbruck, Tirol, Austria|Rheuma-Zentrum Wien-Oberlaa GmbH /ID# 201781, Vienna, Wien, Austria|Cliniques Universitaires Saint Luc /ID# 203146, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 202778, Gent, Oost-Vlaanderen, Belgium|UZ Gasthuisberg Leuven /ID# 202779, Leuven, Belgium|University of Alberta - Division of Rheumatology /ID# 208629, Edmonton, Alberta, Canada|St. Joseph's Healthcare /ID# 204160, Hamilton, Ontario, Canada|Ctr. de Recherche Musculo-Sque /ID# 201224, Trois-rivières, Quebec, Canada|Polmed Research Inc /ID# 201843, Saskatoon, Saskatchewan, Canada|Fakultni Nemocnice Olomouc /ID# 202041, Olomouc, Olomoucky Kraj, Czechia|Axon Clinical, s.r.o. /ID# 202468, Praha, Praha 5, Czechia|Medical Plus, s.r.o. /ID# 200865, Uherské Hradište, Czechia|Aarhus Universitetshospital /ID# 171177, Aarhus C, Midtjylland, Denmark|Sydvestjysk Sygehus Esbjerg /ID# 200216, Esbjerg, Denmark|Odense University Hospital /ID# 171179, Odense, Denmark|CHRU Lille - Hôpital Claude Huriez /ID# 171543, Lille CEDEX, Hauts-de-France, France|Hopital de la Cavale Blanche /ID# 171549, Brest, France|CHU de CAEN - Hopital de la Cote de Nacre /ID# 171539, Caen Cedex 9, France|Hopital de la Croix Rousse /ID# 211184, Lyon, France|Hopital Saint Joseph /ID# 171540, Marseille, France|CHU de Nantes, Hotel Dieu -HME /ID# 171544, Nantes, France|CHU Paris-GH La Pitie Salpetri /ID# 171542, Paris, France|CHU Paris Centre - Hopital Coc /ID# 171545, Paris, France|CHU de TOULOUSE - Hopital Purpan /ID# 171547, Toulouse Cedex 9, France|Medius Klinik Kirchheim /ID# 200637, Kirchheim unter Teck, Baden-Wuerttemberg, Germany|Medizinische Versorgungszentren Burghausen.Altoetting /ID# 208773, Burghausen, Germany|Med Hochschule Hanover /ID# 200632, Hannover, Germany|Univ-Klinikum Wuerzburg /ID# 213340, Wuerzburg, Germany|Genl Hosp Athens Gennimatas /ID# 210129, Athens, Greece|General Hospital of Athens ""Ippokratio"" /ID# 202181, Athens, Greece|424 General MILITARY Hospital /ID# 210973, Thessaloniki, Greece|Szent Imre Egyetemi Oktatokorhaz /ID# 201838, Budapest XI, Budapest, Hungary|Betegapolo Irgalmas Rend - Bud /ID# 204018, Budapest, Hungary|Orszagos Reumatologiai es Fizi /ID# 211454, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 201526, Debrecen, Hungary|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 200079, Modena, Emilia-Romagna, Italy|Ospedale di Bolzano /ID# 200081, Bolzano, Italy|Azienda Sanitaria Universitaria Integrata di Udine /ID# 200082, Udine, Italy|Chubu Rosai Hospital /ID# 202946, Nagoya-shi, Aichi, Japan|Kagawa University Hospital /ID# 200171, Kita-gun, Kagawa, Japan|Japanese Red Cross Kumamoto Hospital /ID# 203507, Kumamoto-shi, Kumamoto, Japan|Tohoku University Hospital /ID# 200172, Sendai-shi, Miyagi, Japan|Tomishiro Central Hospital /ID# 203897, Tomigusuku-shi, Okinawa, Japan|Sakai City Medical Center /ID# 202643, Sakai-shi, Osaka, Japan|St.Luke's International Hospital /ID# 200170, Chuo-ku, Tokyo, Japan|Jichi Medical University Hosp /ID# 200169, Shimotsuke-shi, Japan|Radboud Universitair Medisch Centrum /ID# 212925, Nijmegen, Gelderland, Netherlands|ZiekenhuisGroep Twente /ID# 200038, Almelo, Netherlands|Universitair Medisch Centrum Groningen /ID# 201715, Groningen, Netherlands|Medisch Centrum Leeuwarden /ID# 201716, Leeuwarden, Netherlands|Erasmus Medisch Centrum /ID# 201717, Rotterdam, Netherlands|Waikato Hospital /ID# 201944, Hamilton, Waikato, New Zealand|Optimal Clinical Trials Ltd /ID# 201946, Auckland, New Zealand|Middlemore Clinical Trials /ID# 201942, Auckland, New Zealand|Timaru Medical Specialists Ltd /ID# 201943, Timaru, New Zealand|Drammen Sykehus /ID# 201560, Drammen, Buskerud, Norway|Haukeland universitetssjukehus /ID# 201602, Bergen, Hordaland, Norway|Haugesund Sanitetsforening Rev /ID# 208728, Haugesund, Rogaland, Norway|Rikshospitalet OUS HF /ID# 202004, Oslo, Norway|Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 208151, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 203530, Lisboa, Portugal|Unidade Local De Saude Do Alto Minho /ID# 205186, Viana Do Castelo, Portugal|Colentina Clinical Hospital /ID# 204889, Bucharest, Romania|Spitalul Clinic Sf. Maria /ID# 203809, Bucuresti, Romania|Clin County Hosp Cluj-Napoca /ID# 204887, Cluj, Romania|Federal State Budgetary Educational Institution of Higher Education ""Kemerovo St /ID# 203676, Kemerovo, Kemerovskaya Oblast, Russian Federation|Sechenov First Moscow Medical /ID# 203673, Moscow, Russian Federation|PMI Euromedservice /ID# 205345, Pushkin, Russian Federation|Clinical Rheumatologic Hospital No 25 /ID# 208950, Sankt-Peterburg, Russian Federation|H. Un. Marques de Valdecilla /ID# 201604, Santander, Cantabria, Spain|H.U. Clinico San Carlos /ID# 204871, Madrid, Madrid, Comunidad De, Spain|Hospital Clinic de Barcelona /ID# 201878, Barcelona, Spain|Hospital Universitario Gregorio Marañon /ID# 201326, Madrid, Spain|Hospital do Meixoeiro /ID# 212084, Vigo/pontevedra, Spain|Skanes Universitetssjukhus /ID# 171407, Malmö, Skane Lan, Sweden|Karolinska Univ Sjukhuset /ID# 204945, Solna, Sweden|Danderyds sjukhus /ID# 171404, Stockholm, Sweden|Vastmanlands Sjukhus /ID# 171429, Vasteras, Sweden|Kantonsspital St. Gallen /ID# 201134, St. Gallen, Sankt Gallen, Switzerland|University Hospital of Basel /ID# 201767, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 201364, Bern, Switzerland|HFR Fribourg - Hopital Canton /ID# 201114, Fribourg, Switzerland|RD&E Hospital /ID# 202834, Exeter, Devon, United Kingdom|Whipps Cross Univ Hospital /ID# 210511, London, London, City Of, United Kingdom|UH Coventry & Warwickshire /ID# 202838, Coventry, United Kingdom|Poole Hospital NHS Foundation /ID# 202836, Poole, United Kingdom|Southend Hospital /ID# 202839, Southend, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03725202"
57,"NCT03725007","A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis",,"Recruiting","No Results Available","Juvenile Idiopathic Arthritis (JIA)","Drug: Upadacitinib","Treatment Emergent Adverse Events (TEAEs)|Maximum observed plasma concentration (Cmax)|Time to maximum observed plasma concentration (Tmax)|Area under plasma concentration versus time curve during a dosing interval (AUCtau)|Apparent oral clearance at steady state (CL/F)|Half-life","AbbVie","All","2 Years to 17 Years   (Child)","Phase 1","54","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-340|2018-000715-25","June 24, 2019","July 31, 2021","August 10, 2024","October 30, 2018",,"November 13, 2019","Ann & Robert H. Lurie Children's Hospital of Chicago /ID# 211162, Chicago, Illinois, United States|University of Louisville /ID# 202896, Louisville, Kentucky, United States|Boston Childrens Hospital /ID# 202993, Boston, Massachusetts, United States|Cincinnati Childrens Hosp Med /ID# 209697, Cincinnati, Ohio, United States|Randall Children's Hospital /ID# 213609, Portland, Oregon, United States|Children's Hospital of Philadelphia /ID# 209617, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC /ID# 202994, Pittsburgh, Pennsylvania, United States|Seattle Children's Hospital /ID# 203003, Seattle, Washington, United States|PRI - Pediatric Rheumatology Research Institute /ID# 205954, Bad Bramstedt, Germany|Helios Klinikum Berlin Buch /ID# 206859, Berlin, Germany|Kinder- & Jugendrheumatologie /ID# 206571, Hamburg, Germany|Asklepios Klinik St. Augustin /ID# 203264, Sankt Augustin, Germany|Semmelweis Egyetem II. Számú Gyermekgyógyászati Klinika /ID# 208970, Budapest VIII, Pest, Hungary|IRCCS Ospedale Pediatrico Bambino Gesù /ID# 203835, Rome, Lazio, Italy|Azienda Ospedaliero Universitaria Meyer /ID# 215576, Florence, Italy|IRCCS Istituto G. Gaslini /ID# 203648, Genoa, Italy|Centro de Reumatologia Pediatrico de Puerto Rico /Id# 204406, Bayamon, Puerto Rico|GCM Medical Group PSC - Hato Rey /ID# 211702, San Juan, Puerto Rico|Mindful Medical Research /ID# 204488, San Juan, Puerto Rico|Hospital Sant Joan de Deu /ID# 203915, Esplugues de Llobregat, Spain|Hosp Infantil Univ Nino Jesus /ID# 206466, Madrid, Spain|Hospital Univ Ramon y Cajal /ID# 203917, Madrid, Spain|Hospital Universitario La Paz /ID# 203927, Madrid, Spain|Hospital Universitario La Fe /ID# 203914, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT03725007"
58,"NCT03712787","An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)",,"Enrolling by invitation","No Results Available","Alzheimer's Disease","Drug: ABBV-8E12","Adverse Events","AbbVie","All","57 Years to 87 Years   (Adult, Older Adult)","Phase 2","360","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-570|2018-000268-26","March 22, 2019","August 11, 2026","August 11, 2026","October 19, 2018",,"November 19, 2019","Banner University MC Phoenix /ID# 203959, Phoenix, Arizona, United States|Banner Sun Health Res Inst /ID# 204012, Sun City, Arizona, United States|Irvine Clinical Research /ID# 204000, Irvine, California, United States|University of California, San /ID# 204011, San Francisco, California, United States|Brain Matters Research /ID# 203957, Delray Beach, Florida, United States|Southwest Florida Neuropsych /ID# 203956, Fort Myers, Florida, United States|Mayo Clinic /ID# 203995, Jacksonville, Florida, United States|Bioclinica Research - Orlando /ID# 203992, Orlando, Florida, United States|University of South Florida /ID# 204009, Tampa, Florida, United States|Bioclinica Research - The Villages /ID# 204010, The Villages, Florida, United States|Emory University /ID# 203999, Atlanta, Georgia, United States|NeuroStudies.net, LLC /ID# 204004, Decatur, Georgia, United States|Advocate Lutheran General Hosp /ID# 203993, Park Ridge, Illinois, United States|Southern IL Univ School of Med /ID# 203952, Springfield, Illinois, United States|Indiana University /ID# 203989, Indianapolis, Indiana, United States|University of Kansas Medical Center - Alzheimer's Disease Center /ID# 203960, Fairway, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 203996, Lexington, Kentucky, United States|Massachusetts General Hospital /ID# 203954, Boston, Massachusetts, United States|Brigham and Women's Physicians /ID# 204003, Boston, Massachusetts, United States|Princeton Medical Institute /ID# 203953, Princeton, New Jersey, United States|North Shore University Hospital /ID# 203994, New Hyde Park, New York, United States|Duke Univ Med Ctr /ID# 203958, Durham, North Carolina, United States|Oregon Health and Science University /ID# 203997, Portland, Oregon, United States|Rhode Island Hospital /ID# 204005, Providence, Rhode Island, United States|Vanderbilt University Med Ctr /ID# 203951, Nashville, Tennessee, United States|Kerwin Research Center /ID# 203998, Dallas, Texas, United States|Houston Methodist Hospital /ID# 204002, Houston, Texas, United States|University of Utah /ID# 203991, Salt Lake City, Utah, United States|Integrated Neurology Services /ID# 203990, Alexandria, Virginia, United States|St Vincent's Centre for Applied Medical Research, Translational Research Centre /ID# 204903, Darlinghurst, New South Wales, Australia|Griffith University /ID# 204905, Southport, Queensland, Australia|Austin Hospital /ID# 204906, Heidelberg, Victoria, Australia|Australian Alzheimer's Res Fou /ID# 204904, Nedlands, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 204963, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 204965, Leuven, Belgium|Centre Hospitalier Universitaire du Sart Tilman (CHU de Liège) /ID# 204964, Liège, Belgium|Parkwood Institute /ID# 204121, London, Ontario, Canada|Toronto Memory Program /ID# 204120, Toronto, Ontario, Canada|Rigshospitalet, Memory Clinic /ID# 204591, Copenhagen Ø, Hovedstaden, Denmark|Clinical Research Services Turku /ID# 205924, Turku, Varsinais-Suomi, Finland|Ita-Suomen Yliopisto /ID# 204538, Kuopio, Finland|AOU di Modena /ID# 203904, Modena, Emilia-Romagna, Italy|AO Univ Policlinico Agostino G /ID# 203906, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 203901, Milano, Lombardia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 203902, Milan, Lombardia, Italy|IRCCS - San Giovanni di /ID# 203903, Brescia, Italy|Azienda Ospedaliera di Perugia /ID# 203905, Perugia, Italy|CGM Research Trust /ID# 204907, Burwood Christchurch, New Zealand|Fundacion CITA Alzheimer /ID# 204521, Donostia, Pais Vasco, Spain|Hospital Clinic de Barcelona /ID# 204519, Barcelona, Spain|Fundacio ACE /ID# 204520, Barcelona, Spain|Hospital Universitario Doce de /ID# 204518, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03712787"
59,"NCT03706040","A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis",,"Recruiting","No Results Available","Dermatitis","Biological: placebo for rizankizumab|Biological: risankizumab","Percentage of Participants Achieving At Least a 75% Reduction from Baseline in Eczema Area and Severity Index (EASI 75)|Percentage of Participants Achieving Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) Score of ""0"" Or ""1"" With a Reduction From Baseline of ≥ 2 Points|Percentage of Participants Achieving a Reduction of ≥ 4 Points in Worst Pruritus Numerical Rating Scale (NRS) from Baseline","AbbVie","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-813","December 27, 2018","November 12, 2020","April 7, 2021","October 15, 2018",,"January 21, 2020","UAB Department of Dermatology /ID# 211561, Birmingham, Alabama, United States|Cognitive Clinical Trials /ID# 208895, Scottsdale, Arizona, United States|Cosmetic Dermatology of Orange County /ID# 205801, Anaheim, California, United States|Center for Dermatology Clin Res /ID# 204950, Fremont, California, United States|Integrative Skin Science and Research /ID# 212486, Sacramento, California, United States|Cosmetic Laser Dermatology /ID# 210560, San Diego, California, United States|Therapeutics Clinical Research /ID# 203422, San Diego, California, United States|Colorado Dermatology /ID# 216260, Centennial, Colorado, United States|Park Avenue Dermatology, PA /ID# 203378, Orange Park, Florida, United States|MetroDerm ACC Research /ID# 205958, Atlanta, Georgia, United States|Skin Care Physicians of Georgia /ID# 213188, Macon, Georgia, United States|University Dermatology and Vein Clinic, LLC /ID# 210702, Darien, Illinois, United States|The Indiana Clinical Trials Center /ID# 211618, Plainfield, Indiana, United States|Tulane Univ /ID# 203214, New Orleans, Louisiana, United States|DermAssociates /ID# 206189, Rockville, Maryland, United States|Great Lakes Research Group,Inc /ID# 206447, Bay City, Michigan, United States|Grekin Skin Institute /ID# 210485, Warren, Michigan, United States|Skin Cancer and Dermatology Institute (SCDI) /ID# 213041, Reno, Nevada, United States|Psoriasis Treatment Ctr NJ /ID# 203203, East Windsor, New Jersey, United States|Icahn School of Med Mt. Sinai /ID# 203650, New York, New York, United States|Darst Dermatology /ID# 215100, Charlotte, North Carolina, United States|Dermatologists of Southwest Ohio, Inc /ID# 215104, Mason, Ohio, United States|Oregon Derm & Res. Ctr /ID# 202880, Portland, Oregon, United States|Dermatologic SurgiCenter /ID# 208972, Drexel Hill, Pennsylvania, United States|Dermdox Center for Dermatology /ID# 212259, Hazleton, Pennsylvania, United States|University of Pittsburgh MC /ID# 203296, Pittsburgh, Pennsylvania, United States|Derm Assoc of Plymouth Meeting /ID# 208925, Plymouth Meeting, Pennsylvania, United States|RI SkinDoc /ID# 203417, Johnston, Rhode Island, United States|Omega Medical Research /ID# 216022, Warwick, Rhode Island, United States|Health Concepts /ID# 203205, Rapid City, South Dakota, United States|Rivergate Dermatology & Skin Care Center /ID# 203372, Goodlettsville, Tennessee, United States|Arlington Research Center, Inc /ID# 215899, Arlington, Texas, United States|Tekton Research, Inc. /ID# 211558, Austin, Texas, United States|Center for Clinical Studies - Houston (Binz) /ID# 203383, Houston, Texas, United States|Acclaim Dermatology /ID# 213026, Sugar Land, Texas, United States|Virginia Dermatology Research, PLLC /ID# 210154, Norfolk, Virginia, United States|Dominion Medical Associates /ID# 212986, Richmond, Virginia, United States|The Vancouver Clinic, INC. PS /ID# 202930, Vancouver, Washington, United States|Woden Dermatology /ID# 204778, Phillip, Australian Capital Territory, Australia|St George Hospital /ID# 204780, Kogarah, New South Wales, Australia|Veracity Clinical Research /ID# 204786, Woolloongabba, Queensland, Australia|North Eastern Health Specialis /ID# 204785, Hectorville, South Australia, Australia|Skin Health Institute Inc /ID# 204779, Carlton, Victoria, Australia|Fremantle Dermatology /ID# 204784, Fremantle, Western Australia, Australia|Kirk Barber Research, CA /ID# 201046, Calgary, Alberta, Canada|Institute for Skin Advancement /ID# 213003, Calgary, Alberta, Canada|University of Alberta - Division of Rheumatology /ID# 213008, Edmonton, Alberta, Canada|Stollery Children's Hospital /ID# 213009, Edmonton, Alberta, Canada|Karma Clinical Trials /ID# 215439, St. John's, Newfoundland and Labrador, Canada|Dr. Wei Jing Loo Medicine Prof /ID# 208849, London, Ontario, Canada|Lynderm Research Inc. /ID# 201050, Markham, Ontario, Canada|Medicor Research Inc. /ID# 211274, Sudbury, Ontario, Canada|CHU Sainte-Justine /ID# 215263, Montreal, Quebec, Canada|Dre. Angelique Gagne-Henley /ID# 208189, St-Jerome, Quebec, Canada|Chukyo Hospital /ID# 213667, Nagoya-shi, Aichi, Japan|Kurume University Hospital /ID# 203139, Kurume-shi, Fukuoka, Japan|Nippon Medical School Musashi Kosugi Hospital /ID# 213961, Kawasaki-shi, Kanagawa, Japan|Nagaoka Red Cross Hospital /ID# 214140, Nagaoka-shi, Niigata, Japan|University of the Ryukyus Hospital /ID# 203974, Nakagami-gun, Okinawa, Japan|Osaka City University Hospital /ID# 203410, Osaka-shi, Osaka, Japan|Hamamatsu University Hospital /ID# 203270, Hamamatsu-shi, Shizuoka, Japan|Tokyo Teishin Hospital /ID# 204101, Chiyoda-ku, Tokyo, Japan|Teikyo University Hospital /ID# 202884, Itabashi-ku, Tokyo, Japan|Tokyo Medical University Hospital /ID# 203647, Shinjuku-ku, Tokyo, Japan|Dr. Samuel Sanchez, PSC /ID# 213117, Caguas, Puerto Rico|Cruz-Santana, Carolina, PR /ID# 213229, Carolina, Puerto Rico|Clinical Research Puerto Rico /ID# 213118, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03706040"
60,"NCT03695237","A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)",,"Recruiting","No Results Available","Central Precocious Puberty (CPP)","Drug: Leuprolide Acetate (LA)","Percentage of Participants with suppression of GnRHa-stimulated luteinizing hormone (LH)(<4 milli-international units per milliliter (mlU/mL))|Percentage of female participants with suppression of basal estradiol to <20 pg/mL|Percentage of male participants with suppression of testosterone to <30 ng/dL|Percentage of participants with maintenance of suppression of GnRHa-stimulated LH (<4 mlU/mL)|Percentage of female participants with maintenance of suppression of basal estradiol to <20 pg/mL|Percentage of male participants with maintenance of suppression of testosterone to <30 ng/dL|Percentage of participants with suppression of the physical signs of puberty|Incremental growth rate|Ratio of change from baseline in bone age vs chronological age|Percentage of Participants with suppression of GnRHa-stimulated luteinizing hormone (LH)(<4 mlU/mL)","AbbVie","All","2 Years to 11 Years   (Child)","Phase 3","40","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-904","October 24, 2018","May 6, 2020","May 29, 2023","October 4, 2018",,"October 22, 2019","Pediatric Endocrinology Associates /ID# 200629, Long Beach, California, United States|Rady Children's Hosp San Diego /ID# 202491, San Diego, California, United States|Colorado Children's Hospital /ID# 201645, Aurora, Colorado, United States|Pediatric Endocrine Associates /ID# 201089, Greenwood Village, Colorado, United States|Nemour Child Clin FL, US /ID# 201331, Jacksonville, Florida, United States|Arnold Palmer Hosp Children /ID# 201624, Orlando, Florida, United States|Van Meter Pediatric Endocrinology /ID# 201688, Atlanta, Georgia, United States|Rocky Mountain Diabetes and Osteoporosis Center /ID# 209878, Idaho Falls, Idaho, United States|Indiana University /ID# 200526, Indianapolis, Indiana, United States|Mass General Hospital /ID# 202396, Boston, Massachusetts, United States|UMass Memorial Medical Center /ID# 203327, Worcester, Massachusetts, United States|University of Minnesota /ID# 200508, Minneapolis, Minnesota, United States|Childrens Mercy Hosp and Clin /ID# 200221, Kansas City, Missouri, United States|UBMD - Pediatrics /ID# 201978, Buffalo, New York, United States|Icahn School of Med Mt. Sinai /ID# 200675, New York, New York, United States|University of Oklahoma /ID# 200659, Tulsa, Oklahoma, United States|Penn State Hershey Medical Ctr /ID# 200287, Hershey, Pennsylvania, United States|Children's Hosp of PA (CHOP) /ID# 203846, Philadelphia, Pennsylvania, United States|Cook Children's Med. Center /ID# 212937, Fort Worth, Texas, United States|MultiCare Institute Health Sys /ID# 202188, Tacoma, Washington, United States|Pediatric Endocrine Research Associates /ID# 200131, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03695237"
61,"NCT03695185","A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy",,"Recruiting","No Results Available","Ulcerative Colitis (UC)","Drug: ABBV-323 Dose A|Drug: ABBV-323 Dose B","Percentage of participants with endoscopic improvement|Percentage of participants with clinical remission per Adapted Mayo score|Percentage of participants with clinical response per Adapted Mayo score|Percentage of participants with clinical response per Partial Adapted Mayo score|Percentage of participants with clinical remission per Full Mayo score in participants with a Full Mayo score of 6 to 12 at Baseline|Percentage of participants with endoscopic remission","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-722|2018-000930-37","March 26, 2019","December 18, 2020","November 22, 2021","October 4, 2018",,"December 19, 2019","Banner University Medical Cent /ID# 208392, Tucson, Arizona, United States|TLC Clinical Research Inc /ID# 206626, Beverly Hills, California, United States|Meridian Investigator Network /ID# 204646, Huntington Beach, California, United States|Orange County Institute of Gastroenterology and Endoscopy /ID# 207405, Mission Viejo, California, United States|UC Davis Medical Center /ID# 209402, Sacramento, California, United States|University of Chicago /ID# 207086, Chicago, Illinois, United States|Chicago Association for Research and Education in Science (CARES) /ID# 208092, North Chicago, Illinois, United States|Affinity Clinical Research /ID# 206211, Oak Brook, Illinois, United States|Penn Presbyterian Medical Center /ID# 206826, Philadelphia, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 204670, Nashville, Tennessee, United States|Clinical Associates in Researc /ID# 204689, San Antonio, Texas, United States|Zeidler Ledcor Centre /ID# 205069, Edmonton, Alberta, Canada|Mount Sinai Hosp.-Toronto /ID# 206180, Toronto, Ontario, Canada|Montreal General Hospital /ID# 204732, Montréal, Quebec, Canada|Chu de Nice-Hopital L'Archet Ii /Id# 208131, Nice CEDEX 3, Alpes-Maritimes, France|Hopital Beaujon /ID# 208129, Clichy, Ile-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 208133, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|Univ Hosp Schleswig-Holstein /ID# 207571, Kiel, Schleswig-Holstein, Germany|Charité Universitätsmedizin Campus Mitte /ID# 207570, Berlin, Germany|Universitaetsklinikum Frankfurt /ID# 207569, Frankfurt, Germany|Universita di Catanzaro Magna Graecia /ID# 204546, Catanzaro, Calabria, Italy|Complesso integrato Columbus /ID# 204549, Rome, Italy|Kyungpook National Univ Hosp /ID# 209912, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 210447, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Maastricht Universitair Medisch Centrum /ID# 204428, Maastricht, Netherlands|Franciscus Gasthuis & Vlietland /ID# 206976, Rotterdam, Netherlands|Elisabeth Tweesteden Ziekenhuis /ID# 206272, Tilburg, Netherlands|Hosp Univ Girona Josep Trueta /ID# 208230, Girona, Spain|Hospital General Universitario Gregorio Maranon /ID# 204504, Madrid, Spain|Hospital Universitario La Paz /ID# 210065, Madrid, Spain|Queen Elizabeth University Hos /ID# 206574, Glasgow, Glasgow City, United Kingdom|Royal Victoria Hospital /ID# 206744, Belfast, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03695185"
62,"NCT03682705","A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis.",,"Active, not recruiting","No Results Available","Rheumatoid Arthritis (RA)","Drug: Upadacitinib|Drug: ABBV-105|Drug: Upadacitinib placebo|Drug: ABBV-105 placebo","Change from Baseline in Disease Activity Score (DAS) 28 (C-reactive protein [CRP])|Change from baseline in Clinical Disease Activity Index (CDAI)|Proportion of participants achieving Clinical Remission (CR)|Proportion of participants achieving Low Disease Activity (LDA)|American College of Rheumatology (ACR)20 response rate|Change from baseline in individual components of ACR response|Change from baseline in DAS28(CRP)|Change from baseline in morning stiffness|Change from baseline in HAQ-DI|Proportion of participants achieving Minimal Clinically Important Difference (MCID) in change from baseline in HAQ-DI|Proportion of participants achieving European League Against Rheumatism (EULAR) Boolean remission|Change from baseline in Simplified Disease Activity Index (SDAI)|ACR 50 response rate|ACR 70 response rate|Change from baseline in DAS28 (Erythrocyte Sedimentation Rate (ESR))|Proportion of participants achieving ACR remission","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-063|2018-000666-10","October 8, 2018","February 14, 2020","March 19, 2020","September 25, 2018",,"December 18, 2019","Rheum Assoc of North Alabama /ID# 167382, Huntsville, Alabama, United States|AZ Arthritis & Rheum Research /ID# 167446, Mesa, Arizona, United States|SunValley Arthritis Center, Lt /ID# 213073, Peoria, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 167448, Phoenix, Arizona, United States|Rheumatology Ctr of San Diego /ID# 170690, Escondido, California, United States|St. Joseph Heritage Healthcare /ID# 167379, Fullerton, California, United States|Purushotham, Akther & Roshan K /ID# 168121, La Mesa, California, United States|Valerius Medical Group /ID# 168123, Los Alamitos, California, United States|Sierra Rheumatology /ID# 167976, Roseville, California, United States|Iraj Sabahi Research, Inc /ID# 201923, Turlock, California, United States|Inland Rheum Clin Trials Inc. /ID# 167459, Upland, California, United States|Medvin Clinical Research /ID# 205731, Whittier, California, United States|Rheumatology Consultants of De /ID# 208238, Lewes, Delaware, United States|Bay Area Arthritis and Osteo /ID# 208111, Brandon, Florida, United States|Clinical Res of West FL, Inc. /ID# 167462, Clearwater, Florida, United States|Omega Research Consultants, LLC /ID# 167376, DeBary, Florida, United States|Riverside Clinical Research /ID# 167982, Edgewater, Florida, United States|Lakes Research, LLC /ID# 170660, Miami, Florida, United States|Kendall South Medical Center, Inc. /ID# 206857, Miami, Florida, United States|Medallion Clinical Research Institute, LLC /ID# 201710, Naples, Florida, United States|Rheum Assoc of Central FL /ID# 170858, Orlando, Florida, United States|HMD Research LLC /ID# 208381, Orlando, Florida, United States|International Medical Research - Ormond /ID# 170864, Ormond Beach, Florida, United States|Millennium Research /ID# 167453, Ormond Beach, Florida, United States|Arthritis Center, Inc. /ID# 170695, Palm Harbor, Florida, United States|Integral Rheumatology & Immunology Specialists /ID# 206724, Plantation, Florida, United States|BayCare Medical Group /ID# 170860, Saint Petersburg, Florida, United States|St. Anthony Comprehensive Rese /ID# 170668, Saint Petersburg, Florida, United States|Clinical Research West FL /ID# 169099, Tampa, Florida, United States|ForCare Clinical Research /ID# 206280, Tampa, Florida, United States|FL Med Clinic, PA /ID# 206279, Zephyrhills, Florida, United States|Institute of Arthritis Researc /ID# 170694, Idaho Falls, Idaho, United States|Great Lakes Clinical Trials /ID# 167471, Chicago, Illinois, United States|Clinical Investigation Special /ID# 167468, Skokie, Illinois, United States|Deerbrook Medical Associates /ID# 207098, Vernon Hills, Illinois, United States|PRN of Kansas /ID# 167985, Wichita, Kansas, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 170682, Monroe, Louisiana, United States|Mansfield Health Center /ID# 167372, Mansfield, Massachusetts, United States|Advanced Clinical Care /ID# 167367, Worcester, Massachusetts, United States|June DO, PC /ID# 170670, Lansing, Michigan, United States|Beals Instititute /ID# 170658, Lansing, Michigan, United States|Arthritis Associates /ID# 209075, Hattiesburg, Mississippi, United States|North Mississippi Med Clinics /ID# 167377, Tupelo, Mississippi, United States|Clayton Medical Associates dba Saint Louis Rheumatology /ID# 170650, Saint Louis, Missouri, United States|Physician Res. Collaboration /ID# 200480, Lincoln, Nebraska, United States|Dhmc /Id# 167476, Lebanon, New Hampshire, United States|Ocean Rheumatology /ID# 170673, Toms River, New Jersey, United States|Arthritis and Osteo Assoc /ID# 167443, Las Cruces, New Mexico, United States|DJL Clinical Research, PLLC /ID# 167374, Charlotte, North Carolina, United States|EmergeOrtho, P.A. /ID# 209154, Durham, North Carolina, United States|Cape Fear Arthritis Care /ID# 167413, Leland, North Carolina, United States|New Horizons Clinical Research /ID# 170862, Blue Ash, Ohio, United States|Marietta Memorial Hospital /ID# 210968, Marietta, Ohio, United States|STAT Research, Inc. /ID# 200485, Vandalia, Ohio, United States|Health Research Oklahoma /ID# 167370, Oklahoma City, Oklahoma, United States|Clinical Research Ctr Reading /ID# 170708, Wyomissing, Pennsylvania, United States|West Tennessee Research Inst /ID# 167366, Jackson, Tennessee, United States|Nashville Arthritis and Rheumatology /ID# 206699, Nashville, Tennessee, United States|Amarillo Ctr for Clin Research /ID# 200484, Amarillo, Texas, United States|Tekton Research, Inc. /ID# 167475, Austin, Texas, United States|Trinity Universal Res Assoc /ID# 209252, Carrollton, Texas, United States|Arth and Osteo Clin Brazo Valley /ID# 209401, College Station, Texas, United States|Metroplex Clinical Research /ID# 167458, Dallas, Texas, United States|Rheumatic Disease Clin Res Ctr /ID# 167474, Houston, Texas, United States|Rheumatology Clinic of Houston /ID# 203689, Houston, Texas, United States|Accurate Clinical Research /ID# 207059, Houston, Texas, United States|West Texas Clinical Research /ID# 205732, Lubbock, Texas, United States|SW Rheumatology Res. LLC /ID# 167383, Mesquite, Texas, United States|Trinity Universal Research Association /ID# 209253, Plano, Texas, United States|Sun Research Institute /ID# 170667, San Antonio, Texas, United States|Accurate Clinical Management /ID# 200481, San Antonio, Texas, United States|DM Clinical Research /ID# 167444, Tomball, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 167407, Waco, Texas, United States|Tidewater Physicians Medical Center /ID# 210884, Newport News, Virginia, United States|Western Washington Arthritis C /ID# 205821, Bothell, Washington, United States|Arthritis Northwest, PLLC /ID# 200479, Spokane, Washington, United States|Rheumatology and Pulmonary cli /ID# 170863, Beckley, West Virginia, United States|Rheumatology and Immunotherapy Center /ID# 167385, Franklin, Wisconsin, United States|CUB Hospital Erasme /ID# 201965, Brussels, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 201756, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 201757, Gent, Oost-Vlaanderen, Belgium|UZ Leuven /ID# 201927, Leuven, Belgium|Rheumatology Research Assoc /ID# 207299, Edmonton, Alberta, Canada|Manitoba Clinic /ID# 202126, Winnipeg, Manitoba, Canada|CIADS Research Co Ltd /ID# 202125, Winnipeg, Manitoba, Canada|Credit Valley Rheumatology /ID# 202124, Mississauga, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 202652, Toronto, Ontario, Canada|Dr. Latha Naik /ID# 212972, Saskatoon, Saskatchewan, Canada|Revmatolog s.r.o. /ID# 202610, Jihlava 1, Jihlava, Czechia|Revmatologicky ustav Praha /ID# 202142, Prague 2, Praha 2, Czechia|Revmatologie MUDr. Klara Sirova /ID# 205185, Ostrava, Czechia|CCR Czech a.s /ID# 202144, Pardubice, Czechia|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 202439, Miskolc, Borsod-Abauj-Zemplen, Hungary|Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház /ID# 202441, Nyíregyháza, Szabolcs-Szatmar-Bereg, Hungary|Vital Medical Center Orvosi es /ID# 202437, Veszprém, Veszprem, Hungary|Revita Reumatologiai Rendelo /ID# 202438, Budapest, Hungary|C-MED/CMED Rehabilitációsközpont /ID# 205804, Szekesfehervar, Hungary|Malopolskie Centrum Kliniczne /ID# 206473, Cracow, Malopolskie, Poland|McBk Sc /Id# 212575, Grodzisk Mazowiecki, Mazowieckie, Poland|NBR Polska /ID# 206476, Warsaw, Mazowieckie, Poland|ClinicMed Daniluk, Nowak Sp.j. /ID# 212576, Białystok, Podlaskie, Poland|Reumatika - Centrum Reumatologii NZOZ /ID# 206472, Warsaw, Poland|GCM Medical Group, PSC /ID# 167983, San Juan, Puerto Rico|H. Un. Marques de Valdecilla /ID# 202133, Santander, Cantabria, Spain|H.U. Clinico San Carlos /ID# 202135, Madrid, Madrid, Comunidad De, Spain|Hospital Regional de Malaga /ID# 202137, Málaga, Malaga, Spain|Comple Hosp Univ de A Coruna /ID# 202140, A Coruna, Spain|Hospital Santa Creu i Sant Pau /ID# 206535, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 206575, Barcelona, Spain|Hospital Universitario Basurto /ID# 206462, Bilbao, Spain|Hospital Virgen Nieves /ID# 209705, Granada, Spain|Hospital Universitario La Fe /ID# 202139, Valencia, Spain|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 201976, Newcastle Upon Tyne, United Kingdom|University of Oxford /ID# 201974, Oxford, United Kingdom|Warrington + Halton Hosp NHS /ID# 206002, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03682705"
63,"NCT03675308","A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy",,"Recruiting","No Results Available","Psoriatic Arthritis","Biological: placebo for rizankizumab|Biological: risankizumab","Percentage of Participants Achieving at least 20% Improvement in American College of Rheumatology (ACR20) at Week 24|Change from Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)|Percentage of Participants With ≥ 90% Reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 24 in Participants With ≥ 3% Body Surface Area (BSA) Involving Psoriasis at Baseline|Change from Baseline to Week 24 in modified Total Sharp Score (PsA-mTSS) at Week 24|Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24|Change from Baseline to Week 24 in Fingernail Psoriasis|Change from Baseline to Week 24 in Leeds Enthesitis Index (LEI) in Participants with Enthesitis at Baseline|Change from Baseline to Week 24 in Leeds Dactylitis Index (LDI) in Participants With Dactylitis at Baseline|Change from Baseline to Week 24 in the 36-Item Short Form Health Questionnaire (SF-36) Physical Component Summary (PCS) Score|Change from Baseline to Week 24 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionnaire Score","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","880","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-011|2017-002465-22","March 25, 2019","January 8, 2021","December 3, 2024","September 18, 2018",,"January 18, 2020","Pinnacle Research Group /ID# 167955, Anniston, Alabama, United States|SunValley Arthritis Center, Lt /ID# 200270, Peoria, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 209873, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Research, PLLC /ID# 209875, Tucson, Arizona, United States|Southern Arizona VA Health Care System /ID# 209247, Tucson, Arizona, United States|Arthritis and Rheumatism Associates /ID# 209882, Jonesboro, Arkansas, United States|Valerius Med Grp & Res Ctr /ID# 207428, Los Alamitos, California, United States|Iraj Sabahi Research, Inc /ID# 208353, Turlock, California, United States|Inland Rheum Clin Trials Inc. /ID# 201641, Upland, California, United States|Medvin Clinical Research /ID# 211127, Whittier, California, United States|New England Research Associates, LLC /ID# 207237, Bridgeport, Connecticut, United States|Danbury Clinical Research, LLC /ID# 209517, Danbury, Connecticut, United States|Yale University /ID# 207236, New Haven, Connecticut, United States|AARDS Research, Inc. /ID# 210802, Aventura, Florida, United States|RASF - Clinical Research /ID# 211099, Boca Raton, Florida, United States|Southeastern Integrated Med /ID# 207461, Gainesville, Florida, United States|Sweet Hope Research Specialty Inc /ID# 209393, Hialeah, Florida, United States|River City Clinical Research /ID# 209876, Jacksonville, Florida, United States|Rheum Assoc of Central FL /ID# 201622, Orlando, Florida, United States|Heuermd Research Inc /Id# 208427, Orlando, Florida, United States|Integral Rheumatology & Immunology Specialists /ID# 208955, Plantation, Florida, United States|ForCare Clinical Research /ID# 168034, Tampa, Florida, United States|Arthritis and Rheumatology /ID# 168046, Atlanta, Georgia, United States|Affinity Health /ID# 210816, Oak Brook, Illinois, United States|OrthoIllinois /ID# 205300, Rockford, Illinois, United States|Springfield Clinic /ID# 200244, Springfield, Illinois, United States|Klein & Associates, M.D., P.A. /ID# 169483, Cumberland, Maryland, United States|The Center for Rheumatology & /ID# 168017, Wheaton, Maryland, United States|Clinical Pharmacology Study Gr /ID# 168019, Worcester, Massachusetts, United States|Advanced Rheumatology, PC /ID# 168042, Lansing, Michigan, United States|June DO, PC /ID# 208915, Lansing, Michigan, United States|Saint Paul Rheumatology /ID# 208471, Eagan, Minnesota, United States|Glacier View Research Institut /ID# 213707, Kalispell, Montana, United States|Physician Res. Collaboration /ID# 208670, Lincoln, Nebraska, United States|Arthritis and Osteoporosis Ass /ID# 210906, Freehold, New Jersey, United States|Center for Rheumatology LLP /ID# 207313, Albany, New York, United States|NYU Langone Ambulatory Care Brooklyn Heights /ID# 207310, Brooklyn, New York, United States|Joint & Muscle Research Instit /ID# 208620, Charlotte, North Carolina, United States|Medication Management, LLC /ID# 211734, Greensboro, North Carolina, United States|Coastal Carolina Health Care /ID# 208619, New Bern, North Carolina, United States|New Horizons Clinical Research /ID# 200452, Blue Ash, Ohio, United States|Marietta Memorial Hospital /ID# 210179, Marietta, Ohio, United States|Paramount Medical Research Con /ID# 201583, Middleburg Heights, Ohio, United States|STAT Research, Inc. /ID# 213805, Springboro, Ohio, United States|Health Research Oklahoma /ID# 168027, Oklahoma City, Oklahoma, United States|Altoona Ctr Clinical Res /ID# 168037, Duncansville, Pennsylvania, United States|Allegheny-Singer Research Institute dba AHN Research Institute /ID# 210349, Pittsburgh, Pennsylvania, United States|Clinical Research Ctr Reading /ID# 168070, Wyomissing, Pennsylvania, United States|RIH / Alpert Medical School /ID# 207232, Providence, Rhode Island, United States|Nashville Arthritis and Rheumatology /ID# 168069, Nashville, Tennessee, United States|Amarillo Ctr for Clin Research /ID# 208347, Amarillo, Texas, United States|PCCR Solution /ID# 208386, Colleyville, Texas, United States|Dallas VA Medical Center /ID# 208389, Dallas, Texas, United States|PCCR Solutions /ID# 210597, Fort Worth, Texas, United States|Adv Rheumatology of Houston /ID# 208354, The Woodlands, Texas, United States|DM Clinical Research /ID# 208351, Tomball, Texas, United States|Kadlec Clinic Rheumatology /ID# 207969, Kennewick, Washington, United States|Swedish Medical Center /ID# 217319, Seattle, Washington, United States|Rheumatology and Pulmonary cli /ID# 200446, Beckley, West Virginia, United States|Aurora Rheumatology and Immunotherapy Center /ID# 168066, Franklin, Wisconsin, United States|Holy Family Memorial, Inc. /ID# 209387, Manitowoc, Wisconsin, United States|Gundersen Clinic, Ltd /ID# 209459, Onalaska, Wisconsin, United States|Hospital Italiano de Buenos Aires /ID# 208474, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Framingham Centro Medico /ID# 210409, La Plata, Buenos Aires, Argentina|Fundacion CIDEA /ID# 210494, Buenos Aires, Argentina|Hospital General de Agudos Ram /ID# 169164, Buenos Aires, Argentina|Hospital Militar Central Ciruj /ID# 211622, Buenos Aires, Argentina|Inst de Rehab Psicofisica /ID# 214681, Buenos Aires, Argentina|DOM Centro de Reumatologia /ID# 208479, Ciudad Autonoma Buenos Aires, Argentina|Hosp Privado Ctr Med Cordoba /ID# 211623, Cordoba, Argentina|Instituto CAICI /ID# 169168, Rosario, Santa FE, Argentina|Centro Medico Privado/Reuma /ID# 208343, San Miguel de Tucuman, Argentina|Cimer /Id# 169167, San Miguel de Tucuman, Argentina|Centro de Enfermedades /ID# 169163, Santa Fe, Argentina|The Canberra Hospital /ID# 207592, Garran, Australian Capital Territory, Australia|Royal Brisbane and Women's Hospital /ID# 212785, Herston, Queensland, Australia|Rheumatology Research Unit /ID# 207200, Maroochydore, Queensland, Australia|Griffith University /ID# 207505, Southport, Queensland, Australia|Flinders Medical Centre /ID# 210562, Bedford Park, South Australia, Australia|Emeritus Research /ID# 207202, Camberwell, Victoria, Australia|Monash Health /ID# 208034, Clayton, Victoria, Australia|UZ Ghent /ID# 210036, Ghent, Oost-Vlaanderen, Belgium|Reuma clinic /ID# 208213, Genk, Belgium|ZNA - Jan Palfijn /ID# 208212, Merksem, Belgium|University Clinical Centre of the Republic of Srpska /ID# 208268, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 208269, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 210047, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 208272, Sarajevo, Bosnia and Herzegovina|SER - Serviços Especializados em Reumatologia da Bahia. /ID# 207489, Salvador, Bahia, Brazil|CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 207496, Juiz de Fora, Minas Gerais, Brazil|EDUMED Educacao em Saude S/S L /ID# 207488, Curitiba, Parana, Brazil|LMK Sevicos Medicos S/S /ID# 207491, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 211783, Sao Jose Do Rio Preto, Sao Paulo, Brazil|CPCLIN - Centro de Pesquisas Clínicas /ID# 207493, Sao Paulo, Brazil|Medical Center Medconsult /ID# 211399, Pleven, Bulgaria|MHAT Kaspela /ID# 210505, Plovdiv, Bulgaria|MHAT-Plovdiv AD /ID# 167739, Plovdiv, Bulgaria|Excelsior Medical Center /ID# 167741, Sofia, Bulgaria|Diag Consult Ctr 17 Sofia EOOD /ID# 210506, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment - Sofia at Military Medical Academy /ID# 210829, Sofia, Bulgaria|Medical Center Academy /ID# 211467, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 167742, Sofia, Bulgaria|Percuro Clinical Research, Ltd /ID# 169601, Victoria, British Columbia, Canada|Manitoba Clinic /ID# 206819, Winnipeg, Manitoba, Canada|CIADS Research Co Ltd /ID# 169600, Winnipeg, Manitoba, Canada|SKIN Centre for Dermatology /ID# 169604, Peterborough, Ontario, Canada|K. Papp Clinical Research /ID# 169603, Waterloo, Ontario, Canada|Groupe de Recherche en Maladies Osseuses /ID# 169598, Sainte-foy, Quebec, Canada|Dr. Latha Naik /ID# 212188, Saskatoon, Saskatchewan, Canada|Servicio de Salud Atacama Hospital Regional Copiapo San Jose del Carmen /ID# 209203, Copiapó, Atacama, Chile|Research Group Ltda /ID# 208164, Santiago, Region Metropolitana De Santiago, Chile|CTR Estudios SpA /ID# 208166, Providencia, Chile|Centro Inter Estud Clin CIEC /ID# 209908, Santiago, Chile|Clínica Dermacross S.A /ID# 208163, Vitacura, Santiago, Chile|Poliklinika Repromed /ID# 208628, Zagreb, Grad Zagreb, Croatia|Poliklinika Solmed /ID# 210965, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 208623, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Rijeka /ID# 208621, Rijeka, Primorsko-goranska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 208626, Split, Croatia|Medical Center Kuna-Peric /ID# 208047, Zagreb, Croatia|Poliklinika Bonifarm /ID# 208750, Zagreb, Croatia|Nuselská poliklinika, Revmatologie /ID# 209027, Prague 4, Praha 4, Czechia|PV MEDICAL Services s.r.o. /ID# 210222, Zlín 1, Zlin, Czechia|Revmacentrum BRNO /ID# 209025, Brno-zidenice, Czechia|Reumatologicka ambulancia /ID# 210223, Prague, Czechia|Medical Plus, s.r.o. /ID# 210439, Uherské Hradište, Czechia|Aarhus Universitetshospital /ID# 168761, Aarhus C, Midtjylland, Denmark|Frederiksberg Hospital /ID# 207576, Frederiksberg, Denmark|MediTrials /ID# 207816, Tartu, Tartumaa, Estonia|Innomedica /ID# 211416, Tallinn, Estonia|North Estonian Medical Centre /ID# 208325, Tallinn, Estonia|Helsinki Univ Central Hospital /ID# 207724, Helsinki, Finland|Ite Pihlajanlinna Kuopio /ID# 208322, Kuopio, Finland|Turku University Hospital /ID# 207726, Turku, Finland|Rheumazentrum Ruhrgebiet /ID# 207216, Herne, Nordrhein-Westfalen, Germany|Immanuel-Krankenhaus /ID# 207218, Berlin-buch, Germany|Cent fur Innovative Diagnostik /ID# 209483, Frankfurt, Germany|Rheumaforschungszentrum II /ID# 209484, Hamburg, Germany|General Hospital Asklepieio Voulas /ID# 212956, Athens, Attiki, Greece|Naval Hospital of Athens /ID# 206838, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 206839, Heraklion, Greece|Olympion General Clinic SA /ID# 207048, Patras, Greece|424 General MILITARY Hospital /ID# 210974, Thessaloniki, Greece|Rabin Medical Center /ID# 207475, Petakh Tikva, Tel-Aviv, Israel|Barzilai Medical Center /ID# 207476, Ashkelon, Israel|Rambam Health Care Campus /ID# 208170, Haifa, Israel|Meir Medical Center /ID# 207473, Kfar Saba, Israel|Sheba Medical Center /ID# 207474, Ramat Gan, Israel|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 207799, Modena, Emilia-Romagna, Italy|AOU Ospedali Riuniti di Ancona - G.M. Lancisi, G. Salesi /ID# 207269, Ancona, Marche, Italy|AOU Policlinico Vittorio Emanuele /ID# 207795, Catania, Italy|Policlinico Univ Tor Vergata /ID# 207271, Rome, Italy|Ospedale Policlinico G. B. Ros /ID# 207265, Verona, Italy|Kyungpook National Univ Hosp /ID# 207408, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Hanyang University Seoul Hospi /ID# 209263, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Konkuk University Medical Ctr /ID# 207509, Seoul, Seoul Teugbyeolsi, Korea, Republic of|LTD M+M Centers /ID# 208733, Adazi, Latvia|D.Saulites-Kandevicas PP /ID# 207224, Liepaja, Latvia|Clinic ORTO /ID# 216218, Riga, Latvia|Riga East Clinical Univ Hosp /ID# 207223, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 207220, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 207331, Kovno, Kaunas, Lithuania|VAKK dr. Kildos Clinic /ID# 207330, Kaunas, Lithuania|Klaipeda University Hospital /ID# 207329, Klaipeda, Lithuania|Public Institution Republican /ID# 207328, Siauliai, Lithuania|Vilnius University Hospital /ID# 216752, Vilnius, Lithuania|Hospital Raja Permaisuri Bainun /ID# 207920, Ipoh, Perak, Malaysia|Hospital Selayang /ID# 208938, Batu Caves, Malaysia|University Malaya Med Ctr /ID# 208937, Kuala Lumpur, Malaysia|Hospital Tuanku Ja afar /ID# 207919, Seremban, Malaysia|CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 208331, Mexico City, Ciudad De Mexico, Mexico|Centro Integral en Reumatología S.A de C.V /ID# 208346, Guadalajara, Jalisco, Mexico|Consultorio Privado /ID# 211667, Guadalajara, Jalisco, Mexico|Hospital Universitario ""Dr. José Eleuterio González"" /ID# 208344, Monterrey, Nuevo Leon, Mexico|Eukarya PharmaSite, SC /ID# 208431, Monterrey, Nuevo Leon, Mexico|Centro Peninsular de Investigación Clínica SCP /ID# 208345, Colonia Centro, Yucatan, Mexico|Hospital General Regional No. 1 Dr. Carlos Mac Gregor Sánchez Navarro /ID# 210835, Ciudad de Mexico, Mexico|RM Pharma Specialists, S.A de C.V /ID# 208330, Mexico City, Mexico|Antonius Ziekenhuis /ID# 208587, Sneek, Fryslan, Netherlands|Universitair Medisch Centrum Groningen /ID# 208580, Groningen, Netherlands|Medisch Centrum Leeuwarden /ID# 168453, Leeuwarden, Netherlands|Waikato Hospital /ID# 213257, Hamilton, Waikato, New Zealand|Middlemore Hospital /ID# 213256, Auckland, New Zealand|CGM Research Trust /ID# 210498, Burwood Christchurch, New Zealand|NZOZ Nasz Lekarz /ID# 216176, Toruń, Kujawsko-pomorskie, Poland|Malopolskie Centrum Kliniczne /ID# 208007, Cracow, Malopolskie, Poland|McBk Sc /Id# 209132, Grodzisk Mazowiecki, Mazowieckie, Poland|Centrum Reumatologii Reumatika /ID# 210352, Warsaw, Mazowieckie, Poland|Osteo-Medic S.C. /ID# 208008, Białystok, Podlaskie, Poland|ClinicMed Daniluk, Nowak Sp.j. /ID# 210824, Białystok, Podlaskie, Poland|ETYKA-Osrodek Badan Klinicznyc /ID# 216241, Olsztyn, Warminsko-mazurskie, Poland|Centrum Medyczne ""INTERCOR"" /ID# 210191, Bydgoszcz, Poland|Centrum Kliniczno-Badawcze /ID# 208010, Elblag, Poland|Instituto Portugues De Reumatologia /ID# 208149, Lisbon, Lisboa, Portugal|Centro Hospitalar De Vila Nova /ID# 208145, Vila Nova De Gaia, Porto, Portugal|Hospital de Braga /ID# 208146, Braga, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 208148, Lisboa, Portugal|Centro Hospitalar Baixo Vouga /ID# 215979, Porto, Portugal|Unidade Local De Saude Do Alto Minho /ID# 208147, Viana Do Castelo, Portugal|Mindful Medical Research /ID# 211129, San Juan, Puerto Rico|Cabinet Medical Dr Triff Carina /Id# 207528, Timişoara, Timis, Romania|Spitalul Clinic Sf. Maria /ID# 210054, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta /ID# 207340, Cluj, Romania|Rehabilitation Clinical Hosp /ID# 207371, Iasi, Romania|NW State Medical Univ na Mechn /ID# 207641, St. Petersburg, Leningradskaya Oblast, Russian Federation|LLC Family Outpatient Clinic № /ID# 169510, Korolev, Moskva, Russian Federation|FSFSI SRI of Rheumatology n.a.V.A.Nasonova /ID# 207643, Moscow, Moskva, Russian Federation|LLC Medical Center /ID# 169516, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Kazan State Medical University /ID# 169511, Kazan, Tatarstan, Respublika, Russian Federation|Russian National Research Medi /ID# 207646, Moscow, Russian Federation|Perm Region Clinical Hospital /ID# 207642, Perm, Russian Federation|Ulyanovsk Regional Clinical Ho /ID# 169515, Ulyanovsk, Russian Federation|Institute for Rheumatology /ID# 168194, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 168197, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 168198, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 168199, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 168218, Belgrade, Beograd, Serbia|Special Hospital for Rheuma /ID# 168255, Novi Sad, Vojvodina, Serbia|Special Hospital for Rheuma /ID# 210284, Novi Sad, Vojvodina, Serbia|National University Hospital /ID# 208599, Singapore, Singapore|Singapore General Hospital /ID# 207917, Singapore, Singapore|Changi General Hospital /ID# 208965, Singapore, Singapore|MEDMAN s.r.o. /ID# 208018, Martin, Slovakia|Reumatologická ambulancia Reum.hapi s.r.o. /ID# 208016, Nové Mesto Nad Váhom, Slovakia|Slovak research center Team Member, Thermium s.r.o. /ID# 208015, Pieštany, Slovakia|REUMAMED POPRAD s.r.o. /ID# 208407, Poprad, Slovakia|REUMA-GLOBAL, s.r.o. /ID# 208017, Trnava, Slovakia|Dr Jenny Potts /ID# 168691, Port Elizabeth, Eastern Cape, South Africa|University of Pretoria /ID# 167621, Pretoria, Gauteng, South Africa|Jakaranda Hospital /ID# 207577, Pretoria, Gauteng, South Africa|Synexus Helderberg Clinical Tr /ID# 210891, Cape Town, Western Cape, South Africa|Arthritis Clinical Research Tr /ID# 167625, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 167629, Stellenbosch, Western Cape, South Africa|Corporac Sanitaria Parc Tauli /ID# 207830, Sabadell, Barcelona, Spain|H.U. Clinico San Carlos /ID# 207832, Madrid, Madrid, Comunidad De, Spain|Comple Hosp Univ de A Coruna /ID# 207826, A Coruna, Spain|Complejo Hosp Torrecardenas /ID# 212716, Almería, Spain|Hospital Parc de Salut del Mar /ID# 209698, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 208543, Barcelona, Spain|Hosp Univ 12 de Octubre /ID# 207827, Madrid, Spain|Hospital Universitario La Fe /ID# 207831, Valencia, Spain|Skanes Universitetssjukhus /ID# 210070, Malmö, Skane Lan, Sweden|Falu Lasarett /ID# 210322, Falun, Sweden|Orebro Universitetssjukhuset /ID# 207948, Orebro, Sweden|Karolinska Univ Sjukhuset /ID# 208175, Solna, Sweden|Uppsala University Hospital /ID# 207944, Uppsala, Sweden|Vastmanlands Sjukhus /ID# 207943, Vasteras, Sweden|Dalin Tzu Chi General Hospital /ID# 207567, Dalin Township, Taiwan|Chung Shan Medical University /ID# 207257, Taichung City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 207255, Taoyuan City, Taiwan|GI ""National Institute of Therapy named by L.T. Malaya"" /ID# 209556, Kharkiv, Kharkivska Oblast, Ukraine|Medical Centre of OK!Clinic of International Institute of Clinical Trials /ID# 207749, Kiev, Kyivska Oblast, Ukraine|Clinic of Scientific Research Institute of Invalid Rehabilitation /ID# 207873, Vinnytsia, Vinnytska Oblast, Ukraine|Volyn regional clinical hospital /ID# 208276, Lutsk, Volynska Oblast, Ukraine|CNE ""Cherkasy Regional Hospital of Cherkasy Regional Council"" /ID# 207912, Cherkasy, Ukraine|MNPE ""Chernihiv Regional Hospital"" /ID# 207730, Chernihiv, Ukraine|PNE ""City Multifunctional Hospital #18"" /ID# 207911, Kharkiv, Ukraine|MNI ""Khmelnitskyi Regional Hospital"" /ID# 207753, Khmelnitskyi, Ukraine|ME Kryvyi Rih City Clinical Hospital #2 /ID# 207748, Kryvyi Rih, Ukraine|MNCE ""Lviv City Clinical Hospital #4"" /ID# 207715, Lviv, Ukraine|PI ""Poltava Regional Clinical Hospital n.a. M.V.Sklifosovsky"" /ID# 207872, Poltava, Ukraine|NPE ""City Hospital #6"" Zaporizhzhia City Counsil /ID# 207754, Zaporizhia, Ukraine|Whipps Cross Univ Hospital /ID# 210534, London, London, City Of, United Kingdom|Glasgow Royal Infirmary /ID# 214942, Glasgow, United Kingdom|Manchester Royal Infirmary, Ma /ID# 207928, Manchester, United Kingdom|Queen Alexandra Hospital /ID# 207932, Portsmouth, United Kingdom|Haywood Hospital /Id# 214941, Stoke on Trent, United Kingdom|Torbay and South Devon /Id# 207931, Torquay, United Kingdom|Arrowe Park Hospital /ID# 210535, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03675308"
64,"NCT03671148","A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)",,"Active, not recruiting","No Results Available","Psoriatic Arthritis","Biological: placebo for rizankizumab|Biological: risankizumab","Percentage of Participants Achieving at least 20% Improvement in American College of Rheumatology (ACR20) at Week 24|Change from Baseline to Week 24 in Health Assessment Questionnaire-Disability Index (HAQ-DI)|Percentage of Participants With ≥ 90% Reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 24 in Participants With ≥ 3% Body Surface Area (BSA) Involving Psoriasis at Baseline|Percentage of Participants Achieving Minimal Disease Activity (MDA) at Week 24|Change from Baseline to Week 24 in Leeds Enthesitis Index (LEI) in Participants with Enthesitis at Baseline|Change from Baseline to Week 24 in Leeds Dactylitis Index (LDI) in Participants With Dactylitis at Baseline|Change from Baseline to Week 24 in the 36-Item Short Form Health Questionnaire (SF-36) Physical Component Summary (PCS) Score|Change from Baseline to Week 24 in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Questionnaire Score","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","444","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M15-998|2017-002464-40","March 7, 2019","June 19, 2020","May 17, 2024","September 14, 2018",,"January 18, 2020","Pinnacle Research Group /ID# 167953, Anniston, Alabama, United States|Saint Jude Heritage /ID# 166842, Fullerton, California, United States|Care Access Research, Huntingt /ID# 207423, Huntington Beach, California, United States|Arthritis & Osteo Medical Ctr /ID# 166541, La Palma, California, United States|East Bay Rheumatology Medical /ID# 166845, San Leandro, California, United States|Inland Rheum Clin Trials Inc. /ID# 166621, Upland, California, United States|Denver Arthritis Clinic /ID# 166442, Denver, Colorado, United States|New England Research Associates, LLC /ID# 166525, Bridgeport, Connecticut, United States|Yale University /ID# 166330, New Haven, Connecticut, United States|AARDS Research, Inc. /ID# 212582, Aventura, Florida, United States|Southeastern Integrated Med /ID# 207457, Gainesville, Florida, United States|Sweet Hope Research Specialty Inc /ID# 168163, Hialeah, Florida, United States|Rheum Assoc of Central FL /ID# 201629, Orlando, Florida, United States|Heuermd Research Inc /Id# 208428, Orlando, Florida, United States|Millennium Research /ID# 201627, Ormond Beach, Florida, United States|Arthritis Center, Inc. /ID# 208116, Palm Harbor, Florida, United States|Integral Rheumatology & Immunology Specialists /ID# 166351, Plantation, Florida, United States|BayCare Medical Group /ID# 201630, Saint Petersburg, Florida, United States|W. Broward Rheum Assoc Inc. /ID# 201234, Tamarac, Florida, United States|University of South Florida /ID# 208467, Tampa, Florida, United States|ForCare Clinical Research /ID# 166375, Tampa, Florida, United States|Arthritis and Rheumatology /ID# 169438, Atlanta, Georgia, United States|Clinical Investigation Special /ID# 166681, Skokie, Illinois, United States|Springfield Clinic /ID# 166345, Springfield, Illinois, United States|Ochsner Clinic Foundation /ID# 166622, Baton Rouge, Louisiana, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 166707, Monroe, Louisiana, United States|MMP Women's Health /ID# 169334, Portland, Maine, United States|Klein & Associates, M.D., P.A. /ID# 166549, Cumberland, Maryland, United States|The Center for Rheumatology & /ID# 166448, Wheaton, Maryland, United States|Clinical Pharmacology Study Gr /ID# 166455, Worcester, Massachusetts, United States|Saint Paul Rheumatology /ID# 166599, Eagan, Minnesota, United States|Clayton Medical Associates dba Saint Louis Rheumatology /ID# 166389, Saint Louis, Missouri, United States|Clinvest Research LLC /ID# 166745, Springfield, Missouri, United States|Glacier View Research Institut /ID# 169344, Kalispell, Montana, United States|Mary Hitchcock Memorial Hospit /ID# 169443, Lebanon, New Hampshire, United States|Ocean Rheumatology, PA /ID# 166561, Toms River, New Jersey, United States|Arthritis Rheumatic Back Disorder /ID# 166658, Voorhees, New Jersey, United States|NYU Langone Ambulatory Care Brooklyn Heights /ID# 169335, Brooklyn, New York, United States|Paramount Medical Research Con /ID# 166334, Middleburg Heights, Ohio, United States|Health Research Oklahoma /ID# 166408, Oklahoma City, Oklahoma, United States|Altoona Ctr Clinical Res /ID# 166691, Duncansville, Pennsylvania, United States|Clinical Research Ctr Reading /ID# 166354, Wyomissing, Pennsylvania, United States|West Tennessee Research Inst /ID# 166429, Jackson, Tennessee, United States|Nashville Arthritis and Rheumatology /ID# 208395, Nashville, Tennessee, United States|Amarillo Ctr for Clin Research /ID# 208340, Amarillo, Texas, United States|Tekton Research, Inc. /ID# 166493, Austin, Texas, United States|PCCR Solution /ID# 208156, Colleyville, Texas, United States|Rheumatology Clinic of Houston /ID# 166636, Houston, Texas, United States|West Texas Clinical Research /ID# 208155, Lubbock, Texas, United States|SW Rheumatology Res. LLC /ID# 166587, Mesquite, Texas, United States|Trinity Universal Research Association /ID# 208387, Plano, Texas, United States|DM Clinical Research /ID# 208350, Tomball, Texas, United States|Kadlec Clinic Rheumatology /ID# 167667, Kennewick, Washington, United States|Arthritis Northwest, PLLC /ID# 169535, Spokane, Washington, United States|Rheumatology and Pulmonary cli /ID# 169341, Beckley, West Virginia, United States|Aurora Rheumatology and Immunotherapy Center /ID# 166742, Franklin, Wisconsin, United States|The Rheumatic Disease Center /ID# 166682, Glendale, Wisconsin, United States|Hospital Italiano de Buenos Aires /ID# 208473, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Hospital General de Agudos Ram /ID# 169152, Buenos Aires, Argentina|DOM Centro de Reumatologia /ID# 208478, Ciudad Autonoma Buenos Aires, Argentina|Instituto CAICI /ID# 169156, Rosario, Santa FE, Argentina|Centro Medico Privado/Reuma /ID# 208342, San Miguel de Tucuman, Argentina|Cimer /Id# 169155, San Miguel de Tucuman, Argentina|Centro de Enfermedades /ID# 169151, Santa Fe, Argentina|The Canberra Hospital /ID# 207591, Garran, Australian Capital Territory, Australia|Rheumatology Research Unit /ID# 207191, Maroochydore, Queensland, Australia|Griffith University /ID# 207504, Southport, Queensland, Australia|Emeritus Research /ID# 207195, Camberwell, Victoria, Australia|Monash Health /ID# 208033, Clayton, Victoria, Australia|UZ Ghent /ID# 210037, Ghent, Oost-Vlaanderen, Belgium|Reuma clinic /ID# 208211, Genk, Belgium|UZ Leuven /ID# 208209, Leuven, Belgium|ZNA - Jan Palfijn /ID# 208210, Merksem, Belgium|SER - Serviços Especializados em Reumatologia da Bahia. /ID# 169491, Salvador, Bahia, Brazil|CIP - Centro Internacional de Pesquisa /ID# 169524, Goiânia, Goias, Brazil|CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 169489, Juiz de Fora, Minas Gerais, Brazil|EDUMED Educacao em Saude S/S L /ID# 169492, Curitiba, Parana, Brazil|LMK Sevicos Medicos S/S /ID# 169541, Porto Alegre, Rio Grande Do Sul, Brazil|CPCLIN - Centro de Pesquisas Clínicas /ID# 169520, Sao Paulo, Brazil|Percuro Clinical Research, Ltd /ID# 169530, Victoria, British Columbia, Canada|CIADS Research Co Ltd /ID# 169526, Winnipeg, Manitoba, Canada|Dermatrials Research /ID# 208303, Hamilton, Ontario, Canada|K. Papp Clinical Research /ID# 169527, Waterloo, Ontario, Canada|Ctr. de Rheum de l'est du QC /ID# 208302, Rimouski, Quebec, Canada|Aarhus Universitetshospital /ID# 168762, Aarhus C, Midtjylland, Denmark|Frederiksberg Hospital /ID# 168763, Frederiksberg, Denmark|MediTrials /ID# 207815, Tartu, Tartumaa, Estonia|East Tallinn Central Hospital /ID# 208317, Tallinn, Estonia|North Estonian Medical Centre /ID# 208319, Tallinn, Estonia|Ite Pihlajanlinna Kuopio /ID# 208316, Kuopio, Finland|Turku University Hospital /ID# 208199, Turku, Finland|CHU Toulouse /ID# 209344, Toulouse CEDEX 3, Occitanie, France|CHU Bordeaux-Hopital Pellegrin /ID# 211159, Bordeaux, France|CHRU Tours - Hopital Trousseau /ID# 209343, Chambray Les Tours, France|Rheumazentrum Ruhrgebiet /ID# 207212, Herne, Nordrhein-Westfalen, Germany|Immanuel-Krankenhaus /ID# 207214, Berlin-buch, Germany|Cent fur Innovative Diagnostik /ID# 209494, Frankfurt, Germany|Rheumaforschungszentrum II /ID# 209493, Hamburg, Germany|Naval Hospital of Athens /ID# 206928, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 206930, Heraklion, Greece|Olympion General Clinic SA /ID# 207047, Patras, Greece|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 169248, Miskolc, Borsod-Abauj-Zemplen, Hungary|Vital Medical Center Orvosi es /ID# 208123, Veszprém, Veszprem, Hungary|Budai Irgalmasrendi Korhaz /ID# 209054, Budapest, Hungary|Szent-Gyorgyi Albert Klinikai Kozpont /ID# 169237, Szeged, Hungary|Rabin Medical Center /ID# 207470, Petakh Tikva, Tel-Aviv, Israel|Barzilai Medical Center /ID# 207471, Ashkelon, Israel|Rambam Health Care Campus /ID# 208169, Haifa, Israel|Meir Medical Center /ID# 207469, Kfar Saba, Israel|Sheba Medical Center /ID# 207468, Ramat Gan, Israel|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 207800, Modena, Emilia-Romagna, Italy|AOU Ospedali Riuniti di Ancona - G.M. Lancisi, G. Salesi /ID# 207268, Ancona, Marche, Italy|AOU Policlinico Vittorio Emanuele /ID# 207792, Catania, Italy|Ospedale Policlinico G. B. Ros /ID# 207264, Verona, Italy|Antonius Ziekenhuis /ID# 208581, Sneek, Fryslan, Netherlands|Universitair Medisch Centrum Groningen /ID# 168450, Groningen, Netherlands|Medisch Centrum Leeuwarden /ID# 168449, Leeuwarden, Netherlands|Waikato Hospital /ID# 214276, Hamilton, Waikato, New Zealand|Middlemore Clinical Trials /ID# 214293, Auckland, New Zealand|CGM Research Trust /ID# 210596, Burwood Christchurch, New Zealand|Malopolskie Centrum Kliniczne /ID# 208011, Cracow, Malopolskie, Poland|Centrum Reumatologii Reumatika /ID# 210956, Warsaw, Mazowieckie, Poland|Osteo-Medic S.C. /ID# 208013, Białystok, Podlaskie, Poland|Centrum Badań Klinicznych Pi-House /ID# 208012, Gdansk, Pomorskie, Poland|Centrum Kliniczno-Badawcze /ID# 208014, Elblag, Poland|Instituto Portugues De Reumatologia /ID# 208140, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 208139, Lisboa, Portugal|Unidade Local De Saude Do Alto Minho /ID# 208138, Viana Do Castelo, Portugal|GCM Medical Group /ID# 208461, San Juan, Puerto Rico|Changi General Hospital /ID# 208966, Singapore, Singapore|Dr Jenny Potts /ID# 167628, Port Elizabeth, Eastern Cape, South Africa|Arthritis Clinical Research Tr /ID# 167611, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 167630, Stellenbosch, Western Cape, South Africa|Corporac Sanitaria Parc Tauli /ID# 207822, Sabadell, Barcelona, Spain|H. Un. Marques de Valdecilla /ID# 208541, Santander, Cantabria, Spain|H.U. Clinico San Carlos /ID# 207824, Madrid, Madrid, Comunidad De, Spain|Comple Hosp Univ de A Coruna /ID# 207819, A Coruna, Spain|Hosp Univ 12 de Octubre /ID# 207820, Madrid, Spain|Hospital Universitario La Fe /ID# 207823, Valencia, Spain|Orebro Universitetssjukhuset /ID# 169400, Orebro, Sweden|Karolinska Univ Sjukhuset /ID# 208174, Solna, Sweden|Uppsala University Hospital /ID# 169098, Uppsala, Sweden|Vastmanlands Sjukhus /ID# 168620, Vasteras, Sweden|Whipps Cross Univ Hospital /ID# 210794, London, London, City Of, United Kingdom|Manchester Royal Infirmary, Ma /ID# 207923, Manchester, United Kingdom|Torbay and South Devon /Id# 207926, Torquay, United Kingdom|Arrowe Park Hospital /ID# 210536, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03671148"
65,"NCT03661138","A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis",,"Active, not recruiting","No Results Available","Atopic Dermatitis","Drug: Upadacitinib|Drug: Placebo for upadacitinib|Drug: Topical Corticosteroids (TCS)","Number of participants experiencing adverse events","AbbVie","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","272","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M17-377","October 27, 2018","February 25, 2022","February 25, 2022","September 7, 2018",,"June 21, 2019","Central Clinic /ID# 206558, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 207566, Nagoya-shi, Aichi, Japan|Yasumoto Dermatology Clinic /ID# 206480, Chikushino-shi, Fukuoka, Japan|Kiryu Dermatology Clinic /ID# 206044, Fukuoka City, Fukuoka, Japan|Matsuda Tomoko Dermatological Clinic /ID# 206288, Fukuoka-shi, Fukuoka, Japan|Medical Corporation Matsuo Clinic /ID# 207323, Fukuoka-shi, Fukuoka, Japan|Higuchi Dermatology Urology Clinic /ID# 206287, Kasuga-shi, Fukuoka, Japan|Kiryu Kosei General Hospital /ID# 206155, Kiryu-shi, Gunma, Japan|Gunma University Hospital /ID# 207016, Maebashi-shi, Gunma, Japan|Fukuyama City Hospital /ID# 206761, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 206521, Asahikawa-shi, Hokkaido, Japan|Kitago Dermatology Clinic /ID# 207025, Sapporo-shi, Hokkaido, Japan|Kato Dermatology Clinic /ID# 206561, Sapporo-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 206519, Sapporo-shi, Hokkaido, Japan|Hyogo Prefectural Amagasaki General Medical Center /ID# 206974, Amagasaki-shi, Hyogo, Japan|Kobe University Hospital /ID# 206200, Kobe, Hyogo, Japan|Medical corporation Kojunkai Kosugi Dermatology Clinic /ID# 206766, Kawasaki-shi, Kanagawa, Japan|Nippon Medical School Musashi Kosugi Hospital /ID# 206656, Kawasaki-shi, Kanagawa, Japan|Suizenji Dermatology Clinic /ID# 205871, Kumamoto-shi, Kumamoto, Japan|Nagasaki University Hospital /ID# 206118, Nagasaki-shi, Nagasaki, Japan|Nagaoka Red Cross Hospital /ID# 209817, Nagaoka-shi, Niigata, Japan|Isonokami dermatological clinic /ID# 206923, Daito-shi, Osaka, Japan|Medical corporation Kojinkai Yoshioka Dermatology Clinic /ID# 209704, Neyagawa-shi, Osaka, Japan|Shizuoka General Hospital /ID# 207122, Shizuoka-shi, Shizuoka, Japan|Medical Corporation Seikakai Mildix Skin Clinic /ID# 206829, Adachi-ku, Tokyo, Japan|Fukuwa clinic /ID# 206760, Chuo-ku, Tokyo, Japan|Hosono Clinic /ID# 205953, Chuo-ku, Tokyo, Japan|Ichinomiya Municipal Hospital /ID# 205942, Ichinomiya-shi, Tokyo, Japan|Mita Dermatology Clinic /ID# 206694, Minato-ku, Tokyo, Japan|Medical Corporation Jitai-kai Nakano Dermatology Clinic /ID# 206882, Nakano-ku, Tokyo, Japan|Matsuyama Dermatology Clinic /ID# 205998, Nakano-ku, Tokyo, Japan|Tokyo Rosai Hospital /ID# 205809, Ohta-ku, Tokyo, Japan|Miu Skin Clinic /ID# 206911, Ota-ku, Tokyo, Japan|Tampopo Dermatology Clinic /ID# 207013, Ota-ku, Tokyo, Japan|Naoko Dermatology Clinic /ID# 205334, Setagaya-ku, Tokyo, Japan|Tachikawa Dermatology Clinic /ID# 206996, Tachikawa-shi, Tokyo, Japan|Kansai Rosai Hospital /ID# 205918, Amagasaki, Japan|Yaesu Nihonbashi Skin Clinic /ID# 207125, Chuo-ku, Japan|Tokai University Hospital /ID# 206657, Isehara, Japan|Kizawa Memorial Hospital /ID# 205684, Minokamo, Japan|Nihon University Itabashi Hosp /ID# 206186, Tokyo, Japan|Toyama Prefectural Ctr Hosp /ID# 206286, Toyama, Japan|Yokohama Rosai Hospital /ID# 206648, Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT03661138"
66,"NCT03659669","A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice","REVEAL","Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)",,"Overall Response Rate (ORR)|Complete Response (CR) Rate|Time to Response (TTR)|Time to Best Response to Treatment|Overall Survival (OS)|Time To Progression (TTP)|Progression-Free Survival (PFS)|Time To Next Treatment|Duration of Response (DOR)|PFS after Disease Progression Following Venetoclax Treatment|Best Response under Next CLL Treatment|Minimal Residual Disease|Change in Score of EuroQol 5 Dimensions (EQ‐5D‐5L)","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"66","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P19-287","February 10, 2019","October 31, 2024","October 31, 2024","September 6, 2018",,"February 15, 2019","Soroka Medical Center /ID# 207897, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 206961, Petakh Tikva, Tel-Aviv, Israel|HaEmek Medical Center /ID #210900, Afula, Israel|Bnai Zion Medical Center /ID# 206963, Haifa, Israel|Rambam Medical Center /ID# 210320, Haifa, Israel|Shaare Zedek Medical Center /ID# 207896, Jerusalem, Israel|Hadassah /ID# 207898, Jerusalem, Israel|Galilee Medical Center /ID# 207899, Nahariya, Israel|Sheba Medical Center /ID #207900, Ramat Gan, Israel|Kaplan Medical Center /ID# 207902, Rehovot, Israel|Tel Aviv Medical Center /ID# 206962, Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT03659669"
67,"NCT03653026","A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis","U-Accomplish","Recruiting","No Results Available","Ulcerative Colitis (UC)","Drug: Upadacitinib (ABT-494)|Drug: Placebo","Percentage of participants who achieve clinical remission per Adapted Mayo score|Percentage of participants with endoscopic improvement|Percentage of participants with endoscopic remission|Percentage of participants achieving clinical response per Adapted Mayo score|Percentage of participants achieving clinical response per Partial Adapted Mayo score|Percentage of participants who reported no bowel urgency|Percentage of participants who reported no abdominal pain|Percentage of participants who achieved histologic improvement|Percentage of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom domain|Percentage of participants with mucosal healing|Percentage of participants with UC-related hospitalizations|Percentage of participants with UC-related surgeries|Percentage of participants achieving response in IBDQ fatigue item","AbbVie","All","16 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","462","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-675|2016-000642-62","October 4, 2018","February 23, 2021","February 23, 2021","August 31, 2018",,"January 22, 2020","Alabama Medical Group, PC /ID# 216933, Mobile, Alabama, United States|CB Flock Research Corporation /ID# 206094, Mobile, Alabama, United States|Arizona Arthritis & Rheumatolo /ID# 211030, Phoenix, Arizona, United States|Physician's Research Group /ID# 211887, Tempe, Arizona, United States|University of Arizona /ID# 208856, Tucson, Arizona, United States|TLC Clinical Research Inc /ID# 216831, Beverly Hills, California, United States|Citrus Valley Gastroenterology /ID# 205627, Covina, California, United States|Newport Huntington Medical Group /ID# 217003, Huntington Beach, California, United States|Ucsd /Id# 204919, La Jolla, California, United States|United Gastroenterologists /ID# 207867, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 205314, Los Angeles, California, United States|Facey Medical Foundation /ID# 205301, Mission Hills, California, United States|United Gastroenterologists - Murrieta /ID# 205313, Murrieta, California, United States|Ventura County Gastroenterology /ID# 205628, Oxnard, California, United States|Palo Alto Medical Foundation /ID# 215795, Palo Alto, California, United States|Inland Empire Liver Foundation /ID# 216164, Rialto, California, United States|San Diego Clinical Trials /ID# 212122, San Diego, California, United States|Medical Assoc Research Grp /ID# 205626, San Diego, California, United States|University of California, San /ID# 205070, San Francisco, California, United States|Peak Gastroenterology Associat /ID# 214077, Colorado Springs, Colorado, United States|Delta Waves, Inc. /ID# 206170, Colorado Springs, Colorado, United States|Western States Clinical Res /ID# 206091, Wheat Ridge, Colorado, United States|Western Connecticut Medical Group /ID# 208290, Danbury, Connecticut, United States|Gastroenterology Center of CT /ID# 208291, Hamden, Connecticut, United States|Gastro Florida /ID# 206174, Clearwater, Florida, United States|Universal Axon Clinical Resear /ID# 213462, Doral, Florida, United States|Palmetto Research, LLC /ID# 208293, Hialeah, Florida, United States|Nature Coast Clinical Research /ID# 206087, Inverness, Florida, United States|Borland-Groover Clinic /ID# 208128, Jacksonville, Florida, United States|Alliance Medical Research /ID# 215091, Lighthouse Point, Florida, United States|Ctr for Advanced Gastroenterol /ID# 207995, Maitland, Florida, United States|University of Miami /ID# 215445, Miami, Florida, United States|Coral Research Clinic /ID# 208292, Miami, Florida, United States|Advanced Research Institute /ID# 206077, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 207360, Orlando, Florida, United States|Omega Research Consultants /ID# 206066, Orlando, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 206068, Tampa, Florida, United States|University of South Florida /ID# 214495, Tampa, Florida, United States|Florida Hospital Tampa /ID# 207363, Tampa, Florida, United States|Gastro Assoc of Central GA /ID# 216940, Macon, Georgia, United States|Infinite Clinical Trials /ID# 215343, Riverdale, Georgia, United States|Atlanta Gastroenterology Spec /ID# 206173, Suwanee, Georgia, United States|Next Innovative Clinical Research - Chicago /ID# 217324, Chicago, Illinois, United States|Northwestern Medical Group - Saint Clair /ID# 206084, Chicago, Illinois, United States|Rush University Medical Center /ID# 206158, Chicago, Illinois, United States|University of Chicago /ID# 206172, Chicago, Illinois, United States|Carle Foundation Hospital /ID# 207397, Effingham, Illinois, United States|MediSphere Medical Research Center /ID# 206073, Evansville, Indiana, United States|Indianapolis Gastroenterology /ID# 206381, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics /ID# 206167, Iowa City, Iowa, United States|Cotton-O'Neil Clinical Res Ctr /ID# 206175, Topeka, Kansas, United States|Tri-State Gastroenterology /ID# 206124, Crestview Hills, Kentucky, United States|Houma Digestive Health Special /ID# 206176, Houma, Louisiana, United States|Nola Research Works, LLC /ID# 206089, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 206064, Shreveport, Louisiana, United States|Gastro Center of Maryland /ID# 206883, Columbia, Maryland, United States|University of Michigan Hospitals /ID# 206918, Ann Arbor, Michigan, United States|Huron Gastroenterology Assoc /ID# 205109, Ann Arbor, Michigan, United States|Clin Res Inst of Michigan, LLC /ID# 207078, Chesterfield, Michigan, United States|Revival Research Institute, LLC /ID# 207282, Southfield, Michigan, United States|Center for Digestive Health /ID# 207080, Troy, Michigan, United States|Univ of Mississippi Med Ctr /ID# 213116, Jackson, Mississippi, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 206069, Jackson, Mississippi, United States|Las Vegas Medical Research /ID# 206814, Las Vegas, Nevada, United States|AGA Clinical Research Associates, LLC /ID# 206880, Egg Harbor Township, New Jersey, United States|Atlantic Digestive Health Inst /ID# 208748, Morristown, New Jersey, United States|Rutgers Robert Wood Johnson /ID# 207382, New Brunswick, New Jersey, United States|Univ New Mexico /ID# 214397, Albuquerque, New Mexico, United States|Advantage Clinical Trials /ID# 206082, Bronx, New York, United States|NY Scientific /ID# 206080, Brooklyn, New York, United States|NYU Langone Long Island CRA /ID# 206079, Great Neck, New York, United States|DiGiovanna Institute for Medic /ID# 206885, North Massapequa, New York, United States|Premier Medical Group /ID# 206097, Poughkeepsie, New York, United States|Gastro Group of Rochester /ID# 206881, Rochester, New York, United States|Richmond University Medical Center /ID# 213185, Staten Island, New York, United States|Digestive Health Partners, P.A /ID# 206842, Asheville, North Carolina, United States|Carolinas Medical Center /ID# 206085, Charlotte, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 206067, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 205111, Fargo, North Dakota, United States|University of Cincinnati /ID# 205633, Cincinnati, Ohio, United States|Cleveland Clinic Main Campus /ID# 209239, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 205637, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 205638, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 205630, Dayton, Ohio, United States|Dayton Gastroenterology, Inc. /ID# 205639, Englewood, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 205631, Mentor, Ohio, United States|Hightower Clinical /ID# 216336, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists /ID# 206076, Oklahoma City, Oklahoma, United States|Options Health Research, LLC /ID# 206707, Tulsa, Oklahoma, United States|Healthcare Research Consultant /ID# 206706, Tulsa, Oklahoma, United States|Guthrie Medical Group, PC /ID# 206078, Sayre, Pennsylvania, United States|Pharmacorp Clinical Trials /ID# 206074, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 206098, Greenville, South Carolina, United States|Gastro One /ID# 206178, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 206169, Johnson City, Tennessee, United States|Quality Medical Research, PLLC /ID# 206088, Nashville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 210405, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 206718, Arlington, Texas, United States|Inquest Clinical Research /ID# 206132, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209805, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209948, Cedar Park, Texas, United States|Baylor Scott & White Research /ID# 207484, Dallas, Texas, United States|DHAT Research Institute /ID# 206716, Garland, Texas, United States|Vilo Research Group Inc /ID# 212625, Houston, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center /ID# 206717, Houston, Texas, United States|Houston Methodist Hospital /ID# 207659, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 206168, Houston, Texas, United States|GI Specialists of Houston /ID# 206090, Houston, Texas, United States|Caprock Gastro Research /ID# 215115, Lubbock, Texas, United States|Clinical Associates in Researc /ID# 206710, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 205379, San Antonio, Texas, United States|Baylor Scott & White Health - Temple /ID# 206096, Temple, Texas, United States|Tyler Research Institue /ID# 206075, Tyler, Texas, United States|Victoria gastroenterology /ID# 205378, Victoria, Texas, United States|Advanced Research Institute /ID# 206133, Ogden, Utah, United States|Ctr for Gastrointestinal Healt /ID# 208475, Franklin, Virginia, United States|Washington Gastroenterology /ID# 206177, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 206070, Seattle, Washington, United States|The Vancouver Clinic, INC. PS /ID# 204973, Vancouver, Washington, United States|WI Center for Advanced Res /ID# 206917, Milwaukee, Wisconsin, United States|Froedtert & the Medical College of Wisconsin /ID# 206945, Milwaukee, Wisconsin, United States|Hospital Italiano de Buenos Aires /ID# 215539, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Cardio Alem /ID# 211282, San Isidro, Buenos Aires, Argentina|Mautalen Salud e Investigacion /ID# 206033, Buenos Aires, Argentina|Hospital Britanico de Bs As /ID# 209497, Caba, Argentina|Gedyt /ID# 210017, Ciudad Autonoma Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 206030, Cordoba, Argentina|Instituto Medico DAMIC /ID# 206470, Cordoba, Argentina|Macquarie University /ID# 211955, Macquarie Park, New South Wales, Australia|Mater Misericordiae /ID# 212687, South Brisbane, Queensland, Australia|Griffith University /ID# 211956, Southport, Queensland, Australia|St. Vincents Hosp Melbourne /ID# 205758, Fitzroy, Victoria, Australia|Monash Medical Centre /ID# 206486, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 211642, Murdoch, Western Australia, Australia|Krankenanstalt Rudolfstiftung /ID# 205764, Vienna, Wien, Austria|Medical University of Vienna /ID# 205763, Vienna, Wien, Austria|LKH Salzburg and Paracelsus /ID# 208788, Salzburg, Austria|AZ Maria Middelares /ID# 210928, Ghent, Belgium|UZ Leuven /ID# 205988, Leuven, Belgium|University Clinical Centre of the Republic of Srpska /ID# 208053, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 208055, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Center Tuzla /ID# 208057, Tuzla, Tuzlanski, Bosnia and Herzegovina|University Clinical Hospital Mostar /ID# 208054, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 208058, Sarajevo, Bosnia and Herzegovina|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 206983, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 206981, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 206985, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 206986, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 206504, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 206984, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 206982, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hospital Universitario Clement /ID# 210651, Rio de Janeiro, Brazil|University of Calgary /ID# 205755, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 211167, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 207383, Edmonton, Alberta, Canada|Covenant Health /ID# 205500, Edmonton, Alberta, Canada|Percuro Clinical Research, Ltd /ID# 205501, Victoria, British Columbia, Canada|Dr. Everett Chalmers Reg Hosp. /ID# 211439, Fredericton, New Brunswick, Canada|Dr Chadwick Ian Williams Professional Corporation /ID# 214201, St. John, New Brunswick, Canada|Toronto Digestive Disease Asso /ID# 205498, Vaughan, Ontario, Canada|Crchum /Id# 207387, Montreal, Quebec, Canada|CRCHUS Hotel-Dieu /ID# 205499, Sherbrooke, Quebec, Canada|Research Group Ltda /ID# 208037, Santiago, Region Metropolitana De Santiago, Chile|M y F Estudios Clínicos Ltda. /ID# 208035, Ñuñoa, Region Metropolitana De Santiago, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 212426, Concepción, Chile|CTR Estudios SpA /ID# 208036, Providencia, Chile|Hospital Clinico Universidad De Los Andes /ID# 207426, Santiago, Chile|Hospital Clinico San Borja Arr /ID# 216530, Santiago, Chile|Clinica Las Condes /ID# 212735, Santiago, Chile|The First Affiliated Hosp, Sun /ID# 205267, Guangzhou, Anhui, China|Shanghai Tenth People's Hosp /ID# 211033, Shanghai, Anhui, China|The Sixth Affiliated Hosp, Sun /ID# 205268, Guangzhou, Guangdong, China|Affiliated Taihe Hospital of Hubei University of Medicine /ID# 216406, Shiyan, Hubei, China|Xiangya Hospital Central South University /ID# 205245, Changsha, Hunan, China|Wuxi People's Hospital /ID# 216143, Wuxi, Jiangsu, China|1st Aff Hosp Nanchang Univ /ID# 212186, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 210088, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 205333, Shanghai, Shanghai, China|Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 205269, Shanghai, Shanghai, China|The second affiliated hospital of Zhejiang University school of medicine /ID# 205271, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 205270, Hangzhou, Zhejiang, China|The 2nd Affiliated Hospital and Yuying Children's Hospital of WMU /ID# 217559, Wenzhou, Zhejiang, China|West China Hospital, Sichuan University /ID# 205332, Chengdu, China|Shengjing Hospital of China Medical University /ID# 205244, Shenyang, China|Tianjin Med Univ General Hosp /ID# 205246, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 205266, Wuhan, China|Tongji Hosp Tongji Med College /ID# 205265, Wuhan, China|Corporacion Hospitalaria Juan Ciudad sede Denominada Hospital Universitario Mayo /ID# 208886, Bogota DC, Cundinamarca, Colombia|Instituto de Coloproctologia /ID# 208885, Antioquia, Colombia|Hospital Univ San Ignacio /ID# 209160, Bogota, Colombia|Hospital Universitario San Vic /ID# 208888, Medellin, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 208887, Montería, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 208460, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 207904, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 207906, Zagreb, Grad Zagreb, Croatia|Poliklinika Solmed /ID# 211568, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 207903, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Rijeka /ID# 208650, Rijeka, Primorsko-goranska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 217027, Split, Croatia|Zadar General Hospital /ID# 207905, Zadar, Croatia|CTCenter MaVe, s.r.o. /ID# 205671, Olomouc, Olomoucky Kraj, Czechia|Axon Clinical, s.r.o. /ID# 205670, Praha, Praha 5, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 205672, Hradec Kralove, Czechia|Artroscan s.r.o. /ID# 205668, Ostrava, Czechia|Nemocnice Pardubickeho kraje, a.s. /ID# 213540, Pardubice, Czechia|Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 216223, Praha 1, Czechia|ISCARE a.s. /ID# 209240, Praha 9, Czechia|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 213820, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 213821, Alexandria, Egypt|Nat Hep & Trop Med Res Inst /ID# 213822, Cairo, Egypt|Air Force Specialized Hospital /ID# 214475, Cairo, Egypt|East Tallinn Central Hospital /ID# 207564, Tallinn, Estonia|West Tallinn Central Hospital /ID# 207356, Tallinn, Estonia|North Estonian Medical Centre /ID# 207357, Tallinn, Estonia|Tartu University Hospital /ID# 212282, Tartu, Estonia|Tampere University Hospital /ID# 206161, Tampere, Pirkanmaa, Finland|Keski-Suomen Keskussairaala /ID# 206159, Jyvaskyla, Finland|Laakarikeskus Ikioma /ID# 205814, Mikkeli, Finland|Tyks /Id# 205813, Turku, Finland|Chu de Nice-Hopital L'Archet Ii /Id# 209118, Nice CEDEX 3, Alpes-Maritimes, France|Hopital Haut-Lévêque /ID# 213832, Pessac CEDEX, Gironde, France|CHRU Lille - Hôpital Claude Huriez /ID# 209125, Lille CEDEX, Hauts-de-France, France|Hopital Beaujon /ID# 209128, Clichy, Ile-de-France, France|CHU de SAINT ETIENNE - Hopital Nord /ID# 209123, St. Priest En Jarez, Loire, France|CHU NANCY - Hôpital Brabois Adultes /ID# 209120, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|Centre Hospitalier Lyon Sud /ID# 209121, Pierre Benite CEDEX, Rhone, France|CHU Amiens Picardie - Site Sud /ID# 209119, Amiens Cedex 1, France|CHD Vendee /ID# 209122, La Roche Sur Yon, France|CHU de Montpellier - Hôpital S /ID# 209127, Montpellier Cedex 5, France|Polyclinique Grand Sud /ID# 214081, Nimes Cedex, France|Universitatsklinikum Mannheim /ID# 206811, Mannheim, Baden-Wuerttemberg, Germany|Gastroenterologische Gemeinschaftspraxis Herne /ID# 214576, Herne, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 215813, Saarbrücken, Saarland, Germany|Praxis am Bayrischen Platz /ID# 206733, Berlin, Germany|Agaplesion Markus Krankenhaus /ID# 206731, Frankfurt, Germany|Univ Hosp Schleswig-Holstein /ID# 206791, Kiel, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 207137, Munster, Germany|Helwig, Oldenburg, DE /ID# 213438, Oldenburg, Germany|Universitatsklinikum Tubingen /ID# 206737, Tuebingen, Germany|General Hospital of Athens Laiko /ID# 208671, Athens, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 206332, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 207061, Heraklion, Greece|Theageneio Anticancer Hospital /ID# 206331, Thessaloniki, Greece|Genl Hosp Thessaloniki Hipp /ID# 208822, Thessaloniki, Greece|Bekes Megyei Kozponti Korhaz /ID# 205885, Bekescsaba, Hungary|Semmelweis Egyetem /ID# 205883, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont /ID# 217884, Debrecen, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 207992, Sopron, Hungary|Mentahaz Maganorvosi Kozpont /ID# 205882, Szekesfehervar, Hungary|St. James's Hospital /ID# 209649, Dublin 8, Dublin, Ireland|St Vincent's University Hosp /ID# 209210, Dublin, Ireland|Beaumont Hospital /ID# 206509, Dublin, Ireland|University Hospital Galway /ID# 218035, Galway, Ireland|Rambam Health Care Campus /ID# 206362, Haifa, Israel|Shaare Zedek Medical Center /ID# 206365, Jerusalem, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 206351, Bologna, Emilia-Romagna, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 206349, Milan, Lombardia, Italy|ASST Rhodense /ID# 216611, Rho, Lombardia, Italy|Istituto Clinico Humanitas /ID# 206346, Rozzano, Milano, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 206347, Rome, Roma, Italy|A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 206350, Palermo, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 206354, Negrar, Verona, Italy|A.O.U. Consorziale Policlinico di Bari /ID# 216438, Bari, Italy|ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico /ID# 206348, Milano, Italy|Nagoya University Hospital /ID# 206355, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 206058, Nagoya-shi, Aichi, Japan|Hirosaki National Hospital /ID# 206387, Hirosaki-shi, Aomori, Japan|Tokatsu Tsujinaka Hospital /ID# 214963, Abiko-shi, Chiba, Japan|Toho University Sakura Medical Center /ID# 207705, Sakura-shi, Chiba, Japan|Juntendo University Urayasu Hospital /ID# 208784, Urayasu Shi, Chiba, Japan|Fukuoka University Chikushi Hospital /ID# 214405, Chikushino, Fukuoka, Japan|Kurume University Hospital /ID# 206385, Kurume-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 208227, Ogaki-shi, Gifu, Japan|NHO Fukuyama Medical Center /ID# 206295, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 206404, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 206059, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 206314, Sapporo-shi, Hokkaido, Japan|Sapporo Tokushukai Hospital /ID# 209448, Sapporo, Hokkaido, Japan|Aoyama Clinic /ID# 206452, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 206455, Nishinomiya-shi, Hyogo, Japan|Kanazawa University Ho /ID# 206316, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital /ID# 207051, Morioka-shi, Iwate, Japan|Idzuro Imamura Hospital /ID# 207639, Kagishimashi, Kagoshima, Japan|Mie University Hospital /ID# 206803, Tsu-shi, Mie, Japan|National Hospital Organization Sendai Medical Center /ID# 209528, Sendai-shi, Miyagi, Japan|Ishida Clinic of IBD and Gastroenterology /ID# 210119, Oita-shi, Oita, Japan|Kinshukai Infusion Clinic /ID# 207865, Osaka-shi, Osaka, Japan|Japanese Red Cross Osaka Hospi /ID# 209478, Osaka-shi, Osaka, Japan|Osaka City University Hospital /ID# 206457, Osaka-shi, Osaka, Japan|Saga University Hospital /ID# 209270, Saga-shi, Saga, Japan|Saitama Medical Center, Saitama Medical University /ID# 206393, Kawagoe-shi, Saitama, Japan|Tokito Clinic /ID# 206313, Saitama-shi, Saitama, Japan|National Hospital Organization Higashi-Ohmi General Medical Center /ID# 210710, Higashiohmi-shi, Shiga, Japan|Hamamatsu University Hospital /ID# 206459, Hamamatsu-shi, Shizuoka, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 206453, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 208076, Chuo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 208903, Hachioji, Tokyo, Japan|Teikyo University Hospital /ID# 209866, Itabashi-ku, Tokyo, Japan|Center hospital of the National Center for Global Health and Medicine /ID# 209532, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 206460, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 206465, Yamagata-shi, Yamagata, Japan|Tokuyama Central Hospital /ID# 216994, Shunan-shi, Yamaguchi, Japan|Fukui Prefectural Hospital /ID# 210449, Fukui, Japan|Saiseikai Fukuoka General Hosp /ID# 209482, Fukuoka, Japan|Hiroshima University Hospital /ID# 206464, Hiroshima, Japan|Shimane University School of Medicine /ID# 208905, Izumo, Japan|Sameshima Hospital /ID# 207935, Kagoshima, Japan|Tsujinaka Hospital Kashiwanoha /ID# 209573, Kashiwa, Japan|St. Marianna Univ Hospital /ID# 209451, Kawasaki, Japan|Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 206646, Kurashiki, Japan|Saiseikai Niigata Hosp /ID# 209921, Niigata, Japan|Obihiro-Kosei General Hospital /ID# 210424, Obihiro, Japan|NHO Nagasaki Medical Center /ID# 210822, Omura-shi, Japan|Kitano Hospital /ID# 210397, Osaka, Japan|Kyoto University Hospital /ID# 211809, Sakyo-ku, Japan|Sapporo Higashi Tokushukai /ID# 208494, Sapporo, Japan|NHO Shizuoka Medical Center /ID# 208785, Shimizu-sho, Japan|Fujita Gastroenterological Hos /ID# 216493, Takatsuki-shi, Japan|Toyohashi Municipal Hospital /ID# 207625, Toyohashi, Japan|Toyonaka Municipal Hospital /ID# 217082, Toyonaka, Japan|Ieda Hospital /ID# 207479, Toyota-shi, Japan|Kenseikai Dongo Hospital /ID# 208101, Yamatotakada, Japan|Yokkaichi Hazu Medical Center /ID# 214348, Yokkaichi-shi, Japan|Showa Univ Fujigaoka Hosp /ID# 208224, Yokohama-shi, Japan|Dong-A University Hospital /ID# 206955, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 206956, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 206959, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Kangbuk Samsung Hospital /ID# 206960, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|CHA Bundang Medical Center /ID# 207432, Seongnam-si, Gyeonggi-do, Korea, Republic of|Severance Hospital /ID# 206958, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 206828, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 206827, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 209052, Kovno, Kaunas, Lithuania|Klaipeda University Hospital /ID# 208790, Klaipeda, Lithuania|Klaipeda Seamens Hospital /ID# 208791, Klaipeda, Lithuania|Vilnius University Hospital /ID# 209051, Vilnius, Lithuania|UKM Medical Centre /ID# 207662, Kuala Lumpur, Selangor, Malaysia|Hospital Ampang /ID# 213530, Ampang, Selangor, Malaysia|Uni Malaya MC /ID# 208936, Kuala Lumpur, Malaysia|Morales Vargas Centro de Investigacion S.C. /ID# 211326, Leon, Guanajuato, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 208068, Guadalajara, Jalisco, Mexico|Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 208067, Monterrey, Nuevo Leon, Mexico|Erasmus Medisch Centrum /ID# 205280, Rotterdam, Netherlands|Akershus Universitetssykehus_MAIN /ID# 205293, Lorenskog, Akershus, Norway|Universitetssykehuset Nord-Norge /ID# 205691, Tromsø, Troms, Norway|Centrum Zdrowia MDM /ID# 205874, Warsaw, Mazowieckie, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 215070, Warsaw, Mazowieckie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 212913, Warszawa, Mazowieckie, Poland|Endoskopia Sp. z o.o. /ID# 212964, Sopot, Zachodniopomorskie, Poland|Gastromed /Id# 216108, Toruń, Poland|NZOZ Vivamed /ID# 216697, Warsaw, Poland|Hospital Senhora da Oliveira de Guimarães, EPE /ID# 205554, Guimarães, Braga, Portugal|Hospital Garcia de Orta, E.P.E /ID# 206143, Almada, Setubal, Portugal|Hospital de Braga /ID# 206144, Braga, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 206117, Lisboa, Portugal|Hospital Santo Antonio dos Cap /ID# 206145, Lisbon, Portugal|Centro Hospitalar de Sao Joao /ID# 206142, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 205563, Santa Maria Da Feira, Portugal|Unidade Local De Saude Do Alto Minho /ID# 205556, Viana Do Castelo, Portugal|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 209626, San Juan, Puerto Rico|Institutul Clinic Fundeni /ID# 206011, Bucharest, Romania|Institutul Clinic Fundeni /ID# 206012, Bucharest, Romania|Cabinet Particular Policlinic Algomed /ID# 206010, Timisoara, Romania|Immanuel Kant Baltic Federal University /ID# 208264, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|Scientific Research Center Eco-Safety LLC /ID# 217930, Sankt-Peterburg, Leningradskaya Oblast, Russian Federation|NW State Medical Univ na Mechn /ID# 208258, St. Petersburg, Leningradskaya Oblast, Russian Federation|Perm Clinical Center of FMBA /ID# 211653, Perm, Permskiy Kray, Russian Federation|LLC Medical Company Hepatolog /ID# 208261, Samara, Samarskaya Oblast, Russian Federation|Private institution Center of educational and clinical gastroenterology, hepatol /ID# 211652, Stavropol, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 208256, Kazan, Tatarstan, Respublika, Russian Federation|Llc Olla-Med /Id# 215335, Moscow, Russian Federation|Scien Ctr Coloproctology Rosme /ID# 217932, Moscow, Russian Federation|Republican Clin Hos n.a. Baran /ID# 206507, Petrozavodsk, Russian Federation|PMI Euromedservice /ID# 208265, Pushkin, Russian Federation|LLC Novaya Clinica /ID# 208260, Pyatigorsk, Russian Federation|I-Clinic Petrogradskaya /ID# 217931, Saint Petersburg, Russian Federation|Clinical Center Serbia /ID# 205256, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 205258, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 205257, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 206413, Belgrade, Beograd, Serbia|Clinical Center of Nis /ID# 206411, NIS, Nisavski Okrug, Serbia|Clinical Center Kragujevac /ID# 206410, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 205259, Novi Sad, Vojvodina, Serbia|General Hospital Leskovac /ID# 217881, Leskovac, Serbia|National University Hospital /ID# 209099, Singapore, Singapore|Gleneagles Medical Centre /ID# 206954, Singapore, Singapore|Tan Tock Seng Hospital /ID# 207663, Singapore, Singapore|Medak s.r.o., gastroenterologi /ID# 205191, Bratislava, Bratislavsky Kraj, Slovakia|FN s poliklinikou F.D. Rooseve /ID# 205147, Banska Bystrica, Slovakia|B and B MED s.r.o. /ID# 205213, Kosice, Slovakia|Fakultna nemocnica s poliklini /ID# 211372, Nove Zamky, Slovakia|Gastro I.S.R.O. /ID# 205148, Presov, Slovakia|Clinresco Centres /ID# 208083, Johannesburg, Gauteng, South Africa|Lenasia Clinical Trial Centre /ID# 214359, Johannesburg, Gauteng, South Africa|Chris Hani Baragwanath Hosp /ID# 208082, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 208949, Johannesburg, Gauteng, South Africa|Mediclinic Milnerton /ID# 207979, CAPE TOWN,Milnerton, Western Cape, South Africa|Allergy & Immunology (AIU) /ID# 214360, Cape Town, Western Cape, South Africa|Kingsbury Hospital /ID# 205281, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 205273, Cape Town, Western Cape, South Africa|MD Search /ID# 208084, Boksburg North, South Africa|Comple Hospi Univ de Santiago /ID# 204411, Santiago de Compostela, A Coruna, Spain|H. Un. Marques de Valdecilla /ID# 216622, Santander, Cantabria, Spain|Comple Hosp Univ de A Coruna /ID# 206907, A Coruna, Spain|Hospital Clinico y Provincial Barcelona /ID# 206906, Barcelona, Spain|Hospital Universitario Reina S /ID# 204412, Cordoba, Spain|Hospital Univ Dr. Negrin /ID# 206905, Las Palmas de Gran Canaria, Spain|Hospital Univ Ramon y Cajal /ID# 204410, Madrid, Spain|Hospital Universitario La Paz /ID# 214540, Madrid, Spain|Complejo Asistencial de Salama /ID# 205013, Salamanca, Spain|Hospital Universitario La Fe /ID# 206904, Valencia, Spain|Karolinska Universitetssjukhuset /ID# 217501, Stockholm, Stockholms Lan, Sweden|Sodersjukhuset /ID# 216618, Stockholm, Sweden|Kantonsspital St. Gallen /ID# 211310, St. Gallen, Sankt Gallen, Switzerland|Universitaetsspital Basel /ID# 211381, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 211312, Bern, Switzerland|Universitaetsspital Zuerich /ID# 211308, Zurich, Switzerland|China Medical University Hosp /ID# 207845, Taichung City, Taichung, Taiwan|National Taiwan University Hospital /ID# 207847, Taipei City, Taipei, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 207848, Kaohsiung, Taiwan|Taipei Veterans General Hosp /ID# 207849, Taipei City, Taiwan|Erciyes University Medical Fac /ID# 207506, Melikgazi, Kayseri, Turkey|Gazi University Med. Faculty /ID# 208040, Ankara GAZI, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 207507, Istanbul, Turkey|Umraniye Training and Res Hosp /ID# 208206, Istanbul, Turkey|Marmara University Medical Fac /ID# 214727, Istanbul, Turkey|Mersin University Medical /ID# 208039, Mersin, Turkey|Communal Non-Commercial Enterprize of Kharkiv Regional Council Regional Clinical /ID# 206939, Kharkiv, Kharkivska Oblast, Ukraine|Kyiv Regional Hospital #2 /ID# 217373, Київ, Kyivska Oblast, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 216300, Vinnytsia, Vinnytska Oblast, Ukraine|Medical centre of CONSILIUM MEDICAL LLC /ID# 217447, Kiev, Ukraine|Medical and Diagnostic Center /ID# 217218, Kropyvnytskyi, Ukraine|RD&E Hospital /ID# 206750, Exeter, Devon, United Kingdom|Basingstoke & North Hampshire /ID# 207985, Basingstoke, United Kingdom|Queen Elizabeth University Hos /ID# 205154, Glasgow, United Kingdom|Huddersfield Royal Infirmary /ID# 217660, Huddersfield, United Kingdom|St. George's Healthcare NHS /ID# 208375, London, United Kingdom|Barts and the London NHS Trust /ID# 205153, Whitechapel, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03653026"
68,"NCT03646604","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis",,"Recruiting","No Results Available","Atopic Dermatitis","Drug: Upadacitinib (ABT-494)","Maximum Plasma Concentration (Cmax)|Time to Maximum Observed Plasma Concentration (Tmax)|Area under the plasma concentration-time curve within a dosing interval (AUC)|Oral Clearance|Treatment Emergent Adverse Events (TEAE)","AbbVie","All","2 Years to 11 Years   (Child)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-049|2018-004409-17","January 31, 2019","December 29, 2021","July 25, 2024","August 24, 2018",,"November 13, 2019","Beach Pediatrics /ID# 207834, Huntington Beach, California, United States|Childrens Hospital LA /ID# 206042, Los Angeles, California, United States|Pediatric Skin Research, LLC /ID# 213468, Coral Gables, Florida, United States|Northwestern University Feinberg School of Medicine /ID# 206224, Chicago, Illinois, United States|Dawes Fretzin, LLC /ID# 214958, Indianapolis, Indiana, United States|Washington University of St. Louis /ID# 206972, Saint Louis, Missouri, United States|University of New Mexico School of Medicine /ID# 206757, Albuquerque, New Mexico, United States|Cincinnati Children's Hospital /ID# 207071, Cincinnati, Ohio, United States|Oregon Health and Science University (OHSU) /ID# 206226, Portland, Oregon, United States|Penn State University and Milton S. Hershey Medical Center /ID# 207096, Hershey, Pennsylvania, United States|Paddington Testing Co., Inc. /ID# 207079, Philadelphia, Pennsylvania, United States|West Virginia University /ID# 206792, Morgantown, West Virginia, United States|Our Lady's Children's Hospital /ID# 211199, Dublin, Ireland|Haukeland University Hospital /ID# 210162, Bergen, Hordaland, Norway|Rikshospitalet OUS HF /ID# 210163, Oslo, Norway|Cruz-Santana, Carolina, PR /ID# 214890, Carolina, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03646604"
69,"NCT03639194","A Study of ABBV-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer",,"Recruiting","No Results Available","Small Cell Lung Cancer","Drug: ABBV-011|Drug: ABBV-181","MTD and/or RPTD of ABBV-011|Maximum Serum Concentration (Cmax) of ABBV-011|AUCinf of ABBV-011|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Progression-Free Survival (PFS)|Duration of Objective Response (DOR)|Duration of Clinical Benefit (DOCB)|Overall Survival (OS)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","188","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M17-327","October 24, 2018","September 26, 2023","September 26, 2023","August 21, 2018",,"June 6, 2019","University of Alabama /ID# 207295, Birmingham, Alabama, United States|Highlands Oncology Group /ID# 207176, Fayetteville, Arkansas, United States|UC Davis Comp Cancer Ctr /ID# 207548, Sacramento, California, United States|Yale School of Medicine /ID# 207559, New Haven, Connecticut, United States|University of Iowa Hospitals and Clinics /ID# 207560, Iowa City, Iowa, United States|University of Kentucky Chandler Medical Center /ID# 208217, Lexington, Kentucky, United States|Johns Hopkins University /ID# 207562, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 207549, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 207177, Ann Arbor, Michigan, United States|Mayo Clinic - /ID# 207555, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 207168, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center /ID# 208216, New York, New York, United States|Duke Cancer Center /ID# 207547, Durham, North Carolina, United States|University Hospitals Cleveland /ID# 207561, Cleveland, Ohio, United States|The Ohio State University Comp /ID# 207552, Columbus, Ohio, United States|Tennessee Oncology-Nashville Centennial /ID# 207175, Nashville, Tennessee, United States|Vanderbilt University Med Ctr /ID# 207551, Nashville, Tennessee, United States|NEXT Oncology /ID# 207167, San Antonio, Texas, United States|University of Utah Huntsman /ID# 207553, Salt Lake City, Utah, United States|University of Washington /ID# 207557, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 207556, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03639194"
70,"NCT03625505","A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Acute Myeloid Leukemia (AML)","Drug: Venetoclax|Drug: Gilteritinib","Recommended Phase 2 Dose (RPTD) of co-administered Study Drugs|Composite Complete Remission (CRc) Rate|Pharmacokinetics - Cmax|Pharmacokinetics - Tmax|Pharmacokinetics - AUCt|Pharmacokinetics - AUC0-24 Post-dose of study drug|Duration of Response (DOR) of Composite Complete Remission (CRc)|Duration of Complete Remission (CR) + Complete Remission with incomplete hematologic recovery (CRh)|Complete Remission (CR) + with incomplete hematologic recovery (CRh)","AbbVie|Astellas Pharma Inc|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-802","October 18, 2018","October 14, 2021","October 14, 2021","August 10, 2018",,"November 8, 2019","David Geffen School of Medicin /ID# 200166, Los Angeles, California, United States|UC San Francisco Medical Center-Parnassus /ID# 200205, San Francisco, California, United States|Sylvester Comprehensive Cancer /ID# 200268, Miami, Florida, United States|Northwestern Memorial Hospital /ID# 200230, Chicago, Illinois, United States|Norton Cancer Institute /ID# 200623, Louisville, Kentucky, United States|Johns Hopkins University /ID# 200349, Baltimore, Maryland, United States|Mayo Clinic - Rochester /ID# 200346, Rochester, Minnesota, United States|Hackensack Univ Med Ctr /ID# 200229, Hackensack, New Jersey, United States|Weill Cornell Medical College /ID# 200109, New York, New York, United States|Hosp of the Univ of Penn /ID# 200348, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center at Texas Medical Center /ID# 206686, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03625505"
71,"NCT03607422","A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis",,"Recruiting","No Results Available","Atopic Dermatitis","Drug: Upadacitinib|Drug: Placebo for Upadacitinib","Percentage of participants achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75)|Percentage of participants achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 with at least two grades of reduction|Percentage of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 from baseline for participants with pruritus NRS ≥ 4 at Baseline|Percentage of participants achieving EASI 90|Percentage of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants with NRS ≥ 4 at Baseline and randomized to dose A|Proportion of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants with NRS ≥ 4 at Baseline and randomized to dose B|Percentage of participants achieving an improvement (reduction) in Atopic dermatitis impact scale (ADerm-IS) sleep domain score ≥ Minimal clinically important difference (MCID)|Percentage of participants achieving an improvement (reduction) in Atopic dermatitis symptom scale (ADerm-SS) skin pain score ≥ MCID|Percentage of participants achieving an improvement (reduction) in Atopic dermatitis symptom scale (ADerm-SS) total score ≥ MCID|Percentage of participants achieving EASI 100|Percentage of participants achieving vIGA-AD of 0 with a reduction of ≥ 2 points from Baseline|Percentage of participants achieving EASI 75|Percentage of participants experiencing a flare|Percentage of participants achieving an improvement (reduction) in ADerm-IS emotional state domain score ≥ MCID|Percentage of participants achieving an improvement (reduction) in ADerm-IS daily activities score ≥ MCID","AbbVie","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","810","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M18-891|2018-001383-28","July 27, 2018","February 14, 2020","September 26, 2022","July 31, 2018",,"January 13, 2020","Total Skin and Beauty Derm Ctr /ID# 205129, Birmingham, Alabama, United States|Medical Dermatology Specialist /ID# 205516, Phoenix, Arizona, United States|Arizona Research Center, Inc. /ID# 205795, Phoenix, Arizona, United States|Wallace Medical Group, Inc. /ID# 205701, Beverly Hills, California, United States|Encino Research Center / T. Jo /ID# 207472, Encino, California, United States|University of California Irvine /ID# 205136, Irvine, California, United States|Keck School of Medicine of USC /ID# 206971, Los Angeles, California, United States|Child Hosp of Orange County,CA /ID# 205735, Orange, California, United States|UCSD Rady's Children's Hospital /ID# 208244, San Diego, California, United States|Southern California Derma. Inc /ID# 205734, Santa Ana, California, United States|Innovative Clinical Research - Lafayette /ID# 208400, Lafayette, Colorado, United States|New England Research Associates, LLC /ID# 206896, Bridgeport, Connecticut, United States|Ideal Clinical Research Inc. /ID# 209880, Aventura, Florida, United States|Skin Care Research, LLC /ID# 207099, Boca Raton, Florida, United States|Midflorida Clinical Research, Inc. /ID# 213700, Brandon, Florida, United States|Clinical Res of West FL, Inc. /ID# 206146, Clearwater, Florida, United States|Revival Research /ID# 208383, Doral, Florida, United States|Universal Axon Clinical Resear /ID# 213703, Doral, Florida, United States|Floridian Clinical Research /ID# 207433, Hialeah, Florida, United States|Savin Medical Group, LLC /ID# 206902, Miami Lakes, Florida, United States|Lakes Research, LLC /ID# 209156, Miami, Florida, United States|Miami Dade Medical Research In /ID# 209413, Miami, Florida, United States|Ormond Medical Arts Pharmaceutical Research Center /ID# 213459, Ormond Beach, Florida, United States|Precision Clinical Research /ID# 207364, Sunrise, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 206840, Tampa, Florida, United States|ForCare Clinical Research /ID# 205120, Tampa, Florida, United States|Marietta Dermatology Clinical Research /ID# 210317, Marietta, Georgia, United States|Treasure Valley Medical Research /ID# 210298, Boise, Idaho, United States|Great Lakes Clinical Trials /ID# 205830, Chicago, Illinois, United States|Northshore University Health System-Evanston /ID# 205135, Evanston, Illinois, United States|Ashira Dermatology /ID# 205512, Gurnee, Illinois, United States|Clinical Investigation Specialists, Inc. /ID# 206898, Gurnee, Illinois, United States|Raga Clinical Studies, LLC. /ID# 206749, Crown Point, Indiana, United States|Hutchinson Clinic /ID# 205970, Hutchinson, Kansas, United States|Continental Clinical Solutions /ID# 210327, Towson, Maryland, United States|Beacon Clinical Research, LLC /ID# 206894, Quincy, Massachusetts, United States|David Fivenson, MD, PLC /ID# 206903, Ann Arbor, Michigan, United States|University of Michigan Hospitals /ID# 206895, Ann Arbor, Michigan, United States|Skin Specialists, PC /ID# 205515, Omaha, Nebraska, United States|Summit Medical Group /ID# 213863, Clifton, New Jersey, United States|Skin Laser and Surgery Specialists /ID# 206754, Hackensack, New Jersey, United States|University of New Mexico School of Medicine /ID# 206756, Albuquerque, New Mexico, United States|PMG Research of Wilmington LLC /ID# 205968, Wilmington, North Carolina, United States|University Hospitals Case Medical Center /ID# 206639, Cleveland, Ohio, United States|Awasty Research Network, LLC /ID# 206748, Marion, Ohio, United States|Southside Dermatology /ID# 214451, Tulsa, Oklahoma, United States|Vital Prospects Clinical Research Institution /ID# 205824, Tulsa, Oklahoma, United States|Clinical Research Institute of Southern Oregon /ID# 207544, Medford, Oregon, United States|Stones River Dermatology /ID# 205178, Murfreesboro, Tennessee, United States|Metroplex Dermatology /ID# 213307, Arlington, Texas, United States|Bellaire Dermatology /ID# 205470, Bellaire, Texas, United States|Center for Clinical Studies /ID# 213186, Cypress, Texas, United States|Derm Treatment and Res Ctr /ID# 205473, Dallas, Texas, United States|Epiphany Dermatology /ID# 210073, Fort Worth, Texas, United States|Styde Research, LLC /ID# 213469, Lewisville, Texas, United States|Austin Center for Clinical Research /ID# 206640, Pflugerville, Texas, United States|Derm Clin Res Ctr San Antonio /ID# 205469, San Antonio, Texas, United States|EPIC Medical Research /ID# 206382, Murray, Utah, United States|Aspen Clinical Research /ID# 208399, Orem, Utah, United States|Timber Lane Allergy & Asthma Research, LLC /ID# 206897, South Burlington, Vermont, United States|The Education & Research Foundation, Inc. /ID# 206900, Lynchburg, Virginia, United States|Bellingham Asthma Allergy and Immunology Clinic /ID# 210357, Bellingham, Washington, United States|Clinical Investigation Specialist, Inc - Kenosha /ID# 215933, Kenosha, Wisconsin, United States|Palmtree Clinical Research Inc. /Id# 206184, Palm Springs, American Samoa|The Skin Centre /ID# 205922, Benowa, Queensland, Australia|Sinclair Dermatology /ID# 217791, East Melbourne, Victoria, Australia|Box Hill Hospital /ID# 206023, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 205919, Parkville, Victoria, Australia|Murdoch Children's Research Institute /ID# 205667, Parkville, Victoria, Australia|University Hospital St. Polten /ID# 206909, St. Pölten, Niederoesterreich, Austria|Ordensklinikum Linz GmbH, Elisabethinen /ID# 206573, Linz, Austria|Salzburger Landeskliniken (SALK) /ID# 208281, Salzburg, Austria|Sozialmedizinisches Zentrum Ost - Donauspital /ID# 206572, Vienna, Austria|Cliniques Universitaires Saint Luc /ID# 205537, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 205181, Gent, Oost-Vlaanderen, Belgium|Centre Hospitalier Universitaire du Sart Tilman (CHU de Liège) /ID# 204938, Liège, Belgium|Medical Center ""Sv. Panteleimon"" /ID# 210414, Sofia, Bulgaria|Acibadem City Clinic Tokuda /ID# 205292, Sofia, Bulgaria|Military Medical Academy Multiprofile Hospital /ID# 205291, Sofia, Bulgaria|Medical Center Doverie /ID# 211289, Sofia, Bulgaria|Stratica Medical /ID# 205415, Edmonton, Alberta, Canada|Alberta DermaSurgery Centre /ID# 205422, Edmonton, Alberta, Canada|Univ British Columbia /ID# 207837, Vancouver, British Columbia, Canada|Pacific Derm /ID# 206797, Vancouver, British Columbia, Canada|Dr. Brown-Maher PMC INC. /ID# 205420, St. John's, Newfoundland and Labrador, Canada|SimcoMed Health Ltd /ID# 206333, Barrie, Ontario, Canada|Kingsway Clinical Research /ID# 206005, Etobicoke, Ontario, Canada|Guenther Derma Res Ctr, CA /ID# 206772, London, Ontario, Canada|DermEdge Research Inc. /ID# 206036, Mississauga, Ontario, Canada|Dr. S.K. Siddha Medicine Professional Corporation /ID# 207138, Newmarket, Ontario, Canada|Allergy Research Canada Inc. /ID# 213547, Niagara Falls, Ontario, Canada|Sudbury Skin Clinique /ID# 206771, Sudbury, Ontario, Canada|Niakosari Medicine Professional Corporation /ID# 206004, Toronto, Ontario, Canada|Skinsense Medical Research /ID# 206873, Saskatoon, Saskatchewan, Canada|Guelph Dermatology Research /ID# 206890, Guelph, Canada|DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 205429, Zagreb, Grad Zagreb, Croatia|Poliklinika Vlatka Cavka d.o.o. /ID# 211126, Zagreb, Grad Zagreb, Croatia|Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 203448, Ivanić-Grad, Zagrebacka Zupanija, Croatia|Djecja bolnica Srebrnjak /ID# 205926, Zagreb, Croatia|Fakultni nemocnice Plzen /ID# 205096, Plzeň 1, Plzen-jih, Czechia|Sanatorium prof. Arenbergera /ID# 205098, Prague 1, Praha 1, Czechia|Vseobecna Fakultni Nemocnice /ID# 205201, Prague, Czechia|Krajska zdravotni, a.s. - Masarykova nemocnice v Usti nad Labem, o. z. /ID# 205097, Usti nad Labem, Czechia|Aarhus University Hospital /ID# 205524, Aarhus N, Midtjylland, Denmark|Sjaellands Universitets Hospit /ID# 205960, Roskilde, Sjælland, Denmark|Hopital Prive d'Antony /ID# 206553, Antony, Ile-de-France, France|Hopital Saint-Andre /ID# 206554, Bordeaux, France|CHRU de Brest - Hopital Morvan /ID# 206555, Brest, France|C.H. de Bretagne Sud /ID# 206910, Lorient, France|Hopital Saint Louis /ID# 206552, Paris, France|Gemeinschaftspraxis /ID# 205765, Blankenfeld-mahlow, Germany|Klinikum Darmstadt GmbH /ID# 207483, Darmstadt, Germany|Universitaetklinikum Dresden /ID# 205767, Dresden, Germany|Univ Klinik Eppendorf Hamburg /ID# 207982, Hamburg, Germany|Univ Hosp Schleswig-Holstein /ID# 206658, Kiel, Germany|Asefi, Simmern, DE /ID# 205768, Simmern, Germany|Hoffmann, Witten, DE /ID# 205766, Witten, Germany|Centroderm Wuppertal /ID# 206861, Wuppertal, Germany|Papageorgiou General Hospital Thessaloniki /ID# 204526, Nea Efkarpia, Thessaloniki, Greece|251 Airforce General Hospital /ID# 205841, Athens, Greece|Genl Hospital Andreas Syggros /ID# 204527, Athens, Greece|401 GSNA - 401 Army Gen Hosp /ID# 205352, Αthens, Greece|Bugat Pal Korhaz /ID# 211247, Gyöngyös, Heves, Hungary|Pecsi Tudomanyegyetem /ID# 205085, Pécs, Pecs, Hungary|Clinexpert Kft. /ID# 211246, Budapest, Hungary|Synexus Magyarorszag Kft. /ID# 206008, Budapest, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 205611, Kaposvár, Hungary|St. James's Hospital /ID# 204264, Dublin 8, Dublin, Ireland|South Infirmary Victoria Univ /ID# 204265, Cork, Ireland|Galway University Hospital /ID# 209965, Galway, Ireland|University Hospital Waterford /ID# 204266, Waterford, Ireland|Istituto Dermatologico San Gallicano /ID# 205986, Rome, Lazio, Italy|Università Cattolica Sacro Cuore /ID# 205987, Rome, Roma, Italy|A.O.U. di Brescia /ID# 205927, Brescia, Italy|Ospedale San Giovanni di Dio /ID# 205168, Cagliari, Italy|Ospedale San Salvatore - ASL 01 Avezzano - Sulmona - L'Aquila /ID# 205167, L'Aquila, Italy|AO Univ di Modena /ID# 205169, Modena, Italy|Soon Chun Hyang University Hospital Bucheon /ID# 206391, Buncheon, Gyeonggido, Korea, Republic of|Ajou University Hospital /ID# 206341, Suwon-si, Gyeonggido, Korea, Republic of|Korea University Ansan Hosp /ID# 206342, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea Incheon St.Mary's Hospital /ID# 206529, Incheon, Korea, Republic of|Seoul National University Hospital /ID# 206396, Seoul, Korea, Republic of|Chung-Ang University Hostipal /ID# 206397, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital /ID# 206343, Seoul, Korea, Republic of|Bravis Ziekenhuis /ID# 206676, Bergen op Zoom, Noord-Brabant, Netherlands|Centrum Oosterwal /ID# 209640, Alkmaar, Netherlands|Reinier de Graaf /ID# 205811, Delft, Netherlands|Universitair Medisch Centrum Groningen /ID# 205162, Groningen, Netherlands|Greenlane Clinical Centre /ID# 205664, Auckland, New Zealand|CCA Braga - Hospital de Braga /ID# 205854, Braga, Portugal|Centro Hospitalar de Leiria, EPE /ID# 209906, Leiria, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 205839, Lisboa, Portugal|Hospital CUF Descobertas /ID# 205431, Lisbon, Portugal|CHP, EPE- Hospital Geral de Sa /ID# 205187, Porto, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 205679, Porto, Portugal|National Skin Centre /ID# 205222, Singapore, Central Singapore, Singapore|National University Hospital /ID# 205224, Singapore, Singapore|Singapore General Hospital /ID# 205225, Singapore, Singapore|KK Women's & Children Hospital /ID# 206693, Singapore, Singapore|Changi General Hospital /ID# 205223, Singapore, Singapore|Hospital Vital Alvarez Buylla /ID# 205770, Mieres, Asturias, Spain|H. Del Mar, Barcelona /ID# 204709, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 210564, Barcelona, Spain|Hospital Reina Sofia de Cordob /ID# 204712, Cordoba, Spain|Hospital Campus de la Salud /ID# 205544, Granada, Spain|Hosp Infantil Univ Nino Jesus /ID# 210437, Madrid, Spain|Hosp. Gral. Univ. Gregorio Mar /ID# 204380, Madrid, Spain|Hospital Universitario Infanta Leonor /ID# 204710, Madrid, Spain|Hospital General U de Valencia /ID# 210565, Valencia, Spain|National Taiwan University Hospital /ID# 204803, Taipei City, Taipei, Taiwan|Chung Shan Medical University /ID# 205092, Taichung City, Taiwan|Taipei Medical University Hospital /ID# 204804, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 204783, Taoyuan City, Taiwan|The Royal London Hospital /ID# 206491, London, London, City Of, United Kingdom|Northwick Park Hospital /ID# 205250, Harrow, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 204993, Newcastle Upon Tyne, United Kingdom|Plymouth Hospitals NHS Trust /ID# 204649, Plymouth, United Kingdom|Southampton General Hospital /ID# 205711, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03607422"
72,"NCT03595059","A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: ABBV-155|Drug: Paclitaxel|Drug: Docetaxel","MTD and/or RPTD of ABBV-155|Objective Response Rate (ORR)|Duration of Response (DOR)|Rate of Complete Response (CR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Cmax|Tmax of ABBV-155|Terminal Phase Elimination Rate constant of ABBV-155|AUCt|AUC∞|QTcF Change from Baseline|t1/2","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","152","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-573","July 13, 2018","December 30, 2021","December 30, 2021","July 23, 2018",,"November 4, 2019","University of Alabama at Birmingham - Main /ID# 214024, Birmingham, Alabama, United States|Highlands Oncology Group /ID# 201568, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center - LaJolla /ID# 201570, La Jolla, California, United States|UC Irvine Medical Center - Chao Family Comprehensive Cancer Center /ID# 206105, Orange, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 204267, West Hollywood, California, United States|Univ of Colorado Cancer Center /ID# 208365, Aurora, Colorado, United States|Yale University, Yale Cancer Center /ID# 201542, New Haven, Connecticut, United States|Northwestern University Feinberg School of Medicine /ID# 201563, Chicago, Illinois, United States|Johns Hopkins Bayview Med Cnt /ID# 215095, Baltimore, Maryland, United States|Johns Hopkins University /ID# 201320, Baltimore, Maryland, United States|Dana-Farber Cancer Institute /ID# 201564, Boston, Massachusetts, United States|Northwell Health - Marcus Ave /ID# 204376, New Hyde Park, New York, United States|Carolina BioOncology Institute /ID# 201577, Huntersville, North Carolina, United States|Univ Hosp Cleveland /ID# 201567, Cleveland, Ohio, United States|University of Oklahoma, Stephenson Cancer Center /ID# 206820, Oklahoma City, Oklahoma, United States|Lifespan Cancer Institute /ID# 204256, Providence, Rhode Island, United States|Vanderbilt University Med Ctr /ID# 201575, Nashville, Tennessee, United States|Mary Crowley Cancer Research /ID# 214168, Dallas, Texas, United States|MD Anderson Cancer Center /ID# 201558, Houston, Texas, United States|NEXT Oncology /ID# 204893, San Antonio, Texas, United States|Inova Medical Group /ID# 204413, Fairfax, Virginia, United States|Cross Cancer Institute /ID# 213838, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre /ID# 204539, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal /ID# 213840, Montreal, Quebec, Canada|National Cancer Center Hospital East /ID# 215130, Kashiwa-shi, Chiba, Japan|National Cancer Center Hospital /ID# 215003, Chuo-ku, Tokyo, Japan|National Cheng Kung University Hospital /ID# 206304, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 205673, Taipei City, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03595059"
73,"NCT03592576","Expanded Access to Navitoclax",,"Available","No Results Available","Myelofibrosis|Acute Lymphocytic Leukemia (ALL)|Lymphoblastic Lymphoma|Thyroid Cancer","Drug: Navitoclax",,"AbbVie",,"18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"C19-199|C19-922",,,,"July 19, 2018",,"March 25, 2019",,,"https://ClinicalTrials.gov/show/NCT03592576"
74,"NCT03569293","Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1","Measure Up 1","Recruiting","No Results Available","Atopic Dermatitis","Drug: Upadacitinib|Drug: Placebo for Upadacitinib","Percentage of participants achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75)|Percentage of participants achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 with at least two grades of reduction|Percentage of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants with NRS ≥ 4 at Baseline|Percentage of participants achieving EASI 90|Percentage of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants with NRS ≥ 4 at Baseline and randomized to dose A|Percentage of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants with NRS ≥ 4 at Baseline and randomized to dose B|Percentage of participants achieving an improvement (reduction) in Atopic dermatitis impact scale (ADerm-IS) sleep domain score ≥ Minimal clinically important difference (MCID)|Percentage of participants achieving an improvement (reduction) in Atopic dermatitis symptom scale (ADerm-SS) skin pain score ≥ Minimal clinically important difference (MCID)|Percentage of participants achieving an improvement (reduction) in Atopic dermatitis symptom scale (ADerm-SS) total score ≥ Minimal clinically important difference (MCID)|Percentage of participants achieving EASI 100|Percentage of participants achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 with a reduction of ≥ 2 points|Percentage of participants achieving EASI 75|Percentage of participants experiencing a flare|Percentage of participants achieving an improvement (reduction) in ADerm-IS emotional state domain score ≥ MCID at Baseline|Percentage of participants achieving an improvement (reduction) in ADerm-IS daily activities score ≥ MCID","AbbVie","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","810","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-045|2017-005125-20","August 13, 2018","March 20, 2020","May 8, 2023","June 26, 2018",,"January 21, 2020","Alliance Dermatology and MOHs /ID# 200375, Phoenix, Arizona, United States|Investigate MD /ID# 201256, Scottsdale, Arizona, United States|Bakersfield Derma & Skin Cance /ID# 200433, Bakersfield, California, United States|Tien Q Nguyen MD, Inc /ID# 201910, Fountain Valley, California, United States|California Allergy and Asthma Medical Group /ID# 200727, Los Angeles, California, United States|Allergy & Asthma Associates of Southern California /ID# 200733, Mission Viejo, California, United States|Dermatology Clinical Trials /ID# 205876, Newport Beach, California, United States|UC Davis /ID# 203622, Sacramento, California, United States|Synergy Dermatology /ID# 200842, San Francisco, California, United States|San Luis Derm and Laser Clinic /ID# 200372, San Luis Obispo, California, United States|Stanford University /ID# 200440, Stanford, California, United States|Care Access Research /ID# 200940, Walnut Creek, California, United States|Dermatology Physicians of CT /ID# 200928, Shelton, Connecticut, United States|Foxhall Dermatology /ID# 213682, Washington, District of Columbia, United States|George Washington Univ Med /ID# 200364, Washington, District of Columbia, United States|Clearlyderm Dermatology /ID# 208371, Boca Raton, Florida, United States|Skin Care Research, LLC /ID# 200811, Boca Raton, Florida, United States|Olympian Clinical Research /ID# 202914, Clearwater, Florida, United States|Multi-Speciality Research Associates /ID# 213254, Lake City, Florida, United States|GSI Clinical Research, LLC /ID# 200849, Margate, Florida, United States|Sullivan Dermatology /ID# 200671, North Miami Beach, Florida, United States|Leavitt Medical Associates of Florida /ID# 200880, Ormond Beach, Florida, United States|Precision Clinical Research /ID# 209002, Sunrise, Florida, United States|Integrated Clinical Research LLC /ID# 200900, West Palm Beach, Florida, United States|Christie Clinic, LLC /ID# 200427, Champaign, Illinois, United States|Northwestern University Feinberg School of Medicine /ID# 201644, Chicago, Illinois, United States|Dawes Fretzin, LLC /ID# 200366, Indianapolis, Indiana, United States|The South Bend Clinic Center /ID# 200371, South Bend, Indiana, United States|Clinical Trials Management, LLC - Covington /ID# 212658, Covington, Louisiana, United States|Clinical Trials Management, LLC - Metairie /ID# 212659, Metairie, Louisiana, United States|Northeast Dermatology /ID# 201338, Beverly, Massachusetts, United States|Massachusetts General Hospital /ID# 200474, Boston, Massachusetts, United States|Integrated Dermatology of Massachusetts, LLC /ID# 209468, Quincy, Massachusetts, United States|Clin Res Inst of Michigan, LLC /ID# 208019, Chesterfield, Michigan, United States|Henry Ford Medical Center /ID# 204191, Detroit, Michigan, United States|Cleaver Dermatology /ID# 202825, Kirksville, Missouri, United States|Advanced Dermatology of the Midlands /ID# 201689, Omaha, Nebraska, United States|Clinical Research Consortium /ID# 200734, Las Vegas, Nevada, United States|Northeast Dermatology Associates /ID# 200981, Dover, New Hampshire, United States|Montefiore Medical Center /ID# 200456, Bronx, New York, United States|Forest Hills Dermatology Group /ID# 209244, Forest Hills, New York, United States|Icahn School of Med Mt. Sinai /ID# 200370, New York, New York, United States|Joseph Schwartz MD Medical Cosmetic Derm /ID# 202121, Troy, New York, United States|Rapid Medical Research, INC /ID# 202653, Cleveland, Ohio, United States|Lynn Health Science Institute (LHSI) /ID# 212676, Oklahoma City, Oklahoma, United States|Newton Clinical Research /ID# 204169, Oklahoma City, Oklahoma, United States|Oregon Medical Res Center PC /ID# 200428, Portland, Oregon, United States|Oregon Health and Science University /ID# 200992, Portland, Oregon, United States|Dermdox Center for Dermatology /ID# 213782, Hazleton, Pennsylvania, United States|Clinical Partners, LLC /ID# 200460, Johnston, Rhode Island, United States|Derm & Laser Ctr of Charleston /ID# 200402, Charleston, South Carolina, United States|Arlington Research Center, Inc /ID# 200391, Arlington, Texas, United States|Orion Clinical Research /ID# 204703, Austin, Texas, United States|Modern Research Associates, PL /ID# 200705, Dallas, Texas, United States|Menter Dermatology Res Inst /ID# 200390, Dallas, Texas, United States|Center for Clinical Studies - Webster TX /ID# 203185, Webster, Texas, United States|Dermatology Specialists of Spo /ID# 202068, Spokane, Washington, United States|Instituto de Neumonología y Dermatología /ID# 203444, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Framingham Centro Medico /ID# 202688, La Plata, Buenos Aires, Argentina|Psoriahue Med Interdisciplinar /ID# 202451, Buenos Aires, Argentina|Woden Dermatology /ID# 205799, Phillip, Australian Capital Territory, Australia|Holdsworth House Medical Practice /ID# 211236, Sydney, New South Wales, Australia|North Eastern Health Specialis /ID# 205802, Hectorville, South Australia, Australia|Skin Health Institute Inc /ID# 204791, Carlton, Victoria, Australia|Fremantle Dermatology /ID# 205305, Fremantle, Western Australia, Australia|University Clinical Centre of the Republic of Srpska /ID# 202666, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 202667, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 202668, Sarajevo, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 202669, Sarajevo, Bosnia and Herzegovina|UMHAT Dr Georgi Stranski EAD /ID# 201521, Pleven, Bulgaria|UMHAT Aleksandrovska /ID# 201519, Sofia, Bulgaria|UMHAT Stoyan Kirkovich /ID# 201522, Stara Zagora, Bulgaria|Dermatology Research Institute Inc. /ID# 200318, Calgary, Alberta, Canada|Kirk Barber Research, CA /ID# 200324, Calgary, Alberta, Canada|Dr. Chih-ho Hong Medical Inc. /ID# 200311, Surrey, British Columbia, Canada|Enverus Medical Research /ID# 200307, Surrey, British Columbia, Canada|Wiseman Dermatology Research /ID# 200323, Winnipeg, Manitoba, Canada|Dr. Irina Turchin PC Inc. /ID# 200322, Fredericton, New Brunswick, Canada|Karma Clinical Trials /ID# 200316, St. John's, Newfoundland and Labrador, Canada|McMaster University Med Cent /ID# 200313, Hamilton, Ontario, Canada|Dr. Wei Jing Loo Medicine Prof /ID# 206051, London, Ontario, Canada|Lynderm Research Inc. /ID# 200315, Markham, Ontario, Canada|Dermatology Ottawa Research Centre /ID# 200319, Ottawa, Ontario, Canada|K. Papp Clinical Research /ID# 200317, Waterloo, Ontario, Canada|Dr. David Gratton Dermat Inc. /ID# 200309, Montreal, Quebec, Canada|Innovaderm Research Inc. /ID# 200320, Montréal, Quebec, Canada|Dre. Angelique Gagne-Henley /ID# 200326, St-Jerome, Quebec, Canada|Peking Univ Peoples Hospital /ID# 202549, Beijing, Beijing, China|Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 208597, Guangzhou, Guangdong, China|The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 202548, Guangzhou, Guangdong, China|First Hospital of China Medical University /ID# 202615, Shenyang, Liaoning, China|Ruijin Hospital, Shanghai Jiaotong /ID# 202554, Shanghai, Shanghai, China|Huashan Hospital of Fudan University /ID# 205760, Shanghai, Shanghai, China|The Second Affiliated Hospital /ID# 202608, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 202601, Beijing, China|Peking University 3rd Hospital /ID# 202612, Beijing, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 208598, Wuhan, China|Fundacion Hospital San Vicente de Paul - Rionegro /ID# 202043, Rionegro, Antioquia, Colombia|Fundacion Centro de Excelencia en Enfermedades Cronicas no Transmisibles - FUNCE /ID# 201905, Monteria, Cordoba, Colombia|Sociedad de Cirugía de Bogotá- Hospital de San José /ID# 203074, Bogota, Cundinamarca, Colombia|Ctr Int de Reum del Caribe SAS /ID# 201620, Barranquilla, Colombia|Klinicki bolnicki centar Zagreb /ID# 201879, Zagreb, Grad Zagreb, Croatia|Klinika za dječje bolesti Zagreb /ID# 203151, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 201523, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 201527, Split, Croatia|Bispebjerg Hospital /ID# 200979, Copenhagen NV, Hovedstaden, Denmark|Gentofte Hospital /ID# 200736, Hellerup, Hovedstaden, Denmark|Aarhus University Hospital /ID# 200737, Aarhus N, Midtjylland, Denmark|East Tallinn Central Hospital /ID# 200846, Tallinn, Estonia|North Estonian Medical Centre /ID# 200951, Tallinn, Estonia|Tartu University Clinic /ID# 200847, Tartu, Estonia|Mehiläinen Neo /ID# 201116, Turku, Varsinais-Suomi, Finland|Kuopio University Hospital /ID# 202449, Kuopio, Finland|Terveystalo Tampere /ID# 201117, Tampere, Finland|CHU Hotel Dieu /ID# 206377, Nantes CEDEX 1, Pays-de-la-Loire, France|Centre Hospitalier Le Mans /ID# 205991, Le Mans CEDEX 9, Sarthe, France|Charles Nicolle CHU Rouen /ID# 201525, Rouen CEDEX, Seine-Maritime, France|Le Bateau BLanc /ID# 206833, Martigues, France|Chu Lyon Sud /Id# 201529, Pierre Benite, France|Hopital Larrey /ID# 201528, Toulouse, France|CMS3 Company for Medical Study /ID# 205193, Selters (Westerwald), Rheinland-Pfalz, Germany|Universitaets-Hautklinik Kiel /ID# 202255, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Bonn /ID# 202086, Bonn, Germany|Universitaetsklinikum Frankfurt /ID# 202089, Frankfurt, Germany|TFS Trial Form Support GmbH /ID# 202083, Hamburg, Germany|Med Hochschule Hanover /ID# 202091, Hannover, Germany|Univ Johannes Gutenberg /ID# 205192, Mainz, Germany|Universitatsklinikum Munster /ID# 202085, Muenster, Germany|TU Uniklinik Munchen /ID# 202087, Munich, Germany|AOU Federico II /ID# 200750, Naples, Campania, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200692, Ancona, Italy|A.O. Policlinico Sant'Orsola Malpighi /ID# 200746, Bologna, Italy|Universita di Catania /ID# 200741, Catania, Italy|Ospedale Santa Chiara - Università di Pisa /ID# 200695, Pisa, Italy|Policlinico Univ Tor Vergata /ID# 201136, Rome, Italy|Aichi Medical University Hosp /ID# 202833, Nagakute, Aichi, Japan|Fukuoka University Hospital /ID# 201309, Fukuoka-shi, Fukuoka, Japan|Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers /ID# 202891, Fukuoka-shi, Fukuoka, Japan|Gifu University Hospital /ID# 201760, Gifu-shi, Gifu, Japan|Ogaki Municipal Hospital /ID# 203463, Ogaki-shi, Gifu, Japan|Takagi Dermatological Clinic /ID# 201238, Obihiro-shi, Hokkaido, Japan|Medical Cooperation Kojinkai Sapporo Skin Clinic /ID# 201239, Sapporo-shi, Hokkaido, Japan|University Hospital Kyoto Prefectural University of Medicine /ID# 201876, Kyoto-shi, Kyoto, Japan|Kume Clinic /ID# 201912, Sakai-shi, Osaka, Japan|NTT Medical Center Tokyo /ID# 201759, Shinagawa-ku, Tokyo, Japan|University of Yamanashi Hospital /ID# 204174, Chuo-shi, Yamanashi, Japan|Hospital Sultan Ismail /ID# 211277, Johor Bahru, Johor, Malaysia|Hospital Raja Permaisuri Bainun /ID# 204375, Ipoh, Perak, Malaysia|Hospital Selayang /ID# 204378, Batu Caves, Malaysia|Hospital Queen Elizabeth /ID# 204379, Kota Kinabalu, Malaysia|Clinical Trials NZ /ID# 205335, Hamilton, New Zealand|Cruz-Santana, Carolina, PR /ID# 201096, Carolina, Puerto Rico|Ponce Medical School Foundatio /ID# 201821, Ponce, Puerto Rico|Clinical Research Puerto Rico /ID# 203309, San Juan, Puerto Rico|Colentina Clinical Hospital /ID# 205860, Bucharest, Romania|Cabinet Medical de Dermatovenerologie Dr. Remus Orasan /ID# 205862, Cluj Napoca, Romania|Chelyabinsk Regional Clinical Dermatovenerologic Dispensary /ID# 201996, Chelyabinsk, Chelyabinskaya Oblast, Russian Federation|GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 203439, Krasnodar, Krasnodarskiy Kray, Russian Federation|National Medical Research Center of Children's Health /ID# 203440, Moscow, Moskovskaya Oblast, Russian Federation|Saratov State Medical University n.a. V.I. Razumovskiy /ID# 201595, Saratov, Saratovskaya Oblast, Russian Federation|Ural Research Institute of dermatovenerology and immunopathology /ID# 201593, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|Hopitaux Universitaires de Geneve /ID# 201600, Genève, Geneve, Switzerland|CHUV - Hôpital de l'Enfance /ID# 206505, Lausanne, Vaud, Switzerland|Universitaetsspital Basel /ID# 201599, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 201598, Bern, Switzerland|Centre Hospitalier Univ Vaudoi /ID# 200910, Lausanne, Switzerland|Erciyes University Medical Fac /ID# 204098, Melikgazi, Kayseri, Turkey|Hacettepe University Medical Faculty /ID# 204099, Ankara, Turkey|Gazi Universitesi Tip Fakultes /ID# 204176, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 204100, Istanbul, Turkey|CI Zaporizhzhya Regional Skin and Venereal Clinical Dispensary /ID# 201962, Zaporizhzhya, Zaporizka Oblast, Ukraine|ME ""Rivne Regional Dermatology and Venereology Dispensary"" of RRC /ID# 210504, Rivne, Ukraine|West Middlesex University Hospital /ID# 202273, Isleworth, London, City Of, United Kingdom|Whipps Cross Univ Hospital /ID# 201043, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 201192, London, London, City Of, United Kingdom|Chelsea and Westminster Hosp /ID# 201971, London, United Kingdom|The University of Manchester /ID# 201194, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03569293"
75,"NCT03568318","A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis","AD Up","Recruiting","No Results Available","Atopic Dermatitis","Drug: Upadacitinib|Drug: Placebo for Upadacitinib|Drug: Topical corticosteroids (TCS)","Percentage of participants achieving at least a 75% reduction in Eczema Area and Severity Index (EASI 75)|Percentage of participants achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 with at least two grades of reduction|Percentage of participants achieving an improvement (reduction) in worst pruritus Numerical Rating Scale (NRS) ≥ 4 for participants with pruritus NRS ≥ 4 at Baseline|Percentage of participants achieving EASI 90|Percentage of participants achieving EASI 75|Percentage of participants in Arm A and Arm C achieving EASI 100|Percentage of participants in Arm A or Arm C achieving validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0","AbbVie","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","810","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-047|2017-005126-37","August 9, 2018","August 7, 2022","August 29, 2022","June 26, 2018",,"January 22, 2020","Total Skin and Beauty Derm Ctr /ID# 200548, Birmingham, Alabama, United States|Clinical Research Center AL /ID# 201865, Birmingham, Alabama, United States|Horizon Research Partners, LLC /ID# 213550, Mobile, Alabama, United States|Arizona Research Center, Inc. /ID# 200546, Phoenix, Arizona, United States|Investigate MD /ID# 201257, Scottsdale, Arizona, United States|University of Arizona /ID# 201059, Tucson, Arizona, United States|Bakersfield Derma & Skin Cance /ID# 200892, Bakersfield, California, United States|University of California Irvine /ID# 200902, Irvine, California, United States|Therapeutics Clinical Research /ID# 200593, San Diego, California, United States|Mosaic Dermatology /ID# 200553, Santa Monica, California, United States|Stanford University /ID# 200597, Stanford, California, United States|University of Colorado Anchutz Medical Campus /ID# 202822, Aurora, Colorado, United States|Colorado Dermatology /ID# 203626, Centennial, Colorado, United States|Western States Clinical Research, Inc. /ID# 201702, Wheat Ridge, Colorado, United States|Dermatology Physicians of CT /ID# 201004, Shelton, Connecticut, United States|Clearlyderm Dermatology /ID# 207709, Boca Raton, Florida, United States|Skin Care Research, LLC /ID# 200812, Boca Raton, Florida, United States|Clinical Res of West FL, Inc. /ID# 203643, Clearwater, Florida, United States|Florida Academic Centers Research and Education /ID# 200544, Coral Gables, Florida, United States|ACCEL Research Sites /ID# 213364, DeLand, Florida, United States|Sullivan Dermatology /ID# 201174, North Miami Beach, Florida, United States|Park Avenue Dermatology, PA /ID# 201012, Orange Park, Florida, United States|Precision Clinical Research /ID# 208734, Sunrise, Florida, United States|Advanced Clinical Research at Treasure Valley Dermatology & Skin Cancer Center /ID# 203628, Boise, Idaho, United States|Northwestern University Feinberg School of Medicine /ID# 201646, Chicago, Illinois, United States|Northshore University Health System-Evanston /ID# 200556, Evanston, Illinois, United States|DuPage Medical Group /ID# 202065, Wheaton, Illinois, United States|Deaconess Clinic Downtown /ID# 201001, Evansville, Indiana, United States|Indiana University /ID# 200515, Indianapolis, Indiana, United States|Kansas City Dermatology PA /ID# 203026, Overland Park, Kansas, United States|ORA Clinical Res & Development /ID# 202824, Andover, Massachusetts, United States|Tufts Medical Center /ID# 200570, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 200545, Boston, Massachusetts, United States|Clin Res Inst of Michigan, LLC /ID# 208020, Chesterfield, Michigan, United States|Clarkston Skin Research /ID# 200560, Clarkston, Michigan, United States|MediSearch Clinical Trials /ID# 201006, Saint Joseph, Missouri, United States|Skin Specialists, PC /ID# 200573, Omaha, Nebraska, United States|Darmouth-Hitchcock Medical Cen /ID# 200918, Lebanon, New Hampshire, United States|Psoriasis Treatment Ctr NJ /ID# 200714, East Windsor, New Jersey, United States|Juva Skin and Laser Center /ID# 200997, New York, New York, United States|Joseph Schwartz MD Medical Cosmetic Derm /ID# 202122, Troy, New York, United States|Bexley Dermatology Research /ID# 200899, Bexley, Ohio, United States|The Ohio State University /ID# 200542, Columbus, Ohio, United States|Vital Prospects Clinical Research Institution /ID# 200901, Tulsa, Oklahoma, United States|Oregon Derm & Res. Ctr /ID# 200601, Portland, Oregon, United States|University of Pittsburgh MC /ID# 206057, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital /ID# 200566, Providence, Rhode Island, United States|Rivergate Dermatology & Skin Care Center /ID# 201698, Goodlettsville, Tennessee, United States|Stones River Dermatology /ID# 204962, Murfreesboro, Tennessee, United States|Arlington Research Center, Inc /ID# 200559, Arlington, Texas, United States|Center for Clinical Studies /ID# 200582, Houston, Texas, United States|Progressive Clinical Research /ID# 201582, San Antonio, Texas, United States|Center for Clinical Studies - Webster TX /ID# 203186, Webster, Texas, United States|Advanced Clinical Research - Woseth Dermatology /ID# 213745, Salt Lake City, Utah, United States|Eastern Virginia Med School /ID# 200994, Norfolk, Virginia, United States|Dermatology Associates /ID# 200717, Seattle, Washington, United States|University of Wisconsin - Madison /ID# 204933, Madison, Wisconsin, United States|St George Dermatology & Skin Cancer Centre /ID# 204788, Kogarah, New South Wales, Australia|Royal North Shore Hospital /ID# 204639, Saint Leonards, New South Wales, Australia|Westmead Hospital /ID# 205682, Westmead, New South Wales, Australia|Veracity Clinical Research /ID# 204793, Woolloongabba, Queensland, Australia|Fremantle Dermatology /ID# 205306, Fremantle, Western Australia, Australia|Kepler Universitätsklinikum /ID# 201075, Linz, Oberoesterreich, Austria|Medizinische Universitat Wien, Universitatsklinik fur Dermatologie /ID# 201080, Vienna, Wien, Austria|Medical University Innsbruck /ID# 210897, Innsbruck, Austria|Ordensklinikum Linz GmbH, Elisabethinen /ID# 209567, Linz, Austria|UZ Brussel /ID# 203557, Jette, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 202028, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 202030, Gent, Oost-Vlaanderen, Belgium|Grand Hopital de Charleroi /ID# 202029, Loverval, Belgium|Dermatology Research Institute Inc. /ID# 200341, Calgary, Alberta, Canada|Kirk Barber Research, CA /ID# 200329, Calgary, Alberta, Canada|Alberta DermaSurgery Centre /ID# 205674, Edmonton, Alberta, Canada|Karma Clinical Trials /ID# 200339, St. John's, Newfoundland and Labrador, Canada|Eastern Canada Cutaneous Resea /ID# 200335, Halifax, Nova Scotia, Canada|Lynderm Research Inc. /ID# 200338, Markham, Ontario, Canada|DermEdge Research Inc. /ID# 200337, Mississauga, Ontario, Canada|The Centre for Clinical Trials /ID# 205404, Oakville, Ontario, Canada|JRB Research /ID# 212653, Ottawa, Ontario, Canada|Dr. Melinda Gooderham Medicine /ID# 200331, Peterborough, Ontario, Canada|Ctr for Derma & Cosmetic Surge /ID# 205409, Richmond Hill, Ontario, Canada|Toronto Research Centre /ID# 205411, Toronto, Ontario, Canada|Research Toronto /ID# 205410, Toronto, Ontario, Canada|XLR8 Medical Research /ID# 205405, Windsor, Ontario, Canada|CHU Sainte-Justine /ID# 206013, Montreal, Quebec, Canada|Ctr Derma du QC Metropolitain /ID# 205403, Quebec City, Quebec, Canada|Dre. Angelique Gagne-Henley /ID# 200330, St-Jerome, Quebec, Canada|Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 206728, Guangzhou, Guangdong, China|Xiangya Hospital Central South University /ID# 207510, Changsha, Hunan, China|First Hospital of China Medical University /ID# 209840, Shenyang, Liaoning, China|Huashan Hospital of Fudan University /ID# 207437, Shanghai, Shanghai, China|1st Hosp College Med Zhejian /ID# 207132, Hangzhou, Zhejiang, China|The Second Affiliated Hospital /ID# 207442, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 207434, Beijing, China|The General hospital of people's Liberation Amy(301 hospital) /ID# 206786, Beijing, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 206669, Wuhan, China|Fakultni nemocnice Plzen /ID# 202044, Plzeň 1, Plzen-jih, Czechia|Sanatorium prof. Arenbergera /ID# 202082, Prague 1, Praha 1, Czechia|Vseobecna fakultni nemoc Praze /ID# 202045, Prague 2, Czechia|Vseobecna Fakultni Nemocnice /ID# 205248, Prague, Czechia|Hopital Saint-Andre /ID# 206129, Bordeaux, France|Hopital de la Timone /ID# 206128, Marseille, France|Hopital de L'archet 2 /ID# 205780, Nice, France|Polyclinique Courlancy /ID# 201537, Reims, France|Universitaetsklinik Heidelberg /ID# 202097, Heidelberg, Baden-Wuerttemberg, Germany|CMS3 Company for Medical Study /ID# 205195, Selters (Westerwald), Rheinland-Pfalz, Germany|Universitaets-Hautklinik Kiel /ID# 202256, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Bonn /ID# 202092, Bonn, Germany|Universitaetsklinikum Frankfurt /ID# 202095, Frankfurt, Germany|TFS Trial Form Support GmbH /ID# 202096, Hamburg, Germany|Med Hochschule Hanover /ID# 202098, Hannover, Germany|Univ Johannes Gutenberg /ID# 205194, Mainz, Germany|Universitatsklinikum Munster /ID# 202094, Muenster, Germany|TU Uniklinik Munchen /ID# 202093, Munich, Germany|General Univ Hosp ""Attikon"" /ID# 201126, Athens, Attiki, Greece|Papageorgiou General Hospital Thessaloniki /ID# 202392, Nea Efkarpia, Thessaloniki, Greece|Children`s Hosp P. A. Kyriakou /ID# 217573, Athens, Greece|Genl Hospital Andreas Syggros /ID# 201123, Athens, Greece|Hosp Skin and Venereal Dis /ID# 201124, Thessaloniki, Greece|401 GSNA - 401 Army Gen Hosp /ID# 211963, Αthens, Greece|Queen Mary Hospital /ID# 205146, Hong Kong, Hong Kong|Prince of Wales Hospital /ID# 205152, Sha Tin, Hong Kong|Oroshazi Korhaz /ID# 203525, Oroshaza, Bekes, Hungary|Debreceni Egyetem Klinikai Központ /ID# 201765, Debrecen, Hungary|Szegedi Tudomanyegyetem /ID# 204144, Szeged, Hungary|Allergo-Derm Bakos /ID# 205361, Szolnok, Hungary|St. James's Hospital /ID# 201118, Dublin 8, Dublin, Ireland|South Infirmary Victoria Univ /ID# 201079, Cork, Ireland|University Hospital Waterford /ID# 201253, Waterford, Ireland|Soroka Medical Center /ID# 206652, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 201959, Petakh Tikva, Tel-Aviv, Israel|HaEmek Medical Center /ID# 201958, Afula, Israel|Sheba Medical Center /ID# 201611, Ramat Gan, Israel|Ichilov Medical Center /ID# 201608, Tel Aviv, Israel|AOU Federico II /ID# 200751, Naples, Campania, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 200744, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 200739, Rozzano, Milano, Italy|Università Cattolica Sacro Cuore /ID# 203014, Rome, Roma, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200690, Ancona, Italy|Universita di Catania /ID# 200742, Catania, Italy|Chukyo Hospital /ID# 202311, Nagoya-shi, Aichi, Japan|Medical Corporation Matsuo Clinic /ID# 202312, Fukuoka-shi, Fukuoka, Japan|HIRAMOTO skin clinic /ID# 204048, Amagasaki-shi, Hyogo, Japan|National Hospital Organization Sagamihara National Hospital /ID# 201658, Sagamihara-shi, Kanagawa, Japan|Queen's Square Medical Center dermatology, allergology /ID# 203850, Yokohama City, Kanagawa, Japan|Tohoku University Hospital /ID# 206322, Sendai-shi, Miyagi, Japan|Osaka Habikino Medical Center /ID# 204243, Habikino-shi, Osaka, Japan|Jichi Medical University Hospital /ID# 201913, Shimotsuke-shi, Tochigi, Japan|Juntendo University Hospital /ID# 202888, Bunkyo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 201711, Hachioji, Tokyo, Japan|Ｍaruyama Dermatology Clinic /ID# 202350, Koto-ku, Tokyo, Japan|Yamate Dermatological Clinic /ID# 202130, Shinjuku-ku, Tokyo, Japan|Hiroshima University Hospital /ID# 201914, Hiroshima, Japan|Kyoto University Hospital /ID# 201654, Sakyo-ku, Japan|Academisch Medisch Centrum /ID# 202193, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 202195, Groningen, Netherlands|Erasmus Medisch Centrum /ID# 202196, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 202194, Utrecht, Netherlands|Clinical Trials NZ /ID# 205336, Hamilton, New Zealand|Haukeland University Hospital /ID# 201152, Bergen, Hordaland, Norway|Universitetssykehuset N-Norge, Harstad /ID# 201269, Harstad, Troms, Norway|Universitetssykehuset N-Norge, Tromso /ID# 201270, Tromso, Troms, Norway|Rikshospitalet OUS HF /ID# 201271, Oslo, Norway|Dr. Samuel Sanchez, PSC /ID# 202002, Caguas, Puerto Rico|GCM Medical Group /ID# 202003, San Juan, Puerto Rico|Clinical Research Puerto Rico /ID# 203644, San Juan, Puerto Rico|FNsP F.D.Roosevelta Banska Bys /ID# 204372, Banska Bystrica, Banskobystricky Kraj, Slovakia|FNsP Nove Zamky /ID# 204240, Nové Zámky, Nitriansky Kraj, Slovakia|Univerzitna nemocnica Martin /ID# 203851, Martin, Zilinsky Kraj, Slovakia|FNsP J.A. Reimana /ID# 204373, Presov, Slovakia|Hospital General Univ Alicante /ID# 200873, Alicante, Spain|Hospital Santa Creu i Sant Pau /ID# 201325, Barcelona, Spain|Hospital Univ de la Princesa /ID# 201517, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 201135, Madrid, Spain|Hospital Universitario La Paz /ID# 205438, Madrid, Spain|Hospital Univ de Puerto Real /ID# 200875, Puerto Real, Spain|Skane University Hospital Lund /ID# 201244, Lund, Skane Lan, Sweden|Hudkliniken SU/Sahlgrenska /ID# 201274, Goteborg, Sweden|Sodersjukhuset /ID# 201242, Stockholm, Sweden|Karolinska University Hospital /ID# 201243, Stockholm, Sweden|St. Thomas Hospital /ID# 204642, London, England, United Kingdom|Whipps Cross Univ Hospital /ID# 201044, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 201193, London, London, City Of, United Kingdom|Ninewells Hospital /ID# 202081, Dundee, United Kingdom|Chapel Allerton Hospital /ID# 201106, Leeds, United Kingdom|Churchill Hospital /ID# 202052, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03568318"
76,"NCT03567616","A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma",,"Suspended","No Results Available","Multiple Myeloma","Drug: Venetoclax|Drug: Pomalidomide|Drug: Dexamethasone","Number of Participants With Adverse Events|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Duration of Response (DOR)|Time-to-progression (TTP)","AbbVie|Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-085|2017-004232-11","October 18, 2018","January 22, 2021","January 22, 2021","June 26, 2018",,"November 13, 2019","John B. Amos Cancer Center - C /ID# 202055, Columbus, Georgia, United States|University of Kansas Cancer Center /ID# 201292, Fairway, Kansas, United States|Dana-Farber Cancer Institute /ID# 201297, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 201287, Saint Louis, Missouri, United States|Duke University Hospital /ID# 200805, Durham, North Carolina, United States|Ohio State Cancer Center /ID# 202443, Columbus, Ohio, United States|Oregon Health and Science University /ID# 205582, Portland, Oregon, United States|Aurora Health Care, Aurora Cancer Center /ID# 201153, Wauwatosa, Wisconsin, United States|Hospital Clinic de Barcelona /ID# 200957, Barcelona, Spain|Hospital Vall d'Hebron /ID# 200967, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 200959, Barcelona, Spain|Hospital Universitario La Paz /ID# 200969, Madrid, Spain|Hospital Clinico Univ de Salamanca /ID# 200958, Salamanca, Spain|Leicester Royal Infirmary /ID# 202238, Leicester, England, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 203188, Birmingham, United Kingdom|St. James University Hospital /ID# 202243, Leeds, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 202240, Norwich, United Kingdom|Royal Marsden Hospital, The Ro /ID# 202242, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03567616"
77,"NCT03557619","A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies",,"Recruiting","No Results Available","Hematologic Malignancies","Drug: Venetoclax|Drug: ethinyl estradiol/levonorgestrel","Tmax of (ethinyl estradiol) EE/Levonorgestrel and Venetoclax|Cmax of EE/Levonorgestrel and Venetoclax|t1/2 of EE/Levonorgestrel and Venetoclax|AUCt of EE/Levonorgestrel and Venetoclax|AUCinf of EE/Levonorgestrel","AbbVie","Female","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M16-185","July 30, 2019","January 31, 2020","June 15, 2021","June 15, 2018",,"August 13, 2019","Henry Ford Health System /ID# 209090, Detroit, Michigan, United States|Dartmouth-Hitchock Med Ctr /ID# 169097, Lebanon, New Hampshire, United States|Gabrail Cancer Center Research /ID# 207039, Canton, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03557619"
78,"NCT03543358","A Long-Term Study of Rovalpituzumab Tesirine",,"Completed","No Results Available","Cancer","Drug: rovalpituzumab tesirine","Number of Participants who Receive Treatment or Retreatment and who Experience a Treatment-Emergent Adverse Events.","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","3","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-291","September 10, 2018","November 26, 2019","November 26, 2019","June 1, 2018",,"December 17, 2019","Arizona Oncology Associates, PC-HOPE (Rudasill) /ID# 204818, Tucson, Arizona, United States|City of Hope National Medical Center /ID# 204885, Duarte, California, United States|Univ of Pittsburgh Med Ctr /ID# 204763, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03543358"
79,"NCT03539744","A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma","CANOVA","Recruiting","No Results Available","Multiple Myeloma","Drug: Pomalidomide|Drug: Dexamethasone|Drug: Venetoclax","Progression-Free Survival (PFS)|Very Good Partial Response or Better Response Rate (VGPR)|Overall Response Rate (ORR)|Overall survival (OS)|Duration of response (DOR)|Time to Disease Progression (TTP)|Time to Response (TTR)|Minimal Residual Disease (MRD) Negativity Rate|Cmax of Venetoclax|Trough Concentration (Ctrough) of Venetoclax|Change from Baseline in PROMIS Fatigue Score.|Change from Baseline in BPI-SF Worst Pain Score|Change from Baseline in EORTC QLQ-30 Physical Functioning Score|Change from Baseline in EORTC QLQ-30 Global Health Status/Quality of Life Score","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","244","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-494|2017-003838-88","October 22, 2018","January 12, 2021","July 7, 2022","May 29, 2018",,"December 30, 2019","VA Central California Health C /ID# 200047, Fresno, California, United States|University of California, Los Angeles /ID# 171524, Los Angeles, California, United States|Mayo Clinic /ID# 200075, Jacksonville, Florida, United States|Cleveland Clinic Foundation-Florida /ID# 208884, Weston, Florida, United States|Norton Cancer Institute /ID# 200834, Louisville, Kentucky, United States|Karmanos Cancer Institute /ID# 201377, Detroit, Michigan, United States|Henry Ford Hospital /ID# 171531, Detroit, Michigan, United States|Mayo Clinic - /ID# 201091, Rochester, Minnesota, United States|Fairview Hospital - Moll Pavilion /ID# 208919, Cleveland, Ohio, United States|Cleveland Clinic Main Campus /ID# 202247, Cleveland, Ohio, United States|UPMC Hillman Cancer Ctr /ID# 200063, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center at Texas Medical Center /ID# 200060, Houston, Texas, United States|Liverpool Hospital /ID# 202431, Liverpool, New South Wales, Australia|Wollongong Hospital /ID# 205545, Wollongong, New South Wales, Australia|Icon Cancer Care - Townsville /ID# 206565, Hyde Park, Queensland, Australia|Icon Cancer Centre /ID# 205663, South Brisbane, Queensland, Australia|The Queen Elizabeth Hospital /ID# 202432, Woodville, South Australia, Australia|Perth Blood Institute Ltd /ID# 206649, Nedlands, Western Australia, Australia|Beijing chaoyang hospital, capital medical university /ID# 216014, Beijing, Beijing, China|Peking University Third Hospital /ID# 216371, Beijing, Beijing, China|Fujian Medical Univ Union Hosp /ID# 215832, Fuzhou, Fujian, China|Guangdong Provincial People's Hospital /ID# 215860, Guangzhou, Guangdong, China|1st Aff Hosp Nanchang Univ /ID# 216954, Nanchang, Jiangxi, China|First Hospital of China Medical University /ID# 215996, Shenyang, Liaoning, China|Shanghai Changzheng Hospital /ID# 215838, Shanghai, Shanghai, China|Ruijin Hospital, Shanghai Jiaotong /ID# 216643, Shanghai, Shanghai, China|Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 216041, Tianjin, Tianjin, China|1st Hosp College Med Zhejian /ID# 215989, Hangzhou, Zhejiang, China|Peking Union Medical College H /ID# 216040, Beijing, China|West China Hospital, Sichuan University /ID# 216647, Chengdu, China|The First Affiliated Hospital /ID# 216094, Soochow, China|Wuhan Union Hospital of Tongji /ID# 216648, Wuhan, China|Henan Cancer Hospital /ID# 215987, Zhengzhou, Henan, China|Fakultni nemocnice Ostrava /ID# 204515, Ostrava, Praha 5, Czechia|Fakultni Nemocnice Brno /ID# 204512, Brno, Czechia|CHRU Lille - Hôpital Claude Huriez /ID# 202213, Lille CEDEX, Hauts-de-France, France|CHU Nancy - Brabois /ID# 201076, Vandoeuvre-Lès-Nancy, Lorraine, France|Centre Hospitalier Lyon Sud /ID# 200097, Pierre Benite CEDEX, Rhone, France|CHU Henri Mondor /ID# 202211, Creteil, France|CHU de Nantes, Hotel Dieu -HME /ID# 200099, Nantes, France|Hopital Pitie Salpetriere /ID# 214173, Paris, France|Univ Hosp Schleswig-Holstein /ID# 201830, Kiel, Schleswig-Holstein, Germany|Charite-Univ. Berlin, Benjamin-Franklin /ID# 200051, Berlin, Germany|Universitaetsklinikum Hamburg /ID# 215495, Hamburg, Germany|Universitaetsklinikum Jena /ID# 201254, Jena, Germany|Univ-Klinikum Wuerzburg /ID# 200055, Wuerzburg, Germany|Alexandra General Hospital /ID# 202386, Athens, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 213982, Athens, Greece|University Gen Hosp of Patra /ID# 201691, Patras, Greece|Theageneio Anticancer Hospital /ID# 213983, Thessaloniki, Greece|G. Papanikolaou Hospital /ID# 201692, Thessaloniki, Greece|Sheba Medical Center /ID# 169778, Ramat Gan, Tel-Aviv, Israel|Bnai Zion Medical Center /ID# 169466, Haifa, Israel|Rambam Medical Center /ID# 169678, Haifa, Israel|Hadassah /ID# 169474, Jerusalem, Israel|Tel Aviv Medical Center /ID# 169437, Tel Aviv, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 170952, Bologna, Emilia-Romagna, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 212498, Milan, Lombardia, Italy|AOU Ospedali Riuniti di Ancona - G.M. Lancisi, G. Salesi /ID# 170950, Ancona, Marche, Italy|AOU Citta della Salute Scienza /ID# 170962, Turin, Piemonte, Italy|Irccs-Crob /Id# 170955, Rionero in Vulture, Italy|A.O. Santa Maria /ID# 170948, Terni, Italy|Nagoya City University Hospital /ID# 170880, Nagoya-shi, Aichi, Japan|Kyushu University Hospital /ID# 171117, Fukuoka-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 171043, Ogaki-shi, Gifu, Japan|Gunma University Hospital /ID# 170966, Maebashi-shi, Gunma, Japan|Kobe City Medical Center General Hospital /ID# 170992, Kobe-shi, Hyogo, Japan|Hitachi General Hospital /ID# 200843, Hitachi-shi, Ibaraki, Japan|Tohoku University Hospital /ID# 201935, Sendai-shi, Miyagi, Japan|Okayama Medical Center /ID# 200119, Okayama-shi, Okayama, Japan|Japanese Red Cross Osaka Hospi /ID# 171493, Osaka-shi, Osaka, Japan|Osaka University Hospital /ID# 201966, Suita-shi, Osaka, Japan|Tokushima University Hospital /ID# 202571, Tokushima-shi, Tokushima, Japan|Japanese Red Cross Medical Center /ID# 171256, Shibuya-ku, Tokyo, Japan|Gachon University Gil Medical Center /ID# 202827, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 202709, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 202710, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 202711, Seoul, Korea, Republic of|Moscow State budget healthcare /ID# 169685, Moscow, Moskva, Russian Federation|City Clinical Hospital 52 /ID# 206289, Moscow, Russian Federation|LLC Novaya Clinica /ID# 169689, Pyatigorsk, Russian Federation|SBI of Health Leningrad regional clinical hospital /ID# 202776, Saint. Petersburg, Russian Federation|Almazov North-West Federal Med /ID# 169681, Sankt-peterburg, Russian Federation|National University Hospital ( /ID# 203988, Singapore, Singapore|Singapore General Hospital /ID# 202131, Singapore, Singapore|Tan Tock Seng Hospital /ID# 204374, Singapore, Singapore|Institut Catala d'Oncologia /ID# 171311, Girona, Spain|Hospital Fundacion Jimenez Dia /ID# 171304, Madrid, Spain|Hospital 12 de Octubre /ID# 171288, Madrid, Spain|Hospital Clinico Univ de Salamanca /ID# 171294, Salamanca, Spain|Hospital Virgen del Rocio /ID# 171286, Sevilla, Spain|Sunderby sjukhus /ID# 201314, Luleå, Norrbottens Lan, Sweden|Södra Älvsborgs sjukhus /ID# 213061, Borås, Vastra Gotalands Lan, Sweden|Universitetssjukhuset Linköping /ID# 200789, Linkoping, Vastra Gotalands Lan, Sweden|Uddevalla sjukhus /ID# 201315, Uddevalla, Vastra Gotalands Lan, Sweden|Cukurova Universitesi Tip Fakultesi /ID# 201955, Saricam Adana, Adana, Turkey|Medical Park İzmir Hastanesi /ID# 201954, Karşiyaka, Izmir, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi /ID# 201956, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 201881, Ankara, Turkey|Istanbul University Istanbul Medical Faculty /ID# 201953, Istanbul, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 201952, Istanbul, Turkey|Beatson Oncology Centre /ID# 202199, Glasgow, United Kingdom|UCLH, University College Hospi /ID# 171428, London, United Kingdom|QE Woolwich, Lewisham and Gree /ID# 171445, London, United Kingdom|Hammersmith Hospital, Imperial /ID# 171446, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 171440, Manchester, United Kingdom|Queen Alexandra Hospital, Port /ID# 171444, Portsmouth, United Kingdom|Royal Hallamshire Hospital, Sh /ID# 171447, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03539744"
80,"NCT03539536","Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer",,"Recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: Telisotuzumab vedotin","Overall Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Duration of Disease Control (DDC)|Progression-Free Survival (PFS)|Overall Survival (OS)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","310","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-239|2018-001772-38","October 10, 2018","October 27, 2021","May 15, 2024","May 29, 2018",,"December 30, 2019","University of South Alabama /ID# 212939, Mobile, Alabama, United States|Highlands Oncology Group /ID# 215600, Fayetteville, Arkansas, United States|University of California, Los Angeles /ID# 203219, Los Angeles, California, United States|Sutter Medical Center Sacramen /ID# 203299, Sacramento, California, United States|Univ of Colorado Cancer Center /ID# 203212, Aurora, Colorado, United States|Northwestern University Feinberg School of Medicine /ID# 203239, Chicago, Illinois, United States|University of Chicago /ID# 203216, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 215583, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 203228, Harvey, Illinois, United States|Joliet Oncology-Hematology /ID# 203238, Joliet, Illinois, United States|Cancer Center of Kansas /ID# 203235, Wichita, Kansas, United States|Baptist Health /ID# 203283, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 203284, Louisville, Kentucky, United States|Central Maine Medical Center /ID# 216583, Lewiston, Maine, United States|Massachusetts General Hospital /ID# 203215, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 208124, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 203248, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 215646, Ann Arbor, Michigan, United States|Henry Ford Hospital - West Bloomfield /ID# 203220, West Bloomfield, Michigan, United States|Mayo Clinic - Rochester /ID# 215603, Rochester, Minnesota, United States|Mmcorc /Id# 203231, Saint Louis Park, Minnesota, United States|Washington University-School of Medicine /ID# 203217, Saint Louis, Missouri, United States|St. Vincent Frontier Cancer Center /ID# 203292, Billings, Montana, United States|Univ Nebraska Med Ctr /ID# 203388, Omaha, Nebraska, United States|Dartmouth-Hitchcock Med Ctr /ID# 203350, Lebanon, New Hampshire, United States|Atlantic Health System /ID# 203404, Morristown, New Jersey, United States|Overlook Medical Center /ID# 211160, Summit, New Jersey, United States|Univ Hosp Cleveland /ID# 215648, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care - Westside Portland /ID# 203301, Portland, Oregon, United States|Thomas Jefferson University /ID# 203317, Philadelphia, Pennsylvania, United States|Vanderbilt University Med Ctr /ID# 203281, Nashville, Tennessee, United States|Houston Methodist Hospital - Scurlock Tower /ID# 213268, Houston, Texas, United States|Baylor Scott & White Medical Center- Temple /ID# 216578, Temple, Texas, United States|Virginia Cancer Specialists /ID# 203224, Fairfax, Virginia, United States|University of Washington /ID# 206056, Seattle, Washington, United States|Medical College of Wisconsin /ID# 210062, Milwaukee, Wisconsin, United States|The Kinghorn Cancer Centre /ID# 207666, Darlinghurst, New South Wales, Australia|Newcastle Private Hospital /ID# 206600, Lambton Heights, New South Wales, Australia|The Tweed Hospital /ID# 206601, Tweed Heads, New South Wales, Australia|Cross Cancer Institute /ID# 204540, Edmonton, Alberta, Canada|The Ottawa Hospital /ID# 205579, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre /ID# 204423, Toronto, Ontario, Canada|CISSS de la Monteregie /ID# 211356, Greenfield Park, Quebec, Canada|Anhui Provincial Hospital /ID# 212096, Hefei, Anhui, China|Fujian Provincial Cancer Hospital /ID# 210808, Fuzhou, Fujian, China|Jilin Cancer Hosptial /ID# 210563, Changchun, Jilin, China|Fudan University Shanghai Cancer Center /Id# 210084, Shanghai, Shanghai, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 211154, Hangzhou, Zhejiang, China|Zhejiang Cancer hospital /ID# 210085, Hangzhou, Zhejiang, China|Beijing Cancer Hospital /ID# 210133, Beijing, China|West China Hospital, Sichuan University /ID# 210022, Chengdu, China|Shanghai Chest Hospital /ID# 210930, Shanghai, China|Henan Cancer Hospital /ID# 210961, Zhengzhou, Henan, China|CHU Hopital Nord /ID# 209854, Marseille, Bouches-du-Rhone, France|Institut Curie /ID# 207046, Paris CEDEX 05, Ile-de-France, France|Centre Leon Berard /ID# 205107, Lyon CEDEX 08, Rhone, France|Institut Gustave Roussy /ID# 205149, Villejuif, Val-de-Marne, France|CHRU de Lille - Hopital Albert Calmette /ID# 205105, Lille, France|Nouvel Hopital Civil (NHC) /ID# 208080, Strasbourg, France|KH Martha-Maria Halle Dolau /ID# 205442, Halle (Saale), Sachsen-Anhalt, Germany|Vivantes Klinikum Neukolln /ID# 205928, Berlin, Germany|Asklepios Fachkliniken M. Gaut /ID# 207789, Gauting, Germany|Evangelisches Krankenhaus Hamm /ID# 208043, Hamm, Germany|Klinikum Kassel /ID# 205443, Kassel, Germany|Pius Hospital Oldenburg /ID# 211615, Oldenburg, Germany|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 205528, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 205530, Heraklion, Greece|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 204878, Miskolc, Borsod-Abauj-Zemplen, Hungary|Torokbalinti Tudogyogyintezet /ID# 204883, Budapest, Pest, Hungary|Semmelweis Egyetem /ID# 204434, Budapest, Hungary|Veszprem Megyei Tudogyogyintez /ID# 213950, Farkasgyepu, Hungary|Matrahaza Gyogyintezet /ID# 204432, Kékesteto, Hungary|St. James's Hospital /ID# 205104, Dublin 8, Dublin, Ireland|Cork University Hospital /ID# 205103, Cork, Ireland|St Vincent's University Hosp /ID# 205102, Dublin, Ireland|Soroka Medical Center /ID# 204898, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 215322, Petakh Tikva, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 204866, Haifa, Israel|Meir Medical Center /ID# 204255, Kfar Saba, Israel|Sheba Medical Center /ID# 204254, Ramat Gan, Israel|IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 205601, Meldola, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 205163, Rome, Lazio, Italy|AO San Giuseppe Moscati /ID# 204707, Avellino, Italy|A.O.U. San Luigi Gonzaga /ID# 204706, Orbassano, Italy|Azienda Ospedaliero Uni Parma /ID# 204983, Parma, Italy|National Hospital Organization Kyushu Cancer Center /ID# 206061, Fukuoka-shi, Fukuoka, Japan|Kinki-Chuo Chest Medical Center /ID# 216461, Kita-ku, Osaka, Japan|Shizuoka Cancer Center /ID# 205065, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital /ID# 205066, Chuo-ku, Tokyo, Japan|Osaka Inter. Cancer Institute /ID# 210735, Osaka, Japan|Kanagawa Cancer Center /ID# 205068, Yokohama, Japan|National Cancer Center /ID# 204241, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 204237, Seongnam, Gyeonggido, Korea, Republic of|Chungbuk National Univ Hosp /ID# 205680, Cheongju, Korea, Republic of|Chonnam National University Hwasun Hospital /ID# 206951, Jeonnam, Korea, Republic of|Severance Hospital /ID# 204238, Seoul, Korea, Republic of|Asan Medical Center /ID# 204236, Seoul, Korea, Republic of|VA Caribbean Healthcare System /ID# 206336, San Juan, Puerto Rico|Puerto Rico Hematology Oncolog /ID# 206337, San Juan, Puerto Rico|Institutul Oncologic /ID# 206320, Cluj Napoca, Romania|Oncomed SRL /ID# 205616, Timisoara, Romania|""Avicenna"" medical center /ID# 212397, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Tatarstan Cancer Center /ID# 206463, Kazan, Tatarstan, Respublika, Russian Federation|Volgograd Regional Clinical Oncology Dispensary /ID# 206520, Volgograd, Volgogradskaya Oblast, Russian Federation|Arkhangelsk clinical oncology /ID# 216418, Arkhangelsk, Russian Federation|LLC Evimed /ID# 216473, Chelyabinsk, Russian Federation|Univercity Headache Clynic,LTD /ID# 212080, Moscow, Russian Federation|PMI Euromedservice /ID# 206390, Pushkin, Russian Federation|LLC Novaya Clinica /ID# 216262, Pyatigorsk, Russian Federation|OOO Centre of Palliative Medicine De Vita /ID# 212900, Saint Petersburg, Russian Federation|St.Petersburg City Cancer Center /ID# 206405, Sankt-Peterburg, Russian Federation|Hospital Clínico Universitario de Santiago /ID# 204367, Santiago de Compostela, A Coruna, Spain|Instituto Catalán de Oncología (ICO) Badalona /ID# 216106, Badalona, Barcelona, Spain|Hospital Regional Universitario de Málaga /ID# 216081, Málaga, Malaga, Spain|Hospital Universitario y Politecnico La Fe /ID# 203862, Valencia, Valenciana, Spain|Hospital Vall d'Hebron /ID# 206997, Barcelona, Spain|Hospital Univ Ramon y Cajal /ID# 203922, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 203913, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 216058, Sevilla, Spain|National Cheng Kung University Hospital /ID# 205307, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 205100, Taipei City, Taipei, Taiwan|Dalin Tzu Chi General Hospital /ID# 205309, Dalin Township, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 205831, Kaohsiung, Taiwan|Taipei Med Univ Shuang Ho Hosp /ID# 215356, New Taipei City, Taiwan|Taichung Veterans General Hosp /ID# 205308, Taichung City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 205424, Taoyuan City, Taiwan|Adana Sehir Egitim ve Arastirma Hastanesi /ID# 206000, Adana, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi /ID# 205243, Ankara, Turkey|Akdeniz Universitesi Tip Fakul /ID# 205238, Antalya, Turkey|Trakya University Medical Facu /ID# 205242, Edirne, Istanbul, Turkey|Heart of England NHS Foundation Trust /ID# 206209, Birmingham, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 205890, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03539536"
81,"NCT03518047","Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation","IMMPRESS","Active, not recruiting","No Results Available","Psoriasis","Drug: risankizumab|Drug: placebo for rizankizumab","Proportion of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16|Proportion of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 16|Proportion of participants with a 75% reduction from Baseline Psoriasis Area and Severity Index (PASI 75) at Week 16|Proportion of participants with a 100% reduction from Baseline Psoriasis Area and Severity Index (PASI 100) at Week 16|Proportion of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-176","July 19, 2018","April 2, 2019","February 11, 2020","May 8, 2018",,"December 30, 2019","GBUZ Clinical Dermatovenerology Dispensary of MoH of Krasnodar region /ID# 201713, Krasnodar, Krasnodarskiy Kray, Russian Federation|Family Outpatient clinic#4,LLC /ID# 207441, Korolev, Moskva, Russian Federation|SBHI KVD # 10 Clinic of Dermatology and venerology /ID# 200615, Saint-Petersburg, Sankt-Peterburg, Russian Federation|LLC ArsVitae Severo-Zapad /ID# 200658, Saint-Petersburg, Sankt-Peterburg, Russian Federation|LLC Kurator /ID# 200616, Saint-Petersburg, Sankt-Peterburg, Russian Federation|Alliance Biomedical Ural Group /ID# 201681, Izhevsk, Udmurtskaya Respublika, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03518047"
82,"NCT03518034","A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men","TRAVERSE","Recruiting","No Results Available","Hypogonadism|Cardiovascular Diseases","Drug: Testosterone|Drug: Placebo","Time to Major Adverse Cardiac Event (MACE)|Assessing cardiovascular safety|Assessing prostate safety","AbbVie|Acerus Pharmaceuticals Corporation|Allergan Sales, LLC|Endo Pharmaceuticals|Upsher-Smith Laboratories","Male","45 Years to 80 Years   (Adult, Older Adult)","Phase 4","6000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-100","May 3, 2018","June 30, 2022","June 30, 2022","May 8, 2018",,"January 13, 2020","Wright Clinical Research, LLC /ID# 210864, Alabaster, Alabama, United States|Alabama Clinical Therapeutics, LLC /ID# 202982, Birmingham, Alabama, United States|Cahaba Research, Inc. /ID# 167928, Birmingham, Alabama, United States|Atlanta VAMC /ID# 170318, Decatur, Alabama, United States|G & L Research, LLC /ID# 170365, Foley, Alabama, United States|Fundamental Research /ID# 170504, Gulf Shores, Alabama, United States|Urology Centers of Alabama /ID# 206197, Homewood, Alabama, United States|Longwood Research /ID# 201754, Huntsville, Alabama, United States|Medical Affiliated Research Center, Inc. /ID# 170569, Huntsville, Alabama, United States|Mostellar Medical Center /ID# 170329, Irvington, Alabama, United States|Terence T. Hart, MD /ID# 201561, Tuscumbia, Alabama, United States|Alaska Urological Institute /ID# 167894, Anchorage, Alaska, United States|East Valley Family Physicians /ID# 170530, Chandler, Arizona, United States|Fountain Hills Family Practice P.C /ID# 170419, Fountain Hills, Arizona, United States|Horizon Clinical Research Asoc /ID# 202937, Gilbert, Arizona, United States|Lenzmeier Family Medicine /ID# 202945, Glendale, Arizona, United States|Desert Clinical Rsch, LLC /ID# 170428, Mesa, Arizona, United States|Phoenix Medical Group, PC /ID# 170516, Peoria, Arizona, United States|Phoenix VA Healthcare /ID# 202962, Phoenix, Arizona, United States|Elite Clinical Studies, LLC /ID# 168058, Phoenix, Arizona, United States|Family Practice Specialists /ID# 167859, Phoenix, Arizona, United States|Central Phoenix Medical Clinic /ID# 170333, Phoenix, Arizona, United States|Tatum Highlands Medical Assoc /ID# 208277, Phoenix, Arizona, United States|Fiel Family & Sports Medicine /ID# 203034, Tempe, Arizona, United States|Quality of Life Medical & Research Center /ID# 167915, Tucson, Arizona, United States|Arizona Research Assoc /ID# 170421, Tucson, Arizona, United States|Veterans Affairs (VA) Health Care System - Tucson /ID# 167600, Tucson, Arizona, United States|Verde Valley Medical Center /ID# 202955, Tucson, Arizona, United States|Eclipse Clinical Research /ID# 170381, Tucson, Arizona, United States|B.G. Clinical Research Center, LLC /ID# 170461, Little Rock, Arkansas, United States|Preferred Research Partners In /ID# 170539, Little Rock, Arkansas, United States|Applied Research Center of Arkansas /ID# 170487, Little Rock, Arkansas, United States|Pacific Oaks Medical Group /ID# 170540, Beverly Hills, California, United States|TriWest Research Associates /ID# 170498, El Cajon, California, United States|Diagnamics Inc. /ID# 205836, Encinitas, California, United States|Cedars-Sinai Medical Group (MGOE) /ID# 170383, Encino, California, United States|St. Jude Hospital Yorba Linda /ID# 170437, Fullerton, California, United States|Arizona Internal Medicine Specialists, LLC- Glendale /ID# 203011, Glendale, California, United States|Allied Clinical Research /ID# 170519, Gold River, California, United States|Marvel Clinical Research, LLC /ID# 170324, Huntington Beach, California, United States|Irvine Center for Clinical Research /ID# 170368, Irvine, California, United States|Clinical Trials Research /ID# 210862, Lincoln, California, United States|Torrance Clinical Research Institute, Inc. /ID# 170307, Lomita, California, United States|VA Long Beach Healthcare System /ID# 170374, Long Beach, California, United States|Tower Urology /ID# 170330, Los Angeles, California, United States|VA Greater Los Angeles Healthcare System /ID# 167948, Los Angeles, California, United States|Facey Medical Foundation /ID# 203004, Mission Hills, California, United States|Catalina Research Institute, LLC /ID# 170501, Montclair, California, United States|NewportNativeMD, Inc. /ID# 168110, Newport Beach, California, United States|Translational Res Group, Inc. /ID# 168115, North Hollywood, California, United States|Valley Clinical Trials, Inc /ID# 201587, Northridge, California, United States|Amicis Research /Id# 170587, Northridge, California, United States|Diabetes Associates Medical Gr /ID# 170499, Orange, California, United States|Desert Oasis Healthcare Medica /ID# 170841, Palm Springs, California, United States|Saviers Medical Group /ID# 170327, Port Hueneme, California, United States|Center for Clinical Trials of Sacramento, Inc. /ID# 168108, Sacramento, California, United States|Integrated Research Center, Inc. /ID# 170391, San Diego, California, United States|Ritchken & First MD's /ID# 201341, San Diego, California, United States|San Diego Sexual Medicine /ID# 170457, San Diego, California, United States|San Diego Clinical Trials /ID# 170468, San Diego, California, United States|Comprehensive Oncology Centre - Vratsa EOOD /ID# 168252, San Diego, California, United States|West Coast Research LLC /ID# 167903, San Ramon, California, United States|Syrentis Clinical Research /ID# 168056, Santa Ana, California, United States|Care Access Research, Santa Clarita /ID# 167916, Santa Clarita, California, United States|Encompass Clinical Research /ID# 202203, Spring Valley, California, United States|Stanford University /ID# 167595, Stanford, California, United States|St. Joseph's Medical Associate /ID# 170424, Stockton, California, United States|Olive View UCLA Medical Center /ID# 206131, Sylmar, California, United States|Millennium Clinical Trials /ID# 210695, Thousand Oaks, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center /ID# 170400, Torrance, California, United States|Bayview Research Group LLC /ID# 203036, Valley Village, California, United States|Anthony Mills, MD, Inc. /ID# 170571, West Hollywood, California, United States|Lynn Institute of Denver /ID# 170312, Aurora, Colorado, United States|Colorado Springs Family Practice /ID# 168231, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies /ID# 170477, Colorado Springs, Colorado, United States|Urology Associates, P.C. /ID# 170484, Englewood, Colorado, United States|Foothills Urology /ID# 170406, Golden, Colorado, United States|New West Physicians /ID# 203032, Golden, Colorado, United States|Complete Family Care Research /ID# 170371, Northglenn, Colorado, United States|Aventura Heart Center /ID# 170354, Aventura, Florida, United States|MB Clinical Research /ID# 202970, Boca Raton, Florida, United States|Imagine Research of Palm Beach County /ID# 212140, Boynton Beach, Florida, United States|Helix Biomedics, LLC /ID# 202310, Boynton Beach, Florida, United States|Meridien Research Inc. - Brooksville /ID# 170556, Brooksville, Florida, United States|Innovative Research /ID# 170360, Clearwater, Florida, United States|Tampa Bay Medical Res, Inc /ID# 170512, Clearwater, Florida, United States|ALL Medical Research /ID# 170493, Cooper City, Florida, United States|Century Clinical Research, Inc /ID# 167597, Daytona Beach, Florida, United States|Seidman Clinical Trials,Delray /ID# 170418, Delray Beach, Florida, United States|S&W Clinical Research /ID# 170311, Fort Lauderdale, Florida, United States|Invesclinic, U.S., LLC /ID# 202553, Fort Lauderdale, Florida, United States|Office of Sam N. Lerman, MD /ID# 170373, Fort Lauderdale, Florida, United States|University of Florida - Hull Rd /ID# 170518, Gainesville, Florida, United States|Malcom Randall VAMC /ID# 170645, Gainesville, Florida, United States|International Research Associates, LLC - Hialeah /ID# 170543, Hialeah, Florida, United States|Indago Research and Health Cen /ID# 170420, Hialeah, Florida, United States|The University of Florida Heal /ID# 170450, Jacksonville, Florida, United States|Jacksonville Center for Clinical Research /ID# 170446, Jacksonville, Florida, United States|Solutions Through Adv Rch /ID# 201590, Jacksonville, Florida, United States|Care Partners Clinical Researc /ID# 202520, Jacksonville, Florida, United States|Care Research center Inc. /ID# 167924, Kendall, Florida, United States|Meridien Research /ID# 170370, Kenneth City, Florida, United States|Meridien Research /ID# 167846, Lakeland, Florida, United States|South Florida Wellness & Clinic /ID# 170510, Margate, Florida, United States|Panax Clinical Research /ID# 170525, Miami, Florida, United States|Veritas Research, Corp. /ID# 202975, Miami, Florida, United States|Pharmax Research Clinic /ID# 170403, Miami, Florida, United States|APF Research, LLC. /ID# 170412, Miami, Florida, United States|Well Pharma Med Res Corp /ID# 170337, Miami, Florida, United States|Floridian Research Institute LLC /ID# 167882, Miami, Florida, United States|Advanced Pharma CR, LLC /ID# 167840, Miami, Florida, United States|Applemed Research Inc. /ID# 170364, Miami, Florida, United States|Future Care Solution LLc /ID# 170361, Miami, Florida, United States|New Horizon Research Center /ID# 170574, Miami, Florida, United States|Office of Francisco G Miranda, /ID# 203184, Miami, Florida, United States|International Research Associates, LLC /ID# 170563, Miami, Florida, United States|Bravo Health Care Center /ID# 202201, North Bay Village, Florida, United States|Harmony Clinical Research, Inc. /ID# 201816, North Miami Beach, Florida, United States|Endocrine Associates of Florida, P.A. /ID# 167839, Ocoee, Florida, United States|Sensible Healthcare /ID# 170402, Ocoee, Florida, United States|Omega Research Consultants /ID# 170340, Orlando, Florida, United States|IMIC Inc. /ID# 167899, Palmetto Bay, Florida, United States|South Broward Research /ID# 170480, Pembroke Pines, Florida, United States|DBC Research USA /ID# 170332, Pembroke Pines, Florida, United States|South Florida Research Solutio /ID# 167972, Pembroke Pines, Florida, United States|DBC Research USA Corporation /ID# 170435, Pembroke Pines, Florida, United States|Synexus Clinical Research US, Inc /ID# 209955, Pinellas Park, Florida, United States|Synexus Clinical Research US, Inc /ID# 210249, Pinellas Park, Florida, United States|DMI Research, Inc. /ID# 170893, Pinellas Park, Florida, United States|Clinical Research Center FL /ID# 202979, Pompano Beach, Florida, United States|St. Johns Center /ID# 212654, Ponte Vedra, Florida, United States|Charlotte Heart & Vascular Institute /ID# 202965, Port Charlotte, Florida, United States|Health Awareness, Inc. /ID# 170507, Port Saint Lucie, Florida, United States|Prof Health Care of Pinellas /ID# 167895, Saint Petersburg, Florida, United States|Advance Medical Research /ID# 170532, Saint Petersburg, Florida, United States|Precision Clinical Research /ID# 170469, Sunrise, Florida, United States|Meridien Research Inc. - Tampa /ID# 170377, Tampa, Florida, United States|Winter Park Urology Center/Charter Research /ID# 210542, Winter Park, Florida, United States|Atlanta Vascular Research Foundation - Atlanta Clinical Research Centers /ID# 170894, Atlanta, Georgia, United States|Masters of Clinical Research, Inc. /ID# 167950, Augusta, Georgia, United States|Endocrine Consustants Research /ID# 168147, Columbus, Georgia, United States|Physicians Research Associates, LLC /ID# 170313, Lawrenceville, Georgia, United States|Atlanta Center for Clinical Research /ID# 202984, Roswell, Georgia, United States|Meridian Clinical Research, LLC /ID# 167854, Savannah, Georgia, United States|Meridian Clinical Research, LLC /ID# 170548, Savannah, Georgia, United States|Herman Clinical Research, LLC /ID# 170474, Suwanee, Georgia, United States|North Georgia Clin Res /ID# 170467, Woodstock, Georgia, United States|East-West Medical Research Institute /ID# 202959, Honolulu, Hawaii, United States|Institute of Arthritis Researc /ID# 170495, Idaho Falls, Idaho, United States|Solaris Clinical Research /ID# 202936, Meridian, Idaho, United States|Biofortis, Inc. /ID# 167856, Addison, Illinois, United States|Synexus Clinical Research US, Inc /ID# 209956, Chicago, Illinois, United States|Chicago Clinical Research Institute, Inc /ID# 203190, Chicago, Illinois, United States|Loretto Hospital.Affnity Clinical Research Institute /ID# 207262, Chicago, Illinois, United States|Midwest Endocrinology /ID# 202992, Crystal Lake, Illinois, United States|Pharmakon Inc /ID# 206149, Evergreen Park, Illinois, United States|Clinical Investigation Specialists, Inc. /ID# 170631, Gurnee, Illinois, United States|Edward Hines Jr. VA Hospital /ID# 167944, Hines, Illinois, United States|Koch Family Medicine SC /ID# 202205, Morton, Illinois, United States|Affinity Clinical Research /ID# 202552, Oak Brook, Illinois, United States|American Health Network of IN /ID# 170359, Avon, Indiana, United States|American Health Network of IN /ID# 170483, Avon, Indiana, United States|Investigators Research Group, LLC /ID# 170557, Brownsburg, Indiana, United States|Investigative Clinical Research of Indiana, LLC /ID# 170473, Elwood, Indiana, United States|Deaconess Clinic Downtown /ID# 167855, Evansville, Indiana, United States|Clinical Research Advantage, Inc. /ID# 170656, Evansville, Indiana, United States|MediSphere Medical Research Center /ID# 170317, Evansville, Indiana, United States|Richard L. Roudebush VA Medical Center /ID# 203020, Indianapolis, Indiana, United States|Urology of Indiana /ID# 203469, Indianapolis, Indiana, United States|First Urology,PSC /ID# 167719, Jeffersonville, Indiana, United States|LaPorte County Institute for Clinical Research, Inc. /ID# 170331, Michigan City, Indiana, United States|American Health Network of Ind /ID# 170578, Muncie, Indiana, United States|West Broadway Clinic /ID# 202204, Council Bluffs, Iowa, United States|IA Diabetes & Endo Res Ctr /ID# 170462, West Des Moines, Iowa, United States|The Iowa Clinic, PC /ID# 202986, West Des Moines, Iowa, United States|Heartland Research Associates, LLC /ID# 203031, Augusta, Kansas, United States|PRN Professional Research Network of Kansas, LLC /ID# 170415, Wichita, Kansas, United States|Drs. Borders, Hood, and Assoc /ID# 170536, Lexington, Kentucky, United States|The Research Grp of Lexington /ID# 202900, Lexington, Kentucky, United States|University of Louisville /ID# 170607, Louisville, Kentucky, United States|Research Integrity, LLC /ID# 168264, Owensboro, Kentucky, United States|Alexandria Cardiology Clinic /ID# 170463, Alexandria, Louisiana, United States|Centex Studies, Inc - Lake Charles /ID# 170416, Lake Charles, Louisiana, United States|Tandem Clinical Research, LLC /ID# 206203, Marrero, Louisiana, United States|Tulane School of Medicine /ID# 170472, New Orleans, Louisiana, United States|Chesapeake Urology Associates /ID# 211874, Baltimore, Maryland, United States|Maryland Cardiovascular Specialists /ID# 168057, Baltimore, Maryland, United States|Johns Hopkins University /ID# 203006, Baltimore, Maryland, United States|Centennial Medical Group /ID# 170568, Elkridge, Maryland, United States|Massachusetts General Hospital /ID# 167969, Boston, Massachusetts, United States|NECCR PrimaCare Research, LLC /ID# 170326, Fall River, Massachusetts, United States|Oakland Medical Research /ID# 170389, Troy, Michigan, United States|Arcturus Healthcare, PLC, Troy /ID# 170431, Troy, Michigan, United States|Olive Branch Family Med Ctr /ID# 170409, Olive Branch, Mississippi, United States|David M. Headley, MD, P.A. /ID# 205428, Port Gibson, Mississippi, United States|West Florissant Internists /ID# 170314, Bridgeton, Missouri, United States|Med Research One /ID# 167923, Florissant, Missouri, United States|Saint Louis University School of Medicine /ID# 170531, Saint Louis, Missouri, United States|Radiant Research, Inc. /ID# 209957, Saint Louis, Missouri, United States|Mercy Clinic Endocrinology, LLC /ID# 170367, Springfield, Missouri, United States|Montana Medical Research /ID# 170579, Missoula, Montana, United States|Skyline Medical Center /ID# 168234, Elkhorn, Nebraska, United States|VA Nebraska-Western Iowa Health Care System /ID# 167892, Omaha, Nebraska, United States|Heartland Clinical Research /ID# 170541, Omaha, Nebraska, United States|Meridian Clinical Research, LLC - Omaha /ID# 167836, Omaha, Nebraska, United States|Clinical Research Advantage, Inc. /ID# 202966, Omaha, Nebraska, United States|McGill Family Practice, P.C. /ID# 170560, Papillion, Nebraska, United States|Synexus Clinical Research US, Inc. /ID# 210232, Henderson, Nevada, United States|Palm Research Center, Inc. /ID# 168224, Las Vegas, Nevada, United States|AB Clinical Trials /ID# 170612, Las Vegas, Nevada, United States|Alas Science Clinical Research /ID# 170352, Las Vegas, Nevada, United States|Clinical Research of So Nevada /ID# 167594, Las Vegas, Nevada, United States|Advanced Biomedical Research of America /ID# 202202, Las Vegas, Nevada, United States|Sheldon Freedman MD, ltd /ID# 170434, Las Vegas, Nevada, United States|Allied Clinical Research /ID# 210859, Reno, Nevada, United States|Internal Medicine Associates /ID# 170538, Bridgeton, New Jersey, United States|Medicor Cardiology /ID# 170436, Bridgewater, New Jersey, United States|Cooper Health System /ID# 170417, Camden, New Jersey, United States|Union Square Medical Associates,PC /ID# 170346, Elizabeth, New Jersey, United States|Amici Clinical Research /ID# 170452, Warren, New Jersey, United States|NM Clin Res & Osteoporosis Center, Inc /ID# 170386, Albuquerque, New Mexico, United States|Albany VA Medical Center /ID# 167862, Albany, New York, United States|James J. Peters VA Medical Center /ID# 202980, Bronx, New York, United States|NY Total Medical Care, PC /ID# 170423, Brooklyn, New York, United States|AccuMed Research Associates /ID# 202200, Garden City, New York, United States|Office of Bruce R. Gilbert, MD /ID# 202963, Great Neck, New York, United States|Synexus Clinical Research US, Inc. /ID# 210293, Jamaica, New York, United States|Mid Hudson Medical Research, PLLC /ID# 170511, New Windsor, New York, United States|Manhattan Medical Research /ID# 167956, New York, New York, United States|DiGiovanna Institute for Medic /ID# 170613, North Massapequa, New York, United States|Premier Medical Group of the Hudson Valley PC /ID# 170456, Poughkeepsie, New York, United States|Endocrine Assc Long Island PC /ID# 170425, Smithtown, New York, United States|Randolph Health Internal Medic /ID# 168227, Asheboro, North Carolina, United States|PMG Research of Charlotte /ID# 202985, Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC /ID# 170349, Charlotte, North Carolina, United States|OnSite Clinical Solutions, LLC /ID# 170634, Charlotte, North Carolina, United States|Rapha Institute for Clinical Research /ID# 170362, Fayetteville, North Carolina, United States|Bland Clinic, PA /ID# 204943, Greensboro, North Carolina, United States|Medication Management, LLC /ID# 205260, Greensboro, North Carolina, United States|Triad Clinical Trials /ID# 170376, Greensboro, North Carolina, United States|OnSite Clinical Solutions, LLC - Charlotte /ID# 170449, Hickory, North Carolina, United States|OnSite Clinical Solutions, LLC - Charlotte /ID# 202968, Hickory, North Carolina, United States|Northstate Clinical Research /ID# 170414, Lenoir, North Carolina, United States|Research Institute of the Caro /ID# 170341, Mooresville, North Carolina, United States|Carteret Medical Group LLC /ID# 170771, Morehead City, North Carolina, United States|Diabetes and Endo Consultants /ID# 201589, Morehead City, North Carolina, United States|Family Medical Associates of Raleigh /ID# 203979, Raleigh, North Carolina, United States|Goshen Medical Center - Vineland /ID# 170342, Whiteville, North Carolina, United States|PMG Research of Wilmington LLC /ID# 170492, Wilmington, North Carolina, United States|Radiant Research, Inc /ID# 202976, Akron, Ohio, United States|New Horizons Clinical Research /ID# 170460, Blue Ash, Ohio, United States|Clinical Research Trials (CRT) /ID# 170533, Canton, Ohio, United States|Diabetes and Endocrinology Associates of Stark County Inc /ID# 170356, Canton, Ohio, United States|Cincinnati Veterans Affairs Medical Center /ID# 170385, Cincinnati, Ohio, United States|Synexus Research Cincinnati /ID# 209958, Cincinnati, Ohio, United States|Rapid Medical Research, INC /ID# 170513, Cleveland, Ohio, United States|Endocrinology Associates, Inc. /ID# 168113, Columbus, Ohio, United States|Synexus Clinical Research US, Inc. /ID# 210234, Columbus, Ohio, United States|The Ohio State University Wexner Medical Center - Department of Urology /ID# 170551, Columbus, Ohio, United States|Aventiv Research, Inc. /ID# 170338, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 168111, Columbus, Ohio, United States|PriMed Clinical Research /ID# 170310, Dayton, Ohio, United States|Dayton VA Medical Center /ID# 168251, Dayton, Ohio, United States|WVVA Healthcare Alliance dba. /ID# 168246, Lewisburg, Ohio, United States|Awasty Research Network, LLC /ID# 210860, Marion, Ohio, United States|Advanced Medical Research, LLC /ID# 170488, Maumee, Ohio, United States|Cardiovascular Research Center, LLC /ID# 203035, Toledo, Ohio, United States|Intend Research /ID# 170581, Norman, Oklahoma, United States|IPS Research Company /ID# 168117, Oklahoma City, Oklahoma, United States|Oklahoma City Clinic /ID# 170497, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute (LHSI) /ID# 202973, Oklahoma City, Oklahoma, United States|Urologic Consultants of Southeastern Pennsylvania /ID# 170351, Bala-Cynwyd, Pennsylvania, United States|Heritage Valley Medical Group /ID# 170387, Beaver, Pennsylvania, United States|AJH/Feasterville Family Health /ID# 168235, Feasterville, Pennsylvania, United States|Indiana-Armstrong Endocrinolgy /ID# 168249, Indiana, Pennsylvania, United States|Richard M Kastelic, MD and Ass /ID# 170382, Johnstown, Pennsylvania, United States|Family Medical Associates /ID# 170396, Levittown, Pennsylvania, United States|Founders Research Corp /ID# 170610, Philadelphia, Pennsylvania, United States|Allegheny Health Network /ID# 210544, Pittsburgh, Pennsylvania, United States|VA Pittsburgh HealthcareSystem /ID# 205837, Pittsburgh, Pennsylvania, United States|SFM Clinical Trials /ID# 168250, Scotland, Pennsylvania, United States|Frontier Clinical Research, LLC - Scottdale /ID# 167864, Scottdale, Pennsylvania, United States|Frontier Clinical Research /ID# 167842, Smithfield, Pennsylvania, United States|Ocean State Clin Rese Part,LLC /ID# 170547, Lincoln, Rhode Island, United States|Synexus Clinical Research US, Inc. /ID# 210228, Anderson, South Carolina, United States|Synexus Clinical Research US, Inc. /ID# 210230, Anderson, South Carolina, United States|Medical Research South, LLC /ID# 203068, Charleston, South Carolina, United States|Synexus Clinical Research US, Inc. /ID# 210237, Greer, South Carolina, United States|DeGarmo Institute of Med Res /ID# 170528, Greer, South Carolina, United States|Self Medical Group - Advanced /ID# 170336, Hodges, South Carolina, United States|Main Street Physician's Care - Waterway /ID# 210441, Little River, South Carolina, United States|PMG Research of Charleston /ID# 170572, Mount Pleasant, South Carolina, United States|Palmetto Institute of Clinical Research, Inc. /ID# 170395, Pelzer, South Carolina, United States|Palmetto Clinical Research /ID# 170524, Summerville, South Carolina, United States|Regional Health - Black Hills Cardiovascular Research /ID# 170576, Rapid City, South Dakota, United States|Holston Medical Group /ID# 170565, Bristol, Tennessee, United States|University Diabetes & Endocrine Consultants /ID# 170392, Chattanooga, Tennessee, United States|Consolidated Medical Practices of Memphis, PLLC /ID# 170328, Collierville, Tennessee, United States|PMG Research of Knoxville /ID# 170393, Jefferson City, Tennessee, United States|Holston Medical Group Clinical /ID# 168165, Kingsport, Tennessee, United States|New Phase Research & Developme /ID# 170526, Knoxville, Tennessee, United States|PMG Research of Knoxville /ID# 170451, Knoxville, Tennessee, United States|PMG Research of Knoxville /ID# 170514, Knoxville, Tennessee, United States|Baptist Memorial Medical Group /ID# 168061, Memphis, Tennessee, United States|Clinical Neuroscience Solution /ID# 170559, Memphis, Tennessee, United States|Methodist Medical Group /ID# 168148, Memphis, Tennessee, United States|University of Tennessee Health /ID# 170321, Memphis, Tennessee, United States|Trinity Clinical Research, LLC /ID# 170369, Tullahoma, Tennessee, United States|Arlington Family Health Pavilion /ID# 170366, Arlington, Texas, United States|Premier Family Physicians /ID# 167946, Austin, Texas, United States|Texas Diabetes and Endocrinology /ID# 170517, Austin, Texas, United States|DiscoveResearch, Inc. /ID# 170320, Beaumont, Texas, United States|Pioneer Research Solutions, Inc. /ID# 168062, Beaumont, Texas, United States|Family Medicine Associates of Texas, PA /ID# 167849, Carrollton, Texas, United States|3rd Coast Research Associates /ID# 203091, Corpus Christi, Texas, United States|Dallas VA Medical Center /ID# 170325, Dallas, Texas, United States|Urology Clinics of North Texas /ID# 203033, Dallas, Texas, United States|North TX Endocrine Ctr /ID# 170552, Dallas, Texas, United States|Radiant Research Dallas /ID# 170319, Dallas, Texas, United States|San Gabriel Clinical Research /ID# 167929, Georgetown, Texas, United States|East Texas Cardiology /ID# 170638, Houston, Texas, United States|PrimeCare Medical Group /ID# 168146, Houston, Texas, United States|Associates in Medicine, P.A. /ID# 170439, Houston, Texas, United States|University of Texas Health /ID# 168239, Houston, Texas, United States|M.E. DeBakey VAMC /ID# 167598, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 170537, Houston, Texas, United States|Discovery MM Services, Inc - Houston - Broadway St /ID# 170558, Houston, Texas, United States|Memorial Clinical Associates R /ID# 170443, Houston, Texas, United States|The Endocrine Center /ID# 170653, Houston, Texas, United States|Texas Center for Drug Development, Inc. /ID# 170404, Houston, Texas, United States|Methodist Urology Associates /ID# 170575, Houston, Texas, United States|Endocrine and Psychiatry Cente /ID# 170520, Houston, Texas, United States|Pioneer Research Solutions, Inc. /ID# 170379, Houston, Texas, United States|Research Trials Wroldwide /ID# 210694, Humble, Texas, United States|Protenium Clinical Research /ID# 170397, Hurst, Texas, United States|Discovery MM Services, Inc - Katy /ID# 202958, Katy, Texas, United States|Texas Cardio Association of Ho /ID# 170494, Kingwood, Texas, United States|FMC Science /ID# 170407, Lampasas, Texas, United States|Centex Studies, Inc /ID# 203019, McAllen, Texas, United States|Discovery MM Services, Inc. /ID# 170562, Missouri City, Texas, United States|Hill Country Medical Assoc /ID# 170444, New Braunfels, Texas, United States|DCT-AACT, LLC dba Discovery Clinical Trials /ID# 170394, Pflugerville, Texas, United States|ClinRx Research, LLC /ID# 203067, Plano, Texas, United States|Village Health Partners /ID# 170659, Plano, Texas, United States|DeLeon Research /ID# 210861, Plano, Texas, United States|Research Across America /ID# 168229, Plano, Texas, United States|South Texas Cardiovascular Consultants /ID# 203088, San Antonio, Texas, United States|Radiant Research, Inc. /ID# 202947, San Antonio, Texas, United States|Covenant Clinical Research, PA /ID# 170564, San Antonio, Texas, United States|Victorium Clinical Research /ID# 168112, San Antonio, Texas, United States|Discovery Clinical Trials-San Antonio /ID# 200845, San Antonio, Texas, United States|ALM VA Hospital /ID# 167973, San Antonio, Texas, United States|Northeast Endocrinology Associates, PA /ID# 202951, Schertz, Texas, United States|Consano Clinical Research, LLC /ID# 167848, Shavano Park, Texas, United States|Spring Family Practice Associates, PA /ID# 203470, Spring, Texas, United States|Hillcroft Medical Clinic /ID# 170500, Sugar Land, Texas, United States|Northwest Houston Clinical Research PLLC /ID# 168223, Tomball, Texas, United States|Crossroads Clinical Research, /ID# 170372, Victoria, Texas, United States|Hillcrest Clinics /ID# 202961, Waco, Texas, United States|Physicians Research Options, L /ID# 170441, Draper, Utah, United States|Tanner Clinic /ID# 168145, Layton, Utah, United States|Wasatch Peak Family Practice / Synexus Clinical Research US, Inc. /ID# 210175, Layton, Utah, United States|Radiant Research, Inc. /ID# 168248, Murray, Utah, United States|Advanced Research Institute /ID# 170445, Ogden, Utah, United States|Optimum Clinical Research /ID# 170322, Salt Lake City, Utah, United States|VA Salt Lake City Health Care System-George E Wahlen /ID# 167971, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 167596, West Jordan, Utah, United States|Connecticut Clinical Research Center /ID# 207771, Middlebury, Vermont, United States|Burke Internal Medicine & Research /ID# 202981, Burke, Virginia, United States|Seven Corners Medical Center /ID# 170577, Falls Church, Virginia, United States|Manassas Clinical Research Center /ID# 201815, Manassas, Virginia, United States|Virginia Research Center /ID# 170471, Midlothian, Virginia, United States|Health Research of Hampton Roads, Inc. (HRHR) /ID# 204937, Newport News, Virginia, United States|Clinical Research Associates of Tidewater /ID# 170609, Norfolk, Virginia, United States|Clinical Research Partners, LLC - Family Medicine/ Internal Medicine /ID# 170490, Richmond, Virginia, United States|Hunter Holmes McGuire VA Medical Center /ID# 170630, Richmond, Virginia, United States|Salem VA Medical Center /ID# 167925, Salem, Virginia, United States|NW Clinical Research Ctr /ID# 201588, Bellevue, Washington, United States|Sound Medical Research /ID# 202938, Port Orchard, Washington, United States|VA Puget Sound Health Care System /ID# 170555, Seattle, Washington, United States|Universal Research Group, LLC /ID# 170442, Tacoma, Washington, United States|American Health Network - Family Medicine and Specialty Care Services in Greenfi /ID# 202987, Greenfield, Wisconsin, United States|Emanuelli Research & Development Center LLC /ID# 206202, Arecibo, Puerto Rico|Research & Cardiovascular Corp /ID# 170353, Ponce, Puerto Rico|GCM Medical Group /ID# 170466, San Juan, Puerto Rico|Centro de Endocrinologia Alcantara-Gonzalez /ID# 207260, San Juan, Puerto Rico|Advanced Clinical Research /ID# 170553, Toa Baja, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03518034"
83,"NCT03505892","A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)","EAST","Recruiting","No Results Available","Ankylosing Spondylitis (AS)",,"Percentage of participants that achieve 50% improvement of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24|Percentages of participants who achieve major improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 24|Percentages of participants who achieve clinically important improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 24|Percentage of participants that achieve 50% improvement of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|Percentages of participants who achieve clinically important improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS)|Percentages of participants who achieve major improvement of Ankylosing Spondylitis Disease Activity Score (ASDAS)|Percentages of participants whose disease activity states are inactive per ASDAS score|Percentages of participants whose disease activity states are moderate per ASDAS score|Changes of the frequency of overall extra-articular manifestations (EAM) of interest|Changes of the respective frequency of each EAM|Changes in the percentage of participants who have enthesitis of the plantar fascia or Achilles tendon|Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)|Change in Tender Joint Counts (TJC)|Change in Swollen Joint Counts (SJC)","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"140","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-326","June 5, 2018","March 14, 2020","March 14, 2020","April 23, 2018",,"June 27, 2019","Hualien Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Hualien City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03505892"
84,"NCT03503890","Expanded Access to Rovalpituzumab Tesirine",,"No longer available","No Results Available","Small Cell Lung Cancer","Drug: rovalpituzumab tesirine",,"AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients|Intermediate-size Population",,"C18-915|C19-917",,,,"April 20, 2018",,"September 10, 2019",,,"https://ClinicalTrials.gov/show/NCT03503890"
85,"NCT03484520","A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Cancer - Acute Myeloid Leukemia","Drug: Venetoclax|Drug: Dinaciclib","Tmax of Venetoclax|Recommended Phase 2 Dose (RPTD) of co-administered Dinaciclib and Venetoclax|Cmax of Venetoclax|AUCt of Venetoclax|AUC0-24 Post-dose of Venetoclax|Cmax of Dinaciclib|Half-life (t1/2) of Dinaciclib|AUCt Post-dose of Dinaciclib|AUC0-∞ of Dinaciclib|Clearance of Dinaciclib|Complete Response (CR) Rate|Composite CR Rate (CR + CRi)|Objective Response Rate (ORR)","AbbVie|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-183|2017-003213-26","July 23, 2018","January 21, 2020","October 5, 2021","March 30, 2018",,"November 20, 2019","University of Arkansas /ID# 200016, Little Rock, Arkansas, United States|David Geffen School of Medicin /ID# 200015, Los Angeles, California, United States|The University of Chicago /ID# 200017, Chicago, Illinois, United States|Univ Maryland School Medicine /ID# 204015, Baltimore, Maryland, United States|Wake Forest Baptist Medical Center /ID# 200288, Winston-Salem, North Carolina, United States|The Ohio State University - Columbus /ID# 200668, Columbus, Ohio, United States|University of Texas MD Anderson Cancer Center /ID# 205215, Houston, Texas, United States|Gold Coast University Hospital /ID# 202759, Southport, Queensland, Australia|Royal Hobart Hospital /ID# 202763, Hobart, Tasmania, Australia|Monash Medical Centre /ID# 202762, Melbourne, Victoria, Australia|Hospital Universitario y Politecnico La Fe /ID# 202318, Valencia, Valenciana, Spain|Hospital Ramon y Cajal /ID# 201729, Madrid, Spain|Hospital Clinico Univ de Salamanca /ID# 201728, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT03484520"
86,"NCT03478787","Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis",,"Active, not recruiting","No Results Available","Psoriasis","Drug: risankizumab|Drug: secukinumab","Percentage of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 52|Percentage of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16|Percentage of participants with a 100% reduction from Baseline Psoriasis Area and Severity Index (PASI 100) at Week 52|Percentage of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 52|Percentage of participants with a 75% reduction from Baseline Psoriasis Area and Severity Index (PASI 75) at Week 52","AbbVie",,"18 Years and older   (Adult, Older Adult)","Phase 3","327","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","M16-766|2017-004932-12","May 1, 2018","February 20, 2020","February 20, 2020","March 27, 2018",,"September 20, 2019","Advanced Research Associates /ID# 204335, Glendale, Arizona, United States|Alliance Dermatology and MOHs /ID# 204336, Phoenix, Arizona, United States|Bakersfield Derma & Skin Cance /ID# 202115, Bakersfield, California, United States|Center for Dermatology Clin Res /ID# 202116, Fremont, California, United States|Dermatology Res. Assoc., CA /ID# 202170, Los Angeles, California, United States|UC Davis, Dermatology /ID# 202263, Sacramento, California, United States|Medderm Associates /ID# 202162, San Diego, California, United States|UConn Health /ID# 201745, Farmington, Connecticut, United States|Sullivan Dermatology /ID# 202177, North Miami Beach, Florida, United States|Renstar Medical Research /ID# 202113, Ocala, Florida, United States|Progressive Medical Research /ID# 202183, Port Orange, Florida, United States|Integrated Clinical Research LLC /ID# 202152, West Palm Beach, Florida, United States|Dermatology Specialists Resear /ID# 202145, Louisville, Kentucky, United States|Dermatology and Skin Cancer Specialists, LLC /ID# 203938, Rockville, Maryland, United States|ORA Clinical Res & Development /ID# 204342, Andover, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 204340, Boston, Massachusetts, United States|Minnesota Clinical Study Center /ID# 202369, Fridley, Minnesota, United States|Central Dermatology, PC /ID# 202156, Saint Louis, Missouri, United States|Psoriasis Treatment Ctr NJ /ID# 202107, East Windsor, New Jersey, United States|Synexus Research Cincinnati /ID# 202161, Cincinnati, Ohio, United States|Oregon Derm & Res. Ctr /ID# 201652, Portland, Oregon, United States|Oregon Medical Res Center PC /ID# 201651, Portland, Oregon, United States|Clinical Partners, LLC /ID# 201736, Johnston, Rhode Island, United States|Center for Clinical Studies - Houston (Binz) /ID# 202178, Houston, Texas, United States|Progressive Clinical Research /ID# 202155, San Antonio, Texas, United States|Center for Clinical Studies - Webster TX /ID# 202154, Webster, Texas, United States|University of Utah /ID# 204035, Salt Lake City, Utah, United States|Froedtert Mem Lutheran Hosp /ID# 204896, Milwaukee, Wisconsin, United States|Institute for Skin Advancement /ID# 203054, Calgary, Alberta, Canada|Enverus Medical Research /ID# 203043, Surrey, British Columbia, Canada|Dr. Irina Turchin PC Inc. /ID# 203052, Fredericton, New Brunswick, Canada|Eastern Canada Cutaneous Resea /ID# 203045, Halifax, Nova Scotia, Canada|Dermatrials Research /ID# 203051, Hamilton, Ontario, Canada|Dre. Angelique Gagne-Henley /ID# 203053, St-Jerome, Quebec, Canada|Dermatologique du Quebec /ID# 203050, Quebec, Canada|Charles Nicolle CHU Rouen /ID# 203590, Rouen CEDEX, Seine-Maritime, France|Hopital de L'archet 2 /ID# 203591, Nice, France|Hopital Saint-Louis /ID# 203586, Paris, France|Polyclinique Courlancy /ID# 203588, Reims, France|Hopital Larrey - CHU de Toulouse /ID# 203587, Toulouse, France|Universitaetsklinikum Frankfurt /ID# 203916, Frankfurt, Germany|TU Uniklinik Munchen /ID# 203919, Munich, Germany|Policlinico A. Gemelli /ID# 203009, Roma, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 204982, Milan, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 202940, Ancona, Italy|Radboud Universitair Medisch Centrum /ID# 202560, Nijmegen, Gelderland, Netherlands|Bravis Ziekenhuis /ID# 205232, Bergen op Zoom, Noord-Brabant, Netherlands|Academisch Medisch Centrum /ID# 202556, Amsterdam, Netherlands|Dermed Centrum Medyczne Sp. z o.o /ID# 203171, Lodz, Lodzkie, Poland|Klinika Dermatologii Pod Fortem /ID# 204180, Krakow, Malopolskie, Poland|Przychodnia Specjalistyczna High-Med /ID# 203183, Warsaw, Mazowieckie, Poland|Klinika Ambroziak Sp. z o.o. /ID# 203928, Warsaw, Mazowieckie, Poland|KSW nr1 w Rzeszowie /ID# 203776, Rzeszów, Podkarpackie, Poland|Osteo-Medic S.C. /ID# 203742, Białystok, Podlaskie, Poland|Hospital General Univ Alicante /ID# 203764, Alicante, Spain|Hosp San Cecillio, Granada, ES /ID# 203760, Granada, Spain|Hospital Univ de la Princesa /ID# 203754, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 203756, Madrid, Spain|Hospital de Manises /ID# 203757, Manises, Spain|Arnau de Vilanova Hospital /ID# 203763, Valencia, Spain|Whipps Cross Univ Hospital /ID# 204723, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 204721, London, London, City Of, United Kingdom|Chapel Allerton Hospital /ID# 204727, Leeds, United Kingdom|The University of Manchester /ID# 204720, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03478787"
87,"NCT03441555","A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Acute Myeloid Leukemia (AML)","Drug: Venetoclax|Drug: Alvocidib","Tmax of venetoclax|Clearance of Alvocidib|AUC0-∞ of Alvocidib|Cmax of Venetoclax|Half-life (t1/2) of Alvocidib|AUC0-24 Post-dose of Venetoclax|Cmax of Alvocidib|AUCt Post-dose of Alvocidib|Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for Venetoclax and Alvocidib|Complete Response (CR) Rate|Combined CR Rate|Objective Response Rate (ORR)","AbbVie|Tolero Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","44","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-186|2017-002531-42","May 30, 2018","May 15, 2020","September 28, 2021","February 22, 2018",,"November 15, 2019","USC Norris Cancer Center /ID# 170844, Los Angeles, California, United States|UC Irvine /ID# 201093, Orange, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 170799, Sacramento, California, United States|Sylvester Comprehensive Cancer /ID# 170761, Miami, Florida, United States|Indiana Blood & Marrow Transpl /ID# 170793, Indianapolis, Indiana, United States|NYU Langone Medical Center /ID# 201559, New York, New York, United States|Weill Cornell Medical College /ID# 170800, New York, New York, United States|Duke University Medical Center /ID# 170842, Durham, North Carolina, United States|University of Pittsburgh Medic /ID# 170790, Pittsburgh, Pennsylvania, United States|Universitaetsklinikum Ulm /ID# 203649, Ulm, Thueringen, Germany|Universitaetklinikum Dresden /ID# 168636, Dresden, Germany|Univ Klinik Eppendorf Hamburg /ID# 168633, Hamburg, Germany|University Hospital of Wales /ID# 202302, Cardiff, United Kingdom|Ninewells Hospital /ID# 202304, Dundee, United Kingdom|St. James University Hospital /ID# 202303, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03441555"
88,"NCT03419403","UNITE Study: Understanding New Interventions With GBM ThErapy",,"Active, not recruiting","No Results Available","Glioblastoma Multiforme","Drug: Steroid eye drop|Drug: Ophthalmic steroid ointment|Radiation: Radiation|Drug: Temozolomide|Drug: depatuxizumab mafodotin|Other: cold compress|Drug: Vasoconstrictor eye drop","Participants who Require a Change in Ocular Side Effect (OSE) Management|Cumulative Dose of Depatuxizumab Mafodotin|Change from Baseline In Logarithm of the Minimum Angle of Resolution (LogMAR) Scale after Bandage Contact Lenses (BCL) Intervention|Time to OSE Symptom Resolution after Drug Discontinuation (reversibility)|Time to BCL Intervention|Participants that recover to <3-line decline from Baseline (<= +0.3 LogMAR) in visual acuity after BCL Intervention|Corneal Epithelial Adverse Event (CEAE) Grade|Time to Re-initiation of Depatuxizumab Mafodotin after Dose Interruption|Participants with Depatuxizumab Mafodotin Dose Interruptions due to OSEs|Participants with Depatuxizumab Mafodotin Dose Reductions due to OSEs|Maximum Change from Baseline on LogMAR Scale","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","40","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-534|2017-003171-64","July 30, 2018","February 17, 2020","July 16, 2020","February 5, 2018",,"September 12, 2019","Usc /Id# 164235, Los Angeles, California, United States|Moffitt Cancer Center /ID# 164234, Tampa, Florida, United States|Rush University Medical Center /ID# 171003, Chicago, Illinois, United States|Northshore University Health System-Evanston /ID# 164221, Evanston, Illinois, United States|CDH-Delnor Health System /ID# 169909, Warrenville, Illinois, United States|Columbia Univ Medical Center /ID# 164220, New York, New York, United States|Levine Cancer Ins, Carolina Me /ID# 171271, Charlotte, North Carolina, United States|UT Health Science Ctr-Houston /ID# 164223, Houston, Texas, United States|Scott & White Mem Hosp & Clin /ID# 170792, Temple, Texas, United States|Royal North Shore Hospital /ID# 169673, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 169672, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 169674, Herston, Queensland, Australia|Austin Hospital /ID# 169671, Heidelberg, Victoria, Australia|Universitaetsklinik Heidelberg /ID# 169970, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Leipzig /ID# 169969, Leipzig, Sachsen, Germany|Klinikum Univ Regensburg /ID# 169963, Regensburg, Germany|Universitatsklinikum Tubingen /ID# 169965, Tuebingen, Germany|Vrije Universiteit Medisch Centrum /ID# 170152, Amsterdam, Netherlands|Medisch Spectrum Twente /ID# 201603, Enschede, Netherlands|Universitair Medisch Centrum Utrecht /ID# 170149, Utrecht, Netherlands|Guy's and St Thomas' NHS Found /ID# 207752, London, London, City Of, United Kingdom|Queen Elizabeth Hospital - BIRMINGHAM /ID# 200657, Birmingham, United Kingdom|Castle Hill Hospital /ID# 200662, Cottingham, United Kingdom|Western General Hospital /ID# 203040, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03419403"
89,"NCT03415035","Study Venetoclax Effectiveness and Real Life Treatment Management in Participants With Chronic Lymphocytic Leukemia","VERONE","Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)",,"Best Response of Venetoclax in Participants with Chronic Lymphocytic Leukemia (CLL) up to 12 Months|Time To Next Treatment|Time to First Response to Treatment (TTR)|Minimal Residual Disease|Overall Response Rate (ORR)|Change in Score of EuroQol 5 Dimensions (EQ‐5D‐5L)|Time to Best Response to Treatment|Response Duration|PFS after Disease Progression Following Venetoclax Treatment|Overall survival (OS)|Best Response under Next CLL Treatment|Progression‐Free Survival (PFS)|Time To Progression (TTP)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"270","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-913","March 9, 2018","March 30, 2022","March 30, 2022","January 30, 2018",,"August 29, 2019","CH Cannes /ID# 201108, Cannes CEDEX, Alpes-Maritimes, France|CH Antoine Gayraud /ID# 202530, Carcassonne, Aude, France|Clinique Pole santé République /ID# 204658, Clermont Ferrand, Auvergne, France|Centre Hospitalier Haute-Saone /ID# 205150, Vesoul CEDEX, Bourgogne-Franche-Comte, France|CH Bretagne Atlantique /ID# 200191, Vannes CEDEX, Bretagne, France|CHU de Besancon - Jean Minjoz /ID# 170721, Besancon, Doubs, France|CHU Dupuytren /ID# 200193, Limoges CEDEX 1, Franche-Comte, France|CH Annecy Genevois Site Annecy /ID# 200826, Epagny Metz Tessy, Haute-Savoie, France|Gustave Roussy /ID# 202436, Villejuif, Ile-de-France, France|Hopital Bretonneau - CHU Tours /ID# 169469, Tours CEDEX 9, Indre-et-Loire, France|CHU de la Réunion Site SUD /ID# 204093, Saint Pierre, La Reunion, France|Centre Leon Berard /ID# 170018, Lyon CEDEX 08, Rhone, France|Centre Hospitalier Le Mans /ID# 169451, Le Mans CEDEX 9, Sarthe, France|Hopital de Melun /ID# 202569, Melun CEDEX, Seine-et-Marne, France|CHU Amiens Picardie /ID# 170724, Amiens CEDEX 1, Somme, France|Ch Agen /Id# 170742, Agen Cedex 9, France|CH du Pays d'AIX /ID# 169923, Aix En Provence Cedex 1, France|CH d'ARGENTEUIL /ID# 169946, Argenteuil, France|CH Cote BASQUE /ID# 170735, Bayonne, France|Ch Blois /Id# 170727, Blois, France|Hopital Avicenne /ID# 169940, Bobigny, France|Institut Bergonie /ID# 170746, Bordeaux, France|Hopital Fleyriat, Centre Hospi /ID# 170017, Bourg En Bresse, France|Centre Hospitalier de BREST /ID# 169457, Brest, France|CHU Caen, France /ID# 169941, Caen, France|Hopital Prive Sevigne /Id# 170718, Cesson Sevigne, France|Medipole de Savoie /ID# 169454, Challes Les Eaux, France|Groupe Hospitalier de CHALON S /ID# 169939, Chalon Sur Saone, France|Centre Hospitalier de CHOLET /ID# 171215, Cholet, France|Hopital d'Instructiond es Arme /ID# 170740, Clamart, France|Chu de Clermont Ferrand /Id# 170736, Clermont Ferrand Cedex 1, France|Centre Joseph BELOT /ID# 170853, Desertines, France|CHU de Grenoble - Albet Michal /ID# 170741, Grenoble, France|GHR D'ORLEANS-Hopital La Sourc /ID# 169453, La Source, France|GHU Paris SUD /ID# 170747, Le Kremlin Bicetre, France|Clinique Victor Hugo /ID# 169973, Le Mans, France|Hopital Robert BOULIN /ID# 170739, Libourne Cedex, France|Hopital Saint Vincent de Paul /ID# 169956, Lille Cedex, France|Clinique de la Sauvegarde /ID# 169904, Lyon, France|Hopital de la Conception /ID# 201981, Marseille, France|Chr Metz Thionville /Id# 170722, Metz, France|Centre Hosp Princesse Grace /ID# 200196, Monaco, France|CH Mont de MARSAN /ID# 169955, Mont de Marsan, France|CHU Saint ELOIS /ID# 200192, Montpellier Cedex 5, France|Ch Mulhouse /Id# 170726, Mulhouse, France|Centre Catherine de Sienne /ID# 170938, Nantes, France|Polyclinique le LANGUEDOC /ID# 169925, Narbonne, France|Institut de Cancérologie du GA /ID# 169975, Nimes Cedex 09, France|Institut du Cancer du Gard /ID# 171207, Nimes Cedex 09, France|Hopital Saint-Louis /ID# 170856, Paris, France|Hopital Pitie Salpetriere /ID# 169974, Paris, France|Centre Hospitalier de PERIGUEU /ID# 169458, Perigueux, France|Centre Hospitalier PERPIGNAN /ID# 170743, Perpignan, France|CHU Poitiers /ID# 169470, Poitiers, France|Centre Hospitalier Rene Dubos /ID# 170720, Pontoise, France|Centre Hospitalier Rene Dubos /ID# 201329, Pontoise, France|CHIC de Cornouaille /ID# 169937, Quimper, France|Hopital Robert Debre /ID# 170917, Reims, France|CHU de RENNES /ID# 169944, Rennes, France|Chu Roubaix /Id# 170909, Roubaix Cedex 1, France|Centre Henri Becquerel /ID# 169948, Rouen, France|Centre Hospitalier Saint-BRIE /ID# 171076, Saint-brieuc, France|Centre Hospitalier de SAINT-MA /ID# 169935, Saint-malo, France|Centre coordination en cancero /ID# 169966, St Germain En Laye Cedex, France|Nouvel Hopital Civil (NHC) /ID# 200195, Strasbourg, France|GCS IUCT - Oncopole /ID# 170749, Toulouse, France|Gh Nord Franche-Compte /Id# 170744, Trevenans, France|CHU De Nancy /ID# 170855, Vandoeuvre Les Nancy Cedex, France|Hopital Andre MIGNOT /ID# 169950, Versailles, France|Hopital Prive de VILLENEUVE D' /ID# 169924, Villeneuve D'ascq, France",,"https://ClinicalTrials.gov/show/NCT03415035"
90,"NCT03413319","Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104",,"Completed","No Results Available","Progressive Supranuclear Palsy (PSP)","Drug: ABBV-8E12","Adverse Events","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-948","April 17, 2018","November 20, 2019","November 20, 2019","January 29, 2018",,"December 3, 2019","University of California, San /ID# 170113, La Jolla, California, United States|Texas Health Physicians Group /ID# 170112, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03413319"
91,"NCT03406156","A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)","Drug: Obinutuzumab|Drug: Bendamustine|Drug: Venetoclax","Percent of Participants Achieving Low Tumor Burden Status with induction of Obinutuzumab or Obinutuzumab plus Bendamustine (Debulking Period)|Complete Remission Rate (CR) and Complete Remission with Incomplete Marrow Recovery (CRi)|Overall Response Rate (ORR)|Duration of Response (DoR)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Overall Survival (OS)|Undetectable Minimal Residual Disease (UMRD) Rate","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-788","August 10, 2018","April 3, 2022","July 16, 2024","January 23, 2018",,"January 18, 2020","Arizona Oncology Associates, PC-HOPE /ID# 202335, Tucson, Arizona, United States|Rocky Mountain Cancer Centers - Denver Midtown /ID# 202328, Denver, Colorado, United States|MidAmerica Division, Inc. /ID# 201099, Kansas City, Missouri, United States|Oncology Hematology Care, Inc - Kenwood /ID# 202397, Cincinnati, Ohio, United States|Willamette Valley Cancer Institute /ID# 201201, Eugene, Oregon, United States|Greenville Health System - Int'l Dr /ID# 202329, Greenville, South Carolina, United States|Tennessee Oncology - Chattanooga /ID# 202840, Chattanooga, Tennessee, United States|Tennessee Oncology-Nashville Centennial /ID# 201098, Nashville, Tennessee, United States|Texas Oncology - Austin Midtown /ID# 201199, Austin, Texas, United States|Texas Oncology - Beaumont /ID# 202359, Beaumont, Texas, United States|Texas Oncology - Medical City Dallas /ID# 201196, Dallas, Texas, United States|Texas Oncology - McAllen /ID# 202331, McAllen, Texas, United States|Texas Oncology - San Antonio Medical Center /ID# 202332, San Antonio, Texas, United States|Texas Oncology - Tyler /ID# 201211, Tyler, Texas, United States|Northwest Cancer Specialists, P.C. /ID# 201198, Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03406156"
92,"NCT03400306","A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer",,"Not yet recruiting","No Results Available","Cancer - Ovarian","Drug: Veliparib, capsule|Drug: Veliparib, tablet|Drug: Carboplatin|Drug: Paclitaxel","Maximum observed plasma concentration (Cmax)|Time to Maximum Observed Plasma Concentration (Tmax)|Apparent Terminal Phase Elimination Rate Constant (β or Beta)|Terminal Phase Elimination Half-life (t1/2)|Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of the Last Measurable Concentration (AUCt)|AUC from time 0 to infinite time (AUC∞)","AbbVie","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-536|2018-000313-20","May 24, 2022","June 7, 2024","June 7, 2024","January 17, 2018",,"October 1, 2019","Karmanos Cancer Center /ID# 200136, Detroit, Michigan, United States|Lifespan Cancer Institute /ID# 200130, Providence, Rhode Island, United States|Huntsman Cancer Institute /ID# 200135, Salt Lake City, Utah, United States|Herlev Hospital /ID# 201073, Herlev, Hovedstaden, Denmark",,"https://ClinicalTrials.gov/show/NCT03400306"
93,"NCT03398148","A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy",,"Recruiting","No Results Available","Ulcerative Colitis (UC)","Drug: risankizumab IV|Drug: placebo for risankizumab|Drug: risankizumab SC","Percentage of participants with clinical remission per adapted Mayo Score at Week 12|Percentage of participants achieving clinical remission per full Mayo Score at Week 12 in subjects with a full Mayo score of 6 to 12 at Baseline|Ulcerative Colitis Symptom Questionnaire (UC-SQ): Change from Baseline to Week 12|Inflammatory Bowel Disease Questionnaire (IBDQ): Change from Baseline to Week 12|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue): Change from Baseline to Week 12|Percentage of participants achieving clinical response per adapted Mayo Score at week 12|Percentage of participants with endoscopic remission at Week 12|Percentage of participants achieving clinical response per partial adapted Mayo Score at week 4|Percentage of participants with mucosal healing at Week 12|36-Item Short Form Health Status Survey (SF-36): Change from Baseline to Week 12|Percentage of participants with hospitalization through Week 12|Percentage of participants with Ulcerative Colitis (UC)-related surgeries through Week 12|Percentage of participants with endoscopic improvement at Week 12","AbbVie","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","720","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-067|2016-004677-40","March 7, 2018","September 23, 2020","August 29, 2022","January 12, 2018",,"December 23, 2019","Southern California Res. Ctr. /ID# 169660, Coronado, California, United States|Ucsd /Id# 160452, La Jolla, California, United States|United Gastroenterologists /ID# 158528, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 200931, Los Angeles, California, United States|UCSF Center for Colitis and Crohn's Disease /ID# 201210, San Francisco, California, United States|Kaiser Permanente - San Francisco /ID# 211627, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 163851, West Hollywood, California, United States|Peak Gastroenterology Associat /ID# 165841, Colorado Springs, Colorado, United States|Rocky Mountain Pediatric Gastroenterology /ID# 207174, Lone Tree, Colorado, United States|Medical Research Ctr CT /ID# 160311, Hamden, Connecticut, United States|Yale Univ Digestive Diseases /ID# 213179, New Haven, Connecticut, United States|South Lake Pain Institute, Inc /ID# 162878, Clermont, Florida, United States|Ctr for Advanced Gastroenterol /ID# 202811, Maitland, Florida, United States|Coral Research Clinic /ID# 158584, Miami, Florida, United States|Nirvana Research Center /ID# 161848, Miami, Florida, United States|Gastroenterology Group Naples /ID# 165212, Naples, Florida, United States|Advanced Research Institute /ID# 161938, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 206711, Orlando, Florida, United States|Florida Hospital /ID# 160433, Orlando, Florida, United States|Omega Research Maitland /ID# 203059, Orlando, Florida, United States|Lenus Research & Medical Group /ID# 169730, Sweetwater, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 201783, Tampa, Florida, United States|Florida Hospital Tampa /ID# 170503, Tampa, Florida, United States|Atlanta Gastro Assoc /ID# 160415, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 160523, Macon, Georgia, United States|Atlanta Gastroenterology Spec /ID# 161372, Suwanee, Georgia, United States|University of Chicago /ID# 160521, Chicago, Illinois, United States|DM Clinical Research/Southwest /ID# 165012, Oak Lawn, Illinois, United States|Indiana University /ID# 167252, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Res Ctr /ID# 160412, Topeka, Kansas, United States|Houma Digestive Health Special /ID# 158317, Houma, Louisiana, United States|Delricht Research /ID# 206815, New Orleans, Louisiana, United States|Nola Research Works, LLC /ID# 161368, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 201204, Shreveport, Louisiana, United States|Johns Hopkins University School of Medicine /ID# 211793, Baltimore, Maryland, United States|MGH Digestive Health Center /ID# 164255, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 158524, Ann Arbor, Michigan, United States|Center for Digestive Health /ID# 160327, Troy, Michigan, United States|Mayo Clinic - Rochester /ID# 200458, Rochester, Minnesota, United States|Quality Clinical Research Inc. /ID# 167313, Omaha, Nebraska, United States|Concorde Medical Group PLLC /ID# 211805, New York, New York, United States|Weill Cornell Medicine /ID# 165887, New York, New York, United States|Weill Cornell Medicine /ID# 161934, New York, New York, United States|Lenox Hill Hospital, Northwell /ID# 168470, New York, New York, United States|DiGiovanna Institute for Medic /ID# 171129, North Massapequa, New York, United States|Univ Rochester Med Ctr /ID# 161664, Rochester, New York, United States|Carolinas Medical Center /ID# 158512, Charlotte, North Carolina, United States|Carolina Research, Greenville, NC /ID# 201090, Greenville, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 169732, Fargo, North Dakota, United States|Cleveland Clinic Main Campus /ID# 209232, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 164714, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 167113, Columbus, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 201777, Mentor, Ohio, United States|ProMedica Physicians Digestive Healthcare /ID# 215623, Sylvania, Ohio, United States|Digestive Disease Specialists /ID# 170779, Oklahoma City, Oklahoma, United States|Adult Gastroenterology Associates - Main /ID# 208867, Tulsa, Oklahoma, United States|University of Pennsylvania /ID# 166266, Philadelphia, Pennsylvania, United States|Gastroenterology Associates, P.A. /ID# 160472, Greenville, South Carolina, United States|Gastro One /ID# 160418, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 168747, Johnson City, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 160580, Nashville, Tennessee, United States|Inquest Clinical Research /ID# 165685, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209798, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209950, Cedar Park, Texas, United States|DHAT Research Institute /ID# 158226, Garland, Texas, United States|Vilo Research Group Inc /ID# 207656, Houston, Texas, United States|CliniCore International, LLC /ID# 158218, Houston, Texas, United States|Baylor College of Medicine /ID# 158221, Houston, Texas, United States|Precision Research Institute - Houston /ID# 201351, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201222, Houston, Texas, United States|Caprock Gastro Research /ID# 215432, Lubbock, Texas, United States|Clinical Associates in Researc /ID# 161376, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 168776, San Antonio, Texas, United States|Baylor Scott & White Health - Temple /ID# 204130, Temple, Texas, United States|Tyler Research Institute, LLC /ID# 166800, Tyler, Texas, United States|Victoria gastroenterology /ID# 164321, Victoria, Texas, United States|Advanced Research Institute /ID# 160480, Ogden, Utah, United States|Virginia Mason Medical Center /ID# 160466, Seattle, Washington, United States|Hopital Centenario /ID# 170898, Rosario, Santa Fe, Argentina|Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quimo"" - CEMIC /ID# 167782, Buenos Aires, Argentina|Sanatorio 9 de Julio S.A. /ID# 167780, San Miguel de Tucuman, Argentina|Universitätsklinikum St.Pölten /ID# 169048, St. Pölten, Niederoesterreich, Austria|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 215320, Linz, Oberoesterreich, Austria|Medical University of Vienna /ID# 169050, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 169053, Graz, Austria|LKH Salzburg and Paracelsus /ID# 200685, Salzburg, Austria|CUB Hospital Erasme /ID# 200252, Brussels, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 200039, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 200253, Liège, Liege, Belgium|UZ Gent /ID# 200251, Gent, Oost-Vlaanderen, Belgium|Imelda Ziekenhuis /ID# 211100, Bonheiden, Belgium|UZ Brussels /ID# 164176, Jette, Brussels, Belgium|UZ Leuven /ID# 170812, Leuven, Belgium|Clinique St Joseph /ID# 200250, Liege, Belgium|AZ-Delta /ID# 200040, Roeselare, Belgium|CHU Dinant Godinne - UCL Namur /ID# 200254, Yvoir, Belgium|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 157679, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 157671, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 157662, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 157690, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 157660, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 163995, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 157680, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hosp U Clementino Fraga Filho /ID# 157661, Rio de Janeiro, Brazil|MBAL Hadzhi Dimitar /ID# 207945, Sliven, Bulgaria|II MHAT - Sofia /ID# 200799, Sofia, Bulgaria|UMHAT Tsaritsa Joanna - ISUL /ID# 209977, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 210797, Sofia, Bulgaria|University of Calgary /ID# 169111, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 169767, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 204588, Edmonton, Alberta, Canada|Covenant Health /ID# 169114, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 169102, New Westminster, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 169109, Victoria, British Columbia, Canada|IWK Health Center /ID# 169110, Halifax, Nova Scotia, Canada|London Health Sciences Centre /ID# 169103, London, Ontario, Canada|Scott Shulman Medicine Professional Corporation /ID# 169113, North Bay, Ontario, Canada|Toronto Digestive Diseases Ass /ID# 169106, Vaughan, Ontario, Canada|Hopital Charles-Lemoyne /ID# 169105, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 214378, Levis, Quebec, Canada|CIUSSS de l'Est de l'Ile de Montréal /ID# 169108, Montréal, Quebec, Canada|Montreal General Hospital /ID# 169104, Montréal, Quebec, Canada|Servicio de Salud Araucanía Norte Hospital Victoria /ID# 213151, Victoria, Araucania, Chile|Complejo Asistencial Dr. Sotero del Rio /ID# 169385, Santiago, Region Metropolitana De Santiago, Chile|Servicio de Salud Occidente Hospital San Juan de Dios /ID# 171125, Santiago, Region Metropolitana De Santiago, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 210761, Concepción, Chile|Hospital Las Higueras /ID# 167093, Talcahuano, Chile|Hospital Dr. Hernán Henríquez Aravena /ID# 210731, Temuco, Chile|The First Affiliated Hospital of Anhui Medical University /ID# 211228, Hefei, Anhui, China|The Sixty Affiliated Hospital of Sun Yat-Sen University /ID# 211231, Guangzhou, Guangdong, China|The Second Hospital of Hebei Medical University /ID# 213018, Shijiazhuang, Hebei, China|Xiangya Hospital Central South University /ID# 211197, Changsha, Hunan, China|1st Aff Hosp Nanchang Univ /ID# 212183, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 212278, Changchun, Jilin, China|General Hospital of Ningxia Medical University /ID# 213911, Yinchuan, Ningxia, China|Xijing Hospital /ID# 211639, Xian, Shaanxi, China|Ruijin Hospital, Shanghai Jiaotong /ID# 210962, Shanghai, Shanghai, China|Renji Hosp, Shanghai Jiaotong /ID# 211233, Shanghai, Shanghai, China|West China Hospital /ID# 211276, Chengdu, Sichuan, China|The second affiliated hospital of Zhejiang University school of medicine /ID# 211025, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 211064, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 211066, Beijing, China|The Second Xiangya Hospital of Central South University /ID# 211198, Changsha, China|Jiangsu Province Hospital /ID# 211232, Nanjing, China|Shengjing Hospital of China Medical University /ID# 211646, Shenyang, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 211071, Wuhan, China|Tongji Hosp Tongji Med College /ID# 211072, Wuhan, China|Renmin Hospital of Wuhan Univ /ID# 212868, Wuhan, China|4th Military Medical Universit /ID# 215504, Xi'an, China|Corporacion Hospitalaria Juan Ciudad sede Denominada Hospital Universitario Mayo /ID# 158717, Bogota DC, Cundinamarca, Colombia|Instituto de Coloproctologia /ID# 158739, Medellin, Colombia|Hospital Universitario San Vic /ID# 171490, Medellin, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 206937, Montería, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 157475, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 157471, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 201917, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 157472, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 157473, Split, Croatia|Bispebjerg Hospital /ID# 208945, Copenhagen NV, Hovedstaden, Denmark|Sjaellands Universitets Hospit /ID# 200033, Roskilde, Sjælland, Denmark|Odense Universitets Hospital /ID# 205602, Odense C, Syddanmark, Denmark|Hvidovre Hospital /ID# 202266, Hvidovre, Denmark|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 200848, Alexandria, Egypt|Air Force Specialized Hospital /ID# 170986, Cairo, Egypt|National Liver Institute /ID# 171040, Menoufiya, Egypt|Chu de Nice-Hopital L'Archet Ii /Id# 171577, Nice CEDEX 3, Alpes-Maritimes, France|Hôpital Haut-Lévêque /ID# 171579, Pessac CEDEX, Gironde, France|Hopital Beaujon /ID# 200092, Clichy, Ile-de-France, France|CHU de SAINT ETIENNE - Hopital Nord /ID# 171580, St. Priest En Jarez, Loire, France|CHU Amiens Picardie - Site Sud /ID# 171576, Amiens Cedex 1, France|Universitatsklinikum Mannheim /ID# 162035, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 159354, Erlangen, Bayern, Germany|Uniklinik Koln /ID# 164991, Köln, Nordrhein-Westfalen, Germany|Univ Hosp Schleswig-Holstein /ID# 159360, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 164992, Ulm, Thueringen, Germany|Praxis am Bayrischen Platz /ID# 159361, Berlin, Germany|Charite; Campus Benjamin Frank /ID# 210510, Berlin, Germany|DRK Kliniken Berlin /ID# 166153, Berlin, Germany|Stadtisches Klinikum Braunschw /ID# 163687, Braunschweig, Germany|Agaplesion Markus Krankenhaus /ID# 159356, Frankfurt, Germany|Universitätsklinikum Freiburg /ID# 162034, Freiburg, Germany|Med Hochschule Hanover /ID# 162036, Hannover, Germany|Praxis fuer Gastroenterologie /ID# 166152, Heidelberg, Germany|Gastroenterologie Opernstrasse /ID# 163683, Kassel, Germany|Klinikum Landshut /ID# 211551, Landshut, Germany|Klinikum Lueneburg /ID# 163685, Lueneburg, Germany|Gastro Gemeinschaftspraxis /ID# 162033, Minden, Germany|LMU Klinikum der Universität München /ID# 210481, Munich, Germany|Klinikum Univ Regensburg /ID# 163686, Regensburg, Germany|Universitatsklinikum Tubingen /ID# 159363, Tuebingen, Germany|General Hospital of Athens Laiko /ID# 206440, Athens, Attiki, Greece|Tzaneio general hospital of Piraeus /ID# 206439, Piraeus, Attiki, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 170915, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 165216, Heraklion, Greece|General Hospital Nikaias-Piraeus St. Panteleimon /ID# 165218, Pireaus, Greece|Theageneio Anticancer Hospital /ID# 165217, Thessaloniki, Greece|Soroka Medical Center /ID# 171100, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 167403, Petakh Tikva, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 171099, Jerusalem, Yerushalayim, Israel|Rambam Medical Center /ID# 171101, Haifa, Israel|Rambam Medical Center /ID# 171103, Haifa, Israel|Shaare Zedek Medical Center /ID# 163544, Jerusalem, Israel|Shaare Zedek Medical Center /ID# 171102, Jerusalem, Israel|Sheba Medical Center /ID# 171104, Ramat Gan, Israel|Sheba Medical Center /ID# 211278, Ramat Gan, Israel|Universita di Catanzaro Magna Graecia /ID# 200125, Catanzaro, Calabria, Italy|Ospedale Sant Orsola Malpighi /ID# 155611, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 201819, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 163992, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 155612, Rome, Lazio, Italy|Azienda Policlinico Universitario Umberto I /ID# 171226, Rome, Lazio, Italy|ASST Rhodense /ID# 211449, Rho, Lombardia, Italy|Istituto Clinico Humanitas /ID# 155610, Rozzano, Milano, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 164036, Catania, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 164041, Negrar, Verona, Italy|Ospedale Policlinico San Martino - IRCCS /ID# 164031, Genoa, Italy|Azienda Ospedaliera Ospedale N /ID# 170947, Milano, Italy|Azienda Ospedaliera Luigi Sacc /ID# 155607, Milan, Italy|Policlinico Tor Vergata /ID# 158018, Rome, Italy|UOC Medicina Interna e Gastroe /ID# 155608, Rome, Italy|Aichi Medical University Hosp /ID# 164332, Nagakute, Aichi, Japan|Daido Clinic /ID# 211479, Nagoya-shi, Aichi, Japan|Nagoya University Hospital /ID# 164271, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 164331, Nagoya-shi, Aichi, Japan|Toho University Sakura Medical Center /ID# 164254, Sakura-shi, Chiba, Japan|Fukuoka University Chikushi Hospital /ID# 209055, Chikushino, Fukuoka, Japan|Kurume University Hospital /ID# 164427, Kurume-shi, Fukuoka, Japan|Gifu University Hospital /ID# 208081, Gifu-shi, Gifu, Japan|National Hospital Organization Takasaki General Medical Center /ID# 164437, Takasaki-shi, Gunma, Japan|NHO Fukuyama Medical Center /ID# 164439, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 164433, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 164251, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 164432, Sapporo-shi, Hokkaido, Japan|Aoyama Clinic /ID# 164425, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 164424, Nishinomiya-shi, Hyogo, Japan|Kanazawa University Ho /ID# 169224, Kanazawa, Ishikawa, Japan|Gokeikai Ofuna Chuo Hospital /ID# 169300, Kamakura-shi, Kanagawa, Japan|Mie University Hospital /ID# 203633, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 164430, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 202674, Nagasaki-shi, Nagasaki, Japan|Saga University Hospital /ID# 209396, Saga-shi, Saga, Japan|Tokito Clinic /ID# 164253, Saitama-shi, Saitama, Japan|Shiga University of Medical Science Hospital /ID# 164440, Otsu, Shiga, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 164258, Bunkyo-ku, Tokyo, Japan|Kyorin University Hospital /ID# 164259, Mitaka-shi, Tokyo, Japan|Keio University Hospital /ID# 203629, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 171474, Yamagata-shi, Yamagata, Japan|Hiroshima University Hospital /ID# 164426, Hiroshima, Japan|Tokai University Hospital /ID# 209204, Isehara, Japan|Sameshima Hospital /ID# 211181, Kagoshima, Japan|Nara Medical Univ Hospital /ID# 169225, Kashihara, Japan|The Jikei University Hospital /ID# 164434, Minato-ku, Japan|Kitasato University Kitasato I /ID# 164256, Minato-ku, Japan|Kitasato University Hospital /ID# 169226, Sagamihara-shi, Japan|NHO Shizuoka Medical Center /ID# 164435, Shimizu-sho, Japan|Fujita Health University Hosp /ID# 164261, Toyoake, Japan|Wakayama Medical University /ID# 169487, Wakayama, Japan|JP Red Cross Wakayama Med Ctr /ID# 171195, Wakayama, Japan|Yokkaichi Hazu Medical Center /ID# 164441, Yokkaichi-shi, Japan|Showa Univ Fujigaoka Hosp /ID# 209555, Yokohama-shi, Japan|Dong-A University Hospital /ID# 158705, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 158711, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 158703, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA bundang medical center, CHA University /ID# 158710, Seongnam-si, Gyeonggido, Korea, Republic of|St. Vincent's Hospital /ID# 158706, Suwon, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 158707, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 158701, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 158704, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Haeundae Paik Hospital /ID# 203028, Busan, Korea, Republic of|Hanyang University Guri Hosp /ID# 158702, Guri-si, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 163802, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 163803, Riga, Latvia|Hospital of Lithuanian Univers /ID# 170714, Kovno, Kaunas, Lithuania|Vilnius University Hospital /ID# 170614, Vilnius, Lithuania|UKM Medical Centre /ID# 200635, Kuala Lumpur, Selangor, Malaysia|JM Research /ID# 203593, Cuernavaca, Morelos, Mexico|Health Pharma Professional Research S.A de C.V /ID# 203597, Del. Benito Juárez, Mexico|Unidad de Atencion Medica e Investigacion en Salud /ID# 203595, Merida Yucatan, Mexico|Academisch Medisch Centrum /ID# 157959, Amsterdam, Noord-Holland, Netherlands|Elisabeth Tweesteden Ziekenhuis /ID# 163767, Tilburg, Netherlands|Tauranga Hospital /ID# 212792, Tauranga, Bay Of Plenty, New Zealand|Christchurch Hospital /ID# 205342, Christchurch, Canterbury, New Zealand|Waikato Hospital /ID# 212789, Hamilton, Waikato, New Zealand|Hutt Valley Dist Health Board /ID# 212786, Lower Hutt, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 205343, Wellington, New Zealand|Vistamed /ID# 210105, Wrocław, Dolnoslaskie, Poland|Centrum Medyczne Plejady /ID# 170633, Krakow, Malopolskie, Poland|Centrum Zdrowia MDM /ID# 170597, Warsaw, Mazowieckie, Poland|WIP Warsaw IBD Point Profesor Kierkus /ID# 216102, Warsaw, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 170601, Warszawa, Mazowieckie, Poland|Centrum Onkologii-Instytut im.M.Sklodowskiej-Curie w Warszawie /ID# 170600, Warszawa, Mazowieckie, Poland|NZOZ All-Medicus /ID# 170596, Katowice, Slaskie, Poland|NZOZ Vitamed /ID# 213283, Bydgoszcz, Poland|NZOZ Vivamed /ID# 216307, Warsaw, Poland|Centro Hospitalar do Algarve - Hospital de Portimão /ID# 166551, Portimao, Faro, Portugal|Centro Hosp de Lisboa Central /ID# 165582, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 165583, Almada, Setubal, Portugal|Centro Hospitalar e Universitário de Coimbra, EPE /ID# 166054, Coimbra, Portugal|HSOG - Hospital Senhora da Oli /ID# 165580, Guimaraes, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 165581, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 166052, Santa Maria Da Feira, Portugal|Centro Hosp de Tondela-Viseu /ID# 166053, Viseu, Portugal|San Jorge Children Hospital /ID# 166954, San Juan, Puerto Rico|Institutul Clinic Fundeni /ID# 171264, Bucharest, Romania|Cabinet Particular Policlinic Algomed /ID# 171266, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 171268, Timisoara, Romania|GBUZ Interdisctrict Multidisciplinary Hospital /ID# 203335, Anzorey, Kabardino-Balkarskaya Respublika, Russian Federation|Immanuel Kant Baltic Federal University /ID# 204888, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 165750, Kemerovo, Kemerovskaya Oblast, Russian Federation|LLC Korolev Medicina /ID# 208946, Korolev, Moskovskaya Oblast, Russian Federation|Regional Clinical Hospital #1 /ID# 165754, Tyumen, Tyumenskaya Oblast, Russian Federation|Clinic of New Technologies of /ID# 203369, Dzerzhinskiy, Russian Federation|Sechenov First Moscow Medical /ID# 204978, Moscow, Russian Federation|Scien Ctr Coloproctology Rosme /ID# 203512, Moscow, Russian Federation|Central Clinical Hosp 2 /ID# 204917, Moscow, Russian Federation|PMI Euromedservice /ID# 204892, Pushkin, Russian Federation|International Medical Center SOGAZ /ID# 206727, Sankt-Peterburg, Russian Federation|City Clinical Hospital #40 /ID# 203370, St. Petersburg, Russian Federation|Ulyanovsk Regional Clin Hosp /ID# 203368, Ulyanovsk, Russian Federation|Clinical Center Serbia /ID# 200152, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 200151, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 202059, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 156913, Kragujevac, Sumadijski Okrug, Serbia|Singapore General Hospital /ID# 204227, Singapore, Singapore|KL Ling Gastroenterology and Liver Clinic /ID# 205738, Singapore, Singapore|FN s poliklinikou F.D. Rooseve /ID# 164347, Banska Bystrica, Slovakia|KM Management s.r.o, Nitra, SK /ID# 206602, Nitra, Slovakia|Gastro I.S.R.O. /ID# 164346, Presov, Slovakia|Univ Medical Ctr Ljubljana /ID# 210627, Ljubljana, Slovenia|Farmovs (Pty) Ltd /Id# 207537, Bloemfontein, Free State, South Africa|Mediclinic Constantiaberg /ID# 171137, Cape Town, Western Cape, South Africa|Dr JP Wright /ID# 171138, Cape Town, South Africa|Complejo Hospitalario Universitario de Ferrol /ID# 159440, Ferrol, Galicia, Spain|Hospital Alvaro Cunqueiro /ID# 167360, Vigo, Pontevedra, Spain|Hospital Universitario Parc Tauli /ID# 159461, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 159439, Barcelona, Spain|Hospital Universitario Reina S /ID# 167058, Cordoba, Spain|Hospital Universitario de Cabu /ID# 170748, Gijon, Spain|Hospital General Universitario Gregorio Maranon /ID# 161146, Madrid, Spain|Hospital Universitario La Paz /ID# 159459, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 159443, Majadahonda, Spain|Complejo Hosp Pontevedra /ID# 216182, Pontevedra, Spain|Hospital Clinico Univ de Salamanca /ID# 159446, Salamanca, Spain|Hospital Universitario Virgen Macarena /ID# 159968, Sevilla, Spain|Hospital de Manises /ID# 167059, Valencia, Spain|Hospital Univ Miguel Servet /ID# 159445, Zaragoza, Spain|Alingsås lasarett /ID# 202074, Alingsås, Vastra Gotalands Lan, Sweden|SU Molndal. /ID# 202843, Molndal, Sweden|Danderyds sjukhus AB /ID# 202035, Stockholm, Sweden|University Hospital Zurich /ID# 202910, Zurich, Zuerich, Switzerland|National Taiwan University Hospital /ID# 162187, Taipei City, Taipei, Taiwan|Chung Shan Medical University /ID# 163651, Taichung City, Taiwan|Taichung Veterans General Hosp /ID# 163649, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 163650, Taipei City, Taiwan|Acibadem Kozyatagi Hospital /ID# 213276, Kadikoy, Istanbul, Turkey|Erciyes University Medical Fac /ID# 171291, Melikgazi, Kayseri, Turkey|Ankara Univ Medical Faculty /ID# 167210, Ankara, Turkey|Inonu Universitesi Turgut Ozal /ID# 203981, Battalgazi/malatya, Turkey|Uludag University Medical Faculty /ID# 204182, Bursa, Turkey|Fırat University Medical Facul /ID# 171292, Elazig, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 167207, Istanbul, Turkey|Marmara University Medical Fac /ID# 171293, Istanbul, Turkey|Sisli Etfal Train & Res Hosp /ID# 171409, Sisli, Turkey|Medical Centre of OK!Clinic of International Institute of Clinical Trials /ID# 205482, Kiev, Kyivska Oblast, Ukraine|Regional Clinical Hospital /ID# 203367, Ivano-frankivsk, Ukraine|RD&E Hospital /ID# 157587, Exeter, Devon, United Kingdom|Barnsley Hospital NHS Foundation Trust /ID# 202770, Barnsley, United Kingdom|Royal United Hospitals Bath /ID# 157592, Bath, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 157588, Birmingham, United Kingdom|Addenbrookes Hospital /ID# 158040, Cambridge, United Kingdom|Western General Hospital /ID# 208802, Edinburgh, United Kingdom|Royal Liverpool and Broadgreen /ID# 203858, Liverpool, United Kingdom|Barts and the London NHS Trust /ID# 157590, London, United Kingdom|King's College Hospital NHS /ID# 158766, London, United Kingdom|St. George's Healthcare NHS /ID# 208378, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 158041, Newcastle Upon Tyne, United Kingdom|Univ Hosp Southampton NHS /ID# 210813, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03398148"
94,"NCT03398135","A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065",,"Recruiting","No Results Available","Ulcerative Colitis (UC)","Drug: risankizumab|Drug: placebo for risankizumab","Percentage of participants with clinical remission per adapted Mayo Score at Week 52|Percentage of participants with clinical remission per adapted Mayo Score at Week 52 in subjects with a clinical remission at Week 0|Percentage of participants who discontinued corticosteroid use at Week 52 in subjects who were taking steroids at Baseline (of induction)|Percentage of participants who discontinued corticosteroid use, remained corticosteroid free for 90 days, and achieved clinical remission per adapted Mayo Score at Week 52 in subjects taking steroids at Baseline (of induction).|Percentage of participants with endoscopic remission at Week 52|Ulcerative Colitis Symptom Questionnaire (UC-SQ): Change from Week 0 to Week 52|Percentage of participants with Ulcerative Colitis (UC)-related surgeries through Week 52|Percentage of participants with hospitalization through Week 52|36-Item Short Form Health Status Survey (SF-36): Change from Week 0 to Week 52|Inflammatory Bowel Disease Questionnaire (IBDQ): Change from Week 0 to Week 52|Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue): Change from Week 0 to Week 52|Percentage of participants with endoscopic improvement at Week 52|Percentage of participants with clinical remission per full Mayo Score at Week 52 in subjects with a full Mayo Score of 6 to 12 at Baseline (of Induction)|Percentage of participants with endoscopic improvement at Week 52 in participants with endoscopic improvement at Week 0|Percentage of participants with clinical response per adapted Mayo score at Week 52|Percentage of participants with histologic remission at Week 52|Percentage of participants with mucosal healing at Week 52","AbbVie","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","760","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-066|2016-004676-22","August 28, 2018","December 4, 2022","June 30, 2024","January 12, 2018",,"December 23, 2019","Southern California Res. Ctr. /ID# 169659, Coronado, California, United States|Ucsd /Id# 160430, La Jolla, California, United States|United Gastroenterologists /ID# 158574, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 200934, Los Angeles, California, United States|UCSF Center for Colitis and Crohn's Disease /ID# 201209, San Francisco, California, United States|Kaiser Permanente - San Francisco /ID# 212087, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 163848, West Hollywood, California, United States|Peak Gastroenterology Associat /ID# 165838, Colorado Springs, Colorado, United States|Rocky Mountain Pediatric Gastroenterology /ID# 207173, Lone Tree, Colorado, United States|Medical Research Ctr CT /ID# 160287, Hamden, Connecticut, United States|Yale Univ Digestive Diseases /ID# 213265, New Haven, Connecticut, United States|South Lake Pain Institute, Inc /ID# 162859, Clermont, Florida, United States|Ctr for Advanced Gastroenterol /ID# 202820, Maitland, Florida, United States|Coral Research Clinic /ID# 158608, Miami, Florida, United States|Nirvana Research Center /ID# 161844, Miami, Florida, United States|Gastroenterology Group Naples /ID# 165210, Naples, Florida, United States|Advanced Research Institute /ID# 161945, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 206709, Orlando, Florida, United States|Florida Hospital /ID# 160393, Orlando, Florida, United States|Omega Research Maitland /ID# 203105, Orlando, Florida, United States|Lenus Research & Medical Group /ID# 169727, Sweetwater, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 201794, Tampa, Florida, United States|Florida Hospital Tampa /ID# 170482, Tampa, Florida, United States|Atlanta Gastro Assoc /ID# 160370, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 160513, Macon, Georgia, United States|University of Chicago /ID# 160511, Chicago, Illinois, United States|DM Clinical Research/Southwest /ID# 165009, Oak Lawn, Illinois, United States|Indiana University /ID# 167250, Indianapolis, Indiana, United States|Cotton-O'Neil Clinical Res Ctr /ID# 160367, Topeka, Kansas, United States|Houma Digestive Health Special /ID# 158377, Houma, Louisiana, United States|Delricht Research /ID# 206817, New Orleans, Louisiana, United States|Nola Research Works, LLC /ID# 161356, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 201205, Shreveport, Louisiana, United States|Johns Hopkins University School of Medicine /ID# 211792, Baltimore, Maryland, United States|MGH Digestive Health Center /ID# 164257, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 159430, Ann Arbor, Michigan, United States|Center for Digestive Health /ID# 160300, Troy, Michigan, United States|Mayo Clinic - Rochester /ID# 200455, Rochester, Minnesota, United States|Quality Clinical Research Inc. /ID# 167312, Omaha, Nebraska, United States|Concorde Medical Group PLLC /ID# 211803, New York, New York, United States|Weill Cornell Medicine /ID# 165884, New York, New York, United States|Weill Cornell Medicine /ID# 161929, New York, New York, United States|Lenox Hill Hospital, Northwell /ID# 168469, New York, New York, United States|DiGiovanna Institute for Medic /ID# 171128, North Massapequa, New York, United States|Univ Rochester Med Ctr /ID# 161660, Rochester, New York, United States|Carolinas Medical Center /ID# 158543, Charlotte, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 169729, Fargo, North Dakota, United States|Cleveland Clinic Main Campus /ID# 209235, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 164713, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 167112, Columbus, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 201778, Mentor, Ohio, United States|ProMedica Physicians Digestive Healthcare /ID# 215622, Sylvania, Ohio, United States|Digestive Disease Specialists /ID# 170777, Oklahoma City, Oklahoma, United States|Adult Gastroenterology Associates - Main /ID# 208873, Tulsa, Oklahoma, United States|University of Pennsylvania /ID# 166262, Philadelphia, Pennsylvania, United States|Gastroenterology Associates, P.A. /ID# 160457, Greenville, South Carolina, United States|Gastro One /ID# 160373, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 168744, Johnson City, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 160567, Nashville, Tennessee, United States|Inquest Clinical Research /ID# 165686, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209799, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209951, Cedar Park, Texas, United States|DHAT Research Institute /ID# 158235, Garland, Texas, United States|Vilo Research Group Inc /ID# 207657, Houston, Texas, United States|CliniCore International, LLC /ID# 158227, Houston, Texas, United States|Baylor College of Medicine /ID# 158230, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201221, Houston, Texas, United States|Caprock Gastro Research /ID# 215433, Lubbock, Texas, United States|Clinical Associates in Researc /ID# 161364, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 168774, San Antonio, Texas, United States|Baylor Scott & White Health - Temple /ID# 204132, Temple, Texas, United States|Tyler Research Institute, LLC /ID# 166799, Tyler, Texas, United States|Victoria gastroenterology /ID# 164308, Victoria, Texas, United States|Advanced Research Institute /ID# 160465, Ogden, Utah, United States|Pediatric Specialty of VA /ID# 166819, Fairfax, Virginia, United States|Virginia Mason Medical Center /ID# 160432, Seattle, Washington, United States|Hopital Centenario /ID# 170896, Rosario, Santa Fe, Argentina|Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quimo"" - CEMIC /ID# 167805, Buenos Aires, Argentina|Sanatorio 9 de Julio S.A. /ID# 167803, San Miguel de Tucuman, Argentina|Universitätsklinikum St.Pölten /ID# 169049, St. Pölten, Niederoesterreich, Austria|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 216043, Linz, Oberoesterreich, Austria|Medical University of Vienna /ID# 169051, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 169052, Graz, Austria|LKH Salzburg and Paracelsus /ID# 200686, Salzburg, Austria|CUB Hospital Erasme /ID# 200256, Brussels, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 200260, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 200257, Liège, Liege, Belgium|UZ Gent /ID# 200261, Gent, Oost-Vlaanderen, Belgium|Imelda Ziekenhuis /ID# 211101, Bonheiden, Belgium|UZ Brussels /ID# 164175, Jette, Brussels, Belgium|UZ Leuven /ID# 170829, Leuven, Belgium|Clinique St Joseph /ID# 200255, Liege, Belgium|AZ-Delta /ID# 200258, Roeselare, Belgium|CHU Dinant Godinne - UCL Namur /ID# 200259, Yvoir, Belgium|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 157683, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 157677, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 157670, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 157691, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 157668, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 163993, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 157686, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hosp U Clementino Fraga Filho /ID# 157669, Rio de Janeiro, Brazil|MBAL Hadzhi Dimitar /ID# 207947, Sliven, Bulgaria|II MHAT - Sofia /ID# 200794, Sofia, Bulgaria|UMHAT Tsaritsa Joanna - ISUL /ID# 209978, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 210798, Sofia, Bulgaria|University of Calgary /ID# 169125, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 169770, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 204589, Edmonton, Alberta, Canada|Covenant Health /ID# 169128, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 169116, New Westminster, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 169123, Victoria, British Columbia, Canada|IWK Health Center /ID# 169124, Halifax, Nova Scotia, Canada|London Health Sciences Centre /ID# 169117, London, Ontario, Canada|Scott Shulman Medicine Professional Corporation /ID# 169127, North Bay, Ontario, Canada|Toronto Digestive Diseases Ass /ID# 169120, Vaughan, Ontario, Canada|Hopital Charles-Lemoyne /ID# 169119, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 214379, Levis, Quebec, Canada|CIUSSS de l'Est de l'Ile de Montréal /ID# 169122, Montréal, Quebec, Canada|Montreal General Hospital /ID# 169118, Montréal, Quebec, Canada|Servicio de Salud Araucanía Norte Hospital Victoria /ID# 213152, Victoria, Araucania, Chile|Complejo Asistencial Dr. Sotero del Rio /ID# 169386, Santiago, Region Metropolitana De Santiago, Chile|Servicio de Salud Occidente Hospital San Juan de Dios /ID# 171124, Santiago, Region Metropolitana De Santiago, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 210762, Concepción, Chile|Hospital Las Higueras /ID# 167094, Talcahuano, Chile|Hospital Dr. Hernán Henríquez Aravena /ID# 210732, Temuco, Chile|The First Affiliated Hospital of Anhui Medical University /ID# 211227, Hefei, Anhui, China|The Sixty Affiliated Hospital of Sun Yat-Sen University /ID# 211229, Guangzhou, Guangdong, China|The Second Hospital of Hebei Medical University /ID# 213019, Shijiazhuang, Hebei, China|Xiangya Hospital Central South University /ID# 211195, Changsha, Hunan, China|1st Aff Hosp Nanchang Univ /ID# 212182, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 212277, Changchun, Jilin, China|General Hospital of Ningxia Medical University /ID# 213912, Yinchuan, Ningxia, China|Xijing Hospital /ID# 210708, Xian, Shaanxi, China|Ruijin Hospital, Shanghai Jiaotong /ID# 210960, Shanghai, Shanghai, China|Renji Hosp, Shanghai Jiaotong /ID# 211230, Shanghai, Shanghai, China|West China Hospital /ID# 211275, Chengdu, Sichuan, China|The second affiliated hospital of Zhejiang University school of medicine /ID# 211024, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 211062, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 211061, Beijing, China|The Second Xiangya Hospital of Central South University /ID# 211196, Changsha, China|Jiangsu Province Hospital /ID# 211234, Nanjing, China|Shengjing Hospital of China Medical University /ID# 211643, Shenyang, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 211070, Wuhan, China|Tongji Hosp Tongji Med College /ID# 211069, Wuhan, China|Renmin Hospital of Wuhan Univ /ID# 212867, Wuhan, China|4th Military Medical Universit /ID# 215505, Xi'an, China|Corporacion Hospitalaria Juan Ciudad sede Denominada Hospital Universitario Mayo /ID# 158736, Bogota DC, Cundinamarca, Colombia|Instituto de Coloproctologia /ID# 158742, Medellin, Colombia|Hospital Universitario San Vic /ID# 171488, Medellin, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 207041, Montería, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 157598, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 157594, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 201915, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 157595, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 157596, Split, Croatia|Bispebjerg Hospital /ID# 208953, Copenhagen NV, Hovedstaden, Denmark|Sjaellands Universitets Hospit /ID# 200073, Roskilde, Sjælland, Denmark|Hvidovre Hospital /ID# 205093, Hvidovre, Denmark|Odense University Hospital /ID# 209502, Odense, Denmark|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 201824, Alexandria, Egypt|Air Force Specialized Hospital /ID# 170984, Cairo, Egypt|National Liver Institute /ID# 171042, Menoufiya, Egypt|Chu de Nice-Hopital L'Archet Ii /Id# 207881, Nice CEDEX 3, Alpes-Maritimes, France|Hôpital Haut-Lévêque /ID# 207883, Pessac CEDEX, Gironde, France|Hopital Beaujon /ID# 207876, Clichy, Ile-de-France, France|CHU de SAINT ETIENNE - Hopital Nord /ID# 207882, St. Priest En Jarez, Loire, France|CHU Amiens Picardie - Site Sud /ID# 207880, Amiens Cedex 1, France|Universitatsklinikum Mannheim /ID# 162039, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 159373, Erlangen, Bayern, Germany|Uniklinik Koln /ID# 164993, Köln, Nordrhein-Westfalen, Germany|Univ Hosp Schleswig-Holstein /ID# 159379, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 164994, Ulm, Thueringen, Germany|Praxis am Bayrischen Platz /ID# 159380, Berlin, Germany|Charite; Campus Benjamin Frank /ID# 210508, Berlin, Germany|DRK Kliniken Berlin /ID# 166155, Berlin, Germany|Stadtisches Klinikum Braunschw /ID# 163694, Braunschweig, Germany|Agaplesion Markus Krankenhaus /ID# 159375, Frankfurt, Germany|Universitätsklinikum Freiburg /ID# 162038, Freiburg, Germany|Med Hochschule Hanover /ID# 162040, Hannover, Germany|Praxis fuer Gastroenterologie /ID# 166154, Heidelberg, Germany|Gastroenterologie Opernstrasse /ID# 163690, Kassel, Germany|Klinikum Landshut /ID# 211552, Landshut, Germany|Klinikum Lueneburg /ID# 163692, Lueneburg, Germany|Gastro Gemeinschaftspraxis /ID# 162037, Minden, Germany|LMU Klinikum der Universität München /ID# 210484, Munich, Germany|Klinikum Univ Regensburg /ID# 163693, Regensburg, Germany|Universitatsklinikum Tubingen /ID# 159382, Tuebingen, Germany|General Hospital of Athens Laiko /ID# 206438, Athens, Attiki, Greece|Tzaneio general hospital of Piraeus /ID# 206437, Piraeus, Attiki, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 170910, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 165327, Heraklion, Greece|General Hospital Nikaias-Piraeus St. Panteleimon /ID# 165313, Pireaus, Greece|Theageneio Anticancer Hospital /ID# 165329, Thessaloniki, Greece|Mohacsi Korhaz /ID# 205285, Mohács, Baranya, Hungary|Miskolci Semmelweis Korhaz es /ID# 201281, Miskolc, Borsod-Abauj-Zemplen, Hungary|Bugat Pal Korhaz /ID# 202526, Gyöngyös, Heves, Hungary|Obudai Egeszsegugyi Kozpont /ID# 201921, Budapest III, Pest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont /ID# 157338, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 201280, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 206151, Kistarcsa, Hungary|Clinfan Szolgaltato Kft. /ID# 206345, Szekszárd, Hungary|Soroka Medical Center /ID# 171093, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 167402, Petakh Tikva, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 171092, Jerusalem, Yerushalayim, Israel|Rambam Medical Center /ID# 171094, Haifa, Israel|Rambam Medical Center /ID# 171096, Haifa, Israel|Shaare Zedek Medical Center /ID# 163543, Jerusalem, Israel|Shaare Zedek Medical Center /ID# 171095, Jerusalem, Israel|Sheba Medical Center /ID# 211279, Ramat Gan, Israel|Universita di Catanzaro Magna Graecia /ID# 200124, Catanzaro, Calabria, Italy|Ospedale Sant Orsola Malpighi /ID# 155627, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 201818, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 163994, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 155628, Rome, Lazio, Italy|Azienda Policlinico Universitario Umberto I /ID# 171223, Rome, Lazio, Italy|ASST Rhodense /ID# 211450, Rho, Lombardia, Italy|Istituto Clinico Humanitas /ID# 155626, Rozzano, Milano, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 164039, Catania, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 164029, Negrar, Verona, Italy|Ospedali Riuniti Universita /ID# 206809, Ancona, Italy|Ospedale Policlinico San Martino - IRCCS /ID# 164030, Genoa, Italy|Azienda Ospedaliera Ospedale N /ID# 170959, Milano, Italy|Azienda Ospedaliera Luigi Sacc /ID# 155623, Milan, Italy|Policlinico Tor Vergata /ID# 158020, Rome, Italy|UOC Medicina Interna e Gastroe /ID# 155624, Rome, Italy|Aichi Medical University Hosp /ID# 164227, Nagakute, Aichi, Japan|Daido Clinic /ID# 211478, Nagoya-shi, Aichi, Japan|Nagoya University Hospital /ID# 164230, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 164229, Nagoya-shi, Aichi, Japan|Toho University Sakura Medical Center /ID# 164219, Sakura-shi, Chiba, Japan|Fukuoka University Chikushi Hospital /ID# 209056, Chikushino, Fukuoka, Japan|Kurume University Hospital /ID# 164237, Kurume-shi, Fukuoka, Japan|Gifu University Hospital /ID# 208490, Gifu-shi, Gifu, Japan|National Hospital Organization Takasaki General Medical Center /ID# 164312, Takasaki-shi, Gunma, Japan|NHO Fukuyama Medical Center /ID# 164315, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 164324, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 164215, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 164278, Sapporo-shi, Hokkaido, Japan|Aoyama Clinic /ID# 164236, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 164238, Nishinomiya-shi, Hyogo, Japan|Kanazawa University Ho /ID# 169221, Kanazawa, Ishikawa, Japan|Gokeikai Ofuna Chuo Hospital /ID# 169296, Kamakura-shi, Kanagawa, Japan|Mie University Hospital /ID# 203635, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 164276, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 205326, Nagasaki-shi, Nagasaki, Japan|Saga University Hospital /ID# 209273, Saga-shi, Saga, Japan|Tokito Clinic /ID# 164218, Saitama-shi, Saitama, Japan|Shiga University of Medical Science Hospital /ID# 164323, Otsu, Shiga, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 164225, Bunkyo-ku, Tokyo, Japan|Kitasato Univ Kitasato Inst Ho /ID# 164222, Minato-ku, Tokyo, Japan|Kyorin University Hospital /ID# 164226, Mitaka-shi, Tokyo, Japan|Keio University Hospital /ID# 203630, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 171481, Yamagata-shi, Yamagata, Japan|Hiroshima University Hospital /ID# 164240, Hiroshima, Japan|Tokai University Hospital /ID# 209207, Isehara, Japan|Sameshima Hospital /ID# 211182, Kagoshima, Japan|Nara Medical Univ Hospital /ID# 169222, Kashihara, Japan|Kitasato University Hospital /ID# 169223, Sagamihara-shi, Japan|NHO Shizuoka Medical Center /ID# 164314, Shimizu-sho, Japan|The Jikei University Hospital /ID# 164279, Tokyo, Japan|Fujita Health University Hosp /ID# 164313, Toyoake, Japan|Wakayama Medical University /ID# 169485, Wakayama, Japan|JP Red Cross Wakayama Med Ctr /ID# 171196, Wakayama, Japan|Yokkaichi Hazu Medical Center /ID# 164316, Yokkaichi-shi, Japan|Showa Univ Fujigaoka Hosp /ID# 209606, Yokohama-shi, Japan|Dong-A University Hospital /ID# 158665, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 158670, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 158662, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA bundang medical center, CHA University /ID# 158669, Seongnam-si, Gyeonggido, Korea, Republic of|St. Vincent's Hospital /ID# 158664, Suwon, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 158666, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 158660, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 158663, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Haeundae Paik Hospital /ID# 203027, Busan, Korea, Republic of|Hanyang University Guri Hosp /ID# 158661, Guri-si, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 160204, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 160205, Riga, Latvia|Veselibas Centrs 4 Ltd /ID# 163156, Riga, Latvia|Hospital of Lithuanian Univers /ID# 201142, Kovno, Kaunas, Lithuania|Vilnius University Hospital /ID# 201144, Vilnius, Lithuania|UKM Medical Centre /ID# 200634, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia /ID# 200633, Kelantan, Malaysia|JM Research /ID# 206518, Cuernavaca, Morelos, Mexico|Health Pharma Professional Research S.A de C.V /ID# 206516, Del. Benito Juárez, Mexico|Unidad de Atencion Medica e Investigacion en Salud /ID# 206515, Merida Yucatan, Mexico|Academisch Medisch Centrum /ID# 157965, Amsterdam, Noord-Holland, Netherlands|Elisabeth Tweesteden Ziekenhuis /ID# 163738, Tilburg, Netherlands|Tauranga Hospital /ID# 212793, Tauranga, Bay Of Plenty, New Zealand|Christchurch Hospital /ID# 205337, Christchurch, Canterbury, New Zealand|Waikato Hospital /ID# 212788, Hamilton, Waikato, New Zealand|Hutt Valley Dist Health Board /ID# 212787, Lower Hutt, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 205338, Wellington, New Zealand|Vistamed /ID# 210106, Wrocław, Dolnoslaskie, Poland|NZOZ Centrum Medyczne-Szpital Sw.Rodziny Sp.zo.o. /ID# 170288, Lodz, Lodzkie, Poland|Centrum Medyczne Plejady /ID# 170635, Krakow, Malopolskie, Poland|Centrum Zdrowia MDM /ID# 170283, Warsaw, Mazowieckie, Poland|WIP Warsaw IBD Point Profesor Kierkus /ID# 216103, Warsaw, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 170286, Warszawa, Mazowieckie, Poland|Centrum Onkologii-Instytut im.M.Sklodowskiej-Curie w Warszawie /ID# 170285, Warszawa, Mazowieckie, Poland|NZOZ All-Medicus /ID# 170282, Katowice, Slaskie, Poland|Endoskopia Sp. z o.o. /ID# 170284, Sopot, Zachodniopomorskie, Poland|NZOZ Vitamed /ID# 213358, Bydgoszcz, Poland|NZOZ Vivamed /ID# 216308, Warsaw, Poland|Centro Hospitalar do Algarve - Hospital de Portimão /ID# 166563, Portimao, Faro, Portugal|Centro Hosp de Lisboa Central /ID# 165578, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 165579, Almada, Setubal, Portugal|Centro Hospitalar e Universitário de Coimbra, EPE /ID# 166050, Coimbra, Portugal|HSOG - Hospital Senhora da Oli /ID# 165576, Guimaraes, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 165577, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 166048, Santa Maria Da Feira, Portugal|Centro Hosp de Tondela-Viseu /ID# 166049, Viseu, Portugal|San Jorge Children Hospital /ID# 166953, San Juan, Puerto Rico|Institutul Clinic Fundeni /ID# 171259, Bucharest, Romania|Cabinet Particular Policlinic Algomed /ID# 171260, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 171263, Timisoara, Romania|GBUZ Interdisctrict Multidisciplinary Hospital /ID# 204921, Anzorey, Kabardino-Balkarskaya Respublika, Russian Federation|Immanuel Kant Baltic Federal University /ID# 204920, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 165759, Kemerovo, Kemerovskaya Oblast, Russian Federation|LLC Korolev Medicina /ID# 208947, Korolev, Moskovskaya Oblast, Russian Federation|Regional Clinical Hospital #1 /ID# 165763, Tyumen, Tyumenskaya Oblast, Russian Federation|Clinic of New Technologies of /ID# 204926, Dzerzhinskiy, Russian Federation|Sechenov First Moscow Medical /ID# 204981, Moscow, Russian Federation|Scien Ctr Coloproctology Rosme /ID# 203513, Moscow, Russian Federation|Central Clinical Hosp 2 /ID# 204922, Moscow, Russian Federation|PMI Euromedservice /ID# 204918, Pushkin, Russian Federation|International Medical Center SOGAZ /ID# 206832, Sankt-Peterburg, Russian Federation|City Clinical Hospital #40 /ID# 204927, St. Petersburg, Russian Federation|Ulyanovsk State clinical hospi /ID# 204923, Ulyanovsk, Russian Federation|Clinical Center Serbia /ID# 200153, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 200150, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 202060, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 156879, Kragujevac, Sumadijski Okrug, Serbia|Singapore General Hospital /ID# 204225, Singapore, Singapore|KL Ling Gastroenterology and Liver Clinic /ID# 206563, Singapore, Singapore|FN s poliklinikou F.D. Rooseve /ID# 164348, Banska Bystrica, Slovakia|KM Management s.r.o, Nitra, SK /ID# 206603, Nitra, Slovakia|Gastro I.S.R.O. /ID# 164345, Presov, Slovakia|Univ Medical Ctr Ljubljana /ID# 210628, Ljubljana, Slovenia|Farmovs (Pty) Ltd /Id# 207538, Bloemfontein, Free State, South Africa|Wits Clinical Research Site /ID# 171140, Johannesburg, Gauteng, South Africa|Allergy & Immunology (AIU) /ID# 171439, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 171141, Cape Town, Western Cape, South Africa|Dr JP Wright /ID# 171142, Cape Town, South Africa|Complejo Hospitalario Universitario de Ferrol /ID# 159463, Ferrol, Galicia, Spain|Hospital Alvaro Cunqueiro /ID# 167359, Vigo, Pontevedra, Spain|Hospital Universitario Parc Tauli /ID# 159473, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 159462, Barcelona, Spain|Hospital Universitario Reina S /ID# 167062, Cordoba, Spain|Hospital Universitario de Cabu /ID# 170745, Gijon, Spain|Hosp Univ Girona Josep Trueta /ID# 205678, Girona, Spain|Hospital General Universitario Gregorio Maranon /ID# 161147, Madrid, Spain|Hospital Universitario La Paz /ID# 159471, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 159466, Majadahonda, Spain|Complejo Hosp Pontevedra /ID# 216183, Pontevedra, Spain|Hospital Clinico Univ de Salamanca /ID# 159469, Salamanca, Spain|Hospital Universitario Virgen Macarena /ID# 159969, Sevilla, Spain|Hospital de Manises /ID# 167063, Valencia, Spain|Hospital Univ Miguel Servet /ID# 159468, Zaragoza, Spain|Alingsås lasarett /ID# 202075, Alingsås, Vastra Gotalands Lan, Sweden|SU Molndal. /ID# 202841, Molndal, Sweden|Danderyds sjukhus AB /ID# 202036, Stockholm, Sweden|University Hospital Zurich /ID# 202908, Zurich, Zuerich, Switzerland|National Taiwan University Hospital /ID# 162188, Taipei City, Taipei, Taiwan|Chung Shan Medical University /ID# 171426, Taichung City, Taiwan|Taichung Veterans General Hosp /ID# 171433, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 171436, Taipei City, Taiwan|Acibadem Kozyatagi Hospital /ID# 213277, Kadikoy, Istanbul, Turkey|Erciyes University Medical Fac /ID# 171283, Melikgazi, Kayseri, Turkey|Ankara Univ Medical Faculty /ID# 167205, Ankara, Turkey|Inonu Universitesi Turgut Ozal /ID# 203980, Battalgazi/malatya, Turkey|Uludag University Medical Faculty /ID# 204179, Bursa, Turkey|Fırat University Medical Facul /ID# 171285, Elazig, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 167202, Istanbul, Turkey|Marmara University Medical Fac /ID# 171290, Istanbul, Turkey|Sisli Etfal Train & Res Hosp /ID# 171415, Sisli, Turkey|Medical Centre of OK!Clinic of International Institute of Clinical Trials /ID# 205484, Kiev, Kyivska Oblast, Ukraine|Regional Clinical Hospital /ID# 203366, Ivano-frankivsk, Ukraine|RD&E Hospital /ID# 157614, Exeter, Devon, United Kingdom|Barnsley Hospital NHS Foundation Trust /ID# 202771, Barnsley, United Kingdom|Royal United Hospitals Bath /ID# 157619, Bath, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 157615, Birmingham, United Kingdom|Addenbrookes Hospital /ID# 158046, Cambridge, United Kingdom|Western General Hospital /ID# 208801, Edinburgh, United Kingdom|Royal Liverpool and Broadgreen /ID# 203860, Liverpool, United Kingdom|Barts and the London NHS Trust /ID# 157617, London, United Kingdom|King's College Hospital NHS /ID# 158762, London, United Kingdom|St. George's Healthcare NHS /ID# 208379, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 158047, Newcastle Upon Tyne, United Kingdom|Univ Hosp Southampton NHS /ID# 210814, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03398135"
95,"NCT03391765","An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)",,"Completed","No Results Available","Progressive Supranuclear Palsy (PSP)","Drug: ABBV-8E12","Change in Progressive Supranuclear Palsy Rating Scale (PSPRS) Total Score from baseline up to 5 years|Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)|Change in Clinical Global Impression of Change (CGI-C)|Change in Schwab and England Activities of Daily Living Scale (SEADL)","AbbVie","All","40 Years and older   (Adult, Older Adult)","Phase 2","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-563|2017-001590-16","January 24, 2018","November 20, 2019","November 20, 2019","January 5, 2018",,"December 16, 2019","Univ Alabama-Birmingham /ID# 165522, Birmingham, Alabama, United States|Mayo Clinic Arizona /ID# 165521, Phoenix, Arizona, United States|Cedars-Sinai Medical Center /ID# 165567, Beverly Hills, California, United States|Usc /Id# 165529, Los Angeles, California, United States|University of California, Los Angeles /ID# 165669, Los Angeles, California, United States|University of California, San /ID# 165560, San Diego, California, United States|Univ California, San Francisco /ID# 165553, San Francisco, California, United States|Rocky Mountain Movement Disorders Center /ID# 165559, Englewood, Colorado, United States|UF Center for Movement Disorde /ID# 165561, Gainesville, Florida, United States|Mayo Clinic /ID# 165554, Jacksonville, Florida, United States|University of South Florida /ID# 165556, Tampa, Florida, United States|Augusta University Medical Center /ID# 165562, Augusta, Georgia, United States|Rush University Medical Center /ID# 165527, Chicago, Illinois, United States|University of Chicago Medical /ID# 165555, Chicago, Illinois, United States|Indiana University /ID# 165519, Indianapolis, Indiana, United States|University of Kentucky Chandler Medical Center /ID# 165566, Lexington, Kentucky, United States|Mayo Clinic - Rochester /ID# 165518, Rochester, Minnesota, United States|Cleveland Clinic Lou Ruvo Cent /ID# 165538, Las Vegas, Nevada, United States|Rutgers Robert Wood Johnson /ID# 165526, New Brunswick, New Jersey, United States|Weill Cornell Medicine /ID# 165528, New York, New York, United States|Cleveland Clinic Main Campus /ID# 165537, Cleveland, Ohio, United States|Oregon Health and Science University /ID# 165564, Portland, Oregon, United States|Vanderbilt Univ Med Ctr /ID# 165520, Nashville, Tennessee, United States|Kerwin Research Center /ID# 206872, Dallas, Texas, United States|McGovern Medical School /ID# 165565, Houston, Texas, United States|Central Texas Neurology Consul /ID# 202223, Round Rock, Texas, United States|Westmead Hospital /ID# 170218, Westmead, New South Wales, Australia|Q-Pharm Pty Limited /ID# 165452, Herston, Queensland, Australia|Royal Adelaide Hospital /ID# 165451, Adelaide, South Australia, Australia|Alfred Hospital /ID# 165454, Melbourne, Victoria, Australia|University of Calgary /ID# 165667, Calgary, Alberta, Canada|Toronto Western Hospital /ID# 165462, Toronto, Ontario, Canada|Montreal Neurological Institut /ID# 165546, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 165461, Montréal, Quebec, Canada|AO Univ Policlinico Agostino G /ID# 165536, Rome, Lazio, Italy|Istituto Clinico Humanitas /ID# 165531, Rozzano, Milano, Italy|University of Catanzaro /ID# 170214, Catanzaro, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 208737, Milan, Italy|Istituto Neuro Mediterraneo IR /ID# 165533, Pozzilli, Italy|A.O. Santa Maria /ID# 165535, Terni, Italy|IRCCS San Camillo /ID# 201229, Venice, Italy|National Hospital Organization Higashinagoya National Hospital /ID# 208786, Nagoya-shi, Aichi, Japan|National Hospital Organization Asahikawa Medical Center /ID# 208818, Asahikawa, Hokkaido, Japan|National Hospital Organization Utano National Hospital /ID# 208780, Kyoto City, Kyoto, Japan|Tohoku University Hospital /ID# 209015, Sendai-shi, Miyagi, Japan|NHO Sendai Nishitaga National Hospital /ID# 209014, Sendai, Miyagi, Japan|Niigata University Medical & Dental Hospital /ID# 208819, Niigata-shi, Niigata, Japan|Osaka University Hospital /ID# 208787, Suita-shi, Osaka, Japan|Juntendo University Hospital /ID# 208779, Bunkyo-ku, Tokyo, Japan|National Center of Neurology and Psychiatry /ID# 208820, Kodaira, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03391765"
96,"NCT03383263","A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)","PETITE","Active, not recruiting","No Results Available","Polyarticular Juvenile Arthritis",,"Assessing Humira persistence|Proportion of patients with Humira adherence|Proportion of patients with 30% American College of Rheumatology (ACR) pediatric responses|Proportion of patients with 50% American College of Rheumatology (ACR) pediatric responses|Proportion of patients with 70% American College of Rheumatology (ACR) pediatric responses|Change from baseline in physician overall disease activity|Change from baseline in patient (if appropriate in age) or parent overall well-being|Assessing Childhood Health Assessment Questionnaire-Disability Index (CHAQ-DI) score|Change from baseline in number of joints with active arthritis|Change from baseline in number of joints with limited range of motion|Change from baseline in Erythrocyte Sedimentation Rate (ESR)|Change from baseline in 10-joint Juvenile Arthritis Disease Activity Score (JADAS10)|Proportion of patient with low diseases activity (1.1 - 2 score)|Proportion of patient with moderate disease activity (2.1 - 4.2 score)|Proportion of patients with missed dosed of HUMIRA|Proportion of patients with predefined Extra-articular manifestations (EAMs)|Proportion of patients with any comorbidity","AbbVie","All","2 Years to 18 Years   (Child, Adult)",,"70","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P17-164","May 4, 2018","March 31, 2021","March 31, 2021","December 26, 2017",,"August 20, 2019","Republican Children's Clinical Hospital /ID# 204830, Ufa, Bashkortostan, Respublika, Russian Federation|Chelyabinsk Regional Children's Clinical Hospital /ID# 204829, Chelyabinsk, Chelyabinskaya Oblast, Russian Federation|Saratov State Medical University n.a. V.I. Razumovskiy /ID# 206319, Saratov, Saratovskaya Oblast, Russian Federation|Kazan State Medical Academy /ID# 207004, Kazan, Russian Federation|Morozovskaya Children's City Clinical Hospital /ID# 207006, Moscow, Russian Federation|Sechenov First Moscow Medical /ID# 207005, Moscow, Russian Federation|State Budgetary Healthcare Institution Moscow Region ""Moscow Regional Consultati /ID# 212874, Mytischi, Russian Federation|GBUZ NO ""Regional Children's Clinical Hospital"" /ID# 212362, Nizhniy Novgorod, Russian Federation|Privolzhsky Federal Medical Research Center /ID# 206318, Nizhniy Novgorod, Russian Federation|Regional Children's Clinical Hospital /ID# 206121, Orenburg, Russian Federation|Samara Regional Clinical Cardiology Clinic /ID# 206120, Samara, Russian Federation|Saint Petersburg State Pediatric Medical University /ID# 203169, Sankt-Peterburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education ""National Re /ID# 212361, Saransk, Russian Federation|State Budgetary Health Institution ""Regional Children's Clinical Hospital №1"" /ID# 212363, Yekaterinburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03383263"
97,"NCT03374917","A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment",,"Completed","No Results Available","Parkinson's Disease (PD)","Drug: ABBV-951","Percentage of Participants with Infusion Site Reactions|Number of Participants with Adverse Events|Percentage of Participants with Markedly Abnormal Vital Signs Values|Columbia-Suicide Severity Rating Scale (C-SSRS)|Percentage of Participants with Potentially Clinically Significant Laboratory Values|Percentage of Participants with Potentially Clinically Significant Electrocardiogram (ECG) Results|Plasma Concentrations of Levodopa","AbbVie","All","30 Years to 85 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-739","April 18, 2018","March 4, 2019","March 4, 2019","December 15, 2017",,"March 13, 2019","Banner Sun Health Res Inst /ID# 165840, Sun City, Arizona, United States|Loma Linda University /ID# 165592, Loma Linda, California, United States|Univ CA, Irvine Med Ctr /ID# 165594, Orange, California, United States|Compass Research /ID# 167329, Orlando, Florida, United States|Univ Kansas Med Ctr /ID# 166280, Kansas City, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 164407, Lexington, Kentucky, United States|University of Louisville /ID# 164997, Louisville, Kentucky, United States|Washington University-School of Medicine /ID# 164412, Saint Louis, Missouri, United States|NYU Langone Medical Center /ID# 164924, New York, New York, United States|University of Cincinnati /ID# 165142, Cincinnati, Ohio, United States|Cleveland Clinic Foundation /ID# 164413, Cleveland, Ohio, United States|Neurology Consultants of Dallas /ID# 167116, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03374917"
98,"NCT03368859","A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab",,"Active, not recruiting","No Results Available","Cancer","Drug: Leucovorin|Drug: Fluorouracil - bolus|Drug: Bevacizumab|Drug: Fluorouracil - infusion|Drug: ABT-165|Drug: Irinotecan","Progression Free Survival (PFS)|Objective Response Rate (ORR)|Overall Survival (OS)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-064|2017-003669-87","February 19, 2018","January 31, 2020","January 31, 2020","December 11, 2017",,"October 1, 2019","Ironwood Cancer & Res Ctr /ID# 200044, Chandler, Arizona, United States|Highlands Oncology Group /ID# 169289, Fayetteville, Arkansas, United States|City of Hope /ID# 200501, Duarte, California, United States|St. Joseph Heritage Healthcare /ID# 200100, Fullerton, California, United States|USC Norris Cancer Center /ID# 200410, Los Angeles, California, United States|Hoag Memorial Hosp Presbyterian /ID# 202661, Newport Beach, California, United States|Torrance Health Association (DBA)Torrance Memorial Physician Network/Cancer Care /ID# 202488, Redondo Beach, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 207227, Sacramento, California, United States|Pacific Central Coast Health Centers-SLO Oncology and Hematology Health Center /ID# 201215, San Luis Obispo, California, United States|Central Coast Medical Oncology /ID# 200227, Santa Maria, California, United States|University of California, Los /ID# 169294, Santa Monica, California, United States|Kaiser Permanente, Waterpark III Institute for Health Research /ID# 200801, Aurora, Colorado, United States|Medstar Georgetown Univ Med Ct /ID# 202903, Washington, District of Columbia, United States|Florida Cancer Specialist - South /ID# 203796, Fort Myers, Florida, United States|MD Anderson Cancer Ctr Orlando /ID# 200068, Orlando, Florida, United States|Florida Cancer Specialists-Panhandle /ID# 203787, Tallahassee, Florida, United States|IACT Health /ID# 169292, Columbus, Georgia, United States|Ingalls Memorial Hosp /ID# 169892, Harvey, Illinois, United States|Illinois Cancer Care, PC /ID# 202189, Peoria, Illinois, United States|Fort Wayne Medical Oncology /ID# 201616, Fort Wayne, Indiana, United States|Cancer Center of Kansas /ID# 200627, Wichita, Kansas, United States|Norton Cancer Institute /ID# 200674, Louisville, Kentucky, United States|Ochsner Clinic Foundation-New Orleans /ID# 169291, New Orleans, Louisiana, United States|Whiteside Institute for Clinic /ID# 200802, Duluth, Minnesota, United States|Mmcorc /Id# 202099, Saint Louis Park, Minnesota, United States|Washington University School /ID# 200621, Saint Louis, Missouri, United States|University of Nebraska /ID# 203195, Omaha, Nebraska, United States|The Valley Hospital /ID# 169999, Paramus, New Jersey, United States|Duke University Medical Center /ID# 169657, Durham, North Carolina, United States|Fairview Hospital - Moll Pavilion /ID# 205910, Cleveland, Ohio, United States|Cleveland Clinic Main Campus /ID# 200325, Cleveland, Ohio, United States|Hillcrest Hospital /ID# 205911, Mayfield Heights, Ohio, United States|INTEGRIS Cancer Institute of OK/INTEGRIS Southwest Medical Center /ID# 200831, Oklahoma City, Oklahoma, United States|INTEGRIS Cancer Institute /ID# 200832, Oklahoma City, Oklahoma, United States|Oregon Health and Science University /ID# 170807, Portland, Oregon, United States|Thomas Jefferson University /ID# 200833, Philadelphia, Pennsylvania, United States|UPMC Hillman Cancer Ctr /ID# 200672, Pittsburgh, Pennsylvania, United States|Greenville Hospital System /ID# 203021, Greenville, South Carolina, United States|Tennessee Oncology-Nashville Centennial /ID# 203424, Nashville, Tennessee, United States|Tennessee Oncology, PLLC /ID# 203581, Nashville, Tennessee, United States|Vanderbilt University Med Ctr /ID# 200861, Nashville, Tennessee, United States|Ut Southwestern Medical Center /Parkland Health and Hospital System /Id# 210112, Dallas, Texas, United States|UTSW-Dallas /ID# 204031, Dallas, Texas, United States|Millennium Oncology /ID# 204925, Houston, Texas, United States|Virginia Cancer Specialists /ID# 169293, Fairfax, Virginia, United States|Kadlec Clinic Hematology and O /ID# 170811, Kennewick, Washington, United States|Medical Oncology Associates /ID# 169290, Spokane, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 200424, Madison, Wisconsin, United States|Marshfield Clinic - Marshfield /ID# 202084, Marshfield, Wisconsin, United States|UZ Gent /ID# 200691, Gent, Oost-Vlaanderen, Belgium|Imelda Ziekenhuis /ID# 200693, Bonheiden, Belgium|Cliniques universitaires Saint /ID# 203101, Brussels, Belgium|UZ Antwerp /ID# 200694, Edegem, Belgium|UZ Leuven /ID# 200001, Leuven, Belgium|Hospital Maisonneuve-Rosemont /ID# 171590, Montreal, Quebec, Canada|Jewish General Hospital /ID# 171584, Montreal, Quebec, Canada|National Cancer Center /ID# 170879, Goyang, Gyeonggido, Korea, Republic of|Samsung Medical Center /ID# 170875, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 170878, Seoul, Korea, Republic of|Asan Medical Center /ID# 170877, Seoul, Korea, Republic of|Hospital Univ Vall d'Hebron /ID# 200186, Barcelona, Spain|Hospital General Universitario Gregorio Maranon /ID# 200189, Madrid, Spain|Hospital Clin Univ San Carlos /ID# 201721, Madrid, Spain|Hospital Fundacion Jimenez Dia /ID# 200187, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 200190, Madrid, Spain|National Taiwan Univ Hosp /ID# 170677, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 170123, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 170675, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03368859"
99,"NCT03362879","COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel","COSMOS","Completed","Has Results","Parkinson's Disease (PD)",,"Percentage of Participants on Levodopa-Carbidopa Intestinal Gel (LCIG) Monotherapy From LCIG Initiation to 12 Months|Percentage of Participants Starting Add-On PD Medication Within 12 Months of LCIG Monotherapy Initiation|Total Daily Dose (in Milliliters) of LCIG Infusion at 12 Months After LCIG Initiation|Healthcare Resource Utilization (HCRU): Primary Occupation by Number of Participants|HCRU: Caregiver Support by Number of Participants|Percentage of Physicians With Overall Preference for LCIG Monotherapy|Predictors for Monotherapy (Participant Data): Forward Selection for Monotherapy 1 (12 Months After LCIG Initiation)|Predictors for Monotherapy (Physician Data): Forward Selection for Monotherapy 1 (12 Months After LCIG Initiation)|Duration (Days) of LCIG Monotherapy 1 or Monotherapy 2|Time (Days) From Initial LCIG Administration to Substantial Dose Adjustments by Country|Time (Days) From Initial LCIG Administration to Substantial Dose Adjustment|Days From Initial LCIG Administration to the Initiation of LCIG Monotherapy|Tapering Duration (Days) From Initial LCIG Administration of Each PD Medication","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"412","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","P16-831","December 14, 2017","December 17, 2018","December 17, 2018","December 5, 2017","January 6, 2020","January 6, 2020","Gailtal Klinik /ID# 202505, Hermagor-Pressegger See, Kaernten, Austria|Medizinische Universität Graz /ID# 202559, Graz, Steiermark, Austria|University of Calgary /ID# 206550, Calgary, Alberta, Canada|Ottawa Hospital /ID# 169448, Ottawa, Ontario, Canada|Toronto Western Hospital /ID# 169038, Toronto, Ontario, Canada|Clinique Neuro Levis /ID# 206549, Lévis, Quebec, Canada|Clinical Hosp Center Zagreb /ID# 203553, Zagreb, Croatia|Fakultni nemocnice u sv. Anny v Brne /ID# 209774, Brno 2, Brno-mesto, Czechia|Fakultni Nemocnice Olomouc /ID# 209776, Olomouc, Olomoucky Kraj, Czechia|Vseobecna Fakultni Nemocnice /ID# 209775, Prague, Czechia|Aiginiteio University Hospital /ID# 203476, Athens, Attiki, Greece|HYGEIA Hospital /ID# 203474, Athens, Greece|Mediterraneo Hospital /ID# 203472, Glyfada, Greece|University Hospital of Ioannin /ID# 203471, Ioannina, Greece|Pecsi Tudomanyegyetem /ID# 170026, Pécs, Pecs, Hungary|Semmelweis Egyetem /ID# 170025, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei /ID# 170027, Miskolc, Hungary|Szegedi Tudomanyegyetem /ID# 170028, Szeged, Hungary|Bon Secours Hospital /ID# 168424, Cork, Ireland|University Hospital Galway /ID# 170754, Galway, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 167542, Tel Aviv-Yafo, Tel-Aviv, Israel|Sheba Medical Center /ID# 167543, Ramat Gan, Israel|Clinic Fundeni Institute /ID# 169265, Bucharest, Bucuresti, Romania|Colentina Clinical Hospital /ID# 169263, Bucharest, Romania|Emergency Clinical County Hosp /ID# 169269, Targu Mures, Romania|Timisoara County /ID# 169266, Timisoara, Romania|Timisoara County /ID# 169268, Timisoara, Romania|AbbVie Farmaceutica SLU /ID# 164364, Madrid, Spain|Centrum for neurologi /ID# 171391, Stockholm, Sweden|Neurologmottagningen /ID# 171390, Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03362879/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/79/NCT03362879/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03362879"
100,"NCT03360006","A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer",,"Recruiting","No Results Available","Prostate Cancer|Acute Myeloid Leukemia (AML)","Drug: ABBV-744","Dose-limiting toxicity (DLT) of ABBV-744|Time of ABBV-744|Cmax of ABBV-744|Recommended Phase 2 Dose (RPTD) for ABBV-744|AUCt of ABBV-744|Maximum Tolerated Dose (MTD) for ABBV-744|Duration of Response (DOR) for CRPC|Objective Response Rate (ORR) for CRPC|ORR for AML|Time to Prostate-specific Antigen (PSA) Progression for CRPC|Progression-free survival (PFS) for Acute Myeloid Leukemia (AML)|DOR for AML|Overall PSA Response Rate for CRPC|Radiographic Progression Free Survival (rPFS) for CRPC|Time to Disease Progression (TTP) for CRPC","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-415","March 16, 2018","September 27, 2019","March 31, 2022","December 2, 2017",,"May 15, 2019","UC Irvine /ID# 160789, Orange, California, United States|UC Davis Comp Cancer Ctr /ID# 202729, Sacramento, California, United States|Northwestern /ID# 171098, Chicago, Illinois, United States|University of Chicago /ID# 160702, Chicago, Illinois, United States|Cleveland Clinic Main Campus /ID# 160756, Cleveland, Ohio, United States|Univ TX, MD Anderson /ID# 160701, Houston, Texas, United States|Swedish-Center for Blood Disor /ID# 166487, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03360006"
101,"NCT03345849","A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies",,"Recruiting","No Results Available","Crohn's Disease","Drug: Upadacitinib|Drug: Placebo for Upadacitinib","Proportion of participants with endoscopic response|Proportion of participants with clinical remission|Change from Baseline in Crohn's Symptoms Severity Questionnaire (CSS)|Proportion of participants with enhanced clinical response|Proportion of participants who discontinue corticosteroid use and achieve clinical remission|Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)|Proportion of participants with endoscopic remission|Proportion of participants with >= 50% reduction in draining fistulas|Proportion of participants with clinical remission per Crohn's Disease Activity Index (CDAI) remission in participants with a Baseline CDAI of 220 to 450|Proportion of participants with hospitalizations due to CD|Proportion of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom domain","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","501","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-433|2017-001240-35","December 7, 2017","September 8, 2021","September 8, 2021","November 17, 2017",,"December 23, 2019","Alabama Medical Group, PC /ID# 171176, Mobile, Alabama, United States|CB Flock Research Corporation /ID# 166185, Mobile, Alabama, United States|Delsol Research Management, Ll /Id# 170145, Chandler, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 164803, Phoenix, Arizona, United States|HonorHealth Research Institute - Shea /ID# 164821, Scottsdale, Arizona, United States|Southern California Res. Ctr. /ID# 169655, Coronado, California, United States|Citrus Valley Gastroenterology /ID# 166173, Covina, California, United States|United Gastroenterologists /ID# 207449, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 164762, Los Angeles, California, United States|Facey Medical Foundation /ID# 203136, Mission Hills, California, United States|United Gastroenterologists - Murrieta /ID# 164945, Murrieta, California, United States|Ucsd /Id# 164910, San Diego, California, United States|Medical Assoc Research Grp /ID# 169706, San Diego, California, United States|Univ of California San Francis /ID# 164944, San Francisco, California, United States|Care Access Research /ID# 167767, San Pablo, California, United States|Peak Gastroenterology Associat /ID# 170143, Colorado Springs, Colorado, United States|Delta Waves, Inc. /ID# 164776, Colorado Springs, Colorado, United States|Western States Clinical Res /ID# 164760, Wheat Ridge, Colorado, United States|Medical Research Ctr CT /ID# 164926, Hamden, Connecticut, United States|Clinical Res of West FL, Inc. /ID# 205827, Clearwater, Florida, United States|Clinical Res of West FL, Inc. /ID# 208118, Clearwater, Florida, United States|Borland-Groover Clinic /ID# 203499, Jacksonville, Florida, United States|Ctr for Advanced Gastroenterol /ID# 165353, Maitland, Florida, United States|Crystal Pharmacology Research /ID# 166081, Miami, Florida, United States|Coral Research Clinic /ID# 164890, Miami, Florida, United States|Advanced Research Institute /ID# 164921, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 206136, Orlando, Florida, United States|Omega Research Consultants /ID# 203481, Orlando, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 203485, Tampa, Florida, United States|Florida Hospital Tampa /ID# 171167, Tampa, Florida, United States|Gastro Assoc of Central GA /ID# 165478, Macon, Georgia, United States|Atlanta Gastroenterology Spec /ID# 164799, Suwanee, Georgia, United States|Treasure Valley Medical Research /ID# 215032, Boise, Idaho, United States|Northwestern University Feinberg School of Medicine /ID# 165345, Chicago, Illinois, United States|Rush University Medical Center /ID# 165497, Chicago, Illinois, United States|University of Chicago /ID# 165503, Chicago, Illinois, United States|DuPage Medical Group /ID# 205328, Downers Grove, Illinois, United States|MediSphere Medical Research Center /ID# 166175, Evansville, Indiana, United States|Indianapolis Gastroenterology /ID# 164938, Indianapolis, Indiana, United States|Aquiant Research /ID# 205503, New Albany, Indiana, United States|University of Iowa Hospitals and Clinics /ID# 165436, Iowa City, Iowa, United States|Tri-State Gastroenterology /ID# 165496, Crestview Hills, Kentucky, United States|University of Louisville /ID# 165366, Louisville, Kentucky, United States|University of Louisville /ID# 168572, Louisville, Kentucky, United States|CroNOLA, LLC /ID# 164823, Houma, Louisiana, United States|Nola Research Works, LLC /ID# 164759, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 164894, Shreveport, Louisiana, United States|Johns Hopkins University School of Medicine /ID# 211941, Baltimore, Maryland, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 164935, Chevy Chase, Maryland, United States|Gastro Center of Maryland /ID# 171161, Columbia, Maryland, United States|Lahey Hospital and Medical Center /ID# 214726, Burlington, Massachusetts, United States|University of Michigan Hospitals /ID# 164943, Ann Arbor, Michigan, United States|Clin Res Inst of Michigan, LLC /ID# 170133, Chesterfield, Michigan, United States|Digestive Health Associates (DHA) - Farmington Hills /ID# 205793, Farmington Hills, Michigan, United States|Center for Digestive Health /ID# 164822, Troy, Michigan, United States|Minneapolis VA Medical Center /ID# 204624, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester /ID# 164783, Rochester, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 165343, Jackson, Mississippi, United States|Quality Clinical Research, Inc /ID# 170137, Omaha, Nebraska, United States|CHI Nebraska d/b/a CHI Health /ID# 168578, Omaha, Nebraska, United States|Comprehensive Digestive Instit /ID# 168588, Las Vegas, Nevada, United States|AGA Clinical Research Associates, LLC /ID# 164769, Egg Harbor Township, New Jersey, United States|Rutgers, The State University /ID# 166073, New Brunswick, New Jersey, United States|Montefiore Medical Center /ID# 166193, Bronx, New York, United States|Advantage Clinical Trials /ID# 168546, Bronx, New York, United States|NY Scientific /ID# 164931, Brooklyn, New York, United States|NYU Langone Long Island CRA /ID# 164927, Great Neck, New York, United States|Weill Cornell Medicine/NYP /ID# 165504, New York, New York, United States|Icahn School of Med Mt. Sinai /ID# 170257, New York, New York, United States|Weill Cornell Medicine /ID# 164782, New York, New York, United States|Gastro Group of Rochester /ID# 166177, Rochester, New York, United States|Richmond University Medical Center /ID# 201857, Staten Island, New York, United States|Carolinas Medical Center /ID# 164932, Charlotte, North Carolina, United States|PMG Research of Charlotte /ID# 171160, Charlotte, North Carolina, United States|Wake Research Associates, LLC /ID# 164904, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 164908, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 170140, Fargo, North Dakota, United States|Consultants for Clinical Res /ID# 164791, Cincinnati, Ohio, United States|University of Cincinnati /ID# 164825, Cincinnati, Ohio, United States|Cleveland Clinic Main Campus /ID# 209231, Cleveland, Ohio, United States|Ohio State University/ Gastroe /ID# 170141, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 205624, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 201291, Dayton, Ohio, United States|Dayton Gastroenterology, Inc. /ID# 167627, Englewood, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 202010, Mentor, Ohio, United States|Digestive Disease Specialists /ID# 201064, Oklahoma City, Oklahoma, United States|Options Health Research, LLC /ID# 164820, Tulsa, Oklahoma, United States|Healthcare Research Consultant /ID# 166195, Tulsa, Oklahoma, United States|University of Pennsylvania /ID# 168430, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 168028, Philadelphia, Pennsylvania, United States|Pharmacorp Clinical Trials /ID# 164916, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 164771, Greenville, South Carolina, United States|Rapid City Medical Center /ID# 201735, Rapid City, South Dakota, United States|Gastro One /ID# 164826, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 203613, Johnson City, Tennessee, United States|Quality Medical Research, PLLC /ID# 205263, Nashville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 164946, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 164896, Arlington, Texas, United States|Inquest Clinical Research /ID# 164785, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209801, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209953, Cedar Park, Texas, United States|Baylor Scott & White Research /ID# 170144, Dallas, Texas, United States|DHAT Research Institute /ID# 164800, Garland, Texas, United States|CliniCore International, LLC /ID# 164902, Houston, Texas, United States|Baylor College of Medicine /ID# 164947, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201214, Houston, Texas, United States|GI Specialists of Houston /ID# 202339, Houston, Texas, United States|Caprock Gastro Research /ID# 215438, Lubbock, Texas, United States|Clinical Associates in Researc /ID# 164786, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 169755, San Antonio, Texas, United States|Carl R. Meisner Medical Clinic /ID# 201061, Sugar Land, Texas, United States|Tyler Research Institute, LLC /ID# 168687, Tyler, Texas, United States|Victoria gastroenterology /ID# 167812, Victoria, Texas, United States|HP Clinical Research /ID# 164933, Bountiful, Utah, United States|Advanced Research Institute /ID# 164784, Ogden, Utah, United States|Care Access Research /ID# 164794, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 166076, West Jordan, Utah, United States|Washington Gastroenterology /ID# 164824, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 164913, Seattle, Washington, United States|University of Washington /ID# 164774, Seattle, Washington, United States|The Vancouver Clinic, INC. PS /ID# 164918, Vancouver, Washington, United States|Allegiance Research Specialist /ID# 165346, Wauwatosa, Wisconsin, United States|Hospital Italiano de Buenos Aires /ID# 215541, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Cardio Alem /ID# 211285, San Isidro, Buenos Aires, Argentina|Hopital Centenario /ID# 171252, Rosario, Santa Fe, Argentina|Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quimo"" - CEMIC /ID# 169182, Buenos Aires, Argentina|Gedyt /ID# 210020, Ciudad Autonoma Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 169230, Cordoba, Argentina|Concord Repatriation & Gen Hos /ID# 171512, Concord, New South Wales, Australia|Coral Sea Clinical Research /ID# 212988, North Mackay, Queensland, Australia|Mater Misericordiae /ID# 204909, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 171514, Adelaide, South Australia, Australia|Box Hill Hospital /ID# 203736, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 171513, Murdoch, Western Australia, Australia|Medical University of Vienna /ID# 169465, Vienna, Wien, Austria|LKH Salzburg and Paracelsus /ID# 214470, Salzburg, Austria|Cliniques Universitaires Saint Luc /ID# 200303, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|AZ Sint-Lucas /ID# 200302, Ghent, Belgium|CHU de Liege Sart Tilman /ID# 217534, Liege, Belgium|University Clinical Centre of the Republic of Srpska /ID# 208051, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Center Tuzla /ID# 210325, Tuzla, Tuzlanski, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 203887, Sarajevo, Bosnia and Herzegovina|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 166852, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 166863, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 166862, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 166867, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 166866, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 208323, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 166865, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hospital Universitario Clement /ID# 210648, Rio de Janeiro, Brazil|UMHAT Kaspela EOOD /ID# 167613, Plovdiv, Bulgaria|II MHAT - Sofia /ID# 167614, Sofia, Bulgaria|MHAT Trakia /ID# 201679, Stara Zagora, Bulgaria|University Multiprofile Hospit /ID# 167559, Varna, Bulgaria|University of Calgary /ID# 166974, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 168044, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 166971, Edmonton, Alberta, Canada|Covenant Health /ID# 166978, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 166968, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 166975, Vancouver, British Columbia, Canada|QEII - Victoria Building /ID# 169307, Halifax, Nova Scotia, Canada|Scott Schulman medicine profes /ID# 169066, North Bay, Ontario, Canada|Taunton surgical centre /ID# 168043, Oshawa, Ontario, Canada|The Ottawa Hospital /ID# 212414, Ottawa, Ontario, Canada|Medicor Research Inc. /ID# 166979, Sudbury, Ontario, Canada|Toronto Digestive Disease Asso /ID# 166972, Vaughan, Ontario, Canada|Hopital Hotel-Dieu de Levis /ID# 166969, Levis, Quebec, Canada|Crchum /Id# 170120, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre /ID# 170119, Montréal, Quebec, Canada|CRCHUS Hotel-Dieu /ID# 170940, Sherbrooke, Quebec, Canada|Research Group Ltda /ID# 203179, Santiago, Region Metropolitana De Santiago, Chile|M y F Estudios Clínicos Ltda. /ID# 169984, Ñuñoa, Region Metropolitana De Santiago, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 212423, Concepción, Chile|CTR Estudios SpA /ID# 203941, Providencia, Chile|Hospital Clinico Universidad De Los Andes /ID# 207466, Santiago, Chile|Hospital Clinico San Borja Arr /ID# 169983, Santiago, Chile|The First Affiliated Hosp, Sun /ID# 205228, Guangzhou, Anhui, China|Zhongshan Hospital Xiamen Univ /ID# 204984, Xiamen, Anhui, China|Nanfang Hospital of Southern Medical University /ID# 204083, Guangzhou, Guangdong, China|The Sixth Affiliated Hosp, Sun /ID# 204077, Guangzhou, Guangdong, China|1st Aff Hosp Nanchang Univ /ID# 204092, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 206868, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 204091, Shanghai, Shanghai, China|Renji Hosp, Shanghai Jiaotong /ID# 204087, Shanghai, Shanghai, China|The Second Affiliated Hospital /ID# 204073, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 204076, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 204173, Beijing, China|The Second Xiangya Hospital of Central South University /ID# 204082, Changsha, China|Nanjing Drum Tower Hospital /ID# 204900, Nanjing, Jiangsu, China|Tianjin Med Univ General Hosp /ID# 206994, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 204081, Wuhan, China|Tongji Hosp Tongji Med College /ID# 204088, Wuhan, China|Instituto de Coloproctologia /ID# 169199, Medellin, Colombia|Hospital Universitario San Vic /ID# 200029, Medellin, Colombia|Hospital Pablo Tobon Uribe /ID# 202404, Medellín, Colombia|Poliklinika Solmed /ID# 211519, Zagreb, Grad Zagreb, Croatia|UHC Split /ID# 171191, Split, Croatia|Zadar General Hospital /ID# 205536, Zadar, Croatia|CH Dubrava /ID# 171185, Zagreb, Croatia|UHC Sestre Milosrdnice /ID# 205535, Zagreb, Croatia|UHC Zagreb /ID# 171203, Zagreb, Croatia|Nemocnice Horovice, NH Hospita /ID# 209870, Horovice, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 171401, Hradec Kralove, Czechia|Artroscan s.r.o. /ID# 200790, Ostrava, Czechia|Restrial /ID# 208653, Prague 412, Czechia|Nordsjallands Hospital /ID# 202424, Frederikssund, Hovedstaden, Denmark|Herlev Hospital /ID# 202423, Herlev, Hovedstaden, Denmark|Sjaellands Universitets Hospit /ID# 209445, Roskilde, Sjælland, Denmark|Hvidovre Hospital /ID# 202425, Hvidovre, Denmark|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 171012, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 171013, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 209564, Alexandria, Egypt|Nat Hep & Trop Med Res Inst /ID# 170989, Cairo, Egypt|Air Force Specialized Hospital /ID# 170996, Cairo, Egypt|National Liver Institute /ID# 170988, Menoufiya, Egypt|West Tallinn Central Hospital /ID# 202785, Tallinn, Estonia|Universitatsklinikum Mannheim /ID# 168759, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 203552, Erlangen, Bayern, Germany|Universitaetsmedizin St. Josef Krankenhaus Werden /ID# 203570, Essen, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 206741, Saarbrücken, Saarland, Germany|Univ Hosp Schleswig-Holstein /ID# 168757, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 203560, Ulm, Thueringen, Germany|Gastroenterologie am Mexikoplatz /ID# 203575, Berlin, Germany|Agaplesion Markus Krankenhaus, /ID# 168758, Frankfurt, Germany|Universitaetsklinikum Frankfurt /ID# 203566, Frankfurt, Germany|Universitaetsklinikum Halle (S /ID# 207455, Halle, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 200214, Munster, Germany|Tzaneio general hospital of Piraeus /ID# 206433, Piraeus, Attiki, Greece|General Hospital of Athens ""Ippokratio"" /ID# 167045, Athens, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 202104, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 167044, Heraklion, Greece|Genl Hosp Thessaloniki Hipp /ID# 208825, Thessaloniki, Greece|Tuen Mun Hospital /ID# 171218, Tuen Mun, Hong Kong|Mohacsi Korhaz /ID# 209441, Mohács, Baranya, Hungary|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 205547, Miskolc, Borsod-Abauj-Zemplen, Hungary|Bugat Pal Korhaz /ID# 201893, Gyöngyös, Heves, Hungary|Obudai Egeszsegugyi Centrum Kft. /ID# 201892, Budapest, Hungary|MH Honvedkorhaz /ID# 201724, Budapest, Hungary|Semmelweis Egyetem /ID# 210167, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 201723, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 206154, Kistarcsa, Hungary|Mentahaz Maganorvosi Kozpont /ID# 201895, Szekesfehervar, Hungary|Szent Borbala Korhaz /ID# 209897, Tatabánya, Hungary|Mercy University Hospital /ID# 206511, Cork, Ireland|Soroka Medical Center /ID# 169913, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 202636, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 204877, Tel Aviv-Yafo, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 169928, Jerusalem, Yerushalayim, Israel|Assaf Harofeh Medical Center /ID# 204872, Be'er Ya'akov, Israel|Kaplan Medical Center /ID# 170276, Rehovot, Israel|AOU Policlinico S. Orsola Malpighi /ID# 168187, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 201897, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 168183, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 168184, Rome, Lazio, Italy|Istituto Clinico Humanitas /ID# 168185, Rozzano, Milano, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 168182, Rome, Roma, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 168190, Catania, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 168186, Negrar, Verona, Italy|Policlinico San Martino/Univer /ID# 168191, Genova, Italy|ASST Fatebenefratelli Sacco- O /ID# 168181, Milano, Italy|Azienda Ospedaliera Ospedale N /ID# 170849, Milano, Italy|Ospedali Riuniti Villa Sofia-C /ID# 168189, Palermo, Italy|AOU Pisana /ID# 202421, Pisa, Italy|Policlinico Tor Vergata /ID# 168188, Rome, Italy|Aichi Medical University Hosp /ID# 165971, Nagakute, Aichi, Japan|Nagoya University Hospital /ID# 165969, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 165970, Nagoya-shi, Aichi, Japan|Hirosaki National Hospital /ID# 165961, Hirosaki-shi, Aomori, Japan|Toho University Sakura Medical Center /ID# 165963, Sakura-shi, Chiba, Japan|Fukuoka University Chikushi Hospital /ID# 214404, Chikushino, Fukuoka, Japan|Kurume University Hospital /ID# 166012, Kurume-shi, Fukuoka, Japan|National Hospital Organization Takasaki General Medical Center /ID# 167127, Takasaki-shi, Gunma, Japan|NHO Fukuyama Medical Center /ID# 167131, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 167120, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 165960, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 167124, Sapporo-shi, Hokkaido, Japan|Aoyama Clinic /ID# 166009, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 165973, Nishinomiya-shi, Hyogo, Japan|Kanazawa University Ho /ID# 169218, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital /ID# 202464, Morioka-shi, Iwate, Japan|Yokohama City Univ Medical Ctr /ID# 167128, Yokohama, Kanagawa, Japan|JP Red Cross Kyoto Daiichi Hos /ID# 165972, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 167122, Sendai-shi, Miyagi, Japan|Niigata University Medical & Dental Hospital /ID# 170045, Niigata-shi, Niigata, Japan|Ishida Clinic of IBD and Gastroenterology /ID# 167121, Oita-shi, Oita, Japan|Osaka City University Hospital /ID# 166015, Osaka-shi, Osaka, Japan|Shiga University of Medical Science Hospital /ID# 167129, Otsu, Shiga, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 165965, Bunkyo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 165967, Hachioji, Tokyo, Japan|Kyorin University Hospital /ID# 165966, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 205980, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 200157, Yamagata-shi, Yamagata, Japan|Hiroshima University Hospital /ID# 166014, Hiroshima, Japan|Sameshima Hospital /ID# 206675, Kagoshima, Japan|Nara Medical Univ Hospital /ID# 169219, Kashihara, Japan|Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 166010, Kurashiki, Japan|The Jikei University Hospital /ID# 167130, Minato-ku, Japan|Kyoto University Hospital /ID# 169889, Sakyo-ku, Japan|NHO Shizuoka Medical Center /ID# 167125, Shimizu-sho, Japan|Toyohashi Municipal Hospital /ID# 200175, Toyohashi, Japan|Wakayama Medical University /ID# 169482, Wakayama, Japan|JP Red Cross Wakayama Med Ctr /ID# 200643, Wakayama, Japan|Kenseikai Dongo Hospital /ID# 208104, Yamatotakada, Japan|Yokkaichi Hazu Medical Center /ID# 167196, Yokkaichi-shi, Japan|Dong-A University Hospital /ID# 167591, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 167589, Busan, Busan Gwang Yeogsi, Korea, Republic of|Kyungpook National Univ Hosp /ID# 207019, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 167592, Seongnam-si, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 167586, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 167590, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 167588, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Haeundae Paik Hospital /ID# 202630, Busan, Korea, Republic of|Hanyang University Guri Hosp /ID# 167587, Guri-si, Korea, Republic of|Chung-Ang University Hostipal /ID# 207018, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 169498, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 169519, Riga, Latvia|Digestive Diseases Ctr Gastro /ID# 169508, Riga, Latvia|Duplicate_LUHS hospital Kauno Klinikos /ID# 206936, Kovno, Lithuania|Vilnius University Hospital /ID# 203286, Vilnius, Lithuania|Hospital Sultanah Bahiyah /ID# 202626, Alor Setar, Kedah, Malaysia|UKM Medical Centre /ID# 170773, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia /ID# 200102, Kelantan, Malaysia|Instituto de Investigaciones Aplicadas a la Neurociencias A.C. /ID# 207579, Victoria de Durango, Durango, Mexico|Morales Vargas Centro de Investigacion S.C. /ID# 203494, Leon, Guanajuato, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 207238, Guadalajara, Jalisco, Mexico|Radboud Universitair Medisch Centrum /ID# 166928, Nijmegen, Gelderland, Netherlands|Academisch Medisch Centrum /ID# 166927, Amsterdam, Noord-Holland, Netherlands|Onze Lieve Vrouwe Gasthuis /ID# 166929, Amsterdam, Netherlands|Medisch Spectrum Twente /ID# 170298, Enschede, Netherlands|Atrium-Orbis Zuyderland Medisch Centrum /ID# 169700, Heerlen, Netherlands|Vistamed /ID# 208572, Wrocław, Dolnoslaskie, Poland|Malopolskie Centrum Kliniczne /ID# 202167, Cracow, Malopolskie, Poland|Centrum Zdrowia MDM /ID# 200491, Warsaw, Mazowieckie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 200490, Warszawa, Mazowieckie, Poland|Hospital Egas Moniz /ID# 170253, Lisbon, Porto, Portugal|HGO - Hospital Garcia de Orta /ID# 170241, Almada, Portugal|Centro Hospitalar e Universitário de Coimbra, EPE /ID# 170251, Coimbra, Portugal|HSOG - Hospital Senhora da Oli /ID# 170245, Guimaraes, Portugal|Centro Hospitalar de Sao Joao /ID# 170248, Porto, Portugal|Unidade Local De Saude Do Alto Minho /ID# 200607, Viana Do Castelo, Portugal|Mindful Medical Research /ID# 203358, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 166771, San Juan, Puerto Rico|Institutul Clinic Fundeni /ID# 167817, Sector 2, Bucuresti, Romania|Clinica GASTRO MED SRL /ID# 206369, Cluj-Napoca, Cluj, Romania|Cabinet Particular Policlinic Algomed /ID# 167818, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 167820, Timisoara, Romania|Immanuel Kant Baltic Federal University /ID# 203811, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|Perm Clinical Center of FMBA /ID# 202990, Perm, Permskiy Kray, Russian Federation|LLC Novaya Klinika /ID# 206616, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Private institution Center of educational and clinical gastroenterology, hepatol /ID# 202997, Stavropol, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 169638, Kazan, Tatarstan, Respublika, Russian Federation|Llc Olla-Med /Id# 208720, Moscow, Russian Federation|P.A. Bayandin Murmansk Regiona /ID# 169639, Murmansk, Russian Federation|LLC Medical center Zdorovaya s /ID# 209236, Novosibirsk, Russian Federation|Republican Clin Hos n.a. Baran /ID# 206488, Petrozavodsk, Russian Federation|PMI Euromedservice /ID# 206610, Pushkin, Russian Federation|Clinical Center Serbia /ID# 168215, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 168214, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 168783, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 168750, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 205859, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 168213, Novi Sad, Vojvodina, Serbia|Gleneagles Medical Centre /ID# 206531, Singapore, Singapore|Tan Tock Seng Hospital /ID# 203160, Singapore, Singapore|FNsP F.D.Roosevelta Banska Bys /ID# 169958, Banska Bystrica, Banskobystricky Kraj, Slovakia|KM Management s.r.o. /ID# 170201, Nitra, Slovakia|Farmovs (Pty) Ltd /Id# 207535, Bloemfontein, Free State, South Africa|Lenasia Clinical Trial Centre /ID# 205145, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 170852, Johannesburg, Gauteng, South Africa|Allergy & Immunology (AIU) /ID# 171431, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 169853, Cape Town, Western Cape, South Africa|Dr JP Wright /ID# 170887, Cape Town, South Africa|Hospital Universitario y Politecnico La Fe /ID# 201992, Valencia, Valenciana, Spain|Comple Hosp Univ de A Coruna /ID# 203910, A Coruna, Spain|Hospital Clinic de Barcelona /ID# 201990, Barcelona, Spain|Hosp Univ Girona Josep Trueta /ID# 202645, Girona, Spain|Hospital Juan Ramon Jimenez /ID# 201995, Huelva, Spain|Hospital Universitario La Paz /ID# 201994, Madrid, Spain|Hospital Univ. Son Espases /ID# 201998, Palma de Mallorca, Spain|Complejo Hospitalario de Navar /ID# 202355, Pamplona, Spain|Hospital Clinico Universitario de Salamanca /ID# 206358, Salamanca, Spain|Hospital Universitario Virgen Macarena /ID# 201993, Sevilla, Spain|Hosp Clin Univ de Valencia /ID# 209657, Valencia, Spain|Alingsås lasarett /ID# 170826, Alingsås, Vastra Gotalands Lan, Sweden|Södra Älvsborgs sjukhus /ID# 203077, Borås, Vastra Gotalands Lan, Sweden|Sahlgrenska US Gbg /ID# 169171, Göteborg, Vastra Gotalands Lan, Sweden|Hallands sjukhus Halmstad /ID# 170828, Halmstad, Sweden|Inselspital, Universitaetsklinik /ID# 170997, Bern, Switzerland|Universitatsspital Zurich /ID# 170998, Zurich, Switzerland|China Medical University Hosp /ID# 169791, Taichung City, Taichung, Taiwan|Taichung Veterans General Hosp /ID# 169790, Taichung City, Taiwan|National Taiwan University Hos /ID# 169792, Taipei, Taiwan|Acibadem Kozyatagi Hospital /ID# 209406, Kadikoy, Istanbul, Turkey|Erciyes University Medical Fac /ID# 171331, Melikgazi, Kayseri, Turkey|Gazi Universitesi Tip Fakultes /ID# 217444, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 206409, Ankara, Turkey|Inonu Universitesi Turgut Ozal /ID# 201268, Battalgazi/malatya, Turkey|Mustafa Kemal University Medic /ID# 171336, Hatay, Turkey|Istanbul University Istanbul Medical Faculty /ID# 171364, Istanbul, Turkey|Marmara University Medical Fac /ID# 171332, Istanbul, Turkey|Mersin University Medical /ID# 171338, Mersin, Turkey|Sisli Etfal Train & Res Hosp /ID# 171334, Sisli, Turkey|Medical Centre of ""Ukrainian German Antiulcer Gastroenterology Centre BYK-KYIV"" /ID# 203738, Kyiv, Kyivska Oblast, Ukraine|Kyiv Municipal Clinical Hospital #18 /ID# 207889, Kiev, Kyiv, Ukraine|MI of Kyiv Regional Rada Kyiv Regional Clinical Hospital /ID# 202454, Kyiv, Ukraine|Lviv Railway Clinical Hospital /ID# 167908, Lviv, Ukraine|Kharkiv City Clinical Hospital /ID# 167907, Харків, Ukraine|South Eastern Health and Social Care Trust /ID# 205323, Belfast, Antrim, United Kingdom|Warrington and Halton Hospitals NHS Foundation Trust /ID# 171383, Warrington, Cheshire West And Chester, United Kingdom|Royal United Hospitals Bath /ID# 169074, Bath, United Kingdom|Queen Elizabeth Hospital - BIRMINGHAM /ID# 169070, Birmingham, United Kingdom|Russells Hall Hospital, Dudley /ID# 169069, Dudley, United Kingdom|King's College Hospital NHS /ID# 169072, London, United Kingdom|St. George's Healthcare NHS /ID# 205552, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 169075, Newcastle Upon Tyne, United Kingdom|St. Helens and Knowsley Teach /ID# 209086, Prescot, United Kingdom|Stockport NHS foundation trust /ID# 208719, Stockport, United Kingdom|Taunton and Somerset NHS Found /ID# 209665, Tauntojn, United Kingdom|New Cross Hospital, Royal Wolv /ID# 171382, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03345849"
102,"NCT03345836","A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy",,"Recruiting","No Results Available","Crohn's Disease","Other: Matching placebo for upadacitinib|Drug: upadacitinib","Proportion of participants with clinical remission|Proportion of participants with endoscopic response|Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)|Proportion of participants with enhanced clinical response|Proportion of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom domain|Proportion of participants with hospitalizations due to CD|Proportion of participants with clinical remission per Crohn's Disease Activity Index (CDAI) remission in participants with a Baseline CDAI of 220 to 450|Proportion of participants with endoscopic remission|Proportion of participants with >= 50% reduction in draining fistulas|Change from Baseline in Crohn's Symptoms Severity Questionnaire (CSS)|Proportion of participants who discontinue corticosteroid use for Crohn's disease (CD) and achieve clinical remission","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","645","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-431|2017-001226-18","November 29, 2017","June 6, 2021","June 6, 2021","November 17, 2017",,"December 30, 2019","Alabama Medical Group, PC /ID# 171133, Mobile, Alabama, United States|CB Flock Research Corporation /ID# 166220, Mobile, Alabama, United States|Delsol Research Management, Ll /Id# 170179, Chandler, Arizona, United States|HonorHealth Research Institute - Shea /ID# 164734, Scottsdale, Arizona, United States|Arizona Arthritis & Rheumatolo /ID# 203891, Sun City, Arizona, United States|Southern California Res. Ctr. /ID# 169654, Coronado, California, United States|Citrus Valley Gastroenterology /ID# 166201, Covina, California, United States|United Gastroenterologists /ID# 207452, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 164887, Los Angeles, California, United States|Facey Medical Foundation /ID# 203137, Mission Hills, California, United States|United Gastroenterologists - Murrieta /ID# 164845, Murrieta, California, United States|Ucsd /Id# 164679, San Diego, California, United States|Medical Assoc Research Grp /ID# 169705, San Diego, California, United States|UCSF Center for Colitis and Crohn's Disease /ID# 202373, San Francisco, California, United States|Univ of California San Francis /ID# 164843, San Francisco, California, United States|Care Access Research /ID# 167766, San Pablo, California, United States|Peak Gastroenterology Associat /ID# 170181, Colorado Springs, Colorado, United States|Delta Waves, Inc. /ID# 164872, Colorado Springs, Colorado, United States|Western States Clinical Research, Inc. /ID# 164895, Wheat Ridge, Colorado, United States|Medical Research Ctr CT /ID# 164829, Hamden, Connecticut, United States|Clinical Res of West FL, Inc. /ID# 205825, Clearwater, Florida, United States|Clinical Res of West FL, Inc. /ID# 208117, Clearwater, Florida, United States|Borland-Groover Clinic /ID# 203498, Jacksonville, Florida, United States|Ctr for Advanced Gastroenterol /ID# 165332, Maitland, Florida, United States|Crystal Pharmacology Research /ID# 166101, Miami, Florida, United States|Coral Research Clinic /ID# 164657, Miami, Florida, United States|Advanced Research Institute /ID# 164814, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 205893, Orlando, Florida, United States|Omega Research Consultants /ID# 203480, Orlando, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 203484, Tampa, Florida, United States|Florida Hospital Tampa /ID# 171175, Tampa, Florida, United States|Gastro Assoc of Central GA /ID# 165460, Macon, Georgia, United States|Atlanta Gastroenterology Spec /ID# 164780, Suwanee, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 165320, Chicago, Illinois, United States|Rush University Medical Center /ID# 165485, Chicago, Illinois, United States|University of Chicago /ID# 165472, Chicago, Illinois, United States|DuPage Medical Group /ID# 205303, Downers Grove, Illinois, United States|MediSphere Medical Research Center /ID# 166209, Evansville, Indiana, United States|Indianapolis Gastroenterology /ID# 164837, Indianapolis, Indiana, United States|Aquiant Research /ID# 205504, New Albany, Indiana, United States|University of Iowa Hospitals and Clinics /ID# 165330, Iowa City, Iowa, United States|Tri-State Gastroenterology /ID# 165484, Crestview Hills, Kentucky, United States|University of Louisville /ID# 168536, Louisville, Kentucky, United States|University of Louisville /ID# 208093, Louisville, Kentucky, United States|CroNOLA, LLC /ID# 164722, Houma, Louisiana, United States|Nola Research Works, LLC /ID# 164897, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 164659, Shreveport, Louisiana, United States|Johns Hopkins University School of Medicine /ID# 211940, Baltimore, Maryland, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 164835, Chevy Chase, Maryland, United States|Gastro Center of Maryland /ID# 171171, Columbia, Maryland, United States|Lahey Hospital and Medical Center /ID# 214725, Burlington, Massachusetts, United States|University of Michigan Hospitals /ID# 164844, Ann Arbor, Michigan, United States|Clin Res Inst of Michigan, LLC /ID# 170178, Chesterfield, Michigan, United States|Digestive Health Associates (DHA) - Farmington Hills /ID# 206099, Farmington Hills, Michigan, United States|Center for Digestive Health /ID# 164733, Troy, Michigan, United States|Minneapolis VA Medical Center /ID# 204622, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester /ID# 164868, Rochester, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 165318, Jackson, Mississippi, United States|Quality Clinical Research, Inc /ID# 170177, Omaha, Nebraska, United States|CHI Nebraska d/b/a CHI Health /ID# 168545, Omaha, Nebraska, United States|Comprehensive Digestive Instit /ID# 168562, Las Vegas, Nevada, United States|AGA Clinical Research Associates, LLC /ID# 164883, Egg Harbor Township, New Jersey, United States|Rutgers, The State University /ID# 166092, New Brunswick, New Jersey, United States|Montefiore Medical Center /ID# 166226, Bronx, New York, United States|Advantage Clinical Trials /ID# 168557, Bronx, New York, United States|NY Scientific /ID# 164833, Brooklyn, New York, United States|NYU Langone Long Island CRA /ID# 164830, Great Neck, New York, United States|Weill Cornell Medicine/NYP /ID# 165480, New York, New York, United States|Icahn School of Med Mt. Sinai /ID# 170172, New York, New York, United States|Weill Cornell Medicine /ID# 164870, New York, New York, United States|Gastro Group of Rochester /ID# 166216, Rochester, New York, United States|Richmond University Medical Center /ID# 201855, Staten Island, New York, United States|Carolinas Medical Center /ID# 164834, Charlotte, North Carolina, United States|PMG Research of Charlotte /ID# 171170, Charlotte, North Carolina, United States|Wake Research Associates, LLC /ID# 164663, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 201225, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 170184, Fargo, North Dakota, United States|Consultants for Clinical Res /ID# 164855, Cincinnati, Ohio, United States|University of Cincinnati /ID# 164720, Cincinnati, Ohio, United States|Cleveland Clinic Main Campus /ID# 208220, Cleveland, Ohio, United States|Ohio State University/ Gastroe /ID# 170174, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 205618, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 201290, Dayton, Ohio, United States|Dayton Gastroenterology, Inc. /ID# 167624, Englewood, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 202007, Mentor, Ohio, United States|Digestive Disease Specialists /ID# 201062, Oklahoma City, Oklahoma, United States|Options Health Research, LLC /ID# 164737, Tulsa, Oklahoma, United States|Healthcare Research Consultant /ID# 166228, Tulsa, Oklahoma, United States|University of Pennsylvania /ID# 168402, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 168014, Philadelphia, Pennsylvania, United States|Pharmacorp Clinical Trials /ID# 164809, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 164880, Greenville, South Carolina, United States|Rapid City Medical Center /ID# 201734, Rapid City, South Dakota, United States|Gastro One /ID# 164718, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 203612, Johnson City, Tennessee, United States|Quality Medical Research, PLLC /ID# 205262, Nashville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 164846, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 164848, Arlington, Texas, United States|Inquest Clinical Research /ID# 164865, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209802, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209952, Cedar Park, Texas, United States|DHAT Research Institute /ID# 164777, Garland, Texas, United States|CliniCore International, LLC /ID# 164662, Houston, Texas, United States|Baylor College of Medicine /ID# 164847, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201213, Houston, Texas, United States|GI Specialists of Houston /ID# 202338, Houston, Texas, United States|Caprock Gastro Research /ID# 215437, Lubbock, Texas, United States|Clinical Associates in Researc /ID# 164863, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 169754, San Antonio, Texas, United States|Carl R. Meisner Medical Clinic /ID# 201060, Sugar Land, Texas, United States|Tyler Research Institute, LLC /ID# 168681, Tyler, Texas, United States|Victoria gastroenterology /ID# 167813, Victoria, Texas, United States|HP Clinical Research /ID# 164929, Bountiful, Utah, United States|Advanced Research Institute /ID# 164866, Ogden, Utah, United States|Care Access Research /ID# 164853, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 166095, West Jordan, Utah, United States|Washington Gastroenterology /ID# 164721, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 164680, Seattle, Washington, United States|University of Washington /ID# 164875, Seattle, Washington, United States|The Vancouver Clinic, INC. PS /ID# 164811, Vancouver, Washington, United States|Froedtert & the Medical College of Wisconsin /ID# 202286, Milwaukee, Wisconsin, United States|Allegiance Research Specialist /ID# 165321, Wauwatosa, Wisconsin, United States|Hospital Italiano de Buenos Aires /ID# 215543, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Cardio Alem /ID# 211284, San Isidro, Buenos Aires, Argentina|Hopital Centenario /ID# 171254, Rosario, Santa Fe, Argentina|Centro de Educación Médica e Investigaciones Clínicas ""Norberto Quimo"" - CEMIC /ID# 169184, Buenos Aires, Argentina|Gedyt /ID# 210019, Ciudad Autonoma Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 169228, Cordoba, Argentina|Concord Repatriation & Gen Hos /ID# 171509, Concord, New South Wales, Australia|Coral Sea Clinical Research /ID# 212987, North Mackay, Queensland, Australia|Mater Misericordiae /ID# 204908, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 171511, Adelaide, South Australia, Australia|Box Hill Hospital /ID# 203734, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 171510, Murdoch, Western Australia, Australia|Krankenanstalt Rudolfstiftung /ID# 203437, Vienna, Wien, Austria|Medical University of Vienna /ID# 169462, Vienna, Wien, Austria|LKH Salzburg and Paracelsus /ID# 214467, Salzburg, Austria|Cliniques Universitaires Saint Luc /ID# 200297, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|AZ Sint-Lucas /ID# 200301, Ghent, Belgium|UZ Leuven /ID# 200298, Leuven, Belgium|CHU de Liege Sart Tilman /ID# 200299, Liege, Belgium|CHU Dinant Godinne - UCL Namur /ID# 200300, Yvoir, Belgium|University Clinical Centre of the Republic of Srpska /ID# 208050, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Center Tuzla /ID# 210324, Tuzla, Tuzlanski, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 203885, Sarajevo, Bosnia and Herzegovina|Polyclinic and Daily Hospital ""Dr. Al-Tawil"" /ID# 217841, Sarajevo, Bosnia and Herzegovina|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 166870, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 166869, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 166872, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 166876, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 166874, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 208327, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 166873, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hospital Universitario Clement /ID# 210646, Rio de Janeiro, Brazil|UMHAT Kaspela EOOD /ID# 167617, Plovdiv, Bulgaria|II MHAT - Sofia /ID# 167618, Sofia, Bulgaria|MHAT Trakia /ID# 201678, Stara Zagora, Bulgaria|University Multiprofile Hospit /ID# 167570, Varna, Bulgaria|University of Calgary /ID# 166963, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 168041, Edmonton, Alberta, Canada|Covenant Health /ID# 166966, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 166957, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 166964, Vancouver, British Columbia, Canada|QEII - Victoria Building /ID# 169306, Halifax, Nova Scotia, Canada|Scott Schulman medicine profes /ID# 169064, North Bay, Ontario, Canada|Taunton surgical centre /ID# 168039, Oshawa, Ontario, Canada|The Ottawa Hospital /ID# 212413, Ottawa, Ontario, Canada|Medicor Research Inc. /ID# 166967, Sudbury, Ontario, Canada|Toronto Digestive Disease Asso /ID# 166961, Vaughan, Ontario, Canada|Hopital Hotel-Dieu de Levis /ID# 166958, Levis, Quebec, Canada|Crchum /Id# 170121, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre /ID# 170010, Montréal, Quebec, Canada|CRCHUS Hotel-Dieu /ID# 170935, Sherbrooke, Quebec, Canada|Research Group Ltda /ID# 203180, Santiago, Region Metropolitana De Santiago, Chile|M y F Estudios Clínicos Ltda. /ID# 169995, Ñuñoa, Region Metropolitana De Santiago, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 212422, Concepción, Chile|CTR Estudios SpA /ID# 200650, Providencia, Chile|Hospital Clinico Universidad De Los Andes /ID# 207465, Santiago, Chile|Hospital Clinico San Borja Arr /ID# 169994, Santiago, Chile|The First Affiliated Hosp, Sun /ID# 205226, Guangzhou, Anhui, China|Zhongshan Hospital Xiamen Univ /ID# 204985, Xiamen, Anhui, China|Nanfang Hospital of Southern Medical University /ID# 204074, Guangzhou, Guangdong, China|The Sixth Affiliated Hosp, Sun /ID# 204049, Guangzhou, Guangdong, China|1st Aff Hosp Nanchang Univ /ID# 204070, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 206867, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 204072, Shanghai, Shanghai, China|Renji Hosp, Shanghai Jiaotong /ID# 204172, Shanghai, Shanghai, China|The Second Affiliated Hospital /ID# 204078, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 204068, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 204536, Beijing, China|The Second Xiangya Hospital of Central South University /ID# 204075, Changsha, China|Nanjing Drum Tower Hospital /ID# 204869, Nanjing, Jiangsu, China|Tianjin Med Univ General Hosp /ID# 206993, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 204096, Wuhan, China|Tongji Hosp Tongji Med College /ID# 204069, Wuhan, China|Hospital San Vicente de Paul /ID# 200028, Medellin, Antioquia, Colombia|Instituto de Coloproctologia /ID# 168416, Antioquia, Colombia|Hospital Pablo Tobon Uribe /ID# 202405, Medellín, Colombia|Poliklinika Solmed /ID# 211518, Zagreb, Grad Zagreb, Croatia|UHC Split /ID# 171206, Split, Croatia|Zadar General Hospital /ID# 205534, Zadar, Croatia|CH Dubrava /ID# 171186, Zagreb, Croatia|UHC Sestre Milosrdnice /ID# 171190, Zagreb, Croatia|UHC Zagreb /ID# 171201, Zagreb, Croatia|Nemocnice Horovice, NH Hospita /ID# 209869, Horovice, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 171566, Hradec Kralove, Czechia|Artroscan , s.r.o. /ID# 171592, Ostrava, Czechia|Restrial /ID# 208652, Prague 412, Czechia|Nordsjallands Hospital /ID# 200613, Frederikssund, Hovedstaden, Denmark|Herlev Hospital /ID# 200782, Herlev, Hovedstaden, Denmark|Sjaellands Universitets Hospit /ID# 200783, Roskilde, Sjælland, Denmark|Hvidovre Hospital /ID# 200611, Hvidovre, Denmark|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 171010, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 171015, Alexandria, Egypt|Cairo University /ID# 209557, Cairo, Egypt|Nat Hep & Trop Med Res Inst /ID# 170990, Cairo, Egypt|Ain Shams University Hospital /ID# 209565, Cairo, Egypt|Air Force Specialized Hospital /ID# 170995, Cairo, Egypt|Zagazig University Hospital /ID# 209558, EL Sharkya, Egypt|Tartu University Hospital /ID# 203140, Tartu, Estonia|Chu de Nice-Hopital L'Archet Ii /Id# 171009, Nice CEDEX 3, Alpes-Maritimes, France|Hôpital Haut-Lévêque /ID# 207414, Pessac CEDEX, Gironde, France|CHRU Lille - Hôpital Claude Huriez /ID# 206539, Lille CEDEX, Hauts-de-France, France|Hopital Saint Eloi /ID# 170646, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 171011, Clichy, Ile-de-France, France|CHU de SAINT ETIENNE - Hopital Nord /ID# 171018, St. Priest En Jarez, Loire, France|Centre Hospitalier Lyon Sud /ID# 171014, Pierre Benite CEDEX, Rhone, France|Chu Amiens Picardie - Hopital /Id# 171016, Amiens Cedex 01, France|Chru Trousseau /Id# 169786, Chambray-les-tours, France|CHU Henri Mondor /ID# 169787, Creteil, France|Polyclinique Grand Sud /ID# 170649, Nimes Cedex, France|Hopital Rangueil /ID# 169785, Toulouse, France|Duplicate_CHRU de NANCY /ID# 170985, Vandoeuvre-les-nancy Cedex, France|Universitatsklinikum Mannheim /ID# 168778, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 203551, Erlangen, Bayern, Germany|Universitaetsmedizin St. Josef Krankenhaus Werden /ID# 203571, Essen, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 206740, Saarbrücken, Saarland, Germany|Univ Hosp Schleswig-Holstein /ID# 168779, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 203563, Ulm, Thueringen, Germany|Charite; Campus Benjamin Frank /ID# 169067, Berlin, Germany|Gastroenterologie am Mexikoplatz /ID# 203573, Berlin, Germany|Agaplesion Markus Krankenhaus /ID# 168777, Frankfurt, Germany|Universitaetsklinikum Frankfurt /ID# 203565, Frankfurt, Germany|Universitaetsklinikum Halle (S /ID# 207454, Halle, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 200213, Munster, Germany|Tzaneio general hospital of Piraeus /ID# 206432, Piraeus, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 167037, Athens, Greece|General Hospital of Athens ""Ippokratio"" /ID# 167036, Athens, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 202103, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 167035, Heraklion, Greece|Genl Hosp Thessaloniki Hipp /ID# 208824, Thessaloniki, Greece|Queen Mary Hospital /ID# 171217, Hong Kong, Hong Kong|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 205546, Miskolc, Borsod-Abauj-Zemplen, Hungary|Bugat Pal Korhaz /ID# 201889, Gyöngyös, Heves, Hungary|Obudai Egeszsegugyi Centrum Kft. /ID# 201891, Budapest, Hungary|MH Honvedkorhaz /ID# 201719, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 201720, Debrecen, Hungary|Mentahaz Maganorvosi Kozpont /ID# 201890, Szekesfehervar, Hungary|Mercy University Hospital /ID# 206510, Cork, Ireland|Soroka Medical Center /ID# 169912, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 202635, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 204876, Tel Aviv-Yafo, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 169927, Jerusalem, Yerushalayim, Israel|Assaf Harofeh Medical Center /ID# 204870, Be'er Ya'akov, Israel|Kaplan Medical Center /ID# 170277, Rehovot, Israel|Universita di Catanzaro Magna Graecia /ID# 201920, Catanzaro, Calabria, Italy|AOU Policlinico S. Orsola Malpighi /ID# 168173, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 200008, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 168169, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 168170, Rome, Lazio, Italy|Istituto Clinico Humanitas /ID# 168171, Rozzano, Milano, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 168168, Rome, Roma, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 168176, Catania, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 168172, Negrar, Verona, Italy|Policlinico San Martino/Univer /ID# 168177, Genova, Italy|ASST Fatebenefratelli Sacco- O /ID# 168167, Milano, Italy|Ospedali Riuniti Villa Sofia-C /ID# 168175, Palermo, Italy|AOU Pisana /ID# 202420, Pisa, Italy|Policlinico Tor Vergata /ID# 168174, Rome, Italy|Aichi Medical University Hosp /ID# 165957, Nagakute, Aichi, Japan|Nagoya University Hospital /ID# 165955, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 165956, Nagoya-shi, Aichi, Japan|Hirosaki National Hospital /ID# 165944, Hirosaki-shi, Aomori, Japan|Toho University Sakura Medical Center /ID# 165949, Sakura-shi, Chiba, Japan|Kurume University Hospital /ID# 166004, Kurume-shi, Fukuoka, Japan|National Hospital Organization Takasaki General Medical Center /ID# 167136, Takasaki-shi, Gunma, Japan|NHO Fukuyama Medical Center /ID# 167139, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 167133, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 165943, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 167137, Sapporo-shi, Hokkaido, Japan|Aoyama Clinic /ID# 166001, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 200173, Nishinomiya-shi, Hyogo, Japan|Kanazawa University Ho /ID# 169215, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital /ID# 202407, Morioka-shi, Iwate, Japan|JP Red Cross Kyoto Daiichi Hos /ID# 165958, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 167135, Sendai-shi, Miyagi, Japan|Niigata University Medical & Dental Hospital /ID# 170044, Niigata-shi, Niigata, Japan|Ishida Clinic of IBD and Gastroenterology /ID# 167134, Oita-shi, Oita, Japan|Osaka City University Hospital /ID# 166007, Osaka-shi, Osaka, Japan|Shiga University of Medical Science Hospital /ID# 167141, Otsu, Shiga, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 165948, Bunkyo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 165951, Hachioji, Tokyo, Japan|Kyorin University Hospital /ID# 165950, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 205981, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 200156, Yamagata-shi, Yamagata, Japan|Hiroshima University Hospital /ID# 166006, Hiroshima, Japan|Sameshima Hospital /ID# 206674, Kagoshima, Japan|Nara Medical Univ Hospital /ID# 169216, Kashihara, Japan|Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 166002, Kurashiki, Japan|The Jikei University Hospital /ID# 167142, Minato-ku, Japan|Kyoto University Hospital /ID# 169888, Sakyo-ku, Japan|NHO Shizuoka Medical Center /ID# 167138, Shimizu-sho, Japan|Toyohashi Municipal Hospital /ID# 200174, Toyohashi, Japan|Wakayama Medical University /ID# 169481, Wakayama, Japan|JP Red Cross Wakayama Med Ctr /ID# 200638, Wakayama, Japan|Kenseikai Dongo Hospital /ID# 208103, Yamatotakada, Japan|Yokkaichi Hazu Medical Center /ID# 167191, Yokkaichi-shi, Japan|Dong-A University Hospital /ID# 167582, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 167580, Busan, Busan Gwang Yeogsi, Korea, Republic of|Kyungpook National Univ Hosp /ID# 207015, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 167583, Seongnam-si, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 167577, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 167581, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 167579, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Haeundae Paik Hospital /ID# 202629, Busan, Korea, Republic of|Hanyang University Guri Hosp /ID# 167578, Guri-si, Korea, Republic of|Chung-Ang University Hostipal /ID# 207017, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 169496, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 169493, Riga, Latvia|Digestive Diseases Ctr Gastro /ID# 169517, Riga, Latvia|Hospital of lithuanian university of Health Science Kauno Klinikos /ID# 207263, Kaunas, Lithuania|Vilnius University Hospital /ID# 203285, Vilnius, Lithuania|Hospital Sultanah Bahiyah /ID# 202627, Alor Setar, Kedah, Malaysia|UKM Medical Centre /ID# 170778, Kuala Lumpur, Selangor, Malaysia|Instituto de Investigaciones Aplicadas a la Neurociencias A.C. /ID# 207143, Victoria de Durango, Durango, Mexico|Morales Vargas Centro de Investigacion S.C. /ID# 203495, Leon, Guanajuato, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 206779, Guadalajara, Jalisco, Mexico|Radboud Universitair Medisch Centrum /ID# 166925, Nijmegen, Gelderland, Netherlands|Academisch Medisch Centrum /ID# 166924, Amsterdam, Noord-Holland, Netherlands|Medisch Spectrum Twente /ID# 170297, Enschede, Netherlands|Atrium-Orbis Zuyderland Medisch Centrum /ID# 169698, Heerlen, Netherlands|Vistamed /ID# 208570, Wrocław, Dolnoslaskie, Poland|Malopolskie Centrum Kliniczne /ID# 202166, Cracow, Malopolskie, Poland|Centrum Zdrowia MDM /ID# 200486, Warsaw, Mazowieckie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 200488, Warszawa, Mazowieckie, Poland|Hospital Egas Moniz /ID# 170249, Lisbon, Porto, Portugal|HGO - Hospital Garcia de Orta /ID# 170234, Almada, Portugal|Centro Hospitalar e Universitário de Coimbra, EPE /ID# 170240, Coimbra, Portugal|HSOG - Hospital Senhora da Oli /ID# 170225, Guimaraes, Portugal|Centro Hospitalar de Sao Joao /ID# 170231, Porto, Portugal|Unidade Local De Saude Do Alto Minho /ID# 200606, Viana Do Castelo, Portugal|Mindful Medical Research /ID# 203357, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 166770, San Juan, Puerto Rico|Institutul Clinic Fundeni /ID# 167826, Sector 2, Bucuresti, Romania|Clinica GASTRO MED SRL /ID# 206367, Cluj-Napoca, Cluj, Romania|Cabinet Particular Policlinic Algomed /ID# 167827, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 167829, Timisoara, Romania|Immanuel Kant Baltic Federal University /ID# 202128, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|Perm Clinical Center of FMBA /ID# 202988, Perm, Permskiy Kray, Russian Federation|Private institution Center of educational and clinical gastroenterology, hepatol /ID# 202995, Stavropol, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 169574, Kazan, Tatarstan, Respublika, Russian Federation|Llc Olla-Med /Id# 208721, Moscow, Russian Federation|P.A. Bayandin Murmansk Regiona /ID# 169575, Murmansk, Russian Federation|LLC Medical center Zdorovaya s /ID# 209233, Novosibirsk, Russian Federation|Republican Clin Hos n.a. Baran /ID# 206487, Petrozavodsk, Russian Federation|PMI Euromedservice /ID# 206609, Pushkin, Russian Federation|LLC Novaya Clinica /ID# 206615, Pyatigorsk, Russian Federation|Clinical Center Serbia /ID# 168220, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 168221, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 168784, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 168799, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 205858, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 168222, Novi Sad, Vojvodina, Serbia|Gleneagles Medical Centre /ID# 206530, Singapore, Singapore|Tan Tock Seng Hospital /ID# 203159, Singapore, Singapore|FNsP F.D.Roosevelta Banska Bys /ID# 169952, Banska Bystrica, Banskobystricky Kraj, Slovakia|KM Management s.r.o. /ID# 170199, Nitra, Slovakia|Univ Medical Ctr Ljubljana /ID# 211042, Ljubljana, Slovenia|Farmovs (Pty) Ltd /Id# 207536, Bloemfontein, Free State, South Africa|Lenasia Clinical Trial Centre /ID# 205144, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 170851, Johannesburg, Gauteng, South Africa|Mediclinic Constantiaberg /ID# 169852, Cape Town, Western Cape, South Africa|Dr JP Wright /ID# 170885, Cape Town, South Africa|H. Un. Marques de Valdecilla /ID# 202039, Santander, Cantabria, Spain|Hospital Universitario y Politecnico La Fe /ID# 201988, Valencia, Valenciana, Spain|Comple Hosp Univ de A Coruna /ID# 203908, A Coruna, Spain|Hospital Clinic de Barcelona /ID# 171242, Barcelona, Spain|Vall d'Hebron University Hospi /ID# 171237, Barcelona, Spain|Hosp Univ Girona Josep Trueta /ID# 202040, Girona, Spain|Hospital Juan Ramon Jimenez /ID# 171243, Huelva, Spain|Hospital Univ Dr. Negrin /ID# 171238, Las Palmas de Gran Canaria, Spain|Hospital Universitario La Paz /ID# 171241, Madrid, Spain|Hospital Univ. Son Espases /ID# 201997, Palma de Mallorca, Spain|Complejo Hospitalario de Navar /ID# 202038, Pamplona, Spain|Hospital Universitario Virgen Macarena /ID# 171240, Sevilla, Spain|Alingsås lasarett /ID# 170838, Alingsås, Vastra Gotalands Lan, Sweden|Södra Älvsborgs sjukhus /ID# 202889, Borås, Vastra Gotalands Lan, Sweden|Sahlgrenska US Gbg /ID# 169031, Göteborg, Vastra Gotalands Lan, Sweden|Hallands sjukhus Halmstad /ID# 170840, Halmstad, Sweden|Inselspital, Universitaetsklinik /ID# 171006, Bern, Switzerland|Universitatsspital Zurich /ID# 170999, Zurich, Switzerland|National Taiwan University Hos /ID# 169789, Taipei, Taiwan|Chang Gung Memorial Hospital /ID# 169788, Taoyuan, Taiwan|Acibadem Kozyatagi Hospital /ID# 209405, Kadikoy, Istanbul, Turkey|Erciyes University Medical Fac /ID# 171321, Melikgazi, Kayseri, Turkey|Gazi Universitesi Tip Fakultes /ID# 217443, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 206412, Ankara, Turkey|Inonu Universitesi Turgut Ozal /ID# 201267, Battalgazi/malatya, Turkey|Mustafa Kemal University Medic /ID# 171318, Hatay, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 200280, Istanbul, Turkey|Marmara University Medical Fac /ID# 171316, Istanbul, Turkey|Mersin University Medical /ID# 171320, Mersin, Turkey|Sisli Etfal Train & Res Hosp /ID# 171317, Sisli, Turkey|Kyiv Municipal Clinical Hospital #18 /ID# 207870, Kiev, Kyiv, Ukraine|South Eastern Health and Social Care Trust /ID# 205322, Belfast, Antrim, United Kingdom|Warrington and Halton Hospitals NHS Foundation Trust /ID# 171388, Warrington, Cheshire West And Chester, United Kingdom|Royal United Hospitals Bath /ID# 169084, Bath, United Kingdom|Queen Elizabeth Hospital - BIRMINGHAM /ID# 169080, Birmingham, United Kingdom|Russells Hall Hospital, Dudley /ID# 169079, Dudley, United Kingdom|London North West Healthcare N /ID# 169078, Harrow, United Kingdom|King's College Hospital NHS /ID# 169082, London, United Kingdom|St. George's Healthcare NHS /ID# 205551, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 169085, Newcastle Upon Tyne, United Kingdom|St. Helens and Knowsley Teach /ID# 209085, Prescot, United Kingdom|Stockport NHS foundation trust /ID# 208718, Stockport, United Kingdom|Taunton and Somerset NHS Found /ID# 209664, Tauntojn, United Kingdom|New Cross Hospital, Royal Wolv /ID# 171387, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03345836"
103,"NCT03345823","A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433",,"Enrolling by invitation","No Results Available","Crohn's Disease","Drug: Upadacitinib|Drug: Placebo for Upadacitinib","Proportion of participants with clinical remission|Proportion of participants with endoscopic response|Proportion of participants with endoscopic remission|Proportion of participants who discontinue corticosteroid use and achieve clinical remission|Proportion of subjects with clinical remission and endoscopic remission|Proportion of participants with hospitalizations due to CD|Proportion of participants with >= 50% reduction in draining fistulas|Proportion of participants who discontinue corticosteroid use|Proportion of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom domain|Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)|Proportion of participants with clinical remission per Crohn's Disease Activity Index (CDAI) remission in participants with a Baseline CDAI of 220 to 450|Proportion of participants with draining fistulas|Change from Baseline in Crohn's Symptoms Severity Questionnaire (CSS)|Proportion of participants with enhanced clinical response","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","738","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-430|2017-001225-41","March 21, 2018","January 31, 2022","September 27, 2026","November 17, 2017",,"March 18, 2019","Alabama Medical Group,PC /ID# 171132, Mobile, Alabama, United States|CB Flock Research Corporation /ID# 166239, Mobile, Alabama, United States|Delsol Research Management, Ll /Id# 170164, Chandler, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 164702, Phoenix, Arizona, United States|HonorHealth Research Institute - Shea /ID# 164725, Scottsdale, Arizona, United States|Citrus Valley Gastroenterology /ID# 166230, Covina, California, United States|United Gastroenterologists /ID# 207458, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 164640, Los Angeles, California, United States|Facey Medical Foundation /ID# 203138, Mission Hills, California, United States|United Gastroenterologists - Murrieta /ID# 164602, Murrieta, California, United States|Ucsd /Id# 164763, San Diego, California, United States|Medical Assoc Research Grp /ID# 169704, San Diego, California, United States|UCSF Center for Colitis and Crohn's Disease /ID# 202372, San Francisco, California, United States|Univ of California San Francis /ID# 164653, San Francisco, California, United States|Care Access Research /ID# 167765, San Pablo, California, United States|Peak Gastroenterology Associat /ID# 170166, Colorado Springs, Colorado, United States|Delta Waves, Inc. /ID# 164656, Colorado Springs, Colorado, United States|Western States Clinical Res /ID# 164625, Wheat Ridge, Colorado, United States|Medical Research Ctr CT /ID# 164614, Hamden, Connecticut, United States|Clinical Res of West FL, Inc. /ID# 205828, Clearwater, Florida, United States|Clinical Res of West FL, Inc. /ID# 208119, Clearwater, Florida, United States|Borland-Groover Clinic /ID# 203500, Jacksonville, Florida, United States|Ctr for Advanced Gastroenterol /ID# 165306, Maitland, Florida, United States|Crystal Pharmacology Research /ID# 166118, Miami, Florida, United States|Coral Research Clinic /ID# 164604, Miami, Florida, United States|Advanced Research Institute /ID# 164601, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 206139, Orlando, Florida, United States|Omega Research Consultants /ID# 203482, Orlando, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 203486, Tampa, Florida, United States|Florida Hospital Tampa /ID# 171181, Tampa, Florida, United States|Gastro Assoc of Central GA /ID# 165492, Macon, Georgia, United States|Atlanta Gastroenterology Spec /ID# 164698, Suwanee, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 165297, Chicago, Illinois, United States|Rush University Medical Center /ID# 165470, Chicago, Illinois, United States|University of Chicago /ID# 165509, Chicago, Illinois, United States|DuPage Medical Group /ID# 205320, Downers Grove, Illinois, United States|MediSphere Medical Research Center /ID# 166233, Evansville, Indiana, United States|Indianapolis Gastroenterology /ID# 164649, Indianapolis, Indiana, United States|Aquiant Research /ID# 205505, New Albany, Indiana, United States|University of Iowa Hospitals /ID# 165405, Iowa City, Iowa, United States|Tri-State Gastroenterology /ID# 165469, Crestview Hills, Kentucky, United States|University of Louisville /ID# 165391, Louisville, Kentucky, United States|University of Louisville /ID# 168520, Louisville, Kentucky, United States|Houma Digestive Health Special /ID# 164727, Houma, Louisiana, United States|Nola Research Works, LLC /ID# 164612, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 164694, Shreveport, Louisiana, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 164647, Chevy Chase, Maryland, United States|Gastro Center of Maryland /ID# 171180, Columbia, Maryland, United States|University of Michigan Hospitals /ID# 164654, Ann Arbor, Michigan, United States|Clin Res Inst of Michigan, LLC /ID# 170163, Chesterfield, Michigan, United States|Digestive Health Associates (DHA) - Farmington Hills /ID# 206101, Farmington Hills, Michigan, United States|Center for Digestive Health /ID# 164726, Troy, Michigan, United States|Minneapolis VA Medical Center /ID# 204623, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester /ID# 164691, Rochester, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 165295, Jackson, Mississippi, United States|Quality Clinical Research, Inc /ID# 170162, Omaha, Nebraska, United States|CHI Nebraska d/b/a CHI Health /ID# 168513, Omaha, Nebraska, United States|Comprehensive Digestive Instit /ID# 168551, Las Vegas, Nevada, United States|AGA Clinical Research Associates, LLC /ID# 164641, Egg Harbor Township, New Jersey, United States|Montefiore Medical Center /ID# 166242, Bronx, New York, United States|Advantage Clinical Trials /ID# 168582, Bronx, New York, United States|NY Scientific /ID# 164630, Brooklyn, New York, United States|NYU Langone Long Island CRA /ID# 164627, Great Neck, New York, United States|Weill Cornell Medicine/NYP /ID# 165510, New York, New York, United States|Icahn School of Med Mt. Sinai /ID# 170256, New York, New York, United States|Columbia Univ Medical Center /ID# 164692, New York, New York, United States|Gastro Group of Rochester /ID# 166235, Rochester, New York, United States|Richmond University Medical Center /ID# 201858, Staten Island, New York, United States|Carolinas Medical Center /ID# 164632, Charlotte, North Carolina, United States|PMG Research of Charlotte /ID# 171178, Charlotte, North Carolina, United States|Wake Research Associates, LLC /ID# 164752, Raleigh, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 164755, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 170169, Fargo, North Dakota, United States|Consultants for Clinical Res /ID# 164668, Cincinnati, Ohio, United States|University of Cincinnati /ID# 164729, Cincinnati, Ohio, United States|Cleveland Clinic Foundation /ID# 209230, Cleveland, Ohio, United States|Ohio State University/ Gastroe /ID# 170159, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 205625, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 201289, Dayton, Ohio, United States|Dayton Gastroenterology, Inc. /ID# 167623, Englewood, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 202006, Mentor, Ohio, United States|Digestive Disease Specialists /ID# 201063, Oklahoma City, Oklahoma, United States|Options Health Research, LLC /ID# 164704, Tulsa, Oklahoma, United States|Healthcare Research Consultant /ID# 166244, Tulsa, Oklahoma, United States|University of Pennsylvania /ID# 168406, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 168003, Philadelphia, Pennsylvania, United States|Pharmacorp Clinical Trials /ID# 165008, Charleston, South Carolina, United States|Greenville Endoscopy Center /ID# 164643, Greenville, South Carolina, United States|Rapid City Medical Center /ID# 201733, Rapid City, South Dakota, United States|Gastro One /ID# 164730, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 203614, Johnson City, Tennessee, United States|Quality Medical Research, PLLC /ID# 205264, Nashville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 164607, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 164719, Arlington, Texas, United States|Inquest Clinical Research /ID# 164676, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209803, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209954, Cedar Park, Texas, United States|Baylor Scott & White Research /ID# 170161, Dallas, Texas, United States|DHAT Research Institute /ID# 164699, Garland, Texas, United States|Baylor College of Medicine /ID# 164609, Houston, Texas, United States|Houston Methodist Hospital /ID# 207661, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201212, Houston, Texas, United States|GI Specialists of Houston /ID# 202340, Houston, Texas, United States|Clinical Associates in Researc /ID# 164675, San Antonio, Texas, United States|Sagact Pllc /Id# 169756, San Antonio, Texas, United States|Carl R. Meisner Medical Clinic /ID# 171057, Sugar Land, Texas, United States|Tyler Research Institute, LLC /ID# 168679, Tyler, Texas, United States|Victoria gastroenterology /ID# 167810, Victoria, Texas, United States|HP Clinical Research /ID# 164631, Bountiful, Utah, United States|Advanced Research Institute /ID# 164689, Ogden, Utah, United States|Care Access Research /ID# 164685, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 166113, West Jordan, Utah, United States|Washington Gastroenterology /ID# 164728, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 164862, Seattle, Washington, United States|University of Washington /ID# 164646, Seattle, Washington, United States|The Vancouver Clinic, INC. PS /ID# 164874, Vancouver, Washington, United States|Froedtert and Medical College /ID# 202285, Milwaukee, Wisconsin, United States|Allegiance Research Specialist /ID# 165298, Wauwatosa, Wisconsin, United States|Southern California Res. Ctr. /ID# 169653, Coronado, American Samoa|Cardio Alem /ID# 211283, San Isidro, Buenos Aires, Argentina|Hopital Centenario /ID# 171251, Rosario, Santa Fe, Argentina|Cemic /Id# 169183, Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 169229, Cordoba, Argentina|Concord Repatriation & Gen Hos /ID# 171506, Concord, New South Wales, Australia|Mater Misericordiae /ID# 204910, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 171508, Adelaide, South Australia, Australia|Box Hill Hospital /ID# 203735, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 171507, Murdoch, Western Australia, Australia|Krankenanstalt Rudolfstiftung /ID# 203438, Vienna, Wien, Austria|Medical University of Vienna /ID# 169459, Vienna, Wien, Austria|Cliniques Universitaires Saint Luc /ID# 200293, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|AZ Sint-Lucas /ID# 200296, Ghent, Belgium|UZ Leuven /ID# 200031, Leuven, Belgium|CHU de Liege Sart Tilman /ID# 200294, Liege, Belgium|CHU Dinant Godinne - UCL Namur /ID# 200295, Yvoir, Belgium|Brcko District General Hospital /ID# 201347, Brcko, Brcko Distrikt, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 200743, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Center Tuzla /ID# 210323, Tuzla, Tuzlanski, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 201346, Sarajevo, Bosnia and Herzegovina|Instituto Goiano de Gastroenterologia /ID# 166853, Goiânia, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 166856, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 166855, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 166860, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 166859, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 166854, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 166858, Sao Jose Do Rio Preto, Sao Paulo, Brazil|UMHAT ""Kaspela"" EOOD /ID# 167615, Plovdiv, Bulgaria|II MHAT - Sofia /ID# 167616, Sofia, Bulgaria|MHAT Trakia /ID# 201677, Stara Zagora, Bulgaria|University Multiprofile Hospit /ID# 167566, Varna, Bulgaria|University of Calgary /ID# 166990, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 168047, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 166987, Edmonton, Alberta, Canada|Covenant Health /ID# 166996, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 166984, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 166994, Vancouver, British Columbia, Canada|QEII Health Sciences Centre /ID# 169308, Halifax, Nova Scotia, Canada|Scott Schulman medicine profes /ID# 169065, North Bay, Ontario, Canada|Taunton surgical centre /ID# 168045, Oshawa, Ontario, Canada|Medicor Research Inc. /ID# 166997, Sudbury, Ontario, Canada|Toronto Digestive Disease Asso /ID# 166988, Vaughan, Ontario, Canada|Hopital Charles-Lemoyne /ID# 166986, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 166985, Levis, Quebec, Canada|Crchum /Id# 170122, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre /ID# 170011, Montréal, Quebec, Canada|CRCHUS Hotel-Dieu /ID# 170936, Sherbrooke, Quebec, Canada|Research Group Ltda /ID# 203178, Santiago, Region Metropolitana De Santiago, Chile|Hospital Clinico Universidad /ID# 169864, Santiago, Region Metropolitana De Santiago, Chile|M y F Estudios Clínicos Ltda. /ID# 169872, Ñuñoa, Region Metropolitana De Santiago, Chile|CTR Estudios SpA /ID# 203940, Providencia, Chile|Hospital Clinico Universidad De Los Andes /ID# 207463, Santiago, Chile|The First Affiliated Hosp, Sun /ID# 205227, Guangzhou, Anhui, China|The Sixth Affiliated Hosp, Sun /ID# 204054, Guangzhou, Anhui, China|Zhongshan Hosp. of Fudan Uni. /ID# 204535, Shanghai, Anhui, China|Renji Hosp, Shanghai Jiaotong /ID# 204067, Shanghai, Anhui, China|Zhongshan Hospital Xiamen Univ /ID# 204986, Xiamen, Anhui, China|Nanfang Hospital of Southern Medical University /ID# 204056, Guangzhou, Guangdong, China|1st Aff Hosp Nanchang Univ /ID# 204052, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 206865, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 204055, Shanghai, Shanghai, China|The Second Affiliated Hospital /ID# 204058, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 204050, Hangzhou, Zhejiang, China|Beijing Friendship Hospital /ID# 204175, Beijing, China|The Second Xiangya Hospital /ID# 204057, Changsha, China|Daping Hospital /ID# 207145, Chongqing, China|Nanjing Drum Tower Hospital /ID# 204899, Nanjing, Jiangsu, China|Tianjin Med Univ General Hosp /ID# 206979, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 204065, Wuhan, China|Tongji Hosp Tongji Med College /ID# 204051, Wuhan, China|Hospital San Vicente de Paul /ID# 200020, Medellin, Antioquia, Colombia|Instituto de Coloproctologia /ID# 168418, Antioquia, Colombia|Hospital Pablo Tobon Uribe /ID# 202403, Medellín, Colombia|UHC Osijek /ID# 171164, Osijek, Croatia|UHC Split /ID# 171205, Split, Croatia|Zadar General Hospital /ID# 205533, Zadar, Croatia|Clinical Hospital Dubrava /ID# 171165, Zagreb, Croatia|UHC Sestre Milosrdnice /ID# 171194, Zagreb, Croatia|UHC Zagreb /ID# 171168, Zagreb, Croatia|Nemocnice Horovice, NH Hospita /ID# 209867, Horovice, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 171564, Hradec Kralove, Czechia|Artroscan , s.r.o. /ID# 171575, Ostrava, Czechia|Restrial /ID# 208651, Prague 412, Czechia|Bispebjerg Hospital /ID# 208944, Copenhagen NV, Hovedstaden, Denmark|Nordsjallands Hospital /ID# 200788, Frederikssund, Hovedstaden, Denmark|Herlev Hospital /ID# 200785, Herlev, Hovedstaden, Denmark|Sjaellands Universitets Hospit /ID# 200786, Roskilde, Sjælland, Denmark|Hvidovre Hospital /ID# 200787, Hvidovre, Denmark|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 171008, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 171017, Alexandria, Egypt|University of Alexandria /ID# 209561, Alexandria, Egypt|Cairo University /ID# 209559, Cairo, Egypt|Nat Hep & Trop Med Res Inst /ID# 170991, Cairo, Egypt|Nat Hep & Trop Med Res Inst /ID# 209562, Cairo, Egypt|Ain Shams University Hospital /ID# 209566, Cairo, Egypt|Air Force Specialized Hospital /ID# 170993, Cairo, Egypt|Zagazig University Hospital /ID# 209560, EL Sharkya, Egypt|National Liver Institute /ID# 170987, Menoufiya, Egypt|West Tallinn Central Hospital /ID# 202787, Tallinn, Estonia|Tartu University Hospital /ID# 203141, Tartu, Estonia|Chu de Nice-Hopital L'Archet Ii /Id# 171004, Nice CEDEX 3, Alpes-Maritimes, France|Hôpital Haut-Lévêque /ID# 207812, Pessac CEDEX, Gironde, France|CHRU Lille - Hôpital Claude Huriez /ID# 206653, Lille CEDEX, Hauts-de-France, France|Hopital Saint Eloi /ID# 170039, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 171007, Clichy, Ile-de-France, France|CHU de SAINT ETIENNE - Hopital Nord /ID# 171027, St. Priest En Jarez, Loire, France|Centre Hospitalier Lyon Sud /ID# 171030, Pierre Benite CEDEX, Rhone, France|Chu Amiens Picardie - Hopital /Id# 171023, Amiens Cedex 01, France|Chru Trousseau /Id# 169783, Chambray-les-tours, France|CHU Henri Mondor /ID# 169782, Creteil, France|Polyclinique Grand Sud /ID# 170037, Nimes Cedex, France|Hopital Rangueil /ID# 169784, Toulouse, France|Duplicate_CHRU de NANCY /ID# 170970, Vandoeuvre-les-nancy Cedex, France|Universitatsklinikum Mannheim /ID# 168754, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 203550, Erlangen, Bayern, Germany|Universitaetsmedizin St. Josef Krankenhaus Werden /ID# 203569, Essen, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 206739, Saarbrücken, Saarland, Germany|Univ Hosp Schleswig-Holstein /ID# 168755, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 203554, Ulm, Thueringen, Germany|Charite; Campus Benjamin Frank /ID# 169271, Berlin, Germany|Gastroenterologie am Mexikoplatz /ID# 203574, Berlin, Germany|Agaplesion Markus Krankenhaus /ID# 168753, Frankfurt, Germany|Universitaetsklinikum Frankfur /ID# 203567, Frankfurt, Germany|Universitaetsklinikum Halle (S /ID# 207453, Halle, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 200212, Munster, Germany|Tzaneio general hospital of Piraeus /ID# 206435, Piraeus, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 167033, Athens, Greece|General Hospital of Athens ""Ippokratio"" /ID# 167032, Athens, Greece|General Hospital of Chest Diseases of Athens ""SOTIRIA"" /ID# 202102, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 167031, Heraklion, Greece|Genl Hosp Thessaloniki Hipp /ID# 208823, Thessaloniki, Greece|Queen Mary Hospital /ID# 171214, Hong Kong, Hong Kong|Tuen Mun Hospital /ID# 171213, Tuen Mun, Hong Kong|Mohacsi Korhaz /ID# 209440, Mohács, Baranya, Hungary|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 205549, Miskolc, Borsod-Abauj-Zemplen, Hungary|Bugat Pal Korhaz /ID# 201885, Gyöngyös, Heves, Hungary|Obudai Egeszsegugyi Centrum Kft. /ID# 201886, Budapest, Hungary|MH Honvedkorhaz /ID# 200888, Budapest, Hungary|Semmelweis Egyetem /ID# 210166, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 200887, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 206153, Kistarcsa, Hungary|Mentahaz Maganorvosi Kozpont /ID# 201888, Szekesfehervar, Hungary|Clinexpert Tatabanya /ID# 209896, Tatabánya, Hungary|Mercy University Hospital /ID# 206512, Cork, Ireland|Soroka Medical Center /ID# 169911, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 202634, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 206450, Tel Aviv-Yafo, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 169926, Jerusalem, Yerushalayim, Israel|Assaf Harofeh Medical Center /ID# 206449, Be'er Ya'akov, Israel|Kaplan Medical Center /ID# 170275, Rehovot, Israel|Università di Catanzaro ""Magna Graecia"" /ID# 201986, Catanzaro, Calabria, Italy|AOU Policlinico S. Orsola Malpighi /ID# 168155, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 200009, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 168151, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 168152, Rome, Lazio, Italy|Istituto Clinico Humanitas /ID# 168153, Rozzano, Milano, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 168150, Rome, Roma, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 168161, Catania, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 168154, Negrar, Verona, Italy|Policlinico San Martino/Univer /ID# 168162, Genova, Italy|ASST Fatebenefratelli Sacco- O /ID# 168149, Milano, Italy|Azienda Ospedaliera Ospedale N /ID# 170906, Milano, Italy|Ospedali Riuniti Villa Sofia-C /ID# 168157, Palermo, Italy|AOU Pisana /ID# 202419, Pisa, Italy|Policlinico Tor Vergata /ID# 168156, Rome, Italy|Aichi Medical University Hosp /ID# 165989, Nagakute, Aichi, Japan|Nagoya University Hospital /ID# 165987, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 165988, Nagoya-shi, Aichi, Japan|Hirosaki National Hospital /ID# 165976, Hirosaki-shi, Aomori, Japan|Toho University Sakura Medical Center /ID# 165978, Sakura-shi, Chiba, Japan|Kurume University Hospital /ID# 165996, Kurume-shi, Fukuoka, Japan|National Hospital Organization Takasaki General Medical Center /ID# 167151, Takasaki-shi, Gunma, Japan|NHO Fukuyama Medical Center /ID# 167155, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 167148, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 165975, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 167152, Sapporo-shi, Hokkaido, Japan|Aoyama Clinic /ID# 165993, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 165991, Nishinomiya-shi, Hyogo, Japan|Kanazawa University Ho /ID# 169212, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital /ID# 202465, Morioka-shi, Iwate, Japan|Yokohama City Univ Medical Ctr /ID# 167156, Yokohama, Kanagawa, Japan|JP Red Cross Kyoto Daiichi Hos /ID# 165990, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 167150, Sendai-shi, Miyagi, Japan|Niigata University Medical & Dental Hospital /ID# 170042, Niigata-shi, Niigata, Japan|Ishida Clinic of IBD and Gastroenterology /ID# 167149, Oita-shi, Oita, Japan|Osaka City University Hospital /ID# 165999, Osaka-shi, Osaka, Japan|Shiga Univ Med Science Hosp /ID# 167157, Otsu, Shiga, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 165982, Bunkyo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 165984, Hachioji, Tokyo, Japan|Kyorin University Hospital /ID# 165983, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 205979, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 200158, Yamagata-shi, Yamagata, Japan|Hiroshima University Hospital /ID# 165998, Hiroshima, Japan|Sameshima Hospital /ID# 206677, Kagoshima, Japan|Nara Medical Univ Hospital /ID# 169213, Kashihara, Japan|The Jikei University Hospital /ID# 167154, Minato-ku, Japan|Kyoto University Hospital /ID# 169887, Sakyo-ku, Japan|NHO Shizuoka Medical Center /ID# 167153, Shimizu-sho, Japan|Toyohashi Municipal Hospital /ID# 200176, Toyohashi, Japan|Wakayama Medical University /ID# 169480, Wakayama, Japan|JP Red Cross Wakayama Med Ctr /ID# 200641, Wakayama, Japan|Kenseikai Dongo Hospital /ID# 208105, Yamatotakada, Japan|Yokkaichi Hazu Medical Center /ID# 167201, Yokkaichi-shi, Japan|Dong-A University Hospital /ID# 167568, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 167565, Busan, Busan Gwang Yeogsi, Korea, Republic of|Kyungpook National Univ Hosp /ID# 207020, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 167569, Seongnam-si, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 167562, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 167567, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 167564, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Haeundae Paik Hospital /ID# 202631, Busan, Korea, Republic of|Hanyang University Guri Hosp /ID# 167563, Guri-si, Korea, Republic of|Chung-Ang University Med. Ctr. /ID# 207021, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 169499, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 169494, Riga, Latvia|Digestive Diseases Ctr Gastro /ID# 169518, Riga, Latvia|Hospital of lithuanian university of Health Science Kauno Klinikos /ID# 207030, Kaunas, Lithuania|Vilnius University Hospital /ID# 203269, Vilnius, Lithuania|Hospital Sultanah Bahiyah /ID# 201317, Alor Setar, Kedah, Malaysia|UKM Medical Centre /ID# 170780, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia /ID# 200101, Kelantan, Malaysia|Instituto de Investigaciones Aplicadas a la Neurociencias A.C. /ID# 207681, Victoria de Durango, Durango, Mexico|Morales Vargas Centro de Investigación S.C /ID# 203496, León de los Aldama, Guanajuato, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 206843, Guadalajara, Jalisco, Mexico|Radboud Universitair Medisch Centrum /ID# 166931, Nijmegen, Gelderland, Netherlands|Academisch Medisch Centrum /ID# 166930, Amsterdam, Noord-Holland, Netherlands|Onze Lieve Vrouwe Gasthuis /ID# 166932, Amsterdam, Netherlands|Medisch Spectrum Twente /ID# 170299, Enschede, Netherlands|Zuyderland Medisch Centrum /ID# 169699, Heerlen, Netherlands|Vistamed /ID# 208571, Wrocław, Dolnoslaskie, Poland|Malopolskie Centrum Kliniczne /ID# 202169, Cracow, Malopolskie, Poland|Centrum Zdrowia MDM /ID# 200493, Warszawa, Mazowieckie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 200489, Warszawa, Mazowieckie, Poland|Hospital Egas Moniz /ID# 170232, Lisbon, Porto, Portugal|HGO - Hospital Garcia de Orta /ID# 170209, Almada, Portugal|CHUC- Centro Hospitalar e Univ /ID# 170221, Coimbra, Portugal|HSOG - Hospital Senhora da Oli /ID# 170204, Guimaraes, Portugal|Centro Hospitalar de Sao Joao /ID# 170211, Porto, Portugal|Unidade Local De Saude Do Alto Minho /ID# 200608, Viana Do Castelo, Portugal|Mindful Medical Research /ID# 203356, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 166769, San Juan, Puerto Rico|Clinic Fundeni Institute /ID# 167831, Bucharest, Bucuresti, Romania|Clinic Fundeni Institute /ID# 167833, Bucharest, Bucuresti, Romania|Clinica GASTRO MED SRL /ID# 206363, Cluj-Napoca, Cluj, Romania|Cabinet Particular Policlinic Algomed /ID# 167832, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 167834, Timisoara, Romania|Immanuel Kant Baltic Federal University /ID# 203810, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|Perm Clinical Center of FMBA /ID# 202989, Perm, Permskiy Kray, Russian Federation|LLC Novaya Klinika /ID# 206613, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Private institution Center of educational and clinical gastroenterology, hepatol /ID# 202996, Stavropol, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 169589, Kazan, Tatarstan, Respublika, Russian Federation|Llc Olla-Med /Id# 208723, Moscow, Russian Federation|P.A. Bayandin Murmansk Regiona /ID# 169590, Murmansk, Russian Federation|LLC Medical center Zdorovaya s /ID# 209234, Novosibirsk, Russian Federation|Republican Clin Hos n.a. Baran /ID# 206497, Petrozavodsk, Russian Federation|PMI Euromedservice /ID# 206608, Pushkin, Russian Federation|Clinical Center Serbia /ID# 168217, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 168216, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 168785, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 168787, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 205856, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 168196, Novi Sad, Vojvodina, Serbia|Gleneagles Medical Centre /ID# 206019, Singapore, Singapore|Tan Tock Seng Hospital /ID# 203158, Singapore, Singapore|FNsP F.D.Roosevelta Banska Bys /ID# 169960, Banska Bystrica, Banskobystricky Kraj, Slovakia|KM Management s.r.o. /ID# 170202, Nitra, Slovakia|Univ Medical Ctr Ljubljana /ID# 211041, Ljubljana, Slovenia|FARMOVS Integrated Research Solutions /ID# 207534, Bloemfontein, Free State, South Africa|Lenasia Clinical Trial Centre /ID# 205143, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 170850, Johannesburg, Gauteng, South Africa|Allergy & Immunology (AIU) /ID# 171427, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 169851, Cape Town, Western Cape, South Africa|Dr JP Wright /ID# 170882, Cape Town, South Africa|H. Un. Marques de Valdecilla /ID# 202495, Santander, Cantabria, Spain|Hospital Universitario y Politecnico La Fe /ID# 202720, Valencia, Valenciana, Spain|Comple Hosp Univ de A Coruna /ID# 203909, A Coruna, Spain|Hospital Clinic de Barcelona /ID# 202726, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 202721, Barcelona, Spain|Hosp Univ Girona Josep Trueta /ID# 202644, Girona, Spain|Hospital Juan Ramon Jimenez /ID# 202727, Huelva, Spain|Hospital Univ Dr. Negrin /ID# 202723, Las Palmas de Gran Canaria, Spain|Hospital Universitario La Paz /ID# 202725, Madrid, Spain|Hospital Univ. Son Espases /ID# 201969, Palma de Mallorca, Spain|Complejo Hospitalario de Navar /ID# 202354, Pamplona, Spain|Hospital Clinico Universitario de Salamanca /ID# 206359, Salamanca, Spain|Hospital Universitario Virgen Macarena /ID# 202722, Sevilla, Spain|Hosp Clin Univ de Valencia /ID# 209658, Valencia, Spain|Alingsås lasarett /ID# 170814, Alingsås, Vastra Gotalands Lan, Sweden|Södra Älvsborgs sjukhus /ID# 203078, Borås, Vastra Gotalands Lan, Sweden|Sahlgrenska US Gbg /ID# 169032, Göteborg, Vastra Gotalands Lan, Sweden|Sahlgrenska US Gbg /ID# 169170, Göteborg, Vastra Gotalands Lan, Sweden|Hallands sjukhus Halmstad /ID# 170815, Halmstad, Sweden|Inselspital, Universitaetsklinik /ID# 170994, Bern, Switzerland|Universitatsspital Zurich /ID# 171000, Zurich, Switzerland|China Medical University Hosp /ID# 169803, Taichung City, Taichung, Taiwan|Taichung Veterans General Hosp /ID# 169802, Taichung City, Taiwan|National Taiwan University Hos /ID# 169805, Taipei, Taiwan|Chang Gung Memorial Hospital /ID# 169804, Taoyuan, Taiwan|Erciyes University Medical Fac /ID# 171325, Melikgazi, Kayseri, Turkey|Ankara Univ Medical Faculty /ID# 206408, Ankara, Turkey|Inonu Universitesi Turgut Ozal /ID# 201266, Battalgazi/malatya, Turkey|Mustafa Kemal University Medic /ID# 171328, Hatay, Turkey|Istanbul University Istanbul Medical Faculty /ID# 171365, Istanbul, Turkey|Marmara University Medical Fac /ID# 171326, Istanbul, Turkey|Sisli Etfal Train & Res Hosp /ID# 171327, Sisli, Turkey|Medical Centre of ""Ukrainian German Antiulcer Gastroenterology Centre BYK-KYIV"" /ID# 203739, Kiev, Kyivska Oblast, Ukraine|Medical Centre of OK!Clinic of International Institute of Clinical Trials /ID# 205481, Kiev, Kyivska Oblast, Ukraine|Medical Centre CARDIOCOM /ID# 200266, Kozyn, Kyivska Oblast, Ukraine|Kyiv Municipal Clinical Hospital #18 /ID# 207890, Kiev, Kyiv, Ukraine|Kharkiv City Clinical Hospital /ID# 167918, Kharkiv, Ukraine|Kiev Regional Clinical Hosp /ID# 202456, Kiev, Ukraine|Lviv Railway Clinical Hospital /ID# 167917, Lviv, Ukraine|South Eastern Health and Social Care Trust /ID# 205324, Belfast, Antrim, United Kingdom|Warrington and Halton Hospitals NHS Foundation Trust /ID# 171396, Warrington, Cheshire West And Chester, United Kingdom|Kingston Hosp NHS Foundation /ID# 200647, Kingston upon Thames, England, United Kingdom|Royal United Hospitals Bath /ID# 169062, Bath, United Kingdom|Queen Elizabeth Hospital - BIRMINGHAM /ID# 169058, Birmingham, United Kingdom|Russells Hall Hospital, Dudley /ID# 169057, Dudley, United Kingdom|London North West Healthcare N /ID# 169056, Harrow, United Kingdom|Guy's and St Thomas NHS Founda /ID# 169059, London, United Kingdom|King's College Hospital NHS /ID# 169060, London, United Kingdom|St. George's Healthcare NHS /ID# 205550, London, United Kingdom|Royal Victoria Infirmary, Newc /ID# 169063, Newcastle Upon Tyne, United Kingdom|St. Helens and Knowsley Teach /ID# 209087, Prescot, United Kingdom|Stockport NHS foundation trust /ID# 208717, Stockport, United Kingdom|Taunton and Somerset NHS Found /ID# 209666, Tauntojn, United Kingdom|New Cross Hospital, Royal Wolv /ID# 171395, Walverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03345823"
104,"NCT03343067","A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain",,"Terminated","Has Results","Endometriosis","Drug: elagolix|Drug: estradiol/norethindrone acetate (E2/NETA)","Proportion of Responders at Month 6 Based on DYS Pain Scale|Proportion of Responders at Month 6 Based on NMPP Pain Scale|Change From Baseline in DYS at Month 6|Change From Baseline in NMPP at Month 6|Change From Baseline in Dyspareunia at Month 6|Change From Baseline in Daily Diary Endometriosis-Associated Pain Score Via Numeric Rating Scale (NRS) at Month 6|Change From Baseline in Rescue Analgesic Use Across Both Classes of Rescue Analgesics (NSAIDs/Opioids) at Month 6|Percentage of Participants With 30% or More Reduction From Baseline Based on the 35 Day Mean of the Daily Diary Endometriosis-Associated Pain Score Via NRS at Month 6|Proportion of Responders Over Time|Proportion of Responders Over Time (Not Taking Into Consideration of Analgesic Use)|Change From Baseline Over Time in Monthly Average DYS Pain Score|Change From Baseline Over Time in Monthly Average NMPP Pain Score|Change From Baseline Over Time in Monthly Average Dyspareunia Pain Score|Change From Baseline Over Time in Monthly Average Daily Diary Endometriosis-Associated Pain Score Via NRS|Percent Change From Baseline to Each Month During the Treatment Period for DYS|Percent Change From Baseline to Each Month During the Treatment Period for NMPP|Percent Change From Baseline to Each Month During the Treatment Period for Dyspareunia|Percent Change From Baseline to Each Month During the Treatment Period for Daily Diary Endometriosis-Associated Pain Score Via NRS|Change From Baseline Over Time in Daily Rescue Analgesic Use Across Both Classes of Rescue Analgesics|Number of Analgesic Use Responders and Non-Responders Over Time|Patient Global Impression of Change (PGIC) Scores Over Time|Overall Endometriosis-Associated Pain Via NRS (7-Day Recall) Scores Over Time|Endometriosis Health Profile-30 (EHP-30) Scores Over Time: Pain|EHP-30 Scores Over Time: Control and Powerlessness|EHP-30 Scores Over Time: Emotional Well-Being|EHP-30 Scores Over Time: Social Support|EHP-30 Scores Over Time: Self-Image|EHP-30 Scores Over Time: Sexual Intercourse|EuroQol-5D 5 Level (EQ-5D-5L) Scores Over Time: Mobility|EQ-5D-5L Scores Over Time: Self-Care|EQ-5D-5L Scores Over Time: Usual Activities|EQ-5D-5L Scores Over Time: Pain/Discomfort|EQ-5D-5L Scores Over Time: Anxiety/Depression|EQ-5D-5L VAS Scores Over Time: Health Today|Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) Scores Over Time: Percent Work Missed Due to Problem|WPAI:SHP Scores Over Time: Percent Impairment While Working Due to Problem|WPAI:SHP Scores Over Time: Percent Overall Work Impairment Due to Problem|WPAI:SHP Scores Over Time: Percent Activity Impairment Due to Problem|Health Endometriosis Treatment Satisfaction Questionnaire (ETSQ) Scores Over Time|PROMIS Fatigue Short Form 6a Scores Over Time","AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 3","11","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-383","December 27, 2017","October 23, 2018","October 23, 2018","November 17, 2017","November 27, 2019","November 27, 2019","Pinnacle Research Group /ID# 202016, Anniston, Alabama, United States|Noble Clinical Research /ID# 170628, Tucson, Arizona, United States|Lynn Institute of the Ozarks /ID# 165052, Little Rock, Arkansas, United States|SC Clinical Research /ID# 165049, Garden Grove, California, United States|Marvel Clinical Research /ID# 169633, Huntington Beach, California, United States|Health care Affiliates Medical Group /ID# 165048, Santa Ana, California, United States|Western States Clinical Res /ID# 169809, Wheat Ridge, Colorado, United States|Nova Clinical Research, LLC /ID# 202227, Bradenton, Florida, United States|Midland Florida Clinical Research Center /ID# 201327, DeLand, Florida, United States|Southeastern Integrated Med /ID# 203109, Gainesville, Florida, United States|Care Partners Clinical Researc /ID# 168395, Jacksonville, Florida, United States|LCC Medical Research Institute /ID# 168888, Miami, Florida, United States|A Premier Clinical Research of Florida, LLC /ID# 201887, Orange City, Florida, United States|GCP Clinical Research, LLC /ID# 169774, Tampa, Florida, United States|Triple O Research Institute /ID# 201128, West Palm Beach, Florida, United States|Bingham Memorial Hospital /ID# 170110, Blackfoot, Idaho, United States|Leavitt Womens Healthcare /ID# 169495, Idaho Falls, Idaho, United States|Quad Clinical Research, LLC /ID# 168294, Chicago, Illinois, United States|Quad Clinical Research, LLC /ID# 170629, Chicago, Illinois, United States|Women's Health Care, PC /ID# 165033, Newburgh, Indiana, United States|Delricht Research /ID# 200219, New Orleans, Louisiana, United States|Quad Clinical Research, LLC /ID# 200180, Saint Louis, Missouri, United States|Montana Health Research Inst /ID# 170624, Billings, Montana, United States|Excel Clinical Research /ID# 170620, Las Vegas, Nevada, United States|Northwell health system /ID# 200162, Manhasset, New York, United States|Radiant Research, Inc /ID# 200045, Akron, Ohio, United States|Central Ohio Clinical Research /ID# 170750, Columbus, Ohio, United States|Optimed Research /ID# 167642, Columbus, Ohio, United States|VitaLink Research /ID# 168401, Greenville, South Carolina, United States|VitaLink Research /ID# 170625, Greenville, South Carolina, United States|Fusion Clinical Research of Spartanburg /ID# 200010, Spartanburg, South Carolina, United States|Centex Studies, Inc /ID# 169897, Houston, Texas, United States|America's Adv. Wellness Center /ID# 170005, Houston, Texas, United States|ClinRx Research, LLC /ID# 201189, Plano, Texas, United States|Progressive Clinical Research /ID# 205565, San Antonio, Texas, United States|Eastern Virginia Med School /ID# 165016, Norfolk, Virginia, United States|Seattle Reproductive Medicine /ID# 171079, Seattle, Washington, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT03343067/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03343067"
105,"NCT03342144","Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real‑Life Setting",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)",,"Percentage of Patients Achieving Overall Response Rate (ORR)|Progression-Free Survival (PFS) Rate|Overall Survival (OS) Rate|EORTC QLQ-C30 Scores|Percentage of Patients Achieving Complete Response with Incomplete Regeneration of Bone Marrow (CRi)|European Quality of Life 5 Dimensions (EQ-5D-5L) including visual analogue scale (VAS)|QLQ-CLL 16/17 Scores|Percentage of Patients with Progressive Disease (PD)|Percentage of Patients Achieving Partial Response (PR)|Percentage of Patients Administering Venetoclax|Percentage of Patients with Stable Disease (SD)|Percentage of Patients Achieving Complete Response (CR)|Minimal Residual Disease (MRD) measurement on plasma circulating tumor Deoxyribo nucleic acid (DNA) (Switzerland Only)|Clonal evolution and eradication of Tumor Protein p53 (TP53) mutated clones associated with treatment in relation to MRD negativity (Switzerland Only)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"250","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P17-132","December 4, 2017","December 31, 2021","December 31, 2021","November 14, 2017",,"February 28, 2019","Onkologische Praxis /ID# 201545, Stuttgart, Baden-Wuerttemberg, Germany|Medizinisches Versorgungszentrum (MVZ) /ID# 201548, Aschaffenburg, Bayern, Germany|Studienzentrum Aschaffenburg /ID# 204125, Aschaffenburg, Bayern, Germany|Praxis Dres. Hornberger & Kollegen /ID# 202613, Bad Reichenhall, Bayern, Germany|Onkologie am Segelfliegerdamm /ID# 202603, Berlin, Bayern, Germany|Onkologie Hof /ID# 201531, Hof, Bayern, Germany|Praxis Dr. Vehling-Kaiser /ID# 202614, Landshut, Bayern, Germany|Hämato-Onkologie /ID# 205236, Munich, Bayern, Germany|Praxis Dres. Kröber/Stosiek /ID# 206729, Ratisbon, Berlin, Germany|Praxis Dr. Kreher /ID# 202604, Bad Liebenwerda, Brandenburg, Germany|MVZ f. Blut- u.Krebserkrankungen /ID# 206704, Potsdam, Brandenburg, Germany|MVZ Dres. Cordes & Partner /ID# 202598, Frankfurt am Main, Hessen, Germany|OAZ Hannover /ID# 201538, Hanover, Niedersachsen, Germany|Onkolologische Praxis Oldenburg /ID# 202607, Oldenburg, Niedersachsen, Germany|MVZ der Paracelsus-Klinik /ID# 201541, Osnabrück, Niedersachsen, Germany|Med. Studiengesellschaft Nord West GmbH /ID# 201535, Westerstede, Niedersachsen, Germany|Praxis Dres. Plewe/Losem /ID# 202606, Neuss, Nordrhein-Westfalen, Germany|Onkozentrum Dresden /ID# 202599, Dresden, Sachsen, Germany|BAG Freiberg-Richter /ID# 201532, Dresden, Sachsen, Germany|Onkologische Schwerpunktpraxis /ID# 200953, Berlin, Germany|Internistische Schwerpunktprax /ID# 200949, Erlangen, Germany|Luebecker Oncology Practice /ID# 200952, Luebeck, Germany|Stauferklinikum Schwaebisch Gm /ID# 201518, Mutlangen, Germany|Onkologische Praxis GbR /ID# 206705, Porta Westfalica, Germany|Praxis Dres. Decker/Lakner/Leithäuser /ID# 206208, Rostock, Germany|Kantonsspital Aarau /ID# 210034, Aarau, Switzerland|Ospedale San Giovanni /ID# 208782, Bellinzona, Switzerland|Inselspital, Universitaetsklinik /ID# 210031, Bern, Switzerland|Luzerner Kantonsspital /ID# 210029, Luzern, Switzerland|Kantonsspital Muensterlingen /ID# 210035, Münsterlingen, Switzerland",,"https://ClinicalTrials.gov/show/NCT03342144"
106,"NCT03341871","Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6",,"Active, not recruiting","No Results Available","Hepatitis C Virus (HCV)",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants with Post-treatment Relapse|Percentage of Participants with On-treatment Virologic Failure|Percentage of Participants Achieving SVR4|Percentage of Participants Achieving SVR8|Percentage of Participants Achieving SVR24","AbbVie",,"up to 99 Years   (Child, Adult, Older Adult)",,"1095","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-570","December 27, 2017","December 31, 2020","December 31, 2020","November 14, 2017",,"December 16, 2019","Abbvie Japan /ID# 161985, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03341871"
107,"NCT03339102","Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients",,"Recruiting","No Results Available","Uveitis",,"Percentage (%) of patients reported with serious adverse event|Change in Visual acuity|Assessing Presence /absence of new active inflammatory chorioretinal lesions|Assessing Treatment Response","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"415","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P17-176","January 25, 2018","September 30, 2020","September 30, 2020","November 13, 2017",,"January 2, 2020","Pusan National University Hosp /ID# 202026, Busan, Busan Gwang Yeogsi, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital /ID# 204551, Cheonan, Chungcheongnamdo, Korea, Republic of|Yeungnam University Med Ctr /ID# 201361, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Seoul National Univ Bundang ho /ID# 201657, Seongnam, Gyeonggido, Korea, Republic of|Ajou University Hospital /ID# 201516, Suwon-si, Gyeonggido, Korea, Republic of|HanGil Eye Hospital /ID# 201655, Bupyeong, Incheon Gwang Yeogsi, Korea, Republic of|Wonkwang University Hospital /ID# 204545, Iksan, Jeonrabugdo, Korea, Republic of|Gangnam Severance Hospital /ID# 202027, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 201515, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Nune Eye Hospital /ID# 211613, Seoul City, Seoul, Korea, Republic of|Maryknoll Medical Center /ID# 201370, Busan, Korea, Republic of|Chungbuk National Univ Hosp /ID# 204544, Cheongju, Korea, Republic of|Apgujung St. Mary's Eye Center /ID# 210721, Gangnam-gu, Korea, Republic of|Inje University Ilsan Paik Hos /ID# 204543, Goyang, Korea, Republic of|Chosun University Hospital /ID# 204542, Gwangju, Korea, Republic of|Seoul National University Hospital /ID# 201656, Seoul, Korea, Republic of|Kim's Eye Hospital /ID# 205685, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03339102"
108,"NCT03339089","Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases","ADMIT","Recruiting","No Results Available","Ankylosing Spondylitis (AS)|Psoriasis|Rheumatoid Arthritis (RA)",,"Change from baseline in EuroQoL-5 Dimension (EQ-5D) index score up to Week 24|Assessing drug persistence|Change from baseline in Healthcare Resource Utilization (HCRU)|Change from baseline in Work productivity and Activity Impairment questionnaire - Specific Health Problem (WPAI-SHP) in participants with Ankylosing spondylitis (AS)|Change from Baseline in Dermatology Life Quality Index (DLQI) in participants with Psoriasis (Ps)|Change from baseline in Work productivity and Activity Impairment questionnaire - Specific Health Problem (WPAI-SHP) in participants with Rheumatoid Arthritis (RA)|Change from baseline in Clinical Disease Activity Index (CDAI) in participants with Rheumatoid Arthritis (RA)|Percentage of participants achieving low disease activity (CDAI 2.8-10) in participants with Rheumatoid Arthritis (RA)|Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in participants with Ankylosing spondylitis (AS)|Percentage of participants achieving remission (CDAI<=2.8) in participants with Rheumatoid Arthritis (RA)|Change from baseline in EQ-5D Visual analog scale (VAS)|Change from baseline in EQ-5D index score up to Week 52|Proportion of participants achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response in participants with Ankylosing spondylitis (AS)|Change from baseline in Psoriasis Area and Severity Index (PASI) in participants with Psoriasis (Ps)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-828","May 18, 2018","April 15, 2020","April 15, 2020","November 13, 2017",,"September 26, 2019","AbbVie China /ID# 164373, Shanghai, Anhui, China|Shenzhen Xiangmihu Hospital /ID# 209340, Shenzhen, Guangdong, China|First affiliated hospital of chengdu medical university /ID# 210745, Chengdu, Sichuan, China|Zhejiang provincial people's hospital /ID# 209342, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 210820, Hangzhou, Zhejiang, China|The first hospital of Jiaxing /ID# 213686, Jiaxing, Zhejiang, China|The Second hospital of Jiaxing /ID# 210744, Jiaxing, Zhejiang, China|Jinhua Central Hospital /ID# 209339, Jinhua, Zhejiang, China|Sichuan Provincial orthopedic hospital /ID# 209341, Chengdu, China|West China Hospital, SCU West China School of Medicine, SCU /ID# 209333, Chengdu, China",,"https://ClinicalTrials.gov/show/NCT03339089"
109,"NCT03334487","Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer",,"Withdrawn","No Results Available","Small Cell Lung Cancer","Drug: Dexamethasone|Drug: Rovalpituzumab tesirine","Number of Participants with a High Grade (>= Grade 3) Protocol Specified TEAE|Change in Participant Reported Outcome EORTC QLQC15-PAL|Progression Free Survival (PFS)|Overall Survival (OS)|Objective response rate (ORR)|Change in EORTC QLQ-LC-13|Duration of Objective Response (DOR)|Clinical Benefit Rate (CBR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-292|2017-003173-33","March 15, 2018","December 20, 2018","December 20, 2018","November 7, 2017",,"December 26, 2018","Ironwood Cancer & Res Ctr /ID# 171335, Chandler, Arizona, United States|Mayo Clinic - Scottsdale /ID# 171359, Scottsdale, Arizona, United States|VA Central California Health C /ID# 170951, Fresno, California, United States|Loma Linda University Medical /ID# 171377, Loma Linda, California, United States|UC Irvine Health /ID# 171343, Orange, California, United States|Kaiser Permanente - Roseville /ID# 200779, Roseville, California, United States|Kaiser Permanente-Santa Clara /ID# 203024, Santa Clara, California, United States|Kaiser Permanente Medical Ctr-Vallejo /ID# 169758, Vallejo, California, United States|Kaiser Permanente- Walnut Creek /ID# 201305, Walnut Creek, California, United States|Univ of Colorado Cancer Center /ID# 200810, Aurora, Colorado, United States|Boca Raton Regional Hospital /ID# 200168, Boca Raton, Florida, United States|UMHC/Sylvester Comprehensive /ID# 171462, Deerfield Beach, Florida, United States|Mount Sinai Comp Cancer Ctr /ID# 169759, Miami, Florida, United States|Illinois Cancer Care, PC /ID# 171310, Peoria, Illinois, United States|Baptist Health /ID# 171379, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 200827, Louisville, Kentucky, United States|Tulane Cancer Center Clinic /ID# 171376, New Orleans, Louisiana, United States|Sandra Malcolm Berman Cncr Ins /ID# 171346, Baltimore, Maryland, United States|St. Luke's University Hospital /ID# 171374, Duluth, Minnesota, United States|Valley Hospital - Westwood, NJ /ID# 171357, Westwood, New Jersey, United States|Wake Forest Baptist Medical Center /ID# 169799, Winston-Salem, North Carolina, United States|The Ohio State University Comp /ID# 171352, Columbus, Ohio, United States|St. Luke's Hematology Oncology /ID# 171378, Bethlehem, Pennsylvania, United States|Tennessee Oncology PLLC: Sarah /ID# 171380, Nashville, Tennessee, United States|Vanderbilt Ingram Henry Cancer /ID# 171356, Nashville, Tennessee, United States|VCS, Virginia Cancer Specialis /ID# 169760, Arlington, Virginia, United States|Kadlec Clinic Hematology and O /ID# 169797, Kennewick, Washington, United States|Coffs Harbour Health Campus /ID# 200642, Coffs Harbour, New South Wales, Australia|The Tweed Hospital /ID# 200646, Tweed Heads, New South Wales, Australia|The Townsville Hospital /ID# 200640, Douglas, Queensland, Australia|Austin Hospital /ID# 200639, Heidelberg, Victoria, Australia|Border Medical /ID# 200645, Wodonga, Victoria, Australia|Perron Institute for Neurological and Translational Science /ID# 200644, Nedlands, Western Australia, Australia|Bahia Oncology Center - NOB /ID# 201272, Salvador, Bahia, Brazil|Associação Hospital de Caridade Ijuí - Centro de Tratamento de Cancer - CACON /ID# 200496, Ijuí, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUCRS /ID# 201258, Porto Alegre, Rio Grande Do Sul, Brazil|Icesp /Id# 201036, São Paulo, Sao Paulo, Brazil|Inca /Id# 202594, Rio de Janeiro, Brazil|Instituto COI de Educacao e Pe /ID# 200499, Rio de Janeiro, Brazil|Fundacao Antonio Prudente /ID# 200218, Sao Paulo, Brazil|Hospital de Cancer de Barretos /ID# 200104, Sao Paulo, Brazil|Tom Baker Cancer Centre /ID# 171561, Calgary, Alberta, Canada|QE II Health Sciences Centre /ID# 171569, Halifax, Nova Scotia, Canada|London Health Sciences Centre /ID# 171567, London, Ontario, Canada|The Ottawa Hospital /ID# 200682, Ottawa, Ontario, Canada|Franziskus-Hospital Harderberg /ID# 201145, Georgsmarienhütte, Niedersachsen, Germany|Charite Universitatsmedizin B- /ID# 170079, Berlin, Germany|Asklepios Fachkliniken M. Gaut /ID# 170081, Gauting, Germany|Thoraxklinik Heidelberg gGmbH /ID# 170078, Heidelberg, Germany|Klinikum Kassel - Onkologie /ID# 170083, Kassel, Germany|Universitatsklinikum Munster /ID# 170087, Muenster, Germany|Pius Hospital Oldenburg /ID# 170080, Oldenburg, Germany|Akademiska Sjukhuset /ID# 171248, Uppsala, Uppsala Lan, Sweden|Gavle Hospital /ID# 171253, Gavle, Sweden|University Hospital Linkoping /ID# 201666, Linkoping, Sweden|Karolinska University Hospital /ID# 201967, Stockholm, Sweden|Norrlands Universitetssjukhus /ID# 171250, Umeå, Sweden|Leicester Royal Infirmary /ID# 201154, Leicester, England, United Kingdom|Christie NHS Foundation Trust /ID# 201149, Manchester, United Kingdom|Royal Preston Hospital /ID# 201146, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03334487"
110,"NCT03316794","A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)",,"Terminated","No Results Available","Breast Cancer","Drug: SC-005","Number of Participants with Dose-limiting Toxicities (DLTs)|QTcF Change from Baseline|Area Under the Plasma Concentration-time Curve (AUC)|Clinical benefit rate (CBR)|Maximum plasma concentration observed (Cmax)|Overall Survival (OS)|Observed Plasma Concentrations at Trough|Duration of Clinical Benefit (DOCB)|Objective Response Rate (ORR)Up to approximately 4 years|Time of Cmax (Tmax)|Progression Free Survival (PFS)|Duration of Response (DOR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","2","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-735","January 4, 2018","October 5, 2018","October 5, 2018","October 20, 2017",,"December 17, 2018","University of Chicago /ID# 169231, Chicago, Illinois, United States|Washington University School /ID# 169177, Saint Louis, Missouri, United States|Memorial Sloan Kettering /ID# 201016, New York, New York, United States|Gabrail Cancer Center Research /ID# 168756, Canton, Ohio, United States|Oklahoma University /ID# 200937, Oklahoma City, Oklahoma, United States|Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233, Nashville, Tennessee, United States|Baylor University /ID# 169860, Houston, Texas, United States|MD Anderson Cancer Center /ID# 169232, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03316794"
111,"NCT03314181","A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Dexamethasone|Drug: Daratumumab|Drug: Venetoclax|Drug: Bortezomib","Overall Response Rate (ORR)|Complete Response (CR) or Better Rate|Very Good Partial Response or Better Response Rate (VGPR)|Time to Progression (TTP)|Duration of Response (DOR)|Progression-Free Survival (PFS)|Cmax of Venetoclax|AUC0-24 of Venetoclax|Tmax of Venetoclax|Minimal Residual Disease (MRD)|Time to Response (TTR)|Overall Survival (OS)","AbbVie|Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-654|2017-002099-26","March 12, 2018","June 25, 2024","June 25, 2024","October 19, 2017",,"October 28, 2019","Univ of Colorado Cancer Center /ID# 167331, Aurora, Colorado, United States|Duplicate_Moffitt Cancer Center /ID# 169614, Tampa, Florida, United States|Emory University Hospital /ID# 165427, Atlanta, Georgia, United States|University of Chicago /ID# 165429, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center /ID# 210904, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 166886, Boston, Massachusetts, United States|Roswell Park Comprehensive Cancer Center /ID# 169615, Buffalo, New York, United States|Weill Cornell Medicine/NYP /ID# 167605, New York, New York, United States|Carolinas Medical Center /ID# 164948, Charlotte, North Carolina, United States|Duke University Medical Center /ID# 165104, Durham, North Carolina, United States|Oregon Health Science Universi /ID# 166822, Portland, Oregon, United States|University of Washington /ID# 164884, Seattle, Washington, United States|St. Vincent's Hospital, Darlinghurst /ID# 165431, Darlinghurst, New South Wales, Australia|St George Hospital /ID# 171063, Kogarah, New South Wales, Australia|Royal Adelaide Hospital /ID# 171060, Adelaide, South Australia, Australia|Eastern Health /ID# 165850, Box Hill, Victoria, Australia|St. Vincents Hosp Melbourne /ID# 165853, Fitzroy, Victoria, Australia|Peter MacCallum Cancer Ctr /ID# 164742, Melbourne, Victoria, Australia|University of Calgary /ID# 167822, Calgary, Alberta, Canada|Cross Cancer Institute /ID# 203114, Edmonton, Alberta, Canada|McGill Univ HC /ID# 167824, Montreal, Quebec, Canada|Rigshospitalet /ID# 164420, Copenhagen Ø, Hovedstaden, Denmark|Aarhus University Hospital /ID# 164509, Aarhus N, Midtjylland, Denmark|Odense Universitets Hospital /ID# 164417, Odense C, Syddanmark, Denmark|Sygehus Lillebaelt - Vejle Syg /ID# 164418, Vejle, Syddanmark, Denmark|Hopital Bretonneau - CHU Tours /ID# 164795, Tours CEDEX 9, Indre-et-Loire, France|CHU Hotel Dieu /ID# 164767, Nantes CEDEX 1, Pays-de-la-Loire, France|CHU Poitiers /ID# 164806, Poitiers, France|Institute Gustave Roussy /ID# 164807, Villejuif, France|University Hospital Cologne /ID# 166037, Cologne, Germany|Universitätsklinikum Freiburg /ID# 166036, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT03314181"
112,"NCT03311477","A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-399","Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)|Maximum Tolerated Dose (MTD) or maximally administered dose (MAD) for ABBV-399|Terminal elimination half life (t1/2)|Maximum Observed Concentration (Cmax)|Time to Cmax (Tmax)|Progression-Free Survival (PFS) Time|Objective Response Rate (ORR)|Duration of response (DOR)","AbbVie","All","20 Years and older   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-080","November 6, 2017","March 4, 2019","March 4, 2019","October 17, 2017",,"March 14, 2019","Shizuoka Cancer Center /ID# 166940, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital /ID# 166939, Chuo-ku, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT03311477"
113,"NCT03311464","A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan",,"Active, not recruiting","No Results Available","Pyoderma Gangrenosum","Drug: adalimumab","Proportion of participants who have achieved target Pyoderma Gangrenosum Area Reduction (PGAR)|Proportion of participants achieving Physician's Global Assessment (PGA) 0 or 1|Mean time to occurrence of new PG ulcers|Change from Baseline in total number of active ulcers|Change from Baseline in Dermatology Life Quality Index (DLQI)|Changes from Baseline in total ulcer area|Proportion of participants with inflammation reduction as assessed on an Investigator Inflammation Assessment (IIA) Score|Mean time to occurrence of a new PG ulcer(s)|Mean time to healing of target ulcer|Proportion of participants achieving healing per PGAR for the target ulcer|Proportion of participants who have achieved target PGAR|Percentage change in target Pyoderma Gangrenosum (PG) ulcer area|Proportion of participants achieving PGA 0|Change from Baseline in Pain as measured by Numerical Rating Scale (NRS)|Changes from baseline in the proportion of participants taking analgesics|Velocities of healing|Proportion of participants achieving ulcer healing as assessed by PGAR|Proportion of participants achieving PGA 0 of all PG ulcers|Mean time to relapse of the target PG ulcer|Mean time to healing as defined by PGAR","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","22","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-119","October 27, 2017","August 20, 2019","May 8, 2020","October 17, 2017",,"September 12, 2019","Nagoya City University Hospital /ID# 164510, Nagoya-shi, Aichi, Japan|Juntendo University Urayasu Hospital /ID# 164422, Urayasu Shi, Chiba, Japan|Fukuoka University Hospital /ID# 164416, Fukuoka-shi, Fukuoka, Japan|Fukushima Medical University Hospital /ID# 164358, Fukushima-shi, Fukushima, Japan|Gunma University Hospital /ID# 164464, Maebashi-shi, Gunma, Japan|Asahikawa Medical University Hospital /ID# 164589, Asahikawa-shi, Hokkaido, Japan|Mie University Hospital /ID# 164389, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 164360, Sendai-shi, Miyagi, Japan|Shinshu University Hospital /ID# 164852, Matsumoto-shi, Nagano, Japan|Nagasaki University Hospital /ID# 167604, Nagasaki-shi, Nagasaki, Japan|University of the Ryukyus Hospital /ID# 164981, Nakagami-gun, Okinawa, Japan|Hamamatsu University Hospital /ID# 165890, Higashi-ku, Shizuoka, Japan|Tokushima University Hospital /ID# 164359, Tokushima-shi, Tokushima, Japan|Teikyo University Hospital /ID# 165665, Itabashi-ku, Tokyo, Japan|Tokyo Medical University Hospital /ID# 165810, Shinjuku-ku, Tokyo, Japan|Keio University Hospital /ID# 165680, Shinjuku-ku, Tokyo, Japan|Kansai Medical Univ Hosp /ID# 165802, Hirakata-shi, Osaka, Japan|Hokkaido University Hospital /ID# 164419, Sapporo, Japan|Yamaguchi University Hospital /ID# 164562, UBE, Japan|Showa Univ Fujigaoka Hosp /ID# 164406, Yokohama-shi, Japan",,"https://ClinicalTrials.gov/show/NCT03311464"
114,"NCT03310190","Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice","DEVOTE","Recruiting","No Results Available","Chronic Lymphocytic Leukemia",,"Duration of Prophylactic Hospitalization|Number of Hours from Dosing to Blood Draw|Intravenous (IV) fluid hydration|Percent of Participants with Tumor Burden of Low, Medium, and High|Other Actions Taken within the First 24 Hours of each Dose Ramp-up|Change from Baseline in Health Care Resource Utilization (HCRU)|Change in Metabolites Post Dose|Percentage of Participants with Prophylactic Hospitalization|Reasons for Dose Interruptions|Change in Creatinine Clearance|Number of Hours for Dose Interruptions|Number of Weeks for Ramping up Venetoclax Dose to 400 mg daily (QD) or maximum dose reached|Number of Days on Each Dose of Venetoclax|Percentage of Participants with Other Mutations|Weeks since Last CLL Relapse|Percentage of Participants with Major Co-Morbidities|Percentage of Participants with Exposure to Ibrutinib and/or Idelalisib Prior to Baseline|Change from Baseline in EORTC QLQ-C30 Scores|Change from Baseline in Eastern Cooperative Oncology Group Performance Status|Change from Baseline in QLQ-CLL17 Scores|Weeks Since Initiating First Line of Therapy for CLL|Percent of Participants at Each Stage in the Rai Staging System|Percentage of Participants with Del(17p)|Percent of Participants at Each Stage in the Binet Staging System|Number of Prior Lines of Therapy for CLL|Years to Treatment from Initial Diagnosis of Chronic Lymphocytic Leukemia (CLL)|Weeks since the Last Line of Therapy (Agent) for CLL Prior to Baseline|Weeks since First CLL Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"70","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-489","January 10, 2018","December 15, 2020","December 15, 2020","October 16, 2017",,"January 2, 2020","University of Calgary /ID# 166416, Calgary, Alberta, Canada|Cross Cancer Institute /ID# 166417, Edmonton, Alberta, Canada|Jack Ady Cancer Centre /ID# 217491, Lethbridge, Alberta, Canada|The Moncton Hospital /ID# 166043, Moncton, New Brunswick, Canada|Qe Ii Hsc /Id# 213548, Halifax, Nova Scotia, Canada|William Osler Health System /ID# 202049, Brampton, Ontario, Canada|Kingston Health Sciences Centr /ID# 169252, Kingston, Ontario, Canada|The Ottawa Hospital Research /ID# 166041, Ottawa, Ontario, Canada|health sciences north /ID# 205817, Sudbury, Ontario, Canada|PEI Cancer Treatment Centre, Queen Elizabeth Hospital /ID# 214394, Charlottetown, Prince Edward Island, Canada|Jewish General Hospital /ID# 166418, Montreal, Quebec, Canada|Cisss Du Bas-Saint-Laurent Hopital Regional de Rimouski /Id# 201202, Rimouski, Quebec, Canada|CancerCare Manitoba /ID# 170751, Manitoba, Canada|Thunder Bay Regional Health Research /ID# 204740, Thunder Bay, Canada",,"https://ClinicalTrials.gov/show/NCT03310190"
115,"NCT03303599","Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6",,"Active, not recruiting","No Results Available","Hepatitis C Virus (HCV)",,"Percentage of participants achieving sustained virological response 12 weeks post-treatment (SVR12)|Percentage of Participants Taking Concomitant Medications|Percentage of Glecaprevir plus Pibrentasvir (GLE/PIB) Doses Taken out of that Prescribed|Changes from Baseline in Estimated Glomerular Filtration Rate (eGFR)|Number of Healthcare Resource Utilization (HCRU)|Percentage of Participants Using Each Treatment Regimen|Percentage of Participants with Co-morbidities","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"2118","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P17-094","November 13, 2017","February 15, 2020","February 15, 2020","October 6, 2017",,"November 26, 2019","University Hospital St. Polten /ID# 169918, St. Pölten, Niederoesterreich, Austria|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 169915, Linz, Oberoesterreich, Austria|LKH-Univ. Klinikum Graz /ID# 169932, Graz, Austria|Landeskrankenhaus Hall i. Tiro /ID# 169930, HALL I. Tirol, Austria|Landeskrankenhaus /ID# 169922, Innsbruck, Austria|KABEG Klinikum Anstaltsapothek /ID# 169931, Oesterreich, Austria|Klinikum Wels - Grieskirchen /ID# 169916, Wels, Austria|Wilhelminenspital der Stadt Wien /ID# 169914, Wien, Austria|Uza /Id# 170960, Edegem, Antwerpen, Belgium|Cliniques Universitaires Saint Luc /ID# 170964, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Algemeen Stedelijk Ziekenhuis /ID# 170876, Aalst, Oost-Vlaanderen, Belgium|UZ Gent /ID# 170922, Gent, Oost-Vlaanderen, Belgium|Centre Hospitalier de Wallonie Picarde /ID# 200822, Tournai, Wallonne, Region, Belgium|Zna /Id# 170927, Antwerpen, Belgium|CHU Saint-Pierre /ID# 170920, Brussels, Belgium|CHU Brugmann /ID# 170956, Brussels, Belgium|Hopital Erasme /ID# 170918, Brussels, Belgium|Z.O.L - Campus St. Jan /ID# 171058, Genk, Belgium|AZ Middelares Gent /ID# 170874, Gent, Belgium|Jessa Ziekenhuis /ID# 170958, Hasselt, Belgium|AZ Groeninge /ID# 170931, Kortrijk, Belgium|UZ Leuven /ID# 170921, Leuven, Belgium|CHC Liege /ID# 170926, Liege, Belgium|Centre Hospitalier Universitaire du Sart Tilman (CHU de Liège) /ID# 170930, Liège, Belgium|CHU Ambroise Pare /ID# 171107, Mons, Belgium|CHIREC Edith Cavell /ID# 170932, Uccle, Belgium|CHU Dinant Godinne /ID# 170929, Yvoir, Belgium|CHR Orleans - Hopital de la Source /ID# 202360, Orleans CEDEX 2, Centre-Val De Loire, France|CH Georges Renon /ID# 202737, Niort CEDEX, Deux-Sevres, France|CHU de Besancon - Jean Minjoz /ID# 208502, Besancon, Doubs, France|CHU Dupuytren /ID# 202514, Limoges CEDEX 1, Franche-Comte, France|Hopital Haut-Lévêque /ID# 202501, Pessac CEDEX, Gironde, France|Hôpital Purpan /ID# 202357, TOULOUSE Cedex 9, Haute-Garonne, France|Hôpital Purpan /ID# 204201, TOULOUSE Cedex 9, Haute-Garonne, France|CH Annecy Genevois Site Annecy /ID# 202804, Epagny Metz Tessy, Haute-Savoie, France|CH Spécialisé Esquirol /ID# 204522, Limoges, Haute-Vienne, France|Centre Hospitalier de Béziers /ID# 202948, Beziers CEDEX, Herault, France|Hopital Saint Eloi /ID# 202512, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 202675, Clichy, Ile-de-France, France|Hopital Broussais /ID# 202677, St Malo CEDEX, Ille-et-Vilaine, France|Maison de Santé pluridisciplianaire /ID# 202519, Orleans, Loiret, France|CHU NANCY - Hôpital Brabois Adultes /ID# 202570, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|Hopital de la Timone /ID# 202792, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Charles Nicolle CHU Rouen /ID# 203518, Rouen CEDEX, Seine-Maritime, France|Centre Hosp Intercommunal de Creteil /ID# 202566, Creteil, Val-de-Marne, France|Cabinet medical /ID# 202794, Aix En Provence, France|CHU d'Angers /ID# 202500, Angers, France|Clinique du Tondu /ID# 207508, Bordeaux, France|Centre Endo Nord Isere /ID# 204181, Bourgoin Jallieu, France|Hopital de la Cavale Blanche /ID# 202640, Brest, France|Hopital Antoine Beclere /ID# 202676, Clamart, France|CHU Estaing /ID# 202949, Clermont Ferrand, France|Hopital Henri Mondor /ID# 202806, Creteil, France|CHU de Grenoble - Albet Michal /ID# 202957, Grenoble, France|CH d'Hyeres /ID# 202515, Hyeres, France|Dr. Cuissard, Le Port, FR /ID# 203487, Le Port, France|C.H. de Bretagne Sud /ID# 202362, Lorient, France|Hopital de la Croix Rousse /ID# 203071, Lyon, France|Hopital Edouard Herriot /ID# 203149, Lyon, France|Hopital Europeen /ID# 205073, Marseille, France|Cabinet Medical, Boyer Darrigr /ID# 202050, Nanterre, France|CHU de Nice /ID# 205295, Nice, France|CHU Nimes /ID# 208200, Nimes Cedex 9, France|Hopital Saint Antoine /ID# 202565, Paris Cedex 12, France|Hopital Bichat-Claude Bernard /ID# 202513, Paris, France|Hopital Pitie Salpetriere /ID# 202364, Paris, France|Centre Hospitalier PERPIGNAN /ID# 205762, Perpignan, France|Hopital Robert Debre /ID# 202953, Reims, France|Institut Arnault Tzanck /ID# 202363, Saint Laurent Du Var, France|Gastrodoc /Id# 206290, St Jean de Vedas, France|Cabinet Medical, Dr. Constant, /ID# 202361, Toulon, France|Clinique Amroise Pare /ID# 205064, Toulouse, France|Hopital Joseph Ducuing /ID# 205666, Toulouse, France|Ctre Hospitalier de Tourcoing /ID# 202358, Tourcoing, France|Ctre Hospitalier de Tourcoing /ID# 202805, Tourcoing, France|Hopital Paul Brousse /ID# 202623, Villejuif, France|General Hospital of Athens Laiko /ID# 206421, Athens, Attiki, Greece|Tzaneio general hospital of Piraeus /ID# 208828, Piraeus, Attiki, Greece|Papageorgiou General Hospital Thessaloniki /ID# 207980, Nea Efkarpia, Thessaloniki, Greece|Gen Univ Hosp Alexandroupolis /ID# 206416, Alexandroupolis, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 206414, Athens, Greece|General and Oncology Hospital /ID# 206419, Kifissia, Greece|General Hospital Nikaias-Piraeus St. Panteleimon /ID# 206420, Pireaus, Greece|Bioclinic Thessaloniki /ID# 207981, Thessaloniki, Greece|University Gen Hosp ""AHEPA"" /ID# 209961, Thessaloniki, Greece|Interbalkan Medical Center /ID# 206417, Thessaloniki, Greece|Soroka Medical Center /ID# 169321, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 169320, Petakh Tikva, Tel-Aviv, Israel|HaEmek Medical Center /ID# 169318, Afula, Israel|Assaf Harofeh Medical Center /ID# 169370, Be'er Ya'akov, Israel|Maccabi Health Services /ID# 169372, Gush Dan, Israel|Hillel Yaffe Medical Center /ID# 169368, Hadera, Israel|Bnai Zion Medical Center /ID# 169358, Haifa, Israel|Carmel Medical Center /ID# 169309, Haifa, Israel|Rambam Medical Center /ID# 169316, Haifa, Israel|Shaare Zedek Medical Center /ID# 169329, Jerusalem, Israel|Hadassah University Hospital /ID# 169360, Jerusalem, Israel|Meir Medical Center /ID# 169327, Kfar Saba, Israel|Galilee Medical Center /ID# 169325, Nahariya, Israel|Sheba Medical Center /ID# 169365, Ramat Gan, Israel|Tel Aviv Medical Center /ID# 169313, Tel Aviv, Israel|AOU Federico II /ID# 168131, Naples, Campania, Italy|Ospedale Sant Orsola Malpighi /ID# 168127, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 168711, Modena, Emilia-Romagna, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 168138, Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 168712, Milano, Lombardia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 168137, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 169353, Rozzano, Milano, Italy|AOU Citta della Salute Scienza /ID# 168142, Turin, Piemonte, Italy|Fondazione PTV Policlinico Tor Vergata /ID# 168709, Rome, Roma, Italy|Università Cattolica Sacro Cuore /ID# 168781, Rome, Roma, Italy|Policlinico Paolo Giaccone /Id# 168134, Palermo, Sicilia, Italy|Azienda Universitaria Ospedali /ID# 168129, Bari, Italy|AOU di Cagliari - Presidio di /ID# 168132, Cagliari, Italy|A.O.U Sant'Anna di Ferrara /ID# 168714, Ferrara, Italy|AOU Riuniti di Foggia /ID# 168143, Foggia, Italy|Ospedale SM Goretti /ID# 169257, Latina, Italy|A.O.U. Policlinico G. Martino /ID# 168139, Messina, Italy|Ospedale S. Carlo Borromeo /ID# 168144, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 168136, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 168140, Milan, Italy|Azienda Ospedaliera di Rilievo /ID# 168141, Naples, Italy|AO Domenico Cutugno /ID# 168133, Napoli, Italy|Universita degli Studi della /ID# 168135, Napoli, Italy|Azienda Ospedaliera Maggiore d /ID# 168710, Novara, Italy|Azienda Ospedaliera di Padova /ID# 168125, Padua, Italy|Azienda Ospedaliera di Padova /ID# 168126, Padua, Italy|Azienda Ospedaliero - Universi /ID# 168130, Pisa, Italy|IRCCS Lazzaro Spallanzani /ID# 169234, Rome, Italy|AOU OO. RR. San Giovanni di Di /ID# 168715, Salerno, Italy|NZOZ All-Medicus /ID# 208452, Katowice, Slaskie, Poland|Uniwersytecki Szpital Kliniczn /ID# 208604, Bialystok, Poland|Wojewodzki Szpital Obserwacyjn /ID# 209345, Bydgoszcz, Poland|Szpital Specjalistyczny Chorzo /ID# 209129, Chorzow, Poland|Wojewódzki Szpital Zespolony w Kielcach /ID# 210569, Kielce, Poland|SPZOZ Krakowie Szpital /ID# 208451, Krakow, Poland|Wojewodzki Szpit Bieganskiego /ID# 208445, Lodz, Poland|Wojewodzki Szpit Bieganskiego /ID# 209608, Lodz, Poland|ID Clinic /ID# 208332, Myslowice, Poland|Szpital Wojewodzki w Opolu /ID# 208444, Opole, Poland|Spec Szpital A. Sokolowskiego /ID# 208862, Walbrzych, Poland|MED-FIX Centrum Medyczne Sp. z /ID# 208453, Warsaw, Poland|NZOZ-Lubuska Secjalistyczna Po /ID# 208449, Zielona Gora, Poland|NZOZ Przychodnia Specjalistycz /ID# 208334, Zychlin, Poland|Centro Hospitalar do Barreiro Montijo, EPE /ID# 211267, Barreiro, Lisboa, Portugal|Hospital Curry Cabral, EPE /ID# 208463, Lisbon, Lisboa, Portugal|Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 208195, Vila Nova De Gaia, Porto, Portugal|Hospital Garcia de Orta, E.P.E /ID# 207717, Almada, Setubal, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 207910, Lisboa, Portugal|Centro Hospitalar do Porto EPE /ID# 207733, Porto, Portugal|Hopitaux Universitaires de Geneve /ID# 203435, Genève, Geneve, Switzerland|Kantonsspital St. Gallen /ID# 201025, St. Gallen, Sankt Gallen, Switzerland|Inselspital, Universitaetsklinik /ID# 201022, Bern, Switzerland|Fondazione Epatocentro Ticino /ID# 201024, Lugano, Switzerland|Hopital Neuchatelois /ID# 201026, Neuchatel, Switzerland|Universitaetsspital Zuerich /ID# 201023, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03303599"
116,"NCT03271489","Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women",,"Active, not recruiting","No Results Available","Heavy Menstrual Bleeding|Uterine Fibroids","Other: Elagolix Placebo|Drug: E2/NETA|Other: E2/NETA Placebo|Drug: Elagolix","Change in Bone Mineral Density (BMD)","AbbVie","Female","18 Years to 50 Years   (Adult)","Phase 3","478","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-283","September 13, 2017","August 18, 2023","July 19, 2024","September 5, 2017",,"January 13, 2020","Alabama Clinical Therapeutics, LLC /ID# 160835, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC /ID# 160927, Birmingham, Alabama, United States|Choice Research, LLC /ID# 161498, Dothan, Alabama, United States|Brown, Pearson, Guepet Gynecology /ID# 161531, Fairhope, Alabama, United States|E Squared Research /ID# 163645, Huntsville, Alabama, United States|Women's Health Alliance of Mobile /ID# 161443, Mobile, Alabama, United States|Mobile, Ob-Gyn, P.C. /ID# 161530, Mobile, Alabama, United States|Mesa Obstetricians and Gynecol /ID# 160955, Mesa, Arizona, United States|Noble Clinical Research /ID# 166949, Tucson, Arizona, United States|Visions Clinical Research-Tucs /ID# 161508, Tucson, Arizona, United States|Eclipse Clinical Research /ID# 161516, Tucson, Arizona, United States|Northern California Research /ID# 161561, Carmichael, California, United States|Core Healthcare Group /ID# 160858, Cerritos, California, United States|Diagnamics Inc. /ID# 160950, Encinitas, California, United States|HRC Fertility /ID# 161493, Encino, California, United States|SC Clinical Research /ID# 164395, Garden Grove, California, United States|Marvel Clinical Research /ID# 167297, Huntington Beach, California, United States|Grossmont Ctr Clin Research /ID# 165120, La Mesa, California, United States|Olympia Clinical Trials /ID# 201562, Los Angeles, California, United States|National Research Institute /ID# 160952, Los Angeles, California, United States|Futura Research, Inc. /ID# 160924, Montebello, California, United States|California Medical Research As /ID# 161481, Northridge, California, United States|Precision Research Institute - San Diego /ID# 163069, San Diego, California, United States|MD Strategies Research Centers /ID# 161544, San Diego, California, United States|Health care Affiliates Medical Group /ID# 163324, Santa Ana, California, United States|Alta California Medical Group /ID# 163564, Simi Valley, California, United States|Upland Clinical Research /ID# 164528, Upland, California, United States|Bayview Research Group LLC /ID# 161484, Valley Village, California, United States|Advanced RX Clinical Research /ID# 161599, Westminster, California, United States|Emerson Clinical Research Inst /ID# 162181, Washington, District of Columbia, United States|James A. Simon, MD, PC /ID# 160931, Washington, District of Columbia, United States|Women's Health Partners /ID# 203577, Boca Raton, Florida, United States|David Lubetkin MD LLC /ID# 203578, Boca Raton, Florida, United States|Brandon Premier Health Care, PA /ID# 160910, Brandon, Florida, United States|Omega Research Consultants, LLC /ID# 160857, DeBary, Florida, United States|Midland Florida Clinical Research Center /ID# 161487, DeLand, Florida, United States|KO Clinical Research, LLC /ID# 160928, Fort Lauderdale, Florida, United States|Sweet Hope Research Specialty Inc /ID# 163522, Hialeah, Florida, United States|Solutions Through Adv Rch /ID# 160935, Jacksonville, Florida, United States|Meridien Research /ID# 160913, Kenneth City, Florida, United States|Altus Research, Inc /ID# 160912, Lake Worth, Florida, United States|Wellington Anti-Aging LLC /ID# 203540, Loxahatchee Groves, Florida, United States|South Florida Wellness & Clinic /ID# 161535, Margate, Florida, United States|Precision Research Org, LLC /ID# 161522, Miami Lakes, Florida, United States|Invictus Clinical Research Group,LLC /ID# 160925, Miami, Florida, United States|Healthcare Clinical Data, Inc /ID# 160888, Miami, Florida, United States|Ocean Blue Med Research Ctr /ID# 161549, Miami, Florida, United States|Vista Health Research LLC - Miami /ID# 163044, Miami, Florida, United States|Palmetto Professional Research /ID# 161442, Miami, Florida, United States|Salom Tangir, LLC /ID# 162542, Miramar, Florida, United States|Advanced Research Institute /ID# 163748, New Port Richey, Florida, United States|A Premier Clinical Research of Florida, LLC /ID# 201882, Orange City, Florida, United States|Clinical Associates of Orlando /ID# 160889, Orlando, Florida, United States|Oncova Clinical Research, Inc. /ID# 160937, Saint Cloud, Florida, United States|Physician Care Clin. Res., LLC /ID# 161547, Sarasota, Florida, United States|Treasure Coast Research /ID# 161824, Stuart, Florida, United States|Discovery Clinical Research /ID# 160891, Sunrise, Florida, United States|Precision Clinical Research /ID# 165377, Sunrise, Florida, United States|GCP Clinical Research, LLC /ID# 164593, Tampa, Florida, United States|University of South Florida /ID# 160960, Tampa, Florida, United States|Jedidiah Clinical Research /ID# 167114, Tampa, Florida, United States|Virtus Research Consultant,LLC /ID# 160855, Wellington, Florida, United States|Comprehensive Clinical Trials /ID# 161479, West Palm Beach, Florida, United States|Journey Medical Research Insti /ID# 160958, Alpharetta, Georgia, United States|Paramount Research Solutions /ID# 161557, Alpharetta, Georgia, United States|Agile Clinical Research Trials /ID# 160941, Atlanta, Georgia, United States|Mount Vernon Clinical Res, LLC /ID# 161491, Atlanta, Georgia, United States|Atlanta Women's Research Inst /ID# 160844, Atlanta, Georgia, United States|Medisense Inc /ID# 161494, Atlanta, Georgia, United States|Atlanta Gynecology Research Institute /ID# 160851, Suwanee, Georgia, United States|Bingham Memorial Hospital /ID# 201130, Blackfoot, Idaho, United States|Leavitt Womens Healthcare /ID# 163419, Idaho Falls, Idaho, United States|Womens Healthcare Assoc, DBA /ID# 160933, Idaho Falls, Idaho, United States|Sonora Clinical Research /ID# 167610, Meridian, Idaho, United States|Asr, Llc /Id# 162179, Nampa, Idaho, United States|Women's Health Practice, LLC /ID# 161553, Champaign, Illinois, United States|Moore for Women Healthcare and Wellness Institute, LLC /ID# 167118, Chicago, Illinois, United States|University of Chicago /ID# 162667, Chicago, Illinois, United States|Affinity Clinical Research /ID# 160932, Oak Brook, Illinois, United States|Women's Health Advantage /ID# 161537, Fort Wayne, Indiana, United States|Womens & Family Care, LLC dba /ID# 160890, Shawnee Mission, Kansas, United States|Bluegrass Clinical Research /ID# 163485, Louisville, Kentucky, United States|Clinical Trials Management, LLC - Covington /ID# 160838, Covington, Louisiana, United States|Clinical Trials Management, LLC - Covington /ID# 160893, Covington, Louisiana, United States|Praetorian Pharmaceutical Res /ID# 161532, Marrero, Louisiana, United States|Ochsner Baptist Medical Centre /ID# 161507, New Orleans, Louisiana, United States|Women Under Study, LLC /ID# 163990, New Orleans, Louisiana, United States|Willis-Knighton Pediatric GI S /ID# 161534, Shreveport, Louisiana, United States|Genesis Clinical Research - Fall River /ID# 160853, Fall River, Massachusetts, United States|Great Lakes Research Group,Inc /ID# 161511, Bay City, Michigan, United States|Wayne State University /ID# 160944, Detroit, Michigan, United States|Valley OB-Gyn Clinic /ID# 203579, Saginaw, Michigan, United States|Saginaw Valley Med Res Group /ID# 160840, Saginaw, Michigan, United States|Quad Clinical Research, LLC /ID# 200943, Saint Louis, Missouri, United States|Excel Clinical Research /ID# 165588, Las Vegas, Nevada, United States|Office of Edmond E. Pack, MD /ID# 162604, Las Vegas, Nevada, United States|R. Garn Mabey Jr, MD /ID# 160915, Las Vegas, Nevada, United States|Jersey Shore University Medical Center /ID# 160916, Neptune, New Jersey, United States|Lovelace Scientific Resources /ID# 163644, Albuquerque, New Mexico, United States|Bosque Women's Care /ID# 162606, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center /ID# 160922, Brooklyn, New York, United States|Northwell Health System - Manhasset /ID# 201058, Manhasset, New York, United States|Weill Cornell Medicine /ID# 161519, New York, New York, United States|Hamburg Regional Gynecology Gr /ID# 161427, Orchard Park, New York, United States|DJL Clinical Research, PLLC /ID# 161548, Charlotte, North Carolina, United States|Carolina Women's Research and Wellness Center /ID# 160914, Durham, North Carolina, United States|Unified Women's Clinical Resea /ID# 163014, Raleigh, North Carolina, United States|Wake Research Associates, LLC /ID# 161490, Raleigh, North Carolina, United States|Unified Women's Clinical Resea /ID# 160957, Winston-Salem, North Carolina, United States|Clinical Inquest Center Ltd /ID# 160892, Beavercreek, Ohio, United States|CTI Clinical Research Center /ID# 160942, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 160953, Cleveland, Ohio, United States|Central Ohio Clinical Research /ID# 201162, Columbus, Ohio, United States|Optimed Research /ID# 165600, Columbus, Ohio, United States|Hilltop Obstetrics & Gynecology /ID# 203576, Middletown, Ohio, United States|University of Toledo /ID# 160923, Toledo, Ohio, United States|Oregon Health and Science University /ID# 161514, Portland, Oregon, United States|OB/GYN Associates of Erie /ID# 161541, Erie, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 160896, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 160936, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 200304, Philadelphia, Pennsylvania, United States|Vista Clinical Research /ID# 160946, Columbia, South Carolina, United States|VitaLink Research-Spartanburg /ID# 164592, Spartanburg, South Carolina, United States|Chattanooga Medical Research /ID# 160885, Chattanooga, Tennessee, United States|WR-ClinSearch /ID# 160887, Chattanooga, Tennessee, United States|The Jackson Clinic, PA /ID# 162496, Jackson, Tennessee, United States|Research Memphis Associates, LLC /ID# 160939, Memphis, Tennessee, United States|OBGYN North /ID# 203580, Austin, Texas, United States|AA (Austin Area) ObGyn PLLC /ID# 203542, Austin, Texas, United States|Texas Health Presbyterian Hosp /ID# 161543, Dallas, Texas, United States|The University of Texas Southwestern Medical Center /ID# 161496, Dallas, Texas, United States|Texas Health Care, PLLC /ID# 161515, Fort Worth, Texas, United States|Willowbend Health and Wellness - Frisco /ID# 160954, Frisco, Texas, United States|Advances in Health, Inc. /ID# 160930, Houston, Texas, United States|The Ob/Gyn Center /ID# 165928, Houston, Texas, United States|Precision Research Institute - Houston /ID# 161554, Houston, Texas, United States|The Woman's Hospital of Texas /ID# 160959, Houston, Texas, United States|Centex Studies, Inc /ID# 163858, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 160917, Houston, Texas, United States|UAG Innovation Women Research, /ID# 167415, Houston, Texas, United States|America's Adv. Wellness Center /ID# 167548, Houston, Texas, United States|FMC Science /ID# 160886, Lampasas, Texas, United States|ClinRx Research, LLC /ID# 201170, Plano, Texas, United States|Clinical Trials of Texas,Inc. /ID# 161510, San Antonio, Texas, United States|Victorium Clinical Research /ID# 161546, San Antonio, Texas, United States|Houston Ctr for Clin Research /ID# 160837, Sugar Land, Texas, United States|The Univ Texas HSC at Tyler /ID# 161533, Tyler, Texas, United States|Center of Reproductive Medicin /ID# 162498, Webster, Texas, United States|Univ of Virgnia Medical center /ID# 166283, Charlottesville, Virginia, United States|Eastern Virginia Med School /ID# 160856, Norfolk, Virginia, United States|Clinical Research Partners, LL /ID# 160929, North Chesterfield, Virginia, United States|Clinical Research Partners, LL /ID# 160948, North Chesterfield, Virginia, United States|Clinical Trials Virginia, Inc. /ID# 160943, Richmond, Virginia, United States|Specialists for Women /ID# 201129, Suffolk, Virginia, United States|Tidewater Clinical Research /ID# 160949, Virginia Beach, Virginia, United States|Rodriguez-Ginorio, San Juan /ID# 160861, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 160862, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03271489"
117,"NCT03258814","A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA)","Treat & Train","Terminated","Has Results","Axial Spondyloarthritis","Behavioral: Active Supervised Training (AST)|Behavioral: Standard of Care (SOC) Physiotherapy","Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 6|Change Form Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Month 3|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)|Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)|Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)|Percentage of Participants Achieving a BASDAI 50 Response|Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)|Percentage of Participants With ASDAS Inactive Disease|Percentage of Participants With ASDAS Low Disease Activity|Percentage of Participants With ASDAS Moderate Disease Activity|Percentage of Participants With ASDAS High Disease Activity|Percentage of Participants With ASDAS Very High Disease Activity|Percentage of Participants Achieving ASDAS Major Improvement|Percentage of Participants Achieving ASDAS Clinically Important Improvement|Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response|Percentage of Participants Achieving an ASAS 40 Response|Percentage of Participants Achieving ASAS Partial Remission|Change From Baseline in Patient's Global Assessment of Pain|Change From Baseline in Patient's Assessment of Total Back Pain|Change From Baseline in Patient's Assessment of Nocturnal Back Pain|Change From Baseline in Modified Work Ability Index (WAI)|Change From Baseline in Fatigue|Change From Baseline in Severity and Duration of Morning Stiffness|Change From Baseline in Fear-Avoidance Belief Questionnaire Score (FABQ)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"17","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-710","December 8, 2017","September 14, 2018","September 14, 2018","August 23, 2017","October 2, 2019","October 2, 2019","Rheumahaus Studien GbR, Potsdam, DE /ID# 164494, Potsdam, Brandenburg, Germany|MVZ Wittenbergplatz PP Orthos /ID# 204802, Berlin, Germany|Rheumapraxis /ID# 164461, Halle, Germany|Praxis Ortho DE /ID# 204149, Hamburg, Germany|Praxis internistische Rheumato /ID# 164463, Leipzig, Germany|Krankenhaus St. Josef /ID# 164501, Wuppertal, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03258814/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT03258814/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03258814"
118,"NCT03255382","A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy",,"Completed","Has Results","Psoriasis","Drug: Fumaderm|Drug: risankizumab","Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI90) at Week 24|Percentage of Participants Achieving 50% Improvement in PASI Score (PASI50) at Week 4|Percentage of Participants Achieving 50% Improvement in PASI Score (PASI50) at Week 8|Percentage of Participants Achieving 50% Improvement in PASI Score (PASI50) at Week 12|Percentage of Participants Achieving 50% Improvement in PASI Score (PASI50) at Week 16|Percentage of Participants Achieving 50% Improvement in PASI Score (PASI50) at Week 20|Percentage of Participants Achieving 50% Improvement in PASI Score (PASI50) at Week 24|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 4|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 8|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 12|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 20|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 24|Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 4|Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 8|Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 12|Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 16|Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 20|Percentage of Participants Achieving 100% Improvement in PASI (PASI100) at Week 4|Percentage of Participants Achieving 100% Improvement in PASI (PASI100) at Week 8|Percentage of Participants Achieving 100% Improvement in PASI (PASI100) at Week 12|Percentage of Participants Achieving 100% Improvement in PASI (PASI100) at Week 16|Percentage of Participants Achieving 100% Improvement in PASI (PASI100) at Week 20|Percentage of Participants Achieving 100% Improvement in PASI (PASI100) at Week 24|Psoriasis Area and Severity Index (PASI): Change From Baseline to Week 4|PASI: Change From Baseline to Week 8|PASI: Change From Baseline to Week 12|PASI: Change From Baseline to Week 16|PASI: Change From Baseline to Week 20|PASI: Change From Baseline to Week 24|Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 4|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 8|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 12|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 16|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 20|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 24|Percentage of Participants Achieving sPGA Score of Clear at Week 4|Percentage of Participants Achieving sPGA Score of Clear at Week 8|Percentage of Participants Achieving sPGA Score of Clear at Week 12|Percentage of Participants Achieving sPGA Score of Clear at Week 16|Percentage of Participants Achieving sPGA Score of Clear at Week 20|Percentage of Participants Achieving sPGA Score of Clear at Week 24|Percentage of Participants With Psoriasis Symptoms Scale (PSS) Score of 0 at Week 16|Percentage of Participants With PSS Score of 0 at Week 24|PSS Total Score: Change From Baseline to Week 16|PSS Total Score: Change From Baseline to Week 24|Summary of Patient Benefit Index (PBI) at Week 16|Summary of PBI at Week 24|Clinical Severity of Nail Psoriasis (NAPPA-CLIN) Total Score: Change From Baseline to Week 16|NAPPA-CLIN Total Score: Change From Baseline to Week 24|Palmoplantar Psoriasis Severity Index (PPASI): Change From Baseline to Week 16|PPASI: Change From Baseline to Week 24|Body Surface Area (BSA) Affected by Psoriasis: Change From Baseline to Week 4|BSA Affected by Psoriasis: Change From Baseline to Week 8|BSA Affected by Psoriasis: Change From Baseline to Week 12|BSA Affected by Psoriasis: Change From Baseline to Week 16|BSA Affected by Psoriasis: Change From Baseline to Week 20|BSA Affected by Psoriasis: Change From Baseline to Week 24|Short Form Health Survey 36, Version 2 (SF-36 V2) Physical Component Summary (PCS) Score: Change From Baseline to Week 16|SF-36 V2 PCS Score: Change From Baseline to Week 24|SF-36 V2 Mental Component Summary (MCS) Score: Change From Baseline: to Week 16|SF-36 V2 MCS Score: Change From Baseline to Week 24|Patient's Global Assessment (PtGA): Change From Baseline to Week 16|PtGA: Change From Baseline to Week 24|Hospital Anxiety & Depression Scale (HADS) Total Score-Anxiety: Change From Baseline to Week 16|HADS Total Score-Anxiety: Change From Baseline to Week 24|HADS Total Score-Depression: Change From Baseline to Week 16|HADS Total Score-Depression: Change From Baseline to Week 24|Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16|Percentage of Participants Achieving DLQI Score of 0 or 1 at Week 24|DLQI Total Score: Change From Baseline to Week 16|DLQI: Change From Baseline to Week 24|Psoriasis Scalp Severity Index (PSSI): Change From Baseline at Week 16|PSSI: Change From Baseline at Week 24|European Quality of Life 5 Dimensions (EQ-5D-5L) Total Score: Change From Baseline to Week 16|EQ-5D-5L Total Score: Change From Baseline to Week 24|EQ-5D-5L Visual Analog Scale (VAS): Change From Baseline to Week 16|EQ-5D-5L VAS: Change From Baseline to Week 24|Nail Psoriasis Severity Index (NAPSI): Change From Baseline to Week 16|NAPSI: Change From Baseline to Week 24|Participants With Baseline NAPSI ˃0: Change From Baseline to Week 16|Participants With Baseline NAPSI ˃0: Change From Baseline to Week 24","AbbVie","All","18 Years to 79 Years   (Adult, Older Adult)","Phase 3","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-178|2016-003718-28","August 22, 2017","July 6, 2018","July 6, 2018","August 21, 2017","September 13, 2019","September 13, 2019","Universitaetsklinik Heidelberg /ID# 161014, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 161035, Erlangen, Bayern, Germany|Universitatsklinikum Frankfurt /ID# 161036, Frankfurt, Hessen, Germany|Universitatsklinikum Munster /ID# 165739, Munster, Niedersachsen, Germany|Johannes Wesling Klin Minden /ID# 161015, Minden, Nordrhein-Westfalen, Germany|CMS3 Company for Medical Study /ID# 161103, Selters (Westerwald), Rheinland-Pfalz, Germany|Univ Hosp Schleswig-Holstein /ID# 160995, Kiel, Schleswig-Holstein, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH /ID# 161102, Kiel, Schleswig-Holstein, Germany|Charité Universitätsmedizin Campus Mitte /ID# 165621, Berlin, Germany|ISA GmbH /ID# 165619, Berlin, Germany|Gemeinschaftspraxis /ID# 161037, Blankenfeld-mahlow, Germany|Hautzentrum Niesmann Othlingha /ID# 161034, Bochum, Germany|Universitaetsklinikum Bonn /ID# 165618, Bonn, Germany|Hautklinik Klinikum Darmstadt /ID# 164940, Darmstadt, Germany|Universitaetklinikum Dresden /ID# 160983, Dresden, Germany|Univ Klinik Eppendorf Hamburg /ID# 161038, Hamburg, Germany|Tfs /Id# 160994, Hamburg, Germany|Klinik fur Dermatologie /ID# 161101, Leipzig, Germany|Univ Johannes Gutenberg /ID# 161104, Mainz, Germany|TU Uniklinik Munchen /ID# 160996, Munich, Germany|Universitatsklinikum Tubingen /ID# 165620, Tuebingen, Germany|Hoffmann, Witten, DE /ID# 165622, Witten, Germany|Centroderm Wuppertal /ID# 165615, Wuppertal, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03255382/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT03255382/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03255382"
119,"NCT03253185","A Study of SC-007 in Subjects With Advanced Cancer",,"Terminated","No Results Available","Colorectal Cancer (CRC)|Gastric Cancer","Drug: SC-007","Number of participants with dose-limiting toxicities (DLTs)|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)|Observed plasma concentrations at trough (Ctrough) of SC-007|Incidence of Anti-therapeutic Antibodies (ATAs) against SC-007|Overall Survival (OS)|Terminal half life (T1/2) of SC-007|Objective Response Rate (ORR)|Duration of Response (DOR)|Time to Cmax (Tmax) of SC-007|Area under the plasma concentration-time curve within a dosing interval (AUC) of SC-007|QTcF Change from Baseline|Maximum observed serum concentration (Cmax) of SC-007","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-310","September 13, 2017","March 20, 2018","April 2, 2018","August 17, 2017",,"April 27, 2018","University of California, Los Angeles, Los Angeles, California, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University-School of Medicine, Saint Louis, Missouri, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Tennessee Oncology-Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03253185"
120,"NCT03236870","A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China","ADAPT","Active, not recruiting","No Results Available","Psoriasis",,"Proportion of patients achieving at least a 75% reduction in Psoriasis Area Severity Index (PASI) relative to the baseline PASI score|Change from Baseline in Dermatology Life Quality Index (DLQI)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"181","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-986","September 8, 2017","September 8, 2020","September 8, 2020","August 2, 2017",,"January 2, 2020","Guangzhou 1st Muni People Hosp /ID# 208858, Guangzhou, Anhui, China|The First Affiliated Hospital /ID# 171398, Hefei, Anhui, China|AbbVie China /ID# 151567, Shanghai, Anhui, China|Ruijin Hospital, Shanghai Jiaotong /ID# 169833, Shanghai, Shanghai, China|Traditional Chinese Medical Hospital of xinjiang uygur autonomous region /ID# 209183, Wulumuqi, Xinjiang, China|The Second Affiliated Hospital /ID# 169842, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 169834, Hangzhou, Zhejiang, China|Peking University 3rd Hospital /ID# 213443, Beijing, China|Dermatology Hospital of southe /ID# 169830, Guangzhou, China|2nd Aff. Hosp Harbin Med Univ /ID# 169827, Haerbin, China|Shandong Provincial Hospital /ID# 169841, Jinan, China|The Tenth People's Hospital of /ID# 169831, Shanghai, China|The First Affiliated Hospital of Shantou University Medical College /ID# 209260, Shantou, China|The 7th People's Hospital of Shenyang /ID# 169829, Shenyang, China|Shenzhen Hospital of Southern /ID# 169828, Shenzhen, China|Jing Tai Tianjin Hospital Co.,Ltd /ID# 208201, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT03236870"
121,"NCT03236857","A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies",,"Recruiting","No Results Available","Malignancies|Acute Lymphoblastic Leukemia (ALL)|Acute Myeloid Leukemia (AML)|Non-Hodgkin's Lymphoma|Neuroblastoma","Drug: chemotherapy|Drug: venetoclax","AUC0-24 post-dose of venetoclax|Recommended Phase 2 dose (RPTD) of venetoclax|Number of Participants with Dose limiting toxicities (DLT) of Venetoclax Monotherapy|Tmax of venetoclax|Cmax of venetoclax|Objective Response Rate (ORR)|Partial Response (PR) rate|Complete Response (CR) rate","AbbVie|Roche-Genentech","All","up to 25 Years   (Child, Adult)","Phase 1","165","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-833|2017-000439-14","November 8, 2017","April 7, 2022","April 7, 2022","August 2, 2017",,"September 26, 2019","Phoenix Children's Hospital /ID# 202022, Phoenix, Arizona, United States|Univ California, San Francisco /ID# 163460, San Francisco, California, United States|Children's Hospital Colorado /ID# 161551, Aurora, Colorado, United States|Children's Healthcare of Atlan /ID# 161552, Atlanta, Georgia, United States|Dana-Farber Cancer Institute /ID# 163440, Boston, Massachusetts, United States|Mott Children's Hospital /ID# 211253, Ann Arbor, Michigan, United States|Memorial Sloan Kettering Cancer Center /ID# 163444, New York, New York, United States|Cincinnati Children's Hospital /ID# 161550, Cincinnati, Ohio, United States|Children's Hosp Philadelphia /ID# 163445, Philadelphia, Pennsylvania, United States|St. Jude Childrens Res Hosp /ID# 163447, Memphis, Tennessee, United States|Primary Children's /ID# 164399, Salt Lake City, Utah, United States|Seattle Children's Hospital /ID# 163459, Seattle, Washington, United States|Medical College of Wisconsin /ID# 163461, Milwaukee, Wisconsin, United States|Sydney Children's Hospital /ID# 163148, Randwick, New South Wales, Australia|Queensland Children's Hospital /ID# 163146, South Brisbane, Queensland, Australia|Women and Childrens Hospital /ID# 163147, North Adelaide, South Australia, Australia|Royal Children's Hospital /ID# 163104, Melbourne, Victoria, Australia|Hospital for Sick Children /ID# 163726, Toronto, Ontario, Canada|CHU Sainte-Justine /ID# 163725, Montreal, Quebec, Canada|Centre Leon Berard /ID# 163707, Lyon CEDEX 08, Rhone, France|Hopital de la Timone /ID# 161465, Marseille, France|Robert Debre Hopital, FR /ID# 161464, Paris, France|Hopital Armand Trousseau /Id# 163728, Paris, France|CHU Toulouse - Hôpital des enfants /ID# 163727, Toulouse CEDEX 9, France|Charite Campus Virchow-Klinikum /ID# 161730, Berlin, Germany|Universitaetsklinikum Essen /ID# 164207, Essen, Germany|Universitaetsklinikum Freiburg /ID# 164206, Freiburg, Germany|Univ Hosp Schleswig-Holstein /ID# 161729, Kiel, Germany|Erasmus MC - Sophia /ID# 161579, Rotterdam, Netherlands|Prinses Maxima Centrum /ID# 162670, Utrecht, Netherlands|University Children's Hospital /ID# 163037, Zurich, Switzerland|Great Ormond St Hospital NHS /ID# 169238, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 162938, Newcastle Upon Tyne, United Kingdom|Royal Marsden Hospital /ID# 162937, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03236857"
122,"NCT03235349","Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection","VOYAGE-2","Completed","Has Results","Hepatitis C Virus (HCV)","Drug: Glecaprevir/Pibrentasvir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse|Percentage of HCV/HIV Co-infected Participants Achieving SVR12","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","160","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-593","September 29, 2017","November 15, 2018","February 25, 2019","August 1, 2017","November 21, 2019","November 21, 2019","Peking University Peoples Hospit /ID# 156851, Beijing, Beijing, China|Guangzhou Eighth People's Hosp /ID# 156865, Guangzhou, Guangdong, China|Guangdong General Hospital /ID# 156827, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University /ID# 156866, Guangzhou, Guangdong, China|The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 156905, Guangzhou, Guangdong, China|The Second Hospital of Nanjing /ID# 156869, Nanjing, Jiangsu, China|Jiangsu Province People's Hospital /ID# 156867, Nanjing, Jiangsu, China|The First Hosp of Jilin Univ /ID# 156825, Changchun, Jilin, China|The Sixth People's Hospital of Shenyang /ID# 156854, Shenyang, Liaoning, China|Ruijin Hospital, Shanghai Jiaotong /ID# 157337, Shanghai, Shanghai, China|Huashan Hospital of Fudan University /ID# 156909, Shanghai, Shanghai, China|Shanghai Public Health Cli Ctr /ID# 156837, Shanghai, Shanghai, China|West China Hospital /ID# 156835, Chengdu, Sichuan, China|Beijing Di Tan Hospital, Capital Medical University /ID# 156852, Beijing, China|1st Hospital of Peking Uni /ID# 156850, Beijing, China|Beijing Friendship Hospital /ID# 156843, Beijing, China|Beijing Youan Hosp, Cap Med Un /ID# 163418, Beijing, China|2nd Affiliated Hosp Chongqing /ID# 156838, Chongqing, China|Mengchao Hepatobiliary Hospita /ID# 156907, Fuzhou, China|Chinese People's Liberation Army 81 Hospital /ID# 156868, Nanjing, China|Shengjing Hospital of China Medical University /ID# 156829, Shenyang, China|1st Aff Hosp Xinjiang Med Uni /ID# 156891, Urumqi, China|Fourth Military Medical University Tangdu Hospital, PLA /ID# 156767, Xi'an, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University /ID# 163420, Xi'an, China|Henan Provincial Peoples Hosp /ID# 157371, Zhengzhou, Henan, China|Pusan National University Hosp /ID# 163411, Busan, Busan Gwang Yeogsi, Korea, Republic of|Seoul National Univ Bundang ho /ID# 163408, Seongnam, Gyeonggido, Korea, Republic of|Inje University Busan Paik Hospital /ID# 163384, Busan, Gyeongsangbugdo, Korea, Republic of|Pusan Nat Univ Yangsan Hosp /ID# 163385, Yangsan-si,, Gyeongsangnamdo, Korea, Republic of|Severance Hospital /ID# 163399, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 163402, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Guro Hospital /ID# 163412, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 163401, Seoul, Korea, Republic of|Asan Medical Center /ID# 163398, Seoul, Korea, Republic of","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03235349/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03235349/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03235349"
123,"NCT03234712","A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)",,"Recruiting","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-321","AUCt for ABBV-321|AUC∞ for ABBV-321|Tmax of ABBV-321|Terminal phase elimination rate constant (β) for ABBV-321|Cmax of ABBV-321|Dose Escalation Phase: Recommended Phase 2 dose (RPTD) for ABBV-321|t1/2 for ABBV-321|Dose Escalation Phase: Maximum tolerated dose (MTD) of ABBV-321|Progression-Free Survival (PFS)|Duration of Response (DOR)|Disease Control Rate (DCR)|Time to progression (TTP)|Change from Baseline in QTcF|Overall Survival (OS)|Objective response rate (ORR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","120","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-438","October 10, 2017","March 7, 2024","September 4, 2025","July 31, 2017",,"November 18, 2019","University of Arizona Cancer Center - Tucson /ID# 213220, Tucson, Arizona, United States|Highlands Oncology Group /ID# 166132, Fayetteville, Arkansas, United States|UCSD Moores Cancer Center - LaJolla /ID# 215366, La Jolla, California, United States|The Angeles Clinic and Researc /ID# 166133, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 215012, Sacramento, California, United States|Cancer Specialists of North Florida - Southpoint /ID# 212940, Jacksonville, Florida, United States|Northwestern University Feinberg School of Medicine /ID# 165191, Chicago, Illinois, United States|University of Chicago /ID# 166064, Chicago, Illinois, United States|Northshore University Health System-Evanston /ID# 201095, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 214950, Harvey, Illinois, United States|Massachusetts General Hospital /ID# 213173, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 213174, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 212920, Boston, Massachusetts, United States|Columbia Univ Med Ctr /ID# 167184, New York, New York, United States|Duke University Medical Center /ID# 166135, Durham, North Carolina, United States|Lifespan Cancer Institute /ID# 168600, Providence, Rhode Island, United States|South Texas Accelerated Research Therapeutics /ID# 166134, San Antonio, Texas, United States|Northern Cancer Institute /ID# 166138, St Leonards, New South Wales, Australia|Austin Hospital /ID# 166137, Heidelberg, Victoria, Australia|Sheba Medical Center /ID# 166398, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT03234712"
124,"NCT03223012","Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service","IMPROVE","Completed","No Results Available","Crohn's Disease|Ulcerative Colitis (UC)|Rheumatoid Arthritis (RA)|Psoriatic Arthritis|Psoriasis|Ankylosing Spondylitis (AS)|Non-radiographic Axial Spondyloarthritis",,"Proportion of patients with Medication Possession Ratio (MPR)>=80%|Mean number of injections administered/ prescribed for adalimumab|Assessing Patient's overall satisfaction with AbbVie Care 2.0 program|Number of Sick Leaves|Time Spent by the Patient to Refill Prescription|Number of Hospital Inpatient Days|Number of Emergency Visits|Assessing Working Status|Proportion of patients with MPR>=80%|Mean score of Treatment Satisfaction Questionnaire for Medication (TSQM)-II|Mean Change in EuroQoL (EQ-5D) score|Number of Complementary Exams/ Techniques|Number of Hospitalizations|Time Spent by the Health Care Providers (HCPs) During Medical Appointments|Mean Change in Patient Activation Measure (PAM-13)|Mean Change in Beliefs about Medication Questionnaire (BMQ)|Change in Work Productivity and Activity Impairment- General Health (WPAI-GH)|Number of Outpatient Visits (in-office and remote) in Hospital Setting|Number of Days of Sick Leaves|Proportion of patients who are still on adalimumab after 6 and 12 months","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"116","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-321","November 15, 2017","February 28, 2019","February 28, 2019","July 19, 2017",,"November 6, 2019","Instituto Portugues De Reumatologia /ID# 205963, Lisbon, Lisboa, Portugal|Centro Hosp de Lisboa Central /ID# 205698, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 201328, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 201330, Lisbon, Lisboa, Portugal|CCA Braga - Hospital de Braga /ID# 201322, Braga, Portugal|CCA Braga - Hospital de Braga /ID# 201323, Braga, Portugal|CCA Braga - Hospital de Braga /ID# 201324, Braga, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 201335, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 201336, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 201337, Lisboa, Portugal|Hospital Santo Antonio dos Cap /ID# 205700, Lisbon, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 203535, Porto, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 206278, Porto, Portugal|Centro Hosp de Tondela-Viseu /ID# 203774, Viseu, Portugal|Centro Hosp de Tondela-Viseu /ID# 203775, Viseu, Portugal",,"https://ClinicalTrials.gov/show/NCT03223012"
125,"NCT03222609","A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis",,"Recruiting","No Results Available","Myelofibrosis (MF)","Drug: Ruxolitinib|Drug: Navitoclax","Percentage of Participants who achieve Spleen Volume Reduction of greater than or equal to 35% (SVR35) from baseline|Percent Change in Total System Score (TSS)|Overall Response Rate (ORR)|Anemia Response Rate|Change in Degree of Bone Marrow Fibrosis|Maximum Observed Plasma Concentration (Cmax)|Time to Cmax (peak time, Tmax)|Area Under the Plasma Concentration-time Curve from time 0 to the time of the last measurable concentration (AUCt)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","164","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-109|2017-001398-17","October 31, 2017","March 25, 2020","September 20, 2028","July 19, 2017",,"December 11, 2019","UAB Comprehensive Cancer Cente /ID# 165464, Birmingham, Alabama, United States|Ucsd /Id# 164084, La Jolla, California, United States|Usc /Id# 164095, Los Angeles, California, United States|Mayo Clinic /ID# 164201, Jacksonville, Florida, United States|Moffitt Cancer Center /ID# 164082, Tampa, Florida, United States|University of Chicago /ID# 164115, Chicago, Illinois, United States|Indiana Blood & Marrow Transpl /ID# 165075, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute /ID# 162675, Boston, Massachusetts, United States|Henry Ford Hospital /ID# 162682, Detroit, Michigan, United States|Weill Cornell Medical College /ID# 162679, New York, New York, United States|Duke University Medical Center /ID# 214744, Durham, North Carolina, United States|MD Anderson Cancer Center at Texas Medical Center /ID# 162683, Houston, Texas, United States|UT Health Cancer Center /ID# 164094, San Antonio, Texas, United States|University of Utah /ID# 164116, Salt Lake City, Utah, United States|St. Vincent's Hospital, Darlinghurst /ID# 214657, Darlinghurst, New South Wales, Australia|The Alfred Hospital /ID# 215545, Prahran, Victoria, Australia|Fiona Stanley Hospital /ID# 216809, Murdoch, Western Australia, Australia|University of Alberta Hospital /ID# 217698, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre /ID# 214483, Toronto, Ontario, Canada|Fondazione Policlinico Universitario Agostino Gemelli /ID# 214553, Rome, Lazio, Italy|ASST Papa Giovanni XXIII /ID# 214900, Bergamo, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele /ID# 214549, Catania, Italy|A.O. Circolo e Fondazione Macc /ID# 214551, Varese, Italy|Hospital Univ Germans Trias I /ID# 214704, Barcelona, Spain|Hospital Universitario Gregori /ID# 214676, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 214710, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 214709, Malaga, Spain|Guy's and St Thomas' NHS Found /ID# 164110, London, London, City Of, United Kingdom|Belfast City Hospital /ID# 216991, Belfast, United Kingdom|Christie NHS Foundation Trust /ID# 164111, Manchester, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 214503, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03222609"
126,"NCT03222583","A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection","VOYAGE-1","Completed","Has Results","Hepatitis C Virus (HCV)","Drug: Placebo|Drug: Glecaprevir/Pibrentasvir","Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12)|Percentage of HCV GT1-Infected Participants in Arm A Who Achieved SVR12|Percentage of HCV GT2-Infected Participants in Arm A Who Achieved SVR12|Percentage of Participants in Arm A With On-treatment Virologic Failure|Percentage of Participants in Arm A With Post-treatment Relapse|Percentage of HCV/HIV Co-infected Participants in Arm A Who Achieved SVR12","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-592","October 4, 2017","October 18, 2018","February 15, 2019","July 19, 2017","December 23, 2019","December 23, 2019","Peking University Peoples Hospit /ID# 156846, Beijing, Beijing, China|Guangzhou Eighth People's Hosp /ID# 156859, Guangzhou, Guangdong, China|Guangdong General Hospital /ID# 156822, Guangzhou, Guangdong, China|Nanfang Hospital of Southern Medical University /ID# 156860, Guangzhou, Guangdong, China|The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 156900, Guangzhou, Guangdong, China|Xiangya Hospital Central South University /ID# 156901, Changsha, Hunan, China|The Second Hospital of Nanjing /ID# 156863, Nanjing, Jiangsu, China|Jiangsu Province People's Hospital /ID# 156861, Nanjing, Jiangsu, China|The First Hosp of Jilin Univ /ID# 156820, Changchun, Jilin, China|The Sixth People's Hospital of Shenyang /ID# 156849, Shenyang, Liaoning, China|Shanghai Changzheng Hospital /ID# 158072, Shanghai, Shanghai, China|Ruijin Hospital, Shanghai Jiaotong /ID# 157336, Shanghai, Shanghai, China|Huashan Hospital of Fudan University /ID# 156904, Shanghai, Shanghai, China|Shanghai Public Health Cli Ctr /ID# 156832, Shanghai, Shanghai, China|West China Hospital /ID# 156830, Chengdu, Sichuan, China|Beijing Di Tan Hospital, Capital Medical University /ID# 156847, Beijing, China|1st Hospital of Peking Uni /ID# 156845, Beijing, China|302 Military Hospital Of China /ID# 156841, Beijing, China|Beijing Friendship Hospital /ID# 156840, Beijing, China|Beijing Youan Hosp, Cap Med Un /ID# 163430, Beijing, China|1st Affiliated Hosp 3rd Milita /ID# 156831, Chongqing, China|Dalian Sixth Peoples Hospital /ID# 163433, Dalian, China|Mengchao Hepatobiliary Hospita /ID# 156902, Fuzhou, China|Hainan General Hospital /ID# 156839, Haikou, Hainan, China|Jinan Infectious Diseases Hosp /ID# 156886, Jinan, Shandong, China|Chinese People's Liberation Army 81 Hospital /ID# 156862, Nanjing, China|Shengjing Hospital of China Medical University /ID# 156824, Shenyang, China|Tianjin Third Central Hospital /ID# 156816, Tianjin, China|1st Aff Hosp Xinjiang Med Uni /ID# 156887, Urumqi, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 156884, Wuhan, China|Tongji Hosp Tongji Med College /ID# 156885, Wuhan, China|Fourth Military Medical University Tangdu Hospital, PLA /ID# 156765, Xi'an, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University /ID# 163432, Xi'an, China|Henan Provincial Peoples Hosp /ID# 157197, Zhengzhou, Henan, China|Pusan National University Hosp /ID# 163371, Busan, Busan Gwang Yeogsi, Korea, Republic of|Seoul National Univ Bundang ho /ID# 163367, Seongnam, Gyeonggido, Korea, Republic of|Inje University Busan Paik Hospital /ID# 163329, Busan, Gyeongsangbugdo, Korea, Republic of|Pusan Nat Univ Yangsan Hosp /ID# 163334, Yangsan-si,, Gyeongsangnamdo, Korea, Republic of|Inha University Hospital /ID# 163320, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 163339, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 163364, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 163341, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea Universtiy Guro Hospital /ID# 163380, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 163348, Seoul, Korea, Republic of|Asan Medical Center /ID# 163336, Seoul, Korea, Republic of|National University Hospital ( /ID# 163272, Singapore, Singapore|Singapore General Hospital /ID# 163271, Singapore, Singapore|Changi General Hospital /ID# 163270, Singapore, Singapore","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03222583/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT03222583/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03222583"
127,"NCT03219437","A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis",,"Active, not recruiting","No Results Available","Psoriasis","Drug: risankizumab|Drug: methotrexate","Percentage of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 28.|Percentage of participants with a ≥ 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 28|Percentage of participants with a 100% reduction from Baseline PASI score (PASI 100) at Week 28|Percentage of participants with a ≥ 75% reduction from Baseline PASI score (PASI 75) at Week 28|Percentage of participants with Static Physician Global Assessment (sPGA) score of clear (0) at Week 28|Change from baseline in EQ-5D-5L at all visits collected|Achievement of an increase of 0.1 or more points from baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) at all visits","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-177","July 30, 2018","February 20, 2020","September 30, 2021","July 17, 2017",,"August 19, 2019","Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 208593, Curitiba, Parana, Brazil|PUC Trials-Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR /ID# 164401, Curitiba, Parana, Brazil|Instituto de Educação e Pesquisa do Hospital Moinhos de Vento /ID# 208592, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre /ID# 164565, Porto Alegre, Rio Grande Do Sul, Brazil|Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu /ID# 164743, Botucatu, Sao Paulo, Brazil|Hospital de Clinicas da Universidade Estadual de Campinas - UNICAMP /ID# 164521, Campinas, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 164768, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 164519, Santo André, Sao Paulo, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 164723, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HC /ID# 164805, São Paulo, Sao Paulo, Brazil|Instituto de Dermatologia e Estética do Brasil /ID# 164754, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT03219437"
128,"NCT03219216","A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection",,"Completed","No Results Available","Hepatitis C Virus (HCV)","Drug: Glecaprevir/Pibrentasvir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Post-treatment Relapse|Percentage of Participants With On-treatment Virologic Failure","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-156","June 6, 2018","March 11, 2019","March 11, 2019","July 17, 2017",,"March 28, 2019","Hospital Universitário Cassiano Antônio Moraes - HCUFES /ID# 163512, Vitoria, Espirito Santo, Brazil|Hospital Universitario da Universidade Federal do Maranhao - CEPEC /ID# 163169, São Luís, Maranhao, Brazil|Universidade Estadual de Maringá /ID# 166436, Maringá, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 163166, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre /ID# 163167, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Ernesto Dornelles /ID# 163171, Porto Alegre, Rio Grande Do Sul, Brazil|Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu /ID# 163066, Botucatu, Sao Paulo, Brazil|Instituto de Infectologia Campinas /ID# 163175, Campinas, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 163054, Ribeirão Preto, Sao Paulo, Brazil|Instituto de Infectologia Emilio Ribas /ID# 163170, São Paulo, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HC /ID# 163168, São Paulo, Sao Paulo, Brazil|UNIFESP/Unidade de Atendimento Pesquisa Clínica 1 /ID# 164188, Sao Paulo, Brazil|Centro de Referência e Treinamento DST/AIDS /ID# 163174, Sao Paulo, Brazil|Hospital Heliopolis /ID# 163063, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT03219216"
129,"NCT03213457","A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain",,"Active, not recruiting","No Results Available","Endometriosis","Drug: Estradiol/Norethindrone Acetate|Other: Placebo for Elagolix|Drug: Elagolix|Other: Placebo for E2/NETA","Proportion of responders based on Dysmenorrhea (DYS)|Proportion of responders based on Non-menstrual pelvic pain (NMPP)|Change from baseline in Dysmenorrhea (DYS)|Change from baseline in dyspareunia|Change from baseline in Numeric Rating Scale (NRS)|Change from baseline in Non-menstrual pelvic pain (NMPP)","AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 3","681","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-702","July 7, 2017","October 14, 2019","January 30, 2023","July 11, 2017",,"July 16, 2019","Central Research Associates /ID# 163087, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC /ID# 145503, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC /ID# 151468, Birmingham, Alabama, United States|Brown, Pearson, Guepet Gynecology /ID# 148750, Fairhope, Alabama, United States|Women's Health Alliance of Mobile /ID# 150083, Mobile, Alabama, United States|University of South Alabama /ID# 148774, Mobile, Alabama, United States|Mobile, Ob-Gyn, P.C. /ID# 145364, Mobile, Alabama, United States|Mesa Obstetricians and Gynecol /ID# 147320, Mesa, Arizona, United States|Arizona Research Assoc /ID# 161703, Tucson, Arizona, United States|Eclipse Clinical Research /ID# 155600, Tucson, Arizona, United States|Unity Health- Searcy Medical Center /ID# 203674, Searcy, Arkansas, United States|Northern California Research /ID# 159753, Carmichael, California, United States|Core Healthcare Group /ID# 149321, Cerritos, California, United States|HRC Fertility /ID# 154143, Encino, California, United States|Glendale Adventist Medical Ctr /ID# 160530, Glendale, California, United States|Alliance Research Centers /ID# 151240, Laguna Hills, California, United States|Long Beach Clinical Trial Serv /ID# 152428, Long Beach, California, United States|Olympic Clinical Trials /ID# 202325, Los Angeles, California, United States|California Medical Research As /ID# 154746, Northridge, California, United States|Futura Research, Inc. /ID# 145406, Norwalk, California, United States|Huntington Medical Foundation /ID# 154750, Pasadena, California, United States|Healthcare Partners Med Group /ID# 152045, Redondo Beach, California, United States|Precision Research Institute - San Diego /ID# 152557, San Diego, California, United States|MD Strategies Research Centers /ID# 152429, San Diego, California, United States|Alta California Medical Group /ID# 155706, Simi Valley, California, United States|Downtown Womens Health Care /ID# 147955, Denver, Colorado, United States|Advanced Women's Health Institution /ID# 145396, Greenwood Village, Colorado, United States|Red Rocks OB/GYN /ID# 145325, Lakewood, Colorado, United States|The Women's Health Group - Thornton /ID# 203707, Thornton, Colorado, United States|James A. Simon, MD, PC /ID# 145480, Washington, District of Columbia, United States|Helix Biomedics, LLC /ID# 147108, Boynton Beach, Florida, United States|Gulf Coast Research Group /ID# 162895, Brandon, Florida, United States|Olympian Clinical Research /ID# 148167, Clearwater, Florida, United States|Omega Research Consultants, LLC /ID# 145167, DeBary, Florida, United States|KO Clinical Research, LLC /ID# 145410, Fort Lauderdale, Florida, United States|Clinical Physiology Associates /ID# 145237, Fort Myers, Florida, United States|Solutions Through Adv Rch /ID# 148768, Jacksonville, Florida, United States|Meridien Research /ID# 145345, Kenneth City, Florida, United States|Hope Clin Research /ID# 150282, Kissimmee, Florida, United States|Axcess Medical Center /ID# 148169, Loxahatchee Groves, Florida, United States|Precision Research Org, LLC /ID# 145337, Miami Lakes, Florida, United States|Genoma Research Group, Inc /ID# 152558, Miami, Florida, United States|Ocean Blue Med Research Ctr /ID# 145514, Miami, Florida, United States|Vista Health Research LLC - Miami /ID# 151455, Miami, Florida, United States|Palmetto Professional Research /ID# 153838, Miami, Florida, United States|Salom Tangir, LLC /ID# 148739, Miramar, Florida, United States|Suncoast Clinical Research /ID# 145484, New Port Richey, Florida, United States|Oncova Clinical Research, Inc. /ID# 148175, Saint Cloud, Florida, United States|Physician Care Clin. Res., LLC /ID# 145511, Sarasota, Florida, United States|Treasure Coast Research /ID# 148174, Stuart, Florida, United States|University of South Florida /ID# 145424, Tampa, Florida, United States|Stedman Clinical Trials /ID# 152554, Tampa, Florida, United States|Virtus Research Consultant,LLC /ID# 147101, Wellington, Florida, United States|Comprehensive Clinical Trials /ID# 145148, West Palm Beach, Florida, United States|Paramount Research Solutions /ID# 145226, Alpharetta, Georgia, United States|Paramount Research Solutions /ID# 149320, Alpharetta, Georgia, United States|Agile Clinical Research Trials /ID# 145494, Atlanta, Georgia, United States|Atlanta Women's Research Inst /ID# 145543, Atlanta, Georgia, United States|Apogee Women's Health Inc. /ID# 145149, College Park, Georgia, United States|Columbus Regional Research Ins /ID# 159752, Columbus, Georgia, United States|Meridian Clinical Research, LLC /ID# 148176, Savannah, Georgia, United States|Atlanta Gynecology Research Institute /ID# 149322, Suwanee, Georgia, United States|Clinical Research Prime /ID# 161724, Idaho Falls, Idaho, United States|Womens Healthcare Assoc, DBA /ID# 148744, Idaho Falls, Idaho, United States|Advanced Clinical Research /ID# 147086, Meridian, Idaho, United States|Sonora Clinical Research /ID# 145541, Meridian, Idaho, United States|Asr, Llc /Id# 161680, Nampa, Idaho, United States|Women's Health Practice, LLC /ID# 145517, Champaign, Illinois, United States|Affinity Clinical Research /ID# 151469, Oak Brook, Illinois, United States|Center for Women's Research, Inc /ID# 145486, Palos Heights, Illinois, United States|The Adv Gynecologic Surg Ins /ID# 151459, Park Ridge, Illinois, United States|American Health Network of Ind /ID# 167996, Avon, Indiana, United States|Women's Health Advantage /ID# 145495, Fort Wayne, Indiana, United States|The Iowa Clinic /ID# 145409, West Des Moines, Iowa, United States|Womens & Family Care, LLC dba /ID# 145211, Shawnee Mission, Kansas, United States|PRN Professional Research Network of Kansas, LLC /ID# 151463, Wichita, Kansas, United States|Cypress Medical Research Ctr /ID# 147159, Wichita, Kansas, United States|University of Louisville /ID# 154751, Louisville, Kentucky, United States|Bluegrass Clinical Research /ID# 151209, Louisville, Kentucky, United States|Clinical Trials Management,LLC /ID# 145220, Covington, Louisiana, United States|Clinical Trials Management,LLC /ID# 145520, Covington, Louisiana, United States|Horizon Research Group /ID# 148171, Eunice, Louisiana, United States|Praetorian Pharmaceutical Res /ID# 145405, Marrero, Louisiana, United States|Ochsner Baptist OB/GYN Clinic /ID# 147144, New Orleans, Louisiana, United States|Women Under Study, LLC /ID# 151216, New Orleans, Louisiana, United States|Women's Health Clinic /ID# 155707, Shreveport, Louisiana, United States|Omni Fertility and Laser Insti /ID# 145532, Shreveport, Louisiana, United States|Eastern Maine Medical Center /ID# 161681, Bangor, Maine, United States|Univ Maryland School Medicine /ID# 151739, Baltimore, Maryland, United States|Baltimore Suburban Health /ID# 147164, Baltimore, Maryland, United States|Continental Clinical Solutions /ID# 152041, Towson, Maryland, United States|Neccr /Id# 145329, Fall River, Massachusetts, United States|Genesis Clinical Research - Fall River /ID# 148573, Fall River, Massachusetts, United States|ClinSite, LLC /ID# 145314, Ann Arbor, Michigan, United States|Great Lakes Research Group,Inc /ID# 145308, Bay City, Michigan, United States|Saginaw Valley Med Res Group /ID# 145527, Saginaw, Michigan, United States|Wayne State University Physician Group - Southfield /ID# 145431, Southfield, Michigan, United States|Prism Research /ID# 159751, Saint Paul, Minnesota, United States|Womens Clinic of Lincoln, P.C. /ID# 145366, Lincoln, Nebraska, United States|Accent Clinical Trials /ID# 147109, Las Vegas, Nevada, United States|Office of Edmond E. Pack, MD /ID# 148747, Las Vegas, Nevada, United States|Mabey, Las Vegas, NV /ID# 145361, Las Vegas, Nevada, United States|Jersey Shore University Medical Center /ID# 148756, Neptune, New Jersey, United States|Rutgers Robert Wood Johnson /ID# 152858, New Brunswick, New Jersey, United States|St. Joseph's Regional Medical /ID# 157759, Totowa, New Jersey, United States|Albuquerque Clinical Trials, Inc /ID# 154747, Albuquerque, New Mexico, United States|Bosque Women's Care /ID# 147084, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center /ID# 148749, Brooklyn, New York, United States|Scott Research Inc. /ID# 161704, Laurelton, New York, United States|Manhattan Medical Research /ID# 145175, New York, New York, United States|Columbia Univ Medical Center /ID# 145334, New York, New York, United States|Hamburg Regional Gynecology Gr /ID# 161705, Orchard Park, New York, United States|OB.GYN Associates of WNY /ID# 161665, West Seneca, New York, United States|PMG Research of Charlotte /ID# 145432, Charlotte, North Carolina, United States|DJL Clinical Research, PLLC /ID# 154679, Charlotte, North Carolina, United States|Cwrwc /Id# 145356, Durham, North Carolina, United States|Unified Women's Clinical Research-Greensboro /ID# 155543, Greensboro, North Carolina, United States|Pinewest Ob-Gyn, Inc. /ID# 151743, High Point, North Carolina, United States|Eastern Carolina Women's Centr /ID# 145386, New Bern, North Carolina, United States|Unified Women's Clinical Resea /ID# 145353, Raleigh, North Carolina, United States|PMG Research of Wilmington /ID# 152555, Wilmington, North Carolina, United States|Trinity Health Center Town /ID# 147102, Minot, North Dakota, United States|Clinical Inquest Center Ltd /ID# 147107, Beavercreek, Ohio, United States|CTI Clinical Research Center /ID# 145428, Cincinnati, Ohio, United States|The Christ Hospital /ID# 149244, Cincinnati, Ohio, United States|University of Cincinnati /ID# 145496, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 148741, Cleveland, Ohio, United States|The Ohio State University /ID# 145444, Columbus, Ohio, United States|Aventiv Research, Inc. /ID# 162896, Columbus, Ohio, United States|Comprehensive Women's Care /ID# 145492, Columbus, Ohio, United States|Wright State University & CTRA /ID# 145512, Fairborn, Ohio, United States|University of Toledo /ID# 145403, Toledo, Ohio, United States|Oregon Health and Science University /ID# 155705, Portland, Oregon, United States|Main Line Fertility Center /ID# 150099, Bryn Mawr, Pennsylvania, United States|OB/GYN Associates of Erie /ID# 157935, Erie, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 145231, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 145470, Philadelphia, Pennsylvania, United States|Drexel Univ College of Med /ID# 149789, Philadelphia, Pennsylvania, United States|Frontier Clinical Research /ID# 162091, Smithfield, Pennsylvania, United States|Vista Clinical Research /ID# 148767, Columbia, South Carolina, United States|University Medical Group /ID# 148777, Greenville, South Carolina, United States|Magnolia Ob/Gyn Research Cente /ID# 145336, Myrtle Beach, South Carolina, United States|James T. Martin, Jr., MD., Obs /ID# 148755, North Charleston, South Carolina, United States|Palmetto Clinical Research /ID# 150992, Summerville, South Carolina, United States|Brown Clinic, PLLP /ID# 154372, Watertown, South Dakota, United States|Holston Medical Group /ID# 145449, Bristol, Tennessee, United States|Chattanooga Medical Research /ID# 145184, Chattanooga, Tennessee, United States|WR-ClinSearch /ID# 145205, Chattanooga, Tennessee, United States|The Jackson Clinic, PA /ID# 145303, Jackson, Tennessee, United States|Research Memphis Associates, LLC /ID# 150100, Memphis, Tennessee, United States|Access Clinical Trials, Inc. /ID# 145224, Nashville, Tennessee, United States|Lotus Gynecology /ID# 148479, Austin, Texas, United States|AA (Austin Area) ObGyn PLLC /ID# 205696, Austin, Texas, United States|Sirius Clinical Research, LLC /ID# 154749, Austin, Texas, United States|Gadolin Research, LLC /ID# 201383, Beaumont, Texas, United States|Center for Assisted Reprod. /ID# 154748, Bedford, Texas, United States|Texas Health Presbyterian Hosp /ID# 150098, Dallas, Texas, United States|UT Southwestern Medical Center /ID# 145201, Dallas, Texas, United States|Baylor Scott & White /ID# 170430, Fort Worth, Texas, United States|Signature Gyn Services /ID# 145534, Fort Worth, Texas, United States|Willowbend Health and Wellness /ID# 145245, Frisco, Texas, United States|Next Innovative Clinical Research /ID# 203863, Houston, Texas, United States|Advances in Health, Inc. /ID# 145425, Houston, Texas, United States|Houston Methodist Hospital /ID# 170586, Houston, Texas, United States|Precision Research Institute - Houston /ID# 154370, Houston, Texas, United States|The Woman's Hospital of Texas /ID# 145316, Houston, Texas, United States|Centex Studies, Inc /ID# 148776, Houston, Texas, United States|FMC Science /ID# 150981, Lampasas, Texas, United States|Clinical Trials of Texas,Inc. /ID# 147100, San Antonio, Texas, United States|Victorium Clinical Research /ID# 151745, San Antonio, Texas, United States|Discovery Clinical Trials-San Antonio /ID# 145363, San Antonio, Texas, United States|Houston Ctr for Clin Research /ID# 148799, Sugar Land, Texas, United States|Center of Reproductive Medicin /ID# 145467, Webster, Texas, United States|Revere Health /ID# 145540, American Fork, Utah, United States|Corner Canyon Obstetrics and G /ID# 145519, Draper, Utah, United States|Tanner Clinic /ID# 148786, Layton, Utah, United States|Southampton Women's Health /ID# 151691, Franklin, Virginia, United States|Health Research of Hampton Roads, Inc. (HRHR) /ID# 156477, Newport News, Virginia, United States|Clinical Research Partners, LL /ID# 145392, North Chesterfield, Virginia, United States|Clinical Research Partners, LL /ID# 145416, North Chesterfield, Virginia, United States|Clinical Trials Virginia, Inc. /ID# 145430, Richmond, Virginia, United States|Alliance Womens Health /ID# 148770, Richmond, Virginia, United States|Tidewater Clinical Research /ID# 145397, Virginia Beach, Virginia, United States|Clinical Research Adv, Inc. /ID# 149257, Puyallup, Washington, United States|Virginia Mason Medical Center /ID# 145387, Seattle, Washington, United States|Seattle Women's Health, Research, Gynecology /ID# 145341, Seattle, Washington, United States|North Spokane Women's Health /ID# 145382, Spokane, Washington, United States|Madigan Army Medical Center /ID# 145186, Tacoma, Washington, United States|Strand Clinic /ID# 152582, St. John's, Newfoundland and Labrador, Canada|The Ottawa Hospital /ID# 148927, Ottawa, Ontario, Canada|Medicor Research Inc. /ID# 151453, Sudbury, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 148972, Toronto, Ontario, Canada|Victory Reproductive Care /ID# 149016, Windsor, Ontario, Canada|Puerto Rico Medical Research /ID# 152040, Ponce, Puerto Rico|Clinical Research Puerto Rico /ID# 149018, San Juan, Puerto Rico|Rodriguez-Ginorio, San Juan /ID# 145545, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 145546, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT03213457"
130,"NCT03212521","Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1",,"Completed","Has Results","Hepatitis C Virus (HCV)","Drug: Glecaprevir/Pibrentasvir","Percentage of Participants in the Modified Intention-to-Treat Population With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants in the Intention-to-Treat Population With SVR12|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","230","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-133|2016-004876-23","August 7, 2017","August 13, 2018","August 13, 2018","July 11, 2017","September 4, 2019","September 4, 2019","Parkway Medical Center /ID# 161261, Birmingham, Alabama, United States|Arkansas Gastroenterology /ID# 161266, North Little Rock, Arkansas, United States|UC Davis Medical Center /ID# 161138, Sacramento, California, United States|Yale University /ID# 161258, New Haven, Connecticut, United States|Univ Maryland School Medicine /ID# 161157, Baltimore, Maryland, United States|Digestive Disease Associates - Baltimore /ID# 161260, Baltimore, Maryland, United States|University of Michigan Hospitals /ID# 161265, Ann Arbor, Michigan, United States|Northwest Gastroenterology Cli /ID# 161257, Portland, Oregon, United States|Liver Associates of Texas, P.A /ID# 161262, Houston, Texas, United States|University of Vermont Medical Center /ID# 161263, Burlington, Vermont, United States|Digestive and Liver Disease Sp /ID# 161259, Norfolk, Virginia, United States|DCC Aleksandrovska /ID# 161340, София, Sofia, Bulgaria|DCC Mladost M /ID# 161339, Varna, Bulgaria|South Health Campus /ID# 161385, Calgary, Alberta, Canada|The Moncton Hospital /ID# 161384, Moncton, New Brunswick, Canada|Brampton Civic Hospital /ID# 161380, Brampton, Ontario, Canada|Toronto Liver Centre /ID# 161381, Toronto, Ontario, Canada|Hopital Saint Joseph /ID# 161571, Marseille CEDEX 08, Bouches-du-Rhone, France|CHU de Rennes - PONTCHAILLOU /ID# 161492, Rennes, Bretagne, France|CHU de Besancon - Jean Minjoz /ID# 161485, Besancon, Doubs, France|Hopitaux de Brabois Adultes /ID# 161482, Vandoeuvre les Nancy, Lorraine, France|Universitätsklinikum Frankfurt /ID# 161397, Frankfurt am Main, Hessen, Germany|Universitaetsmedizin der Johannes-Gutenberg Universität Mainz /ID# 161396, Mainz, Rheinland-Pfalz, Germany|Charité Universitätsmedizin Campus Mitte /ID# 161395, Berlin, Germany|ICH Study Center GmbH & Co KG /ID# 161394, Hamburg, Germany|Centrum Badan Klinicznych /Id# 162218, Wrocław, Dolnoslaskie, Poland|HepID - Diagnostyka I Terapia /ID# 162219, Lublin, Lubelskie, Poland|Uniwersytecki Szpital Kliniczn /ID# 162216, Bialystok, Poland|ID Clinic /ID# 162217, Myslowice, Poland|Innovative Care P.S.C. /ID# 162787, San Juan, Puerto Rico|A. F. Agafonov Republican Clin /ID# 163164, Kazan, Tatarstan, Respublika, Russian Federation|South Ural State Medical univ /ID# 163163, Chelyabinsk, Russian Federation|A.I. Evdokimov Moscow State Un /ID# 163162, Moscow, Russian Federation|Hospital Fundacion Alcorcon /ID# 161436, Alcorcon, Spain|Hospital Clinic de Barcelona /ID# 161437, Barcelona, Spain|Hospital Vall d'Hebron /ID# 162022, Barcelona, Spain|Hosp Uni Virgen de la Victoria /ID# 164383, Malaga, Spain|Complexo Hospitalario universi /ID# 165603, Pontevedra, Spain|Bradford Teaching Hospitals /ID# 161424, Bradford, United Kingdom|Glasgow Royal Infirmary /ID# 161458, Glasgow, United Kingdom|Gloucester Royal Hospital /ID# 161423, Gloucester, United Kingdom|Freeman Hospital /ID# 161459, Newcastle Upon Tyne, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03212521/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03212521/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03212521"
131,"NCT03201718","A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs","HCV PMS","Completed","No Results Available","Hepatitis C Virus (HCV)",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"505","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-666","August 17, 2017","October 11, 2019","October 11, 2019","June 28, 2017",,"December 19, 2019","Dong-A University Hospital /ID# 167362, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 167363, Busan, Busan Gwang Yeogsi, Korea, Republic of|Kyungpook National Univ Hosp /ID# 168731, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 167425, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Chungnam National University Hospital /ID# 167724, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Soon Chun Hyang University Hospital Bucheon /ID# 201803, Buncheon, Gyeonggido, Korea, Republic of|National health insurance cooperation ilsan hospital /ID# 201806, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 167394, Seongnam, Gyeonggido, Korea, Republic of|Ajou University Hospital /ID# 167729, Suwon-si, Gyeonggido, Korea, Republic of|St. Vincent's Hospital /ID# 201660, Suwon, Gyeonggido, Korea, Republic of|Inje University Busan Paik Hospital /ID# 167392, Busan, Gyeongsangbugdo, Korea, Republic of|Changwon Fatima Hospital /ID# 201664, Changwon, Gyeongsangnamdo, Korea, Republic of|Inha University Hospital /ID# 201802, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 167423, Gwangju, Jeonranamdo, Korea, Republic of|Kwangju Christian Hospital /ID# 210823, Gwangju, Jeonranamdo, Korea, Republic of|Kyungpook National University Chilgok Hospital /ID# 201804, Daegu, Seoul Teugbyeolsi, Korea, Republic of|SMG-SNU Boramae Medical Center /ID# 201805, Dongjak-gu, Seoul Teugbyeolsi, Korea, Republic of|Kangbuk Samsung Hospital /ID# 168792, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 167361, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Konkuk University Medical Ctr /ID# 167723, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 167722, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea Universtiy Guro Hospital /ID# 167388, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Bucheon St. Mary's hospital /ID# 170782, Bucheon, Korea, Republic of|Dongnam Institute of Radiologi /ID# 167721, Busan, Korea, Republic of|Good Samsun Hospital /ID# 167365, Busan, Korea, Republic of|Haeundae Paik Hospital /ID# 170767, Busan, Korea, Republic of|Maryknoll Medical Center /ID# 167418, Busan, Korea, Republic of|Kosin University Gospel Hosp /ID# 168797, Busan, Korea, Republic of|Samsung Changwon Hospital /ID# 167732, Changwon, Korea, Republic of|Dankook University Hospital /ID# 167730, Cheonan, Korea, Republic of|Chuncheon Sacred Heart Hosp /ID# 167419, Chuncheon, Korea, Republic of|Kim Jun Hwan Sok Internal Medi /ID# 168794, Daegu, Korea, Republic of|Keimyung Univ Dongsan medical /ID# 168793, Daegu, Korea, Republic of|Daegu Catholic University Med /ID# 167714, Daegu, Korea, Republic of|Daegu Catholic University Med /ID# 168729, Daegu, Korea, Republic of|The Catholic Univ. of Korea /ID# 167733, Daejeon, Korea, Republic of|Dongguk University Ilsan Hosp /ID# 168795, Goyang, Korea, Republic of|Myongji Hospital /ID# 170784, Goyang, Korea, Republic of|CHA Gumi Medical Center /ID# 170783, Gumi, Korea, Republic of|Korea University Ansan Hosp /ID# 201661, Gyeonggi-do, Korea, Republic of|Dongtan Sacred Heart Hospital /ID# 170759, Hwaseong, Korea, Republic of|The Catholic University of Korea Incheon St.Mary's Hospital /ID# 170769, Incheon, Korea, Republic of|Presbyterian Medical Center /ID# 167424, Jeonju, Korea, Republic of|CHA Bundang Medical Center /ID# 170757, Seongnam, Korea, Republic of|Bundang Jesaeng hospital /ID# 167725, Seongnam, Korea, Republic of|Korea University Anam Hospital /ID# 167731, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 167364, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 167389, Seoul, Korea, Republic of|SoonChunHyang University Seoul /ID# 167711, Seoul, Korea, Republic of|Asan Medical Center /ID# 167390, Seoul, Korea, Republic of|Chung-Ang University Hostipal /ID# 167420, Seoul, Korea, Republic of|Inje University Seoul Paik Hos /ID# 167426, Seoul, Korea, Republic of|Inje University Sanggye Paik H /ID# 167427, Seoul, Korea, Republic of|St. Carollo General Hospital /ID# 167712, Suncheon, Korea, Republic of|Uijeongbu St. Mary's Hospital /ID# 168730, Uijeongbu, Korea, Republic of|Ulsan University Hospital /ID# 168796, Ulsan, Korea, Republic of|Wonju Severance Christian Hosp /ID# 167713, Wonju, Korea, Republic of|Pusan National University Yang /ID# 167710, Yangsan-si, Korea, Republic of|Yeosoo Hankook Hospital /ID# 168728, Yeosu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03201718"
132,"NCT03181126","A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma",,"Recruiting","No Results Available","Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma","Drug: Navitoclax|Drug: Chemotherapy|Drug: Venetoclax","Cmax of Venetoclax + Navitoclax|AUC of Venetoclax + Navitoclax|Tmax of Venetoclax + Navitoclax|CL/F of Venetoclax + Navitoclax|Number of participants with dose-limiting toxicities (DLT)|Progression-free survival (PFS)|Partial Response (PR) rate|Number of Participant who Proceed to Stem Cell Transplantation or Chimeric antigen receptor T-cell (CAR-T) Therapy|Overall survival (OS)|Objective response rate (ORR)|Complete Response (CR) rate","AbbVie","All","4 Years and older   (Child, Adult, Older Adult)","Phase 1","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-106","November 27, 2017","September 30, 2020","October 15, 2020","June 8, 2017",,"September 25, 2019","City of Hope /ID# 169029, Duarte, California, United States|LPCH Stanford /ID# 163337, Palo Alto, California, United States|University of Chicago /ID# 163369, Chicago, Illinois, United States|Washington University-School of Medicine /ID# 165689, Saint Louis, Missouri, United States|Univ NC Chapel Hill /ID# 163509, Chapel Hill, North Carolina, United States|Cincinnati Children's Hospital /ID# 164619, Cincinnati, Ohio, United States|Nationwide Childrens Hospital /ID# 163372, Columbus, Ohio, United States|Oregon Health and Science University /ID# 165690, Portland, Oregon, United States|St. Jude Childrens Res Hosp /ID# 163335, Memphis, Tennessee, United States|UT Southwestern Medical Center /ID# 163346, Dallas, Texas, United States|MD Anderson Cancer Center at Texas Medical Center /ID# 163327, Houston, Texas, United States|University of Wisconsin-Madiso /ID# 165691, Madison, Wisconsin, United States|Alfred Hospital /ID# 169576, Melbourne, Victoria, Australia|Victorian Comprehensive Cancer /ID# 165710, Melbourne, Victoria, Australia|Royal Children's Hospital /ID# 163322, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03181126"
133,"NCT03178487","A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis ( SELECT Axis 1 )","SELECT Axis 1","Active, not recruiting","No Results Available","Ankylosing Spondylitis (AS)","Drug: Upadacitinib|Drug: Upadacitinib Placebo","Proportion of participants with Assessment of SpondyloArthritis international Society (ASAS) 40 response|Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)|Proportion of participants with ASAS partial remission (PR)|Change from Baseline in Work Productivity and Activity Impairment (WPAI)|Change from Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)|Change from Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)|Change from Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)|ASAS 20 response|Change from Baseline in magnetic resonance imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) score (Spine)|Change from Baseline in Ankylosing Spondylitis (AS) Quality of Life (QoL)|Proportion of participants with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response|Change from Baseline in ASAS Health Index (HI)|Change from Baseline in MRI Spondyloarthritis Research Consortium of Canada (SPARCC) score Sacroiliac (SI) joints","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","M16-098|2017-000431-14","October 24, 2017","January 21, 2019","November 11, 2020","June 7, 2017",,"November 25, 2019","Arizona Arthritis & Rheumatolo /ID# 164446, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 165705, Phoenix, Arizona, United States|David S. Hallegua MD /ID# 165090, Beverly Hills, California, United States|Covina Arthritis Clinic /ID# 165061, Covina, California, United States|Rheumatology Ctr of San Diego /ID# 166167, Escondido, California, United States|St. Joseph Health System /ID# 166166, Fullerton, California, United States|Global Research Foundation /ID# 165130, Los Angeles, California, United States|Colorado Arthritis Associates /ID# 164444, Lakewood, Colorado, United States|Bay Area Arthritis and Osteo /ID# 165023, Brandon, Florida, United States|LeJenue Research Associates /ID# 165202, Miami, Florida, United States|HMD Research LLC /ID# 205172, Orlando, Florida, United States|St. Lukes Clinic /ID# 165827, Meridian, Idaho, United States|Clinical Investigation Special /ID# 164385, Skokie, Illinois, United States|Henry Ford Health System /ID# 165515, Detroit, Michigan, United States|Aa Mrc Llc /Id# 165100, Grand Blanc, Michigan, United States|St. Lawrence Health System /ID# 165025, Potsdam, New York, United States|DJL Clinical Research, PLLC /ID# 165044, Charlotte, North Carolina, United States|Altoona Ctr Clinical Res /ID# 164470, Duncansville, Pennsylvania, United States|Clinical Research Ctr Reading /ID# 164876, Wyomissing, Pennsylvania, United States|Comprehensive Arthritis Care, a division of Comprehensive Rheumatology Care PLLC /ID# 168107, Hendersonville, Tennessee, United States|Diagnostic Group Integrated He /ID# 165195, Beaumont, Texas, United States|Arth and Osteo Clin Brazo Valley /ID# 165194, College Station, Texas, United States|Princess Alexandra Hospital /ID# 169239, Woolloongabba, Queensland, Australia|Emeritus Research /ID# 169240, Camberwell, Victoria, Australia|UZ Gent /ID# 166017, Gent, Oost-Vlaanderen, Belgium|ReumaClinic Genk /ID# 166018, Genk, Belgium|UZ Leuven /ID# 166019, Leuven, Belgium|Rheumatology Research Assoc /ID# 165240, Edmonton, Alberta, Canada|University of Alberta - Division of Rheumatology /ID# 165239, Edmonton, Alberta, Canada|Credit Valley Rheumatology /ID# 200087, Mississauga, Ontario, Canada|Groupe de Recherche en Maladies Osseuses /ID# 165238, Sainte-foy, Quebec, Canada|Clinical Hospital Dubrava /ID# 167049, Zagreb, Croatia|Medical Center Kuna-Peric /ID# 164851, Zagreb, Croatia|Revmatologicky ustav Praha /ID# 167004, Prague 2, Praha 2, Czechia|Thomayerova nemocnice /ID# 167003, Prague 4, Praha 4, Czechia|REVMACLINIC s.r.o. /ID# 167171, Brno, Czechia|ARTHROHELP, s.r.o. /ID# 167001, Pardubice, Czechia|Vejle Sygehus /ID# 165190, Vejle, Syddanmark, Denmark|Helsinki Univ Central Hospital /ID# 165794, Helsinki, Finland|Kiljava Medical Research /ID# 165793, Hyvinkaa, Finland|Hopital Saint Eloi /ID# 166308, Montpellier CEDEX 5, Herault, France|CHU Bordeaux-Hopital Pellegrin /ID# 166309, Bordeaux, France|CHRU Tours - Hopital Trousseau /ID# 165109, Chambray Les Tours, France|Rheumazentrum Ruhrgebiet /ID# 165148, Herne, Nordrhein-Westfalen, Germany|Kerckhoff Klinik GmbH /ID# 165158, Bad Nauheim, Germany|Charit Centrm Innr Medizn mit /ID# 165153, Berlin, Germany|Rheumaforschungszentrum II /ID# 165146, Hamburg, Germany|Vital Medical Center Orvosi es /ID# 164741, Veszprém, Veszprem, Hungary|Revita Reumatologiai Rendelo /ID# 164724, Budapest, Hungary|University of Debrecen /ID# 165674, Debrecen, Hungary|Mentahaz Maganorvosi Kozpont /ID# 165066, Szekesfehervar, Hungary|Ospedale Sant Orsola Malpighi /ID# 165692, Bologna, Emilia-Romagna, Italy|Policlinico Paolo Giaccone /Id# 165663, Palermo, Sicilia, Italy|ASST G. Pini /ID# 165715, Milan, Italy|A.O. Universitaria Senese /ID# 165716, Siena, Italy|Gunma University Hospital /ID# 165683, Maebashi-shi, Gunma, Japan|National Hospital Organization Asahikawa Medical Center /ID# 164566, Asahikawa, Hokkaido, Japan|Kagawa University Hospital /ID# 167517, Kita-gun, Kagawa, Japan|Shinshu University Hospital /ID# 165304, Matsumoto-shi, Nagano, Japan|Japanese Red Cross Okayama Hospital /ID# 164376, Okayama-shi, Okayama, Japan|NHO Osaka Minami Med Ctr /ID# 164365, Kawachinagano-shi, Osaka, Japan|Osaka City University Hospital /ID# 165253, Osaka-shi, Osaka, Japan|Osaka University Hospital /ID# 166033, Suita-shi, Osaka, Japan|Saitama Medical University Hospital /ID# 164577, Iruma-gun, Saitama, Japan|Juntendo University Koshigaya Hospital /ID# 165809, Koshigaya-shi, Saitama, Japan|Tokushima University Hospital /ID# 165108, Tokushima-shi, Tokushima, Japan|Juntendo University Hospital /ID# 164738, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 165219, Chuo-ku, Tokyo, Japan|Hopsital of the University of Occupational and Enviromental Health /ID# 164380, Fukuoka, Japan|Daido Hospital /ID# 163886, Nagoya, Japan|Kochi Medical School Hospital /ID# 164460, Nankoku-shi, Japan|Okayama Saiseikai Outpatient Center Hospital /ID# 165595, Okayama, Japan|Chungnam National University Hospital /ID# 164561, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Gachon University Gil Medical Center /ID# 165114, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 164541, Gwangju, Jeonranamdo, Korea, Republic of|Hanyang University Seoul Hospi /ID# 165811, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 164549, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Kyunghee University Hospital /ID# 164569, Seoul, Korea, Republic of|Asan Medical Center /ID# 164557, Seoul, Korea, Republic of|Universitair Medisch Centrum Groningen /ID# 165681, Groningen, Netherlands|Medisch Centrum Leeuwarden /ID# 166937, Leeuwarden, Netherlands|Waikato Hospital /ID# 169242, Hamilton, Waikato, New Zealand|Middlemore Hospital /ID# 169241, Auckland, New Zealand|NZOZ Nasz Lekarz /ID# 166023, Toruń, Kujawsko-pomorskie, Poland|Osteo-Medic S.C. /ID# 165646, Białystok, Podlaskie, Poland|ETYKA-Osrodek Badan Klinicznyc /ID# 165634, Olsztyn, Warminsko-mazurskie, Poland|Instituto Portugues De Reumatologia /ID# 168314, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 168312, Lisbon, Lisboa, Portugal|Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 168313, Vila Nova De Gaia, Porto, Portugal|Hospital CUF Descobertas /ID# 168311, Lisbon, Portugal|Unidade Local De Saude Do Alto Minho /ID# 168310, Viana Do Castelo, Portugal|H. Un. Marques de Valdecilla /ID# 165028, Santander, Cantabria, Spain|Hospital Parc de Salut del Mar /ID# 165027, Barcelona, Spain|Corp Sanit Parc Tauli Sabadell /ID# 165029, Barcelona, Spain|Skanes Universitetssjukhus /ID# 165712, Malmö, Skane Lan, Sweden|Reumatologkliniken /ID# 165713, Vaesteras, Sweden|Warrington and Halton Hospitals NHS Foundation Trust /ID# 166202, Warrington, Cheshire West And Chester, United Kingdom|Whipps Cross Univ Hospital /ID# 165150, London, London, City Of, United Kingdom|Royal National Hosp for Rheuma /ID# 165147, Bath, United Kingdom|Glasgow Royal Infirmary /ID# 165152, Glasgow, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 165149, Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03178487"
134,"NCT03155243","Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice","HOPE","Active, not recruiting","No Results Available","Uveitis",,"Proportion of participants who achieve treatment response at any of the follow-up visits|Proportion of participants with maintained response at any of follow up visits|Percent change in Presenteeism|Proportion of participants with maintained response separately for each follow-up visit|Percent Change in Total activity impairment|Changes in total score of Work Productivity & Activity Impairment (WPAI)-UV score|Change in emergency room admissions|Proportion of participants with treatment response separately for each follow-up visit|Change from baseline in Best corrected visual acuity (BCVA)|Change in cumulative hospital admissions|Change from baseline in Central Retinal Thickness (CRT)|Proportion of participants with flare at any of follow up visit|Percent change in Absenteeism|Percent Change in Total work productivity impairment|Change in outpatient visits|Change in hospitalization days prior to and during Humira® treatment|Change from baseline in intraocular pressure","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"145","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-537","June 20, 2017","December 31, 2019","December 31, 2019","May 16, 2017",,"February 8, 2019","Medizinische Universität Graz /ID# 206301, Graz, Steiermark, Austria|Medical University of Vienna /ID# 206190, Vienna, Wien, Austria|Clinica Oftalmologica del Caribe /ID# 206448, Barranquilla, Atlantico, Colombia|Foscal /Id# 207362, Bucaramanga, Colombia|Fundacion hospitalaria San Vicente de Paul /ID# 208295, Medellín, Colombia|Vseobecna Fakultni Nemocnice /ID# 209530, Prague, Czechia|Charite Campus Virchow-Klinikum /ID# 204879, Berlin, Germany|Universitätsklinikum Hamburg-Eppendorf /ID# 205234, Hamburg, Germany|St. Franziskus Hosp Muenster /ID# 206695, Munster, Germany|Omma /Id# 163750, Athens, Greece|Athens Eye Hospital /ID# 163751, Athens, Greece|University General Hospital of Ioannina /ID# 163752, Ioannina, Greece|Interbalkan Medical Center /ID# 163753, Thessaloniki, Greece|Semmelweis Egyetem /ID# 163647, Budapest, Hungary|Szegedi Tudomanyegyetem /ID# 163646, Szeged, Hungary|Royal Victoria Eye and Ear Hos /ID# 163653, Dublin, Ireland|Rabin Medical Center /ID# 163108, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 163024, Tel Aviv-Yafo, Tel-Aviv, Israel|Hadassah Medical Center /ID# 169305, Jerusalem, Yerushalayim, Israel|Barzilai Medical Center /ID# 163025, Ashkelon, Israel|Bnai Zion Medical Center /ID# 163026, Haifa, Israel|Sheba Medical Center /ID# 163109, Ramat Gan, Israel|Albahar Ophtalmology Center /ID# 210124, Kuwait, Kuwait|American University of Beirut /ID# 210122, Beirut, Lebanon|Stadtspital Triemli /ID# 206204, Zurich, Zuerich, Switzerland|Inselspital, Universitaetsklin /ID# 201027, Bern, Switzerland|Hop Ophtalmique Jules Gonin /ID# 201028, Lausanne, Switzerland|Cleveland Clinic Abu Dhabi /ID# 210123, Abu Dhabi, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT03155243"
135,"NCT03145948","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis",,"Terminated","No Results Available","Psoriasis","Drug: ABBV-553|Drug: Placebo","Substudy 1: Maximum observed plasma concentration (Cmax) of ABBV-553|Substudy 2: Maximum observed plasma concentration (Cmax) of ABBV-553|Substudy 1: Time to Cmax (peak time, Tmax)|Substudy 2: Time to Cmax (peak time, Tmax)|Substudy 1: Area under the concentration time curve (AUC) from time zero to 24 hours after dosing|Substudy 2: Area under the concentration time curve (AUC) from time zero to 24 hours after dosing|Substudy 1: Observed plasma concentration at the end of the dosing interval (Ctrough)|Substudy 2: Observed plasma concentration at the end of the dosing interval (Ctrough)|Substudy 1: Apparent clearance (CL/F)|Substudy 2: Apparent clearance (CL/F)|Substudy 1: Volume of distribution (Vβ/F)|Substudy 2: Volume of distribution (Vβ/F)|Substudy 1: Fraction excreted unchanged in urine (fe)|Substudy 1: Apparent renal clearance (CLR)|Substudy 2: Psoriasis Area and Severity Index (PASI)|Substudy 2: Self-Assessment of Psoriasis Symptoms (SAPS) scores","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","M16-058","May 9, 2017","August 16, 2017","August 16, 2017","May 9, 2017",,"November 6, 2017","Anaheim Clinical Trials LLC /ID# 164101, Anaheim, California, United States|Providence Clinical Research /ID# 163867, Toluca, California, United States|Progressive Medical Research /ID# 163868, Port Orange, Florida, United States|Abbvie Clinical Pharmacology Research Unit /ID# 163866, Grayslake, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03145948"
136,"NCT03145909","A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)",,"Terminated","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-176","Dose Escalation Cohort: Tmax of ABBV-176|Dose Escalation Cohort: AUC∞ for ABBV-176|Dose Escalation Cohort: Terminal phase elimination rate constant (β) for ABBV-176|Dose Escalation Cohort: Recommended Phase 2 dose (RPTD) for ABBV-176|Dose Escalation Cohort: Cmax of ABBV-176|Dose Escalation Cohort: Maximum tolerated dose (MTD) of ABBV-176|Expanded Recommended Phase Two Dose (RPTD) Cohort: Objective Response Rate (ORR)|Dose Escalation Cohort: AUCt for ABBV-176|Dose Escalation Cohort: t1/2 for ABBV-176|Expanded RPTD Cohort: AUCt for ABBV-176|Expanded RPTD Cohort: Tmax of ABBV-176|Expanded RPTD Cohort: Overall Survival (OS)|Expanded RPTD Cohort: Cmax of ABBV-176|Expanded RPTD Cohort: Duration of Response (DOR)|Expanded RPTD Cohort: Terminal phase elimination rate constant (β) for ABBV-176|Expanded Recommended Phase Two Dose (RPTD) Cohort: Progression-Free Survival (PFS)|Expanded RPTD Cohort: Change in ECOG Performance Status|Expanded RPTD Cohort: AUC∞ for ABBV-176|Expanded RPTD Cohort: t1/2 for ABBV-176|Dose Escalation Cohort: Change from Baseline in QTcF","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-916|2016-004597-18","July 3, 2017","November 27, 2018","November 27, 2018","May 9, 2017",,"November 29, 2018","HonorHealth Research Institute - Pima /ID# 161078, Scottsdale, Arizona, United States|City of Hope /ID# 161079, Duarte, California, United States|Yale University /ID# 201357, New Haven, Connecticut, United States|St. Lukes Cancer Institute /ID# 201353, Kansas City, Missouri, United States|Washington University-School of Medicine /ID# 162745, Saint Louis, Missouri, United States|Rutgers Cancer Institute of NJ /ID# 161080, New Brunswick, New Jersey, United States|University of Utah /ID# 161606, Salt Lake City, Utah, United States|Sydney Children's Hospital /ID# 162917, Randwick, New South Wales, Australia|Mater Misericordiae /ID# 162918, South Brisbane, Queensland, Australia|Rigshospitalet /ID# 159707, Copenhagen Ø, Hovedstaden, Denmark|Hosp Univ Madrid Sanchinarro /ID# 161644, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03145909"
137,"NCT03138408","SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers",,"Terminated","No Results Available","Cancer","Drug: SC-004|Drug: ABBV-181","Number of participants with dose-limiting toxicities (DLT)|Observed plasma concentrations at trough (Ctrough)|Overall Survival (OS)|Objective Response Rate (ORR)|Terminal half life (T1/2)|Maximum observed serum concentration (Cmax)|Time to Cmax (Tmax)|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)|Duration of Response (DOR)|Area under the plasma concentration-time curve within a dosing interval (AUC)|QTcF Change from Baseline|Duration of Clinical Benefit (DOCB)","AbbVie","Female","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-553","June 14, 2017","May 2, 2019","May 2, 2019","May 3, 2017",,"May 14, 2019","University of Alabama /ID# 202249, Birmingham, Alabama, United States|Highlands Oncology Group /ID# 209165, Fayetteville, Arkansas, United States|City of Hope /ID# 202493, Duarte, California, United States|University of Chicago /ID# 200735, Chicago, Illinois, United States|Henry Ford Health System /ID# 202480, Detroit, Michigan, United States|Mayo Clinic - Rochester /ID# 200732, Rochester, Minnesota, United States|Washington University School /ID# 164091, Saint Louis, Missouri, United States|The Ohio State University - Columbus /ID# 164089, Columbus, Ohio, United States|Univ Oklahoma HSC /ID# 164090, Oklahoma City, Oklahoma, United States|Tennessee Oncology-Nashville Centennial /ID# 164088, Nashville, Tennessee, United States|MD Anderson Cancer Center /ID# 200048, Houston, Texas, United States|Huntsman Cancer Institute /ID# 209164, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03138408"
138,"NCT03123965","Expanded Access to Glecaprevir/ Pibrentasvir",,"Approved for marketing","No Results Available","Hepatitis C Virus Infection","Drug: glecaprevir|Drug: pibrentasvir",,"AbbVie",,"18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"C16-563",,,,"April 21, 2017",,"January 18, 2020","Univ Medical Ctr Ljubljana /ID# 161419, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT03123965"
139,"NCT03123952","Expanded Access to ABT-414",,"No longer available","No Results Available","Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis","Drug: ABT-414",,"AbbVie","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients|Intermediate-size Population",,"C16-478|C19-919",,,,"April 21, 2017",,"July 15, 2019",,,"https://ClinicalTrials.gov/show/NCT03123952"
140,"NCT03123211","Expanded Access to Veliparib",,"Available","No Results Available","Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound|Triple Negative Breast Cancer (TNBC)|High Grade Serous Ovarian Cancer","Drug: Veliparib",,"AbbVie","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients|Intermediate-size Population",,"C16-468|C19-918",,,,"April 21, 2017",,"March 25, 2019",,,"https://ClinicalTrials.gov/show/NCT03123211"
141,"NCT03123029","Expanded Access to Venetoclax",,"Available","No Results Available","Chronic Lymphocytic Leukemia (CLL)|Multiple Myeloma|Acute Myeloid Leukemia (AML)|Non-Hodgkin's Lymphoma|Acute Lymphoblastic Leukemia (ALL)|Amyloidosis","Drug: Venetoclax",,"AbbVie","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"C16-431|C19-920",,,,"April 21, 2017",,"July 15, 2019",,,"https://ClinicalTrials.gov/show/NCT03123029"
142,"NCT03105128","A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease",,"Recruiting","No Results Available","Crohn's Disease","Drug: placebo for risankizumab|Drug: risankizumab IV|Drug: risankizumab SC","Percentage of Participants With Clinical Remission|Percentage of Participants With Endoscopic Response|Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission|Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response|Mean Change From Baseline of Induction in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue|Mean Change From Baseline of Induction in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score|Percentage of Participants With Enhanced Clinical Response and Endoscopic Response|Percentage of Participants With Endoscopic Remission|Percentage of Participants With Enhanced Clinical Response|Percentage of Participants With Ulcer-Free Endoscopy|Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline|Percentage of Participants With CD-Related Hospitalization|Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline","AbbVie","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","940","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-006|2016-003123-32","May 10, 2017","March 17, 2021","March 17, 2021","April 7, 2017",,"January 21, 2020","Phoenix VA Healthcare /ID# 162267, Phoenix, Arizona, United States|HonorHealth Research Institute - Shea /ID# 161783, Scottsdale, Arizona, United States|Physician's Research Group /ID# 211883, Tempe, Arizona, United States|University of Arizona /ID# 158469, Tucson, Arizona, United States|Atria Clinical Research /ID# 164740, Little Rock, Arkansas, United States|TLC Clinical Research Inc /ID# 212503, Beverly Hills, California, United States|Newport Huntington Medical Group /ID# 213033, Huntington Beach, California, United States|United Gastroenterologists /ID# 207040, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 162656, Los Angeles, California, United States|United Gastroenterologists - Murrieta /ID# 158424, Murrieta, California, United States|Southern CA Research Ctr., Inc /ID# 167875, Riverside, California, United States|University of California, San /ID# 157143, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 163842, West Hollywood, California, United States|Peak Gastroenterology Associat /ID# 165834, Colorado Springs, Colorado, United States|Rocky Mountain Pediatric Gastroenterology /ID# 207169, Lone Tree, Colorado, United States|Western Connecticut Medical Group /ID# 165849, Danbury, Connecticut, United States|Brandon Premier Health Care, PA /ID# 162265, Brandon, Florida, United States|Clinical Res of West FL, Inc. /ID# 204859, Clearwater, Florida, United States|Clinical Res of West FL, Inc. /ID# 207450, Clearwater, Florida, United States|South Lake Pain Institute, Inc /ID# 162825, Clermont, Florida, United States|Universal Axon Clinical Resear /ID# 165432, Doral, Florida, United States|Nature Coast Clinical Research /ID# 159414, Inverness, Florida, United States|SIH Research, LLC /ID# 163082, Kissimmee, Florida, United States|Alliance Medical Research /ID# 163840, Lighthouse Point, Florida, United States|Ctr for Advanced Gastroenterol /ID# 201571, Maitland, Florida, United States|ITB Research /ID# 161334, Miami, Florida, United States|Vista Health Research LLC - Miami /ID# 212664, Miami, Florida, United States|Coral Research Clinic /ID# 158549, Miami, Florida, United States|Nirvana Research Center /ID# 161836, Miami, Florida, United States|Gastroenterology Group Naples /ID# 165206, Naples, Florida, United States|Advanced Research Institute /ID# 161959, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 205901, Orlando, Florida, United States|Omega Research Consultants,LLC Debary /ID# 171081, Orlando, Florida, United States|IMIC Inc. /ID# 154943, Palmetto Bay, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 201014, Tampa, Florida, United States|Atlanta Gastro Assoc /ID# 154740, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 154857, Macon, Georgia, United States|Northwestern University /ID# 158283, Chicago, Illinois, United States|University of Chicago /ID# 157141, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 158287, Evanston, Illinois, United States|Southwest Gastroenterology /ID# 165002, Oak Lawn, Illinois, United States|Cotton-O'Neil Clinical Res Ctr /ID# 154738, Topeka, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 157137, Lexington, Kentucky, United States|University of Louisville /ID# 210521, Louisville, Kentucky, United States|Gastroenterology Assoc. LA /ID# 161956, Baton Rouge, Louisiana, United States|Houma Digestive Health Special /ID# 158286, Houma, Louisiana, United States|Delricht Research /ID# 206542, New Orleans, Louisiana, United States|Nola Research Works, LLC /ID# 161330, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 162236, Shreveport, Louisiana, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 154839, Chevy Chase, Maryland, United States|Gastro Center of Maryland /ID# 165004, Columbia, Maryland, United States|University of Michigan Hospitals /ID# 157144, Ann Arbor, Michigan, United States|Center for Digestive Health /ID# 154690, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC /ID# 161328, Wyoming, Michigan, United States|Mayo Clinic - Rochester /ID# 163085, Rochester, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 162388, Jackson, Mississippi, United States|Saint Louis University School of Medicine /ID# 161902, Saint Louis, Missouri, United States|University of Nebraska Med Ctr /ID# 210057, Omaha, Nebraska, United States|Comprehensive Digestive Instit /ID# 160172, Las Vegas, Nevada, United States|Revival Research Institute, LLC /ID# 210984, Las Vegas, Nevada, United States|NY Scientific /ID# 158418, Brooklyn, New York, United States|Saratoga Schenectady Gastroenterology Associates - Burnt Hills /ID# 212036, Burnt Hills, New York, United States|Intercity Advanced Gastroentertology Center /ID# 213399, Fresh Meadows, New York, United States|Long Island Clinical Research /ID# 154836, Great Neck, New York, United States|Digestive Dis Care/Excel Med /ID# 209619, New Hyde Park, New York, United States|North Shore University Hospital /ID# 168736, New Hyde Park, New York, United States|NYU Langone Medical Center /ID# 160171, New York, New York, United States|Weill Cornell Medicine /ID# 161911, New York, New York, United States|Lenox Hill Hospital, Northwell /ID# 168465, New York, New York, United States|DiGiovanna Institute for Medic /ID# 171118, North Massapequa, New York, United States|Univ NC Chapel Hill /ID# 154840, Chapel Hill, North Carolina, United States|Carolinas Medical Center /ID# 158481, Charlotte, North Carolina, United States|Clinical Trials America /ID# 158484, Hickory, North Carolina, United States|Vidant Medical Group, d/b/a Vidant Multi-Specialty Clinic-Kinston /ID# 161111, Kinston, North Carolina, United States|Wake Research Associates, LLC /ID# 154880, Raleigh, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 169715, Fargo, North Dakota, United States|Tri-State Endoscopy /ID# 154933, Cincinnati, Ohio, United States|Cleveland Clinic Main Campus /ID# 208171, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 164709, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 167901, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 170453, Dayton, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 201732, Mentor, Ohio, United States|Hightower Clinical /ID# 211938, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists /ID# 170774, Oklahoma City, Oklahoma, United States|Adult Gastroenterology Associates - Main /ID# 206125, Tulsa, Oklahoma, United States|Northwest Gastroenterology Cli /ID# 158288, Portland, Oregon, United States|PennState Milton S.Hershey Med /ID# 154883, Hershey, Pennsylvania, United States|Child Hosp of Pittsburgh,PA /ID# 210920, Pittsburgh, Pennsylvania, United States|Digestive Disease Associates, LTD /ID# 208847, Wyomissing, Pennsylvania, United States|Medical University of South Carolina /ID# 212579, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 154911, Greenville, South Carolina, United States|Rapid City Medical Center /ID# 163841, Rapid City, South Dakota, United States|Gastro One /ID# 154742, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 168737, Johnson City, Tennessee, United States|Clinical Neuroscience /ID# 164181, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 157138, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 159410, Arlington, Texas, United States|Inquest Clinical Research /ID# 165695, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209596, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209785, Cedar Park, Texas, United States|Baylor Scott & White Research /ID# 201848, Dallas, Texas, United States|DHAT Research Institute /ID# 158217, Garland, Texas, United States|Vilo Research Group Inc /ID# 206130, Houston, Texas, United States|CliniCore International, LLC /ID# 158209, Houston, Texas, United States|Baylor College of Medicine /ID# 158212, Houston, Texas, United States|Precision Research Institute - Houston /ID# 200503, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 200720, Houston, Texas, United States|Clinical Associates in Researc /ID# 161336, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 168770, San Antonio, Texas, United States|Tyler Research Institute, LLC /ID# 166796, Tyler, Texas, United States|Victoria gastroenterology /ID# 164296, Victoria, Texas, United States|HP Clinical Research /ID# 162998, Bountiful, Utah, United States|Advanced Research Institute /ID# 154914, Ogden, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 161781, West Jordan, Utah, United States|University of Vermont Medical Center /ID# 215407, Burlington, Vermont, United States|McGuire DV AMC /ID# 159990, Richmond, Virginia, United States|Washington Gastroenterology /ID# 162120, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 155545, Seattle, Washington, United States|University of Washington /ID# 155553, Seattle, Washington, United States|West Virginia University /ID# 167940, Morgantown, West Virginia, United States|Hopital Centenario /ID# 170883, Rosario, Santa Fe, Argentina|Hospital Privado Univesitario /ID# 161988, Cordoba, Argentina|Mater Hospital /ID# 167990, Brisbane, Queensland, Australia|Griffith University /ID# 212627, Southport, Queensland, Australia|Lyell McEwin Hospital /ID# 211363, Elizabeth Vale, South Australia, Australia|Emeritus Research /ID# 213511, Camberwell, Victoria, Australia|Footscray Hospital /ID# 211361, Footscray, Victoria, Australia|Universitätsklinikum St.Pölten /ID# 166425, St. Pölten, Niederoesterreich, Austria|LKH-Univ. Klinikum Graz /ID# 158137, Graz, Steiermark, Austria|Krankenhaus der Barmherzigen Brüder Wien /ID# 212059, Vienna, Wien, Austria|Medical University of Vienna /ID# 158138, Vienna, Wien, Austria|Gomel Regional Clinical Hospit /ID# 159498, Gomel, Belarus|Grodno city clinical hospital №2 /ID# 159499, Grodno, Belarus|Vitebsk Regional Advanced CC /ID# 159497, Vitebsk, Belarus|Cliniques Universitaires Saint Luc /ID# 157395, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 157398, Liège, Liege, Belgium|UZ Gent /ID# 157394, Gent, Oost-Vlaanderen, Belgium|Imelda Ziekenhuis /ID# 157392, Bonheiden, Belgium|ULB Erasme /ID# 157397, Brussels, Belgium|UZ Leuven /ID# 157396, Leuven, Belgium|Clinique St Joseph /ID# 157393, Liege, Belgium|AZ-Delta /ID# 157391, Roeselare, Belgium|CHU Dinant Godinne - UCL Namur /ID# 157401, Yvoir, Belgium|University Clinical Centre of the Republic of Srpska /ID# 157717, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 164512, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 165134, Sarajevo, Bosnia and Herzegovina|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 157672, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 157646, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 157653, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 157688, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 157649, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 159672, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 157656, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hosp U Clementino Fraga Filho /ID# 157650, Rio de Janeiro, Brazil|UMHAT Dr Georgi Stranski EAD /ID# 203977, Pleven, Bulgaria|University Multiprofile Hospit /ID# 158644, Plovdiv, Bulgaria|Second Multiprofile Hospital f /ID# 158646, Sofia, Bulgaria|Tokuda Hospital Sofia /ID# 158645, Sofia, Bulgaria|UMHAT Tsaritsa Joanna - ISUL /ID# 211240, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 204714, Sofia, Bulgaria|MHAT Trakia /ID# 201672, Stara Zagora, Bulgaria|University Multiprofile Hospit /ID# 167575, Varna, Bulgaria|University of Calgary /ID# 157152, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 169761, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 157098, Edmonton, Alberta, Canada|Covenant Health /ID# 161617, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 159053, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 157095, Vancouver, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 161616, Victoria, British Columbia, Canada|QEII - Victoria Building /ID# 157087, Halifax, Nova Scotia, Canada|IWK Health Center /ID# 165900, Halifax, Nova Scotia, Canada|London Health Sciences Centre /ID# 157160, London, Ontario, Canada|Scott Shulman Medicine Professional Corporation /ID# 165903, North Bay, Ontario, Canada|Medicor Research Inc. /ID# 157149, Sudbury, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 169762, Toronto, Ontario, Canada|Toronto Digestive Disease Asso /ID# 157157, Vaughan, Ontario, Canada|CISSS de la Monteregie /ID# 161615, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 214375, Levis, Quebec, Canada|Hospital Maisonneuve-Rosemont /ID# 159054, Montreal, Quebec, Canada|Centre Recherche luniver Montr /ID# 167066, Montreal, Quebec, Canada|McGill Univ HC /ID# 157084, Montreal, Quebec, Canada|Complejo Asistencial Dr. Sotero del Rio /ID# 169382, Santiago, Region Metropolitana De Santiago, Chile|Servicio de Salud Occidente Hospital San Juan de Dios /ID# 171119, Santiago, Region Metropolitana De Santiago, Chile|Centro de Investigaciones Clínicas Viña del Mar /ID# 203589, Viña del Mar, Valparaíso, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 210759, Concepción, Chile|Hospital Las Higueras /ID# 167090, Talcahuano, Chile|Hospital Dr. Hernán Henríquez Aravena /ID# 210728, Temuco, Chile|Xinqiao Hospital of 3rd Military Medical University /ID# 212994, Chongqing, Chongqing, China|The Sixth Affiliated Hosp, Sun /ID# 210785, Guangzhou, Guangdong, China|The University of Hong Kong- Shenzhen Hospital /ID# 213110, Shenzhen, Guangdong, China|The Second Hospital of Hebei Medical University /ID# 212740, Shijiazhuang, Hebei, China|1st Aff Hosp Nanchang Univ /ID# 211034, Nanchang, Jiangxi, China|Ruijin Hospital, Shanghai Jiaotong /ID# 210841, Shanghai, Shanghai, China|Renji Hosp, Shanghai Jiaotong /ID# 210707, Shanghai, Shanghai, China|The second affiliated hospital of Zhejiang University school of medicine /ID# 210725, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 210624, Hangzhou, Zhejiang, China|Jinhua Central Hospital /ID# 215626, Jinhua, Zhejiang, China|The Second Xiangya Hospital of Central South University /ID# 211696, Changsha, China|West China Hospital, Sichuan University /ID# 210889, Chengdu, China|Guangdong Provincial People's Hospital /ID# 212948, Guangzhou, China|Jiangsu Province Hospital /ID# 210502, Nanjing, China|Shanghai Dongfang Hospital /ID# 212683, Shanghai, China|Tianjin Med Univ General Hosp /ID# 210927, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 211038, Wuhan, China|Tongji Hosp Tongji Med College /ID# 210856, Wuhan, China|Renmin Hospital of Wuhan Univ /ID# 214873, Wuhan, China|Hospital Univ San Ignacio /ID# 158733, Bogota, Colombia|Instituto de Coloproctologia /ID# 158741, Medellin, Colombia|Hospital Universitario San Vic /ID# 171487, Medellin, Colombia|Hospital Pablo Tobon Uribe /ID# 158735, Medellín, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 157565, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Sestre milosrdnice /ID# 157721, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 157566, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 157564, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 157567, Split, Croatia|CTCenter MaVe, s.r.o. /ID# 163149, Olomouc, Olomoucky Kraj, Czechia|Ikem /Id# 165463, Prague 4, Praha 4, Czechia|Thomayerova nemocnice /ID# 162940, Prague, Praha 4, Czechia|Axon Clinical, s.r.o. /ID# 163176, Praha, Praha 5, Czechia|Nemocnice Horovice, NH Hospita /ID# 211076, Horovice, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 163134, Hradec Kralove, Czechia|Nemocnice Pardubickeho kraje, a.s. /ID# 163182, Pardubice, Czechia|Restrial /ID# 211075, Prague 412, Czechia|Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 211305, Praha 1, Czechia|East Tallinn Central Hospital /ID# 157076, Tallinn, Estonia|West Tallinn Central Hospital /ID# 157077, Tallinn, Estonia|North Estonian Medical Centre /ID# 163507, Tallinn, Estonia|Universitatsklinikum Mannheim /ID# 162020, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 159315, Erlangen, Bayern, Germany|Universitatsklinikum Munster /ID# 159316, Munster, Niedersachsen, Germany|Evangelisches Krankenhaus Kalk /ID# 212725, Cologne, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 164985, Köln, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 210529, Saarbrücken, Saarland, Germany|Univ Hosp Schleswig-Holstein /ID# 159321, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 164986, Ulm, Thueringen, Germany|Charité Universitätsmedizin Campus Mitte /ID# 212219, Berlin, Germany|Charité Universitätsmedizin Campus Mitte /ID# 212893, Berlin, Germany|Gastroenterologische Spezialpraxis am Wittenbergplatz /ID# 211972, Berlin, Germany|Praxis am Bayrischen Platz /ID# 159322, Berlin, Germany|DRK Kliniken Berlin /ID# 166146, Berlin, Germany|Krankenhaus Waldfriede /ID# 212728, Berlin, Germany|Stadtisches Klinikum Braunschw /ID# 163666, Braunschweig, Germany|Medizinisches Versorgungszent /ID# 211557, Dachau, Germany|Agaplesion Markus Krankenhaus /ID# 159317, Frankfurt, Germany|Universitaetsklinikum Frankfurt /ID# 212978, Frankfurt, Germany|Universitätsklinikum Freiburg /ID# 162019, Freiburg, Germany|Praxis Dres. Hülsdonk/Naumann /ID# 211964, Grevenbroich, Germany|Asklepios Westklinikum Hamburg /ID# 159319, Hamburg, Germany|Med Hochschule Hanover /ID# 162021, Hannover, Germany|Praxis fuer Gastroenterologie /ID# 166145, Heidelberg, Germany|Universitaetsklinikum Jena /ID# 159323, Jena, Germany|EUGASTRO GmbH /ID# 212076, Leipzig, Germany|Klinikum Lueneburg /ID# 163664, Lueneburg, Germany|Universitatsklinikum Magdeburg /ID# 211847, Magdeburg, Germany|Gastro Gemeinschaftspraxis /ID# 162018, Minden, Germany|Klinikum Univ Regensburg /ID# 163665, Regensburg, Germany|Universitatsklinikum Tubingen /ID# 159324, Tuebingen, Germany|Gastro-Praxis Wiesbaden /ID# 159318, Wiesbaden, Germany|Tzaneio general hospital of Piraeus /ID# 206445, Piraeus, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 157428, Athens, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 171077, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 157427, Heraklion, Greece|University General Hospital of Ioannina /ID# 157425, Ioannina, Greece|General Hospital Nikaias-Piraeus St. Panteleimon /ID# 157429, Pireaus, Greece|Theageneio Anticancer Hospital /ID# 163921, Thessaloniki, Greece|Queen Mary Hospital /ID# 163902, Hong Kong, Hong Kong|Tuen Mun Hospital /ID# 163901, Tuen Mun, Hong Kong|Obudai Egeszsegugyi Centrum Kft. /ID# 213190, Budapest, Hungary|Semmelweis Egyetem I. Belgyogyaszati Klinika /ID# 213136, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 162985, Debrecen, Hungary|Debrecen University /ID# 157769, Debrecen, Hungary|Almasi Balogh Pal korhaz /ID# 213137, Ozd, Hungary|St Vincent's University Hospit /ID# 157512, Dublin, Ireland|Beaumont Hospital /ID# 157515, Dublin, Ireland|University Hospital Galway /ID# 157513, Galway, Ireland|Soroka Medical Center /ID# 157798, Be'er Sheva, HaDarom, Israel|Tel Aviv Sourasky Medical Ctr /ID# 157796, Tel Aviv-Yafo, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 165913, Jerusalem, Yerushalayim, Israel|Rambam Medical Center /ID# 171072, Haifa, Israel|The Edith Wolfson Medical Cent /ID# 217329, Holon, Israel|Shaare Zedek Medical Center /ID# 163540, Jerusalem, Israel|Shaare Zedek Medical Center /ID# 171073, Jerusalem, Israel|Sheba Medical Center /ID# 171074, Ramat Gan, Israel|Universita di Catanzaro Magna Graecia /ID# 212012, Catanzaro, Calabria, Italy|AOU Policlinico S.Orsola Malpighi /ID# 155635, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 212019, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 162429, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 155636, Rome, Lazio, Italy|Azienda Policlinico Universitario Umberto I /ID# 166911, Rome, Lazio, Italy|Ospedale Policlinico San Martino/ Università Degli Studi Di Genova /ID# 162430, Genoa, Liguria, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 155633, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 155634, Rozzano, Milano, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 155632, Rome, Roma, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 161306, Catania, Sicilia, Italy|A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 155637, Palermo, Sicilia, Italy|Azienda Ospedaliera Univ. Meyer /ID# 168051, Florence, Toscana, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 161305, Negrar, Verona, Italy|Ospedali Riuniti Universita /ID# 162427, Ancona, Italy|ASST Fatebenefratelli Sacco /ID# 155631, Milan, Lombardia, Italy|IRCCS Policlinico S. Matteo /ID# 212029, Pavia, Italy|Policlinico Tor Vergata /ID# 158021, Rome, Italy|Aichi Medical University Hosp /ID# 160159, Nagakute, Aichi, Japan|Daido Clinic /ID# 211477, Nagoya-shi, Aichi, Japan|Nagoya University Hospital /ID# 160150, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 160162, Nagoya-shi, Aichi, Japan|Tokatsu Tsujinaka Hospital /ID# 163362, Abiko-shi, Chiba, Japan|Toho University Sakura Medical Center /ID# 160161, Sakura-shi, Chiba, Japan|Kurume University Hospital /ID# 160138, Kurume-shi, Fukuoka, Japan|NHO Fukuyama Medical Center /ID# 163578, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 162844, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 160158, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 163028, Sapporo-shi, Hokkaido, Japan|Sapporo Tokushukai Hospital /ID# 213493, Sapporo, Hokkaido, Japan|Nishinomiya Munic Central Hosp /ID# 210104, Nishinomiya-shi, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 160164, Nishinomiya-shi, Hyogo, Japan|National Hospital Organization Mito Medical Center /ID# 160154, Higashi Ibaraki-gun, Ibaraki, Japan|Kanazawa University Ho /ID# 201766, Kanazawa, Ishikawa, Japan|Gokeikai Ofuna Chuo Hospital /ID# 171070, Kamakura-shi, Kanagawa, Japan|Yokohama City Univ Medical Ctr /ID# 163906, Yokohama, Kanagawa, Japan|Yokohama Municipal Citizen's Hospital /ID# 204126, Yokohama, Kanagawa, Japan|Mie University Hospital /ID# 203639, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 162843, Sendai-shi, Miyagi, Japan|Tohoku Rosai Hospital /ID# 163189, Sendai-shi, Miyagi, Japan|Osaka City University Hospital /ID# 160146, Osaka-shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 160155, Kawagoe-shi, Saitama, Japan|Tokito Clinic /ID# 160145, Saitama-shi, Saitama, Japan|Shiga University of Medical Science Hospital /ID# 164022, Otsu, Shiga, Japan|Hamamatsu University Hospital /ID# 205689, Hamamatsu-shi, Shizuoka, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 160157, Bunkyo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 160160, Hachioji, Tokyo, Japan|Kitasato Univ Kitasato Inst Ho /ID# 160144, Minato-ku, Tokyo, Japan|Kyorin University Hospital /ID# 160149, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 205973, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 200154, Yamagata-shi, Yamagata, Japan|Yamanashi Prefectural Ctr Hosp /ID# 160156, Kofu-shi, Yamanashi, Japan|Chiba University Hospital /ID# 217532, Chiba, Japan|Hiroshima University Hospital /ID# 160139, Hiroshima, Japan|The Jikei Univ. Kashiwa Hosp. /ID# 200007, Kashiwa-shi, Japan|Tsujinaka Hospital Kashiwanoha /ID# 213847, Kashiwa, Japan|The Jikei University Hospital /ID# 163190, Minato-ku, Japan|Kitasato University Hospital /ID# 171071, Sagamihara-shi, Japan|NHO Shizuoka Medical Center /ID# 163029, Shimizu-sho, Japan|Fujita Health University Hosp /ID# 163214, Toyoake, Japan|Wakayama Medical University /ID# 200183, Wakayama, Japan|Yokkaichi Hazu Medical Center /ID# 163741, Yokkaichi-shi, Japan|Pusan National University Hosp /ID# 158677, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 158680, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA bundang medical center, CHA University /ID# 158672, Seongnam-si, Gyeonggido, Korea, Republic of|St. Vincent's Hospital /ID# 158681, Suwon, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 158676, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 158671, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 158674, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Dong-A University Hospital /ID# 158675, Busan, Korea, Republic of|Daejeon St. Mary's Hospital /ID# 213552, Daejeon, Korea, Republic of|Hanyang University Guri Hosp /ID# 158673, Guri-si, Korea, Republic of|Asan Medical Center /ID# 158678, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 159613, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 159614, Riga, Latvia|Digestive Diseases Ctr Gastro /ID# 163105, Riga, Latvia|Hospital of lithuanian university of Health Science Kauno Klinikos /ID# 162582, Kaunas, Lithuania|Vilnius University Hospital /ID# 162507, Vilnius, Lithuania|UKM Medical Centre /ID# 163654, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia /ID# 160656, Kelantan, Malaysia|Queen Elizabeth Hospital /ID# 160654, Kota Kinabalu, Malaysia|Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V. /ID# 167648, Zapopan, Jalisco, Mexico|JM Research /ID# 161733, Cuernavaca, Morelos, Mexico|Health Pharma Professional Research S.A de C.V /ID# 161734, Del. Benito Juárez, Mexico|Unidad de Atencion Medica e Investigacion en Salud /ID# 163624, Merida Yucatan, Mexico|Academisch Medisch Centrum /ID# 157950, Amsterdam, Noord-Holland, Netherlands|Elisabeth Tweesteden Ziekenhuis /ID# 163631, Tilburg, Netherlands|Christchurch Hospital /ID# 163074, Christchurch, Canterbury, New Zealand|Dunedin Hospital /ID# 167989, Dunedin, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 167987, Wellington, New Zealand|Akershus universitetssykehus /ID# 169378, Nordbyhagen, Akershus, Norway|Vestre viken - Baerum Sykehus /ID# 157886, Gjettum, Norway|Sykehuset Levanger Helse NT /ID# 157885, Levanger, Norway|Helse More og Romsdal HF, Alesund sjukehus /ID# 212811, Ålesund, Norway|Planetmed Sp. z o.o. /ID# 202798, Wrocław, Dolnoslaskie, Poland|Centrum Zdrowia MDM /ID# 160794, Warsaw, Mazowieckie, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 213579, Warsaw, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 160797, Warszawa, Mazowieckie, Poland|Centrum Medyczne Medyk /ID# 212889, Rzeszów, Podkarpackie, Poland|Centrum Medyczne LukaMed /ID# 212081, Chojnice, Poland|Uniwersytecki Szpital Kliniczn /ID# 212297, Lodz, Poland|1 Wojskowy Szpital Kliniczny Z Poliklinika /Id# 209985, Lublin, Poland|SPSK Nr 4 /ID# 209981, Lublin, Poland|Wojewódzki Szpital Specjalistyczny w Olsztynie /ID# 212402, Olsztyn, Poland|Solumed Sp. zoo Cent Medyczne /ID# 160793, Poznan, Poland|Gastromed /Id# 212099, Toruń, Poland|H-T. Centrum Medyczne Spółka z o.o. Spółka Komandytowa /ID# 212459, Tychy, Poland|NZOZ Vivamed /ID# 205160, Warsaw, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu /ID# 212602, Wrocław, Poland|Hospital Senhora da Oliveira de Guimarães, EPE /ID# 160739, Guimarães, Braga, Portugal|Centro Hospitalar do Algarve - Hospital de Portimão /ID# 167750, Portimao, Faro, Portugal|Centro Hosp de Lisboa Central /ID# 160675, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 167749, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 160747, Almada, Setubal, Portugal|Hospital de Faro /ID# 160715, Faro, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 160694, Lisboa, Portugal|Hospital Beatriz Angelo /ID# 207757, Loures, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 160695, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 160674, Santa Maria Da Feira, Portugal|Centro Hospi de Tondela Viseu /ID# 160697, Viseu, Portugal|Institutul Clinic Fundeni /ID# 163046, Sector 2, Bucuresti, Romania|Institutul Clinic Fundeni /ID# 163264, Sector 2, Bucuresti, Romania|Tvm Med Serv Srl /Id# 166294, Cluj, Romania|Cabinet Particular Policlinic Algomed /ID# 163047, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 166295, Timisoara, Romania|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 161310, Kemerovo, Kemerovskaya Oblast, Russian Federation|Perm state medical university n.a. E.A. Vagner /ID# 207440, Perm, Permskiy Kray, Russian Federation|Private institution Center of educational and clinical gastroenterology, hepatol /ID# 156949, Stavropol, Stavropol Skiy Kray, Russian Federation|Tver Regional Clinical Hosp. /ID# 205925, Tver, Tverskaya Oblast, Russian Federation|Regional Clinical Hospital #1 /ID# 163453, Tyumen, Tyumenskaya Oblast, Russian Federation|Alliance Biomedical Ural Group /ID# 156950, Izhevsk, Udmurtskaya Respublika, Russian Federation|State Scientific Ctr Coloproct /ID# 204809, Moscow, Russian Federation|Saint Petersburg State Pediatric Medical University /ID# 211977, Sankt-Peterburg, Russian Federation|City Clinical Hospital # 31 /ID# 208866, St. Petersburg, Russian Federation|Ulyanovsk State clinical hospi /ID# 156946, Ulyanovsk, Russian Federation|Clinical Center Serbia /ID# 156973, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 156978, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 156979, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 156976, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 156975, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 156972, Novi Sad, Vojvodina, Serbia|University Children's Hospital 'Tirsova' /ID# 211481, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 212797, Belgrade, Serbia|General Hospital Leskovac /ID# 209574, Leskovac, Serbia|National University Hospital /ID# 160658, Singapore, Singapore|Singapore General Hospital /ID# 160657, Singapore, Singapore|KL Ling Gastroenterology and Liver Clinic /ID# 205737, Singapore, Singapore|Univerzitna nemocnica Martin /ID# 163200, Martin, Zilinsky Kraj, Slovakia|FN s poliklinikou F.D. Rooseve /ID# 156465, Banska Bystrica, Slovakia|KM Management s.r.o. /ID# 206763, Nitra, Slovakia|Gastro I.S.R.O. /ID# 156466, Presov, Slovakia|Clinresco Centres /ID# 163864, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 158115, Johannesburg, Gauteng, South Africa|Dr Eduan Deetlefs /ID# 158117, Cape Town,Milnerton, Western Cape, South Africa|Kingsbury Hospital /ID# 163116, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 163115, Cape Town, Western Cape, South Africa|Complejo Hospitalario Universitario de Ferrol /ID# 157527, Ferrol, Galicia, Spain|Hospital Universitario Parc Tauli /ID# 159230, Barcelona, Spain|Hospital Clinico y Provincial Barcelona /ID# 157526, Barcelona, Spain|Hospital Universitario Basurto /ID# 205189, Bilbao, Spain|Hospital General Universitario Gregorio Maranon /ID# 161435, Madrid, Spain|Hospital Universitario La Paz /ID# 159228, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 157575, Majadahonda, Spain|Hospital Clinico Univ de Salamanca /ID# 157532, Salamanca, Spain|Hospital Universitario Virgen Macarena /ID# 160819, Sevilla, Spain|Hospital Universitario y Politecnico La Fe /ID# 157530, Valencia, Spain|Hosp Clin Univ Lozano Blesa /ID# 212523, Zaragoza, Spain|Hospital Univ Miguel Servet /ID# 157531, Zaragoza, Spain|Skanes Universitetssjukhus /ID# 211235, Malmö, Skane Lan, Sweden|GHP Stockholm Gastro Center /ID# 210479, Stockholm, Stockholms Lan, Sweden|Sahlgrenska University Hosp /ID# 157879, Goteborg, Sweden|SU Molndal. /ID# 157880, Molndal, Sweden|Karolinska Univ Sjukhuset /ID# 209966, Solna, Sweden|Ersta diakoni /ID# 157878, Stockholm, Sweden|Danderyd Hospital /ID# 202136, Stockholm, Sweden|Universitaetsspital Basel /ID# 164555, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 163531, Bern, Switzerland|Universitatsspital Zurich /ID# 163532, Zurich, Switzerland|Medical Centre of OK!Clinic of International Institute of Clinical Trials /ID# 211997, Kiev, Kyivska Oblast, Ukraine|Kyiv Municipal Clinical Hospital #18 /ID# 162521, Kiev, Kyiv, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 216265, Vinnytsia, Vinnytska Oblast, Ukraine|Scientific Research Institute of Invalid Rehabilitation /ID# 211516, Vinnytsia, Vinnytska Oblast, Ukraine|Volyn regional clinical hospital /ID# 206788, Lutsk, Volynska Oblast, Ukraine|Kherson City Clinical Hospital /ID# 212050, Kherson, Ukraine|Consultative and Diagnostic Ce /ID# 165651, Kyiv, Ukraine|Medical Center of LLC Medbud-Clinic /ID# 216929, Kyiv, Ukraine|Kyiv Railway Clinical Hosp №2 /ID# 217330, Kyiv, Ukraine|Lviv Railway Clinical Hospital /ID# 165650, Lviv, Ukraine|Odessa National Medical Univ /ID# 217365, Odesa, Ukraine|Transcarpathian Regional Clin. /ID# 168419, Uzhhorod, Ukraine|Kharkiv City Clinical Hospital /ID# 165649, Харків, Ukraine|RD&E Hospital /ID# 157517, Exeter, Devon, United Kingdom|The Royal London Hospital /ID# 163710, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 157519, London, London, City Of, United Kingdom|Ashford and St Peter's Hospitals NHS Foundation Trust /ID# 207937, Chertsey, Surrey, United Kingdom|Fairfield General Hospital /ID# 207764, Bury, United Kingdom|Addenbrookes Hospital /ID# 158031, Cambridge, United Kingdom|Western General Hospital /ID# 207447, Edinburgh, United Kingdom|Huddersfield Royal Infirmary /ID# 209569, Huddersfield, United Kingdom|Hull and East Yorkshire NHS /ID# 158757, Hull, United Kingdom|St. James University Hospital /ID# 157523, Leeds, United Kingdom|Kings Healthcare NHS Trust /ID# 158756, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 163709, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital /ID# 158033, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03105128"
143,"NCT03105102","A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989",,"Recruiting","No Results Available","Crohn's Disease","Drug: placebo for risankizumab SC|Drug: risankizumab IV|Drug: placebo for risankizumab IV|Drug: risankizumab SC","Percentage of Participants With Clinical Remission|Percentage of Participants With Endoscopic Response|Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission|Percentage of Participants With Clinical Remission Among Participants With Clinical Remission in Week 0|Percentage of Participants With Ulcer-Free Endoscopy|Percentage of Participants With Endoscopic Remission|Mean Change From Baseline of Induction in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score|Mean Change From Baseline of Induction in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)|Percentage of Participants Who Discontinued Corticosteroid Use for 90 Days and Achieved Clinical Remission in Participants Taking Steroids at Baseline|Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response|Percentage of Participants With Clinical Remission and Endoscopic Response|Percentage of Participants With Enhanced Clinical Response|Percentage of Participants With Deep Remission|Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) in Participants With Any EIMs at Baseline of Induction|Percentage of Participants With CD-Related Hospitalizations|Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline of Induction|Percentage of Participants With Crohn's Disease (CD)-Related Surgeries","AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-000|2016-003191-50","April 9, 2018","October 18, 2025","June 2, 2026","April 7, 2017",,"January 21, 2020","Phoenix VA Healthcare /ID# 162264, Phoenix, Arizona, United States|HonorHealth Research Institute - Shea /ID# 161780, Scottsdale, Arizona, United States|Physician's Research Group /ID# 211884, Tempe, Arizona, United States|University of Arizona /ID# 158502, Tucson, Arizona, United States|Atria Clinical Research /ID# 164505, Little Rock, Arkansas, United States|TLC Clinical Research Inc /ID# 212719, Beverly Hills, California, United States|Southern California Res. Ctr. /ID# 211991, Coronado, California, United States|Newport Huntington Medical Group /ID# 213035, Huntington Beach, California, United States|UC San Diego Health Systems /ID# 155555, La Jolla, California, United States|United Gastroenterologists /ID# 207888, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 162657, Los Angeles, California, United States|United Gastroenterologists - Murrieta /ID# 158300, Murrieta, California, United States|University of California, San /ID# 157127, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 163839, West Hollywood, California, United States|Peak Gastroenterology Associat /ID# 165843, Colorado Springs, Colorado, United States|Rocky Mountain Pediatric Gastroenterology /ID# 207170, Lone Tree, Colorado, United States|Western Connecticut Medical Group /ID# 165879, Danbury, Connecticut, United States|Brandon Premier Health Care, PA /ID# 162262, Brandon, Florida, United States|Clinical Res of West FL, Inc. /ID# 205865, Clearwater, Florida, United States|Clinical Res of West FL, Inc. /ID# 208125, Clearwater, Florida, United States|South Lake Pain Institute, Inc /ID# 162808, Clermont, Florida, United States|Omega Research Consultants, LLC /ID# 171082, DeBary, Florida, United States|Universal Axon Clinical Resear /ID# 165428, Doral, Florida, United States|Nature Coast Clinical Research /ID# 159408, Inverness, Florida, United States|SIH Research, LLC /ID# 163083, Kissimmee, Florida, United States|Alliance Medical Research /ID# 163837, Lighthouse Point, Florida, United States|Ctr for Advanced Gastroenterol /ID# 202479, Maitland, Florida, United States|University of Miami /ID# 155007, Miami, Florida, United States|Vista Health Research LLC - Miami /ID# 212829, Miami, Florida, United States|Coral Research Clinic /ID# 158456, Miami, Florida, United States|Nirvana Research Center /ID# 161832, Miami, Florida, United States|Gastroenterology Group Naples /ID# 165204, Naples, Florida, United States|Advanced Research Institute /ID# 161966, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 205906, Orlando, Florida, United States|IMIC Inc. /ID# 154942, Palmetto Bay, Florida, United States|Atlanta Gastro Assoc /ID# 154724, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 154850, Macon, Georgia, United States|Northwestern University /ID# 158261, Chicago, Illinois, United States|University of Chicago /ID# 157124, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 158265, Evanston, Illinois, United States|Southwest Gastroenterology /ID# 164781, Oak Lawn, Illinois, United States|Cotton-O'Neil Clinical Res Ctr /ID# 154722, Topeka, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 157120, Lexington, Kentucky, United States|University of Louisville /ID# 210525, Louisville, Kentucky, United States|Gastroenterology Associates LLC - Jefferson Hwy /ID# 161963, Baton Rouge, Louisiana, United States|Houma Digestive Health Special /ID# 158264, Houma, Louisiana, United States|Delricht Research /ID# 206644, New Orleans, Louisiana, United States|Nola Research Works, LLC /ID# 161317, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 162237, Shreveport, Louisiana, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 154832, Chevy Chase, Maryland, United States|Gastro Center of Maryland /ID# 165001, Columbia, Maryland, United States|University of Michigan Hospitals /ID# 157126, Ann Arbor, Michigan, United States|Clin Res Inst of Michigan, LLC /ID# 169179, Chesterfield, Michigan, United States|Center for Digestive Health /ID# 154683, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC /ID# 161313, Wyoming, Michigan, United States|Mayo Clinic - Rochester /ID# 163086, Rochester, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 154831, Jackson, Mississippi, United States|Saint Louis University School of Medicine /ID# 161883, Saint Louis, Missouri, United States|University of Nebraska Med Ctr /ID# 210058, Omaha, Nebraska, United States|Comprehensive Digestive Instit /ID# 160170, Las Vegas, Nevada, United States|Revival Research Institute, LLC /ID# 210985, Las Vegas, Nevada, United States|NY Scientific /ID# 158294, Brooklyn, New York, United States|Saratoga Schenectady Gastroenterology Associates - Burnt Hills /ID# 213447, Burnt Hills, New York, United States|Intercity Advanced Gastroentertology Center /ID# 215205, Fresh Meadows, New York, United States|Long Island Clinical Research /ID# 154829, Great Neck, New York, United States|Digestive Dis Care/Excel Med /ID# 211777, New Hyde Park, New York, United States|North Shore University Hospital /ID# 168738, New Hyde Park, New York, United States|NYU Langone Medical Center /ID# 160169, New York, New York, United States|Weill Cornell Medicine /ID# 165878, New York, New York, United States|Icahn School of Med Mt. Sinai /ID# 165612, New York, New York, United States|Weill Cornell Medicine /ID# 161899, New York, New York, United States|Lenox Hill Hospital, Northwell /ID# 168467, New York, New York, United States|DiGiovanna Institute for Medic /ID# 171126, North Massapequa, New York, United States|Univ NC Chapel Hill /ID# 154833, Chapel Hill, North Carolina, United States|Carolinas Medical Center /ID# 158428, Charlotte, North Carolina, United States|Wake Research Associates, LLC /ID# 154873, Raleigh, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 169718, Fargo, North Dakota, United States|Tri-State Endoscopy /ID# 154927, Cincinnati, Ohio, United States|Cleveland Clinic Main Campus /ID# 209226, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 164708, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 167887, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 170464, Dayton, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 201770, Mentor, Ohio, United States|Hightower Clinical /ID# 211993, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists /ID# 170775, Oklahoma City, Oklahoma, United States|Adult Gastroenterology Associates - Main /ID# 208864, Tulsa, Oklahoma, United States|Children's Hospital of Pittsburgh of UPMC /ID# 212544, Pittsburgh, Pennsylvania, United States|Digestive Disease Associates, LTD /ID# 208297, Wyomissing, Pennsylvania, United States|Medical University of South Carolina /ID# 212858, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 154904, Greenville, South Carolina, United States|Rapid City Medical Center /ID# 163838, Rapid City, South Dakota, United States|Gastro One /ID# 154726, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 168739, Johnson City, Tennessee, United States|Clinical Neuroscience /ID# 164180, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 157121, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 159404, Arlington, Texas, United States|Inquest Clinical Research /ID# 165694, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209797, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209946, Cedar Park, Texas, United States|Baylor Scott & White Research /ID# 159406, Dallas, Texas, United States|DHAT Research Institute /ID# 158208, Garland, Texas, United States|Vilo Research Group Inc /ID# 207655, Houston, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center /ID# 158203, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201219, Houston, Texas, United States|Clinical Associates in Researc /ID# 161323, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 168773, San Antonio, Texas, United States|Baylor Scott & White Health - Temple /ID# 204131, Temple, Texas, United States|Tyler Research Institute, LLC /ID# 166797, Tyler, Texas, United States|Victoria gastroenterology /ID# 164290, Victoria, Texas, United States|Advanced Research Institute /ID# 154907, Ogden, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 161778, West Jordan, Utah, United States|University of Vermont Medical Center /ID# 216006, Burlington, Vermont, United States|Hunter Holmes McGuire VA Medical Center /ID# 159988, Richmond, Virginia, United States|Virginia Mason Medical Center /ID# 155556, Seattle, Washington, United States|University of Washington /ID# 155563, Seattle, Washington, United States|West Virginia University /ID# 167941, Morgantown, West Virginia, United States|Hopital Centenario /ID# 170886, Rosario, Santa Fe, Argentina|Cemic /Id# 168078, Buenos Aires, Argentina|Hospital Britanico de Buenos /ID# 168077, Ciudad Autonomade Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 168076, Cordoba, Argentina|Mater Hospital /ID# 167220, Brisbane, Queensland, Australia|Griffith University /ID# 212635, Southport, Queensland, Australia|Lyell McEwin Hospital /ID# 212215, Elizabeth Vale, South Australia, Australia|Emeritus Research /ID# 213512, Camberwell, Victoria, Australia|Footscray Hospital /ID# 212213, Footscray, Victoria, Australia|Universitätsklinikum St.Pölten /ID# 166424, St. Pölten, Niederoesterreich, Austria|LKH-Univ. Klinikum Graz /ID# 158140, Graz, Steiermark, Austria|Krankenhaus der Barmherzigen Brüder Wien /ID# 212060, Vienna, Wien, Austria|Medical University of Vienna /ID# 158141, Vienna, Wien, Austria|Gomel Regional Clinical Hospit /ID# 205112, Gomel, Belarus|Grodno city clinical hospital №2 /ID# 205113, Grodno, Belarus|Vitebsk Regional Advanced Clin /ID# 206778, Vitebsk, Belarus|AZ Sint-Maarten /ID# 212876, Mechelen, Antwerpen, Belgium|Cliniques Universitaires Saint Luc /ID# 157406, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 157409, Liège, Liege, Belgium|UZ Gent /ID# 157405, Gent, Oost-Vlaanderen, Belgium|Imelda Ziekenhuis /ID# 157403, Bonheiden, Belgium|ULB Erasme /ID# 157408, Brussels, Belgium|AZ Maria Middelares /ID# 213532, Ghent, Belgium|AZ Groeninge /ID# 211513, Kortrijk, Belgium|UZ Leuven /ID# 157407, Leuven, Belgium|Clinique St Joseph /ID# 157404, Liege, Belgium|ZNA - Jan Palfijn /ID# 212877, Merksem, Belgium|AZ-Delta /ID# 157402, Roeselare, Belgium|CHU Dinant Godinne - UCL Namur /ID# 157412, Yvoir, Belgium|University Clinical Centre of the Republic of Srpska /ID# 164513, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 165139, Sarajevo, Bosnia and Herzegovina|UMHAT Dr Georgi Stranski EAD /ID# 203976, Pleven, Bulgaria|University Multiprofile Hospit /ID# 165700, Plovdiv, Bulgaria|Second Multiprofile Hospital f /ID# 165702, Sofia, Bulgaria|Tokuda Hospital Sofia /ID# 165701, Sofia, Bulgaria|UMHAT Tsaritsa Joanna - ISUL /ID# 211242, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 204815, Sofia, Bulgaria|MHAT Trakia /ID# 201668, Stara Zagora, Bulgaria|University Multiprofile Hospit /ID# 167574, Varna, Bulgaria|University of Calgary /ID# 157155, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 169763, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 157099, Edmonton, Alberta, Canada|Covenant Health /ID# 161632, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 159055, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 157096, Vancouver, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 161631, Victoria, British Columbia, Canada|QEII - Victoria Building /ID# 157088, Halifax, Nova Scotia, Canada|IWK Health Center /ID# 165905, Halifax, Nova Scotia, Canada|McMaster University Med Cent /ID# 157184, Hamilton, Ontario, Canada|London Health Sciences Centre /ID# 157161, London, Ontario, Canada|Scott Shulman Medicine Professional Corporation /ID# 165906, North Bay, Ontario, Canada|Medicor Research Inc. /ID# 157150, Sudbury, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 169764, Toronto, Ontario, Canada|Toronto Digestive Disease Asso /ID# 157158, Vaughan, Ontario, Canada|CISSS de la Monteregie /ID# 161630, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 214377, Levis, Quebec, Canada|Hospital Maisonneuve-Rosemont /ID# 159056, Montreal, Quebec, Canada|Centre Recherche luniver Montr /ID# 167068, Montreal, Quebec, Canada|McGill Univ HC /ID# 157085, Montreal, Quebec, Canada|Complejo Asistencial Dr. Sotero del Rio /ID# 169384, Santiago, Region Metropolitana De Santiago, Chile|Servicio de Salud Occidente Hospital San Juan de Dios /ID# 171122, Santiago, Region Metropolitana De Santiago, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 210760, Concepción, Chile|Hospital Las Higueras /ID# 167092, Talcahuano, Chile|Xinqiao Hospital of 3rd Military Medical University /ID# 212995, Chongqing, Chongqing, China|The Sixth Affiliated Hosp, Sun /ID# 210784, Guangzhou, Guangdong, China|The University of Hong Kong- Shenzhen Hospital /ID# 213112, Shenzhen, Guangdong, China|The Second Hospital of Hebei Medical University /ID# 212738, Shijiazhuang, Hebei, China|1st Aff Hosp Nanchang Univ /ID# 211036, Nanchang, Jiangxi, China|Ruijin Hospital, Shanghai Jiaotong /ID# 210840, Shanghai, Shanghai, China|Renji Hosp, Shanghai Jiaotong /ID# 210705, Shanghai, Shanghai, China|The second affiliated hospital of Zhejiang University school of medicine /ID# 210724, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 210625, Hangzhou, Zhejiang, China|Jinhua Central Hospital /ID# 215628, Jinhua, Zhejiang, China|The Second Xiangya Hospital of Central South University /ID# 211700, Changsha, China|West China Hospital, Sichuan University /ID# 210890, Chengdu, China|Guangdong Provincial People's Hospital /ID# 212949, Guangzhou, China|Jiangsu Province Hospital /ID# 210501, Nanjing, China|Shanghai Dongfang Hospital /ID# 212684, Shanghai, China|Tianjin Med Univ General Hosp /ID# 210926, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 211039, Wuhan, China|Tongji Hosp Tongji Med College /ID# 210858, Wuhan, China|Renmin Hospital of Wuhan Univ /ID# 214874, Wuhan, China|Hospital Univ San Ignacio /ID# 158734, Bogota, Colombia|Instituto de Coloproctologia /ID# 158743, Medellin, Colombia|Hospital Universitario San Vic /ID# 171486, Medellin, Colombia|Hospital Pablo Tobon Uribe /ID# 158730, Medellín, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 157560, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Sestre milosrdnice /ID# 157728, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 157561, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 157559, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 157562, Split, Croatia|Zadar General Hospital /ID# 157563, Zadar, Croatia|Ikem /Id# 165465, Prague 4, Praha 4, Czechia|Thomayerova nemocnice /ID# 162941, Prague, Praha 4, Czechia|Axon Clinical, s.r.o. /ID# 163223, Praha, Praha 5, Czechia|Nemocnice Horovice, NH Hospita /ID# 211077, Horovice, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 163225, Hradec Kralove, Czechia|Nemocnice Pardubickeho kraje, a.s. /ID# 163226, Pardubice, Czechia|Restrial /ID# 211078, Prague 412, Czechia|Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 211306, Praha 1, Czechia|Aarhus University Hospital /ID# 155664, Aarhus N, Midtjylland, Denmark|Sjaellands Universitets Hospit /ID# 155532, Roskilde, Sjælland, Denmark|Svendborg Sygehus, Sygehusenhe /ID# 161525, Nyborg, Syddanmark, Denmark|Hvidovre Hospital /ID# 155530, Hvidovre, Denmark|Odense Universitets Hospital /ID# 155531, Odense C, Denmark|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 157187, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 164540, Alexandria, Egypt|Internal Medicine Department, Cairo University /ID# 157175, Cairo, Egypt|Nat Hep & Trop Med Res Inst /ID# 157874, Cairo, Egypt|Ain Shams University Hospital /ID# 157506, Cairo, Egypt|Zagazig University Hospital /ID# 164539, EL Sharkya, Egypt|East Tallinn Central Hospital /ID# 157074, Tallinn, Estonia|West Tallinn Central Hospital /ID# 157075, Tallinn, Estonia|North Estonian Medical Centre /ID# 164326, Tallinn, Estonia|Hopital Saint Eloi /ID# 215147, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 166284, Clichy, Ile-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 162561, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Amiens Picardie /ID# 165058, Amiens CEDEX 1, Somme, France|CHU Grenoble Alpes - Hopital /ID# 212834, Grenoble, France|Chu Lille /Id# 162559, Lille, France|CHU de Nice /ID# 162557, Nice, France|CHU Bordeaux /ID# 162558, Pessac, France|Chu Lyon Sud /Id# 162560, Pierre Benite, France|Hospital Pontchaillou /ID# 213209, Rennes, France|Hopital Nord /ID# 162562, Saint Priest En Jarez, France|Universitatsklinikum Mannheim /ID# 162031, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 159343, Erlangen, Bayern, Germany|Universitatsklinikum Munster /ID# 159344, Munster, Niedersachsen, Germany|Evangelisches Krankenhaus Kalk /ID# 212726, Cologne, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 164989, Köln, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 210528, Saarbrücken, Saarland, Germany|Univ Hosp Schleswig-Holstein /ID# 159349, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 164990, Ulm, Thueringen, Germany|Charité Universitätsmedizin Campus Mitte /ID# 212220, Berlin, Germany|Charité Universitätsmedizin Campus Mitte /ID# 212894, Berlin, Germany|Gastroenterologische Spezialpraxis am Wittenbergplatz /ID# 211974, Berlin, Germany|Praxis am Bayrischen Platz /ID# 159350, Berlin, Germany|DRK Kliniken Berlin /ID# 166151, Berlin, Germany|Krankenhaus Waldfriede /ID# 212727, Berlin, Germany|Stadtisches Klinikum Braunschw /ID# 163680, Braunschweig, Germany|Medizinisches Versorgungszent /ID# 211555, Dachau, Germany|Agaplesion Markus Krankenhaus /ID# 159345, Frankfurt, Germany|Universitaetsklinikum Frankfurt /ID# 212979, Frankfurt, Germany|Universitätsklinikum Freiburg /ID# 162030, Freiburg, Germany|Praxis Dres. Hülsdonk/Naumann /ID# 211966, Grevenbroich, Germany|Med Hochschule Hanover /ID# 162032, Hannover, Germany|Praxis fuer Gastroenterologie /ID# 166150, Heidelberg, Germany|Universitaetsklinikum Jena /ID# 159351, Jena, Germany|EUGASTRO GmbH /ID# 212078, Leipzig, Germany|Stadtisches Klin Luneburg GmbH /ID# 163678, Lueneburg, Germany|Universitatsklinikum Magdeburg /ID# 211843, Magdeburg, Germany|Gastro Gemeinschaftspraxis /ID# 162029, Minden, Germany|Klinikum Univ Regensburg /ID# 163813, Regensburg, Germany|Tzaneio general hospital of Piraeus /ID# 206443, Piraeus, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 157423, Athens, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 170914, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 157422, Heraklion, Greece|University General Hospital of Ioannina /ID# 157420, Ioannina, Greece|General Hospital Nikaias-Piraeus St. Panteleimon /ID# 157424, Pireaus, Greece|Theageneio Anticancer Hospital /ID# 163897, Thessaloniki, Greece|Queen Mary Hospital /ID# 163923, Hong Kong, Hong Kong|Tuen Mun Hospital /ID# 163905, Tuen Mun, Hong Kong|Obudai Egeszsegugyi Centrum Kft. /ID# 213191, Budapest, Hungary|Semmelweis Egyetem I. Belgyogyaszati Klinika /ID# 213134, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 166816, Debrecen, Hungary|Debrecen University /ID# 157349, Debrecen, Hungary|Almasi Balogh Pal korhaz /ID# 213135, Ozd, Hungary|St Vincent's University Hospit /ID# 157540, Dublin, Ireland|Beaumont Hospital /ID# 157543, Dublin, Ireland|University Hospital Galway /ID# 157541, Galway, Ireland|Soroka Medical Center /ID# 157794, Be'er Sheva, HaDarom, Israel|Tel Aviv Sourasky Medical Ctr /ID# 157792, Tel Aviv-Yafo, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 165914, Jerusalem, Yerushalayim, Israel|Rambam Medical Center /ID# 171067, Haifa, Israel|The Edith Wolfson Medical Cent /ID# 217331, Holon, Israel|Shaare Zedek Medical Center /ID# 163541, Jerusalem, Israel|Shaare Zedek Medical Center /ID# 171068, Jerusalem, Israel|Sheba Medical Center /ID# 157793, Ramat Gan, Israel|Sheba Medical Center /ID# 171069, Ramat Gan, Israel|Universita di Catanzaro Magna Graecia /ID# 212016, Catanzaro, Calabria, Italy|AOU Policlinico S. Orsola Malpighi /ID# 155643, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 212028, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 162438, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 155644, Rome, Lazio, Italy|Azienda Policlinico Universitario Umberto I /ID# 166912, Rome, Lazio, Italy|Ospedale Policlinico San Martino/ Università Degli Studi Di Genova /ID# 162439, Genoa, Liguria, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 155641, Milan, Lombardia, Italy|ASST Rhodense /ID# 212227, Rho, Lombardia, Italy|Istituto Clinico Humanitas /ID# 155642, Rozzano, Milano, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 155640, Rome, Roma, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 161300, Catania, Sicilia, Italy|A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 155645, Palermo, Sicilia, Italy|Azienda Ospedaliera Univ. Meyer /ID# 167992, Florence, Toscana, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 161299, Negrar, Verona, Italy|Ospedali Riuniti Universita /ID# 162436, Ancona, Italy|ASST Fatebenefratelli Sacco /ID# 155639, Milan, Lombardia, Italy|IRCCS Policlinico S. Matteo /ID# 212031, Pavia, Italy|Policlinico Tor Vergata /ID# 158022, Rome, Italy|Aichi Medical University Hosp /ID# 160097, Nagakute, Aichi, Japan|Daido Clinic /ID# 211476, Nagoya-shi, Aichi, Japan|Nagoya University Hospital /ID# 160116, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 160100, Nagoya-shi, Aichi, Japan|Tokatsu Tsujinaka Hospital /ID# 163352, Abiko-shi, Chiba, Japan|Toho University Sakura Medical Center /ID# 160099, Sakura-shi, Chiba, Japan|Kurume University Hospital /ID# 160106, Kurume-shi, Fukuoka, Japan|NHO Fukuyama Medical Center /ID# 163577, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 162848, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 160096, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 163056, Sapporo-shi, Hokkaido, Japan|Sapporo Tokushukai Hospital /ID# 213492, Sapporo, Hokkaido, Japan|Nishinomiya Munic Central Hosp /ID# 210103, Nishinomiya-shi, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 160107, Nishinomiya-shi, Hyogo, Japan|National Hospital Organization Mito Medical Center /ID# 160092, Higashi Ibaraki-gun, Ibaraki, Japan|Kanazawa University Ho /ID# 202258, Kanazawa, Ishikawa, Japan|Gokeikai Ofuna Chuo Hospital /ID# 171066, Kamakura-shi, Kanagawa, Japan|Yokohama City Univ Medical Ctr /ID# 163907, Yokohama, Kanagawa, Japan|Yokohama Municipal Citizen's Hospital /ID# 207161, Yokohama, Kanagawa, Japan|Mie University Hospital /ID# 203640, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 162847, Sendai-shi, Miyagi, Japan|Tohoku Rosai Hospital /ID# 163229, Sendai-shi, Miyagi, Japan|Osaka City University Hospital /ID# 160117, Osaka-shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 160093, Kawagoe-shi, Saitama, Japan|Tokito Clinic /ID# 160110, Saitama-shi, Saitama, Japan|Shiga University of Medical Science Hospital /ID# 164025, Otsu, Shiga, Japan|Hamamatsu University Hospital /ID# 205690, Hamamatsu-shi, Shizuoka, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 160095, Bunkyo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 160098, Hachioji, Tokyo, Japan|Kitasato Univ Kitasato Inst Ho /ID# 160105, Minato-ku, Tokyo, Japan|Kyorin University Hospital /ID# 160114, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 205974, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 200159, Yamagata-shi, Yamagata, Japan|Yamanashi Prefectural Ctr Hosp /ID# 160094, Kofu-shi, Yamanashi, Japan|Hiroshima University Hospital /ID# 160109, Hiroshima, Japan|The Jikei Univ. Kashiwa Hosp. /ID# 200030, Kashiwa-shi, Japan|Tsujinaka Hospital Kashiwanoha /ID# 213848, Kashiwa, Japan|The Jikei University Hospital /ID# 163209, Minato-ku, Japan|Kitasato University Hospital /ID# 171065, Sagamihara-shi, Japan|NHO Shizuoka Medical Center /ID# 163057, Shimizu-sho, Japan|Fujita Health University Hosp /ID# 163234, Toyoake, Japan|Wakayama Medical University /ID# 202561, Wakayama, Japan|Yokkaichi Hazu Medical Center /ID# 163764, Yokkaichi-shi, Japan|Dong-A University Hospital /ID# 158699, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 158695, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 158691, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 158698, Seongnam-si, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 158694, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 158689, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 158692, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Haeundae Paik Hospital /ID# 202518, Busan, Korea, Republic of|Daejeon St. Mary's Hospital /ID# 213554, Daejeon, Korea, Republic of|Hanyang University Guri Hosp /ID# 158690, Guri-si, Korea, Republic of|The Catholic Univ. of Korea /ID# 158693, Gyeonggi-do, Korea, Republic of|Asan Medical Center /ID# 158696, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 159611, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 159612, Riga, Latvia|Digestive Diseases Ctr Gastro /ID# 163107, Riga, Latvia|Hospital of lithuanian university of Health Science Kauno Klinikos /ID# 162583, Kaunas, Lithuania|Vilnius University Hospital /ID# 162514, Vilnius, Lithuania|UKM Medical Centre /ID# 201363, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia /ID# 160666, Kelantan, Malaysia|Queen Elizabeth Hospital /ID# 160664, Kota Kinabalu, Malaysia|Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V. /ID# 170734, Zapopan, Jalisco, Mexico|JM Research /ID# 170729, Cuernavaca, Morelos, Mexico|Health Pharma Professional Research S.A de C.V /ID# 170730, Del. Benito Juárez, Mexico|Unidad de Atencion Medica e Investigacion en Salud /ID# 170732, Merida Yucatan, Mexico|Academisch Medisch Centrum /ID# 157956, Amsterdam, Noord-Holland, Netherlands|Elisabeth Tweesteden Ziekenhuis /ID# 163632, Tilburg, Netherlands|Christchurch Hospital /ID# 167224, Christchurch, Canterbury, New Zealand|Middlemore Clinical Trials /ID# 167226, Auckland, New Zealand|Dunedin Hospital /ID# 167227, Dunedin, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 167225, Wellington, New Zealand|Akershus universitetssykehus /ID# 169379, Nordbyhagen, Akershus, Norway|Vestre viken - Baerum Sykehus /ID# 212996, Gjettum, Norway|Sykehuset Levanger Helse NT /ID# 201669, Levanger, Norway|Helse More og Romsdal HF, Alesund sjukehus /ID# 212810, Ålesund, Norway|Planetmed Sp. z o.o. /ID# 202799, Wrocław, Dolnoslaskie, Poland|Centrum Zdrowia MDM /ID# 163570, Warsaw, Mazowieckie, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 213580, Warsaw, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 163582, Warszawa, Mazowieckie, Poland|Centrum Medyczne Medyk /ID# 212891, Rzeszów, Podkarpackie, Poland|Centrum Medyczne LukaMed /ID# 212478, Chojnice, Poland|Uniwersytecki Szpital Kliniczn /ID# 212477, Lodz, Poland|1 Wojskowy Szpital Kliniczny Z Poliklinika /Id# 210940, Lublin, Poland|SPSK Nr 4 /ID# 210941, Lublin, Poland|Wojewódzki Szpital Specjalistyczny w Olsztynie /ID# 212474, Olsztyn, Poland|SOLUMED Sp. z o.o., Sp.k. /ID# 163569, Poznan, Poland|Gastromed /Id# 212476, Toruń, Poland|H-T. Centrum Medyczne Spółka z o.o. Spółka Komandytowa /ID# 212475, Tychy, Poland|NZOZ Vivamed /ID# 202800, Warsaw, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu /ID# 212601, Wrocław, Poland|Hospital Senhora da Oliveira de Guimarães, EPE /ID# 160737, Guimarães, Braga, Portugal|Centro Hospitalar do Algarve - Hospital de Portimão /ID# 167752, Portimao, Faro, Portugal|Centro Hosp de Lisboa Central /ID# 160673, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 167751, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 160745, Almada, Setubal, Portugal|Hospital de Faro /ID# 160713, Faro, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 160692, Lisboa, Portugal|Hospital Beatriz Angelo /ID# 207759, Loures, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 160693, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 160672, Santa Maria Da Feira, Portugal|Centro Hosp de Tondela-Viseu /ID# 160699, Viseu, Portugal|Institutul Clinic Fundeni /ID# 170899, Bucharest, Romania|Tvm Med Serv Srl /Id# 170902, Cluj, Romania|Cabinet Particular Policlinic Algomed /ID# 170900, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 170903, Timisoara, Romania|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 200962, Kemerovo, Kemerovskaya Oblast, Russian Federation|Perm state medical university n.a. E.A. Vagner /ID# 207439, Perm, Permskiy Kray, Russian Federation|Private institution Center of educational and clinical gastroenterology, hepatol /ID# 200970, Stavropol, Stavropol Skiy Kray, Russian Federation|Tver Regional Clinical Hosp. /ID# 206858, Tver, Tverskaya Oblast, Russian Federation|Regional Clinical Hospital #1 /ID# 200973, Tyumen, Tyumenskaya Oblast, Russian Federation|Alliance Biomedical Ural Group /ID# 200972, Izhevsk, Udmurtskaya Respublika, Russian Federation|Scien Ctr Coloproctology Rosme /ID# 204808, Moscow, Russian Federation|Saint Petersburg State Pediatric Medical University /ID# 211978, Sankt-Peterburg, Russian Federation|City Clinical Hospital # 31 /ID# 208872, St. Petersburg, Russian Federation|Ulyanovsk State clinical hospi /ID# 200964, Ulyanovsk, Russian Federation|Clinical Center Serbia /ID# 157047, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 157052, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 157053, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 157050, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 157049, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 157046, Novi Sad, Vojvodina, Serbia|University Children's Hospital 'Tirsova' /ID# 211482, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 212799, Belgrade, Serbia|General Hospital Leskovac /ID# 209575, Leskovac, Serbia|National University Hospital /ID# 160667, Singapore, Singapore|Singapore General Hospital /ID# 160668, Singapore, Singapore|KL Ling Gastroenterology and Liver Clinic /ID# 205741, Singapore, Singapore|FN s poliklinikou F.D. Rooseve /ID# 156468, Banska Bystrica, Slovakia|KM Management s.r.o. /ID# 206764, Nitra, Slovakia|Gastro I.S.R.O. /ID# 156469, Presov, Slovakia|Clinresco Centres /ID# 163865, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 158114, Johannesburg, Gauteng, South Africa|Dr Eduan Deetlefs /ID# 158116, Cape Town,Milnerton, Western Cape, South Africa|Kingsbury Hospital /ID# 163113, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 163112, Cape Town, Western Cape, South Africa|Hospital Universitario de Bellvitge /ID# 208207, L'Hospitalet de Llobregat, Barcelona, Spain|Complejo Hospitalario Universitario de Ferrol /ID# 157553, Ferrol, Galicia, Spain|Hospital Universitario y Politecnico La Fe /ID# 157556, Valencia, Valenciana, Spain|Hospital Clinico y Provincial Barcelona /ID# 157552, Barcelona, Spain|Hospital Parc Tauli /ID# 159237, Barcelona, Spain|Hospital Universitario Basurto /ID# 205190, Bilbao, Spain|Hospital General Universitario Gregorio Maranon /ID# 161145, Madrid, Spain|Hospital Universitario La Paz /ID# 159235, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 157573, Majadahonda, Spain|Complejo Asistencial de Salama /ID# 157558, Salamanca, Spain|Hospital Universitario Virgen Macarena /ID# 159967, Sevilla, Spain|Hosp Clin Univ de Valencia /ID# 209700, Valencia, Spain|Hosp Clin Univ Lozano Blesa /ID# 212525, Zaragoza, Spain|Hospital Univ Miguel Servet /ID# 157557, Zaragoza, Spain|Skanes Universitetssjukhus /ID# 211745, Malmö, Skane Lan, Sweden|GHP Stockholm Gastro Center /ID# 211748, Stockholm, Stockholms Lan, Sweden|Sahlgrenska US Gbg /ID# 163797, Göteborg, Vastra Gotalands Lan, Sweden|Sahlgrenska University Hosp /ID# 163792, Goteborg, Sweden|Karolinska Univ Sjukhuset /ID# 212025, Solna, Sweden|Medicinkliniken, Gastroenheten /ID# 163744, Stockholm, Sweden|Danderyd Hospital /ID# 202138, Stockholm, Sweden|University Hospital Zurich /ID# 163536, Zurich, Zuerich, Switzerland|Universitaetsspital Basel /ID# 164554, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 163535, Bern, Switzerland|China Medical University Hosp /ID# 160141, Taichung City, Taichung, Taiwan|National Cheng Kung University Hospital /ID# 160142, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 162190, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 160140, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 212712, Taipei City, Taiwan|Medical Centre of OK!Clinic of International Institute of Clinical Trials /ID# 211998, Kiev, Kyivska Oblast, Ukraine|Kyiv Municipal Clinical Hospital #18 /ID# 162531, Kiev, Kyiv, Ukraine|Hospital of Scientific Research Institute of Invalid Rehabilitation /ID# 212000, Vinnytsia, Vinnytska Oblast, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 216474, Vinnytsia, Vinnytska Oblast, Ukraine|Volyn regional clinical hospital /ID# 206789, Lutsk, Volynska Oblast, Ukraine|Kherson City Clinical Hospital /ID# 212399, Kherson, Ukraine|Consultative and Diagnostic Ce /ID# 165659, Kyiv, Ukraine|Medical Center of LLC Medbud-Clinic /ID# 216998, Kyiv, Ukraine|Kyiv Railway Clinical Hosp №2 /ID# 217366, Kyiv, Ukraine|Lviv Railway Clinical Hospital /ID# 165658, Lviv, Ukraine|Odessa National Medical Univ /ID# 217470, Odesa, Ukraine|Transcarpathian Regional Clin. /ID# 167960, Uzhhorod, Ukraine|Kharkiv City Clinical Hospital /ID# 165657, Харків, Ukraine|RD&E Hospital /ID# 157544, Exeter, Devon, United Kingdom|The Royal London Hospital /ID# 163713, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 157546, London, London, City Of, United Kingdom|Ashford and St Peter's Hospitals NHS Foundation Trust /ID# 207936, Chertsey, Surrey, United Kingdom|Barnsley Hospital NHS Foundation Trust /ID# 202773, Barnsley, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 157545, Birmingham, United Kingdom|Fairfield General Hospital /ID# 207766, Bury, United Kingdom|Addenbrookes Hospital /ID# 158034, Cambridge, United Kingdom|Western General Hospital /ID# 207448, Edinburgh, United Kingdom|Queen Elizabeth University Hos /ID# 202568, Glasgow, United Kingdom|Huddersfield Royal Infirmary /ID# 209570, Huddersfield, United Kingdom|Hull and East Yorkshire NHS /ID# 158761, Hull, United Kingdom|St. James University Hospital /ID# 157550, Leeds, United Kingdom|Kings Healthcare NHS Trust /ID# 158760, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 163708, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital /ID# 158036, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03105102"
144,"NCT03104413","A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment",,"Recruiting","No Results Available","Crohn's Disease","Drug: placebo for risankizumab IV|Drug: risankizumab SC|Drug: risankizumab IV","Percentage of Participants With Clinical Remission|Percentage of Participants With Endoscopic Response|Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission|Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response|Mean Change From Baseline of Induction in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue|Mean Change From Baseline of Induction in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score|Percentage of Participants With Enhanced Clinical Response and Endoscopic Response|Percentage of Participants With Endoscopic Remission|Percentage of Participants With Enhanced Clinical Response|Percentage of Participants With Ulcer-Free Endoscopy|Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs), in Participants With EIMs at Baseline|Percentage of Participants With CD-Related Hospitalization|Percentage of Participants Without Draining Fistulas in Participants With Draining Fistulas at Baseline","AbbVie","All","16 Years to 80 Years   (Child, Adult, Older Adult)","Phase 3","579","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M15-991|2016-003190-17","December 18, 2017","March 17, 2021","March 17, 2021","April 7, 2017",,"January 21, 2020","Phoenix VA Healthcare /ID# 162261, Phoenix, Arizona, United States|HonorHealth Research Institute - Shea /ID# 165825, Scottsdale, Arizona, United States|Physician's Research Group /ID# 211882, Tempe, Arizona, United States|University of Arizona /ID# 158305, Tucson, Arizona, United States|Atria Clinical Research /ID# 164504, Little Rock, Arkansas, United States|TLC Clinical Research Inc /ID# 212501, Beverly Hills, California, United States|Southern California Res. Ctr. /ID# 211989, Coronado, California, United States|Newport Huntington Medical Group /ID# 213034, Huntington Beach, California, United States|UC San Diego Health Systems /ID# 155576, La Jolla, California, United States|United Gastroenterologists /ID# 207887, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 162655, Los Angeles, California, United States|United Gastroenterologists - Murrieta /ID# 158278, Murrieta, California, United States|Peak Gastroenterology Associat /ID# 165832, Colorado Springs, Colorado, United States|Rocky Mountain Pediatric Gastroenterology /ID# 207171, Lone Tree, Colorado, United States|Western Connecticut Medical Group /ID# 165874, Danbury, Connecticut, United States|Seffner Premier Health Care, P /ID# 162259, Brandon, Florida, United States|Clinical Res of West FL, Inc. /ID# 205864, Clearwater, Florida, United States|Clinical Res of West FL, Inc. /ID# 208127, Clearwater, Florida, United States|South Lake Pain Institute, Inc /ID# 162798, Clermont, Florida, United States|Omega Research Consultants, LLC /ID# 171080, DeBary, Florida, United States|Universal Axon Clinical Resear /ID# 165426, Doral, Florida, United States|SIH Research, LLC /ID# 163081, Kissimmee, Florida, United States|Alliance Medical Research /ID# 163834, Lighthouse Point, Florida, United States|Ctr for Advanced Gastroenterol /ID# 202482, Maitland, Florida, United States|University of Miami /ID# 155011, Miami, Florida, United States|ITB Research /ID# 161278, Miami, Florida, United States|Vista Health Research LLC - Miami /ID# 212828, Miami, Florida, United States|Coral Research Clinic /ID# 158330, Miami, Florida, United States|Nirvana Research Center /ID# 161825, Miami, Florida, United States|Gastroenterology Group Naples /ID# 165192, Naples, Florida, United States|Advanced Research Institute /ID# 161973, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 205903, Orlando, Florida, United States|IMIC Inc. /ID# 154944, Palmetto Bay, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 201606, Tampa, Florida, United States|Atlanta Gastro Assoc /ID# 154755, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 154865, Macon, Georgia, United States|Northwestern University /ID# 158250, Chicago, Illinois, United States|University of Chicago /ID# 157113, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 158254, Evanston, Illinois, United States|Southwest Gastroenterology /ID# 164764, Oak Lawn, Illinois, United States|Cotton-O'Neil Clinical Res Ctr /ID# 154753, Topeka, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 157109, Lexington, Kentucky, United States|University of Louisville /ID# 210523, Louisville, Kentucky, United States|Gastroenterology Assoc. LA /ID# 161970, Baton Rouge, Louisiana, United States|Houma Digestive Health Special /ID# 158253, Houma, Louisiana, United States|Delricht Research /ID# 206567, New Orleans, Louisiana, United States|Nola Research Works, LLC /ID# 161271, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 162239, Shreveport, Louisiana, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 154846, Chevy Chase, Maryland, United States|Gastro Center of Maryland /ID# 164766, Columbia, Maryland, United States|Center for Digestive Health /ID# 154697, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC /ID# 161267, Wyoming, Michigan, United States|Mayo Clinic - Rochester /ID# 163084, Rochester, Minnesota, United States|University of Nebraska Med Ctr /ID# 210056, Omaha, Nebraska, United States|Comprehensive Digestive Instit /ID# 160167, Las Vegas, Nevada, United States|Revival Research Institute, LLC /ID# 210986, Las Vegas, Nevada, United States|NY Scientific /ID# 158272, Brooklyn, New York, United States|Saratoga Schenectady Gastroenterology Associates - Burnt Hills /ID# 213446, Burnt Hills, New York, United States|Intercity Advanced Gastroentertology Center /ID# 215204, Fresh Meadows, New York, United States|Long Island Clinical Research /ID# 154843, Great Neck, New York, United States|Digestive Dis Care/Excel Med /ID# 211776, New Hyde Park, New York, United States|North Shore University Hospital /ID# 168734, New Hyde Park, New York, United States|NYU Langone Medical Center /ID# 160166, New York, New York, United States|Weill Cornell Medicine /ID# 165856, New York, New York, United States|Icahn School of Med Mt. Sinai /ID# 165610, New York, New York, United States|Columbia Univ Med Ctr /ID# 167545, New York, New York, United States|Lenox Hill Hospital, Northwell /ID# 168466, New York, New York, United States|DiGiovanna Institute for Medic /ID# 171130, North Massapequa, New York, United States|Carolinas Medical Center /ID# 158364, Charlotte, North Carolina, United States|Vidant Medical Group, d/b/a Vidant Multi-Specialty Clinic-Kinston /ID# 161109, Kinston, North Carolina, United States|Wake Research Associates, LLC /ID# 154891, Raleigh, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 169712, Fargo, North Dakota, United States|Tri-State Endoscopy /ID# 154939, Cincinnati, Ohio, United States|Cleveland Clinic Main Campus /ID# 209225, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 164706, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 167877, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 170447, Dayton, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 201774, Mentor, Ohio, United States|Hightower Clinical /ID# 211992, Oklahoma City, Oklahoma, United States|Digestive Disease Specialists /ID# 170772, Oklahoma City, Oklahoma, United States|Adult Gastroenterology Associates - Main /ID# 208857, Tulsa, Oklahoma, United States|Northwest Gastroenterology Cli /ID# 158255, Portland, Oregon, United States|PennState Milton S.Hershey Med /ID# 154894, Hershey, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC /ID# 212543, Pittsburgh, Pennsylvania, United States|Digestive Disease Associates, LTD /ID# 208296, Wyomissing, Pennsylvania, United States|Medical University of South Carolina /ID# 212859, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 154919, Greenville, South Carolina, United States|Rapid City Medical Center /ID# 163835, Rapid City, South Dakota, United States|Gastro One /ID# 154757, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 168735, Johnson City, Tennessee, United States|Clinical Neuroscience /ID# 164179, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 157110, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 159396, Arlington, Texas, United States|Inquest Clinical Research /ID# 165696, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209781, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209945, Cedar Park, Texas, United States|DHAT Research Institute /ID# 158199, Garland, Texas, United States|Vilo Research Group Inc /ID# 207654, Houston, Texas, United States|CliniCore International, LLC /ID# 158191, Houston, Texas, United States|Baylor College of Medicine /ID# 158194, Houston, Texas, United States|Precision Research Institute - Houston /ID# 201072, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201218, Houston, Texas, United States|Clinical Associates in Researc /ID# 161307, San Antonio, Texas, United States|Southern Star Research Institute, LLC /ID# 168772, San Antonio, Texas, United States|Baylor Scott & White Health - Temple /ID# 204129, Temple, Texas, United States|Tyler Research Institute, LLC /ID# 166795, Tyler, Texas, United States|Victoria gastroenterology /ID# 164284, Victoria, Texas, United States|HP Clinical Research /ID# 162992, Bountiful, Utah, United States|Advanced Research Institute /ID# 154922, Ogden, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 161775, West Jordan, Utah, United States|Hunter Holmes McGuire VA Medical Center /ID# 159977, Richmond, Virginia, United States|Washington Gastroenterology /ID# 162101, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 155577, Seattle, Washington, United States|University of Washington /ID# 155584, Seattle, Washington, United States|West Virginia University /ID# 167942, Morgantown, West Virginia, United States|Hopital Centenario /ID# 170904, Rosario, Santa Fe, Argentina|Cemic /Id# 168082, Buenos Aires, Argentina|Hospital Britanico de Buenos /ID# 168081, Ciudad Autonomade Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 168080, Cordoba, Argentina|Mater Hospital /ID# 167216, Brisbane, Queensland, Australia|Griffith University /ID# 212631, Southport, Queensland, Australia|Lyell McEwin Hospital /ID# 211364, Elizabeth Vale, South Australia, Australia|Emeritus Research /ID# 213510, Camberwell, Victoria, Australia|Footscray Hospital /ID# 211362, Footscray, Victoria, Australia|Universitätsklinikum St.Pölten /ID# 166423, St. Pölten, Niederoesterreich, Austria|LKH-Univ. Klinikum Graz /ID# 158134, Graz, Steiermark, Austria|Krankenhaus der Barmherzigen Brüder Wien /ID# 211418, Vienna, Wien, Austria|Medical University of Vienna /ID# 158135, Vienna, Wien, Austria|Vitebsk Regional Advanced Clin /ID# 204807, Vitebsk, Belarus|AZ Sint-Maarten /ID# 212280, Mechelen, Antwerpen, Belgium|Cliniques Universitaires Saint Luc /ID# 157384, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 157383, Gent, Oost-Vlaanderen, Belgium|Imelda Ziekenhuis /ID# 157381, Bonheiden, Belgium|ULB Erasme /ID# 157386, Brussels, Belgium|AZ Maria Middelares /ID# 212871, Ghent, Belgium|AZ Groeninge /ID# 212571, Kortrijk, Belgium|ZNA - Jan Palfijn /ID# 212822, Merksem, Belgium|University Clinical Centre of the Republic of Srpska /ID# 157710, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 165018, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 165132, Sarajevo, Bosnia and Herzegovina|UMHAT Dr Georgi Stranski EAD /ID# 203975, Pleven, Bulgaria|University Multiprofile Hospit /ID# 165697, Plovdiv, Bulgaria|Second Multiprofile Hospital f /ID# 165699, Sofia, Bulgaria|Acibadem City Clinic Tokuda /ID# 165698, Sofia, Bulgaria|UMHAT Tsaritsa Joanna - ISUL /ID# 211241, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 204713, Sofia, Bulgaria|MHAT Trakia /ID# 201665, Stara Zagora, Bulgaria|University Multiprofile Hospit /ID# 167576, Varna, Bulgaria|University of Calgary /ID# 157156, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 169766, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 157100, Edmonton, Alberta, Canada|Covenant Health /ID# 161636, Edmonton, Alberta, Canada|Fraser Clinical Trials Inc /ID# 159057, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 157097, Vancouver, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 161635, Victoria, British Columbia, Canada|QEII - Victoria Building /ID# 157089, Halifax, Nova Scotia, Canada|IWK Health Center /ID# 165909, Halifax, Nova Scotia, Canada|London Health Sciences Centre /ID# 157162, London, Ontario, Canada|Scott Shulman Medicine Professional Corporation /ID# 165910, North Bay, Ontario, Canada|Medicor Research Inc. /ID# 157151, Sudbury, Ontario, Canada|Toronto Digestive Disease Asso /ID# 157159, Vaughan, Ontario, Canada|CISSS de la Monteregie /ID# 161634, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 214376, Levis, Quebec, Canada|Hospital Maisonneuve-Rosemont /ID# 159058, Montreal, Quebec, Canada|Centre Recherche luniver Montr /ID# 167070, Montreal, Quebec, Canada|McGill Univ HC /ID# 157086, Montreal, Quebec, Canada|Complejo Asistencial Dr. Sotero del Rio /ID# 169383, Santiago, Region Metropolitana De Santiago, Chile|Servicio de Salud Occidente Hospital San Juan de Dios /ID# 171121, Santiago, Region Metropolitana De Santiago, Chile|Centro de Investigaciones Clínicas Viña del Mar /ID# 203585, Viña del Mar, Valparaíso, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 210758, Concepción, Chile|Hospital Las Higueras /ID# 167091, Talcahuano, Chile|Hospital Dr. Hernán Henríquez Aravena /ID# 210729, Temuco, Chile|Xinqiao Hospital of 3rd Military Medical University /ID# 212954, Chongqing, Chongqing, China|The Sixth Affiliated Hosp, Sun /ID# 210783, Guangzhou, Guangdong, China|The University of Hong Kong- Shenzhen Hospital /ID# 213108, Shenzhen, Guangdong, China|The Second Hospital of Hebei Medical University /ID# 212739, Shijiazhuang, Hebei, China|1st Aff Hosp Nanchang Univ /ID# 211035, Nanchang, Jiangxi, China|Ruijin Hospital, Shanghai Jiaotong /ID# 210842, Shanghai, Shanghai, China|Renji Hosp, Shanghai Jiaotong /ID# 210706, Shanghai, Shanghai, China|Sir Run Run Shaw Hospital /ID# 210626, Hangzhou, Zhejiang, China|The Second Xiangya Hospital of Central South University /ID# 211698, Changsha, China|West China Hospital, Sichuan University /ID# 210888, Chengdu, China|Guangdong Provincial People's Hospital /ID# 212950, Guangzhou, China|Jiangsu Province Hospital /ID# 210500, Nanjing, China|Shanghai Dongfang Hospital /ID# 212671, Shanghai, China|Tianjin Med Univ General Hosp /ID# 210925, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 211040, Wuhan, China|Tongji Hosp Tongji Med College /ID# 210857, Wuhan, China|Hospital Univ San Ignacio /ID# 158737, Bogota, Colombia|Instituto de Coloproctologia /ID# 158740, Medellin, Colombia|Hospital Pablo Tobon Uribe /ID# 158732, Medellín, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 157719, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Sestre milosrdnice /ID# 157720, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 157703, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 157704, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 157705, Split, Croatia|Zadar General Hospital /ID# 157706, Zadar, Croatia|CTCenter MaVe, s.r.o. /ID# 163215, Olomouc, Olomoucky Kraj, Czechia|Ikem /Id# 165479, Prague 4, Praha 4, Czechia|Thomayerova nemocnice /ID# 162942, Prague, Praha 4, Czechia|Axon Clinical, s.r.o. /ID# 163216, Praha, Praha 5, Czechia|Nemocnice Horovice, NH Hospita /ID# 211073, Horovice, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 163218, Hradec Kralove, Czechia|Nemocnice Pardubickeho kraje, a.s. /ID# 163219, Pardubice, Czechia|Restrial /ID# 211074, Prague 412, Czechia|Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 211304, Praha 1, Czechia|Aarhus University Hospital /ID# 155534, Aarhus N, Midtjylland, Denmark|Sjaellands Universitets Hospit /ID# 155537, Roskilde, Sjælland, Denmark|Svendborg Sygehus, Sygehusenhe /ID# 161591, Nyborg, Syddanmark, Denmark|Aalborg Universitets Hospital /ID# 160685, Aalborg, Denmark|Hvidovre Hospital /ID# 155535, Hvidovre, Denmark|Odense Universitets Hospital /ID# 155536, Odense C, Denmark|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 157876, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 164423, Alexandria, Egypt|Internal Medicine Department, Cairo University /ID# 157176, Cairo, Egypt|Nat Hep & Trop Med Res Inst /ID# 157875, Cairo, Egypt|Internal Med Dept Ainshams uni /ID# 158630, Cairo, Egypt|Zagazig University Hospital /ID# 164018, EL Sharkya, Egypt|East Tallinn Central Hospital /ID# 157072, Tallinn, Estonia|West Tallinn Central Hospital /ID# 157073, Tallinn, Estonia|Hopital Saint Eloi /ID# 215146, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 166287, Clichy, Ile-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 162549, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Amiens Picardie /ID# 165056, Amiens CEDEX 1, Somme, France|CHU Grenoble Alpes - Hopital /ID# 211980, Grenoble, France|Chu Lille /Id# 162547, Lille, France|CHU de Nice /ID# 162545, Nice, France|CHU Bordeaux /ID# 162546, Pessac, France|Chu Lyon Sud /Id# 162548, Pierre Benite, France|Hospital Pontchaillou /ID# 213207, Rennes, France|Hopital Nord /ID# 162550, Saint Priest En Jarez, France|Universitatsklinikum Mannheim /ID# 162026, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 159332, Erlangen, Bayern, Germany|Universitatsklinikum Munster /ID# 159333, Munster, Niedersachsen, Germany|Evangelisches Krankenhaus Kalk /ID# 212724, Cologne, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 164987, Köln, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 210527, Saarbrücken, Saarland, Germany|Univ Hosp Schleswig-Holstein /ID# 159338, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 164988, Ulm, Thueringen, Germany|Charité Universitätsmedizin Campus Mitte /ID# 212218, Berlin, Germany|Charité Universitätsmedizin Campus Mitte /ID# 212892, Berlin, Germany|Gastroenterologische Spezialpraxis am Wittenbergplatz /ID# 211976, Berlin, Germany|Praxis am Bayrischen Platz /ID# 159339, Berlin, Germany|DRK Kliniken Berlin /ID# 166149, Berlin, Germany|Krankenhaus Waldfriede /ID# 212729, Berlin, Germany|Stadtisches Klinikum Braunschw /ID# 163673, Braunschweig, Germany|Medizinisches Versorgungszent /ID# 211550, Dachau, Germany|Agaplesion Markus Krankenhaus /ID# 159334, Frankfurt, Germany|Universitaetsklinikum Frankfurt /ID# 212977, Frankfurt, Germany|Universitätsklinikum Freiburg /ID# 162025, Freiburg, Germany|Praxis Dres. Hülsdonk/Naumann /ID# 211965, Grevenbroich, Germany|Asklepios Westklinikum Hamburg /ID# 159336, Hamburg, Germany|Med Hochschule Hanover /ID# 162027, Hannover, Germany|Praxis fuer Gastroenterologie /ID# 166148, Heidelberg, Germany|EUGASTRO GmbH /ID# 212077, Leipzig, Germany|Stadtisches Klin Luneburg GmbH /ID# 163671, Lueneburg, Germany|Universitatsklinikum Magdeburg /ID# 211840, Magdeburg, Germany|Gastro Gemeinschaftspraxis /ID# 162024, Minden, Germany|Klinikum Univ Regensburg /ID# 163812, Regensburg, Germany|Universitatsklinikum Tubingen /ID# 159341, Tuebingen, Germany|Gastro-Praxis Wiesbaden /ID# 159335, Wiesbaden, Germany|Tzaneio general hospital of Piraeus /ID# 206441, Piraeus, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 157418, Athens, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 170905, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 157417, Heraklion, Greece|University General Hospital of Ioannina /ID# 157415, Ioannina, Greece|General Hospital Nikaias-Piraeus St. Panteleimon /ID# 157419, Pireaus, Greece|Theageneio Anticancer Hospital /ID# 163922, Thessaloniki, Greece|Obudai Egeszsegugyi Centrum Kft. /ID# 213192, Budapest, Hungary|Semmelweis Egyetem I. Belgyogyaszati Klinika /ID# 213132, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 166814, Debrecen, Hungary|Debrecen University /ID# 157318, Debrecen, Hungary|St Vincent's University Hospit /ID# 157569, Dublin, Ireland|Beaumont Hospital /ID# 157572, Dublin, Ireland|University Hospital Galway /ID# 157570, Galway, Ireland|Soroka Medical Center /ID# 157789, Be'er Sheva, HaDarom, Israel|Tel Aviv Sourasky Medical Ctr /ID# 157787, Tel Aviv-Yafo, Tel-Aviv, Israel|Hadassah Ein Kerem Medical Ctr /ID# 171062, Jerusalem, Yerushalayim, Israel|Rambam Medical Center /ID# 171056, Haifa, Israel|Shaare Zedek Medical Center /ID# 163539, Jerusalem, Israel|Shaare Zedek Medical Center /ID# 171055, Jerusalem, Israel|Sheba Medical Center /ID# 171059, Ramat Gan, Israel|Universita di Catanzaro Magna Graecia /ID# 212017, Catanzaro, Calabria, Italy|AOU Policlinico S.Orsola Malpighi /ID# 155659, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliero-Universitaria Policlinico di Modena /ID# 212018, Modena, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 162433, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 155660, Rome, Lazio, Italy|Azienda Policlinico Universitario Umberto I /ID# 166910, Rome, Lazio, Italy|Ospedale Policlinico San Martino/ Università Degli Studi Di Genova /ID# 162434, Genoa, Liguria, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 155657, Milan, Lombardia, Italy|ASST Rhodense /ID# 211453, Rho, Lombardia, Italy|Istituto Clinico Humanitas /ID# 155658, Rozzano, Milano, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 155656, Rome, Roma, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 161303, Catania, Sicilia, Italy|Azienda Ospedaliera Univ. Meyer /ID# 168049, Florence, Toscana, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 161302, Negrar, Verona, Italy|Ospedali Riuniti Universita /ID# 162431, Ancona, Italy|ASST Fatebenefratelli Sacco /ID# 155655, Milan, Lombardia, Italy|IRCCS Policlinico S. Matteo /ID# 212030, Pavia, Italy|Policlinico Tor Vergata /ID# 158023, Rome, Italy|Dong-A University Hospital /ID# 163370, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 163376, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 163366, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 163377, Seongnam-si, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 163354, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 163374, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 163426, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Haeundae Paik Hospital /ID# 202516, Busan, Korea, Republic of|Daejeon St. Mary's Hospital /ID# 213553, Daejeon, Korea, Republic of|Hanyang University Guri Hosp /ID# 163351, Guri-si, Korea, Republic of|The Catholic Univ. of Korea /ID# 163365, Gyeonggi-do, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 159615, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 159616, Riga, Latvia|Hospital of lithuanian university of Health Science Kauno Klinikos /ID# 162584, Kaunas, Lithuania|Vilnius University Hospital /ID# 162524, Vilnius, Lithuania|UKM Medical Centre /ID# 201362, Kuala Lumpur, Selangor, Malaysia|Universiti Sains Malaysia /ID# 160661, Kelantan, Malaysia|Queen Elizabeth Hospital /ID# 160659, Kota Kinabalu, Malaysia|Investigación Biomédica para el Desarrollo de Fármacos, S.A. de C.V. /ID# 170766, Zapopan, Jalisco, Mexico|JM Research /ID# 170762, Cuernavaca, Morelos, Mexico|Health Pharma Professional Research S.A de C.V /ID# 170763, Del. Benito Juárez, Mexico|Unidad de Atencion Medica e Investigacion en Salud /ID# 170765, Merida Yucatan, Mexico|Academisch Medisch Centrum /ID# 157953, Amsterdam, Noord-Holland, Netherlands|Elisabeth Tweesteden Ziekenhuis /ID# 163620, Tilburg, Netherlands|Christchurch Hospital /ID# 167212, Christchurch, Canterbury, New Zealand|Middlemore Clinical Trials /ID# 167214, Auckland, New Zealand|Dunedin Hospital /ID# 167215, Dunedin, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 167213, Wellington, New Zealand|Planetmed Sp. z o.o. /ID# 205159, Wrocław, Dolnoslaskie, Poland|Centrum Zdrowia MDM /ID# 163602, Warsaw, Mazowieckie, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 213578, Warsaw, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 163604, Warszawa, Mazowieckie, Poland|Centrum Medyczne Medyk /ID# 212888, Rzeszów, Podkarpackie, Poland|Centrum Medyczne LukaMed /ID# 212079, Chojnice, Poland|Uniwersytecki Szpital Kliniczn /ID# 212290, Lodz, Poland|1 Wojskowy Szpital Kliniczny Z Poliklinika /Id# 209984, Lublin, Poland|SPSK Nr 4 /ID# 209980, Lublin, Poland|Wojewódzki Szpital Specjalistyczny w Olsztynie /ID# 212400, Olsztyn, Poland|H-T. Centrum Medyczne Spółka z o.o. Spółka Komandytowa /ID# 212458, Tychy, Poland|NZOZ Vivamed /ID# 202434, Warsaw, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu /ID# 212534, Wrocław, Poland|Hospital Senhora da Oliveira de Guimarães, EPE /ID# 160691, Guimarães, Braga, Portugal|Centro Hospitalar do Algarve - Hospital de Portimão /ID# 167754, Portimao, Faro, Portugal|Centro Hosp de Lisboa Central /ID# 160677, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 167753, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 160688, Almada, Setubal, Portugal|Centro Hospitalar do Algarve /ID# 160732, Faro, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 160741, Lisboa, Portugal|Hospital Beatriz Angelo /ID# 207758, Loures, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 160742, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 160676, Santa Maria Da Feira, Portugal|Centro Hosp de Tondela-Viseu /ID# 160731, Viseu, Portugal|Institutul Clinic Fundeni /ID# 170890, Sector 2, Bucuresti, Romania|Institutul Clinic Fundeni /ID# 170888, Bucharest, Romania|Tvm Med Serv Srl /Id# 170891, Cluj, Romania|Cabinet Particular Policlinic Algomed /ID# 170889, Timisoara, Romania|Centrul Medical Tuculanu SRL /ID# 170892, Timisoara, Romania|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 200707, Kemerovo, Kemerovskaya Oblast, Russian Federation|Perm state medical university n.a. E.A. Vagner /ID# 207438, Perm, Permskiy Kray, Russian Federation|Private institution Center of educational and clinical gastroenterology, hepatol /ID# 200701, Stavropol, Stavropol Skiy Kray, Russian Federation|Tver Regional Clinical Hosp. /ID# 206586, Tver, Tverskaya Oblast, Russian Federation|Regional Clinical Hospital #1 /ID# 200708, Tyumen, Tyumenskaya Oblast, Russian Federation|Alliance Biomedical Ural Group /ID# 200703, Izhevsk, Udmurtskaya Respublika, Russian Federation|Scien Ctr Coloproctology Rosme /ID# 204806, Moscow, Russian Federation|City Clinical Hospital # 31 /ID# 208865, St. Petersburg, Russian Federation|Ulyanovsk State clinical hospi /ID# 200700, Ulyanovsk, Russian Federation|Clinical Center Serbia /ID# 156957, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 156956, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 156963, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 156959, Belgrade, Beograd, Serbia|Clinical Center Kragujevac /ID# 156961, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 156958, Novi Sad, Vojvodina, Serbia|University Children's Hospital 'Tirsova' /ID# 211480, Belgrade, Serbia|Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 212798, Belgrade, Serbia|National University Hospital /ID# 160662, Singapore, Singapore|Singapore General Hospital /ID# 160663, Singapore, Singapore|KL Ling Gastroenterology and Liver Clinic /ID# 205736, Singapore, Singapore|Univerzitna nemocnica Martin /ID# 163205, Martin, Zilinsky Kraj, Slovakia|FN s poliklinikou F.D. Rooseve /ID# 156453, Banska Bystrica, Slovakia|KM Management s.r.o. /ID# 206762, Nitra, Slovakia|Gastro I.S.R.O. /ID# 156455, Presov, Slovakia|Wits Clinical Research Site /ID# 171169, Parktown, Gauteng, South Africa|Mediclinic Milnerton /ID# 171172, CAPE TOWN,Milnerton, Western Cape, South Africa|Kingsbury Hospital /ID# 171158, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 171159, Cape Town, Western Cape, South Africa|Complejo Hospitalario Universitario de Ferrol /ID# 157534, Ferrol, Galicia, Spain|Hospital Universitario y Politecnico La Fe /ID# 157537, Valencia, Valenciana, Spain|Hospital Clinico y Provincial Barcelona /ID# 157533, Barcelona, Spain|Corp Sanit Parc Tauli Sabadell /ID# 159234, Barcelona, Spain|Hospital Universitario Basurto /ID# 205188, Bilbao, Spain|Hospital General Universitario Gregorio Maranon /ID# 161144, Madrid, Spain|Hospital Universitario La Paz /ID# 159232, Madrid, Spain|Hospital Clinico Univ de Salamanca /ID# 157539, Salamanca, Spain|Hospital Universitario Virgen Macarena /ID# 159966, Sevilla, Spain|Hosp Clin Univ de Valencia /ID# 209699, Valencia, Spain|Hospital Univ Miguel Servet /ID# 157538, Zaragoza, Spain|University Hospital Zurich /ID# 163528, Zurich, Zuerich, Switzerland|Universitaetsspital Basel /ID# 166321, Basel, Switzerland|China Medical University Hosp /ID# 160130, Taichung City, Taichung, Taiwan|National Cheng Kung University Hospital /ID# 160129, Tainan City, Tainan, Taiwan|Taichung Veterans General Hosp /ID# 160134, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 212711, Taipei City, Taiwan|National Taiwan University Hos /ID# 162189, Taipei, Taiwan|Kyiv Municipal Clinical Hospital #18 /ID# 162527, Kiev, Kyiv, Ukraine|Transcarpathian Regional Clin. /ID# 167958, Uzhhorod, Ukraine|Queen Elizabeth University Hos /ID# 202314, Glasgow, Glasgow City, United Kingdom|Ashford and St Peter's Hospitals NHS Foundation Trust /ID# 207938, Chertsey, Surrey, United Kingdom|Barnsley Hospital NHS Foundation Trust /ID# 202772, Barnsley, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 157577, Birmingham, United Kingdom|Fairfield General Hospital /ID# 207765, Bury, United Kingdom|Addenbrookes Hospital /ID# 158037, Cambridge, United Kingdom|Western General Hospital /ID# 207446, Edinburgh, United Kingdom|Hull and East Yorkshire NHS /ID# 158759, Hull, United Kingdom|Kings Healthcare NHS Trust /ID# 158758, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 163889, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital /ID# 158039, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03104413"
145,"NCT03104400","A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug","SELECT - PsA 1","Active, not recruiting","No Results Available","Psoriatic Arthritis","Drug: Adalimumab|Drug: ABT-494|Drug: Placebo for ABT-494|Drug: Placebo for Adalimumab","Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response|Change From Baseline in HAQ-DI|Percentage of Participants Achieving a Static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point Improvement From Baseline|Psoriasis Area Severity Index (PASI) 75 Response (For Participants With >= 3% BSA Psoriasis at Baseline)|Change From Baseline in Modified PsA Sharp/van der Heijde Score (SHS)|Percentage of Participants Achieving Minimal Disease Activity (MDA)|Percentage of Participants With Resolution of Enthesitis (Leeds Enthesitis Index (LEI)=0)|ACR 20 Response Rate (Non-Inferiority of ABT-494 vs Adalimumab)|Change From Baseline in Physical Component Summary (PCS) Score of the Short-Form 36 Health Survey - Version 2 (SF-36v2)|Change from Baseline in FACIT-Fatigue Questionnaire|ACR 20 Response Rate (Superiority of ABT-494 vs. Adalimumab)|Percentage of Participants With Resolution of Dactylitis (Leeds Dactylitis Index (LDI)=0)|Change From Baseline in Patient's Assessment of Pain NRS (Superiority of ABT-494 vs. Adalimumab)|Change From Baseline in HAQ-DI (Superiority of ABT-494 vs. Adalimumab)|Change From Baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire|ACR 50 Response|ACR 70 Response|ACR 20 Response","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","1705","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-572|2016-004130-24","April 27, 2017","September 20, 2019","August 5, 2022","April 7, 2017",,"January 13, 2020","Rheum Assoc of North Alabama /ID# 163231, Huntsville, Alabama, United States|SunValley Arthritis Center, Lt /ID# 161221, Peoria, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 159981, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 160033, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 160036, Phoenix, Arizona, United States|AZ Arthritis & Rheuma Research /ID# 160037, Phoenix, Arizona, United States|AZ Arth & Rheum Res /ID# 166381, Tucson, Arizona, United States|Covina Arthritis Clinic /ID# 159891, Covina, California, United States|St. Joseph Heritage Healthcare /ID# 159980, Fullerton, California, United States|Care Access Research, Huntingt /ID# 160038, Huntington Beach, California, United States|Kotha and Kotha /ID# 159823, La Mesa, California, United States|TriWest Research Associates- La Mesa /ID# 159887, La Mesa, California, United States|Arthritis & Osteo Medical Ctr /ID# 166760, La Palma, California, United States|VA Sacramento Medical Center /ID# 164196, Mather, California, United States|East Bay Rheumatology Medical /ID# 166382, San Leandro, California, United States|Inland Rheum Clin Trials Inc. /ID# 159828, Upland, California, United States|Medvin Clinical Research /ID# 160034, Whittier, California, United States|Arthritis and Rheum Clin N. CO /ID# 160039, Fort Collins, Colorado, United States|Stamford Therapeutics Consorti /ID# 165131, Stamford, Connecticut, United States|Clinical Res of West FL, Inc. /ID# 159829, Clearwater, Florida, United States|International Medical Research - Daytona /ID# 160040, Daytona Beach, Florida, United States|Omega Research Consultants, LLC /ID# 164193, DeBary, Florida, United States|LeJenue Research Associates /ID# 170965, Miami, Florida, United States|Medallion Clinical Research Institute, LLC /ID# 161228, Naples, Florida, United States|Millennium Research /ID# 159822, Ormond Beach, Florida, United States|Gulf Region Clinical Res Inst /ID# 159851, Pensacola, Florida, United States|St. Anthony Comprehsve Res Ins /ID# 159792, Saint Petersburg, Florida, United States|W. Broward Rheum Assoc Inc. /ID# 161388, Tamarac, Florida, United States|BayCare Medical Group, Inc. /ID# 159879, Tampa, Florida, United States|OrthoIllinois /ID# 164546, Rockford, Illinois, United States|Deerbrook Medical Associates /ID# 159804, Vernon Hills, Illinois, United States|Four Rivers Clinical Research /ID# 159982, Paducah, Kentucky, United States|Ochsner Clinic Foundation /ID# 165672, Baton Rouge, Louisiana, United States|Johns Hopkins University /ID# 167665, Baltimore, Maryland, United States|Klein & Associates, M.D., P.A. /ID# 164013, Cumberland, Maryland, United States|The Center for Rheumatology & /ID# 159874, Wheaton, Maryland, United States|Clinical Pharmacology Study Gr /ID# 158700, Worcester, Massachusetts, United States|Univ of Michigan Hospitals /ID# 164014, Ann Arbor, Michigan, United States|Aa Mrc Llc /Id# 159846, Grand Blanc, Michigan, United States|Advanced Rheumatology, PC /ID# 159893, Lansing, Michigan, United States|Beals Institute PC /ID# 163128, Lansing, Michigan, United States|Shores Rheumatology, PC /ID# 159889, Saint Clair Shores, Michigan, United States|Clinvest Research LLC /ID# 161227, Springfield, Missouri, United States|Glacier View Research Institut /ID# 167023, Kalispell, Montana, United States|Westroads Clinical Research /ID# 159979, Omaha, Nebraska, United States|Dartmouth-Hitchcock Med Ctr /ID# 161235, Lebanon, New Hampshire, United States|Arthritis and Osteoporosis /ID# 159802, Freehold, New Jersey, United States|Atlantic Coast Research /ID# 159799, Toms River, New Jersey, United States|Ocean Rheumatology, PA /ID# 163898, Toms River, New Jersey, United States|Arthritis and Osteo Assoc /ID# 159994, Las Cruces, New Mexico, United States|Santa Fe Rheumatology /ID# 163783, Santa Fe, New Mexico, United States|EmergeOrtho, P.A. /ID# 161391, Durham, North Carolina, United States|Trinity Health Med Arts Clinic /ID# 159800, Minot, North Dakota, United States|MetroHealth Medical Center /ID# 159888, Cleveland, Ohio, United States|Clinical Research Source, Inc. /ID# 164545, Perrysburg, Ohio, United States|STAT Research, Inc. /ID# 161392, Vandalia, Ohio, United States|Health Research Oklahoma /ID# 159880, Oklahoma City, Oklahoma, United States|Altoona Ctr Clinical Res /ID# 159852, Duncansville, Pennsylvania, United States|PA Regional Center /ID# 165670, Wyomissing, Pennsylvania, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 163464, Summerville, South Carolina, United States|West Tennessee Research Inst /ID# 159871, Jackson, Tennessee, United States|Rheumatology Consultants, PLLC /ID# 159796, Knoxville, Tennessee, United States|Dr. Ramesh Gupta /ID# 160061, Memphis, Tennessee, United States|Accurate Clinical Management /ID# 159905, Baytown, Texas, United States|PCCR Solution /ID# 205723, Colleyville, Texas, United States|Adriana Pop-Moody MD Clinic PA /ID# 159984, Corpus Christi, Texas, United States|Metroplex Clinical Research /ID# 159785, Dallas, Texas, United States|Rheumatic Disease Clin Res Ctr /ID# 161240, Houston, Texas, United States|Rheumatology Clinic of Houston /ID# 161234, Houston, Texas, United States|West Texas Clinical Research /ID# 205722, Lubbock, Texas, United States|P&I Clinical Research /ID# 159826, Lufkin, Texas, United States|SW Rheumatology Res. LLC /ID# 159993, Mesquite, Texas, United States|Trinity Universal Research Association /ID# 205721, Plano, Texas, United States|Arthritis Clinic of Central TX /ID# 164049, San Marcos, Texas, United States|DM Clinical Research /ID# 161735, Tomball, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 159786, Waco, Texas, United States|Arthritis Northwest, PLLC /ID# 166380, Spokane, Washington, United States|West Virginia Research Inst /ID# 159791, South Charleston, West Virginia, United States|Aurora Rheumatology and Immunotherapy Center /ID# 160043, Franklin, Wisconsin, United States|Psoriahue Med Interdisciplinar /ID# 160506, Buenos Aires, Argentina|Org Medica de Investigacion /ID# 160118, Buenos Aires, Argentina|Hospital General de Agudos Ram /ID# 164378, Buenos Aires, Argentina|Inst. de Rehab. Psicofisica /ID# 165154, Caba, Argentina|Instituto CAICI /ID# 160119, Rosario, Santa FE, Argentina|Centro Integral de Medicina Re /ID# 160258, SAN Miguel DE Tucuman, Latam, Argentina|Centro Medico Privado/Reuma /ID# 159775, San Miguel de Tucuman, Argentina|Centro de Enfermedades /ID# 165795, Santa Fe, Argentina|The Queen Elizabeth Hospital /ID# 169333, Woodville, South Australia, Australia|Barwon Rheumatology /ID# 166782, Geelong, Victoria, Australia|Heidelberg Repatriation Hospital /ID# 167450, Heidelberg West, Victoria, Australia|Brest Regional Hospital /ID# 164535, Brest, Belarus|First City Clinical Hospital /ID# 164534, Minsk, Belarus|Reuma clinic /ID# 164243, Genk, Belgium|University Clinical Centre of the Republic of Srpska /ID# 164503, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 164502, Sarajevo, Bosnia and Herzegovina|CIP - Centro Internacional de Pesquisa /ID# 161821, Goiânia, Goias, Brazil|CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 161819, Juiz de Fora, Minas Gerais, Brazil|EDUMED Educacao em Saude S/S L /ID# 161816, Curitiba, Parana, Brazil|Instituto de Educação e Pesquisa do Hospital Moinhos de Vento /ID# 161813, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre /ID# 161820, Porto Alegre, Rio Grande Do Sul, Brazil|LMK Sevicos Medicos S/S /ID# 161812, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 163273, Ribeirao Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 163491, Santo André, Sao Paulo, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos do ABC /ID# 161810, Santo André, Sao Paulo, Brazil|CPCLIN - Centro de Pesquisas Clínicas /ID# 161818, Sao Paulo, Brazil|Department of Rheumatology, Mu /ID# 169606, Plovdiv, Bulgaria|Excelsior Medical Center /ID# 169609, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment - Sofia at Military Medical Academy /ID# 169608, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 202393, Sofia, Bulgaria|Medical Centre Synexus Sofia /ID# 202394, Sofia, Bulgaria|Medical Centre Synexus Sofia, branch Stara Zagora /ID# 202524, Stara Zagora, Bulgaria|Diagnostic Consultative Center /ID# 169607, Varna, Bulgaria|Percuro Clinical Research, Ltd /ID# 157823, Victoria, British Columbia, Canada|Manitoba Clinic /ID# 157829, Winnipeg, Manitoba, Canada|Ciads /Id# 157831, Winnipeg, Manitoba, Canada|The Waterside Clinic /ID# 157826, Barrie, Ontario, Canada|Groupe de Recherche en Maladies Osseuses /ID# 157824, Sainte-foy, Quebec, Canada|Ctr. de Recherche Musculo-Sque /ID# 207069, Trois-rivières, Quebec, Canada|CTR Estudios SpA /ID# 206217, Providencia, Chile|Centro Inter Estud Clin CIEC /ID# 168725, Santiago, Chile|Prosalud Ltda. /ID# 169546, Santiago, Chile|Clínica Dermacross S.A /ID# 168726, Vitacura, Santiago, Chile|1st Aff Hosp of Bengbu Med Col /ID# 201021, Bengbu, Anhui, China|Peking University Third Hospital /ID# 201973, Beijing, Beijing, China|Zhuzhou Central Hospital /ID# 200201, Zhuzhou, Hunan, China|The First People's Hospital of Linyi /ID# 201970, Linyi, Shandong, China|Huashan Hospital of Fudan University /ID# 202191, Shanghai, Shanghai, China|Shanghai Changhai Hospital /ID# 200202, Shanghai, Shanghai, China|West China Hospital /ID# 200199, Chengdu, Sichuan, China|Ningbo First Hospital /ID# 201874, Ningbo, Zhejiang, China|The Aff Hosp Inner Mongolia /ID# 207787, Huhehaote, China|First Affiliated Hospital of Kunming Medical University /ID# 201264, Kunming, China|Affiliated hospital of nantong university /ID# 208234, Nantong, China|1st Aff Hosp of Shantou Univ /ID# 203371, Shantou, Guangdong, China|The First Affiliated Hospital /ID# 201875, Soochow, China|People's Hospital of Xinjiang /ID# 201592, Urumqi, China|Centro de Investigaciòn en Reumatologia CIREEM /ID# 166030, Bogota, Cundinamarca, Colombia|Fundacion Centro de Investigac /Id# 168201, Antioquia, Colombia|Ctr Int de Reum del Caribe SAS /ID# 164051, Barranquilla, Colombia|Preventive Care Sas /Id# 163781, Chia, Colombia|Hospital Pablo Tobon Uribe /ID# 164233, Medellín, Colombia|Poliklinika Repromed /ID# 203555, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Rijeka /ID# 161159, Rijeka, Primorsko-goranska Zupanija, Croatia|Medical Center Kuna-Peric /ID# 161160, Zagreb, Croatia|Poliklinika Bonifarm /ID# 206662, Zagreb, Croatia|Revmatologická ambulance /ID# 159637, Prague 4, Praha 4, Czechia|Revmatologická ambulance /ID# 159671, Prague 4, Praha 4, Czechia|Revmatologie Bruntal, s.r.o /ID# 159636, Bruntál, Czechia|Artroscan s.r.o. /ID# 159634, Ostrava, Czechia|Medical Plus, s.r.o. /ID# 159635, Uherské Hradište, Czechia|Center of Clinical and Basic Research /ID# 163870, Tallinn, Harjumaa, Estonia|MediTrials /ID# 163706, Tartu, Tartumaa, Estonia|East Tallinn Central Hospital /ID# 163790, Tallinn, Estonia|Immanuel-Krankenhaus /ID# 163931, Berlin-buch, Germany|University Clinic Carl Gustav /ID# 163926, Dresden, Germany|Cent fur Innovative Diagnostik /ID# 163927, Frankfurt, Germany|Rheumaforschungszentrum II /ID# 204421, Hamburg, Germany|Dr. med. Jochen Walter FA fuer /ID# 168638, Rendsburg, Germany|General Hospital of Athens Laiko /ID# 163478, Athens, Attiki, Greece|University General Hospital Attikon /ID# 163477, Athens, Attiki, Greece|Naval Hospital of Athens /ID# 163486, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 163472, Heraklion, Greece|Queen Mary Hospital /ID# 162492, Hong Kong, Hong Kong|Prince of Wales Hospital /ID# 163506, Sha Tin, Hong Kong|Tuen Mun Hospital /ID# 162493, Tuen Mun, Hong Kong|Synexus Magyarorszag Kft. - Gyula DRS /ID# 202209, Gyula, Bekes, Hungary|Qualiclinic Kft. /ID# 163278, Budapest III, Pest, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak & Egyetemi Oktatok.- Klinikai Kutatasi O. /ID# 202584, Nyíregyháza, Szabolcs-Szatmar-Bereg, Hungary|Vital Medical Center Orvosi es /ID# 163275, Veszprém, Veszprem, Hungary|Synexus Magyarorszag Kft. - Zalaegerszeg AS /ID# 201884, Zalaegerszeg, Zala, Hungary|Betegapolo Irgalmas Rend - Bud /ID# 170719, Budapest, Hungary|Revita Reumatologiai Rendelo /ID# 163277, Budapest, Hungary|Obudai Egeszsegugyi Centrum Kft. /ID# 163279, Budapest, Hungary|Synexus Magyarorszag Kft. /ID# 203012, Budapest, Hungary|Croom Orthopaedic Hospital /ID# 164998, Limerick, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 169845, Tel Aviv-Yafo, Tel-Aviv, Israel|The Lady Davis Carmel MC /ID# 170262, Haifa, Israel|Sheba Medical Center /ID# 202532, Ramat Gan, Israel|AOU Federico II /ID# 202411, Naples, Campania, Italy|Azienda Unità Sanitaria Locale/IRCCS c/o ""Arcispedale Santa Maria Nuova"" /ID# 161090, Reggio Emilia, Emilia-Romagna, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele /ID# 161084, Catania, Italy|Nagoya City University Hospital /ID# 162564, Nagoya-shi, Aichi, Japan|Fukuoka University Hospital /ID# 162086, Fukuoka-shi, Fukuoka, Japan|Hospital of the University of Occupational and Environmental Health /ID# 161473, Kitakyushu-shi, Fukuoka, Japan|Mie University Hospital /ID# 162080, Tsu-shi, Mie, Japan|NHO Osaka Minami Med Ctr /ID# 162590, Kawachinagano-shi, Osaka, Japan|St.Luke's International Hospital /ID# 162016, Chuo-ku, Tokyo, Japan|Inha University Hospital /ID# 163890, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|M &M Centrs /Id# 161483, Adazi, Latvia|D.Saulites-Kandevicas PP /ID# 161488, Liepaja, Latvia|Clinic ORTO /ID# 161486, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 164442, Riga, Latvia|VAKK dr. Kildos Clinic /ID# 167257, Kaunas, Lithuania|Klaipeda University Hospital /ID# 167258, Klaipeda, Lithuania|Public Institution Republican /ID# 165155, Siauliai, Lithuania|Vilnius University Hospital /ID# 165123, Vilnius, Lithuania|Hospital Raja Permaisuri Bainun /ID# 161099, Ipoh, Perak, Malaysia|Hospital Tuanku Ja afar /ID# 161096, Seremban, Malaysia|CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 164006, Mexico City, Ciudad De Mexico, Mexico|Instituto Jalisciense de Metabolismo,SC /ID# 164005, Guadalajara, Jalisco, Mexico|Invest y Biomed de Chihuahua /ID# 164007, Chihuahua, Mexico|Medisch Centrum Leeuwarden /ID# 161575, Leeuwarden, Netherlands|Maasstad Ziekenhuis /ID# 160168, Rotterdam, Netherlands|Waikato Hospital /ID# 166415, Hamilton, Waikato, New Zealand|North Shore Hospital /ID# 169409, Auckland, New Zealand|Middlemore Hospital /ID# 166414, Auckland, New Zealand|Porter Rheumatology Ltd /ID# 200421, Nelson, New Zealand|Timaru Rheumatology Studies /ID# 166413, Timaru, New Zealand|Synexus Polska Sp. z o.o. /ID# 204506, Wrocław, Dolnoslaskie, Poland|NZOZ Nasz Lekarz /ID# 163774, Toruń, Kujawsko-pomorskie, Poland|Salve Medica Sp. z o.o. S.K. /ID# 206300, Lodz, Lodzkie, Poland|Malopolskie Centrum Kliniczne /ID# 163777, Cracow, Malopolskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdansku /ID# 206299, Gdańsk, Pomorskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni /ID# 207157, Gdynia, Pomorskie, Poland|Synexus Polska Sp. z o.o. Oddzial Katowice /ID# 204510, Katowice, Slaskie, Poland|ETYKA-Osrodek Badan Klinicznyc /ID# 163776, Olsztyn, Warminsko-mazurskie, Poland|Centrum Kliniczno-Badawcze /ID# 161830, Elblag, Poland|Krakowskie Centrum Medyczne /ID# 206302, Krakow, Poland|Synexus Polska Sp. z o.o. Oddzial w Poznaniu /ID# 207158, Poznan, Poland|Medycyna Kliniczna /ID# 166288, Warsaw, Poland|Synexus Polska Sp. z.o.o. /ID# 203987, Warsaw, Poland|Reumatika - Centrum Reumatologii NZOZ /ID# 161831, Warsaw, Poland|Instituto Portugues De Reumatologia /ID# 165858, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 165861, Lisbon, Lisboa, Portugal|Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 165862, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 165860, Lisboa, Portugal|Hospital CUF Descobertas /ID# 165866, Lisbon, Portugal|Hospital Beatriz Angelo /ID# 165865, Loures, Portugal|Unidade Local De Saude Do Alto Minho /ID# 165863, Viana Do Castelo, Portugal|GCM Medical Group /ID# 162160, San Juan, Puerto Rico|Family Outpatient clinic#4,LLC /ID# 164530, Korolev, Moskva, Russian Federation|LLC Medical Center /ID# 164529, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Kazan State Medical University /ID# 164531, Kazan, Tatarstan, Respublika, Russian Federation|Moscow S.P.Botkin City Clinica /ID# 164533, Moscow, Russian Federation|State budgetary institution /ID# 164532, St. Petersburg, Russian Federation|Institute for Rheumatology /ID# 166217, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 166223, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 166229, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 166231, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 166293, Belgrade, Beograd, Serbia|Singapore General Hospital /ID# 161094, Singapore, Central Singapore, Singapore|Tan Tock Seng Hospital /ID# 161095, Singapore, Singapore|MEDMAN s.r.o. /ID# 165892, Martin, Slovakia|Reumatologická ambulancia Reum.hapi s.r.o. /ID# 166486, Nové Mesto Nad Váhom, Slovakia|Slovak research center Team Member, Thermium s.r.o. /ID# 166489, Pieštany, Slovakia|Univ Medical Ctr Ljubljana /ID# 164212, Ljubljana, Slovenia|General Hospital Murska Sobota /ID# 164211, Murska Sobota, Slovenia|Greenacres Hospital /ID# 164190, Port Elizabeth, Eastern Cape, South Africa|Wits Clinical Research Site /ID# 163919, Johannesburg, Gauteng, South Africa|University of Pretoria /ID# 163852, Pretoria, Gauteng, South Africa|Jakaranda Hospital /ID# 164242, Pretoria, Gauteng, South Africa|Arthritis Clinical Research Tr /ID# 163855, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 163853, Stellenbosch, Western Cape, South Africa|Comple Hosp Univ de A Coruna /ID# 161129, A Coruna, Spain|Hospital Ramon y Cajal /ID# 161130, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 163198, Madrid, Spain|Kantonsspital St. Gallen /ID# 158131, St. Gallen, Sankt Gallen, Switzerland|China Medical University Hosp /ID# 159402, Taichung City, Taichung, Taiwan|Chung Shan Medical University /ID# 159403, Taichung, Taiwan|Taipei Veterans General Hosp /ID# 166222, Taipei City, Taiwan|National Taiwan University Hos /ID# 160878, Taipei, Taiwan|Linkou Chang Gung Memorial Ho /ID# 166221, Taoyuan City, Taiwan|Hacettepe Universitesi Tip Fak /ID# 162518, Sihhiye, Ankara, Turkey|Bakirkoy Dr. Sadi Konuk Training & Research Hospital /ID# 162517, Istanbul, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 163383, Istanbul, Turkey|Sakarya Universitesi Egitim /ID# 163397, Sakarya, Turkey|GI ""National Institute of Therapy named by L.T. Malaya"" /ID# 164170, Kharkiv, Kharkivska Oblast, Ukraine|Lviv Regional Clinical Hospita /ID# 164178, Lviv, Lvivska Oblast, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 164245, Vinnytsia, Vinnytska Oblast, Ukraine|Kharkiv Regional Council Regional Clinical Hospital /ID# 210189, Kharkiv, Ukraine|NSC-Strazhesko Ist Cardiology /ID# 164043, Kiev, Ukraine|Municipal Institution of Kyiv Region Council Kyiv Regional Clinical Hospital /ID# 210188, Kiev, Ukraine|Med Ctr of Private High Ed Ins /ID# 208527, Kyiv, Ukraine|Medical Center of LLC Medbud-Clinic /ID# 208528, Kyiv, Ukraine|Kyiv Railway Clinical Hosp №2 /ID# 208951, Kyiv, Ukraine|LLC Revmocentr /ID# 164177, Kyiv, Ukraine|Odessa National Medical Univ /ID# 164244, Odesa, Ukraine|Whipps Cross Univ Hospital /ID# 161055, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 161065, London, London, City Of, United Kingdom|Christchurch Hospital /ID# 162702, Christchurch, United Kingdom|UH Coventry & Warwickshire /ID# 162701, Coventry, United Kingdom|Glasgow Royal Infirmary /ID# 162703, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03104400"
146,"NCT03104374","A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug","SELECT - PsA 2","Active, not recruiting","No Results Available","Psoriatic Arthritis","Drug: Placebo|Drug: ABT-494","Proportion of participants achieving American College of Rheumatology (ACR) 20 response|ACR 50 response|Proportion of participants achieving a static Investigator Global Assessment (sIGA) of Psoriasis of 0 or 1 and at least a 2-point improvement from baseline|Psoriasis Area Severity Index (PASI) 75 response (for participants with >= 3% BSA psoriasis at baseline)|Proportion of participants achieving Minimal Disease Activity (MDA)|Change from baseline in HAQ-DI|ACR 70 response|ACR 20 response|Change from baseline in Short-Form (SF)-36 Physical Component Summary (PCS)|Change from baseline in FACIT-Fatigue Questionnaire|Change from baseline in Self-Assessment of Psoriasis Symptoms (SAPS) Questionnaire","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","642","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-554|2016-004152-30","April 17, 2017","July 17, 2019","April 22, 2022","April 7, 2017",,"January 13, 2020","Alabama Medical Group, PC /ID# 159836, Mobile, Alabama, United States|AZ Arthritis & Rheum Research /ID# 160047, Mesa, Arizona, United States|SunValley Arthritis Center, Lt /ID# 161203, Peoria, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 160006, Phoenix, Arizona, United States|Osteoporosis Medical Center /ID# 161411, Beverly Hills, California, United States|Covina Arthritis Clinic /ID# 159919, Covina, California, United States|TriWest Research Associates /ID# 159915, El Cajon, California, United States|Saint Jude Heritage /ID# 160005, Fullerton, California, United States|C.V. Mehta MD, Med Corporation /ID# 161192, Hemet, California, United States|Care Access Research, Huntingt /ID# 160049, Huntington Beach, California, United States|Kotha and Kotha /ID# 159834, La Mesa, California, United States|Stanford University School of Med /ID# 161402, Stanford, California, United States|Inland Rheum Clin Trials Inc. /ID# 159839, Upland, California, United States|Medvin Clinical Research /ID# 160045, Whittier, California, United States|Denver Arthritis Clinic /ID# 159899, Denver, Colorado, United States|Colorado Arthritis Associates /ID# 159856, Lakewood, Colorado, United States|AARDS Research, Inc. /ID# 161409, Aventura, Florida, United States|Clinical Res of West FL, Inc. /ID# 159840, Clearwater, Florida, United States|International Medical Research - Daytona /ID# 160051, Daytona Beach, Florida, United States|Precision Research Org, LLC /ID# 161293, Miami Lakes, Florida, United States|Suncoast Clinical Research /ID# 161417, New Port Richey, Florida, United States|Millennium Research /ID# 159833, Ormond Beach, Florida, United States|Arthritis Center, Inc. /ID# 163463, Palm Harbor, Florida, United States|Gulf Region Clinical Res Inst /ID# 159860, Pensacola, Florida, United States|St. Anthony Comprehsve Res Ins /ID# 161405, Saint Petersburg, Florida, United States|Sarasota Arthritis Center /ID# 159854, Sarasota, Florida, United States|W. Broward Rheum Assoc Inc. /ID# 161412, Tamarac, Florida, United States|Clinical Research West FL /ID# 160069, Tampa, Florida, United States|USF Health Morsani Center for /ID# 161291, Tampa, Florida, United States|BayCare Medical Group, Inc. /ID# 159912, Tampa, Florida, United States|FL Med Clinic, PA /ID# 160013, Zephyrhills, Florida, United States|Jefrey D. Lieberman, MD, P.C. /ID# 159842, Decatur, Georgia, United States|Marietta Rheumatology Assoc /ID# 161201, Marietta, Georgia, United States|Advanced Clinical Research /ID# 159922, Meridian, Idaho, United States|Great Lakes Clinical Trials /ID# 163438, Chicago, Illinois, United States|Clinical Investigation Special /ID# 160068, Skokie, Illinois, United States|Deerbrook Medical Associates /ID# 159815, Vernon Hills, Illinois, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 161294, Monroe, Louisiana, United States|Arthritis Treatment Center /ID# 160053, Frederick, Maryland, United States|The Center for Rheumatology & /ID# 159900, Wheaton, Maryland, United States|Clinical Pharma Study Group /ID# 158712, Worcester, Massachusetts, United States|Clinvest Research LLC /ID# 161208, Springfield, Missouri, United States|Westroads Clinical Research /ID# 160004, Omaha, Nebraska, United States|Atlantic Coast Research /ID# 159810, Toms River, New Jersey, United States|Arthritis and Osteo Assoc /ID# 160015, Las Cruces, New Mexico, United States|The Center for Rheumatology /ID# 167046, Albany, New York, United States|St. Lawrence Health System /ID# 159857, Potsdam, New York, United States|DJL Clinical Research, PLLC /ID# 161414, Charlotte, North Carolina, United States|Physicians East, PA /ID# 159898, Greenville, North Carolina, United States|Shanahan Rheuma & Immuno /ID# 160012, Raleigh, North Carolina, United States|PMG Research of Wilmington LLC /ID# 161403, Wilmington, North Carolina, United States|Trinity Health Med Arts Clinic /ID# 159811, Minot, North Dakota, United States|STAT Research, Inc. /ID# 161416, Vandalia, Ohio, United States|Health Research Oklahoma /ID# 159913, Oklahoma City, Oklahoma, United States|Altoona Ctr Clinical Res /ID# 159861, Duncansville, Pennsylvania, United States|University of Pittsburgh MC /ID# 161193, Pittsburgh, Pennsylvania, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 163462, Summerville, South Carolina, United States|Rheumatology Consultants, PLLC /ID# 161408, Knoxville, Tennessee, United States|Dr. Ramesh Gupta /ID# 160067, Memphis, Tennessee, United States|Tekton Research, Inc. /ID# 160008, Austin, Texas, United States|Diagnostic Group Integrated He /ID# 161406, Beaumont, Texas, United States|Arth and Osteo Clin Brazo Valley /ID# 163439, College Station, Texas, United States|Adriana Pop-Moody MD Clinic PA /ID# 160009, Corpus Christi, Texas, United States|Metroplex Clinical Research /ID# 159818, Dallas, Texas, United States|Rheumatic Disease Clin Res Ctr /ID# 161252, Houston, Texas, United States|Accurate Clinical Research /ID# 160052, Houston, Texas, United States|P&I Clinical Research /ID# 159837, Lufkin, Texas, United States|SW Rheumatology Res. LLC /ID# 160014, Mesquite, Texas, United States|DM Clinical Research /ID# 161753, Tomball, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 161400, Waco, Texas, United States|Arthritis Clinic of N. VA, P.C /ID# 159858, Arlington, Virginia, United States|Swedish Medical Center /ID# 159918, Seattle, Washington, United States|Optimus Clinical Research Pty. /ID# 166751, Kogarah, New South Wales, Australia|The Queen Elizabeth Hospital /ID# 200840, Woodville, South Australia, Australia|Heidelberg Repatriation Hospital /ID# 167441, Heidelberg West, Victoria, Australia|Box Hill Hospital /ID# 166752, Melbourne, Victoria, Australia|UZ Gent /ID# 164210, Gent, Oost-Vlaanderen, Belgium|Reuma clinic /ID# 164214, Genk, Belgium|CIP - Centro Internacional de Pesquisa /ID# 161808, Goiânia, Goias, Brazil|Hospital de Clínicas da Universidade Federal de Uberlândia /ID# 161794, Uberlândia, Minas Gerais, Brazil|Hospital de Clinicas de Porto Alegre /ID# 161795, Porto Alegre, Rio Grande Do Sul, Brazil|LMK Sevicos Medicos S/S /ID# 161806, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 163317, Ribeirao Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 163489, Santo André, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HC /ID# 161793, São Paulo, Sao Paulo, Brazil|Percuro Clinical Research, Ltd /ID# 157835, Victoria, British Columbia, Canada|Ciads /Id# 157843, Winnipeg, Manitoba, Canada|The Waterside Clinic /ID# 157838, Barrie, Ontario, Canada|Groupe de Recherche en Maladies Osseuses /ID# 157836, Sainte-foy, Quebec, Canada|Ctr. de Recherche Musculo-Sque /ID# 163557, Trois-rivières, Quebec, Canada|CTR Estudios SpA /ID# 206038, Providencia, Chile|Centro Inter Estud Clin CIEC /ID# 169543, Santiago, Chile|Prosalud Ltda. /ID# 169542, Santiago, Chile|Clínica Dermacross S.A /ID# 169537, Vitacura, Santiago, Chile|Revmatologie Bruntal, s.r.o /ID# 159632, Bruntál, Czechia|Medical Plus, s.r.o. /ID# 159631, Uherské Hradište, Czechia|Hopital Saint Joseph /ID# 163755, Marseille CEDEX 08, Bouches-du-Rhone, France|CHU Toulouse /ID# 163743, Toulouse CEDEX 3, Occitanie, France|Centre Hospitalier Le Mans /ID# 163746, Le Mans CEDEX 9, Sarthe, France|CHU-Hospital Henri Mondor /ID# 163895, Creteil, France|Hopital Lariboisiere /ID# 163773, Paris, France|Hopital Trousseau /ID# 163772, Tours, France|General Hospital of Athens Laiko /ID# 163474, Athens, Attiki, Greece|Naval Hospital of Athens /ID# 163495, Athens, Greece|Reg Gen Univ Hosp Larissa /ID# 163493, Larisa, Greece|Vital Medical Center Orvosi es /ID# 162571, Veszprém, Veszprem, Hungary|Betegapolo Irgalmas Rend - Bud /ID# 170911, Budapest, Hungary|Revita Reumatologiai Rendelo /ID# 162575, Budapest, Hungary|Obudai Egeszsegugyi Centrum Kft. /ID# 162576, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula /ID# 162572, Debrecen, Hungary|Petz Aladar Megyei Oktato Kor /ID# 162573, Gyor, Hungary|MAV Korhaz ess Rendelointezet /ID# 162574, Szolnok, Hungary|AOU Federico II /ID# 202410, Naples, Campania, Italy|Azienda Unità Sanitaria Locale/IRCCS c/o ""Arcispedale Santa Maria Nuova"" /ID# 162751, Reggio Emilia, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 164123, Rome, Lazio, Italy|A.O. Univ. Ospedali Riuniti /ID# 162748, Ancona, Marche, Italy|Fondazione PTV Policlinico Tor Vergata /ID# 162749, Rome, Roma, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele /ID# 164126, Catania, Italy|AOU Arcispedale Sant Anna di /ID# 164127, Cona, Italy|ASST G. Pini /ID# 164125, Milan, Italy|Nagoya City University Hospital /ID# 162563, Nagoya-shi, Aichi, Japan|Fukuoka University Hospital /ID# 161774, Fukuoka-shi, Fukuoka, Japan|Kitakyushu City Hospital Organization Kitakyushu Municipal Medical Center /ID# 163516, Kitakyushu-shi, Fukuoka, Japan|Hospital of the University of Occupational and Environmental Health /ID# 161472, Kitakyushu-shi, Fukuoka, Japan|Asahikawa Medical University Hospital /ID# 200684, Asahikawa-shi, Hokkaido, Japan|Mie University Hospital /ID# 162085, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 164035, Sendai-shi, Miyagi, Japan|Oribe Clinic of Rheumatism and Medicine /ID# 163704, Oita-shi, Oita, Japan|Kansai Medical University Hospital /ID# 162081, Hirakata-shi, Osaka, Japan|NHO Osaka Minami Med Ctr /ID# 162589, Kawachinagano-shi, Osaka, Japan|Osaka City University Hospital /ID# 162082, Osaka-shi, Osaka, Japan|Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 161773, Osaka-shi, Osaka, Japan|Juntendo University Hospital /ID# 162089, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 162013, Chuo-ku, Tokyo, Japan|Keio University Hospital /ID# 162130, Shinjuku-ku, Tokyo, Japan|Daido Hospital /ID# 163639, Nagoya, Japan|Ajou University Hospital /ID# 163893, Suwon-si, Gyeonggido, Korea, Republic of|Inha University Hospital /ID# 163892, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Medisch Centrum Leeuwarden /ID# 163049, Leeuwarden, Netherlands|Sint Maartenskliniek /ID# 163703, Nijmegen, Netherlands|Erasmus Medisch Centrum /ID# 163052, Rotterdam, Netherlands|Maasstad Ziekenhuis /ID# 163050, Rotterdam, Netherlands|Waikato Hospital /ID# 166412, Hamilton, Waikato, New Zealand|Middlemore Hospital /ID# 166411, Auckland, New Zealand|Porter Rheumatology Ltd /ID# 200422, Nelson, New Zealand|Timaru Rheumatology Studies /ID# 166410, Timaru, New Zealand|Instituto Portugues De Reumatologia /ID# 165894, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 165896, Lisbon, Lisboa, Portugal|Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 165897, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 165895, Lisboa, Portugal|Unidade Local De Saude Do Alto Minho /ID# 165898, Viana Do Castelo, Portugal|Cruz-Santana, Carolina, PR /ID# 163308, Carolina, Puerto Rico|Ponce School of Medicine /ID# 163918, Ponce, Puerto Rico|GCM Medical Group /ID# 163716, San Juan, Puerto Rico|Comple Hosp Univ de A Coruna /ID# 161019, A Coruna, Spain|Hospital Universitario Reina S /ID# 170764, Cordoba, Spain|Hospital Virgen de La Arrixaca /ID# 163138, El Palmar, Spain|Hospital Universitario Campus /ID# 170768, Granada, Spain|Hospital Univ Ramon y Cajal /ID# 161020, Madrid, Spain|Royal United Hospitals Bath /ID# 161054, Bath, Bath And North East Somerset, United Kingdom|Whipps Cross Univ Hospital /ID# 161053, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 161063, London, London, City Of, United Kingdom|Christchurch Hospital /ID# 162711, Christchurch, United Kingdom|Glasgow Royal Infirmary /ID# 162712, Glasgow, United Kingdom|Luton & Dunstable University Hospital /ID# 162713, Luton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03104374"
147,"NCT03099083","Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab","RAPSODI","Completed","No Results Available","Psoriasis",,"Change in EuroQol 5 dimension (EQ-5D) score up to week 24|Change in EuroQol 5 dimension (EQ-5D) score up to week 16|Change in PASI score|Percentage of participants achieving Psoriasis Area and Severity Index (PASI) 90|Change in EQ-5D Visual Analogue Scale (VAS)|Percentage of participants achieving Psoriasis Area and Severity Index (PASI) 75|Change in Nail Psoriasis Severity Index (NAPSI) score in participants with nail psoriasis|Change in Short Form (36) Health Survey (SF-36) domain scales|Change in Dermatology Life Quality Index (DLQI)|Percentage of participants achieving Psoriasis Area and Severity Index (PASI) 100|Change in subject satisfaction questions","AbbVie","All","19 Years to 99 Years   (Adult, Older Adult)",,"97","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-346","March 31, 2017","April 5, 2019","April 5, 2019","April 4, 2017",,"April 16, 2019","Hallym University Sacred Heart Hospital /ID# 161697, Anyang-si, Gyeonggi-do, Gyeonggido, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 161696, Seongnam-si, Gyeonggido, Korea, Republic of|Ajou University Hospital /ID# 161698, Suwon-si, Gyeonggido, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 166300, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Hanyang University Seoul Hospi /ID# 169553, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Busan National University Hosp /ID# 166299, Busan, Korea, Republic of|Inje University Ilsan Paik Hos /ID# 166302, Goyang, Korea, Republic of|Korea University Ansan Hosp /ID# 161695, Gyeonggi-do, Korea, Republic of|Korea University Ansan Hosp /ID# 161699, Gyeonggi-do, Korea, Republic of|Kyunghee University Hospital /ID# 161694, Seoul, Korea, Republic of|National Medical Center /ID# 166298, Seoul, Korea, Republic of|Inje University Sanggye Paik H /ID# 166301, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03099083"
148,"NCT03089944","A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis","EXPEDITION-8","Completed","No Results Available","Hepatitis C Virus (HCV)","Drug: Glecaprevir/Pibrentasvir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected participants in the Per Protocol (PP) Population|Percentage of Participants With SVR12 in HCV GT 1,2,4,5 and 6-infected participants in the Intent-To-Treat (ITT) Population|Percentage of Participants With SVR12 in HCV GT3-infected and HCV GT1-6-infected participants in the PP Population|Percentage of Participants With SVR12 in HCV GT3-infected and HCV GT1-6-infected participants in the ITT Population|Percentage of Participants (for HCV GT1,2,4,5 and 6-infected, HCV GT3-infected and HCV GT1-6-infected) with On-treatment Virologic Failure|Percentage of Participants (for HCV GT1,2,4,5 and 6-infected, HCV GT3-infected and HCV GT1-6-infected) With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","343","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-135|2016-004967-38","April 28, 2017","July 31, 2019","October 18, 2019","March 24, 2017",,"November 7, 2019","St. Josephs Hosp and Med Ctr /ID# 162762, Phoenix, Arizona, United States|Mayo Clinic Arizona /ID# 162314, Phoenix, Arizona, United States|Liver Wellness Center /ID# 162244, Little Rock, Arkansas, United States|Felizarta /ID# 162295, Bakersfield, California, United States|VA Long Beach Healthcare System /ID# 162298, Long Beach, California, United States|Usc /Id# 162248, Los Angeles, California, United States|Kaiser Permanente - San Diego (Palm Ave) /ID# 162289, San Diego, California, United States|Stanford University School of Med /ID# 162209, Stanford, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 162313, West Hollywood, California, United States|University of Miami /ID# 162210, Miami, Florida, United States|Triple O Research Institute /ID# 162300, West Palm Beach, Florida, United States|Piedmont Hospital /ID# 162646, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 162208, Chicago, Illinois, United States|Unity Point Health /ID# 162247, Des Moines, Iowa, United States|The University of Iowa Hospita /ID# 162214, Iowa City, Iowa, United States|University of Louisville /ID# 162242, Louisville, Kentucky, United States|Louisiana Research Ctr. LLC /ID# 162567, Shreveport, Louisiana, United States|Mercy Medical Center /ID# 162291, Baltimore, Maryland, United States|Mayo Clinic - Rochester /ID# 162251, Rochester, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 162241, Jackson, Mississippi, United States|CHI Health Alegent Creighton /ID# 162286, Omaha, Nebraska, United States|Univ Nebraska Med Ctr /ID# 162285, Omaha, Nebraska, United States|Rnjms /Id# 162213, Newark, New Jersey, United States|Montefiore Medical Center /ID# 162312, Bronx, New York, United States|James J. Peters VA Medical Center /ID# 162644, Bronx, New York, United States|Weill Cornell Medical College /ID# 161051, New York, New York, United States|Icahn School of Med Mt. Sinai /ID# 162294, New York, New York, United States|Duke University Medical Center /ID# 162299, Durham, North Carolina, United States|Cumberland Research Assoc /ID# 162212, Fayetteville, North Carolina, United States|Carolinas Center for Liver Dis /ID# 162569, Statesville, North Carolina, United States|University Hospitals Cleveland /ID# 162243, Cleveland, Ohio, United States|Cleveland Clinic /ID# 162570, Cleveland, Ohio, United States|Osuchs /Id# 162284, Tulsa, Oklahoma, United States|Lehigh Valley Health Network /ID# 162603, Allentown, Pennsylvania, United States|Center for Liver Diseases, Oakland /ID# 162568, Pittsburgh, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 162211, Nashville, Tennessee, United States|Texas Digestive Disease Consul /ID# 162648, Dallas, Texas, United States|University of Texas Health /ID# 162288, Houston, Texas, United States|Virginia Commonwealth Univ /ID# 162215, Richmond, Virginia, United States|Univ of Wisconsin Hosp/Clinics /ID# 162645, Madison, Wisconsin, United States|Tokuda Hospital Sofia /ID# 163422, Sofia, Bulgaria|DCC Fokus-5 - LZIP /ID# 163338, Sofia, Bulgaria|Univ Hosp for Active Treat /ID# 163330, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 163332, Sofia, Bulgaria|University of Calgary /ID# 161185, Calgary, Alberta, Canada|Percuro Clinical Research, Ltd /ID# 161184, Victoria, British Columbia, Canada|Qe Ii Hsc /Id# 161178, Halifax, Nova Scotia, Canada|The Ottawa Hospital Research /ID# 161179, Ottawa, Ontario, Canada|Toronto General Hospital /ID# 161182, Toronto, Ontario, Canada|Research Site s.r.o /ID# 163020, Plzen, Czechia|KlinMed s.r.o. /ID# 162893, Prague, Czechia|Institut Klinicke a Experimeth /ID# 162900, Prague, Czechia|CHR Orleans - Hopital de la Source /ID# 163072, Orleans CEDEX 2, Centre-Val De Loire, France|Hôpital Purpan /ID# 163065, TOULOUSE Cedex 9, Haute-Garonne, France|CHU Amiens Picardie /ID# 163071, Amiens CEDEX 1, Somme, France|CHU Estaing /ID# 163058, Clermont Ferrand, France|Hospital Henri Mondor /ID# 163061, Creteil, France|Hopital de la Croix Rousse /ID# 163073, Lyon, France|General Hospital of Athens Laiko /ID# 162786, Athens, Attiki, Greece|General and Oncology Hospital /ID# 162784, Kifissia, Greece|Reg Gen Univ Hosp Larissa /ID# 162783, Larisa, Greece|Bioclinic Thessaloniki /ID# 162785, Thessaloniki, Greece|Budai Hepatologiai Centrum /ID# 166511, Budapest, Hungary|Szent Janos Korhaz /ID# 166542, Budapest, Hungary|St. James's Hospital /ID# 162619, Dublin 8, Dublin, Ireland|St Vincent's Hospital /ID# 162617, Dublin 4, Ireland|Beaumont Hospital /ID# 162618, Dublin, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 162185, Tel Aviv-Yafo, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 162023, Haifa, Israel|The Lady Davis Carmel MC /ID# 162017, Haifa, Israel|Sheba Medical Center /ID# 162028, Ramat Gan, Israel|Universita della Campania Luigi Vanvitelli /ID# 162337, Napoli, Campania, Italy|A.O.U. Policlinico S.Orsola-Malpighi /ID# 162335, Bologna, Emilia-Romagna, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 162340, Milano, Lombardia, Italy|Istituto Clinico Humanitas /ID# 162336, Rozzano, Milano, Italy|Polo Universitario Luigi Sacco /ID# 162339, Milan, Italy|Centrum Badan Klinicznych, Przychodnia Badan Klinicznych /ID# 162760, Wrocław, Dolnoslaskie, Poland|HepID - Diagnostyka I Terapia /ID# 162761, Lublin, Lubelskie, Poland|Uniwersytecki Szpital Kliniczn /ID# 162757, Bialystok, Poland|ID Clinic /ID# 162759, Myslowice, Poland|Centro Hosp de Lisboa Central /ID# 163770, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 163785, Lisboa, Portugal|Centro Hospitalar do Porto EPE /ID# 163765, Porto, Portugal|Centro Hospitalar de Sao Joao /ID# 163766, Porto, Portugal|GHGCPR Research Institute /ID# 162608, Ponce, Puerto Rico|Instituto de Investigacion Cientifica del Sur /ID# 162566, Ponce, Puerto Rico|Klinical Investigations Group /ID# 162565, San Juan, Puerto Rico|Institutul National de Boli Infectioase ""Prof. Dr. Matei Bals"" /ID# 163484, Sector 2, Bucuresti, Romania|Institutul National de Boli Infectioase ""Prof. Dr. Matei Bals"" /ID# 164449, Sector 2, Bucuresti, Romania|Institutul Clinic Fundeni /ID# 163479, Sector 2, Bucuresti, Romania|Institutul Clinic Fundeni /ID# 163500, Sector 2, Bucuresti, Romania|Institutul Nat. de Boli Infectioase /ID# 163488, Bucuresti, Romania|LLC Medical Company Hepatolog /ID# 161998, Samara, Samarskaya Oblast, Russian Federation|CBSI Central scientific and research institute of epidemiology /ID# 161996, Moscow, Russian Federation|Central Clinical Hospital of R /ID# 163434, Moscow, Russian Federation|Stavropol State Medical Univ /ID# 161999, Stavropol, Russian Federation|RSAHI Consulting and Diagnostic Centre /ID# 161995, Tyumen, Russian Federation|Hospital Parc de Salut del Mar /ID# 162198, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 162199, Barcelona, Spain|Hospital Universitario Reina S /ID# 162200, Cordoba, Spain|Hospital Donostia /ID# 162197, Donostia, Spain|Hospital Univ Central Asturias /ID# 162195, Oviedo, Spain|China Medical University Hosp /ID# 162950, Taichung City, Taichung, Taiwan|Kaohsiung Medical University /ID# 162949, Kaohsiung, Taiwan|Taipei Veterans General Hosp /ID# 162776, Taipei City, Taiwan|Basildon University Hospital /ID# 162616, Basildon, Essex, United Kingdom|The Royal Free Hospital /ID# 162614, London, London, City Of, United Kingdom|North Manchester General /ID# 163945, Crumpsall, United Kingdom|Western General Hospital /ID# 162612, Edinburgh, United Kingdom|Queens Medical Centre /ID# 162615, Nottinghamshire, United Kingdom|National Hospital of Tropical Diseases /ID# 167974, Hanoi, Vietnam|Hoa Hao Medic Co. Ltd. /ID# 168178, Ho Chi Minh, Vietnam|Tropical Diseases Hospital /ID# 168211, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03089944"
149,"NCT03086343","A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )","SELECT-CHOICE","Active, not recruiting","No Results Available","Rheumatoid Arthritis (RA)","Drug: Upadacitinib matching placebo|Drug: Abatacept matching placebo|Drug: Upadacitinib|Drug: Abatacept","Change in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) (non-inferiority)|Proportion of participants achieving Disease Activity Score (DAS) 28 based Clinical Remission (CR)|Change in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) (superiority)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","657","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-925|2016-000933-37","May 9, 2017","June 13, 2019","June 5, 2022","March 22, 2017",,"October 8, 2019","SunValley Arthritis Center, Lt /ID# 154558, Peoria, Arizona, United States|AZ Arthritis & Rheum Research /ID# 156539, Sun City, Arizona, United States|AZ Arth & Rheum Res /ID# 167161, Tucson, Arizona, United States|CHI St. Vincent Medical Group /ID# 154561, Hot Springs, Arkansas, United States|Saint Jude Heritage /ID# 158833, Fullerton, California, United States|Kotha and Kotha /ID# 154573, La Mesa, California, United States|Denver Arthritis Clinic /ID# 159195, Denver, Colorado, United States|Arthritis and Rheum Clin N. CO /ID# 155673, Fort Collins, Colorado, United States|Scientia Medical Research /ID# 159189, Lakewood, Colorado, United States|Clinical Res of West FL, Inc. /ID# 154576, Clearwater, Florida, United States|Advanced Clin Res of Orlando /ID# 154580, Ocoee, Florida, United States|Gulf Region Clinical Res Inst /ID# 154597, Pensacola, Florida, United States|W. Broward Rheum Assoc Inc. /ID# 158835, Tamarac, Florida, United States|Lovelace Scientific Resources /ID# 154600, Venice, Florida, United States|Jefrey D. Lieberman, MD, P.C. /ID# 157178, Decatur, Georgia, United States|Advanced Clinical Research /ID# 154603, Meridian, Idaho, United States|PMG Research of Christie Clini /ID# 154569, Champaign, Illinois, United States|Bluegrass Community Research /ID# 154604, Lexington, Kentucky, United States|Four Rivers Clinical Research /ID# 154606, Paducah, Kentucky, United States|Ochsner Clinic Foundation /ID# 154585, New Orleans, Louisiana, United States|The Center for Rheumatology & /ID# 158723, Wheaton, Maryland, United States|West Michigan Rheumatology /ID# 154551, Grand Rapids, Michigan, United States|Advanced Rheumatology, PC /ID# 154589, Lansing, Michigan, United States|Clinvest Research LLC /ID# 154554, Springfield, Missouri, United States|Overlook Medical Center /ID# 154794, Summit, New Jersey, United States|Atlantic Coast Research /ID# 155234, Toms River, New Jersey, United States|Ocean Rheumatology, PA /ID# 162980, Toms River, New Jersey, United States|Arthritis and Osteo Assoc /ID# 154560, Las Cruces, New Mexico, United States|The Center for Rheumatology /ID# 162979, Albany, New York, United States|NYU Langone Rheum Assoc /ID# 155236, Lake Success, New York, United States|NYU Langone Medical Center /ID# 158829, New York, New York, United States|Physicians East, PA /ID# 154565, Greenville, North Carolina, United States|PMG Research of Salisbury /ID# 154605, Salisbury, North Carolina, United States|PMG Research of Wilmington LLC /ID# 154584, Wilmington, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 154586, Winston-Salem, North Carolina, United States|Oregon Health and Science University /ID# 163822, Portland, Oregon, United States|East Penn Rheumatology Assoc /ID# 159193, Bethlehem, Pennsylvania, United States|Altoona Ctr Clinical Res /ID# 154572, Duncansville, Pennsylvania, United States|University of Pittsburgh MC /ID# 157434, Pittsburgh, Pennsylvania, United States|West Tennessee Research Inst /ID# 158721, Jackson, Tennessee, United States|Adriana Pop-Moody MD Clinic PA /ID# 154607, Corpus Christi, Texas, United States|P&I Clinical Research /ID# 159191, Lufkin, Texas, United States|DM Clinical Research /ID# 158722, Tomball, Texas, United States|Care Access Research /ID# 158098, Salt Lake City, Utah, United States|Aprillus Asistencia e Investig /ID# 159173, Capital Federal, Buenos Aires, Argentina|Ctr Privado Med Familiar /ID# 158814, Buenos Aires, Argentina|Atencion Integral en Reuma /ID# 155696, Buenos Aires, Argentina|Hospital General de Agudos /ID# 167117, Buenos Aires, Argentina|Inst. de Rehab. Psicofisica /ID# 167768, Caba, Argentina|Inst. Rheumatologic Strusberg /ID# 159021, Cordoba, Argentina|Instituto Medico DAMIC /ID# 167770, Cordoba, Argentina|DIM Clinica Privada /ID# 167769, Ramos Mejía, Argentina|Instituto CAICI SRL /ID# 159022, Rosario, Santa FE, Argentina|Rheumatology Research Unit /ID# 159174, Maroochydore, Queensland, Australia|The Queen Elizabeth Hospital /ID# 159175, Woodville, South Australia, Australia|Western Health Footscray Hospi /ID# 157968, Footscray, Victoria, Australia|CHU UCL Namur /ID# 157628, Namur, Belgium|CEDOES-Centro de Diagnóstico e Pesquisa da Osteoporose do Espírito Santo LTDA /ID# 155228, Vitoria, Espirito Santo, Brazil|Santa Casa de Belo Horizonte /ID# 154631, Belo Horizonte, Minas Gerais, Brazil|CMiP - Centro Mineiro de Pesquisa Ltda - ME /ID# 154564, Juiz de Fora, Minas Gerais, Brazil|Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 154634, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 161211, Porto Alegre, Rio Grande Do Sul, Brazil|LMK Sevicos Medicos S/S /ID# 159176, Porto Alegre, Rio Grande Do Sul, Brazil|CEMEC - Centro Multidisciplinar de Estudos Clínicos /ID# 154632, Santo André, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 159587, São Paulo, Sao Paulo, Brazil|MHAT Trimontsium /ID# 155226, Plovdiv, Bulgaria|Diag Consult Ctr 17 Sofia EOOD /ID# 169298, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 155000, Sofia, Bulgaria|Medical Centre Synexus Sofia /ID# 201807, Sofia, Bulgaria|The Waterside Clinic /ID# 159178, Barrie, Ontario, Canada|Adachi Medicine Prof. Corp /ID# 158024, Hamilton, Ontario, Canada|Institut de Rhum. de Montreal /ID# 155001, Montreal, Quebec, Canada|Groupe de Recherche en Maladies Osseuses /ID# 154601, Sainte-foy, Quebec, Canada|Revmatologicky ustav Praha /ID# 154612, Prague 2, Praha 2, Czechia|Medical Plus, s.r.o. /ID# 155230, Uherské Hradište, Czechia|Uniklinik Koln /ID# 156047, Köln, Nordrhein-Westfalen, Germany|Praxis fuer Rheumatologie /ID# 156156, Berlin, Germany|Rheumaforschungszentrum II /ID# 157177, Hamburg, Germany|Welcker, Planegg, DE /ID# 160185, Planegg, Germany|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 163916, Heraklion, Greece|Budai Irgalmasrendi Korhaz /ID# 154457, Budapest, Hungary|Obudai Egeszsegugyi Centrum Kft. /ID# 156159, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 159183, Debrecen, Hungary|Markhot Ferenc Oktatokorhaz es Rendelointezet /ID# 159689, Eger, Hungary|MAV Korhaz ess Rendelointezet /ID# 154455, Szolnok, Hungary|Our Lady's Hospital /ID# 161149, Manorhamilton, Ireland|Barzilai Medical Center /ID# 161685, Ashkelon, Israel|The Lady Davis Carmel MC /ID# 161686, Haifa, Israel|Meir Medical Center /ID# 162774, Kfar Saba, Israel|Sheba Medical Center /ID# 163154, Ramat Gan, Israel|A.O. Univ. Ospedali Riuniti /ID# 161707, Ancona, Marche, Italy|Istituto Clinico Humanitas /ID# 154999, Rozzano, Milano, Italy|AOU Citta della Salute Scienza /ID# 154577, Turin, Piemonte, Italy|Presidio Columbus, Fondazione Policlinico Gemelli Universita Cattolica S. Cuore /ID# 162252, Rome, Roma, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele /ID# 161172, Catania, Italy|ASST G. Pini /ID# 162223, Milan, Italy|SMG-SNU Boramae Medical Center /ID# 155788, Seoul, Seoul Teugbyeolsi, Korea, Republic of|The Catholic University of Korea, Yeouido St. Mary's Hospital /ID# 155231, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Asan Medical Center /ID# 154639, Seoul, Korea, Republic of|D.Saulites-Kandevicas PP /ID# 154578, Liepaja, Latvia|Riga East Clinical Univ Hosp /ID# 155024, Riga, Latvia|CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 154579, Mexico City, Ciudad De Mexico, Mexico|Morales Vargas Centro de Investigación S.C /ID# 200800, León de los Aldama, Guanajuato, Mexico|Centro Integral en Reumatología S.A de C.V /ID# 204493, Guadalajara, Jalisco, Mexico|RM Pharma Specialists, S.A de C.V /ID# 159588, Mexico City, Mexico|Centro Especializado en Diabetes, Obesidad y Prevención de Enfermedades Cardiova /ID# 160126, Mexico City, Mexico|Antonius Ziekenhuis /ID# 155737, Sneek, Fryslan, Netherlands|Reade /ID# 161002, Amsterdam, Netherlands|Spaarne Gasthuis /ID# 161003, Haarlem, Netherlands|Medisch Centrum Leeuwarden /ID# 156043, Leeuwarden, Netherlands|Timaru Medical Specialists Ltd /ID# 159184, Timaru, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 154591, Wellington, New Zealand|Salve Medica Sp. z o.o. S.K. /ID# 202473, Lodz, Lodzkie, Poland|Malopolskie Centrum Kliniczne /ID# 157180, Cracow, Malopolskie, Poland|Centrum Medyczne AMED Warszawa Targowek /ID# 159589, Warszawa, Mazowieckie, Poland|Gabinet Internistyczno Reum. /ID# 157433, Białystok, Podlaskie, Poland|ClinicMed Daniluk, Nowak Sp.j. /ID# 202998, Białystok, Podlaskie, Poland|Synexus Polska Sp. z o.o. Oddzial w Gdyni /ID# 202472, Gdynia, Pomorskie, Poland|Medyczne Centrum Hetmanska /ID# 155746, Poznań, Wielkopolskie, Poland|Centrum Med Amed Oddzial Lodzi /ID# 154458, Lodz, Poland|Instituto Portugues De Reumatologia /ID# 155698, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 200035, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 164056, Almada, Setubal, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 200037, Lisboa, Portugal|Unidade Local De Saude Do Alto Minho /ID# 200036, Viana Do Castelo, Portugal|Centro Hosp de Tondela-Viseu /ID# 155699, Viseu, Portugal|Dr. Ramon L. Ortega-Colon, MD /ID# 158097, Carolina, Puerto Rico|GCM Medical Group /ID# 156158, San Juan, Puerto Rico|Spitalul Clinic Dr. I. Cantacuzino /ID# 155893, Bucharest, Bucuresti, Romania|Spitalul Clinic Sf. Maria /ID# 167245, Bucuresti, Romania|Family Outpatient clinic#4,LLC /ID# 203524, Korolev, Moskva, Russian Federation|LLC Medical Center /ID# 203523, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Alliance Biomedical Ural Group /ID# 154609, Izhevsk, Udmurtskaya Respublika, Russian Federation|State Budget Healthcare Instit /ID# 154593, Moscow, Russian Federation|Nort-Western State Medical Uni /ID# 154610, St. Petersburg, Russian Federation|Novamed,spol.s.r.o. /ID# 157928, Banska Bystrica, Slovakia|Univerzitna Nemocnica Bratislava /ID# 161143, Bratislava, Slovakia|Narodny ustav reumatickych chorob Piestany /ID# 156864, Pieštany, Slovakia|Hospital Universitario Reina S /ID# 155701, Cordoba, Spain|Hospital General Univ de Elche /ID# 158825, Elche, Spain|Hospital Universitario La Paz /ID# 163636, Madrid, Spain|Corp Sanitaria Parc Tauli /ID# 163634, Sabadell, Barcelona, Spain|Complejo Hospitalario /ID# 155700, Santiago de Compostela, Spain|Hospital Infanta Luisa /ID# 154641, Sevilla, Spain|Skanes Universitetssjukhus /ID# 165133, Malmö, Skane Lan, Sweden|Akademiskt specialistcentrum Centrum for reumatologi /ID# 156046, Stockholm, Stockholms Lan, Sweden|Sahlgrenska University Hosp /ID# 162775, Goteborg, Sweden|Vastmanlands Sjukhus /ID# 159186, Vasteras, Sweden|Hopitaux Universitaires de Geneve /ID# 159083, Genève, Geneve, Switzerland|Kantonsspital St. Gallen /ID# 155232, St. Gallen, Sankt Gallen, Switzerland|University Hospital of Basel /ID# 160860, Basel, Switzerland|HFR Fribourg - Hopital Canton /ID# 160970, Fribourg, Switzerland|Hacettepe University Medical Faculty /ID# 167995, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 162691, Ankara, Turkey|Akdeniz University Faculty /ID# 163153, Antalya, Turkey|Istanbul Fizik Tedavi Rehabilitasyon Egitim ve Arastırma Hastanesi /ID# 169479, Istanbul, Turkey|Whipps Cross Univ Hospital /ID# 205985, London, London, City Of, United Kingdom|Ninewells Hospital /ID# 156050, Dundee, United Kingdom|Altnagelvin Area Hospital /ID# 156540, Londonderry, United Kingdom|Lancashire Care NHS Foundation /ID# 156042, Preston, United Kingdom|Royal Cornwall Hospital /ID# 157785, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03086343"
150,"NCT03086239","A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: Rovalpituzumab tesirine","Number of participants with dose-limiting toxicities (DLT)|Duration of response (DOR)|Objective Response Rate (ORR)|Overall survival (OS)|Progression-free survival (PFS)|Clinical benefit rate (CBR)","AbbVie","All","20 Years and older   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRX001-008","April 28, 2017","January 30, 2018","August 20, 2018","March 22, 2017",,"August 27, 2018","National Cancer Ctr Hosp East /ID# 161432, Kashiwa-shi, Chiba, Japan|Kyushu University Hospital /ID# 161430, Fukuoka-shi, Fukuoka, Japan|Kinki University -Osakasayama Campus /ID# 161431, Osakasayama-shi, Osaka, Japan|National Cancer Center Hospital /ID# 161429, Chuo-ku, Tokyo, Japan|Wakayama Medical University /ID# 161428, Wakayama, Japan",,"https://ClinicalTrials.gov/show/NCT03086239"
151,"NCT03082209","A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies",,"Recruiting","No Results Available","Advanced Solid Tumors Cancer|Hematologic Malignancies","Drug: ABBV-621|Drug: Venetoclax|Drug: Bevacizumab|Drug: FOLFIRI","Area under the serum/plasma concentration time curve (AUC) of ABBV-621|Maximum observed serum concentration (Cmax) of ABBV-621|Terminal phase elimination rate constant (β)|Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621|Time to Cmax (Tmax) of ABBV-621|QTcF Change from Baseline|Number of Participants with Dose-limiting Toxicities (DLTs)","AbbVie","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 1","205","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-913|2016-003887-37","March 20, 2017","February 2, 2021","December 2, 2021","March 17, 2017",,"August 15, 2019","Yale University /ID# 158029, New Haven, Connecticut, United States|University of Chicago /ID# 158030, Chicago, Illinois, United States|Ingalls Memorial Hosp /ID# 171221, Harvey, Illinois, United States|Univ Michigan Med Ctr /ID# 207134, Ann Arbor, Michigan, United States|Rhode Island Hospital /ID# 171157, Providence, Rhode Island, United States|MD Anderson Cancer Center /ID# 202187, Houston, Texas, United States|South Texas Accelerated Research Therapeutics /ID# 160574, San Antonio, Texas, United States|Medical College of Wisconsin /ID# 171152, Milwaukee, Wisconsin, United States|National Cancer Ctr Hosp East /ID# 160596, Kashiwa-shi, Chiba, Japan|Yamagata University Hospital /ID# 200681, Yamagata-shi, Yamagata, Japan|Universitair Medisch Centrum Groningen /ID# 169748, Groningen, Netherlands|Erasmus Medisch Centrum /ID# 160869, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 169747, Utrecht, Netherlands|Hospital General Vall D'Hebron /ID# 170809, Barcelona, Spain|Hospital Fundacion Jimenez Dia /ID# 200106, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 165136, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03082209"
152,"NCT03071757","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-368|Drug: ABBV-181","Terminal half-life (t1/2) of ABBV-368|Area under the serum concentration-time curve (AUC) of ABBV-368|Maximum tolerated dose (MTD) of ABBV-368 when administered as monotherapy or in combination with ABBV-181|Recommended Phase 2 dose (RPTD) for ABBV-368 when administered as monotherapy or as combination therapy with ABBV-181|Time to Cmax (Tmax) of ABBV-368|Terminal phase elimination rate constant (β) of ABBV-368|Number of Participants With Adverse Events|Maximum observed serum concentration (Cmax) of ABBV-368|Objective Response Rate (ORR)|Clinical benefit rate (CBR)|Duration of Objective Response (DOR)|Progression-Free Survival (PFS)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","170","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-074|2016-004205-14","March 21, 2017","June 15, 2020","September 29, 2021","March 7, 2017",,"November 5, 2019","Ucsd /Id# 201334, La Jolla, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 201342, Sacramento, California, United States|Stanford University /ID# 206949, Stanford, California, United States|Yale University /ID# 207895, New Haven, Connecticut, United States|University of Iowa Hospitals and Clinics /ID# 213170, Iowa City, Iowa, United States|Carolina BioOncology Institute /ID# 160786, Huntersville, North Carolina, United States|Greenville Hospital System /ID# 160785, Greenville, South Carolina, United States|UT Southwestern Medical Center /ID# 201934, Dallas, Texas, United States|South Texas Accelerated Research Therapeutics /ID# 160788, San Antonio, Texas, United States|University of Virginia /ID# 212895, Charlottesville, Virginia, United States|Virginia Cancer Specialists /ID# 160787, Fairfax, Virginia, United States|Institut Curie /ID# 165038, Paris CEDEX 05, Ile-de-France, France|Hopital de la Timone /ID# 165036, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Centre Leon Berard /ID# 165037, Lyon CEDEX 08, Rhone, France|Institut Gustave Roussy /ID# 165035, Villejuif, Val-de-Marne, France|National Cancer Center Hospital East /ID# 214530, Kashiwa-shi, Chiba, Japan|National Cancer Center Hospital /ID# 214531, Chuo-ku, Tokyo, Japan|Pan American Center for Oncology Trials, LLC /ID# 213809, Rio Piedras, Puerto Rico|Hospital Duran i Reynals /ID# 205997, L'Hospitalet de Llobregat, Barcelona, Spain|Clinica Universitar de Navarra - Pamplona /ID# 208879, Pamplona, Navarra, Comunidad, Spain|Hospital General Universitario Gregorio Maranon /ID# 205999, Madrid, Spain|Clinica Universidad de Navarra - Madrid /ID# 205996, Madrid, Spain|Hospital Puerta de Hierro /ID# 206973, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 211500, Madrid, Spain|Hosp Clin Univ de Valencia /ID# 211499, Valencia, Spain|National Cheng Kung University Hospital /ID# 164002, Tainan City, Tainan, Taiwan|National Taiwan Univ Hosp /ID# 164000, Taipei City, Taipei, Taiwan|Taipei Medical University Hospital /ID# 164001, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03071757"
153,"NCT03069365","A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment","EXPEDITION-5","Completed","Has Results","Hepatitis C Virus (HCV)","Drug: Glecaprevir/pibrentasvir","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Dosing (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","101","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-127|2016-004182-60","March 28, 2017","February 20, 2018","June 5, 2018","March 3, 2017","March 4, 2019","March 4, 2019","Scripps Clinic /ID# 159116, La Jolla, California, United States|Huntington Medical Foundation /ID# 160653, Pasadena, California, United States|Tampa General Medical Group /ID# 159115, Tampa, Florida, United States|Northwest Louisiana Nephrology /ID# 160652, Shreveport, Louisiana, United States|Massachusetts General Hospital /ID# 159114, Boston, Massachusetts, United States|North Shore University Hospital /ID# 159108, New Hyde Park, New York, United States|Columbia Univ Medical Center /ID# 159112, New York, New York, United States|Carolinas Medical Center /ID# 159113, Charlotte, North Carolina, United States|University of Pennsylvania /ID# 159117, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 159754, Philadelphia, Pennsylvania, United States|TX Liver Inst, Americ Res Corp /ID# 159111, San Antonio, Texas, United States|Zeidler Ledcor Centre /ID# 160600, Edmonton, Alberta, Canada|Vancouver ID Research and Care /ID# 160598, Vancouver, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 160599, Vancouver, British Columbia, Canada|Toronto General Hospital /ID# 160601, Toronto, Ontario, Canada|Universitatsklinikum Mannheim /ID# 160829, Mannheim, Baden-Wuerttemberg, Germany|Universitätsklinikum Frankfurt /ID# 160826, Frankfurt am Main, Hessen, Germany|Med Hochschule Hanover /ID# 160827, Hannover, Germany|Univ Johannes Gutenberg /ID# 160828, Mainz, Germany|General Hospital of Athens Laiko /ID# 160725, Athens, Attiki, Greece|Gen Univ Hosp Alexandroupolis /ID# 160724, Alexandroupolis, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 160726, Athens, Greece|Bioclinic Thessaloniki /ID# 160723, Thessaloniki, Greece|A.O.U. Policlinico S.Orsola-Malpighi /ID# 163349, Bologna, Emilia-Romagna, Italy|Policlinico A. Gemelli /ID# 160719, Roma, Lazio, Italy|Policlinico Paolo Giaccone /Id# 160718, Palermo, Sicilia, Italy|A.O. Uni Giovanni e Ruggi /ID# 160720, Salerno, Italy|Hanyang University Seoul Hospi /ID# 160259, Seongdong, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 160261, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Asan Medical Center /ID# 160260, Seoul, Korea, Republic of|HepID - Diagnostyka I Terapia /ID# 161083, Lublin, Lubelskie, Poland|Uniwersytecki Szpital Kliniczn /ID# 161081, Bialystok, Poland|VA Caribbean Healthcare System /ID# 160754, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 160755, San Juan, Puerto Rico|Hospital Regional de Malaga /ID# 159976, Málaga, Malaga, Spain|Hospital Parc de Salut del Mar /ID# 159975, Barcelona, Spain|Hospital Universitario Doce de /ID# 159974, Madrid, Spain|Karolinska Uni /ID# 159523, Stockholm, Sweden","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03069365/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT03069365/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03069365"
154,"NCT03069352","A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy",,"Active, not recruiting","No Results Available","Acute Myeloid Leukemia (AML)","Drug: Placebo|Drug: Venetoclax|Drug: Cytarabine","Overall survival (OS)|Event-free survival (EFS)|Composite Complete Remission Rate by Initiation of Cycle 2|Patient Reported Outcomes|Complete Remission Rate|Composite Complete Remission Rate|Post Baseline Red Blood Cell (RBC) Transfusion Independence|Complete Remission and Complete Remission With Partial Hematologic Recovery (CR + CRh)|Post Baseline Platelets Transfusion Independence|Minimal Residual Disease (MRD) Response Rate|The Rate of Conversion (RBC)|The Rate of Conversion (Platelets)|Complete Remission and Complete Remission With Partial Hematologic Recovery by Initiation of Cycle 2|CR + CRi Rate, CR + CRh rate, and OS in molecular subgroups","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","211","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-043|2016-003900-30","May 24, 2017","July 13, 2020","July 13, 2020","March 3, 2017",,"May 30, 2019","H. Lee Moffit Cancer Center /ID# 164273, Tampa, Florida, United States|Norton Cancer Institute /ID# 158998, Louisville, Kentucky, United States|Univ of Pittsburgh Med Ctr /ID# 158997, Pittsburgh, Pennsylvania, United States|Univ TX, MD Anderson /ID# 159678, Houston, Texas, United States|Swedish Medical Center /ID# 161280, Seattle, Washington, United States|Gundersen Health System /ID# 164272, La Crosse, Wisconsin, United States|Cemic /Id# 159676, Buenos Aires, Argentina|Sanatorio Allende /ID# 159675, Cordoba, Argentina|Calvary Mater Newcastle /ID# 160123, Waratah, New South Wales, Australia|Westmead Hospital /ID# 160121, Westmead, New South Wales, Australia|Alfred Hospital /ID# 160125, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 162920, Melbourne, Victoria, Australia|Universitair Ziekenhuis Antwerpen /ID# 159566, Edegem, Antwerpen, Belgium|Cliniques Universitaires Saint Luc /ID# 159567, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Centro de Pesquisas Oncologicas /ID# 163567, Florianopolis, Santa Catarina, Brazil|Hospital de Cancer de Barretos /ID# 163568, Barretos, Sao Paulo, Brazil|Hospital do Cancer Mae de Deus /ID# 163416, Porto Alegre, Brazil|Casa de Saúde Santa Marcelina /ID# 163413, Sao Paulo, Brazil|University of Alberta Hospital /ID# 159646, Edmonton, Alberta, Canada|CISSS de la Monteregie /ID# 159782, Greenfield Park, Quebec, Canada|Hospital Maisonneuve-Rosemont /ID# 159780, Montreal, Quebec, Canada|Hopital Sacre Coeur Montreal /ID# 160982, Montreal, Quebec, Canada|Fujian Medical Univ Union Hosp /ID# 167321, Fuzhou, Fujian, China|Nanfang Hospital of Southern Medical University /ID# 170147, Guangzhou, Guangdong, China|Jiangsu Province People's Hospital /ID# 167511, Nanjing, Jiangsu, China|The First Hosp of Jilin Univ /ID# 167512, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 167325, Shanghai, Shanghai, China|West China Hospital /ID# 167514, Chengdu, Sichuan, China|Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 167509, Tianjin, Tianjin, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 167324, Hangzhou, Zhejiang, China|Qilu Hospital of Shandong Univ /ID# 167507, Jinan, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167515, Wuhan, China|Henan Cancer Hospital /ID# 167327, Zhengzhou, Henan, China|Fakultni Nemocnice Brno /ID# 159247, Brno, Czechia|Univ Hosp Ostrava-Poruba /ID# 159246, Ostrava, Czechia|Fakult Nem Kralovske Vinohrady /ID# 159248, Prague, Czechia|Centre Hospitalier Lyon Sud /ID# 159705, Pierre Benite CEDEX, Rhone, France|Centre Hospitalier Le Mans /ID# 159702, Le Mans CEDEX 9, Sarthe, France|Centre Hospitalier de la Cote /ID# 159697, Bayonne, France|CHU Bordeaux /ID# 159704, Pessac, France|CHU De Nancy /ID# 159700, Vandoeuvre Les Nancy Cedex, France|Schwarzwald-Baar-Klinikum /ID# 159571, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|Vivantes Klinikum Am Urban /ID# 159569, Berlin, Germany|Universitaetsklinikum Hamburg /ID# 161760, Hamburg, Germany|General Hospital of Athens Laiko /ID# 157870, Athens, Attiki, Greece|Gen Univ Hosp Alexandroupolis /ID# 157868, Alexandroupolis, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 157869, Athens, Greece|University Gen Hosp of Patra /ID# 157871, Patras, Greece|General Hospital of Thessaloniki George Papanikolaou /ID# 157867, Thessaloniki, Greece|Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 159127, Budapest IX, Budapest, Hungary|Pecsi Tudomanyegyetem /ID# 163161, Pécs, Pecs, Hungary|Semmelweis Egyetem I. Belklini /ID# 158180, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 158178, Debrecen, Hungary|Petz Aladar Megyei Oktato Korh /ID# 161739, Gyor, Hungary|Kaposi Mor Oktato Korhaz /ID# 158175, Kaposvar, Hungary|Bacs-Kiskun Megyei Korhaz /ID# 160973, Kecskemét, Hungary|St. James's Hospital /ID# 162730, Dublin 8, Dublin, Ireland|Beaumont Hospital /ID# 162733, Dublin, Ireland|University Hospital Galway /ID# 162734, Galway, Ireland|University Hospital Limerick /ID# 162735, Limerick, Ireland|University of Fukui Hospital /ID# 159770, Yoshida-gun, Fukui, Japan|Kyushu University Hospital /ID# 159688, Fukuoka-shi, Fukuoka, Japan|Gunmaken Saiseikai Maebashi Hospital /ID# 160597, Maebashi-shi, Gunma, Japan|National Hospital Organization Mito Medical Center /ID# 162988, Higashi Ibaraki-gun, Ibaraki, Japan|Kyoto Prefect Univ Med /ID# 160101, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 161151, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 160233, Nagasaki-shi, Nagasaki, Japan|Osaka City University Hospital /ID# 159722, Osaka-shi, Osaka, Japan|Kinki University -Osakasayama Campus /ID# 160777, Osakasayama-shi, Osaka, Japan|Tokyo Metropolitan Komagome Hospital /ID# 160759, Bunkyo-ku, Tokyo, Japan|Tokyo Jikei Daisan Hospital /ID# 159769, Komae-shi, Tokyo, Japan|NTT Medical Center Tokyo /ID# 160678, Shinagawa-ku, Tokyo, Japan|Yamagata University Hospital /ID# 161223, Yamagata-shi, Yamagata, Japan|Akita University Hospital /ID# 160602, Akita, Japan|Saitama Med Univ Int Med Ctr /ID# 161308, Hidaka, Japan|NHO Nagoya Medical Center /ID# 159768, Nagoya, Japan|Dokkyo Medical University Hosp /ID# 159650, Shimotsuga, Japan|Juntendo University Hospital /ID# 159781, Tokyo, Japan|Pusan National University Hosp /ID# 158725, Busan, Busan Gwang Yeogsi, Korea, Republic of|Chungnam National University Hospital /ID# 158726, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 158724, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 162253, Seoul, Korea, Republic of|Instituto Nacional de Cancerol /ID# 159269, Ciudad de México, Ciudad De Mexico, Mexico|Centro de Invest Clin Chapulte /ID# 162625, Morelia, Michoacan, Mexico|Hosp. Univ. Dr. Jose E. Gonz /ID# 159268, Monterrey, Nuevo Leon, Mexico|North Shore Hospital /ID# 160132, Auckland, New Zealand|Middlemore Clinical Trials /ID# 160131, Auckland, New Zealand|Haukeland University Hospital /ID# 165630, Bergen, Hordaland, Norway|Sykehuset Ostfold Kalnes /ID# 165632, Gralum, Norway|VA Caribbean Healthcare System /ID# 158999, San Juan, Puerto Rico|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 162991, Kemerovo, Kemerovskaya Oblast, Russian Federation|Nizhniy Novgorod regional clinical hospital named N. A. Semashko /ID# 163186, Nizhnij Novgorod, Nizhegorodskaya Oblast, Russian Federation|State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 163126, Ryazan, Ryazanskaya Oblast, Russian Federation|City Clinical Hospital Botkina /ID# 164086, Moscow, Russian Federation|Samara State Medical Universit /ID# 164173, Samara, Russian Federation|Almazov North-West Federal Med /ID# 162170, Sankt-peterburg, Russian Federation|saratov state medical /ID# 163130, Saratov, Russian Federation|Saint Petersburg State Institu /ID# 162171, St. Petersburg, Russian Federation|Yaroslavl Regional Clinic Hosp /ID# 162172, Yaroslavl, Russian Federation|Netcare Pretoria East Hospital /ID# 157373, Pretoria, Gauteng, South Africa|Tshwane District Hospital /ID# 157361, Pretoria, Gauteng, South Africa|Hospital Universitario y Politecnico La Fe /ID# 161181, Valencia, Valenciana, Spain|Hospital Infanta Leonor /ID# 161180, Madrid, Spain|National Taiwan Univ Hosp /ID# 162781, Taipei City, Taipei, Taiwan|Tri-Service General Hospital /ID# 161683, Taipei City, Taipei, Taiwan|Kaohsiung Medical University /ID# 161693, Kaohsiung, Taiwan|Heartlands Hospital /ID# 163534, Birmingham, United Kingdom|University Hospital of Wales /ID# 162726, Cardiff, United Kingdom|Northwick Park Hospital /ID# 162727, Harrow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03069352"
155,"NCT03067129","A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection","DORA","Active, not recruiting","No Results Available","Hepatitis C Virus (HCV)","Drug: Glecaprevir/Pibrentasvir","Area under the curve (AUC) of Glecaprevir (GLE)|AUC of Pibrentasvir (PIB)|Percentage of participants who with post-treatment HCV virologic relapse|Percentage of participants with new HCV infection at any time up to the last study visit|Clearance of GLE|Percentage of participants who experience on-treatment virologic failure (i.e., breakthrough or fail to suppress at the end of treatment)|Maximum observed plasma concentration (Cmax) of PIB|Clearance of PIB|Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)|Maximum observed plasma concentration (Cmax) of GLE","AbbVie","All","3 Years to 17 Years   (Child)","Phase 3","129","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-123|2016-004102-34","March 20, 2017","December 23, 2019","November 21, 2022","March 1, 2017",,"December 5, 2019","Univ of California San Francis /ID# 158002, San Francisco, California, United States|Childrens Hospital Colorado /ID# 157996, Aurora, Colorado, United States|CT Childrens Medical Ctr, US /ID# 158639, Hartford, Connecticut, United States|UF Hepatology Research at CTRB /ID# 158008, Gainesville, Florida, United States|Florida Hospital /ID# 166022, Orlando, Florida, United States|Indiana University /ID# 158001, Indianapolis, Indiana, United States|Boston Childrens Hospital /ID# 157988, Boston, Massachusetts, United States|Boston Medical Center /ID# 157997, Boston, Massachusetts, United States|Weill Cornell Medicine /ID# 158000, New York, New York, United States|UNC Health Care /ID# 157991, Chapel Hill, North Carolina, United States|Cincinnati Childrens Hosp Med /ID# 158007, Cincinnati, Ohio, United States|Children's Hosp Philadelphia /ID# 158003, Philadelphia, Pennsylvania, United States|Child Hosp of Pittsburgh,PA /ID# 158004, Pittsburgh, Pennsylvania, United States|Monroe-Carell Jr. Children's H /ID# 169037, Nashville, Tennessee, United States|Baylor College of Medicine /ID# 157989, Houston, Texas, United States|Cliniques Universitaires Saint Luc /ID# 162173, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 162174, Leuven, Belgium|Alberta Child. Hosp, Calg, CAN /ID# 163449, Calgary, Alberta, Canada|Stollery Children's Hospital /ID# 163450, Edmonton, Alberta, Canada|Children's and Women's Health Centre of British Columbia Branch /ID# 163934, Vancouver, British Columbia, Canada|Hospital for Sick Children /ID# 163448, Toronto, Ontario, Canada|Universitatsklinikum Freiburg /ID# 165187, Freiburg im Breisgau, Baden-Wuerttemberg, Germany|Charité Universitätsmedizin Campus Mitte /ID# 165186, Berlin, Germany|Helios Klinikum Wuppertal /ID# 165185, Wuppertal, Germany|Kurume University Hospital /ID# 165718, Kurume-shi, Fukuoka, Japan|Osaka University Hospital /ID# 165709, Suita-shi, Osaka, Japan|Juntendo University Hospital /ID# 212912, Bunkyo-ku, Tokyo, Japan|Osaka General Medical Center /ID# 212745, Osaka, Japan|San Jorge Children Hospital /ID# 160850, San Juan, Puerto Rico|Federal State Budgetary Institution - Institute of Nutrition /ID# 163345, Moscow, Moskva, Russian Federation|National Medical Scientific Centre of children health /ID# 163344, Moscow, Moskva, Russian Federation|Scientific and Research Instit /ID# 163343, Saint-petersburg, Russian Federation|Hospital Univ Vall d'Hebron /ID# 163323, Barcelona, Spain|Hospital Sant Joan de Deu /ID# 163282, Esplugues de Llobregat, Spain|Hospital Universitario La Paz /ID# 163283, Madrid, Spain|Hosp Univ Politecnico la Fe /ID# 163325, Valencia, Spain|Birmingham Childrens Hospital /ID# 162718, Birmingham, United Kingdom|Queen Elizabeth University Hos /ID# 162719, Glasgow, United Kingdom|King's College Hospital NHS /ID# 162717, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03067129"
156,"NCT03061812","Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","TAHOE","Active, not recruiting","No Results Available","Small Cell Lung Cancer","Drug: Rovalpituzumab tesirine|Drug: Topotecan","Overall Survival (OS)|Objective response rate (ORR)|Change from baseline of the Physical functioning scale score in QLQ-C15-PAL|Progression Free Survival (PFS)|Duration of Objective Response (DOR)|Clinical Benefit Rate (CBR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","444","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-289|2016-003726-17","April 10, 2017","February 12, 2020","February 12, 2020","February 23, 2017",,"November 29, 2019","Clearview Cancer Institute /ID# 155873, Huntsville, Alabama, United States|Mitchell Cancer Institute /ID# 158151, Mobile, Alabama, United States|Highlands Oncology Group /ID# 155902, Fayetteville, Arkansas, United States|Carti /Id# 156982, Little Rock, Arkansas, United States|Cedars-Sinai Medical Center /ID# 157102, Beverly Hills, California, United States|Ucsd /Id# 156965, La Jolla, California, United States|Los Angeles Hematology Oncolog /ID# 155879, Los Angeles, California, United States|UC Davis Comp Cancer Ctr /ID# 157001, Sacramento, California, United States|St Jude Hospital dba St Joseph /ID# 155899, Santa Rosa, California, United States|Icri /Id# 157090, Whittier, California, United States|Christiana Care Health Service /ID# 158171, Newark, Delaware, United States|Cancer Specialists of North Florida - Southpoint /ID# 155828, Jacksonville, Florida, United States|Georgia Cancer Center /ID# 160206, Atlanta, Georgia, United States|St. Luke's Mt States Tumor /ID# 164550, Meridian, Idaho, United States|NorthShore University HealthSystem - Evanston /ID# 157054, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 155871, Harvey, Illinois, United States|Goshen Center for Cancer Care /ID# 155946, Goshen, Indiana, United States|University of Louisville /ID# 155947, Louisville, Kentucky, United States|Ochsner Clinic Foundation /ID# 160807, New Orleans, Louisiana, United States|Beth Israel Deaconess Med Ctr /ID# 203386, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 160210, Boston, Massachusetts, United States|Edward W. Sparrow Hosp Assn /ID# 157021, Lansing, Michigan, United States|Nebraska Hematology Oncology /ID# 155900, Lincoln, Nebraska, United States|Gabrail Cancer Center Research /ID# 155920, Canton, Ohio, United States|Oregon Health and Science University /ID# 157055, Portland, Oregon, United States|UPMC Hillman Cancer Ctr /ID# 164403, Pittsburgh, Pennsylvania, United States|Univ Medical Ctr Brackenridge /ID# 156967, Austin, Texas, United States|UT Southwestern Medical Center /ID# 158150, Dallas, Texas, United States|University of Vermont Medical Center /ID# 162317, Burlington, Vermont, United States|University of Washington /ID# 162626, Seattle, Washington, United States|Medical Oncology Associates /ID# 156856, Spokane, Washington, United States|West Virginia Univ School Med /ID# 155872, Morgantown, West Virginia, United States|Blacktown Hospital /ID# 158907, Blacktown, New South Wales, Australia|St George Hospital /ID# 158855, Kogarah, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 158853, Wollongong, New South Wales, Australia|The Prince Charles Hospital /ID# 158897, Chermside, Queensland, Australia|Ballarat Health Service /ID# 158904, Ballarat, Victoria, Australia|Austin Hospital /ID# 158898, Heidelberg, Victoria, Australia|Bobruysk Interdistrict Onco. /ID# 169394, Bobruisk, Belarus|Belarus Cancer Center N.N. Alexandrov /ID# 159325, Lesnoy, Belarus|Mogilev Reg. Oncologic dispe /ID# 159326, Mogilev, Belarus|CHU Saint-Pierre /ID# 159521, Bruxelles, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 158748, Charleroi, Hainaut, Belgium|Cliniques universitaires Saint /ID# 158751, Brussels, Belgium|Hopital de Jolimont /ID# 159755, Haine Saint Paul, Belgium|UZ Leuven /ID# 158752, Leuven, Belgium|CHU de Liege Sart Tilman /ID# 158753, Liege, Belgium|CHU Charleroi (Vesale) /ID# 159756, Montigny-le-tilleul, Belgium|Liga Norte Rio Grandense Cont. /ID# 159015, Natal, Rio Grande Do Norte, Brazil|Associação Hospital Beneficente São Vicente de Paulo - Hospital São Vicente de P /ID# 159668, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUCRS /ID# 159669, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos /ID# 159017, Barretos, Sao Paulo, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 159666, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Inca /Id# 159665, Rio de Janeiro, Brazil|UMHAT Tsaritsa Joanna - ISUL /ID# 159641, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 159642, Sofia, Bulgaria|Cross Cancer Institute /ID# 159519, Edmonton, Alberta, Canada|Juravinski Cancer Clinic /ID# 159514, Hamilton, Ontario, Canada|Hopital Sacre Coeur Montreal /ID# 159515, Montreal, Quebec, Canada|CHU de Quebec-Universite Laval /ID# 159093, Quebec City, Quebec, Canada|Cisss Du Bas-Saint-Laurent Hopital Regional de Rimouski /Id# 208931, Rimouski, Quebec, Canada|Jilin Cancer Hosptial /ID# 204059, Changchun, Jilin, China|4th Military Medical Universit /ID# 203985, Xi'an, China|Klinicki bolnicki centar Sestre milosrdnice /ID# 158811, Zagreb, Grad Zagreb, Croatia|Klinika za plucne bolesti Jordanovac /ID# 159502, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Rijeka /ID# 159501, Rijeka, Primorsko-goranska Zupanija, Croatia|Thomayerova nemocnice /ID# 159061, Prague, Praha 4, Czechia|Nemocnice Na Plesi s.r.o. /ID# 161190, Nová Ves pod Pleší, Pribram, Czechia|Nemocnice Rudolfa a Stefanie /ID# 159652, Benesov, Czechia|Nemocnice Horovice a.s. /ID# 161191, Horovice, Czechia|Krajska nemocnice Liberec a.s. /ID# 159653, Liberec, Czechia|Herlev Hospital /ID# 158049, Herlev, Hovedstaden, Denmark|Odense Universitets Hospital /ID# 158050, Odense C, Syddanmark, Denmark|Rigshospitalet, Finsen Centre /ID# 158051, Copenhagen, Denmark|Hopital Haut-Lévêque /ID# 160558, Pessac CEDEX, Gironde, France|Assis.Publique-Hopital Nord /ID# 160554, Marseille, Provence-Alpes-Cote-d Azur, France|Centre Leon Berard /ID# 160561, Lyon CEDEX 08, Rhone, France|Centre Hosp Intercommunal /ID# 162684, Creteil, France|Assistance Publique- Hopitaux /ID# 160552, Paris, France|Hospital Pontchaillou /ID# 160555, Rennes, France|KH Martha-Maria Halle Dolau /ID# 158796, Halle (Saale), Sachsen-Anhalt, Germany|Evangelische Lungenklinik Berl /ID# 159168, Berlin, Germany|Asklepios Fachkliniken M. Gaut /ID# 158791, Gauting, Germany|Lungen Clinic Grosshansdorf /ID# 158770, Grosshansdorf, Germany|Thoraxklinik Heidelberg gGmbH /ID# 159169, Heidelberg, Germany|Klinikum Kassel /ID# 158788, Kassel, Germany|Klinik Loewenstein GmbH /ID# 159167, Löwenstein, Germany|General Hospital of Chest Diseases of Athens ""SOTIRIA"" /ID# 159165, Athens, Greece|Metropolitan Hospital /ID# 159162, Athens, Greece|University Hospital of Ioannin /ID# 159163, Ioannina, Greece|Euromedica General Clinic /ID# 159161, Thessaloniki, Greece|Torokbalinti Tudogyogyintezet /ID# 207053, Budapest, Pest, Hungary|Semmelweis Egyetem /ID# 161197, Budapest, Hungary|Orszagos Koranyi Pulmonologiai /ID# 158967, Budapest, Hungary|Debreceni Egyetem /ID# 161209, Debrecen, Hungary|Veszprem Megyei Tuedoegyogyint /ID# 162607, Farkasgyepu, Hungary|Petz Aladar Megyei Oktato Korh /ID# 158978, Gyor, Hungary|Matrai Gyogyintezet /ID# 158979, Matrahaza, Hungary|AUSL 8 Arezzo Ospedale San Don /ID# 160967, Arezzo, Italy|Istituto Europeo di Oncologia /ID# 158942, Milan, Italy|AO Univ San Luigi Gonzaga /ID# 158945, Orbassano, Italy|Ospedale Santa Maria delle Cro /ID# 158940, Ravenna, Italy|IFO Istituto Nazionale Tumori /ID# 158941, Rome, Italy|Aichi Cancer Center Hospital /ID# 164975, Nagoya-shi, Aichi, Japan|National Cancer Ctr Hosp East /ID# 165726, Kashiwa-shi, Chiba, Japan|Kyushu University Hospital /ID# 165723, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 164586, Kurume-shi, Fukuoka, Japan|Kanazawa University Hospital /ID# 165129, Kanazawa, Ishikawa, Japan|Yokohama City University Hospital /ID# 165748, Yokohama-shi, Kanagawa, Japan|Japanese Red Cross Okayama Hospital /ID# 165156, Okayama-shi, Okayama, Japan|Kansai Medical University Hospital /ID# 165055, Hirakata-shi, Osaka, Japan|Kinki University -Osakasayama Campus /ID# 166394, Osakasayama-shi, Osaka, Japan|Shizuoka cancer center /ID# 166466, Sunto-gun, Shizuoka, Japan|Tokushima University Hospital /ID# 165812, Tokushima-shi, Tokushima, Japan|National Cancer Center Hospital /ID# 166768, Chuo-ku, Tokyo, Japan|The Cancer Institute Hosp JFCR /ID# 166249, Koto-ku, Tokyo, Japan|Showa University Hospital /ID# 165574, Shinagawa-ku, Tokyo, Japan|Hyogo Cancer Center /ID# 165125, Akashi, Japan|National Hospital Organization Himeji Medical Center /ID# 165893, Himeji, Japan|Matsusaka City Hospital /ID# 166126, Matsusaka-shi, MIE, Japan|Osaka City General Hospital /ID# 165717, Osaka, Japan|Hokkaido Cancer Center /ID# 165237, Sapporo, Japan|Sendai Kousei Hospital /ID# 166061, Sendai, Japan|Wakayama Medical University /ID# 166032, Wakayama, Japan|Kanagawa Cardio Resp Center /ID# 164374, Yokohama, Japan|Kanagawa Cancer Center /ID# 165816, Yokohama, Japan|Dong-A University Hospital /ID# 159296, Busan, Busan Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 204416, Seongnam-si, Gyeonggido, Korea, Republic of|Chonnam National University Hospital /ID# 159294, Gwangju, Jeonranamdo, Korea, Republic of|Kyungpook National University Chilgok Hospital /ID# 159292, Daegu, Seoul Teugbyeolsi, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 159288, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Korea University Guro Hospital /ID# 159293, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Chungbuk National University /ID# 159291, Cheongju-si, Korea, Republic of|Asan Medical Center /ID# 159290, Seoul, Korea, Republic of|Pauls Stradins Clinical /ID# 158713, Riga, Latvia|Riga East Clinical University /ID# 158714, Riga, Latvia|Instituto Nacional de Cancerol /ID# 171350, Ciudad de México, Ciudad De Mexico, Mexico|Centro de Invest Clin Chapulte /ID# 161000, Morelia, Michoacan, Mexico|Health Pharma Professional Res /ID# 160020, Mexico, Mexico|Universitair Medisch Centrum Groningen /ID# 158088, Groningen, Netherlands|Ziekenhuis St. Jansdal /ID# 158652, Harderwijk, Netherlands|Isala /ID# 158653, Zwolle, Netherlands|Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 160537, Rzeszów, Podkarpackie, Poland|Copernicus PL Sp. z o. o., WCO /ID# 160538, Gdansk, Poland|Szpitale Pomorskie Sp. z o.o /ID# 160536, Gdynia, Poland|Centro Hospitalar Lisboa Norte, EPE /ID# 158687, Lisbon, Lisboa, Portugal|IPO Lisboa FG, EPE /ID# 158995, Lisboa, Portugal|Hospital da Luz, SA /ID# 158996, Lisbon, Portugal|Unidade Local Saude Matosinhos /ID# 158682, Matosinhos, Portugal|Hospital CUF Porto /ID# 158685, Porto, Portugal|IPO Porto FG, EPE /ID# 158686, Porto, Portugal|S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 160847, Craiova, Dolj, Romania|Oncocenter Oncologie Clinica S /ID# 160848, Timisoara, Timis, Romania|Spitalul Judetean de Urgenta A /ID# 160846, Alba, Romania|National Medical Research Cntr /ID# 207436, Moscow, Moskovskaya Oblast, Russian Federation|LLC Novaya Klinika /ID# 205539, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Arkhangelsk clinical oncology /ID# 159309, Arkhangelsk, Russian Federation|Kaluga Regional Clinical Oncol /ID# 160179, Kaluga, Russian Federation|Clinical Onco Dispensary /ID# 159307, Omsk, Russian Federation|PMI Euromedservice /ID# 159311, Pushkin, Russian Federation|Smolensk Regional Onc Clin Dis /ID# 159314, Smolensk, Russian Federation|LLC BioEq Ltd. /ID# 159310, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 159312, St. Petersburg, Russian Federation|Clinical Center of Nis /ID# 160059, NIS, Nisavski Okrug, Serbia|Institut za onkologiju i radio /ID# 160058, Belgrade, Serbia|Klinicki centar Srbije /ID# 160024, Belgrade, Serbia|Institute For Pulmonary Diseas /ID# 158813, Sremska Kamenica, Serbia|National University Hospital /ID# 158802, Singapore, Singapore|National Cancer Ctr Singapore /ID# 158803, Singapore, Singapore|Hosp. Sta Creu i Sant Pau /ID# 159028, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 159031, Barcelona, Spain|Hosp. Gral. Univ. Gregorio Mar /ID# 159025, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 159024, Madrid, Spain|Hosp Clin Univ de Valencia /ID# 159027, Valencia, Spain|Sahlgrenska US Gbg /ID# 159534, Göteborg, Vastra Gotalands Lan, Sweden|Uppsala University Hospital /ID# 159050, Uppsala, Sweden|National Cheng Kung University Hospital /ID# 158844, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 158865, Taipei City, Taipei, Taiwan|Tri-Service General Hospital /ID# 158985, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 158866, Taichung City, Taiwan|Hacettepe University Medical Faculty /ID# 159238, Altindağ, Ankara, Turkey|Inonu Universitesi Turgut Ozal /ID# 159241, Battalgazi/malatya, Turkey|Ege University Medical Faculty /ID# 159239, Izmir, Turkey|Dr. Suat Seren Gogus Has /ID# 159240, Izmir, Turkey|Ataturk Gogus Hastaliklari ve /ID# 160056, Kecioren/ankara, Turkey|Municipal institution /ID# 159867, Chernivtsi, Ukraine|Municipal institution Multifie /ID# 159121, Dnipro, Ukraine|Regional Center of Oncology /ID# 159123, Kharkiv, Ukraine|Medical and Diagnostic Center /ID# 159125, Kropyvnytskyi, Ukraine|Kryviy Rih Oncology Center /ID# 159119, Kryviy RIH, Ukraine|Treatment and prevention /ID# 159124, Lutsk, Ukraine|Central Regional Clinical Hos. /ID# 159868, Uzhgorod, Ukraine|Communal Institution Zaporizhz /ID# 159122, Zaporizhzhia, Ukraine|Guy's and St Thomas' NHS Found /ID# 159581, London, London, City Of, United Kingdom|United Lincolnshire Hospitals /ID# 159579, Boston, United Kingdom|Charing Cross Hospital /ID# 159582, London, United Kingdom|Christie NHS Foundation Trust /ID# 159099, Manchester, United Kingdom|James Cook University Hospital /ID# 159583, Middlesborough, United Kingdom|Royal Preston Hospital /ID# 159578, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03061812"
157,"NCT03053180","Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation","CITRIN","Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants Achieving Virological Response at End of Treatment (EoT)|Percentage of Participants With Relapse|Percentage of Participants With Breakthrough|Percentage of Participants With Failure to Suppress|Percentage of Participants With Missing SVR12 Data","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"60","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-253","March 20, 2017","December 18, 2017","December 18, 2017","February 15, 2017","March 14, 2019","March 14, 2019","South-Ural State Med. Academy, Chelyabinsk, Russian Federation|KOGBUZ Kirovsk Infect Hosp, Kirov, Russian Federation|Specialized Clinical Infectiou, Krasnodar, Russian Federation|Orenburg Regional Clinical Hos, Orenburg, Russian Federation|LLC Medical Company, Samara, Russian Federation|GBOU VPO Saratov state Med Uni, Saratov, Russian Federation|Ulyanovsk Regional Clin Hosp, Ulyanovsk, Russian Federation","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03053180/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03053180/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03053180"
158,"NCT03047395","A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )","LIMMITLESS","Enrolling by invitation","No Results Available","Psoriasis","Biological: risankizumab","Number of Participants With Adverse Events|Percentage of Participants Achieving an Static Physician Global Assessment (sPGA) Score of Clear|Percentage of Participants Achieving At Least 100% Reduction in PASI Score From Baseline (PASI 100)|Percentage of Participants Achieving At Least 75% Reduction in PASI Score From Baseline (PASI 75)|Percentage of Participants Achieving At Least 90% Reduction in Psoriasis Area and Severity Index (PASI) Score From Baseline (PASI 90)|Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","2200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-997|2016-003046-87|1311.31","February 27, 2017","November 30, 2023","November 30, 2023","February 9, 2017",,"October 29, 2019","Total Skin and Beauty Derm Ctr /ID# 154000, Birmingham, Alabama, United States|University of Alabama at Birmingham - Main /ID# 153983, Birmingham, Alabama, United States|NW Arkansas Clin Trials Center /ID# 154014, Rogers, Arkansas, United States|Bakersfield Derma & Skin Cance /ID# 154008, Bakersfield, California, United States|Wallace Medical Group, Inc. /ID# 154025, Beverly Hills, California, United States|CA Dermatology & Clinical Rese /ID# 154007, Encinitas, California, United States|T. Joseph Raoof, MD, Inc. /ID# 154078, Encino, California, United States|Center for Dermatology Clin Res /ID# 154009, Fremont, California, United States|Kaiser Permanente Los Angeles /ID# 154079, Los Angeles, California, United States|Dermatology Res. Assoc., CA /ID# 153977, Los Angeles, California, United States|Dermatology Specialists, Inc /ID# 153984, Oceanside, California, United States|Huntington Medical Foundation /ID# 154002, Pasadena, California, United States|Medderm Associates /ID# 154098, San Diego, California, United States|Southern California Derma. Inc /ID# 154006, Santa Ana, California, United States|UNISON Center for Clinical Tri /ID# 153979, Sherman Oaks, California, United States|New England Research Associates, LLC /ID# 154004, Bridgeport, Connecticut, United States|UConn Health /ID# 154128, Farmington, Connecticut, United States|Florida Academic Centers Research /ID# 154045, Coral Gables, Florida, United States|Leavitt Medical Associates of Florida /ID# 154046, Ormond Beach, Florida, United States|Progressive Medical Research /ID# 154027, Port Orange, Florida, United States|ATL Derma, Vein & Res Ctr /ID# 153980, Alpharetta, Georgia, United States|Europaeisches Brusstzentrum /ID# 153999, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 153974, Chicago, Illinois, United States|Rush University Medical Center /ID# 154099, Chicago, Illinois, United States|Northshore University Health System-Evanston /ID# 154011, Evanston, Illinois, United States|Arlington Dermatology /ID# 153975, Rolling Meadows, Illinois, United States|Dundee Dermatology /ID# 154110, West Dundee, Illinois, United States|Dawes Fretzin, LLC /ID# 154146, Indianapolis, Indiana, United States|The Dermatology Center PSC - New Albany /ID# 154075, New Albany, Indiana, United States|The Indiana Clinical Trials Center /ID# 153976, Plainfield, Indiana, United States|The South Bend Clinic Center /ID# 154147, South Bend, Indiana, United States|Kansas City Dermatology PA /ID# 153993, Overland Park, Kansas, United States|Skin Sciences, PLLC /ID# 153991, Louisville, Kentucky, United States|DS Research /ID# 154028, Louisville, Kentucky, United States|Massachusetts General Hospital /ID# 153990, Boston, Massachusetts, United States|ActivMed Practices and Researc /ID# 154044, Methuen, Massachusetts, United States|University of Michigan Hospitals /ID# 154111, Ann Arbor, Michigan, United States|Great Lakes Research Group,Inc /ID# 153998, Bay City, Michigan, United States|Michigan Center for Skin Care /ID# 153986, Clinton Township, Michigan, United States|Somerset Skin Centre /ID# 154097, Troy, Michigan, United States|Minnesota Clinical Study Center /ID# 154015, Fridley, Minnesota, United States|Central Dermatology, PC /ID# 154013, Saint Louis, Missouri, United States|Skin Specialists, PC /ID# 154024, Omaha, Nebraska, United States|Dartmouth-Hitchcock Med Ctr /ID# 154095, Lebanon, New Hampshire, United States|Psoriasis Treatment Ctr NJ /ID# 154001, East Windsor, New Jersey, United States|The Dermatology Group, PC /ID# 202489, Verona, New Jersey, United States|Forest Hills Dermatology Group /ID# 154113, Forest Hills, New York, United States|Icahn School of Med Mt. Sinai /ID# 154129, New York, New York, United States|The Rockefeller University /ID# 153994, New York, New York, United States|DermResearchCenter of NY, Inc. /ID# 154012, Stony Brook, New York, United States|Buffalo Medical Group /ID# 154148, Williamsville, New York, United States|Darst Dermatology /ID# 154076, Charlotte, North Carolina, United States|Dermatology Consulting Service /ID# 154010, High Point, North Carolina, United States|Wake Research Associates, LLC /ID# 202490, Raleigh, North Carolina, United States|Wilmington Dermatology Center /ID# 154109, Wilmington, North Carolina, United States|Synexus Research Cincinnati /ID# 153997, Cincinnati, Ohio, United States|Oregon Derm & Res. Ctr /ID# 153982, Portland, Oregon, United States|Oregon Medical Res Center PC /ID# 154003, Portland, Oregon, United States|Altoona Ctr Clinical Res /ID# 153981, Duncansville, Pennsylvania, United States|Paddington Testing Co., Inc. /ID# 154022, Philadelphia, Pennsylvania, United States|University of Pittsburgh MC /ID# 153995, Pittsburgh, Pennsylvania, United States|Clinical Partners, LLC /ID# 154096, Johnston, Rhode Island, United States|Derm & Laser Ctr of Charleston /ID# 154112, Charleston, South Carolina, United States|Radiant Research - Salt Lake City /ID# 154127, Greer, South Carolina, United States|Coastal Carolina Research Ctr /ID# 153992, Mount Pleasant, South Carolina, United States|Health Concepts /ID# 153996, Rapid City, South Dakota, United States|Austin Dermatology Associates /ID# 154042, Austin, Texas, United States|Bellaire Dermatology Associate /ID# 153987, Bellaire, Texas, United States|Modern Research Associates, PL /ID# 154043, Dallas, Texas, United States|Menter Dermatology Res Inst /ID# 153985, Dallas, Texas, United States|Center for Clinical Studies /ID# 154005, Houston, Texas, United States|Suzanne Bruce and Associates /ID# 154026, Houston, Texas, United States|Derm Clin Res Ctr San Antonio /ID# 153978, San Antonio, Texas, United States|Progressive Clinical Research /ID# 154149, San Antonio, Texas, United States|Stephen Miller, MD PA /ID# 154077, San Antonio, Texas, United States|Center for Clinical Studies - Webster TX /ID# 154150, Webster, Texas, United States|Virginia Clinical Research /ID# 154016, Norfolk, Virginia, United States|Dermatology Associates /ID# 153988, Seattle, Washington, United States|Premier Clinical Research /ID# 154284, Spokane, Washington, United States|Woden Dermatology /ID# 154307, Phillip, Australian Capital Territory, Australia|St George Dermatology & Skin Cancer Centre /ID# 154308, Kogarah, New South Wales, Australia|Specialist Connect Pty Ltd /ID# 154311, Woolloongabba, Queensland, Australia|North Eastern Health Specialis /ID# 154309, Hectorville, South Australia, Australia|Skin Health Institute Inc /ID# 154305, Carlton, Victoria, Australia|Sinclair Dermatology /ID# 154310, East Melbourne, Victoria, Australia|Fremantle Dermatology /ID# 154306, Fremantle, Western Australia, Australia|Krankenanstalt Rudolfstiftung /ID# 154300, Vienna, Wien, Austria|Medizinische Universität Wien /ID# 154302, Vienna, Wien, Austria|Landeskrankenhaus Feldkirch /ID# 154303, Feldkirch, Austria|CUB Hospital Erasme /ID# 154293, Brussels, Bruxelles-Capitale, Belgium|UZ Brussel /ID# 154295, Jette, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 154294, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 154296, Gent, Oost-Vlaanderen, Belgium|Centre Hosp. Univ. de Liege /ID# 154297, Liege, Belgium|Grand Hopital de Charleroi /ID# 154298, Loverval, Belgium|Dermatology Research Institute Inc. /ID# 153850, Calgary, Alberta, Canada|Kirk Barber Research, CA /ID# 153840, Calgary, Alberta, Canada|Stratica Medical /ID# 153848, Edmonton, Alberta, Canada|Dr. Chih-ho Hong Medical Inc. /ID# 153842, Surrey, British Columbia, Canada|Enverus Medical Research /ID# 153851, Surrey, British Columbia, Canada|Karma Clinical Trials /ID# 153876, St. John's, Newfoundland and Labrador, Canada|Eastern Canada Cutaneous Resea /ID# 153870, Halifax, Nova Scotia, Canada|CCA Medical Research /ID# 153859, Ajax, Ontario, Canada|Kingsway Clinical Research /ID# 154292, Etobicoke, Ontario, Canada|Dermatrials Research /ID# 153847, Hamilton, Ontario, Canada|Guenther Derma Res Ctr, CA /ID# 153841, London, Ontario, Canada|Lynderm Research Inc. /ID# 153861, Markham, Ontario, Canada|DermEdge Research Inc. /ID# 153843, Mississauga, Ontario, Canada|North Bay Dermatology Centre /ID# 153845, North Bay, Ontario, Canada|The Centre for Clinical Trials /ID# 153871, Oakville, Ontario, Canada|Dermatology Ottawa Research Centre /ID# 153862, Ottawa, Ontario, Canada|SKIN Centre for Dermatology /ID# 153853, Peterborough, Ontario, Canada|The Center For Dermatology /ID# 153844, Richmond Hill, Ontario, Canada|York Dermatology Clinic and Research Centre /ID# 153860, Richmond Hill, Ontario, Canada|Toronto Research Centre /ID# 153852, Toronto, Ontario, Canada|Research Toronto /ID# 153854, Toronto, Ontario, Canada|K. Papp Clinical Research /ID# 153855, Waterloo, Ontario, Canada|XLR8 Medical Research /ID# 153858, Windsor, Ontario, Canada|Windsor Clinical Research, Inc /ID# 153877, Windsor, Ontario, Canada|Innovaderm Research Inc. /ID# 153846, Montreal, Quebec, Canada|Ctr Derma du QC Metropolitain /ID# 153856, Quebec City, Quebec, Canada|CCBR Clinical Research Brno /ID# 153887, Brno, Czechia|Dermamedica, s. r. o. /ID# 153890, Nachod, Czechia|Clinic of dermatology VZHLED /ID# 153898, Orlová, Czechia|Dermatovenerology and Correcti /ID# 153888, Prague 1, Czechia|Clintrial s.r.o. /ID# 153889, Prague, Czechia|CCBR Czech Prague s.r.o. /ID# 153897, Prague, Czechia|Terveystalo Tampere /ID# 154118, Tampere, Finland|Mehilainen Turku /ID# 154120, Turku, Finland|Charles Nicolle CHU Rouen /ID# 205842, Rouen CEDEX, Seine-Maritime, France|Hopital de L'archet 2 /ID# 153948, Nice, France|Hopital Larrey /ID# 153951, Toulouse, France|Universitaetsklinik Heidelberg /ID# 153910, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 154093, Erlangen, Bayern, Germany|Universitatsklinikum Frankfurt /ID# 153891, Frankfurt, Hessen, Germany|Universitatsklinikum Munster /ID# 153895, Munster, Niedersachsen, Germany|CMS3 Company for Medical Study /ID# 201318, Selters, Rheinland-Pfalz, Germany|Universitaetsklinikum Leipzig /ID# 153909, Leipzig, Sachsen, Germany|Univ Hosp Schleswig-Holstein /ID# 153916, Kiel, Schleswig-Holstein, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH /ID# 201316, Kiel, Schleswig-Holstein, Germany|Charité Universitätsmedizin Campus Mitte /ID# 153896, Berlin, Germany|ISA GmbH /ID# 153907, Berlin, Germany|Hautzentrum Niesmann Othlingha /ID# 154289, Bochum, Germany|Universitaetsklinikum Bonn /ID# 154094, Bonn, Germany|Klinikum Darmstadt GmbH /ID# 153893, Darmstadt, Germany|Universitaetklinikum Dresden /ID# 153906, Dresden, Germany|Universitaetsmedizin Goettinge /ID# 154091, Göttingen, Germany|Univ Klinik Eppendorf Hamburg /ID# 154089, Hamburg, Germany|Klinische Forschung GmbH /ID# 154290, Hamburg, Germany|TFS Trial Form Support GmbH /ID# 153894, Hamburg, Germany|Drs Scholz/Sebastian/Schilling /ID# 153892, Mahlow, Germany|Univ Johannes Gutenberg /ID# 154092, Mainz, Germany|TU Uniklinik Munchen /ID# 153915, Munich, Germany|Klinische Forschung Schwerin /ID# 154291, Schwerin, Germany|Universitatsklinikum Tubingen /ID# 153912, Tuebingen, Germany|Hoffmann, Witten, DE /ID# 153917, Witten, Germany|Centroderm Wuppertal /ID# 153914, Wuppertal, Germany|Nagoya City University Hospital /ID# 153866, Nagoya-shi, Aichi, Japan|Fukuoka University Hospital /ID# 153864, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 156320, Kurume-shi, Fukuoka, Japan|Fukushima Medical University Hospital /ID# 153873, Fukushima-shi, Fukushima, Japan|Gifu University Hospital /ID# 169410, Gifu-shi, Gifu, Japan|JR Sapporo Hospital /ID# 201963, Sapporo-shi, Hokkaido, Japan|Medical Cooperation Kojinkai Sapporo Skin Clinic /ID# 154083, Sapporo-shi, Hokkaido, Japan|Kobe University Hospital /ID# 170706, Kobe, Hyogo, Japan|Iwate Medical University Hospital /ID# 170843, Morioka-shi, Iwate, Japan|Kagawa University Hospital /ID# 168656, Kita-gun, Kagawa, Japan|Japan Organization of Occupational Health and Society Kanto Rosai Hospital /ID# 169172, Kawasaki-shi, Kanagawa, Japan|National Hospital Organization Sagamihara National Hospital /ID# 153867, Sagamihara-shi, Kanagawa, Japan|Yokohama City University Hospital /ID# 168831, Yokohama-shi, Kanagawa, Japan|University Hospital Kyoto Prefectural University of Medicine /ID# 169415, Kyoto-shi, Kyoto, Japan|Mie University Hospital /ID# 156317, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 169006, Sendai-shi, Miyagi, Japan|Shinshu University Hospital /ID# 170937, Matsumoto-shi, Nagano, Japan|Nagasaki University Hospital /ID# 170219, Nagasaki-shi, Nagasaki, Japan|Okayama University Hospital /ID# 200631, Okayama-shi, Okayama, Japan|Kansai Medical University Hospital /ID# 170884, Hirakata-shi, Osaka, Japan|Kindai University Hospital /ID# 153865, Osaka-sayama, Osaka, Japan|Osaka City University Hospital /ID# 153869, Osaka-shi, Osaka, Japan|Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 156319, Osaka-shi, Osaka, Japan|Osaka University Hospital /ID# 156321, Suita-shi, Osaka, Japan|Kyoto University Hospital /ID# 156318, Kyoto, Sakyo-ku, Japan|Hamamatsu University Hospital /ID# 170132, Hamamatsu-shi, Shizuoka, Japan|Jichi Medical University Hospital /ID# 154286, Shimotsuke-shi, Tochigi, Japan|Juntendo University Hospital /ID# 200292, Bunkyo-ku, Tokyo, Japan|Tokyo Teishin Hospital /ID# 165912, Chiyoda-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 153863, Chuo-ku, Tokyo, Japan|Teikyo University Hospital /ID# 154287, Itabashi-ku, Tokyo, Japan|NTT Medical Center Tokyo /ID# 154082, Shinagawa-ku, Tokyo, Japan|Tokyo Medical University Hospital /ID# 153874, Shinjuku-ku, Tokyo, Japan|Hokkaido University Hospital /ID# 154285, Sapporo, Japan|The Jikei University Hospital /ID# 154080, Tokyo, Japan|Nippon Medical School Hospital /ID# 154084, Tokyo, Japan|Tokyo Yamate Medical Center /ID# 153868, Tokyo, Japan|Nihon University Itabashi Hosp /ID# 154081, Tokyo, Japan|Yamaguchi University Hospital Institutional Review Board /ID# 156322, Ube-shi, Japan|Pusan National University Hosp /ID# 153485, Busan, Busan Gwang Yeogsi, Korea, Republic of|Gachon University Gil Medical Center /ID# 153489, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 153488, Gwangju, Jeonranamdo, Korea, Republic of|Konkuk University Medical Ctr /ID# 153483, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 153487, Seoul, Seoul Teugbyeolsi, Korea, Republic of|St. Mary's Hospital of the Cat /ID# 153486, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea Universtiy Guro Hospital /ID# 153490, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 153484, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 153491, Seoul, Korea, Republic of|Hospital Universitario ""Dr. José Eleuterio González"" /ID# 153882, Monterrey, Nuevo Leon, Mexico|Derma Norte del Bajio S.C. /ID# 153880, Aguascalientes, Mexico|Centro de Dermatologia de Mont /ID# 153881, Monterrey, Mexico|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu /ID# 153473, Wrocław, Dolnoslaskie, Poland|Pratia MCM Krakow /ID# 153472, Krakow, Malopolskie, Poland|Uniwersyteckie Centrum Kliniczne /ID# 153471, Gdansk, Mazowieckie, Poland|Przychodnia Specjalistyczna High-Med /ID# 153468, Warsaw, Mazowieckie, Poland|Klinika Ambroziak Sp. z o.o. /ID# 153467, Warsaw, Mazowieckie, Poland|Osteo-Medic S.C. /ID# 156535, Białystok, Podlaskie, Poland|Centrum Badań Klinicznych Pi-House /ID# 153884, Gdansk, Pomorskie, Poland|Dermoklinika Medical Center /ID# 153470, Lodz, Poland|KO-MED Centra Kliniczne Lublin /ID# 153469, Lublin, Poland|SOLUMED Sp. z o.o., Sp.k. /ID# 153466, Poznan, Poland|CCA Braga - Hospital de Braga /ID# 156323, Braga, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 153462, Lisboa, Portugal|CHP, EPE- Hospital Geral de Sa /ID# 153464, Porto, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 153463, Porto, Portugal|Hospital Santa Creu i Sant Pau /ID# 154125, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 153465, Barcelona, Spain|Hospital Infanta Leonor /ID# 154121, Madrid, Spain|Hospital General U de Valencia /ID# 154126, Valencia, Spain|Hudkliniken SU/Sahlgrenska /ID# 154132, Goteborg, Sweden|Karolinska Univ Sjukhuset /ID# 154131, Solna, Sweden|Sodersjukhuset /ID# 154130, Stockholm, Sweden|National Cheng Kung University Hospital /ID# 154135, Tainan City, Tainan, Taiwan|National Taiwan Univ Hosp /ID# 154136, Taipei City, Taipei, Taiwan|Taipei Med Univ Shuang Ho Hosp /ID# 154134, New Taipei City, Taiwan|Taiwan Adventist Hospital /ID# 154137, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03047395"
159,"NCT03035279","A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer",,"Terminated","No Results Available","Colorectal Cancer","Drug: SC-006|Drug: ABBV-181","Number of participants with dose-limiting toxicities (DLT)|Overall Survival (OS)|Progression Free Survival (PFS)|Time to Cmax (Tmax) of SC-006|Area under the plasma concentration-time curve within a dosing interval (AUC) of SC-006|Duration of Clinical Benefit (DOCB)|Objective Response Rate (ORR)|Terminal half life (T1/2) of SC-006|Duration of response (DOR)|Observed plasma concentrations at trough (Ctrough) of SC-006|Clinical Benefit Rate (CBR) defined as CR, PR, or stable disease (SD)|Maximum observed serum concentration (Cmax) of SC-006","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-312","March 8, 2017","March 28, 2019","March 28, 2019","January 30, 2017",,"April 29, 2019","Highlands Oncology Group /ID# 201182, Fayetteville, Arkansas, United States|University of California, Los Angeles /ID# 160882, Los Angeles, California, United States|University of Michigan Hospitals /ID# 167101, Ann Arbor, Michigan, United States|Mayo Clinic - Rochester /ID# 160884, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 160883, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center /ID# 160881, New York, New York, United States|Carolina BioOncology Institute /ID# 202712, Huntersville, North Carolina, United States|Oklahoma University /ID# 202713, Oklahoma City, Oklahoma, United States|Tennessee Oncology-Nashville Centennial /ID# 160880, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03035279"
160,"NCT03033511","A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)","MERU","Terminated","No Results Available","Small Cell Lung Cancer","Drug: Placebo for dexamethasone|Drug: Placebo for rovalpituzumab tesirine|Drug: Rovalpituzumab tesirine|Drug: Dexamethasone","Progression-free survival (PFS) determined by a Central Radiographic Assessment Committee (CRAC) in participants with ED SCLC tumors with a high level of DLL3 expression|Overall survival (OS) in participants with ED SCLC tumors with a high level of DLL3 expression|Change in patient reported outcomes (PROs)--physical functioning domain|Progression-free survival (PFS) per RECIST v1.1 in all randomized participants|Overall survival (OS) in all randomized participants","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","748","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-298|2016-003503-64","February 7, 2017","November 20, 2019","November 20, 2019","January 26, 2017",,"December 5, 2019","Clearview Cancer Institute /ID# 156699, Huntsville, Alabama, United States|University of South Alabama /ID# 160975, Mobile, Alabama, United States|Highlands Oncology Group /ID# 156722, Fayetteville, Arkansas, United States|Marin Cancer Care /ID# 159207, Greenbrae, California, United States|Ucsd /Id# 157764, La Jolla, California, United States|LA Hem-Oncology Med Group /ID# 156717, Los Angeles, California, United States|Palo Alto Veterans Institute for Research /ID# 203695, Palo Alto, California, United States|St Jude Hospital dba St Joseph /ID# 156526, Santa Rosa, California, United States|Icri /Id# 157765, Whittier, California, United States|Kaiser Permanente Lone Tree /ID# 159331, Lone Tree, Colorado, United States|Christiana Care Health Service /ID# 159212, Newark, Delaware, United States|Holy Cross Hospital /ID# 156716, Fort Lauderdale, Florida, United States|University of Florida /ID# 155799, Gainesville, Florida, United States|Memorial Cancer Institute /ID# 156673, Hollywood, Florida, United States|Memorial Cancer Institute /ID# 164052, Hollywood, Florida, United States|Cancer Specialists of North Florida - Southpoint /ID# 156595, Jacksonville, Florida, United States|Georgia Cancer Center /ID# 201894, Atlanta, Georgia, United States|Southeastern Regional Medical /ID# 163064, Newnan, Georgia, United States|St. Luke's Mountain States Tumor Institute /ID# 156691, Boise, Idaho, United States|NorthShore University HealthSystem - Evanston /ID# 156664, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 156685, Harvey, Illinois, United States|Goshen Center for Cancer Care /ID# 156682, Goshen, Indiana, United States|Ashland-Bellefonte Cancer Ctr /ID# 202901, Ashland, Kentucky, United States|University of Louisville /ID# 156683, Louisville, Kentucky, United States|Ochsner Clinic Foundation /ID# 159136, New Orleans, Louisiana, United States|Henry Ford Health System /ID# 156712, Detroit, Michigan, United States|Edward W. Sparrow Hosp Assn /ID# 156590, Lansing, Michigan, United States|Mayo Clinic - Rochester /ID# 160181, Rochester, Minnesota, United States|MidAmerica Division, Inc. /ID# 163530, Kansas City, Missouri, United States|Billings Clinic /ID# 201788, Billings, Montana, United States|Nebraska Hematology Oncology /ID# 156534, Lincoln, Nebraska, United States|MD Anderson Cancer Center at Cooper - Camden /ID# 156681, Camden, New Jersey, United States|Montefiore Medical Center /ID# 201845, Bronx, New York, United States|Northwell Health, Monter Cance /ID# 159252, Lake Success, New York, United States|Icahn School of Med Mt. Sinai /ID# 159210, New York, New York, United States|Stony Brook University Hospital /ID# 159272, Stony Brook, New York, United States|Duke University Medical Center /ID# 156706, Durham, North Carolina, United States|Cone Health /ID# 156689, Greensboro, North Carolina, United States|Cone Health /ID# 163612, Greensboro, North Carolina, United States|Eastern Carolina University /ID# 159264, Greenville, North Carolina, United States|Gabrail Cancer Center Research /ID# 156667, Canton, Ohio, United States|Kaiser Permanente, NW /ID# 201793, Portland, Oregon, United States|Thomas Jefferson University /ID# 156719, Philadelphia, Pennsylvania, United States|VA Pittsburgh HealthcareSystem /ID# 159284, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital /ID# 160834, Providence, Rhode Island, United States|Sarah Cannon Research Institute-Chattanooga /ID# 202933, Chattanooga, Tennessee, United States|Thompson Cancer Survival Ctr /ID# 202460, Knoxville, Tennessee, United States|Tennessee Oncology-Nashville Centennial /ID# 161168, Nashville, Tennessee, United States|Univ Medical Ctr Brackenridge /ID# 155798, Austin, Texas, United States|Parkland Health and Hosp Syste /ID# 170933, Dallas, Texas, United States|UT Southwestern Medical Center /ID# 157848, Dallas, Texas, United States|Houston Methodist Hospital - Scurlock Tower /ID# 202323, Houston, Texas, United States|Medical Oncology Associates /ID# 156715, Spokane, Washington, United States|West Virginia Univ School Med /ID# 156687, Morgantown, West Virginia, United States|Coffs Harbour Hospital /ID# 158880, Coffs Harbour, New South Wales, Australia|Gosford Hospital /ID# 158884, Gosford, New South Wales, Australia|Newcastle Private Hospital /ID# 203506, Lambton Heights, New South Wales, Australia|Royal North Shore Hospital /ID# 158881, Saint Leonards, New South Wales, Australia|Calvary North Adelaide Hospita /ID# 161701, Adelaide, South Australia, Australia|Sunshine Hospital /ID# 161700, St Albans, Victoria, Australia|Affinity Clinical Research Ser /ID# 158887, Nedlands, Australia|SMZ Baumgartner Höhe, Otto-Wagner-Spital und Pflegezentrum /ID# 201776, Vienna, Wien, Austria|Krankenhaus Nord - Klinik Floridsdorf /ID# 201768, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 159563, Graz, Austria|Ordensklinikum Linz GmbH, Elisabethinen /ID# 159564, Linz, Austria|Salzburger Landeskliniken (SALK) /ID# 201779, Salzburg, Austria|Bobruysk Interdistrict Onco. /ID# 169393, Bobruisk, Belarus|Belarus Cancer Center N.N. Alexandrov /ID# 159383, Lesnoy, Belarus|Mogilev Reg Clin Oncology Dis /ID# 159384, Mogilev, Belarus|CHU Saint-Pierre /ID# 159009, Bruxelles, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 159006, Charleroi, Hainaut, Belgium|ZNA Middelheim /ID# 159007, Antwerp, Belgium|Hopital de Jolimont /ID# 159005, Haine Saint Paul, Belgium|CHU Charleroi (Vesale) /ID# 159008, Montigny-le-tilleul, Belgium|Hospital Evangelico de Cachoei /ID# 159657, Cachoeiro de Itapemirim, Espirito Santo, Brazil|Liga Norte Rio Grandense Cont. /ID# 159011, Natal, Rio Grande Do Norte, Brazil|Associação Hospital de Caridade Ijuí - Centro de Tratamento de Cancer - CACON /ID# 159013, Ijuí, Rio Grande Do Sul, Brazil|Associação Hospital Beneficente São Vicente de Paulo - Hospital São Vicente de P /ID# 159661, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Sao Lucas da PUCRS /ID# 159662, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos /ID# 159012, Barretos, Sao Paulo, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 159659, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Inca /Id# 159658, Rio de Janeiro, Brazil|UMHAT Tsaritsa Joanna - ISUL /ID# 159638, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 159639, Sofia, Bulgaria|British Columbia Cancer Agency /ID# 163721, Surrey, British Columbia, Canada|Brampton Civic Hospital /ID# 204425, Brampton, Ontario, Canada|R.S. McLaughlin Durham Regional /ID# 170870, Oshawa, Ontario, Canada|Princess Margaret /ID# 170868, Toronto, Ontario, Canada|Windsor Regional Cancer Centre /ID# 170869, Windsor, Ontario, Canada|Iucpq /Id# 159530, Québec, Quebec, Canada|Fujian Provincial Cancer Hospital /ID# 204864, Fuzhou, Fujian, China|Harbin Medical University Cancer Hospital /Id# 203638, Harbin, Heilongjiang, China|Hubei Cancer Hospital /ID# 202886, Wuhan, Hubei, China|Jilin Cancer Hosptial /ID# 204060, Changchun, Jilin, China|The Affiliated Cancer Hospital of Xinjiang Medical university /ID# 203641, Urumqi, Xinjiang, China|Yunnan Cancer Hospital /ID# 204911, Kunming, Yunnan, China|Sir Run Run Shaw Hospital /ID# 206802, Hangzhou, Zhejiang, China|Zhejiang Cancer hospital /ID# 204640, Hangzhou, Zhejiang, China|Jiangsu Province Hospital /ID# 205183, Nanjing, China|4th Military Medical Universit /ID# 203986, Xi'an, China|First Affiliated Hospital of Xi'an Jiaotong University /ID# 203733, Xi'an, China|Henan Cancer Hospital /ID# 203983, Zhengzhou, Henan, China|Henan Cancer Hospital /ID# 204636, Zhengzhou, Henan, China|Klinicki bolnicki centar Sestre milosrdnice /ID# 159090, Zagreb, Grad Zagreb, Croatia|Klinika za plucne bolesti Jordanovac /ID# 159505, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Rijeka /ID# 159504, Rijeka, Primorsko-goranska Zupanija, Croatia|Thomayerova nemocnice /ID# 159062, Prague, Praha 4, Czechia|Nemocnice Rudolfa a Stefanie /ID# 159655, Benesov, Czechia|Nemocnice Horovice a.s. /ID# 161186, Horovice, Czechia|Vitkovicka nemocnice a. s. /ID# 161187, Ostrava, Czechia|FN Plzen /ID# 204097, Plzen, Czechia|Oblastni Nemocnice Pribram /ID# 159654, Pribram, Czechia|Rigshospitalet /ID# 158055, Copenhagen Ø, Hovedstaden, Denmark|Herlev Hospital /ID# 158053, Herlev, Hovedstaden, Denmark|Aalborg University Hospital /ID# 203737, Aalborg, Nordjylland, Denmark|Odense Universitets Hospital /ID# 158054, Odense C, Syddanmark, Denmark|East Tallinn Central Hospital /ID# 160019, Tallinn, Estonia|North Estonian Medical Centre /ID# 159779, Tallinn, Estonia|Docrates Cancer Center /ID# 159591, Helsinki, Finland|CHU Hopital Nord /ID# 160543, Marseille, Bouches-du-Rhone, France|Hopital Haut-Lévêque /ID# 160547, Pessac CEDEX, Gironde, France|CHU Calmette /ID# 202706, Lille, Hauts-de-France, France|Institut Curie /ID# 207514, Paris CEDEX 05, Ile-de-France, France|Centre Leon Berard /ID# 160550, Lyon CEDEX 08, Rhone, France|Centre Hosp Intercommunal de Creteil /ID# 162686, Creteil, Val-de-Marne, France|Hopital Tenon /ID# 160541, Paris, France|Hospital Pontchaillou /ID# 160544, Rennes, France|Nouvel Hopital Civil (NHC) /ID# 204427, Strasbourg, France|Hopital Larrey /ID# 204290, Toulouse, France|KH Martha-Maria Halle Dolau /ID# 158794, Halle (Saale), Sachsen-Anhalt, Germany|Charité Universitätsmedizin Campus Mitte /ID# 158783, Berlin, Germany|Evangelische Lungenklinik Berl /ID# 158935, Berlin, Germany|Asklepios Fachkliniken M. Gaut /ID# 158789, Gauting, Germany|Thoraxklinik Heidelberg gGmbH /ID# 158871, Heidelberg, Germany|Lungenklinik Hemer /ID# 158790, Hemer, Germany|Klinikum Kassel /ID# 158786, Kassel, Germany|Klinik Loewenstein GmbH /ID# 158870, Löwenstein, Germany|Fachkliniken Wangen /ID# 160779, Wangen, Germany|Metropolitan General Hospital /ID# 202422, Cholargos, Attiki, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 159160, Athens, Greece|Metropolitan Hospital /ID# 159157, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 202409, Heraklion, Greece|University Hospital of Ioannin /ID# 159158, Ioannina, Greece|General Oncological Hospital /ID# 159159, Nea Kifisia, Greece|Euromedica General Clinic /ID# 159156, Thessaloniki, Greece|Queen Elizabeth Hospital /ID# 159565, Kowloon, Hong Kong|Princess Margaret Hospital /ID# 162810, Lai Chi Kok, Hong Kong|Tuen Mun Hospital /ID# 162435, Tuen Mun, Hong Kong|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 158962, Miskolc, Borsod-Abauj-Zemplen, Hungary|Orszagos Koranyi Pulmonologiai Intezet /ID# 158953, Budapest XII, Budapest, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz - Pulmonologia /ID# 202466, Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|Semmelweis Egyetem /ID# 158955, Budapest, Hungary|Csongrad Megyei Mellkasi Beteg /ID# 158952, Deszk, Hungary|St. James's Hospital /ID# 159712, Dublin 8, Dublin, Ireland|Cork University Hospital /ID# 159715, Cork, Ireland|St Vincent's University Hosp /ID# 161678, Dublin, Ireland|Beaumont Hospital /ID# 159711, Dublin, Ireland|University Hospital Limerick /ID# 159714, Limerick, Ireland|University Hospital Waterford /ID# 159713, Waterford, Ireland|Rabin Medical Center /ID# 159764, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 161467, Tel Aviv-Yafo, Tel-Aviv, Israel|Soroka Medical Ctr /ID# 159762, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 201883, Be'er Ya'akov, Israel|Rambam Health Care Campus /ID# 202336, Haifa, Israel|Hadassah /ID# 159763, Jerusalem, Israel|Meir Medical Center /ID# 159761, Kfar Saba, Israel|Sheba Medical Center /ID# 159760, Ramat Gan, Israel|IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 160898, Meldola, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 160874, Rome, Lazio, Italy|AUSL 8 Arezzo Ospedale San Don /ID# 160897, Arezzo, Italy|A.O.U. San Luigi Gonzaga /ID# 158916, Orbassano, Italy|Ospedale Santa Maria delle Cro /ID# 158911, Ravenna, Italy|IFO Istituto Nazionale Tumori /ID# 158912, Rome, Italy|Aichi Cancer Center Hospital /ID# 164976, Nagoya-shi, Aichi, Japan|National Cancer Center Hospital East /ID# 165721, Kashiwa-shi, Chiba, Japan|Kyushu University Hospital /ID# 165722, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 164595, Kurume-shi, Fukuoka, Japan|Kanazawa University Hospital /ID# 165127, Kanazawa, Ishikawa, Japan|Kanagawa Cardiovascular and Respiratory Center /ID# 165015, Yokohama-shi, Kanagawa, Japan|Yokohama City University Hospital /ID# 165746, Yokohama-shi, Kanagawa, Japan|Japanese Red Cross Okayama Hospital /ID# 165157, Okayama-shi, Okayama, Japan|Kansai Medical University Hospital /ID# 165054, Hirakata-shi, Osaka, Japan|Kindai University Hospital /ID# 166395, Osaka-sayama, Osaka, Japan|Shizuoka Cancer Center /ID# 166272, Sunto-gun, Shizuoka, Japan|Tokushima University Hospital /ID# 166105, Tokushima-shi, Tokushima, Japan|National Cancer Center Hospital /ID# 166547, Chuo-ku, Tokyo, Japan|Showa University Hospital /ID# 165575, Shinagawa-ku, Tokyo, Japan|Hyogo Cancer Center /ID# 165138, Akashi, Japan|National Hospital Organization Himeji Medical Center /ID# 165899, Himeji, Japan|Matsusaka City Hospital /ID# 166156, Matsusaka-shi, MIE, Japan|Osaka City General Hospital /ID# 165714, Osaka, Japan|Hokkaido Cancer Center /ID# 165236, Sapporo, Japan|Sendai Kousei Hospital /ID# 166491, Sendai, Japan|Wakayama Medical University /ID# 165946, Wakayama, Japan|Kanagawa Cancer Center /ID# 165814, Yokohama, Japan|Dong-A University Hospital /ID# 159305, Busan, Busan Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 161281, Seongnam-si, Gyeonggido, Korea, Republic of|Kyungpook National University Chilgok Hospital /ID# 159301, Daegu, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 159304, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Guro Hospital /ID# 159302, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Chungbuk National University /ID# 159300, Cheongju-si, Korea, Republic of|Severance Hospital /ID# 159297, Seoul, Korea, Republic of|Asan Medical Center /ID# 159299, Seoul, Korea, Republic of|Pauls Stradins Clinical /ID# 158715, Riga, Latvia|Riga East Clinical University /ID# 158716, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 160016, Kovno, Kaunas, Lithuania|Klaipeda University Hospital /ID# 160018, Klaipeda, Lithuania|National Cancer Institute /ID# 160017, Vilnius, Lithuania|Centro de Invest Clin Chapulte /ID# 160965, Morelia, Michoacan, Mexico|Health Pharma professional Ser /ID# 160734, Ciudad de México, Mexico|Meander Medisch Centrum /ID# 159064, Amersfoort, Netherlands|Rijnstate /ID# 159063, Arnhem, Netherlands|Amphia Ziekenhuis /ID# 159065, Breda, Netherlands|Catharina Ziekenhuis /ID# 158082, Eindhoven, Netherlands|Maastricht Universitair Medisch Centrum /ID# 161669, Maastricht, Netherlands|Jeroen Bosch Ziekenhuis /ID# 158081, S Hertogenbosch, Netherlands|Universitair Medisch Centrum Utrecht /ID# 158083, Utrecht, Netherlands|Akershus universitetssykehus /ID# 201682, Nordbyhagen, Akershus, Norway|Drammen Sykehus /ID# 159572, Drammen, Buskerud, Norway|Haukeland University Hospital /ID# 159573, Bergen, Hordaland, Norway|St. Olavs Hospital HF /ID# 163110, Trondheim, Sor-Trondelag, Norway|Radiumhospitalet, OUS /ID# 159574, Oslo, Norway|Stavanger Universitetssykehus /ID# 159575, Stavanger, Norway|Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 159604, Rzeszów, Podkarpackie, Poland|Wojewodzki Szpital Specjalisty /ID# 159603, Bytom, Poland|Szpitale Pomorskie Sp. z o.o /ID# 159605, Gdynia, Poland|Centro Hospitalar Lisboa Norte, EPE /ID# 159957, Lisbon, Lisboa, Portugal|IPO Lisboa FG, EPE /ID# 159949, Lisboa, Portugal|Hospital da Luz, SA /ID# 159954, Lisbon, Portugal|Unidade Local Saude Matosinhos /ID# 159950, Matosinhos, Portugal|Centro Hospitalar do Porto EPE /ID# 203582, Porto, Portugal|Hospital CUF Porto /ID# 159955, Porto, Portugal|IPO Porto FG, EPE /ID# 159956, Porto, Portugal|National Medical Research Cntr /ID# 169885, Moscow, Moskovskaya Oblast, Russian Federation|Arkhangelsk clinical oncology /ID# 159367, Arkhangelsk, Russian Federation|Kaluga Regional Clinical Oncol /ID# 160180, Kaluga, Russian Federation|Clinical Onco Dispensary /ID# 159365, Omsk, Russian Federation|PMI Euromedservice /ID# 159369, Pushkin, Russian Federation|LLC Novaya Clinica /ID# 205523, Pyatigorsk, Russian Federation|OOO Centre of Palliative Medicine De Vita /ID# 206855, Saint Petersburg, Russian Federation|Ogarev Mordovia State Univ /ID# 205742, Saransk, Russian Federation|Smolensk Regional Onc Clin Dis /ID# 159372, Smolensk, Russian Federation|LLC BioEq Ltd. /ID# 159368, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 159370, St. Petersburg, Russian Federation|Clinical Center Serbia /ID# 160902, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 160903, Belgrade, Beograd, Serbia|Clinical Center of Nis /ID# 160905, NIS, Nisavski Okrug, Serbia|Institut za onkologiju i radio /ID# 160904, Belgrade, Serbia|Institute For Pulmonary Diseas /ID# 164250, Sremska Kamenica, Serbia|Cancercare Langenhoven Drive Oncology Centre /ID# 159126, Port Elizabeth, Eastern Cape, South Africa|Life Wilgers Hospital /ID# 158873, Pretoria, Gauteng, South Africa|Mary Potter Oncology Centre /ID# 158877, Pretoria, Gauteng, South Africa|The Oncology Centre /ID# 158872, Durban, Kwazulu-Natal, South Africa|Cape Town Oncology Trials /ID# 201311, Cape Town, Western Cape, South Africa|Cancercare Outeniqua Oncology Unit /ID# 200689, George, Western Cape, South Africa|Hospital Regional de Malaga /ID# 164371, Málaga, Malaga, Spain|Hospital Teresa Herrera /ID# 164368, A Coruna, Spain|H. Del Mar, Barcelona /ID# 159690, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 159708, Barcelona, Spain|Fundacion Jimenez Diaz /ID# 159693, Madrid, Spain|Hospital Clin Univ San Carlos /ID# 159706, Madrid, Spain|Hospital Universitario La Paz /ID# 159692, Madrid, Spain|Dup_Hosp Clin Univ Lozano Blesa /ID# 159709, Zaragoza, Spain|Centralsjukhuset, Karlstad /ID# 163451, Karlstad, Varmlands Lan, Sweden|Sahlgrenska US Gbg /ID# 159524, Göteborg, Vastra Gotalands Lan, Sweden|University Hospital Linkoping /ID# 159046, Linkoping, Sweden|Karolinska Univ Sjukhuset /ID# 159649, Solna, Sweden|Uppsala University Hospital /ID# 159052, Uppsala, Sweden|Hopitaux Universitaires de Geneve /ID# 160603, Genève, Geneve, Switzerland|Kantonsspital St. Gallen /ID# 160604, St. Gallen, Sankt Gallen, Switzerland|Universitaetsspital Basel /ID# 160605, Basel, Switzerland|Luzerner Kantonsspital /ID# 160607, Luzern, Switzerland|Kantonsspital Winterthur /ID# 161379, Winterthur, Switzerland|China Medical University Hosp /ID# 158981, Taichung City, Taichung, Taiwan|National Cheng Kung University Hospital /ID# 158799, Tainan City, Tainan, Taiwan|National Taiwan Univ Hosp /ID# 159049, Taipei City, Taipei, Taiwan|Tri-Service General Hospital /ID# 158980, Taipei City, Taipei, Taiwan|Dalin Tzu Chi General Hospital /ID# 158983, Dalin Township, Taiwan|Kaohsiung Medical University /ID# 158798, Kaohsiung, Taiwan|Taichung Veterans General Hosp /ID# 159047, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 203699, Taipei City, Taiwan|Hacettepe University Medical Faculty /ID# 159242, Altindağ, Ankara, Turkey|Erciyes University Medical Fac /ID# 202269, Melikgazi, Kayseri, Turkey|Ataturk Gogus Hastalikl /ID# 159556, Ankara, Turkey|Akdeniz Universitesi Tip Fakul /ID# 160791, Antalya, Turkey|Bezmi alem Vakif Universitesi /ID# 202267, Istanbul, Turkey|Istanbul Medeniyet Universites /ID# 200126, Istanbul, Turkey|Ege University Medical Faculty /ID# 159243, Izmir, Turkey|Dr. Suat Seren Gogus Has /ID# 159244, Izmir, Turkey|Inonu University /ID# 159245, Malatya, Turkey|CI Zaporizhzhia Regional Clinical Oncological Dispensary /ID# 159131, Zaporizhzhia, Zaporizka Oblast, Ukraine|Chernivetskyi Reg Clin Onc Hos /ID# 159864, Chernivtsi, Ukraine|Municipal institution Multifie /ID# 159130, Dnipro, Ukraine|Regional Center of Oncology /ID# 159132, Kharkiv, Ukraine|Medical and Diagnostic Center /ID# 165543, Kropyvnytskyi, Ukraine|Volyn Regional Medical Oncology Centre /ID# 159133, Lutsk, Ukraine|Communal Nonprofit Enterprise ""Central City Clinical Hospital"" of Uzhhorod City /ID# 159865, Uzhhorod, Ukraine|Cheltenham General Hospital /ID# 169096, Cheltenham, Gloucestershire, United Kingdom|Queen Elizabeth Medical Centre /ID# 162899, Birmingham, United Kingdom|The Royal Bournemouth Hospital /ID# 159039, Bournemouth, United Kingdom|Colchester General Hospital /ID# 159042, Colchester, United Kingdom|Hereford County Hospital /ID# 159038, Hereford, United Kingdom|St. George's Healthcare NHS /ID# 202416, London, United Kingdom|Charing Cross Hospital /ID# 161399, London, United Kingdom|Maidstone Hospital /ID# 159043, Maidstone, United Kingdom|Christie NHS Foundation Trust /ID# 159037, Manchester, United Kingdom|Freeman Hospital /ID# 159044, Newcastle Upon Tyne, United Kingdom|Torbay Hospital - So Devon HC /ID# 159041, Torquay, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03033511"
161,"NCT03033498","A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease",,"Completed","No Results Available","Parkinson's Disease (PD)","Drug: ABBV-951","Maximum Observed Plasma Concentration (Cmax) of Levodopa|Time to maximum observed plasma concentration (Tmax) of Levodopa|Area Under the Plasma Concentration-Time Curve (AUC) of Levodopa|Adverse Events|Terminal phase elimination rate constant (β)|Terminal phase elimination half-life (T1/2)|Corrected QT (QTc) Interval","AbbVie","All","45 Years to 85 Years   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","M15-738","May 17, 2017","June 8, 2019","June 8, 2019","January 26, 2017",,"November 15, 2019","Glendale Adventist Medical Ctr /ID# 166512, Glendale, California, United States|Bioclinica Research - Orlando /ID# 169687, Orlando, Florida, United States|Acpru /Id# 154976, Grayslake, Illinois, United States|University of Kentucky Chandler Medical Center /ID# 169086, Lexington, Kentucky, United States|Parexel Baltimore /ID# 169255, Baltimore, Maryland, United States|QUEST Research Institute /ID# 166035, Farmington Hills, Michigan, United States|Carolina Phase I, LLC /ID# 166034, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT03033498"
162,"NCT03026166","A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: ipilimumab|Drug: nivolumab|Drug: rovalpituzumab tesirine","Number of Participants With Adverse Events (AEs)|Number of participants with dose-limiting toxicities (DLT)|Clinical benefit rate (CBR)|Duration of response (DOR)|PFS status after 6 months from the initiation of study treatment|Objective Response Rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)","AbbVie|Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","42","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-300|2016-003686-26","March 30, 2017","July 3, 2019","July 3, 2019","January 20, 2017",,"July 17, 2019","Ucsd /Id# 161030, La Jolla, California, United States|Florida Hospital /ID# 161017, Orlando, Florida, United States|University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States|University of Chicago /ID# 161006, Chicago, Illinois, United States|The University of Kansas Clini /ID# 162915, Fairway, Kansas, United States|Washington University-School of Medicine /ID# 161011, Saint Louis, Missouri, United States|Rutgers Cancer Institute of NJ /ID# 161032, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center /ID# 161010, New York, New York, United States|Duke Univ Med Ctr /ID# 161009, Durham, North Carolina, United States|Oregon Health and Science University /ID# 161029, Portland, Oregon, United States|Medical University of South Carolina /ID# 161007, Charleston, South Carolina, United States|Tennessee Oncology, PLLC /ID# 161012, Nashville, Tennessee, United States|Vanderbilt University Med Ctr /ID# 162916, Nashville, Tennessee, United States|Virginia Cancer Institute /ID# 161025, Richmond, Virginia, United States|University of Wisconsin Clinic /ID# 161013, Madison, Wisconsin, United States|CHU de Besancon - Jean Minjoz /ID# 165173, Besancon, Doubs, France|Centre Oscar Lambret /ID# 165169, Lille, Hauts-de-France, France|Institut Gustave Roussy /ID# 165168, Villejuif, Val-de-Marne, France|Institut Sainte Catherine /ID# 165172, Avignon, France|CHRU de Brest - Hospital Morva /ID# 165170, Brest Cedex, France|Hopital La Timone /ID# 165171, Marseille, France|KH Martha-Maria Halle Dolau /ID# 165180, Halle (Saale), Sachsen-Anhalt, Germany|Asklepios Fachkliniken M. Gaut /ID# 165183, Gauting, Germany|Lungen Clinic Grosshansdorf /ID# 165182, Grosshansdorf, Germany|Lungenfachklinik Immenhausen /ID# 165181, Immenhausen, Germany|Istituto Clinico Humanitas /ID# 165176, Rozzano, Milano, Italy|Centro di Riferimento Oncologi /ID# 165174, Aviano, Italy|Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele /ID# 165178, Catania, Italy|Istituto Europeo di Oncologia /ID# 165175, Milan, Italy|AO Univ di Modena /ID# 165177, Modena, Italy|Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain|Hosp Univ Quiron Dexues /ID# 165166, Barcelona, Spain|Hospital Genl Gregorio Maranon /ID# 165162, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz /ID# 165164, Madrid, Spain|Hospital Universitario Madrid /ID# 165163, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03026166"
163,"NCT03022045","A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis",,"Active, not recruiting","Has Results","Psoriasis","Drug: risankizumab","Percentage of Participants With Generalized Pustular Psoriasis (GPP) Achieving GPP Clinical Response at Week 16|Percentage of Participants With Erythrodermic Psoriasis (EP) Achieving EP Clinical Response at Week 16|Percentage of Participants With GPP Achieving GPP Clinical Response at Week 52|Percentage of Participants With EP Achieving EP Clinical Response at Week 52|Percentage of Participants With GPP Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16|Percentage of Participants With EP Achieving PASI90 at Week 16|Percentage of Participants With GPP Achieving PASI90 at Week 52|Percentage of Participants With EP Achieving PASI90 at Week 52","AbbVie","All","20 Years and older   (Adult, Older Adult)","Phase 3","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-988","January 26, 2017","September 17, 2017","November 19, 2020","January 16, 2017","February 6, 2019","December 2, 2019","Nagoya City University Hospital, Nagoya-shi, Aichi, Japan|Juntendo Univ Urayasu Hosp, Urayasu Shi, Chiba, Japan|Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan|Mie University Hospital, Tsu-shi, Mie, Japan|Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan|Shizuoka General Hospital, 静岡市, Shizuoka, Japan|Tokyo Medical University Hosp, Shinjuku-ku, Tokyo, Japan|Fukuoka University Hospital, Fukuoka, Japan|The University of Tokyo Hosp, Tokyo, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03022045/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT03022045/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03022045"
164,"NCT03017014","A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions","LEA","Terminated","No Results Available","Crohn's Disease",,"Time to loss of clinical benefit|Proportion of participants with dose escalation (dose and/or frequency of injections)|Median percent change from baseline in C-reactive protein (CRP)|Median percent change from baseline in calprotectin|Change from baseline in weighted Pediatric Crohn's Disease Activity Index (PCDAI)|Change in wPCDAI >= 37.5|Incidence rate of CD-related hospitalizations|Rate of clinical remission|Proportion of participants achieving mucosal healing at each time point|Proportion of participants with steroid-free clinical remission at each time point|Change in weight z-score|Median percent change from baseline in high sensitivity C-reactive protein (hs-CRP)|Assessing Mucosal healing|Rate of steroid-free remission|Proportion of participants with fistula remission (in participants with fistulizing CD at entry)|Change in Tanner's staging|Proportion of participants with immunomodulator-free clinical remission at each time point|Incidence rate of infectious events|Incidence rate of all-cause hospitalizations|Proportion of participants with steroid tapering at each time point (steroids daily dosing lower than at baseline)|Change in height z-score|Proportion of participants with CD-related surgery|Incidence rate of CD- or drug-related hospitalizations","AbbVie","All","6 Years to 17 Years   (Child)",,"62","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-759","September 26, 2017","October 14, 2019","October 14, 2019","January 11, 2017",,"October 23, 2019","Centre Hospitalier Lyon Sud /ID# 152667, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|Centre Hospitalier Lyon Sud /ID# 152668, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|Hopital Clocheville /ID# 152831, Tours, Centre-Val De Loire, France|CHU de Besancon - Jean Minjoz /ID# 154197, Besancon, Doubs, France|Hopitaux de Brabois Adultes /ID# 152729, Vandoeuvre les Nancy, Lorraine, France|CHU Toulouse /ID# 153251, Toulouse CEDEX 3, Occitanie, France|CHU Batiment Robert Debre /ID# 152665, Angers, France|CHU Bordeaux-Hopital Pellegrin /ID# 154620, Bordeaux, France|Chu de Bordeaux Hopital /Id# 157926, Bordeaux, France|Centre Hospitalier Universitai /ID# 155465, Caen, France|CHU Hopital d'Estaing /ID# 152664, Clermont Ferrand, France|Hopital Jeanne de Flandre /Id# 155464, Lille, France|Hopital de la Timone /ID# 160133, Marseille, France|Hopital Jacques Monod /ID# 152663, Montivillier, France|Hopital de la Source /ID# 159947, Orleans, France|Hopital de la Source /ID# 165534, Orleans, France|Robert Debre Hopital, FR /ID# 152666, Paris, France|Hopital Armand Trousseau /Id# 152669, Paris, France|Hopital Armand Trousseau /Id# 157092, Paris, France|Necker Hopital, FR /ID# 152830, Paris, France|Chu Lyon Sud /Id# 152838, Pierre Benite, France|CHU de Rennes - Hospital Sud /ID# 152730, Rennes, France|Charles Nicolle Hosp chu rouen /ID# 152670, Rouen, France|Charles Nicolle Hosp chu rouen /ID# 158688, Rouen, France",,"https://ClinicalTrials.gov/show/NCT03017014"
165,"NCT03006068","A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis (UC)",,"Enrolling by invitation","No Results Available","Ulcerative Colitis (UC)","Drug: Upadacitinib (ABT-494)|Drug: Placebo","Assessing Treatment-Emergent Adverse Events|Percentage of participants achieving clinical response per Partial Mayo score|Percentage of participants achieving clinical remission per Adapted Mayo score|Percentage of participants in clinical remission per Full Mayo score at Week 0 who maintain remission at Week 48|Percentage of participants achieving clinical remission per Partial Mayo score|Percentage of participants in clinical remission per Adapted Mayo score at Week 0 who maintain remission at Week 48|Percentage of participants achieving clinical remission per Full Mayo score|Percentage of participants achieving clinical response per Adapted Mayo score|Percentage of participants with Stool Frequency Subscore (SFS) of 0, Rectal Bleeding Subscore (RBS) of 0, and endoscopic subscore of <=1|Percentage of participants who had upadacitinib dose-escalation and achieved clinical remission per Full Mayo Score|Percentage of participants who had upadacitinib dose-escalation and achieved endoscopic improvement|Percentage of participants who had upadacitinib dose-escalation and achieved endoscopic remission|Percentage of participants achieving clinical remission|Percentage of participants who had upadacitinib dose-escalation and achieved clinical response per Adapted Mayo score|Percentage of participants who had upadacitinib dose-escalation and achieved clinical remission (after dose-escalation) per Adapted Mayo score|Percentage of participants who had upadacitinib dose-escalation and achieved clinical remission (after dose-escalation) per Full Mayo score|Percentage of participants with endoscopic improvement|Percentage of participants with endoscopic remission|Percentage of Participants with endoscopic remission at Week 0 and maintained at Week 48 and every 48 Weeks|Percentage of participants taking steroids at Baseline (Week 0) who are steroid-free over time|Percentage of participants taking steroids at Baseline (Week 0) who discontinued corticosteroid use and achieved clinical remission per Adapted Mayo score|Percentage of participants achieving Inflammatory Bowel Disease Questionnaire (IBDQ) response|Percentage of participants with Inflammatory Bowel Disease Questionnaire (IBDQ) remission|Percentage of participants who reported no abdominal pain|Percentage of participants who reported no bowel urgency|Change from Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total and domain score|Change from Baseline in individual Inflammatory Bowel Disease Questionnaire (IBDQ) item under Bowel Symptom domain (for Q1, Q5, Q9, Q13, Q17, Q20, Q22, Q24, Q26, and Q29)|Change from Baseline in corticosteroid dose|Change from Baseline in Adapted Mayo score, Full Mayo score, Partial Mayo score, and Mayo subscores|Change from Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)|Change from Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) scores|Change from Baseline in fecal calprotectin|Change from Baseline in European Quality of Life 5 -Dimensions 5 Levels (EQ-5D-5L) score|Change from Baseline in subject-reported stool frequency (absolute values)|Change from Baseline in Short Form 36 (SF-36) scores|Percentage of participants by Patient Global Impression of Severity (PGIS) category|Change from Baseline in Ulcerative Colitis Symptoms Questionnaire (UC-SQ) score|Percentage of participants by Patient Global Impression of Change (PGIC) category|Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) score|Health care resource utilization (HCRU), including all-cause and UC-related hospitalizations and surgeries","AbbVie","All","16 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","950","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-533|2016-000674-38","January 31, 2017","January 7, 2022","August 28, 2024","December 30, 2016",,"May 16, 2019","CB Flock Research Corporation /ID# 165986, Mobile, Alabama, United States|Delsol Research Management, Ll /Id# 170130, Chandler, Arizona, United States|Arizona Arthritis & Rheumatolo /ID# 169823, Phoenix, Arizona, United States|Physician's Research Group /ID# 211886, Tempe, Arizona, United States|Adobe Clinical Research LLC /ID# 155249, Tucson, Arizona, United States|Banner University Medical Cent /ID# 150568, Tucson, Arizona, United States|Citrus Valley Gastroenterology /ID# 151915, Covina, California, United States|UC San Diego Health System /ID# 155187, La Jolla, California, United States|United Gastroenterologists /ID# 207467, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 157082, Los Angeles, California, United States|Facey Medical Foundation /ID# 203135, Mission Hills, California, United States|United Gastroenterologists - Murrieta /ID# 151213, Murrieta, California, United States|Ventura County Gastroenterology /ID# 163417, Oxnard, California, United States|San Diego Clinical Trials /ID# 212121, San Diego, California, United States|Medical Assoc Research Grp /ID# 169149, San Diego, California, United States|Univ of California San Francis /ID# 164583, San Francisco, California, United States|Delta Waves, Inc. /ID# 151727, Colorado Springs, Colorado, United States|Western States Clinical Res /ID# 158078, Wheat Ridge, Colorado, United States|Western Connecticut Medical Group /ID# 169211, Danbury, Connecticut, United States|Medical Research Ctr CT /ID# 150534, Hamden, Connecticut, United States|West Central Gastroenterology /ID# 155242, Clearwater, Florida, United States|Moonshine Research Center, Inc /ID# 152534, Doral, Florida, United States|Palmetto Research, LLC /ID# 151724, Hialeah, Florida, United States|Nature Coast Clinical Research /ID# 154070, Inverness, Florida, United States|Borland-Groover Clinic /ID# 170913, Jacksonville, Florida, United States|Florida Research Institute /ID# 211605, Lakewood Ranch, Florida, United States|Ctr for Advanced Gastroenterol /ID# 202018, Maitland, Florida, United States|Crystal Pharmacology Research /ID# 151848, Miami, Florida, United States|New Horizon Research Center /ID# 152475, Miami, Florida, United States|Coral Research Clinic /ID# 150524, Miami, Florida, United States|Advanced Research Institute /ID# 163093, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 151725, Orlando, Florida, United States|Omega Research Consultants /ID# 200271, Orlando, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 201791, Tampa, Florida, United States|Florida Hospital Tampa /ID# 200274, Tampa, Florida, United States|Atlanta Gastroenterology Spec /ID# 150565, Suwanee, Georgia, United States|Northwestern Medical /ID# 151157, Chicago, Illinois, United States|Rush University Medical Center /ID# 153050, Chicago, Illinois, United States|University of Chicago /ID# 150564, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 150570, Evanston, Illinois, United States|Carle Foundation Hospital /ID# 151155, Urbana, Illinois, United States|MediSphere Medical Research Center /ID# 152080, Evansville, Indiana, United States|Indianapolis Gastroenterology /ID# 162914, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics /ID# 157059, Iowa City, Iowa, United States|Cotton-O'Neil Clinical Res Ctr /ID# 167183, Topeka, Kansas, United States|Tri-State Gastroenterology /ID# 169812, Crestview Hills, Kentucky, United States|Houma Digestive Health Special /ID# 151851, Houma, Louisiana, United States|Nola Research Works, LLC /ID# 153365, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 150526, Shreveport, Louisiana, United States|University of Maryland Med Ctr /ID# 150529, Baltimore, Maryland, United States|Gastro Center of Maryland /ID# 200024, Columbia, Maryland, United States|Massachusetts General Hospital /ID# 165678, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 151158, Ann Arbor, Michigan, United States|Huron Gastroenterology Assoc /ID# 152712, Ann Arbor, Michigan, United States|Clin Res Inst of Michigan, LLC /ID# 153031, Chesterfield, Michigan, United States|Revival Research Institute, LLC /ID# 207281, Southfield, Michigan, United States|Center for Digestive Health /ID# 161983, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC /ID# 157487, Wyoming, Michigan, United States|Minneapolis VA Medical Center /ID# 204621, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester /ID# 151681, Rochester, Minnesota, United States|Minnesota Gastroenterology P.A /ID# 151682, Saint Paul, Minnesota, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 170713, Jackson, Mississippi, United States|Washington University-School of Medicine /ID# 150537, Saint Louis, Missouri, United States|Las Vegas Medical Research /ID# 153052, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Med Ctr /ID# 150566, Lebanon, New Hampshire, United States|AGA Clinical Research Associates, LLC /ID# 153048, Egg Harbor Township, New Jersey, United States|Atlantic Digestive Health Inst /ID# 150527, Morristown, New Jersey, United States|Rutgers Robert Wood Johnson /ID# 155247, New Brunswick, New Jersey, United States|Montefiore Medical Center /ID# 150559, Bronx, New York, United States|Advantage Clinical Trials /ID# 163940, Bronx, New York, United States|NY Scientific /ID# 152708, Brooklyn, New York, United States|NYU Langone Long Island Clin. Res. Assoc. /ID# 155271, Great Neck, New York, United States|Columbia Univ Medical Center /ID# 163409, New York, New York, United States|DiGiovanna Institute for Medic /ID# 201534, North Massapequa, New York, United States|Premier Medical Group /ID# 153366, Poughkeepsie, New York, United States|Gastro Group of Rochester /ID# 151080, Rochester, New York, United States|Richmond University Medical Center /ID# 201860, Staten Island, New York, United States|Digestive Health Partners, P.A /ID# 167238, Asheville, North Carolina, United States|Carolinas Medical Center /ID# 157060, Charlotte, North Carolina, United States|Charlotte Gastro Hepatology /ID# 150561, Charlotte, North Carolina, United States|Clinical Trials of America /ID# 153453, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 150528, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 170291, Fargo, North Dakota, United States|Consultants for Clinical Res /ID# 151683, Cincinnati, Ohio, United States|University of Cincinnati /ID# 164584, Cincinnati, Ohio, United States|The Ohio State University - Columbus /ID# 169417, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 169697, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 200066, Dayton, Ohio, United States|Dayton Gastroenterology, Inc. /ID# 167632, Englewood, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 201773, Mentor, Ohio, United States|Ohio Clinical Research Partner /ID# 154074, Mentor, Ohio, United States|Digestive Disease Specialists /ID# 201057, Oklahoma City, Oklahoma, United States|Options Health Research, LLC /ID# 150569, Tulsa, Oklahoma, United States|Healthcare Research Consultant /ID# 163096, Tulsa, Oklahoma, United States|Northwest Gastroenterology Cli /ID# 152528, Portland, Oregon, United States|Allegheny General Hospital /ID# 163828, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC /ID# 150533, Sayre, Pennsylvania, United States|Penn State Health Colonnade /ID# 150267, State College, Pennsylvania, United States|Pharmacorp Clinical Trials /ID# 153363, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 150557, Greenville, South Carolina, United States|Gastro One /ID# 151154, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 203611, Johnson City, Tennessee, United States|Quality Medical Research, PLLC /ID# 203427, Nashville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 153364, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 151528, Arlington, Texas, United States|Inquest Clinical Research /ID# 164636, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209806, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209949, Cedar Park, Texas, United States|Baylor Scott & White Research /ID# 200771, Dallas, Texas, United States|DHAT Research Institute /ID# 151221, Garland, Texas, United States|Vilo Research Group Inc /ID# 212626, Houston, Texas, United States|CliniCore International, LLC /ID# 152078, Houston, Texas, United States|Baylor College of Medicine /ID# 150538, Houston, Texas, United States|Houston Methodist Hospital /ID# 207660, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201217, Houston, Texas, United States|GI Specialists of Houston /ID# 202337, Houston, Texas, United States|Clinical Associates in Researc /ID# 167954, San Antonio, Texas, United States|Sagact Pllc /Id# 169397, San Antonio, Texas, United States|Carl R. Meisner Medical Clinic /ID# 171270, Sugar Land, Texas, United States|Baylor Scott & White Health /ID# 204777, Temple, Texas, United States|Tyler Research Institute, LLC /ID# 169147, Tyler, Texas, United States|Victoria gastroenterology /ID# 167764, Victoria, Texas, United States|HP Clinical Research /ID# 163941, Bountiful, Utah, United States|Advanced Research Institute /ID# 162640, Ogden, Utah, United States|Utah Gastroenterology /ID# 163097, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 163180, West Jordan, Utah, United States|Ctr for Gastrointestinal Healt /ID# 153369, Franklin, Virginia, United States|Washington Gastroenterology /ID# 163630, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 153030, Seattle, Washington, United States|The Polyclinic /ID# 165117, Seattle, Washington, United States|The Vancouver Clinic, INC. PS /ID# 162334, Vancouver, Washington, United States|Aurora Medical Center - Grafto /ID# 151726, Grafton, Wisconsin, United States|WI Center for Advanced Res /ID# 151845, Milwaukee, Wisconsin, United States|Medical College of Wisconsin /ID# 151850, Milwaukee, Wisconsin, United States|Cardio Alem /ID# 211281, San Isidro, Buenos Aires, Argentina|Mautalen Salud e Investigacion /ID# 171174, Buenos Aires, Argentina|Hospital Britanico de Bs As /ID# 209496, Caba, Argentina|Gedyt /ID# 210016, Ciudad Autonoma Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 164186, Cordoba, Argentina|Damic /Id# 152548, Cordoba, Argentina|Instituto Medico CER /ID# 152343, Quilmes, Argentina|Sanatorio 9 de Julio S.A. /ID# 150215, San Miguel de Tucuman, Argentina|Mater Misericordiae /ID# 212686, South Brisbane, Queensland, Australia|Griffith University /ID# 211954, Southport, Queensland, Australia|Monash Health /ID# 150218, Clayton, Victoria, Australia|St. Vincents Hosp Melbourne /ID# 152503, Fitzroy, Victoria, Australia|Fiona Stanley Hospital /ID# 211641, Murdoch, Western Australia, Australia|Krankenanstalt Rudolfstiftung /ID# 162867, Vienna, Wien, Austria|Medizinische Universität Wien /ID# 150616, Vienna, Wien, Austria|Ordensklinikum Linz GmbH, Elisabethinen /ID# 150462, Linz, Austria|LKH Salzburg and Paracelsus /ID# 150463, Salzburg, Austria|Wilhelminenspital der Stadt Wien /ID# 150615, Wien, Austria|Vitebsk Regional Advanced Clin /ID# 169592, Vitebsk, Belarus|UZ Leuven /ID# 150468, Leuven, Belgium|AZ-Delta /ID# 150467, Roeselare, Belgium|University Clinical Centre of the Republic of Srpska /ID# 150223, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 150712, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Center Tuzla /ID# 150224, Tuzla, Tuzlanski, Bosnia and Herzegovina|University Clinical Hospital Mostar /ID# 150711, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 150222, Sarajevo, Bosnia and Herzegovina|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 153744, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 152488, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 153745, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 152493, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 152492, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 152489, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 152491, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hospital Universitario Clement /ID# 152495, Rio de Janeiro, Brazil|University of Calgary /ID# 151818, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 211169, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 151824, Edmonton, Alberta, Canada|Covenant Health /ID# 158931, Edmonton, Alberta, Canada|Okanagan Clinical Trials /ID# 153179, Kelowna, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 150479, Victoria, British Columbia, Canada|McMaster University Med Cent /ID# 150477, Hamilton, Ontario, Canada|The Ottawa Hospital /ID# 151817, Ottawa, Ontario, Canada|Medicor Research Inc. /ID# 151825, Sudbury, Ontario, Canada|Toronto Digestive Disease Asso /ID# 150475, Vaughan, Ontario, Canada|CISSS de la Monteregie /ID# 159271, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 150473, Levis, Quebec, Canada|Recherche GCP Research /ID# 151819, Montreal, Quebec, Canada|Crchum /Id# 167170, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre /ID# 170013, Montréal, Quebec, Canada|CRCHUS Hotel-Dieu /ID# 150478, Sherbrooke, Quebec, Canada|Research Group Ltda /ID# 203177, Santiago, Region Metropolitana De Santiago, Chile|M y F Estudios Clínicos Ltda. /ID# 200112, Ñuñoa, Region Metropolitana De Santiago, Chile|Centro de Investigaciones Clínicas Viña del Mar /ID# 150226, Viña del Mar, Valparaíso, Chile|Hospital Clínico Regional Dr. Guillermo Grant Benavente /ID# 212425, Concepción, Chile|CTR Estudios SpA /ID# 200111, Providencia, Chile|Hospital Clinico Universidad De Los Andes /ID# 207427, Santiago, Chile|Clinica Las Condes /ID# 153756, Santiago, Chile|The First Affiliated Hosp, Sun /ID# 150517, Guangzhou, Anhui, China|Shanghai Tenth People's Hosp /ID# 150522, Shanghai, Anhui, China|Renji Hosp, Shanghai Jiaotong /ID# 165826, Shanghai, Anhui, China|Daping Hospital, Research Institute of Surgery Third Military Medical University /ID# 165747, Chongqing, Chongqing, China|The Sixth Affiliated Hosp, Sun /ID# 150518, Guangzhou, Guangdong, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 167089, Wuhan, Hubei, China|1st Aff Hosp Nanchang Univ /ID# 212185, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 210087, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 150523, Shanghai, Shanghai, China|The second affiliated hospital of Zhejiang University school of medicine /ID# 165813, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 150516, Hangzhou, Zhejiang, China|Xiangya Hosp Central South Uni /ID# 167230, Changsha, China|West China Hospital, Sichuan University /ID# 167041, Chengdu, China|Shengjing Hospital of China Medical University /ID# 166921, Shenyang, China|Tianjin Med Univ General Hosp /ID# 170605, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167079, Wuhan, China|Corporacion Hospitalaria Juan Ciudad sede Denominada Hospital Universitario Mayo /ID# 152811, Bogota, Cundinamarca, Colombia|Hospital Univ San Ignacio /ID# 152679, Bogota, Colombia|Instituto de Coloproctologia /ID# 152815, Medellin, Colombia|Hospital Universitario de San /ID# 155388, Medellin, Colombia|Hospital Pablo Tobon Uribe /ID# 159096, Medellín, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 207052, Montería, Colombia|Klinicka bolnica Dubrava Zagreb /ID# 150228, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 150262, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 150715, Zagreb, Grad Zagreb, Croatia|Poliklinika Solmed /ID# 211567, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 150229, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Rijeka /ID# 150714, Rijeka, Primorsko-goranska Zupanija, Croatia|Zadar General Hospital /ID# 150261, Zadar, Croatia|CTCenter MaVe, s.r.o. /ID# 150903, Olomouc, Olomoucky Kraj, Czechia|Axon Clinical, s.r.o. /ID# 152477, Praha, Praha 5, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 150946, Hradec Kralove, Czechia|Artroscan s.r.o. /ID# 150502, Ostrava, Czechia|ISCARE I.V.F. a.s. /ID# 209279, Prague, Czechia|East Tallinn Central Hospital /ID# 150488, Tallinn, Estonia|West Tallinn Central Hospital /ID# 150490, Tallinn, Estonia|North Estonian Medical Centre /ID# 160871, Tallinn, Estonia|Tartu University Hospital /ID# 150489, Tartu, Estonia|Tampere University Hospital /ID# 150376, Tampere, Pirkanmaa, Finland|Helsinki Univ Central Hospital /ID# 154283, Helsinki, Finland|Keski-Suomen Keskussairaala /ID# 155665, Jyvaskyla, Finland|Laakarikeskus Ikioma /ID# 150377, Mikkeli, Finland|Tyks /Id# 169895, Turku, Finland|Centre Hospitalier Lyon Sud /ID# 152540, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHU Hopital Nord /ID# 165773, Marseille, Bouches-du-Rhone, France|CHRU Lille - Hôpital Claude Huriez /ID# 152609, Lille CEDEX, Hauts-de-France, France|Hopital Saint Eloi /ID# 200088, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 211420, Clichy, Ile-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 150392, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Amiens Picardie /ID# 163458, Amiens CEDEX 1, Somme, France|CHD Vendee /ID# 165749, La Roche Sur Yon, France|Hopital de L'archet 2 /ID# 152608, Nice, France|Hopital Saint Antoine /ID# 200089, Paris, France|Hopital Nord /ID# 165756, Saint Priest En Jarez, France|Universitatsklinikum Mannheim /ID# 150405, Mannheim, Baden-Wuerttemberg, Germany|Universitatsklinikum Munster /ID# 150402, Munster, Niedersachsen, Germany|Univ Hosp Schleswig-Holstein /ID# 161871, Kiel, Schleswig-Holstein, Germany|Praxis am Bayerischen Platz /ID# 151697, Berlin, Germany|Agaplesion Markus Krankenhaus /ID# 161870, Frankfurt, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 207136, Munster, Germany|Universitatsklinikum Tubingen /ID# 151698, Tuebingen, Germany|Gastro Data Wiesbaden /ID# 150404, Wiesbaden, Germany|General Hospital of Athens Laiko /ID# 208672, Athens, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 150406, Athens, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 202101, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 150236, Heraklion, Greece|University General Hospital of Ioannina /ID# 164247, Ioannina, Greece|""Theageneio"" Anticancer Hospital /ID# 164187, Thessaloniki, Greece|Genl Hosp Thessaloniki Hipp /ID# 209522, Thessaloniki, Greece|Markusovszky Egyetemi Oktatókórház /ID# 150410, Szombathely, Vas, Hungary|Bekes Megyei Kozponti Korhaz /ID# 151601, Bekescsaba, Hungary|Semmelweis Egyetem /ID# 150409, Budapest, Hungary|Meditres Kft. /ID# 151597, Kecskemet, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 151599, Sopron, Hungary|Mentahaz Maganorvosi Kozpont /ID# 206977, Szekesfehervar, Hungary|Mercy University Hospital /ID# 153794, Cork, Ireland|Trinity College Dublin - St. J /ID# 150413, Dublin, Ireland|St Vincent's University Hosp /ID# 150411, Dublin, Ireland|Beaumont Hospital /ID# 150414, Dublin, Ireland|Galway University Hospital /ID# 150412, Galway, Ireland|Hadassah Ein Kerem Medical Ctr /ID# 165119, Jerusalem, Yerushalayim, Israel|Soroka Medical Ctr /ID# 156562, Be'er Sheva, Israel|Rambam Health Care Campus /ID# 150416, Haifa, Israel|Shaare Zedek Medical Center /ID# 163139, Jerusalem, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 150424, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 151362, Rome, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 150421, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 151363, Rozzano, Milano, Italy|A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 150263, Palermo, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 201726, Negrar, Verona, Italy|ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico /ID# 150605, Milano, Italy|Policlinico Tor Vergata /ID# 150425, Rome, Italy|Complesso integrato Columbus /ID# 150420, Rome, Italy|Aichi Medical University Hosp /ID# 151994, Nagakute, Aichi, Japan|Nagoya University Hospital /ID# 152728, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 151949, Nagoya-shi, Aichi, Japan|Hirosaki National Hospital /ID# 152761, Hirosaki-shi, Aomori, Japan|Toho University Sakura Medical Center /ID# 151935, Sakura-shi, Chiba, Japan|Juntendo University Urayasu Hospital /ID# 208783, Urayasu Shi, Chiba, Japan|Kyushu University Hospital /ID# 152525, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 151977, Kurume-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 208226, Ogaki-shi, Gifu, Japan|National Hospital Organization Higashi-Ohmi General Medical Center /ID# 210711, Shiga, Higashiohmi-shi, Japan|NHO Fukuyama Medical Center /ID# 206294, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 170281, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 151705, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 206493, Sapporo-shi, Hokkaido, Japan|Sapporo Tokushukai Hospital /ID# 209449, Sapporo, Hokkaido, Japan|Aoyama Clinic /ID# 152048, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 152433, Nishinomiya-shi, Hyogo, Japan|Kanazawa University Ho /ID# 207810, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital /ID# 203412, Morioka-shi, Iwate, Japan|Idzuro Imamura Hospital /ID# 207640, Kagoshima, Kagishimashi, Japan|Yokohama City Univ Med Center /ID# 169900, Yokohama-shi, Kanagawa, Japan|JP Red Cross Kyoto Daiichi Hos /ID# 152358, Kyoto-shi, Kyoto, Japan|Mie University Hospital /ID# 207253, Tsu-shi, Mie, Japan|National Hospital Organization Sendai Medical Center /ID# 209529, Sendai-shi, Miyagi, Japan|Ishida Clinic of IBD and Gastroenterology /ID# 210118, Oita-shi, Oita, Japan|Kinshukai Infusion Clinic /ID# 207866, Osaka-shi, Osaka, Japan|Japanese Red Cross Osaka Hospi /ID# 209477, Osaka-shi, Osaka, Japan|Osaka City University Hospital /ID# 152681, Osaka-shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 152019, Kawagoe-shi, Saitama, Japan|Tokito Clinic /ID# 152676, Saitama-shi, Saitama, Japan|Kyoto University Hospital /ID# 211808, Kyoto, Sakyo-ku, Japan|Hamamatsu University Hospital /ID# 205709, Higashi-ku, Shizuoka, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 152017, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 208075, Chuo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 152584, Hachioji, Tokyo, Japan|Teikyo University Hospital /ID# 209865, Itabashi-ku, Tokyo, Japan|Kitasato Univ Kitasato Inst Ho /ID# 152687, Minato-ku, Tokyo, Japan|Kyorin University Hospital /ID# 153195, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 205978, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 171468, Yamagata-shi, Yamagata, Japan|Yamanashi Prefectural Ctr Hosp /ID# 151909, Kofu-shi, Yamanashi, Japan|Fukui Prefectural Hospital /ID# 210450, Fukui, Japan|Saiseikai Fukuoka General Hosp /ID# 209481, Fukuoka, Japan|Hiroshima University Hospital /ID# 151952, Hiroshima, Japan|National Hospital Organization Mito Medical Center /ID# 152626, Ibaraki, Japan|Shimane University School of Medicine /ID# 208906, Izumo, Japan|Sameshima Hospital /ID# 206673, Kagoshima, Japan|Tsujinaka Hospital Kashiwanoha /ID# 209572, Kashiwa, Japan|St. Marianna Univ Hospital /ID# 209452, Kawasaki, Japan|Kitakyushu Municipal Med Ctr /ID# 152589, Kitakyushu, Japan|Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 157820, Kurashiki, Japan|Saiseikai Niigata Daini Hosp /ID# 209923, Niigata, Japan|Obihiro-Kosei General Hospital /ID# 210425, Obihiro, Japan|NHO Nagasaki Medical Center /ID# 210821, Omura-shi, Japan|Kitano Hospital /ID# 210396, Osaka, Japan|Sapporo Higashi Tokushukai /ID# 208495, Sapporo, Japan|NHO Shizuoka Medical Center /ID# 163571, Shizuoka, Japan|Center hospital of the National Center for Global Health and Medicine /ID# 209533, Tokyo, Japan|Toyohashi Municipal Hospital /ID# 171470, Toyohashi, Japan|Ieda Hospital /ID# 157782, Toyota-shi, Japan|Kenseikai Dongo Hospital /ID# 208102, Yamato Takada, Japan|Showa Univ Fujigaoka Hosp /ID# 208223, Yokohama-shi, Japan|Dong-A University Hospital /ID# 161568, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 161569, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 150432, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|St. Vincent's Hospital /ID# 150434, Suwon, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 150435, Seoul, Jongno-Gu, Korea, Republic of|Severance Hospital /ID# 161566, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 150433, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Hanyang University Guri Hosp /ID# 150431, Guri-si, Korea, Republic of|CHA Bundang Medical Center /ID# 161567, Seongnam, Korea, Republic of|Asan Medical Center /ID# 159155, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 150436, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 153183, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 150439, Kaunas, Lithuania|Klaipeda University Hospital /ID# 163719, Klaipeda, Lithuania|Klaipeda Seamens Hospital /ID# 163501, Klaipeda, Lithuania|Vilnius University Hospital /ID# 164172, Vilnius, Lithuania|Hospital Sultanah Bahiyah /ID# 152310, Alor Setar, Kedah, Malaysia|Hospital Ampang /ID# 152311, Ampang, Selangor, Malaysia|UKM Medical Centre /ID# 152313, Kuala Lumpur, Selangor, Malaysia|Uni Malaya MC /ID# 150440, Kuala Lumpur, Malaysia|Morales Vargas Centro de Investigación S.C /ID# 211327, León de los Aldama, Guanajuato, Mexico|Issste /Id# 150239, Guadalajara, Jalisco, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 202334, Guadalajara, Jalisco, Mexico|Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 150265, Monterrey, Nuevo Leon, Mexico|Radboud Universitair Medisch Centrum /ID# 151701, Nijmegen, Gelderland, Netherlands|Academisch Medisch Centrum /ID# 150617, Amsterdam, Noord-Holland, Netherlands|Leids Universitair Medisch Centrum /ID# 152625, Leiden, Netherlands|Erasmus Medisch Centrum /ID# 150619, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 152776, Utrecht, Netherlands|Akershus Universitetssykehus_MAIN /ID# 150622, Lorenskog, Akershus, Norway|Universitetssykehuset Nord-Norge /ID# 152836, Tromsø, Troms, Norway|Zespol Przychodni Prima /Id# 150627, Warsaw, Mazowieckie, Poland|Centrum Zdrowia MDM /ID# 150626, Warszawa, Mazowieckie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 150624, Warszawa, Mazowieckie, Poland|Endoskopia Sp. z o.o. /ID# 152940, Sopot, Zachodniopomorskie, Poland|Hospital Senhora da Oliveira de Guimarães, EPE /ID# 151616, Guimarães, Braga, Portugal|Centro Hosp de Lisboa Central /ID# 151620, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 151622, Almada, Setubal, Portugal|CCA Braga - Hospital de Braga /ID# 151617, Braga, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 151615, Lisboa, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 151619, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 152336, Santa Maria Da Feira, Portugal|Unidade Local De Saude Do Alto Minho /ID# 151618, Viana Do Castelo, Portugal|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 150629, San Juan, Puerto Rico|Clinic Fundeni Institute /ID# 150630, Bucharest, Bucuresti, Romania|Clinic Fundeni Institute /ID# 161604, Bucharest, Bucuresti, Romania|Cabinet Particular Policlinic Algomed /ID# 150631, Timisoara, Romania|Immanuel Kant Baltic Federal University /ID# 202129, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|NW State Medical Univ na Mechn /ID# 169332, St. Petersburg, Leningradskaya Oblast, Russian Federation|Perm Clinical Center of FMBA /ID# 150634, Perm, Permskiy Kray, Russian Federation|LLC Medical Company Hepatolog /ID# 200208, Samara, Samarskaya Oblast, Russian Federation|LLC Uromed /ID# 200728, Smolensk, Smolenskaya Oblast, Russian Federation|LLC Novaya Klinika /ID# 208106, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 166040, Kazan, Tatarstan, Respublika, Russian Federation|City Clinical Hospital 24 /ID# 150638, Moscow, Russian Federation|P.A. Bayandin Murmansk Regiona /ID# 165916, Murmansk, Russian Federation|Republican Clin Hos n.a. Baran /ID# 206508, Petrozavodsk, Russian Federation|PMI Euromedservice /ID# 208968, Pushkin, Russian Federation|Stavropol State Medical Univ /ID# 150635, Stavropol, Russian Federation|Clinical Center Serbia /ID# 150642, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 150641, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 150643, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 150640, Belgrade, Beograd, Serbia|Clinical Center of Nis /ID# 151902, NIS, Nisavski Okrug, Serbia|Clinical Center Kragujevac /ID# 150644, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 150759, Novi Sad, Vojvodina, Serbia|National University Hospital /ID# 150583, Singapore, Singapore|Gleneagles Medical Centre /ID# 206020, Singapore, Singapore|Tan Tock Seng Hospital /ID# 150646, Singapore, Singapore|Medak s.r.o., gastroenterologi /ID# 150550, Bratislava, Bratislavsky Kraj, Slovakia|FN s poliklinikou F.D. Rooseve /ID# 150869, Banska Bystrica, Slovakia|Slovak Research Center Team Me /ID# 150240, Ilava, Slovakia|B and B MED s.r.o. /ID# 150584, Kosice, Slovakia|Fakultna nemocnica s poliklini /ID# 211371, Nove Zamky, Slovakia|Gastro I.S.R.O. /ID# 150585, Presov, Slovakia|Clinresco Centres /ID# 163625, Johannesburg, Gauteng, South Africa|Chris Hani Baragwanath Hosp /ID# 157730, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 150586, Johannesburg, Gauteng, South Africa|Mediclinic Milnerton /ID# 162203, Cape Town, Milnerton, South Africa|Kingsbury Hospital /ID# 150587, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 155145, Cape Town, Western Cape, South Africa|MD Search /ID# 157524, Boksburg North, South Africa|Comple Hospi Univ de Santiago /ID# 171492, Santiago de Compostela, A Coruna, Spain|Hospital Universitario y Politecnico La Fe /ID# 150591, Valencia, Valenciana, Spain|Comple Hosp Univ de A Coruna /ID# 203912, A Coruna, Spain|Hospital Clinic de Barcelona /ID# 150598, Barcelona, Spain|Hospital Reina Sofia de Cordob /ID# 154031, Cordoba, Spain|Hospital Univ Dr. Negrin /ID# 203965, Las Palmas de Gran Canaria, Spain|Hospital Univ Ramon y Cajal /ID# 171491, Madrid, Spain|Complejo Asistencial de Salama /ID# 150590, Salamanca, Spain|Sahlgrenska University Hosp /ID# 152326, Goteborg, Sweden|Kantonsspital St. Gallen /ID# 152601, St. Gallen, Sankt Gallen, Switzerland|Universitaetsspital Basel /ID# 161732, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 152602, Bern, Switzerland|University Hospital Zurich /ID# 152603, Zurich, Switzerland|China Medical University Hosp /ID# 150600, Taichung City, Taichung, Taiwan|National Cheng Kung University Hospital /ID# 151751, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 150604, Taipei City, Taipei, Taiwan|Kaohsiung Medical University /ID# 150606, Kaohsiung, Taiwan|Chung Shan Medical University /ID# 150603, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 151750, Taipei City, Taiwan|Erciyes University Medical Fac /ID# 150495, Melikgazi, Kayseri, Turkey|Gazi Universitesi Tip Fakultes /ID# 150493, Ankara, Turkey|Istanbul Universitesi Cerrahpa /ID# 150491, Cerrahpasa, Turkey|Umraniye Training and Res Hosp /ID# 163136, Istanbul, Turkey|Mersin University Medical /ID# 163135, Mersin, Turkey|Regional Clinical Hospital - Center for Emergency Medical Care and Disaster Med /ID# 206941, Kharkiv, Kharkivska Oblast, Ukraine|Kyiv Municipal Clinical Hospital #18 /ID# 150505, Kiev, Kyiv, Ukraine|Medical Center of the ""Health /ID# 162501, Vinnytsya, Vinnytska Oblast, Ukraine|Municipal Institution City Hospital #7 /ID# 212965, Zaporizhzhia, Zaporizka Oblast, Ukraine|Regional Clin Hosp Mechnykov /ID# 207731, Dnipropetrovsk, Ukraine|Lviv Regional Clinical Hospita /ID# 150508, Lviv, Ukraine|Odessa Regional Clinical Hosp /ID# 162502, Odesa, Ukraine|Public Nonprofit Enterprise Regional Oncology Center of Regional Coun /ID# 211962, Kirovohrad, Кропивницький, Ukraine|RD&E Hospital /ID# 150510, Exeter, Devon, United Kingdom|Queen Elizabeth University Hos /ID# 163788, Glasgow, Glasgow City, United Kingdom|The Royal London Hospital /ID# 150515, London, London, City Of, United Kingdom|Basingstoke & North Hampshire /ID# 150511, Basingstoke, United Kingdom|Royal United Hospitals Bath /ID# 154211, Bath, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 150513, Birmingham, United Kingdom|St. George's Healthcare NHS /ID# 208376, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03006068"
166,"NCT03002818","Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)","HEMATITE","Completed","Has Results","Chronic Hepatitis C Virus (HCV)",,"Change From Baseline at Day 168 in Mean Daytime Physical Activity|Change From Baseline Over Time in Mean Daytime Physical Activity|Change From Baseline Over Time in Fatigue Severity Scale (FSS) Score|Change From Baseline Over Time in Sleep Efficiency|Correlation Coefficients of FSS and Mean Daytime Physical Activity: sdITT Population|Correlation Coefficients of FSS and Mean Daytime Physical Activity: mITT Population|Correlation Coefficients of Change From Baseline Over Time in FSS and Mean Daytime Physical Activity: sdITT Population|Correlation Coefficients of Change From Baseline Over Time in FSS and Mean Daytime Physical Activity: mITT Population|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-Treatment","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"41","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-272","March 1, 2017","April 25, 2018","April 25, 2018","December 26, 2016","October 23, 2019","October 23, 2019","Kantonsspital St. Gallen, St. Gallen, Sankt Gallen, Switzerland|Inselspital, Universitaetsklin, Bern, Switzerland|Fondazione Epatocentro Ticino, Lugano, Switzerland|Hopital Neuchatelois, Neuchatel, Switzerland|Universitaetsspital Zuerich, Zurich, Switzerland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03002818/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03002818/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03002818"
167,"NCT03001115","Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects","HS rPMS","Completed","No Results Available","Hidradenitis Suppurativa (HS)",,"Assessing adverse events|Change from baseline in Dermatology Life Quality Index (DLQI)|Change from baseline in Hidradenitis Suppurativa Clinical Response (HiSCR)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"17","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-052","March 10, 2017","July 31, 2019","July 31, 2019","December 22, 2016",,"October 16, 2019","Kyungpook National Univ Hosp /ID# 162930, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 203364, Seongnam-si, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 202254, Seongnam, Gyeonggido, Korea, Republic of|Ajou University Hospital /ID# 163243, Suwon-si, Gyeonggido, Korea, Republic of|Chonnam National University Hospital /ID# 162932, Gwangju, Jeonranamdo, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 162933, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Seoul SongDo Hospital /ID# 202597, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Gangnam Severance Hospital /ID# 162924, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 162934, Seoul, Seoul Teugbyeolsi, Korea, Republic of|St. Mary's Hospital of the Cat /ID# 162923, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Dong-A University Hospital /ID# 162931, Busan, Korea, Republic of|Korea University Anam Hospital /ID# 162922, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 162935, Seoul, Korea, Republic of|Hangyang University Medical Ce /ID# 162929, Seoul, Korea, Republic of|Konkuk University Medical Cent /ID# 162927, Seoul, Korea, Republic of|Asan Medical Center /ID# 162925, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital /ID# 162926, Seoul, Korea, Republic of|Ewha Womans University Mokdong /ID# 162928, Seoul, Korea, Republic of|National Medical Center /ID# 162936, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03001115"
168,"NCT03000257","A Study of ABBV-181 in Participants With Advanced Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: Venetoclax|Drug: Rovalpituzumab Tesirine|Drug: ABBV-181","Recommended Phase 2 Dose (RPTD) and schedule for ABBV-181 and venetoclax combination.|Maximum tolerated dose (MTD) of ABBV-181|Recommended Phase 2 Dose (RPTD) for ABBV-181|Time to Cmax (Tmax)|Number of participants with adverse events|Area under the serum concentration time curve (AUC)|Maximum observed serum concentration (Cmax)|Terminal half-life (t1/2)|Recommended Phase 2 Dose (RPTD) and schedule for ABBV-181 and Rovalpituzumab Tesirine combination|Objective response rate (ORR)|Clinical benefit rate (CBR, defined as CR, PR or SD)|Progression-free survival (PFS)|Duration of objective response (DOR)|Preliminary response and activity of ABBV-181 and Rovalpituzumab Tesirine when given in combination|Anti-tumor effect of ABBV-181 in combination with venetoclax.","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","221","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-891|2016-002520-89","December 14, 2016","September 25, 2021","December 27, 2021","December 22, 2016",,"July 29, 2019","Ucsd /Id# 157374, La Jolla, California, United States|University of Chicago /ID# 157375, Chicago, Illinois, United States|Carolina BioOncology Institute /ID# 157376, Huntersville, North Carolina, United States|South Texas Accelerated Research Therapeutics /ID# 157378, San Antonio, Texas, United States|Virginia Cancer Specialists /ID# 157377, Fairfax, Virginia, United States|Blacktown Hospital /ID# 167386, Blacktown, New South Wales, Australia|St. Vincents Hosp Melbourne /ID# 167552, Fitzroy, Victoria, Australia|Linear Clinical Research /ID# 170797, Perth, Western Australia, Australia|LKH-Univ. Klinikum Graz /ID# 168752, Graz, Austria|Medizinische Universitaet Wien /ID# 169781, Vienna, Austria|UZ Gent /ID# 170881, Gent, Oost-Vlaanderen, Belgium|UZ Antwerpen /ID# 170702, Edegem, Belgium|Cross Cancer Institute /ID# 167603, Edmonton, Alberta, Canada|Docrates Cancer Center /ID# 166838, Helsinki, Finland|Tampere University Hospital /ID# 166839, Tampere, Finland|Institut Bergonie /ID# 162662, Bordeaux, Gironde, France|Institut Regional du Cancer /ID# 163999, Montpellier CEDEX 5, Herault, France|Centre Leon Berard /ID# 162660, Lyon CEDEX 08, Rhone, France|Institut Gustave Roussy /ID# 162753, Villejuif, Val-de-Marne, France|National Cancer Ctr Hosp East /ID# 166433, Kashiwa-shi, Chiba, Japan|National Hospital Organization Kyushu Cancer Center /ID# 206229, Fukuoka-shi, Fukuoka, Japan|National Cancer Center Hospital /ID# 166279, Chuo-ku, Tokyo, Japan|Hospital Universitario Fundacion Jimenez Diaz /ID# 163862, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 163861, Madrid, Spain|Hosp Clin Univ de Valencia /ID# 163925, Valencia, Spain|National Taiwan Univ Hosp /ID# 163997, Taipei City, Taipei, Taiwan|Taipei Medical University Hosp /ID# 163998, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03000257"
169,"NCT03000075","BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Drug: risankizumab|Drug: placebo for risankizumab","Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)|Percentage of Participants Achieving PASI90 at Week 52 (Part B)|Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 (Part B)|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16 (Part A)|Percentage of Participants Achieving PASI75 at Week 52 (Part B)|Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16 (Part A)|Percentage of Participants Achieving PASI100 at Week 52 (Part B)|Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an American College of Rheumatology 20 Response (ACR20) at Week 16 (Part A)|Percentage of Participants (ITT Participants in Select Study Sites With Confirmed Diagnosis of Psoriatic Arthritis and Baseline Total Tender and Swollen Joint Count ≥ 3) Achieving an ACR20 at Week 52 (Part B)","AbbVie|Boehringer Ingelheim","All","20 Years and older   (Adult, Older Adult)","Phase 2","182","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-004|1311.38","December 2, 2016","September 21, 2017","June 20, 2018","December 21, 2016","February 6, 2019","May 21, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03000075/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03000075/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT03000075"
170,"NCT02993523","A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy",,"Active, not recruiting","No Results Available","Acute Myeloid Leukemia (AML)","Drug: Azacitidine|Drug: Venetoclax|Drug: Placebo","Overall survival (OS)|Percentage of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi)|Event-free survival (EFS)|Global health status/quality of life (GHS/QoL)|Percentage of participants achieving composite complete remission (CR or CRi)|Complete remission or complete remission with partial hematologic recovery rate (CR+CRh)|Post baseline transfusion independence rate|Complete remission (CR) rate|Fatigue/quality of life (QoL)","AbbVie|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","443","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-656|2016-001466-28","February 2, 2017","February 1, 2020","May 23, 2021","December 15, 2016",,"August 28, 2019","City of Hope /ID# 154105, Duarte, California, United States|University of California, Los Angeles /ID# 154107, Los Angeles, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 162725, Sacramento, California, United States|Emory University Hospital /ID# 162534, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 201133, Chicago, Illinois, United States|University of Chicago /ID# 154108, Chicago, Illinois, United States|Fort Wayne Medical Oncology /ID# 157190, Fort Wayne, Indiana, United States|Cotton-O'Neil Clinical Res Ctr /ID# 155136, Topeka, Kansas, United States|Norton Cancer Institute /ID# 154992, Louisville, Kentucky, United States|EMMC Cancer Care /ID# 154991, Brewer, Maine, United States|Johns Hopkins University /ID# 154104, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 200752, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center /ID# 201155, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 167009, Boston, Massachusetts, United States|Sepctrum Health Medical Center /ID# 159522, Grand Rapids, Michigan, United States|Columbia Univ Medical Center /ID# 154101, New York, New York, United States|Memorial Sloan Kettering Cancer Center /ID# 165077, New York, New York, United States|Duke University Medical Center - Main /ID# 154106, Durham, North Carolina, United States|University of Pittsburgh MC /ID# 154102, Pittsburgh, Pennsylvania, United States|Tennessee Oncology-Nashville Centennial /ID# 200854, Nashville, Tennessee, United States|Univ TX, MD Anderson /ID# 154100, Houston, Texas, United States|Scott & White Mem Hosp & Clin /ID# 157191, Temple, Texas, United States|University of Utah Huntsman /ID# 157192, Salt Lake City, Utah, United States|University Of Vermont Medical /ID# 157196, Burlington, Vermont, United States|Princess Alexandra Hospital /ID# 154272, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital /ID# 154271, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 155094, Fitzroy, Victoria, Australia|Royal Melbourne Hospital /ID# 155095, Parkville, Victoria, Australia|The Alfred Hospital /ID# 154275, Prahran, Victoria, Australia|Sir Charles Gairdner Hospital /ID# 163924, Nedlands, Western Australia, Australia|Royal Perth Hospital /ID# 154274, Shenton Park, Western Australia, Australia|University Hospital St. Polten /ID# 167436, St. Pölten, Niederoesterreich, Austria|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 154888, Linz, Oberoesterreich, Austria|LKH-Univ. Klinikum Graz /ID# 157882, Graz, Austria|Ordensklinikum Linz GmbH, Elisabethinen /ID# 154885, Linz, Austria|Uniklinikum Salzburg /ID# 169719, Salzburg, Austria|Hanusch Krankenhaus der WGKK /ID# 155676, Wien, Austria|Cliniques Universitaires Saint Luc /ID# 153391, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Gent /ID# 153392, Gent, Oost-Vlaanderen, Belgium|AZ St-Jan Brugge-Oostende AV /ID# 154041, Brugge, West-Vlaanderen, Belgium|UZ Brussels /ID# 153393, Jette, Brussels, Belgium|Hospital de Clinicas de Porto Alegre /ID# 157779, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 153099, Ribeirão Preto, Sao Paulo, Brazil|Inst Ensino Pesquisa Sao Lucas /ID# 157778, São Paulo, Sao Paulo, Brazil|Icesp /Id# 153095, São Paulo, Sao Paulo, Brazil|University of Calgary /ID# 159645, Calgary, Alberta, Canada|St. Paul's Hospital /ID# 159644, Vancouver, British Columbia, Canada|Juravinski Hosp & Cancer Cntr /ID# 153650, Hamilton, Ontario, Canada|The Ottawa Hospital /ID# 153541, Ottawa, Ontario, Canada|Princess Margaret Cancer Centr /ID# 153651, Toronto, Ontario, Canada|Fujian Medical Univ Union Hosp /ID# 167314, Fuzhou, Fujian, China|Nanfang Hospital of Southern Medical University /ID# 170148, Guangzhou, Guangdong, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 167315, Wuhan, Hubei, Hubei, China|Jiangsu Province People's Hospital /ID# 167489, Nanjing, Jiangsu, China|The First Hosp of Jilin Univ /ID# 167490, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 167318, Shanghai, Shanghai, China|West China Hospital /ID# 167492, Chengdu, Sichuan, China|Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 167487, Tianjin, Tianjin, China|The First Affiliated Hospital,College of Medicine, Zhejiang University /ID# 167317, Hangzhou, Zhejiang, China|Qilu Hospital of Shandong Univ /ID# 167485, Jinan, China|The Second Hospital of Hebei /ID# 167316, Shijiazhuang, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167493, Wuhan, China|Henan Cancer Hospital /ID# 167320, Zhengzhou, Henan, China|Klinicka bolnica Dubrava Zagreb /ID# 153515, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 153383, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 153623, Osijek, Osjecko-baranjska Zupanija, Croatia|Fakultni nemocnice Plzen /ID# 154018, Plzeň 1, Plzen-jih, Czechia|Fakultni Nemocnice Brno /ID# 154019, Brno, Czechia|Fakultni nemocnice Hradec Kral /ID# 154021, Hradec Kralove, Czechia|Univ Hosp Ostrava-Poruba /ID# 154017, Ostrava, Czechia|Aalborg University Hospital /ID# 154047, Aalborg, Nordjylland, Denmark|Tampere University Hospital /ID# 154963, Tampere, Pirkanmaa, Finland|Helsinki University Hospital /ID# 155223, Helsinki, Uusimaa, Finland|Turku University Hospital /ID# 154964, Turku, Finland|CHU d'Angers /ID# 153792, Angers, France|Hopital Saint-Louis /ID# 153787, Paris, France|CHU de Bordeaux /ID# 153789, Pessac Cedex, France|GCS IUCT - Oncopole /ID# 153788, Toulouse, France|Universitaetsklinikum Ulm /ID# 153054, Ulm, Thueringen, Germany|Universitaetsklinikum Frankfurt /ID# 153060, Frankfurt, Germany|Universitatsklinikum Halle (Sa /ID# 153058, Halle, Germany|Universitaetsklinikum Hamburg /ID# 153056, Hamburg, Germany|Med Hochschule Hanover /ID# 153055, Hannover, Germany|Universitatsklinikum Munster /ID# 153059, Muenster, Germany|Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 158990, Budapest IX, Budapest, Hungary|Semmelweis Egyetem I. Belklini /ID# 153816, Budapest, Hungary|Semmelweis Egyeteme III /ID# 153815, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 153814, Debrecen, Hungary|Kaposi Mor Oktato Korhaz /ID# 153813, Kaposvar, Hungary|Szabolcs-Szatmar-Beregi /ID# 169854, Nyíregyhaza, Hungary|Szegedi Tudomanyegyetem /ID# 153812, Szeged, Hungary|Rabin Medical Center /ID# 154176, Petakh Tikva, Tel-Aviv, Israel|Assaf Harofeh Medical Center /ID# 158063, Be'er Ya'akov, Israel|Rambam Health Care Campus /ID# 154174, Haifa, Israel|Hadassah /ID# 154172, Jerusalem, Israel|Sheba Medical Center /ID# 154173, Ramat Gan, Israel|Sourasky Medical Center /ID# 154175, Tel-aviv, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 152883, Bologna, Emilia-Romagna, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 152882, Milan, Lombardia, Italy|AOU Ospedali Riuniti di Ancona - G.M. Lancisi, G. Salesi /ID# 171220, Ancona, Marche, Italy|P.O. Vito Fazzi /ID# 170837, Lecce, Puglia, Italy|Fondazione PTV Policlinico Tor Vergata /ID# 152881, Rome, Roma, Italy|ASST Papa Giovanni XXIII /ID# 152875, Bergamo, Italy|Ospedale Policlinico San Martino - IRCCS /ID# 158104, Genoa, Italy|AORN A. Cardarelli /ID# 152879, Napoli, Italy|Azieda Ospedaliera Bianchi Melacrino Morelli /ID# 152877, Reggio Calabria, Italy|Azienda Ospedaliera Sant' Andrea /ID# 152876, Rome, Italy|Aichi Cancer Center Hospital /ID# 200824, Nagoya-shi, Aichi, Japan|University of Fukui Hospital /ID# 167432, Yoshida-gun, Fukui, Japan|National Hospital Organization Kyushu Cancer Center /ID# 201111, Fukuoka-shi, Fukuoka, Japan|Kyushu University Hospital /ID# 169095, Fukuoka-shi, Fukuoka, Japan|Gunmaken Saiseikai Maebashi Hospital /ID# 168316, Maebashi-shi, Gunma, Japan|National Hospital Organization Mito Medical Center /ID# 168219, Higashi Ibaraki-gun, Ibaraki, Japan|Hitachi General Hospital /ID# 201109, Hitachi-shi, Ibaraki, Japan|Kyoto Prefect Univ Med /ID# 167661, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 169259, Sendai-shi, Miyagi, Japan|Nagasaki University Hospital /ID# 168632, Nagasaki-shi, Nagasaki, Japan|Okayama University Hospital /ID# 204124, Okayama-shi, Okayama, Japan|Kindai University Hospital /ID# 167662, Osaka-sayama, Osaka, Japan|Osaka City University Hospital /ID# 169055, Osaka-shi, Osaka, Japan|Saitama Medical University International Medical Center /ID# 167814, Hidaka-shi, Saitama, Japan|Tokyo Metropolitan Komagome Hospital /ID# 168639, Bunkyo-ku, Tokyo, Japan|Tokyo Jikei Daisan Hospital /ID# 168745, Komae-shi, Tokyo, Japan|NTT Medical Center Tokyo /ID# 167975, Shinagawa-ku, Tokyo, Japan|Yamagata University Hospital /ID# 167634, Yamagata-shi, Yamagata, Japan|Juntendo University Hospital /ID# 168309, Tokyo, Japan|Konkuk University Medical Ctr /ID# 153973, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 153674, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 153675, Seoul, Korea, Republic of|Akershus universitetssykehus /ID# 154279, Nordbyhagen, Akershus, Norway|Drammen Sykehus /ID# 154280, Drammen, Buskerud, Norway|Haukeland University Hospital /ID# 154281, Bergen, Hordaland, Norway|Sykehuset Ostfold Kalnes /ID# 157755, Gralum, Norway|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu /ID# 153389, Wrocław, Dolnoslaskie, Poland|Osrodek Badan Klinicznych przy Szpitalu Specjalistycznym im. Ludwika Rydygiera w /ID# 169846, Cracow, Malopolskie, Poland|Zespol Szpitali Miejskich /ID# 153385, Chorzow, Poland|Hospital de Braga /ID# 154797, Braga, Portugal|IPO Porto FG, EPE /ID# 154138, Porto, Portugal|VA Caribbean Healthcare System /ID# 160507, San Juan, Puerto Rico|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 157461, Kemerovo, Kemerovskaya Oblast, Russian Federation|Nizhniy Novgorod regional clinical hospital named N. A. Semashko /ID# 153268, Nizhnij Novgorod, Nizhegorodskaya Oblast, Russian Federation|Regional Oncology Dispensary /ID# 153264, Penza, Penzenskaya Oblast, Russian Federation|State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 157460, Ryazan, Ryazanskaya Oblast, Russian Federation|Saratov State Medical University n.a. V.I. Razumovskiy /ID# 153267, Saratov, Saratovskaya Oblast, Russian Federation|Federal State Budget Inst. /ID# 155740, Moscow, Russian Federation|City Clinical Hospital Botkina /ID# 155738, Moscow, Russian Federation|Samara State Medical Universit /ID# 157462, Samara, Russian Federation|Tshwane District Hospital /ID# 153682, Pretoria, Gauteng, South Africa|Albert Alberts Stem Cell Transplant Centre /ID# 153684, Pretoria, Gauteng, South Africa|Hospital Santa Creu i Sant Pau /ID# 153193, Barcelona, Spain|Hospital Clinic de Baecelona /ID# 153255, Barcelona, Spain|Hospital Univ de la Princesa /ID# 153256, Madrid, Spain|Hospital Universitario Gregori /ID# 153260, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 153258, Madrid, Spain|Hosp Clinico Virgen Victoria /ID# 153257, Malaga, Spain|Complejo Hospitalario de Navar /ID# 153254, Pamplona, Spain|Hosp Univ Politecnico la Fe /ID# 153259, Valencia, Spain|Akademiska Sjukhuset /ID# 153034, Uppsala, Uppsala Lan, Sweden|Uddevalla sjukhus /ID# 156875, Uddevalla, Vastra Gotalands Lan, Sweden|VO Hematologi /ID# 153174, Lund, Sweden|Karolinska University Hospital /ID# 170003, Stockholm, Sweden|China Medical University Hosp /ID# 153904, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 153900, Taipei City, Taipei, Taiwan|Changhua Christian Hospital /ID# 153899, Changhua County, Taiwan|Kaohsiung Medical University /ID# 153902, Kaohsiung, Taiwan|Hacettepe University Medical Faculty /ID# 202073, Ankara, Turkey|Ankara Universitesi Fakultesi /ID# 155200, Ankara, Turkey|Ondokuz Mayıs Universitesi Tıp /ID# 155201, Samsun, Turkey|Kyiv city clinical hospital #9 /ID# 153510, Kiev, Vinnytska Oblast, Ukraine|City Multi-Field Clin Hosp #4 /ID# 153511, Dnipro, Ukraine|Kyiv Regional Onco Dispensary /ID# 153514, Kyiv, Ukraine|Poltava Reg Clin Hosp Sklifoso /ID# 153513, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT02993523"
171,"NCT02988960","A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-927|Drug: ABBV-181","Maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181|Time to Cmax (Tmax) of ABBV-927|Maximum observed serum concentration (Cmax) of ABBV-927|Terminal half-life (t1/2) of ABBV-927|Area under the serum concentration-time curve (AUC) of ABBV-927|Time to Cmax (Tmax) of ABBV-181|Maximum observed serum concentration (Cmax) of ABBV-181|Terminal half-life (t1/2) of ABBV-181|Area under the serum concentration-time curve (AUC) of ABBV-181|Clinical benefit rate (CBR, defined as the percentage of participants with a confirmed partial, complete response, or stable disease for at least 24 weeks to the treatment)|Duration of objective response (DOR)|Objective response rate (ORR)|Progression-free survival (PFS)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","180","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-862|2016-002219-16","February 22, 2017","April 16, 2019","July 11, 2022","December 12, 2016",,"March 12, 2019","The Angeles Clinic and Researc /ID# 156324, Los Angeles, California, United States|University of Chicago /ID# 155264, Chicago, Illinois, United States|Massachusetts General Hospital /ID# 155267, Boston, Massachusetts, United States|Carolina BioOncology Institute /ID# 155265, Huntersville, North Carolina, United States|Tennessee Oncology-Sarah Cannon Research Institute /ID# 158654, Nashville, Tennessee, United States|Univ TX, MD Anderson /ID# 155263, Houston, Texas, United States|Virginia Cancer Specialists /ID# 155266, Fairfax, Virginia, United States|Peninsula & South Eastern Haem /ID# 164372, Frankston, Victoria, Australia|Austin Health /ID# 171189, Melbourne, Victoria, Australia|Princess Margaret Cancer Centr /ID# 200819, Toronto, Ontario, Canada|Institut Bergonie /ID# 162665, Bordeaux, Gironde, France|Institut Regional du Cancer /ID# 163609, Montpellier CEDEX 5, Herault, France|Gustave Roussy /ID# 162666, Villejuif, Ile-de-France, France|Centre Leon Berard /ID# 162663, Lyon CEDEX 08, Rhone, France|Yonsei University Health System, Severance Hospital /ID# 166292, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 166291, Seoul, Korea, Republic of|Hospital Fundacion Jimenez Dia /ID# 200128, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 200127, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 200129, Majadahonda, Spain|Hospital Universitario La Fe /ID# 200975, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02988960"
172,"NCT02988674","A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation","Adherence","Completed","No Results Available","Spondylarthritis|Psoriatic Arthritis|Ankylosing Spondylitis (AS)",,"Proportion of participants on adalimumab therapy|Number of participants on adalimumab therapy|Assessing medication persistence|Assessing medication adherence|Change of disease activity in participants with PsA|Change of disease activity in participants with AS","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"139","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-672","December 22, 2016","October 16, 2019","October 16, 2019","December 9, 2016",,"October 24, 2019","Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 167025, Kemerovo, Kemerovskaya Oblast, Russian Federation|Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 154379, Moscow, Moskva, Russian Federation|Ivanovo Regional Clinical Hosp /ID# 167028, Ivanovo, Russian Federation|Institution KhMAO-Ugra /ID# 154381, Khanty-mansiysk, Russian Federation|State Clinical policlinic /ID# 154374, Moscow, Russian Federation|Central Research Institute /ID# 154375, Moscow, Russian Federation|Research Institute of Rheum /ID# 154378, Moscow, Russian Federation|Advisory-diagnostic Hospital /ID# 154382, Moscow, Russian Federation|State Clinical Hospital /ID# 154373, Moscow, Russian Federation|GBUZ Republican Hospital /ID# 167029, Petrozavodsk, Russian Federation|Smolensk station JSC Russian R /ID# 167027, Smolensk, Russian Federation|Nort-Western State Medical Uni /ID# 154376, St. Petersburg, Russian Federation|Tula Regional Clinical Hospita /ID# 155539, Tula, Russian Federation|Yaroslavi State Medical Univer /ID# 154383, Yaroslavl, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02988674"
173,"NCT02986373","A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)",,"Completed","Has Results","Psoriatic Arthritis","Biological: risankizumab","Number of Participants With Adverse Events|Modified Total Sharp Score (mTSS): Change From Baseline (in the Lead-in Study) to Week 24 in the Lead-in Study|mTSS: Change From Baseline (in the Lead-in Study) to Week 24|mTSS: Change From Baseline (in the Lead-in Study) to Week 48|Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 0|Percentage of Participants Achieving ACR20 Response at Week 4|Percentage of Participants Achieving ACR20 Response at Week 12|Percentage of Participants Achieving ACR20 Response at Week 24|Percentage of Participants Achieving ACR20 Response at Week 36|Percentage of Participants Achieving ACR20 Response at Week 48|Percentage of Participants Achieving ACR20 Response at Week 52|Health Assessment Questionnaire Disability Index (HAQ-DI): Change From Baseline (in the Lead-in Study) to Week 0|HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 4|HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 12|HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 24|HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 36|HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 48|HAQ-DI: Change From Baseline (in the Lead-in Study) to Week 52|Short Form Health Survey 36 (SF-36) Physical Component Summary (PCS) Score: Change From Baseline (in the Lead-in Study) to Week 0|SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 4|SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 12|SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 24|SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 36|SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 48|SF-36 PCS Score: Change From Baseline (in the Lead-in Study) to Week 52|SF-36 Mental Component Summary (MCS) Score: Change From Baseline (in the Lead-in Study) to Week 0|SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 4|SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 12|SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 24|SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 36|SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 48|SF-36 MCS Score: Change From Baseline (in the Lead-in Study) to Week 52","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-244|2016-003113-94","December 15, 2016","July 8, 2018","July 30, 2018","December 8, 2016","May 28, 2019","May 28, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02986373/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02986373/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02986373"
174,"NCT02985879","A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP).",,"Completed","No Results Available","Progressive Supranuclear Palsy","Drug: placebo|Drug: ABBV-8E12","Change from Baseline to Week 52 in Progressive Supranuclear Palsy Rating Scale (PSPRS) Total Score|Adverse Events|Time to Cmax (Tmax) for ABBV-8E12|Change from Baseline to Week 52 in Clinical Global Impression of Change (CGI-C)|Midbrain Atrophy As Measured by Volumetric Magnetic Resonance Imaging (MRI)|Area under the concentration time curve (AUC) for ABBV-8E12|Maximum observed serum concentration (Cmax) for ABBV-8E12|Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12|Change from Baseline to Week 52 in Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)|Change from Baseline to Week 52 in Schwab and England Activities of Daily Living Scale (SEADL)","AbbVie","All","40 Years and older   (Adult, Older Adult)","Phase 2","378","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-562|2016-001635-12","December 12, 2016","November 20, 2019","November 20, 2019","December 7, 2016",,"January 7, 2020","University of Alabama at Birmingham - Main /ID# 144892, Birmingham, Alabama, United States|Mayo Clinic - Scottsdale /ID# 144893, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center /ID# 149775, Beverly Hills, California, United States|Ucsd /Id# 144905, La Jolla, California, United States|Usc /Id# 149773, Los Angeles, California, United States|University of California, Los Angeles /ID# 144896, Los Angeles, California, United States|Univ California, San Francisco /ID# 144897, San Francisco, California, United States|Rocky Mountain Movement Disorders Center /ID# 153397, Englewood, Colorado, United States|University of Florida - Archer /ID# 144906, Gainesville, Florida, United States|Mayo Clinic /ID# 144911, Jacksonville, Florida, United States|University of South Florida /ID# 144912, Tampa, Florida, United States|Georgia Regents University /ID# 144908, Augusta, Georgia, United States|Rush University Medical Center /ID# 144894, Chicago, Illinois, United States|University of Chicago /ID# 148672, Chicago, Illinois, United States|Indiana University /ID# 149036, Indianapolis, Indiana, United States|University of Kentucky Chandler Medical Center /ID# 144891, Lexington, Kentucky, United States|Mayo Clinic - Rochester /ID# 144895, Rochester, Minnesota, United States|St. Luke's Hosp. of Kansas Cit /ID# 168629, Kansas City, Missouri, United States|Cleveland Clinic Lou Ruvo Cent /ID# 148919, Las Vegas, Nevada, United States|Rutgers Robert Wood Johnson /ID# 144901, New Brunswick, New Jersey, United States|COLUMBIA University Medical Center /ID# 149037, New York, New York, United States|Cleveland Clinic Main Campus /ID# 144885, Cleveland, Ohio, United States|Oregon Health and Science University /ID# 149774, Portland, Oregon, United States|Vanderbilt Univ Med Ctr /ID# 144898, Nashville, Tennessee, United States|Kerwin Research Center /ID# 144904, Dallas, Texas, United States|McGovern Medical School /ID# 149236, Houston, Texas, United States|Central Texas Neurology Consul /ID# 167417, Round Rock, Texas, United States|Westmead Hospital /ID# 154403, Westmead, New South Wales, Australia|Q-Pharm Pty Limited /ID# 154410, Herston, Queensland, Australia|Royal Adelaide Hospital /ID# 153157, Adelaide, South Australia, Australia|Alfred Hospital /ID# 153158, Melbourne, Victoria, Australia|Neurodegenerative Disorders Re /ID# 153770, West Perth, Western Australia, Australia|University of Calgary /ID# 154393, Calgary, Alberta, Canada|Okanagan Clinical Trials /ID# 169688, Kelowna, British Columbia, Canada|Toronto Western Hospital /ID# 152818, Toronto, Ontario, Canada|Crchum /Id# 152819, Montreal, Quebec, Canada|Montreal Neurological Institut /ID# 156413, Montreal, Quebec, Canada|Hopital Universitaire Purpan /ID# 153152, Toulouse, Haute-Garonne, France|Hopital de la Timone /ID# 153113, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Chu de Bordeaux Hopital /Id# 153151, Bordeaux, France|Hopital B Roger Salengro /ID# 153943, Lille, France|Hopital Pitie Salpetriere /ID# 153942, Paris, France|CHU Strasbourg Hautepierre Hos /ID# 206942, Strasbourg, France|St. Josef-Hospital /ID# 201984, Bochum, Nordrhein-Westfalen, Germany|Universitaetsklinikum Leipzig /ID# 201761, Leipzig, Sachsen, Germany|Universitaetsklinikum Ulm /ID# 153155, Ulm, Thueringen, Germany|KH Agatharied /ID# 154166, Hausham, Germany|TU Uniklinik Munchen /ID# 153154, Munich, Germany|Universita di Catanzaro Magna Graecia /ID# 166322, Catanzaro, Calabria, Italy|AOU Policlinico Agostino Gemelli /ID# 153104, Rome, Lazio, Italy|Istituto Clinico Humanitas /ID# 155092, Rozzano, Milano, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 201982, Milan, Italy|Istituto Neuro Mediterraneo IR /ID# 153106, Pozzilli, Italy|A.O. Santa Maria /ID# 153102, Terni, Italy|IRCCS Ospedale San Camillo /ID# 153101, Venezia LIDO, Italy|National Hospital Organization Higashinagoya National Hospital /ID# 201514, Nagoya-shi, Aichi, Japan|National Hospital Organization Asahikawa Medical Center /ID# 201585, Asahikawa, Hokkaido, Japan|National Hospital Organization Utano National Hospital /ID# 201979, Kyoto City, Kyoto, Japan|Tohoku University Hospital /ID# 202307, Sendai-shi, Miyagi, Japan|NHO Sendai Nishitaga National Hospital /ID# 202132, Sendai, Miyagi, Japan|Niigata University Medical & Dental Hospital /ID# 201680, Niigata-shi, Niigata, Japan|Osaka University Hospital /ID# 201980, Suita-shi, Osaka, Japan|Juntendo University Hospital /ID# 200870, Bunkyo-ku, Tokyo, Japan|National Center of Neurology and Psychiatry /ID# 202037, Kodaira, Tokyo, Japan|Hospital General Universitario Gregorio Maranon /ID# 200876, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 201039, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02985879"
175,"NCT02980731","A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).","VENICE II","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: Venetoclax","Change in Global Health Status/Quality of Life (GHS/QoL) subscale of the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30)|Complete Remission rate (complete remission [CR] + complete remission with incomplete marrow recovery [CRi])|Duration of Overall Response (DOR)|Duration of Progression-Free Survival (PFS)|Time to Progression (TTP)|EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L)|Change in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Lymphocytic Leukemia Module (EORTC QLQ-CLL16),|Overall Survival (OS)|Change in the remaining subscales/items from the EORTC QLQ-C30.|Overall Response Rate (ORR)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","210","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-889|2016-001097-15","December 13, 2016","November 11, 2020","June 26, 2022","December 2, 2016",,"December 11, 2019","Hospital Italiano La Plata /ID# 150812, La Plata, Buenos Aires, Argentina|Cemic /Id# 150810, Buenos Aires, Argentina|Fundaleu /Id# 150811, Buenos Aires, Argentina|Sanatorio Allende /ID# 150813, Cordoba, Argentina|St George Hospital /ID# 154212, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 154950, Liverpool, New South Wales, Australia|Gold Coast University Hospital /ID# 150833, Southport, Queensland, Australia|Peter MacCallum Cancer Ctr /ID# 154948, Melbourne, Victoria, Australia|Perth Blood Institute Ltd /ID# 154949, Nedlands, Western Australia, Australia|UMHAT Sv. Georgi EAD /ID# 161594, Plovdiv, Bulgaria|UMHAT Aleksandrovska /ID# 162987, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 163280, Sofia, Bulgaria|SHAT Hematologic Diseases /ID# 161592, Sofia, Bulgaria|Queen Mary Hospital /ID# 150836, Hong Kong, Hong Kong|Prince of Wales Hospital /ID# 150837, Sha Tin, Hong Kong|Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 152842, Budapest IX, Budapest, Hungary|Semmelweis Egyetem /ID# 150792, Budapest, Hungary|Centro de Investigación Clinica Chapultepec /ID# 163641, Morelia, Michoacan, Mexico|Hosp. Univ. Dr. Jose E. Gonz /ID# 150821, Monterrey, Nuevo Leon, Mexico|North Shore Hospital /ID# 157626, Auckland, New Zealand|Middlemore Clinical Trials /ID# 161526, Auckland, New Zealand|Wellington Regional Hospital /ID# 157627, Newtown Wellington, New Zealand|Zespol Szpitali Miejskich /ID# 150877, Chorzow, Poland|Szpitale Pomorskie Sp. z o.o /ID# 164097, Gdynia, Poland|Wojewodzkie Wielospecjalistycz /ID# 150880, Lodz, Poland|Instytut Hematologii i Transfu /ID# 150878, Warsaw, Poland|NN Blokhin Russian Cancer /ID# 166610, Moscow, Moskva, Russian Federation|Moscow State budget healthcare institution City Clinical Hospital n.a. Botkin /ID# 154806, Moscow, Moskva, Russian Federation|Federal State Budgetary Ins""NRC for Hematology"" of MoH of Russian Federation /ID# 154213, Moscow, Russian Federation|Penza Regional Cancer Center /ID# 154202, Penza, Russian Federation|China Medical University Hosp /ID# 150839, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 150838, Taipei City, Taipei, Taiwan|Taipei Veterans General Hosp /ID# 153803, Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT02980731"
176,"NCT02968173","A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus","Synagis Russia","Completed","Has Results","Respiratory Syncytial Virus (RSV)","Drug: Palivizumab","Percentage of Participants With RSV Hospitalization|Total Number of RSV-Hospitalization Days|Percentage of Participants Who Received Supplemental Oxygen While Hospitalized|Total RSV-hospitalization Days With Increased Supplemental Oxygen Requirement|Number of Intensive Care Unit (ICU) Admissions During RSV-hospitalization|Total Days of RSV-ICU Stay|Percentage of Participants Who Received Mechanical Ventilation|Total Days of Mechanical Ventilation During RSV-hospitalization","AbbVie","All","up to 24 Months   (Child)","Phase 3","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-539|2016-000221-39","November 9, 2016","July 13, 2017","July 13, 2017","November 18, 2016","March 13, 2018","March 13, 2018",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02968173/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02968173/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02968173"
177,"NCT02966795","A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection","ENDURANCE-5 6","Completed","Has Results","Hepatitis C Virus (HCV)","Drug: Glecaprevir/Pibrentasvir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post Treatment (SVR12)|Percentage of Participants With On-treatment HCV Virologic Failure|Percentage of Participants With Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","84","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-126|2016-003192-22","January 25, 2017","June 6, 2018","August 29, 2018","November 17, 2016","July 10, 2019","July 10, 2019","Research & Education, Inc. /ID# 157042, San Diego, California, United States|Kaiser Permanente /ID# 157044, San Diego, California, United States|Zuckerberg San Francisco Gener /ID# 157040, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 157045, West Hollywood, California, United States|Einstein Medical Center /ID# 157436, Philadelphia, Pennsylvania, United States|University of Washington /ID# 157041, Seattle, Washington, United States|Nepean Hospital Kingswood /ID# 157027, Kingswood, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 157025, Herston, Queensland, Australia|Royal Melbourne Hospital /ID# 157024, Parkville, Victoria, Australia|AZ Groeninge /ID# 157029, Kortrijk, Belgium|UZ Leuven /ID# 157030, Leuven, Belgium|University of Calgary /ID# 157031, Calgary, Alberta, Canada|Toronto General Hospital /ID# 157032, Toronto, Ontario, Canada|Hopital Haut-Lévêque /ID# 157035, Pessac CEDEX, Gironde, France|Hopital Beaujon /ID# 157028, Clichy, Ile-de-France, France|CHU Estaing /ID# 157034, Clermont Ferrand, France|Hopital Saint Antoine /ID# 157036, Paris, France|Auckland Clinical Studies Ltd /ID# 157033, Auckland, New Zealand|National University Hospital /ID# 156855, Singapore, Singapore|Singapore General Hospital /ID# 157037, Singapore, Singapore|Wits Clinical Research Site /ID# 157038, Johannesburg, Gauteng, South Africa|University of Cape Town /ID# 157039, Cape Town, Western Cape, South Africa|National Hospital of Tropical Diseases /ID# 162282, Hanoi, Vietnam|Hoa Hao Medic Co. Ltd. /ID# 162283, Ho Chi Minh, Vietnam|Tropical Diseases Hospital /ID# 162281, Ho Chi Minh, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02966795/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT02966795/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02966795"
178,"NCT02966782","A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes (MDS)",,"Active, not recruiting","No Results Available","Myelodysplastic Syndromes (MDS)","Drug: venetoclax|Drug: azacitidine","AUCt for azacitidine|Clearance (CL) for azacitidine|Cmax for azacitidine|Tmax for venetoclax|Recommended Phase 2 Dose (RPTD) and dosing schedules of venetoclax as monotherapy and in combination with azacitidine|AUC[0 to infinity] for azacitidine|Tmax for azacitidine|AUC [0-24] for venetoclax|AUCt for venetoclax|Cmax of venetoclax|Half-life (t[1/2]) for azacitidine|Event-Free Survival (EFS)|Overall Survival (OS)|Rate of bone marrow blast response|Time to next treatment (TTNT)|Duration of Response (DOR)|Rate of platelet (PLT) transfusion independence|Time to Transformation acute myeloid leukemia (AML)|Progression-Free Survival (PFS)|Overall Response Rate (ORR)|Complete Remission (CR) Rate|Rate of red blood cell (RBC) transfusion independence|Rate of complete cytogenetic response|Rate of Hematologic Improvement (HI)|Rate of marrow complete remission (mCR)","AbbVie|Celgene|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-522|2016-001904-46","March 7, 2017","October 17, 2020","October 17, 2020","November 17, 2016",,"October 17, 2019","University of Arizona Cancer Center - North Campus /ID# 157503, Tucson, Arizona, United States|University of Colorado /ID# 155365, Aurora, Colorado, United States|Yale University /ID# 162544, New Haven, Connecticut, United States|University of Chicago /ID# 155364, Chicago, Illinois, United States|Mass General Hospital /ID# 171227, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 155361, Boston, Massachusetts, United States|University of Massachusetts Wo /ID# 155366, Worcester, Massachusetts, United States|Weill Cornell Medicine /ID# 156388, New York, New York, United States|Oregon Health and Science University /ID# 155360, Portland, Oregon, United States|University of Texas MD Anderson Cancer Center /ID# 155362, Houston, Texas, United States|St George Hospital /ID# 156037, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 155952, Liverpool, New South Wales, Australia|St. Vincents Hosp Melbourne /ID# 155950, Fitzroy, Victoria, Australia|Royal Perth Hospital /ID# 155951, Shenton Park, Western Australia, Australia|Royal Melbourne Hospital /ID# 155949, Melbourne, Australia|Universitatsklinikum Mannheim /ID# 156038, Mannheim, Baden-Wuerttemberg, Germany|Univ Klinikum Duesseldorf /ID# 154899, Dusseldorf, Nordrhein-Westfalen, Germany|Marien Hospital Dusseldorf /ID# 155518, Dusseldorf, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 155519, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Carl Gus /ID# 154898, Dresden, Sachsen, Germany|Universitaetsklinikum Leipzig /ID# 154897, Leipzig, Sachsen, Germany|Universitatsklinikum Halle /ID# 158643, Halle, Germany|Klinikum Rechts der Isar /ID# 154896, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT02966782"
179,"NCT02966756","A Study of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia (CLL)","Drug: Venetoclax","Overall Response Rate (ORR)|Partial Remission (PR) rate|Event Free Survival (EFS)|Percent of participants who move on to stem cell transplant|Overall Survival (OS)|Progression Free Survival (PFS)|Time to Progression (TTP)|Time to 50% reduction in absolute lymphocyte count (ALC)|Complete Remission (CR) rate","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-728|2017-002413-54","October 12, 2017","August 29, 2021","April 29, 2025","November 17, 2016",,"November 14, 2019","Concord Repatriation & Gen Hos /ID# 201261, Concord, New South Wales, Australia|St George Hospital /ID# 206484, Kogarah, New South Wales, Australia|Monash Medical Centre /ID# 201263, Melbourne, Victoria, Australia|Anhui Provincial Cancer Hospital /ID# 209458, Hefei, Anhui, China|Peking Univ Peoples Hospital /ID# 156575, Beijing, Beijing, China|Fujian Medical Univ Union Hosp /ID# 156579, Fuzhou, Fujian, China|Guangdong Provincial People's Hospital /ID# 160509, Guangzhou, Guangdong, China|Nanfang Hosp Nanfang Med Uni /ID# 156571, Guangzhou, Guangdong, China|Xiangya Hospital Central South University /ID# 208913, Changsha, Hunan, China|Jiangsu Province People's Hospital /ID# 156577, Nanjing, Jiangsu, China|1st Aff Hosp Nanchang Univ /ID# 159142, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 156532, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 156572, Shanghai, Shanghai, China|West China Hospital /ID# 156537, Chengdu, Sichuan, China|Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 157762, Tianjin, Tianjin, China|1st Hosp College Med Zhejian /ID# 156578, Hangzhou, Zhejiang, China|Peking Union Medical College H /ID# 156576, Beijing, China|Chengdu Military General Hosp /ID# 159145, Chengdu, China|Shandong Provincial Hospital /ID# 156574, Jinan, China|The Second Hospital of Hebei /ID# 159143, Shijiazhuang, China|The First Affiliated Hospital /ID# 156536, Soochow, China|Tianjin Medical University /ID# 156542, Tianjin, China|Tongji Hosp Tongji Med College /ID# 156589, Wuhan, China|Henan Cancer Hospital /ID# 156573, Zhengzhou, Henan, China|Christchurch Hospital /ID# 201650, Christchurch, Canterbury, New Zealand|North Shore Hospital /ID# 204637, Auckland, New Zealand|China Medical University Hosp /ID# 202767, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 210733, Taipei City, Taipei, Taiwan|Changhua Christian Hospital /ID# 202768, Changhua County, Taiwan|Kaohsiung Medical University /ID# 202765, Kaohsiung, Taiwan|Linkou Chang Gung Memorial Ho /ID# 203636, Taoyuan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT02966756"
180,"NCT02955251","A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors Cancer","Drug: ABBV-428|Drug: Nivolumab","Number of participants with adverse events|Recommended Phase 2 Dose (RPTD) of ABBV-428 when administered as monotherapy or in combination with nivolumab|Area under the serum concentration-time curve (AUC) of ABBV-428|Terminal half-life (t1/2) of ABBV-428|Maximum observed serum concentration (Cmax) of ABBV-428|Maximum tolerated dose (MTD) of ABBV-428 when administered as monotherapy or in combination with nivolumab|Time to Cmax (Tmax) of ABBV-428|Duration of Objective Response (DOR)|Clinical benefit rate (CBR)|Progression-Free Survival (PFS)|Objective Response Rate (ORR)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-819|2016-001461-88","November 18, 2016","July 30, 2019","October 29, 2019","November 4, 2016",,"November 7, 2019","HonorHealth Research Institute - Pima /ID# 155461, Scottsdale, Arizona, United States|UC Davis Comprehensive Cancer Center - Main /ID# 154439, Sacramento, California, United States|University of Chicago /ID# 154440, Chicago, Illinois, United States|Fox Chase Cancer Center /ID# 170665, Philadelphia, Pennsylvania, United States|Greenville Hospital System /ID# 154437, Greenville, South Carolina, United States|MD Anderson Cancer Center at Texas Medical Center /ID# 154441, Houston, Texas, United States|South Texas Accelerated Research Therapeutics /ID# 154442, San Antonio, Texas, United States|Chris O'Brien Lifehouse /ID# 163131, Camperdown, New South Wales, Australia|Northern Cancer Institute /ID# 163132, St Leonards, New South Wales, Australia|Institut Bergonie /ID# 202391, Bordeaux, Gironde, France|Institut Curie /ID# 162258, Paris CEDEX 05, Ile-de-France, France|Gustave Roussy /ID# 162257, Villejuif, Ile-de-France, France|Hopital de la Timone /ID# 162256, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Centre Leon Berard /ID# 168072, Lyon CEDEX 08, Rhone, France|National Cheng Kung University Hospital /ID# 169035, Tainan City, Tainan, Taiwan|National Taiwan Univ Hosp /ID# 169034, Taipei City, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02955251"
181,"NCT02955212","A Study With Upatacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)",,"Active, not recruiting","No Results Available","Rheumatoid Arthritis (RA)","Drug: Upadacitinib|Drug: Placebo","Proportion of participants achieving American College of Rheumatology (ACR) 20 response|Change from baseline in Short form-36 (SF-36) Physical Component Score (PCS)|Change from baseline in disease activity score (DAS) 28 C-reactive protein (CRP) (Period 1)|Proportion of subjects achieving low disease activity (LDA) based on DAS28 (CRP) <= 3.2|ACR 70 Response Rate|Proportion of subjects achieving clinical remission (CR)|Proportion of subjects achieving LDA based on CDAI ≤ 10|Change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) (Period 1)|ACR 20 response rate|ACR 50 Response Rate","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","338","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-557","January 3, 2018","August 14, 2019","September 10, 2020","November 4, 2016",,"January 13, 2020","Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 152964, Curitiba, Parana, Brazil|Parana Medical Research Center /ID# 153507, Maringa, Parana, Brazil|LMK Sevicos Medicos S/S /ID# 152963, Porto Alegre, Rio Grande Do Sul, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 152961, Sao Jose Do Rio Preto, Sao Paulo, Brazil|CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 152966, São Paulo, Sao Paulo, Brazil|1st Aff Hosp of Bengbu Med Col /ID# 162161, Bengbu, Anhui, China|Anhui Provincial Hospital /ID# 161117, Hefei, Anhui, China|Zhongshan Hosp. of Fudan Uni. /ID# 161108, Shanghai, Anhui, China|The 1st Aff Hosp Xiamen Univ /ID# 162154, Xiamen, Fujian, China|Zhuzhou Central Hospital /ID# 162153, Zhuzhou, Hunan, China|The First Affiliated Hospital /ID# 163747, Baotou, Inner Mongolia, China|The First People's Hospital /ID# 168462, Changzhou, Jiangsu, China|The First People's Hospital of Jiujiang /ID# 168461, Jiujiang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 161116, Changchun, Jilin, China|Jining No.1 People's Hospital /ID# 162158, Jining, Shandong, China|Shanghai Changhai Hospital /ID# 161123, Shanghai, Shanghai, China|West China Hospital /ID# 161119, Chengdu, Sichuan, China|Xuanwu Hosp Capital Med Univ /ID# 161118, Beijing, China|Peking Union Med College Hosp /ID# 161107, Beijing, China|The Second Xiangya Hospital of Central South University /ID# 162152, Changsha, China|First Affiliated Hospital of Kunming Medical University /ID# 164637, Kunming, China|Jiangsu Province Hospital /ID# 161122, Nanjing, China|Pingxiang People's Hospital /ID# 162151, Pingxiang, China|1st Aff Hosp of Shantou Univ /ID# 162165, Shantou, Guangdong, China|The Second Hospital of Shanxi /ID# 162164, Taiyuan, China|Tianjin Med Univ General Hosp /ID# 162155, Tianjin, China|People's Hospital of Xinjiang /ID# 162157, Urumqi, China|First Affiliated Hospital of Xi'an Jiaotong University /ID# 162150, Xi'an, China|SoonChunHyang University CheonAn Hospital /ID# 209078, Cheonan-si, Chungcheongnamdo, Korea, Republic of|Kyungpook National Univ Hosp /ID# 166919, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Chungnam National University Hospital /ID# 167727, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Ajou University Hospital /ID# 163912, Suwon-si, Gyeonggido, Korea, Republic of|St. Vincent's Hospital /ID# 166918, Suwon, Gyeonggido, Korea, Republic of|Inha University Hospital /ID# 163910, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 167726, Gwangju, Jeonranamdo, Korea, Republic of|Kyung Hee University Medical Center /ID# 163908, Dongdaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|SMG-SNU Boramae Medical Center /ID# 163911, Dongjak-gu, Seoul Teugbyeolsi, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 168421, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Hanyang University Seoul Hospi /ID# 163913, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Konkuk University Medical Ctr /ID# 206148, Seoul, Seoul Teugbyeolsi, Korea, Republic of|The Catholic University of Korea, Yeouido St. Mary's Hospital /ID# 204224, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Asan Medical Center /ID# 163909, Seoul, Korea, Republic of|Chung-Ang University Hostipal /ID# 209076, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02955212"
182,"NCT02951117","A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment",,"Withdrawn","No Results Available","Multiple Myeloma","Drug: Venetoclax|Drug: ABBV-838|Drug: Dexamethasone","Maximum tolerated dose (MTD), and recommended phase two dose (RPTD) of venetoclax and ABBV-838 combination therapy when administered with dexamethasone|Number of participants with adverse events|Maximum observed plasma concentration (Cmax) of venetoclax|Time to Cmax (Tmax) of venetoclax|Area under the plasma concentration-time curve over the 24-hour dose interval (AUC0-24) of venetoclax|Objective Response Rate (ORR)|Cmax of ABBV-838|Tmax of ABBV-838|AUC over the dose interval (AUC0-τ) of ABBV-838|Total monoclonal anti-CS1 antibody (total mAb)|Monomethyl auristatin E (MMAE) toxin levels|Minimal Residual Disease (MRD)|Terminal phase elimination rate constant (β) for ABBV-838|Terminal elimination half-life (t1/2) for ABBV-838","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-655|2016-001300-28","August 31, 2017","July 28, 2020","April 28, 2021","November 1, 2016",,"June 5, 2017","St Vincent´s Hospital /ID# 153022, Darlinghurst, Australia|St. Vincents Hospital Melbourne /ID# 157925, Fitzroy, Australia|The Alfred Hospital /ID# 150202, Prahran, Australia",,"https://ClinicalTrials.gov/show/NCT02951117"
183,"NCT02945228","Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2",,"Completed","No Results Available","Chronic Hepatitis C Virus",,"Percentage of Participants with Sustained Virologic Response (SVR12)|Percentage of Participants with Virologic Failure During Treatment (breakthrough)|Percentage of Participants with Virologic Failure After Treatment (relapse)|Percentage of Participants with Sustained Virologic Response (SVR24)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"449","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-764","October 26, 2016","July 26, 2019","July 26, 2019","October 26, 2016",,"August 8, 2019","Aichi Medical University Hosp /ID# 161892, Nagakute, Aichi, Japan|Matsuyama Red Cross Hosp /ID# 162953, Matsuyama, Ehime, Japan|NHO Kyushu Medical Center /ID# 162956, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 164158, Kurume-shi, Fukuoka, Japan|Kusunoki Hospital /ID# 158119, Fujioka, Gunma, Japan|National Hospital Organization Takasaki General Medical Center /ID# 160877, Takasaki-shi, Gunma, Japan|NHO Fukuyama Medical Center /ID# 162909, Fukuyama-shi, Hiroshima, Japan|Fukuyama City Hospital /ID# 161889, Fukuyama-shi, Hiroshima, Japan|The Hospital of Hyogo College of Medicine /ID# 162913, Nishinomiya-shi, Hyogo, Japan|Nanpuh Hospital /ID# 168348, Kagoshima-shi, Kagoshima, Japan|St. Marianna University School of Medicine Hospital /ID# 160876, Kawasaki, Kanagawa, Japan|Yokohama City Univ Medical Ctr /ID# 162905, Yokohama, Kanagawa, Japan|Kumamoto University Hospital /ID# 167048, Kumamoto-shi, Kumamoto, Japan|Kumamoto Shinto General Hospital /ID# 165275, Kumamoto-shi, Kumamoto, Japan|Okayama University Hospital /ID# 165268, Okayama-shi, Okayama, Japan|Osaka Red Cross Hospital /ID# 161888, Osaka-shi, Osaka, Japan|Osaka City University Hospital /ID# 165290, Osaka-shi, Osaka, Japan|Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 167688, Osaka-shi, Osaka, Japan|Osaka Medical College Hospital /ID# 162908, Takatsuki -shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 162911, Kawagoe-shi, Saitama, Japan|Dokkyo Medical University Saitama Medical Center /ID# 162907, Koshigaya, Saitama, Japan|Hamamatsu University Hospital /ID# 171048, Hamamatsu, Shizuoka, Japan|Tokyo Jikei Daisan Hospital /ID# 164159, Komae-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 167685, Shinjuku-ku, Tokyo, Japan|University of Yamanashi Hospital /ID# 161770, Chuo-shi, Yamanashi, Japan|Kato Michio Hepatology Clinic /ID# 159476, Amagasaki, Hyogo, Japan|Aomori Prefectural Central Hos /ID# 160822, Aomori-shi, Japan|Mantani Clinic /ID# 168353, Arida, Japan|Asahikawa City Hospital /ID# 167703, Asahikawa-shi, Japan|Japanese Red Cross Asahikawa /ID# 165265, Asahikawa, Japan|National Hospital Organization /ID# 168346, Chiba, Japan|Chiba University Hospital /ID# 160875, Chiba, Japan|Seirei Sakura Citizen Hospital /ID# 166896, Chiba, Japan|Kenseido-iin /ID# 164166, Chichibu, Japan|Fuji City General Hospital /ID# 165278, Fuji, Japan|Fukui Prefectural Hospital /ID# 168344, Fukui, Japan|Fukui Prefectural Hospital /ID# 169552, Fukui, Japan|University of Fukui Hospital /ID# 166933, Fukui, Japan|Chihaya Hospital /ID# 161893, Fukuoka, Japan|Morichika Internal Medicine /ID# 168351, Fukuyama, Japan|Gifu Municipal Hospital /ID# 165287, Gifu, Japan|Shiroyama Hospital /ID# 164963, Habikino-osaka, Japan|Aomori Rosai Hospital /ID# 167702, Hachinohe, Japan|Tamakoshi Clinic /ID# 165282, Hamamatsu, Japan|Higashihiroshima Medical Ctr /ID# 168343, Higashihiroshima, Japan|Mito Medical Center /ID# 171046, Higashiibaraki-gun, Japan|Higashiomicity Notogawa Hosp /ID# 161891, Higashiomi, Shiga, Japan|Shin-ishikiri Clinic /ID# 169643, Higashiosaka, Japan|Wakakusa Daiichi Hospital /ID# 166882, Higashiosaka, Japan|Hiroshima Red Cross Hosp Atomi /ID# 162912, Hiroshima, Japan|Hiroshima University Hospital /ID# 160815, Hiroshima, Japan|Hiroshima-Nishi Medical Center /ID# 169642, Hiroshima, Japan|Koyo New Town Hospital /ID# 161890, Hiroshima, Japan|Taishi Hospital /ID# 165291, Hyogo, Japan|Iizuka Hospital /ID# 161886, Iizuka, Japan|Ikeda Municipal Hospital /ID# 160814, Ikeda, Japan|Tokyo Med Uni Ibaraki Med Ctr /ID# 162955, Inashiki, Japan|Nippon Med Chiba Hokusoh Hosp /ID# 162902, Inzai, Japan|Saitama Medical University Hos /ID# 161768, Iruma-gun, Japan|Itoigawa Sogo Hospital /ID# 166884, Itoigawa, Japan|Kamiiwade Internal Med-Neuro /ID# 166881, Iwade, Japan|Kaizuka City Hospital /ID# 165256, Kaizuka, Japan|Kamisu Saiseikai Hospital /ID# 167701, Kamisu, Japan|Kiyokawa Hospital /ID# 164961, Kanagawa, Japan|Hiratsuka City Hospital /ID# 161884, Kanagawa, Japan|Niwa Hospital /ID# 167684, Kanagawa, Japan|Fuji Clinic /ID# 160820, Kanonji, Japan|Ibaraki Prefectural Cent. Hosp /ID# 164962, Kasama, Japan|The Jikei Univ. Kashiwa Hosp. /ID# 166888, Kashiwa-shi, Japan|Kashiwazaki General Hospital a /ID# 168352, Kashiwazaki, Japan|Kawase Clinic /ID# 164957, Kasugai, Japan|Hirose Clinic /ID# 167699, Kawagoe, Japan|Sekishindo Hospital /ID# 162960, Kawagoe, Japan|Kawaguchi Municipal Medical Ce /ID# 165270, Kawaguchi, Japan|Kanto Rosai Hospital /ID# 165258, Kawasaki-shi, Kanagawa, Japan|Kawasaki Municipal Tama Hospit /ID# 165267, Kawasaki, Japan|Kishiwada Tokushukai Hospital /ID# 164964, Kishiwada, Osaka, Japan|Kokura Kinen Hospital /ID# 164969, Kitakyusyu, Japan|Kitasato University Medical Ce /ID# 158120, Kitamoto, Japan|Kobe Asahi Hospital /ID# 161896, Kobe, Japan|Kobe Adventist Hospital /ID# 161897, Kobe, Japan|Konan Kosei Hospital /ID# 165277, Konan-shi, Japan|Cosmos Clinic /ID# 164161, Koriyama, Japan|Ishida Medical Clinic /ID# 166887, Koriyama, Japan|Hanada Internal Medicine Clin /ID# 165266, Koshigaya, Saitam, Japan|Kawasaki Medical School Hosp /ID# 162906, Kurashiki, Japan|National Hosp Org Kure Med Cen /ID# 167689, Kure, Hiroshima, Japan|Kurihara Central Hospital /ID# 171047, Kurihara, Japan|Kuroishi Hospital /ID# 164971, Kuroishi-aomori, Japan|Shin Koga Clinic /ID# 164972, Kurume, Japan|Koga Hospital 21 /ID# 167698, Kurume, Japan|Hori Internal Medicine Clinic /ID# 167696, Kushiro, Japan|NHO Kyoto Medical Center /ID# 162910, Kyoto, Japan|Matsuzaki Internal Medicine Cl /ID# 164970, Kyoto, Japan|Gibo Hepatorogy Clinic /ID# 161766, Matsumoto, Japan|Kizawa Memorial Hospital /ID# 162957, Minokamo, Japan|Sumiyoshi Clinic Hospital /ID# 164163, Mito, Japan|South Miyagi Medical Center /ID# 164965, Miyagi, Japan|National Hospital Organization /ID# 168345, Miyakonojo, Japan|University of Miyazaki Hosp /ID# 166880, Miyazaki-shi, Japan|Miyazaki Medical Center Hospit /ID# 165279, Miyazaki, Japan|Matsushita Memorial Hospital /ID# 167693, Moriguchi-shi, Japan|Suzuki Clinic /ID# 165264, Nagareyama, Japan|Meijo Hospital /ID# 164966, Nagoya-aichi, Japan|Nagoya Central Hospital /ID# 166879, Nagoya-shi, Japan|Meitetsu Hospital /ID# 165288, Nagoya, Japan|Aikawa Minnano-shinryojo /ID# 164168, Nagoya, Japan|Nara City Hospital /ID# 162959, Nara, Japan|Tani Internal Medicine Clinic /ID# 164974, Nayoro, Japan|Ooka Clinic /ID# 161887, Nishinomiya, Japan|Noshiro Yamamoto Med. Assoc. /ID# 162964, Noshiro, Japan|Manna Clinic /ID# 169548, Odawara, Japan|Oita Midical Center /ID# 164960, Oita, Japan|Okayama Saiseikai Outpatient Center Hospital /ID# 159475, Okayama, Japan|Omuta City Hospital /ID# 164967, Omuta, Japan|Onomichi Central General Hospi /ID# 162903, Onomichi, Japan|Kita-harima Medical Center /ID# 164165, ONO, Japan|Kenporen Osaka Central Hospita /ID# 164956, Osaka, Japan|Asai Naika /ID# 167691, Osaka, Japan|Osaka Inter. Cancer Institute /ID# 166889, Osaka, Japan|Osaka Police Hospital /ID# 161769, Osaka, Japan|Asai Naika Iin /ID# 164955, Osaka, Japan|Utajima Ueda Clinic /ID# 161894, Osaka, Japan|Tamai Clinic /ID# 164162, Osaka, Japan|Osaka Hospital /ID# 164157, Osaka, Japan|Seko Internal Medicine Clinic /ID# 164169, Otsu, Japan|Kawazoe Internal Medicine Clin /ID# 165292, Saga, Japan|Saitama Citizens Medical Ctr /ID# 169550, Saitama, Japan|Sainokuni Higashiomiya Medical /ID# 167700, Saitama, Japan|Honda Internal Clinic /ID# 161767, Saitama, Japan|Saitama Cooperative Hospital /ID# 167697, Saitama, Japan|Minamitani Clinic /ID# 160821, Sakai, Japan|Kaisei Hospital /ID# 164973, Sapporo, Japan|Sendai Kousei Hospital /ID# 162961, Sendai, Japan|Saka General Hospital /ID# 162962, Shiogama-miyagi, Japan|Suita Municipal Hospital /ID# 164958, Suita-osaka, Japan|Saiseikai Suita Hospital /ID# 165289, Suita, Japan|Kagawa Prefectural Central Hos /ID# 160816, Takamatsu, Japan|Sawada Hepatology & Gastro /ID# 165255, Takaraduka, Japan|Tenjin Tanaka Internal Medicin /ID# 166883, Takatsuki, Japan|Hamada Clinic /ID# 171045, Tatebayashi, Japan|Todachuo General Hospital /ID# 165280, Toda-shi, Saitama, Japan|Eastern Chiba Medical Center /ID# 165257, Togane, Chiba, Japan|Delta Clinic /ID# 164167, Tokorozawa, Japan|The Jikei University Hospital /ID# 169547, Tokyo, Japan|Abbott Japan /ID# 144983, Tokyo, Japan|Juntendo University Hospital /ID# 161771, Tokyo, Japan|Nippon Medical School Hospital /ID# 164164, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hos /ID# 167686, Tokyo, Japan|Ohashi Medical Office /ID# 164968, Tokyo, Japan|Juntendo Univ Nerima Hosp /ID# 164160, Tokyo, Japan|JP Red Cross Musashino Hosp /ID# 162904, Tokyo, Japan|Ehime University Hospital /ID# 161885, Toon, Japan|Toyama University Hospital /ID# 169551, Toyoma, Japan|Toyonaka Municipal Hospital /ID# 167692, Toyonaka, Japan|Mie Syokaki Clinic /ID# 161895, Tsu, Mie, Japan|Saiseikai Utsunomiya Hospital /ID# 162958, Utsunomiya, Japan|Seike Clinic /ID# 166890, Uwajima, Japan|Wakayama Rosai Hospital /ID# 165254, Wakayama-shi, Japan|Saiseikai Wakayama Hospital /ID# 162954, Wakayama, Japan|Tokyo Women's Medical Universi /ID# 167694, Yachiyo, Japan|Tohoku Central Hospital /ID# 166897, Yamagata, Japan|Okuda Gastrointestinal Medicin /ID# 168349, Yamaguchi, Japan|Kainan Hospital /ID# 164959, Yatomi-shi, Japan|Kumamoto Rosai Hospital /ID# 167695, Yatsushiro-shi, Japan|Mie Prefectural General Medica /ID# 162963, Yokkaichi, Japan|Showa Univ Fujigaoka Hosp /ID# 162952, Yokohama-shi, Japan|Oita University Hospital /ID# 169549, Yufu-shi, Japan|Yamaguchi Surgery Clinic /ID# 167704, Yugawara, Japan|Josai Hospital /ID# 168347, Yuki, Japan",,"https://ClinicalTrials.gov/show/NCT02945228"
184,"NCT02944396","Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: pemetrexed|Drug: nivolumab|Drug: paclitaxel|Drug: veliparib|Drug: carboplatin","Progression-free survival (PFS)|Recommended Phase 2 dose (RPTD) of veliparib (ABT-888) in combination with nivolumab and platinum doublet chemotherapy in participants with metastatic or advanced Non-Small Cell Lung Cancer (NSCLC).|Tmax for pemetrexed|AUC for nivolumab|Overall Survival (OS)|Tmax for nivolumab|AUC for pemetrexed|Time to Cmax (peak time, Tmax) for veliparib|Area under the plasma concentration-time curve (AUC) for veliparib|Maximum observed serum concentration (Cmax) of nivolumab anti-drug antibody (ADA)|Duration of Overall Response (DOR)|Maximum observed plasma concentration (Cmax) for pemetrexed|Maximum observed plasma concentration (Cmax) for veliparib|Objective Response Rate (ORR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-534|2016-001658-16","December 23, 2016","October 2, 2019","October 2, 2019","October 25, 2016",,"October 23, 2019","University of Alabama at Birmingham - Main /ID# 155135, Birmingham, Alabama, United States|Icri /Id# 155593, Whittier, California, United States|Univ of Colorado Cancer Center /ID# 153820, Aurora, Colorado, United States|University of Chicago /ID# 153824, Chicago, Illinois, United States|Goshen Center for Cancer Care /ID# 153822, Goshen, Indiana, United States|Duke University Medical Center /ID# 153821, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02944396"
185,"NCT02942290","A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)",,"Active, not recruiting","No Results Available","Myelodysplastic Syndromes (MDS)","Drug: Azacitidine|Drug: Venetoclax","AUCt for azacitidine|Cmax of venetoclax|AUCt for venetoclax|Tmax of venetoclax|AUC[0 to infinity] for azacitidine|Recommended Phase 2 dose (RPTD) and dosing schedule of venetoclax in combination with azacitidine|Half-life (t[1/2]) for azacitidine|Cmax for azacitidine|AUC[0-24] for venetoclax|Clearance (CL) for azacitidine|Tmax for azacitidine|Duration of Response (DOR)|Rate of red blood cell (RBC) transfusion independence|Progression-Free Survival (PFS)|Overall Survival (OS)|Hematologic Improvement (HI) rate|Rate of platelet (PLT) transfusion independence|Event-Free Survival (EFS)|Time to transformation to acute myeloid leukemia (AML)|Complete Remission (CR) rate|Overall Response Rate (ORR)|Rate of complete cytogenetic response|Time to next treatment (TTNT)|Marrow Complete Remission (mCR) Rate","AbbVie|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","82","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-531|2016-001657-41","January 12, 2017","January 14, 2020","June 30, 2021","October 24, 2016",,"December 23, 2019","University of Arizona Arthritis Center /ID# 154155, Tucson, Arizona, United States|University of Chicago /ID# 153673, Chicago, Illinois, United States|Univ Maryland School Medicine /ID# 153669, Baltimore, Maryland, United States|Tufts Medical Center /ID# 153672, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 152735, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 153671, Saint Louis, Missouri, United States|Weill Cornell Medical College /ID# 155524, New York, New York, United States|Weill Cornell Medicine /ID# 153661, New York, New York, United States|Oregon Health and Science University /ID# 152734, Portland, Oregon, United States|University of Pittsburgh MC /ID# 153662, Pittsburgh, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 152738, Nashville, Tennessee, United States|UT MD Anderson Cancer Center /ID# 153809, Houston, Texas, United States|Concord Repatriation & Gen Hos /ID# 154958, Concord, New South Wales, Australia|St George Hospital /ID# 154954, Kogarah, New South Wales, Australia|Calvary Mater Newcastle /ID# 154957, Waratah, New South Wales, Australia|Princess Alexandra Hospital /ID# 154990, Woolloongabba, Queensland, Australia|Austin Hospital /ID# 154955, Heidelberg, Victoria, Australia|Alfred Health /ID# 154956, Melbourne, Victoria, Australia|Juravinski Cancer Clinic /ID# 152947, Hamilton, Ontario, Canada|CHU Hotel Dieu /ID# 153828, Nantes CEDEX 1, Pays-de-la-Loire, France|Hopital Saint-Louis /ID# 153827, Paris, France|Universitatsklinikum Mannheim /ID# 153140, Mannheim, Baden-Wuerttemberg, Germany|Uniklinik Koln /ID# 153141, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Carl Gus /ID# 153958, Dresden, Sachsen, Germany|Universitaetsklinikum Leipzig /ID# 153142, Leipzig, Sachsen, Germany|Universitaetsklinikum Halle (S /ID# 153760, Halle, Germany|Klinikum Rechts der Isar /ID# 153139, Munich, Germany|A.O.U. Policlinico S.Orsola-Malpighi /ID# 153763, Bologna, Emilia-Romagna, Italy|AP Romano Umberto I /ID# 153764, Rome, Lazio, Italy|Norfolk and Norwich Univ Hosp /ID# 156492, Norwich, Norfolk, United Kingdom|Heart of England NHS Foundation Trust /ID# 158810, Birmingham, United Kingdom|King's College Hospital NHS /ID# 156489, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02942290"
186,"NCT02939989","A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study","MAGELLAN-3","Enrolling by invitation","No Results Available","Hepatitis C Virus (HCV)","Drug: Sofosbuvir|Drug: ABT-493/ABT-530|Drug: Ribavirin","Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)|Percentage of participants with on-treatment virologic failure.|Percentage of participants with post-treatment HCV virologic relapse","AbbVie","All","12 Years to 99 Years   (Child, Adult, Older Adult)","Phase 3","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-942|2016-002491-26","November 21, 2016","June 28, 2020","September 28, 2020","October 20, 2016",,"November 29, 2019","Digestive Health Specialists of the Southeast /ID# 155719, Dothan, Alabama, United States|Ruane Clinical Research Group /ID# 155714, Los Angeles, California, United States|Digestive Disease Associates - Baltimore /ID# 155713, Baltimore, Maryland, United States|Henry Ford Health System /ID# 155720, Detroit, Michigan, United States|University of Buffalo /ID# 155721, Buffalo, New York, United States|Carolinas Center For Liver Dis /ID# 155731, Statesville, North Carolina, United States|Gastro One /ID# 155729, Germantown, Tennessee, United States|TX Liver Inst, Americ Res Corp /ID# 157881, San Antonio, Texas, United States|Royal Brisbane and Women's Hospital /ID# 200944, Herston, Queensland, Australia|Royal Melbourne Hospital /ID# 155727, Parkville, Victoria, Australia|University of Calgary /ID# 155726, Calgary, Alberta, Canada|Mauss, Schmutz, Hegener, Athma /ID# 155592, Dusseldorf, Germany|Asklepios Klinik St. Georg /ID# 155733, Hamburg, Germany|Waikato Hospital /ID# 155728, Hamilton, Waikato, New Zealand|Auckland City Hospital /ID# 200945, Auckland, New Zealand|Dunedin Hospital /ID# 155591, Dunedin, New Zealand|Hosp Univ Puerta de Hierro /ID# 155734, Majadahonda, Spain|Karolinska Univ Sjukhuset /ID# 155735, Solna, Sweden|Inselspital, Universitaetsklinik /ID# 155716, Bern, Switzerland|St. Mary's Hospital /ID# 155718, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02939989"
187,"NCT02925494","An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids",,"Completed","No Results Available","Uterine Fibroids|Heavy Menstrual Bleeding","Drug: Estradiol/Norethindrone Acetate|Drug: Elagolix","Percentage of Responders based on menstrual blood loss volume reduction|Change in Menstrual Blood Loss (MBL) Volume|Percentage of participants with increase in Hemoglobin|Percentage of participants with suppression of bleeding|Change in MBL Volume by Month","AbbVie","Female","18 Years to 51 Years   (Adult)","Phase 3","433","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-816","September 14, 2016","May 7, 2018","March 22, 2019","October 6, 2016",,"April 12, 2019","Alabama Clinical Therapeutics, LLC /ID# 153217, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC /ID# 153336, Birmingham, Alabama, United States|Choice Research, LLC /ID# 153492, Dothan, Alabama, United States|Brown, Pearson, Guepet Gynecology /ID# 153278, Fairhope, Alabama, United States|University of South Alabama /ID# 153415, Mobile, Alabama, United States|Mobile, Ob-Gyn, P.C. /ID# 153442, Mobile, Alabama, United States|Mesa Obstetricians and Gynecol /ID# 153269, Mesa, Arizona, United States|Core Healthcare Group /ID# 153282, Cerritos, California, United States|Diagnamics Inc. /ID# 153347, Encinitas, California, United States|Grossmont Ctr Clin Research /ID# 153324, La Mesa, California, United States|Futura Research, Inc. /ID# 153345, Norwalk, California, United States|Farid Yasharpour MD Medical Co /ID# 153482, San Fernando, California, United States|Advanced Women's Health Institution /ID# 153401, Greenwood Village, Colorado, United States|MedStar Washington Hosp Ctr /ID# 153321, Washington, District of Columbia, United States|Emerson Clinical Research Inst /ID# 162755, Washington, District of Columbia, United States|James A. Simon, MD, PC /ID# 153323, Washington, District of Columbia, United States|Helix Biomedics, LLC /ID# 153440, Boynton Beach, Florida, United States|Brandon Premier Health Care, PA /ID# 165791, Brandon, Florida, United States|Florida Fertility Institute /ID# 153308, Clearwater, Florida, United States|Omega Research Consultants, LLC /ID# 153381, DeBary, Florida, United States|KO Clinical Research, LLC /ID# 153198, Fort Lauderdale, Florida, United States|Clinical Physiology Assoc. /ID# 153444, Fort Myers, Florida, United States|Solutions Through Adv Rch /ID# 153283, Jacksonville, Florida, United States|Meridien Research /ID# 153310, Kenneth City, Florida, United States|Altus Research, Inc /ID# 153307, Lake Worth, Florida, United States|South Florida Wellness & Clinic /ID# 153420, Margate, Florida, United States|Precision Research Org, LLC /ID# 153276, Miami Lakes, Florida, United States|LCC Medical Research Institute /ID# 153296, Miami, Florida, United States|Invictus Clinical Research Group,LLC /ID# 153196, Miami, Florida, United States|Healthcare Clinical Data, Inc /ID# 153425, Miami, Florida, United States|Ocean Blue Med Research Ctr /ID# 153225, Miami, Florida, United States|Suncoast Clinical Research /ID# 153206, New Port Richey, Florida, United States|Advanced Research Institute /ID# 153413, New Port Richey, Florida, United States|Clinical Associates of Orlando /ID# 153427, Orlando, Florida, United States|Unified Womens Clin Research /ID# 153229, Panama City, Florida, United States|All Wmns HC of West Broward /ID# 153434, Plantation, Florida, United States|Oncova Clinical Research, Inc. /ID# 153497, Saint Cloud, Florida, United States|Physician Care Clin. Res., LLC /ID# 153210, Sarasota, Florida, United States|Qps-Mra, Llc /Id# 153456, South Miami, Florida, United States|University of South Florida /ID# 153271, Tampa, Florida, United States|Axcess Medical Research /ID# 153500, Wellington, Florida, United States|Virtus Research Consultant,LLC /ID# 153398, Wellington, Florida, United States|Comprehensive Clinical Trials /ID# 153350, West Palm Beach, Florida, United States|Atlanta Medical Research Insti /ID# 153298, Alpharetta, Georgia, United States|Paramount Research Solutions /ID# 153424, Alpharetta, Georgia, United States|Paramount Research Solutions /ID# 160974, Alpharetta, Georgia, United States|Mount Vernon Clinical Res, LLC /ID# 153403, Atlanta, Georgia, United States|Atlanta Women's Research Inst /ID# 153212, Atlanta, Georgia, United States|Masters of Clinical Research, Inc. /ID# 153295, Augusta, Georgia, United States|Georgia Regents University /ID# 153395, Augusta, Georgia, United States|Paramount Research Solutions /ID# 153351, College Park, Georgia, United States|Fellows Research Alliance, Inc /ID# 153227, Savannah, Georgia, United States|Clinical Research Consultants of Atlanta /ID# 153285, Suwanee, Georgia, United States|Atlanta Gynecology Research Institute /ID# 200074, Suwanee, Georgia, United States|Sonora Clinical Research /ID# 153231, Meridian, Idaho, United States|Affinity Clinical Research /ID# 153417, Oak Brook, Illinois, United States|Bluegrass Clinical Research /ID# 153280, Louisville, Kentucky, United States|Clinical Trials Management,LLC /ID# 153211, Covington, Louisiana, United States|Clinical Trials Management,LLC /ID# 153439, Covington, Louisiana, United States|Ochsner Baptist Medical Center /ID# 153459, New Orleans, Louisiana, United States|Omni Fertility and Laser Insti /ID# 153228, Shreveport, Louisiana, United States|Baltimore Suburban Health /ID# 168386, Baltimore, Maryland, United States|Neccr /Id# 153274, Fall River, Massachusetts, United States|Genesis Clinical Research /ID# 153379, Fall River, Massachusetts, United States|Great Lakes Research Group,Inc /ID# 153302, Bay City, Michigan, United States|Saginaw Valley Med Res Group /ID# 153498, Saginaw, Michigan, United States|Wayne State University Physician Group - Southfield /ID# 153418, Southfield, Michigan, United States|Accent Clinical Trials /ID# 153474, Las Vegas, Nevada, United States|Office of Edmond E. Pack, MD /ID# 153411, Las Vegas, Nevada, United States|Mabey, Las Vegas, NV /ID# 153314, Las Vegas, Nevada, United States|Lawrence OB/GYN /ID# 153218, Lawrenceville, New Jersey, United States|Jersey Shore University Medical Center /ID# 153495, Neptune, New Jersey, United States|Bosque Women's Care /ID# 153223, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center /ID# 153344, Brooklyn, New York, United States|Manhattan Medical Research /ID# 153386, New York, New York, United States|Columbia Univ Medical Center /ID# 153275, New York, New York, United States|Cwrwc /Id# 153313, Durham, North Carolina, United States|Unified Women's Clinical Research-Greensboro /ID# 153499, Greensboro, North Carolina, United States|Pinewest Ob-Gyn, Inc. /ID# 153197, High Point, North Carolina, United States|Eastern Carolina Women's Centr /ID# 153341, New Bern, North Carolina, United States|Unified Women's Clinical Resea /ID# 153312, Raleigh, North Carolina, United States|Wake Research Associates, LLC /ID# 153402, Raleigh, North Carolina, United States|Unified Women's Clinical Resea /ID# 153297, Winston-Salem, North Carolina, United States|Clinical Inquest Center Ltd /ID# 153436, Beavercreek, Ohio, United States|CTI Clinical Research Center /ID# 153201, Cincinnati, Ohio, United States|University Hospitals Cleveland /ID# 153450, Cleveland, Ohio, United States|University of Toledo /ID# 153409, Toledo, Ohio, United States|Comprehensive Womens Care /ID# 153396, Westerville, Ohio, United States|Legacy Medical Group-Portland /ID# 168286, Portland, Oregon, United States|Main Line Fertility Center /ID# 153410, Bryn Mawr, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 153443, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 153203, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 153319, Philadelphia, Pennsylvania, United States|Clinical Research of Philadelphia, LLC /ID# 153279, Philadelphia, Pennsylvania, United States|Reading Hosp Clncl Trials Ofc /ID# 153475, West Reading, Pennsylvania, United States|Medical University of South Carolina /ID# 153325, Charleston, South Carolina, United States|Vista Clinical Research /ID# 153399, Columbia, South Carolina, United States|Chattanooga Medical Research /ID# 153405, Chattanooga, Tennessee, United States|WR-ClinSearch /ID# 153404, Chattanooga, Tennessee, United States|Women's Health Trials /ID# 153426, Memphis, Tennessee, United States|Research Memphis Associates, LLC /ID# 153322, Memphis, Tennessee, United States|Access Clinical Trials, Inc. /ID# 153441, Nashville, Tennessee, United States|Lotus Gynecology /ID# 153476, Austin, Texas, United States|Texas Health Presbyterian Hosp /ID# 153339, Dallas, Texas, United States|UT Southwestern Medical Center /ID# 153400, Dallas, Texas, United States|Baylor Scott & White /ID# 153273, Fort Worth, Texas, United States|Willowbend Health and Wellness /ID# 153458, Frisco, Texas, United States|Advances in Health, Inc. /ID# 153414, Houston, Texas, United States|The Woman's Hospital of Texas /ID# 153270, Houston, Texas, United States|FMC Science /ID# 153289, Lampasas, Texas, United States|Clinical Trials of Texas,Inc. /ID# 153209, San Antonio, Texas, United States|Discovery Clinical Trials-San Antonio /ID# 153315, San Antonio, Texas, United States|Houston Ctr for Clin Research /ID# 153221, Sugar Land, Texas, United States|Center of Reproductive Medicin /ID# 153320, Webster, Texas, United States|Tidewater Physicians for Women /ID# 153432, Norfolk, Virginia, United States|Eastern Virginia Med School /ID# 153380, Norfolk, Virginia, United States|Clinical Research Partners, LL /ID# 153412, North Chesterfield, Virginia, United States|Clinical Research Partners, LLC /ID# 153343, Richmond, Virginia, United States|Clinical Trials Virginia, Inc. /ID# 153419, Richmond, Virginia, United States|Emerson Clinical Research Inst /ID# 153416, Vienna, Virginia, United States|Virginia Mason Medical Center /ID# 153342, Seattle, Washington, United States|Seattle Women's Health, Research, Gynecology /ID# 153306, Seattle, Washington, United States|Victory Reproductive Care /ID# 153299, Windsor, Ontario, Canada|Rodriguez-Ginorio, San Juan /ID# 153328, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 153329, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02925494"
188,"NCT02925117","A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis",,"Completed","No Results Available","Atopic Dermatitis","Drug: ABT-494|Drug: Placebo","Mean Percentage Change in EASI score|Percent change in EASI score|Proportion of participants achieving EASI 75 response|Proportion of participants achieving EASI 90 response|Proportion of participants achieving SCORAD 90 response|Proportion of participants achieving SCORAD 50 response|Summary of EASI 75 at all visits in Period 2 among those who were re-randomized as EASI 75 non-responders at Week 16|Proportion of participants with Dermatology Life Quality Index (DLQI) = ""0"" or ""1""|Proportion of participants achieving SCORAD 75 response|Percent change in SCORAD score|Time to loss of EASI 50 response relative to Baseline among those who were re-randomized as EASI 75 responders at Week 16|Change and percent change from Week 16 (re-randomization) in EASI score at all Period 2 visits|Proportion of participants achieving EASI 50 response|Percent change in pruritus/ itch numerical rating scale (NRS)|Proportion of participants achieving an Investigator Global Assessment (IGA) of ""0"" or ""1""|Change from Baseline in DLQI|Proportion of Participants achieving an EASI 75 response","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-048|2016-002451-21","October 25, 2016","August 10, 2017","January 31, 2019","October 5, 2016",,"February 15, 2019","San Luis Derm and Laser Clinic /ID# 154482, San Luis Obispo, California, United States|Forward Clinical Trials, Inc. /ID# 157974, Tampa, Florida, United States|Europaeisches Brusstzentrum /ID# 154516, Atlanta, Georgia, United States|DermAssociates /ID# 153584, Rockville, Maryland, United States|Tufts Medical Center /ID# 153586, Boston, Massachusetts, United States|Psoriasis Treatment Ctr NJ /ID# 153578, East Windsor, New Jersey, United States|Icahn School of Med Mt. Sinai /ID# 153582, New York, New York, United States|Univ Rochester Med Ctr /ID# 154477, Rochester, New York, United States|University of Pittsburgh MC /ID# 154278, Pittsburgh, Pennsylvania, United States|Arlington Research Center, Inc /ID# 154522, Arlington, Texas, United States|Modern Research Associates, PL /ID# 154487, Dallas, Texas, United States|Center for Clinical Studies /ID# 153589, Houston, Texas, United States|Woden Dermatology /ID# 157907, Phillip, Australian Capital Territory, Australia|St George Hospital /ID# 157908, Kogarah, New South Wales, Australia|Specialist Connect Pty Ltd /ID# 157909, Woolloongabba, Queensland, Australia|Skin and Cancer Foundation /ID# 157906, Carlton, Victoria, Australia|Cliniques Universitaires Saint Luc /ID# 155134, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Institute for Skin Advancement /ID# 153246, Calgary, Alberta, Canada|Dr. Chih-ho Hong Medical Inc. /ID# 153241, Surrey, British Columbia, Canada|Enverus Medical Research /ID# 153239, Surrey, British Columbia, Canada|CCA Medical Research /ID# 155817, Ajax, Ontario, Canada|Lynderm Research Inc. /ID# 153242, Markham, Ontario, Canada|Dermatology Ottawa Research Centre /ID# 153248, Ottawa, Ontario, Canada|K. Papp Clinical Research /ID# 153244, Waterloo, Ontario, Canada|Mehiläinen Neo /ID# 154960, Turku, Varsinais-Suomi, Finland|Mikkeli Central Hospital /ID# 154959, Mikkeli, Finland|Univ Hosp Schleswig-Holstein /ID# 154163, Kiel, Schleswig-Holstein, Germany|TFS Trial Form Support GmbH /ID# 155442, Hamburg, Germany|Fukuoka University Hospital /ID# 152714, Fukuoka-shi, Fukuoka, Japan|Takagi Dermatological Clinic /ID# 152706, Obihiro-shi, Hokkaido, Japan|Medical Cooperation Kojinkai Sapporo Skin Clinic /ID# 153781, Sapporo-shi, Hokkaido, Japan|Nippon Medical School Hospital /ID# 153287, Tokyo, Japan|Radboud Universitair Medisch Centrum /ID# 153688, Nijmegen, Gelderland, Netherlands|Academisch Medisch Centrum /ID# 153596, Amsterdam, Noord-Holland, Netherlands|Universitair Medisch Centrum Groningen /ID# 153595, Groningen, Netherlands|Universitair Medisch Centrum Utrecht /ID# 153687, Utrecht, Netherlands|Hosp Santa Creu i Sant Pau /ID# 153519, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 155598, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02925117"
189,"NCT02916017","HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis",,"Active, not recruiting","No Results Available","Uveitis",,"Incidence of adverse drug reactions (ADR)|Change in Visual Functioning Questionnaire (VFQ)-25 score|Change in Visual acuity in each eye|Change in Anterior Chamber (AC) cell grade (standardization of uveitis nomenclature (SUN) criteria) in each eye|Percentage of Overall improvement|Change in retinal lesions in each eye|Change in central retinal thickness in each eye|Change in Vitreous Haze grade in each eye","AbbVie","All","up to 100 Years   (Child, Adult, Older Adult)",,"259","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-665","November 15, 2016","September 27, 2020","September 27, 2020","September 27, 2016",,"December 16, 2019","Juntendo University Urayasu Hospital /ID# 168358, Urayasu Shi, Chiba, Japan|Matsuyama Red Cross Hospital /ID# 164149, Matsuyama-shi, Ehime, Japan|Kyushu University Hospital /ID# 163042, Fukuoka-shi, Fukuoka, Japan|Fukuoka University Hospital /ID# 163043, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 162945, Kurume-shi, Fukuoka, Japan|Gunma University Hospital /ID# 166916, Maebashi-shi, Gunma, Japan|Kobe University Hospital /ID# 165250, Kobe, Hyogo, Japan|Kanazawa University Hospital /ID# 166914, Kanazawa, Ishikawa, Japan|Yokohama Municipal Citizen's Hospital /ID# 161742, Yokohama, Kanagawa, Japan|Shinshu University Hospital /ID# 164153, Matsumoto-shi, Nagano, Japan|Niigata University Medical & Dental Hospital /ID# 169563, Niigata-shi, Niigata, Japan|Osaka University Hospital /ID# 164147, Suita-shi, Osaka, Japan|Saitama Medical University Hospital /ID# 162944, Iruma-gun, Saitama, Japan|Dokkyo Medical University Hospital /ID# 164154, Shimotsuga-gun, Tochigi, Japan|Tokushima University Hospital /ID# 164145, Tokushima-shi, Tokushima, Japan|Juntendo University Hospital /ID# 169564, Bunkyo-ku, Tokyo, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 165251, Bunkyo-ku, Tokyo, Japan|Tokyo Medical University Hospital /ID# 164146, Shinjuku-ku, Tokyo, Japan|Center hospital of the National Center for Global Health and Medicine /ID# 164148, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 165248, Shinjuku-ku, Tokyo, Japan|Hiroshima University Hospital /ID# 166915, Hiroshima, Japan|Kagoshima Uni Med and Dental /ID# 164150, Kagoshima, Japan|Kakogawa Central City Hospital /ID# 167706, Kakogawa, Japan|Miyata Ophthalmic Hospital /ID# 167707, Miyakonojo, Japan|Kochi Medical School Hospital /ID# 164144, Nankoku-shi, Japan|Duplicate_The Hospital of Hyogo College /ID# 166913, Nishinomiya-shi, Japan|Omihachiman Community Med Ctr /ID# 164978, Omihachiman, Japan|Yodogawa Christian Hospital /ID# 161741, Osaka-shi, Japan|Osaka Hospital /ID# 164151, Osaka, Japan|Hokkaido University Hospital /ID# 163041, Sapporo, Japan|Tosei General Hospital /ID# 167708, Seto, Japan|Natl Defense Med College Hosp /ID# 162946, Tokorozawa, Japan|The Jikei University Hospital /ID# 164152, Tokyo, Japan|Abbott Japan /ID# 147893, Tokyo, Japan|The University of Tokyo Hospital /ID# 162943, Tokyo, Japan|Nippon Medical School Hospital /ID# 166938, Tokyo, Japan|Tokyo Shinjuku Medical Center /ID# 166934, Tokyo, Japan|Tottori Municipal Hospital /ID# 159431, Tottori, Japan|Yamaguchi University Hospital Institutional Review Board /ID# 165249, Ube-shi, Japan",,"https://ClinicalTrials.gov/show/NCT02916017"
190,"NCT02906488","Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease",,"Recruiting","No Results Available","Parkinson's Disease (PD)",,"Change in ""Off"" Periods From Start of Treatment to Week 104|Time-dependent Change in ""Off"" Time and ""On"" Time Accompanied By Dyskinesia Interfering with Daily Activities|Time-dependent Change in Unified Parkinson's Disease Rating Scale (UPDRS)|Time-dependent Change in Parkinson's Disease Questionnaire - 8 Items (PDQ-8)|""Off"" Period and ""On"" Period Accompanied by Dyskinesia Interfering with Daily Activities by Patient Characteristic Factor|Time-dependent Change in Parkinson's Disease Quality of Life Questionnaire - Carers (PDQ-Carer)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"512","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-720","September 12, 2016","January 31, 2021","January 31, 2021","September 20, 2016",,"June 19, 2019","Nagoya City University Hospital /ID# 166893, Nagoya-shi, Aichi, Japan|Juntendo University Urayasu Hospital /ID# 162890, Urayasu Shi, Chiba, Japan|Fukuoka University Hospital /ID# 166900, Fukuoka-shi, Fukuoka, Japan|National Hospital Organization Asahikawa Medical Center /ID# 155744, Asahikawa, Hokkaido, Japan|Kobe University Hospital /ID# 166895, Kobe, Hyogo, Japan|Yokohama City Univ Medical Ctr /ID# 165285, Yokohama, Kanagawa, Japan|National Hospital Organization Utano National Hospital /ID# 164139, Kyoto City, Kyoto, Japan|Mie University Hospital /ID# 164140, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 169557, Sendai-shi, Miyagi, Japan|National Hospital Organization Sendai Medical Center /ID# 160831, Sendai-shi, Miyagi, Japan|NHO Sendai Nishitaga National Hospital /ID# 164977, Sendai, Miyagi, Japan|Shinshu University Hospital /ID# 169559, Matsumoto-shi, Nagano, Japan|Osaka Saiseikai Nakatsu Hospital /ID# 168357, Osaka-shi, Osaka, Japan|Osaka University Hospital /ID# 161764, Suita-shi, Osaka, Japan|Dokkyo Medical University Hospital /ID# 171050, Shimotsuga-gun, Tochigi, Japan|Saitama Rihabilitation Center /ID# 168356, Ageo, Japan|Minami Kyushu National Hospita /ID# 171052, Aira, Japan|Aomori Prefectural Central Hos /ID# 165286, Aomori-shi, Japan|Saiseikai Saijo Hospital /ID# 167705, Ehime, Japan|Japanese Red Cross Fukui Hospi /ID# 166907, Fukui, Japan|Fukushima Med Univ Hosp /ID# 169560, Fukushima-shi, Japan|Gifu Prefectural Genl Med Ctr /ID# 166894, Gifu, Japan|Higashiosaka City Medical Cent /ID# 166901, Higashiosaka, Japan|Himeji Central Hospital /ID# 164136, Himeji-shi, Japan|Ina Central Hospital /ID# 166905, INA, Japan|Kayashimaikuno Hospital /ID# 171051, Kadoma, Japan|Kagoshima Uni Med and Dental /ID# 166909, Kagoshima, Japan|Kameda Medical Center /ID# 166906, Kamogawa, Japan|Nara Medical Univ Hospital /ID# 160830, Kashihara, Japan|Wakamatsu Hospital /ID# 160818, Kitakyusyu, Japan|National Center Hospital, NCNP /ID# 160824, Kodaira, Japan|NHO Matsue Medical Center /ID# 164135, Matsue, Japan|Saiseikai Matsuyama Hospital /ID# 169561, Matsuyama, Japan|Mino City Hospital /ID# 161765, Mino-shi, Japan|Junwakai Memorial Hospital /ID# 164141, Miyazaki, Japan|Kochi Medical School Hospital /ID# 166903, Nankoku-shi, Japan|The Hospital of Hyogo College /ID# 169562, Nishinomiya-shi, Japan|Obihiro Kosei General Hospital /ID# 166904, Obihiro, Japan|Okayama Kyokuto Hospital /ID# 166892, Okayama-shi, Japan|Sagamihara National Hospital /ID# 160825, Sagamihara, Japan|Sakai Hospital Kinki Univ /ID# 166908, Sakai-shi, Japan|Kyoto University Hospital /ID# 162891, Sakyo-ku, Japan|Hokkaido Medical Center /ID# 161763, Sapporo-shi, Japan|Hokkaido University Hospital /ID# 166902, Sapporo, Japan|Tohoku Medical and Pharmaceuti /ID# 169558, Sendai, Japan|Tokuyama Central Hospital /ID# 171049, Shunan-shi, Japan|Itsuki Hospital /ID# 164138, Tokushima, Japan|Juntendo University Hospital /ID# 160823, Tokyo, Japan|Ehime University Hospital /ID# 162889, Toon, Japan|Toyota Memorial Hospital /ID# 166891, Toyota, Japan|Wakayama Medical University /ID# 160817, Wakayama, Japan|NHO Yanai Medical Center /ID# 164137, Yanai, Japan",,"https://ClinicalTrials.gov/show/NCT02906488"
191,"NCT02904902","Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa",,"Completed","Has Results","Hidradenitis Suppurativa","Drug: adalimumab","Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12|Percentage of Participants Achieving AN Count of 0, 1, or 2 at Week 12|Percentage of Participants Achieving at Least 30% Reduction and at Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 2 Among Participants With Baseline Numeric Rating Scale (NRS) >=3|Change From Baseline to Week 12 in Modified Sartorius Scale Score","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","15","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-573","September 6, 2016","September 1, 2017","May 30, 2019","September 19, 2016","February 27, 2019","June 18, 2019","Nagoya City University Hospital /ID# 151495, Nagoya-shi, Aichi, Japan|Kurume University Hospital /ID# 152579, Kurume-shi, Fukuoka, Japan|Takagi Dermatological Clinic /ID# 151906, Obihiro, Hokkaido, Japan|University of the Ryukyus Hosp /ID# 152268, Nakagami-gun, Okinawa, Japan|NHO Osaka National Hosp /ID# 152452, Osaka-shi, Osaka, Japan|Tokai University Hachioji Hosp /ID# 151338, Hachioji, Tokyo, Japan|Tokyo Medical University Hospital /ID# 154171, Shinjuku-ku, Tokyo, Japan|Fukuoka University Hospital /ID# 151350, Fukuoka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02904902/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02904902/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02904902"
192,"NCT02899052","Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)",,"Recruiting","No Results Available","Multiple Myeloma","Drug: Carfilzomib|Drug: Venetoclax|Drug: Dexamethasone","Adverse events|Objective Response Rate (ORR) of VenKd in participants with RRMM as well as those with t(11;14)-positive RRMM.|Very Good Partial Response (VGPR) or better response rate of VenKd in participants with relapsed or refractory MM (RRMM) as well as those with t(11;14)-positive RRMM|Very Good Partial Response (VGPR) or better response rate in participants with relapsed or refractory MM and in a subset of participants with high BCL-2 expression|Progression-free survival (PFS) in participants with relapsed or refractory MM and in a subset of participants with high BCL-2 expression|Minimal residual disease (MRD)|Area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24) post-dose of venetoclax|Clearance (CL) of carfilzomib|Duration of overall response (DOR) in participants with relapsed or refractory MM and in a subset of participants with high BCL-2 expression|Terminal phase elimination rate constant (β) of carfilzomib|AUC from 0 to infinity (AUC∞)of carfilzomib|Time to progression (TTP) in participants with relapsed or refractory MM and in a subset of participants with high BCL-2 expression|AUC from time 0 to the time of the last measurable concentration (AUCt) of carfilzomib|Objective response rate (ORR) in participants with relapsed or refractory MM and in a subset of participants with high B-cell lymphocyte-2 (BCL-2) expression|Cmax of carfilzomib|Terminal elimination half-life (t1/2) of carfilzomib|Time to maximum plasma concentration (peak time, Tmax) of venetoclax|Maximum plasma concentration (Cmax) of venetoclax","AbbVie|Genentech, Inc.|Onyx Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-538","January 19, 2017","March 27, 2020","February 19, 2022","September 14, 2016",,"September 25, 2019","University of Alabama at Birmingham - Main /ID# 151405, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences /ID# 151399, Little Rock, Arkansas, United States|St Jude Medical Center / St Joseph Health /ID# 210183, Fullerton, California, United States|Marin Cancer Care /ID# 210408, Greenbrae, California, United States|Emory University Hospital /ID# 161710, Atlanta, Georgia, United States|University of Chicago /ID# 151395, Chicago, Illinois, United States|Univ Kansas Med Ctr /ID# 210203, Kansas City, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 151407, Lexington, Kentucky, United States|Univ Maryland School Medicine /ID# 159721, Baltimore, Maryland, United States|Duke University Medical Center /ID# 162062, Durham, North Carolina, United States|University of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States|University of Utah /ID# 151397, Salt Lake City, Utah, United States|VA Puget Sound Healthcare Syst /ID# 155369, Seattle, Washington, United States|Gundersen Health System /ID# 210807, La Crosse, Wisconsin, United States|Aurora Health Care, Aurora Cancer Center /ID# 209612, Wauwatosa, Wisconsin, United States|Auxilio Mutuo Cancer Center /ID# 157853, San Juan, Puerto Rico|VA Caribbean Healthcare System /ID# 157854, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02899052"
193,"NCT02897115","A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment","STRIKE","Terminated","Has Results","Axial Spondyloarthritis","Biological: Adalimumab|Other: Non-steroidal Anti-inflammatory Drugs (NSAIDs)","Percentage of Participants With an Ankylosing Spondylitis Disease Activity Score (ASDAS) of Inactive Disease at Week 32|Change From Baseline in European Quality of Life-5 Dimensions (EQ-5D) Questionnaire|Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Presenteeism|Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Absenteeism|Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Work Productivity Impairment|Change From Baseline in Work Productivity and Activity Impairment - Axial Spondyloarthritis (WPAI-axSpA): Total Activity Impairment|Change From Baseline in Assessment of Spondyloarthritis International Society (ASAS) Health Index (HI)|Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index|Percentage of Participants Achieving a BASDAI 50 Response|Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)|Change From Baseline in ASDAS(CRP)|Percentage of Participants Achieving ASDAS(CRP) Major Improvement|Percentage of Participants Achieving ASDAS(CRP) Clinically Important Improvement|Percentage of Participants With ASDAS Inactive Disease at Week 52|Percentage of Participants With ASDAS Low Disease Activity|Percentage of Participants With ASDAS Moderate Disease Activity|Percentage of Participants With ASDAS High Disease Activity|Percentage of Participants With ASDAS Very High Disease Activity|Percentage of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response|Percentage of Participants Achieving an ASAS 40 Response|Percentage of Participants Achieving ASAS Partial Remission|Change From Baseline in Active Inflammation of the Sacroiliac Joints and Spine|Change From Baseline in Physician's Global Assessment of Disease Activity|Change From Baseline in Patient's Global Assessment of Disease Activity|Change From Baseline in Patient's Global Assessment of Pain|Change From Baseline in Swollen Joint Count|Change From Baseline in Tender Joint Count|Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES)|Change From Baseline in Dactylitis Count|Change From Baseline in the Erythrocyte Sedimentation Rate (ESR)|Change From Baseline in C-reactive Protein (CRP)|Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)|Number of Participants With New Onset Anterior Uveitis","AbbVie|IST GmbH, Germany|Hannover Medical School|Improvement by Movement GmbH, Germany","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","22","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W15-679|2015-005398-18","September 12, 2016","December 21, 2017","December 21, 2017","September 13, 2016","July 5, 2019","July 5, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02897115/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02897115/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02897115"
194,"NCT02896985","Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )","PRADA","Active, not recruiting","No Results Available","Crohn's Disease",,"Explore the relationship between drug concentration at baseline and recapture of response|Explore the relationship between trough adalimumab concentrations at baseline and change in patient reported outcome 2 (PRO2)|Explore the relationship between trough adalimumab concentrations at baseline and change in C-reactive protein (CRP)|Explore the relationship between trough adalimumab concentrations at baseline and change in fecal calprotectin|Proportion of participants requiring steroids or additional therapy|Proportion of participants with 50% drop from screening in CRP or calprotectin|Explore the relationship between changes in HBI between screening and final trough adalimumab concentrations|Proportion of participants with clinical remission PRO2 < 8|Proportion of participants with normalization of CRP or fecal calprotectin","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"98","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-770","December 16, 2016","March 30, 2020","March 30, 2020","September 12, 2016",,"December 23, 2019","University of Calgary /ID# 157893, Calgary, Alberta, Canada|South Edmonton Gastroenterolog /ID# 170934, Edmonton, Alberta, Canada|Okanagan Clinical Trials /ID# 200046, Kelowna, British Columbia, Canada|Columbia Gastro Mgmnt Ltd /ID# 152507, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 201259, Vancouver, British Columbia, Canada|Discovery Clinical Services /ID# 154682, Victoria, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 202502, Victoria, British Columbia, Canada|Winnipeg Regional Health Autho /ID# 200115, Winnipeg, Manitoba, Canada|Dr. Everett Chalmers Reg Hosp. /ID# 171560, Fredericton, New Brunswick, Canada|Qe Ii Hsc /Id# 152454, Halifax, Nova Scotia, Canada|Dr. Mark Lee Medicine Professi /ID# 153127, Cambridge, Ontario, Canada|McMaster University Med Cent /ID# 151996, Hamilton, Ontario, Canada|London Health Sciences Centre /ID# 152508, London, Ontario, Canada|Jeffrey So Medicine Professional Corporation /ID# 168268, Oakville, Ontario, Canada|Taunton surgical centre /ID# 151998, Oshawa, Ontario, Canada|The Ottawa Hospital /ID# 153771, Ottawa, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 155262, Toronto, Ontario, Canada|Dr O Tarabain Medicine Prof Corp /ID# 163125, Windsor, Ontario, Canada|CISSS de la Monteregie /ID# 162724, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 155493, Levis, Quebec, Canada|Hospital Maisonneuve-Rosemont /ID# 155184, Montreal, Quebec, Canada|McGill Univ HC /ID# 151997, Montreal, Quebec, Canada|Clinique MEDI-CLE /ID# 153772, Montreal, Quebec, Canada|CIUSSS de l'Estrie - CHUS /ID# 157976, Sherbrooke, Quebec, Canada|Royal Uni Saskatchew(CTSU) /ID# 162316, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT02896985"
195,"NCT02896920","Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness","SOLACE","Completed","No Results Available","Hidradenitis Suppurativa (HS)",,"Proportion of participants achieving clinical response using the Hidradenitis Suppurativa Clinical Response measure (HiSCR) at week 24|Proportion of participants who experience flare|Change from Baseline in Hospital Anxiety and Depression Scale (HADS)|Change from Baseline in International Index of Erectile Function (IIEF)|Change from Baseline in Health Care Resource Utilization (HCRU) associated with HS|Change from Baseline in Patient Global Assessment of HS (HS-PtGA)|Proportion of participants achieving clinical response using the Hidradenitis Suppurativa Clinical Response measure (HiSCR) at week 52|Change from Baseline in Health Utility Index Mark 3 (HUI3)|Change from Baseline in Female Sexual Function Index (FSFI)|Proportion of participants who experience worsening of HS by >= 1 Hurley Stage in >= 1 affected anatomic region|Change from Baseline in Hidradenitis Suppurativa Symptom Assessment (HSSA)|Change from Baseline in Hidradenitis Suppurativa Impact Assessment (HSIA)|Change from Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0 (WPAI: SHP)|Number of days where participants experience HS flare-up","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"165","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-696","September 20, 2016","April 29, 2019","April 29, 2019","September 12, 2016",,"May 6, 2019","Institute for Skin Advancement /ID# 152448, Calgary, Alberta, Canada|Alberta DermaSurgery Centre /ID# 153834, Edmonton, Alberta, Canada|Jason Ronald Sneath Medical Co /ID# 152462, Brandon, Manitoba, Canada|Winnipeg Clinic, Manitoba, CA /ID# 153830, Winnipeg, Manitoba, Canada|Wiseman Dermatology Research /ID# 153835, Winnipeg, Manitoba, Canada|Dr. Irina Turchin PC Inc. /ID# 152464, Fredericton, New Brunswick, Canada|Karma Clinical Trials /ID# 152444, St. John's, Newfoundland and Labrador, Canada|NewLab Clinical Research Inc. /ID# 152438, St. John's, Newfoundland and Labrador, Canada|Dr. Brown-Maher PMC INC. /ID# 152407, St. John's, Newfoundland and Labrador, Canada|Eastern Canada Cutaneous Resea /ID# 153832, Halifax, Nova Scotia, Canada|SimcoMed Health Ltd /ID# 152445, Barrie, Ontario, Canada|Dr. Wei Jing Loo Medicine Prof /ID# 157923, London, Ontario, Canada|Lynderm Research Inc. /ID# 152436, Markham, Ontario, Canada|SKIN Centre for Dermatology /ID# 152457, Peterborough, Ontario, Canada|York Dermatology Center /ID# 152403, Richmond Hill, Ontario, Canada|Niakosari Medicine Professional Corporation /ID# 157851, Toronto, Ontario, Canada|K. Papp Clinical Research /ID# 152446, Waterloo, Ontario, Canada|Dr. Isabelle Delorme Inc. /ID# 152408, Drummondville, Quebec, Canada|Clinique D /ID# 152406, Laval, Quebec, Canada|Dre. Angelique Gagne-Henley /ID# 152611, St-Jerome, Quebec, Canada|Dermatologie Sima Inc. /ID# 152443, Verdun, Quebec, Canada|Hopital St-Sacrement /ID# 152456, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02896920"
196,"NCT02880956","A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease",,"Active, not recruiting","No Results Available","Alzheimer's Disease","Drug: ABBV-8E12|Drug: placebo for ABBV-8E12","Adverse Events|Clinical Dementia Rating - Sum of Boxes (CDR-SB)|University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief)|Serum concentration at the end of a dose interval (Ctrough) for ABBV-8E12|Area under the concentration time curve (AUC) for ABBV-8E12|Time to Cmax (Tmax) for ABBV-8E12|Maximum observed serum concentration (Cmax) for ABBV-8E12|Mini-Mental State Examination (MMSE)|24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients with Mild Cognitive Impairment (ADCS-MCI-ADL-24)|Functional Activities Questionnaire (FAQ)|Repeatable Battery for Assessment of Neuropsychological Status (RBANS)|Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI).|Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14)|Neuropsychiatry Inventory (NPI)","AbbVie","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 2","453","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-566|2016-001634-10","October 17, 2016","April 30, 2021","July 28, 2021","August 26, 2016",,"January 18, 2020","Banner University MC Phoenix /ID# 151536, Phoenix, Arizona, United States|Banner Sun Health Res Inst /ID# 151895, Sun City, Arizona, United States|Irvine Clinical Research /ID# 162331, Irvine, California, United States|Ucsd /Id# 152467, La Jolla, California, United States|Ray Dolby Brain Health Center /ID# 154965, San Francisco, California, United States|Univ California, San Francisco /ID# 152053, San Francisco, California, United States|Brain Matters Research /ID# 147796, Delray Beach, Florida, United States|Southwest Florida Neuropsych /ID# 162332, Fort Myers, Florida, United States|Mayo Clinic /ID# 151236, Jacksonville, Florida, United States|Bioclinica Research - Orlando /ID# 147804, Orlando, Florida, United States|University of South Florida /ID# 151890, Tampa, Florida, United States|Bioclinica Research - The Villages /ID# 151633, The Villages, Florida, United States|Emory University Hospital /ID# 151492, Atlanta, Georgia, United States|Atlanta Center for Medical Res /ID# 151550, Atlanta, Georgia, United States|NeuroStudies.net, LLC /ID# 152746, Decatur, Georgia, United States|Great Lakes Clinical Trials /ID# 152754, Chicago, Illinois, United States|Advocate Lutheran General Hosp /ID# 152052, Park Ridge, Illinois, United States|Southern IL Univ School of Med /ID# 151769, Springfield, Illinois, United States|Indiana University /ID# 151861, Indianapolis, Indiana, United States|University of Kansas Medical Center - Alzheimer's Disease Center /ID# 151554, Fairway, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 152753, Lexington, Kentucky, United States|Johns Hopkins Bayview Med Cnt /ID# 151893, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 151770, Boston, Massachusetts, United States|Brigham and Women's Physicians /ID# 151882, Boston, Massachusetts, United States|Hattiesburg Clinic /ID# 202388, Hattiesburg, Mississippi, United States|Princeton Medical Institute /ID# 152934, Princeton, New Jersey, United States|Scott Research Inc. /ID# 151880, Laurelton, New York, United States|North Shore University Hospital /ID# 151632, New Hyde Park, New York, United States|Duke University Medical Center /ID# 147828, Durham, North Carolina, United States|Oregon Health and Science University /ID# 151690, Portland, Oregon, United States|Keystone Clinical Studies LLC /ID# 202305, Norristown, Pennsylvania, United States|Rhode Island Hospital /ID# 151538, Providence, Rhode Island, United States|Vanderbilt Univ Med Ctr /ID# 154547, Nashville, Tennessee, United States|Kerwin Research Center /ID# 147815, Dallas, Texas, United States|Houston Methodist Hospital /ID# 154810, Houston, Texas, United States|McGovern Medical School /ID# 204860, Houston, Texas, United States|University of Utah /ID# 151858, Salt Lake City, Utah, United States|Integrated Neurology Services /ID# 154863, Alexandria, Virginia, United States|St. Vincent's Hospital, Darlinghurst /ID# 152632, Darlinghurst, New South Wales, Australia|Griffith University /ID# 152635, Southport, Queensland, Australia|Austin Hospital /ID# 152637, Heidelberg, Victoria, Australia|Royal Melbourne Hospital /ID# 202633, Parkville, Victoria, Australia|Australian Alzheimer's Res Fou /ID# 152634, Nedlands, Western Australia, Australia|Neurodegenerative Disorders Re /ID# 152826, West Perth, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 152847, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 152642, Leuven, Belgium|CHC Liege /ID# 152846, Liege, Belgium|Parkwood Institute /ID# 164204, London, Ontario, Canada|Toronto Memory Program /ID# 147863, Toronto, Ontario, Canada|Rigshospitalet, Memory Clinic /ID# 153192, Copenhagen Ø, Hovedstaden, Denmark|Clinical Research Services Turku /ID# 152845, Turku, Varsinais-Suomi, Finland|Ita-Suomen Yliopisto /ID# 152959, Kuopio, Finland|AOU di Modena /ID# 152394, Modena, Emilia-Romagna, Italy|AOU Policlinico Agostino Gemelli /ID# 152396, Rome, Lazio, Italy|AOU Policlinico Umberto I /ID# 163144, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 152391, Milano, Lombardia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 152401, Milan, Lombardia, Italy|IIRCCS San Giovanni di Dio Fatebenefratelli /ID# 152395, Brescia, Italy|Azienda Ospedaliera di Perugia /ID# 152397, Perugia, Italy|Universitair Medisch Centrum Utrecht /ID# 163576, Utrecht, Netherlands|CGM Research Trust /ID# 152827, Burwood Christchurch, New Zealand|Fundacion CITA Alzheimer /ID# 152645, Donostia, Pais Vasco, Spain|Hospital Clinic de Barcelona /ID# 152646, Barcelona, Spain|Fundacio ACE /ID# 152643, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 153703, Madrid, Spain|Hospital Universitario Doce de /ID# 152647, Madrid, Spain|Sahlgrenska US Mölndal /ID# 154465, Mölndal, Vastra Gotalands Lan, Sweden|Karolinska University Hospital /ID# 156705, Huddinge, Sweden",,"https://ClinicalTrials.gov/show/NCT02880956"
197,"NCT02851069","Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia","outCome","Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks (SVR12) Post-treatment|Percentage of Participants With Virologic Response at End of Treatment (EoT)|Number of Participants Meeting Premature Study Drug Discontinuation|Percentage of Participants Meeting Each and Any SVR12 Non-response Criteria|Percentage of Participants With Relapse|Percentage of Participants With Relapse at EoT|Percentage of Participants With Viral Breakthrough|Percentage of Participants Meeting On-treatment Virologic Failure|Percentage of Participants With Rapid Virologic Response at Week 4 (RVR4)|Percentage of Participants With Sustained Virologic Response at 24 Weeks (SVR24) After EoT","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"66","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P16-024","February 23, 2017","August 30, 2018","August 30, 2018","August 1, 2016","September 18, 2019","September 18, 2019","Fundacion Cardioinfantil, Bogotá, Colombia|Cic Cali, Cali, Colombia|Centro Medico lmbanaco de Cali I, Cali, Colombia|Pharos Centro de Estudios Clin, Cartagena, Colombia|IPS Medicos Internistas Del Ca I, Manizales, Colombia|Fundacion Hospitalaria San Vin, Medellín, Colombia","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02851069/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/69/NCT02851069/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02851069"
198,"NCT02819999","A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer",,"Terminated","No Results Available","Small Cell Lung Cancer","Drug: Rovalpituzumab Tesirine|Drug: Cisplatin|Drug: Etoposide","Dose limiting toxicities (DLT) of rovalpituzumab tesirine when administered as monotherapy, in series or in combination with frontline chemotherapy to subjects with DLL3 expressing extensive-stage small cell lung cancer (SCLC)|Treatment emergent adverse events (TEAEs)|Incidence of subjects with CTCAE Grade >2 laboratory abnormalities|Progression-Free Survival (PFS)|Best overall response rate|Duration of response (DOR)|Clinical Benefit Rate (CBR)|Overall Survival (OS)|Incidence of anti-therapeutic antibodies (ATAs) against rovalpituzumab tesirine|Progression-free survival (Phase 1a)|Pharmacokinetic parameters: Cmax (Maximum plasma concentration observed )|Pharmacokinetic parameters: AUC0-tau (Area under the plasma concentration-time curve within a dosing interval)|Pharmacokinetic parameters: AUC0-∞ (Area under the curve from time 0 extrapolated to infinity)|Pharmacokinetic parameters: Tmax (Time of Cmax)|Pharmacokinetic parameters: Ctrough (Observed plasma concentrations at trough)|Pharmacokinetic parameters: T1/2 (Terminal half-life)|Pharmacokinetic parameters: CL (Clearance)|Pharmacokinetic parameters: Vss (Volume of distribution at steady state)|Incidence of TEAEs|Changes in vital signs (Heart Rate)|Changes in vital signs (Blood pressure)|Changes in vital signs (Temperature)|Changes in vital signs (Weight)|Changes in vital signs (Respirations)|Eastern Cooperative Oncology Group (ECOG) score","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRX001-004","October 2016","May 31, 2019","May 31, 2019","June 30, 2016",,"June 14, 2019","University of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Cancer Institute of Florida, Orlando, Florida, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Washington University, Saint Louis, Missouri, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|University Hospital of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Texas Oncology, Fort Worth, Texas, United States|Texas Oncology, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02819999"
199,"NCT02819635","A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)",,"Recruiting","No Results Available","Ulcerative Colitis (UC)","Drug: Placebo|Drug: Updacitinib (ABT-494)","Substudy 1/Substudy 2: Percentage of participants who achieve clinical remission per Adapted Mayo score|Substudy 3: Percentage of participants who achieve clinical remission per Adapted Mayo score|Substudy 1: Change in Full Mayo score|Substudy 1/Substudy 2: Percentage of participants achieving clinical response per Adapted Mayo score|Substudy 1/Substudy 2: Percentage of participants achieving clinical remission per Full Mayo score|Substudy 1/Substudy 2: Percentage of participants with endoscopic improvement|Substudy 1/Substudy 2: Percentage of participants achieving clinical response per Partial Mayo score|Substudy 1/Substudy 2: Percentage of participants with endoscopic remission|Substudy 1/Substudy 2: Percentage of participants who achieved histologic improvement|Substudy 2: Percentage of participants who report no bowel urgency|Substudy 2: Percentage of participants who reported no abdominal pain|Substudy 2: Percentage of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom domain|Substudy 2: Percentage of participants achieving clinical response per Adapted Mayo score|Substudy 2: Percentage of participants with mucosal healing|Substudy 2: Percentage of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) fatigue item|Substudy 2: Percentage of participants with UC-related hospitalizations|Substudy 2: Percentage of participants with UC-related surgeries|Substudy 3: Percentage of participants with endoscopic improvement|Substudy 3: Percentage of participants who discontinued corticosteroid use, remained corticosteroid free for >= 90 days and achieved clinical remission per Adapted Mayo score|Substudy 3: Percentage of participants who maintain clinical remission per Adapted Mayo score among participants who received clinical remission per Adapted Mayo score in Study M14-234 (Substudy 1 or 2) or M14-675|Substudy 3: Percentage of participants with endoscopic improvement among participants who had endoscopic improvement in Study M14-234 (Substudy 1 or 2) or Study M14-675|Substudy 3: Percentage of participants with endoscopic remission|Substudy 3: Percentage of participants with mucosal healing|Substudy 3: Percentage of participants who reported no bowel urgency|Substudy 3: Percentage of participants who reported no abdominal pain|Substudy 3: Incidence of Ulcerative Colitis (UC)-related hospitalization|Substudy 3: Percentage of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom domain|Substudy 3: Incidence rate of Ulcerative Colitis (UC)-related surgeries|Substudy 3: Percentage of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) fatigue item|Substudy 3: Percentage of participants who maintain clinical response per Adapted Mayo score|Substudy 3: Percentage of participants who discontinued corticosteroid use that achieved clinical remission per Adapted Mayo score","AbbVie","All","16 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","844","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-234|2016-000641-31","September 26, 2016","April 27, 2021","February 24, 2022","June 30, 2016",,"October 14, 2019","Birmingham Gastroenterology /ID# 151276, Birmingham, Alabama, United States|CB Flock Research Corporation /ID# 165980, Mobile, Alabama, United States|Delsol Research Management, Ll /Id# 170131, Chandler, Arizona, United States|Arizona Arthritis & Rheumatolo /ID# 169822, Phoenix, Arizona, United States|Physician's Research Group /ID# 211885, Tempe, Arizona, United States|Adobe Clinical Research LLC /ID# 155250, Tucson, Arizona, United States|Banner University Medical Cent /ID# 150553, Tucson, Arizona, United States|Citrus Valley Gastroenterology /ID# 151914, Covina, California, United States|UC San Diego Health System /ID# 155185, La Jolla, California, United States|United Gastroenterologists /ID# 207464, Los Alamitos, California, United States|Gastrointestinal Biosciences /ID# 157080, Los Angeles, California, United States|Facey Medical Foundation /ID# 203133, Mission Hills, California, United States|United Gastroenterologists - Murrieta /ID# 151211, Murrieta, California, United States|Ventura County Gastroenterology /ID# 163414, Oxnard, California, United States|San Diego Clinical Trials /ID# 212120, San Diego, California, United States|Medical Assoc Research Grp /ID# 169148, San Diego, California, United States|Univ of California San Francis /ID# 164581, San Francisco, California, United States|Peak Gastroenterology Associat /ID# 214076, Colorado Springs, Colorado, United States|Delta Waves, Inc. /ID# 151721, Colorado Springs, Colorado, United States|South Denver Gastroenterology /ID# 151223, Lone Tree, Colorado, United States|Western States Clinical Res /ID# 158076, Wheat Ridge, Colorado, United States|Western Connecticut Medical Group /ID# 169210, Danbury, Connecticut, United States|Medical Research Ctr CT /ID# 150482, Hamden, Connecticut, United States|Gastro Florida /ID# 155245, Clearwater, Florida, United States|Moonshine Research Center, Inc /ID# 152533, Doral, Florida, United States|Universal Axon Clinical Resear /ID# 213461, Doral, Florida, United States|Palmetto Research, LLC /ID# 151716, Hialeah, Florida, United States|Nature Coast Clinical Research /ID# 154064, Inverness, Florida, United States|Borland-Groover Clinic /ID# 170912, Jacksonville, Florida, United States|SIH Research, LLC /ID# 163319, Kissimmee, Florida, United States|Alliance Medical Research /ID# 215089, Lighthouse Point, Florida, United States|Ctr for Advanced Gastroenterol /ID# 202017, Maitland, Florida, United States|University of Miami /ID# 215441, Miami, Florida, United States|Advanced Pharma CR, LLC /ID# 151719, Miami, Florida, United States|Crystal Pharmacology Research /ID# 151841, Miami, Florida, United States|New Horizon Research Center /ID# 152474, Miami, Florida, United States|Coral Research Clinic /ID# 150444, Miami, Florida, United States|Advanced Research Institute /ID# 163098, New Port Richey, Florida, United States|Endoscopic Research, Inc. /ID# 151720, Orlando, Florida, United States|Omega Research Consultants /ID# 200269, Orlando, Florida, United States|Clinical Research Trials of Florida, Inc. /ID# 201790, Tampa, Florida, United States|University of South Florida /ID# 214493, Tampa, Florida, United States|Florida Hospital Tampa /ID# 200272, Tampa, Florida, United States|Infinite Clinical Trials /ID# 215340, Riverdale, Georgia, United States|Atlanta Gastroenterology Spec /ID# 150548, Suwanee, Georgia, United States|Northwestern Medical /ID# 151139, Chicago, Illinois, United States|Rush University Medical Center /ID# 153042, Chicago, Illinois, United States|University of Chicago /ID# 150547, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 150555, Evanston, Illinois, United States|Northwest Health Care Associat /ID# 151590, Hoffman Estates, Illinois, United States|Carle Foundation Hospital /ID# 151137, Urbana, Illinois, United States|MediSphere Medical Research Center /ID# 152064, Evansville, Indiana, United States|Indianapolis Gastroenterology /ID# 162901, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics /ID# 157058, Iowa City, Iowa, United States|Cotton-O'Neil Clinical Res Ctr /ID# 167182, Topeka, Kansas, United States|Tri-State Gastroenterology /ID# 169811, Crestview Hills, Kentucky, United States|Houma Digestive Health Special /ID# 151844, Houma, Louisiana, United States|Nola Research Works, LLC /ID# 153356, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 150446, Shreveport, Louisiana, United States|University of Maryland Med Ctr /ID# 150449, Baltimore, Maryland, United States|Gastro Center of Maryland /ID# 200022, Columbia, Maryland, United States|Massachusetts General Hospital /ID# 165676, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 151140, Ann Arbor, Michigan, United States|Huron Gastroenterology Assoc /ID# 152710, Ann Arbor, Michigan, United States|Clin Res Inst of Michigan, LLC /ID# 153027, Chesterfield, Michigan, United States|Revival Research Institute, LLC /ID# 207280, Southfield, Michigan, United States|Center for Digestive Health /ID# 161984, Troy, Michigan, United States|Gastroenterology Associates of Western Michigan, PLC /ID# 157484, Wyoming, Michigan, United States|Mayo Clinic - Rochester /ID# 151677, Rochester, Minnesota, United States|Minnesota Gastroenterology P.A /ID# 151678, Saint Paul, Minnesota, United States|Univ of Mississippi Med Ctr /ID# 213139, Jackson, Mississippi, United States|Southern Therapy and Advanced Research (STAR) LLC /ID# 170712, Jackson, Mississippi, United States|Washington University-School of Medicine /ID# 150485, Saint Louis, Missouri, United States|Las Vegas Medical Research /ID# 153044, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Med Ctr /ID# 150549, Lebanon, New Hampshire, United States|AGA Clinical Research Associates, LLC /ID# 153040, Egg Harbor Township, New Jersey, United States|Atlantic Digestive Health Inst /ID# 150447, Morristown, New Jersey, United States|Rutgers Robert Wood Johnson /ID# 155248, New Brunswick, New Jersey, United States|Ladan Golestaneh, MD, MS /ID# 150543, Bronx, New York, United States|Advantage Clinical Trials /ID# 163938, Bronx, New York, United States|NY Scientific /ID# 152707, Brooklyn, New York, United States|NYU Langone Long Island Clin. Res. Assoc. /ID# 155272, Great Neck, New York, United States|Weill Cornell Medicine /ID# 163410, New York, New York, United States|DiGiovanna Institute for Medic /ID# 201533, North Massapequa, New York, United States|Premier Medical Group /ID# 153357, Poughkeepsie, New York, United States|Gastro Group of Rochester /ID# 151079, Rochester, New York, United States|Richmond University Medical Center /ID# 201859, Staten Island, New York, United States|Digestive Health Partners, P.A /ID# 167237, Asheville, North Carolina, United States|Carolinas Medical Center /ID# 156971, Charlotte, North Carolina, United States|Charlotte Gastro Hepatology /ID# 150545, Charlotte, North Carolina, United States|AG Clinical Research, PLLC /ID# 151899, Greenville, North Carolina, United States|Clinical Trials of America /ID# 153448, Winston-Salem, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 150448, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, LLC /ID# 170290, Fargo, North Dakota, United States|Consultants for Clinical Res /ID# 151679, Cincinnati, Ohio, United States|University of Cincinnati /ID# 164582, Cincinnati, Ohio, United States|The Ohio State University - Columbus /ID# 169416, Columbus, Ohio, United States|Optimed Research, Ltd. /ID# 169696, Columbus, Ohio, United States|Hometown Urgent Care and Resea /ID# 200065, Dayton, Ohio, United States|Dayton Gastroenterology, Inc. /ID# 167631, Englewood, Ohio, United States|Great Lakes Gastroenterology Research LLC /ID# 201772, Mentor, Ohio, United States|Ohio Clinical Research Partner /ID# 154068, Mentor, Ohio, United States|Digestive Disease Specialists /ID# 201056, Oklahoma City, Oklahoma, United States|Options Health Research, LLC /ID# 150554, Tulsa, Oklahoma, United States|Healthcare Research Consultant /ID# 163100, Tulsa, Oklahoma, United States|Northwest Gastroenterology Cli /ID# 152527, Portland, Oregon, United States|Allegheny General Hospital /ID# 163826, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, PC /ID# 150481, Sayre, Pennsylvania, United States|Penn State Health Colonnade /ID# 150259, State College, Pennsylvania, United States|Pharmacorp Clinical Trials /ID# 153354, Charleston, South Carolina, United States|Gastroenterology Associates, P.A. /ID# 150541, Greenville, South Carolina, United States|Gastro One /ID# 151144, Germantown, Tennessee, United States|East Tennessee Research Instit /ID# 203610, Johnson City, Tennessee, United States|Quality Medical Research, PLLC /ID# 203426, Nashville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 153355, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 151526, Arlington, Texas, United States|Inquest Clinical Research /ID# 164635, Baytown, Texas, United States|Texas Digestive Disease Consultants /ID# 209804, Cedar Park, Texas, United States|Texas Digestive Disease Consultants /ID# 209947, Cedar Park, Texas, United States|Baylor Scott & White Research /ID# 200770, Dallas, Texas, United States|DHAT Research Institute /ID# 151218, Garland, Texas, United States|Vilo Research Group Inc /ID# 212624, Houston, Texas, United States|CliniCore International, LLC /ID# 152062, Houston, Texas, United States|Baylor College of Medicine /ID# 150486, Houston, Texas, United States|Houston Methodist Hospital /ID# 207658, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 201216, Houston, Texas, United States|GI Specialists of Houston /ID# 202327, Houston, Texas, United States|Caprock Gastro Research /ID# 214754, Lubbock, Texas, United States|Clinical Associates in Researc /ID# 201260, San Antonio, Texas, United States|Sagact Pllc /Id# 169396, San Antonio, Texas, United States|Carl R. Meisner Medical Clinic /ID# 171061, Sugar Land, Texas, United States|Baylor Scott & White Health - Temple /ID# 204499, Temple, Texas, United States|Tyler Research Institute, LLC /ID# 169146, Tyler, Texas, United States|Victoria gastroenterology /ID# 167761, Victoria, Texas, United States|HP Clinical Research /ID# 163939, Bountiful, Utah, United States|Advanced Research Institute /ID# 162624, Ogden, Utah, United States|Utah Gastroenterology /ID# 163101, Salt Lake City, Utah, United States|Advanced Clinical Research (ACR) - Salt Lake City /ID# 163181, West Jordan, Utah, United States|Ctr for Gastrointestinal Healt /ID# 153360, Franklin, Virginia, United States|Emeritas Research Group, LLC /ID# 150258, Leesburg, Virginia, United States|Washington Gastroenterology /ID# 163629, Bellevue, Washington, United States|Virginia Mason Medical Center /ID# 153026, Seattle, Washington, United States|University of Washington /ID# 153041, Seattle, Washington, United States|The Polyclinic /ID# 164369, Seattle, Washington, United States|The Vancouver Clinic, INC. PS /ID# 162333, Vancouver, Washington, United States|Aurora Medical Center - Grafto /ID# 151717, Grafton, Wisconsin, United States|WI Center for Advanced Res /ID# 151838, Milwaukee, Wisconsin, United States|Medical College of Wisconsin /ID# 151843, Milwaukee, Wisconsin, United States|Hospital Italiano de Buenos Aires /ID# 215538, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina|Cardio Alem /ID# 211280, San Isidro, Buenos Aires, Argentina|Mautalen Salud e Investigacion /ID# 171173, Buenos Aires, Argentina|Hospital Britanico de Bs As /ID# 209495, Caba, Argentina|Gedyt /ID# 210015, Ciudad Autonoma Buenos Aires, Argentina|Hospital Privado Univesitario /ID# 164185, Cordoba, Argentina|Instituto Medico DAMIC /ID# 152547, Cordoba, Argentina|Sanatorio 9 de Julio S.A. /ID# 150189, San Miguel de Tucuman, Argentina|Macquarie University /ID# 211951, Macquarie Park, New South Wales, Australia|Mater Misericordiae /ID# 212685, South Brisbane, Queensland, Australia|Griffith University /ID# 211952, Southport, Queensland, Australia|Monash Health /ID# 150206, Clayton, Victoria, Australia|St. Vincents Hosp Melbourne /ID# 152472, Fitzroy, Victoria, Australia|Fiona Stanley Hospital /ID# 211640, Murdoch, Western Australia, Australia|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 150305, Linz, Oberoesterreich, Austria|Krankenanstalt Rudolfstiftung /ID# 162866, Vienna, Wien, Austria|Medical University of Vienna /ID# 150614, Vienna, Wien, Austria|LKH Salzburg and Paracelsus /ID# 150306, Salzburg, Austria|Vitebsk Regional Advanced Clin /ID# 169612, Vitebsk, Belarus|AZ Maria Middelares /ID# 150331, Ghent, Belgium|UZ Leuven /ID# 150332, Leuven, Belgium|AZ-Delta /ID# 150330, Roeselare, Belgium|University Clinical Centre of the Republic of Srpska /ID# 150209, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 150706, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Center Tuzla /ID# 150211, Tuzla, Tuzlanski, Bosnia and Herzegovina|University Clinical Hospital Mostar /ID# 150705, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 150208, Sarajevo, Bosnia and Herzegovina|Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda /ID# 153742, Goiania, Goias, Brazil|Hospital Nossa Senhora das Graças /ID# 152480, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 153743, Porto Alegre, Rio Grande Do Sul, Brazil|Upeclin Fmb - Unesp /Id# 152485, Botucatu, Sao Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto - USP /ID# 152484, Ribeirão Preto, Sao Paulo, Brazil|Faculdade de Medicina do ABC /ID# 152481, Santo André, Sao Paulo, Brazil|Kaiser Clinica e Hospital Dia /ID# 152483, Sao Jose Do Rio Preto, Sao Paulo, Brazil|Hospital Universitario Clement /ID# 152487, Rio de Janeiro, Brazil|University of Calgary /ID# 151821, Calgary, Alberta, Canada|Allen Whey Khye Lim Professional Corporation /ID# 211168, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 151100, Edmonton, Alberta, Canada|Covenant Health /ID# 158930, Edmonton, Alberta, Canada|Okanagan Clinical Trials /ID# 153178, Kelowna, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 150367, Victoria, British Columbia, Canada|Dr. Everett Chalmers Reg Hosp. /ID# 212256, Fredericton, New Brunswick, Canada|McMaster University Med Cent /ID# 150365, Hamilton, Ontario, Canada|The Ottawa Hospital /ID# 151820, Ottawa, Ontario, Canada|Medicor Research Inc. /ID# 151101, Sudbury, Ontario, Canada|Toronto Digestive Disease Asso /ID# 150363, Vaughan, Ontario, Canada|CISSS de la Monteregie /ID# 159215, Greenfield Park, Quebec, Canada|Hopital Hotel-Dieu de Levis /ID# 150361, Levis, Quebec, Canada|Recherche GCP Research /ID# 151822, Montreal, Quebec, Canada|Crchum /Id# 167169, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre /ID# 170012, Montréal, Quebec, Canada|CRCHUS Hotel-Dieu /ID# 150366, Sherbrooke, Quebec, Canada|Research Group Ltda /ID# 203176, Santiago, Region Metropolitana De Santiago, Chile|M y F Estudios Clínicos Ltda. /ID# 200107, Ñuñoa, Region Metropolitana De Santiago, Chile|Centro de Investigaciones Clínicas Viña del Mar /ID# 150212, Viña del Mar, Valparaíso, Chile|Hospital Guillermo Grant Benavente de Concepción /ID# 212424, Concepción, Chile|CTR Estudios SpA /ID# 200110, Providencia, Chile|Hospital Clinico Universidad De Los Andes /ID# 207422, Santiago, Chile|Clinica Las Condes /ID# 153754, Santiago, Chile|The First Affiliated Hosp, Sun /ID# 150455, Guangzhou, Anhui, China|Shanghai Tenth People's Hosp /ID# 150460, Shanghai, Anhui, China|Renji Hosp, Shanghai Jiaotong /ID# 165815, Shanghai, Anhui, China|The Sixth Affiliated Hosp, Sun /ID# 150456, Guangzhou, Guangdong, China|Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 167088, Wuhan, Hubei, Hubei, China|Xiangya Hospital Central South University /ID# 167229, Changsha, Hunan, China|1st Aff Hosp Nanchang Univ /ID# 211750, Nanchang, Jiangxi, China|The First Hosp of Jilin Univ /ID# 209986, Changchun, Jilin, China|Ruijin Hospital, Shanghai Jiaotong /ID# 150461, Shanghai, Shanghai, China|The second affiliated hospital of Zhejiang University school of medicine /ID# 165807, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital /ID# 150454, Hangzhou, Zhejiang, China|West China Hospital, Sichuan University /ID# 167040, Chengdu, China|Shengjing Hospital of China Medical University /ID# 166920, Shenyang, China|Tianjin Med Univ General Hosp /ID# 170604, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 167078, Wuhan, China|Corporacion Hospitalaria Juan Ciudad sede Denominada Hospital Universitario Mayo /ID# 151564, Bogota DC, Cundinamarca, Colombia|Hospital Univ San Ignacio /ID# 152678, Bogota, Colombia|Instituto de Coloproctologia /ID# 152535, Medellin, Colombia|Hospital Universitario de San /ID# 155387, Medellin, Colombia|Hospital Pablo Tobon Uribe /ID# 159095, Medellín, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 207042, Montería, Colombia|Klinicki bolnicki centar Zagreb /ID# 150225, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Zagreb /ID# 150709, Zagreb, Grad Zagreb, Croatia|Poliklinika Solmed /ID# 211483, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 150216, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Rijeka /ID# 150708, Rijeka, Primorsko-goranska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 213988, Split, Croatia|Zadar General Hospital /ID# 150221, Zadar, Croatia|Clinical Hospital Dubrava /ID# 150213, Zagreb, Croatia|CTCenter MaVe, s.r.o. /ID# 150904, Olomouc, Olomoucky Kraj, Czechia|Axon Clinical, s.r.o. /ID# 152479, Praha, Praha 5, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 150912, Hradec Kralove, Czechia|Artroscan s.r.o. /ID# 150401, Ostrava, Czechia|Nemocnice Pardubickeho kraje, /ID# 213539, Pardubice, Czechia|ISCARE I.V.F. a.s. /ID# 209278, Prague, Czechia|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 213818, Alexandria, Egypt|Clinical Research Center, Faculty of Medicine, Alexandria university. /ID# 213819, Alexandria, Egypt|Nat Hep & Trop Med Res Inst /ID# 213816, Cairo, Egypt|Air Force Specialized Hospital /ID# 214472, Cairo, Egypt|East Tallinn Central Hospital /ID# 150417, Tallinn, Estonia|West Tallinn Central Hospital /ID# 150419, Tallinn, Estonia|North Estonian Medical Centre /ID# 160870, Tallinn, Estonia|Tartu University Hospital /ID# 150418, Tartu, Estonia|Helsinki Univ Central Hospital /ID# 150407, Helsinki, Finland|Keski-Suomen Keskussairaala /ID# 155666, Jyvaskyla, Finland|Laakarikeskus Ikioma /ID# 150121, Mikkeli, Finland|Tampere University Hospital /ID# 150114, Tampere, Finland|Tyks /Id# 168301, Turku, Finland|Chu de Nice-Hopital L'Archet Ii /Id# 152606, Nice CEDEX 3, Alpes-Maritimes, France|Centre Hospitalier Lyon Sud /ID# 152539, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHU Hopital Nord /ID# 163508, Marseille, Bouches-du-Rhone, France|Hopital Haut-Lévêque /ID# 213828, Pessac CEDEX, Gironde, France|CHRU Lille - Hôpital Claude Huriez /ID# 152607, Lille CEDEX, Hauts-de-France, France|Hopital Saint Eloi /ID# 200006, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 211421, Clichy, Ile-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 150150, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Amiens Picardie /ID# 163456, Amiens CEDEX 1, Somme, France|CHD Vendee /ID# 154452, La Roche Sur Yon, France|Polyclinique Grand Sud /ID# 214080, Nimes Cedex, France|Hopital Saint Antoine /ID# 170222, Paris, France|Hopital Nord /ID# 154453, Saint Priest En Jarez, France|Universitatsklinikum Mannheim /ID# 150173, Mannheim, Baden-Wuerttemberg, Germany|Universitatsklinikum Munster /ID# 150158, Munster, Niedersachsen, Germany|Gastroenterologische Gemeinschaftspraxis Herne /ID# 214574, Herne, Nordrhein-Westfalen, Germany|Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 215811, Saarbrücken, Saarland, Germany|Univ Hosp Schleswig-Holstein /ID# 161981, Kiel, Schleswig-Holstein, Germany|Praxis am Bayerischen Platz /ID# 150766, Berlin, Germany|Agaplesion Markus Krankenhaus /ID# 161982, Frankfurt, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 207135, Munster, Germany|Helwig, Oldenburg, DE /ID# 150768, Oldenburg, Germany|Universitatsklinikum Tubingen /ID# 150767, Tuebingen, Germany|Gastro Data Wiesbaden /ID# 150166, Wiesbaden, Germany|General Hospital of Athens Laiko /ID# 208669, Athens, Attiki, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 150309, Athens, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 202100, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 150250, Heraklion, Greece|University General Hospital of Ioannina /ID# 164248, Ioannina, Greece|Theageneio Anticancer Hospital /ID# 163896, Thessaloniki, Greece|Genl Hosp Thessaloniki Hipp /ID# 209521, Thessaloniki, Greece|Markusovszky Egyetemi Oktatókórház /ID# 150313, Szombathely, Vas, Hungary|Bekes Megyei Kozponti Korhaz /ID# 151572, Bekescsaba, Hungary|Semmelweis Egyetem /ID# 150312, Budapest, Hungary|Meditres Kft. /ID# 151521, Kecskemet, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 151523, Sopron, Hungary|Mentahaz Maganorvosi Kozpont /ID# 205884, Szekesfehervar, Hungary|Mercy University Hospital /ID# 151529, Cork, Ireland|Trinity College Dublin - St. J /ID# 150320, Dublin, Ireland|St Vincent's University Hosp /ID# 150318, Dublin, Ireland|Beaumont Hospital /ID# 150321, Dublin, Ireland|Galway University Hospital /ID# 150319, Galway, Ireland|Soroka Medical Center /ID# 156561, Be'er Sheva, HaDarom, Israel|Hadassah Ein Kerem Medical Ctr /ID# 165118, Jerusalem, Yerushalayim, Israel|Rambam Health Care Campus /ID# 150325, Haifa, Israel|Shaare Zedek Medical Center /ID# 161677, Jerusalem, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 150337, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 151360, Rome, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 150334, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 151361, Rozzano, Milano, Italy|A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 150253, Palermo, Sicilia, Italy|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 201725, Negrar, Verona, Italy|ASST Fatebenefratelli Sacco - Ospedale Fatebenefratelli e Oftalmico /ID# 150602, Milano, Italy|Policlinico Tor Vergata /ID# 150338, Rome, Italy|Complesso integrato Columbus /ID# 150333, Rome, Italy|Aichi Medical University Hosp /ID# 151993, Nagakute, Aichi, Japan|Nagoya University Hospital /ID# 152709, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 151950, Nagoya-shi, Aichi, Japan|Hirosaki National Hospital /ID# 152763, Hirosaki-shi, Aomori, Japan|Tokatsu Tsujinaka Hospital /ID# 214962, Abiko-shi, Chiba, Japan|Toho University Sakura Medical Center /ID# 151936, Sakura-shi, Chiba, Japan|Juntendo University Urayasu Hospital /ID# 208781, Urayasu Shi, Chiba, Japan|Fukuoka University Chikushi Hospital /ID# 152628, Chikushino, Fukuoka, Japan|Kyushu University Hospital /ID# 152526, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 151976, Kurume-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 208225, Ogaki-shi, Gifu, Japan|NHO Fukuyama Medical Center /ID# 206293, Fukuyama-shi, Hiroshima, Japan|Asahikawa Medical University Hospital /ID# 170289, Asahikawa-shi, Hokkaido, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 151506, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 206492, Sapporo-shi, Hokkaido, Japan|Sapporo Tokushukai Hospital /ID# 209397, Sapporo, Hokkaido, Japan|Aoyama Clinic /ID# 152049, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 152434, Nishinomiya-shi, Hyogo, Japan|National Hospital Organization Mito Medical Center /ID# 152631, Higashi Ibaraki-gun, Ibaraki, Japan|Kanazawa University Ho /ID# 205099, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital /ID# 203411, Morioka-shi, Iwate, Japan|Idzuro Imamura Hospital /ID# 206024, Kagishimashi, Kagoshima, Japan|Yokohama City Univ Med Center /ID# 169899, Yokohama-shi, Kanagawa, Japan|JP Red Cross Kyoto Daiichi Hos /ID# 152359, Kyoto-shi, Kyoto, Japan|Mie University Hospital /ID# 205362, Tsu-shi, Mie, Japan|National Hospital Organization Sendai Medical Center /ID# 209527, Sendai-shi, Miyagi, Japan|Ishida Clinic of IBD and Gastroenterology /ID# 210117, Oita-shi, Oita, Japan|Kinshukai Infusion Clinic /ID# 207864, Osaka-shi, Osaka, Japan|Japanese Red Cross Osaka Hospi /ID# 209476, Osaka-shi, Osaka, Japan|Osaka City University Hospital /ID# 152682, Osaka-shi, Osaka, Japan|Saga University Hospital /ID# 209268, Saga-shi, Saga, Japan|Saitama Medical Center, Saitama Medical University /ID# 152031, Kawagoe-shi, Saitama, Japan|Tokito Clinic /ID# 152677, Saitama-shi, Saitama, Japan|National Hospital Organization Higashi-Ohmi General Medical Center /ID# 210709, Higashiohmi-shi, Shiga, Japan|Hamamatsu University Hospital /ID# 205708, Hamamatsu-shi, Shizuoka, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 152016, Bunkyo-ku, Tokyo, Japan|St.Luke's International Hospital /ID# 208074, Chuo-ku, Tokyo, Japan|Tokai University Hachioji Hospital /ID# 152587, Hachioji, Tokyo, Japan|Teikyo University Hospital /ID# 208897, Itabashi-ku, Tokyo, Japan|Kitasato Univ Kitasato Inst Ho /ID# 152686, Minato-ku, Tokyo, Japan|Kyorin University Hospital /ID# 153194, Mitaka-shi, Tokyo, Japan|Center hospital of the National Center for Global Health and Medicine /ID# 209267, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 205977, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 171454, Yamagata-shi, Yamagata, Japan|Yamanashi Prefectural Ctr Hosp /ID# 151908, Kofu-shi, Yamanashi, Japan|Fukui Prefectural Hospital /ID# 210448, Fukui, Japan|Saiseikai Fukuoka General Hosp /ID# 209479, Fukuoka, Japan|Hiroshima University Hospital /ID# 151951, Hiroshima, Japan|Shimane University School of Medicine /ID# 208899, Izumo, Japan|Sameshima Hospital /ID# 206672, Kagoshima, Japan|Tsujinaka Hospital Kashiwanoha /ID# 209130, Kashiwa, Japan|St. Marianna Univ Hospital /ID# 208654, Kawasaki, Japan|Kitakyushu Municipal Med Ctr /ID# 152588, Kitakyushu, Japan|Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 157821, Kurashiki, Japan|Saiseikai Niigata Hosp /ID# 209916, Niigata, Japan|Obihiro-Kosei General Hospital /ID# 210412, Obihiro, Japan|NHO Nagasaki Medical Center /ID# 209531, Omura-shi, Japan|Kitano Hospital /ID# 210395, Osaka, Japan|Osaka City General Hospital /ID# 152704, Osaka, Japan|Kyoto University Hospital /ID# 211758, Sakyo-ku, Japan|Sapporo Higashi Tokushukai /ID# 208487, Sapporo, Japan|NHO Shizuoka Medical Center /ID# 163572, Shimizu-sho, Japan|Tokyo Yamate Medical Center /ID# 214025, Tokyo, Japan|Toyohashi Municipal Hospital /ID# 171457, Toyohashi, Japan|Ieda Hospital /ID# 157781, Toyota-shi, Japan|Kenseikai Dongo Hospital /ID# 208100, Yamatotakada, Japan|Yokkaichi Hazu Medical Center /ID# 214347, Yokkaichi-shi, Japan|Showa Univ Fujigaoka Hosp /ID# 208222, Yokohama-shi, Japan|Dong-A University Hospital /ID# 159480, Busan, Busan Gwang Yeogsi, Korea, Republic of|Pusan National University Hosp /ID# 159481, Busan, Busan Gwang Yeogsi, Korea, Republic of|Yeungnam University Med Ctr /ID# 150345, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|CHA Bundang Medical center, CHA University /ID# 159479, Seongnam-si, Gyeonggido, Korea, Republic of|St. Vincent's Hospital /ID# 150347, Suwon, Gyeonggido, Korea, Republic of|Kangbuk Samsung Hospital /ID# 150348, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 159478, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 150346, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Hanyang University Guri Hosp /ID# 150344, Guri-si, Korea, Republic of|Asan Medical Center /ID# 150900, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 150354, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 151409, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 150357, Kovno, Kaunas, Lithuania|Klaipeda University Hospital /ID# 158862, Klaipeda, Lithuania|Klaipeda Seamens Hospital /ID# 154319, Klaipeda, Lithuania|Vilnius University Hospital /ID# 154318, Vilnius, Lithuania|Hospital Sultanah Bahiyah /ID# 151687, Alor Setar, Kedah, Malaysia|UKM Medical Centre /ID# 151689, Kuala Lumpur, Selangor, Malaysia|Hospital Ampang /ID# 151298, Ampang, Selangor, Malaysia|Uni Malaya MC /ID# 150359, Kuala Lumpur, Malaysia|Morales Vargas Centro de Investigación S.C /ID# 211325, León de los Aldama, Guanajuato, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 150710, Guadalajara, Jalisco, Mexico|Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 150256, Monterrey, Nuevo Leon, Mexico|Radboud Universitair Medisch Centrum /ID# 151700, Nijmegen, Gelderland, Netherlands|Academisch Medisch Centrum /ID# 150647, Amsterdam, Noord-Holland, Netherlands|Leids Universitair Medisch Centrum /ID# 152624, Leiden, Netherlands|Erasmus Medisch Centrum /ID# 150308, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 152775, Utrecht, Netherlands|Akershus universitetssykehus /ID# 150317, Nordbyhagen, Akershus, Norway|Universitetssykehuset Nord-Norge /ID# 152835, Tromsø, Troms, Norway|Centrum Zdrowia MDM /ID# 150351, Warsaw, Mazowieckie, Poland|Zespol Przychodni Prima /Id# 150580, Warsaw, Mazowieckie, Poland|Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 215732, Warsaw, Mazowieckie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 150349, Warszawa, Mazowieckie, Poland|Endoskopia Sp. z o.o. /ID# 150765, Sopot, Zachodniopomorskie, Poland|Hospital Senhora da Oliveira de Guimarães, EPE /ID# 151607, Guimarães, Braga, Portugal|Centro Hosp de Lisboa Central /ID# 151611, Lisbon, Lisboa, Portugal|Hospital Garcia de Orta, E.P.E /ID# 151613, Almada, Setubal, Portugal|CCA Braga - Hospital de Braga /ID# 151608, Braga, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 151606, Lisboa, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 151610, Porto, Portugal|Centro Hospitalar de Entre o D /ID# 152335, Santa Maria Da Feira, Portugal|Unidade Local De Saude Do Alto Minho /ID# 151609, Viana Do Castelo, Portugal|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 150358, San Juan, Puerto Rico|Institutul Clinic Fundeni /ID# 150368, Sector 2, Bucuresti, Romania|Institutul Clinic Fundeni /ID# 150983, Sector 2, Bucuresti, Romania|Cabinet Particular Policlinic Algomed /ID# 150369, Timisoara, Romania|Immanuel Kant Baltic Federal University /ID# 200719, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|NW State Medical Univ na Mechn /ID# 169322, St. Petersburg, Leningradskaya Oblast, Russian Federation|Perm Clinical Center of FMBA /ID# 150386, Perm, Permskiy Kray, Russian Federation|LLC Medical Company Hepatolog /ID# 200197, Samara, Samarskaya Oblast, Russian Federation|LLC Novaya Klinika /ID# 208107, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 166042, Kazan, Tatarstan, Respublika, Russian Federation|Llc Olla-Med /Id# 215332, Moscow, Russian Federation|City Clinical Hospital 24 /ID# 150395, Moscow, Russian Federation|Republican Clin Hos n.a. Baran /ID# 206506, Petrozavodsk, Russian Federation|PMI Euromedservice /ID# 203800, Pushkin, Russian Federation|Stavropol State Medical Univ /ID# 150387, Stavropol, Russian Federation|Clinical Center Serbia /ID# 150428, Belgrade, Beograd, Serbia|Clinical Hosp Center Zvezdara /ID# 150427, Belgrade, Beograd, Serbia|Military Medical Academy /ID# 150429, Belgrade, Beograd, Serbia|Clin Hosp Ctr Bezanijska Kosa /ID# 150426, Belgrade, Beograd, Serbia|Clinical Center of Nis /ID# 151903, NIS, Nisavski Okrug, Serbia|Clinical Center Kragujevac /ID# 150430, Kragujevac, Sumadijski Okrug, Serbia|Clinical Center Vojvodina /ID# 150764, Novi Sad, Vojvodina, Serbia|National University Hospital /ID# 150453, Singapore, Singapore|Gleneagles Medical Centre /ID# 206018, Singapore, Singapore|Tan Tock Seng Hospital /ID# 150443, Singapore, Singapore|Medak s.r.o., gastroenterologi /ID# 150480, Bratislava, Bratislavsky Kraj, Slovakia|FN s poliklinikou F.D. Rooseve /ID# 150868, Banska Bystrica, Slovakia|Slovak Research Center Team Me /ID# 150257, Ilava, Slovakia|B and B MED s.r.o. /ID# 150471, Kosice, Slovakia|Fakultna nemocnica s poliklini /ID# 211370, Nove Zamky, Slovakia|Gastro I.S.R.O. /ID# 150472, Presov, Slovakia|Clinresco Centres /ID# 163622, Johannesburg, Gauteng, South Africa|Lenasia Clinical Trial Centre /ID# 214344, Johannesburg, Gauteng, South Africa|Chris Hani Baragwanath Hosp /ID# 150785, Johannesburg, Gauteng, South Africa|Wits Clinical Research Site /ID# 150496, Johannesburg, Gauteng, South Africa|Mediclinic Milnerton /ID# 162202, CAPE TOWN,Milnerton, Western Cape, South Africa|Allergy & Immunology (AIU) /ID# 214343, Cape Town, Western Cape, South Africa|Kingsbury Hospital /ID# 150497, Cape Town, Western Cape, South Africa|Mediclinic Constantiaberg /ID# 155144, Cape Town, Western Cape, South Africa|MD Search /ID# 167293, Boksburg North, South Africa|Comple Hospi Univ de Santiago /ID# 151065, Santiago de Compostela, A Coruna, Spain|Hospital Universitario y Politecnico La Fe /ID# 150611, Valencia, Valenciana, Spain|Comple Hosp Univ de A Coruna /ID# 203911, A Coruna, Spain|Hospital Clinic de Barcelona /ID# 150612, Barcelona, Spain|Hospital Reina Sofia de Cordob /ID# 151066, Cordoba, Spain|Hospital Univ Dr. Negrin /ID# 203937, Las Palmas de Gran Canaria, Spain|Hospital Univ Ramon y Cajal /ID# 151067, Madrid, Spain|Hospital Universitario La Paz /ID# 214539, Madrid, Spain|Complejo Asistencial de Salama /ID# 150509, Salamanca, Spain|Sahlgrenska University Hosp /ID# 151496, Goteborg, Sweden|Kantonsspital St. Gallen /ID# 152599, St. Gallen, Sankt Gallen, Switzerland|Universitaetsspital Basel /ID# 161731, Basel, Switzerland|Inselspital, Universitaetsklinik /ID# 152590, Bern, Switzerland|University Hospital Zurich /ID# 152591, Zurich, Switzerland|China Medical University Hosp /ID# 150571, Taichung City, Taichung, Taiwan|National Cheng Kung University Hospital /ID# 151749, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 150574, Taipei City, Taipei, Taiwan|Kaohsiung Medical University /ID# 150575, Kaohsiung, Taiwan|Chung Shan Medical University /ID# 150573, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 151748, Taipei City, Taiwan|Erciyes University Medical Fac /ID# 150129, Melikgazi, Kayseri, Turkey|Gazi Universitesi Tip Fakultes /ID# 150127, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 150125, Istanbul, Turkey|Umraniye Training and Res Hosp /ID# 162659, Istanbul, Turkey|Marmara University Medical Fac /ID# 213969, Istanbul, Turkey|Mersin University Medical /ID# 157849, Mersin, Turkey|Communal Non-Commercial Enterprize of Kharkiv Regional Council Regional Clinical /ID# 206940, Kharkiv, Kharkivska Oblast, Ukraine|Kyiv Municipal Clinical Hospital #18 /ID# 150372, Kiev, Kyiv, Ukraine|Medical Center of the ""Health /ID# 151274, Vinnytsya, Vinnytska Oblast, Ukraine|Volyn regional clinical hospital /ID# 206926, Lutsk, Volynska Oblast, Ukraine|Regional Clin Hosp Mechnykov /ID# 207723, Dnipro, Ukraine|Lviv Regional Clinical Hospita /ID# 150375, Lviv, Ukraine|Odessa Regional Clinical Hosp /ID# 151275, Odesa, Ukraine|Poltava Reg Clin Hosp Sklifoso /ID# 215569, Poltava, Ukraine|RD&E Hospital /ID# 150379, Exeter, Devon, United Kingdom|Queen Elizabeth University Hos /ID# 163787, Glasgow, Glasgow City, United Kingdom|The Royal London Hospital /ID# 150384, London, London, City Of, United Kingdom|Basingstoke & North Hampshire /ID# 150380, Basingstoke, United Kingdom|Royal United Hospitals Bath /ID# 151532, Bath, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 150382, Birmingham, United Kingdom|St. George's Healthcare NHS /ID# 208374, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02819635"
200,"NCT02817594","Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","3DUTCH","Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants Achieving Virological Response at End of Treatment|Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 12 Weeks Post-treatment|Percentage of Participants With Relapse|Percentage of Participants With Breakthrough|Percentage of Participants in Each Non-response Category 12 Weeks Post-treatment|Percentage of the Direct Acting Antiviral (DAA) Dose Taken in Relation to the Target Dose of DAA|Percentage of the Ribavirin Dose Taken in Relation to the Target Dose of Ribavirin|Percentage of Ribavirin (RBV) Treatment Days in Relation to the Target Number of Ribavirin Treatment Days|Number of Participants With Adverse Events, Serious Adverse Events, or Pregnancies|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS Score|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Absenteeism","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"51","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-788","January 20, 2016","March 7, 2018","March 7, 2018","June 29, 2016","May 17, 2019","May 17, 2019","Albert Schweitzer Ziekenhuis /ID# 152597, Dordrecht, Zuid-Holland, Netherlands|Noordwest Ziekenhuisgroep /ID# 152604, Alkmaar, Netherlands|Duplicate_Onze Lieve Vrouwe Gasthuis /ID# 152600, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 152596, Groningen, Netherlands|Leids Universitair Medisch Centrum /ID# 154637, Leiden, Netherlands|Radbound University Medical Ce /ID# 152598, Nijmegen, Netherlands|Erasmus Medisch Centrum /ID# 154635, Rotterdam, Netherlands|Maasstad Ziekenhuis /ID# 152592, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht /ID# 152595, Utrecht, Netherlands","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02817594/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02817594/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02817594"
201,"NCT02814175","A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)","CONTROL","Active, not recruiting","No Results Available","Psoriatic Arthritis","Drug: methotrexate (MTX)|Biological: adalimumab","The proportion of subjects achieving minimal disease activity|Change in DLQI score from baseline|Change in tender dactylitic digit count from baseline|Change in DAS28-CRP score from baseline|Change in PsAID score from baseline|Proportion of subjects achieving ACR 20/50/70 response|Change in Leeds Enthesitis Index (LEI) from baseline|Proportion of subjects in minimal disease activity in Part 2 of the study|Change in PASDAS from baseline|Change in SF-36 score from baseline|Change in HAQ-DI score from baseline|Proportion of subjects achieving PASI 75/90/100 response among subjects with BSA greater than or equal to 3%.|Change in DAPSA score from baseline","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","246","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-496|2016-000191-21","August 5, 2016","September 27, 2019","March 26, 2020","June 27, 2016",,"June 14, 2019","AZ Arthritis & Rheum Research /ID# 161796, Sun City, Arizona, United States|LeJenue Research Associates /ID# 200093, Miami, Florida, United States|Clinical Pharmacology Study Gr /ID# 161057, Worcester, Massachusetts, United States|PMG Research of Wilmington LLC /ID# 152089, Wilmington, North Carolina, United States|Altoona Ctr Clinical Res /ID# 152087, Duncansville, Pennsylvania, United States|Metroplex Clinical Research /ID# 162486, Dallas, Texas, United States|Swedish Medical Center /ID# 162051, Seattle, Washington, United States|West Virginia Research Inst /ID# 157815, South Charleston, West Virginia, United States|Royal Prince Alfred Hospital /ID# 153144, Camperdown, New South Wales, Australia|Optimus Clinical Research Pty. /ID# 153145, Kogarah, New South Wales, Australia|Liverpool Hospital /ID# 153147, Liverpool, New South Wales, Australia|BJC Health /ID# 153875, Paramatta, New South Wales, Australia|Box Hill Hospital /ID# 153146, Melbourne, Victoria, Australia|Hospital de Clinicas de Porto Alegre /ID# 152345, Porto Alegre, Rio Grande Do Sul, Brazil|Faculdade de Medicina do ABC /ID# 152344, Santo André, Sao Paulo, Brazil|MHAT Trimontsium /ID# 152658, Plovdiv, Bulgaria|Diag Consult Ctr 17 Sofia EOOD /ID# 152657, Sofia, Bulgaria|Rheumatology Research Assoc /ID# 161600, Edmonton, Alberta, Canada|Percuro Clinical Research, Ltd /ID# 161601, Victoria, British Columbia, Canada|Manitoba Clinic /ID# 151939, Winnipeg, Manitoba, Canada|St. Clare's Mercy Hospital /ID# 159680, St. John's, Newfoundland and Labrador, Canada|The Waterside Clinic /ID# 151938, Barrie, Ontario, Canada|Adachi Medicine Prof. Corp /ID# 152575, Hamilton, Ontario, Canada|Ctr. de Rheum de l'est du QC /ID# 151937, Rimouski, Quebec, Canada|Groupe de Recherche en Maladies Osseuses /ID# 205693, Sainte-foy, Quebec, Canada|Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 151954, Bogota, Cundinamarca, Colombia|Riesgo de Fractura S.A - CAYRE /ID# 153817, Bogota, Colombia|San Vicente Fundacion /Id# 171324, Medellin, Colombia|Revmatolog s.r.o. /ID# 151753, Jihlava 1, Jihlava, Czechia|Nuselská poliklinika, Revmatologie /ID# 151754, Prague 4, Praha 4, Czechia|Fachpraxis fuer Rheumatologie und Osteologie /ID# 203982, Bruchhausen-Vilsen, Niedersachsen, Germany|Univ Hosp Schleswig-Holstein /ID# 152231, Kiel, Schleswig-Holstein, Germany|CIRI GmbH /ID# 152228, Frankfurt, Germany|Hamburger Rheuma I /ID# 164055, Hamburg, Germany|Universita di Catanzaro Magna Graecia /ID# 152013, Catanzaro, Calabria, Italy|Azienda Ospedaliera Policlinic /ID# 152011, Rome, Italy|A.O. Universitaria Senese /ID# 152012, Siena, Italy|McBk Sc /Id# 163089, Grodzisk Mazowiecki, Mazowieckie, Poland|Centrum Medyczne AMED /ID# 164047, Warsaw, Mazowieckie, Poland|SANUS Szpital Specjalistyczny /ID# 151988, Stalowa Wola, Podkarpackie, Poland|ClinicMed Badurski i wspolnicy SJ /ID# 151987, Bialystok, Poland|Dr. Ramon L. Ortega-Colon, MD /ID# 152957, Carolina, Puerto Rico|GCM Medical Group /ID# 152091, San Juan, Puerto Rico|Hamad Hospital /ID# 152334, Doha, Ad Dawhah, Qatar|Corporac Sanitaria Parc Tauli /ID# 151759, Sabadell, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 151760, Barcelona, Spain|Hospital Univ Canarias /ID# 206489, Santa Cruz de Tenerife, Spain|Hospital de Viladecans /ID# 163875, Viladecans, Spain|Royal National Hosp for Rheuma /ID# 152767, Bath, United Kingdom|Altnagelvin Area Hospital /ID# 152766, Londonderry, United Kingdom|Central Manchester University /ID# 152765, Manchester, United Kingdom|Lancashire Care NHS Foundation /ID# 152769, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02814175"
202,"NCT02808975","Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study)","SHARPS","Completed","No Results Available","Hidradenitis Suppurativa (HS)","Drug: Adalimumab|Drug: Placebo","Proportion of participants achieving Hidradenitis Suppurativa Clinical Response (HiSCR)|Proportion of participants achieving HiSCR-es|Proportion of participants that require less extensive surgery than the surgical plan (determined at Baseline) or no surgery|Percent change in surface area of the Hidradenitis Suppurativa (HS) surgical site","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","206","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-574|2015-005161-23","July 18, 2016","May 16, 2019","October 16, 2019","June 22, 2016",,"November 6, 2019","Wallace Medical Group, Inc. /ID# 171289, Beverly Hills, California, United States|Encino Research Center / T. Jo /ID# 171347, Encino, California, United States|University of California Irvine /ID# 170054, Irvine, California, United States|Tulane Univ /ID# 168441, New Orleans, Louisiana, United States|Beth Israel Deaconess Medical Center /ID# 168438, Boston, Massachusetts, United States|University of Michigan Hospitals /ID# 200667, Ann Arbor, Michigan, United States|Univ NC Chapel Hill /ID# 168446, Chapel Hill, North Carolina, United States|Penn State Hershey Medical Ctr /ID# 168447, Hershey, Pennsylvania, United States|Rhode Island Hospital /ID# 168439, Providence, Rhode Island, United States|CUB Hospital Erasme /ID# 150907, Brussels, Bruxelles-Capitale, Belgium|UZ Gent /ID# 150906, Gent, Oost-Vlaanderen, Belgium|NewLab Clinical Research Inc. /ID# 151315, St. John's, Newfoundland and Labrador, Canada|York Dermatology Clinic and Research Centre /ID# 151314, Richmond Hill, Ontario, Canada|Fundacion Valle Del Lili /ID# 151565, Cali, Colombia|Hospital Pablo Tobon Uribe /ID# 152693, Medellín, Colombia|Fakultni nemocnice Ostrava /ID# 169174, Ostrava, Praha 5, Czechia|Fakult Nem Kralovske Vinohrady /ID# 169173, Prague, Czechia|Bispebjerg Hospital /ID# 150796, Copenhagen NV, Hovedstaden, Denmark|Sjaellands Universitets Hospit /ID# 150795, Roskilde, Sjælland, Denmark|Hopital Prive d'Antony /ID# 157347, Antony, Ile-de-France, France|Polyclinique Courlancy /ID# 157761, Reims, France|Universitaetsklinikum Erlangen /ID# 167251, Erlangen, Bayern, Germany|Charité Universitätsmedizin Campus Mitte /ID# 150875, Berlin, Germany|Klinikum Ruhr Univ Bochum /ID# 150873, Bochum, Germany|Klinikum Darmstadt GmbH /ID# 150874, Darmstadt, Germany|Staedtisches Klinikum Dessau /ID# 150876, Dessau, Germany|University General Hospital Attikon /ID# 150841, Athens, Attiki, Greece|Genl Hospital Andreas Syggros /ID# 150840, Athens, Greece|Genl Hospital Andreas Syggros /ID# 150842, Athens, Greece|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 150069, Milan, Lombardia, Italy|A.O.U Sant'Anna di Ferrara /ID# 150066, Ferrara, Italy|Universita degli Studi di /ID# 150068, Modena, Italy|Policlinico Univ Tor Vergata /ID# 150142, Rome, Italy|Hospital Universitario ""Dr. José Eleuterio González"" /ID# 151027, Monterrey, Nuevo Leon, Mexico|Radboud Universitair Medisch Centrum /ID# 152157, Nijmegen, Gelderland, Netherlands|Universitair Medisch Centrum Groningen /ID# 150662, Groningen, Netherlands|Erasmus Medisch Centrum /ID# 150672, Rotterdam, Netherlands|Haukeland University Hospital /ID# 152662, Bergen, Hordaland, Norway|Prywatny Osrodek Chirurgii Plastycznej Andrzej Bieniek /ID# 169413, Wrocław, Dolnoslaskie, Poland|Centro Hospitalar de Sao Joao, EPE /ID# 150885, Porto, Portugal|Spitalul Universitar de Urgenta Elias /ID# 151072, Bucharest, Bucuresti, Romania|Spitalul Municipal de Urgenta Timisoara /ID# 151073, Timişoara, Timis, Romania|City Clinical Hospital 15 /ID# 151281, Moscow, Russian Federation|NW State Med Univ NA Mechnikov /ID# 151197, St. Petersburg, Russian Federation|King Faisal Specialist Hospital and Research Centre /ID# 153769, Riyadh, Najran, Saudi Arabia|Corporac Sanitaria Parc Tauli /ID# 150789, Sabadell, Barcelona, Spain|Hospital Santa Creu i Sant Pau /ID# 152742, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 150787, Barcelona, Spain|Hospital General Universitario Gregorio Maranon /ID# 150788, Madrid, Spain|Hospital de Manises /ID# 150790, Manises, Spain|Karolinska Univ Sjukhuset /ID# 150817, Solna, Sweden|Hacettepe University Medical Faculty /ID# 150829, Ankara, Turkey|Uludag University Medical Faculty /ID# 150831, Bursa, Turkey|Whipps Cross Univ Hospital /ID# 151699, London, London, City Of, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02808975"
203,"NCT02807402","Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania",,"Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants Achieving Virological Response at End of Treatment|Percentage of Participants in the Core Population With Sufficient Follow-up Data for SVR12 Who Achieved Sustained Virological Response 12 Weeks Post-treatment|Percentage of Participants With Relapse|Percentage of Participants With Breakthrough|Percentage of Participants in Each Non-response Category 12 Weeks Post-treatment|Assigned Treatment Regimen|Percentage of the Direct Acting Antiviral (DAA) Dose Taken in Relation to the Target Dose of DAA|Percentage of the Ribavirin Dose Taken in Relation to the Target Dose of Ribavirin|Percentage of Ribavirin (RBV) Treatment Days in Relation to the Target Number of Ribavirin Treatment Days|Number of Participants With Comorbidities|Number of Participants Who Received Concomitant Medications|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS Score|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Absenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Presenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Work Productivity Impairment (TWP)|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Activity Impairment|Change From Baseline in Patient Activation Measure 13 (PAM-13)|Change From Baseline in Beliefs Medication Questionnaire - (18-item BMQ)|Number of Participants With Adverse Events, Serious Adverse Events, or Pregnancies","AbbVie|IST GmbH, Germany","All","18 Years to 99 Years   (Adult, Older Adult)",,"522","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-698","July 14, 2016","August 4, 2017","August 4, 2017","June 21, 2016","January 25, 2019","January 25, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02807402/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02807402/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02807402"
204,"NCT02806362","Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)","GIFT-R","Withdrawn","No Results Available","Chronic Hepatitis C Virus","Drug: Ombitasvir/paritaprevir/ritonavir","Percentage of participants achieving a 12-week sustained virologic response (SVR12).|Percentage of participants with on-treatment virologic failure|Percentage of participants with relapse","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-733","September 2016","June 2018","August 2018","June 20, 2016",,"December 5, 2016",,,"https://ClinicalTrials.gov/show/NCT02806362"
205,"NCT02803138","Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C","CITRINE","Completed","Has Results","Chronic Hepatitis C","Drug: Ombitasvir/paritaprevir/ritonavir|Drug: Dasabuvir|Drug: Ribavirin|Behavioral: Patient support program","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virologic Response at End of Treatment (EoT)|Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 12 Weeks Posttreatment|Percentage of Participants With Relapse|Percentage of Participants With Viral Breakthrough|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants Meeting Relapse Criteria|Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria|Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"256","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P16-014","July 7, 2016","October 21, 2018","October 21, 2018","June 16, 2016","October 11, 2019","October 11, 2019","Soroka Medical Center /ID# 169357, Be'er Sheva, HaDarom, Israel|Rabin Medical Center /ID# 153696, Petakh Tikva, Tel-Aviv, Israel|Rabin Medical Center /ID# 158648, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 153693, Tel Aviv-Yafo, Tel-Aviv, Israel|Ha'Emek Medical Center /ID# 153695, Afula, Israel|Soroka Medical Ctr /ID# 153697, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 153708, Be'er Ya'akov, Israel|Maccabi Health Services /ID# 158647, Gush Dan, Israel|Hillel Yaffe Medical Center /ID# 153702, Hadera, Israel|Rambam Health Care Campus /ID# 153694, Haifa, Israel|Bnai Zion Medical Center /ID# 153700, Haifa, Israel|The Lady Davis Carmel MC /ID# 153692, Haifa, Israel|The Edith Wolfson Medical Cent /ID# 153706, Holon, Israel|Shaare Zedek Medical Center /ID# 153699, Jerusalem, Israel|Hadassah /ID# 153701, Jerusalem, Israel|Meir Medical Center /ID# 153698, Kfar Saba, Israel|Western Galilee Medical Center /ID# 153705, Nahariya, Israel|Sheba Medical Center /ID# 153707, Ramat Gan, Israel","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02803138/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02803138/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02803138"
206,"NCT02799381","A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)","DYSCOVER","Completed","No Results Available","Parkinson's Disease (PD)","Drug: ABT-SLV187|Drug: optimized antiparkinsonian treatment","Unified Dyskinesia Rating Scale (UDysRS) Total Score|Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination)|OFF time|Clinical Global Impression of Change (CGI-C) Score|ON time without troublesome dyskinesia|Parkinson's Disease Questionaire-8 (PDQ-8) Summary Index|Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living)","AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","63","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-535|2016-001403-23","February 9, 2017","September 19, 2019","September 19, 2019","June 14, 2016",,"December 19, 2019","Parkinson's Disease Treatment Center of Southwest Florida /ID# 150095, Port Charlotte, Florida, United States|Central Texas Neurology Consul /ID# 150088, Round Rock, Texas, United States|Helsinki Univ Central Hospital /ID# 151214, Helsinki, Finland|Oulun yliopistollinen sairaala /ID# 150947, Oulu, Finland|Mediterraneo Hospital /ID# 150955, Glyfada, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 150956, Heraklion, Greece|University Hospital of Ioannin /ID# 150954, Ioannina, Greece|Pecsi Tudomanyegyetem /ID# 170116, Pécs, Pecs, Hungary|Semmelweis Egyetem /ID# 170117, Budapest, Hungary|Szegedi Tudomanyegyetem /ID# 170115, Szeged, Hungary|Policlinico Universitario Campus Bio-Medico /ID# 150846, Rome, Lazio, Italy|A.O. Univ. Ospedali Riuniti /ID# 150853, Ancona, Marche, Italy|Azienda USL Toscana Centro /ID# 150770, Florence, Italy|Seconda Universita' di Napoli /ID# 150851, Naples, Italy|Policlinico Tor Vergata /ID# 151167, Rome, Italy|Univerzitna nemocnica L. Pasteura /ID# 150146, Košice - Západ, Kosicky Kraj, Slovakia|Univerzitna nemocnica Martin /ID# 150145, Martin, Zilinsky Kraj, Slovakia|Univerzitna Nemocnica Bratislava /ID# 150144, Bratislava, Slovakia|Univerzitna Nemocnica Bratislava /ID# 150171, Bratislava, Slovakia|Hospital Regional Universitari /ID# 171485, Málaga, Malaga, Spain|Hospital Universitario Cruces /ID# 203807, Barakaldo, Spain|Hospital General Univ de Elche /ID# 150154, Elche, Spain|Hospital Univ de la Princesa /ID# 150157, Madrid, Spain|Hospital General Universitario Gregorio Maranon /ID# 150155, Madrid, Spain|Hospital Univ Ramon y Cajal /ID# 150152, Madrid, Spain|Hospital Universitario Infanta /ID# 159696, Madrid, Spain|Hospital Universitario Virgen Macarena /ID# 158861, Sevilla, Spain|Hospital Virgen de la Salud /ID# 166297, Toledo, Spain",,"https://ClinicalTrials.gov/show/NCT02799381"
207,"NCT02798315","Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study",,"Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virological Response at End of Treatment (EoT)|Percentage of Participants With Relapse at EoT|Percentage of Participants With Breakthrough.|Percentage of Participants Meeting the SVR Non-response Categories of On-treatment Virologic Failure or Relapse|Percentage of Participants Meeting the SVR Non-response Categories of Premature Study Drug Discontinuation or Missing SVR12 Data and/or None of the Above Criteria|Adherence to ABBVIE Regimen: Percentage of the Direct-acting Antiviral (DAA) Dose Taken in Relation to the Target Dose of DAA|Adherence to RBV: Percentage of RBV Dose Taken in Relation to the Target Dose of RBV|Adherence: Percentage of Planned Duration of RBV Taken by Participant|Change From Baseline in the PAM-13 Questionnaire|Patient Support Program (PSP) Questionnaire: Utilization of PSP Components","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-699","May 25, 2016","June 12, 2017","June 12, 2017","June 14, 2016","December 31, 2018","December 31, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02798315/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02798315/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02798315"
208,"NCT02786576","Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting","HARMONY","Completed","No Results Available","Hidradenitis Suppurativa",,"Proportion of participants with moderate to severe Hidradenitis Suppurativa (HS) who achieve a clinical response|Proportion of participants with moderate to severe HS who achieve a clinical response|Changes from baseline in Dermatology Quality of Life Index (DLQI)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"236","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-769","July 5, 2016","January 7, 2019","January 7, 2019","June 1, 2016",,"January 9, 2020","Krankenanstalt Rudolfstiftung /ID# 166804, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 166802, Graz, Austria|Klinikum Wels - Grieskirchen /ID# 158017, Wels, Austria|UZ Brussel /ID# 154218, Jette, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 154217, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 154220, Liège, Liege, Belgium|UZ Gent /ID# 154221, Gent, Oost-Vlaanderen, Belgium|CLIDERM Bruxelles /ID# 154232, Anderlecht, Belgium|PP Anderlecht /ID# 154230, Anderlecht, Belgium|CHIREC- City Clinic Louise /ID# 154227, Brussels, Belgium|ULB Erasme /ID# 154216, Brussels, Belgium|UZ Antwerp /ID# 154219, Edegem, Belgium|Boonen, Geel, BE /ID# 154233, Geel, Belgium|Coenen, Hasselt, BE /ID# 154234, Hasselt, Belgium|Polyclinique de Herstal /ID# 154226, Herstal, Belgium|Meuleman, Lede, BE /ID# 154238, Lede, Belgium|Grand Hopital de Charleroi /ID# 154222, Loverval, Belgium|Lanssens MD Maldegem BE /ID# 154237, Maldegem, Belgium|C.H.U.de Mons Borinage /ID# 154215, Mons, Belgium|Dr. Pierre-Dominique Ghislain, Mons, BE /ID# 154228, Mons, Belgium|CHU UCL Namur /ID# 154223, Namur, Belgium|CHU UCL Namur /ID# 154224, Namur, Belgium|Ctr Hosp du Bois de l'Abbaye /ID# 154235, Seraing, Belgium|Lecuyer, Thuin, Belgium /ID# 154229, Thuin, Belgium|AZ Sint-Rembert Ziekenhuis /ID# 154231, Torhout, Belgium|Centre Medical 4 sapins /ID# 154236, Wavre, Belgium|Sanatorium, s.r.o /ID# 163593, Chotoviny, Czechia|Vojenska nemocnice /ID# 163592, Olomouc, Czechia|Kozni sanatorium /ID# 163591, Praha, Czechia|Kurzen, Freising, DE /ID# 153913, Freising, Germany|University General Hospital Attikon /ID# 156761, Athens, Attiki, Greece|General Uni hosp of Larissa /ID# 156734, Larissa, Thessalia, Greece|Duplicate_General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens P /ID# 156762, Athens, Greece|251 Airforce General Hospital /ID# 156731, Athens, Greece|Genl Hospital Andreas Syggros /ID# 156759, Athens, Greece|Genl Hospital Andreas Syggros /ID# 156760, Athens, Greece|University Gen Hosp of Patra /ID# 156735, Patras, Greece|General Hospital of Thessaloni /ID# 156728, Thessaloniki, Greece|General Hospital of Thessaloniki George Papanikolaou /ID# 156758, Thessaloniki, Greece|401 GSNA - 401 Army Gen Hosp /ID# 156729, Αthens, Greece|Miskolci Semmelweis Korhaz es /ID# 153175, Miskolc, Borsod-Abauj-Zemplen, Hungary|Pecsi Tudomanyegyetem /ID# 152612, Pécs, Pecs, Hungary|Markusovszky Egyetemi Oktatókórház /ID# 152616, Szombathely, Vas, Hungary|Semmelweis Egyetem /ID# 152613, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 152615, Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 160782, Kaposvár, Hungary|Bacs-Kiskun Megyei Korhaz /ID# 153180, Kecskemét, Hungary|Szegedi Tudomanyegyetem /ID# 152614, Szeged, Hungary|South Infirmary Victoria Univ /ID# 151095, Cork, Ireland|Adelaide and Meath Hosp,IE /ID# 151096, Dublin 24, Ireland|St Vincent's University Hosp /ID# 151084, Dublin, Ireland|Galway University Hospital /ID# 151097, Galway, Ireland|University Hospital Waterford /ID# 153191, Waterford, Ireland|Rabin Medical Center /ID# 149530, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 149528, Tel Aviv-Yafo, Tel-Aviv, Israel|HaEmek Medical Center /ID# 164387, Afula, Israel|Rambam Health Care Campus /ID# 149529, Haifa, Israel|Hadassah University Hospital /ID# 149532, Jerusalem, Israel|Sheba Medical Center /ID# 149531, Ramat Gan, Israel|Rizk Hospital /ID# 166027, Beirut, Lebanon|Saint Georges Hosp Med Cent /ID# 166024, Beirut, Lebanon|American Uni of Beirut Med Cen /ID# 166026, Beirut, Lebanon|Trad Hospital and Medical Cent /ID# 166025, Beirut, Lebanon|C/O Hotel Dieu de France /ID# 166028, Beirut, Lebanon|General Hospital Celje /ID# 164673, Celje, Slovenia|Univ Medical Ctr Ljubljana /ID# 164671, Ljubljana, Slovenia|University Medical Ctr Maribor /ID# 164672, Maribor, Slovenia|GH Novo Mesto /ID# 164674, Novo Mesto, Slovenia|Hopitaux Universitaires de Geneve /ID# 160090, Genève, Geneve, Switzerland|Inselspital, Universitaetsklinik /ID# 160089, Bern, Switzerland|University Hospital Zurich /ID# 160091, Zurich, Switzerland|Marmara University Med Faculty /ID# 157903, Istanbul, Turkey|Whipps Cross Univ Hospital /ID# 150195, London, London, City Of, United Kingdom|NHS Lanakshire (Monklands) /ID# 152885, Airdire, United Kingdom|Belfast City Hospital /ID# 168411, Belfast, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 152884, Birmingham, United Kingdom|Heartlands Hospital /ID# 168409, Birmingham, United Kingdom|Ninewells Hospital /ID# 168410, Dundee, United Kingdom|Hull and East Yorkshire NHS /ID# 168413, Hull, United Kingdom|St. James University Hospital /ID# 150200, Leeds, United Kingdom|St. John's Institute of Dermat /ID# 150197, London, United Kingdom|The Newcastle Upon Tyne Hospitals NHS Foundation Trust' /ID# 150199, Newcastle Upon Tyne, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 168412, Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02786576"
209,"NCT02786563","Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate",,"Withdrawn","No Results Available","Rheumatoid Arthritis (RA)",,"Change from baseline in grey-scale (GS) scores|Change in power Doppler (PD) semi-quantitative scores from baseline|Correlation between the 36-joint plus 4-tendon assessment versus simplified joint power Doppler (PD) ultrasonographic (US) assessments, which include 12-joint/7-joint/6-joint plus 4-tendon systems.|Change from baseline in counts of joints with US detected bone erosion|Percentage of participants achieving low disease activity|Correlation between changes of 36-joint plus 4-tendon PDUS score and disease activity DAS 28-CRP.|Percentage of patients achieving clinical remission|Change in DAS 28-CRP from baseline","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-074","September 30, 2018","November 21, 2018","November 21, 2018","June 1, 2016",,"November 26, 2018","Peking University Peoples Hospit /ID# 148961, Beijing, Beijing, China|Xijing Hospital /ID# 148960, Xian, Shaanxi, China|Hosp Ppl Liberation Army 301 /ID# 148962, Beijing, China|Renji Hosp, Shanghai Jiaotong /ID# 148959, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02786563"
210,"NCT02782663","A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease",,"Active, not recruiting","No Results Available","Crohn's Disease (CD)","Drug: ABT-494","Proportion of participants achieving Remission|Proportion of participants achieving Crohn's Disease Activity Index (CDAI) remission|Proportion of participants achieving Clinical response over time|Proportion of participants achieving Inflammatory Bowel disease Questionnaire (IBDQ) remission|Proportion of participants achieving Endoscopic response|Proportion of participants achieving Crohn's Disease Activity Index (CDAI) response|Proportion of participants achieving Response|Proportion of participants in Endoscopic remission at Week 0 who maintain Endoscopic remission|Proportion of participants in Remission at Week 0 who maintain remission|Proportion of participants achieving Endoscopic remission|Proportion of participants achieving IBDQ response|Proportion of participants achieving Clinical remission over time","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","107","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-327|2015-003759-23","May 18, 2016","September 17, 2025","September 17, 2025","May 25, 2016",,"March 19, 2019","Ucsd /Id# 150041, La Jolla, California, United States|Univ California, San Francisco /ID# 149987, San Francisco, California, United States|University of Florida /ID# 150033, Gainesville, Florida, United States|The Ctr for Gastro Disorders /ID# 150012, Hollywood, Florida, United States|Nature Coast Clinical Research /ID# 149975, Inverness, Florida, United States|Gastro Assoc of Central GA /ID# 149870, Macon, Georgia, United States|Gastrointestinal Specialists /ID# 150015, Marietta, Georgia, United States|Cotton-O'Neil Clinical Res Ctr /ID# 149900, Topeka, Kansas, United States|University of Louisville /ID# 149884, Louisville, Kentucky, United States|Investigative Clinical Research /ID# 149886, Annapolis, Maryland, United States|Charm City Research Group /ID# 150040, Towson, Maryland, United States|Center for Digestive Health /ID# 150008, Troy, Michigan, United States|Mayo Clinic - Rochester /ID# 149894, Rochester, Minnesota, United States|Kansas City Research Institute /ID# 149888, Kansas City, Missouri, United States|Washington University-School of Medicine /ID# 149899, Saint Louis, Missouri, United States|NYU Langone Long Island CRA /ID# 149976, Great Neck, New York, United States|Columbia Univ Medical Center /ID# 149895, New York, New York, United States|Univ NC Chapel Hill /ID# 149982, Chapel Hill, North Carolina, United States|University of Cincinnati /ID# 149977, Cincinnati, Ohio, United States|Options Health Research, LLC /ID# 150010, Tulsa, Oklahoma, United States|Medical University of South Carolina /ID# 150018, Charleston, South Carolina, United States|Texas Digestive Disease Consul /ID# 149869, Southlake, Texas, United States|Texas Digestive Disease Consul /ID# 149989, Southlake, Texas, United States|Aspen Clinical Research /ID# 150020, Orem, Utah, United States|University of Virginia /ID# 149881, Charlottesville, Virginia, United States|University of Washington /ID# 149988, Seattle, Washington, United States|WI Center for Advanced Res /ID# 149863, Milwaukee, Wisconsin, United States|CHU de Liege /ID# 149912, Liège, Liege, Belgium|The University of Alberta /ID# 149873, Emdonton, Alberta, Canada|Univ British Columbia /ID# 149876, Vancouver, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 149878, Vancouver, British Columbia, Canada|Toronto Digestive Disease Asso /ID# 149877, Vaughan, Ontario, Canada|McGill Univ HC /ID# 149871, Montreal, Quebec, Canada|Hepato-Gastroenterologie HK s.r.o. /ID# 149882, Hradec Kralove, Czechia|Aarhus University Hospital /ID# 149919, Aarhus N, Midtjylland, Denmark|Hvidovre Hospital /ID# 149890, Hvidovre, Denmark|CHRU Lille - Hôpital Claude Huriez /ID# 149897, Lille CEDEX, Hauts-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 149896, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Amiens Picardie /ID# 149921, Amiens CEDEX 1, Somme, France|Univ Hosp Schleswig-Holstein /ID# 149936, Kiel, Schleswig-Holstein, Germany|DRK-Kliniken Westend /ID# 149905, Berlin, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 149930, Munster, Germany|Magyar Elhizastudomanyi KKft. /ID# 149907, Budapest, Hungary|Rabin Medical Center /ID# 149942, Petakh Tikva, Tel-Aviv, Israel|Assaf Harofeh Medical Center /ID# 149943, Be'er Ya'akov, Israel|Sheba Medical Center /ID# 149945, Ramat Gan, Israel|Universita di Catanzaro Magna Graecia /ID# 149927, Catanzaro, Calabria, Italy|A.O.U. Policlinico S.Orsola-Malpighi /ID# 149958, Bologna, Emilia-Romagna, Italy|Academisch Medisch Centrum /ID# 149932, Amsterdam, Noord-Holland, Netherlands|Universitair Medisch Centrum Utrecht /ID# 149933, Utrecht, Netherlands|Dunedin Hospital /ID# 149964, Dunedin, New Zealand|Lovisenberg Diakonale Sykehus /ID# 149967, Oslo, Norway|C.M. Szpital Swietej Rodziny /ID# 149979, Lodz, Lodzkie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 149978, Warszawa, Mazowieckie, Poland|Cabinet Particular Policlinic Algomed /ID# 149993, Timisoara, Romania|KM Management s.r.o, Nitra, SK /ID# 149949, Nitra, Slovakia|Gastro I.S.R.O. /ID# 149948, Presov, Slovakia|Hospital Arquitecto Marcide /ID# 149996, Ferrol, Spain|Hospital Universitario La Paz /ID# 149997, Madrid, Spain|Manchester Royal Infirmary, Ma /ID# 150006, Manchester, United Kingdom|John Radcliffe Hospital /ID# 149963, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02782663"
211,"NCT02772601","This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis",,"Completed","No Results Available","Psoriasis","Drug: Caffeine|Drug: Warfarin|Drug: Omeprazole|Drug: Metoprolol|Drug: Midazolam|Drug: Risankizumab","AUC0 - tz (area under the concentration-time curve) of caffeine with risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of caffeine without risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of warfarin with risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of warfarin without risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of omeprazole with risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of omeprazole without risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of metoprolol with risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of metoprolol without risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of midazolam with risankizumab in plasma over time interval from 0 to last quantifiable data point|AUC0 - tz (area under the concentration-time curve) of midazolam without risankizumab in plasma over time interval from 0 to last quantifiable data point|Cmax (maximum measured concentration) of the analyte omeprazole without risankizumab in plasma|Cmax (maximum measured concentration) of the analyte metoprolol with risankizumab in plasma|Cmax (maximum measured concentration) of the analyte metoprolol without risankizumab in plasma|Cmax (maximum measured concentration) of the analyte midazolam with risankizumab in plasma|Cmax (maximum measured concentration) of the analyte midazolam without risankizumab in plasma|Cmax (maximum measured concentration) of the analyte caffeine with risankizumab in plasma|Cmax (maximum measured concentration) of the analyte caffeine without risankizumab in plasma|Cmax (maximum measured concentration) of the analyte warfarin with risankizumab in plasma|Cmax (maximum measured concentration) of the analyte warfarin without risankizumab in plasma|Cmax (maximum measured concentration) of the analyte omeprazole with risankizumab in plasma","AbbVie|Boehringer Ingelheim","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-007|2015-005523-31|1311.36","September 15, 2016","June 15, 2017","September 22, 2017","May 13, 2016",,"September 25, 2017","Boehringer Ingelheim Investigational Site, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02772601"
212,"NCT02756611","A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.","VENICE I","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: Venetoclax","Complete Remission Rate (CR + CRi) as assessed by the investigator|Time to Progression (TTP)|Overall Response Rate (ORR)|Duration of Overall Response (DoR)|CR Rate (CR + CRi)|Overall Survival (OS)|Progression-Free Survival (PFS)|Rate of Minimal Residual Disease (MRD)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","258","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-550|2015-003667-11","June 22, 2016","April 3, 2022","April 3, 2022","April 29, 2016",,"December 11, 2019","Norton Cancer Institute /ID# 149788, Louisville, Kentucky, United States|St. Agnes Cancer Center /ID# 149782, Baltimore, Maryland, United States|Hackensack Univ Med Ctr /ID# 151574, Hackensack, New Jersey, United States|Utah Cancer Specialists /ID# 151604, Salt Lake City, Utah, United States|Cancer Care Northwest /ID# 151605, Spokane, Washington, United States|West Virginia Univ School Med /ID# 151602, Morgantown, West Virginia, United States|LKH-Univ. Klinikum Graz /ID# 147547, Graz, Austria|LKH Salzburg and Paracelsus /ID# 147549, Salzburg, Austria|Hanusch Krankenhaus der WGKK /ID# 147548, Wien, Austria|Cliniques Universitaires Saint Luc /ID# 147388, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 147387, Leuven, Belgium|BC Cancer Agency /ID# 153091, Vancouver, British Columbia, Canada|Qe Ii Hsc /Id# 147460, Halifax, Nova Scotia, Canada|Juravinski Cancer Clinic /ID# 149152, Hamilton, Ontario, Canada|Sunnybrook Health Sciences Ctr /ID# 147462, Toronto, Ontario, Canada|CHU de Quebec-Universite Laval /ID# 150299, Quebec City, Quebec, Canada|Herlev Hospital /ID# 150183, Herlev, Hovedstaden, Denmark|Aarhus University Hospital /ID# 147409, Aarhus N, Midtjylland, Denmark|Turku University Hospital /ID# 147551, Turku, Finland|CHU Dupuytren /ID# 147552, Limoges CEDEX 1, Franche-Comte, France|CHU de la miletrie /ID# 147484, Poitiers, Poitou-Charentes, France|Institut Bergonie /ID# 147482, Bordeaux, France|CHRU de Brest - Hopital Morvan /ID# 147485, Brest, France|clinique Sainte Anne /ID# 147556, Strasbourg, France|Onkologische Schwerpunktpraxis /ID# 147516, Berlin, Germany|Cent fuer Haematologie und Onk /ID# 147511, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH /ID# 164044, Hamburg, Germany|Mannheimer Onkologiepraxis /ID# 147512, Mannheim, Germany|Staedt. Klinikum Schwabing /ID# 147510, Munich, Germany|General Hospital of Athens Laiko /ID# 147517, Athens, Attiki, Greece|G. Papanikolaou Hospital /ID# 147518, Thessaloniki, Greece|St. James's Hospital /ID# 147519, Dublin 8, Dublin, Ireland|Beaumont Hospital /ID# 147522, Dublin, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 151624, Tel Aviv-Yafo, Tel-Aviv, Israel|Galilee Medical Center /ID# 159971, Nahariya, Israel|Sheba Medical Center /ID# 147509, Ramat Gan, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 147505, Bologna, Emilia-Romagna, Italy|AP Romano Umberto I /ID# 147500, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 147503, Milano, Lombardia, Italy|Ospedale San Raffaele IRCCS /ID# 147504, Milan, Italy|AO Maggiore della Carita /ID# 147499, Novara, Italy|Academisch Medisch Centrum /ID# 147494, Amsterdam, Noord-Holland, Netherlands|Albert Schweitzer Ziekenhuis /ID# 147495, Dordrecht, Zuid-Holland, Netherlands|Haukeland University Hospital /ID# 147382, Bergen, Hordaland, Norway|Rikshospitalet OUS HF /ID# 201812, Oslo, Norway|IPO Lisboa FG, EPE /ID# 147385, Lisboa, Portugal|IPO Porto FG, EPE /ID# 147389, Porto, Portugal|Puerto Rico Hematology Oncolog /ID# 150003, San Juan, Puerto Rico|Hospital Santa Creu i Sant Pau /ID# 151230, Barcelona, Spain|Fundacion Jimenez Diaz /ID# 151231, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 147391, Majadahonda, Spain|Hospital Clinico Univ de Salamanca /ID# 147392, Salamanca, Spain|Hosp Clin Univ de Valencia /ID# 147396, Valencia, Spain|Skanes Universitetssjukhus Lund /ID# 147439, Lund, Skane Lan, Sweden|Akademiska Sjukhuset /ID# 150184, Uppsala, Uppsala Lan, Sweden|Hopitaux Universitaires de Geneve /ID# 147930, Genève, Geneve, Switzerland|University Hospital Zurich /ID# 157910, Zurich, Zuerich, Switzerland|Ospedale Regional Bellinzona e /ID# 151232, Bellinzona, Switzerland|Ankara Univ Medical Faculty /ID# 147443, Ankara, Turkey|Istanbul University Istanbul Medical Faculty /ID# 156040, Istanbul, Turkey|Vehbi Koc vakfi Amerikan Hasta /ID# 147325, Istanbul, Turkey|Dokuz Eylul University /ID# 147442, Izmir, Turkey|Ondokuz mayis University Facul /ID# 147326, Samsun, Turkey|Blackpool Teaching Hosp NHS /ID# 149581, Blackpool, United Kingdom|Univ Hosp Bristol NHS Foundati /ID# 147647, Bristol, United Kingdom|Southampton General Hospital /ID# 147646, Southampton, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 147945, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02756611"
213,"NCT02755597","A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy",,"Suspended","No Results Available","Relapsed/Refractory Multiple Myeloma","Drug: Placebo|Drug: Bortezomib|Drug: Dexamethasone|Drug: Venetoclax","Progression-free survival (PFS).|Brief Pain Inventory - Short Form [BPI-SF] - Worst Pain|Duration of Response (DOR).|Progression-Free Survival (PFS) in subjects with high B-cell lymphoma 2 (BCL-2) expression.|Minimal Residual Disease (MRD) status.|Objective Response Rate (ORR).|Patient Reported Outcomes Measurement Information System - (PROMIS)|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) - Physical Functioning|Overall survival (OS).|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core (EORTC QLQ-C30) - Global Health Status|Very Good Partial Response (VGPR) or better response rate.|Time to disease progression (TTP).","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","298","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-031|2015-004411-20","July 12, 2016","October 31, 2020","August 23, 2021","April 29, 2016",,"November 19, 2019","Univ of Colorado Cancer Center /ID# 149130, Aurora, Colorado, United States|VA Eastern Colorado Healthcare /ID# 156524, Aurora, Colorado, United States|Duke University Medical Center /ID# 149099, Durham, North Carolina, United States|Gabrail Cancer Center Research /ID# 149098, Canton, Ohio, United States|Royal Prince Alfred Hospital /ID# 149108, Camperdown, New South Wales, Australia|Concord Repatriation & Gen Hos /ID# 149106, Concord, New South Wales, Australia|Liverpool Hospital /ID# 149110, Liverpool, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 149105, Herston, Queensland, Australia|The Queen Elizabeth Hospital /ID# 149104, Woodville, South Australia, Australia|Royal Hobart Hospital /ID# 149111, Hobart, Tasmania, Australia|Peter MacCallum Cancer Ctr /ID# 149107, Melbourne, Victoria, Australia|Alfred Health /ID# 150085, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 149112, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 148967, Murdoch, Western Australia, Australia|Perth Blood Institute Ltd /ID# 148966, Nedlands, Western Australia, Australia|Universidade Federal de Goias /ID# 149290, Goiania, Goias, Brazil|Liga Norte Rigrandese Contra o /ID# 149023, Natal, Rio Grande Do Norte, Brazil|Hospital Sao Lucas da PUCRS /ID# 149027, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HC /ID# 149025, São Paulo, Sao Paulo, Brazil|Inca /Id# 149020, Rio de Janeiro, Brazil|Clinica Sao Germano /ID# 149851, Sao Paulo, Brazil|Victoria Hospital /ID# 149846, London, Ontario, Canada|CISSS de la Monteregie /ID# 149844, Greenfield Park, Quebec, Canada|CHU Dupuytren /ID# 149292, Limoges CEDEX 1, Franche-Comte, France|Centre Hospitalier Lyon Sud /ID# 149300, Pierre Benite CEDEX, Rhone, France|CHRU de Brest - Hopital Morvan /ID# 149299, Brest, France|CHU de Grenoble - Albet Michal /ID# 149301, Grenoble, France|CHU de Nantes, Hotel Dieu -HME /ID# 149294, Nantes, France|Charité Universitätsmedizin Campus Mitte /ID# 148949, Berlin, Germany|Universitaetklinikum Dresden /ID# 148948, Dresden, Germany|Asklepios Klinik Altona /ID# 150116, Hamburg, Germany|Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 152518, Budapest IX, Budapest, Hungary|Semmelweis Egyetem /ID# 152519, Budapest, Hungary|Semmelweis Egyetem /ID# 152520, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 152517, Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 152516, Kaposvár, Hungary|Galway University Hospital /ID# 149061, Galway, Ireland|A.O.U. Policlinico S.Orsola-Malpighi /ID# 148936, Bologna, Emilia-Romagna, Italy|AP Romano Umberto I /ID# 148939, Rome, Lazio, Italy|A.O. Univ. Ospedali Riuniti /ID# 148942, Ancona, Marche, Italy|Ospedale S.Eugenio /ID# 148938, Rome, Italy|Ospedale Molinette /ID# 148943, Turin, Italy|Nagoya City University Hospital /ID# 150943, Nagoya-shi, Aichi, Japan|Kyushu University Hospital /ID# 150896, Fukuoka-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 150783, Ogaki-shi, Gifu, Japan|Gunma University Hospital /ID# 150275, Maebashi-shi, Gunma, Japan|National Hospital Organization Shibukawa Medical Center /ID# 150281, Shibukawa-shi, Gunma, Japan|Hiroshima Red Cross Hospital /ID# 150242, Hiroshima-shi, Hiroshima, Japan|Kobe City Med Ctr General Hosp /ID# 150944, Kobe-shi, Hyogo, Japan|National Hospital Organization Mito Medical Center /ID# 151051, Higashi Ibaraki-gun, Ibaraki, Japan|Kyoto Prefect Univ Med /ID# 150719, Kyoto-shi, Kyoto, Japan|JCHO Kyoto Kuramaguchi Medical /ID# 150781, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 150945, Sendai-shi, Miyagi, Japan|Okayama Medical Center /ID# 150717, Okayama-shi, Okayama, Japan|Japanese Red Cross Osaka Hospi /ID# 150716, Osaka-shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 151044, Kawagoe-shi, Saitama, Japan|Tochigi Cancer Center /ID# 150192, Utsunomiya-shi, Tochigi, Japan|National Cancer Center Hospital /ID# 151039, Chuo-ku, Tokyo, Japan|The Cancer Institute Hosp JFCR /ID# 150780, Koto-ku, Tokyo, Japan|Japanese Red Cross Medical Center /ID# 149902, Shibuya-ku, Tokyo, Japan|National Hospital Organization Disaster Medical Center /ID# 150784, Tachikawa-shi, Tokyo, Japan|National Cancer Center /ID# 150889, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 150888, Seongnam, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center /ID# 150893, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 150894, Gwangju, Jeonranamdo, Korea, Republic of|Severance Hospital /ID# 150891, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 150892, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 150895, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 150890, Seoul, Korea, Republic of|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 148955, Kemerovo, Kemerovskaya Oblast, Russian Federation|State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 148956, Ryazan, Ryazanskaya Oblast, Russian Federation|LLC Novaya Klinika /ID# 148974, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Central Clinical Hosp 2 /ID# 148954, Moscow, Russian Federation|Clinical Onco Dispensary /ID# 148953, Omsk, Russian Federation|Samara State Medical Universit /ID# 148952, Samara, Russian Federation|Medical Clinica of Bashkir /ID# 151206, UFA, Russian Federation|Hospital Duran i Reynals /ID# 148989, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Univ de la Princesa /ID# 148980, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 148981, Madrid, Spain|Hospital Univ Dr. Peset /ID# 148986, Valencia, Spain|China Medical University Hosp /ID# 154446, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 154444, Taipei City, Taipei, Taiwan|Changhua Christian Hospital /ID# 154447, Changhua County, Taiwan|Taipei Veterans General Hosp /ID# 154445, Taipei City, Taiwan|Cherkassy Regional Onc Ctr /ID# 152414, Cherkasy, Ukraine|City Multi-Field Clin Hosp #4 /ID# 152411, Dnipro, Ukraine|National Cancer Institute /ID# 152413, Kiev, Ukraine|Leicester Royal Infirmary /ID# 149057, Leicester, England, United Kingdom|Blackpool Teaching Hosp NHS /ID# 149058, Blackpool, United Kingdom|East Kent Hosp Univ NHS Trust /ID# 149059, Canterbury, United Kingdom|St Bartholomew's Hospital, Bar /ID# 149050, London, United Kingdom|University College Hospitals /ID# 149044, London, United Kingdom|King's College Hospital NHS /ID# 149045, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 149046, Manchester, United Kingdom|Nottingham Univ Hospitals NHS /ID# 149047, Nottingham, United Kingdom|Queens Hospital /ID# 149055, Romford, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 149043, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02755597"
214,"NCT02750800","Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)","VALUE","Completed","Has Results","Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis|Psoriasis|Crohn's Disease|Ulcerative Colitis","Biological: Adalimumab|Behavioral: AbbVie Care 2.0","Mean Change From Baseline in Short Form 36 Version 2.0 (SF-36 V2) Physical Component Summary (PCS) Score at 12 Months|Mean Change From Baseline in Short Form 36 Version 2.0 (SF-36 V2) Mental Component Summary (MCS) Score at 12 Months|Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score at 12 Months|Mean Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Visual Analog Scale Score at 12 Months|Mean Change From Baseline in Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ) Score at 12 Months in Participants With Crohn's Disease and Ulcerative Colitis|Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score at 12 Months in Participants With Psoriasis and Psoriatic Arthritis|Mean Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at 12 Months in Participants With Ankylosing Spondylitis and Participants With Psoriatic Arthritis With Axial Symptoms|Mean Change From Baseline in Treatment Satisfaction Questionnaire for Medicine (TSQM) Version 1.4 Score at 12 Months|Mean Change From Baseline in Total Satisfaction With Information About Medicines Scale (SIMS) Score at 12 Months|Mean Change From Baseline in Total Morisky Medication Adherence Scale, 4 Questions (MMAS-4) Score at 12 Months|Mean Change From Baseline in in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) Score at 12 Months|Mean Change From the 12 Months Prior to Treatment With Adalimumab to the 12 Months After Beginning Treatment With Adalimumab in Health Resource Utilization: Number of Hospital Inpatient Days and Number of Sick Leave Days|Mean Change From the 12 Months Prior to Treatment With Adalimumab to the 12 Months After Beginning Treatment With Adalimumab in Health Resource Utilization: Number of Hospitalizations and Number of Sick Leaves|Mean Change From the 12 Months Prior to Treatment With Adalimumab to the 12 Months After Beginning Treatment With Adalimumab in Health Resource Utilization: Number of Outpatient Visits|Mean Change From Baseline in Disease Activity Score 28 (DAS28) at 12 Months|Mean Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS ESR) at 12 Months|Mean Change From Baseline in Clinical Disease Activity Index (CDAI) Score at 12 Months|Mean Change From Baseline in Partial Mayo (pMayo) Score at 12 Months|Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at 12 Months|Participants' Rating of the AbbVie Care 2.0 Program at 12 Months|Correlation Between Disease Activity Scores and Disease-specific Quality of Life Scores|Correlation Between the Length of AbbVie Care 2.0 Duration and Participant Outcomes","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"427","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-673","April 7, 2016","April 3, 2018","April 3, 2018","April 26, 2016","November 6, 2019","November 6, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT02750800/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02750800"
215,"NCT02739828","Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients","HOPE","Completed","Has Results","Hidradenitis Suppurativa","Biological: Adalimumab","Change From Baseline in DLQI at Week 12|Change From Baseline in DLQI at Week 4|Change From Baseline in DLQI at Week 24|Change From Baseline in Participant's Global Assessment of Skin Pain - NRS at Week 4|Change From Baseline in Participant's Global Assessment of Skin Pain - NRS at Week 12|Change From Baseline in Participant's Global Assessment of Skin Pain - NRS at Week 24|EQ-5D Questionnaire Responses at Week 4|EQ-5D Questionnaire Responses at Week 12|EQ-5D Questionnaire Responses at Week 24|Change From Baseline in EQ-5D VAS Score at Week 4|Change From Baseline in EQ-5D VAS Score at Week 12|Change From Baseline in EQ-5D VAS Score at Week 24|Change From Baseline in HSIA Overall Score at Week 4|Change From Baseline in HSIA Overall Score at Week 12|Change From Baseline in HSIA Overall Score at Week 24|WPAI-SHP: Mean Change From Baseline in Work Time Missed Due to Health Problem at Week 4|WPAI-SHP: Mean Change From Baseline in Work Time Missed Due to Health Problem at Week 12|WPAI-SHP: Mean Change From Baseline in Work Time Missed Due to Health Problem at Week 24|WPAI-SHP: Mean Change From Baseline in Impairment While Working Due to Health Problem at Week 4|Mean Change From Baseline in Impairment While Working Due to Health Problem at Week 12|Mean Change From Baseline in Impairment While Working Due to Health Problem at Week 24|Mean Change From Baseline in Overall Work Impairment Due to Health Problem at Week 4|Mean Change From Baseline in Overall Work Impairment Due to Health Problem at Week 12|Mean Change From Baseline in Overall Work Impairment Due to Health Problem at Week 24|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem at Week 4|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem at Week 12|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem at Week 24|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem at Week 4: Participants Not Employed at Baseline|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem at Week 12: Participants Not Employed at Baseline|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem at Week 24: Participants Not Employed at Baseline|Percentage of Participants With Hidradenitis Suppurativa Clinical Response (HiSCR) Over Time","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"24","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-692","April 7, 2016","March 28, 2018","March 28, 2018","April 15, 2016","August 9, 2019","August 9, 2019","Universitetssjukhuset Linköping, Linkoping, Vastra Gotalands Lan, Sweden|Hallands Hospital Halmstad, Halmstad, Sweden|Blekinge Hospital, Karlskrona, Sweden|Skaraborgs Hospital, Skovde, Sweden|Karolinska Univ Sjukhuset, Solna, Sweden|Kungsholmens Hudklinik, Stockholm, Sweden|Sodersjukhuset, Stockholm, Sweden|Danderyd Hospital, Stockholm, Sweden|Trelleborg Hospital, Trelleborg, Sweden|Norrlands Universitetssjukhus, Umeå, Sweden|Akademiska sjukhuset, Uppsala, Sweden","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02739828/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02739828/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02739828"
216,"NCT02738138","A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)","EXPEDITION-2","Completed","Has Results","Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics","Drug: ABT-493 coformulated with ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","153","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-730|2015-005577-20","May 17, 2016","March 15, 2017","June 7, 2017","April 14, 2016","May 9, 2018","May 9, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02738138/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02738138/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02738138"
217,"NCT02738125","Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions","SOTHIS","Active, not recruiting","No Results Available","Ulcerative Colitis (UC)",,"Time to loss of clinical benefit|Change from Baseline (Month 0) in Steroid-free remission|Change from Baseline (Month 0) in Clinical Remission|Change from Baseline (Month 0) in Clinical Response","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"265","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-681","April 29, 2016","November 20, 2028","November 20, 2028","April 14, 2016",,"March 6, 2019","Centre Hospitalier Lyon Sud /ID# 165859, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|Hopital Saint Joseph /ID# 164405, Marseille CEDEX 08, Bouches-du-Rhone, France|CHU Hopital Nord /ID# 152620, Marseille, Bouches-du-Rhone, France|Hôpital Purpan /ID# 167179, TOULOUSE Cedex 9, Haute-Garonne, France|CH Annecy Genevois Site Annecy /ID# 151131, Epagny Metz Tessy, Haute-Savoie, France|CHRU Lille - Hôpital Claude Huriez /ID# 151514, Lille CEDEX, Hauts-de-France, France|Hopital Beaujon /ID# 151498, Clichy, Ile-de-France, France|Hopitaux de Brabois Adultes /ID# 151147, Vandoeuvre les Nancy, Lorraine, France|Centre Medical Alexandre Dumas /Id# 165857, Amiens, France|Hopital Robert Ballanger /ID# 151382, Aulnay Sous Bois Cedex, France|CH Henri Duffaut /ID# 151383, Avignon, France|CH Henri Duffaut /ID# 151499, Avignon, France|Cabinet Medical /ID# 155460, BAIE Mahault, France|Centre Hospitalier Cote Basque /ID# 163714, Bayonne, France|Clinique du Tondu /ID# 161977, Bordeaux, France|Centre Endo Nord Isere /ID# 151390, Bourgoin Jallieu, France|CHR Univ de Brest - Hopital /ID# 152618, Brest, France|CHR Univ de Brest - Hopital /ID# 153608, Brest, France|Geier, Cabinet Medical /ID# 149652, Brest, France|Cabinet Medical /ID# 151391, Caen, France|Pole Sante Leonard de Vinci /ID# 151384, Chambray Les Tours, France|CH Heut Anjou de Chateau Gonti /ID# 151151, Chateau Gontier, France|CH de Chauny /ID# 151149, Chauny, France|CHU Estaing /ID# 153527, Clermont Ferrand, France|Hopital Louis Mourier,Colombes /ID# 152650, Colombe, France|GHPSO CH Creil /ID# 151117, Creil, France|Centre Hosp Intercommunal /ID# 152361, Creteil, France|Cabinet Medical /ID# 150978, Douarnenez, France|Cabinet Medical /ID# 150845, Erstein, France|Centre Gastro Loire /ID# 151387, Gien, France|Clinique du Palais /ID# 151175, Grasse, France|CHU de Grenoble - Albet Michal /ID# 151508, Grenoble, France|Hopital Saint Louis /ID# 151182, La Roche Sur Yon, France|Hopital Dupuytren /Id# 157889, Limoges, France|CH Des Deux Vallees Longumeau /ID# 150977, Longjumeau, France|Ctr Consultations La Sauvegard /ID# 151515, Lyon, France|Hopital Edouard Herriot /ID# 151513, Lyon, France|Centre Medical Les Sources /ID# 151174, Montigny Les Cormeilles, France|Hopital de L'archet 2 /ID# 151132, Nice, France|Hopital de L'archet 2 /ID# 151181, Nice, France|CHU Nimes /ID# 169178, Nimes Cedex 9, France|Hopital Saint-Louis /ID# 151509, Paris, France|Hopital Saint Joseph /ID# 153526, Paris, France|Cabinet Medical /ID# 151118, Paris, France|Cabinet Medical /ID# 152362, Paris, France|Hopital Bichat Claude Bernard /ID# 151176, Paris, France|Chu Lyon Sud /Id# 151146, Pierre Benite, France|Chu Lyon Sud /Id# 151505, Pierre Benite, France|Chu Lyon Sud /Id# 153801, Pierre Benite, France|Cabinet Medical /ID# 151092, Plerin, France|Cabinet Medical /ID# 151093, Plerin, France|Cabinet Medical /ID# 151094, Plerin, France|Cabinet Medical /ID# 151148, Poissy, France|Cabinet Medical /ID# 151555, Prades-le-lez, France|Hospital Pontchaillou /ID# 166806, Rennes, France|Hopital Nord /ID# 166807, Saint Priest En Jarez, France|CHU d'Amiens /ID# 152651, Salouel, France|Cabinet Medical /ID# 151558, Saverne, France|CHU la Reunion Site St. Denis /ID# 151556, St Denis, France|Centre de Consultations /ID# 151128, St Nazaire, France|Centre de Consultations /ID# 151164, St Nazaire, France|Centre de Consultations /ID# 155458, St Nazaire, France|Cabinet Medical /ID# 151559, St Quentin, France|Cabinet Medical /ID# 151162, Strasbourg, France|Centre Medical du Clos de Pacy /ID# 151129, Sucy En Brie, France|Fondation Maison Sante Bagatel /ID# 151497, Talence, France|Cabinet Medical, Dr. Constant, /ID# 151119, Toulon, France|Clinique Pasteur /ID# 151088, Toulouse, France|Hopital Rangueil /ID# 157890, Toulouse, France|Clinique /Id# 155792, Toulouse, France|Clinique Amroise Pare /ID# 161978, Toulouse, France|Cabinet Medical /ID# 170136, Toulouse, France|Cabinet Medical /ID# 152841, Toulouse, France|Hopital Trousseau /ID# 150168, Tours, France|Hopital Trousseau /ID# 163503, Tours, France|Cabinet Medical /ID# 151557, Troyes, France|GH Mutualiste Les Port Du Sud /ID# 152374, Venissieux, France|GH Mutualiste Les Port Du Sud /ID# 159231, Venissieux, France|Ceentre Hepatologie Biliaire /ID# 151152, Villejuif, France|Cabinet Medical /ID# 152617, Voiron, France",,"https://ClinicalTrials.gov/show/NCT02738125"
218,"NCT02725866","Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C",,"Completed","Has Results","Chronic Hepatitis C","Drug: Paritaprevir/ritonavir/ombitasvir|Drug: Dasabuvir|Drug: Ribavirin","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virologic Response at End of Treatment (EoT)|Percentage of Participants With Relapse|Percentage of Participants With Viral Breakthrough|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants Meeting Relapse Criteria|Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria|Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"216","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-842","April 5, 2016","October 31, 2017","October 31, 2017","April 1, 2016","March 15, 2019","March 15, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02725866/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02725866/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02725866"
219,"NCT02723084","A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection","CERTAIN-2","Completed","Has Results","Chronic Hepatitis C Virus|Hepatitis C Virus","Drug: ABT-493/ABT-530|Drug: sofosbuvir (SOF)|Drug: ribavirin (RBV)","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Non-inferiority of Arm A to Arm B|Percentage of Participants in Arm A With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With With On-treatment Virologic Failure|Percentage of Participants With Post-Treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-828","April 8, 2016","January 19, 2017","March 24, 2017","March 30, 2016","February 15, 2019","February 15, 2019",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02723084/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02723084/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02723084"
220,"NCT02720523","A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs","SELECTSUNRISE","Active, not recruiting","Has Results","Rheumatoid Arthritis","Drug: Placebo|Drug: Upadacitinib","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12|Change From Baseline in Disease Activity Score 28 (DAS28) (CRP) at Week 12|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 12|Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12|Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12|Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1|Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) at Week 12|Change From Baseline in Rheumatoid Arthritis Work Instability Scale (RA-WIS) at Week 12|Change From Baseline in the Severity of Morning Stiffness at Week 12","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-663","March 22, 2016","August 3, 2017","January 14, 2022","March 28, 2016","October 21, 2019","December 2, 2019","Nagoya University Hospital /ID# 148005, Nagoya-shi, Aichi, Japan|Hamanomachi Hospital /ID# 147991, Fukuoka-shi, Fukuoka, Japan|Kyushu University Hospital /ID# 148008, Fukuoka-shi, Fukuoka, Japan|Inoue Hospital /ID# 147966, Takasaki, Gunma, Japan|National Hospital Organization Asahikawa Medical Center /ID# 147994, Asahikawa, Hokkaido, Japan|Katayama Orthopedic Rheumatology Clinic /ID# 147976, Asahikawa, Hokkaido, Japan|The Hospital of Hyogo College of Medicine /ID# 147978, Nishinomiya-shi, Hyogo, Japan|National Hospital Organization Sagamihara National Hospital /ID# 148221, Sagamihara-shi, Kanagawa, Japan|Kumamoto Orthopaedic Hospital /ID# 147972, Kumamoto-shi, Kumamoto, Japan|Tohoku University Hospital /ID# 148435, Sendai-shi, Miyagi, Japan|Medical Corporation Keiai Kai Clinic /ID# 147975, Miyazaki-shi, Miyazaki, Japan|Nagaoka Red Cross Hospital /ID# 147974, Nagaoka-shi, Niigata, Japan|Niigata Rheumatic Center /ID# 148002, Shibata-shi, Niigata, Japan|NHO Osaka Minami Med Ctr /ID# 147986, Kawachinagano-shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 147965, Kawagoe-shi, Saitama, Japan|Jichi Medical University Hospital /ID# 148220, Shimotsuke-shi, Tochigi, Japan|St.Luke's International Hospital /ID# 147969, Chuo-ku, Tokyo, Japan|Ichinomiya Municipal Hospital /ID# 147992, Ichinomiya-shi, Tokyo, Japan|Toho University Ohashi Medical Center /ID# 148003, Meguro-ku, Tokyo, Japan|Setagaya Rheumatic Clinic /ID# 148009, Setagaya-ku, Tokyo, Japan|Keio University Hospital /ID# 147982, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 148007, Shinjuku-ku, Tokyo, Japan|Medical Corporation Uchida Clinic /ID# 148219, Sumida-ku, Tokyo, Japan|Tokito Clinic Rheumatology and Orthopaedics Surgery /ID# 147980, Shimonoseki-shi, Yamaguchi, Japan|NHO Chiba-East-Hospital /ID# 147996, Chiba, Japan|Sugimoto Rheumatology and Internal Medicine Clinic /ID# 147989, Fukui, Japan|Hopsital of the University of Occupational and Enviromental Health /ID# 147970, Fukuoka, Japan|Shono Rheumatism Clinic /ID# 147971, Fukuoka, Japan|Hiroshima Rheumatology Clinic /ID# 147981, Hiroshima-Shi, Japan|Matsubara Mayflower Hospital /ID# 147967, Kato, Japan|Kumamoto Rheumatology Clinic /ID# 147988, Kumamoto, Japan|St. Mary's Hospital /ID# 147979, Kurume, Japan|Kagawa University Hospital /ID# 148001, Kyoto, Japan|Marunouchi Hospital /ID# 147973, Matsumoto, Japan|Yu Family Clinic /ID# 147990, Miyagi, Japan|JP Red Cross Nagoya Daiichi /ID# 147995, Nagoya, Japan|Kondo Clinic for Ortho & Rheum /ID# 147984, Nagoya, Japan|Oribe Clinic of Rheumatology and Internal Medicine /ID# 149308, Oita, Japan|Okayama City Gen Med Ctr /ID# 148000, Okayama, Japan|Miyashita Rheumatology Clinic /ID# 147997, Omura, Japan|Sagawa Akira Rheumatology Clin /ID# 147987, Sapporo, Japan|Sapporo City General Hospital /ID# 147968, Sapporo, Japan|Hikarigaoka Spellman Hospital /ID# 147993, Sendai, Japan|Honjo Rheumatism Clinic /ID# 147983, Takaoka, Japan|Takikawa Municipal Hospital /ID# 149309, Takikawa, Japan|Juntendo University Hospital /ID# 147999, Tokyo, Japan|National Hospital Organization Tokyo Medical Center /ID# 147998, Tokyo, Japan|Nihon University Itabashi Hosp /ID# 147977, Tokyo, Japan|Oki Medical Clinic /ID# 147985, Tomakomai, Japan|Toneyama National Hospital /ID# 148006, Toyonaka, Japan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02720523/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02720523/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02720523"
221,"NCT02719171","BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis",,"Completed","Has Results","Arthritis, Psoriatic","Drug: risankizumab|Drug: placebo for risankizumab","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16|Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 16|Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 16|Tender Joint Count (TJC68): Change From Baseline to Week 16|Swollen Joint Count (SJC): Change From Baseline to Week 16|Health Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16|Short Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 16|SF-36 Mental Component: Change From Baseline to Week 16|Dactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline|Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline|Modified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16|Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16","AbbVie|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","185","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-002|2015-003625-34|1311.5","April 2016","May 2017","August 2017","March 25, 2016","May 30, 2019","May 30, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02719171/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02719171/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02719171"
222,"NCT02713295","A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece","CONCORDIA","Completed","No Results Available","Moderate to Severe Plaque Psoriasis",,"Proportion of participants who will achieve the European Consensus Programme (ECP)-defined treatment goals at the end of the induction phase (i.e. 16 weeks post-treatment onset)|Proportion of participants achieving intermediate response|Proportion of participant achieving treatment success|Proportion of participant with treatment failure|Proportion of participants achieving the treatment goals|Time to the first missed dose during the study observation period","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"273","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-693","June 16, 2016","April 19, 2019","April 19, 2019","March 18, 2016",,"May 6, 2019","General Univ Hosp ""Attikon"" /ID# 149517, Athens, Attiki, Greece|Tzaneio general hospital of Piraeus /ID# 149518, Piraeus, Attiki, Greece|General Uni hosp of Larissa /ID# 149688, Larissa, Thessalia, Greece|General Uni hosp of Larissa /ID# 151442, Larissa, Thessalia, Greece|PP of Konstantinos Tsaousis /ID# 149704, Amaliada, Greece|PP of Maria Sifaki /ID# 149717, Arkalochori, Greece|PP of Ekaterini Galaterou /ID# 149713, Athens, AGIA Paraskeui, Greece|PP of Ioannis Papaggelopoulos /ID# 149703, Athens, Ampelokipi, Greece|PP of Antonios Seretis /ID# 149714, Athens, Chalandri, Greece|PP of Despoina Arnaoutoglou /ID# 149707, Athens, Glyfada, Greece|PP of Maria Loukatou /ID# 149706, Athens, Glyfada, Greece|PP of Eirini Stefanaki /ID# 149695, Athens, NEA Filadelfeia, Greece|PP of Pantelis Aronis /ID# 149705, Athens, NEA Smyrni, Greece|PP of Theognosia Vergou /ID# 149694, Athens, VARI, Greece|PP of Ioannis Mparkis /ID# 149711, Athens,neo Irakleio, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 158934, Athens, Greece|PP of Michael Kakepis /ID# 149693, Athens, Greece|PP of Georgios Papadopoulos /ID# 149712, Athens, Greece|PP of Ioannis Krikellis /ID# 149715, Athens, Greece|PP of Markos Papakonstantis /ID# 149702, Athens, Greece|PP of Panagiotis Deligiannis /ID# 149708, Athens, Greece|Genl Hospital Andreas Syggros /ID# 149516, Athens, Greece|Genl Hospital Andreas Syggros /ID# 149687, Athens, Greece|PP of Vasilios Chatzakis /ID# 149718, Crete, Heraklion, Greece|PP of Kalliopi Karamanolaki /ID# 149720, Crete, Heraklion, Greece|PP of Vasiliki Tzirka /ID# 149722, Drama, Greece|Kontargiris, MD, Kalamata, GR /ID# 151444, Kalamata, Greece|Konstantopouleio General Hospi /ID# 149690, Nea Ionia, Greece|PP of Konstantinos Markakis /ID# 149723, Orestiada, Greece|Rigatos, MD, Patra, GR /ID# 151446, Patras, Greece|University Gen Hosp of Patra /ID# 149691, Patras, Greece|PP of Chrysa Zisimou Politopou /ID# 149728, Stylida, Greece|PP of Aimilios Lallas /ID# 149721, Thessaloniki, Greece|PP of Pantelis Souvantzidis /ID# 149726, Thessaloniki, Greece|PP of Stelios Charalampidis /ID# 149727, Thessaloniki, Greece|PP of Georgios Chaidemenos /ID# 149724, Thessaloniki, Greece|General Hospital of Thessaloni /ID# 149692, Thessaloniki, Greece|Kallidis, MD, Thessaloniki, GR /ID# 151443, Thessaloniki, Greece|General Hospital of Thessaloniki George Papanikolaou /ID# 149515, Thessaloniki, Greece|Manousari, MD, Veroia, GR /ID# 151445, Veroia, Greece|PP of Prodromos Christoforidis /ID# 149730, Volos, Greece|General Hospital of Xanthi /ID# 149519, Xanthi, Greece|PP of Stathis Gkourvelos /ID# 149709, Xilokastro, Greece",,"https://ClinicalTrials.gov/show/NCT02713295"
223,"NCT02709889","Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors",,"Terminated","No Results Available","Malignant Melanoma|Medullary Thyroid Cancer|Glioblastoma|Large Cell Neuroendocrine Carcinoma|Neuroendocrine Prostate Cancer|High Grade Gastroenteropancreatic Neuroendocrine Carcinoma|Neuroendocrine Carcinoma|Solid Tumors","Drug: Rovalpituzumab tesirine","Maximum tolerated dose (MTD)|Number of subjects with adverse events as a measure of safety and tolerability|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS)|Maximum Plasma Concentration (Cmax)|Overall survival (OS)|Clinical benefit rate (CBR)|Area Under the Curve (AUC)|Anti-therapeutic Antibodies (ATA)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","200","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRX001-006","August 2016","August 27, 2019","August 27, 2019","March 16, 2016",,"September 19, 2019","Banner MD Anderson Cancer Ctr /ID# 155424, Gilbert, Arizona, United States|Mayo Clinic - Scottsdale /ID# 155419, Scottsdale, Arizona, United States|University of California, Los Angeles /ID# 155429, Los Angeles, California, United States|Univ California, San Francisco /ID# 155409, San Francisco, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 155428, West Hollywood, California, United States|Univ of Colorado Cancer Center /ID# 155415, Aurora, Colorado, United States|Sarah Cannon Research Institute at HealthONE - Denver /ID# 155420, Denver, Colorado, United States|University of Florida /ID# 155414, Gainesville, Florida, United States|Moffitt Cancer Center /ID# 170220, Tampa, Florida, United States|Emory University Hospital /ID# 155417, Atlanta, Georgia, United States|University of Kentucky Chandler Medical Center /ID# 155423, Lexington, Kentucky, United States|Johns Hopkins University /ID# 155412, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 155411, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 171044, Boston, Massachusetts, United States|Mayo Clinic - Rochester /ID# 155416, Rochester, Minnesota, United States|Washington University-School of Medicine /ID# 155425, Saint Louis, Missouri, United States|Rutgers Cancer Institute of NJ /ID# 162010, New Brunswick, New Jersey, United States|University of New Mexico /ID# 205054, Albuquerque, New Mexico, United States|Roswell Park /ID# 162015, Buffalo, New York, United States|Weill Cornell Medical College /ID# 155418, New York, New York, United States|Duke University Medical Center - Main /ID# 155421, Durham, North Carolina, United States|Univ Hosp Cleveland /ID# 155410, Cleveland, Ohio, United States|Oregon Health and Science University /ID# 162011, Portland, Oregon, United States|Greenville Hospital System /ID# 155427, Greenville, South Carolina, United States|Mary Crowley Cancer Research /ID# 162014, Dallas, Texas, United States|Texas Oncology - Forth Worth /ID# 162045, Fort Worth, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 155413, Houston, Texas, United States|University of Utah /ID# 155426, Salt Lake City, Utah, United States|Virginia Cancer Specialists /ID# 162006, Fairfax, Virginia, United States|Northwest Cancer Specialists, P.C. /ID# 155431, Vancouver, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02709889"
224,"NCT02707952","A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection","CERTAIN-1","Completed","Has Results","Chronic Hepatitis C Virus|Hepatitis C Virus","Drug: ABT-493/ABT-530|Drug: OBV/PTV/r","Percentage of Participants in Arms A and B With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants in Arm A With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants for Each Sub-Population in Arms C and D With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-Treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","295","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-594","February 22, 2016","November 14, 2016","February 9, 2017","March 14, 2016","July 23, 2018","July 23, 2018",,,"https://ClinicalTrials.gov/show/NCT02707952"
225,"NCT02706951","A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)",,"Active, not recruiting","Has Results","Rheumatoid Arthritis","Drug: Methotrexate|Drug: Upadacitinib|Drug: Upadacitinib matching placebo|Drug: Methotrexate matching placebo","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 14|Change From Baseline in in Disease Activity Score 28 (CRP) at Week 14|Change From Baseline in Heath Assessment Questionnaire and Disability Index (HAQ-DI) at Week 14|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 14|Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 14|Change From Baseline in Duration of Morning Stiffness at Week 14|Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 14|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 14","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","648","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-555|2015-003376-75","March 23, 2016","October 2, 2017","February 27, 2022","March 11, 2016","October 7, 2019","October 7, 2019","Rheum Assoc of North Alabama /ID# 146009, Huntsville, Alabama, United States|Alabama Medical Group, PC /ID# 153941, Mobile, Alabama, United States|ArthroCare Arthritis Care & Re /ID# 143751, Gilbert, Arizona, United States|Elite Clinical Studies, LLC /ID# 143760, Phoenix, Arizona, United States|University Arizona Cancer Ctr /ID# 147175, Tucson, Arizona, United States|NEA Baptist Womens Clinic /ID# 148904, Jonesboro, Arkansas, United States|C.V. Mehta MD, Med Corporation /ID# 143762, Hemet, California, United States|Arthritis Assoc & Osteo Ctr /ID# 147176, Colorado Springs, Colorado, United States|Ctr Rheum, Immuno, Arthritis /ID# 143766, Fort Lauderdale, Florida, United States|South Florida Research Ph I-IV /ID# 151983, Miami Springs, Florida, United States|Advent Clinical Research /ID# 143767, Pinellas Park, Florida, United States|Sarasota Arthritis Center /ID# 146011, Sarasota, Florida, United States|W. Broward Rheum Assoc Inc. /ID# 146010, Tamarac, Florida, United States|Clinical Research West FL /ID# 148726, Tampa, Florida, United States|SW FL Clin Res Ctr, Tampa, FL /ID# 143763, Tampa, Florida, United States|University of South Florida /ID# 146004, Tampa, Florida, United States|BayCare Medical Group, Inc. /ID# 151985, Tampa, Florida, United States|BayCare Medical Group, Inc. /ID# 163595, Tampa, Florida, United States|Jefrey D. Lieberman, MD, P.C. /ID# 151816, Decatur, Georgia, United States|Great Lakes Clinical Trials /ID# 150935, Chicago, Illinois, United States|PRN Professional Research Network of Kansas, LLC /ID# 143761, Wichita, Kansas, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 160809, Monroe, Louisiana, United States|Ochsner Clinic Foundation /ID# 153573, New Orleans, Louisiana, United States|Vanguard Medical Research, LLC /ID# 153124, Shreveport, Louisiana, United States|Mansfield Health Center /ID# 161627, Mansfield, Massachusetts, United States|Quality Clinical Research Inc. /ID# 156415, Omaha, Nebraska, United States|Dartmouth-Hitchcock Med Ctr /ID# 146008, Lebanon, New Hampshire, United States|Albuquerque Clinical Trials, Inc /ID# 147618, Albuquerque, New Mexico, United States|Arthritis and Osteo Assoc /ID# 147177, Las Cruces, New Mexico, United States|Coastal Carolina Health Care /ID# 149275, New Bern, North Carolina, United States|STAT Research, Inc. /ID# 143770, Dayton, Ohio, United States|Health Research Oklahoma /ID# 159550, Oklahoma City, Oklahoma, United States|Healthcare Research Consultant /ID# 147632, Tulsa, Oklahoma, United States|Innovative Clinical Research /ID# 143757, Greenville, South Carolina, United States|Nashville Arthritis and Rheumatology /ID# 162641, Nashville, Tennessee, United States|Tekton Research, Inc. /ID# 159554, Austin, Texas, United States|Diagnostic Group Integrated He /ID# 148725, Beaumont, Texas, United States|Trinity Universal Res Assoc /ID# 150138, Carrollton, Texas, United States|Arth and Osteo Clin Brazo Valley /ID# 160810, College Station, Texas, United States|Adriana Pop-Moody MD Clinic PA /ID# 147627, Corpus Christi, Texas, United States|Accurate Clinical Management /ID# 143768, Houston, Texas, United States|Accurate Clinical Research /ID# 143769, Houston, Texas, United States|Pioneer Research Solutions, Inc. /ID# 143765, Houston, Texas, United States|P&I Clinical Research /ID# 151358, Lufkin, Texas, United States|SW Rheumatology Res. LLC /ID# 147620, Mesquite, Texas, United States|Sun Research Institute /ID# 159553, San Antonio, Texas, United States|Arthritis Clinic of Central TX /ID# 149266, San Marcos, Texas, United States|Adv Rheumatology of Houston /ID# 162609, The Woodlands, Texas, United States|DM Clinical Research /ID# 151359, Tomball, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 143752, Waco, Texas, United States|Ctr for Arth and Rheum Disease /ID# 143759, Chesapeake, Virginia, United States|Rheumatology and Immunotherapy Center /ID# 160811, Franklin, Wisconsin, United States|Mautalen Salud e Investigacion /ID# 145980, Buenos Aires, Argentina|Ctr Privado Med Familiar /ID# 149183, Buenos Aires, Argentina|Consultorio Reumatologic Pampa /ID# 145979, Buenos Aires, Argentina|Cemic /Id# 149176, Buenos Aires, Argentina|Cordis S.A. /Id# 152621, Salta, Argentina|Centro de Enfermedades /ID# 153543, Santa Fe, Argentina|Royal Prince Alfred Hospital /ID# 146028, Camperdown, New South Wales, Australia|Rheuma-Zentrum Wien-Oberlaa /ID# 144728, Wien, Austria|Algemeen Stedelijk Ziekenhuis /ID# 148720, Aalst, Oost-Vlaanderen, Belgium|ReumaClinic Genk /ID# 146030, Genk, Belgium|Diag Consult Ctr 17 Sofia EOOD /ID# 144730, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 147351, Sofia, Bulgaria|Reg. Clinical Hosptial Concepcion /ID# 151267, Concepcion, Chile|Quantum Research LTDA. /ID# 145984, Puerto Varas, Chile|Quantum Research Stgo. /ID# 145983, Santiago, Chile|CTCenter MaVe, s.r.o. /ID# 144823, Olomouc, Olomoucky Kraj, Czechia|Nuselská poliklinika, Revmatologie /ID# 145986, Prague 4, Praha 4, Czechia|Thomayerova nemocnice /ID# 144736, Prague 4, Praha 4, Czechia|RHEUMA s.r.o. /ID# 144737, Breclav, Czechia|Medical Plus, s.r.o. /ID# 144821, Uherské Hradište, Czechia|MediTrials /ID# 159745, Tartu, Tartumaa, Estonia|North Estonian Medical Centre /ID# 145455, Tallinn, Estonia|General Hospital of Athens Ippokratio /ID# 144739, Athens, Greece|Vital Medical Center Orvosi es /ID# 144740, Veszprém, Veszprem, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont /ID# 144743, Budapest, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 144742, Kistarcsa, Hungary|Fejer Megyei Szent Gyorgy Korh /ID# 144741, Szekesfehervar, Hungary|Barzilai Medical Center /ID# 144744, Ashkelon, Israel|Bnai Zion Medical Center /ID# 144745, Haifa, Israel|The Lady Davis Carmel MC /ID# 147174, Haifa, Israel|Sheba Medical Center /ID# 144824, Ramat Gan, Israel|Universita di Catanzaro Magna Graecia /ID# 144747, Catanzaro, Calabria, Italy|A.O.U.I. di Verona Policlinico /ID# 144746, Verona, Italy|Kondo Clinic for Rheum & Ortho /ID# 148268, Fukuoka-shi, Fukuoka, Japan|NHO Kyushu Medical Center /ID# 148279, Fukuoka-shi, Fukuoka, Japan|NHO Kyushu Medical Center /ID# 148280, Fukuoka-shi, Fukuoka, Japan|Aso Iizuka Hospital /ID# 148272, Iizuka-shi, Fukuoka, Japan|Inoue Hospital /ID# 148069, Takasaki, Gunma, Japan|Bay Side Misato Medical Center /ID# 148281, Kochi-shi, Kochi, Japan|Center for Arthritis and Clinical Rheumatology Matsubara Clinic /ID# 148269, Kumamoto-shi, Kumamoto, Japan|Kumamoto Shinto General Hospital /ID# 148286, Kumamoto-shi, Kumamoto, Japan|Nagasaki University Hospital /ID# 149859, Nagasaki-shi, Nagasaki, Japan|Osaka Red Cross Hospital /ID# 148267, Osaka-shi, Osaka, Japan|Seirei Hamamatsu General Hosp /ID# 148270, Hamamatsu, Japan|Ohira Orthopaedic Hospital /ID# 157944, Hyuga, Japan|Shirahama Hamayu Hospital /ID# 148277, Nishimuro, Japan|Sanuki Municipal Hospital /ID# 158080, Sanuki, Japan|Hokkaido University Hospital /ID# 148285, Sapporo, Japan|Hokkaido Medical Center for Rheumatic Diseases /ID# 148274, Sapporo, Japan|Sasebo Chuo Hospital /ID# 148275, Sasebo, Japan|Miyasato Clinic /ID# 148271, Shunan, Japan|Honjo Rheumatism Clinic /ID# 148068, Takaoka, Japan|Matsuta Clinic /ID# 148278, Tokyo, Japan|National Hospital Organization Shimoshizu National Hospital /ID# 148273, Yotsukaido, Japan|Com. MX para la Prevencion /ID# 147095, Mexico City, Mexico|Desarrollos Biomedicos y Biotc /ID# 147379, Monterrey, Nuevo LEON, Mexico|WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 157622, Wrocław, Dolnoslaskie, Poland|REUMED Sp.z o.o. Filia nr 1 /ID# 144752, Lublin, Lubelskie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 149521, Warszawa, Mazowieckie, Poland|Osteo-Medic spolka cywilna /ID# 144753, Białystok, Podlaskie, Poland|Centrum Badań Klinicznych Pi-House /ID# 149520, Gdansk, Pomorskie, Poland|NZOZ Centrum Reumatologiczne /ID# 144749, Elblag, Warminsko-mazurskie, Poland|Medyczne Centrum Hetmanska /ID# 144751, Poznań, Wielkopolskie, Poland|Instituto Portugues De Reumatologia /ID# 149281, Lisbon, Lisboa, Portugal|Centro Hospitalar De Vila Nova /ID# 146036, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 146035, Lisboa, Portugal|Centro Hospitalar Baixo Vouga /ID# 152916, Porto, Portugal|Dr. Ramon L. Ortega-Colon, MD /ID# 145989, Carolina, Puerto Rico|Ponce School of Medicine /ID# 145990, Ponce, Puerto Rico|Spitalul Municipal Ploiesti /ID# 144756, Ploiesti, Romania|Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 147255, Moscow, Moskva, Russian Federation|LLC Medical Center /ID# 144758, Novosibirsk, Novosibirskaya Oblast, Russian Federation|Perm Clinical Center of FMBA /ID# 145993, Perm, Permskiy Kray, Russian Federation|Tver Regional Clinical Hosp. /ID# 147254, Tver, Tverskaya Oblast, Russian Federation|Сity Clinical Hospital #4 /ID# 145994, Ivanovo, Russian Federation|City Clinical Hospital Botkina /ID# 145995, Moscow, Russian Federation|City Clinical Hospital #5 /ID# 149832, Nizhnij Novgorod, Russian Federation|Orenburg State Medical Academy /ID# 145992, Orenburg, Russian Federation|Republican Clin Hos n.a. Baran /ID# 147251, Petrozavodsk, Russian Federation|Samara Regional Clinical Hosp /ID# 150934, Samara, Russian Federation|Reg Clin Hosp n.a. Kuvatova G. /ID# 144757, UFA, Russian Federation|Yaroslavi State Medical Univer /ID# 147253, Yaroslavl, Russian Federation|Institute for Rheumatology /ID# 144759, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 144761, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 144762, Belgrade, Beograd, Serbia|Special Hospital for Rheuma /ID# 144760, Novi Sad, Vojvodina, Serbia|Wits Clinical Research Site /ID# 149835, Johannesburg, Gauteng, South Africa|University of Pretoria /ID# 148740, Pretoria, Gauteng, South Africa|Synexus Helderberg Clinical Tr /ID# 148724, Cape Town, Western Cape, South Africa|Tiervlei Trial Centre /ID# 153086, Cape Town, Western Cape, South Africa|Hospital Plató /ID# 145999, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 146037, Barcelona, Spain|Hospital Infanta Luisa /ID# 144771, Sevilla, Spain|Hospital Universitario de Valm /ID# 144770, Sevilla, Spain|Hospital Universitario La Fe /ID# 158013, Valencia, Spain|Uludağ Üniversitesi Atatürk Rehabilitasyon Uygulama ve Araştırma Merkezi /ID# 144772, Osmangazi, Bursa, Turkey|Lviv Regional Clinical Hospita /ID# 154448, Lviv, Lvivska Oblast, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 146002, Vinnytsia, Vinnytska Oblast, Ukraine|Regional Clinical Hospital /ID# 152007, Ivano-frankivsk, Ukraine|NSC-Strazhesko Ist Cardiology /ID# 152004, Kiev, Ukraine|Zaporizhzhia Regional Clinical /ID# 146000, Zaporizhia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02706951/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02706951/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02706951"
226,"NCT02706873","A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","SELECT-EARLY","Active, not recruiting","Has Results","Rheumatoid Arthritis","Drug: Upadacitinib|Drug: Methotrexate|Drug: Methotrexate Matching Placebo|Drug: Upadacitinib Matching Placebo","Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global Analysis|Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Global Analysis|Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 - Global Analysis|Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Global Analysis|Change From Baseline in DAS28 (CRP) at Week 12 - Global Analysis|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 - Global Analysis|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 - Global Analysis|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 - Global Analysis|Change From Baseline in DAS28 (CRP) at Week 24 - Global Analysis|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 24 - Global Analysis|Percentage of Participants With an ACR50 Response at Week 24 - Global Analysis|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 24 - Global Analysis|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 24 - Global Analysis|Percentage of Participants With No Radiographic Progression at Week 24 - Global Analysis|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12 - Global Analysis|Percentage of Participants With an ACR20 Response at Week 24 - Global Analysis|Percentage of Participants With an ACR70 Response at Week 24 - Global Analysis|Percentage of Participants With an ACR20 Response at Week 12 - Japan Sub-study|Percentage of Participants With an ACR50 Response at Week 12 - Japan Sub-study|Percentage of Participants With an ACR70 Response at Week 12 - Japan Sub-study|Change From Baseline in DAS28 (CRP) at Week 12 - Japan Sub-study|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12 - Japan Sub-study|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12 - Japan Sub-study|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12 - Japan Sub-study|Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 24 - Japan Sub-study|Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24 - Japan Sub-study|Percentage of Participants With No Radiographic Progression at Week 24 - Japan Sub-study","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","1002","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-545|2015-003334-27","February 23, 2016","March 15, 2018","June 4, 2022","March 11, 2016","October 4, 2019","October 4, 2019","TriWest Research Associates- La Mesa /ID# 143738, La Mesa, California, United States|Desert Medical Advances /ID# 143730, Palm Desert, California, United States|International Medical Research /ID# 143748, Daytona Beach, Florida, United States|FL Med Ctr and Research, Inc. /ID# 143724, Miami, Florida, United States|Millennium Research /ID# 143736, Ormond Beach, Florida, United States|Arthritis Research of Florida /ID# 143743, Palm Harbor, Florida, United States|Sarasota Arthritis Center /ID# 145978, Sarasota, Florida, United States|FL Med Clinic, PA /ID# 143744, Zephyrhills, Florida, United States|Deerbrook Medical Associates /ID# 143728, Vernon Hills, Illinois, United States|Four Rivers Clinical Research /ID# 143741, Paducah, Kentucky, United States|Ocean Rheumatology, PA /ID# 143737, Toms River, New Jersey, United States|Arthritis Rheumatic Back Disorder /ID# 143733, Voorhees, New Jersey, United States|Trinity Health Med Arts Clinic /ID# 143727, Minot, North Dakota, United States|STAT Research, Inc. /ID# 143750, Dayton, Ohio, United States|Healthcare Research Consultant /ID# 143747, Tulsa, Oklahoma, United States|Advanced Rheumatology & Arthri /ID# 147947, Wexford, Pennsylvania, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 145653, Summerville, South Carolina, United States|West Tennessee Research Inst /ID# 143723, Jackson, Tennessee, United States|Dr. Ramesh Gupta /ID# 143732, Memphis, Tennessee, United States|Diagnostic Group Integrated He /ID# 152921, Beaumont, Texas, United States|Adriana Pop-Moody MD Clinic PA /ID# 147626, Corpus Christi, Texas, United States|Doctor's Hosp at Renaissance /ID# 156407, Edinburg, Texas, United States|MedResearch Inc. /ID# 156409, El Paso, Texas, United States|Rheumatic Disease Clin Res Ctr /ID# 151103, Houston, Texas, United States|Accurate Clinical Research /ID# 143749, Houston, Texas, United States|SW Rheumatology Res. LLC /ID# 143745, Mesquite, Texas, United States|Sun Research Institute /ID# 159546, San Antonio, Texas, United States|Accurate Clinical Management /ID# 159543, San Antonio, Texas, United States|NextGen Clinical Trials LLP /ID# 150930, San Antonio, Texas, United States|Arthritis Clinic of Central TX /ID# 159541, San Marcos, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 159542, Waco, Texas, United States|Arthritis Clinic of N. VA, P.C /ID# 143734, Arlington, Virginia, United States|Aprillus Asistencia e Investig /ID# 149179, Capital Federal, Buenos Aires, Argentina|Org Medica de Investigacion /ID# 143142, Buenos Aires, Argentina|Consultora Integral de Salud S /ID# 143144, Cordoba, Argentina|Instituto CAICI /ID# 143141, Rosario, Santa FE, Argentina|Iari /Id# 148595, San Fernando, Argentina|Centro Integral de Reumatologi /ID# 143143, San Miguel de Tucuman, Argentina|Centro Medico Privado/Reuma /ID# 143140, San Miguel de Tucuman, Argentina|Royal Prince Alfred Hospital /ID# 143149, Camperdown, New South Wales, Australia|Rheumatology Research Unit /ID# 143147, Maroochydore, Queensland, Australia|The Queen Elizabeth Hospital /ID# 143148, Woodville, South Australia, Australia|Southern Clinical Research Pty /ID# 143150, Hobart, Tasmania, Australia|Emeritus Research /ID# 143146, Camberwell, Victoria, Australia|First City Clinical Hospital /ID# 159020, Minsk, Belarus|City Clinical Hospital #9 /ID# 145650, Minsk, Belarus|Rhumaconsult SPRL /ID# 143158, Charleroi, Hainaut, Belgium|Algemeen Stedelijk Ziekenhuis /ID# 153504, Aalst, Oost-Vlaanderen, Belgium|UZ Gent /ID# 143157, Gent, Oost-Vlaanderen, Belgium|ReumaClinic Genk /ID# 143159, Genk, Belgium|CHU Ambroise Pare /ID# 152955, Mons, Belgium|University Clinical Centre of the Republic of Srpska /ID# 143161, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 143162, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 143164, Sarajevo, Bosnia and Herzegovina|CIP - Centro Internacional de Pesquisa /ID# 143171, Goiânia, Goias, Brazil|Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 143169, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 143168, Porto Alegre, Rio Grande Do Sul, Brazil|LMK Sevicos Medicos S/S /ID# 143167, Porto Alegre, Rio Grande Do Sul, Brazil|CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 143166, São Paulo, Sao Paulo, Brazil|CCBR Brasil /ID# 150925, Rio de Janeiro, Brazil|MHAT Trimontsium /ID# 143173, Plovdiv, Bulgaria|UMHAT Pulmed OOD /ID# 143176, Plovdiv, Bulgaria|MHAT Kaspela /ID# 143172, Plovdiv, Bulgaria|Diagnostic Consultative Center /ID# 143174, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 143175, Sofia, Bulgaria|Rheumatology Research Assoc /ID# 143206, Edmonton, Alberta, Canada|Manitoba Clinic /ID# 143203, Winnipeg, Manitoba, Canada|Ciads /Id# 143205, Winnipeg, Manitoba, Canada|CA Ctr for Clin Trials CCCT /ID# 159080, Thornhill, Ontario, Canada|Ctr. de Rheum de l'est du QC /ID# 151317, Rimouski, Quebec, Canada|Ctr de Inv Clinica del Sur /ID# 143208, Temuco, Araucania, Chile|Someal /Id# 143207, Providencia-santiago, Chile|Quantum Research LTDA. /ID# 143210, Puerto Varas, Chile|Quantum Research Stgo. /ID# 145651, Santiago, Chile|Soc. de Prestaciones medicas y Paramedicas Goecke /ID# 143209, Santiago, Chile|Investigaciones Medicas SSMSO /ID# 151685, Santiago, Chile|Centro de Estudios Clinicos Qu /ID# 152913, Vina Del Mar, Chile|1st Aff Hosp of Bengbu Med Col /ID# 162974, Bengbu, Anhui, China|The 1st Aff Hosp Xiamen Univ /ID# 162076, Xiamen, Fujian, China|1st Aff Hosp of Shantou Univ /ID# 162968, Shantou, Guangdong, China|Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 143214, Bogota, Cundinamarca, Colombia|Ctr Int de Reum del Caribe SAS /ID# 143211, Barranquilla, Colombia|Fund Inst de Reum F. Chalem /ID# 159544, Bogota DC, Colombia|Riesgo de Fractura S.A - CAYRE /ID# 143212, Bogota, Colombia|Simedics IPS SAS /ID# 152572, Bogota, Colombia|Medicity S.A.S. /ID# 143213, Bucaramanga, Colombia|Klinicki bolnicki centar Split /ID# 143216, Split, Croatia|Clinical Hospital Dubrava /ID# 143217, Zagreb, Croatia|Medical Center Kuna-Peric /ID# 143218, Zagreb, Croatia|Poliklinika Bonifarm /ID# 143215, Zagreb, Croatia|L.K.N. Arthrocentrum, s.r.o /ID# 143224, Hlučín, Moravskoslezsky Kraj, Czechia|CTCenter MaVe, s.r.o. /ID# 143226, Olomouc, Olomoucky Kraj, Czechia|Nuselská poliklinika, Revmatologie /ID# 143232, Prague 4, Praha 4, Czechia|Nuselská poliklinika, Revmatologie /ID# 143233, Prague 4, Praha 4, Czechia|Thomayerova nemocnice /ID# 143228, Prague, Praha 4, Czechia|PV MEDICAL Services s.r.o. /ID# 143234, Zlín 1, Zlin, Czechia|RHEUMA s.r.o. /ID# 143230, Breclav, Czechia|Revmatologie, s.r.o. /ID# 143223, Brno, Czechia|Revmatologie Bruntal, s.r.o /ID# 143220, Bruntál, Czechia|Nemocnice Slany /ID# 143221, Slany, Czechia|Medical Plus, s.r.o. /ID# 143219, Uherské Hradište, Czechia|Center of Clinical and Basic Research /ID# 143239, Tallinn, Harjumaa, Estonia|Paernu Hospital /ID# 143238, Pärnu, Estonia|East Tallinn Central Hospital /ID# 143240, Tallinn, Estonia|North Estonian Medical Centre /ID# 145456, Tallinn, Estonia|Rheumazentrum Ruhrgebiet /ID# 145652, Herne, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 143248, Köln, Nordrhein-Westfalen, Germany|Praxis Walter, Rendsburg /ID# 143250, Rendsburg, Schleswig-Holstein, Germany|Rheumaforschungszentrum II /ID# 143247, Hamburg, Germany|Schoen Klinikum Hamburg Eilbek /ID# 143251, Hamburg, Germany|LMU Klinikum der Universität München /ID# 143249, Munich, Germany|University General Hospital Attikon /ID# 143252, Athens, Attiki, Greece|Clinicas Hospital Herrera Ller /ID# 153715, Ciudad de Guatemala, Guatemala|Creer /Id# 153713, Ciudad de Guatemala, Guatemala|Clin Especializada Med Interna /ID# 153716, Ciudad de Guatemala, Guatemala|Clinica Medica Reumatologia /ID# 153714, Ciudad de Guatemala, Guatemala|Clinica Medica Reumatologia /ID# 153931, Ciudad de Guatemala, Guatemala|Queen Mary Hospital /ID# 143255, Hong Kong, Hong Kong|Tuen Mun Hospital /ID# 143256, Tuen Mun, Hong Kong|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 143258, Miskolc, Borsod-Abauj-Zemplen, Hungary|Qualiclinic Kft. /ID# 143259, Budapest III, Pest, Hungary|Markusovszky Egyetemi Oktatókórház /ID# 143261, Szombathely, Vas, Hungary|Hevizgyogyfurdo es Szent Andra /ID# 143257, Heviz, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 143260, Kistarcsa, Hungary|Fejer Megyei Szent Gyorgy Korh /ID# 144724, Szekesfehervar, Hungary|St Vincent's University Hosp /ID# 143262, Dublin, Ireland|Barzilai Medical Center /ID# 144725, Ashkelon, Israel|Rambam Health Care Campus /ID# 143263, Haifa, Israel|Sheba Medical Center /ID# 145975, Ramat Gan, Israel|Istituto Clinico Humanitas /ID# 147531, Rozzano, Milano, Italy|Azienda Ospedaliera Luigi Sacc /ID# 143270, Milan, Italy|Fondazione IRCCS Policlinico /ID# 143265, Pavia, Italy|A.O.U.I. di Verona Policlinico /ID# 143266, Verona, Italy|Nagoya University Hospital /ID# 148031, Nagoya-shi, Aichi, Japan|NHO Toyohashi Medical Center /ID# 161033, Toyohashi-shi, Aichi, Japan|Teikyo University Chiba Medical Center /ID# 159618, Ichihara, Chiba, Japan|NHO Kyushu Medical Center /ID# 148263, Fukuoka-shi, Fukuoka, Japan|NHO Kyushu Medical Center /ID# 148264, Fukuoka-shi, Fukuoka, Japan|National Hospital Organization Asahikawa Medical Center /ID# 148021, Asahikawa, Hokkaido, Japan|Katayama Orthopedic Rheumatology Clinic /ID# 148029, Asahikawa, Hokkaido, Japan|Kobe University Hospital /ID# 153461, Kobe, Hyogo, Japan|National Hospital Organization Sagamihara National Hospital /ID# 148019, Sagamihara-shi, Kanagawa, Japan|Bay Side Misato Medical Center /ID# 148256, Kochi-shi, Kochi, Japan|Center for Arthritis and Clinical Rheumatology Matsubara Clinic /ID# 148254, Kumamoto-shi, Kumamoto, Japan|Kumamoto Orthopaedic Hospital /ID# 148054, Kumamoto-shi, Kumamoto, Japan|Kumamoto Shinto General Hospital /ID# 148266, Kumamoto-shi, Kumamoto, Japan|Nagaoka Red Cross Hospital /ID# 148018, Nagaoka-shi, Niigata, Japan|Japanese Red Cross Okayama Hospital /ID# 159619, Okayama-shi, Okayama, Japan|Kansai Medical University Hospital /ID# 159622, Hirakata-shi, Osaka, Japan|NHO Osaka Minami Med Ctr /ID# 148042, Kawachinagano-shi, Osaka, Japan|Osaka Medical College Hospital /ID# 159624, Takatsuki -shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 148015, Kawagoe-shi, Saitama, Japan|Jichi Medical University Hospital /ID# 159620, Shimotsuke-shi, Tochigi, Japan|St.Luke's International Hospital /ID# 148041, Chuo-ku, Tokyo, Japan|Toho University Ohashi Medical Center /ID# 148027, Meguro-ku, Tokyo, Japan|Keio University Hospital /ID# 148057, Shinjuku-ku, Tokyo, Japan|Tokito Clinic Rheumatology and Orthopaedics Surgery /ID# 148052, Shimonoseki-shi, Yamaguchi, Japan|National Hospital Organization Beppu Medical Center /ID# 161058, Beppu, Japan|NHO Chiba-East-Hospital /ID# 148035, Chiba, Japan|Sugimoto Rheumatology and Internal Medicine Clinic /ID# 148047, Fukui, Japan|Shono Rheumatism Clinic /ID# 148046, Fukuoka, Japan|Matsubara Mayflower Hospital /ID# 148033, Kato, Japan|St. Mary's Hospital /ID# 148038, Kurume, Japan|Kagawa University Hospital /ID# 148016, Kyoto, Japan|Yu Family Clinic /ID# 148048, Miyagi, Japan|Daido Hospital /ID# 160868, Nagoya, Japan|Kondo Clinic for Ortho & Rheum /ID# 148032, Nagoya, Japan|Shirahama Hamayu Hospital /ID# 148253, Nishimuro, Japan|Oribe Clinic of Rheumatology and Internal Medicine /ID# 156035, Oita, Japan|Osaka City General Hospital /ID# 159617, Osaka, Japan|Sanuki Municipal Hospital /ID# 158842, Sanuki, Japan|Sagawa Akira Rheumatology Clin /ID# 148043, Sapporo, Japan|Sapporo City General Hospital /ID# 148037, Sapporo, Japan|Hokkaido University Hospital /ID# 148262, Sapporo, Japan|Hokkaido Medical Center for Rheumatic Diseases /ID# 148259, Sapporo, Japan|Sasebo Chuo Hospital /ID# 148261, Sasebo, Japan|Azuma Rheumatology Clinic /ID# 161050, Sayama, Japan|Hikarigaoka Spellman Hospital /ID# 148020, Sendai, Japan|Honjo Rheumatism Clinic /ID# 148022, Takaoka, Japan|Juntendo University Hospital /ID# 148050, Tokyo, Japan|National Hospital Organization Tokyo Medical Center /ID# 148040, Tokyo, Japan|National Hospital Organization Shimoshizu National Hospital /ID# 148258, Yotsukaido, Japan|JSC Nat Scientific Med Res Ctr /ID# 143272, Astana, Kazakhstan|Karaganda State Medical Univ /ID# 153431, Karaganda, Kazakhstan|Semey State Medical University /ID# 152661, Semey, Kazakhstan|Regional Clinical Hospital /ID# 147173, Shymkent, Kazakhstan|LTD M+M Centers /ID# 143279, Adazi, Latvia|Hosp Lithuanian Univ Health Sc /ID# 143582, Kovno, Kaunas, Lithuania|Klaipeda University Hospital /ID# 143583, Klaipeda, Lithuania|Vilnius University Hospital /ID# 143584, Vilnius, Lithuania|Clinstile, S.A. de C.V. /ID# 143591, Mexico, Ciudad De Mexico, Mexico|Invest y Biomed de Chihuahua /ID# 143595, Chihuahua, Mexico|RM Pharma Specialists, S.A de C.V /ID# 143593, Mexico City, Mexico|Hospital de Jesús Nazareno /ID# 143592, Mexico City, Mexico|Centro Especializado en Diabetes, Obesidad y Prevención de Enfermedades Cardiova /ID# 143589, Mexico City, Mexico|(CINTRE) Centro de Investigac. /ID# 153562, Mexico City, Mexico|Centro Reumatologico de Queret /ID# 149493, Queretaro, Mexico|Waikato Hospital /ID# 143602, Hamilton, Waikato, New Zealand|Middlemore Clinical Trials /ID# 143600, Auckland, New Zealand|Porter Rheumatology Ltd /ID# 143601, Nelson, New Zealand|Timaru Medical Specialists Ltd /ID# 143599, Timaru, New Zealand|WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 143606, Wrocław, Dolnoslaskie, Poland|Centrum Medyczne AMED /ID# 143604, Warsaw, Mazowieckie, Poland|Centrum Medyczne Pratia Warszawa /ID# 143608, Warsaw, Mazowieckie, Poland|Centrum Medyczne Pratia Gdynia /ID# 143607, Gdynia, Pomorskie, Poland|Silmedic Sp z o.o /ID# 143605, Katowice, Slaskie, Poland|NZOZ Centrum Reumatologiczne /ID# 143603, Elblag, Warminsko-mazurskie, Poland|Medyczne Centrum Hetmanska /ID# 144726, Poznań, Wielkopolskie, Poland|Instituto Portugues De Reumatologia /ID# 148313, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 151009, Lisbon, Lisboa, Portugal|Centro Hospitalar De Vila Nova /ID# 143615, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 143613, Lisboa, Portugal|Centro Hospitalar Baixo Vouga /ID# 153726, Porto, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 153575, Porto, Portugal|Unidade Local De Saude Do Alto Minho /ID# 143611, Viana Do Castelo, Portugal|Centro Hosp de Tondela-Viseu /ID# 143612, Viseu, Portugal|Ponce School of Medicine /ID# 145657, Ponce, Puerto Rico|GCM Medical Group /ID# 143618, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 143619, San Juan, Puerto Rico|Spitalul Clinic Dr. I. Cantacuzino /ID# 143622, Bucharest, Bucuresti, Romania|Spitalul Clinic Sf. Maria /ID# 143623, Bucuresti, Romania|Spitalul Clinic Sf. Maria /ID# 143625, Bucuresti, Romania|Spitalul Clinic Sf. Maria /ID# 143627, Bucuresti, Romania|Spitalul Clinic de Recuperare /ID# 143620, Iasi, Romania|Ecomed SRL /ID# 143629, Oradea, Romania|Family Outpatient clinic#4,LLC /ID# 151010, Korolev, Moskva, Russian Federation|Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 143641, Moscow, Moskva, Russian Federation|LLC Medical Center /ID# 143647, Novosibirsk, Novosibirskaya Oblast, Russian Federation|LLC Novaya Klinika /ID# 143631, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 143645, Kazan, Tatarstan, Respublika, Russian Federation|Tver Regional Clinical Hosp. /ID# 143639, Tver, Tverskaya Oblast, Russian Federation|Russian National Research Medi /ID# 143642, Moscow, Russian Federation|Orenburg Regional Clinical Hos /ID# 143630, Orenburg, Russian Federation|Republican Clin Hos n.a. Baran /ID# 143634, Petrozavodsk, Russian Federation|Ryazan State Medical Universit /ID# 143646, Ryazan, Russian Federation|Samara Regional Clinical Hosp /ID# 150928, Samara, Russian Federation|Reg Clin Hosp n.a. Kuvatova G. /ID# 143632, UFA, Russian Federation|Ulyanovsk Regional Clin Hosp /ID# 143644, Ulyanovsk, Russian Federation|Voronezh State Medical Univers /ID# 150926, Voronezh, Russian Federation|Clinical Center Serbia /ID# 143649, Belgrade, Beograd, Serbia|Clinical Center Serbia /ID# 143650, Belgrade, Beograd, Serbia|Special Hospital for Rheuma /ID# 143648, Novi Sad, Vojvodina, Serbia|MEDMAN s.r.o. /ID# 143661, Martin, Slovakia|Reumatologická ambulancia Reum.hapi s.r.o. /ID# 143657, Nové Mesto Nad Váhom, Slovakia|REUMACENTRUM s.r.o. /ID# 143653, Partizanske, Slovakia|Slovak research center Team Member, Thermium s.r.o. /ID# 143663, Pieštany, Slovakia|Slovak Research Center /ID# 143659, Puchov, Slovakia|TIMMED spol. s r.o. /ID# 143664, Stará Lubovna, Slovakia|Reumatologicka ambulancia, LER /ID# 143660, Topolcany, Slovakia|MEDEOS s.r.o. /ID# 143656, Trencin, Slovakia|REUMA-GLOBAL, s.r.o. /ID# 143655, Trnava, Slovakia|ALBAMED s.r.o. /ID# 143654, Zvolen, Slovakia|Reuma -MUDr. Maria Palasthyova /ID# 143662, Žiar nad Hronom, Slovakia|Univ Medical Ctr Ljubljana /ID# 143667, Ljubljana, Slovenia|Jakaranda Hosp, Emmed Research /ID# 143668, Pretoria, Gauteng, South Africa|Jakaranda Hosp, Emmed Research /ID# 145976, Pretoria, Gauteng, South Africa|Arthritis Clinical Research Tr /ID# 143670, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 143669, Stellenbosch, Western Cape, South Africa|H. Un. Marques de Valdecilla /ID# 143671, Santander, Cantabria, Spain|Comple Hosp Univ de A Coruna /ID# 143672, A Coruna, Spain|Hospital Univ Vall d'Hebron /ID# 143675, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 143674, Madrid, Spain|Clinica Gaias /ID# 143673, Santiago de Compostela, Spain|Hosp Nuestra Senora Esperanza /ID# 143677, Santiago de Compostela, Spain|HFR Fribourg - Hopital Canton /ID# 143700, Fribourg, Switzerland|China Medical University Hosp /ID# 143703, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 143702, Taipei City, Taipei, Taiwan|Dalin Tzu Chi General Hospital /ID# 153535, Dalin Township, Taiwan|Hopital Mongi Slim /ID# 152870, La Marsa, Tunisia|Institut Mohamed Kassab /ID# 152869, Manouba, Tunisia|Hopital Farhat Hached /ID# 152868, Sousse, Tunisia|Charles Nicolle Univ Hosp /ID# 152866, Tunis, Tunisia|Hospital La Rabta /ID# 152867, Tunis, Tunisia|Uludag Universitesi Ataturk Rehabilitasyon ve Uygulama Merkezi /ID# 143705, Osmangazi, Bursa, Turkey|Izmir Tepecik Training and Research Hospital /ID# 157863, Konak, Izmir, Turkey|Izmir Katip Celebi Ataturk Training & Research Hospital /ID# 143704, Izmir, Turkey|LLC Revmocentr /ID# 143710, Kiev, Kyiv, Ukraine|Lviv Regional Clinical Hospita /ID# 154449, Lviv, Lvivska Oblast, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 143714, Vinnytsia, Vinnytska Oblast, Ukraine|Regional Clinical Hospital /ID# 152029, Ivano-frankivsk, Ukraine|NSC-Strazhesko Ist Cardiology /ID# 152026, Kiev, Ukraine|Lviv Municipal City Clinical /ID# 143711, Lviv, Ukraine|Odessa National Medical Univ /ID# 143715, Odesa, Ukraine|Zaporizhzhia Regional Clinical /ID# 143712, Zaporizhia, Ukraine|Leicester Royal Infirmary /ID# 143718, Leicester, England, United Kingdom|Whipps Cross Univ Hospital /ID# 143721, London, London, City Of, United Kingdom|Western General Hospital /ID# 144431, Edinburgh, United Kingdom|Chapel Allerton Hospital /ID# 143717, Leeds, United Kingdom|Queen Alexandra Hospital /ID# 143722, Portsmouth, United Kingdom|Southampton General Hospital /ID# 143716, Southampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02706873/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/73/NCT02706873/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02706873"
227,"NCT02706847","A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs","SELECT-BEYOND","Active, not recruiting","Has Results","Rheumatoid Arthritis","Drug: Placebo|Drug: Upadacitinib","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12|Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12|Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12|Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","499","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-542|2015-003335-35","March 15, 2016","April 3, 2017","September 16, 2021","March 11, 2016","October 7, 2019","October 7, 2019","Rheum Assoc of North Alabama /ID# 145959, Huntsville, Alabama, United States|AZ Arthritis and Rheum Assoc /ID# 148593, Mesa, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 142816, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 146075, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 148592, Phoenix, Arizona, United States|Arizona Research Center, Inc. /ID# 142741, Phoenix, Arizona, United States|AZ Arthr & Rheum Research /ID# 155256, Prescott, Arizona, United States|AZ Arthritis & Rheum Research /ID# 156090, Sun City, Arizona, United States|NEA Baptist Clinic /ID# 149280, Jonesboro, Arkansas, United States|Covina Arthritis Clinic /ID# 142794, Covina, California, United States|Rheumatology Ctr of San Diego /ID# 153576, Escondido, California, United States|St. Jude Heritage /ID# 149273, Fullerton, California, United States|TriWest Research Associates- La Mesa /ID# 142792, La Mesa, California, United States|Arthritis & Osteo Medical Ctr /ID# 142770, La Palma, California, United States|Valerius Med Grp & Res Ctr /ID# 142799, Los Alamitos, California, United States|Pacific Arthritis Ctr Med Grp /ID# 142783, Los Angeles, California, United States|University of California, Los Angeles /ID# 148348, Los Angeles, California, United States|Desert Medical Advances /ID# 142765, Palm Desert, California, United States|Stanford Univ School of Med /ID# 142761, Stanford, California, United States|Robin K. Dore MD, Inc /ID# 150908, Tustin, California, United States|Inland Rheum Clin Trials Inc. /ID# 142787, Upland, California, United States|Medvin Clinical Research /ID# 142814, Whittier, California, United States|Arthritis Assoc & Osteo Ctr /ID# 142809, Colorado Springs, Colorado, United States|Denver Arthritis Clinic /ID# 142771, Denver, Colorado, United States|New England Research Associates, LLC /ID# 142763, Bridgeport, Connecticut, United States|Delaware Arthritis /ID# 142803, Lewes, Delaware, United States|Lakes Research, LLC /ID# 142755, Miami, Florida, United States|Medallion Clinical Research Institute, LLC /ID# 142740, Naples, Florida, United States|Omega Research Consultants /ID# 142780, Orlando, Florida, United States|Millennium Research /ID# 142782, Ormond Beach, Florida, United States|Arthritis Research of Florida /ID# 142811, Palm Harbor, Florida, United States|Arthritis Center, Inc. /ID# 142822, Palm Harbor, Florida, United States|Advent Clinical Research /ID# 142817, Pinellas Park, Florida, United States|St. Anthony Comprehsve Res Ins /ID# 148349, Saint Petersburg, Florida, United States|University of South Florida /ID# 145611, Tampa, Florida, United States|BayCare Medical Group, Inc. /ID# 142747, Tampa, Florida, United States|Lovelace Scientific Resources /ID# 142779, Venice, Florida, United States|Jefrey D. Lieberman, MD, P.C. /ID# 151713, Decatur, Georgia, United States|Marietta Rheumatology Assoc /ID# 151347, Marietta, Georgia, United States|St. Luke's Clinic - Rheumatolo /ID# 150923, Boise, Idaho, United States|Institute of Arthritis Res /ID# 142810, Idaho Falls, Idaho, United States|Advanced Clinical Research /ID# 153089, Meridian, Idaho, United States|Great Lakes Clinical Trials /ID# 148341, Chicago, Illinois, United States|Clinical Investigation Special /ID# 149270, Skokie, Illinois, United States|Springfield Clinic /ID# 142818, Springfield, Illinois, United States|Deerbrook Medical Associates /ID# 151712, Vernon Hills, Illinois, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 142793, Monroe, Louisiana, United States|Vanguard Medical Research, LLC /ID# 153123, Shreveport, Louisiana, United States|Rheumatology Associates,PA /ID# 145612, Portland, Maine, United States|The Center for Rheumatology & /ID# 142742, Wheaton, Maryland, United States|Mansfield Health Center /ID# 147628, Mansfield, Massachusetts, United States|Clinical Pharmacology Study Gr /ID# 142744, Worcester, Massachusetts, United States|Justus J. Fiechtner, MD, PC /ID# 142756, Lansing, Michigan, United States|North Mississippi Med Clinics /ID# 142781, Tupelo, Mississippi, United States|Clayton Medical Associates, PC /ID# 142745, Saint Louis, Missouri, United States|St. Louis Center for Clin Res /ID# 142749, Saint Louis, Missouri, United States|Westroads Clinical Research /ID# 142802, Omaha, Nebraska, United States|Dartmouth-Hitchcock Med Ctr /ID# 145958, Lebanon, New Hampshire, United States|Atlantic Coast Research /ID# 148347, Toms River, New Jersey, United States|Ocean Rheumatology, PA /ID# 142785, Toms River, New Jersey, United States|The Center for Rheumatology /ID# 142784, Albany, New York, United States|North Shore University Hospital /ID# 142772, New Hyde Park, New York, United States|Buffalo Rheumatology /ID# 142766, Orchard Park, New York, United States|Joint & Muscle Research Instit /ID# 142797, Charlotte, North Carolina, United States|DJL Clinical Research, PLLC /ID# 142769, Charlotte, North Carolina, United States|Cape Fear Arthritis Care /ID# 148344, Leland, North Carolina, United States|Coastal Carolina Health Care /ID# 148351, New Bern, North Carolina, United States|Shanahan Rheuma & Immuno /ID# 142812, Raleigh, North Carolina, United States|Trinity Health Med Arts Clinic /ID# 142754, Minot, North Dakota, United States|Cincinnati Rheumatic Disease /ID# 142791, Cincinnati, Ohio, United States|STAT Research, Inc. /ID# 142821, Dayton, Ohio, United States|Health Research Oklahoma /ID# 142751, Oklahoma City, Oklahoma, United States|Healthcare Research Consultant /ID# 142815, Tulsa, Oklahoma, United States|East Penn Rheumatology Assoc /ID# 142790, Bethlehem, Pennsylvania, United States|Clinical Research Ctr Reading /ID# 151714, Wyomissing, Pennsylvania, United States|Columbia Arthritis Center /ID# 153728, Columbia, South Carolina, United States|West Tennessee Research Inst /ID# 142739, Jackson, Tennessee, United States|Arthritis Associates, PLLC /ID# 142774, Kingsport, Tennessee, United States|Arthritis Associates, PLLC /ID# 155462, Kingsport, Tennessee, United States|Dr. Ramesh Gupta /ID# 142767, Memphis, Tennessee, United States|Tekton Research, Inc. /ID# 142805, Austin, Texas, United States|Diagnostic Group Integrated He /ID# 148340, Beaumont, Texas, United States|Arth & Osteo Clin Brazo Valley /ID# 148343, College Station, Texas, United States|Arthritis Care and Diagnostic /ID# 151344, Dallas, Texas, United States|Metroplex Clinical Research /ID# 142758, Dallas, Texas, United States|Rheumatic Disease Clin Res Ctr /ID# 150914, Houston, Texas, United States|Baylor College of Medicine /ID# 142753, Houston, Texas, United States|Rheumatology Clinic of Houston /ID# 150915, Houston, Texas, United States|Houston Institute for Clin Res /ID# 142768, Houston, Texas, United States|Pioneer Research Solutions, Inc. /ID# 151346, Houston, Texas, United States|Arthritis & Osteoporosis Assoc /ID# 147567, Lubbock, Texas, United States|P&I Clinical Research /ID# 151345, Lufkin, Texas, United States|SW Rheumatology Res. LLC /ID# 142813, Mesquite, Texas, United States|Trinity Universal Research Association /ID# 149278, Plano, Texas, United States|Arthritis & Osteo Ctr of S. TX /ID# 142773, San Antonio, Texas, United States|Arthritis Clinic of Central TX /ID# 148346, San Marcos, Texas, United States|DM Clinical Research /ID# 151007, Tomball, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 142760, Waco, Texas, United States|Western Washington Arthritis C /ID# 142776, Bothell, Washington, United States|Arthritis Northwest, PLLC /ID# 150924, Spokane, Washington, United States|The Vancouver Clinic, INC. PS /ID# 147946, Vancouver, Washington, United States|West Virginia Research Inst /ID# 153087, South Charleston, West Virginia, United States|Rheumatology and Immunotherapy /ID# 142820, Franklin, Wisconsin, United States|The Queen Elizabeth Hospital /ID# 142419, Woodville, South Australia, Australia|Emeritus Research /ID# 142416, Camberwell, Victoria, Australia|Medizinische Universität Wien /ID# 142424, Vienna, Wien, Austria|Universitaetsklinik fuer Inner /ID# 142423, Graz, Austria|Rheuma Zentrum Favoriten GmbH /ID# 142421, Vienna, Austria|Rheuma-Zentrum Wien-Oberlaa /ID# 142425, Wien, Austria|Wilhelminenspital der Stadt Wien /ID# 142422, Wien, Austria|Cliniques Universitaires Saint Luc /ID# 142426, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Rhumaconsult SPRL /ID# 151378, Charleroi, Hainaut, Belgium|UZ Gent /ID# 142429, Gent, Oost-Vlaanderen, Belgium|ReumaClinic Genk /ID# 142431, Genk, Belgium|AZ Damiaan /ID# 142427, Oostende, Belgium|Ciads /Id# 142526, Winnipeg, Manitoba, Canada|Revmatologie MUDr. Klara Sirov /ID# 142536, Ostrava, Czechia|Medical Plus, s.r.o. /ID# 148345, Uherské Hradište, Czechia|MediTrials /ID# 151777, Tartu, Tartumaa, Estonia|East Tallinn Central Hospital /ID# 142543, Tallinn, Estonia|Kiljava Medical Research /ID# 142546, Hyvinkaa, Finland|Paijat-Hame Central Hospital /ID# 149185, Lahti, Finland|CHR Orleans - Hopital de la Source /ID# 142557, Orleans CEDEX 2, Centre-Val De Loire, France|Hopital Universitaire Purpan /ID# 144697, Toulouse, Haute-Garonne, France|Hopital Saint Eloi /ID# 142552, Montpellier CEDEX 5, Herault, France|Centre Hospitalier Le Mans /ID# 145956, Le Mans CEDEX 9, Sarthe, France|CHU Bordeaux-Hopital Pellegrin /ID# 144700, Bordeaux, France|Centre Hospitalier Jean Rougie /ID# 142556, Cahors, France|Hopital Edouard Herriot /ID# 144698, Lyon, France|Rheumazentrum Ruhrgebiet /ID# 145600, Herne, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 142563, Köln, Nordrhein-Westfalen, Germany|Charité Universitätsmedizin Campus Mitte /ID# 142559, Berlin, Germany|Rheumaforschungszentrum II /ID# 142560, Hamburg, Germany|Schoen Klinikum Hamburg Eilbek /ID# 142566, Hamburg, Germany|Asklepios Klinik Altona /ID# 142561, Hamburg, Germany|LMU Klinikum der Universität München /ID# 142564, Munich, Germany|MVZ Planegg /ID# 142565, Planegg, Germany|Knappschaftsklinikum Saar /ID# 142562, Puettlingen, Germany|General Hospital of Athens Laiko /ID# 142579, Athens, Attiki, Greece|Vital Medical Center Orvosi es /ID# 142586, Veszprém, Veszprem, Hungary|Revita Reumatologiai Rendelo /ID# 142590, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 142587, Debrecen, Hungary|Bekes Megyei Pandy Kalman Korh /ID# 142588, Gyula, Hungary|St Vincent's University Hosp /ID# 142593, Dublin, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 142597, Tel Aviv-Yafo, Tel-Aviv, Israel|Bnai Zion Medical Center /ID# 151945, Haifa, Israel|The Lady Davis Carmel MC /ID# 142599, Haifa, Israel|Inha University Hospital /ID# 150881, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Hanyang University Seoul Hospi /ID# 150883, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 142622, Seoul, Korea, Republic of|LTD M+M Centers /ID# 142624, Adazi, Latvia|P. Stradins Clinical Univ Hosp /ID# 142623, Riga, Latvia|Arthritis Clinic Ltd /ID# 153560, Riga, Latvia|Timaru Medical Specialists Ltd /ID# 142657, Timaru, New Zealand|WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 142665, Wrocław, Dolnoslaskie, Poland|Centrum Medyczne Pratia Krakow /ID# 142664, Krakow, Malopolskie, Poland|Centrum Medyczne Pratia Warszawa /ID# 142667, Warsaw, Mazowieckie, Poland|Centrum Medyczne AMED Warszawa Targowek /ID# 142663, Warszawa, Mazowieckie, Poland|Centrum Medyczne Pratia Gdynia /ID# 142666, Gdynia, Pomorskie, Poland|Centro Hospitalar De Vila Nova /ID# 142670, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 142668, Lisboa, Portugal|GCM Medical Group /ID# 142671, San Juan, Puerto Rico|Family Outpatient clinic#4,LLC /ID# 150910, Korolev, Moskva, Russian Federation|ARTROMAC n.o. /ID# 142692, Kosice, Slovakia|Nemocnica Kosice Saca, a.s. /ID# 142693, Kosice, Slovakia|Narodny ustav reumatickych chorob Piestany /ID# 142691, Pieštany, Slovakia|H. Un. Marques de Valdecilla /ID# 142706, Santander, Cantabria, Spain|Hospital Regional de Malaga /ID# 142707, Málaga, Malaga, Spain|Comple Hosp Univ de A Coruna /ID# 142708, A Coruna, Spain|Hospital Clin Univ San Carlos /ID# 142711, Madrid, Spain|Clinica Gaias /ID# 142709, Santiago de Compostela, Spain|Hospital Universitario La Fe /ID# 142716, Valencia, Spain|Sahlgrenska University Hosp /ID# 142720, Goteborg, Sweden|Capio Movement Halmstad /ID# 148236, Halmstad, Sweden|Orebro Universitetssjukhuset /ID# 142718, Orebro, Sweden|Vastmanlands Sjukhus /ID# 142721, Vasteras, Sweden|Universitaetsspital Basel /ID# 145610, Basel, Switzerland|HFR Fribourg - Hopital Canton /ID# 142723, Fribourg, Switzerland|Hacettepe University Medical Faculty /ID# 142729, Ankara, Turkey|Ankara Ataturk Training & Res /ID# 142727, Ankara, Turkey|Ondokuz mayis University Facul /ID# 142728, Samsun, Turkey|Whipps Cross Univ Hospital /ID# 145957, London, London, City Of, United Kingdom|The Royal Free Hospital /ID# 142733, London, London, City Of, United Kingdom|Mid Essex Hospitals NHS Trust /ID# 148992, Chelmsford, United Kingdom|Western General Hospital /ID# 142732, Edinburgh, United Kingdom|West Suffolk Hospital /ID# 148993, Ipswich, United Kingdom|Queen Alexandra Hospital /ID# 142735, Portsmouth, United Kingdom|Arrowe Park Hospital /ID# 148991, Wirral, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02706847/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02706847/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02706847"
228,"NCT02694523","BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Drug: risankizumab|Biological: adalimumab|Drug: placebo for risankizumab|Biological: placebo for adalimumab","Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 (Part A)|Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 (Part A)|Percentage of Participants Who Were Re-Randomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI90 at Week 44 (Part B)|Percentage of Participants Achieving PASI75 at Week 16 (Part A)|Percentage of Participants Achieving PASI100 at Week 16 (Part A)|Percentage of Participants Who Were Rerandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving PASI100 at Week 44 (Part B)|Percentage of Participants Who Were ReRandomized to Receive Either Adalimumab or Risankizumab in Part B Achieving sPGA Score of Clear at Week 44 (Part B)","AbbVie|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","684","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-010|2015-003623-65|1311.30","March 2016","August 2017","August 2017","February 29, 2016","May 28, 2019","May 28, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02694523/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/23/NCT02694523/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02694523"
229,"NCT02692703","A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)",,"Completed","Has Results","Chronic Hepatitis C|HCV|Hepatitis C Virus","Drug: glecaprevir/pibrentasvir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-596|2015-005616-14","April 22, 2016","April 13, 2017","June 29, 2017","February 26, 2016","April 4, 2018","April 4, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02692703/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02692703/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02692703"
230,"NCT02691494","Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)",,"Completed","No Results Available","Uterine Fibroids|Heavy Menstrual Bleeding","Drug: Elagolix|Drug: Placebo for Estradiol/Norethindrone Acetate|Drug: Estradiol/Norethindrone Acetate|Drug: Placebo for Elagolix","Percentage of Responders With Menstrual Blood Loss (MBL) Volume of < 80 mL at Final Month and >= 50% Reduction in MBL Volume|Change from Baseline in MBL volume|Percentage of Participants with Suppression of Bleeding|Percentage of Participants with Baseline hemoglobin <= 10.5 g/dL who have an increase in hemoglobin > 2 g/dL","AbbVie","Female","18 Years to 51 Years   (Adult)","Phase 3","378","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-817","February 3, 2016","February 14, 2018","January 23, 2019","February 25, 2016",,"February 11, 2019","Alabama Clinical Therapeutics, LLC /ID# 152258, Birmingham, Alabama, United States|Choice Research, LLC /ID# 150988, Dothan, Alabama, United States|Brown, Pearson, Guepet Gynecology /ID# 151020, Fairhope, Alabama, United States|Mobile, Ob-Gyn, P.C. /ID# 144294, Mobile, Alabama, United States|Mesa Obstetricians and Gynecol /ID# 149139, Mesa, Arizona, United States|Visions Clinical Research-Tucs /ID# 151017, Tucson, Arizona, United States|Core Healthcare Group /ID# 151016, Cerritos, California, United States|Diagnamics Inc. /ID# 152469, Encinitas, California, United States|HCP Clinical Research LLC /ID# 154434, Huntington Beach, California, United States|Alliance Research Centers /ID# 149752, Laguna Hills, California, United States|University of California, Los Angeles /ID# 149760, Los Angeles, California, United States|Futura Research, Inc. /ID# 149759, Norwalk, California, United States|Farid Yasharpour MD Medical Co /ID# 149770, San Fernando, California, United States|Clinical Trial Investigators /ID# 152470, Tustin, California, United States|Bayview Research Group LLC /ID# 153799, Valley Village, California, United States|Emerson Clinical Research Inst /ID# 152348, Washington, District of Columbia, United States|Ideal Clinical Research Inc. /ID# 149757, Aventura, Florida, United States|Seffner Premier Health Care, P /ID# 167480, Brandon, Florida, United States|KO Clinical Research, LLC /ID# 144299, Fort Lauderdale, Florida, United States|University of Florida /ID# 149751, Gainesville, Florida, United States|Solutions Through Adv Rch /ID# 151021, Jacksonville, Florida, United States|Meridien Research /ID# 167100, Kenneth City, Florida, United States|Precision Research Org, LLC /ID# 144335, Miami Lakes, Florida, United States|Invictus Clinical Research Group,LLC /ID# 141859, Miami, Florida, United States|Suncoast Clinical Research /ID# 149765, New Port Richey, Florida, United States|All Wmns HC of West Broward /ID# 144298, Plantation, Florida, United States|Oncova Clinical Research, Inc. /ID# 149764, Saint Cloud, Florida, United States|Physician Care Clin. Res., LLC /ID# 149766, Sarasota, Florida, United States|Qps-Mra, Llc /Id# 144325, South Miami, Florida, United States|University of South Florida /ID# 149754, Tampa, Florida, United States|Olympian Clinical Research /ID# 149756, Tampa, Florida, United States|Axcess Medical Research /ID# 149769, Wellington, Florida, United States|Virtus Research Consultant,LLC /ID# 144296, Wellington, Florida, United States|Paramount Research Solutions /ID# 149291, Alpharetta, Georgia, United States|Agile Clinical Research Trials /ID# 167074, Atlanta, Georgia, United States|Mount Vernon Clinical Res, LLC /ID# 144297, Atlanta, Georgia, United States|Atlanta Women's Research Inst /ID# 144303, Atlanta, Georgia, United States|Masters of Clinical Research, Inc. /ID# 167400, Augusta, Georgia, United States|Georgia Regents University /ID# 144295, Augusta, Georgia, United States|Meridian Clinical Research, LLC /ID# 149144, Savannah, Georgia, United States|Gyn-Care, Inc. /ID# 149341, Smyrna, Georgia, United States|Atlanta Gynecology Research Institute /ID# 151014, Suwanee, Georgia, United States|Womens Healthcare Assoc, DBA /ID# 149762, Idaho Falls, Idaho, United States|Advanced Clinical Research /ID# 149767, Meridian, Idaho, United States|University of Chicago /ID# 152257, Chicago, Illinois, United States|Affinity Clinical Research /ID# 167119, Oak Brook, Illinois, United States|Center for Women's Research, Inc /ID# 144300, Palos Heights, Illinois, United States|Women's Health Advantage /ID# 144301, Fort Wayne, Indiana, United States|The Iowa Clinic /ID# 150105, West Des Moines, Iowa, United States|PRN Professional Research Network of Kansas, LLC /ID# 152265, Wichita, Kansas, United States|Bluegrass Clinical Research /ID# 150103, Louisville, Kentucky, United States|Clinical Trials Management,LLC /ID# 144314, Covington, Louisiana, United States|Women Under Study, LLC /ID# 144312, New Orleans, Louisiana, United States|Baltimore Suburban Health /ID# 154638, Baltimore, Maryland, United States|Womens Health Center /ID# 154209, Glen Burnie, Maryland, United States|Maryland Ctr for Sexual Health /ID# 149778, Lutherville, Maryland, United States|Neccr /Id# 149584, Fall River, Massachusetts, United States|Saginaw Valley Med Res Group /ID# 149768, Saginaw, Michigan, United States|Accent Clinical Trials /ID# 149753, Las Vegas, Nevada, United States|Jersey Shore University Medical Center /ID# 149779, Neptune, New Jersey, United States|Rowan University SOM /ID# 152697, Stratford, New Jersey, United States|SUNY Downstate Medical Center /ID# 144311, Brooklyn, New York, United States|Columbia Univ Medical Center /ID# 149585, New York, New York, United States|Duplicate_Unified Women's Clinical Research-Fayetteville /ID# 149587, Fayetteville, North Carolina, United States|Unified Women's Clinical Research-Greensboro /ID# 149588, Greensboro, North Carolina, United States|Pinewest Ob-Gyn, Inc. /ID# 145671, High Point, North Carolina, United States|Eastern Carolina Women's Centr /ID# 144309, New Bern, North Carolina, United States|Wake Research Associates, LLC /ID# 144307, Raleigh, North Carolina, United States|Clinical Inquest Center Ltd /ID# 148728, Beavercreek, Ohio, United States|CTI Clinical Research Center /ID# 149761, Cincinnati, Ohio, United States|The Christ Hospital /ID# 150104, Cincinnati, Ohio, United States|Alpha Research Associates LLC /ID# 152471, Dayton, Ohio, United States|Comprehensive Womens Care /ID# 144306, Westerville, Ohio, United States|Family Medical Associates /ID# 145668, Levittown, Pennsylvania, United States|University of Pennsylvania /ID# 149586, Philadelphia, Pennsylvania, United States|Clinical Research of Philadelphia, LLC /ID# 151015, Philadelphia, Pennsylvania, United States|Reading Hosp Clncl Trials Ofc /ID# 149583, West Reading, Pennsylvania, United States|Holston Medical Group /ID# 149763, Bristol, Tennessee, United States|Chattanooga Medical Research /ID# 145667, Chattanooga, Tennessee, United States|Chattanooga Women for Women /ID# 167051, Hixson, Tennessee, United States|The Jackson Clinic, PA /ID# 145670, Jackson, Tennessee, United States|The Womens Physician Group /ID# 144317, Memphis, Tennessee, United States|Access Clinical Trials, Inc. /ID# 167333, Nashville, Tennessee, United States|Lotus Gynecology /ID# 149140, Austin, Texas, United States|Inquest Clinical Research /ID# 149755, Baytown, Texas, United States|Texas Health Presbyterian Hosp /ID# 149142, Dallas, Texas, United States|Baylor College of Medicine /ID# 149141, Houston, Texas, United States|The Woman's Hospital of Texas /ID# 144319, Houston, Texas, United States|Centex Studies, Inc. - Houston /ID# 150106, Houston, Texas, United States|BI Research Center /ID# 149143, Houston, Texas, United States|FMC Science /ID# 151802, Lampasas, Texas, United States|Willowbend Health and Wellness /ID# 144318, Plano, Texas, United States|Clinical Trials of Texas,Inc. /ID# 144322, San Antonio, Texas, United States|Center of Reproductive Medicin /ID# 167235, Webster, Texas, United States|Southampton Women's Health /ID# 152325, Franklin, Virginia, United States|Tidewater Physicians for Women /ID# 144321, Norfolk, Virginia, United States|Clinical Research Partners, LL /ID# 167064, North Chesterfield, Virginia, United States|Clinical Research Partners, LLC /ID# 144310, Richmond, Virginia, United States|Alliance Womens Health /ID# 152468, Richmond, Virginia, United States|Zain Research /ID# 151018, Richland, Washington, United States|Virginia Mason Medical Center /ID# 149758, Seattle, Washington, United States|Medicor Research Inc. /ID# 153406, Sudbury, Ontario, Canada|Victory Reproductive Care /ID# 150247, Windsor, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02691494"
231,"NCT02687828","A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients","AMORE","Active, not recruiting","No Results Available","Intestinal Behcet's Disease (BD)",,"Number of participants with adverse events|Number of participants with adverse drug reactions","AbbVie","All","19 Years to 99 Years   (Adult, Older Adult)",,"59","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-760","February 18, 2016","March 30, 2020","March 30, 2020","February 22, 2016",,"December 16, 2019","Kyungpook National Univ Hosp /ID# 147937, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Ajou University Hospital /ID# 147938, Suwon-si, Gyeonggido, Korea, Republic of|Pusan Nat Univ Yangsan Hosp /ID# 169243, Yangsan-si,, Gyeongsangnamdo, Korea, Republic of|Yonsei University Health System, Severance Hospital /ID# 147932, Seodaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 147934, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 147936, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Kosin University Gospel Hosp /ID# 169244, Busan, Korea, Republic of|The Catholic Univ. of Korea /ID# 169245, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital /ID# 147933, Seoul, Korea, Republic of|Asan Medical Center /ID# 147935, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02687828"
232,"NCT02684370","BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Drug: risankizumab|Drug: placebo for risankizumab|Drug: ustekinumab|Drug: placebo for ustekinumab","Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving sPGA Score of Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving PASI100 at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving Psoriasis Symptoms Scale (PSS) Total Score of 0 at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving PASI90 at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving PASI100 at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving sPGA Score of Clear at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving PASI90 at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)|Percentage of Participants Achieving PASI100 at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)|Percentage of Participants Achieving sPGA Score of Clear at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)|Percentage of Participants Achieving PASI75 at Week 12 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 12 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving DLQI Score of 0 or 1 at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|PSS Total Score: Change From Baseline to Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)","AbbVie|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","560","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M16-008|2014-005117-23|1311.3","February 2016","December 2016","September 2017","February 18, 2016","June 18, 2019","June 18, 2019",,,"https://ClinicalTrials.gov/show/NCT02684370"
233,"NCT02684357","BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Drug: risankizumab|Drug: ustekinumab|Drug: placebo for risankizumab|Drug: placebo for ustekinumab","Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving sPGA Score of Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving PASI100 at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving a Psoriasis Symptom Scale (PSS) Score of 0 at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving PASI90 at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving PASI100 at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving sPGA Score of Clear at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving PASI90 at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)|Percentage of Participants Achieving PASI100 at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)|Percentage of Participants Achieving sPGA Score of Clear at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)|Percentage of Participants Achieving PASI75 at Week 12 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 12 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16 in Participants Who Received Risankizumab Compared With Ustekinumab (Part A)|Change From Baseline to Week 16 in PSS Total Score in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving PASI75 at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)|Percentage of Participants Achieving PASI75 at Week 52 in Participants Who Received Risankizumab Compared With Ustekinumab (Part B)","AbbVie|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","577","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M15-995|2015-003622-13|1311.28","March 2016","December 2016","September 2017","February 18, 2016","July 15, 2019","July 15, 2019",,,"https://ClinicalTrials.gov/show/NCT02684357"
234,"NCT02675426","A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone","SELECT-NEXT","Active, not recruiting","Has Results","Rheumatoid Arthritis","Drug: Placebo|Drug: Upadacitinib","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12|Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12|Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12|Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12|Change From Baseline in Duration of Morning Stiffness at Week 12|Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)|Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12|Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","661","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-549|2015-003332-13","December 17, 2015","April 21, 2017","October 1, 2021","February 5, 2016","October 7, 2019","October 7, 2019","AZ Arthritis and Rheum Assoc /ID# 148651, Mesa, Arizona, United States|SunValley Arthritis Center, Lt /ID# 140452, Peoria, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 138500, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 139286, Phoenix, Arizona, United States|AZ Arthritis & Rheuma Research /ID# 138598, Phoenix, Arizona, United States|Arizona Research Center, Inc. /ID# 140448, Phoenix, Arizona, United States|University Arizona Cancer Ctr /ID# 140451, Tucson, Arizona, United States|Covina Arthritis Clinic /ID# 139881, Covina, California, United States|T. Joseph Raoof, MD, Inc. /ID# 140964, Encino, California, United States|Allergy and Rheum Med Clin /ID# 146082, La Jolla, California, United States|Pacific Arthritis Ctr Med Grp /ID# 138744, Los Angeles, California, United States|Robin K. Dore MD, Inc /ID# 138688, Tustin, California, United States|Inland Rheum Clin Trials Inc. /ID# 138853, Upland, California, United States|Denver Arthritis Clinic /ID# 139876, Denver, Colorado, United States|Clinical Res of West FL, Inc. /ID# 138854, Clearwater, Florida, United States|Ctr Arthritis & Rheumatic Dise /ID# 141696, Miami, Florida, United States|Medallion Clinical Research Institute, LLC /ID# 140074, Naples, Florida, United States|Suncoast Clinical Research /ID# 138633, New Port Richey, Florida, United States|Omega Research Consultants /ID# 139877, Orlando, Florida, United States|Arthritis Center, Inc. /ID# 141363, Palm Harbor, Florida, United States|Institute of Arthritis Res /ID# 138548, Idaho Falls, Idaho, United States|OrthoIllinois /ID# 139695, Rockford, Illinois, United States|Clinical Investigation Special /ID# 139696, Skokie, Illinois, United States|Springfield Clinic /ID# 138602, Springfield, Illinois, United States|Deerbrook Medical Associates /ID# 139694, Vernon Hills, Illinois, United States|Indiana Univ School of Med /ID# 140077, Indianapolis, Indiana, United States|Bluegrass Community Research /ID# 138295, Lexington, Kentucky, United States|Four Rivers Clinical Research /ID# 141134, Paducah, Kentucky, United States|Rheumatology Associates,PA /ID# 141542, Portland, Maine, United States|The Center for Rheumatology & /ID# 139203, Wheaton, Maryland, United States|Mansfield Health Center /ID# 141357, Mansfield, Massachusetts, United States|Advanced Rheumatology, PC /ID# 140071, Lansing, Michigan, United States|Justus J. Fiechtner, MD, PC /ID# 138697, Lansing, Michigan, United States|Physician Res. Collaboration /ID# 138533, Lincoln, Nebraska, United States|Westroads Clinical Research /ID# 138304, Omaha, Nebraska, United States|The Center for Rheumatology /ID# 138746, Albany, New York, United States|PMG Research of Salisbury /ID# 141023, Salisbury, North Carolina, United States|PMG Research of Wilmington LLC /ID# 140951, Wilmington, North Carolina, United States|Cincinnati Rheumatic Disease /ID# 138868, Cincinnati, Ohio, United States|Arthritis Assoc of NW Ohio /ID# 140953, Toledo, Ohio, United States|Health Research Oklahoma /ID# 138535, Oklahoma City, Oklahoma, United States|Altoona Ctr Clinical Res /ID# 138741, Duncansville, Pennsylvania, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 138689, Summerville, South Carolina, United States|Comprehensive Arthritis Care, a division of Comprehensive Rheumatology Care PLLC /ID# 141021, Hendersonville, Tennessee, United States|Tekton Research, Inc. /ID# 141428, Austin, Texas, United States|Trinity Universal Res Assoc /ID# 149271, Carrollton, Texas, United States|Arth & Osteo Clin Brazo Valley /ID# 147809, College Station, Texas, United States|Metroplex Clinical Research /ID# 138698, Dallas, Texas, United States|Baylor College of Medicine /ID# 138682, Houston, Texas, United States|Houston Institute for Clin Res /ID# 138716, Houston, Texas, United States|Arthritis Consultants, P.A. /ID# 141138, Killeen, Texas, United States|Trinity Universal Research Association /ID# 148649, Plano, Texas, United States|Accurate Clinical Management /ID# 139338, San Antonio, Texas, United States|Arthritis & Osteoporosis Clinic /ID# 138703, Waco, Texas, United States|Western Washington Arthritis C /ID# 138728, Bothell, Washington, United States|Arthritis Northwest, PLLC /ID# 138539, Spokane, Washington, United States|Rheumatology and Immunotherapy /ID# 139306, Franklin, Wisconsin, United States|Mautalen Salud e Investigacion /ID# 141419, Buenos Aires, Argentina|Inst. Rheumatologic Strusberg /ID# 145648, Cordoba, Argentina|Coffs Clinical Trials /ID# 138747, Coffs Harbour, New South Wales, Australia|Optimus Clinical Research Pty. /ID# 138769, Kogarah, New South Wales, Australia|Emeritus Research /ID# 138773, Camberwell, Victoria, Australia|Barwon Rheumatology /ID# 138772, Geelong, Victoria, Australia|Rheuma Zentrum Favoriten GmbH /ID# 138787, Vienna, Austria|Wilhelminenspital der Stadt Wien /ID# 138788, Wien, Austria|Rhumaconsult SPRL /ID# 138813, Charleroi, Hainaut, Belgium|UZ Gent /ID# 138806, Gent, Oost-Vlaanderen, Belgium|AZ Sint Lucas /ID# 141338, Brugge, Belgium|University Clinical Centre of the Republic of Srpska /ID# 138819, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 140372, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Diag Consult Ctr 17 Sofia EOOD /ID# 141006, Sofia, Bulgaria|Diagnostic Consultative Center /ID# 138882, Sofia, Bulgaria|Manitoba Clinic /ID# 139086, Winnipeg, Manitoba, Canada|Eastern Health /ID# 140431, St. John's, Newfoundland and Labrador, Canada|Groupe de Recherche en Maladies Osseuses /ID# 138906, Sainte-foy, Quebec, Canada|Dr. Latha Naik /ID# 139089, Saskatoon, Saskatchewan, Canada|Klinicki bolnicki centar Rijeka /ID# 138649, Rijeka, Primorsko-goranska Zupanija, Croatia|Klinicka bolnica Sveti Duh /ID# 152812, Zagreb, Croatia|Medical Center Kuna-Peric /ID# 140365, Zagreb, Croatia|Poliklinika Bonifarm /ID# 141415, Zagreb, Croatia|L.K.N. Arthrocentrum, s.r.o /ID# 141340, Hlučín, Moravskoslezsky Kraj, Czechia|Revmatologie, s.r.o. /ID# 138899, Brno, Czechia|Artroscan s.r.o. /ID# 138833, Ostrava, Czechia|Nemocnice Slany /ID# 141112, Slany, Czechia|PV-MEDICAL s.r.o. /ID# 138913, Zlin, Czechia|Center of Clinical and Basic Research /ID# 141116, Tallinn, Harjumaa, Estonia|Paernu Hospital /ID# 138961, Pärnu, Estonia|East Tallinn Central Hospital /ID# 140618, Tallinn, Estonia|Helsinki Univ Central Hospital /ID# 140381, Helsinki, Finland|Kiljava Medical Research /ID# 139260, Hyvinkaa, Finland|South Karelia Central Hospital /ID# 139973, Lappeenranta, Finland|Hopital Saint Joseph /ID# 149188, Marseille CEDEX 08, Bouches-du-Rhone, France|CHRU Tours - Hopital Trousseau /ID# 138969, Chambray Les Tours, France|Uniklinik Koln /ID# 139084, Köln, Nordrhein-Westfalen, Germany|Immanuel-Krankenhaus /ID# 139059, Berlin-buch, Germany|Charité Universitätsmedizin Campus Mitte /ID# 139052, Berlin, Germany|Asklepios Klinik Altona /ID# 140466, Hamburg, Germany|Welcker, Planegg, DE /ID# 140467, Planegg, Germany|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 139115, Heraklion, Greece|Prince of Wales Hospital /ID# 139314, Sha Tin, Hong Kong|Revita Reumatologiai Rendelo /ID# 140761, Budapest, Hungary|Fejer Megyei Szent Gyorgy Korh /ID# 138554, Szekesfehervar, Hungary|St Vincent's University Hosp /ID# 138562, Dublin, Ireland|Universita di Catanzaro Magna Graecia /ID# 139316, Catanzaro, Calabria, Italy|JSC Nat Scientific Med Res Ctr /ID# 140575, Astana, Kazakhstan|Chungnam National University Hospital /ID# 138653, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Ajou University Hospital /ID# 149311, Suwon-si, Gyeonggido, Korea, Republic of|Inha University Hospital /ID# 149310, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 138651, Gwangju, Jeonranamdo, Korea, Republic of|Hanyang University Seoul Hospi /ID# 138655, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 138652, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu Catholic University Med /ID# 139249, Daegu, Korea, Republic of|Seoul National University Hospital /ID# 138659, Seoul, Korea, Republic of|Asan Medical Center /ID# 140579, Seoul, Korea, Republic of|LTD M+M Centers /ID# 138818, Adazi, Latvia|Klaipeda University Hospital /ID# 141416, Klaipeda, Lithuania|Vilnius University Hospital /ID# 141348, Vilnius, Lithuania|Hospital de Jesús Nazareno /ID# 138841, Mexico City, Mexico|Centro Peninsular de Investiga /ID# 148160, Mérida, Mexico|Porter Rheumatology Ltd /ID# 138347, Nelson, New Zealand|NZOZ Nasz Lekarz /ID# 138374, Toruń, Kujawsko-pomorskie, Poland|McBk Sc /Id# 138360, Grodzisk Mazowiecki, Mazowieckie, Poland|Osteo-Medic spolka cywilna /ID# 138371, Białystok, Podlaskie, Poland|NZOZ Centrum Reumatologiczne /ID# 138353, Elblag, Warminsko-mazurskie, Poland|Rheuma Medicus /ID# 138372, Warsaw, Poland|Instituto Portugues De Reumatologia /ID# 148315, Lisbon, Lisboa, Portugal|Centro Hospitalar Lisboa Ocidental, EPE /ID# 140594, Lisbon, Lisboa, Portugal|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 139328, San Juan, Puerto Rico|Spitalul Clinic Judetean de Urgenta /ID# 138407, Cluj, Romania|Spitalul Municipal Ploiesti /ID# 138405, Ploiesti, Romania|Spitalul Clinic Judetean de Ur /ID# 138393, Sibiu, Romania|LLC Novaya Klinika /ID# 139269, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 138413, Kazan, Tatarstan, Respublika, Russian Federation|Republican Clin Hos n.a. Baran /ID# 139273, Petrozavodsk, Russian Federation|Samara Regional Clinical Hosp /ID# 148642, Samara, Russian Federation|Ulyanovsk Regional Clin Hosp /ID# 139279, Ulyanovsk, Russian Federation|Voronezh State Medical Univers /ID# 148431, Voronezh, Russian Federation|Yaroslavi State Medical Univer /ID# 139908, Yaroslavl, Russian Federation|ARTROMAC n.o. /ID# 138428, Kosice, Slovakia|Nemocnica Kosice Saca, a.s. /ID# 138918, Kosice, Slovakia|Narodny ustav reumatickych chorob Piestany /ID# 138427, Pieštany, Slovakia|Slovak research center Team Member, Thermium s.r.o. /ID# 139924, Pieštany, Slovakia|REUMA-GLOBAL, s.r.o. /ID# 139912, Trnava, Slovakia|St. Augustine's Medical Centre /ID# 141352, Berea, Durban, Kwazulu-Natal, South Africa|Arthritis Clinical Research Tr /ID# 138945, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 138944, Stellenbosch, Western Cape, South Africa|Hospital Regional de Malaga /ID# 138975, Málaga, Malaga, Spain|Hospital General Univ de Elche /ID# 138991, Elche, Spain|Hospital Clin Univ San Carlos /ID# 138993, Madrid, Spain|Hosp Nuestra Senora Esperanza /ID# 138997, Santiago de Compostela, Spain|HFR Fribourg - Hopital Canton /ID# 139155, Fribourg, Switzerland|China Medical University Hosp /ID# 139232, Taichung City, Taichung, Taiwan|National Cheng Kung University Hospital /ID# 140868, Tainan City, Tainan, Taiwan|National Taiwan Univ Hosp /ID# 141443, Taipei City, Taipei, Taiwan|Kaohsiung Medical University /ID# 140869, Kaohsiung, Taiwan|Far Eastern Memorial Hospital /ID# 140871, New Taipei City, Taiwan|Taipei Veterans General Hosp /ID# 139234, Taipei City, Taiwan|Ankara Numune Training and Res /ID# 139237, Ankara, Turkey|LLC Revmocentr /ID# 139872, Kiev, Kyiv, Ukraine|Lviv Municipal City Clinical /ID# 139873, Lviv, Ukraine|Odessa National Medical Univ /ID# 139179, Odesa, Ukraine|Leicester Royal Infirmary /ID# 139184, Leicester, England, United Kingdom|Whipps Cross Univ Hospital /ID# 139523, London, London, City Of, United Kingdom|The Royal Free Hospital /ID# 139191, London, London, City Of, United Kingdom|Western General Hospital /ID# 139524, Edinburgh, United Kingdom|Southampton General Hospital /ID# 139169, Southampton, United Kingdom|Warrington + Halton Hosp NHS /ID# 139195, Warrington, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02675426/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02675426/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02675426"
235,"NCT02674568","Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer","TRINITY","Completed","Has Results","Small Cell Lung Cancer","Drug: Rovalpituzumab tesirine","Objective Response Rate|Overall Survival|Overall Response Rate|Duration of Objective Response|Progression-Free Survival|Clinical Benefit Rate|Duration of Clinical Benefit|Rovalpituzumab Tesirine Antibody-Drug Conjugate Plasma Concentrations by Study Visit|Number of Anti-Therapeutic Antibody (ATA) Positive Participants|Number of Participants With Treatment-Related Adverse Events (TEAEs) During Initial Treatment|Number of Participants With TEAEs Occurring in at Least 10% of All Participants During Initial Treatment","AbbVie",,"18 Years and older   (Adult, Older Adult)","Phase 2","342","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRX001-002|2015-004506-42","January 25, 2016","October 19, 2018","October 19, 2018","February 4, 2016","October 23, 2019","November 15, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02674568/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT02674568/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02674568"
236,"NCT02672852","BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment",,"Completed","Has Results","Psoriasis","Drug: Risankizumab|Drug: Placebo","Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16|Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16|Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 16|Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 16|Percentage of Participants Achieving an sPGA Score of Clear at Week 16|Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16|Percentage of Participants Achieving an sPGA Score of Clear or Almost Clear at Week 104|Percentage of Participants Achieving 75% Improvement in PASI Score (PASI75) at Week 52|Percentage of Participants Achieving 90% Improvement in PASI Score (PASI90) at Week 52|Percentage of Participants Achieving 100% Improvement in PASI Score (PASI100) at Week 52","AbbVie|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","507","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M15-992|2014-005102-38|1311.4","February 29, 2016","August 2, 2017","July 26, 2018","February 3, 2016","May 28, 2019","October 9, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02672852/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/52/NCT02672852/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02672852"
237,"NCT02669940","Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation","HCV RWE","Completed","Has Results","Chronic Hepatitis C|Genotype 1",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-Treatment (SVR12)|Percentage of Participants Meeting SVR12 Non-Response Categories of Breakthrough, Failure to Suppress, and/or Relapse|SVR12 Non-Response: Percentage of Participants With Breakthrough|SVR12 Non-Response: Percentage of Participants With Failure to Suppress|SVR12 Non-Response: Percentage of Participants With Relapse|SVR12 Non-Response: Percentage of Participants With Premature Study Drug Discontinuation With No On-Treatment Virologic Failure|SVR12 Non-Response: Percentage of Participants With Missing SVR12 Data|Percentage of Participants Achieving Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)|Percentage of Participants Achieving Virological Response at End of Treatment","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"158","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-743","April 15, 2016","July 4, 2017","July 4, 2017","February 1, 2016","November 14, 2018","November 14, 2018",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02669940/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02669940/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02669940"
238,"NCT02668640","Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Adalimumab","Median Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score at Week 24|Median Change From Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score at Week 12|Median Change From Baseline in Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score and Mental Component Summary (MCS) Scores at Weeks 12 and 24|Median Change From Baseline in EuroQol 5-dimension, 3-level Quality of Life Questionnaire (EQ-5D-3L) Index|Median Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Overall Work Impairment Score|Median Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) Activity Impairment Score|Number of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score|Percentage of Participants Achieving Clinically Meaningful Improvement in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"55","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-776","May 1, 2016","June 12, 2018","August 13, 2018","January 29, 2016","September 13, 2019","September 13, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02668640/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02668640/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02668640"
239,"NCT02654054","Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women",,"Completed","No Results Available","Uterine Fibroids|Heavy Menstrual Bleeding","Drug: Elagolix|Drug: Placebo for Estradiol/Norethindrone Acetate|Drug: Estradiol/Norethindrone Acetate|Drug: Placebo for Elagolix","Percentage of Responders With Menstrual Blood Loss (MBL) Volume of < 80 mL at Final Month and >= 50% Reduction in MBL Volume|Change from Baseline in MBL Volume|Percentage of Participants with Suppression of Bleeding|Percentage of Participants with Baseline hemoglobin <= 10.5 g/dL who have an increase in hemoglobin > 2 g/dL","AbbVie","Female","18 Years to 51 Years   (Adult)","Phase 3","412","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-815","December 22, 2015","January 18, 2018","December 12, 2018","January 13, 2016",,"February 11, 2019","Summers, Birmingham, AL /ID# 139684, Birmingham, Alabama, United States|University of South Alabama /ID# 148763, Mobile, Alabama, United States|WCCT Global, LLC /ID# 145666, Costa Mesa, California, United States|American Clinical Trials /ID# 147374, Hawaiian Gardens, California, United States|Grossmont Ctr Clin Research /ID# 144011, La Mesa, California, United States|Long Beach Clinical Trial Serv /ID# 152424, Long Beach, California, United States|National Research Institute /ID# 151629, Los Angeles, California, United States|University of California, Los Angeles /ID# 144107, Los Angeles, California, United States|Beach OBGYN Medical Group /ID# 151414, Newport Beach, California, United States|Advanced RX Clinical Research /ID# 149168, Westminster, California, United States|Bluebird Clinical Trials, LLC /ID# 144843, Colorado Springs, Colorado, United States|Advanced Women's Health Institution /ID# 144108, Greenwood Village, Colorado, United States|MedStar Washington Hosp Ctr /ID# 145933, Washington, District of Columbia, United States|James A. Simon, MD, PC /ID# 139675, Washington, District of Columbia, United States|Helix Biomedics, LLC /ID# 147114, Boynton Beach, Florida, United States|Brandon Premier Health Care, PA /ID# 153130, Brandon, Florida, United States|Florida Clin Res Group /ID# 139811, Clearwater, Florida, United States|Universal Clinical Research A /ID# 139742, Doral, Florida, United States|Clinical Physiology Associates /ID# 139736, Fort Myers, Florida, United States|Meridien Research /ID# 139663, Kenneth City, Florida, United States|Altus Research, Inc /ID# 139662, Lake Worth, Florida, United States|South Florida Wellness & Clinic /ID# 143558, Margate, Florida, United States|LCC Medical Research Institute /ID# 143551, Miami, Florida, United States|Healthcare Clinical Data, Inc /ID# 139650, Miami, Florida, United States|Ocean Blue Med Research Ctr /ID# 139826, Miami, Florida, United States|Salom Tangir, LLC /ID# 151732, Miramar, Florida, United States|Advanced Research Institute /ID# 143554, New Port Richey, Florida, United States|Clinical Associates of Orlando /ID# 148123, Orlando, Florida, United States|Omega Research Consultants /ID# 139648, Orlando, Florida, United States|Unified Womens Clin Research /ID# 145169, Panama City, Florida, United States|Comprehensive Clinical Trials /ID# 139644, West Palm Beach, Florida, United States|Atlanta Medical Research Insti /ID# 147117, Alpharetta, Georgia, United States|Paramount Research Solutions /ID# 139645, Alpharetta, Georgia, United States|Agile Clinical Research Trials /ID# 143563, Atlanta, Georgia, United States|Perimeter Inst Clinical Resear /ID# 148298, Atlanta, Georgia, United States|Masters of Clinical Research, Inc. /ID# 139658, Augusta, Georgia, United States|Fellows Research Alliance, Inc /ID# 139655, Savannah, Georgia, United States|Boise Family Medical Center /ID# 139844, Boise, Idaho, United States|Women's Health Practice, LLC /ID# 143569, Champaign, Illinois, United States|Great Lakes Clinical Trials /ID# 148135, Chicago, Illinois, United States|Affinity Clinical Research /ID# 150980, Oak Brook, Illinois, United States|American Health Network of IN /ID# 139822, Avon, Indiana, United States|GTC Research /ID# 141854, Kansas City, Kansas, United States|Cypress Medical Research Ctr /ID# 147116, Wichita, Kansas, United States|Research Integrity, LLC /ID# 139727, Owensboro, Kentucky, United States|Clinical Trials Management,LLC /ID# 139651, Covington, Louisiana, United States|Ochsner Baptist Medical Center /ID# 139740, New Orleans, Louisiana, United States|Omni Fertility and Laser Insti /ID# 139836, Shreveport, Louisiana, United States|Capital Women's Care /ID# 144109, Frederick, Maryland, United States|Genesis Clinical Research /ID# 148449, Fall River, Massachusetts, United States|Great Lakes Research Group,Inc /ID# 139659, Bay City, Michigan, United States|Grand Rapids Womens Health /ID# 139705, Grand Rapids, Michigan, United States|Wayne State University Physician Group - Southfield /ID# 139802, Southfield, Michigan, United States|Office of Edmond E. Pack, MD /ID# 139792, Las Vegas, Nevada, United States|Mabey, Las Vegas, NV /ID# 148138, Las Vegas, Nevada, United States|Lawrence OB/GYN /ID# 143567, Lawrenceville, New Jersey, United States|Bosque Women's Care /ID# 145934, Albuquerque, New Mexico, United States|Manhattan Medical Research /ID# 144471, New York, New York, United States|Cwrwc /Id# 139664, Durham, North Carolina, United States|Unified Women's Clinical Research-Greensboro /ID# 139829, Greensboro, North Carolina, United States|Unified Women's Clinical Resea /ID# 139774, Raleigh, North Carolina, United States|PMG Research of Wilmington LLC /ID# 152563, Wilmington, North Carolina, United States|Unified Women's Clinical Resea /ID# 144721, Winston-Salem, North Carolina, United States|University of Cincinnati /ID# 139820, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 139741, Cleveland, Ohio, United States|Complete Healthcare for Women /ID# 139673, Columbus, Ohio, United States|Miami Valley Hospital /ID# 144430, Dayton, Ohio, United States|University of Toledo /ID# 139787, Toledo, Ohio, United States|Legacy Medical Group-Portland /ID# 148807, Portland, Oregon, United States|Main Line Fertility Center /ID# 150295, Bryn Mawr, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 139733, Hershey, Pennsylvania, United States|Thomas Jefferson University /ID# 139812, Philadelphia, Pennsylvania, United States|Temple University Hospital /ID# 151429, Philadelphia, Pennsylvania, United States|Clinical Trials Research Svcs /ID# 139707, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina /ID# 148754, Charleston, South Carolina, United States|Vista Clinical Research /ID# 139797, Columbia, South Carolina, United States|WR-ClinSearch /ID# 143538, Chattanooga, Tennessee, United States|Research Memphis Associates, LLC /ID# 139674, Memphis, Tennessee, United States|Access Clinical Trials, Inc. /ID# 139730, Nashville, Tennessee, United States|UT Southwestern Medical Center /ID# 143537, Dallas, Texas, United States|Advances in Health, Inc. /ID# 139672, Houston, Texas, United States|Victorium Clinical Research /ID# 149630, San Antonio, Texas, United States|Discovery Clinical Trials-San Antonio /ID# 139776, San Antonio, Texas, United States|Houston Ctr for Clin Research /ID# 149149, Sugar Land, Texas, United States|Center of Reproductive Medicin /ID# 139813, Webster, Texas, United States|Eastern Virginia Med School /ID# 139647, Norfolk, Virginia, United States|Clinical Research Partners, LL /ID# 143999, North Chesterfield, Virginia, United States|Clinical Trials Virginia, Inc. /ID# 139801, Richmond, Virginia, United States|Emerson Clinical Research /ID# 147373, Vienna, Virginia, United States|Seattle Women's Health, Research, Gynecology /ID# 139768, Seattle, Washington, United States|Premier Clinical Research /ID# 148145, Spokane, Washington, United States|The Ottawa Hospital /ID# 148695, Ottawa, Ontario, Canada|Rodriguez-Ginorio, San Juan /ID# 139847, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 139848, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT02654054"
240,"NCT02651194","A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection","EXPEDITION-4","Completed","Has Results","Chronic Hepatitis C Virus (HCV) Infection","Drug: ABT-493/ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-462|2015‐002353‐35","December 2015","October 2016","January 2017","January 8, 2016","October 16, 2017","October 16, 2017",,,"https://ClinicalTrials.gov/show/NCT02651194"
241,"NCT02642432","A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis","EXPEDITION-1","Completed","Has Results","Hepatitis C Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis","Drug: ABT-493/ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","146","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-172|2015-003797-32","December 7, 2015","October 27, 2016","February 10, 2017","December 30, 2015","September 26, 2017","October 26, 2017",,,"https://ClinicalTrials.gov/show/NCT02642432"
242,"NCT02640833","A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor",,"Withdrawn","No Results Available","Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma|Non-Hodgkin Lymphoma","Drug: Duvelisib|Drug: Venetoclax","Number of participants with adverse events|Maximum observed plasma concentration (Cmax) of duvelisib|Maximum observed plasma concentration (Cmax) of venetoclax|Time to maximum observed plasma concentration (Tmax) of duvelisib|Time to maximum observed plasma concentration (Tmax) of venetoclax|Area under the plasma concentration-time curve from time 0 to 12 hours post-dose (AUC12) of duvelisib|Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC24) of venetoclax|Recommended phase two dose (RPTD) of Duvelisib in combination with venetoclax|Recommended phase two dose (RPTD) of Venetoclax in combination with duvelisib|Progression-free survival (PFS)|Overall Response Rate (ORR)|Time to Tumor Progression (TTP)|Duration of Response (DOR)","AbbVie|Infinity Pharmaceuticals, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-330|2015-003302-16","July 2016","January 2020","February 2021","December 29, 2015",,"July 26, 2016","Site Reference ID/Investigator# 145677, Tucson, Arizona, United States|Site Reference ID/Investigator# 147922, Chicago, Illinois, United States|Site Reference ID/Investigator# 148562, Harvey, Illinois, United States|Site Reference ID/Investigator# 148561, Goshen, Indiana, United States|Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States|Site Reference ID/Investigator# 145145, Boston, Massachusetts, United States|Site Reference ID/Investigator# 148010, Detroit, Michigan, United States|Site Reference ID/Investigator# 147747, St. Louis, Missouri, United States|Site Reference ID/Investigator# 145146, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 148559, Greenville, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02640833"
243,"NCT02640547","Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C",,"Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants Achieving Virological Response at End of Treatment|Percentage of Participants With Relapse|Percentage of Participants With Breakthrough|Percentage of Participants With a Rapid Virological Response at Week 4|Percentage of Participants Achieving Sustained Virological Response 24 Weeks Post-treatment (SVR24)|Percentage of Participants in the Core Population With Sufficient Follow-up Data for SVR12 Who Achieved Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants in Each Non-response Category 12 Weeks Post-treatment|Assigned Treatment Regimen|Percentage of the Direct Acting Antiviral (DAA) Dose Taken in Relation to the Target Dose of DAA|Percentage of the Ribavirin (RBV) Dose Taken in Relation to the Target Dose of RBV|Number of Participants With Comorbidities|Number of Participants Who Received Concomitant Medications|Number of Participants With Adverse Events, Serious Adverse Events, or Pregnancies|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS Score|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Absenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Presenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Work Productivity Impairment (TWP)|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Activity Impairment","AbbVie|IST GmbH, Germany","All","18 Years to 99 Years   (Adult, Older Adult)",,"394","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-767|PLHCVRWE01","November 26, 2015","March 29, 2017","March 29, 2017","December 29, 2015","October 17, 2018","October 17, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02640547/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02640547/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02640547"
244,"NCT02640482","A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","ENDURANCE-2","Completed","Has Results","Chronic Hepatitis C Virus (HCV) Infection","Drug: ABT-493/ABT-530|Drug: Placebo for ABT-493/ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures: Noninferiority Analysis|Percentage of Participants With SVR12 in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures: Superiority Analysis|Percentage of Participants With On-treatment Virologic Failure in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures|Percentage of Participants With Post-treatment Relapse in Arm A DB Active Drug Excluding Prior SOF + Ribavirin (RBV) ± pegIFN Failures|Percentage of Participants With SVR12 in Arm A DB Active Drug With Prior SOF + RBV ± pegIFN Failure","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M15-464|2015-002348-14","November 2015","September 2016","February 2017","December 29, 2015","September 18, 2017","October 23, 2017",,,"https://ClinicalTrials.gov/show/NCT02640482"
245,"NCT02640157","A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection","ENDURANCE-3","Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus|Genotype 3 Hepatitis C Virus","Drug: ABT-493/ABT-530|Drug: Sofosbuvir|Drug: Daclatasvir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Noninferiority of Arm A to Arm B|Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Noninferiority of Arm C to Arm A|Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Superiority of Arm A to Arm B|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","506","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-594|2015-002272-24","December 2015","October 2016","February 2017","December 28, 2015","September 15, 2017","September 15, 2017",,,"https://ClinicalTrials.gov/show/NCT02640157"
246,"NCT02636608","Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary","VERITAS","Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 24 Weeks Post-treatment (SVR24)|Percentage of Participants Achieving Virological Response at End of Treatment|Percentage of Participants With Relapse|Number of Participants With Breakthrough|Percentage of Participants in Each Non-response Category 12 Weeks Post-treatment|Percentage of Participants With Adherence to the ABBVIE Regimen, by Adherence Category|Percentage of Participants With Adherence to Ribavirin by Adherence Category|Percentage of Ribavirin Treatment Days in Relation to the Target Number of Ribavirin Treatment Days|Number of Participants Who Received Concomitant Medications|Number of Participants With Adverse Events, Serious Adverse Events, or Pregnancies|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS Score|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Absenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Presenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Work Productivity Impairment (TWP)|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Activity Impairment|Change From Baseline in Patient Activation Measure 13 (PAM-13)|Number of Participants Who Participated in the AbbVie Patient Support Program (PSP)|Utilization of the AbbVie Patient Support Program (PSP) Components|Satisfaction With the AbbVie Patient Support Program (PSP) Components","AbbVie|IST GmbH, Germany","All","18 Years to 99 Years   (Adult, Older Adult)",,"244","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-709|HU15-01","November 27, 2015","May 23, 2018","May 23, 2018","December 22, 2015","July 26, 2019","July 26, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02636608/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT02636608/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02636608"
247,"NCT02636595","The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)","ENDURANCE-4","Completed","Has Results","Hepatitis C Virus","Drug: ABT-493/ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","121","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-583|2015-002349-80","November 2015","October 2016","January 2017","December 22, 2015","September 14, 2017","September 14, 2017",,,"https://ClinicalTrials.gov/show/NCT02636595"
248,"NCT02632175","Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis",,"Enrolling by invitation","No Results Available","Ulcerative Colitis (UC)","Biological: Adalimumab","Proportion of subjects who achieve clinical remission as measured by PMS|Proportion of subjects who achieve PUCAI response|Proportion of subjects who achieve clinical response as measured by Partial Mayo Score (PMS)|Proportion of subjects who achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) remission|Assessing impact on children who have inflammatory bowel disease (ulcerative colitis) using IMPACT III questionnaire|Assessing activity impairment using the Work Productivity and Activity Impairment Questionnaire: Ulcerative Colitis (WPAI: UC)|Proportion of subjects who achieve remission/response based on Full Mayo score","AbbVie","All","5 Years to 18 Years   (Child, Adult)","Phase 3","93","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-870|2015-001346-29","November 26, 2015","May 19, 2023","March 16, 2026","December 16, 2015",,"March 8, 2019","Arnold Palmer Hosp Children /ID# 147295, Orlando, Florida, United States|Minnesota Gastroenterology /ID# 147294, Minneapolis, Minnesota, United States|Mayo Clinic - Rochester /ID# 147304, Rochester, Minnesota, United States|MultiCare Institute Health Sys /ID# 169005, Tacoma, Washington, United States|Kurume University Hospital /ID# 145710, Kurume-shi, Fukuoka, Japan|National Center for Child Health and Development /ID# 147312, Setagaya-ku, Tokyo, Japan|Juntendo University Hospital /ID# 147315, Tokyo, Japan|Instytut Centrum Zdrowia Matki /ID# 169017, Lodz, Lodzkie, Poland|Uni Szpital Dzieciecy w Krakowie /ID# 147279, Cracow, Malopolskie, Poland|Centrum Zdrowia MDM /ID# 147280, Warszawa, Mazowieckie, Poland|Gabinet Lekarski Bartosz Korcz /ID# 147281, Rzeszow, Poland|Samodzielny Publiczny Szpital /ID# 147310, Wroclaw, Poland|Univerzitna nemocnica Martin /ID# 147283, Martin, Zilinsky Kraj, Slovakia|Hospital Univ Vall d'Hebron /ID# 147288, Barcelona, Spain|The Royal London Hospital /ID# 147290, London, London, City Of, United Kingdom|The Royal Free Hospital /ID# 147292, London, London, City Of, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02632175"
249,"NCT02629172","Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1",,"Completed","No Results Available","Chronic Hepatitis C Virus",,"Percentage of Participants with Sustained Virologic Response (SVR12)|Percentage of Participants with Virologic Failure After Treatment|Percentage of Participants with Sustained Virologic Response (SVR24)|Percentage of Participants with Virologic Failure During Treatment","AbbVie","All","up to 120 Years   (Child, Adult, Older Adult)",,"3043","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-336","January 5, 2016","February 28, 2019","February 28, 2019","December 14, 2015",,"March 28, 2019","Aichi Medical University Hosp /ID# 152220, Nagakute, Aichi, Japan|Nagoya City University Hospital /ID# 153642, Nagoya-shi, Aichi, Japan|Japanese Red Cross Narita Hosp /ID# 155894, Narita-shi, Chiba, Japan|Kikkoman General Hospital /ID# 152139, Noda, Chiba, Japan|Matsuyama Red Cross Hosp /ID# 152271, Matsuyama, Ehime, Japan|NHO Kyushu Medical Center /ID# 153001, Fukuoka-shi, Fukuoka, Japan|Fukuoka University Hospital /ID# 152272, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 152099, Kurume-shi, Fukuoka, Japan|Gifu University Hospital /ID# 152993, Gifu-shi, Gifu, Japan|Kusunoki Hospital /ID# 152072, Fujioka, Gunma, Japan|Gunma University Hospital /ID# 154669, Maebashi-shi, Gunma, Japan|National Hospital Organization Takasaki General Medical Center /ID# 152971, Takasaki-shi, Gunma, Japan|Fukuyama City Hospital /ID# 152322, Fukuyama-shi, Hiroshima, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 152165, Sapporo-shi, Hokkaido, Japan|Sapporo Medical Univ Hosp /ID# 152992, Sapporo-shi, Hokkaido, Japan|Kobe University Hospital /ID# 153004, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 157482, Nishinomiya-shi, Hyogo, Japan|JA Toride Medical Center /ID# 153657, Toride City, Ibaraki, Japan|Kanazawa University Ho /ID# 152174, Kanazawa, Ishikawa, Japan|Iwate Medical University Hospital /ID# 152076, Morioka-shi, Iwate, Japan|Nanpuh Hospital /ID# 153008, Kagoshima-shi, Kagoshima, Japan|Shonan Fujisawa Tokushukai Hospital /ID# 152967, Fujisawa-shi, Kanagawa, Japan|Shonan Kamakura General Hospital /ID# 152070, Kamakura-shi, Kanagawa, Japan|Yokohama City University Hospital /ID# 154663, Yokohama-shi, Kanagawa, Japan|Yokohama City Univ Medical Ctr /ID# 153643, Yokohama, Kanagawa, Japan|Yokohama Municipal Citizen's Hospital /ID# 152151, Yokohama, Kanagawa, Japan|Kumamoto Shinto General Hospital /ID# 152149, Kumamoto-shi, Kumamoto, Japan|Kyoto Prefect Univ Med /ID# 152236, Kyoto-shi, Kyoto, Japan|Kyoto Prefect Univ Med /ID# 152981, Kyoto-shi, Kyoto, Japan|JP Red Cross Kyoto Daiichi Hos /ID# 152221, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 152980, Sendai-shi, Miyagi, Japan|Shinshu University Hospital /ID# 153632, Matsumoto-shi, Nagano, Japan|Nagasaki University Hospital /ID# 152233, Nagasaki-shi, Nagasaki, Japan|Okayama University Hospital /ID# 152287, Okayama-shi, Okayama, Japan|Kansai Medical University Hospital /ID# 152269, Hirakata-shi, Osaka, Japan|Osaka Saiseikai Nakatsu Hospital /ID# 155967, Osaka-shi, Osaka, Japan|Osaka Red Cross Hospital /ID# 152190, Osaka-shi, Osaka, Japan|Osaka City University Hospital /ID# 152160, Osaka-shi, Osaka, Japan|Nippon Life Saiseikai Public Interest Foundation Nippon Life Hospital /ID# 152279, Osaka-shi, Osaka, Japan|Osaka Medical College Hospital /ID# 152307, Takatsuki -shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 153641, Kawagoe-shi, Saitama, Japan|Shiga Univ Med Science Hosp /ID# 153628, Otsu, Shiga, Japan|Hamamatsu University Hospital /ID# 154651, Hamamatsu, Shizuoka, Japan|Shizuoka General Hospital /ID# 152162, Shizuoka-shi, Shizuoka, Japan|Jichi Medical University Hospital /ID# 152069, Shimotsuke-shi, Tochigi, Japan|Tokushima University Hospital /ID# 159455, Tokushima-shi, Tokushima, Japan|Tokyo Teishin Hospital /ID# 157457, Chiyoda-ku, Tokyo, Japan|Tokyo Jikei Daisan Hospital /ID# 155896, Komae-shi, Tokyo, Japan|Kyorin University Hospital /ID# 152990, Mitaka-shi, Tokyo, Japan|Japanese Red Cross Medical Center /ID# 152219, Shibuya-ku, Tokyo, Japan|Showa University Hospital /ID# 153618, Shinagawa-ku, Tokyo, Japan|Tokyo Medical University Hospital /ID# 152288, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 152290, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 156383, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 154664, Yamagata-shi, Yamagata, Japan|University of Yamanashi Hospital /ID# 152164, Chuo-shi, Yamanashi, Japan|Ageo Central General Hospital /ID# 153002, Ageo, Japan|Sangane Clinic /ID# 162885, Aichi, Japan|Banbuntane Hotokukai Hospital /ID# 160909, Aichi, Japan|Masuda Family Clinic /ID# 155961, Aki-takata, Japan|Akita Kousei Medical Center /ID# 152183, Akita, Japan|Kato Michio Hepatology Clinic /ID# 152138, Amagasaki, Hyogo, Japan|Takahashi Naika /ID# 162888, Amagasaki, Japan|Kansai Rosai Hospital /ID# 152239, Amagasaki, Japan|Ikeda Hospital /ID# 152135, Amagasaki, Japan|Aomori Prefectural Central Hos /ID# 161749, Aomori-shi, Japan|Konoe Hospital /ID# 158066, Arao, Japan|Japanese Red Cross Asahikawa /ID# 153552, Asahikawa, Japan|Asakura Medical Association Ho /ID# 152999, Asakura, Japan|Azumino Red Cross Hospital /ID# 160801, Azumino, Japan|Chiba Aoba Municipal Hospital /ID# 153016, Chiba, Japan|Chiba University Hospital /ID# 152988, Chiba, Japan|NHO Chiba-East-Hospital /ID# 152217, Chiba, Japan|Saisei Hospital /ID# 152277, Chiba, Japan|Fujishima Clinic /ID# 152216, Chiba, Japan|Seirei Sakura Citizen Hospital /ID# 152296, Chiba, Japan|Aioi Clinic /ID# 150059, Chichibu, Japan|Shonan Ishiguro Clinic /ID# 165272, Chigasaki, Japan|Shonan Tobu Sogo Hospital /ID# 152979, Chigasaki, Japan|Chikugo City Hospital /ID# 152318, Chikugo, Japan|Chitose City Hospital /ID# 156386, Chitose-shi, Japan|MIne Internal Medicine Clinic /ID# 155885, Fuchu, Japan|Tama Medical Center /ID# 158101, Fuchu, Japan|Fuji City General Hospital /ID# 159456, Fuji, Japan|Fukuchiyama City Hospital /ID# 157455, Fukuchiyama, Japan|Fukui Prefectural Hospital /ID# 152137, Fukui, Japan|Fukui Prefectural Hospital /ID# 152976, Fukui, Japan|University of Fukui Hospital /ID# 152169, Fukui, Japan|Tanaka Internal Medical Clinic /ID# 157499, Fukui, Japan|Hopsital of the University of Occupational and Enviromental Health /ID# 152998, Fukuoka, Japan|Saiseikai Fukuoka General Hosp /ID# 152167, Fukuoka, Japan|Fukuoka City Med Assoc Hosp /ID# 164143, Fukuoka, Japan|Shimizu Clinic /ID# 152166, Fukuoka, Japan|Chihaya Hospital /ID# 152223, Fukuoka, Japan|Fukushima Med Univ Hosp /ID# 154735, Fukushima-shi, Japan|Clinic21 /ID# 153554, Fukushima, Japan|Rai Clinic /ID# 164133, Fukushima, Japan|Ishikawa Clinic /ID# 161747, Fukuyama, Japan|Morichika Internal Medicine /ID# 162887, Fukuyama, Japan|Gifu Municipal Hospital /ID# 152283, Gifu, Japan|Haramachi Red Cross Hospital /ID# 157447, Gunma, Japan|Hospital Hakodate Hokkaido /ID# 159457, Hakodate, Japan|Matsuda Internal Medicine /ID# 165064, Hamamatsu-shizuoka, Japan|Handa City Hospital /ID# 152140, Handa-shi, Japan|Mashiba Clinic /ID# 152097, Hanno, Japan|Hashima City Hospital /ID# 154658, Hashima, Japan|JA Hiroshima General Hospital /ID# 154729, Hatsukaichi, Japan|Higashi-Omi Keiai Hospital /ID# 164954, Higashi-omi, Japan|Higashihiroshima Medical Ctr /ID# 152970, Higashihiroshima, Japan|Mito Medical Center /ID# 154652, Higashiibaraki-gun, Japan|Higashiomicity Notogawa Hosp /ID# 152075, Higashiomi, Shiga, Japan|Higashiosaka City General Hosp /ID# 153630, Higashiosaka-shi, Japan|Wakakusa Daiichi Hospital /ID# 152201, Higashiosaka, Japan|Kousei Hospital /ID# 152159, Himeji, Japan|Kajihara Clinic /ID# 159451, Hiratsuka, Japan|Hirosaki University Hospital /ID# 153633, Hirosaki-aomori, Japan|Nakahata Gastroenterology Clin /ID# 164134, Hirosaki, Japan|Hiroshima Clinic /ID# 153614, Hiroshima-shi, Japan|Hiroshima Red Cross Hosp Atomi /ID# 152098, Hiroshima, Japan|Nishihara Nakamura Med Clinic /ID# 155999, Hiroshima, Japan|Hiroshima University Hospital /ID# 152319, Hiroshima, Japan|Hiroshima-Nishi Medical Center /ID# 161744, Hiroshima, Japan|Hiroshima General Hosp W JP /ID# 152077, Hiroshima, Japan|Hitachi, Ltd., Hitachi Gen Hos /ID# 161748, Hitachi, Japan|Iwao Hospital /ID# 152306, Hita, Japan|Naganuma Municipal Hospital /ID# 152991, Hokkaido, Japan|Japanese Red Cross Kitami Hosp /ID# 153010, Hokkaido, Japan|Akashi City Hospital /ID# 150058, Hyogo, Japan|Ashiya Municipal Hospital /ID# 150054, Hyogo, Japan|Hyogo Prefectural Awaji Hosp /ID# 152237, Hyogo, Japan|Hyogo Prefectural Kakogawa Med /ID# 152280, Hyogo, Japan|Tokyo Dental College Ichikawa /ID# 154665, Ichikawa-shi, Japan|Iizuka Hospital /ID# 152186, Iizuka, Japan|Ikeda Municipal Hospital /ID# 152170, Ikeda, Japan|Nagasaki Prefecture Iki Hospit /ID# 154674, IKI, Japan|Nara Hosp Kinki Uni Fac Of Med /ID# 155895, Ikoma, Japan|Saiseikai Imabari Hospital /ID# 158100, Imabari-shi, Japan|Tokyo Med Uni Ibaraki Med Ctr /ID# 152121, Inashiki, Japan|Ina Central Hospital /ID# 152144, INA, Japan|Inuyama Chuo General /ID# 154672, Inuyama, Japan|Saitama Medical University Hos /ID# 152073, Iruma-gun, Japan|Saitama Medical University Hos /ID# 153616, Iruma-gun, Japan|Yamada Internal Medicine Clini /ID# 154786, Isesaki, Japan|Katakai Clinic /ID# 152163, Isesaki, Japan|Ise Red Cross Hospital /ID# 154670, ISE, Japan|Yawata Medical Center /ID# 152215, Ishikawa, Japan|Matto Ishikawa Public Hospital /ID# 153638, Ishikawa, Japan|Kamiiwade Internal Med-Neuro /ID# 160802, Iwade, Japan|Iwaki Kyoritsu General Hosp /ID# 153617, Iwaki-shi, Japan|Yoshioka Clinic /ID# 152305, Iwaki, Japan|Nishimi Medical Clinic /ID# 161752, Iwakuni, Japan|Kayanoki Internal Medicine Cli /ID# 152235, Izumiotsu, Japan|Juntendo Univ Shizuoka Hosp /ID# 153615, Izunokuni-shi, Japan|Kawabata Internal Medicine Gas /ID# 153629, Joetsu-niigata, Japan|Mitoyo General Hospital /ID# 152185, Kagawa, Japan|Konan Kakogawa Hospital /ID# 158102, Kakogawa, Japan|Yoshii Internal Medicine /ID# 158067, Kaminoyama, Japan|Kiyokawa Hospital /ID# 152156, Kanagawa, Japan|Nagase Medical Clinic /ID# 157498, Kanagawa, Japan|Hiratsuka City Hospital /ID# 154730, Kanagawa, Japan|Niwa Hospital /ID# 154762, Kanagawa, Japan|Fuji Clinic /ID# 152968, Kanonji, Japan|The Jikei Univ. Kashiwa Hosp. /ID# 152281, Kashiwa-shi, Japan|Fujise Internal Medicine Clini /ID# 155886, Kashiwa, Japan|Fukuoka Tokushukai Medical Ctr /ID# 154654, Kasuga-shi, Japan|Kawase Clinic /ID# 152969, Kasugai, Japan|Sakamoto Internal Med Clinic /ID# 161745, Katori, Japan|Sekishindo Hospital /ID# 154653, Kawagoe, Japan|Saiseikai Kawaguchi Gen. Hosp. /ID# 153631, Kawaguchi-saitama, Japan|Kanto Rosai Hospital /ID# 152202, Kawasaki-shi, Kanagawa, Japan|Kawasaki Municipal Tama Hospit /ID# 152132, Kawasaki, Japan|St. Marianna Univ Hospital /ID# 152218, Kawasaki, Japan|Nakano Clinic /ID# 165262, Kazuno, Japan|Kirishima Medical Center /ID# 152095, Kirishima, Japan|Kojima Clinic /ID# 152285, Kiryu, Japan|Kimitsu Chuo Hospital /ID# 152995, Kisarazu, Japan|Kawazoe Internal Medicine Clin /ID# 154789, Kishima-gun, Japan|Kishiwada Tokushukai Hospital /ID# 165260, Kishiwada, Osaka, Japan|JR Kyushu Hospital /ID# 152074, Kitakyushu, Japan|Kokura Kinen Hospital /ID# 152997, Kitakyusyu, Japan|Iwamoto Internal Medical Clini /ID# 152994, Kitakyusyu, Japan|Kitasato University Medical Ce /ID# 150053, Kitamoto, Japan|Kobe City Medical Center West /ID# 152304, Kobe, Japan|Kobe City Medical Center West /ID# 153005, Kobe, Japan|Kobe Asahi Hospital /ID# 152173, Kobe, Japan|Kochi Red Cross Hospital /ID# 159450, Kochi, Japan|Hosoda Clinic /ID# 152978, Kofu, Japan|Cosmos Clinic /ID# 152298, Koriyama, Japan|Ishida Medical Clinic /ID# 152297, Koriyama, Japan|Hanada Internal Medicine Clin /ID# 155785, Koshigaya, Saitam, Japan|National Hosp Org Kumamoto /ID# 154783, Kumamoto, Japan|Seto Hospital /ID# 150056, Kumamoto, Japan|Kawasaki Medical School Hosp /ID# 152119, Kurashiki, Japan|Kurashiki Central Hospital /ID# 154656, Kurashiki, Japan|Mizushima Kyodo Hospital /ID# 152302, Kurashiki, Japan|Fukura Clinic /ID# 165273, Kurayoshi, Japan|National Hosp Org Kure Med Cen /ID# 152071, Kure, Hiroshima, Japan|Kurihara Central Hospital /ID# 152295, Kurihara, Japan|Kuroishi Hospital /ID# 153636, Kuroishi-aomori, Japan|Hori Internal Medicine Clinic /ID# 152291, Kushiro, Japan|Kyoto City Hospital /ID# 152188, Kyoto, Japan|Nakajima Clinic /ID# 157480, Kyoto, Japan|Aiseikai Yamashina Hospital /ID# 152100, Kyoto, Japan|Sawa Clinic /ID# 162881, Kyoto, Japan|NHO Kyoto Medical Center /ID# 152224, Kyoto, Japan|Otokoyama Hospital /ID# 153017, Kyoto, Japan|Kagawa University Hospital /ID# 154731, Kyoto, Japan|Machida Municipal Hospital /ID# 152184, Machida, Japan|Maebashi Red Cross Hospital /ID# 154707, Maebashi-shi, Japan|Kagawa Rosai Hospital /ID# 152131, Marugame, Japan|Kono Naika clinic /ID# 152094, Marugame, Japan|Masuda Red Cross Hospital /ID# 153635, Masuda-shimane, Japan|Shinmatsudo Central General Ho /ID# 154668, Matsudo, Japan|Matsudo City Hospital /ID# 154666, Matsudo, Japan|Matsudo City Hospital /ID# 154764, Matsudo, Japan|Gibo Hepatorogy Clinic /ID# 154763, Matsumoto, Japan|Ehime Prefectural Central Hosp /ID# 154675, Matsuyama, Japan|Saiseikai Matsuyama Hospital /ID# 152270, Matsuyama, Japan|Tajiri Hospital /ID# 152320, Mimasaka, Japan|Kizawa Memorial Hospital /ID# 152096, Minokamo, Japan|Sumiyoshi Clinic Hospital /ID# 152093, Mito, Japan|Miyakonojo National Hospital /ID# 153007, Miyakonojo, Japan|Miyazaki Medical Center Hospit /ID# 152154, Miyazaki, Japan|Hepatopia Nishikohdai-naika /ID# 154788, Miyazaki, Japan|Haga Red Cross Hospital /ID# 152085, Mooka, Tochigi, Japan|Matsushita Memorial Hospital /ID# 154655, Moriguchi-shi, Japan|MC Ryokumeikai Yoshida Clinic /ID# 150055, Morioka, Japan|Abe Saien Clinic /ID# 153014, Morioka, Japan|Nagano Prefectural Kiso Hospit /ID# 152276, Nagano, Japan|Kimura Clinic /ID# 152146, Nagano, Japan|Tachikawa Medical Center /ID# 154784, Nagaoka, Japan|Jap Red Cross Nagasaki Genbaku /ID# 152300, Nagasaki-shi, Japan|Jap Red Cross Nagasaki Genbaku /ID# 152303, Nagasaki-shi, Japan|Japanese Red Cross Nagoya Daii /ID# 158099, Nagoya-shi, Japan|NHO Nagoya Medical Center /ID# 152294, Nagoya, Japan|Kita Hospital /ID# 158065, Nagoya, Japan|Nakatsu Municipal Hospital /ID# 154673, Nakatsu, Japan|Kouseiren Namerikawa Hospital /ID# 154706, Namerikawa, Japan|Nara City Hospital /ID# 152189, Nara, Japan|Miyagiwa Internal Med Clinic /ID# 155887, Nara, Japan|Nara Prefectural Hospital /ID# 152234, Nara, Japan|Tani Internal Medicine Clinic /ID# 157448, Nayoro, Japan|Meiwa Hospital /ID# 152134, Nishinomiya, Hyogo, Japan|Kameda Clinic /ID# 162879, Nishinomiya, Japan|Rinko Clinic /ID# 159449, Nishinomiya, Japan|Ooka Clinic /ID# 162880, Nishinomiya, Japan|Noshiro Yamamoto Med. Assoc. /ID# 154785, Noshiro, Japan|Obihiro Dai-ichi Hospital /ID# 152238, Obihiro, Japan|Odawara Municipal Hospital /ID# 154761, Odawara, Japan|Eguchi Hospital /ID# 152292, OGI, Japan|Tokai University Oiso Hospital /ID# 157456, Oiso-machi, Japan|Oita Red Cross Hospital /ID# 152289, Oita, Japan|Oita Midical Center /ID# 154737, Oita, Japan|Oita Prefectural Hospital /ID# 165261, Oita, Japan|Mori Internal Medicine Clinic /ID# 157446, Oita, Japan|Aso Shoukaki-naika /ID# 164142, Oita, Japan|Okayama Saiseikai Outpatient Center Hospital /ID# 150057, Okayama, Japan|Kawaguchi Internal Medicine Cl /ID# 152301, Okayama, Japan|Heartlife Hospital /ID# 153619, Okinawa, Japan|Ome Municipal General Hospital /ID# 153653, OME, Japan|Omuta City Hospital /ID# 152222, Omuta, Japan|Nishimura Clinic /ID# 154790, Omuta, Japan|Onomichi Central General Hospi /ID# 152150, Onomichi, Japan|Kita-harima Medical Center /ID# 153003, ONO, Japan|Tazuke Kofukai Foundation /ID# 152182, Osaka-shi, Japan|Gokeikai Osaka Kaisei Hospital /ID# 153644, Osaka-shi, Japan|Osaka Gen Hosp West Railway /ID# 155962, Osaka-shi, Japan|Otemae Hospital /ID# 152987, Osaka, Japan|Center Clinic /ID# 161746, Osaka, Japan|Osaka Police Hospital /ID# 154781, Osaka, Japan|NTT WEST Osaka Hospital /ID# 157445, Osaka, Japan|Mori Clinic /ID# 157489, Osaka, Japan|Kansai Denryoku Hospital /ID# 155966, Osaka, Japan|Tamai Clinic /ID# 164951, Osaka, Japan|Osaka General Medical Center /ID# 160907, Osaka, Japan|Kansai Medical Univ Takii Hosp /ID# 152130, Osaka, Japan|Osaka Hospital /ID# 152168, Osaka, Japan|Asai Orthopedic /ID# 153015, Osaka, Japan|Nasu Red Cross Hospital /ID# 152972, Otawara, Japan|Otsu City Hospital /ID# 152155, Otsu, Japan|Japanese Red Cross Otsu Shiga /ID# 153640, Otsu, Japan|Ryugasaki Saiseikai Hospital /ID# 153639, Ryugasaki, Japan|Saga Medical Center Koseikan /ID# 152989, Saga-shi, SAGA, Japan|Japanese Red Cross Sagamihara /ID# 153000, Sagamihara, Japan|Fuchinobe General Hospital /ID# 152996, Sagamihara, Japan|Sagamino Hospital /ID# 154676, Sagamihara, Japan|Nakayama Medical Clinic /ID# 157481, Saga, Japan|Imari Arita Kyoritsu Hospital /ID# 152321, Saga, Japan|Saitama Citizens Medical Ctr /ID# 162882, Saitama, Japan|Honda Internal Clinic /ID# 157497, Saitama, Japan|Osaka Rosai Hospital /ID# 152286, Sakai-shi, Japan|Bellland General Hospital /ID# 152148, Sakai, Japan|Nihonkai General Hospital /ID# 152973, Sakata-shi, Japan|Takayanagi Clinic /ID# 152975, Sakura, Japan|Hyogo-Chuo National Hospital /ID# 157441, Sanda, Japan|Sapporo Hokuyu Hospital /ID# 154709, Sapporo-shi, Japan|Hokkaido University Hospital /ID# 152982, Sapporo, Japan|IMS Sapporo Digestive Disease /ID# 154733, Sapporo, Japan|Sasebo Chuo Hospital /ID# 154657, Sasebo, Japan|JR Sendai Hospital /ID# 152240, Sendai-shi, Japan|Sendai Kousei Hospital /ID# 152181, Sendai, Japan|Sendai Red Cross Hospital /ID# 160908, Sendai, Japan|Shinmen Internal Medicine Clin /ID# 152172, Sennan, Japan|Tosei General Hospital /ID# 154710, Seto, Japan|NHO Shizuoka Medical Center /ID# 155897, Shimizu-sho, Japan|Shimonoseki Medical Center /ID# 165263, Shimonoseki, Japan|Dokkyo Medical University Hosp /ID# 152153, Shimotsuga, Japan|Dokkyo Medical University Hosp /ID# 153656, Shimotsuga, Japan|Anzunomori Clinic /ID# 157491, Shimotsuke, Japan|Saka General Hospital /ID# 153637, Shiogama-miyagi, Japan|Shobara Red Cross Hospital /ID# 156385, Shobara, Japan|Suita Municipal Hospital /ID# 153634, Suita-osaka, Japan|Saiseikai Suita Hospital /ID# 152171, Suita, Japan|Konishi Medical Clinic /ID# 162886, Suzuka, Japan|Tachikawa Hospital /ID# 157458, Tachikawa, Japan|Gifu Prefectural Tajimi Hosp /ID# 152187, Tajimi, Japan|Takamatsu Red Cross Hospital /ID# 154711, Takamatsu, Japan|Kagawa Prefectural Central Hos /ID# 152293, Takamatsu, Japan|Sawada Hepatology & Gastro /ID# 157490, Takaraduka, Japan|Harano Internal Medicine Clini /ID# 154787, Takarazuka, Japan|Takarazuka City Hospital /ID# 152267, Takarazuka, Japan|Tenjin Tanaka Internal Medicin /ID# 162883, Takatsuki, Japan|Hamada Clinic /ID# 152142, Tatebayashi, Japan|Eastern Chiba Medical Center /ID# 155786, Togane, Chiba, Japan|Toki General Hospital /ID# 148821, Toki, Japan|Okubo Hospital /ID# 161751, Tokushima, Japan|Nihon University Hospital /ID# 159453, Tokyo, Japan|Mitsui Memorial Hospital /ID# 155891, Tokyo, Japan|The Jikei University Hospital /ID# 154671, Tokyo, Japan|Tokyo Takanawa Hospital /ID# 152133, Tokyo, Japan|kyo-wa Clinic /ID# 162884, Tokyo, Japan|The University of Tokyo Hospital /ID# 158069, Tokyo, Japan|Juntendo University Hospital /ID# 153555, Tokyo, Japan|Nippon Medical School Hospital /ID# 155787, Tokyo, Japan|Tobu Chiiki Hospital /ID# 155968, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hos /ID# 152977, Tokyo, Japan|Tokyo Rinkai Hospital /ID# 152984, Tokyo, Japan|Shibata Hepatology Clinic /ID# 152141, Tokyo, Japan|Toshiba General Hospital /ID# 152161, Tokyo, Japan|Hojo Clinic /ID# 165271, Tokyo, Japan|Toho Univ Med Ctr Omori Hosp /ID# 153620, Tokyo, Japan|Ebara Hospital /ID# 154650, Tokyo, Japan|Mishuku Hospital /ID# 152136, Tokyo, Japan|Tokyo Yamate Medical Center /ID# 152284, Tokyo, Japan|Sato Gastro Med Clinic /ID# 154791, Tokyo, Japan|Tokyo Metropolitan Geriatric /ID# 153011, Tokyo, Japan|Juntendo Univ Nerima Hosp /ID# 152282, Tokyo, Japan|JP Red Cross Musashino Hosp /ID# 150052, Tokyo, Japan|NHO Tokyo Hospital /ID# 164132, Tokyo, Japan|Tonami General Hospital /ID# 152214, Tonami, Japan|Ehime University Hospital /ID# 152273, Toon, Japan|Matsuda Internal Medicine Clin /ID# 152152, Tottori, Japan|Toyama Prefectural Ctr Hosp /ID# 152102, Toyama, Japan|Fujita Health University Hosp /ID# 156384, Toyoake, Japan|Toyohashi Municipal Hospital /ID# 153012, Toyohashi, Japan|Toyonaka Municipal Hospital /ID# 152299, Toyonaka, Japan|Mie Syokaki Clinic /ID# 158068, Tsu, Mie, Japan|University of Tsukuba Hospital /ID# 155784, Tsukuba-shi, Japan|Sugiyama Clinic /ID# 161750, Tsukuba, Japan|Tsuyama Chuo Hospital /ID# 154736, Tsuyama, Japan|Shizu Clinic /ID# 154766, Tsuyama, Japan|Yamaguchi University Hospital /ID# 153553, UBE, Japan|Shinshu Ueda Medical Center /ID# 153556, Ueda, Japan|Okinawa Prefectural Chubu Hosp /ID# 153006, Uruma, Japan|Sato Daiichi Hospital /ID# 154734, USA, Japan|Saiseikai Utsunomiya Hospital /ID# 152974, Utsunomiya, Japan|Shinozaki Medical Clinic /ID# 159454, Utsunomiya, Japan|Seike Clinic /ID# 154765, Uwajima, Japan|Wakayama Rosai Hospital /ID# 154732, Wakayama-shi, Japan|Saiseikai Wakayama Hospital /ID# 153654, Wakayama, Japan|Wakayama Medical University /ID# 155969, Wakayama, Japan|NHO Saitama National Hospital /ID# 153013, Wako, Japan|Gihoku Kosei Hospital /ID# 152158, Yamagata-shi, Japan|Tohoku Central Hospital /ID# 152101, Yamagata, Japan|Gondo Medical Clinic /ID# 164952, Yame, Japan|Ishinkai Yao General Hospital /ID# 152983, YAO, Japan|Ushiroya Clinic /ID# 157443, Yashio, Japan|Kainan Hospital /ID# 154712, Yatomi-shi, Japan|Mie Prefectural General Medica /ID# 157442, Yokkaichi, Japan|Showa Univ Fujigaoka Hosp /ID# 153655, Yokohama-shi, Japan|Yokohama Rosai Hospital /ID# 154713, Yokohama, Japan|Hayashi Clinic /ID# 152143, Yokohama, Japan|Oka Medical Clinic /ID# 154708, Yokohama, Japan|Shirato Clinic /ID# 154782, Yokohama, Japan|National Hosp Org Yokohama /ID# 159452, Yokohama, Japan|Yamauchi Internal Medicine Cli /ID# 154792, Yokosuka, Japan|Yamauchi Internal Medicine Cli /ID# 154793, Yokosuka, Japan|Josai Hospital /ID# 153009, Yuki, Japan",,"https://ClinicalTrials.gov/show/NCT02629172"
250,"NCT02629159","A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","SELECT-COMPARE","Active, not recruiting","Has Results","Rheumatoid Arthritis","Drug: Placebo for Adalimumab|Drug: Adalimumab|Drug: Placebo for Upadacitinib|Drug: Upadacitinib","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12|Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12|Change From Baseline in DAS28 (CRP) at Week 12|Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12|Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12|Change From Baseline in Short-Form 36 (SF-36) Physical Component Score (PCS) at Week 12|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12|Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12|Change From Baseline in Duration of Morning Stiffness at Week 12|Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)|Change From Baseline in Patient's Assessment of Pain at Week 12|Percentage of Participants With No Radiographic Progression at Week 26|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","1629","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-465|2015-003333-95","December 1, 2015","October 27, 2017","May 20, 2022","December 14, 2015","October 7, 2019","January 10, 2020","Achieve Clinical Research, LLC /ID# 143136, Birmingham, Alabama, United States|AZ Arthritis and Rheum Assoc /ID# 143130, Mesa, Arizona, United States|SunValley Arthritis Center, Lt /ID# 143123, Peoria, Arizona, United States|Elite Clinical Studies, LLC /ID# 144881, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 143080, Phoenix, Arizona, United States|AZ Arthritis and Rheum Researc /ID# 143121, Phoenix, Arizona, United States|AZ Arthritis & Rheuma Research /ID# 143131, Phoenix, Arizona, United States|Arizona Research Center, Inc. /ID# 144877, Phoenix, Arizona, United States|AZ Arthritis & Rheum Research /ID# 156093, Sun City, Arizona, United States|University of Arizona Cancer Center - North Campus /ID# 143114, Tucson, Arizona, United States|Osteoporosis Medical Center /ID# 153935, Beverly Hills, California, United States|T. Joseph Raoof, MD, Inc. /ID# 144884, Encino, California, United States|Rheumatology Ctr of San Diego /ID# 153747, Escondido, California, United States|C.V. Mehta MD, Med Corporation /ID# 143116, Hemet, California, United States|Allergy and Rheum Med Clin /ID# 146083, La Jolla, California, United States|Kotha and Kotha /ID# 161046, La Mesa, California, United States|TriWest Research Associates- La Mesa /ID# 143115, La Mesa, California, United States|Valerius Med Grp & Res Ctr /ID# 143120, Los Alamitos, California, United States|Discovery MM Services, Inc /ID# 163504, Los Angeles, California, United States|Desert Medical Advances /ID# 143097, Palm Desert, California, United States|Sierra Rheumatology /ID# 155672, Roseville, California, United States|Robin K. Dore MD, Inc /ID# 143090, Tustin, California, United States|Medvin Clinical Research /ID# 148362, Whittier, California, United States|Arthritis Assoc & Osteo Ctr /ID# 143122, Colorado Springs, Colorado, United States|Arthritis and Rheum Clin N. CO /ID# 156094, Fort Collins, Colorado, United States|AARDS Research, Inc. /ID# 154190, Aventura, Florida, United States|ZASA Clinical Research /ID# 143134, Boynton Beach, Florida, United States|Clinical Res of West FL, Inc. /ID# 143112, Clearwater, Florida, United States|International Medical Research /ID# 143132, Daytona Beach, Florida, United States|Precision Research Org, LLC /ID# 143092, Miami Lakes, Florida, United States|Lakes Research, LLC /ID# 145630, Miami, Florida, United States|FL Med Ctr and Research, Inc. /ID# 143081, Miami, Florida, United States|Ctr Arthritis & Rheumatic Dise /ID# 143135, Miami, Florida, United States|Advanced Clin Res of Orlando /ID# 154617, Ocoee, Florida, United States|Rheum Assoc of Central FL /ID# 145632, Orlando, Florida, United States|Omega Research Consultants /ID# 145635, Orlando, Florida, United States|HMD Research LLC /ID# 163292, Orlando, Florida, United States|Arthritis Research of Florida /ID# 143125, Palm Harbor, Florida, United States|Arthritis Center, Inc. /ID# 145647, Palm Harbor, Florida, United States|St. Anthony Comprehsve Res Ins /ID# 143095, Saint Petersburg, Florida, United States|Clinical Research West FL /ID# 148358, Tampa, Florida, United States|SW FL Clin Res Ctr, Tampa, FL /ID# 143117, Tampa, Florida, United States|BayCare Medical Group, Inc. /ID# 143085, Tampa, Florida, United States|Lovelace Scientific Resources /ID# 143106, Venice, Florida, United States|Arthritis and Rheumatology /ID# 155668, Atlanta, Georgia, United States|Arthritis Center of North GA /ID# 155258, Gainesville, Georgia, United States|North Georgia Rheumatology Grp /ID# 147170, Lawrenceville, Georgia, United States|Advanced Clinical Research /ID# 153090, Meridian, Idaho, United States|Great Lakes Clinical Trials /ID# 148357, Chicago, Illinois, United States|Arthritis Treatment Center /ID# 155260, Frederick, Maryland, United States|The Center for Rheumatology & /ID# 151356, Wheaton, Maryland, United States|Clinical Pharmacology Study Gr /ID# 143082, Worcester, Massachusetts, United States|Advanced Rheumatology, PC /ID# 143118, Lansing, Michigan, United States|Shores Rheumatology, PC /ID# 162977, Saint Clair Shores, Michigan, United States|St. Luke's Hospital /ID# 156750, Duluth, Minnesota, United States|North Mississippi Med Clinics /ID# 145636, Tupelo, Mississippi, United States|Physician Res. Collaboration /ID# 143087, Lincoln, Nebraska, United States|Quality Clinical Research Inc. /ID# 156394, Omaha, Nebraska, United States|Atlantic Coast Research /ID# 148355, Toms River, New Jersey, United States|Ocean Rheumatology, PA /ID# 143111, Toms River, New Jersey, United States|Arthritis Rheumatic Back Disorder /ID# 143102, Voorhees, New Jersey, United States|Albuquerque Clinical Trials, Inc /ID# 143083, Albuquerque, New Mexico, United States|Arthritis and Osteo Assoc /ID# 143127, Las Cruces, New Mexico, United States|St. Lawrence Health System /ID# 161619, Potsdam, New York, United States|Joint & Muscle Research Instit /ID# 143119, Charlotte, North Carolina, United States|DJL Clinical Research, PLLC /ID# 143101, Charlotte, North Carolina, United States|EmergeOrtho, P.A. /ID# 143100, Durham, North Carolina, United States|Cape Fear Arthritis Care /ID# 148361, Leland, North Carolina, United States|Coastal Carolina Health Care /ID# 148359, New Bern, North Carolina, United States|Shanahan Rheuma & Immuno /ID# 145643, Raleigh, North Carolina, United States|Clinical Research Solutions, LLC /ID# 154619, Dayton, Ohio, United States|Arthritis Assoc of NW Ohio /ID# 143094, Toledo, Ohio, United States|Healthcare Research Consultant /ID# 143129, Tulsa, Oklahoma, United States|Altoona Ctr Clinical Res /ID# 143110, Duncansville, Pennsylvania, United States|Clinical Research Ctr Reading /ID# 143133, Wyomissing, Pennsylvania, United States|Columbia Arthritis Center /ID# 153730, Columbia, South Carolina, United States|Innovative Clinical Research /ID# 145637, Greenville, South Carolina, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 143091, Summerville, South Carolina, United States|Arthritis Associates, PLLC /ID# 155490, Kingsport, Tennessee, United States|Rheumatology Consultants, PLLC /ID# 153731, Knoxville, Tennessee, United States|Dr. Ramesh Gupta /ID# 143099, Memphis, Tennessee, United States|Austin Regional Clinic /ID# 143084, Austin, Texas, United States|Diagnostic Group Integrated He /ID# 148356, Beaumont, Texas, United States|Arthritis Care and Diagnostic /ID# 150677, Dallas, Texas, United States|Metroplex Clinical Research /ID# 145631, Dallas, Texas, United States|Doctor's Hosp at Renaissance /ID# 154616, Edinburg, Texas, United States|MedResearch Inc. /ID# 154618, El Paso, Texas, United States|Accurate Clinical Management /ID# 145644, Houston, Texas, United States|Accurate Clinical Research /ID# 145645, Houston, Texas, United States|Rheumatology Clinic of Houston /ID# 150921, Houston, Texas, United States|Houston Institute for Clin Res /ID# 144879, Houston, Texas, United States|Pioneer Research Solutions, Inc. /ID# 145640, Houston, Texas, United States|Arthritis Consultants, P.A. /ID# 144880, Killeen, Texas, United States|Arthritis & Osteoporosis Assoc /ID# 147364, Lubbock, Texas, United States|P&I Clinical Research /ID# 161625, Lufkin, Texas, United States|SW Rheumatology Res. LLC /ID# 143126, Mesquite, Texas, United States|Discovery MM Services, Inc. /ID# 162578, Missouri City, Texas, United States|Discovery MM Services, Inc. /ID# 163183, Missouri City, Texas, United States|Discovery MM Services, Inc. /ID# 163184, Missouri City, Texas, United States|Sun Research Institute /ID# 159539, San Antonio, Texas, United States|Accurate Clinical Management /ID# 143089, San Antonio, Texas, United States|Arthritis & Osteo Ctr of S. TX /ID# 143103, San Antonio, Texas, United States|DM Clinical Research /ID# 151357, Tomball, Texas, United States|Arthritis Clinic of N. VA, P.C /ID# 143109, Arlington, Virginia, United States|Ctr for Arth and Rheum Disease /ID# 143113, Chesapeake, Virginia, United States|Arthritis Northwest, PLLC /ID# 143088, Spokane, Washington, United States|The Vancouver Clinic, INC. PS /ID# 143107, Vancouver, Washington, United States|West Virginia Research Inst /ID# 153088, South Charleston, West Virginia, United States|Rheumatology and Immunotherapy Center /ID# 145646, Franklin, Wisconsin, United States|Aprillus Asistencia e Investig /ID# 148406, Capital Federal, Buenos Aires, Argentina|Mautalen Salud e Investigacion /ID# 142843, Buenos Aires, Argentina|Fundacion Sanatorio Guemes /ID# 148405, Buenos Aires, Argentina|Consultorio Reumatologic Pampa /ID# 144853, Buenos Aires, Argentina|Cemic /Id# 148404, Buenos Aires, Argentina|Org Medica de Investigacion /ID# 144855, Buenos Aires, Argentina|Inst. Rheumatologic Strusberg /ID# 145601, Cordoba, Argentina|Consultora Integral de Salud S /ID# 144856, Cordoba, Argentina|Instituto CAICI /ID# 144854, Rosario, Santa FE, Argentina|Cordis S.A. /Id# 152622, Salta, Argentina|Iari /Id# 151293, San Fernando, Argentina|Centro Integral de Reumatologi /ID# 142845, San Miguel de Tucuman, Argentina|Centro Medico Privado/Reuma /ID# 142842, San Miguel de Tucuman, Argentina|Centro de Enfermedades /ID# 153542, Santa Fe, Argentina|Royal Prince Alfred Hospital /ID# 144857, Camperdown, New South Wales, Australia|Emeritus Research /ID# 142848, Camberwell, Victoria, Australia|LKH-Univ. Klinikum Graz /ID# 142851, Graz, Austria|First City Clinical Hospital /ID# 158011, Minsk, Belarus|Cliniques Universitaires Saint Luc /ID# 142858, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Rhumaconsult SPRL /ID# 142860, Charleroi, Hainaut, Belgium|CHU de Liege /ID# 148401, Liège, Liege, Belgium|UZ Gent /ID# 142859, Gent, Oost-Vlaanderen, Belgium|CHU Ambroise Pare /ID# 152953, Mons, Belgium|University Clinical Centre of the Republic of Srpska /ID# 142862, Banja Luka, Republika Srpska, Bosnia and Herzegovina|University Clinical Centre of the Republic of Srpska /ID# 142863, Banja Luka, Republika Srpska, Bosnia and Herzegovina|Clinical Center University of Sarajevo /ID# 142865, Sarajevo, Bosnia and Herzegovina|CIP - Centro Internacional de Pesquisa /ID# 142872, Goiânia, Goias, Brazil|Hc Ufmg /Id# 142868, Belo Horizonte, Minas Gerais, Brazil|Ceti - Centro de Estudos Em Terapias Inovadoras Ltda /Id# 142871, Curitiba, Parana, Brazil|Hospital de Clinicas de Porto Alegre /ID# 142870, Porto Alegre, Rio Grande Do Sul, Brazil|LMK Sevicos Medicos S/S /ID# 142869, Porto Alegre, Rio Grande Do Sul, Brazil|CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos Ltda /ID# 142867, São Paulo, Sao Paulo, Brazil|CCBR Brasil /ID# 150918, Rio de Janeiro, Brazil|MHAT Trimontsium /ID# 142874, Plovdiv, Bulgaria|UMHAT Pulmed OOD /ID# 142877, Plovdiv, Bulgaria|MHAT Kaspela /ID# 142873, Plovdiv, Bulgaria|Diagnostic Consultative Center /ID# 142875, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 142876, Sofia, Bulgaria|Manitoba Clinic /ID# 161434, Winnipeg, Manitoba, Canada|Ciads /Id# 142880, Winnipeg, Manitoba, Canada|St. Clare's Mercy Hospital /ID# 142879, St. John's, Newfoundland and Labrador, Canada|Adachi Medicine Prof. Corp /ID# 154205, Hamilton, Ontario, Canada|CA Ctr for Clin Trials CCCT /ID# 157379, Thornhill, Ontario, Canada|Groupe de Recherche en Maladies Osseuses /ID# 142878, Sainte-foy, Quebec, Canada|Ctr de Inv Clinica del Sur /ID# 142888, Temuco, Araucania, Chile|Reg. Clinical Hosptial Concepcion /ID# 151271, Concepcion, Chile|Corp de Beneficencia Osorno /ID# 147941, Osorno, Chile|Someal /Id# 144704, Providencia-santiago, Chile|Quantum Research LTDA. /ID# 142893, Puerto Varas, Chile|Quantum Research Stgo. /ID# 157933, Santiago, Chile|Soc. de Prestaciones medicas y Paramedicas Goecke /ID# 142890, Santiago, Chile|Clinica DermaCross /ID# 142892, Santiago, Chile|Investigaciones Medicas SSMSO /ID# 151686, Santiago, Chile|Centro Inter Estud Clin CIEC /ID# 144777, Santiago, Chile|Centro Medico de Reumatologia /ID# 148402, Temuco, Chile|Cinvec /Id# 144705, Vina Del Mar, Chile|Centro de Investigacion en Reumatologia y Especialidades Medicas- CIREEM SAS /ID# 142898, Bogota, Cundinamarca, Colombia|Ctr Int de Reum del Caribe SAS /ID# 142894, Barranquilla, Colombia|Fund Inst de Reum F. Chalem /ID# 149847, Bogota DC, Colombia|Riesgo de Fractura S.A - CAYRE /ID# 142896, Bogota, Colombia|Medicity S.A.S. /ID# 144860, Bucaramanga, Colombia|Centro Integral de Reumatologi /ID# 142897, Medellín, Colombia|Klinicki bolnicki centar Rijeka /ID# 160232, Rijeka, Primorsko-goranska Zupanija, Croatia|Klinicki bolnicki centar Split /ID# 152530, Split, Croatia|Clinical Hospital Dubrava /ID# 142900, Zagreb, Croatia|Medical Center Kuna-Peric /ID# 142901, Zagreb, Croatia|Poliklinika Bonifarm /ID# 142899, Zagreb, Croatia|L.K.N. Arthrocentrum, s.r.o /ID# 145961, Hlučín, Moravskoslezsky Kraj, Czechia|CTCenter MaVe, s.r.o. /ID# 142905, Olomouc, Olomoucky Kraj, Czechia|Revmatologicky ustav Praha /ID# 142904, Prague 2, Praha 2, Czechia|Nuselská poliklinika, Revmatologie /ID# 144862, Prague 4, Praha 4, Czechia|Revmatologická ambulance /ID# 145963, Prague 4, Praha 4, Czechia|Thomayerova nemocnice /ID# 145962, Prague 4, Praha 4, Czechia|REVMACLINIC s.r.o. /ID# 142906, Brno, Czechia|Revmatologie Bruntal, s.r.o /ID# 142903, Bruntál, Czechia|Revmatologicka a interni ambul /ID# 142907, Kladno, Czechia|Revmatologie MUDr. Klara Sirov /ID# 142908, Ostrava, Czechia|Arthromed, s.r.o. /ID# 144706, Pardubice, Czechia|Aarhus University Hospital /ID# 158838, Aarhus N, Midtjylland, Denmark|Regionhospital Silkeborg /ID# 142914, Silkeborg, Denmark|Center of Clinical and Basic Research /ID# 142922, Tallinn, Harjumaa, Estonia|MediTrials /ID# 151870, Tartu, Tartumaa, Estonia|Paernu Hospital /ID# 142921, Pärnu, Estonia|East Tallinn Central Hospital /ID# 142923, Tallinn, Estonia|North Estonian Medical Centre /ID# 145454, Tallinn, Estonia|Hopital Universitaire Purpan /ID# 144707, Toulouse, Haute-Garonne, France|CHRU Lille - Hôpital Claude Huriez /ID# 151312, Lille CEDEX, Hauts-de-France, France|Hopital Saint Eloi /ID# 142925, Montpellier CEDEX 5, Herault, France|CHU Bordeaux-Hopital Pellegrin /ID# 145618, Bordeaux, France|Hopital de la Cote de Nacre /ID# 145616, Caen, France|CHU Gabriel Montpied /ID# 145619, Clermont Ferrand, France|Hopital de la Conception /ID# 142926, Marseille, France|Hopital Pitie Salpetriere /ID# 145605, Paris, France|CHU de Rennes - Hospital Sud /ID# 151957, Rennes, France|CHU Strasbourg Hautepierre Hos /ID# 144708, Strasbourg, France|Rheumazentrum Ruhrgebiet /ID# 145620, Herne, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 145964, Köln, Nordrhein-Westfalen, Germany|Praxis Walter, Rendsburg /ID# 142932, Rendsburg, Schleswig-Holstein, Germany|Med Versorgungszentrum AGILOME /ID# 154975, Chemnitz, Germany|Rheumaforschungszentrum II /ID# 142930, Hamburg, Germany|LMU Klinikum der Universität München /ID# 142931, Munich, Germany|General Hospital of Athens Laiko /ID# 142934, Athens, Attiki, Greece|University General Hospital Attikon /ID# 142933, Athens, Attiki, Greece|General Hospital of Athens Ippokratio /ID# 142935, Athens, Greece|Queen Mary Hospital /ID# 142938, Hong Kong, Hong Kong|Tuen Mun Hospital /ID# 142939, Tuen Mun, Hong Kong|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 142951, Miskolc, Borsod-Abauj-Zemplen, Hungary|Qualiclinic Kft. /ID# 142953, Budapest III, Pest, Hungary|Markusovszky Egyetemi Oktatókórház /ID# 145621, Szombathely, Vas, Hungary|Vital Medical Center Orvosi es /ID# 145950, Veszprém, Veszprem, Hungary|Budai Irgalmasrendi Korhaz /ID# 142952, Budapest, Hungary|Revita Reumatologiai Rendelo /ID# 142950, Budapest, Hungary|Synexus Magyarorszag Kft. /ID# 153061, Budapest, Hungary|Debreceni Egyetem Kenezy Gyula Egyetemi Korhaz /ID# 142948, Debrecen, Hungary|Hevizgyogyfurdo es Szent Andra /ID# 142949, Heviz, Hungary|Kiskunhalasi Semmelweis Korhaz /ID# 151944, Kiskunhalas, Hungary|Pest Megyei Flor Ferenc Korhaz /ID# 142954, Kistarcsa, Hungary|St Vincent's University Hosp /ID# 142957, Dublin, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 144709, Tel Aviv-Yafo, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 152050, Haifa, Israel|Bnai Zion Medical Center /ID# 151958, Haifa, Israel|The Lady Davis Carmel MC /ID# 142960, Haifa, Israel|Sheba Medical Center /ID# 145965, Ramat Gan, Israel|Istituto Clinico Humanitas /ID# 147528, Rozzano, Milano, Italy|AOU Citta della Salute Scienza /ID# 150070, Turin, Piemonte, Italy|Azienda Ospedaliera Luigi Sacc /ID# 142966, Milan, Italy|A.O.U.I. di Verona Policlinico /ID# 142963, Verona, Italy|JSC Nat Scientific Med Res Ctr /ID# 142971, Astana, Kazakhstan|Karaganda State Medical Univ /ID# 153433, Karaganda, Kazakhstan|Semey State Medical University /ID# 152659, Semey, Kazakhstan|Regional Clinical Hospital /ID# 147168, Shymkent, Kazakhstan|Kyungpook National Univ Hosp /ID# 162073, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Chungnam National University Hospital /ID# 142977, Jung-gu, Daejeon Gwang Yeogsi, Korea, Republic of|Inha University Hospital /ID# 150886, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 142975, Gwangju, Jeonranamdo, Korea, Republic of|Hanyang University Seoul Hospi /ID# 142979, Seongdong-gu, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 142976, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Daegu Catholic University Med /ID# 142973, Daegu, Korea, Republic of|Seoul National University Hospital /ID# 142978, Seoul, Korea, Republic of|Asan Medical Center /ID# 142974, Seoul, Korea, Republic of|LTD M+M Centers /ID# 142984, Adazi, Latvia|Daugavpils Regional Hospital /ID# 142982, Daugavpils, Latvia|D.Saulites-Kandevicas PP /ID# 142985, Liepaja, Latvia|Clinic ORTO /ID# 142983, Riga, Latvia|Riga East Clinical Univ Hosp /ID# 142981, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 142986, Kovno, Kaunas, Lithuania|Vilnius University Hospital /ID# 142987, Vilnius, Lithuania|Hospital Raja Perempuan Zainab II /ID# 157862, Kota Bharu, Kelantan, Malaysia|Hospital Selayang /ID# 156756, Batu Caves, Malaysia|Hospital Umum Sarawak /ID# 142990, Kuching, Malaysia|Hospital Putrajaya /ID# 142989, Putrajaya, Malaysia|Hospital Tuanku Ja afar /ID# 142988, Seremban, Malaysia|Clinstile, S.A. de C.V. /ID# 144866, Cuauhtemoc, Ciudad De Mexico, Mexico|Hosp. Univ. Dr. Jose E. Gonz /ID# 142992, Monterrey, Nuevo Leon, Mexico|Invest y Biomed de Chihuahua /ID# 142996, Chihuahua, Mexico|RM Pharma Specialists, S.A de C.V /ID# 142994, Mexico City, Mexico|Hospital de Jesús Nazareno /ID# 142993, Mexico City, Mexico|Centro Peninsular de Investiga /ID# 148159, Mérida, Mexico|Waikato Hospital /ID# 143002, Hamilton, Waikato, New Zealand|Porter Rheumatology Ltd /ID# 143001, Nelson, New Zealand|Timaru Medical Specialists Ltd /ID# 143000, Timaru, New Zealand|WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 145622, Wrocław, Dolnoslaskie, Poland|NZOZ Nasz Lekarz /ID# 143004, Toruń, Kujawsko-pomorskie, Poland|REUMED Sp.z o.o. Filia nr 1 /ID# 148189, Lublin, Lubelskie, Poland|Malopolskie Centrum Kliniczne /ID# 152782, Cracow, Malopolskie, Poland|Pratia MCM Krakow /ID# 143005, Krakow, Malopolskie, Poland|McBk Sc /Id# 143003, Grodzisk Mazowiecki, Mazowieckie, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 151960, Warszawa, Mazowieckie, Poland|Centrum Medyczne AMED Warszawa Targowek /ID# 157621, Warszawa, Mazowieckie, Poland|Osteo-Medic spolka cywilna /ID# 143006, Białystok, Podlaskie, Poland|Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163293, Gdynia, Pomorskie, Poland|Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163294, Gdynia, Pomorskie, Poland|Synexus Polska Sp. z o.o. Oddz. Poznan /ID# 163295, Gdynia, Pomorskie, Poland|Silmedic Sp z o.o /ID# 152914, Katowice, Slaskie, Poland|ClinicMed Badurski i wspolnicy SJ /ID# 163300, Bialystok, Poland|Solumed Sp. zoo Cent Medyczne /ID# 152783, Poznan, Poland|Rheuma Medicus /ID# 143007, Warsaw, Poland|Instituto Portugues De Reumatologia /ID# 148316, Lisbon, Lisboa, Portugal|Centro Hospitalar De Vila Nova /ID# 143010, Vila Nova De Gaia, Porto, Portugal|CCA Braga - Hospital de Braga /ID# 148317, Braga, Portugal|Hospital CUF Descobertas /ID# 160539, Lisbon, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 152871, Porto, Portugal|Unidade Local De Saude Do Alto Minho /ID# 143009, Viana Do Castelo, Portugal|Ponce School of Medicine /ID# 151961, Ponce, Puerto Rico|GCM Medical Group /ID# 143011, San Juan, Puerto Rico|Spitalul Clinic Dr. I. Cantacuzino /ID# 143012, Bucharest, Bucuresti, Romania|Spitalul Clinic Dr. I. Cantacuzino /ID# 143017, Bucharest, Bucuresti, Romania|Spitalul Clinic Sf. Maria /ID# 144868, Bucuresti, Romania|Spitalul Clinic Sf. Maria /ID# 144869, Bucuresti, Romania|Spitalul Clinic Sf. Maria /ID# 145966, Bucuresti, Romania|Spitalul Clinic de Recuperare /ID# 144867, Iasi, Romania|Ecomed SRL /ID# 144870, Oradea, Romania|Family Outpatient clinic#4,LLC /ID# 148319, Korolev, Moskva, Russian Federation|Clinical Hospital No.1 n.a. N.I.Pirogov /ID# 143138, Moscow, Moskva, Russian Federation|Perm Clinical Center of FMBA /ID# 145627, Perm, Permskiy Kray, Russian Federation|LLC Novaya Klinika /ID# 143019, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Kazan State Medical University /ID# 144871, Kazan, Tatarstan, Respublika, Russian Federation|Tver Regional Clinical Hosp. /ID# 143026, Tver, Tverskaya Oblast, Russian Federation|Сity Clinical Hospital #4 /ID# 143023, Ivanovo, Russian Federation|Russian National Research Medi /ID# 143028, Moscow, Russian Federation|City Clinical Hospital Botkina /ID# 145628, Moscow, Russian Federation|Moscow State Univ Med and Dent /ID# 145623, Moscow, Russian Federation|City Clinical Hospital #5 /ID# 148318, Nizhnij Novgorod, Russian Federation|Orenburg State Medical Academy /ID# 143018, Orenburg, Russian Federation|Ryazan State Medical Universit /ID# 143031, Ryazan, Russian Federation|II Dzhan Research Center /ID# 143027, St. Petersburg, Russian Federation|NW State Med Univ NA Mechnikov /ID# 143022, St. Petersburg, Russian Federation|Republican clinical hospital n /ID# 145626, UFA, Russian Federation|Ulyanovsk Regional Clin Hosp /ID# 143030, Ulyanovsk, Russian Federation|Institute for Rheumatology /ID# 143032, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 143035, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 143036, Belgrade, Beograd, Serbia|Institute for Rheumatology /ID# 143037, Belgrade, Beograd, Serbia|Special Hospital for Rheuma /ID# 143034, Novi Sad, Vojvodina, Serbia|Clinical Center of Vojvodina /ID# 143033, Novi Sad, Vojvodina, Serbia|MEDMAN s.r.o. /ID# 143045, Martin, Slovakia|Reumatologická ambulancia Reum.hapi s.r.o. /ID# 147169, Nové Mesto Nad Váhom, Slovakia|REUMACENTRUM s.r.o. /ID# 143041, Partizanske, Slovakia|Slovak research center Team Member, Thermium s.r.o. /ID# 147614, Pieštany, Slovakia|Reumex, s.r.o. /ID# 143043, Rimavska Sobota, Slovakia|Reumatologicka ambulancia /ID# 144873, Sabinov, Slovakia|TIMMED spol. s r.o. /ID# 144872, Stará Lubovna, Slovakia|Reumatologicka ambulancia, LER /ID# 143044, Topolcany, Slovakia|ALBAMED s.r.o. /ID# 143042, Zvolen, Slovakia|Greenacres Hospital /ID# 144710, Port Elizabeth, Eastern Cape, South Africa|Wits Clinical Research Site /ID# 148320, Johannesburg, Gauteng, South Africa|University of Pretoria /ID# 148353, Pretoria, Gauteng, South Africa|Jakaranda Hosp, Emmed Research /ID# 143046, Pretoria, Gauteng, South Africa|Jakaranda Hosp, Emmed Research /ID# 145968, Pretoria, Gauteng, South Africa|St. Augustine's Hospital /ID# 143047, Durban, Kwazulu-Natal, South Africa|Synexus Helderberg Clinical Tr /ID# 148322, Cape Town, Western Cape, South Africa|Arthritis Clinical Research Tr /ID# 144874, Cape Town, Western Cape, South Africa|Tiervlei Trial Centre /ID# 153085, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 143048, Stellenbosch, Western Cape, South Africa|H. Un. Marques de Valdecilla /ID# 143050, Santander, Cantabria, Spain|Comple Hosp Univ de A Coruna /ID# 143051, A Coruna, Spain|Hospital Universitario Reina S /ID# 153566, Cordoba, Spain|Clinica Gaias /ID# 143052, Santiago de Compostela, Spain|Complejo Hosp Santiago /ID# 153727, Santiago de Compostela, Spain|China Medical University Hosp /ID# 143058, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 143056, Taipei City, Taipei, Taiwan|Kaohsiung Medical University /ID# 143059, Kaohsiung, Taiwan|Kaohsiung Chang Gung Memorial Hospital /ID# 143055, Kaohsiung, Taiwan|Far Eastern Memorial Hospital /ID# 143061, New Taipei City, Taiwan|Chung Shan Medical University /ID# 143060, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 157940, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 143057, Taoyuan City, Taiwan|Istanbul Universitesi Cerrahpa /ID# 156088, Cerrahpasa, Turkey|Istanbul Fizik Tedavi Rehabilitasyon Egitim ve Arastırma Hastanesi /ID# 143063, Istanbul, Turkey|Izmir Katip Celebi Ataturk Training & Research Hospital /ID# 143062, Izmir, Turkey|LLC Revmocentr /ID# 143067, Kiev, Kyiv, Ukraine|Lviv Regional Clinical Hospita /ID# 154450, Lviv, Lvivska Oblast, Ukraine|Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 143071, Vinnytsia, Vinnytska Oblast, Ukraine|Regional Clinical Hospital /ID# 152025, Ivano-frankivsk, Ukraine|NSC-Strazhesko Ist Cardiology /ID# 152030, Kiev, Ukraine|Lviv Municipal City Clinical /ID# 143068, Lviv, Ukraine|Odessa National Medical Univ /ID# 143072, Odesa, Ukraine|Zaporizhzhia Regional Clinical /ID# 143069, Zaporizhia, Ukraine|The Royal Free Hospital /ID# 143074, London, London, City Of, United Kingdom|Queen Alexandra Hospital /ID# 143077, Portsmouth, United Kingdom|Warrington + Halton Hosp NHS /ID# 143075, Warrington, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02629159/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02629159/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02629159"
251,"NCT02627924","Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab","ROCKA","Completed","Has Results","Rheumatoid Arthritis",,"Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 24|Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 12|Percentage of Participants Achieving a Clinically Meaningful Improvement on the HAQ-DI at Weeks 12 and 24|Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary and Mental Component Summary Scores at Weeks 12 and 24|Change From Baseline in EuroQol 5-Dimension 3-Level (EQ-5D-3L) Index at Weeks 12 and 24|Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Weeks 12 and 24|Patient Treatment Satisfaction|Healthcare Resource Utilization: Number of Participants With Visits to Healthcare Professionals for Treatment of Rheumatoid Arthritis|Healthcare Resource Utilization: Number of Participants Who Underwent Procedures Related to Treatment of Rheumatoid Arthritis|Healthcare Resource Utilization: Number of Participants With Hospitalization Related to Rheumatoid Arthritis|Healthcare Resource Utilization: Number of Participants With Surgery Related to Rheumatoid Arthritis|Healthcare Resource Utilization: Number of Participants Who Received Concomitant Medications for Rheumatoid Arthritis","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"91","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-777","November 18, 2015","December 28, 2017","December 28, 2017","December 11, 2015","March 22, 2019","March 22, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02627924/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02627924/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02627924"
252,"NCT02618928","The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France","OPALE","Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants Achieving Virological Response at End of Treatment|Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 12 Weeks Post-treatment|Percentage of Participants With Relapse|Percentage of Participants With Breakthrough|Percentage of Participants With Rapid Virological Response at Week 4 (RVR4)|Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 24 Weeks Post-treatment (SVR24)|Number of Participants in Each Non-response Category 12 Weeks Post-treatment|Percentage of Participants With Adherence to the ABBVIE Regimen, by Adherence Category|Percentage of Participants With Adherence to Ribavirin by Adherence Category|Percentage of Ribavirin Treatment Days in Relation to the Target Number of Ribavirin Treatment Days|Number of Participants Who Received Concomitant Medications|Number of Participants With Adverse Events, Serious Adverse Events, or Pregnancies|Change From Baseline in Fatigue Impact Scale Total Score|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) Index Score|Change From Baseline in EuroQol 5 Dimension 5 Level (EQ-5D-5L) VAS Score|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Absenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Presenteeism|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Work Productivity Impairment (TWP)|Change From Baseline in Work Productivity and Activity Impairment (WPAI): Total Activity Impairment|Change From Baseline in Beliefs Medication Questionnaire - (18-item BMQ)|Change From Baseline in Patient Activation Measure 13 (PAM-13)|Number of Participants With Outpatient Consultations Due to Liver Disease by Category|Number of Participants With Hospitalizations Due to Liver Disease by Category|Change From Baseline in Percent Glycosylated Hemoglobin (HbA1c)","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"735","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-405","December 15, 2015","March 29, 2018","March 29, 2018","December 2, 2015","June 17, 2019","June 17, 2019","Hopital Saint Joseph /ID# 144927, Marseille CEDEX 08, Bouches-du-Rhone, France|Hopital Saint Joseph /ID# 145560, Marseille CEDEX 08, Bouches-du-Rhone, France|Hopital Saint Joseph /ID# 145571, Marseille CEDEX 08, Bouches-du-Rhone, France|CHR Orleans - Hopital de la Source /ID# 147250, Orleans CEDEX 2, Centre-Val De Loire, France|CHU de Besancon - Jean Minjoz /ID# 145884, Besancon, Doubs, France|CHU Dupuytren /ID# 144920, Limoges CEDEX 1, Franche-Comte, France|Hopital Universitaire Purpan /ID# 145869, Toulouse, Haute-Garonne, France|Hopital Universitaire Purpan /ID# 150141, Toulouse, Haute-Garonne, France|Hopital Saint Eloi /ID# 144919, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 147923, Clichy, Ile-de-France, France|Hopital de la Timone /ID# 145558, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|Hopital de la Timone /ID# 145574, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|CHU Amiens Picardie /ID# 145871, Amiens CEDEX 1, Somme, France|C.H. du Pays d'Aix /ID# 144922, Aix En Provence, France|Cabinet medical /ID# 147359, Aix En Provence, France|CHU d'Angers /ID# 145880, Angers, France|Centre Hospitalier Victor Dupo /ID# 147241, Argenteuil, France|Centre Hospitalier D'Avignon /ID# 151098, Avignon, France|Centre Hospitalier D'Avignon /ID# 151343, Avignon, France|Cabinet Medical /ID# 147322, Besancon, France|Centre Endo Nord Isere /ID# 148694, Bourgoin Jallieu, France|Centre Hospitalier Universitai /ID# 147568, Caen, France|CH de Chambery /ID# 145573, Chambery, France|Hopital Antoine Beclere /ID# 149251, Clamart, France|Hopital Antoine Beclere /ID# 149252, Clamart, France|Centre Hosp Intercommunal /ID# 145876, Creteil, France|Hospital Henri Mondor /ID# 144918, Creteil, France|Clinique du Palais /ID# 145563, Grasse, France|CHU de Grenoble - Albet Michal /ID# 145881, Grenoble, France|CH d'Hyeres /ID# 145870, Hyeres, France|Ch Du Mans /Id# 147415, Le Mans, France|Dr. Cuissard, Le Port, FR /ID# 145565, Le Port, France|Centre Hospitalier de Libourne /ID# 145564, Libourne, France|CH Des Deux Vallees Longumeau /ID# 149336, Longjumeau, France|Hopital de la Croix Rousse /ID# 149776, Lyon, France|Ctr Consultations La Sauvegard /ID# 147236, Lyon, France|Hopital de la Timone /ID# 147237, Marseille, France|Ctre Hosp de Montelimar /ID# 147239, Montelimar, France|Cabinet Medical, Boyer Darrigr /ID# 145562, Nanterre, France|CHU de Nice /ID# 144921, Nice, France|Cabinet Medical, Dr. Verdier, /ID# 145575, Nimes, France|Hopital Saint Antoine /ID# 145567, Paris, France|Hopital Saint Antoine /ID# 148635, Paris, France|Hopital Saint Antoine /ID# 148693, Paris, France|Hopital Saint Antoine /ID# 152825, Paris, France|Cabinet Medical, Giuily /ID# 145882, Paris, France|Hopital Bichat-Claude Bernard /ID# 149246, Paris, France|Cabinet Medical /ID# 145559, Paris, France|Hopital Pitie Salpetriere /ID# 145556, Paris, France|Hopital Pitie Salpetriere /ID# 145566, Paris, France|Hopital Pitie Salpetriere /ID# 149337, Paris, France|Hopital Bichat Claude Bernard /ID# 145886, Paris, France|Hopital Tenon /ID# 145885, Paris, France|CH Marechal Joffre /ID# 145875, Perpignan, France|CHU Jean Bernard /ID# 147414, Poitiers, France|CHU de Reims /ID# 148477, Reims, France|Hospital Pontchaillou /ID# 145883, Rennes, France|Charles Nicolle Hosp chu rouen /ID# 145557, Rouen, France|Institut Arnault Tzanck /ID# 144925, Saint Laurent Du Var, France|Hopital Begin /ID# 145872, Saint Mande, France|CHU Strasbourg Hautepierre Hos /ID# 147246, Strasbourg, France|Hopital Foch /ID# 147248, Suresnes, France|Cabinet Medical, Dr. Constant, /ID# 145561, Toulon, France|Clinique Amroise Pare /ID# 144924, Toulouse, France|Hopital Joseph Ducuing /ID# 152832, Toulouse, France|Ctre Hospitalier de Tourcoing /ID# 145568, Tourcoing, France|Cabinet Medical, Barbereau /ID# 145874, Tours, France|Hopital Paul Brousse /ID# 145879, Villejuif, France|Hopital Paul Brousse /ID# 147244, Villejuif, France|Hopital Paul Brousse /ID# 147417, Villejuif, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02618928/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02618928/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02618928"
253,"NCT02616380","Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan","ROCKI","Completed","Has Results","Rheumatoid Arthritis",,"Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24|Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary and Mental Component Summary Scores at Weeks 12 and 24|Change From Baseline in EuroQol 5-Dimension 3-Level (EQ-5D-3L) Index at Weeks 12 and 24|Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI) at Weeks 12 and 24|Change From Baseline in HAQ DI Score at Week 12|Percentage of Participants Achieving a Clinically Meaningful Improvement on the HAQ-DI at Weeks 12 and 24|Healthcare Resource Utilization: Number of Participants With Visits to Healthcare Professionals for Treatment of Rheumatoid Arthritis|Healthcare Resource Utilization: Number of Participants Who Underwent Procedures Related to Treatment of Rheumatoid Arthritis|Healthcare Resource Utilization: Number of Participants With Hospitalization Related to Rheumatoid Arthritis|Healthcare Resource Utilization: Number of Participants Who Received Concomitant Medications for Rheumatoid Arthritis","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","P15-778","November 5, 2015","November 23, 2017","November 23, 2017","November 26, 2015","March 14, 2019","March 14, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02616380/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT02616380/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02616380"
254,"NCT02615145","Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)","LIFE-C","Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants With Sustained Virologic Response (SVR12)|Percentage of Participants With Virological Response at End of Treatment (EoTR)|Number of Participants With On-Treatment Virological Failure or Relapse|Percentage of Participants With Rapid Virological Response at Week 4 (RVR4)|Percentage of Participants With Sustained Virological Response 24 Weeks After EoT (SVR24)|Percentage of Participants With Sustained Virological Response 48 Weeks After EoT (SVR48)|Change From Baseline in PRISM Over Time|Percentage of Participants With ≥ 1 Comorbidity and/or Co-Infection|Percentage of Participants Taking ≥ 1 Co-Medication|Mean Duration of of ABBVIE REGIMEN and RBV Taken|Percentage of Planned Duration of ABBVIE REGIMEN and RBV Taken|Change From Baseline in FACIT-F Scale Over Time|Change From Baseline to EoT in PAM-13 Questionnaire|Change From Baseline Over Time in WPAI: Total Work Productivity Impairment|Change From Baseline Over Time in WPAI: Total Activity Impairment|Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and/or Pregnancies","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"472","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-398","December 3, 2015","March 26, 2018","March 26, 2018","November 26, 2015","October 7, 2019","October 7, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02615145/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT02615145/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02615145"
255,"NCT02611713","Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease","DUOGLOBE","Recruiting","No Results Available","Advanced Parkinson's Disease",,"Change in the number of hours spent in OFF time in Arm A|Change in Duration of OFF time (hours/day) in Arm B|Duration of bradykinesia score above target in Arm B|Average bradykinesia score in Arm B|Change in Disease-Specific Caregiver Burden in Arm A|Change in the Duration of Dyskinesia in Arm A|Change in Disease-Specific Sleep Quality in Arm A|Change in Tremor Severity in Arm A|Change in Motor Function in Arm A|Change in Generic Quality of Life in Arm A|Change in Dyskinesia Severity in Arm A|Change in Overall Clinical Impression of Disease Severity in Arm A|Change in Disease-Specific Quality of Life in Arm A|Change in OFF Time Duration in Arm A|Change in Non-Motor Symptoms in Arm A|Change in Healthcare Resource Utilization in Arm A|Change in Daytime Sleepiness in Arm A|Change in Activities of Daily Living in Arm A|Change in Complications of Therapy in Arm A|Correlation of non-motor and motor improvements with Quality of Life improvements in Arm A|Correlation between duration of OFF time measured by UPDRS IV and duration of bradykinesia score above target in Arm B|Correlation between duration of OFF time measured by patient with PD Diary and average bradykinesia score in Arm B|Correlation between duration of bradykinesia score above target and average bradykinesia score in Arm B|Correlation between duration of OFF time measured by patient with PD Diary and duration of bradykinesia score above target in Arm B|Correlation between duration of OFF time measured by UPDRS IV and average bradykinesia score in Arm B|Correlation between duration of dyskinesia and Unified Dyskinesia Rating Scale (UDysRS) in Arm B|Severity of dyskinesia in Arm B|Motor symptoms in Arm B|Severity of tremor in Arm B|Activities of Daily Living (ADL) in Arm B|Sleep in Arm B|Daytime sleepiness in Arm B|Quality of Life (QoL) in Arm B","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"243","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-494","January 4, 2016","March 27, 2021","March 27, 2021","November 23, 2015",,"May 6, 2019","University of Alabama /ID# 144422, Birmingham, Alabama, United States|Parkinson's Disease and Moveme /ID# 144413, Boca Raton, Florida, United States|University of Florida /ID# 144415, Gainesville, Florida, United States|University of Miami /ID# 144420, Miami, Florida, United States|Georgia Regents University /ID# 144417, Augusta, Georgia, United States|University of Kansas Health Sy /ID# 154242, Kansas City, Kansas, United States|University of Kentucky Chandler Medical Center /ID# 144421, Lexington, Kentucky, United States|Johns Hopkins University /ID# 144416, Baltimore, Maryland, United States|Mercy St. Mary's Health Center /ID# 144418, Grand Rapids, Michigan, United States|Washington University-School of Medicine /ID# 147235, Saint Louis, Missouri, United States|Jared Neuroscience Center /ID# 161629, Springfield, Missouri, United States|Univ Nebraska Med Ctr /ID# 147655, Omaha, Nebraska, United States|Wake Forest Univ HS /ID# 144419, Winston-Salem, North Carolina, United States|Penn State Child Hosp.Hersh,PA /ID# 160671, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 161135, Philadelphia, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 150782, Nashville, Tennessee, United States|University of Vermont Medical Center /ID# 144410, Burlington, Vermont, United States|King County Public Hospital /ID# 144412, Kirkland, Washington, United States|Northwest Neurological, PLLC /ID# 144409, Spokane, Washington, United States|Concord Repatriation & Gen Hos /ID# 144373, Concord, New South Wales, Australia|St. Vincent's Hospital, Darlinghurst /ID# 144376, Darlinghurst, New South Wales, Australia|Kingston Centre /ID# 144374, Cheltenham, Victoria, Australia|Monash Medical Centre /ID# 144375, Clayton, Victoria, Australia|UZ Antwerp /ID# 144378, Edegem, Belgium|AZ Groeninge /ID# 144377, Kortrijk, Belgium|CHU Tivoli /ID# 144379, La Louviere, Belgium|Pecsi Tudomanyegyetem /ID# 144380, Pécs, Pecs, Hungary|Semmelweis Egyetem /ID# 144381, Budapest, Hungary|Tel Aviv Sourasky Medical Ctr /ID# 153779, Tel Aviv-Yafo, Tel-Aviv, Israel|Assaf Harofeh Medical Center /ID# 144383, Be'er Ya'akov, Israel|The Edith Wolfson Medical Cent /ID# 144382, Holon, Israel|Sheba Medical Center /ID# 147099, Ramat Gan, Israel|Ospedale Santo Stefano /ID# 144386, Prato, Italy|Azienda Ospedaliera Sant' Andrea /ID# 144385, Rome, Italy|A.O. Circolo e Fondazione Macc /ID# 144384, Varese, Italy|Clinic Fundeni Institute /ID# 144448, Bucharest, Bucuresti, Romania|Spital Universitar Bucuresti /ID# 144446, Bucharesti, Romania|Spitatlul Clinic Colentina /ID# 144447, Bucharest, Romania|Spitalul Clinic Judetean de Ur /ID# 144451, Oradea, Judet Bihor, Romania|Spitalul Clinic Judetean /ID# 144453, Targu Mures, Romania|Sp. Clinic de Judetean /ID# 144449, Timisoara, Romania|Sp. Clinic de Judetean /ID# 144452, Timisoara, Romania|Univ Medical Ctr Ljubljana /ID# 144387, Ljubljana, Slovenia|Clinica Universitar de Navarra - Pamplona /ID# 162277, Pamplona, Navarra, Comunidad, Spain|OSI Ezkerraldea-Enkarterri-Cruces /ID# 151781, Barakaldo, Spain|Hospital Univ Vall d'Hebron /ID# 151778, Barcelona, Spain|Complejo Hospitalario de Burgo /ID# 144406, Burgos, Spain|Hosp Arquitecto Marcide /ID# 151782, Ferrol, Spain|Hospital Univ Mutua Terrassa /ID# 144405, Terrasa, Spain|Hosp de Tortosa Verge de la Ci /ID# 153502, Tortosa, Spain|King's College Hospital NHS /ID# 147130, London, United Kingdom|St. George's Healthcare NHS /ID# 147131, London, United Kingdom|Queens Hospital /ID# 147133, Romford, United Kingdom|Salford Royal NHS Found Trust /ID# 151783, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02611713"
256,"NCT02609659","Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection","GEODE II","Completed","Has Results","Hepatitis C Virus (HCV)","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Hemoglobin < 10 g/dL During Treatment|Mean Change in Hemoglobin Values From Baseline to End of Treatment|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","105","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-582","October 28, 2015","October 7, 2016","December 28, 2016","November 20, 2015","October 18, 2017","December 10, 2019",,,"https://ClinicalTrials.gov/show/NCT02609659"
257,"NCT02606630","[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis",,"Terminated","No Results Available","Multiple Sclerosis","Drug: ABT-555","Change in translocator protein expression","AbbVie","All","18 Years to 60 Years   (Adult)","Phase 1","4","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-561|2015-001176-22","October 2015","December 2015","December 2015","November 17, 2015",,"February 8, 2017","Site Reference ID/Investigator# 141463, London, United Kingdom|Site Reference ID/Investigator# 141461, Whitechapel, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02606630"
258,"NCT02604017","A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus|HCV","Drug: ABT-493/ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Mono-infected Hepatitis C Virus Genotype 1 (HCV GT1), Direct-acting Antiviral Agent (DAA) Naïve Participants in the 12-Week Treatment Arm|Percentage of Participants With SVR12: Noninferiority of 8-Week Arm to 12-Week Arm in Mono-infected HCV GT1, DAA-Naïve Participants, Excluding Those Who Discontinued/Experienced Virologic Failure by Week 8 or Had No HCV RNA Value at Week 12 or Later|Percentage of Participants With SVR12: Noninferiority of 8-Week Treatment Arm to 12-Week Treatment Arm in Mono-infected HCV GT1, DAA-Naïve Participants|Percentage of Participants With SVR12 in Mono-infected HCV GT1 Participants|Percentage of Participants With SVR12|Percentage of Participants With SVR12 in Co-infected HCV GT1/Human Immunodeficiency Virus Type 1 (HIV-1) Participants|Percentage of Participants With SVR12 in HCV GT1-infected, Prior Sofosbuvir (SOF) Treatment-Experienced Participants|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With On-treatment Virologic Failure in Mono-infected HCV GT1, DAA-Naïve Participants|Percentage of Participants With Post-treatment Relapse|Percentage of Participants With Post-treatment Relapse in Mono-infected HCV GT1, DAA-Naïve Participants","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","703","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-590|2015-002087-17","October 2015","January 2017","January 2017","November 13, 2015","September 14, 2017","September 14, 2017",,,"https://ClinicalTrials.gov/show/NCT02604017"
259,"NCT02601885","A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Drug: ABT-555|Other: Placebo","Number and percentage of participants reporting adverse events|Concentration of anti-drug antibody (ADA) titers of ABT-555|Time to Maximum observed plasma concentration (Tmax) of ABT-555|Maximum observed plasma concentration (Cmax) of ABT-555|Area under the concentration curve (AUC) of ABT-555|Percentage of participants who experience relapse and disability progression|Lesion volume of new, newly enlarging T2 hyperintense lesions|Number of new, newly-enlarging T2 hyperintense lesions|Total number of new Gadolinium-enhancing T1 lesions","AbbVie","All","18 Years to 60 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M14-173","October 18, 2016","April 20, 2018","April 20, 2018","November 11, 2015",,"May 17, 2018","Compass Research LLC, Orlando, Florida, United States|Rowe Neurology Institute, Lenexa, Kansas, United States|Parexel International, Baltimore, Maryland, United States|MIND, Farmington Hills, Michigan, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Tri-State Mountain Neurology, Johnson City, Tennessee, United States|Clinical Trial Network, Houston, Texas, United States|Integrated Neurology Services, Alexandria, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02601885"
260,"NCT02598570","Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma",,"Completed","No Results Available","Lymphoma","Drug: duvelisib","Number of participants reporting Treatment-emergent Adverse Events|Maximum Observed Plasma Concentration (Cmax) of Duvelisib|Time to Maximum Observed Concentration (Tmax) of Duvelisib|Area Under the Plasma Concentration-time Curve (AUC) of Duvelisib|Overall Response Rate|Overall Survival|Progression Free Survival","AbbVie|Infinity Pharmaceuticals, Inc.","All","20 Years to 99 Years   (Adult, Older Adult)","Phase 1","7","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-460","November 2015","December 2016","February 2017","November 6, 2015",,"February 6, 2017","Site Reference ID/Investigator# 141826, Aichi, Japan|Site Reference ID/Investigator# 141595, Fukuoka, Japan|Site Reference ID/Investigator# 141594, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02598570"
261,"NCT02596217","Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers",,"Completed","No Results Available","Healthy","Drug: ABBV-066|Drug: Placebo","Percentage of subjects with drug-related adverse events|Time from dosing to the maximum plasma concentration of the analyte in plasma (tmax)|Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to time of the last quantifiable plasma concentration (AUC0-tz)|Maximum measured plasma concentration of the analyte in plasma (Cmax)|Terminal half-life of the analyte in plasma (t1/2)|Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-infinity)","AbbVie|Boehringer Ingelheim","Male","20 Years to 45 Years   (Adult)","Phase 1","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M16-513|1311.16","August 2015","June 2017","June 2017","November 4, 2015",,"July 6, 2017","Boehringer Ingelheim Investigational Site, Tokyo, Sumida-ku, Japan|Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02596217"
262,"NCT02590263","Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma",,"Active, not recruiting","No Results Available","Malignant Glioma|Glioblastoma Multiforme","Radiation: Whole Brain Radiation|Drug: Temozolomide|Drug: ABT-414","Percentage of participants with adverse events|Number of Dose Limiting Toxicities|Progression-free survival|Area under the plasma concentration-time curve (AUC) of ABT-414|Maximum plasma concentration (Cmax) of ABT-414|Objective Response Rate|Overall Survival|Duration of Overall Response","AbbVie","All","20 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-714","August 24, 2015","December 31, 2020","December 31, 2020","October 29, 2015",,"May 28, 2019","Nagoya University Hospital /ID# 138559, Nagoya-shi, Aichi, Japan|Iwate Medical University Hospital /ID# 149145, Morioka-shi, Iwate, Japan|Kitasato University Hospital /ID# 148493, Sagamihara-shi, Kanagawa, Japan|Kyoto Prefect Univ Med /ID# 149093, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 138464, Sendai-shi, Miyagi, Japan|Okayama University Hospital /ID# 148674, Okayama-shi, Okayama, Japan|Osaka University Hospital /ID# 140438, Suita-shi, Osaka, Japan|Shizuoka Cancer Center /ID# 148673, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital /ID# 140435, Chuo-ku, Tokyo, Japan|Kyorin University Hospital /ID# 140360, Mitaka-shi, Tokyo, Japan|Tokyo Women's Medical University Hospital /ID# 140436, Shinjuku-ku, Tokyo, Japan|Chiba Cancer Center /ID# 164375, Chiba, Japan|Saitama Med Univ Int Med Ctr /ID# 140361, Hidaka, Japan|Hiroshima University Hospital /ID# 139399, Hiroshima, Japan|Kumamoto University Hospital /ID# 138558, Kumamoto, Japan|NHO Kyoto Medical Center /ID# 140437, Kyoto, Japan|Osaka Inter. Cancer Institute /ID# 148494, Osaka, Japan|Kyoto University Hospital /ID# 163206, Sakyo-ku, Japan|Hokkaido University Hospital /ID# 150589, Sapporo, Japan|Dokkyo Medical University Hosp /ID# 150990, Shimotsuga, Japan|Nihon University Itabashi Hosp /ID# 149385, Tokyo, Japan|Tsukuba University Hospital /ID# 140433, Tsukuba, Japan",,"https://ClinicalTrials.gov/show/NCT02590263"
263,"NCT02582671","The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland","REACH","Completed","Has Results","Chronic Hepatitis C","Drug: Ombitasvir/paritaprevir/ritonavir|Drug: Dasabuvir|Drug: Ribavirin","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virologic Response at End of Treatment (EOT)|Percentage of Participants With Relapse|Percentage of Participants With Viral Breakthrough|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants Meeting Relapse Criteria|Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria|Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"101","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-702","November 5, 2015","November 29, 2017","November 29, 2017","October 21, 2015","May 6, 2019","May 6, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02582671/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02582671/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02582671"
264,"NCT02582658","Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)","REAL","Completed","Has Results","Chronic Hepatitis C",,"Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virological Response at End of Treatment (EoTR)|Percentage of Participants With On-treatment Virologic Failure (Breakthrough)|Percentage of Participants Achieving SVR12 (Core Population Sufficient Follow-up)|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"173","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-695","October 6, 2015","January 12, 2017","January 12, 2017","October 21, 2015","June 5, 2019","June 5, 2019",,,"https://ClinicalTrials.gov/show/NCT02582658"
265,"NCT02582632","A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults","GARNET","Completed","Has Results","Hepatitis C Infection|Hepatitis C Virus","Drug: ombitasvir/paritaprevir/ritonavir|Drug: dasabuvir","Percentage of Participants Who Achieve Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-Treatment Virologic Failure During Treatment Period|Percentage of Participants With Post-Treatment Relapse12|Percentage of Female Participants Responding With SVR12|Percentage of Participants With Baseline HCV RNA < 6,000,000 IU/mL Responding With SVR12","AbbVie","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","166","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-684|2015-003370-33","November 24, 2015","August 24, 2016","December 1, 2016","October 21, 2015","December 13, 2017","December 13, 2017",,,"https://ClinicalTrials.gov/show/NCT02582632"
266,"NCT02581202","The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation","SIMPLE","Completed","Has Results","HIV-1 Infection","Drug: lopinavir/ritonavir|Drug: lamivudine","Percentage of Participants on Dual Therapy (LPV/r + 3TC) With Undetectable HIV-1 RNA Level at Week 48|Percentage of Participants on Dual Therapy (LPV/r + 3TC) With Undetectable HIV-1 RNA Level at Week 24|Absolute Values and Change From Baseline (BL) in HIV-1- RNA Viral Load at Week 24 (Untransformed Data)|Absolute Values and Change From Baseline (BL) in HIV-1- RNA Viral Load at Week 24 (Base-10 Logarithm Transformed Data)|Absolute Values and Change From Baseline in HIV-1- RNA Viral Load at Week 48 (Untransformed Data)|Absolute Values and Change From Baseline in HIV-1- RNA Viral Load at Week 48 (Base-10 Logarithm Transformed Data)|Absolute Values and Change From Baseline in CD4+ T-cell Counts (%) at Week 24|Absolute Values and Change From Baseline in CD4+ T-cell Counts (%) at Week 48|Absolute Values and Change From Baseline in CD4+ T-cell Counts (Cells/mm^3) at Week 24|Absolute Values and Change From Baseline in CD4+ T-cell Counts (Cells/mm^3) at Week 48|Number of Participants Who Developed Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), and Protease Inhibitors (PIs)|Absolute Values and Change From Baseline in Anthropometric Measurements At Week 24|Absolute Values and Change From Baseline in Anthropometric Measurements At Week 48|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Alanine Aminotransferase (U/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Alanine Aminotransferase (U/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Alanine Aminotransferase (µmol/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Alanine Aminotransferase (µmol/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Aspartate Aminotransferase (U/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Aspartate Aminotransferase (U/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Aspartate Aminotransferase (µmol/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Aspartate Aminotransferase (µmol/L)|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Glucose|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Glucose|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: HDL|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: HDL|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Insulin|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Insulin|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: LDL|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: LDL|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Serum Creatinine|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Serum Creatinine|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Total Cholesterol|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Total Cholesterol|Absolute Values and Change From Baseline in Metabolic Parameters at Week 24: Triglycerides|Absolute Values and Change From Baseline in Metabolic Parameters at Week 48: Triglycerides|Number of Participants With Adverse Events","AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)",,"216","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-452","December 21, 2015","May 27, 2017","May 27, 2017","October 20, 2015","March 29, 2019","June 6, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT02581202/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02581202"
267,"NCT02581189","Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada","AMBER","Completed","Has Results","Chronic Hepatitis C","Drug: Ombitasvir/paritaprevir/ritonavir|Drug: Dasabuvir|Drug: Ribavirin","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virologic Response at End of Treatment (EoT)|Percentage of Participants With Relapse|Percentage of Participants With Viral Breakthrough|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants Meeting Relapse Criteria|Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria|Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria","AbbVie|IST GmbH, Germany|Cato Research","All","18 Years to 99 Years   (Adult, Older Adult)",,"565","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-651","October 13, 2015","December 20, 2017","December 20, 2017","October 20, 2015","March 27, 2019","March 27, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02581189/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT02581189/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02581189"
268,"NCT02581163","Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium",,"Completed","Has Results","Chronic Hepatitis C, Genotype 1 or 4","Drug: Ombitasvir/paritaprevir/ritonavir|Drug: Dasabuvir|Drug: Ribavirin","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virologic Response at End of Treatment (EoT)|Percentage of Participants With Relapse|Percentage of Participants With Viral Breakthrough|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants Meeting Relapse Criteria|Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria|Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria","AbbVie|IST GmbH, Germany","All","18 Years to 99 Years   (Adult, Older Adult)",,"314","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-650","October 7, 2015","February 12, 2018","February 12, 2018","October 20, 2015","May 6, 2019","May 6, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02581163/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02581163/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02581163"
269,"NCT02581020","The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects",,"Active, not recruiting","No Results Available","Hepatitis C Virus",,"Hepatitis C virus ribonucleic acid (HCV RNA) levels|Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Paritaprevir in Non-structural Viral Protein 3 (NS3)|Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to Ombitasvir in Non-structural Viral Protein 5A (NS5A)|Percentage of participants with hepatocellular carcinoma|Number of participants with serious adverse events (SAEs)","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)",,"345","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","P15-349","January 14, 2016","December 31, 2020","December 31, 2020","October 20, 2015",,"December 11, 2019","Nagoya City University Hospital /ID# 157439, Nagoya-shi, Aichi, Japan|Matsuyama Red Cross Hospital /ID# 152125, Matsuyama-shi, Ehime, Japan|NHO Kyushu Medical Center /ID# 161759, Fukuoka-shi, Fukuoka, Japan|Fukuoka University Hospital /ID# 155965, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 152123, Kurume-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 158105, Ogaki-shi, Gifu, Japan|Gunma University Hospital /ID# 158118, Maebashi-shi, Gunma, Japan|National Hospital Organization Takasaki General Medical Center /ID# 152128, Takasaki-shi, Gunma, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 153019, Sapporo-shi, Hokkaido, Japan|Hitachi General Hospital /ID# 160800, Hitachi-shi, Ibaraki, Japan|Kanazawa University Hospital /ID# 152226, Kanazawa, Ishikawa, Japan|Yokohama City Univ Med Center /ID# 159474, Yokohama-shi, Kanagawa, Japan|Yokohama City University Hospital /ID# 165252, Yokohama-shi, Kanagawa, Japan|Kumamoto Shinto General Hospital /ID# 150061, Kumamoto-shi, Kumamoto, Japan|Okayama University Hospital /ID# 150060, Okayama-shi, Okayama, Japan|Osaka Red Cross Hospital /ID# 155964, Osaka-shi, Osaka, Japan|Saga University Hospital /ID# 161757, Saga-shi, Saga, Japan|Saitama Medical University Hospital /ID# 153544, Iruma-gun, Saitama, Japan|Hamamatsu University Hospital /ID# 152176, Hamamatsu-shi, Shizuoka, Japan|Dokkyo Medical University Hospital /ID# 152225, Shimotsuga-gun, Tochigi, Japan|Jichi Medical University Hospital /ID# 153018, Shimotsuke-shi, Tochigi, Japan|Juntendo University Hospital /ID# 153545, Bunkyo-ku, Tokyo, Japan|Toranomon Hospital /ID# 152124, Minato-ku, Tokyo, Japan|Kitasato Univ Kitasato Inst Ho /ID# 152145, Minato-ku, Tokyo, Japan|University of Yamanashi Hospital /ID# 153547, Chuo-shi, Yamanashi, Japan|Asakura Medical Association Ho /ID# 155963, Asakura, Japan|Fukuiken Saiseikai Hospital /ID# 162898, Fukui, Japan|Gifu Municipal Hospital /ID# 152227, Gifu, Japan|Gifu Prefectural Genl Med Ctr /ID# 154796, Gifu, Japan|Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital /ID# 152178, Hiroshima, Japan|Hiroshima University Hospital /ID# 152232, Hiroshima, Japan|Ikeda Municipal Hospital /ID# 150062, Ikeda, Japan|Tokyo Med Uni Ibaraki Med Ctr /ID# 152127, Inashiki, Japan|Nippon Med Chiba Hokusoh Hosp /ID# 164155, Inzai, Japan|Kagoshima Uni Med and Dental /ID# 157438, Kagoshima, Japan|Toranomon Hospital Kajigaya /ID# 152129, Kawasaki, Japan|Kawasaki Municipal Tama Hospit /ID# 153546, Kawasaki, Japan|Kagawa University Hospital /ID# 153548, Kyoto, Japan|Ehime Prefectural Central Hosp /ID# 158106, Matsuyama, Japan|Obihiro-Kosei General Hospital /ID# 157437, Obihiro, Japan|Kawasaki Hosp, Kawasaki Med /ID# 152180, Okayama, Japan|Osaka City General Hospital /ID# 152126, Osaka, Japan|Osaka Hospital /ID# 152177, Osaka, Japan|Japanese Red Cross Saitama Hos /ID# 166898, Saitama, Japan|Saiseikai Suita Hospital /ID# 153549, Suita, Japan|Kagawa Prefectural Central Hos /ID# 152179, Takamatsu, Japan|Nat Hosp Org Minami Wakayama /ID# 153550, Tanabe, Japan|The University of Tokyo Hospital /ID# 158121, Tokyo, Japan|Toshiba General Hospital /ID# 152122, Tokyo, Japan|JP Red Cross Musashino Hosp /ID# 152175, Tokyo, Japan|Toyama Prefectural Ctr Hosp /ID# 164156, Toyama, Japan|Yamaguchi University Hospital /ID# 166899, Ube-shi, Japan|Oita University Hospital /ID# 165274, Yufu-shi, Japan",,"https://ClinicalTrials.gov/show/NCT02581020"
270,"NCT02578238","Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the ""New-Drug Re-examination""",,"Completed","Has Results","Pediatric Crohn's Disease",,"Percentage of Participants With Adverse Events (AEs)/Adverse Drug Reactions (ADRs), Serious AEs/ADRs and Unexpected AEs/ADRs","AbbVie","All","6 Years to 17 Years   (Child)",,"143","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-619","September 24, 2015","May 31, 2017","May 31, 2017","October 16, 2015","December 19, 2018","December 19, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT02578238/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02578238"
271,"NCT02573740","Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment",,"Terminated","No Results Available","Alzheimer's Disease|Mild Cognitive Impairment","Drug: ABT-957|Other: Placebo","Percentage of participants reporting treatment-emergent adverse events|Level of spectrin breakdown product-145 (SBDP-145)","AbbVie","All","55 Years to 85 Years   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-730","December 2015","June 2016","June 2016","October 12, 2015",,"July 1, 2016","Site Reference ID/Investigator# 143180, Cypress, California, United States|Site Reference ID/Investigator# 143178, Orlando, Florida, United States|Site Reference ID/Investigator# 149484, The Villages, Florida, United States|Site Reference ID/Investigator# 143181, Marlton, New Jersey, United States|Site Reference ID/Investigator# 143182, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 149481, Dallas, Texas, United States|Site Reference ID/Investigator# 143254, Orem, Utah, United States|Site Reference ID/Investigator# 143179, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 143177, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02573740"
272,"NCT02573324","A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","Intellance1","Active, not recruiting","No Results Available","Glioblastoma|Gliosarcoma","Drug: Temozolomide|Drug: ABT-414|Radiation: Radiation|Drug: Placebo for ABT-414","Overall Survival (OS)","AbbVie|Radiation Therapy Oncology Group","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","691","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-813|2015-001166-26","December 7, 2015","July 18, 2020","July 18, 2020","October 9, 2015",,"July 12, 2019","St. Josephs Hosp and Med Ctr /ID# 144149, Phoenix, Arizona, United States|Highlands Oncology Group /ID# 142050, Fayetteville, Arkansas, United States|Usc /Id# 147543, Los Angeles, California, United States|University of California, Los Angeles /ID# 149239, Los Angeles, California, United States|Sharp Memorial Hospital /ID# 148193, San Diego, California, United States|Univ California, San Francisco /ID# 145889, San Francisco, California, United States|St. John's Health Center /ID# 148192, Santa Monica, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 148472, West Hollywood, California, United States|Univ of Colorado Cancer Center /ID# 148194, Aurora, Colorado, United States|Associated Neurologists of Sou /ID# 147701, Fairfield, Connecticut, United States|Yale University /ID# 144170, New Haven, Connecticut, United States|Christiana Care Health Service /ID# 144127, Newark, Delaware, United States|Boca Raton Regional Hospital /ID# 163659, Boca Raton, Florida, United States|Holy Cross Hospital /ID# 156764, Fort Lauderdale, Florida, United States|Baptist Hospital Miami /ID# 152451, Miami, Florida, United States|Florida Hospital /ID# 144128, Orlando, Florida, United States|Moffitt Cancer Center /ID# 144130, Tampa, Florida, United States|Piedmont Hospital /ID# 145892, Atlanta, Georgia, United States|Emory University Hospital /ID# 144015, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 147895, Chicago, Illinois, United States|University of Chicago /ID# 144158, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 144017, Evanston, Illinois, United States|NW Medical Cancer Ctr, Geneva /ID# 151568, Geneva, Illinois, United States|Northwestern Medicine Cancer Center - Warrenville /ID# 148476, Warrenville, Illinois, United States|Parkview Research Ctr, Hosp /ID# 144150, Fort Wayne, Indiana, United States|Univ Kansas Cancer Ctr - Overl /ID# 145895, Westwood, Kansas, United States|Maine Medical Partners Neurolo /ID# 160864, Scarborough, Maine, United States|Tufts Medical Center /ID# 145897, Boston, Massachusetts, United States|Massachusetts General Hospital /ID# 144145, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 148475, Boston, Massachusetts, United States|Wayne State University /ID# 145890, Detroit, Michigan, United States|Henry Ford Health System /ID# 145896, Detroit, Michigan, United States|St. Joseph Mercy Hospital /ID# 144143, Ypsilanti, Michigan, United States|Mmcorc /Id# 144146, Saint Louis Park, Minnesota, United States|Washington University-School of Medicine /ID# 144174, Saint Louis, Missouri, United States|Nebraska Methodist Hospital /ID# 144140, Omaha, Nebraska, United States|Univ Nebraska Med Ctr /ID# 145899, Omaha, Nebraska, United States|MD Anderson Cancer Center at Cooper /ID# 145891, Camden, New Jersey, United States|Rutgers Cancer Institute of NJ /ID# 148190, New Brunswick, New Jersey, United States|Columbia Univ Medical Center /ID# 144020, New York, New York, United States|Univ Rochester Med Ctr /ID# 144166, Rochester, New York, United States|Levine Cancer Ins, Carolina Me /ID# 144124, Charlotte, North Carolina, United States|University of Cincinnati /ID# 144164, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 144153, Cleveland, Ohio, United States|Cleveland Clinic Main Campus /ID# 144023, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 144016, Columbus, Ohio, United States|University of Toledo /ID# 156763, Toledo, Ohio, United States|Univ Oklahoma HSC /ID# 144161, Oklahoma City, Oklahoma, United States|St. Luke's Hospital /ID# 148191, Bethlehem, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 147525, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 157623, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 144191, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center /ID# 145893, Philadelphia, Pennsylvania, United States|Allegheny General Hospital /ID# 144126, Pittsburgh, Pennsylvania, United States|UPMC - Shadyside /ID# 144159, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina /ID# 144141, Charleston, South Carolina, United States|Austin Cancer Centers /ID# 151061, Austin, Texas, United States|Baylor Sammons Cancer Center /ID# 155542, Dallas, Texas, United States|Univ TX, MD Anderson /ID# 144018, Houston, Texas, United States|UT Health Science Ctr-Houston /ID# 144013, Houston, Texas, United States|Scott and White Medical Center /ID# 160743, Temple, Texas, United States|Intermountain Medical Center /ID# 144142, Murray, Utah, United States|University of Utah /ID# 144160, Salt Lake City, Utah, United States|Inova Health System /ID# 152956, Falls Church, Virginia, United States|Virginia Commonwealth Univ /ID# 149014, Richmond, Virginia, United States|Virginia Mason Medical Center /ID# 144022, Seattle, Washington, United States|University of Washington /ID# 144162, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 144167, Madison, Wisconsin, United States|Froedtert and Medical College /ID# 144139, Milwaukee, Wisconsin, United States|Instituto Med Alex Flem /ID# 142884, Buenos Aires, Argentina|Sanatorio Parque S.A. - Grupo /ID# 142825, Rosario, Santa FE, Argentina|Liverpool Hospital /ID# 144392, Liverpool, New South Wales, Australia|The Prince of Wales Hospital /ID# 144882, Randwick, New South Wales, Australia|Royal North Shore Hospital /ID# 143870, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 143860, Waratah, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 143868, Wollongong, New South Wales, Australia|Princess Alexandra Hospital /ID# 143857, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital /ID# 143867, Adelaide, South Australia, Australia|Calvary North Adelaide Hospita /ID# 143866, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 143858, Fitzroy, Victoria, Australia|Austin Hospital /ID# 143859, Heidelberg, Victoria, Australia|St. John of God Subiaco Hosp /ID# 143869, Subiaco, Western Australia, Australia|Medizinische Universität Wien /ID# 141981, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 141982, Graz, Austria|Medical University Innsbruck /ID# 141984, Innsbruck, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus /ID# 141983, Linz, Austria|Cliniques Universitaires Saint Luc /ID# 141648, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 141645, Charleroi, Hainaut, Belgium|CHU de Liege /ID# 162860, Liège, Liege, Belgium|UZ Gent /ID# 141647, Gent, Oost-Vlaanderen, Belgium|Centre Hospitalier Jolimont /ID# 143873, La Louvière, Belgium|UZ Leuven /ID# 143872, Leuven, Belgium|UCL Mont Godinne /ID# 141644, Yvoir, Belgium|Liga Norte Rigrandese Contra o /ID# 143878, Natal, Rio Grande Do Norte, Brazil|Hospital Sao Lucas da PUCRS /ID# 143879, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Cancer de Barretos /ID# 143876, Barretos, Sao Paulo, Brazil|Icesp /Id# 144031, São Paulo, Sao Paulo, Brazil|Inca /Id# 143877, Rio de Janeiro, Brazil|Cancer Care Manitoba /ID# 149253, Winnipeg, Manitoba, Canada|Qe Ii Hsc /Id# 151600, Halifax, Nova Scotia, Canada|Juravinski Cancer Clinic /ID# 152117, Hamilton, Ontario, Canada|Victoria Hospital /ID# 144184, London, Ontario, Canada|The Ottawa Hospital /ID# 150120, Ottawa, Ontario, Canada|Princess Margaret Cancer Centr /ID# 166277, Toronto, Ontario, Canada|Hospital Maisonneuve-Rosemont /ID# 149315, Montreal, Quebec, Canada|McGill Univ HC /ID# 144187, Montreal, Quebec, Canada|Jewish General Hospital /ID# 144029, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 144027, Montréal, Quebec, Canada|CHU de Quebec-Universite Laval /ID# 144189, Quebec City, Quebec, Canada|CHUS - Hopital Fleurimont /ID# 149771, Sherbrooke, Quebec, Canada|Anhui Provincial Hospital /ID# 166320, Hefei, Anhui, China|1st Affil Hosp Soochow Univ /ID# 165596, Suzhou, Jiangsu, China|Huashan Hospital of Fudan University /ID# 159999, Shanghai, Shanghai, China|The Second Affiliated Hospital /ID# 165593, Hangzhou, Zhejiang, China|Sanbo Brain Hospital Capital M /ID# 166422, Beijing, China|Beijing Tian Tan Hospital /ID# 167160, Beijing, China|Peking Union Medical College H /ID# 157430, Beijing, China|Xiangya Hospital Central South University /ID# 166791, Changsha, China|1st Affiliated Hosp Fujian Med /ID# 159166, Fuzhou, China|Sun Yat-Sen Uni Cancer Center /ID# 143919, Guangzhou, Guangdong, China|Shengjing Hospital of China Medical University /ID# 167016, Shenyang, China|Tianjin Med Univ General Hosp /ID# 143923, Tianjin, China|Tongji Hosp Tongji Med College /ID# 163820, Wuhan, China|Fourth Military Medical University Tangdu Hospital, PLA /ID# 143920, Xi'an, China|Administradora del Country_S.A-Clinica Del Country /ID# 143881, Bogota, Cundinamarca, Colombia|Centro Medico Imbanaco de Cali /ID# 143882, Cali, Colombia|Hospital Pablo Tobon Uribe /ID# 143780, Medellín, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 147223, Montería, Colombia|Oncologos de Occidente SA /ID# 147713, Pereira, Colombia|Fakultni Nemocnice v Motole /ID# 142023, Prague 5, Praha 5, Czechia|Masarykuv onkologikcy ustav /ID# 143884, Brno, Czechia|FN Hradec Kralove /ID# 143885, Hradec Kralove, Czechia|Krajska nemocnice Liberec a.s. /ID# 142024, Liberec, Czechia|Univ Hosp Ostrava-Poruba /ID# 143883, Ostrava, Czechia|CHRU Lille - Hôpital Claude Huriez /ID# 143915, Lille CEDEX, Hauts-de-France, France|CHU-Hopital Avicenne /ID# 143910, Bobigny, Ile-de-France, France|Gustave Roussy /ID# 143912, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 143914, St Herblain CEDEX, Loire-Atlantique, France|Hopital de la Timone /ID# 143911, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|CHU de Nice /ID# 143916, Nice CEDEX 1, Provence-Alpes-Cote-d Azur, France|Insititut de Cancerologie /ID# 143908, Angers, France|Hopital Pitie Salpetriere /ID# 143917, Paris, France|Universitaetsklinik Heidelberg /ID# 143927, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinikum Leipzig /ID# 143962, Leipzig, Sachsen, Germany|Knappschaftskrankenhaus /ID# 143961, Bochum, Germany|Universitatsklinikum Tubingen /ID# 143926, Tuebingen, Germany|Prince of Wales Hospital /ID# 143952, Sha Tin, Hong Kong|Beaumont Hospital /ID# 142969, Dublin, Ireland|Rabin Medical Center /ID# 143957, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 143956, Tel Aviv-Yafo, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 143959, Haifa, Israel|Hadassah University Hospital /ID# 143958, Jerusalem, Israel|Sheba Medical Center /ID# 143960, Ramat Gan, Israel|AOU Citta della Salute Scienza /ID# 141801, Turin, Piemonte, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 141800, Milan, Italy|Istituto Oncologico Veneto /ID# 143821, Padova, Italy|Regina Elena National Cancer I /ID# 141795, Rome, Italy|National Cancer Center /ID# 141845, Goyang, Gyeonggido, Korea, Republic of|Severance Hospital /ID# 141846, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 143887, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 141844, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 143886, Seoul, Korea, Republic of|Hospital Zambrano Hellion /ID# 143845, San Pedro Garza García, Mexico|Vrije Universiteit Medisch Centrum /ID# 143889, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 141408, Groningen, Netherlands|Maastricht Universitair Medisch Centrum /ID# 143585, Maastricht, Netherlands|Haaglanden Medisch Centrum /ID# 141405, The Hague, Netherlands|Universitair Medisch Centrum Utrecht /ID# 141406, Utrecht, Netherlands|Canterbury District Health Boa /ID# 143861, Christchurch, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 143890, Wellington, New Zealand|CCA Braga - Hospital de Braga /ID# 141940, Braga, Portugal|Centro Hospitalar do Algarve /ID# 141939, Faro, Portugal|IPO Lisboa FG, EPE /ID# 141938, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 141941, Lisboa, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 142830, Porto, Portugal|Interregional clin.diagnostic cntr /ID# 141702, Kaliningrad, Kaliningradskaya Oblast, Russian Federation|State budgetary healthcare institution Republican Clinical Oncology Dispensary /ID# 141706, UFA, Republic Of Bashkortosta, Kirovskaya Oblast, Russian Federation|GEMC - European Medical Center /ID# 141703, Moscow, Moskovskaya Oblast, Russian Federation|NN Blokhin Russian Cancer /ID# 141707, Moscow, Moskva, Russian Federation|Scientific and Research Inst. /ID# 141701, Moscow, Moskva, Russian Federation|Federal State Treatment and rehabilitation center /ID# 141704, Moscow, Moskva, Russian Federation|Sverdlovsk Regional Oncology Center /ID# 141700, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|National University Hospital /ID# 143933, Singapore, Singapore|National Cancer Ctr Singapore /ID# 143932, Singapore, Singapore|University of Free State, Universitas Annex (National Hospital Grounds) /ID# 144064, Bloemfontein, Free State, South Africa|Unitas Hospital /ID# 152936, Centurion, Gauteng, South Africa|The Oncology Centre /ID# 143950, Durban, Kwazulu-Natal, South Africa|Netcare Oncology Intervent Ctr /ID# 143951, Cape Town, Western Cape, South Africa|Cape Town Oncology Trials /ID# 143948, Cape Town, Western Cape, South Africa|GVI Rondebosch Oncology Centre /ID# 143949, Cape Town, Western Cape, South Africa|Hospital Regional de Malaga /ID# 143902, Málaga, Malaga, Spain|Hosp Santa Creu i Sant Pau /ID# 143900, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 143906, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 143901, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 143930, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 143496, Madrid, Spain|Hospital General Universitario de Valencia /ID# 143903, Valencia, Spain|Kantonsspital Aarau /ID# 141885, Aarau, Switzerland|Ente Ospedaliero Cantonale /ID# 143936, Bellinzona, Switzerland|Inselspital, Universitaetsklinik /ID# 141886, Bern, Switzerland|University Hospital Zurich /ID# 141887, Zurich, Switzerland|National Taiwan Univ Hosp /ID# 143940, Taipei City, Taipei, Taiwan|Taipei Veterans General Hosp /ID# 143955, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 143941, Taoyuan City, Taiwan|Guy's and St Thomas' NHS Found /ID# 142652, London, London, City Of, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 154592, Birmingham, United Kingdom|Velindre Cancer Centre /ID# 141996, Cardiff, United Kingdom|Ninewells Hospital /ID# 141651, Dundee, United Kingdom|Western General Hospital /ID# 141802, Edinburgh, United Kingdom|St. James University Hospital /ID# 141653, Leeds, United Kingdom|University College Hospitals /ID# 142658, London, United Kingdom|Freeman Hospital /ID# 141999, Newcastle Upon Tyne, United Kingdom|Royal Marsden Hospital /ID# 142827, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02573324"
273,"NCT02565758","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors|Undifferentiated Pleomorphic Sarcoma|Squamous Cell Carcinoma of the Head and Neck|Carcinoma of the Breast","Drug: ABBV-085","Terminal elimination half life of ABBV-085.|Maximum observed plasma concentration (Cmax) of ABBV-085.|Number of participants with Adverse Events|Area under the curve (AUC) from time zero to the last measurable concentration AUC(0-t) of ABBV-085.|Objective response rate (ORR)|Progression free survival (PFS)|Duration of overall response (DOR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-394|2015-001645-84","September 18, 2015","March 25, 2019","March 25, 2019","October 1, 2015",,"April 5, 2019","Mayo Clinic Arizona /ID# 148582, Phoenix, Arizona, United States|Scottsdale Healthcare /ID# 151349, Scottsdale, Arizona, United States|University of California, Los Angeles /ID# 148586, Los Angeles, California, United States|Univ of Colorado Cancer Center /ID# 148581, Aurora, Colorado, United States|University of Chicago /ID# 148579, Chicago, Illinois, United States|Dana-Farber Cancer Institute /ID# 143782, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 151348, Saint Louis, Missouri, United States|NYU Langone Medical Center /ID# 150786, New York, New York, United States|Duke Univ Med Ctr /ID# 148200, Durham, North Carolina, United States|Carolina BioOncology Institute /ID# 148583, Huntersville, North Carolina, United States|University of Pennsylvania /ID# 148576, Philadelphia, Pennsylvania, United States|Greenville Hospital System /ID# 148652, Greenville, South Carolina, United States|Mary Crowley Cancer Research /ID# 148580, Dallas, Texas, United States|Univ TX, MD Anderson /ID# 147681, Houston, Texas, United States|South Texas Accelerated Research Therapeutics /ID# 141715, San Antonio, Texas, United States|Virginia Cancer Specialists /ID# 148584, Fairfax, Virginia, United States|Gustave Roussy /ID# 150300, Villejuif, Ile-de-France, France|Hospital Univ Ramon y Cajal /ID# 150799, Madrid, Spain|Fundacion Jimenez Diaz /ID# 148564, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 146039, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02565758"
274,"NCT02549092","A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)",,"Active, not recruiting","No Results Available","Advanced Parkinson's Disease","Drug: ABT-SLV187","Change in the Modified Parkinson's Disease Sleep Scale (PDSS-2) Total Score|Change in the Non-Motor Symptoms Scale (NMSS) Total Score|Columbia-Suicide Severity Rating Scale (C-SSRS)|Change in 12-lead electrocardiogram (ECG)|Change in Patient Global Impression of Change (PGIC) Score|Minnesota Impulsive Disorders Interview (MIDI)|Number of Participants with Adverse Events|Change in King's PD Pain Scale Score|Change in Geriatric Depression Scale (GDS-15) Score|Change in Clinical Global Impression of Change (CGI-C) Score|Change in Unified Parkinson's Disease Rating Scale (UPDRS) Score|Change in Sleep Attack Questionnaire (SAQ) Score|Change in Mini-Mental State Examination (MMSE) Score|Change in Montreal Cognitive Assessment (MoCA) Score|Change in Parkinson's Anxiety Scale (PAS) Score|Change in Parkinson's Disease Questionnaire (PDQ-8) Score","AbbVie","All","30 Years to 99 Years   (Adult, Older Adult)","Phase 3","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-927|2014-004865-26","September 9, 2015","May 7, 2020","May 7, 2020","September 15, 2015",,"November 29, 2019","Parkinson's and Movement /ID# 161596, Fountain Valley, California, United States|Boca Raton Regional Hospital /ID# 200056, Boca Raton, Florida, United States|University of Florida Neurolog /ID# 168699, Jacksonville, Florida, United States|Parkinson's Disease Treatment Center of Southwest Florida /ID# 168085, Port Charlotte, Florida, United States|Rush University Medical Center /ID# 168088, Chicago, Illinois, United States|St. Luke's Health System /ID# 168706, Kansas City, Missouri, United States|Central Texas Neurology Consul /ID# 168087, Round Rock, Texas, United States|Inland Northwest Research /ID# 200113, Spokane, Washington, United States|Westmead Hospital /ID# 136575, Westmead, New South Wales, Australia|Royal Adelaide Hospital /ID# 136577, Adelaide, South Australia, Australia|Royal Melbourne Hospital /ID# 136780, Parkville, Victoria, Australia|Goulburn Valley Hospital /ID# 164202, Shepparton, Victoria, Australia|Zeidler Ledcor Centre /ID# 136586, Edmonton, Alberta, Canada|The Ottawa Hospital /ID# 139341, Ottawa, Ontario, Canada|Toronto Western Hospital /ID# 136585, Toronto, Ontario, Canada|Central Hospital Bremerhaven /ID# 136573, Bremerhaven, Germany|251 Airforce General Hospital /ID# 160594, Athens, Greece|Mediterraneo Hospital /ID# 208042, Glyfada, Greece|A.O. Univ. Ospedali Riuniti /ID# 135964, Ancona, Marche, Italy|Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 136789, Bologna, Italy|A.O.U. Ospedali Riuniti di Fog /ID# 136792, Foggia, Italy|A.O.U. Policlinico G. Martino /ID# 136790, Messina, Italy|Ospedale S.Maria della Miseri /ID# 160609, Perugia, Italy|Azienda Sanitaria Locale di /ID# 160608, Ponderano,biella, Italy|Azienda Policlinico Umberto I /ID# 201223, Roma, Italy|Severance Hospital /ID# 163019, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 162990, Seoul, Korea, Republic of|Asan Medical Center /ID# 163018, Seoul, Korea, Republic of|Hospital Universitario de Bellvitge /ID# 136579, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Santa Creu i Sant Pau /ID# 136581, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 137689, Barcelona, Spain|Hospital Universitario Puerta /ID# 157977, Cadiz, Spain|Hospital Virgen Nieves /ID# 136583, Granada, Spain|CHU Insular-Materno Infantil /ID# 136783, Las Palmas, Spain|Hospital Univ Ramon y Cajal /ID# 136784, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 145624, Sevilla, Spain|Hospital Universitario La Fe /ID# 136722, Valencia, Spain|Karolinska Univ Sjukhuset /ID# 135961, Solna, Sweden",,"https://ClinicalTrials.gov/show/NCT02549092"
275,"NCT02534870","Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects",,"Completed","No Results Available","Healthy Volunteer","Drug: ABT-450/r/ABT-267|Drug: ABT-333","Maximum Plasma Concentration (Cmax) of ABT-450|Maximum Plasma Concentration (Cmax) of ABT-267|Maximum Plasma Concentration (Cmax) of ABT-333|Maximum Plasma Concentration (Cmax) of Ritonavir|Time to Maximum Plasma Concentration (Tmax) of ABT-450|Time to Maximum Plasma Concentration (Tmax) of ABT-267|Time to Maximum Plasma Concentration (Tmax) of ABT-333|Time to Maximum Plasma Concentration (Tmax) of Ritonavir|Trough Concentration (Ctrough) of ABT-450|Trough Concentration (Ctrough) of ABT-267|Trough Concentration (Ctrough) of ABT-333|Trough Concentration (Ctrough) of Ritonavir|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267|Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333|Number of participants with adverse events","AbbVie","All","18 Years to 45 Years   (Adult)","Phase 1","18","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-769","September 2015","September 2015","September 2015","August 28, 2015",,"October 19, 2015","Site Reference ID/Investigator# 137655, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02534870"
276,"NCT02533375","Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)",,"Completed","Has Results","Generalized Pustular Psoriasis (GPP)|Adalimumab|Japanese","Drug: Adalimumab","Proportion of Participants Achieving Clinical Response at Week 16|Number of Participants Achieving Clinical Response Over Time|Number of Participants Achieving Clinical Remission Over Time|Mean Change From Baseline in the Total GPP Score Over Time|Mean Change From Baseline in JDA Severity Index of GPP Over Time|Mean Change From Baseline in Total Skin Score Over Time|Mean Percent Change From Baseline in Total Skin Score Over Time|Mean Change From Baseline in Total Systemic/Laboratory Test Score Over Time|Mean Change From Baseline in Total Erythema Area Over Time|Mean Change From Baseline in Total Erythema Area With Pustules Over Time|Mean Change From Baseline in Total Edema Area Over Time|Mean Change From Baseline in Body Temperature Over Time|Mean Change From Baseline in White Blood Cell (WBC) Concentration Over Time|Mean Change From Baseline in High-Sensitivity C-Reactive Protein (Hs-CRP) Over Time|Mean Change From Baseline in Serum Albumin Over Time|Number of Participants Achieving ""Mild"" in the JDA Severity Index of Generalized Pustular Psoriasis (GPP) for Participants With ""Moderate"" or ""Severe"" at Baseline Over Time|Proportion of Participants Achieving Treatment Success in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Over Time|Change From Baseline in Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade Over Time|Proportion of Participants Achieving Physician's Global Assessment of Generalized Pustular Psoriasis (PGA-GPP) Grade 0 or 1 for Those With PGA Grade of at Least 2 at Baseline Over Time|Proportion of Participants Achieving Psoriasis Area and Severity Index 90 (PASI 90) Over Time|Proportion of Participants Achieving Psoriasis Area and Severity Index 75 (PASI 75) Over Time|Proportion of Participants Achieving Psoriasis Area and Severity Index 50 (PASI 50) Over Time|Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time|Mean Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score Over Time|Proportion of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 Over Time|Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time|Mean Change From Baseline in Short Form-36 Health Status Survey Version 2 (SF-36 V2) Score Over Time|Proportion of Participants Taking Systemic Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study|Proportion of Participants Taking Topical Co-medication for Generalized Pustular Psoriasis (GPP) at Any Time During the Study","AbbVie","All","15 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-193","September 28, 2015","September 15, 2016","July 20, 2017","August 26, 2015","January 14, 2019","January 14, 2019",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02533375/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT02533375/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02533375"
277,"NCT02531178","A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: ABBV-257|Biological: Placebo","Proportion of subjects with adverse events|Change in Vital signs|Change in Physical examination|Changes in Electrocardiogram (ECG)|Maximum observed serum concentration (Cmax)|Time to maximum observed serum concentration (Tmax)|Immunogenicity by measurement of Anti-drug antibody","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","M14-439|2015-000094-12","July 2015","February 2016","February 2016","August 24, 2015",,"March 3, 2016","Site Reference ID/Investigator# 139394, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT02531178"
278,"NCT02517528","ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis",,"Completed","Has Results","Chronic Hepatitis C Virus (HCV)","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: ribavirin","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12)|Percentage of Participants Achieving Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)|Percentage of Participants With On Treatment Virologic Failure|Percentage of Participants With Virologic Relapse|Percentage of Participants With Virologic Relapse by Post-Treatment Week 24","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","104","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-491","July 20, 2015","September 29, 2016","March 16, 2017","August 7, 2015","October 9, 2018","October 9, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02517528/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02517528/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02517528"
279,"NCT02517515","ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection",,"Completed","Has Results","Hepatitis C Virus (HCV)","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse by Post-treatment Week 12|Percentage of Participants With Post-treatment Relapse by Post-treatment Week 24","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","650","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-767","July 2015","October 2016","June 2017","August 7, 2015","October 27, 2017","October 27, 2017",,,"https://ClinicalTrials.gov/show/NCT02517515"
280,"NCT02513459","A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease",,"Completed","No Results Available","Crohn Disease","Drug: ABBV-066","Incidence of drug-related adverse events","AbbVie|Boehringer Ingelheim","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-989|2015-001834-15|1311.20","September 16, 2015","June 19, 2019","June 19, 2019","July 31, 2015",,"June 26, 2019","MGG Group, Inc.Chevy Chase Clinical Research /ID# 155068, Chevy Chase, Maryland, United States|Clin Res Inst of Michigan, LLC /ID# 155066, Chesterfield, Michigan, United States|Cliniques Universitaires Saint Luc /ID# 154985, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 154988, Liège, Liege, Belgium|Imelda Ziekenhuis /ID# 154984, Bonheiden, Belgium|ULB Erasme /ID# 154987, Brussels, Belgium|AZ Groeninge /ID# 154989, Kortrijk, Belgium|UZ Leuven /ID# 154986, Leuven, Belgium|AZ-Delta /ID# 154983, Roeselare, Belgium|McMaster University Med Cent /ID# 155019, Hamilton, Ontario, Canada|Universitaetsklinikum Erlangen /ID# 155039, Erlangen, Bayern, Germany|Med Hochschule Hanover /ID# 155041, Hannover, Germany|Yeungnam University Med Ctr /ID# 155056, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Kangbuk Samsung Hospital /ID# 155054, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 155055, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Asan Medical Center /ID# 165568, Seoul, Korea, Republic of|Academisch Medisch Centrum /ID# 155058, Amsterdam, Noord-Holland, Netherlands|Acad Ziekenhuis Maastricht /ID# 155059, Maastricht, Netherlands|NZOZ Vivamed /ID# 155061, Warsaw, Poland|Lexmedica /Id# 155062, Wroclaw, Poland|Hospital Duran i Reynals /ID# 155063, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 155064, Barcelona, Spain|Hospital Univ de la Princesa /ID# 155065, Madrid, Spain|Guy's and St Thomas' NHS Found /ID# 155046, London, London, City Of, United Kingdom|Addenbrookes Hospital /ID# 155047, Cambridge, United Kingdom|St. James University Hospital /ID# 155050, Leeds, United Kingdom|Royal Victoria Infirmary, Newc /ID# 155049, Newcastle Upon Tyne, United Kingdom|John Radcliffe Hospital /ID# 155048, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02513459"
281,"NCT02506179","Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis","UCanADA","Active, not recruiting","No Results Available","Ulcerative Colitis (UC)",,"Change from baseline in depressive symptoms at Week 52|Change from baseline in depressive symptoms at Week 8|Change from baseline in the proportion of patients with PHQ-9 >= 10|Change from baseline in Disability|Change from baseline in Overall quality of life|Change from baseline in Ulcerative Colitis (UC)-specific quality of life|Change from baseline in Fatigue|Change from baseline in Sleep impairment,|Change from baseline in Work productivity|Assessing Simple Clinical Colitis Activity Index (SCCAI)|Change from baseline in Fecal Calprotectin levels|Mayo endoscopic sub-score|Proportion of patients with Complications including hospitalization and surgery|Proportion of patients on steroids|Change from baseline in Physician's Global Assessment (PGA)","AbbVie|Cato Research","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-325","August 18, 2015","April 30, 2020","April 30, 2020","July 23, 2015",,"April 17, 2019","University of Calgary /ID# 144032, Calgary, Alberta, Canada|Zeidler Ledcor Centre /ID# 145973, Edmonton, Alberta, Canada|Columbia Gastro Mgmnt Ltd /ID# 136820, New Westminster, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 141107, Vancouver, British Columbia, Canada|Discovery Clinical Services /ID# 144102, Victoria, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 136533, Victoria, British Columbia, Canada|Dr. Everett Chalmers Reg Hosp. /ID# 136534, Fredericton, New Brunswick, Canada|Dr Chadwick Ian Williams Prof /ID# 144802, St. John, New Brunswick, Canada|Bellini Medicine Professional /ID# 144241, Brampton, Ontario, Canada|Oshawa Clinic /ID# 144364, Oshawa, Ontario, Canada|The Ottawa Hospital /ID# 139392, Ottawa, Ontario, Canada|Kensington Screening Clinic /ID# 141106, Toronto, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 141108, Toronto, Ontario, Canada|Dr O Tarabain Medicine Prof Corp /ID# 144034, Windsor, Ontario, Canada|Dr. Rahman Bacchus Med. Corp. /ID# 141780, Windsor, Ontario, Canada|Hopital Hotel-Dieu de Levis /ID# 137099, Levis, Quebec, Canada|Hospital Maisonneuve-Rosemont /ID# 137336, Montreal, Quebec, Canada|CHUM - Hopital Saint-Luc /ID# 139393, Montreal, Quebec, Canada|McGill Univ HC /ID# 136821, Montreal, Quebec, Canada|Clinique MEDI-CLE /ID# 153690, Montreal, Quebec, Canada|CHU de Quebec-Universite Laval /ID# 147557, Quebec City, Quebec, Canada|CHUS - Hopital Fleurimont /ID# 137840, Sherbrooke, Quebec, Canada|Royal Univ. Hosp, Saskatoon,CA /ID# 137838, Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT02506179"
282,"NCT02504099","A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","GEODE - I","Terminated","Has Results","Chronic Hepatitis C Infection","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: ombitasvir/paritaprevir/ritonavir|Drug: ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse|Percentage of Participants With Long Term Clinical Outcomes|Percentage of Participants With Recurrent HCV Infection Post Liver Transplant","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","3","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-726|2015-001049-10","July 2015","September 2016","December 2016","July 21, 2015","December 12, 2017","December 12, 2017",,,"https://ClinicalTrials.gov/show/NCT02504099"
283,"NCT02499783","Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease",,"Completed","Has Results","Crohn's Disease","Biological: adalimumab|Other: placebo","Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) at Week 4|Percentage of Participants Who Achieved Clinical Remission at Week 26 (CDAI < 150) in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline at Week 4|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of At Least 50% From Baseline at Week 26 in Participants Who Achieved Clinical Response Plus at Least 30% Reduction in Hs-CRP From Baseline at Week 8|Percentage of Participants Who Discontinued Corticosteroid Use and Achieved Clinical Remission at Week 26 in Participants Who Were Taking Steroids at Baseline and Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8|Percentage of Participants Who Discontinued Corticosteroid Use and Achieved CDAI < 150 Plus a Reduction in Hs-CRP of ≥ 50% From Baseline (BL) at Week 26 in Participants Taking Steroids at BL and Who Achieved CDAI Decrease and Hs-CRP Reduction at Week 8|Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 4|Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline at Week 4|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) and Hs-CRP < 3 mg/L at Week 4|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8|Percentage of Participants Who Achieved Inflammatory Bowel Disease Questionnaire (IBDQ) Remission (IBDQ ≥ 170 Points) at Week 4|Percentage of Participants Who Achieved IBDQ Remission (IBDQ ≥ 170 Points) at Week 26 in Participants With Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8|Change From Baseline in Fecal Calprotectin Level at Week 4|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 4|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150), Hs-CRP < 3 mg/L and Fecal Calprotectin < 250 μg/g at Week 26 in Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) at Week 8|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Double-Blind Weeks 0-4|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Over Time (Any Adalimumab Set)|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus A Reduction in Hs-CRP of at Least 50% From Baseline Over Double-Blind Weeks 0-4|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Plus a Reduction in Hs-CRP of at Least 50% From Baseline Over Time (Any Adalimumab Set)|Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Double-Blind Weeks 0-4|Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Over Time (Any Adalimumab Set)|Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Double-Blind Weeks 0-4|Percentage of Participants Who Achieved Clinical Response (Decrease in CDAI ≥ 70 Points From Baseline) Plus a Reduction in Hs-CRP of at Least 30% From Baseline Over Time (Any Adalimumab Set)|Change From Baseline in CDAI Over Double-Blind Weeks 0-4|Change From Baseline in CDAI Over Time (Any Adalimumab Set)|Change From Baseline in Hs-CRP Level Over Double-Blind Weeks 0-4|Change From Baseline in Hs-CRP Level Over Time (Any Adalimumab Set)|Change From Baseline in Fecal Calprotectin Level Over Time (Any Adalimumab Set)","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","205","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-233","August 17, 2015","May 19, 2017","December 15, 2017","July 16, 2015","January 4, 2019","January 4, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02499783/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02499783/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02499783"
284,"NCT02499263","A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice","EUREKA","Completed","Has Results","Ulcerative Colitis",,"Percentage of Participants Who Were Week 8 Responders With Durable Clinical Response at Week 56|Percentage of Participants With Clinical Response at Week 8|Percentage of Participants With Clinical Response at Week 24|Percentage of Participants With Clinical Response at Week 56|Percentage of Participants With Clinical Remission at Week 8|Percentage of Participants With Clinical Remission at Week 56|Percentage of Participants Who Were Week 8 Responders With Clinical Remission at Week 8|Percentage of Participants Who Were Week 8 Responders With Clinical Remission at Week 56|Percentage of Participants With Steroid-free Remission at Week 8|Percentage of Participants With Steroid-free Remission at Week 56|Percentage of Participants Who Were Week 8 Responders With Steroid-free Remission at Week 8|Percentage of Participants Who Were Week 8 Responders With Steroid-free Remission at Week 56|Percentage of Participants With Steroid-free Response at Week 8|Percentage of Participants With Steroid-free Response at Week 56|Percentage of Participants Who Were Week 8 Responders With Steroid-free Response at Week 8|Percentage of Participants Who Were Week 8 Responders With Steroid-free Response at Week 56|Percentage of Participants With Mucosal Healing at Week 8|Percentage of Participants With Mucosal Healing at Week 56|Percentage of Participants Who Were Week 8 Responders With Mucosal Healing at Week 8|Percentage of Participants Who Were Week 8 Responders With Mucosal Healing at Week 56|Change in Partial Mayo Score From Baseline to Week 8 in Participants Who Were Clinical Responders at Week 56|Change in Full Mayo Score From Baseline to Week 8 in Participants Who Were Clinical Responders at Week 56|Change in Full Mayo Score From Baseline to Week 56 in Participants Who Were Clinical Responders at Week 56|Fecal Calprotectin Level at Week 8|Fecal Calprotectin Level at Week 56|Fecal Calprotectin Level at Week 8 in Participants Who Were Clinical Responders at Week 8|Fecal Calprotectin Level at Week 56 in Participants Who Were Clinical Responders at Week 8|Fecal Calprotectin Level at Week 8 in Participants Who Were Clinical Responders at Week 56|Fecal Calprotectin Level at Week 56 in Participants Who Were Clinical Responders at Week 56|Change in the Composition of Fecal Microbiota From Baseline to Week 8 and Week 56","AbbVie","All","19 Years and older   (Adult, Older Adult)",,"150","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-346","June 11, 2015","September 17, 2018","September 17, 2018","July 16, 2015","November 1, 2019","November 1, 2019","Kyungpook National Univ Hosp /ID# 153133, Daegu, Daegu Gwang Yeogsi, Korea, Republic of|Ajou University Hospital /ID# 138457, Suwon-si, Gyeonggido, Korea, Republic of|St. Vincent's Hospital /ID# 138455, Suwon, Gyeonggido, Korea, Republic of|Inje University Busan Paik Hospital /ID# 138451, Busan, Gyeongsangbugdo, Korea, Republic of|Inha University Hospital /ID# 150176, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 138450, Gwangju, Jeonranamdo, Korea, Republic of|Kyung Hee University Medical Center /ID# 138453, Dongdaemun-gu, Seoul Teugbyeolsi, Korea, Republic of|Kangbuk Samsung Hospital /ID# 150175, Jongno-Gu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 138456, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 138449, Seoul, Seoul Teugbyeolsi, Korea, Republic of|SMG-SNU Boramae Medical Center /ID# 138448, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Keimyung Univ Dongsan medical /ID# 138447, Daegu, Korea, Republic of|Daejeon St. Mary's Hospital /ID# 138445, Daejeon, Korea, Republic of|Chosun University Hospital /ID# 138454, Gwangju, Korea, Republic of|Korea University Anam Hospital /ID# 138446, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 138443, Seoul, Korea, Republic of|Ewha Womans University Mokdong /ID# 138444, Seoul, Korea, Republic of|Inje University Seoul Paik Hos /ID# 138452, Seoul, Korea, Republic of|Chung-Ang University Med. Ctr. /ID# 138441, Seoul, Korea, Republic of","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02499263/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02499263/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02499263"
285,"NCT02493855","Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a","Drug: Ombitasvir/ABT-450/Ritonavir|Drug: Dasabuvir|Drug: Ribavirin (RBV)","Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment","AbbVie","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-242|2014-001478-32","June 2015","April 2016","December 2016","July 10, 2015","May 15, 2017","October 31, 2017",,,"https://ClinicalTrials.gov/show/NCT02493855"
286,"NCT02487199","Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease",,"Completed","Has Results","Hepatitis C Virus (HCV)","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: ombitasvir/paritaprevir/ritonavir","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Number of Participants With Adverse Events|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-461|2015-002012-33","September 30, 2015","December 5, 2016","December 5, 2016","July 1, 2015","December 4, 2017","December 4, 2017",,,"https://ClinicalTrials.gov/show/NCT02487199"
287,"NCT02486406","A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","ZIRCON","Active, not recruiting","No Results Available","Chronic Hepatitis C Infection","Drug: paritaprevir|Drug: ombitasvir|Drug: dasabuvir|Drug: ribavirin|Drug: ritonavir","Part1: Maximum plasma concentration (Cmax) of OBV|Part 1: Maximum plasma concentration (Cmax) of PTV|Part 1: Lowest plasma concentration (Ctrough) of OBV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of OBV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of RTV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of PTV|Part 1: Maximum plasma concentration (Cmax) of DSV|Part 1: Lowest plasma concentration (Ctrough) of DSV|Part 1: concentration of drug in blood plasma against time [Area under the curve (AUC)] of DSV|Part 3: Percentage of participants who relapse out of participants who achieved sustained virologic response (SVR) in Part 1 or Part 2 of the study.|Part 1: Maximum plasma concentration (Cmax) of RTV|Part 1: Lowest plasma concentration (Ctrough) of PTV|Part 1: Lowest plasma concentration (Ctrough) of RTV|Parts 1 and 2: Percentage of participants with sustained virologic response 12 weeks after the last actual dose of study drug (SVR12).|Part 3: Percentage of participants who have new HCV infection|Parts 1 and 2: Percentage of subjects who achieve SVR12 summarized by formulation, age and weight group and across all subjects on the adult formulations.|Parts 1 and 2: Percentage of participants who achieve SVR24 by formulation, age and weight group, across all the subjects, and across all subjects on the adult formulations.|Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on height|Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on waist circumference|Part 3: Assess the impact of OBV, PTV, RTV with or without DSV and with or without RBV on tanner staging|Parts 1 and 2: Percentage of participants with Alanine aminotransferase (ALT) normalization during treatment","AbbVie","All","3 Years to 17 Years   (Child)","Phase 2","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-748|2015-000111-41","October 28, 2015","November 26, 2020","November 26, 2020","July 1, 2015",,"July 1, 2019","Univ California, San Francisco /ID# 136774, San Francisco, California, United States|Children's Hospital Colorado /ID# 137017, Aurora, Colorado, United States|University of Florida /ID# 136830, Gainesville, Florida, United States|Florida Hospital /ID# 167663, Orlando, Florida, United States|Indiana University /ID# 137015, Indianapolis, Indiana, United States|Boston Childrens Hospital /ID# 137174, Boston, Massachusetts, United States|Boston Medical Center /ID# 136831, Boston, Massachusetts, United States|Columbia Univ Medical Center /ID# 136431, New York, New York, United States|Children's Hosp Philadelphia /ID# 137018, Philadelphia, Pennsylvania, United States|Baylor College of Medicine /ID# 136590, Houston, Texas, United States|Seattle Children's Hospital /ID# 137019, Seattle, Washington, United States|Cliniques Universitaires Saint Luc /ID# 136910, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 136911, Leuven, Belgium|Charité Universitätsmedizin Campus Mitte /ID# 141620, Berlin, Germany|Universitätsklinikum Freiburg /ID# 141618, Freiburg, Germany|Helios Klinikum Wuppertal /ID# 142883, Wuppertal, Germany|San Jorge Children Hospital /ID# 136832, San Juan, Puerto Rico|Hospital Univ Vall d'Hebron /ID# 137098, Barcelona, Spain|Hospital Sant Joan de Deu /ID# 137096, Esplugues de Llobregat, Spain|Hospital Universitario La Paz /ID# 137094, Madrid, Spain|Hospital Universitario La Fe /ID# 137097, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02486406"
288,"NCT02485600","Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients",,"Recruiting","No Results Available","Parkinson's Disease (PD)",,"Change in participant's motor symptoms|Change in the cognitive functions.|Change in the Parkinson's Disease Questionnaire (PDQ-39)|Change in caregiver burden|Change in the non-motor symptoms.|Change in caregiver work productivity|Change in the participant's Healthcare Resource Utilization","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-506","October 19, 2015","April 30, 2021","April 30, 2021","June 30, 2015",,"April 1, 2019","University of Calgary /ID# 151948, Calgary, Alberta, Canada|Zeidler Ledcor Centre /ID# 135979, Edmonton, Alberta, Canada|St. Boniface Clinic, CA /ID# 162092, Winnipeg, Manitoba, Canada|Hamilton Health Sciences /ID# 148808, Hamilton, Ontario, Canada|Kingston General Hospital /ID# 144942, Kingston, Ontario, Canada|London Health Sciences Centre /ID# 138434, London, Ontario, Canada|The Ottawa Hospital /ID# 135981, Ottawa, Ontario, Canada|Toronto Western Hospital /ID# 135980, Toronto, Ontario, Canada|McGill Univ HC /ID# 138334, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 135977, Montréal, Quebec, Canada|Ctr Hosp Enfant Jesus /ID# 138435, Quebec City, Quebec, Canada|CSSS Alphonse-Desjardins, CHAU /ID# 144941, Quebec City, Quebec, Canada|CHUS - Hopital Fleurimont /ID# 148811, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02485600"
289,"NCT02483104","Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer",,"Completed","No Results Available","Ovarian Cancer","Drug: veliparib|Drug: carboplatin|Drug: paclitaxel","Number of participants with Dose-limiting toxicities|Number of participants with adverse events|Preliminary tumor response|Maximum observed plasma concentration (Cmax) of Veliparib|The time to Cmax (peak time, Tmax) of Veliparib|The area under the plasma concentration-time curve (AUC) of Veliparib","AbbVie","Female","20 Years to 99 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-488","July 2015","March 2016","July 2016","June 26, 2015",,"November 20, 2017","Site Reference ID/Investigator# 128815, Kurume-shi,Fukuoka, Japan|Site Reference ID/Investigator# 128997, Morioka-shi, Japan|Site Reference ID/Investigator# 128058, Nagaizumi-cho, Japan",,"https://ClinicalTrials.gov/show/NCT02483104"
290,"NCT02476617","Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a","Drug: ombitasvir/paritaprevir/ritonavir|Drug: dasabuvir|Drug: ribavirin","Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12","AbbVie","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","25","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-243","June 2015","August 2016","December 2016","June 19, 2015","September 5, 2017","October 3, 2017",,,"https://ClinicalTrials.gov/show/NCT02476617"
291,"NCT02470585","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",,"Active, not recruiting","No Results Available","Ovarian Cancer|Ovarian Neoplasm","Drug: Veliparib|Drug: Paclitaxel|Drug: Carboplatin|Other: Placebo","Progression-Free survival (PFS)|Overall Survival (OS)|Disease Related Symptom (DRS) scores","AbbVie|Gynecologic Oncology Group|Australia New Zealand Gynaecological Oncology Group","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","1140","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-694|2014-005070-11","July 14, 2015","July 24, 2020","December 8, 2026","June 12, 2015",,"September 24, 2019","University of Alabama at Birmingham - Main /ID# 138087, Birmingham, Alabama, United States|Tennessee Valley Gyn-Onc /ID# 139548, Huntsville, Alabama, United States|University of South Alabama /ID# 138091, Mobile, Alabama, United States|Alaska Womens Cancer Care /ID# 138231, Anchorage, Alaska, United States|Arizona Oncology Associates, PC-HOPE /ID# 142002, Tucson, Arizona, United States|Arizona Oncology Associates, PC-HOPE /ID# 143805, Tucson, Arizona, United States|Arizona Oncology Associates, PC-HOPE /ID# 143806, Tucson, Arizona, United States|Arizona Oncology Associates, PC-HOPE /ID# 143808, Tucson, Arizona, United States|University of Arizona Cancer Center - North Campus /ID# 138084, Tucson, Arizona, United States|University of Arizona Cancer Center - North Campus /ID# 139495, Tucson, Arizona, United States|University of Arkansas for Medical Sciences /ID# 138253, Little Rock, Arkansas, United States|John Muir Medical Center /ID# 139618, Concord, California, United States|Ucsd /Id# 140323, La Jolla, California, United States|Long Beach Memorial Medical Ct /ID# 147526, Long Beach, California, United States|Kaiser Permanente /ID# 141305, Los Angeles, California, United States|University of California, Los Angeles /ID# 138179, Los Angeles, California, United States|Medical Oncology Care Assoc /ID# 139498, Orange, California, United States|Univ CA, Irvine Med Ctr /ID# 139613, Orange, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 144439, Sacramento, California, United States|California Pacific Medical Ctr /ID# 138177, San Francisco, California, United States|Kaiser Permanente - San Francisco /ID# 142051, San Francisco, California, United States|Univ California, San Francisco /ID# 138178, San Francisco, California, United States|Kaiser Permanente-Santa Clara /ID# 142053, Santa Clara, California, United States|Stanford University School of Med /ID# 139450, Stanford, California, United States|Palo Alto Medical Foundation /ID# 139452, Sunnyvale, California, United States|Kaiser Permanente Medical Ctr-Vallejo /ID# 139492, Vallejo, California, United States|Kaiser Permanente- Walnut Creek /ID# 142052, Walnut Creek, California, United States|Kaiser Permanente, Waterpark III Institute for Health Research /ID# 139499, Aurora, Colorado, United States|Univ of Colorado Cancer Center /ID# 138016, Aurora, Colorado, United States|Hartford Healthcare /ID# 138184, New Britain, Connecticut, United States|Yale University /ID# 138056, New Haven, Connecticut, United States|University of Miami /ID# 139457, Miami, Florida, United States|Women's Cancer Associates /ID# 140321, Saint Petersburg, Florida, United States|Sarasota Memorial Health Care /ID# 138180, Sarasota, Florida, United States|Moffitt Cancer Center /ID# 138061, Tampa, Florida, United States|Georgia Regents University /ID# 138085, Augusta, Georgia, United States|IACT Health /ID# 138058, Columbus, Georgia, United States|Memorial Health Univ Med Ctr /ID# 138019, Savannah, Georgia, United States|St. Joseph's/Candler /ID# 138090, Savannah, Georgia, United States|The Queens Medical Center /ID# 141709, Honolulu, Hawaii, United States|Kapiolani Medical Center /ID# 140319, Honolulu, Hawaii, United States|Rush University Medical Center /ID# 143491, Chicago, Illinois, United States|University of Chicago /ID# 139612, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 139451, Evanston, Illinois, United States|Sharma, Hinsdale, IL /ID# 140326, Hinsdale, Illinois, United States|Advocate Lutheran General Hosp /ID# 139489, Park Ridge, Illinois, United States|Indiana Univ School Medicine /ID# 139610, Indianapolis, Indiana, United States|Saint Vincent /ID# 139537, Indianapolis, Indiana, United States|McFarland Clinic, PC /ID# 139455, Ames, Iowa, United States|University of Iowa Hospitals and Clinics /ID# 138082, Iowa City, Iowa, United States|Univ Kansas Med Ctr /ID# 140322, Kansas City, Kansas, United States|Baptist Health Lexington /ID# 139542, Lexington, Kentucky, United States|University of Kentucky Chandler Medical Center /ID# 138060, Lexington, Kentucky, United States|Norton Cancer Institute /ID# 139567, Louisville, Kentucky, United States|Rheumatology Associates,PA /ID# 139544, Portland, Maine, United States|Greater Baltimore Medical Ctr /ID# 138049, Baltimore, Maryland, United States|Sinai Hospital of Baltimore /ID# 141306, Baltimore, Maryland, United States|Weinberg Cancer Inst Franklin /ID# 138235, Rossville, Maryland, United States|Baystate Medical Center /ID# 139456, Springfield, Massachusetts, United States|UMass Memorial Medical Center /ID# 139458, Worcester, Massachusetts, United States|Wayne State University /ID# 139601, Detroit, Michigan, United States|Henry Ford Health System /ID# 139536, Detroit, Michigan, United States|William Beaumont Hospital /ID# 139550, Royal Oak, Michigan, United States|Mayo Clinic - Rochester /ID# 139565, Rochester, Minnesota, United States|Mmcorc /Id# 139534, Saint Louis Park, Minnesota, United States|St. Dominic Hospital /ID# 138241, Jackson, Mississippi, United States|Ellis Fischel Cancer Center /ID# 139571, Columbia, Missouri, United States|Washington University-School of Medicine /ID# 138089, Saint Louis, Missouri, United States|Ozarks /ID# 139538, Springfield, Missouri, United States|Ferrell-Duncan Clinic /ID# 143484, Springfield, Missouri, United States|Nebraska Methodist Hospital /ID# 139600, Omaha, Nebraska, United States|Womens Cancer Center of Nevada /ID# 138092, Las Vegas, Nevada, United States|Renown Regional Medical Center /ID# 138237, Reno, Nevada, United States|Dartmouth-Hitchcock Med Ctr /ID# 139502, Lebanon, New Hampshire, United States|MD Anderson Cancer Ctr at Coop /ID# 139616, Camden, New Jersey, United States|Hackensack Univ Med Ctr /ID# 143776, Hackensack, New Jersey, United States|University of New Mexico /ID# 144220, Albuquerque, New Mexico, United States|SW Gynecologic Oncology Assoc /ID# 147097, Albuquerque, New Mexico, United States|Women's Cancer Care Associates /ID# 138234, Albany, New York, United States|Montefiore Medical Center /ID# 139585, Bronx, New York, United States|SUNY Downstate Medical Center /ID# 139533, Brooklyn, New York, United States|Roswell Park Comprehensive Cancer Center /ID# 138052, Buffalo, New York, United States|Northwell Health /ID# 139572, Lake Success, New York, United States|Icahn School of Med Mt. Sinai /ID# 139617, New York, New York, United States|Weill Cornell Medicine /ID# 138252, New York, New York, United States|Memorial Sloan Kettering Cancer Center /ID# 138017, New York, New York, United States|Memorial Sloan Kettering Cancer Center /ID# 154464, New York, New York, United States|SUNY Upstate Medical University - Downtown /ID# 139513, Syracuse, New York, United States|Hope Womens Cancer Centers /ID# 139614, Asheville, North Carolina, United States|Univ NC Chapel Hill /ID# 138547, Chapel Hill, North Carolina, United States|Carolinas Medical Center /ID# 139568, Charlotte, North Carolina, United States|Presbyterian Cancer Center /ID# 139590, Charlotte, North Carolina, United States|Duke University Medical Center /ID# 138048, Durham, North Carolina, United States|Wake Forest Baptist Medical Center /ID# 139588, Winston-Salem, North Carolina, United States|University of Cincinnati /ID# 139619, Cincinnati, Ohio, United States|Univ Hosp Cleveland /ID# 139615, Cleveland, Ohio, United States|Fairview Hospital /ID# 144403, Cleveland, Ohio, United States|Cleveland Clinic Main Campus /ID# 139501, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 138053, Columbus, Ohio, United States|Columbus NCORP /ID# 139587, Columbus, Ohio, United States|Womens Cancer Center /ID# 138062, Kettering, Ohio, United States|Hillcrest Hospital /ID# 144404, Mayfield Heights, Ohio, United States|Univ Oklahoma HSC /ID# 138020, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists /ID# 138059, Tulsa, Oklahoma, United States|Willamette Valley Cancer Institute /ID# 140318, Eugene, Oregon, United States|Kaiser Permanente, NW /ID# 138249, Portland, Oregon, United States|Abington Memorial Hospital /ID# 138086, Abington, Pennsylvania, United States|University of Pennsylvania /ID# 140079, Philadelphia, Pennsylvania, United States|Thomas Jefferson University /ID# 138239, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center /ID# 149479, Philadelphia, Pennsylvania, United States|University of Pittsburgh MC /ID# 138054, Pittsburgh, Pennsylvania, United States|Reading Hospital /ID# 138057, Reading, Pennsylvania, United States|Women and Infants Hospital /ID# 138083, Providence, Rhode Island, United States|Medical University of South Carolina /ID# 138181, Charleston, South Carolina, United States|Sanford Research/USD /ID# 139624, Sioux Falls, South Dakota, United States|Chattanoogas Program in Womens /ID# 139545, Chattanooga, Tennessee, United States|Texas Oncology - Austin Central /ID# 143817, Austin, Texas, United States|Texas Oncology - South Austin /ID# 143818, Austin, Texas, United States|Texas Oncology - Bedford /ID# 143814, Bedford, Texas, United States|Texas Oncology - Dallas /ID# 143809, Dallas, Texas, United States|Texas Oncology - Dallas /ID# 143812, Dallas, Texas, United States|Texas Oncology - Forth Worth /ID# 143811, Fort Worth, Texas, United States|Houston Methodist Hospital - Scurlock Tower /ID# 138232, Houston, Texas, United States|Memorial Hermann Hospital /ID# 138238, Houston, Texas, United States|Texas Oncology - The Woodlands /ID# 142003, The Woodlands, Texas, United States|Texas Oncology - Tyler /ID# 143810, Tyler, Texas, United States|University of Utah /ID# 138250, Salt Lake City, Utah, United States|University of Vermont Medical Center /ID# 138251, Burlington, Vermont, United States|University of Virginia /ID# 138088, Charlottesville, Virginia, United States|Carilion Roanoke Memorial Hosp /ID# 139602, Roanoke, Virginia, United States|Skagit Valley Medical Center /ID# 139586, Mount Vernon, Washington, United States|MultiCare Regional Cancer Ctr /ID# 149872, Puyallup, Washington, United States|Multicare Institute for Research and Innovation /ID# 143485, Tacoma, Washington, United States|HSHS St. Vincent Hospital /ID# 139453, Green Bay, Wisconsin, United States|Froedtert and Medical College /ID# 139449, Milwaukee, Wisconsin, United States|Coffs Harbour Health Campus /ID# 145132, Coffs Harbour, New South Wales, Australia|Gosford Hospital /ID# 145299, Gosford, New South Wales, Australia|St George Hospital /ID# 145138, Kogarah, New South Wales, Australia|Newcastle Private Hospital /ID# 145834, Lambton Heights, New South Wales, Australia|The Prince of Wales Hospital /ID# 145134, Randwick, New South Wales, Australia|Northern Cancer Institute /ID# 145681, St Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 145139, Waratah, New South Wales, Australia|Westmead Hospital /ID# 145137, Westmead, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 145133, Wollongong, New South Wales, Australia|The Townsville Hospital /ID# 149163, Douglas, Queensland, Australia|Royal Brisbane and Women's Hospital /ID# 145135, Herston, Queensland, Australia|Icon Cancer Centre /ID# 148208, South Brisbane, Queensland, Australia|Mater Misericordiae Limited /ID# 145682, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 150071, Adelaide, South Australia, Australia|Monash Health /ID# 145297, Clayton, Victoria, Australia|Cabrini Health /ID# 145142, Malvern, Victoria, Australia|Royal Womens Hospital /ID# 145136, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital /ID# 145140, Nedlands, Western Australia, Australia|St. John of God Subiaco Hosp /ID# 147742, Subiaco, Western Australia, Australia|Hc Ufmg /Id# 137156, Belo Horizonte, Minas Gerais, Brazil|Hospital Sao Lucas da PUCRS /ID# 137157, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Cancer de Barretos /ID# 137121, Barretos, Sao Paulo, Brazil|Centro de Referencia da Saude da Mulher - Hospital Perola Byington /ID# 137120, São Paulo, Sao Paulo, Brazil|Inca /Id# 137155, Rio de Janeiro, Brazil|Vejle Sygehus /ID# 137262, Vejle, Syddanmark, Denmark|Regionshospitalet Herning /ID# 137260, Herning, Denmark|Rambam Health Care Campus /ID# 137434, Haifa, Israel|The Lady Davis Carmel MC /ID# 137537, Haifa, Israel|Shaare Zedek Medical Center /ID# 137435, Jerusalem, Israel|Meir Medical Center /ID# 139397, Kfar Saba, Israel|Sheba Medical Center /ID# 137436, Ramat Gan, Israel|Kaplan Medical Center /ID# 137536, Rehovot, Israel|Aichi Cancer Center Hospital /ID# 148398, Nagoya-shi, Aichi, Japan|National Hospital Organization Kyushu Cancer Center /ID# 149133, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 148697, Kurume-shi, Fukuoka, Japan|Iwate Medical University Hospital /ID# 147721, Morioka-shi, Iwate, Japan|Kumamoto University Hospital /ID# 154169, Kumamoto-shi, Kumamoto, Japan|Mie University Hospital /ID# 149169, Tsu-shi, Mie, Japan|Tohoku University Hospital /ID# 149818, Sendai-shi, Miyagi, Japan|Niigata University Medical & Dental Hospital /ID# 149488, Niigata-shi, Niigata, Japan|Kindai University Hospital /ID# 154947, Osaka-sayama, Osaka, Japan|Shizuoka Cancer Center /ID# 147723, Sunto-gun, Shizuoka, Japan|The Cancer Institute Hosp JFCR /ID# 148436, Koto-ku, Tokyo, Japan|Keio University Hospital /ID# 148326, Shinjuku-ku, Tokyo, Japan|Yamagata University Hospital /ID# 153646, Yamagata-shi, Yamagata, Japan|Hyogo Cancer Center /ID# 148327, Akashi, Japan|Kansai Rosai Hospital /ID# 149237, Amagasaki, Japan|The Jikei Univ. Kashiwa Hosp. /ID# 149238, Kashiwa-shi, Japan|St. Marianna Univ Hospital /ID# 149327, Kawasaki, Japan|NHO Kure Medical Center and Ch /ID# 148569, Kure, Japan|Shikoku Cancer Center /ID# 148382, Matsuyama, Japan|Osaka International Cancer Institute /ID# 150778, Osaka, Japan|Hokkaido Cancer Center /ID# 148570, Sapporo, Japan|The Jikei University Hospital /ID# 148691, Tokyo, Japan|National Cancer Center /ID# 139404, Goyang, Gyeonggido, Korea, Republic of|Gangnam Severance Hospital /ID# 136835, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 136834, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Anam Hospital /ID# 136908, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 136909, Seoul, Korea, Republic of|Asan Medical Center /ID# 136836, Seoul, Korea, Republic of|Auckland City Hospital /ID# 145123, Auckland, New Zealand|Uniwersyteckie C. Kliniczne /ID# 138021, Gdańsk, Poland|Hospital Duran i Reynals /ID# 137298, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 137297, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 137300, Barcelona, Spain|Hospital Clin Univ San Carlos /ID# 137402, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 137299, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 137414, Madrid, Spain|Fundacion Inst Valenciano Onc /ID# 137403, Valencia, Spain|Beatson west of scotland cancer center /ID# 137965, Glasgow, Scotland, United Kingdom|Ninewells Hospital /ID# 137967, Dundee, United Kingdom|James Paget University Hosp /ID# 137970, Great Yarmouth, United Kingdom|Imanova Limited, Hammersmith Hospital /ID# 137966, London, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 137969, Norwich, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 137973, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02470585"
292,"NCT02462525","Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma",,"Terminated","No Results Available","Multiple Myeloma","Drug: ABBV-838|Drug: Pomalidomide|Drug: Dexamethasone","Maximum plasma concentration (Cmax) of ABBV-838|Maximum tolerated dose of ABBV-838|Preliminary activity of ABBV-838 monotherapy","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","74","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-467|2014-002609-39","May 6, 2015","December 6, 2017","December 6, 2017","June 4, 2015",,"September 13, 2018","The University of Chicago Medical Center /ID# 139403, Chicago, Illinois, United States|University of Michigan Medical Center /ID# 139402, Ann Arbor, Michigan, United States|Washington University School of Medicine /ID# 135708, Saint Louis, Missouri, United States|Mount Sinai Medical Center /ID# 133569, New York, New York, United States|The Sarah Cannon Research Institute /ID# 135814, Nashville, Tennessee, United States|CHRU de Lille, Hopital Claude Huriez /ID# 133634, Lille Cedex, France|CHU de Nantes, Hotel Dieu - HME /ID# 133633, Nantes Cedex 1, France|CHU de la miletrie, Centre d'investigation clinique /ID# 147542, Poitiers, France|Universitaetsklinikum Koeln /ID# 141535, Cologne, Germany|Universitaetklinikum Dresden /ID# 141860, Dresden, Germany|Universitaetsklinikum Heidelberg /ID# 140046, Heidelberg, Germany|Universitaetsklinikum Schleswig-Holstein /ID# 141534, Kiel, Germany|Universitaetsklinikum Tuebingen /ID# 141074, Tuebingen, Germany|Universitaetsklinikum Wuerzburg /ID# 141533, Wuerzburg, Germany|Hospital Clinic de Barcelona /ID# 141643, Barcelona, Spain|Hospital Universitario de la Princesa /ID# 140881, Madrid, Spain|Hospital Universitario 12 de Octubre /ID# 140878, Madrid, Spain|Clinica Universitaria de Navarra /ID# 141411, Pamplona-Navarra, Spain|Hospital Clinico Universitario Salamanca /ID# 140880, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT02462525"
293,"NCT02451839","An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)","VITALITY","Completed","Has Results","Crohn's Disease|Rheumatoid Arthritis|Psoriasis",,"Change From Baseline in WHODAS 2.0 Response Score at Month 6 Across All Indications|Change From Baseline in WHODAS 2.0 Response Score at Month 2 Across All Indications|Change From Baseline in WHODAS 2.0 Response Score at Month 4 Across All Indications|Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Crohn's Disease|Change From Baseline in WHODAS 2.0 Response Score at Month 6 In Participants With Psoriasis|Change From Baseline in WHODAS 2.0 Response Score at Month 6 in Participants With Rheumatoid Arthritis|Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Absenteeism|Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Presenteeism|Change From Baseline in WPAI:GH 2.0 Score at Month 6 Across All Indications: Work Productivity Loss|Change From Baseline in WPAI:GH V2.0 Score at Month 6 Across All Indications: Activity Impairment|Change From Baseline in K10 at Month 6 Across All Indications|Change From Baseline in Flourishing Scale at Month 6 Across All Indications|Change From Baseline in Subjective Vitality Scale at Month 6 Across All Indications|Change From Baseline in HAQ-DI Score at Month 6 in Participants With Rheumatoid Arthritis|Change From Baseline in SIBDQ Score at Month 6 in Participants With Crohn's Disease|Change From Baseline in DLQI Score at Month 6 in Participants With Psoriasis|Number of Participants Remaining on Treatment at Month 6","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)",,"168","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-345","July 6, 2015","December 5, 2017","December 5, 2017","May 22, 2015","June 19, 2019","June 19, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/39/NCT02451839/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02451839"
294,"NCT02446717","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus|HCV|Direct-Acting Antiviral Agent (DAA)-Experienced","Drug: ABT-493, ABT-530|Drug: ribavirin (RBV)|Drug: ABT-493/ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-410|2015-002350-13","April 2015","December 2016","January 2017","May 18, 2015","September 15, 2017","September 15, 2017",,,"https://ClinicalTrials.gov/show/NCT02446717"
295,"NCT02443298","Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma",,"Completed","Has Results","Asthma","Drug: placebo|Drug: risankizumab","Time to First Asthma Worsening During the Planned 24 Week Treatment Period|Time to First Asthma Worsening During the Planned 24 Week Treatment Period According to Alternative Definition|Annualized Rate of Asthma Worsening During the Planned 24 Week Treatment Period|Time to First Severe Asthma Exacerbation During the Planned 24 Week Treatment Period|Annualized Rate of Severe Asthma Exacerbation During the Planned 24-week Treatment Period|Trough Forced Expiratory Volume in 1 Second (FEV1) In-clinic Change From Baseline at Week 24|Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) In-clinic Change From Baseline at Week 24|Weekly Asthma Control Questionaire Score at Week 24","AbbVie|Boehringer Ingelheim","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","214","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1311.14|2014-004932-20","June 23, 2015","October 13, 2017","February 2, 2018","May 13, 2015","April 10, 2019","April 10, 2019","WCCT Global, LLC, Costa Mesa, California, United States|El Camino Hospital, Mountain View, California, United States|IMMUNOe Research Centers, Centennial, Colorado, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Clinical Research Trials of Florida, Inc., Tampa, Florida, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|VA WNY Healthcare System, Buffalo, New York, United States|American Health Research, Inc., Charlotte, North Carolina, United States|Coastal Carolina Health Care, P.A., New Bern, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Research Protocol Mgmt Spc, Pittsburgh, Pennsylvania, United States|MedTrial, LLC, Columbia, South Carolina, United States|VitaLink Research, Greenville, South Carolina, United States|Respiratory and Sleep Disorders Specialists, The Woodlands, Texas, United States|O and O Alpan, LLC, Fairfax, Virginia, United States|ULB Hopital Erasme, Bruxelles, Belgium|Brussels - UNIV St-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Vancouver General Hospital, Vancouver, British Columbia, Canada|Burlington Lung Clinic, Burlington, Ontario, Canada|Airway Inflammometry Laboratory, Hamilton, Ontario, Canada|HOP CHU de Grenoble, Grenoble, France|HOP Nord, Marseille, France|HOP Arnaud de Villeneuve, Montpellier, France|HOP Nord Laënnec, Nantes, France|HOP Bichat, Paris, France|Praxis Dr. Linnhoff, Berlin, Berlin, Germany|MECS Research GmbH, Berlin, Berlin, Germany|Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Bochum, Germany|Praxis Dr. med. Claus Keller, Frankfurt, Germany|IKF Pneumologie GmbH & Co. KG, Frankfurt, Germany|Medaimun GmbH, Frankfurt, Germany|Hamburger Institut für Therapieforschung GmbH (HIT), Hamburg, Germany|Praxis Dr. Hoffmann, Hannover, Hannover, Germany|Universitätsklinikum des Saarlandes, Homburg/Saar, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|KPPK GmbH, Studienzentrum, Koblenz, Germany|KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Institut für klinische Forschung GmbH, Neu-Isenburg, Germany|IFG Institut für Gesundheitsförderung GmbH, Rüdersdorf, Germany|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St.Paul's Hospital, Seoul, Korea, Republic of|HagaZiekenhuis, Den Haag, Netherlands|Leids Universitair Medisch Centrum (LUMC), Leiden, Netherlands|Gibinski Univ.Clin.Cnter of Silesian Med.Uni.Katowice,Outpat, Katowice, Poland|Specjalistyczny Osrodek Alergologiczno-Intern. ALL-MED, Krakow, Poland|Univ. Hospital in Krakow,Pulmonology Clinical Dept, Krakow, Poland|Barlicki University Hospital No. 1, Lodz, Poland|Barlicki University Hospital No. 1, Lodz, Poland|Chang Gung Memorial Hospital Keelung, Keelung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Celerion Inc, Belfast, United Kingdom|Bradford Royal Infirmary, Bradford, United Kingdom|Glenfield Hospital, Leicester, United Kingdom|The Medicines Evaluation Unit, Manchester, United Kingdom|Wishaw General Hospital, Wishaw, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02443298/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02443298/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02443298"
296,"NCT02442284","A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection",,"Completed","Has Results","Chronic Hepatitis C|Cirrhosis|Hepatitis C Virus","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: Ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Post-treatment Relapse|Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) Among Participants With Ongoing Psychiatric Disorders","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","99","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-251","May 13, 2015","August 22, 2016","October 31, 2016","May 13, 2015","August 30, 2017","October 16, 2017",,,"https://ClinicalTrials.gov/show/NCT02442284"
297,"NCT02442271","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil",,"Completed","Has Results","Chronic Hepatitis C Infection","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With SVR12 by Fibrosis Stage|Percentage of Participants With SVR12 by Participant Prior HCV Treatment Experience|Percentage of Participants With SVR12 by Participant Eligibility for Treatment With Interferon (IFN) at Screening|Hepatitis C Virus Patient-Reported Outcomes Instrument (HCV-PRO) Total Score: Change From Baseline to 12 Weeks After the Last Dose of Study Drug|Short-Form 36 Version 2 Health Survey (SF-36v2) Physical Component Summary (PCS) Scores: Change From Baseline to 12 Weeks After the Last Dose of Study Drug|(SF-36v2) Mental Component Summary (MCS) Scores: Change From Baseline to 12 Weeks After the Last Dose of Study Drug","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","222","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-225","April 27, 2015","July 4, 2016","September 26, 2016","May 13, 2015","August 1, 2017","August 1, 2017",,,"https://ClinicalTrials.gov/show/NCT02442271"
298,"NCT02442258","Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function",,"Completed","No Results Available","Renal Impairment","Drug: ABT-493|Drug: ABT-530","(SUB-STUDY 1) Area under the plasma concentration-time curve (AUC) from time 0 to infinity for the ABT-493 study drug.|Overall measurement of safety parameters|Number of subjects with adverse events|Maximum plasma concentration (Cmax) of the ABT-493 study drug.|Area under the plasma concentration-time curve (AUC) for the ABT-493 study drug.|(SUB-STUDY 1) Area under the plasma concentration-time curve (AUC) from time 0 to infinity for the ABT-530 study drug.|Maximum plasma concentration (Cmax) of the ABT-530 study drug.|Area under the plasma concentration-time curve (AUC) for the ABT-530 study drug.|(SUB-STUDY 2) Area under the plasma concentration-time curve (AUC) during hemodialysis for the ABT-493 study drug.|(SUB-STUDY 2) Area under the plasma concentration-time curve (AUC) during hemodialysis for the ABT-530 study drug.","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M13-600","March 2015","December 2015","December 2015","May 13, 2015",,"February 22, 2016","Site Reference ID/Investigator# 132890, Miami, Florida, United States|Site Reference ID/Investigator# 132889, Orlando, Florida, United States|Site Reference ID/Investigator# 137332, Grafton, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT02442258"
299,"NCT02441283","A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530",,"Completed","No Results Available","Hepatitis C","Drug: ABT-530|Drug: ABT-493","Assessing persistence of resistance-associated amino acid variants|Percentage of subjects who maintain a sustained virologic response|Number of medical events related to the progression of liver disease|Participant IP-10 results|Participant Aspartate transaminase to platelet ratio index (APRI)|Participant FibroScan and/or liver biopsy results, if available|Participant FibroTest Score","AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","384","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","M13-576|2015-000452-24","June 22, 2015","October 15, 2019","October 15, 2019","May 12, 2015",,"October 30, 2019","Digestive Health Specialists of the Southeast /ID# 136725, Dothan, Alabama, United States|Felizarta /ID# 141033, Bakersfield, California, United States|Southern California Res. Ctr. /ID# 141799, Coronado, California, United States|Research & Education, Inc. /ID# 169591, San Diego, California, United States|eStudySite San Diego /ID# 141040, San Diego, California, United States|eStudySite San Diego /ID# 141047, San Diego, California, United States|eStudySite San Diego /ID# 141048, San Diego, California, United States|Midway Immunology and Research /ID# 169477, Fort Pierce, Florida, United States|Delta Research Partners /ID# 141028, Bastrop, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 141024, Shreveport, Louisiana, United States|Henry Ford Health System /ID# 141039, Detroit, Michigan, United States|Binghamton Gastroenterology /ID# 141026, Binghamton, New York, United States|Carolinas Center for Liver Dis /ID# 155390, Statesville, North Carolina, United States|Northwest Gastroenterology Cli /ID# 141036, Portland, Oregon, United States|Gastro One /ID# 169478, Germantown, Tennessee, United States|Quality Medical Research, PLLC /ID# 141042, Nashville, Tennessee, United States|TX Clinical Research Institute /ID# 141037, Arlington, Texas, United States|Inquest Clinical Research /ID# 141045, Baytown, Texas, United States|TX Liver Inst, Americ Res Corp /ID# 136727, San Antonio, Texas, United States|Bon Secours St. Mary's Hospita /ID# 165106, Richmond, Virginia, United States|St. Vincent's Hospital, Darlinghurst /ID# 155395, Darlinghurst, New South Wales, Australia|St. Vincents Hospital /ID# 155394, East Lismore, New South Wales, Australia|Westmead Hospital /ID# 155392, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 155396, Herston, Queensland, Australia|Royal Adelaide Hospital /ID# 155391, Adelaide, South Australia, Australia|Royal Melbourne Hospital /ID# 155393, Parkville, Victoria, Australia|Cliniques Universitaires Saint Luc /ID# 155397, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU St. Pierre /ID# 155399, Brussels, Belgium|UZ Leuven /ID# 155398, Leuven, Belgium|University of Calgary /ID# 155400, Calgary, Alberta, Canada|Toronto Liver Centre /ID# 155401, Toronto, Ontario, Canada|Universitätsklinikum Frankfurt /ID# 169817, Frankfurt am Main, Hessen, Germany|Mauss, Schmutz, Hegener, Athma /ID# 155402, Dusseldorf, Germany|Gastroenterologisch-Hepatologi /ID# 169820, Kiel, Germany|Auckland City Hospital /ID# 155403, Auckland, New Zealand|Gastro-Hepato & Geriatric Ctr /ID# 141060, Ponce, Puerto Rico|Klinical Investigations Group /ID# 141059, San Juan, Puerto Rico|Innovative Care P.S.C. /ID# 141061, San Juan, Puerto Rico|The Royal London Hospital /ID# 155405, London, London, City Of, United Kingdom|King's College Hospital NHS /ID# 155406, London, United Kingdom|St. Mary's Hospital /ID# 155404, London, United Kingdom|Derriford Hospital /ID# 155407, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02441283"
300,"NCT02433340","Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study",,"Completed","Has Results","Rheumatoid Arthritis","Drug: ABT-122","American College of Rheumatology (ACR) 20 Response Rate at Week 2|ACR20 Response Rate at Week 4|ACR20 Response Rate at Week 6|ACR20 Response Rate at Week 8|ACR20 Response Rate at Week 12|ACR20 Response Rate at Week 16|ACR20 Response Rate at Week 20|ACR20 Response Rate at Week 24|ACR20 Response Rate at Week 28|ACR20 Response Rate at Week 32|ACR20 Response Rate at Week 36|ACR50 Response Rate at Week 2|ACR50 Response Rate at Week 4|ACR50 Response Rate at Week 6|ACR50 Response Rate at Week 8|ACR50 Response Rate at Week 12|ACR50 Response Rate at Week 16|ACR50 Response Rate at Week 20|ACR50 Response Rate at Week 24|ACR50 Response Rate at Week 28|ACR50 Response Rate at Week 32|ACR50 Response Rate at Week 36|ACR70 Response Rate at Week 2|ACR70 Response Rate at Week 4|ACR70 Response Rate at Week 6|ACR70 Response Rate at Week 8|ACR70 Response Rate at Week 12|ACR70 Response Rate at Week 16|ACR70 Response Rate at Week 20|ACR70 Response Rate at Week 24|ACR70 Response Rate at Week 28|ACR70 Response Rate at Week 32|ACR70 Response Rate at Week 36|Summary of Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation, and Deaths|Change From Baseline In Tender Joint Count (TJC68) at Week 2|Change From Baseline in TJC68 at Week 4|Change From Baseline in TJC68 at Week 6|Change From Baseline in TJC68 at Week 8|Change From Baseline in TJC68 at Week 12|Change From Baseline in TJC68 at Week 16|Change From Baseline in TJC68 at Week 20|Change From Baseline in TJC68 at Week 24|Change From Baseline in TJC68 at Week 28|Change From Baseline in TJC68 at Week 32|Change From Baseline in TJC68 at Week 36|Change From Baseline in Swollen Joint Count (SJC66) at Week 2|Change From Baseline in SJC66 at Week 4|Change From Baseline in SJC66 at Week 6|Change From Baseline in SJC66 at Week 8|Change From Baseline in SJC66 at Week 12|Change From Baseline in SJC66 at Week 16|Change From Baseline in SJC66 at Week 20|Change From Baseline in SJC66 at Week 24|Change From Baseline in SJC66 at Week 28|Change From Baseline in SJC66 at Week 32|Change From Baseline in SJC66 at Week 36|Change From Baseline in Patient's Assessment of Pain at Week 2|Change From Baseline in Patient's Assessment of Pain at Week 4|Change From Baseline in Patient's Assessment of Pain at Week 6|Change From Baseline in Patient's Assessment of Pain at Week 8|Change From Baseline in Patient's Assessment of Pain at Week 12|Change From Baseline in Patient's Assessment of Pain at Week 16|Change From Baseline in Patient's Assessment of Pain at Week 20|Change From Baseline in Patient's Assessment of Pain at Week 24|Change From Baseline in Patient's Assessment of Pain at Week 28|Change From Baseline in Patient's Assessment of Pain at Week 32|Change From Baseline in Patient's Assessment of Pain at Week 36|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 2|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 4|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 6|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 8|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 12|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 16|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 20|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 24|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 28|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 32|Change From Baseline in Patient's Global Assessment of Disease Activity at Week 36|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 2|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 4|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 6|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 8|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 12|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 16|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 20|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 24|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 28|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 32|Change From Baseline in Physician's Global Assessment of Disease Activity at Week 36|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 2|Change From Baseline in HAQ-DI at Week 4|Change From Baseline in HAQ-DI at Week 6|Change From Baseline in HAQ-DI at Week 8|Change From Baseline in HAQ-DI at Week 12|Change From Baseline in HAQ-DI at Week 16|Change From Baseline in HAQ-DI at Week 20|Change From Baseline in HAQ-DI at Week 24|Change From Baseline in HAQ-DI at Week 28|Change From Baseline in HAQ-DI at Week 32|Change From Baseline in HAQ-DI at Week 36|Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 2|Change From Baseline in hsCRP at Week 4|Change From Baseline in hsCRP at Week 6|Change From Baseline in hsCRP at Week 8|Change From Baseline in hsCRP at Week 12|Change From Baseline in hsCRP at Week 16|Change From Baseline in hsCRP at Week 20|Change From Baseline in hsCRP at Week 24|Change From Baseline in hsCRP at Week 28|Change From Baseline in hsCRP at Week 32|Change From Baseline in hsCRP at Week 36|Change From Baseline in Disease Activity Score 28 (DAS28[hsCRP]) at Week 2|Change From Baseline in DAS28 (hsCRP) at Week 4|Change From Baseline in DAS28 (hsCRP) at Week 6|Change From Baseline in DAS28 (hsCRP) at Week 8|Change From Baseline in DAS28 (hsCRP) at Week 12|Change From Baseline in DAS28 (hsCRP) at Week 16|Change From Baseline in DAS28 (hsCRP) at Week 20|Change From Baseline in DAS28 (hsCRP) at Week 24|Change From Baseline in DAS28 (hsCRP) at Week 28|Change From Baseline in DAS28 (hsCRP) at Week 32|Change From Baseline in DAS28 (hsCRP) at Week 36|Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 2|Change From Baseline in CDAI at Week 4|Change From Baseline in CDAI at Week 6|Change From Baseline in CDAI at Week 8|Change From Baseline in CDAI at Week 12|Change From Baseline in CDAI at Week 16|Change From Baseline in CDAI at Week 20|Change From Baseline in CDAI at Week 24|Change From Baseline in CDAI at Week 28|Change From Baseline in CDAI at Week 32|Change From Baseline in CDAI at Week 36|Low Disease Activity (LDA) or Clinical Remission (CR) Response Rate Per DAS28 (hsCRP) at Week 2|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 4|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 6|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 8|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 12|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 16|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 20|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 24|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 28|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 32|LDA or CR Response Rate Per DAS28 (hsCRP) at Week 36|CR Response Rate Per DAS28 (hsCRP) at Week 2|CR Response Rate Per DAS28 (hsCRP) at Week 4|CR Response Rate Per DAS28 (hsCRP) at Week 6|CR Response Rate Per DAS28 (hsCRP) at Week 8|CR Response Rate Per DAS28 (hsCRP) at Week 12|CR Response Rate Per DAS28 (hsCRP) at Week 16|CR Response Rate Per DAS28 (hsCRP) at Week 20|CR Response Rate Per DAS28 (hsCRP) at Week 24|CR Response Rate Per DAS28 (hsCRP) at Week 28|CR Response Rate Per DAS28 (hsCRP) at Week 32|CR Response Rate Per DAS28 (hsCRP) at Week 36|LDA or CR Response Rate Per CDAI at Week 2|LDA or CR Response Rate Per CDAI at Week 4|LDA or CR Response Rate Per CDAI at Week 6|LDA or CR Response Rate Per CDAI at Week 8|LDA or CR Response Rate Per CDAI at Week 12|LDA or CR Response Rate Per CDAI at Week 16|LDA or CR Response Rate Per CDAI at Week 20|LDA or CR Response Rate Per CDAI at Week 24|LDA or CR Response Rate Per CDAI at Week 28|LDA or CR Response Rate Per CDAI at Week 32|LDA or CR Response Rate Per CDAI at Week 36|CR Response Rate Per CDAI Criteria at Week 2|CR Response Rate Per CDAI Criteria at Week 4|CR Response Rate Per CDAI Criteria at Week 6|CR Response Rate Per CDAI Criteria at Week 8|CR Response Rate Per CDAI Criteria at Week 12|CR Response Rate Per CDAI Criteria at Week 16|CR Response Rate Per CDAI Criteria at Week 20|CR Response Rate Per CDAI Criteria at Week 24|CR Response Rate Per CDAI Criteria at Week 28|CR Response Rate Per CDAI Criteria at Week 32|CR Response Rate Per CDAI Criteria at Week 36","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","158","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-965|2014-001471-31","April 2015","May 2016","May 2016","May 5, 2015","June 19, 2017","July 24, 2017",,,"https://ClinicalTrials.gov/show/NCT02433340"
301,"NCT02429895","A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197",,"Terminated","No Results Available","Psoriatic Arthritis","Drug: ABT-122","American College of Rheumatology (ACR) 20 response rate by visit|American College of Rheumatology (ACR) 50 response rate by visit|American College of Rheumatology (ACR) 70 response rate by visit|Change in American College of Rheumatology (ACR) the individual component by visit|Change in Disease Activity Score DAS28 [hsCRP] by visit|Change in Psoriatic Disease Activity Score (PASDAS) by visit|Change in Psoriasis Area and Severity Index (PASI) by visit|Change in Psoriasis Target Lesion Score by visit|Change in Dactylitis Assessment by visit|Change in Enthesitis Sites Comprising the Total Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index by visit|Change in Self-Assessment of Psoriasis Symptoms (SAPS) by visit|Change in skin biopsy/biomarkers|Change in the quality of life, function and work as measured by the Short-Form Health Survey Version 2.0 (SF36v2) by visit|Change in the quality of life, function and work as measured by Bath AS Disease Activity Index (BASDAI) by visit|Change in the quality of life, function and work as measured by the Fatigue Numeric Rating Scale by visit|Change in the quality of life, function and work as measured by the Sleep Quality Scale by visit","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","168","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-198|2014‐005527‐27","October 2015","May 2016","May 2016","April 29, 2015",,"June 17, 2016","Site Reference ID/Investigator# 138922, Woolloongabba, Australia|Site Reference ID/Investigator# 138925, Plovdiv, Bulgaria|Site Reference ID/Investigator# 138926, Plovdiv, Bulgaria|Site Reference ID/Investigator# 138927, Plovdiv, Bulgaria|Site Reference ID/Investigator# 138928, Sofia, Bulgaria|Site Reference ID/Investigator# 138930, Sofia, Bulgaria|Site Reference ID/Investigator# 138929, Sofia, Bulgaria|Site Reference ID/Investigator# 138934, Praha 4, Czech Republic|Site Reference ID/Investigator# 138933, Praha, Czech Republic|Site Reference ID/Investigator# 138932, Uherske Hradiste, Czech Republic|Site Reference ID/Investigator# 141365, Frankfurt, Germany|Site Reference ID/Investigator# 138953, Luebeck, Germany|Site Reference ID/Investigator# 138959, Budapest, Hungary|Site Reference ID/Investigator# 138983, Adazi, Latvia|Site Reference ID/Investigator# 138985, Riga, Latvia|Site Reference ID/Investigator# 138982, Riga, Latvia|Site Reference ID/Investigator# 138984, Valmiera, Latvia|Site Reference ID/Investigator# 138986, Auckland, New Zealand|Site Reference ID/Investigator# 138988, Nelson, New Zealand|Site Reference ID/Investigator# 138987, Newtown, Wellington, New Zealand|Site Reference ID/Investigator# 139000, Bialystok, Poland|Site Reference ID/Investigator# 139012, Bydgoszcz, Poland|Site Reference ID/Investigator# 138999, Elblag, Poland|Site Reference ID/Investigator# 139007, Katowice, Poland|Site Reference ID/Investigator# 139006, Krakow, Poland|Site Reference ID/Investigator# 139005, Lublin, Poland|Site Reference ID/Investigator# 139026, Oswiecim, Poland|Site Reference ID/Investigator# 139004, Poznan, Poland|Site Reference ID/Investigator# 139001, Stalowa Wola, Poland|Site Reference ID/Investigator# 139011, Szczecin, Poland|Site Reference ID/Investigator# 139003, Torun, Poland|Site Reference ID/Investigator# 139010, Wroclaw, Poland|Site Reference ID/Investigator# 139013, Bucuresti, Romania|Site Reference ID/Investigator# 139016, Targu-Mures, Jud. Mures, Romania|Site Reference ID/Investigator# 139022, Elche, Spain|Site Reference ID/Investigator# 139020, Santiago de Compostela, Spain",,"https://ClinicalTrials.gov/show/NCT02429895"
302,"NCT02414633","Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])",,"Completed","Has Results","Psoriatic Arthritis",,"Work Productivity and Activity Impairment Psoriatic Arthritis Questionnaire (WPAI:PsA) Percentage of Overall Work Impairment (OWI): Change From Baseline to Week 24|WPAI:PsA Percentage of OWI: Change From Baseline to Weeks 4, 12, and 16|WPAI:PsA Absenteeism: Change From Baseline to Weeks 4, 12, 16 and 24|WPAI:PsA Presenteeism: Change From Baseline to Weeks 4, 12, 16 and 24|WPAI:PsA Activity Impairment: Change From Baseline to Weeks 4, 12, 16 and 24|Psoriatic Arthritis Screening and Evaluation Questionnaire (PASE): Change From Baseline to Weeks 4, 12, 16 and 24|Psoriasis Area and Severity Index (PASI) Score: Change From Baseline to Weeks 4, 12, 16 and 24|Disease Activity Score 28, C-reactive Protein (DAS28 [CRP]): Change From Baseline to Weeks 4, 12, 16 and 24|Disease Activity Score 28, Erythrocyte Sedimentation Rate (DAS28 [ESR]): Change From Baseline to Weeks 4, 12, 16 and 24|Tender Joint Count (TJC68): Change From Baseline to Weeks 4, 12, 16 and 24|Swollen Joint Count (SJC66): Change From Baseline to Weeks 4, 12, 16 and 24|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI): Change From Baseline to Weeks 12 and 24|Health Assessment Questionnaire Disability Index (HAQ-DI): Change From Baseline to Weeks 12 and 24|Enthesitis: Change From Baseline to Final Visit|Dactylitis: Change From Baseline to Final Visit|Spondylitis: Change From Baseline to Final Visit|Nail Psoriasis: Change From Baseline to Final Visit|Number of Participants With Adverse Events (AEs)","AbbVie","All","16 Years and older   (Child, Adult, Older Adult)",,"148","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P15-084","April 1, 2015","March 13, 2017","March 13, 2017","April 13, 2015","October 16, 2018","October 16, 2018",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT02414633/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02414633"
303,"NCT02412371","A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer",,"Completed","No Results Available","Non-small Cell Lung Cancer Stage III","Drug: Paclitaxel|Other: Placebo for Veliparib|Drug: Carboplatin|Drug: Veliparib|Radiation: Radiotherapy","Recommended Phase 2 dose (RPTD) of veliparib (ABT-888) in combination with radiotherapy, paclitaxel and carboplatin|Progression-free survival (PFS)|Duration of Overall Response (DOR)|Objective Response Rate (ORR)|Overall Survival (OS)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M14-360|2016-001659-32","April 30, 2015","June 13, 2019","June 27, 2019","April 9, 2015",,"September 10, 2019","Ucsd /Id# 133037, La Jolla, California, United States|Christiana Care Health Service /ID# 133486, Newark, Delaware, United States|University of Chicago /ID# 133828, Chicago, Illinois, United States|Univ Maryland School Medicine /ID# 132944, Baltimore, Maryland, United States|Dana-Farber Cancer Institute /ID# 133494, Boston, Massachusetts, United States|SUNY Upstate Medical Center /ID# 133492, Syracuse, New York, United States|Unc /Id# 133496, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr /ID# 133497, Durham, North Carolina, United States|Wake Forest Univ HS /ID# 134608, Winston-Salem, North Carolina, United States|Rhode Island Hospital /ID# 133493, Providence, Rhode Island, United States|The Miriam Hospital /ID# 133910, Providence, Rhode Island, United States|University of Virginia /ID# 133495, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02412371"
304,"NCT02399345","Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults",,"Completed","Has Results","Chronic Hepatitis C Virus (HCV Infection Genotype 1)","Drug: ombitasvir/paritaprevir/ritonavir, dasabuvir|Drug: sofosbuvir (SOF)|Drug: ribavirin (RBV)","Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Subjects With On-treatment Virologic Failure|Percentage of Subjects With Post-treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M15-310|2014-005280-32","March 2015","November 2015","November 2015","March 26, 2015","December 12, 2016","December 12, 2016",,,"https://ClinicalTrials.gov/show/NCT02399345"
305,"NCT02391480","A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer",,"Completed","No Results Available","Cancer|Breast Cancer|Non-Small Cell Lung Cancer|Acute Myeloid Leukemia (AML)|Multiple Myeloma|Prostate Cancer|Small Cell Lung Cancer|Non-Hodgkins Lymphoma","Drug: ABBV-075|Drug: Venetoclax","Maximum Tolerated Dose of ABBV-075|Time to Cmax (peak time, Tmax) for ABBV-075|Number of participants with adverse events|Maximum observed plasma concentration (Cmax) of ABBV-075|Area under the curve (AUC)|Duration of overall response (DOR)|Objective Response Rate (ORR)|Progression Free Survival (PFS)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","128","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-546","April 14, 2015","July 5, 2019","July 5, 2019","March 18, 2015",,"November 29, 2019","Scottsdale Healthcare /ID# 132963, Scottsdale, Arizona, United States|City of Hope /ID# 154053, Duarte, California, United States|UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States|Yale University /ID# 136982, New Haven, Connecticut, United States|University of Chicago /ID# 155453, Chicago, Illinois, United States|Indiana Univ School Medicine /ID# 132946, Indianapolis, Indiana, United States|Duke Univ Med Ctr /ID# 154647, Durham, North Carolina, United States|Mary Crowley Cancer Research /ID# 154059, Dallas, Texas, United States|Univ TX, MD Anderson /ID# 132276, Houston, Texas, United States|UT MD Anderson Cancer Center /ID# 164122, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02391480"
306,"NCT02384538","A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis",,"Completed","Has Results","Erosive Hand Osteoarthritis","Biological: ABT-981|Biological: Placebo for ABT-981","Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16|Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Each Visit|Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Physical Function Subdomain Score: Change From Baseline to Each Visit|Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Stiffness Subdomain Score: Change From Baseline to Each Visit|Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Total Score: Change From Baseline to Each Visit|Participant Assessment of Index Hand Pain Intensity Using Numeric Rating Scale (NRS-11): Change From Baseline to Each Visit|Patient Global Assessment of Hand Osteoarthritis (OA) Status by NRS-11: Change From Baseline to Each Visit","AbbVie","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","132","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-171|2014-001096-31","March 2015","July 2016","July 2016","March 10, 2015","July 13, 2017","August 11, 2017",,,"https://ClinicalTrials.gov/show/NCT02384538"
307,"NCT02381444","Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy","BALANCE","Active, not recruiting","No Results Available","Parkinson's Disease (PD)",,"Change in the Parkinson's Disease Questionnaire (PDQ-39) summary index|Change in Health Related Quality of Life (HRQL)|Change in participant's motor symptoms|Change in participant's Healthcare Resource Utilization|Change in participant's non-motor symptoms|Reason for transition to LCIG (or continuing oral therapy)|Change in participant's caregiver burden","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"108","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P14-322","April 17, 2015","December 31, 2019","December 31, 2019","March 6, 2015",,"March 6, 2019","Universitaetsklinikum Aachen /ID# 204355, Aachen, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 148153, Köln, Nordrhein-Westfalen, Germany|Johannes Wesling Klin Minden /ID# 151481, Minden, Nordrhein-Westfalen, Germany|KH Martha-Maria Halle Dolau /ID# 144634, Halle (Saale), Sachsen-Anhalt, Germany|Klinikum Altenburger Land /ID# 139643, Altenburg, Germany|Hummel/N/W, Bad Krozingen, DE /ID# 148152, Bad Krozingen, Germany|SE Kliniken Neurologisches Ztr /ID# 148223, Bad Segeberg, Germany|Kliniken Beelitz GmbH /ID# 144633, Beelitz-heilstaetten, Germany|Delf, Berlin-Hoppegarten, DE /ID# 144632, Berlin-hoppengarten, Germany|Kupsch, Berlin, DE /ID# 144840, Berlin, Germany|Dr. Puzich, Berlin, DE /ID# 148226, Berlin, Germany|Groot/Gratz/Krumme, Berlin, DE /ID# 148225, Berlin, Germany|Neurologisches Zentrum /ID# 151480, Berlin, Germany|Knappschaftskrankenhaus /ID# 151483, Bochum, Germany|Central Hospital Bremerhaven /ID# 144639, Bremerhaven, Germany|Kliniken der Stadt Koln gGmbH /ID# 156665, Cologne, Germany|Krankenhaus Lindenbrunn /ID# 151485, Coppenbruegge, Germany|Staedtisches Klinikum Dessau /ID# 148227, Dessau, Germany|Bungard/Dats/Lorrain, DE /ID# 144637, Dusseldorf, Germany|Herbst, Falkensee, DE /ID# 139642, Falkensee, Germany|Universitätsklinikum Freiburg /ID# 144640, Freiburg, Germany|Klinik Haag /ID# 137458, Haag, Germany|Wellach/Becker, Hamburg, DE /ID# 148228, Hamburg, Germany|Diak.hospital Henriettenstift /ID# 148222, Hannover, Germany|KH Agatharied /ID# 144636, Hausham, Germany|Klinikum Herford AdoeR /ID# 151482, Herford, Germany|Klinikum Ibbenbueren GmbH /ID# 151479, Ibbenbueren, Germany|Universitatsklinikum Jena_Duplicate /ID# 152813, Jena, Germany|Gertrudis-Klinik /ID# 144631, Leun-biskirchen, Germany|Universitatsklinikum Magdeburg /ID# 163197, Magdeburg, Germany|Philipps-Universitaet Marburg /ID# 116936, Marburg, Germany|Univ Giessen and Marburg /ID# 137455, Marburg, Germany|von Schonaich, Neusass, DE /ID# 137457, Neusass, Germany|Christliches Krankenhaus /ID# 148224, Quakenbruck, Germany|Nordwest KH Sanderbusch /ID# 144635, Sande, Germany|Krankenhaus Rummelsberg /ID# 137459, Schwarzenbruck, Germany|Kliniken Berg /ID# 151484, Tuebingen, Germany|Praxis Dres. Lang & Partner /ID# 147412, ULM, Germany|Evang. Krankenhaus Wesel /ID# 144638, Wesel, Germany|Parkinson-Klinik Wolfach GmbH /ID# 137456, Wolfach, Germany|Luzerner Kantonsspital /ID# 153738, Luzern, Switzerland|Klinik Bethesda /ID# 153739, Tschugg BE, Switzerland|Rehaklinik Zihlschlacht AG /ID# 153710, Zihlschlacht, Switzerland|University Hospital Zurich /ID# 153709, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02381444"
308,"NCT02365662","A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor",,"Terminated","No Results Available","Head and Neck Squamous Cell Carcinoma|Non-small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Carcinoma|Glioblastoma Multiforme","Drug: ABBV-221","Number of participants with adverse events|Maximum Plasma Concentration (Cmax) of ABBV-221|Area Under the Plasma Concentration-time Curve from 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-221|Maximum tolerated dose of ABBV-221|Area Under the Plasma Concentration-time Curve of ABBV-221|Recommended Phase 2 dose of ABBV-221|Assess the effect of systemic ABBV-221 administration on QT prolongation|Objective Response Rate (ORR)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-429|2014-003557-34","January 9, 2015","March 15, 2018","March 15, 2018","February 19, 2015",,"March 30, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Fundacion Jimenez Diaz, Madrid, Spain|Hosp Univ Madrid Sanchinarro, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02365662"
309,"NCT02365649","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy",,"Completed","No Results Available","Crohn's Disease","Drug: ABT-494|Drug: Placebo","Proportion of subjects who achieve endoscopic remission|Proportion of subjects who achieve clinical remission|Proportion of subjects who achieve Crohn's Disease Activity Index (CDAI) less than 150|Proportion of subjects with decrease in CDAI greater than or equal to 70 points|Proportion of subjects who achieve remission at Week 52","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-740|2014-003240-12","March 17, 2015","November 25, 2016","August 4, 2017","February 19, 2015",,"November 6, 2017","University of California San Diego Health System /ID# 136868, La Jolla, California, United States|Community Clinical Trials, Orange, CA /ID# 133110, Orange, California, United States|University of California, San Francisco /ID# 137841, San Francisco, California, United States|Rocky Mountain Clinical Research, LLC /ID# 133116, Wheat Ridge, Colorado, United States|Florida Research Network, LLC /ID# 142856, Gainesville, Florida, United States|University of Florida /ID# 144834, Gainesville, Florida, United States|The Center for Gastrointestinal Disorders /ID# 136728, Hollywood, Florida, United States|Nature Coast Clinical Research /ID# 137225, Inverness, Florida, United States|Center for Advanced Gastroenterology /ID# 136751, Maitland, Florida, United States|University of Miami /ID# 136729, Miami, Florida, United States|Gastroenterology Group of Naples /ID# 133647, Naples, Florida, United States|Internal Medicine Specialists /ID# 133102, Orlando, Florida, United States|Shafran Gastroenterology Center, Winter Park, FL /ID# 133128, Winter Park, Florida, United States|Tri County Research, Inc. /ID# 137309, Athens, Georgia, United States|Gastroenterology Associates of Central Georgia, LLC /ID# 132959, Macon, Georgia, United States|Gastrointestinal Specialists of Georgia /ID# 142290, Marietta, Georgia, United States|Carle Cancer Center /ID# 132954, Urbana, Illinois, United States|Cotton-O'Neil Clinical Research Center /ID# 133132, Topeka, Kansas, United States|University of Louisville, MDA /ID# 133109, Louisville, Kentucky, United States|Louisiana State University Health Sciences Center-Shreveport /ID# 144437, Shreveport, Louisiana, United States|Louisiana Research Center, LLC /ID# 144066, Shreveport, Louisiana, United States|Investigative Clinical Research /ID# 133111, Annapolis, Maryland, United States|MGG Group, Inc. /ID# 132955, Chevy Chase, Maryland, United States|Charm City Research Group /ID# 147049, Towson, Maryland, United States|Center for Digestive Health /ID# 133645, Troy, Michigan, United States|Minnesota Gastroenterology, P.A. /ID# 136869, Plymouth, Minnesota, United States|Mayo Clinic /ID# 133121, Rochester, Minnesota, United States|University of Mississippi Medical Center /ID# 144264, Jackson, Mississippi, United States|Kansas City Research Institute /ID# 133113, Kansas City, Missouri, United States|Washington University School of Medicine /ID# 133130, Saint Louis, Missouri, United States|NYU Langone Long Island Clinical Research Assoc., LLP /ID# 137226, Great Neck, New York, United States|Weill Cornell Medical College of Cornell University /ID# 133126, New York, New York, United States|University of North Carolina at Chapel Hill /ID# 137308, Chapel Hill, North Carolina, United States|Charlotte Gastroenterology and Hepatology, PLLC /ID# 133118, Charlotte, North Carolina, United States|Wake Forest University Health Sciences /ID# 137837, Winston-Salem, North Carolina, United States|Consultants for Clinical Research /ID# 144081, Cincinnati, Ohio, United States|University of Cincinnati Physicians /ID# 137227, Cincinnati, Ohio, United States|Options Health Research, LLC /ID# 133649, Tulsa, Oklahoma, United States|PMA Medical Specialist, LLC /ID# 136750, Limerick, Pennsylvania, United States|Medical University of South Carolina /ID# 143678, Charleston, South Carolina, United States|Gastroenterology Associates, PA /ID# 143799, Greenville, South Carolina, United States|Gastro One /ID# 136747, Germantown, Tennessee, United States|The University of Texas Health Sciences Center at Houston /ID# 142054, Houston, Texas, United States|Texas Digestive Disease Consultants /ID# 132958, Southlake, Texas, United States|Texas Digestive Disease Consultants /ID# 138281, Southlake, Texas, United States|Aspen Clinical Research /ID# 144065, Orem, Utah, United States|University of Virginia Health System /ID# 133104, Charlottesville, Virginia, United States|Carilion Medical Center /ID# 137317, Roanoke, Virginia, United States|University of Washington /ID# 137843, Seattle, Washington, United States|Wisconsin Center for Advanced Research GI Associates, LLC /ID# 132952, Milwaukee, Wisconsin, United States|Allegiance Research Specialists /ID# 136752, Wauwatosa, Wisconsin, United States|Concord Repatriation and General Hospital /ID# 133172, Concord, Australia|Royal Brisbane and Women's Hospital /ID# 138163, Herston, Australia|Universitair Ziekenhuis Leuven /ID# 133176, Leuven, Belgium|CHU Sart Tilman /ID# 133174, Liege, Belgium|AZ Delta /ID# 133175, Roeselare, Belgium|University of Alberta /ID# 133093, Edmonton, Canada|London Health Sciences Centre /ID# 133092, London, Canada|McGill University Health Center (MUHC) /ID# 133088, Montreal, Canada|Medicor Research Inc. /ID# 144833, Sudbury, Canada|The Gordon and Leslie Diamond Centre /ID# 133095, Vancouver, Canada|GIRI Gastrointestinal Research Institute /ID# 137416, Vancouver, Canada|Toronto Digestive Disease Associates /ID# 133098, Vaughan, Canada|Winnipeg Regional Health Authority, HSC Winnipeg /ID# 132947, Winnipeg, Canada|Hepato-Gastroenterologie HK, s.r.o. /ID# 139429, Hradec Kralove, Czechia|Fakultni Nemocnice v Motole /ID# 133181, Prague 5, Czechia|Aarhus University Hospital /ID# 133184, Aarhus C, Denmark|Hvidovre Hospital /ID# 139431, Hvidovre, Denmark|Odense University Hospital /ID# 133186, Odense, Denmark|CHU Amiens Picardie /ID# 133189, Amiens Cedex 1, France|CHRU de Lille, Hopital Claude Huriez /ID# 139432, Lille Cedex, France|Hopital Archet 2 /ID# 133191, Nice Cedex 3, France|Centre Hospitalier Univeritaire de Nancy /ID# 138165, Vandoeuvre Les Nancy Cedex, France|Charite Universitatesmedizin Berlin, CCM /ID# 133194, Berlin, Germany|DRK-Kliniken Westend /ID# 145864, Berlin, Germany|Universitaetsklinikum Erlangen /ID# 142841, Erlangen, Germany|Asklepios Westklinikum Hamburg /ID# 138166, Hamburg, Germany|Universitaetsklinikum Jena /ID# 133193, Jena, Germany|Universitaetsklinikum Schleswig-Holstein /ID# 133198, Kiel, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 133195, Muenster, Germany|Gastroenterologische Gemeinschaftspraxis /ID# 133196, Munster, Germany|Magyar Elhizastudomanyi Kozpont Kft. /ID# 138167, Budapest, Hungary|Pannonia Maganorvosi Centrum Kft /ID# 133200, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz /ID# 133199, Gyor, Hungary|Rambam Health Care Campus /ID# 133204, Haifa, Israel|Rabin Medical Center /ID# 133201, Petah Tikva, Israel|The Chaim Sheba Medical Center /ID# 133203, Ramat Gan, Israel|Assaf Harofeh Medical Center /ID# 133202, Zerifin, Be'er Ya'akov, Israel|Azienda Ospedale Policlinico Sant Orsola Malpighi /ID# 133206, Bologna, Italy|Azienda Ospedaliero- Universitaria Mater Domini /ID# 139437, Catanzaro, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 139436, Rome, Italy|Universita Cattolica del Sacro Cuore /ID# 133205, Rome, Italy|Academic Medical Center Amsterdam /ID# 139439, Amsterdam, Netherlands|Erasmus Medisch Centrum /ID# 133207, Rotterdam, Netherlands|UMC Utrecht /ID# 139440, Utrecht, Netherlands|Southern District Health Board /ID# 133292, Dunedin, New Zealand|Akershus University Hospital /ID# 133299, Nordbyhagen, Norway|Lovisenberg Diakonale Sykehus /ID# 133296, Oslo, Norway|Santa Familia Centrum Badan, Profilaktyki i Leczenia /ID# 133302, Lodz, Poland|Centrum Zdrowia Matki Dziecka I Mlodziezy /ID# 143340, Warsaw, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 133301, Warsaw, Poland|University of Puerto Rico, School of Medicine /ID# 132950, San Juan, Puerto Rico|Spitalul Clinic Colentina /ID# 133304, Bucharest, Romania|University Emergency Hospital Bucharest /ID# 133309, Bucharest, Romania|Algomed Policlinic /ID# 133307, Timisoara, Romania|KM Management s.r.o., Nitra, SK /ID# 138151, Nitra, Slovakia|Gastro I.S.R.O. /ID# 138150, Presov, Slovakia|Hospital Clinic de Barcelona /ID# 144268, Barcelona, Spain|Complex Hospital University of Ferrol (CHUF) /ID# 133312, Ferrol, Spain|Hospital Universitario de Gran Canarias Dr. Negrin /ID# 138437, Las Palmas, Spain|Hospital Universitario La Paz /ID# 133313, Madrid, Spain|Western General Hospital /ID# 133317, Edinburgh, United Kingdom|Manchester Royal Infirmary /ID# 133316, Manchester, United Kingdom|John Radcliffe Hospital /ID# 138172, Oxford, United Kingdom|Southampton General Hospital NHS Foundation Trust /ID# 133315, Southampton, Hampshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02365649"
310,"NCT02362074","Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis","P @ Work","Active, not recruiting","No Results Available","Rheumatoid Arthritis",,"Change in Rheumatoid Arthritis-Work Instability Scale (RA-WIS)|Change in Financial Loss|Change in Rheumatoid Arthritis-Work Instability (RA-WIS)|Change in the Financial Loss|Change in patient pain|Change in Tender Joint Count (TJC)|Change in Disease Activity Score (DAS) 28|Change in patient assessment of Global Disease Activity|Change in Swollen Joint Count (SJC)|Change in physician's assessment of Global Disease Activity|Change in Health Assessment Questionnaire (HAQ)|Change in c-reactive protein (CRP)/erythrocyte sedimentation rate (ESR)|Rate of Remission per Disease Activity Scale (DAS) 28|Rate of Achieving Low Disease Activity (LDA) per Disease Activity Score (DAS) 28|Rate of Remission Per Clinical Disease Activity Index (CDAI)|Rate of Achieving Low Disease Activity (LDA) per CDAI|Rate of Remission per Simplified Disease Activity Index (SDAI)|Rate of Achieving Low Disease Activity (LDA) per SDAI","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"360","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-455","January 21, 2015","February 16, 2020","February 16, 2020","February 12, 2015",,"September 10, 2019","Pont, Cranbrook, BC, CA /ID# 134511, Cranbrook, British Columbia, Canada|Drs. M & W Teo Inc. /ID# 148641, Penticton, British Columbia, Canada|The Arthritis Research Center /ID# 147466, Vancouver, British Columbia, Canada|Kur, Vancouver, CA /ID# 135371, Vancouver, British Columbia, Canada|Manitoba Clinic /ID# 134830, Winnipeg, Manitoba, Canada|Nexus Clinical Research /ID# 135411, St. John's, Newfoundland and Labrador, Canada|St. Clare's Mercy Hospital /ID# 136737, St. John's, Newfoundland and Labrador, Canada|Dr. Juris Lazovskis Inc. /ID# 134510, Sydney, Nova Scotia, Canada|Waterside Clinique /ID# 134190, Barrie, Ontario, Canada|Drs Nalin and Vandana Ahluwali /ID# 136485, Brampton, Ontario, Canada|Dr. Sanjay Dixit Medicine Professional Corporation /ID# 136486, Burlington, Ontario, Canada|Dr. Chrisotomor Kouroukis & Dr /ID# 151189, Dundas, Ontario, Canada|Adachi Medicine Prof. Corp /ID# 152538, Hamilton, Ontario, Canada|West Mountain Medical Center /ID# 134832, Hamilton, Ontario, Canada|Dr. Martin M.S. Lee Med Prof C /ID# 138333, Mississauga, Ontario, Canada|Brandusa Florica Med Prof Corp /ID# 134829, Mississauga, Ontario, Canada|Montgomery, Mississauga, CA /ID# 136943, Mississauga, Ontario, Canada|Credit Valley Rheumatology /ID# 134834, Mississauga, Ontario, Canada|Rajwinder S. Dhillon Medicine /ID# 147756, Niagara Falls, Ontario, Canada|Capital North Therapeutics Res /ID# 134835, Ottawa, Ontario, Canada|Setty, Owen Sound, CA /ID# 134189, Owen Sound, Ontario, Canada|The Medical Centre /ID# 134833, Peterborough, Ontario, Canada|Involved Medicine /ID# 163880, Toronto, Ontario, Canada|Dr. Samuel K Silverberg /ID# 136496, Toronto, Ontario, Canada|Institut de Rhum. de Montreal /ID# 135289, Montreal, Quebec, Canada|Jewish General Hospital /ID# 204168, Montreal, Quebec, Canada|PSS Medical Inc. /ID# 134193, Montreal, Quebec, Canada|Clinique de Rhumatologie de Montréal /ID# 162186, Montréal, Quebec, Canada|Ctr. de Rheum de l'est du QC /ID# 135410, Rimouski, Quebec, Canada|Rheum Disease Ctr of Montreal /ID# 135372, Westmount, Quebec, Canada|Dr. Latha Naik /ID# 135813, Saskatoon, Saskatchewan, Canada|Chuq - Chul /Id# 137054, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02362074"
311,"NCT02356562","A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection",,"Completed","Has Results","Chronic Hepatitis C Infection","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: Sofosbuvir|Drug: Ribavirin","Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment|Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-Treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-224","February 3, 2015","October 28, 2016","July 7, 2017","February 5, 2015","November 24, 2017","December 20, 2017",,,"https://ClinicalTrials.gov/show/NCT02356562"
312,"NCT02349451","A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)",,"Completed","Has Results","Psoriatic Arthritis","Biological: adalimumab|Biological: ABT-122","American College of Rheumatology (ACR) 20 Response Rate at Week 12: ABT-122 Versus Placebo|ACR20 Response Rate at Week 12: ABT-122 Versus Adalimumab|ACR50 Response Rate at Week 12|ACR70 Response Rate at Week 12|ACRn at Week 12|Change From Baseline in Disease Activity Score 28 (DAS28[hsCRP]) at Week 12|Change From Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at Week 12|Change From Baseline in Psoriasis Target Lesion Score at Week 12","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-197|2014-003558-15","April 28, 2015","July 4, 2016","July 4, 2016","January 28, 2015","August 4, 2017","August 4, 2017",,,"https://ClinicalTrials.gov/show/NCT02349451"
313,"NCT02343406","Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE 2)","INTELLANCE 2","Completed","No Results Available","Glioblastoma Multiforme","Drug: Lomustine|Drug: ABT-414|Drug: Temozolomide","Pediatric study: Maximum observed serum concentration (Cmax) for ABT-414|Adult study: Progression Free Survival (PFS)|Pediatric study: AUC for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Pediatric study: Half-life (t1/2) observed for ABT-414|Pediatric study: Area Under the Concentration-time Curve (AUC) observed for ABT-414|Pediatric study: Maximum observed plasma concentration (Cmax) for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Pediatric study: t1/2 for Cys-mcMMAF (toxin, identified as a metabolite of ABT-414)|Adult study: Overall Survival (OS)|Pediatric study: Safety including toxicities according to CTCAE criteria|Pediatric study: Objective response rate, best response rate and duration of response based on RANO criteria|Pediatric study: Overall survival, Time to progression and Time to progression-free survival|Adult study: Overall Response Rate (ORR)|Pediatric study: Changes in neurological status and function (including PedsQL cancer module)|Adult study: Overall Survival in the subgroup with Epithelial Growth Factor Receptor (EGFRvIII) mutation","AbbVie|European Organisation for Research and Treatment of Cancer - EORTC","All","up to 99 Years   (Child, Adult, Older Adult)","Phase 2","255","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-483|2014-004438-24|EORTC 1410-BTG","February 11, 2015","June 24, 2019","June 24, 2019","January 22, 2015",,"August 21, 2019","Lucile Packard Children's Hosp /ID# 153678, Palo Alto, California, United States|Children's Hospital Colorado /ID# 153677, Aurora, Colorado, United States|Univ of Colorado Cancer Center /ID# 134882, Aurora, Colorado, United States|Sarah Cannon Research Institute at HealthONE - Denver /ID# 141798, Denver, Colorado, United States|Rush University Medical Center /ID# 137542, Chicago, Illinois, United States|Dana-Farber Cancer Institute /ID# 154210, Boston, Massachusetts, United States|Long Island Brain Tumor Center /ID# 134496, Lake Success, New York, United States|Columbia Univ Medical Center /ID# 152656, New York, New York, United States|Cleveland Clinic Main Campus /ID# 137540, Cleveland, Ohio, United States|University of Pittsburgh MC /ID# 134491, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, PLLC /ID# 134492, Nashville, Tennessee, United States|UT Southwestern Medical Center /ID# 136718, Dallas, Texas, United States|Swedish Medical Center /ID# 136719, Seattle, Washington, United States|Port Macquarie Base Hospital /ID# 134569, Port Macquarie, New South Wales, Australia|Sydney Children's Hospital /ID# 153533, Randwick, New South Wales, Australia|Royal North Shore Hospital /ID# 147092, Saint Leonards, New South Wales, Australia|Calvary Mater Newcastle /ID# 134570, Waratah, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 134495, Wollongong, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 147091, Herston, Queensland, Australia|Royal Adelaide Hospital /ID# 135208, Adelaide, South Australia, Australia|Royal Hobart Hospital /ID# 135209, Hobart, Tasmania, Australia|Barwon Health University Hospital Geelong /ID# 134493, Geelong, Victoria, Australia|Royal Children's Hospital /ID# 157624, Melbourne, Victoria, Australia|University Hospital St. Polten /ID# 139070, St. Pölten, Niederoesterreich, Austria|LKH-Univ. Klinikum Graz /ID# 139071, Graz, Austria|Kepler Universitätsklinikum GmbH - Neuromed Campus /ID# 139068, Linz, Austria|Cliniques Universitaires Saint Luc /ID# 139391, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 139342, Charleroi, Hainaut, Belgium|UZ Gent /ID# 152944, Gent, Oost-Vlaanderen, Belgium|AZ St-Jan Brugge-Oostende AV /ID# 137927, Brugge, West-Vlaanderen, Belgium|ZNA Middelheim /ID# 137926, Antwerp, Belgium|UZ Leuven /ID# 137925, Leuven, Belgium|Montreal Neurological Institut /ID# 136309, Montreal, Quebec, Canada|Fakultni Nemocnice v Motole /ID# 139509, Prague 5, Praha 5, Czechia|Masarykuv onkologikcy ustav /ID# 139508, Brno, Czechia|FN Hradec Kralove /ID# 139510, Hradec Kralove, Czechia|Univ Hosp Ostrava-Poruba /ID# 139507, Ostrava, Czechia|Helsinki Univ Central Hospital /ID# 140078, Helsinki, Finland|Helsinki Univ Central Hospital /ID# 153069, Helsinki, Finland|Turku University Hospital /ID# 140861, Turku, Finland|CHRU Lille - Hôpital Claude Huriez /ID# 137916, Lille CEDEX, Hauts-de-France, France|Centre Oscar Lambret /ID# 169619, Lille, Hauts-de-France, France|CHU-Hopital Avicenne /ID# 137910, Bobigny, Ile-de-France, France|Gustave Roussy /ID# 137912, Villejuif, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 137914, St Herblain CEDEX, Loire-Atlantique, France|Hopital de la Timone /ID# 137911, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|CHU de Nice /ID# 137917, Nice CEDEX 1, Provence-Alpes-Cote-d Azur, France|Centre Leon Berard /ID# 137918, Lyon CEDEX 08, Rhone, France|Institut de Cancer de l'Ouest /ID# 137909, Angers, France|Hospices Civils de Lyon /ID# 137913, Bron, France|Hopital Pitie Salpetriere /ID# 145887, Paris, France|Universitaetsklinik Heidelberg /ID# 137924, Heidelberg, Baden-Wuerttemberg, Germany|Universitatsklinik Regensburg /ID# 137920, Ratisbon, Bayern, Germany|Univ Klinik Eppendorf Hamburg /ID# 137921, Hamburg, Germany|LMU Klinikum der Universität München /ID# 137922, Munich, Germany|Universitatsklinikum Tubingen /ID# 137923, Tuebingen, Germany|Pecsi Tudomanyegyetem /ID# 136111, Pécs, Pecs, Hungary|Semmelweis Egyetem /ID# 152578, Budapest, Hungary|National Institute of Oncology /ID# 135970, Budapest, Hungary|Orszagos Klinikai Idegtudomany /ID# 135971, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 135969, Debrecen, Hungary|Cork University Hospital /ID# 136828, Cork, Ireland|Beaumont Hospital /ID# 136829, Dublin, Ireland|Ospedale Bellaria.Azienda USL IRCCS.Istituto delle Scienze Neurologiche di Bolog /ID# 138335, Bologna, Italy|Ospedale Generale di Bolzano /ID# 138338, Bolzano, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 140395, Milan, Italy|Istituto Oncologico Veneto /ID# 138336, Padova, Italy|Azienda Ospedaliera Sant' Andrea /ID# 138337, Rome, Italy|Seoul National Univ Bundang ho /ID# 136841, Seongnam, Gyeonggido, Korea, Republic of|Samsung Medical Center /ID# 136842, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 136840, Seoul, Korea, Republic of|Vrije Universiteit Medisch Centrum /ID# 137221, Amsterdam, Netherlands|Universitair Medisch Centrum Groningen /ID# 138266, Groningen, Netherlands|Erasmus Medisch Centrum /ID# 136981, Rotterdam, Netherlands|Haaglanden Medisch Centrum /ID# 137222, The Hague, Netherlands|Universitair Medisch Centrum Utrecht /ID# 137219, Utrecht, Netherlands|Prinses Maxima Centrum /ID# 204409, Utrecht, Netherlands|Uniwersyteckie Centrum Kliniczne /ID# 137919, Gdansk, Mazowieckie, Poland|Wojewodzkie Wielospecjalistycz /ID# 137654, Lodz, Poland|National University Hospital /ID# 135951, Singapore, Singapore|National Cancer Ctr Singapore /ID# 135952, Singapore, Singapore|KK Women's & Children Hospital /ID# 153676, Singapore, Singapore|Clinica Universitar de Navarra - Pamplona /ID# 140047, Pamplona, Navarra, Comunidad, Spain|Instituto Catalan de Oncologia (ICO) /ID# 140976, Barcelona, Spain|Instituto Catalan de Oncologia (ICO) & Hosp. de Bellvitge /ID# 137688, Barcelona, Spain|Hospital Universitario Nino /ID# 153800, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 137908, Madrid, Spain|Centre Hospitalier Univ Vaudoi /ID# 137929, Lausanne, Switzerland|University Hospital Zurich /ID# 137930, Zurich, Switzerland|China Medical University Hosp /ID# 136976, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 136975, Taipei City, Taipei, Taiwan|Taichung Veterans General Hosp /ID# 136977, Taichung City, Taiwan|Taipei Veterans General Hosp /ID# 136974, Taipei City, Taiwan|Linkou Chang Gung Memorial Ho /ID# 136944, Taoyuan City, Taiwan|Guy's and St Thomas' NHS Found /ID# 140312, London, London, City Of, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 136978, Birmingham, United Kingdom|Gartnavel General Hospital /ID# 136979, Glasgow, United Kingdom|Hull and East Yorkshire NHS /ID# 136917, Hull, United Kingdom|University College Hospitals /ID# 136879, London, United Kingdom|Great Ormond St Hospital NHS /ID# 153421, London, United Kingdom|Christie NHS Foundation Trust /ID# 140313, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02343406"
314,"NCT02333383","Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients","AS PMOS","Completed","Has Results","Ankylosing Spondylitis","Drug: Adalimumab","Frequency of Extra-Axial Manifestations (EAMs) of Interest|Proportion of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response|Mean Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) in Participants With Enthesitis at Baseline|Proportion of Participants With Enthesitis of the Plantar Fascia|Mean Change in Dactylitis Score in Participants With Dactylitis at Baseline|Mean Change in Tender Joint Counts (TJC) in Participants With Peripheral Arthritis (≥1 Swollen Joint) at Baseline|Mean Change in Change in Swollen Joint Counts (SJC) in Participants With Peripheral Arthritis (≥1 Swollen Joint) at Baseline","AbbVie","All","19 Years to 100 Years   (Adult, Older Adult)",,"201","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P15-238","December 31, 2014","August 8, 2017","August 8, 2017","January 7, 2015","January 15, 2019","January 15, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02333383/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02333383"
315,"NCT02322723","Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA","ORIENT","Withdrawn","No Results Available","Rheumatoid Arthritis",,"Proportion of patients who reached clinical response at 6 months|Proportion of patients who reached clinical response at 24 months|Change in patient's functional status|Change in frequency of sick leave episodes|Change in frequency of outpatient clinic visits","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-987","February 2016","February 2020","February 2020","December 23, 2014",,"February 19, 2016",,,"https://ClinicalTrials.gov/show/NCT02322723"
316,"NCT02305758","Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer",,"Completed","Has Results","Untreated Metastatic Colorectal Cancer","Drug: Veliparib|Drug: Placebo|Drug: Modified FOLFIRI|Drug: FOLFIRI|Drug: Bevacizumab|Drug: Fluorouracil infusion","Progression-Free Survival (PFS): Time to Event|Overall Survival (OS): Time to Event|Objective Response Rate (ORR)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M14-217|2014-002866-65","December 2, 2014","September 22, 2017","September 22, 2017","December 3, 2014","November 20, 2018","November 20, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02305758/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT02305758/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02305758"
317,"NCT02296905","Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function",,"Completed","No Results Available","Hepatic Impairment","Drug: ABT-493|Drug: ABT-530","Overall measurement of pharmacokinetic parameter values of ABT-493 and ABT-530|Overall measurement of safety parameters|Number of subjects with adverse events","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M13-604","October 2014","September 2015","September 2015","November 21, 2014",,"October 21, 2015","Site Reference ID/Investigator# 130589, Miami, Florida, United States|Site Reference ID/Investigator# 130591, Orlando, Florida, United States|Site Reference ID/Investigator# 130588, San Antonio, Texas, United States|Site Reference ID/Investigator# 130590, Grafton, New Zealand",,"https://ClinicalTrials.gov/show/NCT02296905"
318,"NCT02292719","A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","Quartz II/III","Completed","Has Results","Chronic Hepatitis C Virus Infection","Drug: OBV/PTV/r|Drug: Sofosbuvir|Drug: Ribavirin (RBV)","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-567|2014-003147-35","December 19, 2014","July 14, 2017","July 14, 2017","November 17, 2014","July 6, 2018","July 6, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02292719/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT02292719/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02292719"
319,"NCT02289729","Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease","ADEQUA","Completed","Has Results","Parkinson's Disease",,"Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Global Score at Month 6|Change From Baseline in PDQ-39 Mobility Domain Score at Month 6|Change From Baseline in PDQ-39 Activities of Daily Living Domain Score at Month 6|Change From Baseline in PDQ-39 Emotional Well-Being Domain Score at Month 6|Change From Baseline in PDQ-39 Stigma Domain Score at Month 6|Change From Baseline in PDQ-39 Social Support Domain Score at Month 6|Change From Baseline in PDQ-39 Cognition Domain Score at Month 6|Change From Baseline in PDQ-39 Communication Domain Score at Month 6|Change From Baseline in PDQ-39 Bodily Discomfort Domain Score at Month 6|Change From Baseline in Unified Parkinson's Disease Rating Scale Part III (UPDRS-III): Motor Examination at Month 6|Change From Baseline in the Non-Motor Symptom Scale (NMSS) Global Score at Month 6|Change From Baseline in NMSS Cardiovascular Domain Score at Month 6|Change From Baseline in NMSS Sleep/Fatigue Domain Score at Month 6|Change From Baseline in NMSS Mood/Cognition Domain Score at Month 6|Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score at Month 6|Change From Baseline in NMSS Attention/Memory Domain Score at Month 6|Change From Baseline in NMSS Gastrointestinal Tract Domain Score at Month 6|Change From Baseline in NMSS Urinary Domain Score at Month 6|Change From Baseline in NMSS Sexual Function Domain Score at Month 6|Change From Baseline in NMSS Miscellaneous Domain Score at Month 6|Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Mean Global Score at Month 6|Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Alertness/Sedation Sub-Scale Score at Month 6|Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Contented/Discontented Sub-Scale Score at Month 6|Change From Baseline in the Norris/Bond-Lader Visual Analogue Scale (VAS) Calmness/Relaxation Sub-Scale Score at Month 6|Change From Baseline in Parkinson Fatigue Scale (PFS-16) at Month 6|Change From Baseline in the Score of the Apathy Scale (AS) to Month 6|Change From Baseline in Beck Depression Inventory, Second Edition (BDI-II) at Month 6|Change From Baseline in Beck Anxiety Inventory (BAI) at Month 6|Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Composite Score at Month 6|Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Undesirable Side Effects at Month 6|Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Treatment Effectiveness at Month 6|Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Convenience of Use at Month 6|Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Impact on Daily Living Activities at Month 6|Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Medical Care at Month 6|Change From Baseline in the Treatment Satisfaction With Medicines Questionnaire (SATMED-Q) Global Satisfaction at Month 6|Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Composite Score at Month 6|Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Professional Activities at Month 6|Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Social and Leisure Activities at Month 6|Change From Baseline in the Scale of Quality of Life of Caregivers (SQLC) Caregiving Responsibilities at Month 6|Change From Baseline in Zarit Burden Interview (ZBI) at Month 6|Change From Baseline in the Caregiver Stress Index (CSI) at Month 6|Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Depression Sub-Scale for Caregivers at Month 6|Change From Baseline in Goldberg Anxiety and Depression Score (GADS): Anxiety Sub-Scale for Caregivers at Month 6|Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) at Month 6|Change From Baseline in WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Caregiving (Presenteeism)|Change From Baseline in WPAI Questionnaire: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to Caregiving|Change From Baseline in WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Caregiving|Correlation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Baseline|Correlation Between Participants' Quality of Life (PDQ-39) and Different Questionnaires at Month 6|Correlation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Baseline|Correlation Between Caregivers' Quality of Life (SQLC) and Different Questionnaires at Month 6","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"62","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-335","October 2014","November 2016","November 2016","November 13, 2014","January 30, 2019","January 30, 2019",,,"https://ClinicalTrials.gov/show/NCT02289729"
320,"NCT02289690","Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer",,"Completed","No Results Available","Small Cell Lung Cancer","Drug: Veliparib|Drug: Carboplatin|Drug: Etoposide","Recommended Phase 2 dose of veliparib (ABT-888) in combination with carboplatin and etoposide|Maximum tolerated dose (MTD) of veliparib (ABT-888) in combination with carboplatin and etoposide|Frequency of adverse events during maintenance veliparib monotherapy at 400 mg twice daily (BID)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","219","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-361|2014-001764-35","October 13, 2014","April 17, 2019","April 17, 2019","November 13, 2014",,"April 19, 2019","Mayo Clinic - Scottsdale /ID# 129127, Scottsdale, Arizona, United States|Univ of Colorado Cancer Center /ID# 129220, Aurora, Colorado, United States|Emory University Hospital /ID# 141682, Atlanta, Georgia, United States|Georgia Regents University /ID# 148567, Augusta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 137088, Chicago, Illinois, United States|Herbert Herman Cancer Center /ID# 167020, Lansing, Michigan, United States|Gabrail Cancer Center Research /ID# 129216, Canton, Ohio, United States|Allegheny General Hospital /ID# 147328, Pittsburgh, Pennsylvania, United States|Univ TX, MD Anderson /ID# 129213, Houston, Texas, United States|Southern Medical Day Care Ctr /ID# 155498, Wollongong, New South Wales, Australia|The Townsville Hospital /ID# 155499, Douglas, Queensland, Australia|Peninsula & South Eastern Haem /ID# 155497, Frankston, Victoria, Australia|Border Medical /ID# 157894, Wodonga, Victoria, Australia|Cliniques Universitaires Saint Luc /ID# 151024, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|CHU de Liege /ID# 151025, Liège, Liege, Belgium|UZ Antwerp /ID# 151026, Edegem, Belgium|C.H.U.de Mons Borinage /ID# 151023, Mons, Belgium|CHU UCL Namur /ID# 151022, Namur, Belgium|University of Calgary /ID# 152544, Calgary, Alberta, Canada|Cross Cancer Institute /ID# 132883, Edmonton, Alberta, Canada|Juravinski Cancer Clinic /ID# 152543, Hamilton, Ontario, Canada|Hopital Sacre Coeur Montreal /ID# 154436, Montreal, Quebec, Canada|Nemocnice Na Plesi s.r.o. /ID# 149825, Nová Ves pod Pleší, Pribram, Czechia|Nemocnice Novy Jicin /ID# 149838, Nový Jičín 1, Czechia|Vitkovicka nemocnice a. s. /ID# 149839, Ostrava, Czechia|Multiscan s.r.o. /ID# 150887, Pardubice, Czechia|CHU Dupuytren /ID# 153622, Limoges CEDEX 1, Franche-Comte, France|Centre Hospitalier Le Mans /ID# 158103, Le Mans CEDEX 9, Sarthe, France|Centre Hosp Intercommunal /ID# 157970, Creteil, France|Markusovszky Egyetemi Oktatókórház /ID# 158806, Szombathely, Vas, Hungary|Orszagos Koranyi TBC/Pulmon /ID# 151351, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 151354, Debrecen, Hungary|Veszprem Megyei Tudogyogyintez /ID# 158807, Farkasgyepu, Hungary|Petz Aladar Megyei Oktato Korh /ID# 155352, Gyor, Hungary|Matrahaza Gyogyintezet /ID# 151355, Kékesteto, Hungary|Fejer Megyei Szent Gyorgy Korh /ID# 151352, Szekesfehervar, Hungary|Jasz-Nagykun-Szolnok Megyei /ID# 155090, Szolnok, Hungary|Dong-A University Hospital /ID# 153187, Busan, Busan Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 153188, Gwangju, Jeonranamdo, Korea, Republic of|Chungbuk National Univ Hosp /ID# 153186, Cheongju, Korea, Republic of|Asan Medical Center /ID# 153185, Seoul, Korea, Republic of|Universitair Medisch Centrum Groningen /ID# 131252, Groningen, Netherlands|Ziekenhuis St. Jansdal /ID# 151974, Harderwijk, Netherlands|Zuyderland Medisch Centrum /ID# 149830, Heerlen, Netherlands|Erasmus Medisch Centrum /ID# 131251, Rotterdam, Netherlands|Isala /ID# 151975, Zwolle, Netherlands|S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 161137, Craiova, Dolj, Romania|Oncocenter Oncologie Clinica S /ID# 151694, Timisoara, Timis, Romania|S.C. Radiotherapy Center Cluj /ID# 165137, Cluj, Romania|NN Blokhin Russian Cancer /ID# 152329, Moscow, Moskva, Russian Federation|Sverdlovsk Regional Oncology Center /ID# 152328, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|Belgorod Oncology Dispensary /ID# 152330, Belgorod, Russian Federation|Univercity Headache Clynic,LTD /ID# 161708, Moscow, Russian Federation|Murmansk RCH P.A. Bayandina /ID# 152331, Murmansk, Russian Federation|Ogarev Mordovia State Univ /ID# 152327, Saransk, Russian Federation|Road Hospital Open Joint Stock /ID# 152731, St. Petersburg, Russian Federation|Hosp. Sta Creu i Sant Pau /ID# 151254, Barcelona, Spain|Hosp Univ Quiron Dexues /ID# 130302, Barcelona, Spain|Hospital Universitario Gregori /ID# 164982, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 151252, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 130301, Madrid, Spain|Hosp Univ Puerta de Hierro Maj /ID# 151253, Majadahonda, Spain",,"https://ClinicalTrials.gov/show/NCT02289690"
321,"NCT02287233","A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia",,"Active, not recruiting","No Results Available","Acute Myelogenous Leukemia|AML","Drug: Venetoclax|Drug: Cytarabine","Number of participants with adverse events|Time to maximum observed plasma concentration (Tmax) of venetoclax|Maximum tolerated dose (MTD) of venetoclax in combination with cytarabine|Recommended phase two dose (RPTD) of venetoclax in combination with cytarabine|Maximum observed plasma concentration (Cmax) of cytarabine|Area under the plasma concentration-time curve from time 0 to 6 hours post-dose (AUC6) of cytarabine.|Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC24) of venetoclax|Overall Response Rate- In Cohort C, overall response rate (ORR) will be evaluated for subjects allowed additional supportive meds (e.g strong CYP3A inhibitor) if medically indicated.|Time to maximum observed plasma concentration (Tmax) of cytarabine.|Maximum observed plasma concentration (Cmax) of venetoclax|The number of participants who undergo transplant|Duration of response (DOR)|Overall survival (OS)|Hematologic response rate to venetoclax/cytarabine combination therapy","AbbVie|Genentech, Inc.","All","60 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","91","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-387|2014-002610-23","December 30, 2014","May 12, 2021","May 12, 2021","November 10, 2014",,"November 29, 2019","Univ Kansas Med Ctr /ID# 131175, Kansas City, Kansas, United States|Weill Cornell Medical College /ID# 131170, New York, New York, United States|University of Pittsburgh MC /ID# 131168, Pittsburgh, Pennsylvania, United States|Vanderbilt Univ Med Ctr /ID# 131177, Nashville, Tennessee, United States|Fred Hutchinson Cancer Researc /ID# 131178, Seattle, Washington, United States|Calvary Mater Newcastle /ID# 136076, Waratah, New South Wales, Australia|Alfred Health /ID# 131180, Melbourne, Victoria, Australia|Univ Klinik Eppendorf Hamburg /ID# 133979, Hamburg, Germany|A.O.U. Policlinico S.Orsola-Malpighi /ID# 131183, Bologna, Emilia-Romagna, Italy",,"https://ClinicalTrials.gov/show/NCT02287233"
322,"NCT02282982","Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis","SUNRISE","Completed","Has Results","Respiratory Syncytial Virus (RSV)",,"Proportion of Infants Hospitalized for Lower Respiratory Tract Infection (LRTI) With a Positive Respiratory Syncytial Virus (RSV) Diagnostic Test|Proportion of Infants Who Died From a Confirmed Respiratory Syncytial Virus (RSV) Infection|Median Length of Stay (LOS) of Lower Respiratory Tract Infection (LRTI) Hospitalization With a Positive Respiratory Syncytial Virus (RSV) Test|Proportion of Participants With Intensive Care Unit (ICU) Admission Among Hospitalized Participants|Median Length of Stay (LOS) of Participants in the Intensive Care Unit (ICU)|Proportion of Participants Who Received Supplemental Oxygen While Hospitalized|Proportion of Participants Who Received Mechanical Ventilation While Hospitalized|Proportion of Participants With Missed Doses of Palivizumab|Proportion of Participants With Co-morbidities During Hospitalizations|Median Duration of Mechanical Ventilation Administration During Hospitalizations|Median Duration of Oxygen Administration During Hospitalizations|Proportion of Participants With a Particular Co-morbidity","AbbVie","All","up to 2 Years   (Child)",,"359","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-579","October 2014","May 2015","May 2015","November 5, 2014","June 28, 2016","July 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02282982"
323,"NCT02265731","Study Evaluating Venetoclax in Subjects With Hematological Malignancies",,"Active, not recruiting","No Results Available","Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM)|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Acute Myeloid Leukemia (AML)","Drug: azacitadine|Drug: venetoclax|Drug: rituximab / IDEC-C2B8","Number of participants having treatment-emergent adverse events|Time to maximum plasma concentration (Tmax) of venetoclax|Maximum plasma concentration (Cmax) of venetoclax|Area under the plasma concentration-time curve from 0 to 24 hours (AUC24) post-dose of venetoclax|Objective Response Rate (Phase 2)|Objective Response Rate (Phase 1)|Minimal Residual Disease (MRD)|Duration of Response|Time to disease progression|complete response or remission (CR) rate|Partial response or remission (PR) rate|Progression Free Survival (PFS)","AbbVie|Genentech, Inc.","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","38","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-834","September 22, 2014","February 6, 2020","February 6, 2020","October 16, 2014",,"June 13, 2019","Aichi Cancer Center Hospital /ID# 129061, Nagoya-shi, Aichi, Japan|Nagoya City University Hospital /ID# 129278, Nagoya-shi, Aichi, Japan|University of Fukui Hospital /ID# 165801, Yoshida-gun, Fukui, Japan|National Hospital Organization Kyushu Cancer Center /ID# 149741, Fukuoka-shi, Fukuoka, Japan|Kyushu University Hospital /ID# 163202, Fukuoka-shi, Fukuoka, Japan|Kobe City Medical Center General Hospital /ID# 170919, Kobe-shi, Hyogo, Japan|Tohoku University Hospital /ID# 129275, Sendai-shi, Miyagi, Japan|Kinki University -Osakasayama Campus /ID# 169554, Osakasayama-shi, Osaka, Japan|Osaka University Hospital /ID# 169862, Suita-shi, Osaka, Japan|National Cancer Center Hospital /ID# 129044, Chuo-ku, Tokyo, Japan|The Cancer Institute Hosp JFCR /ID# 129277, Koto-ku, Tokyo, Japan|Toranomon Hospital /ID# 148229, Minato-ku, Tokyo, Japan|NTT Medical Center Tokyo /ID# 166281, Shinagawa-ku, Tokyo, Japan|NHO Nagoya Medical Center /ID# 129222, Nagoya, Japan",,"https://ClinicalTrials.gov/show/NCT02265731"
324,"NCT02265237","A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)","AGATE-1","Completed","Has Results","Hepatitis C Virus","Drug: ombitasvir/paritaprevir/ritonavir|Drug: ribavirin","Percentage of Participants in Arms A, B and C With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With SVR12 in Participants Receiving 12 Weeks (Arm A) of Treatment Compared to Participants Receiving 16 Weeks of Treatment (Arm B)|Percentage of Participants With SVR12 in Participants Receiving 16 Weeks (Arm B) of Treatment Compared to Participants Receiving 24 Weeks of Treatment (Arm C)|Percentage of Participants in Arms A, B and C With On-treatment Virologic Failure|Percentage of Participants in Arms A, B and C With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-665|2014-001496-31","October 28, 2014","July 28, 2016","April 7, 2017","October 15, 2014","August 31, 2017","August 31, 2017",,,"https://ClinicalTrials.gov/show/NCT02265237"
325,"NCT02264990","Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers",,"Active, not recruiting","No Results Available","Non-squamous Non-small Cell Lung Cancer","Drug: Paclitaxel|Drug: Pemetrexed|Drug: Carboplatin|Drug: Cisplatin|Drug: Veliparib","Overall Survival (OS) in the LSP (Lung Subtype Panel) positive subgroup|Objective Response Rate (ORR) in the LSP (Lung Subtype Panel) positive subgroup and all participants|Progression Free Survival (PFS) in the LSP (Lung Subtype Panel) positive subgroup and all participants|Overall Survival (OS) in all participants","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","595","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-359|2014-002565-30","October 6, 2014","October 31, 2019","November 4, 2019","October 15, 2014",,"September 10, 2019","Clearview Cancer Institute /ID# 131434, Huntsville, Alabama, United States|University of South Alabama /ID# 131518, Mobile, Alabama, United States|Highlands Oncology Group /ID# 131250, Fayetteville, Arkansas, United States|CBCC Global Research, Inc. at /ID# 132709, Bakersfield, California, United States|California Cancer Assoc. R&E /ID# 131392, Encinitas, California, United States|California Cancer Assoc. R&E /ID# 131949, Encinitas, California, United States|LA Hem-Oncology Med Group /ID# 131639, Los Angeles, California, United States|St Jude Hospital dba St Joseph /ID# 132943, Santa Rosa, California, United States|Icri /Id# 132942, Whittier, California, United States|University of Florida /ID# 132408, Gainesville, Florida, United States|NorthShore University HealthSystem - Evanston /ID# 130200, Evanston, Illinois, United States|Goshen Center for Cancer Care /ID# 130216, Goshen, Indiana, United States|University of Louisville /ID# 130217, Louisville, Kentucky, United States|Cancer Center of Acadiana /ID# 133611, Lafayette, Louisiana, United States|Henry Ford Health System /ID# 130234, Detroit, Michigan, United States|Herbert Herman Cancer Center /ID# 130239, Lansing, Michigan, United States|Washington University-School of Medicine /ID# 131651, Saint Louis, Missouri, United States|MD Anderson Cancer Center at Cooper /ID# 131490, Camden, New Jersey, United States|Gabrail Cancer Center Research /ID# 130205, Canton, Ohio, United States|Univ Oklahoma HSC /ID# 132888, Oklahoma City, Oklahoma, United States|Albert Einstein Medical Center /ID# 134498, Philadelphia, Pennsylvania, United States|Allegheny General Hospital /ID# 134049, Pittsburgh, Pennsylvania, United States|The Jones Clinic, PC /ID# 130215, Germantown, Tennessee, United States|UT Southwestern Medical Center /ID# 130236, Dallas, Texas, United States|Univ Texas HSC San Antonio /ID# 132972, San Antonio, Texas, United States|Coiba /Id# 132153, Berazategui, Buenos Aires, Argentina|Centro Investigacion Pergamino /ID# 132152, Pergamino, Argentina|Hospital Britanico /ID# 134874, Rosario, Santa FE, Argentina|Instituto de Oncologia de Rosa /ID# 132150, Rosario, Santa FE, Argentina|St George Hospital /ID# 132481, Kogarah, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 132482, Wollongong, New South Wales, Australia|Flinders Centre for Innovation /ID# 134288, Bedford Park, South Australia, Australia|Royal Hobart Hospital /ID# 132477, Hobart, Tasmania, Australia|Qe Ii Hsc /Id# 133408, Halifax, Nova Scotia, Canada|Victoria Hospital /ID# 132161, London, Ontario, Canada|Windsor Regional Hospital /ID# 135989, Windsor, Ontario, Canada|CSSS Alphonse-Desjardins, CHAU /ID# 132155, Quebec City, Quebec, Canada|Krajska nemocnice Liberec a.s. /ID# 132694, Liberec, Czechia|Univ Hosp Ostrava-Poruba /ID# 132690, Ostrava, Czechia|Multiscan s.r.o. /ID# 132689, Pardubice, Czechia|Vseobecna Fakultni Nemocnice /ID# 135118, Prague, Czechia|Odense Universitets Hospital /ID# 131912, Odense C, Syddanmark, Denmark|Satakunnan Sairaanhoitopiiri /ID# 133632, Pori, Finland|Vaasa Central Hospital /ID# 131930, Vaasa, Finland|Charite-Univ. Berlin, Benjamin-Franklin /ID# 131927, Berlin, Germany|Lungen Clinic Grosshansdorf /ID# 131928, Grosshansdorf, Germany|Univ Klinik Eppendorf Hamburg /ID# 131926, Hamburg, Germany|Klinik Loewenstein GmbH /ID# 131925, Löwenstein, Germany|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 133441, Miskolc, Borsod-Abauj-Zemplen, Hungary|Orszagos Koranyi TBC/Pulmon /ID# 132738, Budapest XII, Hungary|Debreceni Egyetem Klinikai Központ /ID# 132742, Debrecen, Hungary|Koch Robert Hospital /ID# 133440, Edelény, Hungary|Veszprem Megyei Tudogyogyintez /ID# 132739, Farkasgyepu, Hungary|Petz Aladar Megyei Oktato Korh /ID# 132741, Gyor, Hungary|Matrahaza Gyogyintezet /ID# 132743, Kékesteto, Hungary|Assaf Harofeh Medical Center /ID# 132830, Be'er Ya'akov, Israel|Shaare Zedek Medical Center /ID# 132834, Jerusalem, Israel|Meir Medical Center /ID# 132832, Kfar Saba, Israel|Sheba Medical Center /ID# 132833, Ramat Gan, Israel|Aichi Cancer Center Hospital /ID# 134129, Nagoya-shi, Aichi, Japan|Kurume University Hospital /ID# 134117, Kurume-shi, Fukuoka, Japan|Kindai University Hospital /ID# 134112, Osaka-sayama, Osaka, Japan|National Cancer Center Hospital /ID# 135129, Chuo-ku, Tokyo, Japan|The Cancer Institute Hosp JFCR /ID# 135492, Koto-ku, Tokyo, Japan|Hiroshima Citizens Hospital /ID# 135130, Hiroshima, Japan|Kishiwada City Hospital /ID# 136548, Kishiwada, Japan|Osaka City General Hospital /ID# 134115, Osaka, Japan|Hokkaido University Hospital /ID# 134123, Sapporo, Japan|Sendai Kousei Hospital /ID# 135491, Sendai, Japan|Yamaguchi - Ube Medical Center /ID# 135284, UBE, Japan|Kanagawa Cardio Resp Center /ID# 134127, Yokohama, Japan|Dong-A University Hospital /ID# 131609, Busan, Busan Gwang Yeogsi, Korea, Republic of|Seoul National Univ Bundang ho /ID# 131610, Seongnam, Gyeonggido, Korea, Republic of|Inha University Hospital /ID# 147924, Jung-gu, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 131612, Gwangju, Jeonranamdo, Korea, Republic of|Samsung Medical Center /ID# 132471, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Chungbuk National Univ Hosp /ID# 131611, Cheongju, Korea, Republic of|Vrije Universiteit Medisch Centrum /ID# 131967, Amsterdam, Netherlands|Catharina Ziekenhuis /ID# 131966, Eindhoven, Netherlands|Ziekenhuis St. Jansdal /ID# 131965, Harderwijk, Netherlands|St. Antonius Ziekenhuis /ID# 133635, Nieuwegein, Netherlands|Jeroen Bosch Ziekenhuis /ID# 131968, S Hertogenbosch, Netherlands|Canterbury District Health Boa /ID# 132469, Christchurch, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 132470, Wellington, New Zealand|NN Blokhin Russian Cancer /ID# 137085, Moscow, Moskva, Russian Federation|Sverdlovsk Regional Oncology Center Dispensary /ID# 132375, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|archangel Clinical Oncology /ID# 132376, Arkhangelsk, Russian Federation|Moscow Regional Onc Dispensary /ID# 132381, Balashikha, Russian Federation|Belgorod Oncology Dispensary /ID# 142638, Belgorod, Russian Federation|Moscow Res Onc Inst Hertsen /ID# 132370, Moscow, Russian Federation|Murmansk RCH P.A. Bayandina /ID# 137087, Murmansk, Russian Federation|Orenburg Regional Clinical Onc /ID# 132371, Orenburg, Russian Federation|""Strategic medical systems"" LLC /ID# 206383, Sankt-Peterburg, Russian Federation|Ogarev Mordovia State Univ /ID# 132377, Saransk, Russian Federation|LLC BioEq Ltd. /ID# 132372, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 137084, St. Petersburg, Russian Federation|GVI Oncology /ID# 133268, Port Elizabeth, Eastern Cape, South Africa|Life Wilgers Hospital /ID# 131775, Pretoria, Gauteng, South Africa|Mary Potter Oncology Centre /ID# 131776, Pretoria, Gauteng, South Africa|The Oncology Centre /ID# 131773, Durban, Kwazulu-Natal, South Africa|Netcare Oncology Intervent Ctr /ID# 131777, Cape Town, Western Cape, South Africa|Cape Town Oncology Trials /ID# 132734, Cape Town, Western Cape, South Africa|GVI Rondebosch Oncology Centre /ID# 132732, Cape Town, Western Cape, South Africa|Sandton Oncology Medical Group /ID# 131774, Johannesburg, South Africa|Hospital Duran i Reynals /ID# 132879, L'Hospitalet de Llobregat, Barcelona, Spain|Hosp Univ Fundacion Alcorcon /ID# 132909, Alcorcon, Spain|Hospital General Univ Alicante /ID# 132881, Alicante, Spain|Hosp Univ Quiron Dexues /ID# 132876, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 132871, Barcelona, Spain|MD Anderson CC Madrid /ID# 132905, Madrid, Spain|Hospital Universitario La Paz /ID# 132870, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 132869, Madrid, Spain|Hosp Clin Univ de Valencia /ID# 132873, Valencia, Spain|China Medical University Hosp /ID# 131870, Taichung City, Taichung, Taiwan|Dalin Tzu Chi General Hospital /ID# 131872, Dalin Township, Taiwan|Taipei Medical University Hosp /ID# 133817, Taipei City, Taiwan|Taipei Veterans General Hosp /ID# 131871, Taipei City, Taiwan|Hacettepe University Medical Faculty /ID# 131913, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 131914, Ankara, Turkey|Uludag University Medical Faculty /ID# 131915, Bursa, Turkey|Dicle Universitesi Tip /ID# 136570, Diyarbakir, Turkey|Gaziantep Universitesi Med /ID# 131917, Gaziantep, Turkey|Dr. Suat Seren Gogus Has /ID# 136568, Izmir, Turkey|Inonu University /ID# 136569, Malatya, Turkey|Leicester Royal Infirmary /ID# 133930, Leicester, England, United Kingdom|Cheltenham General Hospital /ID# 131951, Cheltenham, Gloucestershire, United Kingdom|Royal United Hospitals Bath /ID# 132851, Bath, United Kingdom|Belfast City Hospital /ID# 132858, Belfast, United Kingdom|Heartlands Hospital /ID# 132855, Birmingham, United Kingdom|Royal Blackburn Hospital /ID# 132853, Blackburn, United Kingdom|Colchester General Hospital /ID# 133929, Colchester, United Kingdom|Castle Hill Hospital /ID# 135489, Cottingham, United Kingdom|Scunthorpe General Hospital /ID# 133931, Doncaster, United Kingdom|James Paget University Hosp /ID# 131954, Great Yarmouth, United Kingdom|Royal Gwent Hospital /ID# 133935, Gwent, United Kingdom|Huddersfield Royal Infirmary /ID# 132854, Huddersfield, United Kingdom|Charing Cross Hospital /ID# 131959, London, United Kingdom|Freeman Hospital /ID# 131661, Newcastle Upon Tyne, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 131953, Norwich, United Kingdom|York Hospital /ID# 132859, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02264990"
326,"NCT02247401","Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt",,"Completed","Has Results","HCV|Hepatitis C Infection|Genotype 4","Drug: 2 DAA|Drug: RBV","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Each Treatment Arm|Number of Participants With Adverse Events|Percentage of Participants With On-treatment Virologic Failure in Each Treatment Arm|Percentage of Participants With Post-treatment Relapse Within 12 Weeks Following End of Treatment in Each Arm","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-250","November 4, 2014","August 1, 2016","August 1, 2016","September 25, 2014","July 27, 2017","August 28, 2017",,,"https://ClinicalTrials.gov/show/NCT02247401"
327,"NCT02243293","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus","Drug: ABT-493|Drug: ABT-530|Drug: ribavirin (RBV)|Drug: ABT-493/ABT-530","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control|Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","694","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-868|2014-002927-90","September 19, 2014","October 25, 2016","February 23, 2017","September 17, 2014","October 2, 2017","October 2, 2017",,,"https://ClinicalTrials.gov/show/NCT02243293"
328,"NCT02243280","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus|HCV","Drug: ABT-493|Drug: ABT-530","Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks Post-treatment|Percentage of Participants With Sustained Virologic Response (SVR) 4 Weeks Post-treatment|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","174","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-867|2014-002925-36","August 2014","February 2016","February 2016","September 17, 2014","April 6, 2017","April 6, 2017",,,"https://ClinicalTrials.gov/show/NCT02243280"
329,"NCT02220738","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-957|Other: Placebo for ABT-957","Pharmacokinetic evaluation of the two ABT-957 diastereomers|Number of subjects with adverse events","AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-334","September 2014","March 2016","March 2016","August 20, 2014",,"June 16, 2016","Site Reference ID/Investigator# 129545, Glendale, California, United States|Site Reference ID/Investigator# 129435, Orlando, Florida, United States|Site Reference ID/Investigator# 129641, New York, New York, United States|Site Reference ID/Investigator# 144825, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02220738"
330,"NCT02219503","A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis","TURQUOISE-III","Completed","Has Results","Chronic Hepatitis C Infection|Compensated Cirrhosis","Drug: Ombitasvir/Paritaprevir/Ritonavir|Drug: Dasabuvir","Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Participants With On-Treatment Virologic Failure|Percentage of Participants With Post-Treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-490|2014-001953-18","September 2014","June 2015","September 2015","August 19, 2014","June 29, 2016","June 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02219503"
331,"NCT02219490","A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","TOPAZ-I","Active, not recruiting","No Results Available","Chronic Hepatitis C Virus (HCV) Infection Genotype 1","Drug: ABT-333|Drug: ABT-450/r/ABT-267|Drug: Ribavirin (RBV)","Incidence of pre-defined clinical outcomes observed during the study|Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12)|Change in fibrosis","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","1596","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-423|2014-001022-14","October 30, 2014","May 12, 2021","May 12, 2021","August 19, 2014",,"December 11, 2019","CHU Bab El Oued /ID# 145420, Algiers, Algeria|CHU Bologhine Hospital /ID# 145421, Algiers, Algeria|CHU Mustapha Bacha /ID# 132130, Algiers, Algeria|St. Vincent's Hospital, Darlinghurst /ID# 131001, Darlinghurst, New South Wales, Australia|Nepean Hospital Kingswood /ID# 130999, Kingswood, New South Wales, Australia|Westmead Hospital /ID# 130997, Westmead, New South Wales, Australia|Greenslopes Private Hospital /ID# 131003, Greenslopes, Queensland, Australia|Royal Brisbane and Women's Hospital /ID# 131004, Herston, Queensland, Australia|Royal Adelaide Hospital /ID# 131002, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 131000, Fitzroy, Victoria, Australia|Royal Melbourne Hospital /ID# 130998, Parkville, Victoria, Australia|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 131017, Linz, Oberoesterreich, Austria|Medizinische Universität Wien /ID# 131015, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 131018, Graz, Austria|CUB Hospital Erasme /ID# 131020, Brussels, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 131019, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|UZ Leuven /ID# 131021, Leuven, Belgium|Tokuda Hospital Sofia /ID# 131022, Sofia, Bulgaria|Univ Hosp for Active Treat /ID# 131023, Sofia, Bulgaria|Diagnostic Consultative Center /ID# 131027, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 131026, Sofia, Bulgaria|Univ Hosp MHAT Sveta Marina /ID# 131025, Varna, Bulgaria|University of Calgary /ID# 134370, Calgary, Alberta, Canada|GI Research /ID# 132169, Edmonton, Alberta, Canada|LAIR Centre /ID# 130970, Vancouver, British Columbia, Canada|Vancouver ID Research and Care /ID# 134369, Vancouver, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 132171, Vancouver, British Columbia, Canada|Uni Manitoba /ID# 130969, Winnipeg, Manitoba, Canada|Saint John Regional Hospital /ID# 131210, Saint John, New Brunswick, Canada|The Ottawa Hospital /ID# 132170, Ottawa, Ontario, Canada|Toronto General Hospital /ID# 132134, Toronto, Ontario, Canada|Toronto Liver Centre /ID# 132168, Toronto, Ontario, Canada|Toronto Digestive Disease Asso /ID# 130968, Vaughan, Ontario, Canada|Clinique Medicale L'Actuel /ID# 132167, Montreal, Quebec, Canada|McGill Univ HC /ID# 132166, Montreal, Quebec, Canada|Jewish General Hospital /ID# 132165, Montreal, Quebec, Canada|Chuq - Chul /Id# 132132, Quebec, Canada|Odense Universitets Hospital /ID# 131029, Odense C, Syddanmark, Denmark|Aarhus Univ Hospital, Skejby /ID# 131030, Aarhus, Denmark|Kobenhavns Universitet - Hvidovre Hospital (HH) /ID# 131031, Hvidovre, Denmark|Helsinki Univ Central Hospital /ID# 131034, Helsinki, Finland|Turku University Hospital /ID# 131032, Turku, Finland|Hopital Saint Joseph /ID# 132177, Marseille CEDEX 08, Bouches-du-Rhone, France|CHU Dupuytren /ID# 131038, Limoges CEDEX 1, Franche-Comte, France|Hopital Haut-Lévêque /ID# 131036, Pessac CEDEX, Gironde, France|Hopital Saint Eloi /ID# 131037, Montpellier CEDEX 5, Herault, France|Jean Verdier Hospital /ID# 135877, Bondy, France|CHU de Grenoble - Albet Michal /ID# 131041, Grenoble, France|Hopital de la Croix Rousse /ID# 131042, Lyon, France|CHU de Nantes, Hotel Dieu -HME /ID# 132179, Nantes, France|CHU de Nice /ID# 131040, Nice, France|Hospital Pontchaillou /ID# 132173, Rennes, France|Nouvel Hopital Civil (NHC) /ID# 132174, Strasbourg, France|Hopital Rangueil /ID# 131035, Toulouse, France|Universitaetsklinik Heidelberg /ID# 134371, Heidelberg, Baden-Wuerttemberg, Germany|Universitatsklinikum Frankfurt /ID# 131055, Frankfurt, Hessen, Germany|Zentr. HIV und Hep.Gast.Ent. /ID# 131052, Düsseldorf, Nordrhein-Westfalen, Germany|Charité Universitätsmedizin Campus Mitte /ID# 131053, Berlin, Germany|Universitaetsklinikum Essen /ID# 131048, Essen, Germany|University Hospital Freiburg /ID# 131044, Freiburg, Germany|Univ Klinik Eppendorf Hamburg /ID# 131051, Hamburg, Germany|Med Hochschule Hanover /ID# 131054, Hannover, Germany|Group Practice Gastroenterolog /ID# 131050, Herne, Germany|LMU Klinikum der Universität München /ID# 131049, Munich, Germany|Centr. für Interdiszipl. Med. /ID# 131046, Munster, Germany|Universitatsklinikum Tubingen /ID# 131045, Tuebingen, Germany|General Hospital of Athens Laiko /ID# 131088, Athens, Attiki, Greece|Gen Univ Hosp Alexandroupolis /ID# 131056, Alexandroupolis, Greece|Hippokration General Hospital /ID# 131057, Athens, Greece|St. James's Hospital /ID# 132180, Dublin 8, Dublin, Ireland|St Vincent's University Hosp /ID# 132181, Dublin, Ireland|Beaumont Hospital /ID# 131089, Dublin, Ireland|Tel Aviv Sourasky Medical Ctr /ID# 132182, Tel Aviv-Yafo, Tel-Aviv, Israel|Rambam Health Care Campus /ID# 131090, Haifa, Israel|The Lady Davis Carmel MC /ID# 131091, Haifa, Israel|Sheba Medical Center /ID# 131092, Ramat Gan, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 131095, Bologna, Emilia-Romagna, Italy|AO Univ Policlinico Agostino G /ID# 131098, Rome, Lazio, Italy|ASST Grande Ospedale Metropolitano Niguarda /ID# 131104, Milano, Lombardia, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 131097, Milan, Lombardia, Italy|AOU Citta della Salute Scienza /ID# 131100, Turin, Piemonte, Italy|Policlinico Paolo Giaccone /Id# 132184, Palermo, Sicilia, Italy|ASST Papa Giovanni XXIII /ID# 132188, Bergamo, Italy|A.O.U Sant'Anna di Ferrara /ID# 131102, Ferrara, Italy|A.O. Universitaria Careggi /ID# 132197, Florence, Italy|Ospedali Riuniti Azienda /ID# 132195, Foggia, Italy|A.O.U. Policlinico G. Martino /ID# 132193, Messina, Italy|Ospedale S Giuseppe /ID# 132194, Milan, Italy|Ospedale San Raffaele IRCCS /ID# 131093, Milan, Italy|Azienda Ospedaliera - Polo Uni /ID# 132198, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 134372, Milan, Italy|University of Naples Federico /ID# 131096, Naples, Italy|University of Naples Federico /ID# 132191, Naples, Italy|Azienda Ospedaliero Uni Parma /ID# 132183, Parma, Italy|Policlinico Univ Tor Vergata /ID# 132185, Rome, Italy|A.O. Uni Giovanni e Ruggi /ID# 132192, Salerno, Italy|IRCCS Casa Sollievo /ID# 132190, San Giovanni Rotondo, Italy|Azienda Sanitaria Universitaria Integrata di Udine /ID# 132196, Udine, Italy|Instituto Technologico y de Es /ID# 132383, DEL. Tlalpan, Mexico|Instituto Metropolitano de Inv /ID# 132201, Delegacion Tlalpan, Mexico|Cife /Id# 130974, Guadalajara, Mexico|CIF-BIOTEC/Medica Sur /ID# 134971, Mexico City, Mexico|IBD Clinic /ID# 130975, Mexico, Mexico|Hosp Gen Tijuana & Angeles /ID# 130972, Tijuana, Mexico|Academisch Medisch Centrum /ID# 132205, Amsterdam, Noord-Holland, Netherlands|Leids Universitair Medisch Centrum /ID# 132204, Leiden, Netherlands|Erasmus Medisch Centrum /ID# 132206, Rotterdam, Netherlands|Akershus Universitetssykehus_MAIN /ID# 132212, Lorenskog, Akershus, Norway|St. Olavs Hospital HF /ID# 132213, Trondheim, Sor-Trondelag, Norway|Stavanger University Hospital /ID# 132211, Stavanger, Norway|Uniwersytecki Szpital Kliniczn /ID# 131108, Bialystok, Poland|Wojewodzki Szpital Obserwacyjn /ID# 131106, Bydgoszcz, Poland|Wojewodzki Szpit Bieganskiego /ID# 131107, Lodz, Poland|Samodzielny Publiczny Szpital /ID# 131115, Lublin, Poland|ID Clinic /ID# 131111, Myslowice, Poland|Wojewodzki Szpital Zakazny /ID# 131112, Warsaw, Poland|Centro Hosp de Lisboa Central /ID# 131116, Lisbon, Lisboa, Portugal|Ctr Hosp Univ Coimbra, EPE /ID# 131119, Coimbra, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 131118, Lisboa, Portugal|Centro Hospitalar do Porto EPE /ID# 131117, Porto, Portugal|Institutul National de Boli Infectioase Prof. Dr. Matei Bals /ID# 131120, Sector 2, Bucuresti, Romania|Institutul Clinic Fundeni /ID# 131121, Sector 2, Bucuresti, Romania|Institutul Nat. de Boli Infectioase /ID# 131124, Bucuresti, Romania|SC Gastromedica SRL /ID# 131127, Lasi, Romania|Dr. Victor Babes Clinical Hosp /ID# 131126, Timisoara, Romania|LLC Medical Company Hepatolog /ID# 132277, Samara, Samarskaya Oblast, Russian Federation|State Autonomous Institution /ID# 132270, Kazan, Tatarstan, Respublika, Russian Federation|South-Ural State Med. Academy /ID# 132274, Chelyabinsk, Russian Federation|Sverdlovsk Reg Clin Hosp No. 1 /ID# 132267, Ekaterinburg, Russian Federation|Reg Ctr for AIDS /ID# 132269, Kemerovo, Russian Federation|Reg Ctr for AIDS /ID# 132278, Krasnoyarsk, Russian Federation|Moscow Clinical and Diagnostic /ID# 132266, Moscow, Russian Federation|FSBIH Central Clin Hosp RAMS /ID# 132289, Moscow, Russian Federation|Sechonov First Moscow State /ID# 132275, Moscow, Russian Federation|City Clinical Hospital 24 /ID# 132268, Moscow, Russian Federation|Res Inst Emrg NV Sklifosovskiy /ID# 132288, Moscow, Russian Federation|Clinical Inf. Dis Hospital 1 /ID# 132272, Novosibirsk, Russian Federation|Samara State Medical Universit /ID# 136913, Samara, Russian Federation|Stavropol State Medical Univ /ID# 132279, Stavropol, Russian Federation|Tolya City Clin Hosp /ID# 132273, Tolyatti, Russian Federation|RSAHI Consulting and Diagnostic Centre /ID# 131130, Tyumen, Russian Federation|King Abdulaziz Medical City /ID# 145129, Jeddah, Saudi Arabia|Ministry Nat Guard Hosp Health /ID# 145126, Riyadh, Saudi Arabia|King Khalid University Hospita /ID# 132291, Riyadh, Saudi Arabia|H. Un. Marques de Valdecilla /ID# 131141, Santander, Cantabria, Spain|Comple Hosp Univ de A Coruna /ID# 131137, A Coruna, Spain|OSI Ezkerraldea-Enkarterri-Cruces /ID# 131143, Barakaldo, Spain|Hospital Univ Germans Trias I /ID# 132293, Barcelona, Spain|Hospital Gen Univ Santa Lucia /ID# 131139, Cartagena, Spain|Hospital Universitario Reina S /ID# 131135, Cordoba, Spain|Hospital Donostia /ID# 131144, Donostia, Spain|Hospital Univ de la Princesa /ID# 131131, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 131133, Madrid, Spain|Hospital Universitario La Paz /ID# 131132, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 131136, Malaga, Spain|Hospital Univ Central Asturias /ID# 131138, Oviedo, Spain|Hospital Univ. Son Espases /ID# 131140, Palma de Mallorca, Spain|Hosp Univ Virgen del Rocio /ID# 131134, Sevilla, Spain|Hosp Clin Univ Lozano Blesa /ID# 132292, Zaragoza, Spain|Skanes Universitetssjukhus /ID# 131146, Malmö, Skane Lan, Sweden|Sahlgrenska University Hosp /ID# 131147, Goteborg, Sweden|Karolinska Univ Sjukhuset /ID# 131145, Solna, Sweden|Kantonsspital St. Gallen /ID# 131148, St. Gallen, Sankt Gallen, Switzerland|University Hospital Zurich /ID# 134881, Zurich, Zuerich, Switzerland|Inselspital, Universitaetsklinik /ID# 132294, Bern, Switzerland|Izmir Tepecik Egitim ve Arastirma Hastanesi /ID# 134968, Konak, Izmir, Turkey|Hacettepe University Medical Faculty /ID# 131150, Ankara, Turkey|Ankara Univ Medical Faculty /ID# 131151, Ankara, Turkey|Uludag University Medical Faculty /ID# 132297, Bursa, Turkey|Istanbul University Istanbul Medical Faculty /ID# 131153, Istanbul, Turkey|Ege University Medical Faculty /ID# 132298, Izmir, Turkey|Karadeniz University /ID# 131152, Trabzon, Turkey|The Royal London Hospital /ID# 132302, London, London, City Of, United Kingdom|The Royal Free Hospital /ID# 131159, London, London, City Of, United Kingdom|Univ Hospitals Birmingham NHS Foundation trust /ID# 131154, Birmingham, United Kingdom|The Royal Bournemouth Hospital /ID# 132306, Bournemouth, United Kingdom|North Manchester General /ID# 131156, Crumpsall, United Kingdom|Ninewells Hospital /ID# 132300, Dundee, United Kingdom|Western General Hospital /ID# 134368, Edinburgh, United Kingdom|Gartnavel General Hospital /ID# 131162, Glasgow, United Kingdom|St. James University Hospital /ID# 132305, Leeds, United Kingdom|King's College Hospital NHS /ID# 131157, London, United Kingdom|St. George's Healthcare NHS /ID# 132301, London, United Kingdom|Nottingham University /ID# 131155, Nottingham, United Kingdom|Derriford Hospital /ID# 131160, Plymouth, United Kingdom|Queen Alexandra Hospital /ID# 131158, Portsmouth, United Kingdom|Southampton General Hospital /ID# 131161, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02219490"
332,"NCT02219477","A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis","TURQUOISE-CPB","Completed","Has Results","Chronic Hepatitis C|Decompensated Cirrhosis|Hepatitis C Virus","Drug: ombitasvir/paritaprevir/ritonavir|Drug: dasabuvir|Drug: ribavirin","Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2|Percentage of Participants With SVR12 in Group 3|Percentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure|Percentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅12|Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Hepatic Function Tests|Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest|Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score|Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-227|2014-001477-13","November 24, 2014","June 13, 2016","March 3, 2017","August 19, 2014","July 11, 2017","July 11, 2017",,,"https://ClinicalTrials.gov/show/NCT02219477"
333,"NCT02216422","A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection","Turquoise-IV","Completed","Has Results","Chronic Hepatitis C Virus (HCV) Infection","Drug: Ombitasvir/Paritaprevir/Ritonavir|Drug: Dasabuvir|Drug: Ribavirin (RBV)","Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Participants With On-Treatment Virologic Failure|Percentage of Participants With Post-Treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","36","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-252","September 2014","December 2015","December 2015","August 15, 2014","June 29, 2016","June 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02216422"
334,"NCT02210663","A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: veliparib (ABT-888)","Dose-limiting toxicities of veliparib|Change in participant physical exam measurements|Change in participant clinical lab results|Number of participants with adverse events|Preliminary tumor response|Maximum observed plasma concentration (Cmax)|The time to Cmax (peak time, Tmax)|The area under the plasma concentration-time curve (AUC)","AbbVie","All","20 Years to 99 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-489","July 2014","January 2016","July 2016","August 7, 2014",,"May 7, 2018","Site Reference ID/Investigator# 128056, Hidaka-shi, Japan|Site Reference ID/Investigator# 129976, Hyogo, Japan|Site Reference ID/Investigator# 128057, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT02210663"
335,"NCT02207088","Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease","Drug: ombitasvir/paritaprevir/ritonavir|Drug: dasabuvir|Drug: Ribavirin","Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-Treatment Relapse","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","68","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-226|2014-001527-77","September 23, 2014","December 6, 2016","December 6, 2016","August 1, 2014","November 9, 2017","November 9, 2017",,,"https://ClinicalTrials.gov/show/NCT02207088"
336,"NCT02203851","Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Drug: Risankizumab","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Number of Participants With Drug-related TEAEs|Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs)|Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI90) Score at Week 48 in the Extended Dosing Period|Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 48 of Extended Dosing Period|Percentage of Participants Achieving 50% Improvement in PASI (PASI50) Score at Week 48 in the Extended Dosing Period|Percentage of Participants Achieving 75% Improvement in PASI (PASI75) Score at Week 48 in the Extended Dosing Period|Percentage of Participants Achieving 100% Improvement in PASI (PASI100) Score at Week 48 in the Extended Dosing Period|Percentage of Participants Achieving sPGA of Clear at Week 48 of Extended Dosing Period","AbbVie|Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 2","110","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M16-009|2014-001687-36|1311.13","November 20, 2014","September 4, 2018","September 4, 2018","July 30, 2014","November 8, 2019","November 8, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02203851/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02203851/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02203851"
337,"NCT02203773","Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)",,"Active, not recruiting","No Results Available","Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML","Drug: Posaconazole|Drug: ABT-199|Drug: Decitabine|Drug: Azacitidine","Complete Remission Rate|The area under the plasma concentration-time curve (AUC) from 0 to the time of the last measurable concentration (AUCt)|Complete Remission with incomplete blood count recovery rate|half-life (t1/2)|Maximum observed plasma concentration (Cmax)|Overall Response Rate|Clearance (CL)|AUC from 0-24 (AUC0-24)|Time to Cmax (peak time, Tmax),|AUC from 0 to infinity (AUC∞)|Overall Survival|Percent of subjects who move on to stem cell transplant|Duration of Response|Event Free Survival","AbbVie|Genentech, Inc.","All","60 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","212","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-358|2014-000687-18","October 6, 2014","March 26, 2021","March 26, 2021","July 30, 2014",,"April 25, 2019","City of Hope /ID# 129718, Duarte, California, United States|UC Davis Comp Cancer Ctr /ID# 129719, Sacramento, California, United States|Univ of Colorado Cancer Center /ID# 127859, Aurora, Colorado, United States|Emory University Hospital /ID# 129715, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 128741, Chicago, Illinois, United States|University of Chicago /ID# 128742, Chicago, Illinois, United States|Johns Hopkins University /ID# 129699, Baltimore, Maryland, United States|Dana-Farber Cancer Institute /ID# 127857, Boston, Massachusetts, United States|Columbia Univ Medical Center /ID# 130289, New York, New York, United States|Duke Univ Med Ctr /ID# 129720, Durham, North Carolina, United States|Univ TX, MD Anderson /ID# 127860, Houston, Texas, United States|Univ TX, MD Anderson /ID# 141581, Houston, Texas, United States|University of Washington /ID# 129717, Seattle, Washington, United States|St George Hospital /ID# 130356, Kogarah, New South Wales, Australia|Peter MacCallum Cancer Ctr /ID# 130352, Melbourne, Victoria, Australia|Alfred Health /ID# 130353, Melbourne, Victoria, Australia|Hopital Haut-Lévêque /ID# 134388, Pessac CEDEX, Gironde, France|Hopital Universitaire Purpan /ID# 134389, Toulouse, Haute-Garonne, France|Hopital Saint-Louis /ID# 130349, Paris, France|Universitaetsklinikum Leipzig /ID# 130346, Leipzig, Sachsen, Germany|Universitaetsklinikum Ulm /ID# 130341, Ulm, Thueringen, Germany|Universitaetklinikum Dresden /ID# 130342, Dresden, Germany|Klinikum Rechts der Isar /ID# 130347, Munich, Germany",,"https://ClinicalTrials.gov/show/NCT02203773"
338,"NCT02198651","A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects","PREDICTRA","Completed","Has Results","Rheumatoid Arthritis|Musculoskeletal and Connective Tissue Diseases","Biological: Adalimumab|Other: Placebo","Association Between Baseline Hand and Wrist Synovitis Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score and Flare up to Week 40 in the Tapering Arm|Association Between Baseline Bone Marrow Edema RAMRIS Score and Flare up to Week 40 in the Tapering Arm|Association Between a Composite of Baseline Hand and Wrist Synovitis and Bone Marrow Edema RAMRIS Scores and Flare up to Week 40 in the Tapering Arm|Median Time to Flare|Physicians' Assessment of Flare Severity|Participants' Assessment of Flare Severity|Percentage of Participants With a Flare|Number of Participants Who Regained Clinical Remission in the Open-Label Rescue Arm Over Time|Median Time to Clinical Remission From the Occurrence of Flare|Mean Change From Double-blind Baseline in Disease Activity Score 28 (DAS28)|Mean Change From Double-blind Baseline in Clinical Disease Activity Index (CDAI) Score|Mean Change From Double-blind Baseline in Simplified Disease Activity Index (SDAI) Score|Number of Participants Maintaining Clinical Remission Defined By DAS28 (ESR) < 2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8 at Each Visit By Treatment Arm|Mean Change From Double-blind Baseline to Week 40 or Final Visit in Magnetic Resonance Imaging (MRI) Synovitis Score|Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Marrow Edema (BME) Score|Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Erosions Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score|Mean Change From Double-blind Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score Over Time|Number of Participants With Health Assessment Questionnaire- Disability Index (HAQ-DI) Score ≤ 0.5 at Double-blind Baseline and at Week 40|Mean Change From Double-blind Baseline in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed During In-office Visits|Mean Change From Flare Week 0 in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed at Home|Mean Change From Double-blind Baseline in Swollen Joint Count 28|Mean Change From Double-blind Baseline in Swollen Joint Count 66|Mean Change From Double-blind Baseline in Tender Joint Count 28|Mean Change From Double-blind Baseline in Tender Joint Count 68|Mean Change From Double-blind Baseline in Participant's Global Assessment of Disease Activity|Mean Change From Double-blind Baseline in Participant's Global Assessment of Rheumatoid Arthritis Pain|Mean Change From Double-blind Baseline in Physician's Global Assessment of Disease Activity|Mean Change From Double-blind Baseline in Morning Stiffness Duration|Mean Change From Double-blind Baseline in Morning Stiffness Severity|Mean Change From Double-blind Baseline in Participant's Assessment of Sleep Disturbance|Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Effectiveness Score|Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Side Effects Score|Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Convenience Score|Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score|Mean Change From Double-blind Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment and Activity Impairment Scores|Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Physical Component Summary (PCS) Score|Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Mental Component Summary (MCS) Score|Mean Change From Double-blind Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale|Mean Change From Double-blind Baseline in Serum Levels of C-reactive Protein (CRP)|Mean Change From Double-blind Baseline in Serum Levels of Erythrocyte Sedimentation Rate (ESR)","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","149","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-500|2014-001114-26","January 5, 2015","May 3, 2018","August 8, 2018","July 24, 2014","June 25, 2019","June 25, 2019","J Michael Grelier Research /ID# 149772, Tuscaloosa, Alabama, United States|Westlake Medical Research (WMR) Clinical Trials /ID# 155386, Thousand Oaks, California, United States|University of Florida /ID# 144851, Jacksonville, Florida, United States|North Georgia Rheumatology Grp /ID# 155225, Lawrenceville, Georgia, United States|The Arthritis & Diabetes Clinic, Inc. /ID# 149017, Monroe, Louisiana, United States|Aa Mrc Llc /Id# 151933, Grand Blanc, Michigan, United States|North Mississippi Med Clinics /ID# 149443, Tupelo, Mississippi, United States|Montefiore Medical Center /ID# 155013, Bronx, New York, United States|Shanahan Rheuma & Immuno /ID# 148689, Raleigh, North Carolina, United States|Altoona Ctr Clinical Res /ID# 148448, Duncansville, Pennsylvania, United States|Low Country Rheumatology, PA /ID# 154198, Summerville, South Carolina, United States|West Tennessee Research Inst /ID# 148391, Jackson, Tennessee, United States|Arthritis Centers of Texas /ID# 152843, Dallas, Texas, United States|Royal Prince Alfred Hospital /ID# 154649, Camperdown, New South Wales, Australia|Optimus Clinical Research Pty. /ID# 133881, Kogarah, New South Wales, Australia|John Hunter Hospital /ID# 133884, Newcastle, New South Wales, Australia|Rheumatology Research Unit /ID# 133883, Maroochydore, Queensland, Australia|AKH Wien /ID# 133885, Vienna, Wien, Austria|St. Joseph's Healthcare /ID# 149233, Hamilton, Ontario, Canada|The Arthritis Program Res Grp /ID# 129056, Newmarket, Ontario, Canada|Institut de Rhum. de Montreal /ID# 129055, Montreal, Quebec, Canada|Groupe de Recherche en Maladies Osseuses /ID# 129057, Sainte-foy, Quebec, Canada|CIUSSS de l'Estrie - CHUS /ID# 144839, Sherbrooke, Quebec, Canada|CHU de la miletrie /ID# 133928, Poitiers, Poitou-Charentes, France|CHU Amiens Picardie /ID# 144846, Amiens CEDEX 1, Somme, France|Hospital Louis Pasteur /ID# 134708, Chartres, France|CHU de Grenoble - Albet Michal /ID# 135953, Grenoble, France|Asklepios Klinik /ID# 129146, Bad Abbach, Germany|Immanuel-Krankenhaus /ID# 129143, Berlin-buch, Germany|Charité Universitätsmedizin Campus Mitte /ID# 129142, Berlin, Germany|Krankenhaus Porz am Rhein /ID# 129147, Cologne, Germany|Rheumaforschungszentrum II /ID# 148554, Hamburg, Germany|Klinikum der Univ Munich /ID# 129144, Munich, Germany|Rheumazentrum Ratingen /ID# 129148, Ratingen, Germany|Rheumatologische Praxis /ID# 151979, Rendsburg, Germany|University General Hospital ""Attikon"" /ID# 134709, Athens, Attiki, Greece|General Hospital of Athens /ID# 129202, Athens, Greece|General UH of Heraklion /ID# 134712, Heraklion, Greece|Budai Irgalmasrendi Korhaz /ID# 134714, Budapest, Hungary|Orszagos Reumatologiai es Fizi /ID# 134710, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 134715, Debrecen, Hungary|St Vincent's University Hosp /ID# 129210, Dublin, Ireland|AP Romano Umberto I /ID# 132895, Rome, Lazio, Italy|A.O. Univ Consorziale Policlin /ID# 133932, Bari, Italy|Azienda Istituto Gaetano Pini /ID# 132964, Milan, Italy|Fondazione IRCCS Policlinico /ID# 133886, Pavia, Italy|A.O.U.I. di Verona Policlinico /ID# 132973, Verona, Italy|Jan van Breemen Instituut /ID# 133887, Amsterdam, Netherlands|Rijnstate Hospital /ID# 129206, Arnhem, Netherlands|Medisch Centrum Leeuwarden /ID# 133888, Leeuwarden, Netherlands|UMC Utrecht /ID# 132896, Utrecht, Netherlands|Hospital Parc de Salut del Mar /ID# 148670, Barcelona, Spain|Hosp Sant J. Despi-Moises Brog /ID# 135368, Barcelona, Spain|Hospital Universitario Basurto /ID# 135529, Bilbao, Spain|Hosp Clinico Virgen Arrixaca /ID# 137020, El Palmar, Spain|Hospital General Universitario Gregorio Maranon /ID# 133889, Madrid, Spain|Hospital Universitario La Paz /ID# 135369, Madrid, Spain|Hospital Univ De Mostoles /ID# 134489, Mostoles, Spain|Complejo Hosp Santiago /ID# 133890, Santiago de Compostela, Spain|Hosp General Univ de Valencia /ID# 134488, Valencia, Spain|Akademiska Sjukhuset /ID# 148669, Uppsala, Uppsala Lan, Sweden|Uppsala University Hospital /ID# 133891, Uppsala, Sweden|Vastmanlands Sjukhus /ID# 133892, Vasteras, Sweden|Whipps Cross Univ Hospital /ID# 133893, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 132965, London, London, City Of, United Kingdom|Mid Essex Hospitals NHS Trust /ID# 151636, Chelmsford, United Kingdom|Western General Hospital /ID# 132966, Edinburgh, United Kingdom|Chapel Allerton Hospital /ID# 129208, Leeds, United Kingdom|University Hospital Aintree /ID# 132980, Liverpool, United Kingdom|Queen Alexandra Hospital /ID# 132982, Portsmouth, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02198651/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT02198651/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02198651"
339,"NCT02196701","Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study","CLEAR","Completed","Has Results","Psoriasis","Drug: Adalimumab|Drug: Methotrexate","Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Investigator Assessment|Percentage of Participants Achieving a Satisfactory Response at Week 16 Based on Patient Self-assessment|Percentage of Participants Achieving a Satisfactory Response Based on Investigator Assessment Over Time|Percentage of Participants Achieving a Satisfactory Response Based on Patient Self-assessment Over Time|Number of Participants Achieving Each Satisfactory Category Based on Investigator Assessment Over Time|Number of Participants Achieving Each Satisfactory Category Based on Patient Self-assessment Over Time|Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 50 Response Over Time|Percentage of Participants Who Achieved a PASI 75 Response Over Time|Percentage of Participants Who Achieved a PASI 90 Response Over Time|Percentage of Participants Who Achieved a PASI 100 Response Over Time|Change From Baseline in PASI Score Over Time|Percent Change From Baseline in PASI Score|Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of Cleared or Minimal Over Time|Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis|Percent Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis|Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time|Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score Over Time|Percentage of Participants Who Achieved a DLQI Score of 0 or 1 Over Time|Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 24","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","46","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W14-406","August 5, 2014","March 17, 2017","March 17, 2017","July 22, 2014","March 19, 2018","March 19, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02196701/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/01/NCT02196701/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02196701"
340,"NCT02185014","Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115",,"Completed","Has Results","Crohn's Disease","Drug: Adalimumab","Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","252","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-347|2013-004034-15","August 12, 2014","November 3, 2017","November 3, 2017","July 9, 2014","November 14, 2018","November 14, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02185014/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02185014/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02185014"
341,"NCT02167945","A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","TOPAZ II","Active, not recruiting","No Results Available","Chronic Hepatitis C Virus (HCV) Infection Genotype 1","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","Incidence of pre-defined clinical outcomes observed during the study|Change in Quality of Life|Change in fatigue|Percentage of subjects with sustained virologic response 12 weeks post-treatment (SVR12)|Evaluation of adherence to study drug regimens","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","615","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-222","June 12, 2014","May 5, 2020","May 5, 2020","June 19, 2014",,"November 14, 2019","St. Josephs Hosp and Med Ctr /ID# 127800, Phoenix, Arizona, United States|Felizarta /ID# 126569, Bakersfield, California, United States|Ruane Clinical Research Group /ID# 126577, Los Angeles, California, United States|California Pacific Medical Ctr /ID# 128681, San Francisco, California, United States|Univ of Colorado Cancer Center /ID# 126568, Aurora, Colorado, United States|Medstar Health Research Institute /ID# 128683, Washington, District of Columbia, United States|Bach and Godofsky Infec Dis /ID# 128685, Bradenton, Florida, United States|University of Florida /ID# 127787, Gainesville, Florida, United States|Borland-Groover Clinic /ID# 127781, Jacksonville, Florida, United States|University of Miami /ID# 127622, Miami, Florida, United States|South Florida Ctr Gastro, P.A. /ID# 126567, Wellington, Florida, United States|Atlanta Gastro Assoc /ID# 126571, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 128684, Chicago, Illinois, United States|University of Chicago /ID# 126576, Chicago, Illinois, United States|Indiana University Health /ID# 126573, Indianapolis, Indiana, United States|Tulane Univ /ID# 127779, New Orleans, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 126561, Shreveport, Louisiana, United States|Johns Hopkins University /ID# 127791, Baltimore, Maryland, United States|Digestive Disease Associates /ID# 127624, Catonsville, Maryland, United States|Beth Israel Deaconess Medical Center /ID# 126560, Boston, Massachusetts, United States|Henry Ford Health System /ID# 127783, Detroit, Michigan, United States|Minnesota Gastroenterology, P. A. /ID# 126579, Plymouth, Minnesota, United States|Saint Louis University School of Medicine /ID# 126564, Saint Louis, Missouri, United States|AGA Clinical Research Associates, LLC /ID# 126578, Egg Harbor Township, New Jersey, United States|New Jersey Medical School /ID# 128686, Newark, New Jersey, United States|University of New Mexico /ID# 128859, Albuquerque, New Mexico, United States|Southwest Care Center /ID# 127784, Santa Fe, New Mexico, United States|North Shore University Hospital /ID# 126565, New Hyde Park, New York, United States|Icahn School of Med Mt. Sinai /ID# 128682, New York, New York, United States|Weill Cornell Medicine /ID# 126566, New York, New York, United States|Weill Cornell Medicine /ID# 127621, New York, New York, United States|Premier Medical Group /ID# 127793, Poughkeepsie, New York, United States|Univ Rochester Med Ctr /ID# 127655, Rochester, New York, United States|Carolinas Medical Center /ID# 127632, Charlotte, North Carolina, United States|Carolinas Center For Liver Dis /ID# 127788, Statesville, North Carolina, United States|University of Cincinnati /ID# 127790, Cincinnati, Ohio, United States|Options Health Research, LLC /ID# 127630, Tulsa, Oklahoma, United States|University Gastroenterology /ID# 127789, Providence, Rhode Island, United States|Gastro One /ID# 127792, Germantown, Tennessee, United States|Inquest Clinical Research /ID# 126574, Baytown, Texas, United States|Cure C Consortium /ID# 126570, Houston, Texas, United States|Liver Associates of Texas, P.A /ID# 126563, Houston, Texas, United States|Austin Center for Clinical Research /ID# 126562, Pflugerville, Texas, United States|TX Liver Inst, Americ Res Corp /ID# 127623, San Antonio, Texas, United States|Clinical Research Ctrs America /ID# 127780, Murray, Utah, United States|Virginia Mason Medical Center /ID# 130288, Seattle, Washington, United States|University of Washington /ID# 127785, Seattle, Washington, United States|Dean Clinic /ID# 126575, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02167945"
342,"NCT02163694","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",,"Active, not recruiting","No Results Available","Metastatic Breast Cancer","Drug: Paclitaxel|Drug: Veliparib|Drug: Carboplatin|Other: Placebo","Progression-free survival (PFS)|Duration of overall response (DOR)|Progression-free survival 2 (PFS2)|Objective response rate (ORR)|Overall survival (OS)|Clinical benefit rate (CBR)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","513","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-914|2014-000345-70","August 5, 2014","April 5, 2019","November 13, 2021","June 16, 2014",,"January 13, 2020","Banner MD Anderson Cancer Ctr /ID# 125011, Gilbert, Arizona, United States|University of Arkansas for Medical Sciences /ID# 124992, Little Rock, Arkansas, United States|City of Hope /ID# 127117, Duarte, California, United States|Ucsd /Id# 124991, La Jolla, California, United States|Breastlink of Laguna Hills /ID# 129808, Laguna Hills, California, United States|Breastlink of Temecula Valley /ID# 129809, Murrieta, California, United States|Hematology and Oncology Assoc /ID# 130058, Newport Beach, California, United States|Breastlink /ID# 129807, Santa Ana, California, United States|Cancer Research Collaboration, /ID# 128860, Santa Ana, California, United States|Icri /Id# 128520, Whittier, California, United States|Univ of Colorado Cancer Center /ID# 124983, Aurora, Colorado, United States|Saint Joseph Hospital /ID# 131768, Denver, Colorado, United States|Norwalk Hospital /ID# 133509, Norwalk, Connecticut, United States|Lynn Cancer Institute, Boca /ID# 125013, Boca Raton, Florida, United States|Holy Cross Hospital /ID# 125012, Fort Lauderdale, Florida, United States|Sacred Heart Hospital /ID# 128279, Pensacola, Florida, United States|Sacred Heart Medical Oncology /ID# 133010, Santa Rosa Beach, Florida, United States|Moffitt Cancer Center /ID# 124990, Tampa, Florida, United States|Florida Cancer Specialists - East /ID# 125007, West Palm Beach, Florida, United States|Emory University Hospital /ID# 133192, Atlanta, Georgia, United States|The Cancer Ctr at DeKalb Med C /ID# 125024, Decatur, Georgia, United States|University of Illinois - Chicago /ID# 127576, Chicago, Illinois, United States|Midwestern Regional CTC /ID# 124986, Zion, Illinois, United States|McFarland Clinic, PC /ID# 129904, Ames, Iowa, United States|Johns Hopkins University /ID# 125015, Baltimore, Maryland, United States|Baystate Medical Center /ID# 139461, Springfield, Massachusetts, United States|UMass Memorial Medical Center /ID# 129067, Worcester, Massachusetts, United States|Henry Ford Health System /ID# 134497, Detroit, Michigan, United States|Spectrum Health Medical Group /ID# 133568, Grand Rapids, Michigan, United States|William Beaumont Hospital /ID# 125019, Royal Oak, Michigan, United States|Univ of Mississippi Med Ctr,US /ID# 131352, Jackson, Mississippi, United States|St. Lukes Cancer Institute /ID# 125023, Kansas City, Missouri, United States|Washington University-School of Medicine /ID# 127575, Saint Louis, Missouri, United States|Nebraska Hematology Oncology /ID# 132711, Lincoln, Nebraska, United States|University of New Mexico /ID# 125349, Albuquerque, New Mexico, United States|Beth Israel Medical Center /ID# 125001, New York, New York, United States|Mount Sinai St. Luke's /ID# 125003, New York, New York, United States|Cancer Care of WNC, PA /ID# 134248, Asheville, North Carolina, United States|Duke University Medical Center /ID# 124999, Durham, North Carolina, United States|University of Toledo /ID# 134849, Toledo, Ohio, United States|Oregon Health and Science University /ID# 134229, Portland, Oregon, United States|Lehigh Valley Health Network /ID# 130059, Allentown, Pennsylvania, United States|Lehigh Valley Hosp/Muhlenberg /ID# 130277, Bethlehem, Pennsylvania, United States|Penn State University and Milton S. Hershey Medical Center /ID# 124997, Hershey, Pennsylvania, United States|University of Pittsburgh MC /ID# 125005, Pittsburgh, Pennsylvania, United States|Texas Health Physicians Group /ID# 137740, Arlington, Texas, United States|UT Southwestern Medical Center /ID# 124989, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 125353, Houston, Texas, United States|University of Vermont Medical Center /ID# 125350, Burlington, Vermont, United States|Swedish Cancer Institute /ID# 131534, Seattle, Washington, United States|Swedish Cancer Institute /ID# 131548, Seattle, Washington, United States|Swedish Cancer Institute /ID# 131549, Seattle, Washington, United States|Swedish Medical Center /ID# 125021, Seattle, Washington, United States|Northwest Medical Specialties /ID# 125344, Tacoma, Washington, United States|Coiba /Id# 124839, Berazategui, Buenos Aires, Argentina|Centro Oncologico Riojano /ID# 127938, La Rioja, Argentina|Centro Investigacion Pergamino /ID# 127158, Pergamino, Argentina|Instituto de Oncologia de Rosa /ID# 127157, Rosario, Santa FE, Argentina|St George Hospital /ID# 129416, Kogarah, New South Wales, Australia|The Prince of Wales Hospital /ID# 124845, Randwick, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 124844, Wollongong, New South Wales, Australia|The Townsville Hospital /ID# 126731, Douglas, Queensland, Australia|Flinders Centre for Innovation /ID# 127535, Bedford Park, South Australia, Australia|Royal Hobart Hospital /ID# 124849, Hobart, Tasmania, Australia|Royal Melbourne Hospital /ID# 124846, Parkville, Victoria, Australia|Hollywood Private Hospital /ID# 124843, Nedlands, Western Australia, Australia|Medizinische Universität Wien /ID# 126184, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 126450, Graz, Austria|Ordensklinikum Linz GmbH, Elisabethinen /ID# 126185, Linz, Austria|LKH Salzburg and Paracelsus /ID# 126449, Salzburg, Austria|Bobruysk Interdistrict Onco. /ID# 137729, Bobruisk, Belarus|Belarus Cancer Center N.N. Alexandrov /ID# 125223, Lesnoy, Belarus|Mogilev Reg Clin Oncology Dis /ID# 137728, Mogilev, Belarus|Vitebsk Reg Clin Onc Disp /ID# 125219, Vitebsk, Belarus|Cliniques Universitaires Saint Luc /ID# 124976, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 124981, Charleroi, Hainaut, Belgium|AZ St-Jan Brugge-Oostende AV /ID# 124975, Brugge, West-Vlaanderen, Belgium|ZNA Middelheim /ID# 124978, Antwerp, Belgium|UZ Antwerp /ID# 124977, Edegem, Belgium|UZ Leuven /ID# 124980, Leuven, Belgium|CHU UCL Namur /ID# 124979, Namur, Belgium|Sunnybrook Health Sciences Ctr /ID# 124882, Toronto, Ontario, Canada|Jewish General Hospital /ID# 124880, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 124879, Montréal, Quebec, Canada|CHUQ-Hospital St. Sacrement /ID# 124881, Quebec City, Quebec, Canada|Instituto Nacional de Cancerología INCAN /ID# 129343, Santiago, Chile|ICOS - Inst Clinic Oncology /ID# 125236, Temuco, Chile|Hospital Clinico Vina del Mar /ID# 130100, Vina Del Mar, Chile|Hospital Clinico Vina del Mar /ID# 148502, Vina Del Mar, Chile|Administradora del Country_S.A-Clinica Del Country /ID# 125255, Bogota, Cundinamarca, Colombia|Hospital Univ San Ignacio /ID# 126655, Bogota, Colombia|Centro Medico Imbanaco de Cali /ID# 126656, Cali, Colombia|Hospital Pablo Tobon Uribe /ID# 126657, Medellín, Colombia|Inst Med Alta Tec Onc (IMAT) /ID# 129211, Montería, Colombia|Fakultni Nemocnice Olomouc /ID# 124885, Olomouc, Olomoucky Kraj, Czechia|Fakultni Nemocnice Brno /ID# 128176, Brno, Czechia|Masarykuv onkologikcy ustav /ID# 124886, Brno, Czechia|Vseobecna Fakultni Nemocnice /ID# 124887, Prague, Czechia|Vejle Sygehus /ID# 124892, Vejle, Syddanmark, Denmark|Rigshospitalet, Finsen Centre /ID# 124891, Copenhagen, Denmark|East Tallinn Central Hospital /ID# 126475, Tallinn, Estonia|Docrates Cancer Center /ID# 124896, Helsinki, Finland|Helsinki Univ Central Hospital /ID# 124897, Helsinki, Finland|Tampere University Hospital /ID# 124898, Tampere, Finland|Vaasa Central Hospital /ID# 132548, Vaasa, Finland|Institut Curie /ID# 124902, Paris CEDEX 05, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 137726, St Herblain CEDEX, Loire-Atlantique, France|Institut Paoli-Calmettes /ID# 124903, Marseille, France|Hopital Rene Huguenin /ID# 124904, Saint-cloud, France|Universitaetsklinik Heidelberg /ID# 126664, Heidelberg, Baden-Wuerttemberg, Germany|Uniklinik Koln /ID# 126905, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Ulm /ID# 135230, Ulm, Thueringen, Germany|Universitaetklinikum Dresden /ID# 127180, Dresden, Germany|Klinikum recht der Isar der TU /ID# 125256, Munich, Germany|Sana Klinikum Offenbach /ID# 126733, Offenbach, Germany|Universitatsklinikum Tubingen /ID# 129968, Tuebingen, Germany|Pecsi Tudomanyegyetem /ID# 125259, Pécs, Pecs, Hungary|Semmelweis Egyetem /ID# 132485, Budapest, Hungary|Jasz-Nagykun-Szolnok Megyei /ID# 124911, Szolnok, Hungary|Zala Megyei Korhaz /ID# 131341, Zalaegerszeg, Hungary|Tel Aviv Sourasky Medical Ctr /ID# 130276, Tel Aviv-Yafo, Tel-Aviv, Israel|Soroka Medical Ctr /ID# 124917, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 124915, Be'er Ya'akov, Israel|Rambam Health Care Campus /ID# 124916, Haifa, Israel|Shaare Zedek Medical Center /ID# 130275, Jerusalem, Israel|Hadassah University Hospital /ID# 124919, Jerusalem, Israel|Sheba Medical Center /ID# 124918, Ramat Gan, Israel|Kaplan Medical Center /ID# 124914, Rehovot, Israel|Ospedale Classificato Equiparato Sacro Cuore-Don Calabria /ID# 125262, Negrar, Verona, Italy|Centro di Riferimento Oncologi /ID# 126738, Aviano, Italy|Ospedale San Raffaele IRCCS /ID# 125261, Milan, Italy|Istituto Europeo di Oncologia /ID# 125260, Milan, Italy|AO Bianchi Melacrino Morelli /ID# 125263, Reggio Calabria, Italy|National Cancer Center /ID# 125602, Goyang, Gyeonggido, Korea, Republic of|Severance Hospital /ID# 125599, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 125598, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Anam Hospital /ID# 128968, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 125600, Seoul, Korea, Republic of|Asan Medical Center /ID# 125601, Seoul, Korea, Republic of|Riga East Clinical Univ Hosp /ID# 125265, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 125264, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 125266, Kovno, Kaunas, Lithuania|National Cancer Institute /ID# 125267, Vilnius, Lithuania|Centro de Estudios Clínicos Especializados /ID# 128680, Mérida, Yucatan, Mexico|Centro Oncologico de Chihuahua /ID# 128679, Chihuahua, Mexico|Instituto Nacional de Cancerología INCAN /ID# 128676, Tlapan, Mexico|Universitair Medisch Centrum Groningen /ID# 129069, Groningen, Netherlands|Maastricht Universitair Medisch Centrum /ID# 129068, Maastricht, Netherlands|Erasmus Medisch Centrum /ID# 124935, Rotterdam, Netherlands|Haukeland University Hospital /ID# 124937, Bergen, Hordaland, Norway|Stavanger University Hospital /ID# 150177, Stavanger, Norway|Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 124939, Rzeszów, Podkarpackie, Poland|Centrum Onkologii Lukaszczyka /ID# 124938, Bydgoszcz, Poland|Wojewodzki Szpital Zespolony /ID# 126998, Elblag, Poland|Wojewodzkie Wielospecjalistycz /ID# 126999, Lodz, Poland|Wojewodzki Szpital Specjalisty /ID# 127258, Wroclaw, Poland|Centro Hospitalar De Vila Nova /ID# 126510, Vila Nova De Gaia, Porto, Portugal|Centro Hospitalar do Algarve /ID# 125298, Faro, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 125299, Lisboa, Portugal|Unidade Local Saude Matosinhos /ID# 126511, Matosinhos, Portugal|IPO Porto FG, EPE /ID# 125297, Porto, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 126508, Porto, Portugal|Ad-Vance Medical Research, LLC /ID# 126043, Ponce, Puerto Rico|San Juan Municipal Hospital /ID# 124695, San Juan, Puerto Rico|S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948, Craiova, Dolj, Romania|lnstitutul Oncologic Trestiore /ID# 124943, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta /ID# 124945, Cluj, Romania|Oncomed SRL /ID# 127598, Timisoara, Romania|Sverdlovsk Regional Oncology Center Dispensary /ID# 130950, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|Kursk Regional Oncology Dispen /ID# 125936, Kursk, Tatarstan, Respublika, Russian Federation|archangel Clinical Oncology /ID# 126031, Arkhangelsk, Russian Federation|Altay Regional Oncologic Disp /ID# 127160, Barnaul, Russian Federation|Belgorod Oncology Dispensary /ID# 129315, Belgorod, Russian Federation|GBOU VPO Saratov State Med Uni /ID# 139395, Saratov, Russian Federation|LLC BioEq Ltd. /ID# 134529, St. Petersburg, Russian Federation|Siberian State Med Uni /ID# 127161, Tomsk, Russian Federation|Volgograd Reg Onc Disp #3 /ID# 124952, Volzhsky, Russian Federation|National University Hospital /ID# 125315, Singapore, Singapore|Johns Hopkins Singapore IMC /ID# 125316, Singapore, Singapore|GVI Oncology /ID# 125321, Port Elizabeth, Eastern Cape, South Africa|University of Free State, Universitas Annex (National Hospital Grounds) /ID# 128499, Bloemfontein, Free State, South Africa|Wits Clinical Research Site /ID# 125317, Johannesburg, Gauteng, South Africa|Medical Oncology Ctr Rosebank /ID# 125322, Johannesburg, Gauteng, South Africa|Sandton Oncology Centre /ID# 125323, Johannesburg, Gauteng, South Africa|Mary Potter Oncology Centre /ID# 133269, Pretoria, Gauteng, South Africa|The Oncology Centre /ID# 126104, Durban, Kwazulu-Natal, South Africa|Netcare Oncology Intervent Ctr /ID# 125320, Cape Town, Western Cape, South Africa|Cancercare Outeniqua Oncology Unit /ID# 125319, George, Western Cape, South Africa|Hospital Santa Creu i Sant Pau /ID# 124963, Barcelona, Spain|Hospital General Universitario Gregorio Maranon /ID# 124962, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 124960, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 124961, Malaga, Spain|Hosp Clin Univ de Valencia /ID# 124959, Valencia, Spain|Skanes Universitetssjukhus /ID# 124966, Malmö, Skane Lan, Sweden|Sahlgrenska University Hosp /ID# 124965, Goteborg, Sweden|University Hospital Linkoping /ID# 126795, Linkoping, Sweden|Karolinska Univ Sjukhuset /ID# 124964, Solna, Sweden|Norrlands Universitetssjukhus /ID# 124967, Umeå, Sweden|Uppsala University Hospital /ID# 126512, Uppsala, Sweden|National Taiwan Univ Hosp /ID# 125324, Taipei City, Taipei, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 125575, Kaohsiung, Taiwan|Hacettepe University Medical Faculty /ID# 125336, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi /ID# 125337, Ankara, Turkey|Akdeniz University Medical Fac /ID# 125339, Antalya, Turkey|Bezmi alem Vakif Universitesi /ID# 127901, Istanbul, Turkey|Istanbul University Istanbul Medical Faculty /ID# 145144, Istanbul, Turkey|Cherkassy Regional Onc Ctr /ID# 124970, Cherkasy, Ukraine|Communal Non-profit Enterprise ""City Clinical Hospital#4"" /ID# 124968, Dnipro, Ukraine|Kharkiv Regional Clinical Onco /ID# 124972, Kharkiv, Ukraine|ME Kryviy Rih Oncology Dispensary /ID# 129806, Kryviy RIH, Ukraine|Lviv Oncological Regional Therapeutical and Diagnostic Centre /ID# 124974, Lviv, Ukraine|Poltava Regional Clinical Onco /ID# 124969, Poltava, Ukraine|Zaporizhzhia Med. Academy MOH /ID# 129800, Zaporizhia, Ukraine|University of Birmingham /ID# 125342, Birmingham, United Kingdom|Bristol Haematology and Onc Ct /ID# 128343, Bristol, United Kingdom|Castle Hill Hospital /ID# 133030, Cottingham, United Kingdom|Nottingham Univ Hospitals NHS /ID# 125340, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02163694"
343,"NCT02148718","Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease","RAPIDA","Completed","Has Results","Moderate to Severe Crohn's Disease","Biological: adalimumab","Percentage of Participants With Clinical Response at Day 4|Percentage of Participants With Clinical Response at Week 1|Percentage of Participants With Clinical Remission at Weeks 2 and 4|European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Index Score: Change From Baseline to Week 12|European Quality of Life (EuroQol) 5 Dimensions 3 Levels Questionnaire (EQ-5D-3L) Visual Analog Scale (VAS): Change From Baseline to Week 12|Inflammatory Bowel Disease Quality-36 (IBDQ-36) Questionnaire Overall Score: Change From Baseline to Week 12|Fatigue Impact Scale for Daily Use (D-FIS): Change From Baseline to Week 12|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hemoglobin|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Hematocrit|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Erythrocytes|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Sedimentation Rate (ESR)|Change From Baseline to Week 12 in Analytic Markers of Inflammation: C-reactive Protein (CRP)|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fecal Calprotectin|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Activated Partial Thromboplastin Time (aPTT)|Change From Baseline to Week 12 in Analytic Markers of Inflammation: International Normalized Ratio (INR)|Change From Baseline to Week 12 in Analytic Markers of Inflammation: Fibrinogen|Percentage of Participants With Clinical Response at Day 4 or Week 12 and Clinical Remission at Week 12","AbbVie|Laboratorio Echevarne|Pivotal S.L.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","100","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W13-984|2013-004781-34","June 2014","August 2016","January 2017","May 28, 2014","August 29, 2017","March 1, 2018",,,"https://ClinicalTrials.gov/show/NCT02148718"
344,"NCT02143713","Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain",,"Completed","Has Results","Endometriosis","Drug: Elagolix","Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment|Percentage of Participants With a Response for Non-menstrual Pelvic Pain at Month 6 Based on Daily Assessment|Percentage of Participants With a Response for Dysmenorrhea at Each Month Based on Daily Assessment|Percentage of Participants With a Response for Non-menstrual Pelvic Pain at Each Month Based on Daily Assessment|Percentage of Participants With a Response for Dyspareunia at Each Month Based on Daily Assessment|Percent Change From Baseline in Dysmenorrhea Based on Daily Assessment|Percent Change From Baseline in Non-menstrual Pelvic Pain Based on Daily Assessment|Percent Change From Baseline in Dyspareunia Based on Daily Assessment|Change From Baseline in Any Rescue Analgesic Use|Change From Baseline in NSAID Rescue Analgesic Use|Change From Baseline in Opioid Rescue Analgesic Use|Percent Change From Baseline in Endometriosis-Associated Pain Score Assessed With Numeric Rating Scale (NRS)|Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved|Change From Baseline in Endometriosis Health Profile-30 (EHP-30) Pain Dimension|Change From Baseline in Endometriosis Health Profile-30 (EHP-30) Sexual Intercourse Dimension|Change From Baseline in Health-Related Productivity Questionnaire (HRPQ): Hours of Work Lost in Workplace and Household|Number of Participants With Non-study Health Visits During the Treatment Period|Number of Days in Hospital During the Treatment Period","AbbVie","Female","18 Years to 50 Years   (Adult)","Phase 3","496","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-821|2013-001047-31","May 27, 2014","June 22, 2016","May 23, 2017","May 21, 2014","September 7, 2018","September 7, 2018",,,"https://ClinicalTrials.gov/show/NCT02143713"
345,"NCT02141997","A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",,"Completed","Has Results","Rheumatoid Arthritis","Biological: adalimumab|Biological: ABT-122","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12|Change in Disease Activity Score 28 With High Sensitivity C-Reactive Protein (DAS28 [hsCRP])|Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 12|Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 12|Percentage of Participants Achieving Low Disease Activity (LDA) or Clinical Remission (CR) Based on DAS28 (hsCRP) at Week 12|Percentage of Participants Achieving CR Based on DAS28 (hsCRP) at Week 12|Percentage of Participants Achieving LDA or CR Based on Clinical Disease Activity Index (CDAI) at Week 12|Percentage of Participants Achieving CR Based on Clinical Disease Activity Index (CDAI) at Week 12","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-963|2013-004019-37","July 2014","September 2015","November 2015","May 20, 2014","November 11, 2016","November 11, 2016",,,"https://ClinicalTrials.gov/show/NCT02141997"
346,"NCT02141984","Surveillance of Humira in Korean JIA Patients",,"Completed","Has Results","Polyarticular Juvenile Idiopathic Arthritis",,"Number of Participants With Adverse Events|Changes in Active Joint Count From Baseline and 12 Weeks Post-Treatment|Physician's Global Assessment of the Disease|Parent's Global Assessment for Effectiveness","AbbVie","All","2 Years and older   (Child, Adult, Older Adult)",,"28","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P14-362","May 2014","April 2016","April 2016","May 20, 2014","June 23, 2017","June 23, 2017",,,"https://ClinicalTrials.gov/show/NCT02141984"
347,"NCT02141282","A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: ABT-199","Overall response rate (ORR)|Duration of response|Time to progression (TTP)|Overall survival (OS)|Progression-free survival (PFS)","AbbVie|Roche-Genentech","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","127","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-032","September 10, 2014","December 8, 2021","December 8, 2021","May 19, 2014",,"November 21, 2019","Ucsd /Id# 128535, La Jolla, California, United States|University of California, Los Angeles /ID# 127262, Los Angeles, California, United States|Stanford University School of Med /ID# 126495, Stanford, California, United States|MedStar Georgetown University Hospital /ID# 127261, Washington, District of Columbia, United States|Emory University Hospital /ID# 131249, Atlanta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 126497, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center /ID# 134509, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 126496, Boston, Massachusetts, United States|New York Presbyterian Hospital - Weill Cornell Medical Center /ID# 129648, New York, New York, United States|Weill Cornell Medicine /ID# 128536, New York, New York, United States|Univ Rochester Med Ctr /ID# 130011, Rochester, New York, United States|The Ohio State University - Columbus /ID# 127263, Columbus, Ohio, United States|University of Pennsylvania /ID# 126860, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center /ID# 126498, Houston, Texas, United States|University of Utah /ID# 130813, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT02141282"
348,"NCT02130362","A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)","CAPE","Active, not recruiting","No Results Available","Crohn's Disease",,"Number of treatment-emergent AESI per 100 PYs of infections and malignancies|Percentage of subjects with SAEs|Number of treatment-emergent other AESI per 100 PYs|Percentage of subjects with other AESI|Number of subjects with Adverse Events of Special Interest (AESI) of infections, malignancies, and pregnancies|Number of subjects with other AESI|Number of treatment-emergent SAEs per 100 patient years (PYs)|Number of subjects with Serious Adverse Events (SAEs)|Percentage of subjects with AESI of infections, malignancies, and pregnancies|Short Pediatric Crohn's Disease Activity Index (sh-PCDAI)|Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ)|Work Productivity and Activity Impairment (WPAI) questionnaire|Physician's Global Assessment of Disease Activity (PGA)|IMPACT III","AbbVie","All","6 Years to 17 Years   (Child)",,"1434","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P11-292","August 28, 2014","March 2, 2028","March 2, 2028","May 5, 2014",,"March 5, 2019","Univ Alabama, Birmingham CCC /ID# 146060, Birmingham, Alabama, United States|University of South Alabama /ID# 137255, Mobile, Alabama, United States|Phoenix Children's Hospital /ID# 141336, Phoenix, Arizona, United States|Childrens Hospital LA /ID# 141551, Los Angeles, California, United States|Rabizadeh, MD, Los Angeles, CA /ID# 137269, Los Angeles, California, United States|Rady Children's Hosp San Diego /ID# 140883, San Diego, California, United States|Univ California, San Francisco /ID# 141312, San Francisco, California, United States|Univ of Colorado Cancer Center /ID# 137261, Aurora, Colorado, United States|CT Childrens Medical Ctr, US /ID# 137265, Hartford, Connecticut, United States|Yale University /ID# 137257, New Haven, Connecticut, United States|Nemour Child Clin FL, US /ID# 148498, Jacksonville, Florida, United States|University of Miami /ID# 140893, Miami, Florida, United States|Emory University Hospital /ID# 144274, Atlanta, Georgia, United States|Children's Ctr Digestive, US /ID# 144625, Atlanta, Georgia, United States|Children's Hosp New Orleans /ID# 144477, New Orleans, Louisiana, United States|Maine Medical Partners /ID# 147685, Portland, Maine, United States|Tufts Medical Center /ID# 143581, Boston, Massachusetts, United States|Massachusetts General Hospital /ID# 141552, Boston, Massachusetts, United States|Boston Childrens Hospital /ID# 164102, Boston, Massachusetts, United States|University of Mass Medical Cen /ID# 148325, Worcester, Massachusetts, United States|University of Minnesota /ID# 137238, Minneapolis, Minnesota, United States|Univ of Mississippi Med Ctr,US /ID# 137239, Jackson, Mississippi, United States|Goryeb Children's Hospital /ID# 144275, Morristown, New Jersey, United States|SUNY Downstate Medical Center /ID# 149249, Brooklyn, New York, United States|Women and Childrens Hosp /ID# 143778, Buffalo, New York, United States|North Shore University Hospital /ID# 137266, New Hyde Park, New York, United States|Columbia Univ Medical Center /ID# 144440, New York, New York, United States|Columbia Univ Medical Center /ID# 144475, New York, New York, United States|Univ Med Ctr at Stony Brook /ID# 140913, Stony Brook, New York, United States|SUNY Upstate Medical Center /ID# 148437, Syracuse, New York, United States|Univ NC Chapel Hill /ID# 137236, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr /ID# 137268, Durham, North Carolina, United States|Children's Hospital Oklahoma /ID# 144047, Oklahoma City, Oklahoma, United States|Geisinger Medical Center /ID# 149910, Danville, Pennsylvania, United States|Penn State Child Hosp.Hersh,PA /ID# 144476, Hershey, Pennsylvania, United States|Medical University of South Carolina /ID# 144473, Charleston, South Carolina, United States|Children's Medical Center /ID# 149256, Dallas, Texas, United States|Cook Children's Med. Center /ID# 144474, Fort Worth, Texas, United States|Baylor College of Medicine /ID# 148211, Houston, Texas, United States|University Of Vermont Medical /ID# 137263, Burlington, Vermont, United States|Pediatric Specialty of VA /ID# 142831, Fairfax, Virginia, United States|Swedish Medical Center /ID# 137258, Seattle, Washington, United States|Seattle Children's Hospital /ID# 140879, Seattle, Washington, United States|Multicare Institute for Research and Innovation /ID# 152120, Tacoma, Washington, United States|Children's Hospital Wisconsin /ID# 137259, Milwaukee, Wisconsin, United States|University Clinical Center Tuzla /ID# 130638, Tuzla, Tuzlanski, Bosnia and Herzegovina|SHAT Hematologic Diseases /ID# 143572, Sofia, Bulgaria|Alberta Health Services /ID# 128717, Edmonton, Alberta, Canada|Uni Manitoba /ID# 141310, Winnipeg, Manitoba, Canada|IWK Health Center /ID# 127912, Halifax, Nova Scotia, Canada|The Univ of Western Ontario /ID# 137962, London, Ontario, Canada|Hospital for Sick Children /ID# 127910, Toronto, Ontario, Canada|Klinicki bolnicki centar Sestre milosrdnice /ID# 128256, Zagreb, Grad Zagreb, Croatia|Zadar General Hospital /ID# 129830, Zadar, Croatia|FN Hradec Kralove /ID# 128521, Hradec Kralove, Czechia|Palacky University /ID# 127437, Olomouc, Czechia|Univ Hosp Ostrava-Poruba /ID# 127913, Ostrava, Czechia|Fakult Nem Kralovske Vinohrady /ID# 127697, Prague, Czechia|Masarykova Hospital /ID# 129829, Usti Nad Labem, Czechia|Copenhagen Univ. Hospital /ID# 146013, Hvidovre, Denmark|Tallinn Children's Hospital /ID# 126974, Tallinn, Estonia|Children's Clinic Of Tartu Uni /ID# 146017, Tartu, Estonia|Centre Hospitalier Lyon Sud /ID# 128193, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHRU Lille - Hôpital Claude Huriez /ID# 144276, Lille CEDEX, Hauts-de-France, France|Necker Hopital, FR /ID# 147702, Paris, France|Universitatsklinikum Munster /ID# 148441, Munster, Niedersachsen, Germany|Universitaetsklinikum Ulm /ID# 148444, Ulm, Thueringen, Germany|Universitaetklinikum Dresden /ID# 127696, Dresden, Germany|Universitätsklinikum Freiburg /ID# 130010, Freiburg, Germany|Kinderarztpraxis Neuhausen /ID# 144402, Munich, Germany|Christliches Kinderhospital Os /ID# 136629, Osnabrueck, Germany|Klinikum Univ Regensburg /ID# 137140, Regensburg, Germany|General Hospital of Athens Laiko /ID# 147690, Athens, Attiki, Greece|Agia Sofia Hospital /ID# 134349, Athens, Greece|Venizeleio General Hospital /ID# 147335, Heraklion, Greece|Iatriko Kentro Athinon Hospita /ID# 130639, Marousi, Greece|General Hospital of Thessaloni /Id# 163658, Thessaloniki, Greece|Our Lady's Hospital /ID# 127438, Manorhamilton, Ireland|Ha'Emek Medical Center /ID# 156316, Afula, Israel|Assaf Harofeh Medical Center /ID# 157182, Be'er Ya'akov, Israel|Rambam Health Care Campus /ID# 162061, Haifa, Israel|The Lady Davis Carmel MC /ID# 151519, Haifa, Israel|Shaare Zedek Medical Center /ID# 144277, Jerusalem, Israel|Schneider Childrens Med Ctr /ID# 152683, Petah Tikva, Israel|Edmond And Lily Safra Children /ID# 148730, Ramat Gan, Israel|Kaplan Medical Center /ID# 152945, Rehovot, Israel|AP Romano Umberto I /ID# 141962, Rome, Lazio, Italy|Policlinico Paolo Giaccone /Id# 138410, Palermo, Sicilia, Italy|Policlinico Paolo Giaccone /Id# 152684, Palermo, Sicilia, Italy|Maggiore Hospital /ID# 147347, Bologna, Italy|A.O.U. Policlinico G. Martino /ID# 141683, Messina, Italy|Universita di Milano /ID# 141679, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 144279, Milan, Italy|University of Naples Federico /ID# 144280, Naples, Italy|Azienda Ospedaliero - Universi /ID# 147441, Parma, Italy|Unita Op Complessa di Pediatri /ID# 141307, Pescara, Italy|Hosp Lithuanian Univ Health Sc /ID# 127809, Kovno, Kaunas, Lithuania|Vilnius University Hospital /ID# 127810, Vilnius, Lithuania|Academisch Medisch Centrum /ID# 141843, Amsterdam, Noord-Holland, Netherlands|Erasmus Medisch Centrum /ID# 141841, Rotterdam, Netherlands|CCA Braga - Hospital de Braga /ID# 138269, Braga, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 152532, Lisboa, Portugal|Ctr. Gastroenterologia Ped Oes /ID# 140875, Mayaguez, Puerto Rico|Iuliu Hatieganu Univ Medicine /ID# 131297, Cluj Napoca, Romania|Emergency Clin County Hosp- /ID# 137014, Targu Mures, Romania|Spital Clinic di Urgenta /ID# 130251, Timisoara, Romania|Hospital Regional de Malaga /ID# 144289, Málaga, Malaga, Spain|OSI Ezkerraldea-Enkarterri-Cruces /ID# 141781, Barakaldo, Spain|Granollers General Hospital /ID# 140882, Barcelona, Spain|Hospital Universitario Parc Tauli /ID# 149029, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 141778, Barcelona, Spain|Hospital Universitario Vall d´ /ID# 146015, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 152010, Barcelona, Spain|Hosp Clinico Virgen Arrixaca /ID# 138460, El Palmar, Spain|Hospital Sant Joan de Deu /ID# 152059, Esplugues de Llobregat, Spain|Hospital Arquitecto Marcide /ID# 138462, Ferrol, Spain|Hosp Univ Girona Josep Trueta /ID# 147572, Girona, Spain|Severo Ochoa Hospital /ID# 141545, Leganes-madrid, Spain|Hosp Infantil Univ Nino Jesus /ID# 165738, Madrid, Spain|Hospital Universitario La Paz /ID# 161152, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 157872, Majadahonda, Spain|Hospital Central De Asturias E /ID# 163053, Oviedo, Spain|Hospital Son Espases /ID# 147446, Palma de Mallorca, Spain|Complejo Hosp Santiago /ID# 141667, Santiago de Compostela, Spain|Hospital Univ Dr. Peset /ID# 159484, Valencia, Spain|Hospital Universitario La Fe /ID# 141847, Valencia, Spain|Complejo Hosp Univ de Vigo /ID# 136999, Vigo, Spain|Karolinska Univ Sjukhuset /ID# 129045, Solna, Sweden|South General Hospital /ID# 152610, Stockholm, Sweden|The Royal London Hospital /ID# 128471, London, London, City Of, United Kingdom|The Royal Free Hospital /ID# 149069, London, London, City Of, United Kingdom|Royal Aberdeen Childrens Hosp /ID# 131296, Aberdeen, United Kingdom|Birmingham Childrens Hospital /ID# 136631, Birmingham, United Kingdom|Addenbrookes Hospital /ID# 143779, Cambridge, United Kingdom|St Helier University Hospital /ID# 150097, Carshalton, United Kingdom|University of Dundee /ID# 131592, Dundee, United Kingdom|Royal Hosp for Sick Children /ID# 127436, Glasgow, United Kingdom|Alder Hey Children's Hospital /ID# 138013, Liverpool, United Kingdom|St. George's Healthcare NHS /ID# 131590, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 128476, Manchester, United Kingdom|Royal Victoria Infirmary, Newc /ID# 147438, Newcastle Upon Tyne, United Kingdom|Sheffield Children's Hospital /ID# 130370, Sheffield, United Kingdom|Univ Hosp Southampton NHS /ID# 147538, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02130362"
349,"NCT02118714","Atrasentan Spermatogenesis and Testicular Function",,"Completed","Has Results","Nephropathy|Diabetes","Drug: Atrasentan","Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26|Percentage of Participants Who Entered the Observation Period and Did Not Return to Within 15% of Baseline Sperm Concentration or Above During the 52-Week Observational Period|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Concentration|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Motility|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Sperm Morphology|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Semen Volume|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Serum Testosterone|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Estradiol|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Lutenizing Hormone (LH)|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in in Follicle Stimulating Hormone (FSH)|Change From Baseline up to Treatment Period Week 26 and Observation Period Week 52 in Inhibin B","AbbVie","Male","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","M12-919|2016-000722-19","April 6, 2015","April 18, 2018","July 16, 2018","April 21, 2014","May 7, 2019","May 7, 2019","Alliance Research Centers /ID# 125945, Laguna Hills, California, United States|Frank Clark Urology Center /ID# 147794, Santa Monica, California, United States|Research by Design, LLC /ID# 160784, Evergreen Park, Illinois, United States|Southern IL Univ School of Med /ID# 129010, Springfield, Illinois, United States|Crescent City Clinical Res Ctr /ID# 150989, Metairie, Louisiana, United States|Tulane Univ /ID# 130308, New Orleans, Louisiana, United States|Albany Medical College /ID# 131068, Albany, New York, United States|Urologic Consultants of Southeastern Pennsylvania /ID# 124277, Bala-Cynwyd, Pennsylvania, United States|Eastern Virginia Med School /ID# 153740, Norfolk, Virginia, United States|Charite Research Organisation GmbH /ID# 154264, Berlin, Germany|Ospedale S. Carlo Borromeo /ID# 151672, Milan, Italy|SCDU Nefrologia e dialisi-CMID /ID# 151673, Torino, Italy|Hospital Universitario Reina S /ID# 151692, Cordoba, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02118714/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT02118714/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02118714"
350,"NCT02106546","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",,"Completed","No Results Available","Squamous Non-Small Cell Lung Cancer","Drug: carboplatin|Drug: veliparib|Drug: paclitaxel|Drug: placebo","Overall Survival (OS) in current smokers|Overall Survival (OS) in all subjects|Progressive-Free Survival (PFS) in current smokers and in all subjects|Objective Response Rate (ORR) in current smokers and in all subjects","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","970","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-089|2013-005020-42","April 10, 2014","July 29, 2019","July 29, 2019","April 8, 2014",,"August 13, 2019","Northeast Arkansas Clinical Ch /ID# 128071, Jonesboro, Arkansas, United States|LA Hem-Oncology Med Group /ID# 129178, Los Angeles, California, United States|VA Eastern Colorado Healthcare /ID# 128065, Aurora, Colorado, United States|Holy Cross Hospital /ID# 128074, Fort Lauderdale, Florida, United States|University of Florida /ID# 126476, Gainesville, Florida, United States|Cancer Specialists of North Florida - Southpoint /ID# 127815, Jacksonville, Florida, United States|Emory University Hospital /ID# 124061, Atlanta, Georgia, United States|St. Luke's Mountain States Tumor Institute /ID# 124059, Boise, Idaho, United States|Illinois Cancer Specialists /ID# 127468, Arlington Heights, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 128585, Evanston, Illinois, United States|Ingalls Memorial Hosp /ID# 128360, Harvey, Illinois, United States|Midwestern Regional CTC /ID# 126124, Zion, Illinois, United States|Goshen Center for Cancer Care /ID# 123875, Goshen, Indiana, United States|Franciscan Health /ID# 126678, Indianapolis, Indiana, United States|Kentucky Cancer Clinic /ID# 128061, Hazard, Kentucky, United States|Edward W. Sparrow Hosp Assn /ID# 127156, Lansing, Michigan, United States|Henry Ford Hospital - West Bloomfield /ID# 126500, West Bloomfield, Michigan, United States|Minnesota Oncology Hematology - Coon Rapids /ID# 127474, Coon Rapids, Minnesota, United States|Minnesota Oncology Hematology, /ID# 127473, Minneapolis, Minnesota, United States|Nebraska Hematology Oncology /ID# 127699, Lincoln, Nebraska, United States|SE Nebraska Hema/Oncology /ID# 126477, Lincoln, Nebraska, United States|Comprehensive Cancer Ctrs Neva /ID# 127491, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Med Ctr /ID# 128075, Lebanon, New Hampshire, United States|Hackensack Univ Med Ctr /ID# 124057, Hackensack, New Jersey, United States|Gabrail Cancer Center Research /ID# 127415, Canton, Ohio, United States|NW Cancer Specialists, P.C. /ID# 127488, Portland, Oregon, United States|Penn State University and Milton S. Hershey Medical Center /ID# 126676, Hershey, Pennsylvania, United States|The Jones Clinic, PC /ID# 124062, Germantown, Tennessee, United States|Texas Oncology - Austin Midtown /ID# 127477, Austin, Texas, United States|Texas Oncology - South Austin /ID# 127476, Austin, Texas, United States|Parkland Health and Hosp Syste /ID# 128518, Dallas, Texas, United States|UT Southwestern Medical Center /ID# 127876, Dallas, Texas, United States|Baylor College of Medicine /ID# 128385, Houston, Texas, United States|Univ TX, MD Anderson /ID# 127946, Houston, Texas, United States|Texas Oncology - Paris /ID# 127484, Paris, Texas, United States|Texas Oncology - Waco /ID# 127459, Waco, Texas, United States|University of Vermont Medical Center /ID# 128064, Burlington, Vermont, United States|Virginia Oncology Associates /ID# 127458, Norfolk, Virginia, United States|Northwest Cancer Specialists, P.C. /ID# 127486, Vancouver, Washington, United States|Southern Medical Day Care Ctr /ID# 125604, Wollongong, New South Wales, Australia|Sunshine Coast University Hosp /ID# 125608, Birtinya, Queensland, Australia|The Townsville Hospital /ID# 125609, Douglas, Queensland, Australia|Flinders Centre for Innovation /ID# 125605, Bedford Park, South Australia, Australia|The Queen Elizabeth Hospital /ID# 125607, Woodville, South Australia, Australia|Barwon Health University Hospital Geelong /ID# 125606, Geelong, Victoria, Australia|Ordensklinikum Linz GmbH, Elisabethinen /ID# 126183, Linz, Austria|Bobruysk Interdistrict Onco. /ID# 128999, Bobruisk, Belarus|Brest Regional Hospital /ID# 125955, Brest, Belarus|Belarus Cancer Center N.N. Alexandrov /ID# 125815, Lesnoy, Belarus|Mogilev Reg Clin Oncology Dis /ID# 128639, Mogilev, Belarus|Vitebsk Reg Clin Onc Disp /ID# 125516, Vitebsk, Belarus|Hospital Sao Lucas da PUCRS /ID# 127737, Porto Alegre, Rio Grande Do Sul, Brazil|Clinica de Neoplasias Litoral /ID# 127738, Itajai, Santa Catarina, Brazil|Hospital de Cancer de Barretos /ID# 126736, Barretos, Sao Paulo, Brazil|Inca /Id# 127309, Rio de Janeiro, Brazil|Instituto COI de Educacao e Pe /ID# 127739, Rio de Janeiro, Brazil|Fundacao Antonio Prudente /ID# 126737, Sao Paulo, Brazil|University of Calgary /ID# 126326, Calgary, Alberta, Canada|Cross Cancer Institute /ID# 126154, Edmonton, Alberta, Canada|Juravinski Cancer Clinic /ID# 126153, Hamilton, Ontario, Canada|Victoria Hospital /ID# 126669, London, Ontario, Canada|The Ottawa Hospital /ID# 126522, Ottawa, Ontario, Canada|Princess Margaret Cancer Centr /ID# 126155, Toronto, Ontario, Canada|McGill Univ HC /ID# 130431, Montreal, Quebec, Canada|CSSS Alphonse-Desjardins, CHAU /ID# 126149, Quebec City, Quebec, Canada|Iucpq /Id# 126524, Sainte-foy, Quebec, Canada|Klinika za plucne bolesti Jordanovac /ID# 126537, Zagreb, Grad Zagreb, Croatia|Klinicki bolnicki centar Osijek /ID# 132214, Osijek, Osjecko-baranjska Zupanija, Croatia|Opca bolnica Pula /ID# 126540, Pula, Croatia|Opca bolnica Dr. Josip Bencevi /ID# 126539, Slavonski Brod, Croatia|Fakultni Nemocnice Olomouc /ID# 125820, Olomouc, Olomoucky Kraj, Czechia|Nemocnice Na Plesi s.r.o. /ID# 125817, Nová Ves pod Pleší, Pribram, Czechia|Nemocnice Kyjov /ID# 125819, Kyjov, Czechia|Nemocnice Novy Jicin /ID# 125818, Nový Jičín 1, Czechia|Vitkovicka nemocnice a. s. /ID# 127023, Ostrava, Czechia|Herlev Hospital /ID# 125995, Herlev, Hovedstaden, Denmark|Odense Universitets Hospital /ID# 125996, Odense C, Syddanmark, Denmark|University of Alexandria /ID# 128337, Alexandria, Egypt|Naser Institute for Res & Dev /ID# 129263, Cairo, Egypt|Cairo Uni Hosp Al Kasr El Ainy /ID# 128338, Cairo, Egypt|Cairo Uni Hosp Al Kasr El Ainy /ID# 128340, Cairo, Egypt|North Estonian Medical Centre /ID# 128215, Tallinn, Estonia|Tartu University Hospital /ID# 127735, Tartu, Estonia|Helsinki Univ Central Hospital /ID# 125897, Helsinki, Finland|Vaasa Central Hospital /ID# 125896, Vaasa, Finland|CHU Hopital Nord /ID# 128388, Marseille, Bouches-du-Rhone, France|Hopital Haut-Lévêque /ID# 135270, Pessac CEDEX, Gironde, France|CHRU Lille - Hôpital Claude Huriez /ID# 126353, Lille CEDEX, Hauts-de-France, France|Centre Hospitalier Le Mans /ID# 127902, Le Mans CEDEX 9, Sarthe, France|CHRU de Brest - Hopital Morvan /ID# 127903, Brest, France|Centre Hosp Intercommunal /ID# 125922, Creteil, France|Centre Antoine Lacassagne /ID# 126360, Nice, France|Hospital Pontchaillou /ID# 126356, Rennes, France|Hop Ophtalmique Jules Gonin /ID# 128394, Toulouse, France|Charite-Univ. Berlin, Benjamin-Franklin /ID# 125708, Berlin, Germany|Lungen Clinic Grosshansdorf /ID# 126107, Grosshansdorf, Germany|Klinikum Kassel /ID# 127025, Kassel, Germany|Klinik Loewenstein GmbH /ID# 126191, Löwenstein, Germany|Univ Johannes Gutenberg /ID# 125603, Mainz, Germany|Papageorgiou General Hospital Thessaloniki /ID# 125876, Nea Efkarpia, Thessaloniki, Greece|General Hospital of Chest Diseases of Athens SOTIRIA /ID# 125879, Athens, Greece|Metropolitan Hospital /ID# 125878, Athens, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 125877, Heraklion, Greece|CRU Hungary Egeszsegugyi és Szolgaltato Kft. /ID# 135234, Miskolc, Borsod-Abauj-Zemplen, Hungary|Orszagos Koranyi TBC/Pulmon /ID# 126112, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 126119, Debrecen, Hungary|Veszprem Megyei Tudogyogyintez /ID# 126121, Farkasgyepu, Hungary|Petz Aladar Megyei Oktato Korh /ID# 126110, Gyor, Hungary|Bekes Megyei Pandy Kalman Korh /ID# 126117, Gyula, Hungary|Matrahaza Gyogyintezet /ID# 126109, Kékesteto, Hungary|Fejer Megyei Szent Gyorgy Korh /ID# 126118, Szekesfehervar, Hungary|Jasz-Nagykun-Szolnok Megyei /ID# 126120, Szolnok, Hungary|Tudogyogyintezet Toeroekbalint /ID# 126111, Torokbalint, Hungary|St. James's Hospital /ID# 126177, Dublin 8, Dublin, Ireland|Cork University Hospital /ID# 126176, Cork, Ireland|Beaumont Hospital /ID# 126218, Dublin, Ireland|University Hospital Limerick /ID# 126175, Limerick, Ireland|University Hospital Waterford /ID# 126178, Waterford, Ireland|Assaf Harofeh Medical Center /ID# 127076, Be'er Ya'akov, Israel|Hadassah University Hospital /ID# 127077, Jerusalem, Israel|Meir Medical Center /ID# 127078, Kfar Saba, Israel|Sheba Medical Center /ID# 127079, Ramat Gan, Israel|AO San Giuseppe Moscati /ID# 125701, Avellino, Italy|Istituto Europeo di Oncologia /ID# 125702, Milan, Italy|Azienda Osp San Gerardo /ID# 125704, Monza, Italy|A.O.U. San Luigi Gonzaga /ID# 125700, Orbassano, Italy|Azienda Ospedaliero Uni Parma /ID# 125703, Parma, Italy|AO Universitaria di Perugia /ID# 125699, Perugia, Italy|Istituto Oncologico del Medite /ID# 132844, Viagrande, Italy|Riga East Clinical Univ Hosp /ID# 125597, Riga, Latvia|P. Stradins Clinical Univ Hosp /ID# 126322, Riga, Latvia|Hosp Lithuanian Univ Health Sc /ID# 127176, Kovno, Kaunas, Lithuania|National Cancer Institute /ID# 126323, Vilnius, Lithuania|Centro Estatal de Cancerologia /ID# 127583, Chihuahua, Mexico|Hospital Angeles Centro Medico /ID# 127620, San Luis Potosí, Mexico|Cancerologia de Queretaro S.C. /ID# 125920, Santiago de Querétaro, Mexico|Vrije Universiteit Medisch Centrum /ID# 125578, Amsterdam, Netherlands|Amphia Ziekenhuis /ID# 126466, Breda, Netherlands|Catharina Ziekenhuis /ID# 125577, Eindhoven, Netherlands|Ziekenhuis St. Jansdal /ID# 125576, Harderwijk, Netherlands|Zuyderland Medisch Centrum /ID# 125710, Heerlen, Netherlands|Jeroen Bosch Ziekenhuis /ID# 125709, S Hertogenbosch, Netherlands|Isala /ID# 125579, Zwolle, Netherlands|Wellington Hospital (Capital and Coast District Health Board) /ID# 125755, Wellington, New Zealand|Haukeland University Hospital /ID# 126338, Bergen, Hordaland, Norway|Nordland Hospital /ID# 126337, Bodø, Norway|Sorlandet Sykehus HF /ID# 126341, Kristiansand, Norway|Oslo Universitetssykehus, Radiumhospitalet /ID# 126335, Oslo, Norway|Stavanger University Hospital /ID# 126336, Stavanger, Norway|Sykehuset i Vestfold HF /ID# 126340, Tonsberg, Norway|Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 126548, Rzeszów, Podkarpackie, Poland|Szpital Morski im. PCK /ID# 126547, Gdynia, Poland|NZOZ Magodent Ctr. Med. Ostro /ID# 126545, Warsaw, Poland|Mazowiecki Szpital Onkologiczn /ID# 126546, Wieliszew, Poland|Hospital Senhora da Oliveira de Guimarães, EPE /ID# 126761, Guimarães, Braga, Portugal|CCA Braga - Hospital de Braga /ID# 125837, Braga, Portugal|Ctr Hosp Univ Coimbra, EPE /ID# 125838, Coimbra, Portugal|Hospital Pulido Valente /ID# 125835, Lisbon, Portugal|IPO Porto FG, EPE /ID# 125836, Porto, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 125875, Porto, Portugal|VA Caribbean Healthcare System /ID# 124562, San Juan, Puerto Rico|NN Blokhin Russian Cancer /ID# 128458, Moscow, Moskva, Russian Federation|Sverdlovsk Regional Oncology Center /ID# 128457, Ekaterinburg, Sverdlovskaya Oblast, Russian Federation|Volgograd Regional Clinical Oncology Dispensary /ID# 126350, Volgograd, Volgogradskaya Oblast, Russian Federation|Belgorod Oncology Dispensary /ID# 129899, Belgorod, Russian Federation|Regional Oncology Dispensary /ID# 128460, Irkutsk, Russian Federation|Murmansk RCH P.A. Bayandina /ID# 128461, Murmansk, Russian Federation|Orenburg Regional Clinical Onc /ID# 137474, Orenburg, Russian Federation|Ogarev Mordovia State Univ /ID# 127595, Saransk, Russian Federation|Smolensk Regional Onc Clin Dis /ID# 127144, Smolensk, Russian Federation|Siberian State Med Uni /ID# 127143, Tomsk, Russian Federation|Clinical Center Serbia /ID# 128738, Belgrade, Beograd, Serbia|Clinical Center of Nis /ID# 128735, NIS, Nisavski Okrug, Serbia|Institute for Oncology and Rad /ID# 128721, Belgrade, Serbia|University Hospital Bezanijska /ID# 128761, Belgrade, Serbia|Institute For Pulmonary Diseas /ID# 128737, Sremska Kamenica, Serbia|Univerzitna Nemocnica Bratislava /ID# 126342, Bratislava, Slovakia|Uni Nemoc L. Pasteura Kosice /ID# 126343, Kosice, Slovakia|MEDEON, s.r.o. /ID# 128517, Pieštany, Slovakia|GVI Oncology /ID# 126102, Port Elizabeth, Eastern Cape, South Africa|Wits Clinical Research Site /ID# 126101, Johannesburg, Gauteng, South Africa|Sandton Oncology Centre /ID# 126097, Johannesburg, Gauteng, South Africa|University of Pretoria /ID# 127297, Pretoria, Gauteng, South Africa|Life Wilgers Hospital /ID# 126098, Pretoria, Gauteng, South Africa|Mary Potter Oncology Centre /ID# 126099, Pretoria, Gauteng, South Africa|The Oncology Centre /ID# 126096, Durban, Kwazulu-Natal, South Africa|Netcare Oncology Intervent Ctr /ID# 126100, Cape Town, Western Cape, South Africa|Cancercare Outeniqua Oncology Unit /ID# 126103, George, Western Cape, South Africa|Hospital Duran i Reynals /ID# 125161, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 125159, Barcelona, Spain|Hosp Univ Madrid Sanchinarro /ID# 125162, Madrid, Spain|Hosp Univ Puerta de Hierro /ID# 125160, Majadahonda, Spain|Hosp Univ Virgen del Rocio /ID# 125207, Sevilla, Spain|Fundacion Inst Valenciano Onc /ID# 125205, Valencia, Spain|Gavle Sjukhus /ID# 126444, Gavle, Sweden|Sahlgrenska University Hosp /ID# 129997, Goteborg, Sweden|Karolinska Univ Sjukhuset /ID# 126445, Solna, Sweden|Kantonsspital St. Gallen /ID# 126349, St. Gallen, Sankt Gallen, Switzerland|Hirslanden Medical Center /ID# 128216, Aarau, Switzerland|Inselspital, Universitaetsklinik /ID# 126347, Bern, Switzerland|Spital STS AG /ID# 126348, Thun, Switzerland|Akdeniz University Medical Fac /ID# 126997, Antalya, Turkey|Istanbul University Cerrahpasa Medical Faculty /ID# 126186, Istanbul, Turkey|Marmara University Medical Fac /ID# 126187, Istanbul, Turkey|Ege University Medical Faculty /ID# 126189, Izmir, Turkey|Dr. Suat Seren Gogus Has /ID# 126190, Izmir, Turkey|Cherkassy Regional Onc Ctr /ID# 128222, Cherkasy, Ukraine|Chernivetskyi Reg Clin Onc Hos /ID# 128220, Chernivtsi, Ukraine|City Multi-Field Clin Hosp #4 /ID# 128217, Dnipro, Ukraine|Kharkiv Regional Clinical Onco /ID# 128221, Kharkiv, Ukraine|Lviv State Onc Local Treatment /ID# 128218, Lviv, Ukraine|Poltava Regional Clinical Onco /ID# 128223, Poltava, Ukraine|Sumy Reg Clinical Oncology Ctr /ID# 128219, Sumy, Ukraine|Cheltenham General Hospital /ID# 125692, Cheltenham, Gloucestershire, United Kingdom|Guy's and St Thomas' NHS Found /ID# 125694, London, London, City Of, United Kingdom|Betsi Cadwaladr Univ Health Bo /ID# 127177, Bangor, United Kingdom|North Devon District Hospital /ID# 125689, Barnstaple, United Kingdom|The Royal Bournemouth Hospital /ID# 125690, Bournemouth, United Kingdom|East Kent Hosp Univ NHS Trust /ID# 125698, Canterbury, United Kingdom|Gartnavel General Hospital /ID# 126233, Glasgow, United Kingdom|James Paget University Hosp /ID# 125696, Great Yarmouth, United Kingdom|Charing Cross Hospital /ID# 125688, London, United Kingdom|Maidstone Hospital /ID# 125693, Maidstone, United Kingdom|Wythenshawe Hospital /ID# 126235, Manchester, United Kingdom|Freeman Hospital /ID# 129228, Newcastle Upon Tyne, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 125697, Norwich, United Kingdom|The Clatterbridge Cancer Ctr /ID# 125695, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02106546"
351,"NCT02099058","A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors Cancer","Drug: Osimertinib|Drug: Nivolumab|Drug: ABBV-399|Drug: Erlotinib","Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)|Maximum observed plasma concentration (Cmax)|Time to Cmax (Tmax)|Terminal elimination half life|Objective response rate (ORR)|Progression free survival (PFS)|Duration of overall response (DOR)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","225","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-237|2014-003154-14","January 15, 2014","December 10, 2020","October 6, 2021","March 28, 2014",,"November 1, 2019","Scottsdale Healthcare /ID# 123761, Scottsdale, Arizona, United States|City of Hope /ID# 153759, Duarte, California, United States|University of California, Los Angeles /ID# 148295, Los Angeles, California, United States|UC Irvine /ID# 165107, Orange, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 129805, Sacramento, California, United States|Univ of Colorado Cancer Center /ID# 123759, Aurora, Colorado, United States|University of Chicago /ID# 136995, Chicago, Illinois, United States|Ingalls Memorial Hosp /ID# 165876, Harvey, Illinois, United States|Massachusetts General Hospital /ID# 129804, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 168782, Boston, Massachusetts, United States|Henry Ford Health System /ID# 149857, Detroit, Michigan, United States|Herbert Herman Cancer Center /ID# 149858, Lansing, Michigan, United States|Washington University-School of Medicine /ID# 143798, Saint Louis, Missouri, United States|Duke University Medical Center /ID# 123763, Durham, North Carolina, United States|Tennessee Oncology, PLLC /ID# 129802, Nashville, Tennessee, United States|Mary Crowley Cancer Research /ID# 123760, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 154648, Houston, Texas, United States|Virginia Cancer Specialists /ID# 165708, Fairfax, Virginia, United States|UZ Antwerpen /ID# 170118, Edegem, Belgium|Tays Keskussairaala /ID# 165065, Tampere, Finland|Gustave Roussy /ID# 132747, Villejuif, Ile-de-France, France|Hopital de la Timone /ID# 151570, Marseille CEDEX 05, Provence-Alpes-Cote-d Azur, France|IRST IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori /ID# 164077, Meldola, Emilia-Romagna, Italy|National Cheng Kung University Hospital /ID# 167175, Tainan City, Tainan, Taiwan|National Taiwan University Hospital /ID# 167173, Taipei City, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02099058"
352,"NCT02095574","A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma",,"Withdrawn","No Results Available","Relapsed/Refractory Non-Hodgkin's Lymphoma","Drug: [14C]ABT-199 (GDC-0199)","Maximum observed plasma concentration (Cmax) of ABT-199 and [14C]ABT-199|Time to Cmax (Tmax) for ABT-199 and [14C]ABT-199|Area Under the Time curve (AUC) for ABT-199 and [14C]ABT-199|Number of subjects with adverse events|Percentage of subjects with adverse events","AbbVie|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M13-363","September 2014","September 2014","January 2015","March 26, 2014",,"August 13, 2014",,,"https://ClinicalTrials.gov/show/NCT02095574"
353,"NCT02092389","Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo","AdaProQuo","Terminated","Has Results","Moderate to Severe Ulcerative Colitis",,"Percentage of Patients With Fecal Calprotectin (fC) Level ≤ 150 µg/g After 12 Months of Treatment With Adalimumab|Change From Baseline to Month 12 in Patient's Workability Measured Using the Work Productivity and Activity Impairment:Ulcerative Colitis (WPAI:UC) Questionnaire|Change From Baseline to Month 12 in Patient's Quality of Life (QoL) Measured Using the Short Inflammatory Bowl Disease Questionnaire (sIBDQ)|Change From Baseline to Month 12 in Disease Activity Determined by Partial Mayo Score|Correlation Between fC and Disease Activity Determined by Partial Mayo Score|Correlation Between fC and Patient's QoL Determined by the sIBDQ|Correlation Between fC and Workability Determined by WPAI:UC Questionnaire","AbbVie","All","18 Years and older   (Adult, Older Adult)",,"10","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-323","July 2014","October 2015","March 2016","March 20, 2014","February 23, 2017","February 23, 2017",,,"https://ClinicalTrials.gov/show/NCT02092389"
354,"NCT02087904","A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis",,"Completed","Has Results","Knee Osteoarthritis|Medial Compartment Knee Osteoarthritis","Biological: ABT-981|Other: Placebo","Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Scores of the Index Knee at Week 16|Change From Baseline in Quantitative Synovitis of the Index Knee at Week 26|Change From Baseline in Effusion Volume of the Index Knee at Week 26|Change From Baseline in Whole-Organ Magnetic Resonance Imaging Score (WORMS) Semi-Quantitative Synovitis/Effusion Score of the Index Knee at Week 26|Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 16|Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 26|Change From Baseline in WOMAC Physical Function Scores of the Index Knee at Week 52|Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 26|Change From Baseline in WOMAC Pain Scores of the Index Knee at Week 52|Change From Baseline in Global Total Bone Marrow Lesion (BML) Score of the Index Knee Magnetic Resonance Imaging (MRI) at Week 26|Change From Baseline in Global Total BML Score of the Index Knee MRI at Week 52|Change From Baseline in Index Knee Intermittent and Constant Osteoarthritis Pain (ICOAP) Scores at Week 16|Change From Baseline in Index Knee ICOAP Scores at Week 26|Change From Baseline in Index Knee ICOAP Scores at Week 52|Change From Baseline In Index Knee Pain Intensity at Week 16|Change From Baseline In Index Knee Pain Intensity at Week 26|Change From Baseline In Index Knee Pain Intensity at Week 52|Change From Baseline in Patient Global Assessment (PGA) of Arthritis of the Index Knee at Week 16|Change From Baseline in PGA of Arthritis of the Index Knee at Week 26|Change From Baseline in PGA of Arthritis of the Index Knee at Week 52|Change From Baseline in Cartilage Volume of the Index Knee at Week 26|Change From Baseline in Cartilage Volume of the Index Knee at Week 52|Change From Baseline in Cartilage Thickness of the Index Knee at Week 26|Change From Baseline in Cartilage Thickness of the Index Knee at Week 52|Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 16|Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 26|Outcome Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OMERACT/OARSI) Response Rate at Week 52","AbbVie","All","35 Years to 74 Years   (Adult, Older Adult)","Phase 2","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-741|2013-003467-60","June 4, 2014","June 7, 2016","December 13, 2016","March 14, 2014","August 28, 2019","August 28, 2019",,,"https://ClinicalTrials.gov/show/NCT02087904"
355,"NCT02087878","A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma","HSTCL","Withdrawn","No Results Available","Crohn's Disease|Ulcerative Colitis (UC)|Hepatosplenic T-Cell Lymphoma",,"Collection of Samples","AbbVie","All","1 Year to 99 Years   (Child, Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Other|Time Perspective: Other","F14-258","March 31, 2014","September 30, 2019","September 30, 2019","March 14, 2014",,"November 22, 2019","AOU Pisana /ID# 208952, Pisa, Italy",,"https://ClinicalTrials.gov/show/NCT02087878"
356,"NCT02082249","An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications",,"Completed","No Results Available","Advanced Parkinson's Disease","Drug: ABT-SLV187","Number of Participants with Adverse Events|Change in Patient Global Impression of Change (PGIC) scores|Change in the Unified Parkinson's Disease Rating Scale (UPDRS) score|Change in the Parkinson's Disease Questionnaire-39 (PDQ-39) scores|Change in PD Diary mean daily ""On"" time without troublesome dyskinesia (""On"" time without dyskinesia or with non-troublesome dyskinesia) or ""On"" time with troublesome dyskinesia|Change in the mean daily ""Off"" time (hours) as measured by the Parkinson's Disease (PD) Diary ©|Change in Clinical Global Impression of Change (CGI-C) scores","AbbVie","All","30 Years to 99 Years   (Adult, Older Adult)","Phase 3","23","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-923","March 10, 2014","October 31, 2019","October 31, 2019","March 10, 2014",,"November 25, 2019","National Hospital Organization Asahikawa Medical Center /ID# 101178, Asahikawa, Hokkaido, Japan|National Hospital Organization Sagamihara National Hospital /ID# 98662, Sagamihara-shi, Kanagawa, Japan|Osaka University Hospital /ID# 108335, Suita-shi, Osaka, Japan|National Center of Neurology and Psychiatry /ID# 98664, Kodaira, Tokyo, Japan|Kyoto University Hospital /ID# 112136, Sakyo-ku, Japan|Seoul National University Hospital /ID# 105935, Seoul, Korea, Republic of|Linkou Chang Gung Memorial Ho /ID# 102297, Taoyuan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT02082249"
357,"NCT02082197","An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men",,"Withdrawn","No Results Available","Hypogonadism|Testosterone Deficiency","Drug: ABT-SLV176","Percentage of subjects with serum total testosterone average concentration, Cavg(0-24)|Percentage of subjects falling within the pre-defined ranges of maximum total testosterone concentration (Cmax)|Average serum total testosterone and Dihydrotestosterone (DHT) concentration (Cavg)","AbbVie","Male","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-886","March 2014","June 2015","June 2015","March 10, 2014",,"June 2, 2014","Site Reference ID/Investigator# 124163, Birmingham, Alabama, United States|Site Reference ID/Investigator# 123938, Huntsville, Alabama, United States|Site Reference ID/Investigator# 125782, Mesa, Arizona, United States|Site Reference ID/Investigator# 124157, Phoenix, Arizona, United States|Site Reference ID/Investigator# 123937, Tucson, Arizona, United States|Site Reference ID/Investigator# 123948, Anaheim, California, United States|Site Reference ID/Investigator# 124164, Los Angeles, California, United States|Site Reference ID/Investigator# 123920, Los Gatos, California, United States|Site Reference ID/Investigator# 124038, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 126202, Denver, Colorado, United States|Site Reference ID/Investigator# 123927, Middlebury, Connecticut, United States|Site Reference ID/Investigator# 123947, Clearwater, Florida, United States|Site Reference ID/Investigator# 123929, Jacksonville, Florida, United States|Site Reference ID/Investigator# 123940, Ocala, Florida, United States|Site Reference ID/Investigator# 124166, Orlando, Florida, United States|Site Reference ID/Investigator# 123945, Ponte Vedra Beach, Florida, United States|Site Reference ID/Investigator# 123930, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 124395, Wichita, Kansas, United States|Site Reference ID/Investigator# 125784, Crestview Hills, Kentucky, United States|Site Reference ID/Investigator# 123919, Lexington, Kentucky, United States|Site Reference ID/Investigator# 123925, Baltimore, Maryland, United States|Site Reference ID/Investigator# 123936, Methuen, Massachusetts, United States|Site Reference ID/Investigator# 124160, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 123939, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 123932, Lawrenceville, New Jersey, United States|Site Reference ID/Investigator# 123943, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 123926, Garden City, New York, United States|Site Reference ID/Investigator# 125783, New York, New York, United States|Site Reference ID/Investigator# 123928, Poughkeepsie, New York, United States|Site Reference ID/Investigator# 124165, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 123933, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 123921, Salisbury, North Carolina, United States|Site Reference ID/Investigator# 124162, Cleveland, Ohio, United States|Site Reference ID/Investigator# 123917, Bala Cynwyd, Pennsylvania, United States|Site Reference ID/Investigator# 123931, Jenkintown, Pennsylvania, United States|Site Reference ID/Investigator# 123924, Greer, South Carolina, United States|Site Reference ID/Investigator# 123895, Chattanooga, Tennessee, United States|Site Reference ID/Investigator# 123946, Nashville, Tennessee, United States|Site Reference ID/Investigator# 123923, Austin, Texas, United States|Site Reference ID/Investigator# 123922, Dallas, Texas, United States|Site Reference ID/Investigator# 124167, Dallas, Texas, United States|Site Reference ID/Investigator# 123944, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02082197"
358,"NCT02068222","A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus","Drug: ABT-450/ritonavir (r)|Drug: ABT-530|Drug: Ribavirin (RBV)","The Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12)|The Percentage of Subjects Who Achieve 24-week Sustained Virologic Response (SVR24)|The Percentage of Subjects With Virologic Failure During Treatment|The Percentage of Subjects With Post-Treatment Relapse","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-213","April 2014","March 2015","March 2015","February 21, 2014","February 2, 2017","February 22, 2018",,,"https://ClinicalTrials.gov/show/NCT02068222"
359,"NCT02066389","A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Placebo|Drug: Upadacitinib","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12|Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12|Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12|Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12|Secondary: Percentage of Participants Achieving Clinical Remission (CR) Based on DAS28(CRP) at Week 12|Percentage of Participants Achieving Low Disease Activity (LDA) Based on CDAI at Week 12|Percentage of Participants Achieving Clinical Remission Based on CDAI at Week 12","AbbVie","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-537|2013-003984-72","March 26, 2014","July 2, 2015","July 2, 2015","February 19, 2014","October 4, 2019","October 4, 2019","C.V. Mehta MD, Med Corporation /ID# 126380, Hemet, California, United States|Omega Research Consultants, LLC /ID# 125780, DeBary, Florida, United States|Lovelace Scientific Resources /ID# 127324, Venice, Florida, United States|North Georgia Rheumatology Grp /ID# 125779, Lawrenceville, Georgia, United States|PRN Professional Research Network of Kansas, LLC /ID# 126148, Wichita, Kansas, United States|The Center for Rheumatology & /ID# 127323, Wheaton, Maryland, United States|Summit Medical Group /ID# 125776, Clifton, New Jersey, United States|Arthritis and Osteo Assoc /ID# 134994, Las Cruces, New Mexico, United States|Altoona Ctr Clinical Res /ID# 125777, Duncansville, Pennsylvania, United States|Emkey Arthritis and Osteo Clin /ID# 134716, Wyomissing, Pennsylvania, United States|Accurate Clinical Research /ID# 126535, Houston, Texas, United States|Mountain State Clinical Resear /ID# 127089, Clarksburg, West Virginia, United States|MHAT Trimontsium /ID# 127311, Plovdiv, Bulgaria|UMHAT Pulmed OOD /ID# 127307, Plovdiv, Bulgaria|MHAT Kaspela /ID# 127315, Plovdiv, Bulgaria|Diagnostic Consultative Center /ID# 127313, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 127314, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 131608, Sofia, Bulgaria|Diagnostic Consultative Center /ID# 127312, Varna, Bulgaria|Corp de Beneficencia Osorno /ID# 127337, Osorno, Chile|Quantum Research LTDA. /ID# 127338, Puerto Varas, Chile|Revmatologicky ustav Praha /ID# 127317, Prague 2, Praha 2, Czechia|Nuselská poliklinika, Revmatologie /ID# 127318, Prague 4, Praha 4, Czechia|Revmatologie Bruntal, s.r.o /ID# 126881, Bruntál, Czechia|Artroscan s.r.o. /ID# 126845, Ostrava, Czechia|Qualiclinic Kft. /ID# 127340, Budapest III, Pest, Hungary|Veszprem Megyei Csolnoky Feren /ID# 126876, Veszprém, Hungary|Barzilai Medical Center /ID# 126875, Ashkelon, Israel|Rambam Health Care Campus /ID# 127341, Haifa, Israel|Sheba Medical Center /ID# 126878, Ramat Gan, Israel|LTD M&M Centers /ID# 127346, Adazi, Latvia|Arija's Ancane's Family Doctor /ID# 127342, Baldone, Latvia|Clinic ORTO /ID# 127345, Riga, Latvia|Hospital de Jesús Nazareno /ID# 127352, Mexico City, Mexico|Cliditer SA de CV /ID# 127347, Mexico City, Mexico|Clinstile, S.A. de C.V. /ID# 127350, Mexico City, Mexico|REUMED Sp.z o.o. Filia nr 1 /ID# 127353, Lublin, Lubelskie, Poland|Centrum Medyczne Pratia Krakow /ID# 127358, Krakow, Malopolskie, Poland|NBR Polska /ID# 127359, Warsaw, Mazowieckie, Poland|Medica Pro Familia S.A Warszawa /ID# 127361, Warsaw, Mazowieckie, Poland|Gabinet Internistyczno Reum. /ID# 127357, Białystok, Podlaskie, Poland|Centrum Medyczne Pratia Gdynia /ID# 127360, Gdynia, Pomorskie, Poland|Michal Bazela Higher-Med /ID# 127355, Elbląg, Warminsko-mazurskie, Poland|GCM Medical Group /ID# 127363, San Juan, Puerto Rico|City Clinical Hospital #7 /ID# 127372, Kazan, Tatarstan, Respublika, Russian Federation|Tver Regional Clinical Hosp. /ID# 127375, Tver, Tverskaya Oblast, Russian Federation|II Dzhan Research Center /ID# 127376, St. Petersburg, Russian Federation|MEDMAN s.r.o. /ID# 127381, Martin, Slovakia|Poliklinika Senica /ID# 127396, Senica, Slovakia|Panorama Medical Centre /ID# 126846, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 126844, Stellenbosch, Western Cape, South Africa|Hospital Regional de Malaga /ID# 127385, Málaga, Malaga, Spain|Hospital Plató /ID# 127384, Barcelona, Spain|Hospital CIMA Sanitas /ID# 127383, Barcelona, Spain|Hospital Universitario Basurto /ID# 127391, Bilbao, Spain|Hospital Clin Univ San Carlos /ID# 127382, Madrid, Spain|Clinica Gaias /ID# 127386, Santiago de Compostela, Spain|Hospital Infanta Luisa /ID# 127389, Sevilla, Spain|Hospital Universitario de Valm /ID# 127387, Sevilla, Spain|Medeniyet Univ. Goztepe Traini /ID# 132396, Istanbul, Turkey|Kiev Municipal Clin Hosp 3 /ID# 127419, Kiev, Ukraine|NSC-Strazhesko Ist Cardiology /ID# 127416, Kiev, Ukraine|Sumy State University /ID# 127418, Sumy, Ukraine",,"https://ClinicalTrials.gov/show/NCT02066389"
360,"NCT02065622","Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis",,"Completed","No Results Available","Ulcerative Colitis (UC)","Drug: Adalimumab|Other: Placebo","Proportion of week 8 responders (per full Mayo Score) achieving clinical remission (per full Mayo score)|Proportion of subjects achieving clinical remission (per full Mayo Score)|Proportion of subjects achieving endoscopic improvement (endoscopic subscore of 0 or 1)|Proportion of Week 8 responders (per full Mayo Score) achieving endoscopic improvement (endoscopic subscore of 0 or 1)","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","952","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-033|2013-001682-16","March 27, 2014","September 5, 2019","November 11, 2019","February 19, 2014",,"November 22, 2019","Digestive Health Specialists of the Southeast /ID# 127844, Dothan, Alabama, United States|Ucsd /Id# 122313, La Jolla, California, United States|Rocky Mountain Clinical Resear /ID# 122180, Wheat Ridge, Colorado, United States|Medical Research Ctr CT /ID# 122179, Hamden, Connecticut, United States|Gastro Florida /ID# 170619, Clearwater, Florida, United States|Research Associates of South Florida,LLC /ID# 170309, Miami, Florida, United States|Gastroenterology Group Naples /ID# 127806, Naples, Florida, United States|Shafran Gastroenterology Ctr /ID# 122320, Winter Park, Florida, United States|Atlanta Gastro Assoc /ID# 122336, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 122318, Macon, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 122183, Chicago, Illinois, United States|University of Chicago /ID# 122302, Chicago, Illinois, United States|Carle Foundation Hospital /ID# 135955, Urbana, Illinois, United States|Louisiana Research Ctr. LLC /ID# 141655, Shreveport, Louisiana, United States|University of Maryland Med Ctr /ID# 169734, Baltimore, Maryland, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 122238, Chevy Chase, Maryland, United States|University of Michigan Hospitals /ID# 122240, Ann Arbor, Michigan, United States|Mayo Clinic - Rochester /ID# 122244, Rochester, Minnesota, United States|Ctr for Digest and Liver Dis /ID# 122182, Mexico, Missouri, United States|NYU Langone Long Island CRA /ID# 122177, Great Neck, New York, United States|Icahn School of Med Mt. Sinai /ID# 127047, New York, New York, United States|Charlotte Gastro Hepatology /ID# 122235, Charlotte, North Carolina, United States|Wake Research Associates, LLC /ID# 122157, Raleigh, North Carolina, United States|Consultants for Clinical Res /ID# 122304, Cincinnati, Ohio, United States|Dayton Gastroenterology, Inc. /ID# 127804, Englewood, Ohio, United States|Gastro United of Tulsa /ID# 125436, Tulsa, Oklahoma, United States|The Oregon Clinic- Gastro West /ID# 135273, Portland, Oregon, United States|University of Pittsburgh MC /ID# 122331, Pittsburgh, Pennsylvania, United States|Erlanger Institute for Clinica /ID# 129009, Chattanooga, Tennessee, United States|Gastro One /ID# 122339, Germantown, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 125496, Nashville, Tennessee, United States|DHAT Research Institute /ID# 170616, Garland, Texas, United States|Biopharma Informatic Research /ID# 171150, Houston, Texas, United States|Austin Center for Clinical Research /ID# 125396, Pflugerville, Texas, United States|Texas Digestive Disease Consul /ID# 141677, Southlake, Texas, United States|Texas Digestive Disease Consul /ID# 141678, Southlake, Texas, United States|Advanced Research Institute /ID# 126147, Ogden, Utah, United States|University of Utah /ID# 122333, Salt Lake City, Utah, United States|New River Valley Research Inst /ID# 127801, Christiansburg, Virginia, United States|University of Washington /ID# 169721, Seattle, Washington, United States|WI Center for Advanced Res /ID# 122178, Milwaukee, Wisconsin, United States|Froedtert and Medical College /ID# 122261, Milwaukee, Wisconsin, United States|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 127184, Linz, Oberoesterreich, Austria|Medizinische Universität Wien /ID# 127186, Vienna, Wien, Austria|Ordination Hainburg an der Don /ID# 127185, Hainburg An Der Donau, Austria|LKH Salzburg and Paracelsus /ID# 125944, Salzburg, Austria|KH der Barmherzigen Brueder /ID# 127183, St Veit An Der Glan, Austria|CHU de Liege /ID# 126740, Liège, Liege, Belgium|AZ Sint-Lucas /ID# 127187, Ghent, Belgium|UZ Leuven /ID# 126739, Leuven, Belgium|University of Calgary /ID# 125715, Calgary, Alberta, Canada|Zeidler Ledcor Centre /ID# 125713, Edmonton, Alberta, Canada|Winnipeg Regional Health Autho /ID# 125712, Winnipeg, Manitoba, Canada|Qe Ii Hsc /Id# 127045, Halifax, Nova Scotia, Canada|London Health Sciences Centre /ID# 127055, London, Ontario, Canada|Mount Sinai Hosp.-Toronto /ID# 126590, Toronto, Ontario, Canada|Toronto Digestive Disease Asso /ID# 127075, Vaughan, Ontario, Canada|McGill Univ HC /ID# 127046, Montreal, Quebec, Canada|Hepato-Gastroenterologie HK s.r.o. /ID# 127188, Hradec Kralove, Czechia|ISCARE I.V.F. a.s. /ID# 127837, Prague, Czechia|Herlev Hospital /ID# 127191, Herlev, Hovedstaden, Denmark|Regionhospital Silkeborg /ID# 127190, Silkeborg, Denmark|CHRU Lille - Hôpital Claude Huriez /ID# 127197, Lille CEDEX, Hauts-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 127196, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Amiens Picardie /ID# 127194, Amiens CEDEX 1, Somme, France|CHU Estaing /ID# 127848, Clermont Ferrand, France|CHU Dijon - Complexe du Bocage /ID# 127861, Dijon, France|CHU de Grenoble - Albet Michal /ID# 127195, Grenoble, France|CHU Saint ELOIS /ID# 169007, Montpellier Cedex 5, France|CHU de Nice /ID# 127193, Nice, France|Hopital Nord /ID# 134490, Saint Priest En Jarez, France|Hopital Rangueil /ID# 127192, Toulouse, France|Universitatsklinik Regensburg /ID# 201265, Ratisbon, Bayern, Germany|Universitatsklinikum Frankfurt /ID# 170300, Frankfurt, Hessen, Germany|Univ Hosp Schleswig-Holstein /ID# 127199, Kiel, Schleswig-Holstein, Germany|Charité Universitätsmedizin Campus Mitte /ID# 127203, Berlin, Germany|Mross, Berlin, DE /ID# 127201, Berlin, Germany|Gastrostudien GbR /ID# 169246, Berlin, Germany|Asklepios Westklinikum Hamburg /ID# 127198, Hamburg, Germany|Universitaetsklinikum Jena /ID# 127205, Jena, Germany|EUGASTRO GmbH /ID# 127202, Leipzig, Germany|Universitatsklinikum Magdeburg /ID# 127200, Magdeburg, Germany|Gastro Gemeinschaftspraxis /ID# 126743, Munster, Germany|Pecsi Tudomanyegyetem /ID# 127209, Pécs, Pecs, Hungary|Magyar Elhizastudomanyi KKft. /ID# 126589, Budapest, Hungary|Pannonia Maganorvosi Centrum K /ID# 127207, Budapest, Hungary|Szegedi Tudomanyegyetem /ID# 127208, Szeged, Hungary|Rabin Medical Center /ID# 127212, Petakh Tikva, Tel-Aviv, Israel|Tel Aviv Sourasky Medical Ctr /ID# 201365, Tel Aviv-Yafo, Tel-Aviv, Israel|Soroka Medical Ctr /ID# 127213, Be'er Sheva, Israel|Hadassah University Hospital /ID# 127211, Jerusalem, Israel|Kaplan Medical Center /ID# 127210, Rehovot, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 129322, Bologna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 127216, Rome, Lazio, Italy|AO Univ Policlinico Agostino G /ID# 127217, Rome, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 127138, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 127215, Rozzano, Milano, Italy|Univ. degli Studi di Brescia /ID# 127236, Brescia, Italy|Universita di Padova /ID# 127214, Padua, Italy|Ospedali Riuniti Villa Sofia-C /ID# 129323, Palermo, Italy|Policlinico Univ Tor Vergata /ID# 129321, Rome, Italy|IRCCS Casa Sollievo /ID# 127811, San Giovanni Rotondo, Italy|Nagoya City University Hospital /ID# 124517, Nagoya-shi, Aichi, Japan|Yokoyama IBD Clinic /ID# 151560, Nagoya, Aichi, Japan|Toho University Sakura Medical Center /ID# 124497, Sakura-shi, Chiba, Japan|Fukuoka University Chikushi Hospital /ID# 124155, Chikushino, Fukuoka, Japan|Kyushu University Hospital /ID# 124495, Fukuoka-shi, Fukuoka, Japan|Kurume University Hospital /ID# 125275, Kurume-shi, Fukuoka, Japan|Hidaka Coloproctology Clinic /ID# 125477, Kurume, Fukuoka, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 124480, Sapporo-shi, Hokkaido, Japan|Aoyama Clinic /ID# 127836, Kobe, Hyogo, Japan|The Hospital of Hyogo College of Medicine /ID# 127539, Nishinomiya-shi, Hyogo, Japan|Kitasato University Hospital /ID# 137694, Sagamihara-shi, Kanagawa, Japan|Matsushima Clinic /ID# 148423, Yokohama, Kanagawa, Japan|Susaki Kuroshio Hospital /ID# 125202, Susaki, Kochi, Japan|JP Red Cross Kyoto Daiichi Hos /ID# 127540, Kyoto-shi, Kyoto, Japan|Osaka Medical College Hospital /ID# 126451, Takatsuki -shi, Osaka, Japan|Saitama Medical Center, Saitama Medical University /ID# 128875, Kawagoe-shi, Saitama, Japan|Shiga University of Medical Science Hospital /ID# 127675, Otsu, Shiga, Japan|Hamamatsu Minami Hospital /ID# 124481, Hamamatsu-shi, Shizuoka, Japan|Medical Hospital of Tokyo Medical and Dental University /ID# 128315, Bunkyo-ku, Tokyo, Japan|Kitasato Univ Kitasato Inst Ho /ID# 127001, Minato-ku, Tokyo, Japan|Kyorin University Hospital /ID# 148184, Mitaka-shi, Tokyo, Japan|Hiroshima University Hospital /ID# 124496, Hiroshima, Japan|Tokyo Yamate Medical Center /ID# 125201, Tokyo, Japan|Wakayama Medical University /ID# 124635, Wakayama, Japan|Academisch Medisch Centrum /ID# 126741, Amsterdam, Noord-Holland, Netherlands|Szpital Uniwersytecki Nr 2 im. dr J.Biziela w Bydgoszczy /ID# 127141, Bydgoszcz, Kujawsko-pomorskie, Poland|C.M. Szpital Swietej Rodziny /ID# 127838, Lodz, Lodzkie, Poland|Centrum Zdrowia MDM /ID# 170303, Warsaw, Mazowieckie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 126513, Warszawa, Mazowieckie, Poland|Centrum Medyczne Pratia Gdynia /ID# 170301, Gdynia, Pomorskie, Poland|NZOZ All-Medicus /ID# 128740, Katowice, Slaskie, Poland|H-T.Centrum Medyczne-Endoterapia /ID# 170305, Tychy, Slaskie, Poland|Centrum Medyczne LukaMed /ID# 170302, Chojnice, Poland|Centrum Medyczne Sw. Lukaza /ID# 126515, Czestochowa, Poland|Centrum Diagnostyczno Lecznicz /ID# 170304, Lodz, Poland|KO-MED Centra Kliniczne Sp. zo /ID# 127219, Pulawy, Poland|NZOZ Vivamed /ID# 127218, Warsaw, Poland|Institutul Clinic Fundeni /ID# 127839, Sector 2, Bucuresti, Romania|CMDTA Neomed SRL /ID# 127142, Brasov, Romania|Spitalul Clinic Judetean de Urgenta /ID# 125418, Cluj, Romania|Tvm Med Serv Srl /Id# 127221, Cluj, Romania|Cabinet Medical Dr. Fratila SR /ID# 127002, Oradea, Romania|Salvo-San-Ciobanca SRL /ID# 127140, Zalau, Romania|Lama Medical Care /ID# 127222, Bratislava, Slovakia|Gastroenterologicka Ambulancia /ID# 125632, Bratislava, Slovakia|Nemocnica s poliklinikou Lucenec /ID# 127322, Lucenec, Slovakia|Hospital General Univ Alicante /ID# 129261, Alicante, Spain|Hospital Clinic de Barcelona /ID# 138147, Barcelona, Spain|Hospital Arquitecto Marcide /ID# 127840, Ferrol, Spain|Hospital Univ Dr. Negrin /ID# 127841, Las Palmas de Gran Canaria, Spain|Hospital Univ de la Princesa /ID# 135828, Madrid, Spain|Hospital General Universitario Gregorio Maranon /ID# 127224, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 129257, Madrid, Spain|Hospital Universitario La Paz /ID# 127223, Madrid, Spain|Hosp Clin Univ de Valencia /ID# 170306, Valencia, Spain|Hosp Clin Univ Lozano Blesa /ID# 129255, Zaragoza, Spain|Kantonsspital St. Gallen /ID# 127843, St. Gallen, Sankt Gallen, Switzerland|University Hospital Zurich /ID# 127842, Zurich, Switzerland|SI Inst of Therapy AMS of UA /ID# 127231, Kharkiv, Kharkivska Oblast, Ukraine|Kherson City Clinical Hospital /ID# 127233, Kherson, Ukraine|Municipal Clinical Hospital #8 /ID# 127235, Kiev, Ukraine|Lviv Municipal City Clinical /ID# 127232, Lviv, Ukraine|City Clinical Hospital #6 /ID# 127137, Zaporizhia, Ukraine|Royal Hampshire County Hosp /ID# 169250, Winchester, Hampshire, United Kingdom|Western General Hospital /ID# 204801, Edinburgh, United Kingdom|Northwick Park Hospital /ID# 127226, Harrow, United Kingdom|Hull and East Yorkshire NHS /ID# 127225, Hull, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 127139, Norwich, United Kingdom|John Radcliffe Hospital /ID# 129324, Oxford, United Kingdom|Southampton General Hospital /ID# 127228, Southampton, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 127227, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02065622"
361,"NCT02065570","Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease",,"Active, not recruiting","No Results Available","Crohn's Disease","Drug: Adalimumab","Proportion of participants who achieve clinical remission|Proportion of participants who achieve endoscopic response|Proportion of participants with sustained clinical remission|Change in fecal calprotectin level|Proportion of participants who achieve clinical remission and endoscopic response.|Proportion of participants with clinical remission|Proportion of participants who discontinued corticosteroid use and achieved clinical remission|Proportion of participants with endoscopic remission|Proportion of participants with hs-CRP<5 mg/L and fecal calprotectin <250 microgram/gram|Proportion of participants with clinical remission, hs-C Reactive Protein (CRP)<5 mg/L and fecal calprotectin <250 microgram/gram|Proportion of participants with clinical remission, hs-CRP<5 mg/L and fecal calprotectin<250 microgram/gram and endoscopic remission|Proportion of participants who achieve an SES-CD <=2|Proportion of participants with clinical response|Proportion of participants achieving response in Inflammatory Bowel Disease Questionnaire (IBDQ) Bowel Symptom domain|Proportion of participants achieving response in IBDQ fatigue item","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","514","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-115|2013-001746-33","April 9, 2014","February 3, 2020","February 3, 2020","February 19, 2014",,"February 18, 2019","Birmingham Gastroenterology /ID# 137282, Birmingham, Alabama, United States|Digestive Health Specialists of the Southeast /ID# 122483, Dothan, Alabama, United States|Ucsd /Id# 119053, La Jolla, California, United States|Axis Clinical Trials /ID# 130390, Los Angeles, California, United States|Rocky Mountain Clinical Resear /ID# 119038, Wheat Ridge, Colorado, United States|Medical Research Ctr CT /ID# 119037, Hamden, Connecticut, United States|Gastroenterology Group Naples /ID# 122493, Naples, Florida, United States|Internal Med Specialists /ID# 137737, Orlando, Florida, United States|Shafran Gastroenterology Ctr /ID# 119057, Winter Park, Florida, United States|Emory University Hospital /ID# 136851, Atlanta, Georgia, United States|Atlanta Gastro Assoc /ID# 119065, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 119056, Macon, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 119043, Chicago, Illinois, United States|University of Chicago /ID# 119077, Chicago, Illinois, United States|Carle Cancer Center /ID# 136008, Urbana, Illinois, United States|Louisiana Research Ctr. LLC /ID# 136749, Shreveport, Louisiana, United States|Digestive Disorders Associates /ID# 119033, Annapolis, Maryland, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 119042, Chevy Chase, Maryland, United States|Commonwealth Clinical Studies /ID# 136850, Brockton, Massachusetts, United States|University of Michigan Hospitals /ID# 119076, Ann Arbor, Michigan, United States|Minnesota Gastroenterology, P. A. /ID# 137280, Plymouth, Minnesota, United States|Mayo Clinic - Rochester /ID# 122489, Rochester, Minnesota, United States|Kansas City Research Institute /ID# 119034, Kansas City, Missouri, United States|Ctr for Digest and Liver Dis /ID# 119040, Mexico, Missouri, United States|Albany Medical College /ID# 140200, Albany, New York, United States|NYU Langone Long Island CRA /ID# 119035, Great Neck, New York, United States|Icahn School of Med Mt. Sinai /ID# 127116, New York, New York, United States|Charlotte Gastro Hepatology /ID# 119041, Charlotte, North Carolina, United States|Wake Research Associates, LLC /ID# 119029, Raleigh, North Carolina, United States|Consultants for Clinical Res /ID# 119052, Cincinnati, Ohio, United States|Gastro United of Tulsa /ID# 122485, Tulsa, Oklahoma, United States|The Oregon Clinic- Gastro West /ID# 135272, Portland, Oregon, United States|West Bay Clinical Research /ID# 138330, Warwick, Rhode Island, United States|Medical University of South Carolina /ID# 138122, Charleston, South Carolina, United States|Erlanger Institute for Clinica /ID# 129008, Chattanooga, Tennessee, United States|Gastro One /ID# 119068, Germantown, Tennessee, United States|Nashville Med Res Inst /ID# 119050, Nashville, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 125501, Nashville, Tennessee, United States|Austin Center for Clinical Res /ID# 125500, Austin, Texas, United States|TX Digestive Disease Consultan /ID# 138121, Dallas, Texas, United States|Baylor College of Medicine /ID# 137277, Houston, Texas, United States|Texas Digestive Disease Consul /ID# 137283, Southlake, Texas, United States|Advanced Research Institute /ID# 119048, Ogden, Utah, United States|University of Utah /ID# 119062, Salt Lake City, Utah, United States|Gastro Assoc of Tidewater /ID# 135897, Chesapeake, Virginia, United States|New River Valley Research Inst /ID# 127807, Christiansburg, Virginia, United States|WI Center for Advanced Res /ID# 119036, Milwaukee, Wisconsin, United States|Froedtert and Medical College /ID# 119081, Milwaukee, Wisconsin, United States|Medizinische Universität Wien /ID# 126279, Vienna, Wien, Austria|Medical University Innsbruck /ID# 126249, Innsbruck, Austria|Ordensklinikum Linz GmbH, Elisabethinen /ID# 126280, Linz, Austria|LKH Salzburg and Paracelsus /ID# 126248, Salzburg, Austria|KH der Barmherzigen Brueder /ID# 126270, St Veit An Der Glan, Austria|CHU de Liege /ID# 126241, Liège, Liege, Belgium|AZ Maria Middelares /ID# 126194, Ghent, Belgium|AZ Sint-Lucas /ID# 126242, Ghent, Belgium|UZ Leuven /ID# 126240, Leuven, Belgium|AZ-Delta /ID# 126195, Roeselare, Belgium|University of Calgary /ID# 119017, Calgary, Alberta, Canada|Zeidler Ledcor Centre /ID# 119022, Edmonton, Alberta, Canada|Winnipeg Regional Health Autho /ID# 119015, Winnipeg, Manitoba, Canada|Qe Ii Hsc /Id# 127115, Halifax, Nova Scotia, Canada|London Health Sciences Centre /ID# 119026, London, Ontario, Canada|Medicor Research Inc. /ID# 119024, Sudbury, Ontario, Canada|Toronto Digestive Disease Asso /ID# 119019, Vaughan, Ontario, Canada|McGill Univ HC /ID# 119025, Montreal, Quebec, Canada|Fakultni Nemocnice Olomouc /ID# 126264, Olomouc, Olomoucky Kraj, Czechia|Hospital Ceske Budejovice a.s. /ID# 126266, Ceske Budejovice, Czechia|Hepato-Gastroenterologie HK s.r.o. /ID# 126269, Hradec Kralove, Czechia|ISCARE I.V.F. a.s. /ID# 137977, Prague, Czechia|Masarykova Hospital /ID# 138331, Usti Nad Labem, Czechia|Herlev Hospital /ID# 127741, Herlev, Hovedstaden, Denmark|Regionhospital Silkeborg /ID# 126251, Silkeborg, Denmark|CHRU Lille - Hôpital Claude Huriez /ID# 127743, Lille CEDEX, Hauts-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 127742, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Amiens Picardie /ID# 126237, Amiens CEDEX 1, Somme, France|CHU de Grenoble - Albet Michal /ID# 126200, Grenoble, France|CHU de Nice /ID# 126238, Nice, France|Hopital Nord /ID# 134450, Saint Priest En Jarez, France|Hopital Rangueil /ID# 126239, Toulouse, France|Univ Hosp Schleswig-Holstein /ID# 126260, Kiel, Schleswig-Holstein, Germany|Charité Universitätsmedizin Campus Mitte /ID# 126196, Berlin, Germany|Mross, Berlin, DE /ID# 126257, Berlin, Germany|Israelitisches Krankenhaus /ID# 136549, Hamburg, Germany|Asklepios Westklinikum Hamburg /ID# 126275, Hamburg, Germany|Universitaetsklinikum Jena /ID# 126261, Jena, Germany|EUGASTRO GmbH /ID# 126259, Leipzig, Germany|Universitatsklinikum Magdeburg /ID# 126256, Magdeburg, Germany|Gastro Gemeinschaftspraxis /ID# 126274, Munster, Germany|Pecsi Tudomanyegyetem /ID# 137895, Pécs, Pecs, Hungary|Semmelweis Egyetem /ID# 137896, Budapest, Hungary|Magyar Elhizastudomanyi KKft. /ID# 126276, Budapest, Hungary|Szegedi Tudomanyegyetem /ID# 126263, Szeged, Hungary|Rabin Medical Center /ID# 126198, Petakh Tikva, Tel-Aviv, Israel|Soroka Medical Ctr /ID# 126243, Be'er Sheva, Israel|Hadassah University Hospital /ID# 126245, Jerusalem, Israel|Kaplan Medical Center /ID# 126246, Rehovot, Israel|Azienda Ospedaliera San Camillo Forlanini /ID# 127745, Rome, Lazio, Italy|AO Univ Policlinico Agostino G /ID# 127746, Rome, Lazio, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 126221, Milan, Lombardia, Italy|Istituto Clinico Humanitas /ID# 126226, Rozzano, Milano, Italy|Univ. degli Studi di Brescia /ID# 127744, Brescia, Italy|Azienda Ospedaliera di Padova /ID# 126267, Padua, Italy|IRCCS Casa Sollievo /ID# 129856, San Giovanni Rotondo, Italy|Academisch Medisch Centrum /ID# 126227, Amsterdam, Noord-Holland, Netherlands|Erasmus Medisch Centrum /ID# 126228, Rotterdam, Netherlands|Franciscus Gasthuis & Vlietland /ID# 127877, Rotterdam, Netherlands|Szpital Uniwersytecki Nr 2 im. dr J.Biziela w Bydgoszczy /ID# 126272, Bydgoszcz, Kujawsko-pomorskie, Poland|C.M. Szpital Swietej Rodziny /ID# 137974, Lodz, Lodzkie, Poland|Endoterapia PFG Sp. z.o.o. /ID# 126199, Warszawa, Mazowieckie, Poland|Centrum Medyczne Sw. Lukaza /ID# 126271, Czestochowa, Poland|KO-MED Centra Kliniczne Sp. zo /ID# 126278, Pulawy, Poland|NZOZ Vivamed /ID# 126255, Warsaw, Poland|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 137735, San Juan, Puerto Rico|Clinic Fundeni Institute /ID# 127747, Bucharest, Bucuresti, Romania|CMDTA Neomed SRL /ID# 126277, Brasov, Romania|Tvm Med Serv Srl /Id# 126268, Cluj, Romania|Cabinet Medical Dr. Fratila SR /ID# 126247, Oradea, Romania|Salvo-San-Ciobanca SRL /ID# 126224, Zalau, Romania|Lama Medical Care /ID# 126262, Bratislava, Slovakia|Gastroenterologicka Ambulancia /ID# 137964, Bratislava, Slovakia|Nemocnica s poliklinikou Lucenec /ID# 127748, Lucenec, Slovakia|Poliklinika Libris /ID# 126222, Nove Mesto Nad Vahom, Slovakia|Corporac Sanitaria Parc Tauli /ID# 138124, Sabadell, Barcelona, Spain|Hospital Clinic de Barcelona /ID# 127749, Barcelona, Spain|Hosp Univ Girona Josep Trueta /ID# 137976, Girona, Spain|Hospital de Leo /ID# 141675, Leon, Spain|Hospital Puerta de Hierro /ID# 140425, Madrid, Spain|Hospital Clin Univ San Carlos /ID# 126253, Madrid, Spain|Complejo Hosp Pontevedra /ID# 138126, Pontevedra, Spain|HCU Lozano Blesa /ID# 126252, Zaragoza, Spain|Kantonsspital St. Gallen /ID# 127750, St. Gallen, Sankt Gallen, Switzerland|University Hospital Zurich /ID# 127751, Zurich, Switzerland|SI Inst of Therapy AMS of UA /ID# 127753, Kharkiv, Kharkivska Oblast, Ukraine|Kherson City Clinical Hospital /ID# 127754, Kherson, Ukraine|Municipal Clinical Hospital #8 /ID# 126232, Kiev, Ukraine|Lviv Municipal City Clinical /ID# 126234, Lviv, Ukraine|City Clinical Hospital #6 /ID# 126236, Zaporizhia, Ukraine|Guy's and St Thomas' NHS Found /ID# 144366, London, London, City Of, United Kingdom|Hull and East Yorkshire NHS /ID# 126265, Hull, United Kingdom|Norfolk and Norwich Univ Hosp /ID# 126197, Norwich, United Kingdom|Southampton General Hospital /ID# 126225, Southampton, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 126201, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02065570"
362,"NCT02065557","Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis",,"Active, not recruiting","No Results Available","Ulcerative Colitis (UC)","Biological: Adalimumab","Percentage of participants who responded at Week 8 per PMS and achieve clinical remission|Percentage of participants who achieve clinical remission|Percentage of participants who achieve mucosal healing|Percentage of participants in Mayo clinical response in Week 8 responders|Percentage of participants who achieve Mayo clinical remission in Week 8 remitters|Percentage of participants receiving corticosteroid at Baseline who have discontinued corticosteroid prior to Week 52 and are in Mayo clinical remission in Week 8 responders","AbbVie","All","4 Years to 17 Years   (Child)","Phase 3","101","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-290|2013-003032-77","October 13, 2014","February 7, 2020","February 7, 2020","February 19, 2014",,"January 18, 2020","Childrens Hospital LA /ID# 147452, Los Angeles, California, United States|Univ California, San Francisco /ID# 120901, San Francisco, California, United States|Arnold Palmer Hosp Children /ID# 120898, Orlando, Florida, United States|Emory University Hospital /ID# 121858, Atlanta, Georgia, United States|Children's Ctr Digestive, US /ID# 121855, Atlanta, Georgia, United States|University of Chicago /ID# 120904, Chicago, Illinois, United States|Loyola University Medical Ctr /ID# 120900, Maywood, Illinois, United States|Indiana University /ID# 120908, Indianapolis, Indiana, United States|Massachusetts General Hospital /ID# 124551, Boston, Massachusetts, United States|Boston Childrens Hospital /ID# 147714, Boston, Massachusetts, United States|Mayo Clinic - Rochester /ID# 121056, Rochester, Minnesota, United States|Minnesota Gastroenterology P.A /ID# 120895, Saint Paul, Minnesota, United States|Goryeb Chidlren's Hospital /ID# 121860, Morristown, New Jersey, United States|North Shore University Hospital /ID# 120905, New Hyde Park, New York, United States|Univ Rochester Med Ctr /ID# 127776, Rochester, New York, United States|Multicare Institute for Research and Innovation /ID# 147716, Tacoma, Washington, United States|Womens and Childrens Hospital /ID# 127538, Adelaide, South Australia, Australia|Medizinische Universität Wien /ID# 120802, Vienna, Wien, Austria|LKH Salzburg and Paracelsus /ID# 123457, Salzburg, Austria|UZ Brussel /ID# 120798, Jette, Bruxelles-Capitale, Belgium|Cliniques Universitaires Saint Luc /ID# 120797, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Hosp Univ Enfants Reine Fabiol /ID# 120795, Brussels, Belgium|London Health Sciences Centre /ID# 127777, London, Ontario, Canada|Palacky University /ID# 131388, Olomouc, Czechia|Univ Hosp, Plzen, CZ /ID# 120813, Plzen, Czechia|Petz Aladar Megyei Oktato Korh /ID# 124323, Gyor, Hungary|Balassa Janos County Hospital /ID# 128474, Szekszard, Hungary|Soroka Medical Ctr /ID# 147338, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 147791, Be'er Ya'akov, Israel|Rambam Health Care Campus /ID# 120827, Haifa, Israel|Shaare Zedek Medical Center /ID# 120830, Jerusalem, Israel|Schneider Childrens Med Ctr /ID# 120821, Petah Tikva, Israel|Sheba Medical Center /ID# 124324, Ramat Gan, Israel|Kaplan Medical Center /ID# 150245, Rehovot, Israel|Kurume University Hospital /ID# 125476, Kurume-shi, Fukuoka, Japan|Gunma University Hospital /ID# 126345, Maebashi-shi, Gunma, Japan|Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 124482, Sapporo-shi, Hokkaido, Japan|The Hospital of Hyogo College of Medicine /ID# 131665, Nishinomiya-shi, Hyogo, Japan|Saiseikai Yokohamashi Tobu /ID# 124486, Yokohama-shi, Kanagawa, Japan|Yokohama City Univ Medical Ctr /ID# 147763, Yokohama, Kanagawa, Japan|Miyagi Children's Hospital /ID# 125475, Sendai-shi, Miyagi, Japan|Saitama Children's Medical Center /ID# 124485, Saitama-shi, Saitama, Japan|Juntendo University Hospital /ID# 124536, Bunkyo-ku, Tokyo, Japan|National Center for Child Health and Development /ID# 125203, Setagaya-ku, Tokyo, Japan|Osaka General Medical Center /ID# 124535, Osaka, Japan|Canterbury District Health Boa /ID# 120837, Christchurch, New Zealand|Polish Mothers Memorial Hosp /ID# 148497, Lodz, Lodzkie, Poland|Uni Szpital Dzieciecy w Krakowie /ID# 120915, Cracow, Malopolskie, Poland|Centrum Zdrowia MDM /ID# 120910, Warsaw, Mazowieckie, Poland|Gabinet Lekarski Bartosz Korcz /ID# 120916, Rzeszow, Poland|Samodzielny Publiczny Szpital /ID# 120839, Wroclaw, Poland|Univerzitna nemocnica Martin /ID# 120844, Martin, Zilinsky Kraj, Slovakia|FN s poliklinikou F.D. Rooseve /ID# 120847, Banska Bystrica, Slovakia|Univerzitna Nemocnica Bratislava /ID# 120842, Bratislava, Slovakia|Hospital Univ Vall d'Hebron /ID# 120856, Barcelona, Spain|Hosp Infantil Univ Nino Jesus /ID# 121862, Madrid, Spain|The Royal London Hospital /ID# 120861, London, London, City Of, United Kingdom|The Royal Free Hospital /ID# 123142, London, London, City Of, United Kingdom|Royal Hosp for Sick Children /ID# 120864, Glasgow, United Kingdom|Manchester Royal Infirmary, Ma /ID# 120862, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02065557"
363,"NCT02052362","Bioavailability of ABT-450 and ABT-267 With Ritonavir",,"Completed","No Results Available","Absolute Bioavailability","Drug: ABT-450/r/ABT-267","Absolute bioavailability|Safety Labs|Electrocardiograms (ECGs)|Number of participants with adverse events|Physical Exam","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","M14-229|2013-003685-14","January 2014","February 2014","February 2014","February 3, 2014",,"February 19, 2014","Site Reference ID/Investigator# 118615, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02052362"
364,"NCT02052349","Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects",,"Completed","No Results Available","Relative Bioavailability","Drug: ABT-333","ABT-333 drug concentrations|Physical Exam|Electrocardiograms (ECGs)|Safety Labs|Number of participants with Adverse Events|Relative bioavailability","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","M14-108|2013-003161-34","November 2013","December 2013","December 2013","February 3, 2014",,"February 3, 2014","Site Reference ID/Investigator# 118435, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02052349"
365,"NCT02049138","An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects",,"Active, not recruiting","No Results Available","Rheumatoid Arthritis","Drug: ABT-494","Change in Work Instability Scale - Rheumatoid Arthritis (RA-WIS)|Change in EQ-5D|ACR 70 Response Rate|Change in Health Assessment Questionnaire Disability Index|Change in High-Sensitivity C-Reactive Protein (hsCRP)|Change in Patient's Global Assessment of Disease Activity|Change in DAS28 [CRP]|Change in Patient's Assessment of Pain|Change in Swollen Joint Count|Change in CDAI|ACR 50 Response Rate|Proportion of subjects achieving Low Disease Activity|Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scale|American College Rheumatology (ACR) 20 Response Rate|Proportion of subjects achieving Clinical Remission|Change in Tender Joint Count|Change in Clinical Laboratory Data|Proportion of subjects with satisfactory humoral response to Prevnar 13|Change in geometric mean fold rise of anti-pneumococcal antibody levels","AbbVie","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","494","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-538|2013-003530-33","January 24, 2014","July 24, 2021","July 24, 2021","January 30, 2014",,"January 13, 2020","Rheum Assoc of North Alabama /ID# 135926, Huntsville, Alabama, United States|AZ Arthritis and Rheum Researc /ID# 135902, Phoenix, Arizona, United States|AZ Arthritis & Rheuma Research /ID# 135931, Phoenix, Arizona, United States|C.V. Mehta MD, Med Corporation /ID# 124092, Hemet, California, United States|Ucsd /Id# 128747, La Jolla, California, United States|Desert Medical Advances /ID# 135911, Palm Desert, California, United States|Orrin Troum, M.D. and Medical /ID# 135933, Santa Monica, California, United States|Robin K. Dore MD, Inc /ID# 135906, Tustin, California, United States|Inland Rheum Clin Trials Inc. /ID# 136716, Upland, California, United States|Desert Valley Medical Group /ID# 135932, Victorville, California, United States|Denver Arthritis Clinic /ID# 135901, Denver, Colorado, United States|New England Research Associates, LLC /ID# 124085, Bridgeport, Connecticut, United States|AARDS Research, Inc. /ID# 135910, Aventura, Florida, United States|RASF - Clinical Research /ID# 124082, Boca Raton, Florida, United States|Omega Research Consultants, LLC /ID# 124094, DeBary, Florida, United States|University of Florida /ID# 124087, Jacksonville, Florida, United States|Suncoast Research Group, LLC /ID# 137774, Miami, Florida, United States|Omega Research Consultants /ID# 137398, Orlando, Florida, United States|Millennium Research /ID# 135917, Ormond Beach, Florida, United States|Arthritis Center, Inc. /ID# 124090, Palm Harbor, Florida, United States|Integral Rheumatology & Immunology Specialists /ID# 140362, Plantation, Florida, United States|Lovelace Scientific Resources /ID# 128745, Venice, Florida, United States|North Georgia Rheumatology Grp /ID# 128746, Lawrenceville, Georgia, United States|Kansas City Internal Medicine /ID# 135916, Overland Park, Kansas, United States|PRN Professional Research Network of Kansas, LLC /ID# 124091, Wichita, Kansas, United States|Klein and Associates, MD., PA /ID# 124086, Hagerstown, Maryland, United States|The Center for Rheumatology & /ID# 124077, Wheaton, Maryland, United States|Clinical Pharmacology Study Gr /ID# 124079, Worcester, Massachusetts, United States|June DO, PC /ID# 124081, Lansing, Michigan, United States|Summit Medical Group /ID# 124076, Clifton, New Jersey, United States|Arthritis and Osteoporosis /ID# 135907, Freehold, New Jersey, United States|Arthritis Rheumatic Back Disorder /ID# 135913, Voorhees, New Jersey, United States|Arthritis and Osteo Assoc /ID# 132280, Las Cruces, New Mexico, United States|DJL Clinical Research, PLLC /ID# 131936, Charlotte, North Carolina, United States|Cincinnati Rheumatic Disease Study Group, Inc. /ID# 135921, Cincinnati, Ohio, United States|STAT Research, Inc. /ID# 134906, Vandalia, Ohio, United States|Health Research Oklahoma /ID# 135904, Oklahoma City, Oklahoma, United States|East Penn Rheumatology Assoc /ID# 135920, Bethlehem, Pennsylvania, United States|Altoona Ctr Clinical Res /ID# 124089, Duncansville, Pennsylvania, United States|Emkey Arthritis and Osteo Clin /ID# 135908, Wyomissing, Pennsylvania, United States|Articularis Healthcare Group, Inc d/b/a Low Country Rheumatology /ID# 124080, Summerville, South Carolina, United States|Dr. Ramesh Gupta /ID# 128744, Memphis, Tennessee, United States|Austin Rheum. Research /ID# 124083, Austin, Texas, United States|Accurate Clinical Management /ID# 128751, Baytown, Texas, United States|Accurate Clinical Management /ID# 128752, Houston, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center /ID# 135905, Houston, Texas, United States|Houston Institute for Clin Res /ID# 135912, Houston, Texas, United States|Accurate Clinical Research /ID# 128753, Houston, Texas, United States|Accurate Clinical Research /ID# 128754, Houston, Texas, United States|SW Rheumatology Res. LLC /ID# 135927, Mesquite, Texas, United States|Mountain State Clinical Resear /ID# 124088, Clarksburg, West Virginia, United States|Aurora Rheumatology and Immunotherapy Center /ID# 135922, Franklin, Wisconsin, United States|Cliniques Universitaires Saint Luc /ID# 139348, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|ReumaClinic Genk-Hasselt /ID# 137775, Genk, Belgium|MHAT Trimontsium /ID# 135328, Plovdiv, Bulgaria|MHAT Kaspela /ID# 136212, Plovdiv, Bulgaria|UHMAT Palmed Plovdiv /ID# 135355, Plovdiv, Bulgaria|Diagnostic Consultative Center /ID# 136736, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 135678, Sofia, Bulgaria|UMHAT Sv. Ivan Rilski /ID# 136210, Sofia, Bulgaria|Diagnostic Consultative Center /ID# 136209, Varna, Bulgaria|Corp de Beneficencia Osorno /ID# 136189, Osorno, Chile|Quantum Research LTDA. /ID# 136188, Puerto Varas, Chile|L.K.N. Arthrocentrum, s.r.o /ID# 128782, Hlučín, Moravskoslezsky Kraj, Czechia|Revmatologicky ustav Praha /ID# 137937, Prague 2, Praha 2, Czechia|Nuselská poliklinika, Revmatologie /ID# 137776, Prague 4, Praha 4, Czechia|Revmatologie Bruntal, s.r.o /ID# 137782, Bruntál, Czechia|Artroscan s.r.o. /ID# 139347, Ostrava, Czechia|Orszagos Reumatologiai es Fizi /ID# 128785, Budapest, Hungary|Szent Margit Szakrendelo /ID# 136676, Budapest, Hungary|Qualiclinic Kft. /ID# 134170, Budapest, Hungary|Magyar Allamvasutak Korhaz /ID# 139971, Szolnok, Hungary|Veszprem Megyei Csolnoky Feren /ID# 128784, Veszprém, Hungary|Barzilai Medical Center /ID# 140199, Ashkelon, Israel|Sheba Medical Center /ID# 139295, Ramat Gan, Israel|LTD M+M Centers /ID# 132439, Adazi, Latvia|Arija's Ancane's Family Doctor /ID# 132437, Baldone, Latvia|Clinic ORTO /ID# 132438, Riga, Latvia|Clinstile, S.A. de C.V. /ID# 137075, Cuauhtemoc, Ciudad De Mexico, Mexico|Unidad de Investigacion de las Enfermedades Reumatologicas SA de CV /ID# 137307, Mexico City, Mexico|Cliditer SA de CV /ID# 136876, Mexico City, Mexico|Waikato Hospital /ID# 131908, Hamilton, Waikato, New Zealand|Porter Rheumatology Ltd /ID# 133983, Nelson, New Zealand|Timaru Medical Specialists Ltd /ID# 131909, Timaru, New Zealand|Pratia MCM Krakow /ID# 134749, Krakow, Malopolskie, Poland|NBR Polska /ID# 136208, Warsaw, Mazowieckie, Poland|Centrum Medyczne AMED /ID# 128835, Warsaw, Mazowieckie, Poland|Centrum Medyczne Pratia Warszawa /ID# 136650, Warsaw, Mazowieckie, Poland|Gabinet Internistyczno Reum. /ID# 135876, Białystok, Podlaskie, Poland|Centrum Medyczne Pratia Gdynia /ID# 137362, Gdynia, Pomorskie, Poland|Michal Bazela Higher-Med /ID# 138074, Elbląg, Warminsko-mazurskie, Poland|REUMED Filia nr 2 /ID# 128839, Lublin, Poland|NZOZ Lecznica MAK-MED s.c. /ID# 128838, Nadarzyn, Poland|Twoja Przychodnia Centrum Med /ID# 128840, Nowa Sól, Poland|Medicome sp. z o.o. /ID# 137397, Oswiecim, Poland|Prywatna Praktyka Lekarska /ID# 128837, Poznan, Poland|Reumatika - Centrum Reumatologii NZOZ /ID# 140198, Warsaw, Poland|Reum-Medica S.C. /ID# 128841, Wroclaw, Poland|Dr. Ramon L. Ortega-Colon, MD /ID# 128760, Carolina, Puerto Rico|GCM Medical Group /ID# 128759, San Juan, Puerto Rico|Mindful Medical Research /ID# 136211, San Juan, Puerto Rico|Kazan State Medical University /ID# 136734, Kazan, Tatarstan, Respublika, Russian Federation|Tver Regional Clinical Hosp. /ID# 137576, Tver, Tverskaya Oblast, Russian Federation|II Dzhan Research Center /ID# 136652, St. Petersburg, Russian Federation|MEDMAN s.r.o. /ID# 136649, Martin, Slovakia|Poliklinika Senica /ID# 134728, Senica, Slovakia|Panorama Medical Centre /ID# 138540, Cape Town, Western Cape, South Africa|Winelands Medical Research Ctr /ID# 134669, Stellenbosch, Western Cape, South Africa|Hospital Regional de Malaga /ID# 128847, Málaga, Malaga, Spain|Comple Hosp Univ de A Coruna /ID# 128846, A Coruna, Spain|Hospital CIMA Sanitas /ID# 128849, Barcelona, Spain|Hospital General Univ de Elche /ID# 128851, Elche, Spain|Hospital Clin Univ San Carlos /ID# 128852, Madrid, Spain|Hospital Infanta Sofia /ID# 136653, San Sebastián de Los Reyes, Spain|Clinica Gaias /ID# 133868, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena /ID# 128853, Sevilla, Spain|Hospital Infanta Luisa /ID# 135689, Sevilla, Spain|Hospital Universitario de Valm /ID# 134668, Sevilla, Spain|Kiev Municipal Clin Hosp 3 /ID# 137334, Kiev, Ukraine|NSC-Strazhesko Ist Cardiology /ID# 137330, Kiev, Ukraine|Whipps Cross Univ Hospital /ID# 135683, London, London, City Of, United Kingdom|West Suffolk Hospital /ID# 128858, Ipswich, United Kingdom|Chapel Allerton Hospital /ID# 141308, Leeds, United Kingdom|Warrington + Halton Hosp NHS /ID# 137514, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02049138"
366,"NCT02047110","BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)",,"Completed","Has Results","Ankylosing Spondylitis (AS)","Drug: placebo for risankizumab|Drug: risankizumab","Percentage of Patients Who Achieved Assessment of Spondyloarthritis International Society (ASAS) 40 Improvement Criteria at Week 12.|Change From Baseline to Week 12 in Disease Activity Assessed by the Ankylosing Spondylitis Disease Activity Score (ASDAS).|Percentage of Patients Who Achieved ASAS 5/6 Improvement Criteria at Week 12|Percentage of Patients Who Achieved Partial Remission According to the ASAS Criteria at Week 12|Percentage of Patients Who Achieved ASAS 20 Improvement Criteria at Week 12|Change From Baseline to Week 12 in Disease Activity Assessed by BASDAI|Percentage of Patients Who Achieved ASAS 40 Improvement Criteria at Week 24","AbbVie|Boehringer Ingelheim","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1311.8|2013-003666-13","January 28, 2014","March 5, 2015","July 25, 2016","January 28, 2014","May 31, 2019","May 31, 2019",,,"https://ClinicalTrials.gov/show/NCT02047110"
367,"NCT02033551","A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors",,"Completed","No Results Available","Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors","Drug: Veliparib|Drug: Carboplatin|Drug: Paclitaxel|Drug: FOLFIRI","Number of subjects with adverse events|Objective Response Rate (ORR)|Overall Survival (OS)|Time to Disease Progression (TTP)|Progression Free Survival (PFS)|Clinical Laboratory Tests|Electrocardiogram|Tumor Assessment","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","47","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-144|2013-003137-16","December 2013","September 2016","September 2016","January 13, 2014",,"September 27, 2016","Site Reference ID/Investigator# 117416, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 117415, San Antonio, Texas, United States|Site Reference ID/Investigator# 117337, Groningen, Netherlands|Site Reference ID/Investigator# 117338, Maastricht, Netherlands|Site Reference ID/Investigator# 117451, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02033551"
368,"NCT02032277","A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer",,"Active, not recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Cyclophosphamide|Drug: Placebo|Drug: Doxorubicin|Drug: Paclitaxel|Drug: Carboplatin|Drug: Veliparib","Pathological Complete Response (pCR).|Event Free Survival (EFS)|Rate of eligibility for breast conservation after therapy (BCR).|Overall Survival (OS)","AbbVie|German Breast Group|NSABP Foundation Inc|Grupo Español de Investigación del Cáncer de Mama|US Oncology Research|Alliance for Clinical Trials in Oncology","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","634","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-011|2013-002377-21","April 2, 2014","March 18, 2016","October 18, 2020","January 10, 2014",,"March 6, 2019","Scottsdale Healthcare /ID# 120473, Scottsdale, Arizona, United States|Mayo Clinic - Scottsdale /ID# 139932, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC-HOPE /ID# 126137, Tucson, Arizona, United States|Usc /Id# 123310, Los Angeles, California, United States|Pacific Cancer Care /ID# 120476, Salinas, California, United States|Sharp Memorial Hospital /ID# 119861, San Diego, California, United States|Stanford Univ School of Med /ID# 130316, Stanford, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 137275, West Hollywood, California, United States|Christiana Care Health Service /ID# 137823, Newark, Delaware, United States|Florida Cancer Specialists - Fort Myers /ID# 121835, Fort Myers, Florida, United States|Florida Cancer Specialists - Fort Myers /ID# 126379, Fort Myers, Florida, United States|Mayo Clinic /ID# 132349, Jacksonville, Florida, United States|Mount Sinai Comp Cancer Ctr /ID# 133008, Miami, Florida, United States|Miami Cancer Institute - Baptist Health South Florida /ID# 126145, Miami, Florida, United States|UF Health Cancer Center /ID# 141589, Orlando, Florida, United States|Moffitt Cancer Center /ID# 124063, Tampa, Florida, United States|University of Illinois - Chicago /ID# 134329, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine /ID# 133848, Chicago, Illinois, United States|University of Chicago /ID# 120467, Chicago, Illinois, United States|Loyola University Medical Ctr /ID# 120455, Maywood, Illinois, United States|OSF St. Anthony Medical Center /ID# 139424, Rockford, Illinois, United States|Indiana Univ School Medicine /ID# 118215, Indianapolis, Indiana, United States|Community Rgnal Cancer Care N /ID# 120456, Indianapolis, Indiana, United States|Horizon Oncology Research /ID# 116815, Lafayette, Indiana, United States|Cancer Center of Kansas /ID# 134720, Wichita, Kansas, United States|Univ Maryland School Medicine /ID# 119235, Baltimore, Maryland, United States|St. Joseph Mercy Hospital /ID# 135875, Ypsilanti, Michigan, United States|Minnesota Oncology Hematology, /ID# 126144, Minneapolis, Minnesota, United States|St. Lukes Cancer Institute /ID# 118775, Kansas City, Missouri, United States|Comprehensive Cancer Ctrs Neva /ID# 126136, Las Vegas, Nevada, United States|NH Oncology/Hematology, PA /ID# 131970, Hooksett, New Hampshire, United States|Rutgers Cancer Institute of NJ /ID# 120477, New Brunswick, New Jersey, United States|Columbia Univ Medical Center /ID# 141588, New York, New York, United States|Hope Womens Cancer Centers /ID# 119179, Asheville, North Carolina, United States|Univ NC Chapel Hill /ID# 132893, Chapel Hill, North Carolina, United States|Univ NC Chapel Hill /ID# 147695, Chapel Hill, North Carolina, United States|Novant Health Oncology Special /ID# 139890, Winston-Salem, North Carolina, United States|Sanford Roger Maris Cancer Cen /ID# 132394, Fargo, North Dakota, United States|Oncology Hematology Care, Inc - Blue Ash /ID# 120478, Cincinnati, Ohio, United States|University Hospitals Case Medical Center /ID# 141691, Cleveland, Ohio, United States|Fairview Hospital /ID# 141626, Cleveland, Ohio, United States|Cleveland Clinic Foundation /ID# 126378, Cleveland, Ohio, United States|The Ohio State University - Columbus /ID# 141587, Columbus, Ohio, United States|Lehigh Valley Health Network /ID# 133372, Allentown, Pennsylvania, United States|Guthrie Medical Group, PC /ID# 124397, Sayre, Pennsylvania, United States|Women and Infants Hospital /ID# 123476, Providence, Rhode Island, United States|Avera Cancer Institute /ID# 120466, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC /ID# 124566, Nashville, Tennessee, United States|Texas Oncology - Bedford /ID# 126135, Bedford, Texas, United States|Texas Oncology - Dallas /ID# 126140, Dallas, Texas, United States|Texas Oncology - Dallas /ID# 126141, Dallas, Texas, United States|UT Southwestern Medical Center /ID# 133849, Dallas, Texas, United States|The Ctr for Cancer and Blood D /ID# 120479, Fort Worth, Texas, United States|Texas Oncology - Memorial City /ID# 126139, Houston, Texas, United States|Texas Oncology - Plano East /ID# 126143, Plano, Texas, United States|Texas Oncology - Tyler /ID# 126142, Tyler, Texas, United States|University of Utah /ID# 118677, Salt Lake City, Utah, United States|University of Virginia /ID# 122975, Charlottesville, Virginia, United States|Virginia Commonwealth Univ /ID# 141586, Richmond, Virginia, United States|Virginia Oncology Associates /ID# 127260, Virginia Beach, Virginia, United States|Univ of Wisconsin Hosp/Clinics /ID# 120457, Madison, Wisconsin, United States|The Tweed Hospital /ID# 120235, Tweed Heads, New South Wales, Australia|Cabrini Health /ID# 120236, Malvern, Victoria, Australia|Royal Melbourne Hospital /ID# 127717, Parkville, Victoria, Australia|Western Health Sunshine Hosp. /ID# 120715, St. Albans, Victoria, Australia|Fiona Stanley Hospital /ID# 120716, Murdoch, Western Australia, Australia|St. John of God Hosp - Murdoch /ID# 131788, Murdoch, Western Australia, Australia|St. John of God Subiaco Hosp /ID# 120717, Subiaco, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 120719, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 116678, Charleroi, Hainaut, Belgium|CHU Brugmann /ID# 120376, Brussels, Belgium|UZ Antwerp /ID# 120720, Edegem, Belgium|AZ Groeninge /ID# 120718, Kortrijk, Belgium|CHU UCL Namur /ID# 116677, Namur, Belgium|Sunnybrook Health Sciences Ctr /ID# 123312, Toronto, Ontario, Canada|Jewish General Hospital /ID# 141629, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 141694, Montréal, Quebec, Canada|CHUQ-Hospital St. Sacrement /ID# 141619, Quebec City, Quebec, Canada|Fakultni Nemocnice Olomouc /ID# 120725, Olomouc, Olomoucky Kraj, Czechia|Masarykuv onkologikcy ustav /ID# 120726, Brno, Czechia|FN Hradec Kralove /ID# 120596, Hradec Kralove, Czechia|Hopital Universitaire Purpan /ID# 120731, Toulouse, Haute-Garonne, France|Centre Oscar Lambret /ID# 119958, Lille, Hauts-de-France, France|Institut Curie /ID# 116679, Paris CEDEX 05, Ile-de-France, France|Centre Leon Berard /ID# 120740, Lyon CEDEX 08, Rhone, France|Jean Perrin Centre /ID# 125277, Clermont Ferrand, France|Hosp European, Georges Pompid /ID# 120736, Paris, France|Hopital Rene Huguenin /ID# 120729, Saint-cloud, France|Univ Hosp Schleswig-Holstein /ID# 133454, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 133453, Ulm, Thueringen, Germany|Drs. Brudler, Heinrich und Ban /ID# 133472, Augsburg, Germany|Helios Klinikum Berlin Buch /ID# 133465, Berlin, Germany|Studiengesellschaft Onk Bielef /ID# 133471, Bielefeld, Germany|Klinikum Bremen Mitte gGmbH /ID# 132875, Bremen, Germany|St. Johannes Hospital /ID# 133478, Dortmund, Germany|Kliniken Esslingen /ID# 133475, Esslingen, Germany|Klinikum Frankfurt Hoechst /ID# 145301, Frankfurt, Germany|Wilke/Wagner/Petzoldt, Fuerth /ID# 133481, Fürth, Germany|Evangelisches Krankenhaus /ID# 133457, Gelsenkirchen, Germany|Elisabeth Krankenhaus /ID# 133461, Kassel, Germany|St. Vincenz Krankenhaus /ID# 133466, Limburg, Germany|Onk Zentrum am Rotkreuz /ID# 133482, Munich, Germany|Klinikum recht der Isar der TU /ID# 133449, Munich, Germany|Sana Klinikum Offenbach /ID# 133455, Offenbach, Germany|Leopoldina-Krankenhaus /ID# 133484, Schweinfurt, Germany|Johanniter-Krankenhaus Genthin /ID# 133463, Stendal, Germany|St. Josefs-Hospital /ID# 133464, Wiesbaden, Germany|Marienhospital Witten /ID# 133470, Witten, Germany|National Institute of Oncology /ID# 120828, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont /ID# 120834, Budapest, Hungary|Uzsoki Utcai Korhaz /ID# 120825, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 116681, Debrecen, Hungary|Petz Aladar Megyei Oktato Korh /ID# 120835, Gyor, Hungary|Bacs-Kiskun Megyei Korhaz /ID# 120833, Kecskemét, Hungary|BAZ Megyei E.O. Korhaz /ID# 122215, Miskolc, Hungary|Szegedi Tudomanyegyetem /ID# 120823, Szeged, Hungary|Jasz-Nagykun-Szolnok Megyei /ID# 120818, Szolnok, Hungary|A.O.U. Policlinico S.Orsola-Malpighi /ID# 122855, Bologna, Emilia-Romagna, Italy|Misericordia General Hospital /ID# 119536, Grosseto, Italy|IRCCS-I.R.S.T. srl Meldola /ID# 120255, Meldola, Italy|Istituto Europeo di Oncologia /ID# 120845, Milan, Italy|IRCCS Fondazione Salva Maugeri /ID# 120848, Pavia, Italy|National Cancer Center /ID# 119525, Goyang, Gyeonggido, Korea, Republic of|Ajou University Hospital /ID# 118856, Suwon-si, Gyeonggido, Korea, Republic of|Kyungpook National University Chilgok Hospital /ID# 118855, Daegu, Seoul Teugbyeolsi, Korea, Republic of|Severance Hospital /ID# 116699, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 119276, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Korea University Anam Hospital /ID# 118857, Seoul, Korea, Republic of|Seoul National University Hospital /ID# 116698, Seoul, Korea, Republic of|Asan Medical Center /ID# 116696, Seoul, Korea, Republic of|Vrije Universiteit Medisch Centrum /ID# 126302, Amsterdam, Netherlands|NN Blokhin Russian Cancer /ID# 120944, Moscow, Moskva, Russian Federation|Kursk Regional Oncology Dispen /ID# 116688, Kursk, Tatarstan, Respublika, Russian Federation|archangel Clinical Oncology /ID# 120935, Arkhangelsk, Russian Federation|Medical Radiological Res Ctr /ID# 124017, Obninsk, Russian Federation|Pyatigorsk Oncology Dispensary /ID# 120945, Pyatigorsk, Russian Federation|Leningrad Reg Onc Dispensery /ID# 120938, St. Petersburg, Russian Federation|Birch A Healthcare /ID# 116695, St. Petersburg, Russian Federation|Comple Hosp Univ de A Coruna /ID# 135108, A Coruna, Spain|Hospital General Univ Alicante /ID# 135115, Alicante, Spain|Hospital Parc de Salut del Mar /ID# 135110, Barcelona, Spain|Hosp Santa Creu i Sant Pau /ID# 145400, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 135112, Barcelona, Spain|Hospital Universitario Arnau de Vilanova de Lleida /ID# 120979, Lleida, Spain|Hospital Univ Ramon y Cajal /ID# 135113, Madrid, Spain|Hospital Clin Univ San Carlos /ID# 119959, Madrid, Spain|Hosp Univ Virgen del Rocio /ID# 135114, Sevilla, Spain|Fundacion Inst Valenciano Onc /ID# 135116, Valencia, Spain|Hosp Clin Univ de Valencia /ID# 123076, Valencia, Spain|Hospital General Universitario de Valencia /ID# 135111, Valencia, Spain|Hospital Univ Miguel Servet /ID# 119195, Zaragoza, Spain|National Taiwan Univ Hosp /ID# 122895, Taipei City, Taipei, Taiwan|Changhua Christian Hospital /ID# 119085, Changhua County, Taiwan|Chi Mei Hospital - Liouying /ID# 120982, Tainan City, Taiwan|Univ Hosp Bristol NHS Foundati /ID# 120989, Bristol, United Kingdom|Charing Cross Hospital /ID# 120990, London, United Kingdom|Nottingham Univ Hospitals NHS /ID# 122218, Nottingham, United Kingdom|Royal Stoke Univ Hospital /ID# 120984, Stoke on Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02032277"
369,"NCT02031276","Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.",,"Completed","Has Results","Crohn Disease","Drug: risankizumab IV|Drug: risankizumab SC|Drug: Placebo","Percentage of Participants Achieving Clinical Disease Activity Index (CDAI) Clinical Remission at Week 12|Percentage of Participants Achieving CDAI Clinical Response at Week 12|Percentage of Participants Achieving Crohn's Disease Endoscopic Index of Severity (CDEIS) Remission at Week 12|Percentage of Participants Achieving CDEIS Response at Week 12|Percentage of Participants Achieving Mucosal Healing at Week 12|Percentage of Participants Achieving Deep Remission at Week 12","AbbVie|Boehringer Ingelheim","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M15-993|2013-002902-29|1311.6","February 2014","December 2015","November 2016","January 9, 2014","November 23, 2018","November 23, 2018",,,"https://ClinicalTrials.gov/show/NCT02031276"
370,"NCT02028169","To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)",,"Completed","Has Results","Psoriatic Arthritis|Work Productivity",,"Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) Up to Month 9|WPAI Questionnaire: Mean Percentage of Impairment While Working Due to PsA (Presenteeism) Up to Month 9|WPAI Questionnaire: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to PsA Up to Month 9|WPAI Questionnaire: Mean Percentage of Activity Impairment Due to PsA Up to Month 9|Health Assessment Questionnaire Disability Index (HAQ-DI) Score Up to Month 9|Percentage of Participants With American College of Rheumatology 20%, 50%, 70% (ACR20, ACR50, ACR70) Response at Month 9|Disease Activity Score (DAS 28) Up to Month 9|Maastricht Ankylosing Spondylitis Enthesitis Scale (MASES) Up to Month 9|Dactylitis Score Up to Month 9|Number of Swollen Joints Up to Month 9|Number of Tender Joints Up to Month 9|Levels of Rheumatoid Factor|Erythrocyte Sedimentation Rate (ESR) Up to Month 9|C-reactive Protein (CRP) Up to Month 9|Participant's Global Assessment of Disease Activity Visual Analog Scale (VAS) Up to Month 9|Physician's Global Assessment of Disease Activity VAS Up to Month 9|Participant's Assessment of Nocturnal Back Pain and Fatigue VAS Up to Month 9|Participant's Assessment of Total Back Pain VAS Up to Month 9|Participant's Assessment of Pain and Fatigue VAS Up to Month 9|Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Treatment-Related Adverse Events (AEs) Up to Month 9","AbbVie","All","18 Years to 90 Years   (Adult, Older Adult)",,"120","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","P13-518","January 2014","April 2016","April 2016","January 7, 2014","April 27, 2017","April 27, 2017",,,"https://ClinicalTrials.gov/show/NCT02028169"
371,"NCT02023112","Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection","GIFT-II","Completed","Has Results","Hepatitis C Virus","Drug: ABT-450/r/ABT-267|Drug: Ribavirin","Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period|Percentage of Participants With Post-treatment Relapse|Percentage of Participants With SVR12 Weeks Post-treatment for Each Treatment Arm Within Different Subpopulations|Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period for Each Treatment Arm Within Different Subpopulations|Percentage of Participants With Post-treatment Relapse Within Different Subpopulations","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-153","January 2014","April 2015","September 2015","December 30, 2013","May 13, 2016","October 24, 2016",,,"https://ClinicalTrials.gov/show/NCT02023112"
372,"NCT02023099","Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","GIFT I","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267|Drug: Placebo","Percentage of Non-cirrhotic Treatment-Naïve Participants Who Are Eligible for Interferon (IFN)-Based Therapy and Who Have High Viral Load in the DB Active Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants in the Active Treatment Group With On-treatment Virologic Failure During Treatment|Percentage of Participants in the Substudy 1 Arm A Active Treatment Group With On-treatment Virologic Failure During Treatment, by Subpopulation|Percentage of Participants in the Active Treatment Group With Post-treatment Relapse|Percentage of Participants in Substudy 1 Arm A Active Treatment Group With Post-treatment Relapse, by Subpopulation|Percentage of Participants in the Active Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants in Substudy 1 Arm A Active Treatment Group With Sustained Virologic Response 12 Weeks Post-Treatment, by Subpopulation","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-004","December 2013","October 2014","October 2015","December 30, 2013","November 26, 2015","June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT02023099"
373,"NCT02016690","Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®",,"Completed","Has Results","Respiratory Syncytial Virus Infection",,"Number of Participants With Adverse Events|Number of Participants With Serious Adverse Events|Number of Participants With Adverse Drug Reactions|Change in Lower Respiratory Tract Infection (LRI) Score During the Study|Number of Participants Hospitalized Due to Respiratory Syncytial Virus (RSV) Infection|Mean Hospitalization Length Due to Respiratory Syncytial Virus (RSV) Infection|Number of Hospitalized Participants Requiring Respiratory Support|Mean Duration of Respiratory Support","AbbVie","All","up to 24 Months   (Child)",,"312","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-296","December 2013","December 2015","December 2015","December 20, 2013","February 8, 2017","March 20, 2017",,,"https://ClinicalTrials.gov/show/NCT02016690"
374,"NCT02016482","A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis",,"Completed","Has Results","Nail Psoriasis|Plaque Psoriasis","Biological: Adalimumab|Other: Placebo","Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26|For United States (US) Regulatory Purposes: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of ""Clear"" or ""Minimal"" at Week 26|Percent Change From Baseline in Total Fingernail Nail Psoriasis Severity Index (NAPSI) Score at Week 26|Percentage of Participants Achieving Total Fingernail mNAPSI Score of 0 at Week 26|Percent Change From Baseline in Nail Psoriasis Pain Numeric Rating Scale (NRS) at Week 26|Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26|Percentage of Participants With at Least 50% Improvement in the Scalp Component of the Brigham Scalp Nail Inverse Palmo-Plantar Psoriasis Index (B-SNIPI) at Week 26|Percentage of Participants Achieving ""Clear"" or ""Minimal"" in Nail Bed Component of the PGA-F at Week 26|Percentage of Participants Achieving ""Clear"" or ""Minimal"" in Nail Matrix Component of the PGA-F At Week 26|Percentage of Participants Achieving Target Fingernail mNAPSI Score of 0 at Week 26|Percentage of Participants Achieving Target Fingernail mNAPSI Score of ≤ 2 at Week 26|Percentage of Participants Achieving Total Fingernail mNAPSI Score of ≤ 2 at Week 26|Change From Baseline in Target Fingernail mNAPSI Score at Week 26|Percent Change From Baseline in Target Fingernail mNAPSI Score at Week 26|Change From Baseline in Total Fingernail mNAPSI Score at Week 26|Percent Change From Baseline in Total Fingernail mNAPSI Score at Week 26|Percentage of Participants Achieving Total Fingernail NAPSI Score of 0 at Week 26|Percentage of Participants Achieving Target Fingernail NAPSI Score of 0 at Week 26|Change From Baseline in Target Fingernail NAPSI Score at Week 26|Percent Change From Baseline in Target Fingernail NAPSI Score at Week 26|Change From Baseline in Total Fingernail NAPSI Score at Week 26|Change From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 26|Percent Change From Baseline in PASI Score at Week 26|Percentage of Participants Achieving PASI 75/50/90/100 Responses at Week 26|Percentage of Participants Achieving Physician's Global Assessment of Skin Psoriasis (PGA-S) ""Clear"" or ""Minimal"" at Week 26|Percentage of Participants Achieving PGA-S of ""Clear"" at Week 26|Percentage of Participants Achieving 50% Improvement in the Inverse Psoriasis Component of the B-SNIPI at Week 26|Change From Baseline in Total Body Surface Area (BSA) at Week 26|Percent Change From Baseline in Total BSA at Week 26|Percent Change From Baseline in Nail Psoriasis Pain NRS at Week 26|Percent Change From Baseline in Nail Psoriasis Physical Functioning Severity Score at Week 26|Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPA QoL) at Week 26|Percent Change From Baseline in Nail Assessment in NAPPA QoL at Week 26|Change From Baseline in Dermatology Life Quality Index (DLQI) Score at Week 26|Percentage of Participants Achieving DLQI of 0 and 0/1 at Week 26|Change From Baseline in Work Productivity and Activity Impairment Nail Psoriasis (WPAI:NPSO) at Week 26|Change From Baseline in EuroQol-5 Dimensions-5 Levels (EQ-5D-5L) Health State Assessment at Week 26|Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 26|Change From Baseline in Hospital Anxiety Depression Scale (HADS) at Week 26|Percentage of Participants With a New Diagnosis of Psoriatic Arthritis (PsA) During the Study|Change From Baseline in Nail Psoriasis Quality of Life (Nail PsQoL) Score at Week 26","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","217","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-674|2013-003275-36","January 2014","October 2015","April 2016","December 20, 2013","February 13, 2017","May 30, 2017",,,"https://ClinicalTrials.gov/show/NCT02016482"
375,"NCT02015793","Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease",,"Completed","Has Results","Crohn's Disease","Biological: Adalimumab|Biological: Placebo for adalimumab","Mean Serum Adalimumab Concentration at Week 8|Number of Participants With Potentially Significant Hematology Parameters During Administration of Adalimumab|Number of Participants With Potentially Significant Clinical Chemistry Parameters During Administration of Adalimumab|Number of Participants With Potentially Significant Vital Signs Parameters During Administration of Adalimumab|Number of Participants With Adverse Events (AEs)|Percentage of Participants Who Achieved Clinical Remission (Crohn's Disease Activity Index [CDAI] < 150) Every 2 Weeks up to Week 26|Percentage of Participants Who Achieved Clinical Response (CDAI Decrease ≥ 70 From Week 0) Every 2 Weeks up to Week 26|CDAI: Mean Change From Baseline to Each Visit|High-sensitivity C-reactive Protein (hsCRP): Median Change From Baseline (Week 0) to Week 26|Fecal Calprotectin: Change From Baseline (Week 0) to Week 8","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M14-232","December 2013","February 2015","February 2015","December 19, 2013","May 13, 2016","May 30, 2018",,,"https://ClinicalTrials.gov/show/NCT02015793"
376,"NCT02009631","A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors",,"Completed","No Results Available","Breast Cancer|Ovarian Cancer|Colon Cancer|Lung Cancer|Gastric Cancer|Solid Tumors","Drug: Veliparib (ABT-888)|Drug: Placebo","To evaluate the effect of Veliparib on corrected QT interval calculated by Fridericia's formula (QTcF)|Pharmacokinetic sampling maximum observed plasma concentration (Cmax)|Pharmacokinetic sampling - time to maximum observed plasma concentration (Tmax)|Pharmacokinetic sampling - the area under the plasma concentration-time curve (AUC) from time 0-24 hours (AUC 0-24)|The number of subjects with adverse events|Vital Signs|Clinical Laboratory Tests|Tumor Assessment","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","M12-020|2013-002028-18","November 2013","December 2014","December 2014","December 12, 2013",,"November 20, 2017","Site Reference ID/Investigator# 116015, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 116016, San Antonio, Texas, United States|Site Reference ID/Investigator# 117320, Groningn, Netherlands|Site Reference ID/Investigator# 117336, Maastricht, Netherlands|Site Reference ID/Investigator# 117517, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02009631"
377,"NCT01995071","A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis","Drug: ABT-493|Drug: ABT-530|Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin (RBV)","Maximal Decrease From Baseline in log10 HCV RNA Levels During ABT-493 or ABT-530 Monotherapy Treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","89","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-595","November 2013","June 2015","June 2015","November 26, 2013","October 16, 2017","October 16, 2017",,,"https://ClinicalTrials.gov/show/NCT01995071"
378,"NCT01994837","A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)",,"Completed","Has Results","Acute Myelogenous Leukemia|AML|Acute Myeloid Leukemia","Drug: ABT-199","Objective Remission Rate|Complete Remission Rate|Duration of Remission|Time to Progression|Progression-free Survival|Overall Survival|Percentage of Participants Who Received Subsequent Stem Cell Transplant|Rate of Minimal Residual Disease (MRD) Negativity|Complete Remission With Incomplete Marrow Recovery (CRi) Rate|Complete Remission Rate and Complete Remission With Incomplete Marrow Recovery (CRi) Rate","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-212","November 2013","December 2014","December 2014","November 26, 2013","January 23, 2018","June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT01994837"
379,"NCT01969695","An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: ABT-199","Change in cardiac assessment findings|Percentage of subjects with adverse events|Change in clinical laboratory test results|Number of subjects with adverse events|Change in physical exam finding, including vital signs","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-835","December 20, 2013","December 16, 2019","December 16, 2019","October 25, 2013",,"December 19, 2019","University of Arizona Arthritis Center /ID# 101359, Tucson, Arizona, United States|Dartmouth-Hitchcock Med Ctr /ID# 92596, Lebanon, New Hampshire, United States|Hackensack Univ Med Ctr /ID# 101417, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01969695"
380,"NCT01969682","A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199",,"Withdrawn","No Results Available","Non-Hodgkin's Lymphoma","Drug: ABT-199|Drug: Rifampin","Determination of maximum observed plasma concentration (Cmax), time to Cmax (peak time, Tmax), terminal phase elimination rate constant (beta), terminal phase elimination half-life (t1/2), & area under the plasma concentration-time curve (AUC) of ABT-199|Number of subjects with adverse events|Percentage of subjects with adverse events|Change in physical exam finding, including vital signs|Change in clinical laboratory test results|Change in cardiac assessment findings","AbbVie|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M13-366","April 2014","May 2014","May 2014","October 25, 2013",,"May 26, 2014","Site Reference ID/Investigator# 101416, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01969682"
381,"NCT01969669","A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199",,"Completed","No Results Available","Non-Hodgkin's Lymphoma","Drug: ABT-199|Drug: Ketoconazole","Determination of maximum observed plasma concentration (Cmax), time to Cmax (peak time, Tmax), terminal phase elimination rate constant (beta), terminal phase elimination half-life (t1/2), & area under the plasma concentration-time curve (AUC) of ABT-199|Number of subjects with adverse events|Percentage of subjects with adverse events|Change in physical exam finding, including vital signs|Change in clinical laboratory test results|Change in cardiac assessment findings","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M13-364","December 2013","September 2014","September 2014","October 25, 2013",,"November 20, 2017","Site Reference ID/Investigator# 97498, Tucson, Arizona, United States|Site Reference ID/Investigator# 92593, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 101415, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01969669"
382,"NCT01960881","Evaluation of Diet and Exercise in Prostate Cancer Patients","CRONOS II","Active, not recruiting","No Results Available","Prostate Cancer",,"Changes in the patient quality of life (QoL) using the Medical Outcomes Study Short Form - 36 (SF-36)|Change in exercise duration|Change in dietary habits|Change in the patient quality of life (QoL) using the Medical Outcomes Study Short Form - 36 (SF-36)|Change in weight|Change in Body Mass Index (BMI)|Changes in the University of California Los Angeles Prostate Cancer Index (UCLA-PI)|Changes in the sexual function using the International Index of Erectile Function (IIEF-5)|Number of patients with Adverse Events|Changes in the patient's medical condition|Proportion of patients with castrate levels of testosterone and undetectable levels of Prostatic Specific Antigen (PSA) at 18 months of treatments.|Leuprolide Acetate Utilization|Changes in the Doctor-Patient communication (for patients enrolled prior to protocol amendment 2)|Caregiver Quality of Life (for patients enrolled under protocol amendment 1)|Assessment of Financial Burden on Patient's Family (for patients enrolled under protocol amendment 1)|Lupron Cares Patient Support Program","AbbVie|JSS Medical Research Inc.|CMX Research|Canadian Urology Research Consortium","Male","18 Years to 99 Years   (Adult, Older Adult)",,"1327","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-096","September 19, 2013","July 30, 2021","July 30, 2021","October 11, 2013",,"December 30, 2019","Exdeo Clinical Research Inc /ID# 116040, Abbotsford, British Columbia, Canada|Southern Interior Medical Res /ID# 116025, Kelowna, British Columbia, Canada|Dr. J. Paul Whelan, Inc. /ID# 120415, Victoria, British Columbia, Canada|Cancer Care Manitoba /ID# 135976, Winnipeg, Manitoba, Canada|Saint John Regional Hospital /ID# 141302, Saint John, New Brunswick, Canada|Qe Ii Hsc /Id# 118941, Halifax, Nova Scotia, Canada|The Male/Female Hlth and Res /ID# 116042, Barrie, Ontario, Canada|The Male/Female Hlth and Res /ID# 124295, Barrie, Ontario, Canada|Dr. Edward F. Woods Medical Co /ID# 120695, Belleville, Ontario, Canada|Jonathan Giddens Medicine /ID# 116023, Brampton, Ontario, Canada|Brantford Urology Research /ID# 116026, Brantford, Ontario, Canada|G. Kenneth Jansz Med Prof Corp /ID# 116024, Burlington, Ontario, Canada|William R. Love, Medicine, Professional Corporation /ID# 116035, Burlington, Ontario, Canada|Research St-Joseph's-Hamilton /ID# 163973, Hamilton, Ontario, Canada|Queen's University /ID# 137983, Kingston, Ontario, Canada|London Health Sciences Centre /ID# 118940, London, Ontario, Canada|DiCostanzo, Markham, CA /ID# 137272, Markham, Ontario, Canada|Mor Urology Inc /ID# 116027, Newmarket, Ontario, Canada|Stanley Flax Medical Prof Corp /ID# 116022, North York, Ontario, Canada|Fe/Male Health Centers /ID# 116020, Oakville, Ontario, Canada|The Ottawa Hospital /ID# 132329, Ottawa, Ontario, Canada|Dr. Sean Pierre Medicine /ID# 137986, Ottawa, Ontario, Canada|Kawartha Urology /ID# 116041, Peterborough, Ontario, Canada|The Medical Centre /ID# 128278, Peterborough, Ontario, Canada|Richmond Hill Urology /ID# 137270, Richmond Hill, Ontario, Canada|Dr. Peter Erdeljan Med Corp In /ID# 139641, Scarborough, Ontario, Canada|1837206 Ontario Inc. /Id# 116038, Scarborough, Ontario, Canada|Urology and Male Fertility /ID# 116043, Scarborough, Ontario, Canada|Northern Urology Centre /ID# 141391, Sudbury, Ontario, Canada|Sunnybrook Health Sciences Ctr /ID# 136597, Toronto, Ontario, Canada|Princess Margaret Cancer Centre /ID# 137984, Toronto, Ontario, Canada|Toronto Urology Clin Study Grp /ID# 116044, Toronto, Ontario, Canada|Bloor West Medical Centre /ID# 116021, Toronto, Ontario, Canada|Bloor West Medical Centre /ID# 134134, Toronto, Ontario, Canada|Clinique d'urologie /ID# 116019, Chicoutimi, Quebec, Canada|Hosp de Gatineau,CSSS Gatineau /ID# 131309, Gatineau, Quebec, Canada|CISSS de la Monteregie /ID# 116036, Greenfield Park, Quebec, Canada|CISSS de la Monteregie /ID# 124296, Greenfield Park, Quebec, Canada|CISSS de la Monteregie /ID# 134137, Greenfield Park, Quebec, Canada|Urolaval /ID# 116037, Laval, Quebec, Canada|Hopital Cite-de-la-Sante /ID# 130951, Laval, Quebec, Canada|McGill Univ HC /ID# 141503, Montreal, Quebec, Canada|Jewish General Hospital /ID# 120416, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 137271, Montréal, Quebec, Canada|Ultramed /ID# 116355, Pointe-claire, Quebec, Canada|CHUS Hopital Fleurimont /ID# 124275, Sherbrooke, Quebec, Canada|Groupe de recherche en urologi /ID# 116356, Trois-rivieres, Quebec, Canada|Ctr Sante et Services Sociaux /ID# 131230, Trois-rivières, Quebec, Canada|Clinique des specialites chiru /ID# 116039, Val D'or, Quebec, Canada|9120-1947 Quebec Inc. /ID# 129151, Westmount, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01960881"
383,"NCT01960855","A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy",,"Completed","Has Results","Rheumatoid Arthritis","Drug: ABT-494|Drug: Placebo","Number of Subjects Achieving American College of Rheumatology 20% (ACR20) Response at Week 12|Number of Subjects Achieving American College of Rheumatology 50% (ACR50) Response at Week 12|Number of Subjects Achieving American College of Rheumatology 70% (ACR70) Response at Week 12|Number of Subjects Achieving Low Disease Activity (LDA) Based on Disease Activity Score (DAS28) or Clinical Remission (CR) Based on (DAS28) at Week 12|Number of Subjects Achieving CR Based on DAS28 at Week 12","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","276","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-550|2013-002358-57","October 2013","July 2015","July 2015","October 11, 2013","June 27, 2018","June 27, 2018",,,"https://ClinicalTrials.gov/show/NCT01960855"
384,"NCT01960842","A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications",,"Completed","Has Results","Advanced Parkinson's Disease","Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube","Average Daily Normalized ""Off"" Time: Change From Baseline To The Final PEG-J Visit|Average Daily Normalized ""On"" Time Without Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit|Parkinson's Disease Questionnaire (PDQ-39) Summary Index: Change From Baseline To The Final PEG-J Visit|Clinical Global Impression - Change (CGI-I) Score at the Final PEG-J Visit|Patient Global Impression of Change (PGI-C) Score at the Final PEG-J Visit|Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score: Change From Baseline To The Final PEG-J Visit|Unified Parkinson's Disease Rating Scale (UPDRS) Part IIl Score: Change From Baseline To The Final PEG-J Visit|Average Daily Normalized ""On"" Time With Troublesome Dyskinesia: Change From Baseline To The Final PEG-J Visit|Parkinson's Disease Questionnaire (PDQ-39) Mobility, Emotional Well-Being, Stigma, Social Support, Cognition, Communication, and Bodily Discomfort Domain Scores: Change From Baseline To The Final PEG-J Visit|Unified Parkinson's Disease Rating Scale (UPDRS) Total Score: Change From Baseline To The Final PEG-J Visit|Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score: Change From Baseline To The Final PEG-J Visit|Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score: Change From Baseline To The Final PEG-J Visit|Average Daily Normalized ""Off"" Time Excluding Subjects Who Did Not Receive LCIG During the Entire PEG-J Period: Change From Baseline To The Final PEG-J Visit|Average Daily Normalized ""Off"" Time Including All PD Diaries Regardless if They Were Completed After the Subject Had Used a Concomitant Anti-Parkinsonian Medication: Change From Baseline To The Final PEG-J Visit|Average Daily Normalized ""Off"" Time at Baseline and Each Visit: Change From Baseline To The Final PEG-J Visit|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Potentially Clinically Significant Vital Sign Parameters|Number of Participants With Potentially Clinically Significant Values for Hematology Parameters|Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters|Number of Participants With Potentially Clinically Significant Values for 12-lead Electrocardiogram (ECG)","AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","31","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-921","October 2013","March 2015","March 2015","October 11, 2013","April 20, 2016","May 30, 2018",,,"https://ClinicalTrials.gov/show/NCT01960842"
385,"NCT01960790","Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)",,"Completed","Has Results","Behcet's Disease",,"Number of Participants With Adverse Drug Reactions|Global Assessment of Gastrointestinal Symptoms|Global Assessment of Gastrointestinal Symptoms of Behcet's Disease|Number of Participants With Cardinal Symptoms of Behcet's Disease|Number of Participants With Accessory Symptoms of Behcet's Disease|Number of Participants With Degree of Improvement of Endoscopic Findings|Changes in C-reactive Protein (CRP)","AbbVie","All","Child, Adult, Older Adult",,"473","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-152","May 25, 2013","May 15, 2017","May 15, 2017","October 11, 2013","March 22, 2019","March 22, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT01960790/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT01960790/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01960790"
386,"NCT01958827","A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease",,"Completed","Has Results","Crohn's Disease","Biological: Adalimumab","Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8|Percentage of Participants Who Achieved Clinical Remission (CDAI < 150) Every 4 Weeks up to Week 52|Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) Every 4 Weeks up to Week 52|Percentage of Participants Who Achieved Clinical Response 70 (CR70; Crohn's Disease Activity Index [CDAI] Decrease ≥ 70 From Week 0) Every 4 Weeks up to Week 52|Percentage of Participants Who Achieved Clinical Response 100 (CR100; Crohn's Disease Activity Index [CDAI] Decrease of 100 From Week 0) Every 4 Weeks up to Week 52|C-reactive Protein (CRP): Mean Change From Baseline (Week 0) to Week 52|Number of Participants With Potentially Significant Hematology Parameters|Number of Participants With Potentially Significant Clinical Chemistry Parameters|Systolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit|Diastolic Blood Pressure: Mean Change From Baseline (Week 0) to Each Visit|Heart Rate: Mean Change From Baseline (Week 0) to Each Visit|Body Temperature: Mean Change From Baseline (Week 0) to Each Visit|Number of Participants With Adverse Events (AEs)","AbbVie","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","28","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-687|2015-004121-13","September 2013","March 2015","October 2015","October 9, 2013","April 12, 2016","April 12, 2016",,,"https://ClinicalTrials.gov/show/NCT01958827"
387,"NCT01956032","Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources",,"Completed","Has Results","Parkinson's Disease",,"Median Time Used by Investigator, Duodopa Nurse Specialist, Telemedicine (TM) Technician, and Participant|Median Number of Contacts|Median Total Time for Titration|Median Total Free Time of Participant|Percentage of Participants Who Experienced Technical Events|Incidence of Technical Events Experienced by Participants|Percentage of Participants With Consequences|Incidence of Consequences Due to Technical Events|Percentage of Participants Who Experienced Technical Events, Summarized by Type of Consequence|Incidence of Technical Events Experienced by Participants, Summarized by Type of Consequence|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 1: How Satisfied Were You With Using TM When Starting Duodopa?|Positive Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 2: Did You do Things When at Home That You Could Not Have Done if You Were Hospitalized During the Titration?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 3: How Easy Was the TM Equipment to Use?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 4: How Satisfied Were You With the Video Conversation With Your Investigator?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 5: How Satisfied Were You With the Video Conversation With Your DNS?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 6: How Satisfied Were You With the 3-part Video Conversations (Both Investigator and DNS)?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 7: How Satisfied Were You With the Amount of Time the DNS Were at Your Home?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 8: How Satisfied Were You With Having the Technical Equipment in Your Home?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 9: How Satisfied Were You With the Technician's Visits to Set up and Dismantle the TM Equipment?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 10: How Confident do You Feel Regarding the Pump and the Dose Adjustments?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 11: How Secure Did You Feel Being at Home and Communicating by TM, When Titrating Duodopa?|Positive Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 12: Knowing What You Know Now, Would You Rather Have Stayed in the Hospital to Start Duodopa Treatment?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 13 for Caregiver: How Satisfied Were You With the Titration at the Participant's Home?|Positive Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 14 for Caregiver: Where You Able to Perform Daily Activities During the Titration Period?|Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 15 for Caregiver: How Confident Did You Feel About Helping With the Pump?|Positive Participant Experience of Duodopa Home Titration Using TM Assessed by Question Number 16 for Caregiver: Knowing What You Know Now, Would You Rather Have Had Your Spouse in the Hospital to Start Duodopa Treatment?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 1: How Satisfied Were You With the TM Concept Comports With Your Clinical Needs?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 2: How Satisfied Were You With Using TM for Communication?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 3: How Satisfied Were You With Using TM for Clinical Assessments?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 4: How Satisfied Were You With the Image Quality for Your Assessment of the Participant?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 5: How Satisfied Were You With the Sound Quality for Your Assessment of the Participant?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 6: How Satisfied Were You With the User Interphase for the TM Equipment?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 7: How Satisfied Were You With the Setup and Maintenance of the TM Equipment?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 8: How Satisfied Were You Regarding Participant Safety Using TM?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 9: How Satisfied Were You With the Participant Contact When Using TM?|Positive (Investigator and DNS) Experience of Duodopa Home Titration Using TM Assessed by Question Number 10: Did You Lack Any Dimensions in the Assessment of the Participant Using TM That You Have in the Classical Titration at Hospital?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 11: Compared to Classic Titration at Hospital - How Much Time Did You Spend on TM Communication Based on Real Communication Time for Participant Contact?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 12: Compared to Classic Titration at Hospital - How Much Time Did You Spend on TM Communication Based on Booked Communication Time for Participant Contact?|Investigator and DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 13: Compared to Classic Titration at Hospital - How Much Time Did You Spend on TM Communication Based on Time for Other Tasks Between Contacts?|DNS Experience of Duodopa Home Titration Using TM Assessed by Question Number 14: How Satisfied Were You With Replacing the Participant Home Visit With TM Communication?|Percentage of Participants With Clinical Global Impression - Improvement (CGI-I) in Parkinson's Disease Symptoms|Number of Participants With Health Care Utilization Outside the TM Care Chain, Summarized by Type of Health Care Provider|Number of Participants With Health Care Utilization Outside the TM Care Chain, Summarized by Type of Contact|Median Time Spent for Health Care Utilization Outside the TM Care Chain","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"15","Industry","Observational","Time Perspective: Prospective","P14-000","September 2013","November 2014","November 2014","October 8, 2013","January 25, 2016","February 23, 2016",,,"https://ClinicalTrials.gov/show/NCT01956032"
388,"NCT01947816","Special Investigation in Patients With Ulcerative Colitis",,"Completed","Has Results","Ulcerative Colitis",,"Number of Participants With Adverse Drug Reactions and Serious Adverse Drug Reactions|Change From Baseline in CRP Levels Over Time|Change From Baseline in Mayo Score Over Time|Mayo Endoscopic Sub-Score Over Time|Change From Baseline in Partial Mayo Score Over Time","AbbVie","All","up to 99 Years   (Child, Adult, Older Adult)",,"1621","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P14-190","August 9, 2013","February 15, 2018","February 15, 2018","September 23, 2013","May 13, 2019","May 13, 2019",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT01947816/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/16/NCT01947816/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01947816"
389,"NCT01946074","A Study of ABT-165 in Subjects With Solid Tumors",,"Recruiting","No Results Available","Advanced Solid Tumors","Drug: paclitaxel|Drug: FOLFIRI|Drug: ABT-165|Drug: ABBV-181","Clinical lab testing|Maximum observed serum concentration (Cmax) of ABT-165|The terminal elimination half life of ABT-165|Cardiac assessment|Area under the curve (AUC) form time zero to the last measurable concentration AUC (0-t)|Physical exam|Number of participants with Adverse Events|Vital signs|Duration of overall response (DOR)|Objective response rate (ORR)|Progression free survival (PFS)","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","95","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-006","August 8, 2013","March 19, 2020","March 19, 2020","September 19, 2013",,"June 12, 2019","HonorHealth Research Institute - Pima /ID# 105677, Scottsdale, Arizona, United States|Scottsdale Healthcare /ID# 105678, Scottsdale, Arizona, United States|University of California, Los Angeles /ID# 141389, Los Angeles, California, United States|UC Davis Comp Cancer Ctr /ID# 141164, Sacramento, California, United States|Stanford Univ School of Med /ID# 123758, Stanford, California, United States|Illinois Cancer Care, PC /ID# 151970, Peoria, Illinois, United States|Horizon Oncology Research /ID# 138022, Lafayette, Indiana, United States|Duke Univ Med Ctr /ID# 105679, Durham, North Carolina, United States|Tennessee Oncology-Nashville Centennial /ID# 143280, Nashville, Tennessee, United States|Mary Crowley Cancer Research /ID# 123757, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01946074"
390,"NCT01939197","A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","TURQUOISE-I","Completed","Has Results","Hepatitis C Virus Infection|Human Immunodeficiency Virus Infection|Chronic Hepatitis C|Compensated Cirrhosis and Non-cirrhotics","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: ribavirin","Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12)|Percentage of Participants in Part 1a Achieving SVR12|Percentage of Participants in Part 1b Achieving SVR12|Percentage of Participants in Arm F and Arm G of Part 2 Achieving SVR12|Percentage of Participants With GT4 HCV in Part 2 Achieving SVR12, by Arm and Overall|Percentage of Participants in Part 1a With On-Treatment HCV Virologic Failure During the Treatment Period|Percentage of Participants in Part 1b With On-Treatment HCV Virologic Failure During the Treatment Period|Percentage of Participants in Part 2 With On-Treatment HCV Virologic Failure During the Treatment Period|Percentage of Participants in Part 1a With Relapse12|Percentage of Participants in Part 1b With Relapse12 for Each Arm and Overall|Percentage of Participants in Part 2 With Relapse12|Percentage of Participants in Part 1a With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment|Percentage of Participants in Part 1b With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment|Percentage of Participants in Part 2 With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2|Phase 3","318","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-004|2012-005143-24","August 30, 2013","July 21, 2016","October 25, 2016","September 11, 2013","November 17, 2017","November 17, 2017",,,"https://ClinicalTrials.gov/show/NCT01939197"
391,"NCT01933919","A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder",,"Completed","Has Results","Obsessive Compulsive Disorder","Drug: Fluvoxamine maleate|Drug: Placebo","Mean Change From Baseline in the Japanese Children's Yale-Brown Obsessive Compulsive Scale 10-item Total Score at the End of Treatment in the First Phase|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Age|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at the End of Treatment in the First Phase Stratified by Gender|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the First Phase|JCY-BOCS 10-item Total Score at Each Visit During the First Phase|Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the First Phase|Percentage of Participants With a ≥ 25% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase|Percentage of Participants With a ≥ 35% Decrease From Baseline in JCY-BOCS (10-item) Total Score at the End of Treatment in the First Phase|Mean Change From Baseline in the JCY-BOCS 10-item Total Score at Each Visit During the Second Phase|Percentage of Participants Much Improved in Clinical Global Impression Improvement Assessment During the Second Phase|Number of Participants With Adverse Events During the First Phase|Number of Participants With Adverse Events During the Second Phase","AbbVie|Meiji Seika Pharma Co., Ltd.","All","6 Years to 18 Years   (Child, Adult)","Phase 3","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-970","August 14, 2013","June 18, 2015","July 1, 2016","September 2, 2013","December 4, 2017","December 4, 2017",,,"https://ClinicalTrials.gov/show/NCT01933919"
392,"NCT01931670","A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain","ELARIS EM-II","Completed","Has Results","Endometriosis","Other: placebo|Drug: Elagolix","Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS)|Percentage of Responders at Month 3 Based on Daily Assessment of Non-Menstrual Pelvic Pain (NMPP)|Change From Baseline to Month 3 in Numeric Rating Scale (NRS) Scores|Change From Baseline to Month 6 in DYS|Change From Baseline to Month 6 in NMPP|Change From Baseline to Month 3 in Analgesic Use Across Both Classes of Rescue Analgesics|Change From Baseline to Month 6 in Analgesic Use Across Both Classes of Rescue Analgesics|Change From Baseline to Month 3 in Dyspareunia (DYSP)|Change From Baseline to Month 3 in Use of Narcotic Class of Medication (Opioids)|Percentage of Responders for Each Month, Except Month 3, in DYS|Percentage of Responders for Each Month, Except Month 3, in NMPP|Percentage of Responders at Each Month for DYSP|Change From Baseline to Each Month, Except Month 6, in Mean Pain Score for DYS|Percent Change From Baseline to Each Month in Mean Pain Score for DYS|Change From Baseline to Each Month, Except Month 6, in Mean Pain Score for NMPP|Percent Change From Baseline to Each Month in the Mean Pain Score for NMPP|Change From Baseline to Each Month, Except Month 3, in the Mean Pain Score of DYSP|Change From Baseline to Each Month, Except Months 3 and 6, in Analgesic Use Across Both Classes of Rescue Analgesics|Patient Global Impression of Change (PGIC) Questionnaire|Change From Baseline to Each Month, Except Month 3, in NRS Scores|Change From Baseline to Each Scheduled Assessment in the Pain Domain of Endometriosis Health Profile-30 (EHP-30) Questionnaire Scores|Change From Baseline to Each Scheduled Assessment in the Sexual Intercourse Domain of EHP-30 Questionnaire Scores|Change From Baseline to Each Month in Health Related Productivity Questionnaire (HRPQ): Number of Hours of Work Lost From Workplace Due to Absenteeism|Change From Baseline to Each Month in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism|Change From Baseline to Each Month in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism|Change From Baseline to Each Month in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism|Change From Baseline to Each Month in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace|Change From Baseline to Each Month in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household|Number of Participants With Endometriosis-Related Non-Study Health Visits During the Treatment Period|Number of Days of Hospitalization|Number of Participants With Emergency Room/Outpatient Procedures During the Treatment Period, by Type","AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 3","815","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-671|2011-004295-11","September 9, 2013","January 6, 2016","December 19, 2016","August 29, 2013","September 7, 2018","September 7, 2018",,,"https://ClinicalTrials.gov/show/NCT01931670"
393,"NCT01911845","An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine",,"Completed","Has Results","Chronic Hepatitis C Infection|Chronic Hepatitis C","Drug: ABT-450/r/ABT-267|Drug: ABT-333|Drug: Ribavirin (RBV)","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse Post-treatment|Area Under the Plasma Concentration-time Curve (AUC) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin|Maximum Plasma Concentration (Cmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin|Time to Maximum Plasma Concentration (Tmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin|Plasma Trough Concentration (Ctrough) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","38","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M14-103","April 2013","December 2013","September 2014","July 30, 2013","January 6, 2015","May 30, 2018",,,"https://ClinicalTrials.gov/show/NCT01911845"
394,"NCT01908010","Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-354|Drug: Placebo","Vital signs|ECG (electrocardiogram)|Neurological exam|Laboratory tests|Number of subject with adverse events|C-SSRS (Columbia-Suicide Severity Rating Scale)|Pharmacokinetic parameters","AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-080","July 2013","November 2013","November 2013","July 25, 2013",,"December 11, 2013","Site Reference ID/Investigator# 106999, Miami, Florida, United States|Site Reference ID/Investigator# 106998, Orlando, Florida, United States|Site Reference ID/Investigator# 107000, Overland Park, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT01908010"
395,"NCT01897519","A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery",,"Terminated","No Results Available","Cardiothoracic Surgery|Vascular Surgery","Drug: Placebo|Drug: ABT-719","Change in urine Neutrophil Gelatinase-Associated Lipocalin (NGAL)|Proportion of subjects that develop composite event at 90 days post surgery|Proportion of subjects that develop a composite event at 60 days post surgery|Proportion of subjects that develop the Acute Kidney Injury Network (AKIN) scoring criteria|Proportion of subjects that develop the Kidney Disease Improving Global Outcomes (KDIGO) scoring criteria","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","M13-958|2012-005710-19","May 2013","May 2014","May 2014","July 12, 2013",,"June 6, 2014","Site Reference ID/Investigator# 96295, Gainesville, Florida, United States|Site Reference ID/Investigator# 96778, Jacksonville, Florida, United States|Site Reference ID/Investigator# 96301, Tampa, Florida, United States|Site Reference ID/Investigator# 96302, Fort Wayne, Indiana, United States|Site Reference ID/Investigator# 101961, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 103356, Boston, Massachusetts, United States|Site Reference ID/Investigator# 96303, Boston, Massachusetts, United States|Site Reference ID/Investigator# 96997, Grand Blanc, Michigan, United States|Site Reference ID/Investigator# 97878, Petoskey, Michigan, United States|Site Reference ID/Investigator# 99377, Royal Oak, Michigan, United States|Site Reference ID/Investigator# 99317, West Orange, New Jersey, United States|Site Reference ID/Investigator# 96996, New York, New York, United States|Site Reference ID/Investigator# 96296, Durham, North Carolina, United States|Site Reference ID/Investigator# 102020, Cleveland, Ohio, United States|Site Reference ID/Investigator# 103355, Columbus, Ohio, United States|Site Reference ID/Investigator# 97556, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 103316, Providence, Rhode Island, United States|Site Reference ID/Investigator# 102019, Memphis, Tennessee, United States|Site Reference ID/Investigator# 108255, Charlottesville, Virginia, United States|Site Reference ID/Investigator# 96300, Milwaukee, Wisconsin, United States|Site Reference ID/Investigator# 105755, Aarhus N, Denmark|Site Reference ID/Investigator# 105757, Kolding, Denmark|Site Reference ID/Investigator# 105756, Odense C, Denmark",,"https://ClinicalTrials.gov/show/NCT01897519"
396,"NCT01889186","A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia|17 p Deletion|Cancer of the Blood and Bone Marrow","Drug: ABT-199","Number of subjects with adverse events (Expanded Safety Cohort)|Percentage of subjects with adverse events (Expanded Safety Cohort)|Change in physical exam findings, including vital signs (Expanded Safety Cohort)|Efficacy will be measured by overall response rate (ORR) (Main Cohort)|Change in clinical laboratory test results (Expanded Safety Cohort)|Change in cardiac assessment findings (Expanded Safety Cohort)|Number of subjects with adverse events (Main Cohort)|Percent of subjects who move on to stem cell transplant|Percentage of subjects with adverse events (Main Cohort)|Change in clinical laboratory test results (Main Cohort)|Progression-free survival|Time to 50% reduction in absolute lymphocyte count|Change in cardiac assessment findings (Main Cohort)|Partial Remission (PR) rate|Time to first response|Duration of response|Complete Remission (CR) rate|Overall Response Rate (ORR) (Expanded Safety Cohort)|Time to progression|Event free survival|Overall survival|Change in physical exam findings, including vital signs (Main Cohort)","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","158","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-982|2012-004027-20","June 27, 2013","May 12, 2020","May 12, 2020","June 28, 2013",,"June 7, 2019","University of Arizona Cancer Center - North Campus /ID# 96748, Tucson, Arizona, United States|City of Hope /ID# 112875, Duarte, California, United States|Ucsd /Id# 91793, La Jolla, California, United States|Stanford Univ School of Med /ID# 105117, Stanford, California, United States|Medstar Georgetown Univ Med Ct /ID# 96954, Washington, District of Columbia, United States|Northwestern University Feinberg School of Medicine /ID# 92499, Chicago, Illinois, United States|University of Chicago /ID# 96960, Chicago, Illinois, United States|Ingalls Memorial Hosp /ID# 92497, Harvey, Illinois, United States|Dana-Farber Cancer Institute /ID# 92494, Boston, Massachusetts, United States|Henry Ford Health System /ID# 97795, Detroit, Michigan, United States|Hackensack Univ Med Ctr /ID# 92500, Hackensack, New Jersey, United States|Rutgers Cancer Institute of NJ /ID# 92513, New Brunswick, New Jersey, United States|Columbia Univ Medical Center /ID# 103835, New York, New York, United States|Columbia Univ Medical Center /ID# 94716, New York, New York, United States|Cleveland Clinic Main Campus /ID# 92495, Cleveland, Ohio, United States|Univ TX, MD Anderson /ID# 92521, Houston, Texas, United States|Royal North Shore Hospital /ID# 98836, Saint Leonards, New South Wales, Australia|John Fawkner Hospital /ID# 98835, Coburg, Victoria, Australia|Peter MacCallum Cancer Ctr /ID# 91795, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 91794, Parkville, Victoria, Australia|Jewish General Hospital /ID# 99476, Montreal, Quebec, Canada|Centre Hospitalier Lyon Sud /ID# 98839, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHU-Hopital Avicenne /ID# 98840, Bobigny, Ile-de-France, France|Hopital Pitie Salpetriere /ID# 98842, Paris, France|Centre Henri Becquerel /ID# 98838, Rouen, France|Universitaetsklinik Heidelberg /ID# 98845, Heidelberg, Baden-Wuerttemberg, Germany|Uniklinik Koln /ID# 98847, Köln, Nordrhein-Westfalen, Germany|Univ Hosp Schleswig-Holstein /ID# 113235, Kiel, Schleswig-Holstein, Germany|Universitaetsklinikum Ulm /ID# 92533, Ulm, Thueringen, Germany|Universitaetklinikum Dresden /ID# 113256, Dresden, Germany|Universitätsklinikum Freiburg /ID# 113276, Freiburg, Germany|Universitaetsmedizin Goettinge /ID# 113258, Göttingen, Germany|Univ Johannes Gutenberg /ID# 113236, Mainz, Germany|Staedt. Klinikum Schwabing /ID# 113275, Munich, Germany|SP ZOZ Szpital Uniwersytecki w Krakowie /ID# 98849, Krakow, Malopolskie, Poland|Samodzielny Publiczny Szpital /ID# 98848, Lublin, Poland|Szpital Wojewodzki w Opolu /ID# 102855, Opole, Poland|Leicester Royal Infirmary /ID# 98865, Leicester, England, United Kingdom|The Royal Bournemouth Hospital /ID# 118975, Bournemouth, United Kingdom|Addenbrookes Hospital /ID# 119977, Cambridge, United Kingdom|St. James University Hospital /ID# 98863, Leeds, United Kingdom|Royal Liverpool and Broadgreen /ID# 98860, Liverpool, United Kingdom|St Bartholomew's Hospital, Bar /ID# 98862, London, United Kingdom|King's College Hospital NHS /ID# 119975, London, United Kingdom|Christie NHS Foundation Trust /ID# 98864, Manchester, United Kingdom|Oxford Univ Hosp NHS Trust /ID# 119976, Oxford, United Kingdom|Derriford Hospital /ID# 118335, Plymouth, United Kingdom|Royal Marsden Hospital /ID# 98861, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01889186"
397,"NCT01860846","Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease","IDEA","Completed","Has Results","Crohn's Disease",,"Work Productivity and Activity Index (WPAI): Absenteeism|Work Productivity and Activity Index (WPAI): Presenteeism|Total Work Productivity Impairment (TWPI)|Total Activity Impairment (TAI)|Change in Short Form 36 (SF-36) Health Survey Scores|Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Scores|Change in Extra-intestinal Symptoms|Number of Participants With Serious Adverse Events","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)",,"106","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-338","May 2013","February 2016","February 2016","May 23, 2013","June 16, 2017","June 16, 2017",,,"https://ClinicalTrials.gov/show/NCT01860846"
398,"NCT01858532","Study Of Diabetic Nephropathy With Atrasentan","SONAR","Terminated","Has Results","Diabetic Nephropathy","Drug: Atrasentan|Drug: Placebo","Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)|Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized)|Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)|Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled)|Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized)","AbbVie","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","5107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-352|2012-005848-21","May 17, 2013","March 29, 2018","March 29, 2018","May 21, 2013","April 24, 2019","April 24, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01858532/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT01858532/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01858532"
399,"NCT01858519","Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy",,"Completed","No Results Available","Cystic Fibrosis",,"Seroprevalence of antibodies to hepatitis E virus (HEV) and other selected porcine viruses","AbbVie|Forest Laboratories|Janssen Research & Development, LLC","All","2 Years to 99 Years   (Child, Adult, Older Adult)",,"1310","Industry","Observational","Time Perspective: Prospective","JSPP-12-01","August 2013","September 2016","September 2016","May 21, 2013",,"September 20, 2016","Site Reference ID/Investigator# 116382, Anchorage, Alaska, United States|Site Reference ID/Investigator# 116444, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 116595, Long Beach, California, United States|Site Reference ID/Investigator# 116855, Los Angeles, California, United States|Site Reference ID/Investigator# 116879, Los Angeles, California, United States|Site Reference ID/Investigator# 116448, Los Angeles, California, United States|Site Reference ID/Investigator# 154681, Denver, Colorado, United States|Site Reference ID/Investigator# 116441, Hatford, Connecticut, United States|Site Reference ID/Investigator# 127584, New Haven, Connecticut, United States|Site Reference ID/Investigator# 116440, Gainesville, Florida, United States|Site Reference ID/Investigator# 116882, Miami, Florida, United States|Site Reference ID/Investigator# 116277, Orlando, Florida, United States|Site Reference ID/Investigator# 116435, Tampa, Florida, United States|Site Reference ID/Investigator# 131935, Atlanta, Georgia, United States|Site Reference ID/Investigator# 116452, Boise, Idaho, United States|Site Reference ID/Investigator# 116442, Chicago, Illinois, United States|Site Reference ID/Investigator# 116465, Maywood, Illinois, United States|Site Reference ID/Investigator# 141881, Niles, Illinois, United States|Site Reference ID/Investigator# 127295, Peoria, Illinois, United States|Site Reference ID/Investigator# 116877, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 116436, Wichita, Kansas, United States|Site Reference ID/Investigator# 136816, Louisville, Kentucky, United States|Site Reference ID/Investigator# 116450, New Orleans, Louisiana, United States|Site Reference ID/Investigator# 116455, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 116461, Boston, Massachusetts, United States|Site Reference ID/Investigator# 116463, Grand Rapids, Michigan, United States|Site Reference ID/Investigator# 116445, Jackson, Mississippi, United States|Site Reference ID/Investigator# 116883, Omaha, Nebraska, United States|Site Reference ID/Investigator# 116876, Buffalo, New York, United States|Site Reference ID/Investigator# 130461, New Hyde Park, New York, United States|Site Reference ID/Investigator# 116449, Syracuse, New York, United States|Site Reference ID/Investigator# 116458, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 116276, Toledo, Ohio, United States|Site Reference ID/Investigator# 116464, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 116457, Hershey, Pennsylvania, United States|Site Reference ID/Investigator# 116880, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 116467, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 116466, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 116462, Charleston, South Carolina, United States|Site Reference ID/Investigator# 116453, Sioux Falls, South Dakota, United States|Site Reference ID/Investigator# 116875, Knoxville, Tennessee, United States|Site Reference ID/Investigator# 116856, Houston, Texas, United States|Site Reference ID/Investigator# 116459, Tyler, Texas, United States|Site Reference ID/Investigator# 116278, Norfolk, Virginia, United States|Site Reference ID/Investigator# 116460, Richmond, Virginia, United States|Site Reference ID/Investigator# 116438, Morgantown, West Virginia, United States|Site Reference ID/Investigator# 116439, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01858519"
400,"NCT01854697","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before","MALACHITE 1","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Telaprevir|Drug: Pegylated Interferon alpha 2-a (PegIFN)","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses|Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)|Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)|Percentage of Participants With SVR12 - Secondary Efficacy Analyses|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Post-treatment Relapse|Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","311","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-774|2012-003754-84","March 2013","November 2014","July 2015","May 15, 2013","February 22, 2016","June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT01854697"
401,"NCT01854528","A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults","MALACHITE II","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Pegylated Interferon a-2a (PegINF)|Drug: Telaprevir","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment|Mean Change From Baseline to Final Treatment Visit in the Mental Component Summary (MCS) Score of the Short-Form 36 Health Survey - Version 2 (SF-36v2)|Mean Change From Baseline to Final Treatment Visit in the Physical Component Summary (PCS) Score of the Short-Form 36 Health Survey - Version 2 (SF-36v2)|Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse After Treatment","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","148","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-862|2012-003738-18","June 2013","November 2014","July 2015","May 15, 2013","February 11, 2016","June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT01854528"
402,"NCT01853306","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",,"Completed","No Results Available","Oncology|BRCA Mutated|High Grade Serous Ovarian Cancer|BRCA Mutated Breast Cancer","Drug: Veliparib","Part 2 - Dose Escalation Cohort: Pharmacokinetic testing|Part 1 - Pharmacokinetic profile|Part 3 - Safety Expanded Cohort: Number of subjects with adverse events|Part 3 - Safety Expanded Cohort: Vital signs|Part 3 - Safety Expanded Cohort: Laboratory tests|The number of participants with adverse events who receive the extended release formulations of veliparib.","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","71","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-695","March 18, 2013","May 3, 2017","June 29, 2017","May 15, 2013",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01853306"
403,"NCT01853033","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: ABT-122|Biological: Placebo","Number of participants with Adverse Events|Change in physical exam including vital signs|Change in clinical lab test results|Change in Electrocardiogram (ECG) results|Determination of pharmacokinetic (PK) parameters|Measurement of anti-drug anti-bodies (ADA) of ABT-122","AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M14-048","July 2013","May 2014","May 2014","May 14, 2013",,"November 20, 2017","Site Reference ID/Investigator# 108655, Lenexa, Kansas, United States|Site Reference ID/Investigator# 107115, Raleigh, North Carolina, United States|Site Reference ID/Investigator# 118964, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 100780, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01853033"
404,"NCT01848561","A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)",,"Recruiting","No Results Available","Ulcerative Colitis (UC)",,"Evaluation of long term safety of Adalimumab in patients with moderately to severely active UC|Evaluation of long term effectiveness of Adalimumab in patients with moderately to severely active UC who have had an inadequate response to conventional therapy","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"5450","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P11-282","April 29, 2013","April 6, 2027","April 6, 2027","May 7, 2013",,"December 19, 2019","Birmingham Gastroenterology /ID# 102063, Birmingham, Alabama, United States|University of Alabama at Birmingham - Main /ID# 131646, Birmingham, Alabama, United States|Longwood Research /ID# 118662, Huntsville, Alabama, United States|Alabama Medical Group, PC /ID# 116259, Mobile, Alabama, United States|Mobile Med & Diag Ctr.,AL /ID# 102064, Mobile, Alabama, United States|HOPE Research Institute /ID# 127947, Phoenix, Arizona, United States|University of Arizona /ID# 117836, Tucson, Arizona, United States|Arkansas Gastroenterology /ID# 113898, North Little Rock, Arkansas, United States|Southern California Res. Ctr. /ID# 116898, Coronado, California, United States|Ucsd /Id# 133722, La Jolla, California, United States|McGuire, Jr. La Mirada, CA /ID# 116257, La Mirada, California, United States|Atay, Los Alamitos, CA /ID# 110175, Los Alamitos, California, United States|Alliance Research Institute, Llc /Id# 214718, Los Angeles, California, United States|Temecula Valley Endoscopy Ctr /ID# 118660, Murrieta, California, United States|Community Clinical Trials, CA /ID# 117335, Orange, California, United States|Digestive Care Medical Center /ID# 122075, San Carlos, California, United States|Precision Research Institute - San Diego /ID# 103638, San Diego, California, United States|Precision Research Institute - San Diego /ID# 113445, San Diego, California, United States|Santa Monica Research Institut /ID# 118675, Santa Monica, California, United States|St. Joseph Heritage Group /ID# 133721, Yorba Linda, California, United States|Western States Clinical Research, Inc. /ID# 116237, Wheat Ridge, Colorado, United States|Gastro Assoc of Fair County /ID# 113443, Bridgeport, Connecticut, United States|Medical Research Ctr CT /ID# 102057, Hamden, Connecticut, United States|Middlesex Hospital /ID# 122077, Middletown, Connecticut, United States|Yale Univ Digestive Diseases /ID# 141987, New Haven, Connecticut, United States|MedStar Georgetown University Hospital /ID# 113437, Washington, District of Columbia, United States|Brandon Premier Health Care, PA /ID# 148230, Brandon, Florida, United States|Sarkis Clinical Trials /ID# 137948, Gainesville, Florida, United States|Hollywood Research Center /Id# 214723, Hollywood, Florida, United States|Ctr for Advanced Gastroenterol /ID# 116236, Maitland, Florida, United States|San Marcus Research Site /Id# 212887, Miami Lakes, Florida, United States|Research Associates of South Florida,LLC /ID# 148212, Miami, Florida, United States|Abel & Buchheim, P.R., Inc. /ID# 143863, Miami, Florida, United States|Gastroenterology Group Naples /ID# 105837, Naples, Florida, United States|Advanced Research Institute /ID# 211335, New Port Richey, Florida, United States|Advanced Research Institute /ID# 211343, New Port Richey, Florida, United States|North Florida Gastro Research /ID# 128538, Orange Park, Florida, United States|Combined Res. Orlando Ph I-IV /ID# 141660, Orlando, Florida, United States|Endoscopic Research, Inc. /ID# 136883, Orlando, Florida, United States|Florida Hospital /ID# 145705, Orlando, Florida, United States|Clintheory Healthcare /ID# 213728, Orlando, Florida, United States|Digestive Diseases Center /ID# 118116, Panama City, Florida, United States|Palekar. Parkland, FL /ID# 108202, Parkland, Florida, United States|BRCR Medical Center Inc /ID# 152015, Plantation, Florida, United States|Advanced Medical Research Ctr. /ID# 116235, Port Orange, Florida, United States|Precision Clinical Research /ID# 127849, Sunrise, Florida, United States|Digestive Disease Clinic /ID# 107162, Tallahassee, Florida, United States|Guardian Angels Health Center /ID# 209706, Tampa, Florida, United States|South Florida Ctr Gastro, P.A. /ID# 166784, Wellington, Florida, United States|Shafran Gastroenterology Ctr /ID# 117839, Winter Park, Florida, United States|Emory University Hospital /ID# 133724, Atlanta, Georgia, United States|Atlanta Gastro Assoc /ID# 107164, Atlanta, Georgia, United States|Gastro Assoc of Central GA /ID# 117838, Macon, Georgia, United States|Atlanta Gastroenterology Spec /ID# 103619, Suwanee, Georgia, United States|Grand Teton Research Group /ID# 108197, Idaho Falls, Idaho, United States|Northwest Gastro, S.C. /ID# 103620, Arlington Heights, Illinois, United States|Northwest Gastro, S.C. /ID# 145707, Arlington Heights, Illinois, United States|Christie Clinic, LLC /ID# 116258, Champaign, Illinois, United States|Northwestern University Feinberg School of Medicine /ID# 126760, Chicago, Illinois, United States|Rush University Medical Center /ID# 132979, Chicago, Illinois, United States|University of Chicago /ID# 114115, Chicago, Illinois, United States|NorthShore University HealthSystem - Evanston /ID# 107165, Evanston, Illinois, United States|DM Clinical Research/Southwest /ID# 120635, Oak Lawn, Illinois, United States|North Suburban Gastro Assoc /ID# 134437, Park Ridge, Illinois, United States|Carle Cancer Center /ID# 117417, Urbana, Illinois, United States|Iowa Digestive Disease Center /ID# 107159, Clive, Iowa, United States|University of Iowa Hospitals and Clinics /ID# 134432, Iowa City, Iowa, United States|University of Kansas Health Sy /ID# 134436, Kansas City, Kansas, United States|Univ Kansas Med Ctr /ID# 120917, Kansas City, Kansas, United States|Houma Digestive Health Special /ID# 125711, Houma, Louisiana, United States|Gastro Clinic of Acadiana, LA /ID# 119155, Lafayette, Louisiana, United States|Louisiana Research Ctr. LLC /ID# 102055, Shreveport, Louisiana, United States|Investigative Clinical Research /ID# 102056, Annapolis, Maryland, United States|Univ Maryland School Medicine /ID# 116897, Baltimore, Maryland, United States|John Hopkins Medicine /ID# 212398, Baltimore, Maryland, United States|MGG Group, Inc.Chevy Chase Clinical Research /ID# 107157, Chevy Chase, Maryland, United States|Gastro Center of Maryland /ID# 126969, Columbia, Maryland, United States|Endoscopic Microsurgery Assoc /ID# 102065, Towson, Maryland, United States|Attleboro Gastroenterology, PC /ID# 113899, Attleboro, Massachusetts, United States|Commonwealth Clinical Studies /ID# 118597, Brockton, Massachusetts, United States|UMass Memorial Medical Center /ID# 212924, Worcester, Massachusetts, United States|University of Michigan Hospitals /ID# 105836, Ann Arbor, Michigan, United States|Huron Gastroenterology Assoc /ID# 132484, Ann Arbor, Michigan, United States|Henry Ford Health System /ID# 103617, Detroit, Michigan, United States|Detroit Clinical Research Ctr /ID# 123235, Farmington Hills, Michigan, United States|Mayo Clinic - Rochester /ID# 116899, Rochester, Minnesota, United States|Univ of Mississippi Med Ctr,US /ID# 132981, Jackson, Mississippi, United States|Saint Louis University School of Medicine /ID# 163794, Saint Louis, Missouri, United States|Washington University-School of Medicine /ID# 107156, Saint Louis, Missouri, United States|CHI Health Research Center /ID# 116255, Omaha, Nebraska, United States|Cooper Digestive Health Instit /ID# 103615, Mount Laurel, New Jersey, United States|The Gastro Group of S. Jersey /ID# 129902, Vineland, New Jersey, United States|Allied Gastrointestinal Associ /ID# 107158, Voorhees, New Jersey, United States|NYU Langone Long Island CRA /ID# 107163, Great Neck, New York, United States|Orlin & Cohen /ID# 117895, Lynbrook, New York, United States|Progressive Gastro Consultants /ID# 105835, Mineola, New York, United States|Digestive Dis Care/Excel Med /ID# 133489, New Hyde Park, New York, United States|North Shore University Hospital /ID# 127948, New Hyde Park, New York, United States|Premier Medical Group /ID# 140388, New Windsor, New York, United States|Concorde Medical Group PLLC /ID# 113442, New York, New York, United States|Weill Cornell Medical College /ID# 135052, New York, New York, United States|Westside Gastroenterology /ID# 133689, New York, New York, United States|Icahn School of Med Mt. Sinai /ID# 108201, New York, New York, United States|Premier Medical Group /ID# 140384, Poughkeepsie, New York, United States|Gastro Group of Rochester /ID# 113438, Rochester, New York, United States|Univ Rochester Med Ctr /ID# 126152, Rochester, New York, United States|Ctr Digest, Allergic & Imm Dis /ID# 125502, Williamsville, New York, United States|Asheville Gastro Assoc /ID# 144367, Asheville, North Carolina, United States|Cary Gastroenterology Assoc PA /ID# 108198, Cary, North Carolina, United States|Univ NC Chapel Hill /ID# 102059, Chapel Hill, North Carolina, United States|Carolinas Medical Center /ID# 126970, Charlotte, North Carolina, United States|Charlotte Gastro Hepatology /ID# 102058, Charlotte, North Carolina, United States|Carolina Digest Health Assoc /ID# 108199, Charlotte, North Carolina, United States|Carolinas Research center /ID# 211288, Charlotte, North Carolina, United States|Atlantic Gastroenterology, PA /ID# 135536, Greenville, North Carolina, United States|Carolina Research, Greenville, NC /ID# 134133, Greenville, North Carolina, United States|Boice-Willis Clinic, P.A. /ID# 103618, Rocky Mount, North Carolina, United States|Trial Management Associates /ID# 138459, Wilmington, North Carolina, United States|Southeastern Research Center /ID# 211961, Winston-Salem, North Carolina, United States|Wake Forest Univ HS /ID# 113436, Winston-Salem, North Carolina, United States|Cleveland Clinic Main Campus /ID# 108055, Cleveland, Ohio, United States|Clinical Research Solutions /ID# 207698, Middleburg Heights, Ohio, United States|ProMedica Physicians Digestive Healthcare /ID# 156529, Sylvania, Ohio, United States|Avamar Center for Endoscopy /ID# 113440, Warren, Ohio, United States|Southwoods Surgical Hospital /ID# 133038, Youngstown, Ohio, United States|Northwest Gastroenterology Cli /ID# 116896, Portland, Oregon, United States|Penn State University and Milton S. Hershey Medical Center /ID# 133688, Hershey, Pennsylvania, United States|Main Line Gastro Assoc /ID# 113446, Malvern, Pennsylvania, United States|Drexel Univ College of Med /ID# 126968, Philadelphia, Pennsylvania, United States|Temple University Hospital /ID# 108203, Philadelphia, Pennsylvania, United States|Methodist Hospital /ID# 129461, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, PC /ID# 105838, Sayre, Pennsylvania, United States|Bierwirth, Cranston, RI /ID# 113435, Cranston, Rhode Island, United States|Medical University of South Carolina /ID# 113439, Charleston, South Carolina, United States|Cons Gastro & S. Carolina Endo /ID# 126517, Columbia, South Carolina, United States|Greenville Endoscopy Center /ID# 129900, Greenville, South Carolina, United States|Rapid City Medical Center /ID# 201191, Rapid City, South Dakota, United States|Singaram Gastroenterology /ID# 113447, Sioux Falls, South Dakota, United States|Erlanger Institute for Clinica /ID# 126151, Chattanooga, Tennessee, United States|Franklin Endoscopy Center /ID# 113444, Franklin, Tennessee, United States|Clinical Research Solutions /ID# 154153, Jackson, Tennessee, United States|Mid-State Gastroenterology /ID# 125457, Murfreesboro, Tennessee, United States|Baylor College of Medicine /ID# 103636, Houston, Texas, United States|Kelsey-Seybold Clinic /ID# 125942, Houston, Texas, United States|University of Texas MD Anderson Cancer Center /ID# 144198, Houston, Texas, United States|Precision Research Institute - Houston /ID# 211340, Houston, Texas, United States|Biopharma Informatic, LLC /ID# 210225, Houston, Texas, United States|Houston Endoscopy and Research Center /ID# 206978, Houston, Texas, United States|Biopharma Informatic Research /ID# 210219, Houston, Texas, United States|Houston Digestive Dis Clinic /ID# 102076, Houston, Texas, United States|Rio Grande Gastroenterology /ID# 210218, McAllen, Texas, United States|Digestive Health Center /ID# 113897, Pasadena, Texas, United States|Digestive Health Assoc of TX /ID# 116215, Plano, Texas, United States|Gastroenterology Clinic of San /ID# 113441, San Antonio, Texas, United States|San Antonio Gastro Assoc /ID# 143435, San Antonio, Texas, United States|Scott & White Mem Hosp & Clin /ID# 103639, Temple, Texas, United States|Digestive Health Spec of Tyler /ID# 138144, Tyler, Texas, United States|Care Access Research-Ogden /ID# 213432, Ogden, Utah, United States|Granger Medical Clinic /ID# 122896, West Valley City, Utah, United States|University of Vermont Medical Center /ID# 102075, Burlington, Vermont, United States|Gastro Assoc of Tidewater /ID# 102061, Chesapeake, Virginia, United States|Gastro Assoc. of N. Va. /ID# 125495, Fairfax, Virginia, United States|Emeritas Research Group, LLC /ID# 135537, Leesburg, Virginia, United States|Digestive and Liver Disease Sp /ID# 125943, Norfolk, Virginia, United States|Gastroenterology Ltd. /ID# 103640, Virginia Beach, Virginia, United States|University of Washington /ID# 122076, Seattle, Washington, United States|Wenatchee Valley Hosp & Clinic /ID# 118661, Wenatchee, Washington, United States|Morgantown Surgical Associates /ID# 123082, Morgantown, West Virginia, United States|St. Mary's Hospital /ID# 116915, Madison, Wisconsin, United States|Univ of Wisconsin Hosp/Clinics /ID# 103637, Madison, Wisconsin, United States|WI Center for Advanced Res /ID# 103616, Milwaukee, Wisconsin, United States|Froedtert & the Medical College of Wisconsin /ID# 102066, Milwaukee, Wisconsin, United States|Reach /Id# 116256, Monroe, Wisconsin, United States|The Canberra Hospital /ID# 157980, Garran, Australian Capital Territory, Australia|Royal Prince Alfred Hospital /ID# 157986, Camperdown, New South Wales, Australia|Concord Repatriation General /ID# 157983, Concord, New South Wales, Australia|St. Vincents Hospital /ID# 157978, East Lismore, New South Wales, Australia|Hunter New England Local Healt /ID# 157999, New Lambton, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 158086, Herston, Queensland, Australia|Mater Misericordiae /ID# 164171, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 158026, Adelaide, South Australia, Australia|Flinders Centre for Innovation /ID# 157979, Bedford Park, South Australia, Australia|Austin Hospital /ID# 157998, Heidelberg, Victoria, Australia|Alfred Health /ID# 159261, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 157987, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 157993, Parkville, Victoria, Australia|Fiona Stanley Hospital /ID# 157992, Murdoch, Western Australia, Australia|Ordensklinikum Linz GmbH, Barmherzige Schwestern /ID# 98555, Linz, Oberoesterreich, Austria|Krankenanstalt Rudolfstiftung /ID# 121615, Vienna, Wien, Austria|Medical University Innsbruck /ID# 120775, Innsbruck, Austria|Krankenhaus/Barmherzigen Brued /ID# 120776, Salzburg, Austria|LKH Salzburg and Paracelsus /ID# 127897, Salzburg, Austria|CHU de Liege /ID# 127983, Liège, Liege, Belgium|UZ Gent /ID# 127985, Gent, Oost-Vlaanderen, Belgium|Onze Lieve Vrouw Hospital /ID# 127986, Aalst, Belgium|GZA St. Vincentiusziekenhuis /ID# 127398, Antwerp, Belgium|ZNA Middelheim /ID# 129116, Antwerp, Belgium|Imelda Ziekenhuis /ID# 127497, Bonheiden, Belgium|UZ Antwerp /ID# 142757, Edegem, Belgium|AZ Maria Middelares /ID# 127489, Ghent, Belgium|AZ Sint-Lucas /ID# 127000, Ghent, Belgium|A.Z. Herentals /ID# 127135, Herentals, Belgium|UZ Leuven /ID# 127984, Leuven, Belgium|Clinique St Joseph /ID# 127988, Liege, Belgium|Clinique Saint Luc /ID# 127987, Namur, Belgium|AZ Nikolaas /ID# 141601, Sint-Niklaas, Belgium|Regionaal Ziekenhuis Sint-Trud /ID# 127136, Sint-truiden, Belgium|GI Research /ID# 133723, Edmonton, Alberta, Canada|Zeidler Ledcor Centre /ID# 144673, Edmonton, Alberta, Canada|Columbia Gastro Mgmnt Ltd /ID# 128719, New Westminster, British Columbia, Canada|Dr. M. Prest Inc. /ID# 134309, Surrey, British Columbia, Canada|Univ British Columbia /ID# 129995, Vancouver, British Columbia, Canada|GIRI Gastrointestinal Research Institute /ID# 129095, Vancouver, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 129996, Victoria, British Columbia, Canada|Dr. Everett Chalmers Reg Hosp. /ID# 135408, Fredericton, New Brunswick, Canada|Qe Ii Hsc /Id# 128916, Halifax, Nova Scotia, Canada|Scope Clinic /ID# 145706, Brampton, Ontario, Canada|Guelph GI and Surgery Clinic /ID# 128917, Guelph, Ontario, Canada|Charlton Medical Centre /ID# 135390, Hamilton, Ontario, Canada|London Health Sciences Centre /ID# 128915, London, Ontario, Canada|Lakeridge Hospital /ID# 128275, Oshawa, Ontario, Canada|The Ottawa Hospital /ID# 128918, Ottawa, Ontario, Canada|Hospital Montfort /ID# 151588, Ottawa, Ontario, Canada|Kensington Screening Clinic /ID# 133720, Toronto, Ontario, Canada|Hospital Maisonneuve-Rosemont /ID# 130321, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 151379, Montréal, Quebec, Canada|CHUS - Hopital Fleurimont /ID# 133031, Sherbrooke, Quebec, Canada|Royal Univ. Hosp, Saskatoon,CA /ID# 128720, Saskatoon, Saskatchewan, Canada|Klinicki bolnicki centar Osijek /ID# 127980, Osijek, Osjecko-baranjska Zupanija, Croatia|Klinicki bolnicki centar Rijeka /ID# 127979, Rijeka, Primorsko-goranska Zupanija, Croatia|Official Universtiy Hospital S /ID# 127978, Split, Croatia|Clinical Hospital Dubrava /ID# 127982, Zagreb, Croatia|General Hospital Sveti Duh /ID# 127977, Zagreb, Croatia|Herlev Hospital /ID# 98239, Herlev, Hovedstaden, Denmark|Aalborg University Hospital /ID# 119215, Aalborg, Nordjylland, Denmark|Rigshospitalet, Finsen Centre /ID# 98238, Copenhagen, Denmark|Hvidovre Hospital /ID# 120557, Hvidovre, Denmark|Centre Hospitalier Lyon Sud /ID# 98718, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHU Hopital Nord /ID# 98639, Marseille, Bouches-du-Rhone, France|Hopital Universitaire Purpan /ID# 148183, Toulouse, Haute-Garonne, France|CHRU Lille - Hôpital Claude Huriez /ID# 98737, Lille CEDEX, Hauts-de-France, France|Hopital Saint Eloi /ID# 217142, Montpellier CEDEX 5, Herault, France|Hopital Beaujon /ID# 127395, Clichy, Ile-de-France, France|CHU NANCY - Hôpital Brabois Adultes /ID# 127394, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|Charles Nicolle CHU Rouen /ID# 98721, Rouen CEDEX, Seine-Maritime, France|CHU Amiens Picardie /ID# 98637, Amiens CEDEX 1, Somme, France|Hospitalier Germon et Gauthier /ID# 137874, Bethune, France|CHU Estaing /ID# 98735, Clermont Ferrand, France|CHU de Grenoble - Albet Michal /ID# 98638, Grenoble, France|Hospital Edouard Herriot /ID# 155711, Lyon, France|Ctr Consultations La Sauvegard /ID# 98719, Lyon, France|Private Practice /ID# 161671, Metz, France|Ctr Hosp Inter Le Raincy Montf /ID# 98642, Montfermeil, France|CHU de Nice /ID# 98645, Nice, France|APHP - Groupe Hospitalier 1 /ID# 98736, Paris, France|Hopital Saint Antoine /ID# 141611, Paris, France|Groupe Hospitalier Cochin /ID# 98717, Paris, France|Hopital Bichat Claude Bernard /ID# 98641, Paris, France|Hopital Robert Debre /ID# 98640, Reims, France|Hopital Nord /ID# 130978, Saint Priest En Jarez, France|Thevenin, Saint Quentin, FR /ID# 98720, Saint Quentin, France|Hopital de Rangueil /ID# 147755, Toulouse, France|Hopital Trousseau /ID# 98716, Tours, France|Groupe Hosp Les Portes Au Sud /ID# 98722, Venissieux, France|Universitaetsklinik Heidelberg /ID# 98120, Heidelberg, Baden-Wuerttemberg, Germany|Universitatsklinikum Mannheim /ID# 129279, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 128179, Erlangen, Bayern, Germany|KH Martha-Maria Halle Dolau /ID# 122935, Halle (Saale), Sachsen-Anhalt, Germany|Universitaetsklinikum Leipzig /ID# 98116, Leipzig, Sachsen, Germany|Universitaetsklinikum Ulm /ID# 98202, Ulm, Thueringen, Germany|Klinikum Altenburger Land /ID# 131748, Altenburg, Germany|Prax. Dres. Roesler und Lachma /ID# 128466, Bayreuth, Germany|Charité Universitätsmedizin Campus Mitte /ID# 129115, Berlin, Germany|Charité Universitätsmedizin Campus Mitte /ID# 129117, Berlin, Germany|Charité Universitätsmedizin Campus Mitte /ID# 98124, Berlin, Germany|Mross, Berlin, DE /ID# 98117, Berlin, Germany|Charite-Univ. Berlin, Benjamin-Franklin /ID# 130318, Berlin, Germany|DRK-Kliniken Westend /ID# 98179, Berlin, Germany|Krankenhaus Waldfriede /ID# 98200, Berlin, Germany|Klinikum Ruhr Univ Bochum /ID# 148107, Bochum, Germany|Stadtisches Klinikum Braunschw /ID# 98123, Braunschweig, Germany|Klinikum Dortmund gGmbH /ID# 127061, Dortmund, Germany|Kliniken Essen Sued /ID# 98196, Essen, Germany|Universitätsklinikum Freiburg /ID# 98176, Freiburg, Germany|Klinikum Garmisch-Partenkirchen /ID# 127915, Garmisch-partenkirchen, Germany|Dr. Zeisler, Halle, DE /ID# 98218, Halle, Germany|Asklepios Klinik St. Georg /ID# 125216, Hamburg, Germany|Gastroenterologie Rothenbaum /ID# 98195, Hamburg, Germany|Forstep /ID# 125206, Hamburg, Germany|Magen-Darm-Zentrum /ID# 141610, Hamburg, Germany|Israelitisches Krankenhaus /ID# 98197, Hamburg, Germany|Asklepios Westklinikum Hamburg /ID# 127492, Hamburg, Germany|Gastroenterologie Studien -CED /ID# 98205, Hamburg, Germany|Graefin v.Waldersee&Partner, H /ID# 141607, Hamburg, Germany|Mueller/Mueller-Ziehm, Hanover /ID# 130490, Hannover, Germany|Ehehalt/Helmstadter, Heidelber /ID# 125211, Heidelberg, Germany|Group Practice Gastroenterolog /ID# 98121, Herne, Germany|Hoffstadt, Iserlohn, DE /ID# 98208, Iserlohn, Germany|Universitaetsklinikum Jena /ID# 127496, Jena, Germany|Leberstudienzentrum Kiel /ID# 127798, Kiel, Germany|Benner, Luetke & Weismueller /ID# 129119, Koblenz, Germany|EUGASTRO GmbH /ID# 98178, Leipzig, Germany|Borkenhagen & Teich, Leipzig /ID# 98119, Leipzig, Germany|St. Marien- und Anastiftskrane /ID# 98235, Ludwigshafen, Germany|Otto von Guericke Universitaet /ID# 129227, Magdeburg, Germany|Internistisches Fachzentrum /ID# 123255, Memmingen, Germany|Gastro Gemeinschaftspraxis /ID# 98115, Minden, Germany|Isarkliniken /ID# 125213, Munich, Germany|LMU Klinikum der Universität München /ID# 98198, Munich, Germany|Gastroenterologie Im Josephinu /ID# 123496, Munich, Germany|Medizinisches Versorgungszentrum Portal 10 /ID# 98122, Munster, Germany|Gastro Gemeinschaftspraxis /ID# 125558, Munster, Germany|Klinikum Neumarkt /ID# 123016, Neumarkt, Germany|Innere Am Stadtpark /ID# 123015, Nuremberg, Germany|Klinikum Nuremberg /ID# 134976, Nuremberg, Germany|Helwig, Oldenburg, DE /ID# 129120, Oldenburg, Germany|Klinikum Univ Regensburg /ID# 141606, Regensburg, Germany|Praxiszentrum Altemalzerei /ID# 129001, Regensburg, Germany|Universitaetsklinikum Rostock /ID# 128396, Rostock, Germany|Biewer/Mohl, Saarbruecken, DE /ID# 98204, Saarbruecken, Germany|Ambulanzzentrum Schweinfurt /ID# 123238, Schweinfurt, Germany|Bank, Schwerin, DE /ID# 125215, Schwerin, Germany|Clinics of Sigmaringen /ID# 98216, Sigmaringen, Germany|Ctr Gastro & Hepatology Stade /ID# 98206, Stade, Germany|Kardalinos, Stuhr, DE /ID# 98201, Stuhr, Germany|Internistische Praxisgemeinsch /ID# 129000, Weyhe, Germany|Loehr, Wiesbaden, DE /ID# 98217, Wiesbaden, Germany|General Hospital of Athens Laiko /ID# 129280, Athens, Attiki, Greece|Gen Univ Hosp Alexandroupolis /ID# 128636, Alexandroupolis, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 98756, Athens, Greece|General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 98761, Athens, Greece|General Hospital of Athens ""Ippokratio"" /ID# 128638, Athens, Greece|HYGEIA Hospital /ID# 128637, Athens, Greece|Venizeleio General Hospital /ID# 98757, Heraklion, Greece|University General Hospital of Ioannina /ID# 127390, Ioannina, Greece|Iatriko Kentro Athinon Hospita /ID# 98762, Marousi, Greece|Theageneio Anticancer Hospital /ID# 141670, Thessaloniki, Greece|Genl Hosp Thessaloniki Hipp /ID# 127400, Thessaloniki, Greece|Adelaide and Meath Hosp,IE /ID# 117947, Dublin 24, Ireland|Trinity College Dublin - St. J /ID# 149406, Dublin, Ireland|St Vincent's University Hosp /ID# 116835, Dublin, Ireland|Mater Misericordiae Univ Hosp /ID# 119054, Dublin, Ireland|Beaumont Hospital /ID# 98775, Dublin, Ireland|Connolly Hospital /ID# 98895, Dublin, Ireland|Galway University Hospital /ID# 98763, Galway, Ireland|Assaf Harofeh Medical Center /ID# 128996, Be'er Ya'aqov, Israel|Hillel Jafe Medical Center /ID# 129047, Hadera, Israel|Rambam Health Care Campus /ID# 129282, Haifa, Israel|Shaare Zedek Medical Center /ID# 126638, Jerusalem, Israel|Hadassah University Hospital /ID# 132530, Jerusalem, Israel|Clalit Health Services /ID# 129237, Jerusalem, Israel|Meir Medical Center /ID# 129238, Kfar Saba, Israel|Zavulun Medical Centre /ID# 129048, Kiryat Bialik, Israel|Baruch-Padeh Poriya Medical /ID# 141671, Lower Galilee, Israel|Sheba Medical Center /ID# 129281, Ramat Gan, Israel|A.O.U. Policlinico S.Orsola-Malpighi /ID# 137945, Bologna, Emilia-Romagna, Italy|Policlinico Universitario Campus Bio-Medico /ID# 141393, Rome, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini /ID# 144211, Rome, Lazio, Italy|AOU Policlinico Umberto I /ID# 144080, Rome, Lazio, Italy|Istituto Clinico Humanitas /ID# 141382, Rozzano, Milano, Italy|A.O. Per L'Emergenza Cannizzaro /ID# 138142, Catania, Sicilia, Italy|Policlinico Paolo Giaccone /Id# 141397, Palermo, Sicilia, Italy|A.O. Univ Consorziale Policlin /ID# 144213, Bari, Italy|A.O. Spedali Civili Brescia /ID# 137943, Brescia, Italy|Fondazione Poliambulanza /ID# 141593, Brescia, Italy|Ospedale Valduce /ID# 155712, Como, Italy|A.O. Universitaria Careggi /ID# 137946, Florence, Italy|Azienda Ospedaliera Univ San M /ID# 137947, Genoa, Italy|A.O.U. Policlinico G. Martino /ID# 144212, Messina, Italy|Policlinico San Donato /ID# 141383, Milan, Italy|Ospedale S Giuseppe /ID# 141395, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 137944, Milan, Italy|Azienda Ospedaliera Luigi Sacc /ID# 141716, Milan, Italy|University of Naples Federico /ID# 141381, Naples, Italy|Seconda Universita' di Napoli /ID# 141717, Naples, Italy|AO Maggiore della Carita /ID# 144084, Novara, Italy|Universita di Padova /ID# 137941, Padua, Italy|Ospedali Riuniti Villa Sofia-C /ID# 141392, Palermo, Italy|Policlinico Tor Vergata /ID# 145912, Rome, Italy|AO Univ Policlinico Gemelli /ID# 141396, Rome, Italy|IRCCS Casa Sollievo /ID# 137939, San Giovanni Rotondo, Italy|ASO Ordine Mauriziano, Umberto /ID# 137942, Turin, Italy|A.O. Circolo e Fondazione Macc /ID# 141394, Varese, Italy|Morales Vargas Centro de Investigacion S.C. /ID# 131390, Leon, Guanajuato, Mexico|Asoc Mex Para la Invest Clinic /ID# 128387, Guadalajara, Jalisco, Mexico|Instituto de Salud Digestiva /ID# 157435, Guadalajara, Jalisco, Mexico|Issste /Id# 128386, Guadalajara, Jalisco, Mexico|Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 129318, Guadalajara, Jalisco, Mexico|Hospital Universitario ""Dr. José Eleuterio González"" /ID# 128375, Monterrey, Nuevo Leon, Mexico|Ruiz Flores, Monterrey, MX /ID# 128379, Monterrey, Nuevo Leon, Mexico|Invest y Biomed de Chihuahua /ID# 150115, Chihuahua, Mexico|Clinica de Higado & Gastro Int /ID# 128376, Cuernavaca, Mexico|Torre de Especialidades Medica /ID# 154276, Metepec, Mexico|Centro Especializado en Diabetes, Obesidad y Prevención de Enfermedades Cardiova /ID# 138113, Mexico City, Mexico|Vega Fonseca, San Luis Potosi /ID# 128380, San Luis Potosi, Mexico|Orbis Medisch Centrum /ID# 98241, Sittard, Geleen, Netherlands|Meander Medisch Centrum /ID# 98338, Amersfoort, Netherlands|Onze Lieve Vrouwe Gasthuis /ID# 98336, Amsterdam, Netherlands|Rijnstate /ID# 127397, Arnhem, Netherlands|Leids Universitair Medisch Centrum /ID# 127402, Leiden, Netherlands|Erasmus Medisch Centrum /ID# 98337, Rotterdam, Netherlands|Franciscus Gasthuis & Vlietland /ID# 127904, Rotterdam, Netherlands|Isala /ID# 98317, Zwolle, Netherlands|Christchurch Hospital /ID# 164265, Christchurch, Canterbury, New Zealand|Akershus Universitetssykehus_MAIN /ID# 127159, Lorenskog, Akershus, Norway|Perez Jimenz Gastroenterologo /ID# 110135, Mayaguez, Puerto Rico|Gastro-Hepato & Geriatric Ctr /ID# 113135, Ponce, Puerto Rico|Rodriguez-Ginorio, San Juan /ID# 113448, San Juan, Puerto Rico|School of Medicine University of Puerto Rico-Medical Sciences Campus /ID# 102067, San Juan, Puerto Rico|Hospital Universitario de Bellvitge /ID# 98584, L'Hospitalet de Llobregat, Barcelona, Spain|Corporac Sanitaria Parc Tauli /ID# 98585, Sabadell, Barcelona, Spain|H. Un. Marques de Valdecilla /ID# 98581, Santander, Cantabria, Spain|Hospital de Cabuenes /ID# 141998, Cabueñes, Gijon, Spain|Hospital do Meixoeiro /ID# 128355, Vigo, Pontevedra, Spain|Comple Hosp Univ de A Coruna /ID# 129002, A Coruna, Spain|Hosp Univ Principe de Asturias /ID# 131751, Alcala de Henares, Spain|Hospital la Mancha Centro /ID# 98588, Alcazar de San Juan, Spain|Hosp Univ Fundacion Alcorcon /ID# 98576, Alcorcon, Spain|Hosp Univ San Juan de Alicante /ID# 130167, Alicante, Spain|Hospital General Univ Alicante /ID# 128467, Alicante, Spain|Hospital Alto Guadalquivir /ID# 129006, Andujar, Spain|Hospital de Antequera /ID# 129041, Antequera, Spain|Hospital San Eloy /ID# 147830, Barakaldo, Spain|Hospital Parc de Salut del Mar /ID# 126637, Barcelona, Spain|Hosp Sant J. Despi-Moises Brog /ID# 128347, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 98592, Barcelona, Spain|Hospital viladecans /ID# 155500, Barcelona, Spain|Hospital Universitario Basurto /ID# 129123, Bilbao, Spain|Hosp San Pedro de Alcantara /ID# 98579, Caceres, Spain|Hospital Gen Univ Santa Lucia /ID# 129125, Cartagena, Spain|Hospital General de Castellon /ID# 128351, Castellon de La Plana, Spain|Hospital Universitario Reina S /ID# 98586, Cordoba, Spain|Hospital General Univ de Elche /ID# 129121, Elche, Spain|Hospital Sant Joan de Deu /ID# 155774, Esplugues de Llobregat, Spain|Hospital Arquitecto Marcide /ID# 129124, Ferrol, Spain|Hospital Univ de Fuenlabrada /ID# 98591, Fuenlabrada, Spain|Farmacia Hospitalaria /ID# 98618, Galdakao, Spain|Hosp Univ Girona Josep Trueta /ID# 130049, Girona, Spain|Hospital San Jorge Huesca /ID# 149628, Huesca, Spain|Hospital Complex of Jaen /ID# 129035, Jaen, Spain|Hosp de Jerez de la Frontera /ID# 128345, Jerez, Spain|Hospital Univ Dr. Negrin /ID# 98578, Las Palmas de Gran Canaria, Spain|Hospital de Leo /ID# 131750, Leon, Spain|Hospital Univ de la Princesa /ID# 98580, Madrid, Spain|Hospital General Universitario Gregorio Maranon /ID# 98558, Madrid, Spain|Hospital Univ Ramon y Cajal /ID# 98596, Madrid, Spain|Hospital Clin Univ San Carlos /ID# 98577, Madrid, Spain|Hospital 12 de Octubre /ID# 98575, Madrid, Spain|Hospital Universitario La Paz /ID# 98582, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 129038, Malaga, Spain|Hospital de Manacor /ID# 128348, Manacor, Spain|Hospital Univ De Mostoles /ID# 130319, Mostoles, Spain|Hospital Santa Ana /ID# 129040, Motril, Spain|Complejo Hospitalario Orense /ID# 128349, Orense, Spain|Hospital Univ Central Asturias /ID# 98617, Oviedo, Spain|H. Son Espases /ID# 148214, Palma de Mallorca, Spain|Hospital Infanta Cristina /ID# 98635, Parla, Spain|Complejo Hosp Pontevedra /ID# 128354, Pontevedra, Spain|Hospital Clinico Univ de Salamanca /ID# 98589, Salamanca, Spain|Hospital Infanta Sofia /ID# 98615, San Sebastián de Los Reyes, Spain|Parc Sanitari Sant Joan De Deu /ID# 151342, Sant Boi De Llobregat, Spain|Hospital Univ Canarias /ID# 129037, Santa Cruz de Tenerife, Spain|Complejo Hosp Santiago /ID# 98619, Santiago de Compostela, Spain|Hospital General de Segovia /ID# 148926, Segovia, Spain|Hosp Univ Virgen del Rocio /ID# 98557, Sevilla, Spain|Hospital Universitario Virgen Macarena /ID# 128346, Sevilla, Spain|Hosp Univ Valme, Seville, ES /ID# 129036, Sevilla, Spain|Hospital Unide Tarragona /ID# 129122, Tarragona, Spain|Hospital Virgen de la Salud /ID# 98595, Toledo, Spain|Hosp Clin Univ de Valencia /ID# 131749, Valencia, Spain|Hospital General Universitario de Valencia /ID# 98616, Valencia, Spain|Hospital Universitario La Fe /ID# 98597, Valencia, Spain|Hospital de Sagunto /ID# 98587, Valencia, Spain|Hospital Rio Hortega /ID# 98590, Valladolid, Spain|Hospital Xeral Cies (CHUVI) /ID# 129515, Vigo, Spain|Hosp Clin Univ Lozano Blesa /ID# 98556, Zaragoza, Spain|Hospital Univ Miguel Servet /ID# 131188, Zaragoza, Spain|Hospital Royo Villanova /ID# 149850, Zaragoza, Spain|Sahlgrenska University Hosp /ID# 141672, Goteborg, Sweden|Skaraborgs Sjukhus Skovde /ID# 98898, Skövde, Sweden|Capio St Gorans Sjukhus /ID# 126123, Stockholm, Sweden|Sodersjukhuset /ID# 124158, Stockholm, Sweden|Danderyd Hospital /ID# 98897, Stockholm, Sweden|Karolinska University Hospital /ID# 171247, Stockholm, Sweden|Uppsala University Hospital /ID# 120558, Uppsala, Sweden|Kingston Hosp NHS Foundation /ID# 164109, Kingston upon Thames, England, United Kingdom|Royal Hampshire County Hosp /ID# 98900, Winchester, Hampshire, United Kingdom|County Durham & Darlington NHS /ID# 145914, Bishop Auckland, United Kingdom|Blackpool Teaching Hosp NHS /ID# 164213, Blackpool, United Kingdom|The Royal Bournemouth Hospital /ID# 164108, Bournemouth, United Kingdom|Southmead Hospital /ID# 146043, Bristol, United Kingdom|Addenbrookes Hospital /ID# 145704, Cambridge, United Kingdom|UH Coventry & Warwickshire /ID# 145680, Coventry, United Kingdom|Russells Hall Hospital, Dudley /ID# 164119, Dudley, United Kingdom|Queen Elizabeth University Hos /ID# 153818, Glasgow, United Kingdom|James Paget University Hosp /ID# 164106, Great Yarmouth, United Kingdom|London North West Healthcare N /ID# 145953, Harrow, United Kingdom|Hull and East Yorkshire NHS /ID# 98899, Hull, United Kingdom|West Suffolk Hospital /ID# 164105, Ipswich, United Kingdom|Isle of Wight NHS Trust /ID# 168166, Isle Of Wight, United Kingdom|St. James University Hospital /ID# 157949, Leeds, United Kingdom|King's College Hospital NHS /ID# 145698, London, United Kingdom|Imperial College Healthcare /ID# 145916, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 145702, Manchester, United Kingdom|Queen Elizabeth Hospital Kings /ID# 145937, Norfolk, United Kingdom|Nottingham Univ Hospitals NHS /ID# 145678, Nottingham, United Kingdom|Plymouth Hospitals NHS Trust /ID# 157432, Plymouth, United Kingdom|Plymouth Hospitals NHS Trust /ID# 203182, Plymouth, United Kingdom|St. Helens and Knowsley Teach /ID# 144089, Prescot, United Kingdom|Royal Shrewsbury Hospital /ID# 98901, Shrewsbury, United Kingdom|Southampton General Hospital /ID# 145676, Southampton, United Kingdom|Stepping Hill Hospital /ID# 144090, Stockport, United Kingdom|Barts and the London NHS Trust /ID# 145703, Whitechapel, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 164209, Wolverhampton, United Kingdom|Yeovil District Hospital NHS /ID# 146042, Yeovil, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01848561"
405,"NCT01845818","Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium","SPACTIVE","Completed","Has Results","Ankylosing Spondylitis|Psoriatic Arthritis",,"Change From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Combined)|Change From Baseline at Month 18 in TWPI Due to Disease (Ankylosing Spondylitis and Psoriatic Arthritis Separately)|Number of Participants Employed at Each Assessed Visit|Percentage of Missed Working Hours (Absenteeism) Due to Disease 7 Days Prior to Each Visit|Percentage of Activity Impairment Due to Disease During the 7 Days Prior to Each Visit|Percentage of Impairment While Working Due to Disease (Presenteeism) 7 Days Prior to Each Visit|Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores Over Time (Psoriatic Arthritis)|Dermatology Life Quality Index (DLQI) Scores Over Time (Psoriatic Arthritis)|Health Assessment Questionnaire Modified for Spondyloarthropathies (HAQ-S) Scores Over Time (Ankylosing Spondylitis)|Disease Activity Score 28 (DAS-28) Over Time (Psoriatic Arthritis)|Percentage of Body Surface Area (BSA) Affected Over Time (Psoriatic Arthritis)|Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Scores Over Time (Ankylosing Spondylitis)|Acute Phase Reactant: Erythrocyte Sedimentation Rate (ESR) Values Over Time|Acute Phase Reactant: C-Reactive Protein (CRP) Values Over Time|Physician's Assessment of Disease Activity Visual Analogue Scale (VAS) Scores Over Time|Participant's Assessment of Disease Activity Visual Analogue Scale (VAS) Scores Over Time|Participant's Global Assessment of Pain VAS Scores Over Time","AbbVie","All","18 Years to 50 Years   (Adult)",,"183","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-990","June 5, 2013","June 23, 2017","June 23, 2017","May 3, 2013","January 9, 2019","January 9, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01845818/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01845818/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01845818"
406,"NCT01834638","Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)",,"Terminated","No Results Available","Schizophrenia","Drug: ABT-126","Percentage of subjects with adverse events|Change in laboratory test results|Change in vital signs|Change in electrocardiogram (ECG) data|Change in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)|Change in University of California San Diego Performance-Based Skills Assessment-2 (UPSA-2ER)|Change in the Positive and Negative Syndrome Scale (PANSS)|Change in the 16-item version of the Negative Symptom Assessment Scale (NSA-16)","AbbVie","All","20 Years to 66 Years   (Adult, Older Adult)","Phase 2","268","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-765|2012-005661-13","March 2013","November 2014","November 2014","April 18, 2013",,"May 2, 2018","Site Reference ID/Investigator# 95398, Chino, California, United States|Site Reference ID/Investigator# 95381, Costa Mesa, California, United States|Site Reference ID/Investigator# 95400, Escondido, California, United States|Site Reference ID/Investigator# 95406, Garden Grove, California, United States|Site Reference ID/Investigator# 95378, National City, California, United States|Site Reference ID/Investigator# 95390, Norwalk, California, United States|Site Reference ID/Investigator# 95386, Oakland, California, United States|Site Reference ID/Investigator# 95391, Oceanside, California, United States|Site Reference ID/Investigator# 95380, Orange, California, United States|Site Reference ID/Investigator# 95395, Pico Rivera, California, United States|Site Reference ID/Investigator# 95403, Riverside, California, United States|Site Reference ID/Investigator# 128356, San Bernardino, California, United States|Site Reference ID/Investigator# 95405, San Diego, California, United States|Site Reference ID/Investigator# 95397, San Diego, California, United States|Site Reference ID/Investigator# 95384, San Gabriel, California, United States|Site Reference ID/Investigator# 95385, Santa Ana, California, United States|Site Reference ID/Investigator# 95387, Torrance, California, United States|Site Reference ID/Investigator# 95382, New Haven, Connecticut, United States|Site Reference ID/Investigator# 95399, Atlanta, Georgia, United States|Site Reference ID/Investigator# 95377, Marietta, Georgia, United States|Site Reference ID/Investigator# 120595, Chicago, Illinois, United States|Site Reference ID/Investigator# 129380, Hoffman Estates, Illinois, United States|Site Reference ID/Investigator# 95379, Cedarhurst, New York, United States|Site Reference ID/Investigator# 95392, Rochester, New York, United States|Site Reference ID/Investigator# 95388, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 95402, DeSoto, Texas, United States|Site Reference ID/Investigator# 95393, Houston, Texas, United States|Site Reference ID/Investigator# 117189, Chita, Russian Federation|Site Reference ID/Investigator# 117178, Ekaterinburg, Russian Federation|Site Reference ID/Investigator# 117188, Kazan, Russian Federation|Site Reference ID/Investigator# 117175, Lipetsk, Russian Federation|Site Reference ID/Investigator# 117159, Moscow, Russian Federation|Site Reference ID/Investigator# 117183, Moscow, Russian Federation|Site Reference ID/Investigator# 117182, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 117195, Saint-Petersburg, Russian Federation|Site Reference ID/Investigator# 117156, Saratov, Russian Federation|Site Reference ID/Investigator# 117177, Saratov, Russian Federation|Site Reference ID/Investigator# 117157, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 117185, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 117192, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 117193, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 117176, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 117186, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 117180, Stavropol, Russian Federation|Site Reference ID/Investigator# 117181, Yaroslavl, Russian Federation|Site Reference ID/Investigator# 117194, Yekaterinburg, Russian Federation|Site Reference ID/Investigator# 117422, Edinburgh, United Kingdom|Site Reference ID/Investigator# 117423, London, United Kingdom|Site Reference ID/Investigator# 117425, London, United Kingdom|Site Reference ID/Investigator# 117424, Newcastle upon Tyne, United Kingdom|Site Reference ID/Investigator# 117419, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01834638"
407,"NCT01833533","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection","PEARL-IV","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for Ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses|Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse After Treatment","AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","305","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M14-002|2012-005522-29","March 2013","December 2013","September 2014","April 17, 2013","January 6, 2015","September 21, 2015",,,"https://ClinicalTrials.gov/show/NCT01833533"
408,"NCT01817530","Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)",,"Completed","No Results Available","Heavy Uterine Bleeding|Uterine Fibroids","Other: Elagolix placebo|Drug: Elagolix|Drug: 0.5 mg estradiol / 0.1 mg norethindrone acetate|Drug: 1 mg estradiol / 0.5 mg norethindrone acetate|Drug: E2/NETA placebo","Percentage of Participants With a Menstrual Blood Loss (MBL) Volume of < 80 mL at the Final Month and a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month|Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 56 to 29 Days of Treatment|Percentage of Participants With a MBL Volume < 80 mL and a ≥ 50% Reduction in MBL Volume From Baseline During the Last 84 to 57 Days of Treatment|Percentage of Participants Who Achieved an MBL Volume of < 80 mL at the Final Month|Percentage of Participants With a ≥ 50% Reduction in MBL Volume From Baseline to the Final Month|Percentage of Subjects Who Achieved Amenorrhea During the Last 56 Days of Treatment|Percentage of Participants Who Achieved Suppression of Bleeding During the Last 56 Days of Treatment|Mean Change in the Number of Bleeding Days From Baseline to Month 6|Mean Change in the Number of Heavy Bleeding Days From Baseline to Month 6|Change in Bleeding Severity Scores From Baseline at the Final Month|Mean Change in Hemoglobin Concentration from Baseline to Final Visit|Mean Percentage Change from Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit|Mean Percentage Change From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit|Mean Percentage Change from Baseline in Uterine Volume at Month 3, Month 6, and Final Visit|Percentage of Subjects with ≥ 25% Reduction From Baseline in Total Fibroid Volume at Month 3, Month 6, and Final Visit|Percentage of Subjects With ≥ 25% Reduction From Baseline in Primary Fibroid Volume at Month 3, Month 6, and Final Visit|Percentage of Subjects with ≥ 25% Reduction From Baseline in Uterine Volume at Month 3, Month 6, and Final Visit|Change From Baseline to Each Month in Non-Bleeding Uterine Fibroids Symptom (NBUFSQ) Questionnaire|Percentage of Subjects Who Successfully Avoided Surgical or Invasive Procedures for Uterine Fibroids","AbbVie","Female","18 Years to 51 Years   (Adult)","Phase 2","567","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-813|2013-000082-37","April 8, 2013","June 2015","December 2015","March 25, 2013",,"July 26, 2018",,,"https://ClinicalTrials.gov/show/NCT01817530"
409,"NCT01808118","Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis",,"Completed","Has Results","Axial Spondyloarthritis","Biological: adalimumab|Biological: Placebo","Number of Participants Who Did Not Experience a Flare During Period 2 by Week 68|Number of Participants With Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease at 12 Weeks After Initiation of Rescue Therapy|Number of Participants Achieving ASDAS Major Improvement at 12 Weeks After Initiation of Rescue Therapy|Number of Participants Achieving ASDAS Clinically Important Improvement at 12 Weeks After Initiation of Rescue Therapy|Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response at 12 Weeks After Initiation of Rescue Therapy|Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response at 12 Weeks After Initiation of Rescue Therapy|Number of Participants Achieving an ASAS 5/6 Response at 12 Weeks After Initiation of Rescue Therapy|Number of Participants Achieving ASAS Partial Remission at 12 Weeks After Initiation of Rescue Therapy|Number of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at 12 Weeks After Initiation of Rescue Therapy|Change From Baseline in Disability Index of Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S) at 12 Weeks After Initiation of Rescue Therapy|Number of Participants With Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease at Weeks 28 and 68|Number of Participants Achieving ASDAS Major Improvement at Weeks 28 and 68|Number of Participants Achieving ASDAS Clinically Important Improvement at Weeks 28 and 68|Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response at Weeks 28 and 68|Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response at Weeks 28 and 68|Number of Participants Achieving an ASAS 5/6 Response at Weeks 28 and 68|Number of Participants Achieving ASAS Partial Remission at Weeks 28 and 68|Number of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Weeks 28 and 68|Change From Baseline in Disability Index of Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S) at Weeks 28 and 68|Time to Flare at Week 68|Time to Partial Flare at Week 68|Number of Participants Reaching Flare Definition by Week 68|Number of Participants Reaching Partial Flare Definition by Week 68","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","673","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M13-375|2012-000646-35","April 16, 2013","February 21, 2017","April 14, 2017","March 11, 2013","April 30, 2018","May 30, 2018",,"""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01808118/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT01808118/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01808118"
410,"NCT01800695","Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme",,"Completed","No Results Available","Glioblastoma Multiforme","Drug: ABT-414|Drug: Temozolomide|Radiation: Whole Brain Radiation","Number and percentage of participants with adverse events|Maximum concentration of ABT-414|Number of Dose Limiting Toxicities|Minimum Concentration of ABT-414|Half-life of ABT-414|Biomarker EGFR expression|Progression Free Survival|Overall Survival","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","202","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-356|2012-003884-23","April 2, 2013","June 19, 2017","June 19, 2017","February 28, 2013",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01800695"
411,"NCT01794520","Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma",,"Active, not recruiting","No Results Available","Relapsed/Refractory Multiple Myeloma","Drug: Dexamethasone|Drug: ABT-199","Determination of peak concentration (Cmax) of ABT-199|Calculation of objective response rate|Determine dose and schedule of ABT-199|Number and percentage of subjects with adverse events|Calculation of very good partial response rate or better|Determination of trough concentration (Ctrough) of ABT-199|Determination of area under the concentration versus time curve (AUC) of ABT-199|Calculation of Objective Response Rate|Calculation of Time to Response (TTR)|Calculation of Overall Survival|Calculation of Duration of Response|Calculation of time to disease progression|Progression Free Survival","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","117","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-367|2012-000589-38","October 10, 2012","December 31, 2021","December 31, 2021","February 20, 2013",,"August 28, 2019","Mayo Clinic - Scottsdale /ID# 75808, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences /ID# 170002, Little Rock, Arkansas, United States|Yale University /ID# 203704, New Haven, Connecticut, United States|Emory University Hospital /ID# 74993, Atlanta, Georgia, United States|Ingalls Memorial Hosp /ID# 205346, Harvey, Illinois, United States|Tulane Cancer Center Clinic /ID# 204123, New Orleans, Louisiana, United States|Tufts Medical Center /ID# 203814, Boston, Massachusetts, United States|Univ Mich Health System /ID# 170007, Ann Arbor, Michigan, United States|Mayo Clinic - Rochester /ID# 74994, Rochester, Minnesota, United States|Hattiesburg Clinic /ID# 201187, Hattiesburg, Mississippi, United States|Washington University-School of Medicine /ID# 76094, Saint Louis, Missouri, United States|University of Nebraska Medical Center /ID# 169158, Omaha, Nebraska, United States|The John Theurer Cancer /ID# 200248, Hackensack, New Jersey, United States|Duke University Medical Center - Main /ID# 129356, Durham, North Carolina, United States|Wake Forest Baptist Health /ID# 205182, Winston-Salem, North Carolina, United States|University Hospitals - Seidman Cancer Center /ID# 204502, Cleveland, Ohio, United States|Ohio State Cancer Center /ID# 200249, Columbus, Ohio, United States|Avera Cancer Institute /ID# 204178, Sioux Falls, South Dakota, United States|Baylor University Medical Ctr. /ID# 170056, Dallas, Texas, United States|University of Utah /ID# 205669, Salt Lake City, Utah, United States|Swedish Cancer Institute /ID# 170006, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 200246, Madison, Wisconsin, United States|Medical College of Wisconsin /ID# 205229, Milwaukee, Wisconsin, United States|General Hospital Saint-Jan /ID# 201101, Brugge, Brabant Wallon, Belgium|UZ Brussel /ID# 170711, Jette, Bruxelles-Capitale, Belgium|ZNA Stuivenberg /ID# 170067, Antwerp, Belgium|University Hospital Leuven /ID# 170715, Leuven, Belgium|CHRU Lille - Hôpital Claude Huriez /ID# 74995, Lille CEDEX, Hauts-de-France, France|Hopital Bretonneau - CHU Tours /ID# 126639, Tours CEDEX 9, Indre-et-Loire, France|CHU de Grenoble - Albet Michal /ID# 126658, Grenoble, France|CHU de Nantes, Hotel Dieu -HME /ID# 75033, Nantes, France|Ullevål, OUS /ID# 170707, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT01794520"
412,"NCT01794507","A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy",,"Completed","No Results Available","Relapsed/Refractory Multiple Myeloma","Drug: ABT-199|Drug: bortezomib|Drug: dexamethasone","Determination of peak concentration (Cmax) of ABT-199|Determine maximum tolerated dose (MTD), and recommended phase two dose (RPTD) of ABT-199|Number of participants with adverse events|Determination of trough concentration (Ctrough) of ABT-199|Determination of area under the concentration versus time curve (AUC) of ABT-199|Determine recommended phase two dose (RPTD) of ABT-199|Duration of Response|Objective Response Rate|Time to Disease Progression","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","66","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-901|2011-004626-10","November 19, 2012","July 16, 2019","July 16, 2019","February 20, 2013",,"August 14, 2019","University of Arizona Cancer Center - North Campus /ID# 117876, Tucson, Arizona, United States|Mayo Clinic /ID# 121495, Jacksonville, Florida, United States|Northwestern University Feinberg School of Medicine /ID# 117477, Chicago, Illinois, United States|University of Michigan Hospitals /ID# 80353, Ann Arbor, Michigan, United States|Mayo Clinic - Rochester /ID# 77235, Rochester, Minnesota, United States|Peter MacCallum Cancer Ctr /ID# 79553, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 79533, Parkville, Victoria, Australia|CHRU Lille - Hôpital Claude Huriez /ID# 77234, Lille CEDEX, Hauts-de-France, France|CHU de Nantes, Hotel Dieu -HME /ID# 78773, Nantes, France",,"https://ClinicalTrials.gov/show/NCT01794507"
413,"NCT01783730","Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents",,"Completed","Has Results","Rheumatoid Arthritis",,"Number of Participants With Adverse Events|Mean Disease Activity Score 28 (DAS28-4(ESR)) at Baseline|Mean Disease Activity Score 28 (DAS28-4(ESR)) at Week 4|Mean Disease Activity Score 28 (DAS28-4(ESR)) at Week 12|Mean Disease Activity Score 28 (DAS28-4(ESR)) at Week 24|Percentage of Participants Achieving DAS28-4(ESR) Remission|Mean Clinical Disease Activity Index (CDAI) Score at Baseline|Mean Clinical Disease Activity Index (CDAI) Score at Week 4|Mean Clinical Disease Activity Index (CDAI) Score at Week 12|Mean Clinical Disease Activity Index (CDAI) Score at Week 24|Percentage of Participants Achieving CDAI Remission|Mean Simplified Disease Activity Index (SDAI) Score at Baseline|Mean Simplified Disease Activity Index (SDAI) Score at Week 4|Mean Simplified Disease Activity Index (SDAI) Score at Week 12|Mean Simplified Disease Activity Index (SDAI) Score at Week 24|Percentage of Participants Achieving SDAI Remission","AbbVie","All","15 Years to 99 Years   (Child, Adult, Older Adult)",,"163","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-983","February 2013","September 2015","September 2015","February 5, 2013","October 26, 2016","October 26, 2016",,,"https://ClinicalTrials.gov/show/NCT01783730"
414,"NCT01782495","A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","CORAL-I","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir|Drug: ombitasvir/paritaprevir/ritonavir|Drug: ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)|Percentage of Participants With On-treatment Virologic Failure|Percentage of Participants With Post-treatment Relapse","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","129","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-999|2012-004792-39","February 25, 2013","November 2, 2016","July 13, 2017","February 4, 2013","November 7, 2017","November 7, 2017",,,"https://ClinicalTrials.gov/show/NCT01782495"
415,"NCT01777165","A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery",,"Completed","No Results Available","Acute Kidney Injury","Drug: ABT-719|Drug: Placebo","Number of patients developing acute kidney injury based on the Acute Kidney Injury Network (AKIN) scoring criteria by comparing the ABT-719 dose groups versus placebo group.|Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in estimated glomerular filtration rate or measured glomerular filtration rate|Proportion of subjects developing at least one of the composite events: death, needing renal replacement therapy, or having greater than or equal to 25 percent reduction in serum creatinine based estimated glomerular filtration rate (GFR)|Proportion of subjects developing AKI as defined by the Risk, Injury, Failure, Loss, or ESRD (RIFLE) model|Proportion of subjects developing AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) model|Changes from baseline (defined as within 24 hours of day 0) in serum creatinine (SCr) and S-Cystatin C at all study visits from baseline to Day 90","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","M13-796|2012-003942-33","February 2013","March 2014","March 2014","January 28, 2013",,"April 16, 2015","Site Reference ID/Investigator# 83739, Danbury, Connecticut, United States|Site Reference ID/Investigator# 87720, Gainesville, Florida, United States|Site Reference ID/Investigator# 83746, Jacksonville, Florida, United States|Site Reference ID/Investigator# 83733, Jacksonville, Florida, United States|Site Reference ID/Investigator# 89178, Tampa, Florida, United States|Site Reference ID/Investigator# 87693, Atlanta, Georgia, United States|Site Reference ID/Investigator# 87717, Augusta, Georgia, United States|Site Reference ID/Investigator# 89180, Fort Wayne, Indiana, United States|Site Reference ID/Investigator# 101942, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 85917, Lexington, Kentucky, United States|Site Reference ID/Investigator# 83732, Bethesda, Maryland, United States|Site Reference ID/Investigator# 83724, Boston, Massachusetts, United States|Site Reference ID/Investigator# 83745, Boston, Massachusetts, United States|Site Reference ID/Investigator# 83750, Grand Blanc, Michigan, United States|Site Reference ID/Investigator# 83747, Petoskey, Michigan, United States|Site Reference ID/Investigator# 83744, Royal Oak, Michigan, United States|Site Reference ID/Investigator# 85913, St. Paul, Minnesota, United States|Site Reference ID/Investigator# 96455, St. Louis, Missouri, United States|Site Reference ID/Investigator# 91253, Omaha, Nebraska, United States|Site Reference ID/Investigator# 93673, Newark, New Jersey, United States|Site Reference ID/Investigator# 83722, New York, New York, United States|Site Reference ID/Investigator# 89176, Ashville, North Carolina, United States|Site Reference ID/Investigator# 83723, Durham, North Carolina, United States|Site Reference ID/Investigator# 92413, Gastonia, North Carolina, United States|Site Reference ID/Investigator# 87733, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 83735, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 91813, Columbus, Ohio, United States|Site Reference ID/Investigator# 83738, Toledo, Ohio, United States|Site Reference ID/Investigator# 91693, Portland, Oregon, United States|Site Reference ID/Investigator# 89182, Springfield, Oregon, United States|Site Reference ID/Investigator# 83734, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 83730, Knoxville, Tennessee, United States|Site Reference ID/Investigator# 101876, Memphis, Tennessee, United States|Site Reference ID/Investigator# 90614, Charlottesville, Virginia, United States|Site Reference ID/Investigator# 83725, Richmond, Virginia, United States|Site Reference ID/Investigator# 87714, Tacoma, Washington, United States|Site Reference ID/Investigator# 91814, Madison, Wisconsin, United States|Site Reference ID/Investigator# 87739, Milwaukee, Wisconsin, United States|Site Reference ID/Investigator# 94956, Aarhus N, Denmark|Site Reference ID/Investigator# 109295, Copenhagen O, Denmark|Site Reference ID/Investigator# 94955, Odense C, Denmark",,"https://ClinicalTrials.gov/show/NCT01777165"
416,"NCT01768858","Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice","Adherence","Completed","Has Results","Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis|Crohn´s Disease|Ulcerative Colitis|Plaque Psoriasis","Drug: Adalimumab","Change From Baseline in the Beliefs About Medicines Questionnaire (BMQ) Specific Score at 12 Months|Correlation Between Beliefs About Medicines Questionnaire (BMQ) Specific Score and Adherence to Treatment as Measured by the Morisky Medication Adherence Scale (MMAS) at 12 Months|Change in Morisky Medication Adherence Scale (MMAS) Scores From Month 3 to Month 12|Change in the Treatment Satisfaction Questionnaire for Medication (TSQM) Scores From Month 3 to Month 12|Change in Rheumatoid Arthritis Disease Activity Index (RADAI) Scores Over Time|Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score Over Time|Change in C-reactive Protein (CRP) Concentration Over Time|Changes in Erythrocyte Sedimentation Rate (ESR) Over Time|Change in Psoriasis Area and Severity Index (PASI) Score Over Time","AbbVie|Raffeiner GmbH","All","18 Years to 99 Years   (Adult, Older Adult)",,"96","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-562","February 5, 2013","August 13, 2017","August 13, 2017","January 16, 2013","January 28, 2019","January 28, 2019",,"""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT01768858/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01768858"
417,"NCT01760954","Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain",,"Completed","Has Results","Endometriosis","Drug: Elagolix","Percentage of Participants With a Response for Dysmenorrhea at Month 6 Based on Daily Assessment|Percentage of Participants With a Response for Non-menstrual Pelvic Pain at Month 6 Based on Daily Assessment|Percentage of Participants With a Response for Dysmenorrhea at Each Month Based on Daily Assessment|Percentage of Participants With a Response for Non-menstrual Pelvic Pain at Each Month Based on Daily Assessment|Percentage of Participants With a Response for Dyspareunia at Each Month Based on Daily Assessment|Percent Change From Baseline in Dysmenorrhea Based on Daily Assessment|Percent Change From Baseline in Non-menstrual Pelvic Pain Based on Daily Assessment|Percent Change From Baseline in Dyspareunia Based on Daily Assessment|Change From Baseline in Any Rescue Analgesic Use|Change From Baseline in NSAID Rescue Analgesic Use|Change From Baseline in Opioid Rescue Analgesic Use|Percent Change From Baseline in Endometriosis-Associated Pain Score Assessed With Numeric Rating Scale (NRS)|Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved|Change From Baseline in Endometriosis Health Profile-30 (EHP-30) Pain Dimension|Change From Baseline in Endometriosis Health Profile-30 (EHP-30) Sexual Intercourse Dimension|Change From Baseline in Health-Related Productivity Questionnaire (HRPQ): Hours of Work Lost in Workplace and Household|Number of Participants With Non-study Health Visits During the Treatment Period|Number of Days in Hospital During the Treatment Period","AbbVie","Female","18 Years to 50 Years   (Adult)","Phase 3","506","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-667","December 28, 2012","May 2015","April 15, 2016","January 4, 2013","September 6, 2018","September 6, 2018",,,"https://ClinicalTrials.gov/show/NCT01760954"
418,"NCT01682616","A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",,"Active, not recruiting","No Results Available","Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia","Drug: ABT-199|Drug: Rituximab","Assess the safety profile, to determine the maximum tolerated dose and Recommended Phase Two Dose of ABT-199 when administered in combination with rituximab (R) in subjects with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.|Determination of peak concentration (Cmax) of ABT-199 and/or Rituximab.|Assess the exploratory efficacy of the combination ABT-199 and rituximab.|Determination of trough concentration (Ctrough) of ABT-199 and/or Rituximab|Determination of area under the concentration versus time curve (AUC) of ABT-199 and/or Rituximab|Assess the exploratory efficacy of the combination ABT-199 and rituximab","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-365","July 25, 2012","June 29, 2022","June 29, 2022","September 11, 2012",,"November 22, 2019","Ucsd /Id# 70398, La Jolla, California, United States|Northwestern University Feinberg School of Medicine /ID# 71593, Chicago, Illinois, United States|North Shore University Hospital /ID# 71813, New Hyde Park, New York, United States|Duke University Medical Center /ID# 71393, Durham, North Carolina, United States|Peter MacCallum Cancer Ctr /ID# 70394, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 70393, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01682616"
419,"NCT01652157","Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)",,"Recruiting","No Results Available","Fibrosing Colonopathy","Biological: ULTRESA|Biological: PANCREAZE|Biological: CREON|Biological: ZENPEP|Biological: other non-sponsor pancreatic enzyme replacement therapy|Biological: PERTZYE|Other: No pancreatic enzyme replacement therapy","Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving ZENPEP|Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving ULTRESA|Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving PERTZYE.|Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving CREON|Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving PANCREAZE|Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients not receiving pancreatic enzyme therapy.|Incidence rate of fibrosing colonopathy confirmed by an independent adjudication panel in patients receiving non-sponsor pancreatic enzyme replacement therapy|Odds ratio (95% confidence interval) to quantify the association between possible risk factors and confirmed fibrosing colonopathy","AbbVie|Cystic Fibrosis Foundation|Digestive Care, Inc.|Forest Research Institute, Inc., an affiliate of Actavis, Inc.|VIVUS, Inc.","All","up to 99 Years   (Child, Adult, Older Adult)",,"50","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CFFC-OB-11","July 31, 2012","July 29, 2022","July 29, 2022","July 27, 2012",,"December 19, 2019","Children's Hospital of Alabama /ID# 78920, Birmingham, Alabama, United States|Alaska Medical Center /ID# 79256, Anchorage, Alaska, United States|Phoenix Children's Hospital /ID# 78906, Phoenix, Arizona, United States|University of Arizona Arthritis Center /ID# 78939, Tucson, Arizona, United States|Arkansas Children's Hospital /ID# 79265, Little Rock, Arkansas, United States|University of Arkansas for Medical Sciences /ID# 76785, Little Rock, Arkansas, United States|Ucsd /Id# 105039, La Jolla, California, United States|Loma Linda University /ID# 79237, Loma Linda, California, United States|Miller Childrens Hospital /ID# 78896, Long Beach, California, United States|Kaiser Permanente Regional Met /ID# 79235, Los Angeles, California, United States|Usc /Id# 76793, Los Angeles, California, United States|Children's Hosp and Res Ctr /ID# 79295, Oakland, California, United States|Kaiser Permanente /ID# 78899, Oakland, California, United States|UC Davis Comprehensive Cancer Center - Main /ID# 118935, Sacramento, California, United States|California Pacific Medical Ctr /ID# 76775, San Francisco, California, United States|Univ California, San Francisco /ID# 78925, San Francisco, California, United States|Stanford University /ID# 95156, Stanford, California, United States|Univ of Colorado Cancer Center /ID# 79277, Aurora, Colorado, United States|National Jewish Health /ID# 76784, Denver, Colorado, United States|CT Childrens Medical Ctr, US /ID# 78923, Hartford, Connecticut, United States|Yale University /ID# 78940, New Haven, Connecticut, United States|Nemours/Alfred duPont Hospital for Children /ID# 78945, Wilmington, Delaware, United States|Children's National Medical Center /ID# 79373, Washington, District of Columbia, United States|Central FL Pulmonary Altamonte /ID# 76776, Altamonte Springs, Florida, United States|University of Florida /ID# 76790, Gainesville, Florida, United States|University of Florida /ID# 78928, Gainesville, Florida, United States|Joe DiMaggio Children's Hospital at Memorial /ID# 79234, Hollywood, Florida, United States|Nemour Child Clin FL, US /ID# 78898, Jacksonville, Florida, United States|University of Miami, Miller School of Medicine /ID# 78927, Miami, Florida, United States|Nemours Children's Clinic /ID# 78917, Orlando, Florida, United States|Arnold Palmer Hosp Children /ID# 96075, Orlando, Florida, United States|All Children's Hospital /ID# 79264, Saint Petersburg, Florida, United States|Emory University Hospital /ID# 79394, Atlanta, Georgia, United States|Children's Healthcare of Atlanta - Ferry Rd /ID# 116275, Atlanta, Georgia, United States|Georgia Regents University /ID# 79395, Augusta, Georgia, United States|St Luke's Cystic Fibrosis Center of Idaho /ID# 79259, Boise, Idaho, United States|Duplicate_Childrens Hospital of Chicago /ID# 79296, Chicago, Illinois, United States|University of Chicago /ID# 78924, Chicago, Illinois, United States|Loyola University Medical Ctr /ID# 76780, Maywood, Illinois, United States|Advocate Lutheran Gen Children /ID# 76781, Park Ridge, Illinois, United States|OSF Saint Francis Medical Ctr /ID# 78905, Peoria, Illinois, United States|Lutheran Hospital of Indiana /ID# 79238, Fort Wayne, Indiana, United States|Indiana University /ID# 121395, Indianapolis, Indiana, United States|Indiana University /ID# 78903, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics /ID# 78921, Iowa City, Iowa, United States|University of Kansas Health Sy /ID# 78929, Kansas City, Kansas, United States|Via Christi Specialty Clinics /ID# 78946, Wichita, Kansas, United States|Kentucky Clinic /ID# 78922, Lexington, Kentucky, United States|University of Louisville /ID# 78926, Louisville, Kentucky, United States|Tulane Univ /ID# 78916, New Orleans, Louisiana, United States|Louisiana State Univ HSC /ID# 78943, Shreveport, Louisiana, United States|Rheumatology Associates,PA /ID# 78894, Portland, Maine, United States|Johns Hopkins University /ID# 78893, Baltimore, Maryland, United States|Tufts-New England Medical Ctr /ID# 79254, Boston, Massachusetts, United States|Massachusetts General Hospital /ID# 78895, Boston, Massachusetts, United States|Boston Childrens Hospital /ID# 79276, Boston, Massachusetts, United States|Baystate Medical Center /ID# 103437, Springfield, Massachusetts, United States|UMass Memorial Medical Center /ID# 78954, Worcester, Massachusetts, United States|University of Michigan Hospitals /ID# 99035, Ann Arbor, Michigan, United States|Children's Hospital of MI /ID# 79278, Detroit, Michigan, United States|Michigan State University /ID# 78950, East Lansing, Michigan, United States|Helen DeVos Childrens Hospital /ID# 79397, Grand Rapids, Michigan, United States|University of Minnesota /ID# 76791, Minneapolis, Minnesota, United States|Univ of Mississippi Med Ctr,US /ID# 78934, Jackson, Mississippi, United States|University of Missouri /ID# 109755, Columbia, Missouri, United States|The Children's Mercy Hospital /ID# 78948, Kansas City, Missouri, United States|Cardinal Glennon Children's Ho /ID# 79275, Saint Louis, Missouri, United States|Children's Hospital St Louis /ID# 78910, Saint Louis, Missouri, United States|Univ Nebraska Med Ctr /ID# 78932, Omaha, Nebraska, United States|Dartmouth-Hitchcock Med Ctr /ID# 78957, Lebanon, New Hampshire, United States|St. Barnabas Medical Center /ID# 79258, Livingston, New Jersey, United States|Monmouth Medical Center /ID# 78901, Long Branch, New Jersey, United States|Goryeb Chidlren's Hospital /ID# 76782, Morristown, New Jersey, United States|Rutgers Robert Wood Johnson /ID# 119978, New Brunswick, New Jersey, United States|Albany Medical College /ID# 76774, Albany, New York, United States|Cystic Fibrosis Therapeutics /ID# 78941, Buffalo, New York, United States|North Shore University Hospital /ID# 76779, New Hyde Park, New York, United States|Mount Sinai Beth Israel /ID# 76773, New York, New York, United States|Weill Cornell Medicine /ID# 79376, New York, New York, United States|Univ Rochester Med Ctr /ID# 92713, Rochester, New York, United States|SUNY Upstate Medical University - Downtown /ID# 78912, Syracuse, New York, United States|New York Medical College /ID# 78956, Valhalla, New York, United States|Univ NC Chapel Hill /ID# 78937, Chapel Hill, North Carolina, United States|Duke University Medical Center /ID# 79393, Durham, North Carolina, United States|Mid Dakota Clinic, PC /ID# 78958, Bismarck, North Dakota, United States|Akron Childrens Hospital /ID# 79263, Akron, Ohio, United States|Cincinnati Children's Hospital /ID# 79375, Cincinnati, Ohio, United States|University of Cincinnati /ID# 76789, Cincinnati, Ohio, United States|Case Western Reserve Univ /ID# 78904, Cleveland, Ohio, United States|Nationwide Childrens Hospital /ID# 78897, Columbus, Ohio, United States|The Childrens Medical Center /ID# 78915, Dayton, Ohio, United States|ProMedica Toledo Hospital /ID# 78913, Toledo, Ohio, United States|Univ Oklahoma HSC /ID# 79279, Oklahoma City, Oklahoma, United States|Kaiser Permanente, NW /ID# 79236, Portland, Oregon, United States|Oregon Health and Science University /ID# 78900, Portland, Oregon, United States|Geisinger Medical Center /ID# 79233, Danville, Pennsylvania, United States|Penn State Child Hosp.Hersh,PA /ID# 79398, Hershey, Pennsylvania, United States|Children's Hosp Philadelphia /ID# 79280, Philadelphia, Pennsylvania, United States|Drexel Univ College of Med /ID# 76777, Philadelphia, Pennsylvania, United States|St. Christopher's Hospital /ID# 78908, Philadelphia, Pennsylvania, United States|Child Hosp of Pittsburgh,PA /ID# 79281, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital /ID# 79274, Providence, Rhode Island, United States|Medical University of South Carolina /ID# 79262, Charleston, South Carolina, United States|Sanford Research/USD /ID# 78909, Sioux Falls, South Dakota, United States|LeBonheur Children's Med Ctr /ID# 78938, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr /ID# 78947, Nashville, Tennessee, United States|Specially for Children /ID# 79213, Austin, Texas, United States|UT Southwestern Medical Center /ID# 78914, Dallas, Texas, United States|Cook Children's Med. Center /ID# 78949, Fort Worth, Texas, United States|Baylor College of Medicine /ID# 79273, Houston, Texas, United States|Univ Texas HSC San Antonio /ID# 79374, San Antonio, Texas, United States|The Univ Texas HSC at Tyler /ID# 79261, Tyler, Texas, United States|University of Utah /ID# 76794, Salt Lake City, Utah, United States|University of Vermont Medical Center /ID# 78933, Burlington, Vermont, United States|University of Virginia /ID# 78942, Charlottesville, Virginia, United States|Child Hosp of the King's Dtr's /ID# 79293, Norfolk, Virginia, United States|Children's Hospital of Richmon /ID# 78955, Richmond, Virginia, United States|Seattle Children's Hospital /ID# 78902, Seattle, Washington, United States|Arthritis Northwest, PLLC /ID# 79257, Spokane, Washington, United States|West Virginia Univ School Med /ID# 78953, Morgantown, West Virginia, United States|Univ of Wisconsin Hosp/Clinics /ID# 78944, Madison, Wisconsin, United States|Froedtert & the Medical College of Wisconsin /ID# 76778, Milwaukee, Wisconsin, United States|Children's Hospital Wisconsin - Milwaukee Campus /ID# 79294, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01652157"
420,"NCT01594229","A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma",,"Active, not recruiting","No Results Available","Non-Hodgkin's Lymphoma","Drug: ABT-199|Drug: Rituximab|Drug: Bendamustine","Determination of the maximum tolerated dose of ABT-199 when administered with Bendamustine and Rituximab in subjects with relapsed or refractory non-Hodgkin's lymphoma|Determination of peak concentration (Cmax), trough concentration (Ctrough) and/or area under the concentration versus time curve (AUC) of ABT-199, Bendamustine and Rituximab in the dose escalation cohort|Number of participants with adverse events as a measure of safety and tolerability|Determination of the recommended Phase 2 dose of ABT-199 when administered with Bendamustine and Rituximab in subjects with relapsed or refractory non-Hodgkin's lymphoma|Evaluate preliminary data regarding progression-free survival when ABT-199 is administered in combination with Bendamustine and Rituximab|Evaluate preliminary data regarding overall survival and duration of overall response when ABT-199 is administered in combination with Bendamustine and Rituximab.|Evaluate preliminary data regarding objective response rate when ABT-199 is administered in combination with Bendamustine and Rituximab|Evaluate preliminary data regarding time to tumor progression when ABT-199 is administered in combination with Bendamustine and Rituximab.","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-630","May 21, 2012","October 26, 2020","October 26, 2020","May 9, 2012",,"December 11, 2019","Ucsd /Id# 67350, La Jolla, California, United States|University of California, Los Angeles /ID# 67343, Los Angeles, California, United States|Emory University Hospital /ID# 67349, Atlanta, Georgia, United States|Georgia Regents University /ID# 67342, Augusta, Georgia, United States|Ingalls Memorial Hosp /ID# 67344, Harvey, Illinois, United States|Johns Hopkins University /ID# 67345, Baltimore, Maryland, United States|Henry Ford Health System /ID# 67346, Detroit, Michigan, United States|University of Texas MD Anderson Cancer Center /ID# 69222, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01594229"
421,"NCT01577550","Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: BI 655066 (very high i.v. dose)|Drug: Placebo, i.v.|Drug: BI 655066 (high s.c. dose)|Drug: BI 655066 (low i.v. dose)|Drug: BI 655066 (high medium i.v. dose)|Drug: BI 655066 (very low i.v. dose)|Drug: BI 655066 (low s.c. dose)|Drug: BI 655066 (high i.v. dose)|Drug: Placebo, s.c.|Drug: BI 655066 (low medium i.v. dose)","Number of patients with good and satisfactory assessment of global tolerability by investigator|Number of patients without any symptoms at the drug administration site, at per local assessment of tolerability by investigator|Number of participants with adverse events|Number of participants with clinically relevant findings in vital signs|Number of participants with clinically significant abnormalities in electrocardiogramm (ECG) results|Number of participants with significant changes from baseline laboratory measurements|Psoriasis Area and Severity Index (absolute score)|Percentage of participants with Static Physicians Global Assessment (clear and almost clear)|Cmax (maximum measured concentration of the analyte in plasma)|tmax (time from dosing to maximum measured concentration)|AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)|Psoriasis Area and Severity Index (percentage change from baseline)","AbbVie|Boehringer Ingelheim","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1311.1|2012-000081-37","April 2012","October 2013","May 2014","April 16, 2012",,"November 16, 2016","1311.1.0007 Boehringer Ingelheim Investigational Site, Burbank, California, United States|1311.1.0008 Boehringer Ingelheim Investigational Site, Miami, Florida, United States|1311.1.0003 Boehringer Ingelheim Investigational Site, Port Orange, Florida, United States|1311.1.0005 Boehringer Ingelheim Investigational Site, Normal, Illinois, United States|1311.1.0006 Boehringer Ingelheim Investigational Site, Evansville, Indiana, United States|1311.1.0004 Boehringer Ingelheim Investigational Site, North Dartmouth, Massachusetts, United States|1311.1.0002 Boehringer Ingelheim Investigational Site, Pittsburgh, Pennsylvania, United States|1311.1.4901 Boehringer Ingelheim Investigational Site, Berlin, Germany|1311.1.0009 Boehringer Ingelheim Investigational Site, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01577550"
422,"NCT01506609","The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer",,"Active, not recruiting","No Results Available","Metastatic Breast Cancer","Drug: Placebo|Drug: Veliparib|Drug: Carboplatin|Drug: Temozolomide|Drug: Paclitaxel","Progression -Free Survival|Overall Survival|Clinical Benefit Rate (CBR)|Objective Response Rate","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","294","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-895|2011-002913-12","January 23, 2012","December 13, 2018","January 23, 2020","January 10, 2012",,"November 15, 2019","University of Alabama /ID# 62994, Birmingham, Alabama, United States|Banner MD Anderson Cancer Ctr /ID# 118695, Gilbert, Arizona, United States|University of Arkansas for Medical Sciences /ID# 60750, Little Rock, Arkansas, United States|Ucsd /Id# 60754, La Jolla, California, United States|The Angeles Clinic and Researc /ID# 60743, Los Angeles, California, United States|Stanford Univ School of Med /ID# 65488, Stanford, California, United States|Cedars-Sinai Medical Center - West Hollywood /ID# 60760, West Hollywood, California, United States|Univ of Colorado Cancer Center /ID# 60751, Aurora, Colorado, United States|Lynn Cancer Institute, Boca /ID# 60749, Boca Raton, Florida, United States|Holy Cross Hospital /ID# 62995, Fort Lauderdale, Florida, United States|Moffitt Cancer Center /ID# 60746, Tampa, Florida, United States|Florida Cancer Specialists - East /ID# 60762, West Palm Beach, Florida, United States|University of Illinois - Chicago /ID# 106175, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine /ID# 60755, Chicago, Illinois, United States|Rush University Medical Center /ID# 65489, Chicago, Illinois, United States|Midwestern Regional CTC /ID# 60744, Zion, Illinois, United States|Johns Hopkins University /ID# 60759, Baltimore, Maryland, United States|Massachusetts General Hospital /ID# 64582, Boston, Massachusetts, United States|Dana-Farber Cancer Institute /ID# 93833, Boston, Massachusetts, United States|William Beaumont Hospital /ID# 95417, Royal Oak, Michigan, United States|Washington University-School of Medicine /ID# 62724, Saint Louis, Missouri, United States|Beth Israel Medical Center /ID# 87993, New York, New York, United States|Memorial Sloan Kettering Cancer Center /ID# 63222, New York, New York, United States|Duke Univ Med Ctr /ID# 60747, Durham, North Carolina, United States|Penn State University and Milton S. Hershey Medical Center /ID# 62723, Hershey, Pennsylvania, United States|University of Pennsylvania /ID# 60753, Philadelphia, Pennsylvania, United States|University of Pittsburgh MC /ID# 60758, Pittsburgh, Pennsylvania, United States|University of Pittsburgh MC /ID# 65486, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina /ID# 60752, Charleston, South Carolina, United States|The West Clinic /ID# 65487, Memphis, Tennessee, United States|The West Clinic /ID# 94599, Memphis, Tennessee, United States|The West Clinic /ID# 94600, Memphis, Tennessee, United States|UT Southwestern Medical Center /ID# 60745, Dallas, Texas, United States|The Methodist Hospital /ID# 60742, Houston, Texas, United States|Coiba /Id# 65219, Berazategui, Buenos Aires, Argentina|ISIS Centro Especializado /ID# 65226, Santa Fe, Argentina|The Prince of Wales Hospital /ID# 63271, Randwick, New South Wales, Australia|Southern Medical Day Care Ctr /ID# 63274, Wollongong, New South Wales, Australia|Mater Health Hospital /ID# 63276, South Brisbane, Queensland, Australia|Royal Adelaide Hospital /ID# 63280, Adelaide, South Australia, Australia|Royal Hobart Hospital /ID# 63279, Hobart, Tasmania, Australia|Peter MacCallum Cancer Ctr /ID# 63272, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 63278, Parkville, Victoria, Australia|Mount Hospital /ID# 65262, Perth, Western Australia, Australia|Cliniques Universitaires Saint Luc /ID# 96135, Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium|Grand Hôpital de Charleroi /ID# 96136, Charleroi, Hainaut, Belgium|AZ St-Jan Brugge-Oostende AV /ID# 107315, Brugge, West-Vlaanderen, Belgium|UZ Antwerp /ID# 96945, Edegem, Belgium|UZ Leuven /ID# 96138, Leuven, Belgium|CHU UCL Namur /ID# 110595, Namur, Belgium|Hospital Bruno Born /ID# 65247, Lajeado, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de /ID# 65244, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre /ID# 65242, Porto Alegre, Rio Grande Do Sul, Brazil|Sunnybrook Health Sciences Ctr /ID# 77373, Toronto, Ontario, Canada|Jewish General Hospital /ID# 69893, Montreal, Quebec, Canada|CHUM - Notre-Dame Hospital /ID# 67862, Montréal, Quebec, Canada|CHUQ-Hospital St. Sacrement /ID# 68902, Quebec City, Quebec, Canada|Masarykuv onkologikcy ustav /ID# 65170, Brno, Czechia|Palacky University /ID# 63923, Olomouc, Czechia|Vseobecna Fakultni Nemocnice /ID# 65172, Prague, Czechia|Vejle Sygehus /ID# 65173, Vejle, Syddanmark, Denmark|Rigshospitalet, Finsen Centre /ID# 67822, Copenhagen, Denmark|Docrates Cancer Center /ID# 63924, Helsinki, Finland|Tampere University Hospital /ID# 102417, Tampere, Finland|Hopital Universitaire Purpan /ID# 98815, Toulouse, Haute-Garonne, France|Institut Curie /ID# 63926, Paris CEDEX 05, Ile-de-France, France|Institut de Cancer de l'Ouest /ID# 63927, St Herblain CEDEX, Loire-Atlantique, France|Centre Leon Berard /ID# 106675, Lyon CEDEX 08, Rhone, France|Pays-Basque Ctr Oncology/Radio /ID# 65176, Bayonne, France|Institut Paoli-Calmettes /ID# 65175, Marseille, France|Hopital Rene Huguenin /ID# 65177, Saint-cloud, France|Centre Paul Strauss /ID# 100275, Strasbourg, France|Bajcsy-Zsilinszky Korhaz /ID# 65179, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 65178, Debrecen, Hungary|Jasz-Nagykun-Szolnok Megyei /ID# 63928, Szolnok, Hungary|Rabin Medical Center /ID# 63929, Petakh Tikva, Tel-Aviv, Israel|Soroka Medical Ctr /ID# 65180, Be'er Sheva, Israel|Assaf Harofeh Medical Center /ID# 65181, Be'er Ya'akov, Israel|Rambam Health Care Campus /ID# 63930, Haifa, Israel|Shaare Zedek Medical Center /ID# 116575, Jerusalem, Israel|Hadassah University Hospital /ID# 63931, Jerusalem, Israel|Sheba Medical Center /ID# 63932, Ramat Gan, Israel|Kaplan Medical Center /ID# 63933, Rehovot, Israel|Erasmus Medisch Centrum /ID# 96275, Rotterdam, Netherlands|Haukeland University Hospital /ID# 67982, Bergen, Hordaland, Norway|Mrukmed. Lekarz Beata Madej Mruk i Partner /ID# 94975, Rzeszów, Podkarpackie, Poland|Centrum Onkologii Lukaszczyka /ID# 73393, Bydgoszcz, Poland|Olsztynski Osrodek Onkologi /ID# 71060, Olsztyn, Poland|NZOZ Centrum Medyczne HCP /ID# 68102, Poznan, Poland|Wielkopolskie Centrum Onkologi /ID# 71061, Poznan, Poland|S.C. lanuli Med Consult SRL /ID# 106955, Bucharest, Romania|lnstitutul Oncologic Trestiore /ID# 96742, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta /ID# 96741, Cluj, Romania|Inst Oncology Prof. Chiricuta /ID# 96740, Cluj, Romania|Sc Oncolab Srl /Id# 96745, Craiova, Romania|NN Blokhin Russian Cancer /ID# 65263, Moscow, Moskva, Russian Federation|Chelyabinsk Reg Clin Oncology /ID# 63938, Chelyabinsk, Russian Federation|Murmansk RCH P.A. Bayandina /ID# 102415, Murmansk, Russian Federation|City Clinical Hospital 1 /ID# 102416, Novosibirsk, Russian Federation|Pyatigorsk Oncology Dispensary /ID# 65264, Pyatigorsk, Russian Federation|Birch A Healthcare /ID# 65265, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 65269, St. Petersburg, Russian Federation|N.N. Petrov Research Inst Onc /ID# 78973, St. Petersburg, Russian Federation|Volgograd Reg Onc Disp #3 /ID# 98035, Volzhsky, Russian Federation|Hosp Santa Creu i Sant Pau /ID# 97418, Barcelona, Spain|Hospital Univ Vall d'Hebron /ID# 97415, Barcelona, Spain|Hospital General Universitario Gregorio Maranon /ID# 97417, Madrid, Spain|Hosp Univ Madrid Sanchinarro /ID# 97416, Madrid, Spain|Hosp Uni Virgen de la Victoria /ID# 97976, Malaga, Spain|Hosp Clin Univ de Valencia /ID# 97975, Valencia, Spain|Skanes Universitetssjukhus /ID# 96475, Malmö, Skane Lan, Sweden|Sahlgrenska University Hosp /ID# 97715, Goteborg, Sweden|Karolinska Univ Sjukhuset /ID# 98037, Solna, Sweden|Cherkassy Regional Onc Ctr /ID# 97698, Cherkasy, Ukraine|City Multi-Field Clin Hosp #4 /ID# 63940, Dnipropetrovsk, Ukraine|Kharkiv Regional Clinical Onco /ID# 97696, Kharkiv, Ukraine|Lviv State Onc Local Treatment /ID# 63941, Lviv, Ukraine|Odessa National Medical Univ /ID# 65278, Odesa, Ukraine|Poltava Regional Clinical Onco /ID# 97697, Poltava, Ukraine|Sumy Reg Clinical Oncology Ctr /ID# 65280, Sumy, Ukraine",,"https://ClinicalTrials.gov/show/NCT01506609"
423,"NCT01484990","A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease",,"Completed","No Results Available","Parkinson Disease","Drug: Levodopa-Carbidopa","Profile of Pharmacokinetics|Safety and Tolerability Data Assessments (e.g., clinical laboratory tests, orthostatic vitals, adverse events assessment, physical exam)","AbbVie|Quintiles, Inc.","All","30 Years to 99 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","S187.1.002|2009-016837-84","April 2010","September 2010","September 2010","December 5, 2011",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01484990"
424,"NCT01413893","An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: linifanib","Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety.|Safety: Physical Examination and Vital Signs - Physical examination will be performed and vital signs will be assessed for participants as a measure of safety.|Safety: Multiple Gated Acquisition (MUGA) will be assessed at specified time points as a measure of safety.|Safety: Clinical Lab Tests will be performed for each participant as a safety measure.|There are no secondary outcome measures specified for this study.","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M12-749","June 2011","June 2012","June 2012","August 10, 2011",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01413893"
425,"NCT01412021","Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis",,"Completed","Has Results","Arthritis, Juvenile Rheumatoid",,"Change From Baseline in DAS28-4/ESR at Week 4|Change From Baseline in DAS28-4/ESR at Week 8|Change From Baseline in DAS28-4/ESR at Week 12|Change From Baseline in DAS28-4/ESR at Week 16|Change From Baseline in DAS28-4/ESR at Week 24|Change From Baseline in DAS28-4/CRP at Week 4|Change From Baseline in DAS28-4/CRP at Week 8|Change From Baseline in DAS28-4/CRP at Week 12|Change From Baseline in DAS28-4/CRP at Week 16|Change From Baseline in DAS28-4/CRP at Week 24|Change From Baseline in Serum MMP3 Level at Week 4|Change From Baseline in Serum MMP3 Level at Week 8|Change From Baseline in Serum MMP3 Level at Week 12|Change From Baseline in Serum MMP3 Level at Week 16|Change From Baseline in Serum MMP3 Level at Week 24|Change From Baseline in Physician Global Assessment (VAS) at Week 4|Change From Baseline in Physician Global Assessment (VAS) at Week 8|Change From Baseline in Physician Global Assessment (VAS) at Week 12|Change From Baseline in Physician Global Assessment (VAS) at Week 16|Change From Baseline in Physician Global Assessment (VAS) at Week 24|Change From Baseline in Anti-Cyclic Citrullinated Peptide Antibodies at Week 24|Change From Baseline in Height at Week 4|Change From Baseline in Height at Week 8|Change From Baseline in Height at Week 12|Change From Baseline in Height at Week 16|Change From Baseline in Height at Week 24|Change From Baseline in Weight at Week 4|Change From Baseline in Weight at Week 8|Change From Baseline in Weight at Week 12|Change From Baseline in Weight at Week 16|Change From Baseline in Weight at Week 24","AbbVie","All","up to 99 Years   (Child, Adult, Older Adult)",,"375","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-769","July 1, 2011","April 2, 2018","April 2, 2018","August 8, 2011","August 8, 2019","August 8, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT01412021/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT01412021/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01412021"
426,"NCT01380704","Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder",,"Completed","No Results Available","Major Depressive Disorder","Drug: ABT-436|Drug: Matching Placebo","Pharmacology assays|ABT-436 drug levels|Vital signs|Clinical safety labs|Psychiatric symptom scales","AbbVie","All","18 Years to 55 Years   (Adult)","Phase 1","51","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-674","June 2011","September 2011","September 2011","June 27, 2011",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01380704"
427,"NCT01329380","Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation)",,"Completed","Has Results","Ankylosing Spondylitis",,"Number of Participants With Adverse Drug Reactions|Number of Participants With Adverse Drug Reactions by Baseline Factors|Number of Participants With Adverse Events|Number of Participants With Self-injection Errors|Number of Participants With Markedly Improved or Improved Rating|Percentage of Participants With Markedly Improved or Improved Rating at Last Visit by Baseline Factors|Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)","AbbVie","All","16 Years to 99 Years   (Child, Adult, Older Adult)",,"403","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-764","October 27, 2010","December 28, 2017","December 28, 2017","April 5, 2011","April 3, 2019","April 3, 2019","Nagoya City University Hospital, Nagoya-shi, Aichi, Japan|Kurume University Hospital, Kurume-shi, Fukuoka, Japan|Gunma University Hospital, Maebashi-shi, Gunma, Japan|Hyogo College of Medicine Hosp, Nishinomiya, Hyogo, Japan|Yokohama City Univ Medical Ctr, Yokohama, Kanagawa, Japan|Nagasaki University Hospital, 長崎市, Nagasaki, Japan|Okayama University Hospital, Okayama-shi, Okayama, Japan|Osaka City University Hospital, 大阪市, Osaka, Japan|Saitama Medical Center, Kawagoe, Saitama, Japan|Shiga Univ Med Science Hosp, Otsu, Shiga, Japan|Medical Hospital of Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka-shi, Tokyo, Japan|St. Luke's International Hosp, 中央区, Tokyo, Japan|Teikyo University Hospital, 板橋区, Tokyo, Japan|Asano Orthopedic Clinic, Aichi, Japan|Nagoya Daini Red Cross Hosp, Aichi, Japan|Ozone Surgery Clinic, Aichi, Japan|Yamagiwa Clinic, Aichi, Japan|Narushima Internal Med Clinic, Ami-machi, Japan|Asahikawa Kosei General Hosp, Asahikawa-shi, Japan|Katayama Orthopedic Rheum Clin, Asahikawa, Japan|Asahikawa Med College Hosp, JP, Asahikawa, Japan|Atsugi City Hospital, Atsugi-shi, Japan|Chiba University Hospital, Chiba, Japan|University of Yamanashi Hosp, Chuo, Japan|Tama Medical Center, Fuchu, Japan|Fujieda Municipal General Hosp, Fujieda, Japan|Nakamura Clinic, Fukuchiyama-shi, Japan|Hamanomachi Hospital, Fukuoka, Japan|NHO Kyushu Medical Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|JP Red Cross Fukuoka Hosp, Fukuoka, Japan|Mutaguchi Orthopedics Clinic, Fukuoka, Japan|PS Clinic, Fukuoka, Japan|Fukushima Med Univ Hosp, Fukushima-shi, Japan|Fukushima Red Cross Hospital, Fukushima, Japan|Minami Tohoku Fukushima Hosp, Fukushima, Japan|Gifu University Hospital, Gifu, Japan|Seirei Mikatahara General Hosp, Hamamatsu, Japan|Osaka Rehabilitation Hospital, Hannan, Japan|Matsunami General Hospital, Hashima-gun, Japan|Kono Orthop. and Int. Med Clin, Higashimatsuyama-shi, Japan|Tama-Hokubu Medical Center, Higashimurayama, Japan|NHO Higashi-Ohmi Gen Med Ctr, Higashiomi, Japan|Yamaguchi Clinic, Higashiosaka-shi, Japan|NHO Himeji Medical Center, Himeji, Japan|Hirosaki Uni School Med & Hosp, Hirosaki, Japan|Hirosaki Memorial Hospital, Hirosaki, Japan|Hiroshima Clinic, Hiroshima-shi, Japan|Hiroshima Red Cross Hosp Atomi, Hiroshima, Japan|Hiroshima University Hospital, Hiroshima, Japan|Yamana-kai Higashi Hiroshima, Hiroshima, Japan|Shigenobu Clinic, Hiroshima, Japan|Midori Hospital, Hyogo, Japan|Kohnodai Hospital, Ichikawa-shi, Japan|Iwate Prefectural Iwai Hosp, Ichinoseki-shi, Japan|Saitama Medical University Hos, Iruma-gun, Japan|Suga Orthopedic Hospital, Isahaya, Japan|Isahaya Health Ins Genl Hosp, Isahaya, Japan|NHO Iwakuni Clinical Center, Iwakuni-shi, Japan|Juntendo Univ Shizuoka Hosp, Izunokuni-shi, Japan|Kaga City Hospital, Kaga-shi, Ishikawa, Japan|Kagoshima Univ Medical and Den, Kagoshima-shi, Japan|Kagoshima Red Cross Hospital, Kagoshima, Japan|Kameda Medical Center, Kamogawa, Japan|Saiseikai Kanazawa Hospital, Kanazawa, Japan|Kanazawa University Ho, Kanazawa, Japan|Kasugai Orthopaedic Clinic, Kasugai, Japan|Asahi Hospital, Kasugai, Japan|NHO Osaka Minami Med Ctr, Kawachinagano, Japan|Nagasawa Clinic, Kawagoe-shi, Japan|St. Marianna Univ Hospital, Kawasaki, Japan|Edakuni Orthopedic Clinic, Kiryu, Japan|JR Kyushu Hospital, Kitakyushu, Japan|Univ Occup & Environ Health, Kitakyushu, Japan|Kobe University Hospital, Kobe, Japan|Komaki Daiichi Hospital, Komaki, Japan|Jusendo General Hospital, Koriyama-shi, Japan|Juntendo Univ Koshigaya Hosp, Koshigaya, Japan|Shunan Memorial Hospital, Kudamatsu-shi, Japan|Kumamoto Rheumatology Clinic, Kumamoto, Japan|Kunitachi Clinic, Kunitachi, Japan|Kawasaki Medical School Hosp, Kurashiki, Japan|Kurashiki Central Hospital, Kurashiki, Japan|Jujo Rehabilitation Hospital, Kyoto, Japan|Kyoto Prefect Univ Med, Kyoto, Japan|JP Red Cross Kyoto Daiichi Hos, Kyoto, Japan|Kagawa University Hospital, Kyoto, Japan|Iwasaku Orthopedic Clinic, Kyoto, Japan|Tori Clinic, Maizuru-shi, Japan|Matsuyama Red Cross Hosp, Matsuyama, Japan|Mino Municipal Hospital, Mino, Japan|Suzuki Orthopedic Clinic, Miyashiro-machi, Japan|Miyazaki Prefectural Miyazaki, Miyazaki, Japan|Iwate Medical University Hosp, Morioka, Japan|Noguchi Seikeigeka Naika Iin, Motosu-shi, Japan|Munakata Medical Assoc. Hosp., Munakata-shi, Japan|Aichi Medical University Hosp, Nagakute, Japan|Saiseikai Kyoto Hospital, Nagaokakyo, Japan|Chukyo Social Insurance Hospit, Nagoya-shi, Japan|NHO Nagoya Medical Center, Nagoya, Japan|Shinseikai Daiichi Hospital, Nagoya, Japan|Higashi Hosp City of Nagoya, Nagoya, Japan|Kakinuma Orthopedics Clinic, Nagoya, Japan|Oura Clinic, Naha, Japan|Kochi Medical School Hospital, Nankoku-shi, Japan|Mitsuka Rheumatism Clinic, Narashino-shi, Japan|Nara City Hospital, Nara, Japan|Asahigaoka Hospital, Nara, Japan|Niigata City General Hospital, Niigata, Japan|Nirasaki City Hospital, Nirasaki, Japan|Nisshin Orido Hospital, Nisshin, Japan|Yamachika Memorial Gen Hosp, Odawara-shi, Japan|Oita Red Cross Hospital, Oita, Japan|Saiseikai Hita Hospital, Oita, Japan|Sunrise Sakai Hospital, Oita, Japan|Ohama Daiichi Hospital, Okinawa, Japan|Ome Municipal General Hospital, OME, Japan|Yuri Plastic Surgery, ONO, Japan|Osaka Rheumatology Clinic, Osaka-shi, Japan|Ushio Clinic, Osaka-shi, Japan|Yodogawa Christian Hospital, Osaka-shi, Japan|Yukioka Hospital, Osaka, Japan|Osaka Saiseikai Noe Hospital, Osaka, Japan|NTT WEST Osaka Hospital, Osaka, Japan|Osaka Red Cross Hospital, Osaka, Japan|Kansai Medical Univ Takii Hosp, Osaka, Japan|Kojima Orthopedic Clinic, Osaka, Japan|Murakami Orthopaedics Clinic, Osaka, Japan|Osaki Citizen Hospital, Osaki, Japan|Ota Memorial Hospital, OTA, Japan|Saga University Hospital, Saga, Japan|Osaka Rosai Hospital, Sakai-shi, Japan|Yoshida Internal Med Clinic, Sakaki, Japan|Kyoto University Hospital, Sakyo-ku, Japan|Teine Internal Med Rheuma Clin, Sapporo, Japan|Teine Keijinkai Clinic, Sapporo, Japan|Sapporo Medical Univ Hosp, Sapporo, Japan|Kin-ikyo Chuo Hospital, Sapporo, Japan|KKR Sapporo Med Ctr Tonan Hosp, Sapporo, Japan|Sasebo City General Hospital, Sasebo-shi, Japan|Sasebo Chuo Hospital, Sasebo, Japan|Tohoku University Hospital, Sendai, Japan|NHO Nishitaga National Hospita, Sendai, Japan|Tohoku Pharmaceutical Univ Hos, Sendai, Japan|Jyunshinkai Inoue Hospital, Seto, Japan|Niigata Rheumatic Center, Shibata, Japan|Saiseikai Suita Hospital, Suita, Japan|Osaka University Hospital, Suita, Japan|Kotesashi Orthopedic Clinic, Tokorozawa-shi, Japan|Hirose Clinic, Tokorozawa, Japan|Toyo Hospital, Tokushima-shi, Japan|Hishita-Hiasa Neurosurgery and, Tokushima, Japan|Kyoundo Hospital, Tokyo, Japan|Mitsui Memorial Hospital, Tokyo, Japan|The Jikei University Hospital, Tokyo, Japan|Toranomon Hospital, Tokyo, Japan|The University of Tokyo, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Metropolitan Bokutoh Hos, Tokyo, Japan|Keiyo Hospital, Tokyo, Japan|Toho Univ Med Ctr Omori Hosp, Tokyo, Japan|Tokyo Medical University Hosp, Tokyo, Japan|National Ctr Global Health Med, Tokyo, Japan|Tokyo Womens Med Univ Hosp, Tokyo, Japan|Kawakita General Hospital, Tokyo, Japan|Nihon University Itabashi Hosp, Tokyo, Japan|Juntendo Univ Nerima Hosp, Tokyo, Japan|JP Red Cross Musashino Hosp, Tokyo, Japan|Akasaka Chuo Clinic, Tokyo, Japan|Edogawa Hospital, Tokyo, Japan|Ishigaki Orthopedic Clinic, Tokyo, Japan|Kanamecho Hospital, Tokyo, Japan|Matsuda Orthopedic Rheuma Clin, Tokyo, Japan|NHO Disaster Medical Center, Tokyo, Japan|Showa University Hospital, Tokyo, Japan|Yoshida Internal Med Clinic, Tokyo, Japan|Matsuno Clinic Rheumatic Disea, Toyama, Japan|Toyama Prefectural Ctr Hosp, Toyama, Japan|Fujita Health University Hosp, Toyoake, Japan|Toyama University Hospital, Toyoma, Japan|Toyooka Hospital, Toyooka, Japan|Kishi Orthopedics Medical Clin, Tsuchiura-shi, Japan|Tsukuba University Hospital, Tsukuba, Japan|Tsuyama Chuo Memorial Hospital, Tsuyama, Japan|Daini Okamoto General Hospital, UJI, Japan|Wakayama Medical University, Wakayama, Japan|Yamagata University Hospital, Yamagata, Japan|Yamagata City Hosp Saiseikai, Yamagata, Japan|Yamaguchi Red Cross Hospital, Yamaguchi-shi, Japan|Shuto General Hospital, Yanai-shi, Japan|Kumamoto Rosai Hospital, Yatsushiro-shi, Japan|Showa Univ N Yokohama Hosp, Yokohama-shi, Japan|Tottori University Hospital, Yonago-shi, Japan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT01329380/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01329380"
428,"NCT01328626","A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia|Non-Hodgkin Lymphoma","Drug: ABT-199","Determination of dose limiting toxicity (DLT), maximum tolerated dose (MTD), recommended phase two dose (RPTD), and lead-in period regimen|Number of subjects with adverse events|Determination of plasma peak concentration (Cmax) of ABT-199|Determination of trough concentration (Ctrough) of ABT-199|Determination of area under the concentration versus time curve (AUC) of ABT-199|Food Effect - Cmax|Preliminary efficacy assessment|Minimal residual disease collection (MRD)|Food Effect - Tmax|Food Effect - AUC","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","222","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-175","June 14, 2011","May 15, 2020","May 15, 2020","April 5, 2011",,"November 13, 2019","University of Arizona Cancer Center - North Campus /ID# 52902, Tucson, Arizona, United States|Ucsd /Id# 48325, La Jolla, California, United States|Dana-Farber Cancer Institute /ID# 48324, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center /ID# 56810, New York, New York, United States|University of Texas MD Anderson Cancer Center /ID# 48326, Houston, Texas, United States|Swedish Medical Center /ID# 135853, Seattle, Washington, United States|Fred Hutchinson Cancer Research /ID# 52882, Seattle, Washington, United States|Univ of Wisconsin Hosp/Clinics /ID# 56811, Madison, Wisconsin, United States|Peter MacCallum Cancer Ctr /ID# 48323, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 48322, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT01328626"
429,"NCT01225302","A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: Linifanib|Drug: Carboplatin|Drug: Paclitaxel","Safety (Number of patients with adverse events and/or dose-limiting toxicities)|Preliminary tumor response","AbbVie","All","20 Years to 99 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W12-076","September 2010","June 2012","June 2012","October 21, 2010",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01225302"
430,"NCT01199224","To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: veliparib","Assess the oral bioavailability of veliparib|To evaluate the safety and tolerability of veliparib in patients with solid tumors","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-846","June 2010","November 2010","November 2010","September 10, 2010",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01199224"
431,"NCT01148225","A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis","VISUAL III","Completed","Has Results","Uveitis","Drug: adalimumab","Number of Participants With Adverse Events|Hematology: Number of Participants With Potentially Clinically Significant (PCS) Values|Chemistry: Number of Participants With PCS Values|Pulse (Sitting): Mean Change (Beats Per Minute) From Baseline To Final Visit|Respiratory Rate (Sitting): Mean Change (Respirations Per Minute) From Baseline To Final Visit|Temperature (Sitting): Mean Change (Centigrade) From Baseline To Final Visit|Diastolic and Systolic Blood Pressure (Sitting): Mean Change (mmHg) From Baseline To Final Visit|Percentage of Participants in Quiescence Over Time|Percentage of Participants With Uveitis Flare Among Participants With Inactive Uveitis at Study Start|Percentage of Participants With Uveitis Flare From Week 8 Through Last Visit Among Participants With Active Uveitis at Study Start|Percentage of Participants With New Active Inflammatory Lesions or Grade ≥2 in Anterior Chamber (AC) Cells or Grade ≥2 in Vitreous Haze (VH) Over Time|Percentage of Participants With Steroid-free Quiescence Over Time|Percentage of Participants in Non-quiescence (With/Without Change in Concomitant Medications Within 5 Days and With/Without Quiescence at Next Visit at Least 8 Weeks After Non-quiescence) Among Participants With Inactive Uveitis at Study Start|Percentage of Participants in Non-quiescence (With/Without Change in Concomitant Medications Within 5 Days and With/Without Quiescence at Next Visit at Least 8 Weeks After Non-quiescence) Among Participants With Active Uveitis at Study Start|Percentage of Participants Who Started Uveitis-related Systemic Corticosteroids During the Study|Mean Daily Dose in Milligrams (mg) of Uveitis-related Systemic Corticosteroids in Participants With Active Uveitis Over Time|Mean Daily Dose (mg) of Uveitis-related Systemic Corticosteroids in Participants With Inactive Uveitis Over Time|Percent Change in Mean Daily Dose of Uveitis-related Systemic Corticosteroids Relative to Week 0 in Participants With Inactive Uveitis Using Systemic Corticosteroids at Week 0 Over Time|Percent Change in Mean Daily Dose of Uveitis-related Systemic Corticosteroids Relative to Week 0 in Participants With Active Uveitis Using Systemic Corticosteroids at Week 0 Over Time|Percentage of Participants Not Using Systemic Corticosteroids Over Time|Percentage of Participants Without Worsening of Best Corrected Visual Acuity (BCVA) by ≥15 Letters on Early Treatment Diabetic Retinopathy Study (ETDRS) in Both Eyes Relative to Baseline Over Time Among Participants Who Had Inactive Uveitis at Study Entry|Percentage of Participants Without Worsening of BCVA by ≥15 Letters on the ETDRS in Both Eyes Relative to Week 8 Over Time Among Participants With Active Uveitis at Study Entry|Mean of Both Eyes of the Logarithm of the Minimum Angle of Resolution (LogMAR) BCVA Over Time","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","424","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-327|2009-016196-29","November 23, 2010","May 21, 2018","May 21, 2018","June 22, 2010","April 4, 2019","April 4, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01148225/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01148225/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01148225"
432,"NCT01133548","Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males",,"Completed","No Results Available","Hypogonadism","Drug: Testosterone Gel 1.62%","Maximum Plasma Concentration observed (Cmax)|Area Under the Plasma Concentration-time Curve (AUC)|Time of Cmax (Tmax)|Average Plasma Concentration observed (Cav)|Application site evaluation based on the clinical evaluation of skin reactions grading scale|Adverse events","AbbVie","Male","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","62","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S176.1.010","May 2010","July 2010","July 2010","May 31, 2010",,"December 7, 2017",,,"https://ClinicalTrials.gov/show/NCT01133548"
433,"NCT01130298","An Open-Label Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure to Testosterone Gel 1.62% Applied to the Upper Arms and Shoulders and Use of a T-shirt Barrier",,"Completed","No Results Available","Healthy","Drug: Testosterone Gel 1.62%","Maximum Plasma Concentration observed (Cmax)|Area Under the Plasma Concentration-time Curve (AUC)|Average Plasma Concentration observed (Cav)","AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S176.1.011","May 2010","May 2010","May 2010","May 26, 2010",,"December 7, 2017",,,"https://ClinicalTrials.gov/show/NCT01130298"
434,"NCT01121133","A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax",,"Completed","No Results Available","Lymphoma, Including Chronic Lymphocytic Leukemia|Solid Tumors","Drug: navitoclax|Drug: Rifampin","To determine the effect of rifampin on the pharmacokinetics of navitoclax.|To determine the safety of navitoclax when administered alone and in combination with rifampin in these patients.","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-955","May 2010","May 2011","May 2011","May 12, 2010",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01121133"
435,"NCT00986037","Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma",,"Completed","No Results Available","Asthma","Drug: ABT-308|Drug: Placebo","Safety and tolerability will be determined by evaluation of adverse events, vital sign monitoring, physical examination, electrocardiograms, lung function and laboratory assessments.|Pharmacokinetics will be determined by measuring serum concentration of ABT-308.|Immunogenicity will be determined by measuring serum concentrations of anti-ABT-308 antibodies.","AbbVie","All","18 Years to 55 Years   (Adult)","Phase 1","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-378","October 2009","July 2010",,"September 29, 2009",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00986037"
436,"NCT00982566","Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer",,"Completed","No Results Available","Lymphoid Malignancy|Solid Tumors","Drug: ABT-263","Assessment of Oral Bioavailability|Adverse Events Tabulation","AbbVie|Genentech, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-069","October 2009","October 2010","December 2010","September 23, 2009",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00982566"
437,"NCT00973973","Efficacy and Safety Study of Elagolix in Women With Endometriosis",,"Completed","Has Results","Endometriosis, Pain","Drug: Placebo|Drug: Elagolix","Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Double-blind Treatment Phase|Change From Baseline in the Monthly Mean Dysmenorrhea Score During the Open-label and Posttreatment Phases|Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Double-Blind Treatment Phase|Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score During the Open-label and Posttreatment Phases|Change From Baseline in the Monthly Mean Cumulative Pain Score During the Double-Blind Treatment Phase|Change From Baseline in the Monthly Mean Cumulative Pain Score During the Open-label and Posttreatment Phases|Change From Baseline in the Monthly Mean Dyspareunia Score During the Double-Blind Treatment Phase|Change From Baseline in the Monthly Mean Dyspareunia Score During the Open-label and Posttreatment Phases|Percentage of Participants With a Response in Monthly Mean Dysmenorrhea Score at Week 8|Percentage of Participants With a Response in Monthly Mean Non-menstrual Pelvic Pain Score at Week 8|Percentage of Participants With a Response in Monthly Mean Cumulative Pain Score at Week 8|Percentage of Participants With a Response in Monthly Mean Dyspareunia Score at Week 8|Change From Baseline in the Percentage of Days of Any Analgesic Use During the Double-Blind Treatment Phase|Change From Baseline in the Percentage of Days of Any Analgesic Use During the Open-Label and Posttreatment Phases|Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Double-Blind Treatment Phase|Change From Baseline in the Percentage of Days of Prescription Analgesic Use During the Open-Label and Posttreatment Phases|Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Double-Blind Treatment Phase|Change From Baseline in the Percentage of Days of Narcotic Analgesic Use During the Open-Label and Posttreatment Phases|Change From Baseline to the End of the Double-blind Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores|Change From Baseline to the End of the Open-label Treatment Phase in Composite Pelvic Signs and Symptoms Score (CPSSS) Total Score and Component Scores|Patient Global Impression of Change During the Double-blind Treatment Phase|Patient Global Impression of Change During the Open-Label and Posttreatment Phases|Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Double-blind Treatment Phase|Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved During the Open-label Treatment Phase|Change From Baseline to the End of the Double-blind Treatment Phase in Endometriosis Health Profile-5 (EHP-5)|Change From Baseline to the End of the Open-label Treatment Phase in Endometriosis Health Profile-5 (EHP-5)|Percentage of Days With Uterine Bleeding During the Double- Blind Treatment Phase|Number of Days to First Posttreatment Menses","AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 2","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NBI-56418-0901","October 12, 2009","September 22, 2010","September 22, 2010","September 9, 2009","September 26, 2018","September 26, 2018",,,"https://ClinicalTrials.gov/show/NCT00973973"
438,"NCT00891605","Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: ABT-263|Drug: paclitaxel","Safety Assessment|Efficacy Assessment","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","19","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-589","July 2009","July 2012","July 2012","May 1, 2009",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00891605"
439,"NCT00888693","A Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-288 in Stable Subjects With Schizophrenia",,"Completed","No Results Available","Schizophrenia","Drug: ABT-288|Drug: Placebo","Physical Exams, Brief Neurological Exams, Vitals, Orthostatic Vitals, ECG, Laboratory tests,|Pharmacokinetics; optional CSF for arms 7, 8 & 9|Extrapyramidal Symptom Rating Scale|Columbia Suicide Severity Rating Scale|Pharmacodynamics: CANTAB & PANSS|Pharmacodynamics: Pittsburgh Sleep Quality Index-Modified","AbbVie","All","18 Years to 60 Years   (Adult)","Phase 1","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-752","November 2008","December 2009",,"April 28, 2009",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00888693"
440,"NCT00887757","Safety Study of ABT-263 in Combination With Gemzar (Gemcitabine) in Subjects With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: ABT-263|Drug: gemcitabine","Assess the safety profile of ABT-263 in combination with gemcitabine.|Study the pharmacokinetic interaction between ABT-263 and gemcitabine.|Determine the maximum tolerated dose (MTD) of ABT-263 in combination with gemcitabine.|Evaluate safety at the defined recommended Phase 2 dose (RPTD) and schedule in combination with a standard and weekly regimen of gemcitabine.|Evaluate preliminary data regarding progression free survival (PFS)|Evaluate preliminary data regarding objective response rate (ORR)|Evaluate preliminary data regarding time to tumor progression (TTP)|Evaluate preliminary data regarding overall survival (OS)|Evaluate preliminary data regarding duration of overall response|Evaluate preliminary data with Eastern Cooperative Oncology Group (ECOG) performance status|Evaluate biomarkers to","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-588","September 2009","November 2011","November 2011","April 24, 2009",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00887757"
441,"NCT00850044","Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1",,"Completed","No Results Available","HCV Infection","Drug: ABT-450|Drug: ritonavir|Drug: placebo for ABT-450|Drug: Placebo for ritonavir","Pharmacokinetics (blood draws, pre- and post-dose)|Safety and Tolerability (ECGs, AEs, vitals, physical exams, routine labs)","AbbVie","All","18 Years to 55 Years   (Adult)","Phase 1","87","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-749","February 2009","July 2009",,"February 24, 2009",,"November 20, 2017","Site Reference ID/Investigator# 15981, Waukegan, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT00850044"
442,"NCT00797225","Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis",,"Completed","Has Results","Endometriosis","Drug: Leuprorelin Acetate Depot|Drug: Elagolix|Drug: Placebo to Elagolix|Drug: Placebo to Leuprorelin Acetate","Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain|Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain|Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score|Change From Baseline in the Monthly Mean Dysmenorrhea Score|Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores|Change From Baseline in the Percentage of Days of Any Analgesic Use|Change From Baseline in the Percentage of Days of Prescription Analgesic Use|Change From Baseline in the Percentage of Days of Narcotic Analgesic Use|Change From Baseline in Dyspareunia Component of the Composite Pelvic Signs and Symptoms Score (CPSSS)|Change From Baseline in Dysmenorrhea Component of the CPSSS|Change From Baseline in Non-menstrual Pelvic Pain CPSSS Component|Patient Global Impression of Change at Weeks 4, 8 and 12|Percentage of Participants With a PGIC Response of Minimally Improved, Much Improved, or Very Much Improved|Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved|Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12|Concentration of Serum Estradiol|Percent Change From Baseline in Bone Mineral Density of the Femur at Week 12|Percent Change From Baseline in Bone Mineral Density of the Spine at Week 12|Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24|Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24|Change From Baseline in Serum N-telopeptide Concentration at Week 12|Average Number of Hot Flashes Per Day|Percentage of Days With Uterine Bleeding|Number of Days to First Posttreatment Menses","AbbVie","Female","18 Years to 45 Years   (Adult)","Phase 2","174","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NBI-56418-0703|2007-006474-28","November 26, 2008","February 24, 2010","February 24, 2010","November 25, 2008","September 10, 2018","September 10, 2018",,,"https://ClinicalTrials.gov/show/NCT00797225"
443,"NCT00783510","Juvenile Idiopathic Arthritis (JIA) Registry","STRIVE","Active, not recruiting","No Results Available","Juvenile Idiopathic Arthritis|JIA","Biological: adalimumab|Drug: Methotrexate","Incidence of Serious Adverse Events (SAEs)|Incidence of Adverse Events (AEs) of Interest|Pediatric American College of Rheumatology (PedACR) 50|Pediatric American College of Rheumatology (PedACR) 70|Pediatric American College of Rheumatology (PedACR) - 30|Child Health Questionnaire (CHQ-PF50)|Pediatric American College of Rheumatology (PedACR) 90|Juvenile arthritis disease activity score (JADAS)|Physical function of the Disability Index of Childhood Health Assessment Questionnaire (DIHAQ)","AbbVie","All","2 Years to 17 Years   (Child)",,"849","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P10-262","July 11, 2008","February 6, 2024","February 6, 2024","October 31, 2008",,"August 21, 2019","AZ Arthritis and Rheum Researc /ID# 21023, Phoenix, Arizona, United States|Catalina Pointe Clinical Res /ID# 40227, Tucson, Arizona, United States|Arkansas Children's Hospital /ID# 23505, Little Rock, Arkansas, United States|Childrens Hospital LA /ID# 24386, Los Angeles, California, United States|Children's National Medical Center /ID# 23506, Washington, District of Columbia, United States|Arthritis Associates South FL /ID# 17001, Delray Beach, Florida, United States|Ann & Robert H. Lurie Children's Hospital of Chicago /ID# 20966, Chicago, Illinois, United States|University of Chicago /ID# 21981, Chicago, Illinois, United States|Methodist Medical Group Rheum /ID# 46343, Peoria, Illinois, United States|Indiana University /ID# 11421, Indianapolis, Indiana, United States|University of Louisville /ID# 23507, Louisville, Kentucky, United States|Arthritis Care Spec. of MD /ID# 21961, Ellicott City, Maryland, United States|Tufts Medical Center /ID# 21965, Boston, Massachusetts, United States|Creighton Univ Med Ctr /ID# 11423, Omaha, Nebraska, United States|St. Barnabas Ambulatory Care /ID# 21025, West Orange, New Jersey, United States|North Shore University Hospital /ID# 21022, New Hyde Park, New York, United States|Univ Rochester Med Ctr /ID# 20967, Rochester, New York, United States|New York Medical College /ID# 21964, Valhalla, New York, United States|Duke University Medical Center - Main /ID# 22904, Durham, North Carolina, United States|Bone Spine Sports/Medctr One /ID# 21962, Bismarck, North Dakota, United States|Akron Childrens Hospital /ID# 22907, Akron, Ohio, United States|University of Cincinnati /ID# 14101, Cincinnati, Ohio, United States|Nationwide Childrens Hospital /ID# 21963, Columbus, Ohio, United States|Legacy Emanuel Medical Center /ID# 14102, Portland, Oregon, United States|St. Christopher's Hospital /ID# 24385, Philadelphia, Pennsylvania, United States|Arthritis Associates, PLLC /ID# 44462, Kingsport, Tennessee, United States|Dr. Ramesh Gupta /ID# 45342, Memphis, Tennessee, United States|Scott & White Health Care /ID# 36762, Round Rock, Texas, United States|University of Utah /ID# 21041, Salt Lake City, Utah, United States|Children's Speciality Center /ID# 11503, Burlington, Vermont, United States|Seattle Children's Hospital /ID# 20968, Seattle, Washington, United States|Children's Hospital Wisconsin /ID# 40226, Milwaukee, Wisconsin, United States|Womens and Childrens Hospital /ID# 59182, Adelaide, South Australia, Australia|Medizinische Universität Wien /ID# 26127, Vienna, Wien, Austria|Landeskrankenhaus Bregenz /ID# 26128, Bregenz, Austria|LKH-Univ. Klinikum Graz /ID# 26126, Graz, Austria|Landes-Frauen und Kinderklinik /ID# 39068, Linz, Austria|Revmatologicky ustav Praha /ID# 43344, Prague 2, Praha 2, Czechia|Fakultni Nemocnice v Motole /ID# 37342, Prague 5, Praha 5, Czechia|Fakultni Nemocnice Brno /ID# 37343, Brno, Czechia|Klinika detskeho a dorosto lek /ID# 47401, Prague, Czechia|Aarhus University Hospital /ID# 25445, Aarhus N, Midtjylland, Denmark|Rigshospitalet, Finsen Centre /ID# 25444, Copenhagen, Denmark|CHRU Lille - Hôpital Claude Huriez /ID# 25449, Lille CEDEX, Hauts-de-France, France|Hopital Bretonneau - CHU Tours /ID# 27126, Tours CEDEX 9, Indre-et-Loire, France|CHU NANCY - Hôpital Brabois Adultes /ID# 25452, Vandoeuvre les Nancy CEDEX, Meurthe-et-Moselle, France|CHU Toulouse /ID# 37347, Toulouse CEDEX 3, Occitanie, France|CHU Bordeaux-Hopital Pellegrin /ID# 25454, Bordeaux, France|CHU Bicetre /ID# 25443, Le Kremlin Bicetre, France|Groupe Hospitalier Cochin /ID# 37345, Paris, France|Hospitalier Necker /ID# 25442, Paris, France|CHU de Rennes - Hospital Sud /ID# 27123, Rennes, France|CHU Strasbourg Hautepierre Hos /ID# 25450, Strasbourg, France|Charité Universitätsmedizin Campus Mitte /ID# 41623, Berlin, Germany|Helios Klinikum Berlin Buch /ID# 37348, Berlin, Germany|Klinikum Bremen Mitte gGmbH /ID# 45942, Bremen, Germany|Klinikum Dortmund gGmbH /ID# 44003, Dortmund, Germany|Center Rheumatology Child&Adol /ID# 39069, Garmisch-partenkirchen, Germany|Kinder- & Jugendrheumatologie /ID# 39223, Hamburg, Germany|Klinikum St. Georg gGmbH /ID# 37349, Leipzig, Germany|Asklepios Klinik St. Augustin /ID# 41622, Sankt Augustin, Germany|Universitatsklinikum Tubingen /ID# 39070, Tuebingen, Germany|Rheumazentrum Wedel /ID# 37350, Wedel, Germany|Children`s Hosp P. A. Kyriakou /ID# 25448, Athens, Greece|Genl Hosp Thessaloniki Hipp /ID# 25447, Thessaloniki, Greece|Orszagos Reumatologiai es Fizi /ID# 95095, Budapest, Hungary|Debreceni Egyetem Klinikai Koz /ID# 95863, Debrecen, Hungary|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico /ID# 26124, Milan, Lombardia, Italy|Azienda Ospedaliera Univ. Meyer /ID# 26123, Florence, Toscana, Italy|Univ. degli Studi di Brescia /ID# 39077, Brescia, Italy|Universita di Catania /ID# 39075, Catania, Italy|Univ degli Studi G D'Annunzio /ID# 37353, Chieti, Italy|IRCCS Istituto G. Gaslini /ID# 26668, Genoa, Italy|University of Naples Federico /ID# 39072, Naples, Italy|University of Naples Federico /ID# 39078, Naples, Italy|Fondazione IRCCS Policlinico /ID# 39076, Pavia, Italy|Osp. Pediatrico Bambino Gesu /ID# 39074, Rome, Italy|Universitair Medisch Centrum Utrecht /ID# 48842, Utrecht, Netherlands|Oslo Universitetssykehus, Radiumhospitalet /ID# 46402, Oslo, Norway|Hospital Garcia de Orta, E.P.E /ID# 37355, Almada, Setubal, Portugal|Centro Hospitalar Lisboa Norte, EPE /ID# 42682, Lisboa, Portugal|Centro Hospitalar do Porto /ID# 39081, Porto, Portugal|Centro de Reumatologia Pediatrico de Puerto Rico /Id# 61047, Bayamon, Puerto Rico|Puerto Rico Children Hospital /ID# 47742, Bayamon, Puerto Rico|Narodny ustav reumatickych chorob Piestany /ID# 38102, Pieštany, Slovakia|Hospital Univ Vall d'Hebron /ID# 37357, Barcelona, Spain|Hospital Sant Joan de Deu /ID# 37358, Esplugues de Llobregat, Spain|Severo Ochoa Hospital /ID# 41751, Leganes-madrid, Spain|Hosp Infantil Univ Nino Jesus /ID# 37360, Madrid, Spain|Hospital Univ Ramon y Cajal /ID# 41624, Madrid, Spain|Hospital Universitario La Fe /ID# 37359, Valencia, Spain|Queen Silvia Children's Hosp /ID# 26125, Goteborg, Sweden",,"https://ClinicalTrials.gov/show/NCT00783510"
444,"NCT00718380","A Phase 1 Study of ABT-869 in Subjects With Solid Tumors",,"Completed","No Results Available","Solid Tumor","Drug: ABT-869","Safety tolerability assessment|Dose limiting toxicity determination|Pharmacokinetic profile evaluation|Preliminary tumor response","AbbVie","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-227","September 2008","June 2012","June 2012","July 18, 2008",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00718380"
445,"NCT00696904","Study of ABT-333 in Both Healthy Volunteers and Hepatitis C Virus (HCV) + Genotype 1 Infected Subjects",,"Completed","No Results Available","HCV Infection","Drug: ABT-333|Drug: Placebo","Analysis of pharmacokinetic variables and mean change in HCV RNA level from baseline.|Analysis of safety measures, including but not limited to tabulation of adverse events, physical exam, clinical lab results (include chemistry, hematology and urine) and vital signs.|Analysis of variance of pharmacokinetic variables for subjects fasting or nonfasting.","AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","133","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","M10-351","June 2008","February 2009",,"June 13, 2008",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00696904"
446,"NCT00654758","A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-small Cell Lung Cancer","Drug: M200 (Volociximab), Carboplatin, Paclitaxel","To determine the maximum tolerated dose (MTD) of volociximab given at different doses in combination with carboplatin and paclitaxel|Pharmacokinetics of volociximab|Efficacy of volociximab in combination with carboplatin/paclitaxel","AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M200-1211|2007-003396-39","December 2007","May 2010","May 2010","April 9, 2008",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00654758"
447,"NCT00650156","Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: adalimumab","pharmacokinetic profile of a single subcutaneous dose of 40 and 80 mg adalimumab|Adverse event profile|VAS assessments|Swollen and Tender Joint counts","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-017","June 2007","October 2007",,"April 1, 2008",,"November 20, 2017","Site Reference ID/Investigator# 7181, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT00650156"
448,"NCT00619866","An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis",,"Completed","Has Results","Endometriosis, Pain","Drug: Elagolix|Drug: placebo","Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain at Week 12|Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain|Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain|Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score|Change From Baseline in the Monthly Mean Dysmenorrhea Score|Change From Baseline in the Monthly Mean Total of Dysmenorrhea and Non-menstrual Pelvic Pain Scores|Percentage of Days With No Pain Based on NRS|Percentage of Days With No Pain Based Based on Non-menstrual Pelvic Pain Daily Assessment|Percentage of Days With No Pain Based Based on Dysmenorrhea Daily Assessment|Percentage of Days With No Pain Based Based on Total Score of Non-menstrual Pelvic Pain and Dysmenorrhea Daily Assessment|Change From Baseline in the Percentage of Days of Any Analgesic Use|Change From Baseline in the Percentage of Days of Prescription Analgesic Use|Change From Baseline in the Percentage of Days of Narcotic Analgesic Use|Percentage of Participants With 30% Decrease From Baseline in Monthly Mean NRS|Percentage of Participants With 30% Decrease From Baseline in Monthly Peak NRS|Percentage of Participants With 50% Decrease From Baseline in Monthly Mean NRS|Percentage of Participants With 50% Decrease From Baseline in Monthly Peak NRS|Change From Baseline in Dyspareunia Component of the Composite Pelvic Signs and Symptoms Score (CPSSS)|Patient Global Impression of Change at Weeks 4, 8 and 12|Percentage of Participants With a PGIC Response of Minimally Improved, Much Improved, or Very Much Improved|Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved|Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12|Percent Change From Baseline in Bone Mineral Density of the Femur at Week 12|Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24|Percent Change From Baseline in Bone Mineral Density of the Spine at Week 12|Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24","AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NBI-56418-0702","February 19, 2008","April 20, 2009","August 28, 2009","February 21, 2008","September 7, 2018","September 7, 2018",,,"https://ClinicalTrials.gov/show/NCT00619866"
449,"NCT00526617","A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients",,"Completed","No Results Available","Non-hematologic Malignancies|Metastatic Melanoma|Breast Cancer|Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Hepatocellular Carcinoma","Drug: ABT-888|Drug: Temozolomide","Maximum Tolerated Dose|Safety and Tolerability|Pharmacokinetic Profile","AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-862","August 2007","June 2010",,"September 10, 2007",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00526617"
450,"NCT00481091","A Phase 1/2a Study of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: ABT-263","Number of Subjects with Adverse Events in the in the Dose Escalation Phase (Phase 1)|Number of participants with Potentially Clinically Significant (PCS) Hematology Values in the Dose Escalation Phase (Phase 1)|Number of participants with PCS Clinical Chemistry Values in the Dose Escalation Phase (Phase 1)|Number of participants with PCS Vital Signs Values in the Dose Escalation Phase (Phase 1)|Number of Participants with Dose Limiting Toxicity (DLT) in the Dose Escalation Phase (Phase 1)|Maximum Tolerated Dose (MTD) in the Dose Escalation Phase (Phase 1)|Recommended Phase 2 Dose (RPTD) Determined in the Dose Escalation Phase (Phase 1)|Plasma Concentrations of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)|Plasma Concentrations of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)|Maximum Serum Concentration (Cmax) of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)|Cmax of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)|Area Under the Plasma Concentration-time Curve over time from 0 to 24 hours (AUC0-24) of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)|AUC0-24 of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)|Time to Maximum Observed Plasma Concentration (Tmax) of navitoclax on Cycle 1, Day 1 in the Dose Escalation Phase (Phase 1)|Tmax of navitoclax on Cycle 1, Day 14 in the Dose Escalation Phase (Phase 1)|Number of Subjects with Adverse Events in the Recommended Phase 2 Dose Phase (Phase 2)|Number of participants with PCS Hematology Values in the Recommended Phase 2 (RPTD) Phase (Phase 2)|Number of participants with PCS Clinical Chemistry Values in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)|Number of participants with PCS Vital Signs Values in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)|Plasma Concentrations of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)|Cmax of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)|AUC0-24 of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)|Tmax of navitoclax on Cycle 1, Day 15 in the Recommended Phase 2 Dose (RPTD) Phase (Phase 2)|Number of Subjects with Adverse Events in the Extension Study|Number of participants with PCS Hematology Values in the Extension Study|Number of participants with PCS Clinical Chemistry Values in the Extension Study|Number of participants with PCS Vital Signs Values in the Extension Study|Progression-free Survival (PFS)|Overall Survival (OS)","AbbVie|Genentech, Inc.","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","72","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-873|2007-002143-25","July 25, 2007","September 4, 2020","September 4, 2020","June 1, 2007",,"April 11, 2019","Ucsd /Id# 5566, La Jolla, California, United States|Dana-Farber Cancer Institute /ID# 5547, Boston, Massachusetts, United States|Univ Nebraska Med Ctr /ID# 12261, Omaha, Nebraska, United States|North Shore University Hospital /ID# 12267, New Hyde Park, New York, United States|Univ TX, MD Anderson /ID# 5575, Houston, Texas, United States|Northwest Medical Specialties /ID# 26428, Tacoma, Washington, United States|Peter MacCallum Cancer Ctr /ID# 6583, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 5576, Parkville, Victoria, Australia|Uniklinik Koln /ID# 5924, Köln, Nordrhein-Westfalen, Germany|Leicester Royal Infirmary /ID# 15081, Leicester, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00481091"
451,"NCT00437658","Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis","PETAL","Completed","Has Results","Endometriosis","Drug: Elagolix|Drug: Subcutaneous depot medroxyprogesterone acetate (DMPA-SC)|Drug: Placebo to Elagolix|Drug: Placebo to DMPA-SC","Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24|Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24|Percent Change From Baseline in Bone Mineral Density of the Spine at Weeks 12 and 48|Percent Change From Baseline in Bone Mineral Density of the Femur at Weeks 12 and 48|Change From Baseline in N-telopeptide at Weeks 12, 24 and 48|Percentage of Participants With a Response in the Dysmenorrhea Component of the Composite Pelvic Signs and Symptoms Score (CPSSS) at Week 24|Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS at Week 24|Percentage of Participants With a Response in the Dysmenorrhea Component of the CPSSS Over Time|Percentage of Participants With a Response in the Non-menstrual Pelvic Pain Component of the CPSSS Over Time|Change From Baseline in Total CPSSS During the Treatment Period|Change From Baseline in Total CPSSS Excluding Dyspareunia During the Treatment Period|Change From Baseline in Dysmenorrhea Component of the CPSSS During the Treatment Period|Change From Baseline in Dyspareunia Component of the CPSSS During the Treatment Period|Change From Baseline in Non-menstrual Pelvic Pain Component of the CPSSS During the Treatment Period|Change From Baseline in Pelvic Tenderness Component of the CPSSS During the Treatment Period|Change From Baseline in Pelvic Induration Component of the CPSSS During the Treatment Period|Change From Baseline in in Monthly Peak Visual Analog Scale (VAS) for Pelvic Pain|Change From Baseline in in Monthly Mean Visual Analog Scale (VAS) for Pelvic Pain|Change From Baseline in Endometriosis Health Profile-5 (EHP-5) Pain Dimension|Change From Baseline in EHP-5 Control and Powerlessness Dimension|Change From Baseline in EHP-5 Emotional Well-being Dimension|Change From Baseline in EHP-5 Social Support Dimension|Change From Baseline in EHP-5 Self Image Dimension|Change From Baseline in EHP-5 Work Dimension|Change From Baseline in EHP-5 Relationship With Children Dimension|Change From Baseline in EHP-5 Intercourse Dimension|Change From Baseline in EHP-5 Medical Profession Dimension|Change From Baseline in EHP-5 Treatment Dimension|Percentage of Participants Using Analgesics During the Treatment Phase","AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 2","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NBI-56418-0603","December 11, 2006","November 24, 2008","November 24, 2008","February 21, 2007","October 12, 2018","October 12, 2018",,,"https://ClinicalTrials.gov/show/NCT00437658"
452,"NCT01782469","Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population",,"Terminated","Has Results","Rheumatoid Arthritis",,"Mean Change in Synovitis Measured by B-modal Ultrasonography Assessment Score After 13 Weeks of Treatment With Adalimumab.|Mean Percent Reduction in Ultrasonography Assessment Score|Mean Number of Joints With Detected Erosions|Percentage of Participants Who Achieved ≥ 20% Improvement in Both Tender Joint Count (TJC) and Swollen Joint Count (SJC)|Mean Change in Health Assessment Questionnaire (HAQ) Score","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"16","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P13-708","October 2012","July 2014","July 2014","February 4, 2013","July 30, 2015","July 30, 2015",,,"https://ClinicalTrials.gov/show/NCT01782469"
453,"NCT01773070","A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study",,"Completed","Has Results","Hepatitis C","Drug: ABT-450/ritonavir|Drug: ABT-333|Drug: ABT-267","Percentage of Participants Who Experienced Relapse12overall With and Without New HCV Infection|Number of HCV Genotype (GT)1a-Infected Participants With Persistence of Treatment-Emergent Substitutions in NS3, NS5A, or NS5B|Percentage of Participants Who Experienced Relapse12 Without and With New HCV Infection|Percentage of Participants Who Experienced Relapse24 Without and With New HCV Infection|Percentage of Participants Who Experienced Relapse˅Overall Without and With New HCV Infection","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","478","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","M13-102|2012-003073-26","June 2013","October 2016","October 2016","January 23, 2013","November 6, 2017","December 6, 2017",,,"https://ClinicalTrials.gov/show/NCT01773070"
454,"NCT01767116","A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection","PEARL-III","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV|Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse After Treatment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","419","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-961|2012-003687-52","December 2012","December 2013","August 2014","January 14, 2013","January 6, 2015","August 27, 2015",,,"https://ClinicalTrials.gov/show/NCT01767116"
455,"NCT01759264","An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)","FAIR","Completed","Has Results","Crohn's Disease",,"Percentage of Participants With Fecal Calprotectin Less Than 150 Microgram/Gram|Mean Percent Change of Fecal Calprotectin From Baseline|Percentage of Participants With Remission of Crohn's Disease|Percentage of Participants With Clinical Response (CR) Due to Adalimumab Treatment","AbbVie (prior sponsor, Abbott)|AbbVie","All","19 Years and older   (Adult, Older Adult)",,"101","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P13-974","January 2013","May 2014","May 2014","January 3, 2013","July 8, 2015","July 8, 2015",,,"https://ClinicalTrials.gov/show/NCT01759264"
456,"NCT01758705","Post Marketing Observational Study on Venezuelan Patients With Psoriasis",,"Withdrawn","No Results Available","Moderate to Severe Chronic Plaque Psoriasis",,"Change in PASI 75 (Psoriasis Area and Severity Index score) Response Rate|Change in Percentage of patients with clinical difference in DLQI (Dermatology Life Quality Index) score|Mean change of PASI score|Mean change of DLQI score|Changes in Psoriatic Arthritis Response Criteria (PsARC) score|Mean change of Hospital Anxiety and Depression Score (HADS)|Mean change en Work Productivity and Activity Impairment (WPAI)-Psoriasis score|Percentage of subjects with Serious Adverse Events (SAEs)|Discontinuation of adalimumab for any reason.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"0","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-709","February 2013","March 2016","March 2016","January 1, 2013",,"November 29, 2016",,,"https://ClinicalTrials.gov/show/NCT01758705"
457,"NCT01758289","Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients",,"Terminated","Has Results","Chronic Kidney Disease Stage V|Hemodialysis",,"Percentage of Participants Achieving at Least a 30% Reduction From Baseline in the Levels of Parathyroid Hormone (PTH) at the Final Study Visit|Percentage of Participants With Hypercalcemia, Hyperphosphatemia and Elevations of Calcium-Phosphate Product (Ca x P) at Baseline, Week 12, and Week 24|Number of Participants Achieving Parathyroid Hormone (PTH) Levels < 300 pg/mL|Number of Participants Achieving PTH Level Reductions to < 300 pg/mL or 30% Below Baseline in 12 or 24 Weeks|European Quality of Life 5 Dimensions (EQ-5D) Parameters of Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression At Baseline, Week 12, and Week 24|European Quality of Life 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Scores At Baseline, Week 12, and Week 24|Beck Depression Inventory (BDI) Scores At Baseline and Final Study Visit","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"105","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-785","January 2013","November 2013","November 2013","January 1, 2013","November 17, 2014","November 17, 2014","Site Reference ID/Investigator# 96757, Acarigua, Venezuela|Site Reference ID/Investigator# 96766, Barquisimeto, Venezuela|Site Reference ID/Investigator# 96768, Caracas, Venezuela|Site Reference ID/Investigator# 96760, Maracaibo, Venezuela|Site Reference ID/Investigator# 96761, Maracaibo, Venezuela|Site Reference ID/Investigator# 96770, Miranda, Venezuela|Site Reference ID/Investigator# 96763, Monagas, Venezuela|Site Reference ID/Investigator# 96765, Naguanagua, Venezuela",,"https://ClinicalTrials.gov/show/NCT01758289"
458,"NCT01756235","Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice","PACE","Completed","Has Results","Rheumatoid Arthritis",,"Mean Change From Baseline in Total Physical Activity Short Questionnaire to Assess Health-enhancing Physical Activity (SQUASH) Score|Mean Change From Baseline in Total Physical Activity SQUASH Score|Mean Change From Baseline in SQUASH-A Scores|Mean Change From Baseline in SQUASH-B Scores|Mean Change From Baseline in SQUASH-C Scores|Mean Change From Baseline in SQUASH-D Scores|Mean Change From Baseline in Disease Activity Index - 28 Joints (DAS28) Score|Percentage of Participants in Clinical Disease Remission (DAS28<2.6)|Percentage of Participants With Low Disease Activity State (LDAS, DAS28<3.2)|Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categories' SQUASH Scores in Participants in Remission or LDAS|Mean Change From Baseline in Total Physical Activity SQUASH Scores and Individual Physical Activity Categories' SQUASH Scores in Participants Those Who Did Not Attain Remission or LDAS|Mean Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score|Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) and DAS28 Scores|Correlation Between Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) and HAQ-DI Scores|Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Age Categories|Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Gender|Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Education|Mean Change From Baseline in Physical Activity (Total SQUASH Score and Individual Physical Activity Categories' SQUASH Scores) Influenced by Occupation","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"462","Industry","Observational","Time Perspective: Prospective","P13-683","December 2012","October 2015","October 2015","December 25, 2012","March 6, 2017","March 6, 2017",,,"https://ClinicalTrials.gov/show/NCT01756235"
459,"NCT01754727","Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice","IDEA","Completed","Has Results","Ankylosing Spondylitis",,"Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 at Month 12|Percentage of Participants Achieving BASDAI 50|Percentage of Participants Achieving At Least 2.0 Score Decrease in Ankylosing Spondylitis Disease Activity (ASDAS) Score From Baseline|Mean Change in the Number of Hospital Inpatient Days|Mean Change in the Number of Hospitalizations|Mean Change in the Number of Sick Leave Days|Mean Change in the Number of Sick Leaves|Mean Change in the Number of Outpatient Visits to Each Kind of Health Care Provider|Mean Change From Baseline in BASDAI Score|Mean Change From Baseline in Ankylosing Spondylitis Disease Activity (ASDAS) Score|Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"452","Industry","Observational","Time Perspective: Prospective","P13-682","December 2012","October 2015","October 2015","December 21, 2012","March 6, 2017","March 6, 2017",,,"https://ClinicalTrials.gov/show/NCT01754727"
460,"NCT01754129","Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa","GREENFIELD","Completed","Has Results","Parkinson's Disease",,"Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Proportion of Waking Day Spent in ""Off"") Score: Mean Change From Baseline to the Last Available Follow up|Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Part A+B Score: Mean Change From Baseline to Visits 2 and 3|Change in Unified Parkinson's Disease Rating Scale on Mentation, Behavior and Mood (UPDRS I) and Activities of Daily Living (UPDRS II) During On and Off Phases|Change in Parkinson's Disease Quality of Life Questionnaire (PDQ-39) Scores|Change in Parkinson's Disease Sleep Scale Version 2 (PDSS-2) Scores|Change in Gait and Falls Questionnaire (GFQ) Scores|Change in Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS) Scores|Economic and Social Impact of Family-provided Healthcare|Change in Relative Stress Scale (RSS) Scores|Concomitant Diseases and Medications|Change in Global Effectiveness on Motor Symptoms as Compared to Baseline|Participant Self-assessment Scale of DUODOPA Therapy|DUODOPA Total Daily Infusion Dosage","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"148","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-895","December 2012","May 2016","May 2016","December 21, 2012","August 10, 2018","August 10, 2018",,,"https://ClinicalTrials.gov/show/NCT01754129"
461,"NCT01752855","Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab",,"Completed","Has Results","Rheumatoid Arthritis","Biological: New formulation adalimumab","Mean Change From Baseline in Disease Activity Score 28 (DAS28) at Weeks 36 and 48|Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 36 and 48|Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 36 and 48|Mean Change From Baseline in Health Assessment Questionnaire (HAQ-DI) at Weeks 36 and 48|Percentage of Participants Positive for Anti-adalimumab Antibody","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","88","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-692|2012-003881-42","December 2012","October 2013","October 2013","December 19, 2012","October 29, 2014","October 29, 2014","Site Reference ID/Investigator# 92113, Mesa, Arizona, United States|Site Reference ID/Investigator# 92118, Hemet, California, United States|Site Reference ID/Investigator# 92117, Wichita, Kansas, United States|Site Reference ID/Investigator# 92115, Clifton, New Jersey, United States|Site Reference ID/Investigator# 92116, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 92114, Charleston, South Carolina, United States|Site Reference ID/Investigator# 92053, Brussels, Belgium|Site Reference ID/Investigator# 92054, Liege, Belgium|Site Reference ID/Investigator# 91954, Brno, Czech Republic|Site Reference ID/Investigator# 91955, Prague 2, Czech Republic|Site Reference ID/Investigator# 91953, Uherske Hradiste, Czech Republic|Site Reference ID/Investigator# 91956, Zlin, Czech Republic|Site Reference ID/Investigator# 92073, Ratingen, Germany|Site Reference ID/Investigator# 92074, Vega Baja, Puerto Rico|Site Reference ID/Investigator# 92093, Bucharest, Romania|Site Reference ID/Investigator# 92095, Cluj-Napoca, Romania|Site Reference ID/Investigator# 92094, Ploiesti, Romania|Site Reference ID/Investigator# 92096, Banska Bystrica, Slovakia|Site Reference ID/Investigator# 92097, Senica, Slovakia|Site Reference ID/Investigator# 92098, Zilina, Slovakia",,"https://ClinicalTrials.gov/show/NCT01752855"
462,"NCT01749631","Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to Intubate Egyptian Patients",,"Completed","Has Results","Intubation; Difficult",,"Percentage of Participants With Successful Intubation (Clinical Success)|Mean Duration of Induction (in Seconds)|Percentage of Participants With Mallampati Score III and IV|Mean Duration of Intubation Procedure (in Minutes)|Percentage of Participants Who Experienced Complications Resulting From Intubation Procedure|Percentage of Participants Who Experienced Difficulties Related to the Use of Sevoflurane|Mean Number of Intubation Attempts","AbbVie (prior sponsor, Abbott)|AbbVie","All","19 Years and older   (Adult, Older Adult)",,"97","Industry","Observational","Time Perspective: Prospective","P13-805","December 2012","February 2015","February 2015","December 17, 2012","March 1, 2016","March 1, 2016",,,"https://ClinicalTrials.gov/show/NCT01749631"
463,"NCT01747655","A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study","MONOTREAT","Completed","Has Results","Parkinson's Disease",,"Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 12 Months After Hospital Discharge|Unified Parkinson's Disease Rating Scale (UPDRS) II (Activities of Daily Living) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Percentage of Participants Who Continued With Jejunal Extension Tube of the Percutaneous Endoscopic Gastrostomy (PEG-J) Treatment|Primary Reasons for Discontinuing Duodopa Treatment or for Discontinuing the Study|Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 32 (Duration) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 33 (Disability) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 34 (Pain) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Unified Parkinson's Disease Rating Scale (UPDRS) IV (Complications of Therapy) Item 39 (Clinical Fluctuations) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Unified Parkinson's Disease Rating Scale (UPDRS) III (Motor Examination) Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Non-Motor Symptoms Assessment Scale for Parkinson's Disease (NMSS Rating Scale) Total Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Parkinson's Disease Quality of Life Questionnaire (PDQ-8) Summary Index Score: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Healthcare Resource Utilization (HCRU) Number of Office Visits: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Healthcare Resource Utilization (HCRU) Number of Visits at Home: Mean Change From Baseline to 3, 6, and 12 Months After Hospital Discharge|Healthcare Resource Utilization (HCRU) Emergency Situations: Percentage of Participants With Emergency Situations at 3, 6, and 12 Months After Hospital Discharge|Healthcare Resource Utilization (HCRU) Received Assistance at Home: Percentage of Participants Who Received Assistance at Home at 3, 6, and 12 Months After Hospital Discharge|Healthcare Resource Utilization (HCRU) Falls: Percentage of Participants With Falls at 3, 6, and 12 Months After Hospital Discharge","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"64","Industry","Observational","Time Perspective: Prospective","P13-893","February 2013","July 2015","July 2015","December 12, 2012","October 13, 2016","October 13, 2016",,,"https://ClinicalTrials.gov/show/NCT01747655"
464,"NCT01741727","A Study of ABT-414 in Subjects With Solid Tumors",,"Completed","No Results Available","Squamous Cell Tumors","Drug: ABT-414","Phase 1 - Safety (Number of subjects with adverse events and/or dose limiting toxicities)|Phase 1 - Pharmacokinetic profile|Phase 2 - Efficacy|Phase 2- Safety (Scheduled study visits occurring on average every 3 weeks)|Phase 2- Pharmacokinetic profile|Phase 1&2 - QT assessment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","57","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-379","October 2012","November 2015","November 2015","December 5, 2012",,"November 20, 2017","Site Reference ID/Investigator# 90333, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 83156, Chicago, Illinois, United States|Site Reference ID/Investigator# 117516, Boston, Massachusetts, United States|Site Reference ID/Investigator# 83154, Boston, Massachusetts, United States|Site Reference ID/Investigator# 83155, San Antonio, Texas, United States|Site Reference ID/Investigator# 89035, Ottawa, Canada",,"https://ClinicalTrials.gov/show/NCT01741727"
465,"NCT01741493","A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494",,"Completed","No Results Available","Rheumatoid Arthritis","Drug: ABT-494|Drug: Placebo|Drug: Tofacitinib","Number and percentage of participants with Adverse Events|Vital Signs|Clinical Lab testing|Electrocardiogram (ECG)|Pharmacokinetics of ABT-494|Pharmacokinetics of Methotrexate","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","M13-845","November 2012","December 2013","December 2013","December 5, 2012",,"November 20, 2017","Site Reference ID/Investigator# 95817, Miami, Florida, United States|Site Reference ID/Investigator# 95816, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 95815, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 92153, Austin, Texas, United States|Site Reference ID/Investigator# 97177, Orem, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01741493"
466,"NCT01741142","Efficacy and Safety Study of ABT-436 in Major Depressive Disorder",,"Terminated","No Results Available","Major Depressive Disorder","Drug: ABT-436|Drug: Escitalopram|Drug: Placebo","Primary efficacy variable will be change from baseline to Week 6 visit on Montgomery-Asberg Depression Rating Scale (MADRS) total score.|Secondary efficacy variables include change from Baseline to Week 6 on clinician-rated Hamilton Depression Rating Scale.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-733","January 2012","October 2013","August 2015","December 4, 2012",,"October 8, 2013","Site Reference ID/Investigator# 85593, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 87228, Garden Grove, California, United States|Site Reference ID/Investigator# 87214, National City, California, United States|Site Reference ID/Investigator# 87220, Oakland, California, United States|Site Reference ID/Investigator# 87215, Bradenton, Florida, United States|Site Reference ID/Investigator# 87225, South Miami, Florida, United States|Site Reference ID/Investigator# 85594, Atlanta, Georgia, United States|Site Reference ID/Investigator# 85580, Marlton, New Jersey, United States|Site Reference ID/Investigator# 87227, Brooklyn, New York, United States|Site Reference ID/Investigator# 87223, New York, New York, United States|Site Reference ID/Investigator# 87217, Dayton, Ohio, United States|Site Reference ID/Investigator# 87226, Portland, Oregon, United States|Site Reference ID/Investigator# 87221, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 87219, Austin, Texas, United States|Site Reference ID/Investigator# 87216, Dallas, Texas, United States|Site Reference ID/Investigator# 87933, Houston, Texas, United States|Site Reference ID/Investigator# 88874, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 88876, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01741142"
467,"NCT01736189","Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Adalimumab","Percentage of Participants With a Disease Activity Score 28 (DAS28) Score of <2.6 at Week 52|Percentage of Participants With a Clinical Disease Activity Index (CDAI) Score ≤ 2.8 at Week 104|Percentage of Participants With a Simplified Disease Activity Index (SDAI) Score ≤ 3.3 at Week 104|Percentage of Participants With a Health Assessment Questionnaire Disability Index (HAQ-DI) Score < 0.5 at Week 104|Mean Change From Baseline in European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Index Score at Week 104|Percentage of Participants With a Change From Baseline of ≤ 1.0 in Van Der Heijde Modified Total Sharp Score (mTSS) at Week 104","AbbVie (prior sponsor, Abbott)|AbbVie","All","16 Years to 99 Years   (Child, Adult, Older Adult)",,"346","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-684","October 11, 2012","April 16, 2018","April 16, 2018","November 29, 2012","July 2, 2019","July 2, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01736189/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/89/NCT01736189/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01736189"
468,"NCT01736176","A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease",,"Completed","Has Results","Advanced Parkinson's Disease","Drug: Levodopa-Carbidopa Intestinal Gel|Procedure: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|Drug: Levodopa-carbidopa Immediate Release (LC-IR) Tablets","Change From Baseline to Week 12 in the Non-Motor Symptom Scale (NMSS) Total Score|Number of Participants Who Used Healthcare Resources During the First 4 Weeks|Number of Participants With Adverse Events|Number of Participants Who Used Healthcare Resources Through Week 60|Change From Baseline to Week 60 in the Non-Motor Symptom Scale (NMSS) Total Score|Change From Baseline in NMSS Cardiovascular Domain Score|Change From Baseline in NMSS Sleep/Fatigue Domain Score|Change From Baseline in NMSS Mood/Cognition Domain Score|Change From Baseline in NMSS Perceptual Problems/Hallucinations Domain Score|Change From Baseline in NMSS Attention/Memory Domain Score|Change From Baseline in NMSS Gastrointestinal Tract Domain Score|Change From Baseline in NMSS Urinary Domain Score|Change From Baseline in NMSS Sexual Function Domain Score|Change From Baseline in NMSS Miscellaneous Domain Score|Change From Baseline in Mean Daily Normalized ""Off"" Time Based on Parkinson's Disease Diary|Change From Baseline in Mean Daily Normalized ""On"" Time Without Troublesome Dyskinesia Based on PD Diary|Change From Baseline for Unified Parkinson's Disease Rating Scale (UPDRS) Total Score|Change From Baseline in UPDRS Part I: Mentation, Behavior, and Mood Score|Change From Baseline in UPDRS Part II: Activities of Daily Living (ADL) Score|Change From Baseline in UPDRS Part III: Motor Examination Score|Change From Baseline in UPDRS Part IV: Complications of Therapy Score|Change From Baseline in UPDRS Dyskinesia Items Score|Change From Baseline in UPDRS Part V: Modified Hoehn and Yahr Staging Score|Change From Baseline in Parkinson's Disease Questionnaire-39 Item (PDQ-39) Summary Index|Change From Baseline in PDQ-39 Mobility Domain Score|Change From Baseline in PDQ-39 Activities of Daily Living Domain Score|Change From Baseline in PDQ-39 Emotional Well-Being Domain Score|Change From Baseline in PDQ-39 Stigma Domain Score|Change From Baseline in PDQ-39 Social Support Domain Score|Change From Baseline in PDQ-39 Cognition Domain Score|Change From Baseline in PDQ-39 Communication Domain Score|Change From Baseline in PDQ-39 Bodily Discomfort Domain Score|Percentage of Participants With a Patient Global Impression of Change (PGIC) Response of Improved|Treatment Satisfaction Questionnaire Scores|Change From Baseline in Health-related Productivity|Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Spatial Working Memory Between Errors Score at Week 12|Change From Baseline in CANTAB Spatial Working Memory Strategy Score at Week 12|Change From Baseline in Controlled Oral Word Association Test (COWAT) Verbal Fluency Scores at Week 60","AbbVie (prior sponsor, Abbott)|AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","39","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-920","March 2013","March 2015","December 2015","November 29, 2012","February 8, 2017","February 8, 2017",,,"https://ClinicalTrials.gov/show/NCT01736176"
469,"NCT01716585","A Study to Evaluate Chronic Hepatitis C Infection",,"Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for ABT-450/r/ABT-267|Drug: Placebo for ABT-333|Drug: Placebo for ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period|Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm|Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","636","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M11-646|2012-002019-25","November 2012","October 2013","October 2014","October 30, 2012","January 6, 2015","November 9, 2015",,,"https://ClinicalTrials.gov/show/NCT01716585"
470,"NCT01715857","Clinical Practice of Inhalation Anesthesia With Sevoflurane in China",,"Completed","Has Results","Anesthesia, General",,"Anesthesiologist Satisfaction With the Anesthesia Using a Numeric Analog Scale (NAS)|Participant Satisfaction With the Anesthesia Using a Numeric Analog Scale (NAS)|Time to Eye Opening|Time to Extubation|Cost of Anesthetics Including Sevoflurane (Yuan Renminbi [RMB]/Hour)|Non-compliance of Sevoflurane End Tidal Concentration Following the Consensus|Non-compliance of Sevoflurane Vaporizer Setting Following the Consensus","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)",,"4100","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P13-934","July 2012","July 2013","July 2013","October 29, 2012","August 13, 2014","August 19, 2014","Site Reference ID/Investigator# 84316, Beijing, Xicheng District, China|Site Reference ID/Investigator# 84317, Beijing, China|Site Reference ID/Investigator# 86755, Beijing, China|Site Reference ID/Investigator# 96155, Beijing, China|Site Reference ID/Investigator# 84320, Beijing, China|Site Reference ID/Investigator# 84321, Changchun, Jilin, China|Site Reference ID/Investigator# 86754, Changchun, Jilin, China|Site Reference ID/Investigator# 86764, Changsha, Hunan, China|Site Reference ID/Investigator# 86767, Changsha, Hunan, China|Site Reference ID/Investigator# 100206, Chengdu, China|Site Reference ID/Investigator# 86762, Chongqing, China|Site Reference ID/Investigator# 84333, Guangzhou, Guangdong, China|Site Reference ID/Investigator# 100095, Guangzhou, Guangdong, China|Site Reference ID/Investigator# 84338, Guangzhou, China|Site Reference ID/Investigator# 106416, Guangzhou, China|Site Reference ID/Investigator# 84337, Guangzhou, China|Site Reference ID/Investigator# 102457, Guangzhou, China|Site Reference ID/Investigator# 84334, Harbin, Heilongjiang, China|Site Reference ID/Investigator# 86759, Jinan, Shandong, China|Site Reference ID/Investigator# 84318, Kunming, Yunnan, China|Site Reference ID/Investigator# 86757, Kunming, Yunnan, China|Site Reference ID/Investigator# 84336, Lanzhou, Gansu, China|Site Reference ID/Investigator# 84322, Lanzhou, Gansu, China|Site Reference ID/Investigator# 86761, Nanchang, Jiangxi, China|Site Reference ID/Investigator# 102455, Qingdao, China|Site Reference ID/Investigator# 78434, Shanghai, China|Site Reference ID/Investigator# 86073, Shanghai, China|Site Reference ID/Investigator# 84342, Shanghai, China|Site Reference ID/Investigator# 84314, Shenyang, Liao Ning, China|Site Reference ID/Investigator# 84319, Shijiazhuang Hebei, China|Site Reference ID/Investigator# 100207, Tianjin, China|Site Reference ID/Investigator# 95295, Tianjin, China|Site Reference ID/Investigator# 86760, Wuhan, Hubei, China|Site Reference ID/Investigator# 86766, Zhengzhou, Henan, China|Site Reference ID/Investigator# 86763, Zhengzhou, Henan, China|Site Reference ID/Investigator# 86769, Zunyi, Guizhou, China",,"https://ClinicalTrials.gov/show/NCT01715857"
471,"NCT01715415","A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults",,"Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin|Drug: Placebo for ABT-450/r/ABT-267|Drug: Placebo for ABT-333|Drug: Placebo for ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period|Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment|Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm|Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","395","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-098|2012-002035-29","November 2012","November 2013","October 2014","October 29, 2012","January 6, 2015","November 23, 2015",,,"https://ClinicalTrials.gov/show/NCT01715415"
472,"NCT01712178","A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Adalimumab, current formulation|Biological: Adalimumab, new formulation","Serum Concentrations of Adalimumab at Weeks 12 and 24|Mean Disease Activity Scores (DAS28) at Weeks 12 and 24|Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Weeks 12 and 24|Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Weeks 12 and 24|Mean Health Assessment Questionnaire (HAQ-DI) Scores at Weeks 12 and 24|Mean Short Form-36 (SF-36) Physical Component Summary Scores and Mental Component Summary Scores at Weeks 12 and 24|Percentage of Participants Positive for Anti-adalimumab Antibody|Number of Participants With Adverse Events|Mean Injection Site Pain on a Visual Analogue Scale (VAS)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-390|2012-000535-36","June 2012","May 2013","May 2013","October 23, 2012","June 11, 2014","June 11, 2014","Site Reference ID/Investigator# 75073, Mesa, Arizona, United States|Site Reference ID/Investigator# 75077, Hemet, California, United States|Site Reference ID/Investigator# 75076, Wichita, Kansas, United States|Site Reference ID/Investigator# 75075, Clifton, New Jersey, United States|Site Reference ID/Investigator# 83133, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 75074, Charleston, South Carolina, United States|Site Reference ID/Investigator# 75100, Brussels, Belgium|Site Reference ID/Investigator# 75101, Liege, Belgium|Site Reference ID/Investigator# 75104, Brno, Czech Republic|Site Reference ID/Investigator# 76788, Prague 2, Czech Republic|Site Reference ID/Investigator# 75102, Uherske Hradiste, Czech Republic|Site Reference ID/Investigator# 75103, Zlin, Czech Republic|Site Reference ID/Investigator# 78014, Ratingen, Germany|Site Reference ID/Investigator# 75079, Caguas, Puerto Rico|Site Reference ID/Investigator# 75078, Vega Baja, Puerto Rico|Site Reference ID/Investigator# 76787, Bucharest, Romania|Site Reference ID/Investigator# 75978, Cluj-Napoca, Romania|Site Reference ID/Investigator# 76433, Ploiesti, Romania|Site Reference ID/Investigator# 76934, Banska Bystrica, Slovakia|Site Reference ID/Investigator# 76935, Senica, Slovakia|Site Reference ID/Investigator# 76682, Zilina, Slovakia",,"https://ClinicalTrials.gov/show/NCT01712178"
473,"NCT01704755","A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis","TURQUOISE-II","Completed","Has Results","Chronic Hepatitis C Infection|Compensated Cirrhosis","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin (RBV)","Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm|Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period|Percentage of Participants With Virologic Relapse After Treatment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","381","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-099|2012-003088-23","October 2012","January 2014","September 2014","October 11, 2012","January 6, 2015","October 19, 2015",,,"https://ClinicalTrials.gov/show/NCT01704755"
474,"NCT01690195","Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-126","Adverse Events|Laboratory Data|Vital Signs|Physical examinations|Brief Neurological examination|Brief Psychiatric assessments|Columbia-Suicide Severity Rating Scale|Cornell Scale for Depression in Dementia|Electrocardiogram","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","343","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-428|2012-000537-39","September 2012","February 2014","February 2014","September 21, 2012",,"March 26, 2014","Site Reference ID/Investigator# 84185, Long Beach, California, United States|Site Reference ID/Investigator# 84183, San Francisco, California, United States|Site Reference ID/Investigator# 84187, Hamden, Connecticut, United States|Site Reference ID/Investigator# 84178, Delray Beach, Florida, United States|Site Reference ID/Investigator# 84180, Orlando, Florida, United States|Site Reference ID/Investigator# 84186, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 84182, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 84181, Staten Island, New York, United States|Site Reference ID/Investigator# 84179, Bennington, Vermont, United States|Site Reference ID/Investigator# 84173, Gatineau, Canada|Site Reference ID/Investigator# 84174, Montreal, Canada|Site Reference ID/Investigator# 84177, Peterborough, Canada|Site Reference ID/Investigator# 84175, Toronto, Canada|Site Reference ID/Investigator# 84176, Verdun, Canada|Site Reference ID/Investigator# 84376, Dijon Cedex, France|Site Reference ID/Investigator# 84373, Limoges Cedex, France|Site Reference ID/Investigator# 84374, Paris Cedex 10, France|Site Reference ID/Investigator# 84377, Paris, France|Site Reference ID/Investigator# 84375, Toulouse Cedex 9, France|Site Reference ID/Investigator# 84382, Berlin, Germany|Site Reference ID/Investigator# 84380, Freiburg, Germany|Site Reference ID/Investigator# 84383, Huettenberg, Germany|Site Reference ID/Investigator# 84379, Mittweida, Germany|Site Reference ID/Investigator# 84381, Munich, Germany|Site Reference ID/Investigator# 84378, Schwerin, Germany|Site Reference ID/Investigator# 84385, Athens, Greece|Site Reference ID/Investigator# 84388, Athens, Greece|Site Reference ID/Investigator# 84389, Athens, Greece|Site Reference ID/Investigator# 84386, Haidari, Athens, Greece|Site Reference ID/Investigator# 84390, Thessaloniki, Greece|Site Reference ID/Investigator# 84395, Belville, South Africa|Site Reference ID/Investigator# 84391, Cape Town, South Africa|Site Reference ID/Investigator# 84393, George, South Africa|Site Reference ID/Investigator# 84394, Johannesburg, South Africa|Site Reference ID/Investigator# 84392, Rosebank, South Africa|Site Reference ID/Investigator# 84398, Bath, United Kingdom|Site Reference ID/Investigator# 84397, Glasgow, United Kingdom|Site Reference ID/Investigator# 84400, London, United Kingdom|Site Reference ID/Investigator# 84399, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01690195"
475,"NCT01686555","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)",,"Completed","No Results Available","Lupus Erythematosus","Drug: ABT-199|Other: Placebo","Number of participants with Adverse Events|Physical Exam including vital signs|Clinical Lab Testing|Electrocardiogram (ECG) Measurements|Maximum observed serum concentration (Cmax) of ABT-199|Time to Cmax (Tmax) of ABT-199|The area under the time curve (AUC) of ABT-199|The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-199|Measurement of lymphocyte depletion and recovery","AbbVie (prior sponsor, Abbott)|AbbVie","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-093|2013-000328-33","November 2012","June 2015","June 2015","September 18, 2012",,"November 20, 2017","Site Reference ID/Investigator# 89694, Clearwater, Florida, United States|Site Reference ID/Investigator# 131720, DeBary, Florida, United States|Site Reference ID/Investigator# 124116, Miami Lakes, Florida, United States|Site Reference ID/Investigator# 118637, Miami, Florida, United States|Site Reference ID/Investigator# 89693, Orlando, Florida, United States|Site Reference ID/Investigator# 78256, Overland Park, Kansas, United States|Site Reference ID/Investigator# 129826, Rochester, Minnesota, United States|Site Reference ID/Investigator# 89773, Manhasset, New York, United States|Site Reference ID/Investigator# 78254, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 123335, Dallas, Texas, United States|Site Reference ID/Investigator# 78253, Dallas, Texas, United States|Site Reference ID/Investigator# 107896, Berlin, Germany|Site Reference ID/Investigator# 116395, Distrito Federal, Mexico|Site Reference ID/Investigator# 112555, Monterrey, Mexico|Site Reference ID/Investigator# 132009, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01686555"
476,"NCT01685203","A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection","PEARL-I","Completed","Has Results","Hepatitis C, Chronic","Drug: ABT-450/r|Drug: ABT-267|Drug: Ribavirin (RBV)","Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment|Percentage of Participants in Each Treatment Group With Sustained Virologic Response 24 Weeks Post-treatment|Percentage of Participants in Each Treatment Group With On-treatment Virologic Failure.|Percentage of Participants in Each Treatment Group With Post-treatment Virologic Relapse.|Percentage of Participants in Each Treatment Group With Treatment-emergent Adverse Events","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-393|2011-005762-38","August 2012","June 2014","February 2015","September 14, 2012","August 4, 2015","March 15, 2016",,,"https://ClinicalTrials.gov/show/NCT01685203"
477,"NCT01678755","A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia",,"Completed","No Results Available","Schizophrenia","Drug: ABT-126|Drug: Placebo","Cognition: MCCB (MATRICS Consensus Cognitive Battery) change from baseline to week 12|Functioning: UPSA-2 (University of California San Diego Performance-based Skills Assessment-2)|Symptom Severity: PANSS (Positive and Negative Syndrome Scale)|Symptom Severity: NSA-16 (16-item version of the Negative Symptom Assessment Scale)","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years to 55 Years   (Adult)","Phase 2","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-608","August 2012","March 2014","March 2014","September 5, 2012",,"March 24, 2015","Site Reference ID/Investigator# 74436, Chino, California, United States|Site Reference ID/Investigator# 72704, Garden Grove, California, United States|Site Reference ID/Investigator# 72699, National City, California, United States|Site Reference ID/Investigator# 73983, Oceanside, California, United States|Site Reference ID/Investigator# 73236, Orange, California, United States|Site Reference ID/Investigator# 86974, San Diego, California, United States|Site Reference ID/Investigator# 72701, Torrance, California, United States|Site Reference ID/Investigator# 75314, Bradenton, Florida, United States|Site Reference ID/Investigator# 75146, Maitland, Florida, United States|Site Reference ID/Investigator# 75654, Atlanta, Georgia, United States|Site Reference ID/Investigator# 72703, Chicago, Illinois, United States|Site Reference ID/Investigator# 76534, Hoffman Estates, Illinois, United States|Site Reference ID/Investigator# 73984, Lake Charles, Louisiana, United States|Site Reference ID/Investigator# 73981, St. Louis, Missouri, United States|Site Reference ID/Investigator# 89553, Marlton, New Jersey, United States|Site Reference ID/Investigator# 72700, Cedarhurst, New York, United States|Site Reference ID/Investigator# 73982, New York, New York, United States|Site Reference ID/Investigator# 113035, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 72702, DeSoto, Texas, United States|Site Reference ID/Investigator# 75147, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01678755"
478,"NCT01676935","This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease",,"Terminated","No Results Available","Alzheimer's Disease","Drug: ABT-126","Adverse Events|Laboratory Data|Vital Signs|Physical examinations|Brief Neurological examination|Brief Psychiatric assessments|Columbia-Suicide Severity Rating Scale|Cornell Scale for Depression in Dementia|Electrocardiogram","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","349","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-427|2011-004780-75","August 2012","March 2014","March 2014","August 31, 2012",,"March 26, 2014","Site Reference ID/Investigator# 73493, Delray Beach, Florida, United States|Site Reference ID/Investigator# 73496, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 73495, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 73494, Staten Island, New York, United States|Site Reference ID/Investigator# 97035, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 73514, Poznan, Poland|Site Reference ID/Investigator# 73515, Szczecin, Poland|Site Reference ID/Investigator# 73516, Kazan, Russian Federation|Site Reference ID/Investigator# 73525, Kazan, Russian Federation|Site Reference ID/Investigator# 73523, Kirov, Russian Federation|Site Reference ID/Investigator# 73521, Moscow, Russian Federation|Site Reference ID/Investigator# 73519, Moscow, Russian Federation|Site Reference ID/Investigator# 73517, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 73520, Saratov, Russian Federation|Site Reference ID/Investigator# 73518, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73524, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 84615, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73522, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 73507, Belville, South Africa|Site Reference ID/Investigator# 84614, Cape Town, South Africa|Site Reference ID/Investigator# 73505, George, South Africa|Site Reference ID/Investigator# 73506, Johannesburg, South Africa|Site Reference ID/Investigator# 73533, Donetsk, Ukraine|Site Reference ID/Investigator# 73534, Kiev, Ukraine|Site Reference ID/Investigator# 73535, Poltava, Ukraine|Site Reference ID/Investigator# 73502, Bath, United Kingdom|Site Reference ID/Investigator# 73503, Blackburn, United Kingdom|Site Reference ID/Investigator# 73501, Glasgow, United Kingdom|Site Reference ID/Investigator# 73504, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01676935"
479,"NCT01674725","A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C","PEARL-II","Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/r/ABT-267, ABT-333|Drug: Ribavirin","Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses|Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants With Virologic Relapse After Treatment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-389|2011-005740-95","August 2012","January 2014","October 2014","August 29, 2012","January 6, 2015","November 10, 2015",,,"https://ClinicalTrials.gov/show/NCT01674725"
480,"NCT01672983","A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection",,"Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-450/ritonavir, ABT-267","Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)|Number of Participants With Adverse Events (AEs)|Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12)|Percentage of Participants With End of Treatment (EOT) Response","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-536","July 2012","May 2014","May 2014","August 27, 2012","November 26, 2015","May 30, 2018",,,"https://ClinicalTrials.gov/show/NCT01672983"
481,"NCT01668511","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee",,"Completed","No Results Available","Osteoarthritis","Biological: ABT-981|Biological: Placebo","Number of participants with Adverse Events|Physical Exam including vital signs|Clinical Lab Testing|Change from Baseline in Electrocardiogram (ECG)|Maximum observed serum concentration (Cmax) of ABT-981|Time to Cmax (Tmax) of ABT-981|The area under the time curve (AUC) of ABT-981|The terminal phase elimination rate constant and the terminal elimination half-life (t1/2) of ABT-981|Measurement of anti-drug anti-bodies (ADA) of ABT-981","AbbVie (prior sponsor, Abbott)|AbbVie","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M12-756","September 2012","October 2013","October 2013","August 20, 2012",,"November 20, 2017","Site Reference ID/Investigator# 78613, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01668511"
482,"NCT01662336","Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program",,"Completed","Has Results","Human Immunodeficiency Virus Infection","Drug: Lopinavir / ritonavir|Behavioral: Kaletra Adherence Support Assistance Program","Percentage of Participants Adherent to Treatment at Month 6|Change From Baseline in Adherence Summative Score at Months 6 and 12|Change From Baseline in Adherence Integration Subscale Score at Months 6 and 12|Change From Baseline in Adherence Perseverance Subscale Score at Months 6 and 12|Percentage of Participants Adherent to Treatment at Month 12|Change From Baseline in Health-related Quality of Life General Health Perception Domain Score|Change From Baseline in Health-related Quality of Life Physical Functioning Domain Score|Change From Baseline in Health-related Quality of Life Role Functioning Domain Score|Change From Baseline in Health-related Quality of Life Social Functioning Domain Score|Change From Baseline in Health-related Quality of Life Cognitive Functioning Domain Score|Change From Baseline in Health-related Quality of Life Pain Domain Score|Change From Baseline in Health-related Quality of Life Mental Health Domain Score|Change From Baseline in Health-related Quality of Life Energy/ Fatigue Domain Score|Change From Baseline in Patient Perception of Stress|Change From Baseline in Psychological Well-being|Change From Baseline in Coping Self-Efficacy|Health Resource Utilization|Viral Load at Each Visit|Cluster of Differentiation 4 (CD4) Positive Cell Counts at Each Visit|Healthcare Provider Satisfaction","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"173","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P13-566","June 2012","June 2016","June 2016","August 10, 2012","January 29, 2018","January 29, 2018",,,"https://ClinicalTrials.gov/show/NCT01662336"
483,"NCT01657799","Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer",,"Completed","Has Results","Brain Metastases From Non-small Cell Lung Cancer","Drug: Veliparib|Drug: Placebo|Radiation: Whole brain radiation therapy","Overall Survival|Best Tumor Response Rate|Time to Intracranial Progression (Radiographic)|Time to Clinical Brain Metastasis Progression","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-897|2011-003618-18","October 19, 2012","January 22, 2015","January 22, 2015","August 6, 2012","February 14, 2018","June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT01657799"
484,"NCT01655680","A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia",,"Completed","No Results Available","Schizophrenia","Drug: ABT-126|Drug: Placebo","Cognition: MCCB (MATRICS Consensus Cognitive Battery)|Functioning: UPSA-2 (University of California San Diego Performance-based Skills Assessment-2)|Symptom Severity: PANSS (Positive and Negative Symptom Scale)|Symptom Severity: NSA-16 (16-item version of the Negative Symptom Assessment Scale)","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 2","432","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-855|2012-000418-13","May 2012","April 2014","July 2014","August 2, 2012",,"May 15, 2015","Site Reference ID/Investigator# 75139, Anaheim, California, United States|Site Reference ID/Investigator# 74894, Bellflower, California, United States|Site Reference ID/Investigator# 74434, Chino, California, United States|Site Reference ID/Investigator# 76593, Costa Mesa, California, United States|Site Reference ID/Investigator# 73213, Escondido, California, United States|Site Reference ID/Investigator# 72698, Garden Grove, California, United States|Site Reference ID/Investigator# 75057, La Habra, California, United States|Site Reference ID/Investigator# 72693, National City, California, United States|Site Reference ID/Investigator# 77655, Norwalk, California, United States|Site Reference ID/Investigator# 74895, Oakland, California, United States|Site Reference ID/Investigator# 73977, Oceanside, California, United States|Site Reference ID/Investigator# 73214, Orange, California, United States|Site Reference ID/Investigator# 74453, Pico Rivera, California, United States|Site Reference ID/Investigator# 74898, Riverside, California, United States|Site Reference ID/Investigator# 98016, San Bernardino, California, United States|Site Reference ID/Investigator# 86973, San Diego, California, United States|Site Reference ID/Investigator# 75140, San Diego, California, United States|Site Reference ID/Investigator# 73974, San Gabriel, California, United States|Site Reference ID/Investigator# 74433, Santa Ana, California, United States|Site Reference ID/Investigator# 72695, Torrance, California, United States|Site Reference ID/Investigator# 75136, New Haven, Connecticut, United States|Site Reference ID/Investigator# 75653, Atlanta, Georgia, United States|Site Reference ID/Investigator# 74893, Marietta, Georgia, United States|Site Reference ID/Investigator# 72697, Chicago, Illinois, United States|Site Reference ID/Investigator# 76533, Hoffman Estates, Illinois, United States|Site Reference ID/Investigator# 75056, Wichita, Kansas, United States|Site Reference ID/Investigator# 72694, Cedarhurst, New York, United States|Site Reference ID/Investigator# 75137, Rochester, New York, United States|Site Reference ID/Investigator# 75053, Staten Island, New York, United States|Site Reference ID/Investigator# 75413, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 74553, Dallas, Texas, United States|Site Reference ID/Investigator# 72696, DeSoto, Texas, United States|Site Reference ID/Investigator# 75055, Houston, Texas, United States|Site Reference ID/Investigator# 74896, Houston, Texas, United States|Site Reference ID/Investigator# 94476, Chita, Russian Federation|Site Reference ID/Investigator# 79515, Ekaterinburg, Russian Federation|Site Reference ID/Investigator# 94528, Kazan, Russian Federation|Site Reference ID/Investigator# 79517, Lipetsk, Russian Federation|Site Reference ID/Investigator# 81934, Moscow, Russian Federation|Site Reference ID/Investigator# 81935, Moscow, Russian Federation|Site Reference ID/Investigator# 79516, Moscow, Russian Federation|Site Reference ID/Investigator# 83116, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 97136, Saint-Petersburg, Russian Federation|Site Reference ID/Investigator# 81933, Saratov, Russian Federation|Site Reference ID/Investigator# 79514, Saratov, Russian Federation|Site Reference ID/Investigator# 80673, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 85093, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 97135, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 97137, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 83115, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 84733, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 79520, Stavropol, Russian Federation|Site Reference ID/Investigator# 83117, Yaroslavl, Russian Federation|Site Reference ID/Investigator# 97138, Yekaterinburg, Russian Federation|Site Reference ID/Investigator# 81938, Brentford, United Kingdom|Site Reference ID/Investigator# 81940, Edinburgh, United Kingdom|Site Reference ID/Investigator# 81939, London, United Kingdom|Site Reference ID/Investigator# 92813, London, United Kingdom|Site Reference ID/Investigator# 81937, Newcastle upon Tyne, United Kingdom|Site Reference ID/Investigator# 81943, Oxford, United Kingdom|Site Reference ID/Investigator# 82238, Preston, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01655680"
485,"NCT01646073","Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis",,"Completed","Has Results","Plaque Psoriasis","Biological: Adalimumab|Biological: placebo","Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response at Week 12|Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period A]|Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 75% Reduction (PASI 75) Response [Period B]|Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period A]|Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score [Period B]|Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period A]|Percentage of Participants Achieving a Psoriasis Area and Severity Index Greater Than or Equal to 50%, 90%, or 100% Reduction (PASI 50/90/100) Response [Period B]|Percentage of Participants With a Physician's Global Assessment (PGA) of ""Clear"" [Period A]|Percentage of Participants With a Physician's Global Assessment (PGA) of ""Clear"" [Period B]|Percentage of Participants With a Physician's Global Assessment (PGA) of ""Clear"" or ""Minimal"" [Period A]|Percentage of Participants With a Physician's Global Assessment (PGA) of ""Clear"" or ""Minimal"" [Period B]|Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of ""0"" [Period A]|Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of ""0"" [Period B]|Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of ""0 or 1"" [Period A]|Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Score of ""0 or 1"" [Period B]|Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period A]|Change From Baseline in the Short Form 36 (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) [Period B]","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","425","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M13-606","August 2012","December 2013","December 2013","July 20, 2012","January 19, 2015","January 19, 2015","Site Reference ID/Investigator# 72888, Beijing, China|Site Reference ID/Investigator# 72873, Beijing, China|Site Reference ID/Investigator# 72887, Beijing, China|Site Reference ID/Investigator# 85693, Chengdu, China|Site Reference ID/Investigator# 72976, Chongqing, China|Site Reference ID/Investigator# 72880, Dalian, China|Site Reference ID/Investigator# 72973, Guangzhou, China|Site Reference ID/Investigator# 72974, Guangzhou, China|Site Reference ID/Investigator# 72878, Hangzhou, Zhejiang, China|Site Reference ID/Investigator# 72877, Hangzhou, Zhejiang, China|Site Reference ID/Investigator# 87058, Jinan, China|Site Reference ID/Investigator# 72876, Shanghai, China|Site Reference ID/Investigator# 72875, Shanghai, China|Site Reference ID/Investigator# 72883, Shenyang, China|Site Reference ID/Investigator# 72977, Wuhan, Hubei, China|Site Reference ID/Investigator# 72975, Xi'an, China",,"https://ClinicalTrials.gov/show/NCT01646073"
486,"NCT01644396","An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation",,"Completed","Has Results","Moderate to Severe Plaque Psoriasis","Biological: Adalimumab","Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Week 24|Percentage of Participants Achieving a Physician's Global Assessment of Clear|Percentage of Participants Achieving a Physician's Global Assessment of Clear or Minimal|Percentage of Participants Achieving a One Grade Improvement in Physician's Global Assessment (PGA)|Percentage of Participants Achieving a PASI 50 Response|Percentage of Participants Achieving a PASI 75 Response|Percentage of Participants Achieving a PASI 90 Response|Percentage of Participants Achieving a PASI 100 Response|Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score|Percent Change From Baseline in Dermatology Life Quality Index (DLQI)|Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-279","May 2012","September 2013","September 2013","July 19, 2012","September 17, 2014","October 1, 2014","Site Reference ID/Investigator# 67547, Ekaterinburg, Russian Federation|Site Reference ID/Investigator# 78433, Kazan, Russian Federation|Site Reference ID/Investigator# 67542, Moscow, Russian Federation|Site Reference ID/Investigator# 67546, Saratov, Russian Federation|Site Reference ID/Investigator# 78417, Smolensk, Russian Federation|Site Reference ID/Investigator# 78413, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 67545, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01644396"
487,"NCT01635764","Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa","PIONEER (OLE)","Completed","Has Results","Hidradenitis Suppurativa","Biological: adalimumab","Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit|Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit|Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit|Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit|Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit|Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit|Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population|Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations|Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population|Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3|Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3|Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3|Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3|Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3|Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","508","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-555|2011-003478-98","April 2012","August 2016","August 2016","July 10, 2012","September 5, 2017","January 24, 2018",,,"https://ClinicalTrials.gov/show/NCT01635764"
488,"NCT01620528","A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain","ELARIS EM-I","Completed","Has Results","Endometriosis","Drug: elagolix|Other: placebo","Percentage of Responders at Month 3 Based on Daily Assessment of Dysmenorrhea (DYS)|Percentage of Responders at Month 3 Based on Daily Assessment of Non-Menstrual Pelvic Pain (NMPP)|Change From Baseline to Month 3 in Numeric Rating Scale (NRS) Scores|Change From Baseline to Month 6 in DYS|Change From Baseline to Month 6 in NMPP|Change From Baseline to Month 3 in Analgesic Use Across Both Classes of Rescue Analgesics|Change From Baseline to Month 6 in Analgesic Use Across Both Classes of Rescue Analgesics|Change From Baseline to Month 3 in Dyspareunia (DYSP)|Change From Baseline to Month 3 in Use of Narcotic Class of Medication (Opioids)|Percentage of Responders at Month 1 Based on Daily Assessment of DYS|Percentage of Responders at Month 2 Based on Daily Assessment of DYS|Percentage of Responders at Month 4 Based on Daily Assessment of DYS|Percentage of Responders at Month 5 Based on Daily Assessment of DYS|Percentage of Responders at Month 6 Based on Daily Assessment of DYS|Percentage of Responders at Month 1 Based on Daily Assessment of NMPP|Percentage of Responders at Month 2 Based on Daily Assessment of NMPP|Percentage of Responders at Month 4 Based on Daily Assessment of NMPP|Percentage of Responders at Month 5 Based on Daily Assessment of NMPP|Percentage of Responders at Month 6 Based on Daily Assessment of NMPP|Percentage of Responders at Month 1 for DYSP|Percentage of Responders at Month 2 for DYSP|Percentage of Responders at Month 4 for DYSP|Percentage of Responders at Month 5 for DYSP|Percentage of Responders at Month 6 for DYSP|Change From Baseline to Month 1 in Mean Pain Score for DYS|Change From Baseline to Month 2 in Mean Pain Score for DYS|Change From Baseline to Month 3 in Mean Pain Score for DYS|Change From Baseline to Month 4 in Mean Pain Score for DYS|Change From Baseline to Month 5 in Mean Pain Score for DYS|Percent Change From Baseline to Month 1 in Mean Pain Score for DYS|Percent Change From Baseline to Month 2 in Mean Pain Score for DYS|Percent Change From Baseline to Month 3 in Mean Pain Score for DYS|Percent Change From Baseline to Month 4 in Mean Pain Score for DYS|Percent Change From Baseline to Month 5 in Mean Pain Score for DYS|Percent Change From Baseline to Month 6 in Mean Pain Score for DYS|Change From Baseline to Month 1 in Mean Pain Score for NMPP|Change From Baseline to Month 2 in Mean Pain Score for NMPP|Change From Baseline to Month 3 in Mean Pain Score for NMPP|Change From Baseline to Month 4 in Mean Pain Score for NMPP|Change From Baseline to Month 5 in Mean Pain Score for NMPP|Percent Change From Baseline to Month 1 in Mean Pain Score for NMPP|Percent Change From Baseline to Month 2 in Mean Pain Score for NMPP|Percent Change From Baseline to Month 3 in Mean Pain Score for NMPP|Percent Change From Baseline to Month 4 in Mean Pain Score for NMPP|Percent Change From Baseline to Month 5 in Mean Pain Score for NMPP|Percent Change From Baseline to Month 6 in Mean Pain Score for NMPP|Change From Baseline to Month 1 in Mean Pain Score of DYSP|Change From Baseline to Month 2 in Mean Pain Score of DYSP|Change From Baseline to Month 4 in Mean Pain Score of DYSP|Change From Baseline to Month 5 in Mean Pain Score of DYSP|Change From Baseline to Month 6 in Mean Pain Score of DYSP|Change From Baseline to Month 1 in Analgesic Use Across Both Classes of Rescue Analgesics|Change From Baseline to Month 2 in Analgesic Use Across Both Classes of Rescue Analgesics|Change From Baseline to Month 4 in Analgesic Use Across Both Classes of Rescue Analgesics|Change From Baseline to Month 5 in Analgesic Use Across Both Classes of Rescue Analgesics|Response to Patient Global Impression of Change (PGIC) at Month 1|Response to PGIC at Month 2|Response to PGIC at Month 3|Response to PGIC at Month 4|Response to PGIC at Month 5|Response to PGIC at Month 6|Change From Baseline to Month 1 in NRS Scores|Change From Baseline to Month 2 in NRS Scores|Change From Baseline to Month 4 in NRS Scores|Change From Baseline to Month 5 in NRS Scores|Change From Baseline to Month 6 in NRS Scores|Change From Baseline to Month 1 in the Pain Domain of the Endometriosis Health Profile-30 (EHP-30)|Change From Baseline to Month 3 in the Pain Domain of the EHP-30|Change From Baseline to Month 6 in the Pain Domain of the EHP-30|Change From Baseline to Month 1 in the Sexual Intercourse Domain of the EHP-30|Change From Baseline to Month 3 in the Sexual Intercourse Domain of the EHP-30|Change From Baseline to Month 6 in the Sexual Intercourse Domain of the EHP-30|Change From Baseline to Month 1 in Health Related Productivity Questionnaire (HRPQ): Number of Hours of Work Lost From Workplace Due to Absenteeism|Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism|Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism|Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism|Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism|Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Absenteeism|Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism|Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism|Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism|Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism|Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism|Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Absenteeism|Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism|Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism|Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism|Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism|Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism|Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Workplace Due to Presenteeism|Change From Baseline to Month 1 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism|Change From Baseline to Month 2 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism|Change From Baseline to Month 3 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism|Change From Baseline to Month 4 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism|Change From Baseline to Month 5 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism|Change From Baseline to Month 6 in HRPQ: Number of Hours of Work Lost From Household Due to Presenteeism|Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace|Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace|Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace|Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace|Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace|Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Workplace|Change From Baseline to Month 1 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household|Change From Baseline to Month 2 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household|Change From Baseline to Month 3 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household|Change From Baseline to Month 4 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household|Change From Baseline to Month 5 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household|Change From Baseline to Month 6 in HRPQ: Total (Absenteeism and Presenteeism) Number of Hours of Work Lost From Household|Number of Participants With Endometriosis-Related Non-Study Health Visits During the Treatment Period|Number of Days of Hospitalization|Number of Participants With Emergency Room/Outpatient Procedures During the Treatment Period, by Type","AbbVie (prior sponsor, Abbott)|AbbVie","Female","18 Years to 49 Years   (Adult)","Phase 3","872","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-665","May 22, 2012","November 14, 2014","September 28, 2015","June 15, 2012","September 18, 2018","September 18, 2018",,,"https://ClinicalTrials.gov/show/NCT01620528"
489,"NCT01617928","A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors",,"Completed","No Results Available","Solid Tumors","Drug: veliparib (ABT-888)|Drug: carboplatin|Drug: paclitaxel","Determine the maximum tolerated dose and recommended Phase two dose|Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of veliparib (ABT-888)|Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of veliparib (ABT-888) when administered in combination with carboplatin and paclitaxel|Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of paclitaxel when administered in combination with veliparib (ABT-888) and carboplatin|Pharmacokinetics; Area Under the Curve (AUC), Maximum observed plasma concentration (Cmax) and Time to Cmax (Tmax) of carboplatin when administered in combination with veliparib (ABT-888) and paclitaxel|Preliminary tumor response|Safety assessment; Physical exam including vital signs|Safety assessment; Clinical lab testings|Safety assessment; Adverse event monitoring|Safety assessment; Change from Baseline in Electrocardiogram (ECG)","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years to 99 Years   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-629","May 2012","July 2013","July 2013","June 13, 2012",,"November 20, 2017","Site Reference ID/Investigator# 68622, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01617928"
490,"NCT01609933","A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With Peginterferon Alpha-2a and Ribavirin in People With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie/Abbott Combination Study",,"Completed","Has Results","Chronic Hepatitis C","Drug: ABT-450/r|Drug: ABT-267|Drug: pegylated interferon alpha-2a (pegIFN)|Drug: Ribavirin (RBV)","Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Treatment (SVR12)|Percentage of Participants Achieving Virologic Response 24 Weeks Post Treatment (SVR24)|Percentage of Participants With Extended Rapid Virologic Response (eRVR)|Number of Participants With Adverse Events","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 71 Years   (Adult, Older Adult)","Phase 2","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-101","December 18, 2012","May 3, 2017","May 3, 2017","June 1, 2012","June 19, 2018","June 19, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01609933/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01609933/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01609933"
491,"NCT01589432","A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy",,"Completed","No Results Available","Diabetic Neuropathic Pain","Drug: ABT-639|Drug: Placebo|Drug: Lidocaine","Spontaneous activity in peripheral c-nociceptors|Pain intensity measurements","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","M13-383|2011-005127-40","April 2012","November 2012","November 2012","May 2, 2012",,"January 3, 2013","Site Reference ID/Investigator# 68882, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01589432"
492,"NCT01589419","A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer",,"Completed","No Results Available","Locally Advanced Rectal Cancer","Drug: veliparib|Drug: capecitabine|Radiation: radiation","Determine the maximum tolerated dose (MTD) and/or establish the recommended phase two dose (RPTD)|Assess the safety (number of participants with adverse events and types of adverse events observed)|Assess the tolerability (number of participants with adverse events and types of adverse events observed)|Assess the pharmacokinetic profile by area under the curve vs. dose of veliparib","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-950","June 2012","January 2015","January 2015","May 2, 2012",,"November 20, 2017","Site Reference ID/Investigator# 99095, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 68044, Chicago, Illinois, United States|Site Reference ID/Investigator# 112395, Goshen, Indiana, United States|Site Reference ID/Investigator# 68045, Durham, North Carolina, United States|Site Reference ID/Investigator# 68043, Madison, Wisconsin, United States|Site Reference ID/Investigator# 67882, East Melbourne, Australia",,"https://ClinicalTrials.gov/show/NCT01589419"
493,"NCT01579279","A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain",,"Terminated","No Results Available","Diabetic Neuropathic Pain","Drug: ABT-652 6 mg|Drug: ABT-652 12 mg|Drug: ABT-652 12 mg - 18 mg|Drug: Placebo|Drug: Duloxetine","24-hour Average Pain Score|Neuropathic Pain Symptom Inventory|Patient Global Impression of Change|Brief Pain Inventory|Neuropathic Pain Impact on Quality of Life Questionnaire|EuroQuality of Life - 5 Dimension -5 Level","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","1","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M11-210|2011-003939-56","April 2012","May 2012","May 2012","April 17, 2012",,"September 26, 2013","Site Reference ID/Investigator# 62887, Anaheim, California, United States|Site Reference ID/Investigator# 62824, Walnut Creek, California, United States|Site Reference ID/Investigator# 63710, Milford, Connecticut, United States|Site Reference ID/Investigator# 62884, DeLand, Florida, United States|Site Reference ID/Investigator# 62826, Orlando, Florida, United States|Site Reference ID/Investigator# 63703, Brockton, Massachusetts, United States|Site Reference ID/Investigator# 73913, Olive Branch, Mississippi, United States|Site Reference ID/Investigator# 62886, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01579279"
494,"NCT01563536","Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects",,"Completed","Has Results","Chronic Hepatitis C Infection","Drug: ABT-267|Drug: ABT-450|Drug: ABT-333|Drug: Ritonavir|Drug: Ribavirin","Maximum Plasma Concentration (Cmax) of ABT-267 Following Monotherapy on Day 1|Time of Maximum Plasma Concentration (Tmax) of ABT-267 Following Monotherapy on Day 1|Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC[24]) of ABT-267 Following Monotherapy on Day 1|Plasma Concentration of ABT-267 Pre-dose (Ctrough) on Day 2 and Day 3|Number of Participants With Adverse Events (AEs)|Mean Maximal Decrease From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During ABT-267 Monotherapy|Percentage of Participants With Sustained Virologic Response 12 Weeks and 24 Weeks After Combination Therapy|Percentage of Participants With Rapid Virologic Response|Percentage of Participants With End-of-Treatment Response|Percentage of Participants With Extended Rapid Virologic Response|Mean Change in Viral Load From Baseline to Pre-dose on Day 2 and Day 3 of ABT-267 Monotherapy","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-386","February 2012","April 2012","June 2013","March 27, 2012","January 8, 2015","July 2, 2018","Site Reference ID/Investigator# 68002, Bakersfield, California, United States|Site Reference ID/Investigator# 67383, Orlando, Florida, United States|Site Reference ID/Investigator# 67382, Annapolis, Maryland, United States|Site Reference ID/Investigator# 67385, Poughkeepsie, New York, United States",,"https://ClinicalTrials.gov/show/NCT01563536"
495,"NCT01561313","Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Adalimumab","Mean Injection Site Pain on a Visual Analogue Scale (VAS)|Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale|Percentage of Participants With no Erythema in the Draize Scale|Percentage of Participants With no Edema in the Draize Scale|Percentage of Participants With no Pruritus in the Draize Scale|Number of Participants With Adverse Events (AEs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","M12-783|2011-002275-41","March 2012","November 2012","November 2012","March 23, 2012","February 20, 2014","February 20, 2014","Site Reference ID/Investigator# 63357, Genk, Belgium|Site Reference ID/Investigator# 63359, Ghent, Belgium|Site Reference ID/Investigator# 63360, Ghent, Belgium|Site Reference ID/Investigator# 63363, Brno, Czech Republic|Site Reference ID/Investigator# 63362, Prague 2, Czech Republic|Site Reference ID/Investigator# 63361, Uherske Hradiste, Czech Republic",,"https://ClinicalTrials.gov/show/NCT01561313"
496,"NCT01560104","A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer",,"Completed","No Results Available","Non-Small -Cell Lung Cancer","Drug: Veliparib|Drug: Carboplatin|Drug: paclitaxel|Drug: placebo","Progression Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Chemotherapy Induced Peripheral Neuropathy (CIPN)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-898|2011-003427-36","February 2012","September 2014","September 2014","March 22, 2012",,"October 21, 2015",,,"https://ClinicalTrials.gov/show/NCT01560104"
497,"NCT01559038","Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis","Complete-PsA","Completed","No Results Available","Psoriatic Arthritis",,"Change in the Disease Activity Score - 28 (DAS-28)|Duration of Morning Stiffness (min)|Dermatology Life Quality Index (DLQI)|Health Assessment Questionnaire - Disability Index (HAQ-DI)|Patient Global Assessment of Disease Activity (VAS and 5 Point Scale)|Physician Global Assessment of Disease Activity (VAS and 5 Point Scale)","AbbVie (prior sponsor, Abbott)|Cato Research|JSS Medical Research Inc.|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"483","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-666","February 16, 2012","November 19, 2019","November 19, 2019","March 21, 2012",,"December 11, 2019","Pont, Cranbrook, BC, CA /ID# 69120, Cranbrook, British Columbia, Canada|Dr. Barbara T. Blumenauer Inc. /ID# 75393, Kamloops, British Columbia, Canada|Hudson, Kamloops, Canada /ID# 69104, Kamloops, British Columbia, Canada|Dr. Maqbool R. Sheriff Inc. /ID# 69125, Nanaimo, British Columbia, Canada|Carmi Medical Clinic /ID# 69128, Penticton, British Columbia, Canada|Dr. J. Antonio Avina-Zubieta /ID# 71035, Richmond, British Columbia, Canada|Dr. Alfonso Verdejo Inc. /ID# 69131, Vancouver, British Columbia, Canada|Dr. Milton F. Baker Inc. /ID# 69085, Victoria, British Columbia, Canada|Manitoba Clinic /ID# 69113, Winnipeg, Manitoba, Canada|Nexus Clinical Research /ID# 45622, St. John's, Newfoundland and Labrador, Canada|St. Clare's Mercy Hospital /ID# 69121, St. John's, Newfoundland and Labrador, Canada|Qe Ii Hsc /Id# 69129, Halifax, Nova Scotia, Canada|Dr. Juris Lazovskis Inc. /ID# 69111, Sydney, Nova Scotia, Canada|Waterside Clinique /ID# 72173, Barrie, Ontario, Canada|Shickh, Bowmanville, Canada /ID# 90513, Bowmanville, Ontario, Canada|Brockville Medical Center /ID# 69105, Brockville, Ontario, Canada|Dr. Sanjay Dixit Medicine Professional Corporation /ID# 69092, Burlington, Ontario, Canada|Dr. Chrisotomor Kouroukis & Dr /ID# 137894, Dundas, Ontario, Canada|Charlton Medical Centre /ID# 133073, Hamilton, Ontario, Canada|Charlton Medical Centre /ID# 69122, Hamilton, Ontario, Canada|Dr. William G. Bensen Centre /ID# 69086, Hamilton, Ontario, Canada|West Mountain Medical Center /ID# 128878, Hamilton, Ontario, Canada|Lynderm Research Inc. /ID# 76736, Markham, Ontario, Canada|Brandusa Florica Med Prof Corp /ID# 81876, Mississauga, Ontario, Canada|Credit Valley Rheumatology /ID# 69089, Mississauga, Ontario, Canada|Imtiaz MS Khan Medicine Prof /ID# 69110, Mississauga, Ontario, Canada|Rajwinder S. Dhillon Medicine /ID# 138672, Niagara Falls, Ontario, Canada|Davis, Ottawa, CA /ID# 69091, Ottawa, Ontario, Canada|Setty, Owen Sound, CA /ID# 69123, Owen Sound, Ontario, Canada|York Dermatology Clinic and Research Centre /ID# 127943, Richmond Hill, Ontario, Canada|Pedvis Med Prof Corp /ID# 69388, Toronto, Ontario, Canada|Jonathan Stein Med Prof Corp /ID# 71134, Toronto, Ontario, Canada|Karasik, Toronto, CA /ID# 69109, Toronto, Ontario, Canada|Institut de Rhum. de Montreal /ID# 69100, Montreal, Quebec, Canada|PSS Medical Inc. /ID# 69127, Montreal, Quebec, Canada|Couture, Outremont, CA /ID# 69090, Outremont, Quebec, Canada|Ctr. de Rheum de l'est du QC /ID# 69097, Rimouski, Quebec, Canada|Groupe de Recherche en Maladies Osseuses /ID# 69087, Sainte-foy, Quebec, Canada|CHUS - Hopital Fleurimont /ID# 94735, Sherbrooke, Quebec, Canada|Ctr. de Recherche Musculo-Sque /ID# 69112, Trois-rivières, Quebec, Canada|Rheum Disease Ctr of Montreal /ID# 143964, Westmount, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01559038"
498,"NCT01557777","Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL)",,"Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: Navitoclax","Safety: Adverse Events - The number of participants with adverse events will be reported as a measure of Safety.|Safety: Physical Examination and Vital Signs - Physical examination will be performed and vital signs will be assessed for participants as a measure of safety.|Safety: Clinical Lab Tests will be performed for each participant as a safety measure.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","17","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M13-641|2012-000606-29","June 2012","July 2013","July 2013","March 20, 2012",,"July 4, 2014","Site Reference ID/Investigator# 74036, La Jolla, California, United States|Site Reference ID/Investigator# 74035, Los Angeles, California, United States|Site Reference ID/Investigator# 74038, Pleasant Hill, California, United States|Site Reference ID/Investigator# 74039, Santa Maria, California, United States|Site Reference ID/Investigator# 74033, Bethesda, Maryland, United States|Site Reference ID/Investigator# 79201, Coburg, Australia|Site Reference ID/Investigator# 78993, Greenslopes, Australia|Site Reference ID/Investigator# 77860, Afula, Israel|Site Reference ID/Investigator# 77637, Rechovot, Israel|Site Reference ID/Investigator# 77413, Gdansk, Poland|Site Reference ID/Investigator# 79203, Ivano-Frankivsk, Ukraine|Site Reference ID/Investigator# 79205, Khmelnitsky, Ukraine|Site Reference ID/Investigator# 79202, Kyiv, Ukraine|Site Reference ID/Investigator# 79204, Lviv, Ukraine|Site Reference ID/Investigator# 79206, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT01557777"
499,"NCT01550965","A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting","InspirAda","Completed","Has Results","Ulcerative Colitis","Biological: Adalimumab","Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score|Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Costs of UC-related Medical Care Excluding Adalimumab Costs|Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in Total All-cause Direct Health Care Costs (Excluding Adalimumab Costs)|Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Direct and Indirect Health Care Costs|Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related and All-cause Hospitalization|Mean Change From Baseline in Participant's Satisfaction Using Treatment Satisfaction Questionnaire for Medication (TSQM)|Mean Change From the 6 Months Prior to Treatment With Adalimumab to the 6 Months After Beginning Treatment With Adalimumab in UC-related Outpatient Utilization, Including Emergency Department Visits, Unscheduled Consultation, Exam Procedures|Percentage of Participants With Absence of Blood in Stool|Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score Over Time|Mean Change From Baseline in Physician's Global Assessment (PGA)|Mean Change From Baseline in Total Simple Clinical Colitis Activity Index (SCCAI)|Mean Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Total Score|Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Work Time Missed|Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Impairment While Working|Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Overall Work Impairment Percentage|Mean Change From Baseline in Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP): Percentage of Activity Impairment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","463","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M13-045|2011-002411-29","May 2012","April 2015","April 2015","March 12, 2012","November 1, 2016","July 2, 2018",,,"https://ClinicalTrials.gov/show/NCT01550965"
500,"NCT01549834","Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-126|Drug: placebo","Alzheimer's Disease Assessment Scale - cognitive subscale|Mini Mental Status Exam|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|DEMentia Quality of Life (DEMQOL)|Clinician Interview-Based Impression of Change - plus (CIBIC-plus)|Neuropsychiatry Inventory (NPI)|Partner-Patient Questionnaire for Shared Activities (PPQSA)|Resource Use in Dementia (RUD-Lite)|EuroQol-5D Questionnaires|Wechsler Memory Scale-III (WMS-III) Working Memory Index","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","434","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M11-793|2011-004849-40","March 2012","October 2013","October 2013","March 9, 2012",,"October 31, 2014","Site Reference ID/Investigator# 66528, Fresno, California, United States|Site Reference ID/Investigator# 69602, Long Beach, California, United States|Site Reference ID/Investigator# 66527, San Francisco, California, United States|Site Reference ID/Investigator# 66530, Hamden, Connecticut, United States|Site Reference ID/Investigator# 66522, Delray Beach, Florida, United States|Site Reference ID/Investigator# 66524, Orlando, Florida, United States|Site Reference ID/Investigator# 66531, Tampa, Florida, United States|Site Reference ID/Investigator# 66529, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 66526, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 66525, Staten Island, New York, United States|Site Reference ID/Investigator# 66523, Bennington, Vermont, United States|Site Reference ID/Investigator# 71793, Gatineau, Canada|Site Reference ID/Investigator# 71794, Montreal, Canada|Site Reference ID/Investigator# 71798, Peterborough, Canada|Site Reference ID/Investigator# 71795, Toronto, Canada|Site Reference ID/Investigator# 71796, Verdun, Canada|Site Reference ID/Investigator# 71573, Dijon Cedex, France|Site Reference ID/Investigator# 77833, Limoges Cedex, France|Site Reference ID/Investigator# 68704, Paris Cedex 10, France|Site Reference ID/Investigator# 68706, Paris, France|Site Reference ID/Investigator# 68705, Toulouse Cedex 9, France|Site Reference ID/Investigator# 68768, Berlin, Germany|Site Reference ID/Investigator# 68764, Freiburg, Germany|Site Reference ID/Investigator# 68767, Huettenberg, Germany|Site Reference ID/Investigator# 69960, Mittweida, Germany|Site Reference ID/Investigator# 68765, Munich, Germany|Site Reference ID/Investigator# 69959, Schwerin, Germany|Site Reference ID/Investigator# 68730, Athens, Greece|Site Reference ID/Investigator# 68732, Athens, Greece|Site Reference ID/Investigator# 68733, Athens, Greece|Site Reference ID/Investigator# 68731, Haidari, Athens, Greece|Site Reference ID/Investigator# 68729, Thessaloniki, Greece|Site Reference ID/Investigator# 68735, Thessaloniki, Greece|Site Reference ID/Investigator# 67586, Belville, South Africa|Site Reference ID/Investigator# 67582, Cape Town, South Africa|Site Reference ID/Investigator# 67584, George, South Africa|Site Reference ID/Investigator# 67585, Johannesburg, South Africa|Site Reference ID/Investigator# 67583, Rosebank, South Africa|Site Reference ID/Investigator# 67787, Bath, United Kingdom|Site Reference ID/Investigator# 67784, Glasgow, United Kingdom|Site Reference ID/Investigator# 67786, London, United Kingdom|Site Reference ID/Investigator# 67785, Manchester, United Kingdom|Site Reference ID/Investigator# 67783, Warrington, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01549834"
501,"NCT01537198","Surveillance of Synagis in Korean Pediatric Patients",,"Completed","Has Results","Respiratory Syncytial Virus Infection",,"Number of Subjects With Adverse Events (AEs), Serious AEs (SAEs), and Adverse Drug Reactions (ADRs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","up to 24 Months   (Child)",,"618","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P13-203","January 2012","June 2014","June 2014","February 23, 2012","July 10, 2015","July 10, 2015",,,"https://ClinicalTrials.gov/show/NCT01537198"
502,"NCT01527916","Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: placebo|Drug: donepezil|Drug: ABT-126","Alzheimer's Disease Assessment Scale - cognitive subscale|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)|Mini Mental Status Exam (MMSE)|DEMentia Quality of Life (DEMQOL)|Clinician Interview-Based Impression of Change - plus (CIBIC-plus)|Neuropsychiatry Inventory (NPI)|Partner-Patient Questionnaire for Shared Activities (PPQSA)|Resource Use in Dementia (RUD-Lite)|EuroQol-5D Questionnaires|Wechsler Memory Scale-III (WMS-III) Working Memory Index","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","438","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-985|2011-002004-32","February 2012","November 2013","November 2013","February 7, 2012",,"November 19, 2014","Site Reference ID/Investigator# 56503, Delray Beach, Florida, United States|Site Reference ID/Investigator# 56518, Tampa, Florida, United States|Site Reference ID/Investigator# 56514, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 62611, Elk Grove Village, Illinois, United States|Site Reference ID/Investigator# 56506, Staten Island, New York, United States|Site Reference ID/Investigator# 82994, Jenkintown, Pennsylvania, United States|Site Reference ID/Investigator# 77636, Wichita Falls, Texas, United States|Site Reference ID/Investigator# 56504, Bennington, Vermont, United States|Site Reference ID/Investigator# 62565, Gdynia, Poland|Site Reference ID/Investigator# 62563, Poznan, Poland|Site Reference ID/Investigator# 62562, Szczecin, Poland|Site Reference ID/Investigator# 60945, Kazan, Russian Federation|Site Reference ID/Investigator# 60955, Kazan, Russian Federation|Site Reference ID/Investigator# 60954, Kirov, Russian Federation|Site Reference ID/Investigator# 60951, Moscow, Russian Federation|Site Reference ID/Investigator# 60959, Moscow, Russian Federation|Site Reference ID/Investigator# 60946, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 60950, Saratov, Russian Federation|Site Reference ID/Investigator# 60947, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60958, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60949, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60952, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 60911, Belville, South Africa|Site Reference ID/Investigator# 76073, Cape Town, South Africa|Site Reference ID/Investigator# 60912, George, South Africa|Site Reference ID/Investigator# 60910, Johannesburg, South Africa|Site Reference ID/Investigator# 60909, Donetsk, Ukraine|Site Reference ID/Investigator# 60906, Kiev, Ukraine|Site Reference ID/Investigator# 60905, Poltava, Ukraine|Site Reference ID/Investigator# 60960, Bath, United Kingdom|Site Reference ID/Investigator# 60963, Blackburn, United Kingdom|Site Reference ID/Investigator# 60962, Glasgow, United Kingdom|Site Reference ID/Investigator# 60961, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01527916"
503,"NCT01506947","A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients",,"Completed","Has Results","Moderate to Severe Secondary Hyperparathyroidism|Stage 5 Chronic Kidney Diseases","Drug: Paricalcitol|Drug: Darbepoetin alfa","Mean Erythropoietin Dose Per Visit|Mean Scores of Short Form Health Survey 36 (SF-36) Questionnaire|Mean Intact Parathyroid Hormone (iPTH) Level at Baseline and Month 6|Mean Calcium Level at Baseline and Month 6|Mean Phosphorus Level at Baseline and Month 6|Mean Alkaline Phosphatase Level at Baseline and Month 6|Vitamin B12 Levels|Folic Acid Levels|Mean High Sensitivity C-reactive Protein (hsCRP) Level at Baseline and Month 6|Mean Fibroblast Growth Factor-23 (FGF-23) Level at Baseline and Month 6|Number of Participants With Adverse Events","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","65","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W12-645","May 10, 2012","April 7, 2016","April 7, 2016","January 10, 2012","May 15, 2017","May 15, 2017",,,"https://ClinicalTrials.gov/show/NCT01506947"
504,"NCT01502423","A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab",,"Completed","Has Results","Rheumatoid Arthritis","Biological: Adalimumab","Mean Injection Site Pain on a Visual Analogue Scale (VAS)|Percentage of Participants With no Hemorrhage/Petechiae in the Draize Scale|Percentage of Participants With no Erythema in the Draize Scale|Percentage of Participants With no Edema in the Draize Scale|Percentage of Participants With no Pruritus in the Draize Scale|Number of Participants With Adverse Events (AEs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","M11-964|2011-003953-25","January 2012","November 2012","November 2012","December 30, 2011","February 20, 2014","February 20, 2014","Site Reference ID/Investigator# 63354, Malvern East, Australia|Site Reference ID/Investigator# 63355, Maroochydore, Australia|Site Reference ID/Investigator# 63353, Shenton Park, Australia|Site Reference ID/Investigator# 67105, Hamilton, Canada|Site Reference ID/Investigator# 64122, Winnipeg, Canada|Site Reference ID/Investigator# 63356, Munich, Germany|Site Reference ID/Investigator# 69242, Ostseebad Damp, Germany",,"https://ClinicalTrials.gov/show/NCT01502423"
505,"NCT01479127","Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease",,"Completed","Has Results","Advanced Parkinson's Disease","Drug: ABT-SLV187|Drug: Oral Levodopa/Carbidopa|Device: Infusion Pump: CADD-Legacy® 1400 Pump|Device: NJ-Tube: Silicon ED Tube|Device: Adaptor: Hakko Adaptor","Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation During the Run-in Period|Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation During the ABT-SLV187 Treatment Period|Number of Participants With Potentially Clinically Significant (PCS) Hematology Results During the ABT-SLV187 Treatment Period|Number of Participants With PCS Blood Biochemistry Results During the ABT-SLV187 Treatment Period|Number of Participants With PCS Values in Special Laboratory Parameters During the ABT-SLV187 Treatment Period|Number of Participants With Potentially Clinically Significant Urinalysis Results During the ABT-SLV187 Treatment Period|Number of Participants With Potentially Clinically Significant (PCS) Vital Signs Results During the ABT-SLV187 Treatment Period|Number of Participants With Potentially Clinically Significant 12-lead Electrocardiogram (ECG) Results During the ABT-SLV187 Treatment Period|Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the ""Normal"" State on the Treatment Response Scale (TRS) I|Mean Change From Baseline to the End of Treatment in Percentage of Ratings in the ""OFF"" and ""Dyskinesia"" States on the TRS I and the ""Normal,"" ""OFF,"" and ""Dyskinesia"" States on the TRS II|Change From Baseline to the End of Treatment in Parkinson's Disease Diary Assessment|Baseline and Endpoint (End of Treatment) Video Scoring of Unified Parkinson's Disease Rating Scale (UPDRS) Items and Dyskinesia|Mean Change From Baseline to the End of Treatment in UPDRS Total Scores and Subscores|Change From Baseline to the End of Treatment in the Japanese Version of Parkinson's Disease Questionnaire 39 (PDQ-39) Total Score and Domain Scores|Modified Hoehn and Yahr Staging at Baseline and End of Treatment|Schwab and England Activities of Daily Living Scale at Baseline and End of Treatment|Clinical Global Impression - Severity (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Baseline and End of Treatment|Time to Reach Peak Plasma Concentration (Tmax) After Administration of Oral Levodopa/Carbidopa (L/C) Tablets and Intra-jejunal Administration of ABT-SLV187|Peak Plasma Concentration (Cmax), Average Plasma Concentration (Cavg), Trough Plasma Concentration (Cmin), and Cmin Within 2 and 12 Hours (Cmin [2-12 Hours]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187|The Area Under the Concentrations-time Curve From 0 to 12 and 0 to 16 Hours (AUC0-12, AUC0-16) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187|AUC0-12/Dose0-12, AUC0-16/Dose0-16 After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187|Degree of Fluctuation (2-12 Hours) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187|Ratio of Metabolite 3-OMD to Levodopa (M/P [AUC0-12]) After Administration of Oral L/C Tablets and Intra-jejunal Administration of ABT-SLV187|Number of Participants With Product Quality Complaints (PQC) During the ABT-SLV187 Treatment Period","AbbVie (prior sponsor, Abbott)|Abbott Japan Co.,Ltd|AbbVie","All","30 Years to 99 Years   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-925","October 2011","July 2012","July 2012","November 24, 2011","March 15, 2016","April 21, 2016",,,"https://ClinicalTrials.gov/show/NCT01479127"
506,"NCT01474876","Multi-country Post-Marketing Observational Study on Maintenance of Effectiveness of Adalimumab (Humira®) in Patients With Ankylosing Spondylitis and Psoriatic Arthritis",,"Completed","Has Results","Ankylosing Spondylitis|Psoriatic Arthritis",,"Percentage of Participants With a 50% or More Decrease in Bath Ankylosing Spondylitis Daily Activity Index (BASDAI) Score at 12 Months Relative to Baseline|Percentage of Participants With a Disease Activity Score 28 (DAS28) Decrease ≥1.2 at 12 Months Relative to Baseline|Percentage of Participants With Active Axial Symptoms in Remission|Percentage of Participants With Peripheral Symptoms in Remission|Mean Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (in Case of Axial Symptoms) and/or Disease Activity Score/28 Joints (DAS28) (in Case of Peripheral Symptoms) in Participants With Ankylosing Spondylitis|Mean Change in Ankylosing Spondylitis Disease Activity Score (ASDAS)|Correlation Between Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) in Participants With Ankylosing Spondylitis|Predictors of Maintained Treatment Response and Remission in Participants With Ankylosing Spondylitis|Mean Change in Health Assessment Questionnaire Disability Index (HAQ-DI) Score (in Case of Peripheral Symptoms) or Bath Ankylosing Spondylitis Functional Index (BASFI) Score (in Case of Axial Symptoms) in Participants With Ankylosing Spondylitis|Mean Frequency of Extra-articular Manifestations (EAMs)|Duration of Treatment With Adalimumab|Percentage of Participants Whose Co-medication With Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Was Stopped During the Study|Mean Change in Individual Components of the Work Productivity and Activity Impairment Specific Health Problem Questionnaire in Participants With Ankylosing Spondylitis|Change in the Percentage of Ankylosing Spondylitis Participants Who Have Paid Work|Mean Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (in Case of Axial Symptoms) and/or Disease Activity Score/28 Joints (DAS28) (in Case of Peripheral Symptoms) in Participants With Psoriatic Arthritis|Correlation Between Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) in Participants With Psoriatic Arthritis|Predictors of Maintained Treatment Response and Remission in Participants With Psoriatic Arthritis|Mean Change in Health Assessment Questionnaire Disability Index ( HAQ-DI) Score (in Case of Peripheral Symptoms) or Bath Ankylosing Spondylitis Functional Index (BASFI) Score (in Case of Axial Symptoms) in Participants With Psoriatic Arthritis|Mean Change in Individual Components of the Work Productivity and Activity Impairment Specific Health Problem Questionnaire in Participants With Psoriatic Arthritis|Change in the Percentage of Psoriatic Arthritis Participants Who Have Paid Work","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"566","Industry","Observational","Time Perspective: Prospective","P12-768","November 2011","May 2014","May 2014","November 18, 2011","July 8, 2015","July 8, 2015",,,"https://ClinicalTrials.gov/show/NCT01474876"
507,"NCT01472016","Study of ABT-700 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: ABT-700|Drug: docetaxel|Drug: FOLFIRI|Drug: cetuximab|Drug: erlotinib","To evaluate the safety and tolerability of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib|To Evaluate the pharmacokinetics of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib|To determine the recommended Phase 2 dose for ABT-700|To evaluate the preliminary efficacy of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","74","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-375","October 6, 2011","April 27, 2017","April 27, 2017","November 16, 2011",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01472016"
508,"NCT01472003","An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types",,"Completed","No Results Available","Advanced Solid Tumors","Drug: ABT-806|Drug: ABT-806i","Single-Photon Emission Computerized Tomography (SPECT)|Whole body planar imaging|Pharmacokinetic profile evaluation - Cohort 1|Pharmacokinetic profile evaluation - Cohort 2|Blood pressure - Cohort 1|Heart rate - Cohort 1|Body temperature - Cohort 1|Number of subjects with Adverse Events - Cohort 1|Chemistry - Cohort 1|Hematology - Cohort 1|Urinalysis - Cohort 1|Physical Examination - Cohort 1|Electrocardiogram (ECG) - Cohort 1|Heart rate - Cohort 2|Blood pressure - Cohort 2|Number of subjects with Adverse Events - Cohort 2|Body temperature - Cohort 2|Hematology - Cohort 2|Chemistry - Cohort 2|Physical Examination - Cohort 2|Urinalysis - Cohort 2|Electrocardiogram (ECG) - Cohort 2","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","M11-849","October 2011","December 2012","December 2012","November 16, 2011",,"January 14, 2013","Site Reference ID/Investigator# 52203, Heidelberg, Australia|Site Reference ID/Investigator# 58242, Herston, Australia",,"https://ClinicalTrials.gov/show/NCT01472003"
509,"NCT01468233","Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa","PIONEER II","Completed","Has Results","Hidradenitis Suppurativa (HS)","Biological: adalimumab|Biological: placebo","Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12|Percentage of Participants With Baseline Hurley Stage II Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12|Percentage of Participants Achieving At Least 30% Reduction and At Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 12 Among Participants With Baseline Skin Pain NRS ≥ 3|Change From Baseline to Week 12 in Modified Sartorius Score","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","326","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M11-810|2011-003406-24","November 2011","April 2014","April 2014","November 9, 2011","October 28, 2015","October 28, 2015",,,"https://ClinicalTrials.gov/show/NCT01468233"
510,"NCT01468207","Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa","PIONEER I","Completed","Has Results","Hidradenitis Suppurativa (HS)","Biological: adalimumab|Biological: placebo","Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12|Percentage of Participants With Baseline Hurley Stage II Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Week 12|Percentage of Participants Achieving At Least 30% Reduction and At Least 1 Unit Reduction From Baseline in Patient's Global Assessment of Skin Pain (NRS30) - At Worst at Week 12 Among Participants With Baseline Skin Pain NRS ≥ 3|Change From Baseline to Week 12 in Modified Sartorius Score","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","307","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M11-313|2011-003400-20","November 2011","January 2014","January 2014","November 9, 2011","October 28, 2015","October 28, 2015",,,"https://ClinicalTrials.gov/show/NCT01468207"
511,"NCT01466062","Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions",,"Completed","Has Results","Respiratory Syncytial Virus Infection","Drug: Palivizumab","Serum Palivizumab Trough Concentrations at Day 1, Day 31, and Day 121|Percentage of Participants Requiring Hospitalization For Respiratory Syncytial Virus (RSV) Infection|Percentage of Participants Who Required Treatment for Respiratory Syncytial Virus (RSV) Infection|Duration of Hospitalization Caused by Respiratory Syncytial Virus (RSV) Infection|Duration of Required Treatment for Respiratory Syncytial Virus (RSV) Infection|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs|Mean Baseline and Mean Change From Baseline in Systolic/Diastolic Blood Pressure at Day 121|Mean Baseline and Mean Change From Baseline in Body Temperature at Day 121|Mean Baseline and Mean Change From Baseline in Respiratory Rate at Day 121|Mean Baseline and Mean Change From Baseline in Pulse Rate at Day 121|Mean Baseline and Mean Change From Baseline in Body Weight at Day 121|Hematology: Mean Baseline and Mean Change From Baseline in Hemoglobin at Day 121|Hematology: Mean Baseline and Mean Change From Baseline in Hematocrit at Day 121|Hematology: Mean Baseline and Mean Change From Baseline in White Blood Cells (WBC), Neutrophils, Eosinophils, Basophils, Lymphocytes, and Monocytes at Day 121|Hematology: Mean Baseline and Mean Change From Baseline in Red Blood Cells (RBC) and Platelet Count at Day 121|Blood Chemistry: Mean Baseline and Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) at Day 121|Blood Chemistry: Mean Baseline and Change From Baseline in Total Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, and C-reactive Protein (CRP) at Day 121|Urinalysis: Presence of Urine Protein, Glucose, and Occult Blood at Screening and Day 121","AbbVie (prior sponsor, Abbott)|AbbVie","All","up to 24 Months   (Child)","Phase 3","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","M12-420","August 2011","April 2012","April 2012","November 6, 2011","June 17, 2013","June 17, 2013","Site Reference ID/Investigator# 56847, Hyogo, Japan|Site Reference ID/Investigator# 56845, Shimotsuke, Japan|Site Reference ID/Investigator# 56842, Tokyo, Japan|Site Reference ID/Investigator# 56844, Tokyo, Japan|Site Reference ID/Investigator# 56846, Tokyo, Japan|Site Reference ID/Investigator# 56843, Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT01466062"
512,"NCT01464827","ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1","Drug: ABT-450|Drug: ABT-333|Drug: ABT-267|Drug: Ribavirin|Drug: Ritonavir","Number of Participants With Adverse Events (AEs)|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin|Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","580","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-652|2010-022455-31","October 2011","March 2013","September 2013","November 4, 2011","January 6, 2015","April 22, 2015","Site Reference ID/Investigator# 57583, Birmingham, Alabama, United States|Site Reference ID/Investigator# 55530, Birmingham, Alabama, United States|Site Reference ID/Investigator# 55385, Dothan, Alabama, United States|Site Reference ID/Investigator# 55500, Phoenix, Arizona, United States|Site Reference ID/Investigator# 55382, Tucson, Arizona, United States|Site Reference ID/Investigator# 61042, Bakersfield, California, United States|Site Reference ID/Investigator# 43651, Coronado, California, United States|Site Reference ID/Investigator# 43652, Costa Mesa, California, United States|Site Reference ID/Investigator# 59130, Los Angeles, California, United States|Site Reference ID/Investigator# 43565, San Diego, California, United States|Site Reference ID/Investigator# 43910, Aurora, Colorado, United States|Site Reference ID/Investigator# 43572, Bradenton, Florida, United States|Site Reference ID/Investigator# 43584, Fort Pierce, Florida, United States|Site Reference ID/Investigator# 43917, Gainesville, Florida, United States|Site Reference ID/Investigator# 55384, Jacksonville, Florida, United States|Site Reference ID/Investigator# 44610, Wellington, Florida, United States|Site Reference ID/Investigator# 55531, Wellington, Florida, United States|Site Reference ID/Investigator# 55536, Zephyrhills, Florida, United States|Site Reference ID/Investigator# 55540, Macon, Georgia, United States|Site Reference ID/Investigator# 55527, Marietta, Georgia, United States|Site Reference ID/Investigator# 44621, Chicago, Illinois, United States|Site Reference ID/Investigator# 43576, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 55383, Bowling Green, Kentucky, United States|Site Reference ID/Investigator# 59124, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 43568, Annapolis, Maryland, United States|Site Reference ID/Investigator# 55901, Baltimore, Maryland, United States|Site Reference ID/Investigator# 43588, Lutherville, Maryland, United States|Site Reference ID/Investigator# 55534, Boston, Massachusetts, United States|Site Reference ID/Investigator# 43656, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 43655, Ann Arbor, Michigan, United States|Site Reference ID/Investigator# 43913, Detroit, Michigan, United States|Site Reference ID/Investigator# 43587, St. Paul, Minnesota, United States|Site Reference ID/Investigator# 43661, Jackson, Mississippi, United States|Site Reference ID/Investigator# 43569, Kansas City, Missouri, United States|Site Reference ID/Investigator# 44608, St. Louis, Missouri, United States|Site Reference ID/Investigator# 55526, Egg Harbor Township, New Jersey, United States|Site Reference ID/Investigator# 43566, Manhasset, New York, United States|Site Reference ID/Investigator# 59133, Monticello, New York, United States|Site Reference ID/Investigator# 43586, New York, New York, United States|Site Reference ID/Investigator# 43573, New York, New York, United States|Site Reference ID/Investigator# 55532, Poughkeepsie, New York, United States|Site Reference ID/Investigator# 55386, Rochester, New York, United States|Site Reference ID/Investigator# 55538, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 55522, Fayetteville, North Carolina, United States|Site Reference ID/Investigator# 55542, Statesville, North Carolina, United States|Site Reference ID/Investigator# 55533, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 43665, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 43585, Medford, Oregon, United States|Site Reference ID/Investigator# 55539, Portland, Oregon, United States|Site Reference ID/Investigator# 56622, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 43592, Germantown, Tennessee, United States|Site Reference ID/Investigator# 55723, Germantown, Tennessee, United States|Site Reference ID/Investigator# 43659, Nashville, Tennessee, United States|Site Reference ID/Investigator# 59132, Houston, Texas, United States|Site Reference ID/Investigator# 43577, San Antonio, Texas, United States|Site Reference ID/Investigator# 43662, Annandale, Virginia, United States|Site Reference ID/Investigator# 43666, Newport News, Virginia, United States|Site Reference ID/Investigator# 43574, Seattle, Washington, United States|Site Reference ID/Investigator# 43578, Madison, Wisconsin, United States|Site Reference ID/Investigator# 55387, Milwaukee, Wisconsin, United States|Site Reference ID/Investigator# 44850, Adelaide, Australia|Site Reference ID/Investigator# 44849, Herston, Australia|Site Reference ID/Investigator# 44852, Kogarah, Australia|Site Reference ID/Investigator# 44084, Calgary, Canada|Site Reference ID/Investigator# 43905, Vancouver, Canada|Site Reference ID/Investigator# 44755, Clichy, France|Site Reference ID/Investigator# 44758, Creteil, France|Site Reference ID/Investigator# 58884, Lyon, France|Site Reference ID/Investigator# 58887, Marseilles, France|Site Reference ID/Investigator# 58886, Montpellier - Cedex 5, France|Site Reference ID/Investigator# 44754, Paris, France|Site Reference ID/Investigator# 58889, Pessac, France|Site Reference ID/Investigator# 44760, Vandoeuvre Les Nancy, France|Site Reference ID/Investigator# 59304, Berlin, Germany|Site Reference ID/Investigator# 59303, Berlin, Germany|Site Reference ID/Investigator# 46103, Frankfurt, Germany|Site Reference ID/Investigator# 46106, Hamburg, Germany|Site Reference ID/Investigator# 46102, Hannover, Germany|Site Reference ID/Investigator# 58922, Kiel, Germany|Site Reference ID/Investigator# 46105, Wuerzburg, Germany|Site Reference ID/Investigator# 44847, Auckland, New Zealand|Site Reference ID/Investigator# 43672, San Juan, Puerto Rico|Site Reference ID/Investigator# 43675, San Juan, Puerto Rico|Site Reference ID/Investigator# 46485, Barcelona, Spain|Site Reference ID/Investigator# 45363, Barcelona, Spain|Site Reference ID/Investigator# 45668, Barcelona, Spain|Site Reference ID/Investigator# 46484, Madrid, Spain|Site Reference ID/Investigator# 45667, Madrid, Spain|Site Reference ID/Investigator# 45671, Majadahonda (Madrid), Spain|Site Reference ID/Investigator# 46583, Seville, Spain|Site Reference ID/Investigator# 45405, Valencia, Spain|Site Reference ID/Investigator# 57545, Dundee, United Kingdom|Site Reference ID/Investigator# 59262, London, United Kingdom|Site Reference ID/Investigator# 57547, London, United Kingdom|Site Reference ID/Investigator# 58811, London, United Kingdom|Site Reference ID/Investigator# 57882, Nottingham, United Kingdom|Site Reference ID/Investigator# 57543, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01464827"
513,"NCT01464333","Special Investigation (Long-term Investigation) in Patients With Crohn's Disease",,"Completed","Has Results","Crohn's Disease",,"Number of Participants With Adverse Events|Change in Crohn's Disease Activity Index (CDAI) Score Over Time|Change In Work Productivity and Activity Impairment (WPAI): Crohn's Disease (CD) Absenteeism Over Time|Change in WPAI: CD Presenteeism Over Time|Change in WPAI: CD Overall Work Impairment Over Time|Change in WPAI: CD Activity Impairment Over Time|Percentage of Participants With Endoscopic Remission Over Time by Intestine Segment (Large Intestine, Small Intestine, and Both Large and Small Intestine)|Change in C-Reactive Protein (CRP) Levels Over Time","AbbVie (prior sponsor, Abbott)|AbbVie","All","Child, Adult, Older Adult",,"511","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-170","December 16, 2011","March 31, 2018","March 31, 2018","November 3, 2011","May 20, 2019","May 20, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01464333/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01464333/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01464333"
514,"NCT01464021","A Post-Marketing Observational Study to Evaluate the Effectiveness of Adalimumab in Patients With Moderately to Severely Active Rheumatoid Arthritis in China",,"Terminated","Has Results","Arthritis|Rheumatoid",,"Number of Participants With at Least a Moderate European League Against Rheumatism (EULAR) Response|Percent Change From Baseline in Disease Activity Score (DAS)28 Erythrocyte Sedimentation Rate (ESR)|Percent Change From Baseline in Tender and Swollen Joint Counts|Percent Change From Baseline in C-reactive Protein|Percent Change From Baseline in Erythrocyte Sedimentation Rate (ESR)|Percent Change From Baseline in Patient's Global Assessment of Disease Activity|Percent Change From Baseline in Patient's Assessment of Pain|Percent Change From Baseline in Physician's Global Assessment of RA Disease Activity|Percent Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"26","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P13-194","December 2011","December 2012","December 2012","November 3, 2011","January 30, 2014","March 6, 2014","Site Reference ID/Investigator# 64782, Guangzhou City, China|Site Reference ID/Investigator# 65702, Shanghai, China|Site Reference ID/Investigator# 65706, Wulumuqi, China",,"https://ClinicalTrials.gov/show/NCT01464021"
515,"NCT01458535","A Study to Evaluate Paritaprevir With Ritonavir (ABT-450/r) When Given Together With Ombitasvir and With and Without Ribavirin (RBV) in Treatment-Naïve Participants With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)","Navigator","Completed","Has Results","Hepatitis C Virus","Drug: ABT-450|Drug: ABT-267|Drug: ribavirin|Drug: ritonavir","Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12 [(Extended Rapid Virologic Response (eRVR)]|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment|Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) < 1000 International Units Per Milliliter (IU/mL)|Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Below the Lower Limit of Quantitation (LLOQ) at Week 4 Rapid Virologic Response (RVR)|Percentage of Participants With Virologic Failure During Treatment|Percentage of Participants Who Experienced Virologic Relapse Through End of Post Treatment Period (up to 48 Weeks)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","61","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-998","September 2011","May 2013","May 2013","October 25, 2011","July 11, 2016","July 11, 2016",,,"https://ClinicalTrials.gov/show/NCT01458535"
516,"NCT01444365","A Study of ABT-652 in Combination With a Nonsteroidal Anti-Inflammatory Drug (NSAID) in Adults With Osteoarthritis Pain of the Knee",,"Completed","No Results Available","Osteoarthritis of the Knee","Drug: ABT-652 NSAID|Drug: Placebo NSAID","Subject's Assessment of Arthritis Pain Intensity|Western Ontario and McMaster (WOMAC™ ) Osteoarthritis Index|Subject's Global Assessment of Arthritis Status|Cognitive Functioning in Patients with Chronic Pain","AbbVie (prior sponsor, Abbott)|AbbVie","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M13-237","October 2011","April 2012","April 2012","September 30, 2011",,"May 15, 2013","Site Reference ID/Investigator# 61226, Phoenix, Arizona, United States|Site Reference ID/Investigator# 61221, Phoenix, Arizona, United States|Site Reference ID/Investigator# 61241, Tucson, Arizona, United States|Site Reference ID/Investigator# 61257, Anaheim, California, United States|Site Reference ID/Investigator# 61246, Fresno, California, United States|Site Reference ID/Investigator# 61242, La Mesa, California, United States|Site Reference ID/Investigator# 61204, Long Beach, California, United States|Site Reference ID/Investigator# 61258, North Hollywood, California, United States|Site Reference ID/Investigator# 61265, Milford, Connecticut, United States|Site Reference ID/Investigator# 61234, DeLand, Florida, United States|Site Reference ID/Investigator# 61213, Ocala, Florida, United States|Site Reference ID/Investigator# 61211, Oldsmar, Florida, United States|Site Reference ID/Investigator# 61217, Orlando, Florida, United States|Site Reference ID/Investigator# 61231, Plantation, Florida, United States|Site Reference ID/Investigator# 61245, Tampa, Florida, United States|Site Reference ID/Investigator# 61263, Marietta, Georgia, United States|Site Reference ID/Investigator# 61210, Brockton, Massachusetts, United States|Site Reference ID/Investigator# 61260, Watertown, Massachusetts, United States|Site Reference ID/Investigator# 61244, Florissant, Missouri, United States|Site Reference ID/Investigator# 61266, St. Louis, Missouri, United States|Site Reference ID/Investigator# 61206, Omaha, Nebraska, United States|Site Reference ID/Investigator# 61223, Salisbury, North Carolina, United States|Site Reference ID/Investigator# 61273, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 61228, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 61264, Portland, Oregon, United States|Site Reference ID/Investigator# 61238, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 61205, Beaumont, Texas, United States|Site Reference ID/Investigator# 61218, Bryan, Texas, United States|Site Reference ID/Investigator# 61235, San Antonio, Texas, United States|Site Reference ID/Investigator# 61232, Draper, Utah, United States|Site Reference ID/Investigator# 61269, Franklin, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01444365"
517,"NCT01441635","Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids",,"Completed","No Results Available","Heavy Uterine Bleeding|Uterine Fibroids","Other: Placebo|Drug: Elagolix, elagolix sodium|Drug: Elagolix Dose 1 plus estradiol/norethindrone acetate|Drug: Elagolix Dose 2 plus estradiol|Drug: Elagolix Dose 2 plus cyclical progesterone","Assessment of Bleeding|Number of Bleeding Days|Menstrual Bleeding Scores|Uterine Volume|Hemoglobin Concentration|Safety Evaluation - Adverse event monitoring|Safety Evaluation - Vital signs|Physical examinations (complete or symptom directed)|12-Lead Electrocardiogram (ECG)|Bone Biomarkers|Bone Mineral Density (BMD)|Clinical Laboratory Tests","AbbVie (prior sponsor, Abbott)|AbbVie","Female","20 Years to 49 Years   (Adult)","Phase 2","271","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-663","September 2011","November 2013","February 2014","September 28, 2011",,"December 11, 2014","Site Reference ID/Investigator# 48144, Phoenix, Arizona, United States|Site Reference ID/Investigator# 50273, Tucson, Arizona, United States|Site Reference ID/Investigator# 66423, Carmichael, California, United States|Site Reference ID/Investigator# 50279, La Mesa, California, United States|Site Reference ID/Investigator# 89654, Los Angeles, California, United States|Site Reference ID/Investigator# 48139, San Diego, California, United States|Site Reference ID/Investigator# 48148, San Diego, California, United States|Site Reference ID/Investigator# 57881, San Diego, California, United States|Site Reference ID/Investigator# 58906, San Francisco, California, United States|Site Reference ID/Investigator# 48142, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 50275, Lakewood, Colorado, United States|Site Reference ID/Investigator# 48103, Boynton Beach, Florida, United States|Site Reference ID/Investigator# 77573, Debary, Florida, United States|Site Reference ID/Investigator# 77575, Fort Lauderdale, Florida, United States|Site Reference ID/Investigator# 65924, Lake Worth, Florida, United States|Site Reference ID/Investigator# 48163, New Port Richey, Florida, United States|Site Reference ID/Investigator# 58482, North Miami, Florida, United States|Site Reference ID/Investigator# 48140, South Miami, Florida, United States|Site Reference ID/Investigator# 51491, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 58625, Augusta, Georgia, United States|Site Reference ID/Investigator# 48137, Sandy Springs, Georgia, United States|Site Reference ID/Investigator# 48164, Chicago, Illinois, United States|Site Reference ID/Investigator# 48153, Naperville, Illinois, United States|Site Reference ID/Investigator# 54378, New Orleans, Louisiana, United States|Site Reference ID/Investigator# 57559, Fall River, Massachusetts, United States|Site Reference ID/Investigator# 54063, Saginaw, Michigan, United States|Site Reference ID/Investigator# 57558, Chaska, Minnesota, United States|Site Reference ID/Investigator# 50272, Missoula, Montana, United States|Site Reference ID/Investigator# 58622, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 54369, Plainsboro, New Jersey, United States|Site Reference ID/Investigator# 59722, Brooklyn, New York, United States|Site Reference ID/Investigator# 55109, Durham, North Carolina, United States|Site Reference ID/Investigator# 54368, Raleigh, North Carolina, United States|Site Reference ID/Investigator# 48146, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 48156, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 54389, Medford, Oregon, United States|Site Reference ID/Investigator# 54375, Portland, Oregon, United States|Site Reference ID/Investigator# 54372, Jenkintown, Pennsylvania, United States|Site Reference ID/Investigator# 50271, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 48102, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 58626, Bristol, Tennessee, United States|Site Reference ID/Investigator# 57561, Memphis, Tennessee, United States|Site Reference ID/Investigator# 54142, Nashville, Tennessee, United States|Site Reference ID/Investigator# 89653, Nashville, Tennessee, United States|Site Reference ID/Investigator# 54377, Dallas, Texas, United States|Site Reference ID/Investigator# 48158, Houston, Texas, United States|Site Reference ID/Investigator# 57402, Houston, Texas, United States|Site Reference ID/Investigator# 77574, Irving, Texas, United States|Site Reference ID/Investigator# 48145, San Antonio, Texas, United States|Site Reference ID/Investigator# 48168, Sandy, Utah, United States|Site Reference ID/Investigator# 54370, Norfolk, Virginia, United States|Site Reference ID/Investigator# 48160, Richmond, Virginia, United States|Site Reference ID/Investigator# 48149, Seattle, Washington, United States|Site Reference ID/Investigator# 91333, San Juan, Puerto Rico|Site Reference ID/Investigator# 89661, Santurce, Puerto Rico|Site Reference ID/Investigator# 90294, Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01441635"
518,"NCT01428115","Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab","RELAX","Completed","Has Results","Severe Crohn's Disease|Anxiety",,"Change in State Trait Anxiety Index (STAI) State Scores From Baseline to After 6 Months of Treatment With Adalimumab|Change in State Trait Anxiety Index (STAI) Trait Scores From Baseline to After 6 Months of Treatment With Adalimumab|Change in Hospital Anxiety and Depression Score (HADS) - Anxiety, From Baseline to After 6 Months of Treatment With Adalimumab|Change in Hospital Anxiety and Depression Score (HADS) - Depression, From Baseline to After 6 Months of Treatment With Adalimumab|Short Inflammatory Bowel Disease Questionnaire (sIBDQ) Scores by Visit|Harvey-Bradshaw Index (HBI) Scores by Visit|State Trait Anxiety Index (STAI) State Scores by Visit|State Trait Anxiety Index (STAI) Trait Scores by Visit|Hospital Anxiety and Depression Score (HADS) - Anxiety Scores by Visit|Hospital Anxiety and Depression Score (HADS) - Depression Scores by Visit","AbbVie (prior sponsor, Abbott)|Raffeiner GmbH|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)",,"83","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-705","December 2011","October 2013","October 2013","September 2, 2011","November 2, 2014","November 2, 2014","Site Reference ID/Investigator# 64830, Graz, Austria|Site Reference ID/Investigator# 64832, Innsbruck, Austria|Site Reference ID/Investigator# 64829, Linz, Austria|Site Reference ID/Investigator# 64831, Salzburg, Austria|Site Reference ID/Investigator# 64828, St. Poelten, Austria|Site Reference ID/Investigator# 79613, St. Veit/Glan, Austria|Site Reference ID/Investigator# 47342, Vienna, Austria|Site Reference ID/Investigator# 64833, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01428115"
519,"NCT01424319","Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan",,"Completed","No Results Available","Chronic Kidney Disease|Diabetic Nephropathy","Drug: Atrasentan low dose group|Drug: Atrasentan high dose group|Drug: Atrasentan placebo group","The change from baseline to each post-baseline visit in log-transformed UACR (urinary albumin to creatinine ratio)|The proportion of subjects who have achieved at least 30% reduction on UACR (Urinary Albumin to Creatinine Ratio) who have not had any form of treatment-emergent edema with moderate or severe severity.|The change from baseline to each post-baseline visit on log-transformed UACR (Urinary Albumin to Creatinine Ratio) and estimated GFR (Glomerular Filtration Rate)|The proportion of subjects who achieve various percent of reduction in UACR (Urinary Albumin to Creatinine Ratio) from baseline to final","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years to 99 Years   (Adult, Older Adult)","Phase 2","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-812","August 2011","July 2012","July 2012","August 29, 2011",,"August 29, 2017","Site Reference ID/Investigator# 62022, Azumino, Japan|Site Reference ID/Investigator# 58124, Chiba, Japan|Site Reference ID/Investigator# 57486, Fujisawa, Japan|Site Reference ID/Investigator# 55097, Ibaraki, Japan|Site Reference ID/Investigator# 56982, Ina, Japan|Site Reference ID/Investigator# 55093, Kawagoe, Japan|Site Reference ID/Investigator# 57485, Kawasaki, Japan|Site Reference ID/Investigator# 55092, Koriyama, Japan|Site Reference ID/Investigator# 56524, Matsumoto, Japan|Site Reference ID/Investigator# 57242, Nagano, Japan|Site Reference ID/Investigator# 60965, Nagoya-city, Japan|Site Reference ID/Investigator# 55781, Nagoya, Japan|Site Reference ID/Investigator# 55304, Suwa, Japan|Site Reference ID/Investigator# 59474, Tokyo, Japan|Site Reference ID/Investigator# 59967, Ueda, Japan|Site Reference ID/Investigator# 55095, Yokohama, Japan|Site Reference ID/Investigator# 57484, Yokohama, Japan|Site Reference ID/Investigator# 59842, Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT01424319"
520,"NCT01406119","An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: ABT-806","Safety (Number of subjects with adverse events)|Pharmacokinetic profile (assay for ABT-806)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","14","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-326","October 2011","January 2017","January 2017","August 1, 2011",,"January 27, 2017","Site Reference ID/Investigator# 58883, Baltimore, Maryland, United States|Site Reference ID/Investigator# 58882, Boston, Massachusetts, United States|Site Reference ID/Investigator# 60619, Heidelberg, Australia|Site Reference ID/Investigator# 63845, Herston, Australia",,"https://ClinicalTrials.gov/show/NCT01406119"
521,"NCT01403038","An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females",,"Completed","No Results Available","Folliculogenesis","Drug: Elagolix|Drug: elagolix","Ovulation Classification|Ovarian Activity|Endocrine Parameters|Ovarian Reserve|Adverse events|Clinical Laboratory Tests|12-lead Electrocardiogram|Vital Signs","AbbVie (prior sponsor, Abbott)|Neurocrine Biosciences|AbbVie","Female","18 Years to 40 Years   (Adult)","Phase 1","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M12-673","June 2011","October 2012","November 2012","July 27, 2011",,"January 8, 2013","Site Reference ID/Investigator# 50805, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 51270, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 50884, Denver, Colorado, United States|Site Reference ID/Investigator# 50404, Lonetree, Colorado, United States|Site Reference ID/Investigator# 50904, Miami, Florida, United States|Site Reference ID/Investigator# 50402, South Miami, Florida, United States|Site Reference ID/Investigator# 50808, Tampa, Florida, United States|Site Reference ID/Investigator# 50807, Naperville, Illinois, United States|Site Reference ID/Investigator# 50804, Oak Brook, Illinois, United States|Site Reference ID/Investigator# 50762, Durham, North Carolina, United States|Site Reference ID/Investigator# 50403, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 50810, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 50883, Portland, Oregon, United States|Site Reference ID/Investigator# 50803, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 51546, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 50806, San Antonio, Texas, United States|Site Reference ID/Investigator# 51342, San Antonio, Texas, United States|Site Reference ID/Investigator# 50811, Sandy, Utah, United States|Site Reference ID/Investigator# 50902, Norfolk, Virginia, United States|Site Reference ID/Investigator# 50882, Seattle, Washington, United States|Site Reference ID/Investigator# 53363, San Juan, Puerto Rico|Site Reference ID/Investigator# 53362, Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01403038"
522,"NCT01401478","Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation",,"Completed","Has Results","Secondary Hyperparathyroidism",,"The Percentage of Participants Who Reached a Target Level of Intact Parathyroid Hormone (iPTH) (150-300 pg/mL) Post-baseline at Least Once During the Study|Percentage of Participants Who Reached the Kidney Disease Improving Global Outcomes Target Level of Intact Parathyroid Hormone (iPTH) at Least Once During the Study|Percentage of Participants Who Reached the Kidney Disease Improving Global Outcomes Target Level of Intact Parathyroid Hormone (iPTH) at Each Visit During the Study|Percentage of Participants Who Developed Elevated Calcium (Ca) x Phosphate (P) (> 75 mg˄2/dL˄2) Levels at Least Once Post-baseline During the Study|Percentage of Participants Who Developed Elevated Calcium (Ca) x Phosphate (P) (> 75 mg˄2/dL˄2) Levels at Each Visit Post-baseline During the Study|Percentage of Participants Who Developed Elevated Normalized Total Calcium (> 11.2 mg/dL) at Least Once Post-baseline During the Study|Percentage of Participants Who Developed Elevated Normalized Total Calcium (> 11.2 mg/dL) at Each Visit Post-baseline During the Study|Percentage of Participants Who Developed Hypercalcemia and Hyperphosphatemia Leading to Study Termination","AbbVie (prior sponsor, Abbott)|Almedis|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)",,"86","Industry","Observational","Time Perspective: Prospective","P12-838","July 2011","January 2013","January 2013","July 25, 2011","February 28, 2014","March 3, 2014","Site Reference ID/Investigator# 57348, Almetyevsk, Russian Federation|Site Reference ID/Investigator# 57347, Cheboksary, Russian Federation|Site Reference ID/Investigator# 58347, Chelyabinsk, Russian Federation|Site Reference ID/Investigator# 67404, Iakutsk, Russian Federation|Site Reference ID/Investigator# 57344, Irkutsk, Russian Federation|Site Reference ID/Investigator# 57346, Kazan, Russian Federation|Site Reference ID/Investigator# 58356, Moscow, Russian Federation|Site Reference ID/Investigator# 58348, Moscow, Russian Federation|Site Reference ID/Investigator# 57342, Novosibirsk, Russian Federation|Site Reference ID/Investigator# 57364, Orenburg, Russian Federation|Site Reference ID/Investigator# 69687, Samara, Russian Federation|Site Reference ID/Investigator# 57363, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 69688, Ulan-Ude, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01401478"
523,"NCT01401452","Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities","EPIC","Completed","Has Results","Moderate to Severe Plaque Psoriasis",,"Percentage of Participants Achieving a Psoriasis Area and Severity Index 75 (PASI 75) Response at Months 1, 3, 6, and 9|Mean Dermatology Life Quality Index (DLQI) Scores|Percentage of Participants Achieving a Psoriasis Area and Severity Index 50 (PASI 50) Response at Months 1, 3, 6, and 9|Percentage of Participants Achieving a Psoriasis Area and Severity Index 90 (PASI 90) Response at Months 1, 3, 6, and 9|Percentage of Participants Achieving a Psoriasis Area and Severity Index 100 (PASI 100) Response at Months 1, 3, 6, and 9|Mean Health Assessment Questionnaire Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at 1, 3, 6, and 9 Months|Mean Health Assessment Questionnaire Short Form 36 (SF-36) Mental Component Summary (MCS) Scores at 1, 3, 6, and 9 Months|Percentage of Participants Achieving Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Short Form 36 (SF-36) Physical Component Summary (PCS) Scores at 1, 3, 6, and 9 Months|Percentage of Participants Achieving Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Short Form 36 (SF-36) Mental Component Summary (MCS) Scores at 1, 3, 6, and 9 Months","AbbVie (prior sponsor, Abbott)|Raffeiner GmbH|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"246","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-770","August 2011","May 2016","May 2016","July 25, 2011","October 4, 2017","October 4, 2017",,,"https://ClinicalTrials.gov/show/NCT01401452"
524,"NCT01399580","A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy",,"Completed","No Results Available","Chronic Kidney Disease|Diabetic Nephropathy","Drug: Atrasentan|Drug: Placebo","Change from baseline to each post-baseline visit up to Week 8 in log-transformed Urinary Albumin to Creatinine Ratio (UACR)|Change from baseline to each post baseline measure for estimated glomerular filtration rate (eGFR)|The change from baseline to each post-baseline assessment of thoracic bioimpedance","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-830","August 2011","September 2012","September 2012","July 22, 2011",,"October 25, 2013","Site Reference ID/Investigator# 58144, Phoenix, Arizona, United States|Site Reference ID/Investigator# 71034, Tempe, Arizona, United States|Site Reference ID/Investigator# 56927, Azusa, California, United States|Site Reference ID/Investigator# 70793, Azusa, California, United States|Site Reference ID/Investigator# 64027, Chula Vista, California, United States|Site Reference ID/Investigator# 54120, Concord, California, United States|Site Reference ID/Investigator# 64026, La Mesa, California, United States|Site Reference ID/Investigator# 70173, Los Angeles, California, United States|Site Reference ID/Investigator# 54121, Denver, Colorado, United States|Site Reference ID/Investigator# 56924, Boynton Beach, Florida, United States|Site Reference ID/Investigator# 56642, Hollywood, Florida, United States|Site Reference ID/Investigator# 68986, Augusta, Georgia, United States|Site Reference ID/Investigator# 56644, Chicago, Illinois, United States|Site Reference ID/Investigator# 54129, Baton Rouge, Louisiana, United States|Site Reference ID/Investigator# 68982, Pontiac, Michigan, United States|Site Reference ID/Investigator# 64023, Albany, New York, United States|Site Reference ID/Investigator# 55543, Flushing, New York, United States|Site Reference ID/Investigator# 54164, Fargo, North Dakota, United States|Site Reference ID/Investigator# 58147, Willoughby Hills, Ohio, United States|Site Reference ID/Investigator# 54123, Bethlehem, Pennsylvania, United States|Site Reference ID/Investigator# 61742, Pittsburg, Pennsylvania, United States|Site Reference ID/Investigator# 54132, Chattanooga, Tennessee, United States|Site Reference ID/Investigator# 54108, Dallas, Texas, United States|Site Reference ID/Investigator# 54126, Greenville, Texas, United States|Site Reference ID/Investigator# 58153, Houston, Texas, United States|Site Reference ID/Investigator# 54110, Houston, Texas, United States|Site Reference ID/Investigator# 54116, North Richland Hills, Texas, United States|Site Reference ID/Investigator# 54173, Silverdale, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01399580"
525,"NCT01387815","Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis","Complete-PS","Completed","Has Results","Psoriasis","Biological: Adalimumab","Percentage of Participants With a Physician Global Assessment (PGA) Score ≤1 at Month 6|Time to Achieving PGA ≤ 1|PGA≤1: Percentage of Participants at Month 3|PGA≤1: Percentage of Participants at Month 12|PGA≤1: Percentage of Participants at Month 18|PGA≤1: Percentage of Participants at Month 24|Psoriasis and Arthritis Screening Questionnaire (PASQ) Total Score: Change From Baseline to Month 3|PASQ Total Score: Change From Baseline to Month 6|PASQ Total Score: Change From Baseline to Month 12|PASQ Total Score: Change From Baseline to Month 18|PASQ Total Score: Change From Baseline to Month 24|Body Surface Area of Psoriasis Involvement: Change From Baseline to Month 6|BSA of Psoriasis Involvement: Change From Baseline to Month 12|BSA of Psoriasis Involvement: Change From Baseline to Month 18|BSA of Psoriasis Involvement: Change From Baseline to Month 24|Patient Global Assessment (PtGA) of Disease Activity Based on a Visual Analog Scale (VAS): Change From Baseline to Month 3|PtGA of Disease Activity Based on a VAS: Change From Baseline to Month 6|PtGA of Disease Activity Based on a VAS: Change From Baseline to Month 12|PtGA of Disease Activity Based on a VAS: Change From Baseline to Month 18|PtGA of Disease Activity Based on a VAS: Change From Baseline to Month 24|Dermatology Quality of Life Index (DLQI) Total Score: Change From Baseline to Month 3|DLQI Total Score: Change From Baseline to Month 6|DLQI Total Score: Change From Baseline to Month 12|DLQI Total Score: Change From Baseline to Month 18|DLQI Total Score: Change From Baseline to Month 24|Time to Achieving DLQI ≤1|DLQI ≤1: Percentage of Participants at Month 3|DLQI ≤1: Percentage of Participants at Month 6|DLQI ≤1: Percentage of Participants at Month 12|DLQI ≤1: Percentage of Participants at Month 18|DLQI ≤1: Percentage of Participants at Month 24|Beck Depression Inventory II (BDI-II): Change From Baseline to Month 6|BDI-II: Change From Baseline to Month 12|BDI-II: Change From Baseline to Month 24|Medical Outcomes Study Short Form-12 Health Status Survey (SF-12) Mental Component Summary (MCS) Score: Change From Baseline to Month 6|SF-12 MCS Score: Change From Baseline to Month 12|SF-12 MCS Score: Change From Baseline to Month 24|SF-12 Physical Component Summary (PCS) Score: Change From Baseline to Month 6|SF-12 PCS Score: Change From Baseline to Month 12|SF-12 PCS Score: Change From Baseline to Month 24|Work Limitation Questionnaire (WLQ) Total Score: Change From Baseline to Month 6|WLQ Total Score: Change From Baseline to Month 12|WLQ Total Score: Change From Baseline to Month 24|WLQ Productivity Loss Score: Change From Baseline to Month 6|WLQ Productivity Loss Score: Change From Baseline to Month 12|WLQ Productivity Loss Score: Change From Baseline to Month 24|Healthcare Resource Utilization (HCRU): Number of Participants With Insurance for Prescription Medication at Month 6|HCRU: Number of Participants With Insurance for Prescription Medication at Month 12|HCRU: Number of Participants With Insurance for Prescription Medication at Month 24|HCRU: Number of Participants by Type of Insurance for Prescription Medication at Month 6|HCRU: Number of Participants by Type of Insurance for Prescription Medication at Month 12|HCRU: Number of Participants by Type of Insurance for Prescription Medication at Month 24|HCRU: Number of Participants Seeking Health Care in the Past 4 Weeks for Ankylosing Spondylitis (AS) at Month 6|HCRU: Number of Participants Seeking Health Care in the Past 4 Weeks for AS at Month 12|HCRU: Number of Participants Seeking Health Care in the Past 4 Weeks for AS at Month 24|HCRU: Number of Participants Making Extra or Unscheduled Visits the (Office/Clinic) of the Study Doctor for AS at Month 6|HCRU: Number of Participants Making Extra or Unscheduled Visits the (Office/Clinic) of the Study Doctor for AS at Month 12|HCRU: Number of Participants Making Extra or Unscheduled Visits the (Office/Clinic) of the Study Doctor for AS at Month 24|HCRU: Number of Extra or Unscheduled Visits the (Office/Clinic) of the Study Doctor for AS at Month 6|HCRU: Number of Extra or Unscheduled Visits the (Office/Clinic) of the Study Doctor for AS at Month 12|HCRU: Number of Extra or Unscheduled Visits the (Office/Clinic) of the Study Doctor for AS at Month 24|HCRU: Number of Participants Making Visits to Another Physician at Month 6|HCRU: Number of Participants Making Visits to Another Physician at Month 12|HCRU: Number of Participants Making Visits to Another Physician at Month 24|HCRU: Number of Visits to Another Physician at Month 6|HCRU: Number of Visits to Another Physician at Month 12|HCRU: Number of Visits to Another Physician at Month 24|HCRU: Number of Participants Making Visits to a Healthcare Professional at Month 6|HCRU: Number of Participants Making Visits to a Healthcare Professional at Month 12|HCRU: Number of Participants Making Visits to a Healthcare Professional at Month 24|HCRU: Number of Visits to A Healthcare Professional at Month 6|HCRU: Number of Visits to A Healthcare Professional at Month 12|HCRU: Number of Visits to A Healthcare Professional at Month 24|HCRU: Number of Participants Making Visits to a Hospital Emergency Room at Month 6|HCRU: Number of Participants Making Visits to a Hospital Emergency Room at Month 12|HCRU: Number of Participants Making Visits to a Hospital Emergency Room at Month 24|HCRU: Number of Visits to a Hospital Emergency Room at Month 6|HCRU: Number of Visits to a Hospital Emergency Room at Month 12|HCRU: Number of Visits to a Hospital Emergency Room at Month 24|HCRU: Number of Participants Making Use of an Ambulance Service at Month 6|HCRU: Number of Participants Making Use of an Ambulance Service at Month 12|HCRU: Number of Participants Making Use of an Ambulance Service at Month 24|HCRU: Number of Participants Making Complementary/Alternate Therapy Visits at Month 6|HCRU: Number of Participants Making Complementary/Alternate Therapy Visits at Month 12|HCRU: Number of Participants Making Complementary/Alternate Therapy Visits at Month 24|HCRU: Number of Complementary/Alternate Therapy Visits at Month 6|HCRU: Number of Complementary/Alternate Therapy Visits at Month 12|HCRU: Number of Complementary/Alternate Therapy Visits at Month 24|HCRU: Number of Participants Hospitalized in the Past 4 Weeks at Month 6|HCRU: Number of Participants Hospitalized in the Past 4 Weeks at Month 12|HCRU: Number of Participants Hospitalized in the Past 4 Weeks at Month 24|HCRU: Length of Hospital Stay for Those Participants Hospitalized at Month 6|HCRU: Length of Hospital Stay for Those Participants Hospitalized at Month 12|HCRU: Length of Hospital Stay for Those Participants Hospitalized at Month 24|HCRU: Number of Participants Admitted to the Intensive Care Unit (ICU) in the Past 4 Weeks at Month 6|HCRU: Number of Participants Admitted to the ICU in the Past 4 Weeks at Month 12|HCRU: Number of Participants Admitted to the ICU in the Past 4 Weeks at Month 24|HCRU: Cost of Payment for Over the Counter Medications at Month 6|HCRU: Cost of Payment for Over the Counter Medications at Month 12|HCRU: Cost of Payment for Over the Counter Medications at Month 24|HCRU: Cost of Payments to Healthcare Professionals at Month 6|HCRU: Cost of Payments to Healthcare Professionals at Month 12|HCRU: Cost of Payments to Healthcare Professionals at Month 24|HCRU: Cost of Payments for Medical Procedures or Laboratory Tests at Month 6|HCRU: Cost of Payments for Medical Procedures or Laboratory Tests at Month 12|HCRU: Cost of Payments for Medical Procedures or Laboratory Tests at Month 24|HCRU: Cost of Payments for Medical Devices at Month 6|HCRU: Cost of Payments for Medical Devices at Month 12|HCRU: Cost of Payments for Medical Devices at Month 24|HCRU: Cost of Payments for Health Care or Extra Help at Home at Month 6|HCRU: Cost of Payments for Health Care or Extra Help at Home at Month 12|HCRU: Cost of Payments for Health Care or Extra Help at Home at Month 24|HCRU: Cost of Payments for Transportation at Month 6|HCRU: Cost of Payments for Transportation at Month 12|HCRU: Cost of Payments for Transportation at Month 24|Topical Treatment Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 3|Topical Treatment Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 6|Topical Treatment Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 12|Topical Treatment Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 18|Topical Treatment Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 24|Phototherapy Session Patient Reported Treatment Compliance: Number of Missed Sessions Since Last Visit Assessed at Month 3|Phototherapy Session Patient Reported Treatment Compliance: Number of Missed Sessions Since Last Visit Assessed at Month 6|Phototherapy Session Patient Reported Treatment Compliance: Number of Missed Sessions Since Last Visit Assessed at Month 12|Phototherapy Session Patient Reported Treatment Compliance: Number of Missed Sessions Since Last Visit Assessed at Month 18|Phototherapy Session Patient Reported Treatment Compliance: Number of Missed Sessions Since Last Visit Assessed at Month 24|Traditional Systemic Agent Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 3|Traditional Systemic Agent Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 6|Traditional Systemic Agent Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 12|Traditional Systemic Agent Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 18|Traditional Systemic Agent Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 24|Adalimumab Injection Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 3|Adalimumab Injection Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 6|Adalimumab Injection Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 12|Adalimumab Injection Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 18|Adalimumab Injection Patient Reported Treatment Compliance: Number of Missed Doses Since Last Visit Assessed at Month 24|Medical History: Number of Participants With Any Relevant Physical Changes Since the Last Visit at Month 3|Medical History: Number of Participants With Any Relevant Physical Changes Since the Last Visit at Month 6|Medical History: Number of Participants With Any Relevant Physical Changes Since the Last Visit at Month 12|Medical History: Number of Participants With Any Relevant Physical Changes Since the Last Visit at Month 18|Medical History: Number of Participants With Any Relevant Physical Changes Since the Last Visit at Month 24|Concomitant Medication: Number of Participants With Any Changes in Psoriasis Medication/Treatment Since the Last Visit at Month 3|Concomitant Medication: Number of Participants With Any Changes in Psoriasis Medication/Treatment Since the Last Visit at Month 6|Concomitant Medication: Number of Participants With Any Changes in Psoriasis Medication/Treatment Since the Last Visit at Month 12|Concomitant Medication: Number of Participants With Any Changes in Psoriasis Medication/Treatment Since the Last Visit at Month 18|Concomitant Medication: Number of Participants With Any Changes in Psoriasis Medication/Treatment Since the Last Visit at Month 24","AbbVie (prior sponsor, Abbott)|Cato Research|JSS Medical Research Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"662","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-678","August 16, 2011","June 29, 2018","June 29, 2018","July 6, 2011","December 5, 2019","December 5, 2019","Kirk Barber Research, CA /ID# 57722, Calgary, Alberta, Canada|Richmond Road Diagnostic Treat /ID# 70913, Calgary, Alberta, Canada|Institute for Skin Advancement /ID# 66782, Calgary, Alberta, Canada|Thomas Nakatsui P.C. /ID# 55080, Edmonton, Alberta, Canada|Alberta DermaSurgery Centre /ID# 75513, Edmonton, Alberta, Canada|Wellington Medical Clinic Ltd. /ID# 55083, Nanaimo, British Columbia, Canada|Percuro Clinical Research, Ltd /ID# 54563, Victoria, British Columbia, Canada|Jason Ronald Sneath Medical Co /ID# 138026, Brandon, Manitoba, Canada|Winnipeg Clinic, Manitoba, CA /ID# 56865, Winnipeg, Manitoba, Canada|Maritime Medical Reseach Cente /ID# 128775, Bathurst, New Brunswick, Canada|Dr. Irina Turchin PC Inc. /ID# 66029, Fredericton, New Brunswick, Canada|Dermatologue Inc. /ID# 76074, Moncton, New Brunswick, Canada|Douglas N. Keeling MD Dermatol /ID# 55098, Quispamsis, New Brunswick, Canada|Karma Clinical Trials /ID# 55101, St. John's, Newfoundland and Labrador, Canada|Nexus Clinical Research /ID# 56403, St. John's, Newfoundland and Labrador, Canada|Eastern Canada Cutaneous Resea /ID# 46353, Halifax, Nova Scotia, Canada|SimcoDerm Medical and Surgical /ID# 96915, Barrie, Ontario, Canada|Kingsway Clinical Research /ID# 97255, Etobicoke, Ontario, Canada|Dermatrials Research /ID# 124138, Hamilton, Ontario, Canada|Dr. Wei Jing Loo Medicine Prof /ID# 127546, London, Ontario, Canada|Lynderm Research Inc. /ID# 63206, Markham, Ontario, Canada|Toronto Regional Wound Healing /ID# 55135, Mississauga, Ontario, Canada|Dr. Anna Hinek Medicine Prof /ID# 148305, Mississauga, Ontario, Canada|Oakville Derma and Laser, CA /ID# 55130, Oakville, Ontario, Canada|Dr. Melinda Gooderham Medicine /ID# 54566, Peterborough, Ontario, Canada|York Dermatology Center /ID# 127786, Richmond Hill, Ontario, Canada|Specialized Dermatology Inc. /ID# 64031, St-catharines, Ontario, Canada|Giroux, Sudbury, CA /ID# 55128, Sudbury, Ontario, Canada|Lori Shapiro Medicine Prof Inc /ID# 55126, Thornhill, Ontario, Canada|Toronto Dermatology Centre /ID# 55127, Toronto, Ontario, Canada|Dr. Isabelle Delorme Inc. /ID# 57791, Drummondville, Quebec, Canada|Dre. Angelique Gagne-Henley /ID# 125204, Montreal, Quebec, Canada|Dr. Loukia-Maria Mitsos /ID# 124156, Pierrefonds, Quebec, Canada|Dermatologie Sima Inc. /ID# 54922, Verdun, Quebec, Canada|Dr. Beatrice Wang /ID# 63242, Westmount, Quebec, Canada|Royal Univ. Hosp, Saskatoon,CA /ID# 74613, Saskatoon, Saskatchewan, Canada","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01387815/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT01387815/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01387815"
526,"NCT01387802","Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis","Complete-AS","Completed","No Results Available","Ankylosing Spondylitis",,"Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Uveitis|Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Psoriasis|Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Inflammatory Bowel Disease|Occurrence, flare-up or exacerbation of Extra Articular Manifestations in Enthesitis of the Heel: Achilles Tendon and Plantar Fascia|BASFI (Bath AS Functional Assay)|PASQ (Psoriasis and Arthritis Screening Questionnaire)|BASDAI (Bath AS Disease Activity Index)","AbbVie (prior sponsor, Abbott)|JSS Medical Research Inc.|Cato Research|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"722","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-672","June 29, 2011","December 16, 2019","December 16, 2019","July 6, 2011",,"January 2, 2020","Rheumatology Clinic /ID# 54768, Calgary, Alberta, Canada|Associate Clinic /ID# 64274, Calgary, Alberta, Canada|Pont, Cranbrook, BC, CA /ID# 55242, Cranbrook, British Columbia, Canada|Dr. Barbara T. Blumenauer Inc. /ID# 55226, Kamloops, British Columbia, Canada|Hudson, Kamloops, Canada /ID# 54577, Kamloops, British Columbia, Canada|Dr. Maqbool R. Sheriff Inc. /ID# 55247, Nanaimo, British Columbia, Canada|Stewart, Penticton, CA /ID# 67096, Penticton, British Columbia, Canada|Dr. Michael Buchanan, Inc. /ID# 55227, Prince George, British Columbia, Canada|Dr. J. Antonio Avina-Zubieta /ID# 68263, Richmond, British Columbia, Canada|Dr. Alfonso Verdejo Inc. /ID# 54572, Vancouver, British Columbia, Canada|Dr. Milton F. Baker Inc. /ID# 55197, Victoria, British Columbia, Canada|Manitoba Clinic /ID# 54580, Winnipeg, Manitoba, Canada|Bulleid Henderson Prof. Corp. /ID# 55256, Fredericton, New Brunswick, Canada|Ecker, Fredericton, CA /ID# 54748, Fredericton, New Brunswick, Canada|Nexus Clinical Research /ID# 54757, St. John's, Newfoundland and Labrador, Canada|St. Clare's Mercy Hospital /ID# 54767, St. John's, Newfoundland and Labrador, Canada|Qe Ii Hsc /Id# 55261, Halifax, Nova Scotia, Canada|Dr. Juris Lazovskis Inc. /ID# 61562, Sydney, Nova Scotia, Canada|Pavlova, Hamilton, CA /ID# 65011, Ancaster, Ontario, Canada|Waterside Clinique /ID# 72174, Barrie, Ontario, Canada|Joshi, Brampton, Canada /ID# 54758, Brampton, Ontario, Canada|Brockville Medical Center /ID# 65502, Brockville, Ontario, Canada|Dr. Sanjay Dixit Medicine Professional Corporation /ID# 67347, Burlington, Ontario, Canada|Aviva Clinical Trial Group /ID# 54764, Burlington, Ontario, Canada|Dr. Chrisotomor Kouroukis & Dr /ID# 137831, Dundas, Ontario, Canada|Charlton Medical Centre /ID# 133072, Hamilton, Ontario, Canada|Charlton Medical Centre /ID# 55417, Hamilton, Ontario, Canada|Dr. William G. Bensen Centre /ID# 54762, Hamilton, Ontario, Canada|West Mountain Medical Center /ID# 128877, Hamilton, Ontario, Canada|KW Musculoskeletal Research /ID# 70093, Kitchener, Ontario, Canada|Brandusa Florica Med Prof Corp /ID# 81877, Mississauga, Ontario, Canada|Montgomery, Mississauga, CA /ID# 54581, Mississauga, Ontario, Canada|Credit Valley Rheumatology /ID# 54750, Mississauga, Ontario, Canada|Imtiaz MS Khan Medicine Prof /ID# 55401, Mississauga, Ontario, Canada|Morassut, Nepean, Canada /ID# 55410, Nepean, Ontario, Canada|The Arthritis Program Res Grp /ID# 54755, Newmarket, Ontario, Canada|Rajwinder S. Dhillon Medicine /ID# 138671, Niagara Falls, Ontario, Canada|Kapur, Ottawa, Canada /ID# 55397, Ottawa, Ontario, Canada|Davis, Ottawa, CA /ID# 55296, Ottawa, Ontario, Canada|Setty, Owen Sound, CA /ID# 54583, Owen Sound, Ontario, Canada|Niagara Peninsula Arthritis Ct /ID# 67282, St. Catharines, Ontario, Canada|Pedvis Med Prof Corp /ID# 55411, Toronto, Ontario, Canada|Hamilton, Toronto, CA /ID# 54575, Toronto, Ontario, Canada|Jonathan Stein Med Prof Corp /ID# 55451, Toronto, Ontario, Canada|Karasik, Toronto, CA /ID# 54751, Toronto, Ontario, Canada|Dr. Samuel K Silverberg /ID# 55449, Toronto, Ontario, Canada|Ctr de Med Sportive de Laval /ID# 54576, Laval, Quebec, Canada|Institut de Rhum. de Montreal /ID# 54761, Montreal, Quebec, Canada|Jewish General Hospital /ID# 63655, Montreal, Quebec, Canada|PSS Medical Inc. /ID# 54754, Montreal, Quebec, Canada|Couture, Outremont, CA /ID# 54574, Outremont, Quebec, Canada|Ctr. de Rheum de l'est du QC /ID# 54765, Rimouski, Quebec, Canada|Clinique Medicale Langelier /ID# 55460, Saint-leonard, Quebec, Canada|Groupe de Recherche en Maladies Osseuses /ID# 45623, Sainte-foy, Quebec, Canada|Ctr. de Recherche Musculo-Sque /ID# 55469, Trois-rivières, Quebec, Canada|Rheum Disease Ctr of Montreal /ID# 143963, Westmount, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT01387802"
527,"NCT01387789","A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia","RELIVE","Completed","Has Results","Rheumatoid Arthritis",,"Change in Overall Health Assessment Questionnaire Disability Index (HAQ-DI) Scores From Baseline to 6 Months|Change in Health Assessment Questionnaire Visual Analog Scale (HAQ-VAS) Scores From Baseline to 6 Months|Change in Health Assessment Questionnaire Short Form 36 (SF-36) Scores From Baseline to 6 Months|Change in Overall Health Assessment Questionnaire Disability Index (HAQ-DI) Scores From Baseline to 1 Month|Change in Health Assessment Questionnaire Visual Analog Scale (HAQ-VAS) Scores From Baseline to 1 Month|Change in Mean Health Assessment Questionnaire Short Form 36 (SF-36) Scores From Baseline to 1 Month|Change in Overall Health Assessment Questionnaire Disability Index (HAQ-DI) Scores From Baseline to 3 Months|Change in Health Assessment Questionnaire Visual Analog Scale (HAQ-VAS) Scores From Baseline to 3 Months|Change in Health Assessment Questionnaire Short Form 36 (SF-36) Scores From Baseline to 3 Months","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"71","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-265","August 2011","March 2013","March 2013","July 6, 2011","April 21, 2014","May 5, 2014","Site Reference ID/Investigator# 36098, Batu Caves, Malaysia|Site Reference ID/Investigator# 57914, Ipoh, Malaysia|Site Reference ID/Investigator# 57923, Johor Bahru, Malaysia|Site Reference ID/Investigator# 67602, Klang, Malaysia|Site Reference ID/Investigator# 57925, Kota Kinabalu, Malaysia|Site Reference ID/Investigator# 57916, Kuala Lumpur, Malaysia|Site Reference ID/Investigator# 57928, Kuantan, Malaysia|Site Reference ID/Investigator# 57924, Kuching, Malaysia|Site Reference ID/Investigator# 57927, Melaka, Malaysia|Site Reference ID/Investigator# 57913, Penang, Malaysia|Site Reference ID/Investigator# 57915, Putrajaya, Malaysia|Site Reference ID/Investigator# 57926, Serdang, Malaysia|Site Reference ID/Investigator# 57922, Seremban, Malaysia",,"https://ClinicalTrials.gov/show/NCT01387789"
528,"NCT01386684","Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study",,"Completed","Has Results","Prostate Cancer",,"Progression-free Survival (PFS) Defined as the Time From Patient Recruitment to Biochemical Progression Based on Doubling of Prostate Specific Antigen (PSA) Velocity or PSA > 5.0|Progression-free Survival (PFS) Defined as the Time From Patient Recruitment to a Change to an Absolute Value of PSA > 2 ng/mL on at Least 2 Consecutive Tests|Castration Resistant Prostate Cancer (CRPC): Number of Participants|Castration Resistant Prostate Cancer (CRPC): Time to Event|Total Serum Testosterone: Percentage of Participants With ≤ 0.7 Nmol/L, > 0.7 to ≤ 1.7 Nmol/L, and > 1.7 Nmol/L at Each Visit|Total Serum Testosterone Levels at Each Visit|Total Serum Testosterone: Time to Increase Over Castrate Levels|Prostatic Specific Antigen (PSA): Percentage of Participants With Serum PSA < 1 ng/mL, 1 to < 5 ng/mL, 5 to < 10 ng/mL, and ≥10 ng/mL at Each Visit|Prostatic Specific Antigen (PSA) Levels at Each Visit|Functional Assessment of Cancer Therapy Questionnaire - General (FACT-G) Total Score: Change From Baseline to Each Visit|Functional Assessment of Cancer Therapy Questionnaire - Prostate Cancer (FACT-P) Total Score: Change From Baseline to Each Visit|International Index of Erectile Function (IIEF-5) Total Score: Change From Baseline to Each Visit|Health Care Utilization and Health Economics Questionnaire: Number of Participants With Medical Insurance for Prescription Medications|Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited a Physician for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Visits With a Physician for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited a Healthcare Professional for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Visits With a Healthcare Professional for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited a Hospital Emergency Room for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Visits to A Hospital Emergency Room for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Used an Ambulance Service for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Times That an Ambulance Service Was Used for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Visited Complementary/Alternate Therapy for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Visits For Complementary/Alternate Therapy for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Used Any Other Medical Service for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Visits For Any Other Medical Service for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Participants Who Were Admitted to the Hospital for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Number of Admissions to the Hospital for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Over-the-counter Medications for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Payments to Health Care Professionals for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Medical Procedures for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Payments for Medical Procedures or Laboratory Tests for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Medical Devices for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Health Care or Extra Help At Home for Prostate Cancer|Health Care Utilization and Health Economics Questionnaire: Out of Pocket Expenses for Transportation Costs for Prostate Cancer|Treatment Compliance|Percentage of Participants With Changes in Current Prostate Cancer Treatment Since Last Visit.","AbbVie (prior sponsor, Abbott)|JSS Medical Research Inc.|CMX Research|AbbVie","Male","18 Years and older   (Adult, Older Adult)",,"552","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P12-811","June 28, 2011","September 8, 2016","September 8, 2016","July 1, 2011","April 2, 2018","December 13, 2018",,,"https://ClinicalTrials.gov/show/NCT01386684"
529,"NCT01383421","Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)","PASSION","Completed","Has Results","Rheumatoid Arthritis",,"Percentage of Participants Achieving a Minimal Clinically Important Difference (MCID) in the Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 78|Percentage of Participants Achieving a MCID in the HAQ-DI at Week 12|Percentage of Participants Achieving a MCID in the HAQ-DI at Week 24|Percentage of Participants Achieving a MCID in the HAQ-DI at Week 36|Percentage of Participants Achieving a MCID in the HAQ-DI at Week 52|Percentage of Participants Achieving a MCID in the HAQ-DI at Week 64","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"1036","Industry","Observational","Observational Model: Other|Time Perspective: Other","P12-072","September 2011","April 2016","April 2016","June 28, 2011","June 26, 2017","June 26, 2017",,,"https://ClinicalTrials.gov/show/NCT01383421"
530,"NCT01383005","Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)","QD-Kapital","Completed","Has Results","Human Immunodeficiency Virus Infection",,"Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Individual Item Scores for the Overall Study Population|Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ)Dimension (Overall Satisfaction, General/Clinical Satisfaction, Lifestyle) Scores for the Overall Study Population|Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Individual Item Scores Comparison Between Cohorts|Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Dimension (Overall Satisfaction, General/Clinical Satisfaction, Lifestyle) Scores Comparison Between Cohorts|Number of Days Without Medication, Per Simplified Medication Adherence Questionnaire (SMAQ)|Adherence Classification of Participants Per Simplified Medication Adherence Questionnaire (SMAQ)|Reasons for Starting or Switching to a Lopinavir/Ritonavir Once Daily (LPV/r QD)Regimen|Percentage of Participants With a Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Overall Satisfaction Dimension Mean Score Value of ≥5 and <5|Viral Load (VL) Change After at Least 12 Weeks of Treatment With the Lopinavir/Ritonavir (LPV/r)|Mean Number of Days on LPV/r QD|Comparison of Mean Human Immunodeficiency Virus Treatment Satisfaction Questionnaire (HIVTSQ) Dimension Scores From QD-KAPITAL and KAPITAL2 Studies|Percentage of Participants With Missing Doses During ""the Past 4 Days"" and ""the Last Weekend"" in KAPITAL-2 and QD-KAPITAL Studies","AbbVie (prior sponsor, Abbott)|Triaca Magna, SA|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"97","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","P12-752","June 2011","December 2011","December 2011","June 28, 2011","April 22, 2013","May 6, 2013","Site Ref # / Investigator 52274, A Coruna, Spain|Site Ref # / Investigator 52363, Barakaldo, Spain|Site Ref # / Investigator 52271, Barcelona, Spain|Site Ref # / Investigator 52270, Barcelona, Spain|Site Ref # / Investigator 52362, Cartagena, Spain|Site Ref # / Investigator 53650, Castellon de la Plana, Spain|Site Ref # / Investigator 52273, Ferrol (A Coruna), Spain|Site Ref # / Investigator 52264, Granada, Spain|Site Ref # / Investigator 52267, Hospitalet de Llobregat, Spain|Site Ref # / Investigator 52262, Jaen, Spain|Site Ref # / Investigator 52263, Jerez de la Frontera (Cadiz), Spain|Site Ref # / Investigator 52345, Madrid, Spain|Site Ref # / Investigator 52275, Madrid, Spain|Site Ref # / Investigator 52302, Madrid, Spain|Site Ref # / Investigator 52343, Madrid, Spain|Site Ref # / Investigator 52344, Madrid, Spain|Site Ref # / Investigator 53648, Murcia, Spain|Site Ref # / Investigator 52268, Reus (Tarragona), Spain|Site Ref # / Investigator 52272, Valencia, Spain|Site Ref # / Investigator 52266, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01383005"
531,"NCT01382212","A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis",,"Completed","Has Results","End-Stage Renal Disease|Secondary Hyperparathyroidism","Drug: paricalcitol","Percentage of Subjects With Hypercalcemia|Percentage of Subjects With 2 Consecutive Intact Parathyroid Hormone (iPTH)/120 Between 150 and 300 pg/mL|Percentage of Subjects With 2 Consecutive iPTH Reductions of at Least 30% From Baseline|Hemoglobin: Mean Change From Baseline to Final Visit|Hematocrit: Mean Change From Baseline to Final Visit|Red Blood Cells: Mean Change From Baseline to Final Visit|White Blood Cells (WBC) and Platelet Count: Mean Change From Baseline to Final Visit|Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils: Mean Change From Baseline to Final Visit|Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Lactic Dehydrogenase (LDH), and Bone-Specific Alkaline Phosphatase (BSAP): Mean Change From Baseline to Final Visit|Bilirubin, Blood Urea Nitrogen (BUN), Uric Acid, Magnesium, Glucose, Cholesterol, Triglycerides, High Sensitivity C-Reactive Protein (hsCRP), Inorganic Phosphate, Corrected Calcium, and Creatinine: Mean Change From Baseline to Final Visit|Alkaline Phosphatase: Mean Change From Baseline to Final Visit|Sodium, Potassium, Chloride, Bicarbonate: Mean Change From Baseline to Final Visit|Total Protein and Albumin: Mean Change From Baseline to Final Visit|Fibroblast Growth Factor-23 (FGF-23), 1,25-Hydroxy Vitamin D, 25-Hydroxy Vitamin D, and Intact Parathyroid Hormone (iPTH): Mean Change From Baseline to Final Visit|Osteocalcin: Mean Change From Baseline to Final Visit|Number of Subjects With Adverse Events|Number of Subjects With Potentially Clinically Significant Electrocardiogram (ECG) Findings|Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Mean Change From Baseline to Final Visit|Heart Rate: Mean Change From Baseline to Final Visit|Oral Body Temperature: Mean Change From Baseline to Final Visit|Number of Subjects With Potentially Clinically Significant Physical Examination Findings","AbbVie (prior sponsor, Abbott)|AbbVie","All","10 Years to 16 Years   (Child)","Phase 3","13","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-612|2013-002610-13","October 2011","April 2015","April 2015","June 27, 2011","November 21, 2016","July 2, 2018",,,"https://ClinicalTrials.gov/show/NCT01382212"
532,"NCT01368042","Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous","QUALITIZE","Completed","Has Results","Chronic Kidney Disease|Secondary Hyperparathyroidism",,"Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Physical Functioning' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Role Limitations Due to Physical Health' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Role Limitations Due to Emotional Problems' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Energy/Fatigue' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Emotional Well-Being' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Social Functioning' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Bodily Pain' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'General Health Perceptions' Scale Scores|Change From Baseline to 6 Months Post-enrollment in RAND 36-Item Health Survey 'Health Change' Item Scores|Change Per Month From Baseline to 6 Months Post-enrollment on the 8 Scales of the RAND 36-Item Health Survey|Change From Enrollment to 6 Months Post-enrollment in Urea Levels (mg/dL)|Change From Enrollment to 6 Months Post-enrollment in Creatinine Levels (mg/dL)|Change From Enrollment to 6 Months Post-enrollment in Calcium Levels (mg/dL)|Change From Enrollment to 6 Months Post-enrollment in Phosphorous Levels (mg/dL)|Change From Enrollment to 6 Months Post-enrollment in Calcium-Phosphorous (Ca×P) Product Levels (mg˄2/dL˄2)|Change From Enrollment to 6 Months in Parathyroid Hormone (PTH) Levels (pg/mL)|Change Per Month From Baseline to 6 Months in Parathyroid Hormone (PTH) Levels (pg/mL Per Month)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"265","Industry","Observational","Time Perspective: Prospective","P12-776","August 2011","June 2013","June 2013","June 7, 2011","July 24, 2014","August 1, 2014","Site Reference ID/Investigator# 56803, Arta, Greece|Site Reference ID/Investigator# 53424, Athens, Greece|Site Reference ID/Investigator# 53425, Larissa, Greece|Site Reference ID/Investigator# 56805, Lefkada, Greece|Site Reference ID/Investigator# 56802, Melissia, Greece|Site Reference ID/Investigator# 66291, Patras, Greece|Site Reference ID/Investigator# 56809, Patras, Greece|Site Reference ID/Investigator# 50442, Pylaia Thessaloniki, Greece|Site Reference ID/Investigator# 77554, Thessaloniki, Greece|Site Reference ID/Investigator# 77553, Thessaloniki, Greece|Site Reference ID/Investigator# 53422, Volos, Greece",,"https://ClinicalTrials.gov/show/NCT01368042"
533,"NCT01364922","Phase 2 Chronic Low Back Pain Study",,"Completed","Has Results","Chronic Low Back Pain","Drug: hydrocodone/acetaminophen extended release|Drug: Placebo","Change From Double-blind Baseline in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)|Participant's Global Assessment of Back Pain Status at Final Evaluation|Participant's Global Assessment of Study Drug at Final Evaluation","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-807","June 2011","October 2011","October 2011","June 3, 2011","December 23, 2013","January 29, 2014","Site Reference ID/Investigator# 54875, Tucson, Arizona, United States|Site Reference ID/Investigator# 54876, Anaheim, California, United States|Site Reference ID/Investigator# 54877, Burbank, California, United States|Site Reference ID/Investigator# 54873, Lomita, California, United States|Site Reference ID/Investigator# 54874, DeLand, Florida, United States|Site Reference ID/Investigator# 54866, Oldsmar, Florida, United States|Site Reference ID/Investigator# 54879, Marietta, Georgia, United States|Site Reference ID/Investigator# 54865, Valparaiso, Indiana, United States|Site Reference ID/Investigator# 54782, Prairie Village, Kansas, United States|Site Reference ID/Investigator# 54862, Pasadena, Maryland, United States|Site Reference ID/Investigator# 54878, Watertown, Massachusetts, United States|Site Reference ID/Investigator# 54880, St. Louis, Missouri, United States|Site Reference ID/Investigator# 54881, Williamsville, New York, United States|Site Reference ID/Investigator# 54872, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 54863, Marion, Ohio, United States|Site Reference ID/Investigator# 54745, Killeen, Texas, United States|Site Reference ID/Investigator# 54742, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01364922"
534,"NCT01356849","Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor","RADAR","Completed","No Results Available","Chronic Kidney Disease|Diabetic Nephropathy","Drug: Atrasentan|Drug: Placebo","Change from baseline to Week 12 in Urinary Albumin to Creatinine Ratio (UACR)|Differences in change from baseline to each post baseline measure for estimated glomerular filtration rate (eGFR)|Differences in change from baseline to each post baseline measure for EQ-5D Index Score|Differences in change from baseline to each post baseline measure for each of the Kidney Disease Quality of Life (KDQOL) Kidney Disease Targeted Scales","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","149","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-350","April 2011","August 2012","August 2012","May 20, 2011",,"August 28, 2013","Site Reference ID/Investigator# 46345, Pell City, Alabama, United States|Site Reference ID/Investigator# 46035, Tempe, Arizona, United States|Site Reference ID/Investigator# 46016, Azusa, California, United States|Site Reference ID/Investigator# 45992, Chula Vista, California, United States|Site Reference ID/Investigator# 46000, La Mesa, California, United States|Site Reference ID/Investigator# 46038, Lincoln, California, United States|Site Reference ID/Investigator# 45994, Long Beach, California, United States|Site Reference ID/Investigator# 45998, Los Angeles, California, United States|Site Reference ID/Investigator# 47584, Los Gatos, California, United States|Site Reference ID/Investigator# 64465, National City, California, United States|Site Reference ID/Investigator# 65862, Orange, California, United States|Site Reference ID/Investigator# 46019, Riverside, California, United States|Site Reference ID/Investigator# 46110, Salinas, California, United States|Site Reference ID/Investigator# 46017, Yuba City, California, United States|Site Reference ID/Investigator# 46662, Westminster, Colorado, United States|Site Reference ID/Investigator# 46033, Coral Gables, Florida, United States|Site Reference ID/Investigator# 45989, Hialeah, Florida, United States|Site Reference ID/Investigator# 46667, Lauderdale Lakes, Florida, United States|Site Reference ID/Investigator# 46123, Miami, Florida, United States|Site Reference ID/Investigator# 46115, Ocala, Florida, United States|Site Reference ID/Investigator# 46664, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 46031, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 46040, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 46122, Port Charlotte, Florida, United States|Site Reference ID/Investigator# 46015, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 50482, Jonesboro, Georgia, United States|Site Reference ID/Investigator# 46034, Meridian, Idaho, United States|Site Reference ID/Investigator# 46666, Chicago, Illinois, United States|Site Reference ID/Investigator# 45996, Evergreen Park, Illinois, United States|Site Reference ID/Investigator# 46002, Gurnee, Illinois, United States|Site Reference ID/Investigator# 46111, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 46030, Oxon Hill, Maryland, United States|Site Reference ID/Investigator# 45991, Rockville, Maryland, United States|Site Reference ID/Investigator# 46025, Novi, Michigan, United States|Site Reference ID/Investigator# 46023, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 46062, Farmington, Missouri, United States|Site Reference ID/Investigator# 48942, Omaha, Nebraska, United States|Site Reference ID/Investigator# 46349, Omaha, Nebraska, United States|Site Reference ID/Investigator# 46116, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 50483, Albany, New York, United States|Site Reference ID/Investigator# 68328, New Hyde Park, New York, United States|Site Reference ID/Investigator# 65863, Asheville, North Carolina, United States|Site Reference ID/Investigator# 50529, Greensboro, North Carolina, United States|Site Reference ID/Investigator# 46129, Greenville, North Carolina, United States|Site Reference ID/Investigator# 46022, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 46224, Doylestown, Pennsylvania, United States|Site Reference ID/Investigator# 46028, Orangeburg, South Carolina, United States|Site Reference ID/Investigator# 46702, Orangeburg, South Carolina, United States|Site Reference ID/Investigator# 46024, Greenville, Texas, United States|Site Reference ID/Investigator# 46228, Houston, Texas, United States|Site Reference ID/Investigator# 47068, Houston, Texas, United States|Site Reference ID/Investigator# 64464, Houston, Texas, United States|Site Reference ID/Investigator# 64483, Mission, Texas, United States|Site Reference ID/Investigator# 46348, San Antonio, Texas, United States|Site Reference ID/Investigator# 46063, San Antonio, Texas, United States|Site Reference ID/Investigator# 68486, San Antonio, Texas, United States|Site Reference ID/Investigator# 46669, Bennington, Vermont, United States|Site Reference ID/Investigator# 46026, Alexandria, Virginia, United States|Site Reference ID/Investigator# 46027, Fairfax, Virginia, United States|Site Reference ID/Investigator# 67762, Kitchener, Canada|Site Reference ID/Investigator# 50526, Sarnia, Canada|Site Reference ID/Investigator# 50525, Thornhill, Canada|Site Reference ID/Investigator# 47067, Caguas, Puerto Rico|Site Reference ID/Investigator# 50522, Manati, Puerto Rico|Site Reference ID/Investigator# 46352, Ponce, Puerto Rico|Site Reference ID/Investigator# 46351, Ponce, Puerto Rico|Site Reference ID/Investigator# 46133, Ponce, Puerto Rico|Site Reference ID/Investigator# 46131, Rio Piedras, Puerto Rico|Site Reference ID/Investigator# 46132, San Juan, Puerto Rico|Site Reference ID/Investigator# 46230, Santurce, Puerto Rico|Site Reference ID/Investigator# 51566, Taichung City, Taiwan|Site Reference ID/Investigator# 51567, Taichung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01356849"
535,"NCT01346501","Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069",,"Completed","Has Results","Rheumatoid Arthritis",,"Percentage of Participants With Disease Activity Score 28 - C-Reactive Protein (DAS28-CRP) Score < 3.2 After Discontinuation of Adalimumab Treatment|Percentage of Participants With Positive Serum Level of Matrix Metalloprotease-3 (MMP-3)|Mean Health Assessment Questionnaire (HAQ) Score|Percentage of Participants With Modified Total Sharp Score (mTSS) ≤ 0.5 and ≤ 1.5|Percentage of Participants With Adverse Drug Reactions and Serious Adverse Drug Reactions","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years to 99 Years   (Adult, Older Adult)",,"172","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-707","April 2011","November 2014","November 2014","May 3, 2011","March 11, 2016","March 11, 2016",,,"https://ClinicalTrials.gov/show/NCT01346501"
536,"NCT01346488","Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)",,"Completed","Has Results","Rheumatoid Arthritis",,"Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism)|Change From Baseline in WPAI Questionnaire: Mean Percentage of Impairment While Working Due to RA (Presenteeism)|Change From Baseline in WPAI Questionnaire: Mean Percentage of Overall Work Productivity Impairment (OWPI) Due to RA|Change From Baseline in WPAI Questionnaire: Mean Percentage of Activity Impairment Due to RA|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score|Number of Participants Per Category of the HAQ-DI|Change From Baseline in Disease Activity Score 28-4 C-Reactive Protein (DAS 28-4 CRP)|Number of Participants Per Category of the DAS28-4 CRP|Change From Baseline in DAS28-4 Erythrocyte Sedimentation Rate (ESR)|Number of Participants Per Category of the DAS28-4 ESR|Change From Baseline in Clinical Disease Activity Index (CDAI)|Number of Participants Per Category of the CDAI|Change From Baseline in European Quality of Life-5 Dimensions Questionnaire (EQ-5D) Summary Index Score|Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and Deaths|Number of Participants With Adverse Drug Reactions","AbbVie (prior sponsor, Abbott)|AbbVie","All","15 Years to 87 Years   (Child, Adult, Older Adult)",,"2088","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-772","June 2011","January 2016","January 2016","May 3, 2011","March 3, 2017","April 13, 2017",,,"https://ClinicalTrials.gov/show/NCT01346488"
537,"NCT01345045","A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain",,"Completed","No Results Available","Diabetic Neuropathic Pain","Drug: ABT-639|Drug: pregabalin|Drug: Placebo","A mean of 24-hour average pain score measured by an 11-point Numeric Rating Scale (NRS) based on subject's daily diary|Patient's Global Impression of Change|Brief Pain Inventory (BPI) (short form) including Severity and Interference|Neuropathic Pain Symptom Inventory (NPSI)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","193","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M11-891|2010-024359-99","April 2011","October 2011","October 2011","April 29, 2011",,"January 8, 2013","Site Reference ID/Investigator# 51807, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 51946, Anaheim, California, United States|Site Reference ID/Investigator# 51468, Long Beach, California, United States|Site Reference ID/Investigator# 52744, Walnut Creek, California, United States|Site Reference ID/Investigator# 51079, Clearwater, Florida, United States|Site Reference ID/Investigator# 51076, Hialeah, Florida, United States|Site Reference ID/Investigator# 51945, Hollywood, Florida, United States|Site Reference ID/Investigator# 51077, Ocala, Florida, United States|Site Reference ID/Investigator# 51078, Orlando, Florida, United States|Site Reference ID/Investigator# 51804, Brockton, Massachusetts, United States|Site Reference ID/Investigator# 51263, St. Louis, Missouri, United States|Site Reference ID/Investigator# 51268, St. Louis, Missouri, United States|Site Reference ID/Investigator# 51302, Omaha, Nebraska, United States|Site Reference ID/Investigator# 51271, Flushing, New York, United States|Site Reference ID/Investigator# 52743, Portland, Oregon, United States|Site Reference ID/Investigator# 51806, Altoona, Pennsylvania, United States|Site Reference ID/Investigator# 51265, Tipton, Pennsylvania, United States|Site Reference ID/Investigator# 51548, Dallas, Texas, United States|Site Reference ID/Investigator# 51269, Renton, Washington, United States|Site Reference ID/Investigator# 51425, Hradec Kralove, Czech Republic|Site Reference ID/Investigator# 51426, Mor Ostrava, Czech Republic|Site Reference ID/Investigator# 51424, Olomouc, Czech Republic|Site Reference ID/Investigator# 51428, Prague 10, Czech Republic|Site Reference ID/Investigator# 51423, Prague 6, Czech Republic|Site Reference ID/Investigator# 51427, Zlin, Czech Republic|Site Reference ID/Investigator# 51924, Le Creusot, France|Site Reference ID/Investigator# 51925, Venissieux, France|Site Reference ID/Investigator# 51503, Berlin, Germany|Site Reference ID/Investigator# 51642, Duesseldorf, Germany|Site Reference ID/Investigator# 51502, Mainz, Germany|Site Reference ID/Investigator# 52346, Muenster, Germany|Site Reference ID/Investigator# 51505, Guadalajara, Jal., Mexico|Site Reference ID/Investigator# 51504, Mexico D.F., Mexico|Site Reference ID/Investigator# 51522, Monterrey, N.L., Mexico|Site Reference ID/Investigator# 51506, Monterrey, N.L., Mexico",,"https://ClinicalTrials.gov/show/NCT01345045"
538,"NCT01341782","Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism",,"Completed","Has Results","Secondary Hyperparathyroidism|Hemodialysis","Drug: paricalcitol|Drug: maxacalcitol|Drug: paricalcitol placebo|Drug: maxacalcitol placebo","Percentage of Participants With Target Intact Parathyroid Hormone (iPTH) and Without Hypercalcemia|Percentage of Participants With ≥ 50% Reduction in Intact Parathyroid Hormone (iPTH) From Baseline and With No Hypercalcemia|Percentage of Participants With Target Intact Parathyroid Hormone (iPTH)|Percentage of Participants With ≥ 50% Reduction in Intact Parathyroid Hormone (iPTH) From Baseline|Number of Visits at Which Participants Achieved iPTH Control With ≥ 50% Reduction in Intact Parathyroid Hormone (iPTH) From Baseline|Number of Visits at Which Participants Achieved iPTH Control in the Target Range of 60 to 180 pg/mL","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years and older   (Adult, Older Adult)","Phase 3","255","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M11-517","May 2011","April 2012","April 2012","April 26, 2011","June 6, 2013","June 6, 2013","Site Reference ID/Investigator# 53485, Aichi, Japan|Site Reference ID/Investigator# 51571, Chiba, Japan|Site Reference ID/Investigator# 52963, Chiba, Japan|Site Reference ID/Investigator# 52966, Chiba, Japan|Site Reference ID/Investigator# 51578, Gifu, Japan|Site Reference ID/Investigator# 52965, Gunma, Japan|Site Reference ID/Investigator# 53782, Hadano-City, Japan|Site Reference ID/Investigator# 57483, Himeji-City, Japan|Site Reference ID/Investigator# 57487, Hokkaido, Japan|Site Reference ID/Investigator# 53484, Hyogo, Japan|Site Reference ID/Investigator# 54385, Ibaraki, Japan|Site Reference ID/Investigator# 51581, Kagawa, Japan|Site Reference ID/Investigator# 59164, Kagoshima, Japan|Site Reference ID/Investigator# 51574, Kanagawa, Japan|Site Reference ID/Investigator# 51575, Kanagawa, Japan|Site Reference ID/Investigator# 52751, Kodaira, Japan|Site Reference ID/Investigator# 62025, Koga, Japan|Site Reference ID/Investigator# 54384, Matsumoto, Japan|Site Reference ID/Investigator# 52745, Midori, Japan|Site Reference ID/Investigator# 51569, Mito, Japan|Site Reference ID/Investigator# 52964, Nagano, Japan|Site Reference ID/Investigator# 53483, Nagano, Japan|Site Reference ID/Investigator# 51582, Nagasaki, Japan|Site Reference ID/Investigator# 54388, Nagoya, Japan|Site Reference ID/Investigator# 51576, Niigata, Japan|Site Reference ID/Investigator# 51577, Niigata, Japan|Site Reference ID/Investigator# 51580, Osaka, Japan|Site Reference ID/Investigator# 52747, Osaka, Japan|Site Reference ID/Investigator# 52748, Osaka, Japan|Site Reference ID/Investigator# 52750, Osaka, Japan|Site Reference ID/Investigator# 51570, Saitama, Japan|Site Reference ID/Investigator# 54387, Sakai, Japan|Site Reference ID/Investigator# 52746, Sapporo, Japan|Site Reference ID/Investigator# 51579, Shizuoka, Japan|Site Reference ID/Investigator# 62024, Takasaki, Japan|Site Reference ID/Investigator# 51572, Tokyo, Japan|Site Reference ID/Investigator# 52752, Tokyo, Japan|Site Reference ID/Investigator# 53482, Tokyo, Japan|Site Reference ID/Investigator# 59162, Tokyo, Japan|Site Reference ID/Investigator# 59966, Tokyo, Japan|Site Reference ID/Investigator# 53783, Tomakomai-shi, Japan|Site Reference ID/Investigator# 54383, Toyama, Japan|Site Reference ID/Investigator# 52749, Wakayama, Japan|Site Reference ID/Investigator# 52962, Yachiyoshi, Japan|Site Reference ID/Investigator# 59163, Yokohama-Shi, Japan",,"https://ClinicalTrials.gov/show/NCT01341782"
539,"NCT01339650","Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",,"Completed","No Results Available","Fallopian Tube|Primary Peritoneal Cancer|Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian","Drug: ABT-767","Pharmacokinetic profile|Safety (number of subjects with adverse events and/or dose limiting toxicities)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","93","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-976|2010-020795-37","May 6, 2011","November 30, 2017","November 30, 2017","April 21, 2011",,"January 2, 2018","Univ Med Center Groningen, Groningen, Netherlands|Univ Med Ctr, St. Radboud, Nijmegen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT01339650"
540,"NCT01333722","Acute Pain Study Following Bunionectomy",,"Completed","Has Results","Pain","Drug: Hydrocodone/Acetaminophen Extended Release|Drug: Placebo","Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS)|TOTPAR (Total Pain Relief)|SPRID (Pain Relief and Pain Intensity Difference)|Time to Perceptible and Meaningful Pain Relief","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-169","April 2011","June 2011","June 2011","April 12, 2011","March 7, 2014","April 8, 2014","Site Reference ID/Investigator# 51464, Pasadena, California, United States|Site Reference ID/Investigator# 51602, Austin, Texas, United States|Site Reference ID/Investigator# 51344, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01333722"
541,"NCT01328366","Quality of Life and Psychosocial Factors Associated With Severe Psoriasis Following Treatment With Adalimumab","Body Image","Completed","Has Results","Psoriasis",,"Dermatology Life Quality Index (DLQI) Scores|Mean Change in Dermatology Life Quality Index (DLQI) Scores From Baseline|Self-assessed Psoriasis Area and Severity Index (SAPASI) Scores|Mean Change in Self-assessed Psoriasis Area and Severity Index (SAPASI) Scores From Baseline|Psoriasis Area and Severity Index (PASI) Scores|Mean Change in Psoriasis Area and Severity Index (PASI) Scores From Baseline|Hospital Anxiety and Depression Scale (HADS) Scores|Mean Change in Hospital Anxiety and Depression Scale (HADS) Scores From Baseline|Cutaneous Body Image Scale (CBI) Scores|Mean Change in Cutaneous Body Image (CBI) Scale Scores From Baseline|12-item Short Form Survey (SF-12) Score|Change in 12-item Short Form Survey (SF-12) Score From Baseline|Female Sexual Function Index (FSFI) Score|Mean Change in Female Sexual Function Index (FSFI) Score From Baseline|International Index of Erectile Function Score","AbbVie (prior sponsor, Abbott)|pH Associates|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"153","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-627","May 2011","May 2014","May 2014","April 4, 2011","June 11, 2015","July 9, 2015",,,"https://ClinicalTrials.gov/show/NCT01328366"
542,"NCT01328158","Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection",,"Completed","Has Results","Human Immunodeficiency Virus Infection",,"Percentage of Participants With Adverse Drug Reactions|Number of Adverse Drug Reactions|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Gender|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Pregnancy|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Age|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Inpatient/Outpatient|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Previous Treatment of Human Immunodeficiency Virus (HIV)-Infection|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Races|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Route of Infection|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Disease Duration|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Past Medical History|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Allergy|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Diseases|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Renal Disorder|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Liver Disorder|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Haemophilia With/Without Hepatitis C|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Center for Disease Control (CDC) Classification Category of Severity Before Treatment|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Administration Method of Lopinavir/Ritonavir|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Mean Daily Dose of Lopinavir/Ritonavir|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Use Duration of Lopinavir/Ritonavir|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Drugs|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Anti-HIV Concomitant Non-Drug Treatments|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Types of Concomitant Anti-HIV Drugs|Number of Participants With Adverse Drug Reaction by Patient Characteristic: Presence/Absence of Concomitant Drugs Other Than Anti-HIV Drugs|Number of Participants With Serious Adverse Events|Mean Cluster of Differentiation 4 (CD4) Cell Count in Treatment-Naive Participants at Each Time Point of Observation|Mean CD4 Cell Count in Treatment-Experienced Participants at Each Time Point of Observation|Mean HIV Ribonucleic Acid (RNA) Amount in Treatment-Naive Participants at Each Time Point of Observation|Mean HIV RNA Amount in Treatment-Experienced Participants at Each Time Point of Observation|Number of Participants in Each CDC Classification Category of HIV-infection Over Time|Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Naive Participants|Percentage of Participants With Plasma HIV-1 RNA Levels Less Than 400 Copies/Milliliter [mL]) by Duration in Treatment-Experienced Participants","AbbVie (prior sponsor, Abbott)|AbbVie","All","Child, Adult, Older Adult",,"236","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-760","June 2011","December 2013","December 2013","April 4, 2011","December 22, 2014","December 22, 2014","Site Reference ID/Investigator# 57629, Fukuoka-shi, Japan|Site Reference ID/Investigator# 57630, Hiroshima-shi, Japan|Site Reference ID/Investigator# 57631, Hokkaido, Japan|Site Reference ID/Investigator# 57628, Kitakyushu-shi, Japan|Site Reference ID/Investigator# 57638, Kurashiki-shi, Japan|Site Reference ID/Investigator# 57634, Kyoto, Japan|Site Reference ID/Investigator# 57625, Nagoya-shi, Japan|Site Reference ID/Investigator# 57626, Nagoya-shi, Japan|Site Reference ID/Investigator# 57637, Niigata, Japan|Site Reference ID/Investigator# 57632, Nishinomiya-shi, Japan|Site Reference ID/Investigator# 57639, Osaka-shi, Japan|Site Reference ID/Investigator# 57640, Osaka, Japan|Site Reference ID/Investigator# 57636, Sendai-shi, Japan|Site Reference ID/Investigator# 48722, Tokyo, Japan|Site Reference ID/Investigator# 57641, Tokyo, Japan|Site Reference ID/Investigator# 57643, Tokyo, Japan|Site Reference ID/Investigator# 57644, Tokyo, Japan|Site Reference ID/Investigator# 57645, Tokyo, Japan|Site Reference ID/Investigator# 57646, Tokyo, Japan|Site Reference ID/Investigator# 57647, Tokyo, Japan|Site Reference ID/Investigator# 57648, Tokyo, Japan|Site Reference ID/Investigator# 57650, Tokyo, Japan|Site Reference ID/Investigator# 57633, Yokohama-shi, Japan",,"https://ClinicalTrials.gov/show/NCT01328158"
543,"NCT01320735","Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia",,"Completed","Has Results","Prostate Cancer",,"Mean Duration of Leuprorelin Exposure|Mean Duration of Each Leuprorelin Cycle|Median Number of Leuprorelin Cycles|Percentage of Participants Who Discontinued From Leuprorelin Administration of IAD Regimen|Number of Participants Who Switched to IAD Regimen by Visit|Number of Participants Who Progressed to Hormone Refractory Prostate Cancer (HRPC)|Median Time to Progression of HRPC|Median Time to Progression of HRPC in Participants Not Started on IAD Regimen|Median Survival Time|Mean Duration of Treatment-off Time in IAD Regimen|Median Percentage of Time Off-treatment During 2 Years IAD Regimen","AbbVie (prior sponsor, Abbott)|Almedis|AbbVie","Male","18 Years to 75 Years   (Adult, Older Adult)",,"300","Industry","Observational","Time Perspective: Prospective","P12-763","February 2011","May 2014","May 2014","March 22, 2011","July 8, 2015","July 8, 2015",,,"https://ClinicalTrials.gov/show/NCT01320735"
544,"NCT01316224","Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment","TOGETHER","Completed","Has Results","Psoriasis|Psoriatic Arthritis",,"Percentage of Participants Who Developed Psoriatic Arthritis (PsA)|Percentage of Participants Who Developed Signs or Symptoms of PsA|Mean Time to First Occurrence of PsA Signs or Symptoms|Mean Change From Baseline in Psoriasis Area and Severity Index (PASI) Score|Percentage of Participants With Comorbidities Who Did or Did Not Develop PsA|Mean Change in Quality of Life (QoL)|Mean Change in ClASsification Criteria for Psoriatic ARthritis (CASPAR) Score|Percentage of Participants With a CASPAR Score Greater Than or Equal to 3 at Each Visit to the Rheumatologist|Percentage of Participants With Swollen Joint Count (SJC) and Tender Joint Count (TJC) Greater Than Zero|Percentage of Participants With Joint Symptoms|Incidence Rate of PsA Since Psoriasis Diagnosis|Change in the Subject Proportion That Achieved a PASI (Psoriasis Area and Severity Index) Reduction of ≥50%","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"52","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P12-598","April 2011","April 2014","April 2014","March 16, 2011","May 12, 2015","May 12, 2015","Site Reference ID/Investigator# 48347, Barranquilla, Colombia|Site Reference ID/Investigator# 48349, Barranquilla, Colombia|Site Reference ID/Investigator# 53045, Barranquilla, Colombia|Site Reference ID/Investigator# 53047, Bogota, Colombia|Site Reference ID/Investigator# 78533, Bogota, Colombia|Site Reference ID/Investigator# 48345, Cali, Colombia|Site Reference ID/Investigator# 48346, Cali, Colombia|Site Reference ID/Investigator# 59342, Cali, Colombia|Site Reference ID/Investigator# 48342, Cartagena, Colombia|Site Reference ID/Investigator# 48348, Cartagena, Colombia|Site Reference ID/Investigator# 53050, Cartagena, Colombia|Site Reference ID/Investigator# 48351, Medellin, Colombia|Site Reference ID/Investigator# 48353, Medellin, Colombia|Site Reference ID/Investigator# 53046, Medellin, Colombia|Site Reference ID/Investigator# 53049, Medellin, Colombia",,"https://ClinicalTrials.gov/show/NCT01316224"
545,"NCT01314261","Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects",,"Completed","Has Results","Chronic Hepatitis C|Hepatitis C Virus (HCV) Infection","Drug: ABT-267|Drug: Pegylated interferon (pegIFN)|Drug: Ribavirin (RBV)|Other: Placebo for ABT-267","Percentage of Participants With 4-week Rapid Virologic Response (RVR)|Maximum Plasma Concentration (Cmax) of ABT-267|Time to Maximum Plasma Concentration (Tmax) of ABT-267|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267|Plasma Concentrations of Ribavirin (RBV)|Serum Concentrations of Pegylated Interferon (pegIFN)|Percentage of Participants With Partial Early Virologic Response (pEVR)|Percentage of Participants With Complete Early Virologic Response (cEVR)|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing|Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing|Median Time to Suppression of Hepatitis C Virus Ribonucleic Acid (HCV RNA)|Percentage of Participants With Extended Rapid Virologic Response (eRVR)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M12-114","March 2011","January 2012","February 2013","March 14, 2011","January 26, 2015","July 2, 2018","Site Reference ID/Investigator# 56623, Birmingham, Alabama, United States|Site Reference ID/Investigator# 48476, Los Angeles, California, United States|Site Reference ID/Investigator# 51345, Orlando, Florida, United States|Site Reference ID/Investigator# 51498, Honolulu, Hawaii, United States|Site Reference ID/Investigator# 48473, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 52782, Kansas City, Missouri, United States|Site Reference ID/Investigator# 48471, Houston, Texas, United States|Site Reference ID/Investigator# 48474, San Antonio, Texas, United States|Site Reference ID/Investigator# 48477, Fairfax, Virginia, United States|Site Reference ID/Investigator# 48472, Seattle, Washington, United States|Site Reference ID/Investigator# 48483, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01314261"
546,"NCT01306617","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",,"Completed","Has Results","Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus","Drug: ABT-450|Drug: ABT-333|Drug: ribavirin|Drug: ritonavir","Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12|Percentage of Participants With HCV RNA < 1000 International Units Per Milliliter (IU/mL)|Percentage of Participants With HCV RNA Below the Lower Limit of Quantitation (LLOQ; <25 IU/mL) at Week 4|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment|Time to Failure to Suppress or Rebound During Treatment|Time to Virologic Relapse Post-treatment|Resistance-Associated Variants and Phenotypic Resistance|Pharmacokinetics (C Trough) of ABT 450 in HCV Infected Participants|Pharmacokinetics (C Trough) of ABT-333 in HCV Infected Participants|Pharmacokinetics (C Trough) of Ritonavir in HCV Infected Participants|Pharmacokinetics (C Trough) of Ribavirin in HCV Infected Participants","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-746","February 2011","November 2011","October 2012","March 2, 2011","January 8, 2015","January 8, 2015","Site Reference ID/Investigator# 48263, Los Angeles, California, United States|Site Reference ID/Investigator# 48264, Aurora, Colorado, United States|Site Reference ID/Investigator# 51282, Gainesville, Florida, United States|Site Reference ID/Investigator# 50425, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 50423, Kansas City, Missouri, United States|Site Reference ID/Investigator# 48268, New York, New York, United States|Site Reference ID/Investigator# 50428, Statesville, North Carolina, United States|Site Reference ID/Investigator# 48266, San Antonio, Texas, United States|Site Reference ID/Investigator# 50427, Newport News, Virginia, United States|Site Reference ID/Investigator# 48265, Seattle, Washington, United States|Site Reference ID/Investigator# 50424, Madison, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01306617"
547,"NCT01298648","Special Investigation in Patients With Crohn's Disease (All Patients Investigation)",,"Completed","Has Results","Crohn's Disease",,"Number of Participants With Adverse Events (AEs)|Crohn's Disease Activity Index (CDAI) at Baseline and Week 4|Crohn's Disease Activity Index (CDAI) at Baseline and Week 8|Crohn's Disease Activity Index (CDAI) at Baseline and Week 24|Improvement Rating by Investigator at Week 24|Remission Rate at Week 4, Week 8, and Week 24","AbbVie (prior sponsor, Abbott)|AbbVie","All","16 Years to 99 Years   (Child, Adult, Older Adult)",,"1716","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-706","November 2010","February 2013","February 2013","February 18, 2011","March 18, 2014","July 2, 2018","Site Reference ID/Investigator# 60378, Abiko, Japan|Site Reference ID/Investigator# 48682, Aichi, Japan|Site Reference ID/Investigator# 48693, Aichi, Japan|Site Reference ID/Investigator# 49011, Aichi, Japan|Site Reference ID/Investigator# 49013, Aichi, Japan|Site Reference ID/Investigator# 49015, Aichi, Japan|Site Reference ID/Investigator# 49016, Aichi, Japan|Site Reference ID/Investigator# 49019, Aichi, Japan|Site Reference ID/Investigator# 55615, Aichi, Japan|Site Reference ID/Investigator# 55616, Aichi, Japan|Site Reference ID/Investigator# 55865, Aichi, Japan|Site Reference ID/Investigator# 55869, Aichi, Japan|Site Reference ID/Investigator# 55870, Aichi, Japan|Site Reference ID/Investigator# 55871, Aichi, Japan|Site Reference ID/Investigator# 55872, Aichi, Japan|Site Reference ID/Investigator# 55873, Aichi, Japan|Site Reference ID/Investigator# 55874, Aichi, Japan|Site Reference ID/Investigator# 55875, Aichi, Japan|Site Reference ID/Investigator# 55876, Aichi, Japan|Site Reference ID/Investigator# 55877, Aichi, Japan|Site Reference ID/Investigator# 60203, Aichi, Japan|Site Reference ID/Investigator# 60205, Aichi, Japan|Site Reference ID/Investigator# 60244, Aichi, Japan|Site Reference ID/Investigator# 60508, Aichi, Japan|Site Reference ID/Investigator# 65148, Aichi, Japan|Site Reference ID/Investigator# 67162, Aichi, Japan|Site Reference ID/Investigator# 48652, Aizuwakamatsu, Japan|Site Reference ID/Investigator# 55758, Akashi, Japan|Site Reference ID/Investigator# 89873, Akashi, Japan|Site Reference ID/Investigator# 60398, Aki-gun, Hiroshima, Japan|Site Reference ID/Investigator# 60401, Aki-gun, Hiroshima, Japan|Site Reference ID/Investigator# 48650, Akita, Japan|Site Reference ID/Investigator# 55660, Akita, Japan|Site Reference ID/Investigator# 55705, Akita, Japan|Site Reference ID/Investigator# 55905, Akita, Japan|Site Reference ID/Investigator# 55906, Akita, Japan|Site Reference ID/Investigator# 55907, Akita, Japan|Site Reference ID/Investigator# 55909, Akita, Japan|Site Reference ID/Investigator# 60190, Akita, Japan|Site Reference ID/Investigator# 60261, Akita, Japan|Site Reference ID/Investigator# 60376, Akita, Japan|Site Reference ID/Investigator# 55742, Amagasaki, Japan|Site Reference ID/Investigator# 56030, Anan, Japan|Site Reference ID/Investigator# 49026, Anjo, Japan|Site Reference ID/Investigator# 55617, Anjo, Japan|Site Reference ID/Investigator# 48797, Aomori, Japan|Site Reference ID/Investigator# 55584, Aomori, Japan|Site Reference ID/Investigator# 55585, Aomori, Japan|Site Reference ID/Investigator# 55897, Aomori, Japan|Site Reference ID/Investigator# 55898, Aomori, Japan|Site Reference ID/Investigator# 55899, Aomori, Japan|Site Reference ID/Investigator# 55900, Aomori, Japan|Site Reference ID/Investigator# 60509, Aomori, Japan|Site Reference ID/Investigator# 65111, Aomori, Japan|Site Reference ID/Investigator# 65144, Aomori, Japan|Site Reference ID/Investigator# 80014, Aomori, Japan|Site Reference ID/Investigator# 48648, Asahikawa, Japan|Site Reference ID/Investigator# 55797, Asahikawa, Japan|Site Reference ID/Investigator# 56032, Awa, Japan|Site Reference ID/Investigator# 55778, Ayabe, Japan|Site Reference ID/Investigator# 80233, Azumino, Japan|Site Reference ID/Investigator# 80220, Beppu, Japan|Site Reference ID/Investigator# 48668, Chiba, Japan|Site Reference ID/Investigator# 48672, Chiba, Japan|Site Reference ID/Investigator# 49000, Chiba, Japan|Site Reference ID/Investigator# 49002, Chiba, Japan|Site Reference ID/Investigator# 49006, Chiba, Japan|Site Reference ID/Investigator# 55647, Chiba, Japan|Site Reference ID/Investigator# 55796, Chiba, Japan|Site Reference ID/Investigator# 55820, Chiba, Japan|Site Reference ID/Investigator# 55821, Chiba, Japan|Site Reference ID/Investigator# 55822, Chiba, Japan|Site Reference ID/Investigator# 55826, Chiba, Japan|Site Reference ID/Investigator# 55827, Chiba, Japan|Site Reference ID/Investigator# 55841, Chiba, Japan|Site Reference ID/Investigator# 60257, Chiba, Japan|Site Reference ID/Investigator# 65115, Chiba, Japan|Site Reference ID/Investigator# 65116, Chiba, Japan|Site Reference ID/Investigator# 65117, Chiba, Japan|Site Reference ID/Investigator# 65138, Chiba, Japan|Site Reference ID/Investigator# 67169, Chiba, Japan|Site Reference ID/Investigator# 79900, Chiba, Japan|Site Reference ID/Investigator# 89820, Chichibu, Japan|Site Reference ID/Investigator# 49074, Chikushino, Japan|Site Reference ID/Investigator# 55880, Chita, Japan|Site Reference ID/Investigator# 60210, Chita, Japan|Site Reference ID/Investigator# 55886, Chitose, Japan|Site Reference ID/Investigator# 55920, Chuo, Japan|Site Reference ID/Investigator# 80236, Ebetsu, Japan|Site Reference ID/Investigator# 49076, Ehime, Japan|Site Reference ID/Investigator# 55583, Ehime, Japan|Site Reference ID/Investigator# 56026, Ehime, Japan|Site Reference ID/Investigator# 56044, Ehime, Japan|Site Reference ID/Investigator# 65155, Ehime, Japan|Site Reference ID/Investigator# 67156, Eiheiji, Japan|Site Reference ID/Investigator# 79935, Esashi, Japan|Site Reference ID/Investigator# 48688, Fujieda, Japan|Site Reference ID/Investigator# 48689, Fujinomiya, Japan|Site Reference ID/Investigator# 79876, Fujisawa, Japan|Site Reference ID/Investigator# 89827, Fuji, Japan|Site Reference ID/Investigator# 48744, Fukui, Japan|Site Reference ID/Investigator# 55190, Fukui, Japan|Site Reference ID/Investigator# 55312, Fukui, Japan|Site Reference ID/Investigator# 55771, Fukui, Japan|Site Reference ID/Investigator# 55793, Fukui, Japan|Site Reference ID/Investigator# 80234, Fukui, Japan|Site Reference ID/Investigator# 48760, Fukuoka, Japan|Site Reference ID/Investigator# 48761, Fukuoka, Japan|Site Reference ID/Investigator# 48762, Fukuoka, Japan|Site Reference ID/Investigator# 48763, Fukuoka, Japan|Site Reference ID/Investigator# 48764, Fukuoka, Japan|Site Reference ID/Investigator# 48767, Fukuoka, Japan|Site Reference ID/Investigator# 48784, Fukuoka, Japan|Site Reference ID/Investigator# 49069, Fukuoka, Japan|Site Reference ID/Investigator# 49080, Fukuoka, Japan|Site Reference ID/Investigator# 49083, Fukuoka, Japan|Site Reference ID/Investigator# 49084, Fukuoka, Japan|Site Reference ID/Investigator# 49086, Fukuoka, Japan|Site Reference ID/Investigator# 55305, Fukuoka, Japan|Site Reference ID/Investigator# 56036, Fukuoka, Japan|Site Reference ID/Investigator# 56037, Fukuoka, Japan|Site Reference ID/Investigator# 56040, Fukuoka, Japan|Site Reference ID/Investigator# 56041, Fukuoka, Japan|Site Reference ID/Investigator# 56042, Fukuoka, Japan|Site Reference ID/Investigator# 56043, Fukuoka, Japan|Site Reference ID/Investigator# 56048, Fukuoka, Japan|Site Reference ID/Investigator# 56052, Fukuoka, Japan|Site Reference ID/Investigator# 60426, Fukuoka, Japan|Site Reference ID/Investigator# 60530, Fukuoka, Japan|Site Reference ID/Investigator# 60558, Fukuoka, Japan|Site Reference ID/Investigator# 65130, Fukuoka, Japan|Site Reference ID/Investigator# 65131, Fukuoka, Japan|Site Reference ID/Investigator# 65146, Fukuoka, Japan|Site Reference ID/Investigator# 65151, Fukuoka, Japan|Site Reference ID/Investigator# 68637, Fukuoka, Japan|Site Reference ID/Investigator# 68638, Fukuoka, Japan|Site Reference ID/Investigator# 90413, Fukuoka, Japan|Site Reference ID/Investigator# 48984, Fukushima, Japan|Site Reference ID/Investigator# 55163, Fukushima, Japan|Site Reference ID/Investigator# 55316, Fukushima, Japan|Site Reference ID/Investigator# 55597, Fukushima, Japan|Site Reference ID/Investigator# 55720, Fukushima, Japan|Site Reference ID/Investigator# 55798, Fukushima, Japan|Site Reference ID/Investigator# 55947, Fukushima, Japan|Site Reference ID/Investigator# 55948, Fukushima, Japan|Site Reference ID/Investigator# 55949, Fukushima, Japan|Site Reference ID/Investigator# 55950, Fukushima, Japan|Site Reference ID/Investigator# 55951, Fukushima, Japan|Site Reference ID/Investigator# 60196, Fukushima, Japan|Site Reference ID/Investigator# 60248, Fukushima, Japan|Site Reference ID/Investigator# 60386, Fukushima, Japan|Site Reference ID/Investigator# 60563, Fukushima, Japan|Site Reference ID/Investigator# 90396, Fukushima, Japan|Site Reference ID/Investigator# 55789, Fukuyama, Japan|Site Reference ID/Investigator# 56000, Fukuyama, Japan|Site Reference ID/Investigator# 90416, Fukuyama, Japan|Site Reference ID/Investigator# 48697, Gifu, Japan|Site Reference ID/Investigator# 49020, Gifu, Japan|Site Reference ID/Investigator# 49022, Gifu, Japan|Site Reference ID/Investigator# 55319, Gifu, Japan|Site Reference ID/Investigator# 55620, Gifu, Japan|Site Reference ID/Investigator# 55621, Gifu, Japan|Site Reference ID/Investigator# 55624, Gifu, Japan|Site Reference ID/Investigator# 55626, Gifu, Japan|Site Reference ID/Investigator# 55627, Gifu, Japan|Site Reference ID/Investigator# 55629, Gifu, Japan|Site Reference ID/Investigator# 60246, Gifu, Japan|Site Reference ID/Investigator# 60258, Gifu, Japan|Site Reference ID/Investigator# 60262, Gifu, Japan|Site Reference ID/Investigator# 60368, Gifu, Japan|Site Reference ID/Investigator# 60387, Gifu, Japan|Site Reference ID/Investigator# 60412, Gifu, Japan|Site Reference ID/Investigator# 60423, Gifu, Japan|Site Reference ID/Investigator# 60556, Gifu, Japan|Site Reference ID/Investigator# 60559, Gifu, Japan|Site Reference ID/Investigator# 67159, Gifu, Japan|Site Reference ID/Investigator# 48998, Gunma, Japan|Site Reference ID/Investigator# 55965, Gunma, Japan|Site Reference ID/Investigator# 55966, Gunma, Japan|Site Reference ID/Investigator# 55968, Gunma, Japan|Site Reference ID/Investigator# 60192, Gunma, Japan|Site Reference ID/Investigator# 60214, Gunma, Japan|Site Reference ID/Investigator# 60380, Gunma, Japan|Site Reference ID/Investigator# 65105, Gunma, Japan|Site Reference ID/Investigator# 67157, Gunma, Japan|Site Reference ID/Investigator# 67158, Gunma, Japan|Site Reference ID/Investigator# 55902, Hachinohe, Japan|Site Reference ID/Investigator# 60363, Hachinohe, Japan|Site Reference ID/Investigator# 48646, Hakodate, Japan|Site Reference ID/Investigator# 89856, Hakodate, Japan|Site Reference ID/Investigator# 48690, Hamamatsu, Japan|Site Reference ID/Investigator# 48691, Hamamatsu, Japan|Site Reference ID/Investigator# 55317, Hamamatsu, Japan|Site Reference ID/Investigator# 55613, Hamamatsu, Japan|Site Reference ID/Investigator# 55790, Hamamatsu, Japan|Site Reference ID/Investigator# 89817, Hamamatsu, Japan|Site Reference ID/Investigator# 55622, Hashima, Japan|Site Reference ID/Investigator# 55623, Hashima, Japan|Site Reference ID/Investigator# 56001, Higashihiroshima, Japan|Site Reference ID/Investigator# 55794, Higashiosaka, Japan|Site Reference ID/Investigator# 71467, Higashiosaka, Japan|Site Reference ID/Investigator# 55593, Himeji, Japan|Site Reference ID/Investigator# 55599, Himeji, Japan|Site Reference ID/Investigator# 55703, Himeji, Japan|Site Reference ID/Investigator# 90401, Himeji, Japan|Site Reference ID/Investigator# 55650, Hirakata, Japan|Site Reference ID/Investigator# 55311, Hirosaki, Japan|Site Reference ID/Investigator# 89813, Hirosaki, Japan|Site Reference ID/Investigator# 48751, Hiroshima, Japan|Site Reference ID/Investigator# 49063, Hiroshima, Japan|Site Reference ID/Investigator# 49064, Hiroshima, Japan|Site Reference ID/Investigator# 49068, Hiroshima, Japan|Site Reference ID/Investigator# 55164, Hiroshima, Japan|Site Reference ID/Investigator# 55574, Hiroshima, Japan|Site Reference ID/Investigator# 55581, Hiroshima, Japan|Site Reference ID/Investigator# 55601, Hiroshima, Japan|Site Reference ID/Investigator# 55694, Hiroshima, Japan|Site Reference ID/Investigator# 55997, Hiroshima, Japan|Site Reference ID/Investigator# 56002, Hiroshima, Japan|Site Reference ID/Investigator# 56003, Hiroshima, Japan|Site Reference ID/Investigator# 56004, Hiroshima, Japan|Site Reference ID/Investigator# 56005, Hiroshima, Japan|Site Reference ID/Investigator# 56007, Hiroshima, Japan|Site Reference ID/Investigator# 56008, Hiroshima, Japan|Site Reference ID/Investigator# 56010, Hiroshima, Japan|Site Reference ID/Investigator# 56014, Hiroshima, Japan|Site Reference ID/Investigator# 60554, Hiroshima, Japan|Site Reference ID/Investigator# 60560, Hiroshima, Japan|Site Reference ID/Investigator# 55588, Hitachi, Japan|Site Reference ID/Investigator# 56068, Hitoyoshi, Japan|Site Reference ID/Investigator# 48643, Hokkaido, Japan|Site Reference ID/Investigator# 48644, Hokkaido, Japan|Site Reference ID/Investigator# 48645, Hokkaido, Japan|Site Reference ID/Investigator# 48788, Hokkaido, Japan|Site Reference ID/Investigator# 48792, Hokkaido, Japan|Site Reference ID/Investigator# 48793, Hokkaido, Japan|Site Reference ID/Investigator# 48795, Hokkaido, Japan|Site Reference ID/Investigator# 48796, Hokkaido, Japan|Site Reference ID/Investigator# 55315, Hokkaido, Japan|Site Reference ID/Investigator# 55785, Hokkaido, Japan|Site Reference ID/Investigator# 55791, Hokkaido, Japan|Site Reference ID/Investigator# 55804, Hokkaido, Japan|Site Reference ID/Investigator# 55878, Hokkaido, Japan|Site Reference ID/Investigator# 55885, Hokkaido, Japan|Site Reference ID/Investigator# 55887, Hokkaido, Japan|Site Reference ID/Investigator# 55888, Hokkaido, Japan|Site Reference ID/Investigator# 55889, Hokkaido, Japan|Site Reference ID/Investigator# 55891, Hokkaido, Japan|Site Reference ID/Investigator# 55892, Hokkaido, Japan|Site Reference ID/Investigator# 55893, Hokkaido, Japan|Site Reference ID/Investigator# 55894, Hokkaido, Japan|Site Reference ID/Investigator# 55895, Hokkaido, Japan|Site Reference ID/Investigator# 60193, Hokkaido, Japan|Site Reference ID/Investigator# 60201, Hokkaido, Japan|Site Reference ID/Investigator# 60540, Hokkaido, Japan|Site Reference ID/Investigator# 60552, Hokkaido, Japan|Site Reference ID/Investigator# 60557, Hokkaido, Japan|Site Reference ID/Investigator# 65109, Hokkaido, Japan|Site Reference ID/Investigator# 65110, Hokkaido, Japan|Site Reference ID/Investigator# 48755, Houfu, Japan|Site Reference ID/Investigator# 80219, Houfu, Japan|Site Reference ID/Investigator# 48707, Hyogo, Japan|Site Reference ID/Investigator# 48708, Hyogo, Japan|Site Reference ID/Investigator# 48710, Hyogo, Japan|Site Reference ID/Investigator# 48712, Hyogo, Japan|Site Reference ID/Investigator# 48713, Hyogo, Japan|Site Reference ID/Investigator# 49042, Hyogo, Japan|Site Reference ID/Investigator# 49046, Hyogo, Japan|Site Reference ID/Investigator# 49047, Hyogo, Japan|Site Reference ID/Investigator# 55156, Hyogo, Japan|Site Reference ID/Investigator# 55691, Hyogo, Japan|Site Reference ID/Investigator# 55743, Hyogo, Japan|Site Reference ID/Investigator# 55744, Hyogo, Japan|Site Reference ID/Investigator# 55746, Hyogo, Japan|Site Reference ID/Investigator# 55748, Hyogo, Japan|Site Reference ID/Investigator# 55749, Hyogo, Japan|Site Reference ID/Investigator# 55750, Hyogo, Japan|Site Reference ID/Investigator# 55752, Hyogo, Japan|Site Reference ID/Investigator# 55753, Hyogo, Japan|Site Reference ID/Investigator# 55755, Hyogo, Japan|Site Reference ID/Investigator# 55756, Hyogo, Japan|Site Reference ID/Investigator# 55757, Hyogo, Japan|Site Reference ID/Investigator# 55759, Hyogo, Japan|Site Reference ID/Investigator# 60215, Hyogo, Japan|Site Reference ID/Investigator# 60224, Hyogo, Japan|Site Reference ID/Investigator# 60251, Hyogo, Japan|Site Reference ID/Investigator# 60364, Hyogo, Japan|Site Reference ID/Investigator# 60388, Hyogo, Japan|Site Reference ID/Investigator# 60389, Hyogo, Japan|Site Reference ID/Investigator# 60402, Hyogo, Japan|Site Reference ID/Investigator# 60528, Hyogo, Japan|Site Reference ID/Investigator# 60531, Hyogo, Japan|Site Reference ID/Investigator# 65143, Hyogo, Japan|Site Reference ID/Investigator# 68641, Hyogo, Japan|Site Reference ID/Investigator# 48991, Ibaraki-ken, Japan|Site Reference ID/Investigator# 48994, Ibaraki, Japan|Site Reference ID/Investigator# 49008, Ibaraki, Japan|Site Reference ID/Investigator# 55596, Ibaraki, Japan|Site Reference ID/Investigator# 55693, Ibaraki, Japan|Site Reference ID/Investigator# 55955, Ibaraki, Japan|Site Reference ID/Investigator# 55957, Ibaraki, Japan|Site Reference ID/Investigator# 55958, Ibaraki, Japan|Site Reference ID/Investigator# 55959, Ibaraki, Japan|Site Reference ID/Investigator# 60253, Ibaraki, Japan|Site Reference ID/Investigator# 60362, Ibaraki, Japan|Site Reference ID/Investigator# 60407, Ibaraki, Japan|Site Reference ID/Investigator# 60524, Ibaraki, Japan|Site Reference ID/Investigator# 55824, Ichihara, Japan|Site Reference ID/Investigator# 55825, Ichihara, Japan|Site Reference ID/Investigator# 48667, Ichikawa, Japan|Site Reference ID/Investigator# 60513, Ichinomiya, Japan|Site Reference ID/Investigator# 60216, Ichinoseki, Japan|Site Reference ID/Investigator# 90415, Ichinoseki, Japan|Site Reference ID/Investigator# 49078, Iizuka, Japan|Site Reference ID/Investigator# 55685, Ikoma, Japan|Site Reference ID/Investigator# 49043, Ikomo, Nara, Japan|Site Reference ID/Investigator# 55313, Imabari, Japan|Site Reference ID/Investigator# 55704, Inashiki, Japan|Site Reference ID/Investigator# 94893, Inazawa, Japan|Site Reference ID/Investigator# 80222, Ina, Japan|Site Reference ID/Investigator# 60510, Inzai, Japan|Site Reference ID/Investigator# 94804, Isa, Japan|Site Reference ID/Investigator# 94805, Isa, Japan|Site Reference ID/Investigator# 55571, Isehara, Japan|Site Reference ID/Investigator# 48657, Isesaki, Japan|Site Reference ID/Investigator# 49052, Ishikawa, Japan|Site Reference ID/Investigator# 55162, Ishikawa, Japan|Site Reference ID/Investigator# 55765, Ishikawa, Japan|Site Reference ID/Investigator# 55767, Ishikawa, Japan|Site Reference ID/Investigator# 55768, Ishikawa, Japan|Site Reference ID/Investigator# 55769, Ishikawa, Japan|Site Reference ID/Investigator# 55770, Ishikawa, Japan|Site Reference ID/Investigator# 60555, Ishikawa, Japan|Site Reference ID/Investigator# 65125, Ishikawa, Japan|Site Reference ID/Investigator# 65126, Ishikawa, Japan|Site Reference ID/Investigator# 60375, Itami, Japan|Site Reference ID/Investigator# 55946, Iwaki, Japan|Site Reference ID/Investigator# 49060, Iwakuni, Japan|Site Reference ID/Investigator# 55612, Iwata, Japan|Site Reference ID/Investigator# 48647, Iwate, Japan|Site Reference ID/Investigator# 55842, Iwate, Japan|Site Reference ID/Investigator# 55903, Iwate, Japan|Site Reference ID/Investigator# 60223, Iwate, Japan|Site Reference ID/Investigator# 60249, Iwate, Japan|Site Reference ID/Investigator# 60263, Iwate, Japan|Site Reference ID/Investigator# 60394, Iwate, Japan|Site Reference ID/Investigator# 60538, Iwate, Japan|Site Reference ID/Investigator# 68639, Iwate, Japan|Site Reference ID/Investigator# 49048, Izumiotsu, Japan|Site Reference ID/Investigator# 55673, Izumisano, Japan|Site Reference ID/Investigator# 49061, Izumo, Japan|Site Reference ID/Investigator# 49062, Izumo, Japan|Site Reference ID/Investigator# 55882, Izunokuni, Japan|Site Reference ID/Investigator# 84095, Izunokuni, Japan|Site Reference ID/Investigator# 55954, Joetsu, Japan|Site Reference ID/Investigator# 79878, Jyoyo, Japan|Site Reference ID/Investigator# 55625, Kagamigahara, Japan|Site Reference ID/Investigator# 49070, Kagawa, Japan|Site Reference ID/Investigator# 55716, Kagawa, Japan|Site Reference ID/Investigator# 55782, Kagawa, Japan|Site Reference ID/Investigator# 55805, Kagawa, Japan|Site Reference ID/Investigator# 56017, Kagawa, Japan|Site Reference ID/Investigator# 56018, Kagawa, Japan|Site Reference ID/Investigator# 56019, Kagawa, Japan|Site Reference ID/Investigator# 56020, Kagawa, Japan|Site Reference ID/Investigator# 56021, Kagawa, Japan|Site Reference ID/Investigator# 56022, Kagawa, Japan|Site Reference ID/Investigator# 56025, Kagawa, Japan|Site Reference ID/Investigator# 60221, Kagawa, Japan|Site Reference ID/Investigator# 65129, Kagawa, Japan|Site Reference ID/Investigator# 48777, Kagoshima, Japan|Site Reference ID/Investigator# 48778, Kagoshima, Japan|Site Reference ID/Investigator# 48779, Kagoshima, Japan|Site Reference ID/Investigator# 49091, Kagoshima, Japan|Site Reference ID/Investigator# 49092, Kagoshima, Japan|Site Reference ID/Investigator# 56069, Kagoshima, Japan|Site Reference ID/Investigator# 56070, Kagoshima, Japan|Site Reference ID/Investigator# 56077, Kagoshima, Japan|Site Reference ID/Investigator# 56079, Kagoshima, Japan|Site Reference ID/Investigator# 60222, Kagoshima, Japan|Site Reference ID/Investigator# 60377, Kagoshima, Japan|Site Reference ID/Investigator# 60517, Kagoshima, Japan|Site Reference ID/Investigator# 65134, Kagoshima, Japan|Site Reference ID/Investigator# 65135, Kagoshima, Japan|Site Reference ID/Investigator# 94802, Kagoshima, Japan|Site Reference ID/Investigator# 65122, Kaizuka, Japan|Site Reference ID/Investigator# 89831, Kako, Japan|Site Reference ID/Investigator# 48680, Kamakura, Japan|Site Reference ID/Investigator# 49001, Kamogawa, Japan|Site Reference ID/Investigator# 84098, Kamo, Japan|Site Reference ID/Investigator# 55663, Kanagawa, Japan|Site Reference ID/Investigator# 55699, Kanagawa, Japan|Site Reference ID/Investigator# 55802, Kanagawa, Japan|Site Reference ID/Investigator# 55850, Kanagawa, Japan|Site Reference ID/Investigator# 55857, Kanagawa, Japan|Site Reference ID/Investigator# 55859, Kanagawa, Japan|Site Reference ID/Investigator# 55860, Kanagawa, Japan|Site Reference ID/Investigator# 55861, Kanagawa, Japan|Site Reference ID/Investigator# 55862, Kanagawa, Japan|Site Reference ID/Investigator# 55863, Kanagawa, Japan|Site Reference ID/Investigator# 55864, Kanagawa, Japan|Site Reference ID/Investigator# 60415, Kanagawa, Japan|Site Reference ID/Investigator# 60416, Kanagawa, Japan|Site Reference ID/Investigator# 60422, Kanagawa, Japan|Site Reference ID/Investigator# 60504, Kanagawa, Japan|Site Reference ID/Investigator# 60518, Kanagawa, Japan|Site Reference ID/Investigator# 60520, Kanagawa, Japan|Site Reference ID/Investigator# 60521, Kanagawa, Japan|Site Reference ID/Investigator# 60566, Kanagawa, Japan|Site Reference ID/Investigator# 55194, Kanazawa, Japan|Site Reference ID/Investigator# 55600, Kanazawa, Japan|Site Reference ID/Investigator# 55763, Kanazawa, Japan|Site Reference ID/Investigator# 55764, Kanazawa, Japan|Site Reference ID/Investigator# 55853, Kanazawa, Japan|Site Reference ID/Investigator# 79877, Kanazawa, Japan|Site Reference ID/Investigator# 84093, Kanazawa, Japan|Site Reference ID/Investigator# 48695, Kariya, Japan|Site Reference ID/Investigator# 55189, Kashihara, Japan|Site Reference ID/Investigator# 55602, Kashihara, Japan|Site Reference ID/Investigator# 48671, Kashiwa, Japan|Site Reference ID/Investigator# 84114, Kasukabe, Japan|Site Reference ID/Investigator# 84116, Kawachinagano, Japan|Site Reference ID/Investigator# 48704, Kawachinago, Japan|Site Reference ID/Investigator# 48675, Kawagoe, Japan|Site Reference ID/Investigator# 55844, Kawagoe, Japan|Site Reference ID/Investigator# 67154, Kawagoe, Japan|Site Reference ID/Investigator# 60523, Kawanishi, Japan|Site Reference ID/Investigator# 55324, Kawasaki, Japan|Site Reference ID/Investigator# 55843, Kawasaki, Japan|Site Reference ID/Investigator# 55851, Kawasaki, Japan|Site Reference ID/Investigator# 60533, Kawasaki, Japan|Site Reference ID/Investigator# 60542, Kawasaki, Japan|Site Reference ID/Investigator# 79953, Kawasaki, Japan|Site Reference ID/Investigator# 55614, Kikukawa, Japan|Site Reference ID/Investigator# 49095, Kirishima, Japan|Site Reference ID/Investigator# 55823, Kisarazu, Japan|Site Reference ID/Investigator# 48765, Kitakyushu, Japan|Site Reference ID/Investigator# 49077, Kitakyushu, Japan|Site Reference ID/Investigator# 49079, Kitakyushu, Japan|Site Reference ID/Investigator# 49081, Kitakyushu, Japan|Site Reference ID/Investigator# 55618, Kitakyushu, Japan|Site Reference ID/Investigator# 56039, Kitakyushu, Japan|Site Reference ID/Investigator# 60519, Kitakyushu, Japan|Site Reference ID/Investigator# 71473, Kitakyushu, Japan|Site Reference ID/Investigator# 60537, Kitakyusyu, Japan|Site Reference ID/Investigator# 48709, Kobe, Japan|Site Reference ID/Investigator# 55157, Kobe, Japan|Site Reference ID/Investigator# 55573, Kobe, Japan|Site Reference ID/Investigator# 55692, Kobe, Japan|Site Reference ID/Investigator# 55745, Kobe, Japan|Site Reference ID/Investigator# 55747, Kobe, Japan|Site Reference ID/Investigator# 55751, Kobe, Japan|Site Reference ID/Investigator# 48759, Kochi, Japan|Site Reference ID/Investigator# 49072, Kochi, Japan|Site Reference ID/Investigator# 55657, Kochi, Japan|Site Reference ID/Investigator# 55719, Kochi, Japan|Site Reference ID/Investigator# 56027, Kochi, Japan|Site Reference ID/Investigator# 56031, Kochi, Japan|Site Reference ID/Investigator# 56033, Kochi, Japan|Site Reference ID/Investigator# 56034, Kochi, Japan|Site Reference ID/Investigator# 60195, Kochi, Japan|Site Reference ID/Investigator# 60260, Kochi, Japan|Site Reference ID/Investigator# 60264, Kochi, Japan|Site Reference ID/Investigator# 60408, Kochi, Japan|Site Reference ID/Investigator# 55969, Kofu, Japan|Site Reference ID/Investigator# 79875, Kofu, Japan|Site Reference ID/Investigator# 48995, Koga, Japan|Site Reference ID/Investigator# 55924, Komagane, Japan|Site Reference ID/Investigator# 84097, Komaki, Japan|Site Reference ID/Investigator# 55766, Komatsu, Japan|Site Reference ID/Investigator# 55307, Konan, Japan|Site Reference ID/Investigator# 48654, Koriyama, Japan|Site Reference ID/Investigator# 55603, Koriyama, Japan|Site Reference ID/Investigator# 67265, Koriyama, Japan|Site Reference ID/Investigator# 80013, Koriyama, Japan|Site Reference ID/Investigator# 49017, Koshigaya, Japan|Site Reference ID/Investigator# 94800, Koshigaya, Japan|Site Reference ID/Investigator# 56016, Kudamatsu, Japan|Site Reference ID/Investigator# 55904, Kuji, Japan|Site Reference ID/Investigator# 48773, Kumamoto, Japan|Site Reference ID/Investigator# 48774, Kumamoto, Japan|Site Reference ID/Investigator# 48775, Kumamoto, Japan|Site Reference ID/Investigator# 48776, Kumamoto, Japan|Site Reference ID/Investigator# 48781, Kumamoto, Japan|Site Reference ID/Investigator# 49094, Kumamoto, Japan|Site Reference ID/Investigator# 56065, Kumamoto, Japan|Site Reference ID/Investigator# 56066, Kumamoto, Japan|Site Reference ID/Investigator# 56067, Kumamoto, Japan|Site Reference ID/Investigator# 56071, Kumamoto, Japan|Site Reference ID/Investigator# 60220, Kumamoto, Japan|Site Reference ID/Investigator# 60367, Kumamoto, Japan|Site Reference ID/Investigator# 60369, Kumamoto, Japan|Site Reference ID/Investigator# 60382, Kumamoto, Japan|Site Reference ID/Investigator# 60385, Kumamoto, Japan|Site Reference ID/Investigator# 60411, Kumamoto, Japan|Site Reference ID/Investigator# 60427, Kumamoto, Japan|Site Reference ID/Investigator# 60550, Kumamoto, Japan|Site Reference ID/Investigator# 65141, Kumamoto, Japan|Site Reference ID/Investigator# 79894, Kumamoto, Japan|Site Reference ID/Investigator# 79897, Kumamoto, Japan|Site Reference ID/Investigator# 84113, Kumamoto, Japan|Site Reference ID/Investigator# 48748, Kurashiki, Japan|Site Reference ID/Investigator# 55169, Kurashiki, Japan|Site Reference ID/Investigator# 67165, Kurashiki, Japan|Site Reference ID/Investigator# 56006, Kure, Japan|Site Reference ID/Investigator# 55761, Kurobe, Japan|Site Reference ID/Investigator# 48766, Kurume, Japan|Site Reference ID/Investigator# 48768, Kurume, Japan|Site Reference ID/Investigator# 56038, Kurume, Japan|Site Reference ID/Investigator# 55896, Kushiro, Japan|Site Reference ID/Investigator# 55773, Kyoto, Kyoto, Japan|Site Reference ID/Investigator# 49053, Kyoto-city, Japan|Site Reference ID/Investigator# 48745, Kyoto, Japan|Site Reference ID/Investigator# 48746, Kyoto, Japan|Site Reference ID/Investigator# 48747, Kyoto, Japan|Site Reference ID/Investigator# 49051, Kyoto, Japan|Site Reference ID/Investigator# 49054, Kyoto, Japan|Site Reference ID/Investigator# 55322, Kyoto, Japan|Site Reference ID/Investigator# 55577, Kyoto, Japan|Site Reference ID/Investigator# 55587, Kyoto, Japan|Site Reference ID/Investigator# 55661, Kyoto, Japan|Site Reference ID/Investigator# 55718, Kyoto, Japan|Site Reference ID/Investigator# 55772, Kyoto, Japan|Site Reference ID/Investigator# 55774, Kyoto, Japan|Site Reference ID/Investigator# 55775, Kyoto, Japan|Site Reference ID/Investigator# 55776, Kyoto, Japan|Site Reference ID/Investigator# 55828, Kyoto, Japan|Site Reference ID/Investigator# 55829, Kyoto, Japan|Site Reference ID/Investigator# 60213, Kyoto, Japan|Site Reference ID/Investigator# 60381, Kyoto, Japan|Site Reference ID/Investigator# 65102, Kyoto, Japan|Site Reference ID/Investigator# 65108, Kyoto, Japan|Site Reference ID/Investigator# 71470, Kyoto, Japan|Site Reference ID/Investigator# 79893, Kyoto, Japan|Site Reference ID/Investigator# 94801, Kyoto, Japan|Site Reference ID/Investigator# 49044, Machida, Japan|Site Reference ID/Investigator# 55185, Maebashi, Japan|Site Reference ID/Investigator# 55697, Maebashi, Japan|Site Reference ID/Investigator# 55964, Maebashi, Japan|Site Reference ID/Investigator# 71461, Maebashi, Japan|Site Reference ID/Investigator# 84198, Marugame, Japan|Site Reference ID/Investigator# 65147, Matsubushi, Japan|Site Reference ID/Investigator# 55831, Matsudo, Japan|Site Reference ID/Investigator# 55832, Matsudo, Japan|Site Reference ID/Investigator# 55715, Matsue, Japan|Site Reference ID/Investigator# 48780, Matsumoto, Japan|Site Reference ID/Investigator# 55159, Matsumoto, Japan|Site Reference ID/Investigator# 48757, Matsuyama, Japan|Site Reference ID/Investigator# 48758, Matsuyama, Japan|Site Reference ID/Investigator# 49071, Matsuyama, Japan|Site Reference ID/Investigator# 56024, Matsuyama, Japan|Site Reference ID/Investigator# 60553, Matsuyama, Japan|Site Reference ID/Investigator# 90417, Matsuyama, Japan|Site Reference ID/Investigator# 55960, Mibu, Japan|Site Reference ID/Investigator# 55967, Midori, Japan|Site Reference ID/Investigator# 49024, Mie, Japan|Site Reference ID/Investigator# 55632, Mie, Japan|Site Reference ID/Investigator# 55633, Mie, Japan|Site Reference ID/Investigator# 55634, Mie, Japan|Site Reference ID/Investigator# 55635, Mie, Japan|Site Reference ID/Investigator# 55636, Mie, Japan|Site Reference ID/Investigator# 55637, Mie, Japan|Site Reference ID/Investigator# 65119, Mie, Japan|Site Reference ID/Investigator# 80225, Minato, Japan|Site Reference ID/Investigator# 49021, Mishima, Japan|Site Reference ID/Investigator# 55161, Mitaka, Japan|Site Reference ID/Investigator# 55572, Mitaka, Japan|Site Reference ID/Investigator# 48656, Mito, Japan|Site Reference ID/Investigator# 48651, Miyagi, Japan|Site Reference ID/Investigator# 48653, Miyagi, Japan|Site Reference ID/Investigator# 48655, Miyagi, Japan|Site Reference ID/Investigator# 55917, Miyagi, Japan|Site Reference ID/Investigator# 55918, Miyagi, Japan|Site Reference ID/Investigator# 55929, Miyagi, Japan|Site Reference ID/Investigator# 55930, Miyagi, Japan|Site Reference ID/Investigator# 55931, Miyagi, Japan|Site Reference ID/Investigator# 55932, Miyagi, Japan|Site Reference ID/Investigator# 55942, Miyagi, Japan|Site Reference ID/Investigator# 55943, Miyagi, Japan|Site Reference ID/Investigator# 60207, Miyagi, Japan|Site Reference ID/Investigator# 60208, Miyagi, Japan|Site Reference ID/Investigator# 60379, Miyagi, Japan|Site Reference ID/Investigator# 60384, Miyagi, Japan|Site Reference ID/Investigator# 60561, Miyagi, Japan|Site Reference ID/Investigator# 65150, Miyagi, Japan|Site Reference ID/Investigator# 67161, Miyagi, Japan|Site Reference ID/Investigator# 67164, Miyagi, Japan|Site Reference ID/Investigator# 56055, Miyazaki, Japan|Site Reference ID/Investigator# 56060, Miyazaki, Japan|Site Reference ID/Investigator# 56061, Miyazaki, Japan|Site Reference ID/Investigator# 56063, Miyazaki, Japan|Site Reference ID/Investigator# 56064, Miyazaki, Japan|Site Reference ID/Investigator# 80033, Miyazaki, Japan|Site Reference ID/Investigator# 89837, Monbetsu, Japan|Site Reference ID/Investigator# 49032, Moriguchi, Japan|Site Reference ID/Investigator# 48649, Morioka, Japan|Site Reference ID/Investigator# 89823, Morioka, Japan|Site Reference ID/Investigator# 89835, Morioka, Japan|Site Reference ID/Investigator# 90414, Morioka, Japan|Site Reference ID/Investigator# 55983, Moriyama, Japan|Site Reference ID/Investigator# 89819, Moriya, Japan|Site Reference ID/Investigator# 60535, Munakata, Japan|Site Reference ID/Investigator# 55890, Muroran, Japan|Site Reference ID/Investigator# 90399, Muroran, Japan|Site Reference ID/Investigator# 60532, Musashino, Japan|Site Reference ID/Investigator# 55586, Nagahama, Japan|Site Reference ID/Investigator# 48685, Nagakute, Japan|Site Reference ID/Investigator# 55707, Nagano, Japan|Site Reference ID/Investigator# 55708, Nagano, Japan|Site Reference ID/Investigator# 55921, Nagano, Japan|Site Reference ID/Investigator# 55922, Nagano, Japan|Site Reference ID/Investigator# 55923, Nagano, Japan|Site Reference ID/Investigator# 60507, Nagano, Japan|Site Reference ID/Investigator# 60564, Nagano, Japan|Site Reference ID/Investigator# 48989, Nagaoka, Japan|Site Reference ID/Investigator# 55582, Nagaoka, Japan|Site Reference ID/Investigator# 80235, Nagareyama, Japan|Site Reference ID/Investigator# 48769, Nagasaki, Japan|Site Reference ID/Investigator# 48770, Nagasaki, Japan|Site Reference ID/Investigator# 48782, Nagasaki, Japan|Site Reference ID/Investigator# 49082, Nagasaki, Japan|Site Reference ID/Investigator# 55866, Nagasaki, Japan|Site Reference ID/Investigator# 56053, Nagasaki, Japan|Site Reference ID/Investigator# 56058, Nagasaki, Japan|Site Reference ID/Investigator# 60211, Nagasaki, Japan|Site Reference ID/Investigator# 60217, Nagasaki, Japan|Site Reference ID/Investigator# 60252, Nagasaki, Japan|Site Reference ID/Investigator# 60266, Nagasaki, Japan|Site Reference ID/Investigator# 60545, Nagasaki, Japan|Site Reference ID/Investigator# 65132, Nagasaki, Japan|Site Reference ID/Investigator# 65133, Nagasaki, Japan|Site Reference ID/Investigator# 79873, Nagasaki, Japan|Site Reference ID/Investigator# 94799, Nagasaki, Japan|Site Reference ID/Investigator# 56011, Nagato, Japan|Site Reference ID/Investigator# 48683, Nagoya, Japan|Site Reference ID/Investigator# 48684, Nagoya, Japan|Site Reference ID/Investigator# 48692, Nagoya, Japan|Site Reference ID/Investigator# 55608, Nagoya, Japan|Site Reference ID/Investigator# 55800, Nagoya, Japan|Site Reference ID/Investigator# 60199, Nagoya, Japan|Site Reference ID/Investigator# 65107, Nagoya, Japan|Site Reference ID/Investigator# 71463, Nagoya, Japan|Site Reference ID/Investigator# 71466, Nagoya, Japan|Site Reference ID/Investigator# 80223, Nagoya, Japan|Site Reference ID/Investigator# 84115, Nagoya, Japan|Site Reference ID/Investigator# 89826, Nagoya, Japan|Site Reference ID/Investigator# 89828, Nagoya, Japan|Site Reference ID/Investigator# 94892, Nagoya, Japan|Site Reference ID/Investigator# 71468, Naha, Japan|Site Reference ID/Investigator# 55783, Nankoku, Japan|Site Reference ID/Investigator# 89860, Nankoku, Japan|Site Reference ID/Investigator# 48669, Narashino, Japan|Site Reference ID/Investigator# 55701, Narashino, Japan|Site Reference ID/Investigator# 55680, Nara, Japan|Site Reference ID/Investigator# 55681, Nara, Japan|Site Reference ID/Investigator# 55682, Nara, Japan|Site Reference ID/Investigator# 55683, Nara, Japan|Site Reference ID/Investigator# 55684, Nara, Japan|Site Reference ID/Investigator# 94889, Nara, Japan|Site Reference ID/Investigator# 55788, Narita, Japan|Site Reference ID/Investigator# 79898, Nasushiobara, Japan|Site Reference ID/Investigator# 60421, Neyagawa, Japan|Site Reference ID/Investigator# 48983, Niigata, Japan|Site Reference ID/Investigator# 48985, Niigata, Japan|Site Reference ID/Investigator# 48987, Niigata, Japan|Site Reference ID/Investigator# 48988, Niigata, Japan|Site Reference ID/Investigator# 48990, Niigata, Japan|Site Reference ID/Investigator# 49025, Niigata, Japan|Site Reference ID/Investigator# 55158, Niigata, Japan|Site Reference ID/Investigator# 55320, Niigata, Japan|Site Reference ID/Investigator# 55619, Niigata, Japan|Site Reference ID/Investigator# 55646, Niigata, Japan|Site Reference ID/Investigator# 55952, Niigata, Japan|Site Reference ID/Investigator# 55953, Niigata, Japan|Site Reference ID/Investigator# 65112, Niigata, Japan|Site Reference ID/Investigator# 49096, Nishihara, Japan|Site Reference ID/Investigator# 48711, Nishinomiya, Japan|Site Reference ID/Investigator# 48785, Nishinomiya, Japan|Site Reference ID/Investigator# 48786, Nishinomiya, Japan|Site Reference ID/Investigator# 55803, Nishinomiya, Japan|Site Reference ID/Investigator# 65124, Nishinomiya, Japan|Site Reference ID/Investigator# 67160, Nishitokyo, Japan|Site Reference ID/Investigator# 71471, Nobeoka, Japan|Site Reference ID/Investigator# 84094, Nomi, Japan|Site Reference ID/Investigator# 90394, Numata, Japan|Site Reference ID/Investigator# 48794, Obihiro, Japan|Site Reference ID/Investigator# 94894, Obihiro, Japan|Site Reference ID/Investigator# 55187, Odawara, Japan|Site Reference ID/Investigator# 89853, Ofunato, Japan|Site Reference ID/Investigator# 48696, Ogaki, Japan|Site Reference ID/Investigator# 48772, Oita, Japan|Site Reference ID/Investigator# 49087, Oita, Japan|Site Reference ID/Investigator# 49088, Oita, Japan|Site Reference ID/Investigator# 49089, Oita, Japan|Site Reference ID/Investigator# 49090, Oita, Japan|Site Reference ID/Investigator# 49093, Oita, Japan|Site Reference ID/Investigator# 55607, Oita, Japan|Site Reference ID/Investigator# 56054, Oita, Japan|Site Reference ID/Investigator# 56056, Oita, Japan|Site Reference ID/Investigator# 56059, Oita, Japan|Site Reference ID/Investigator# 56062, Oita, Japan|Site Reference ID/Investigator# 60206, Oita, Japan|Site Reference ID/Investigator# 60410, Oita, Japan|Site Reference ID/Investigator# 67163, Oita, Japan|Site Reference ID/Investigator# 68636, Oita, Japan|Site Reference ID/Investigator# 89836, Oita, Japan|Site Reference ID/Investigator# 48749, Okayama, Japan|Site Reference ID/Investigator# 49055, Okayama, Japan|Site Reference ID/Investigator# 49056, Okayama, Japan|Site Reference ID/Investigator# 49059, Okayama, Japan|Site Reference ID/Investigator# 55984, Okayama, Japan|Site Reference ID/Investigator# 55988, Okayama, Japan|Site Reference ID/Investigator# 55989, Okayama, Japan|Site Reference ID/Investigator# 55990, Okayama, Japan|Site Reference ID/Investigator# 55991, Okayama, Japan|Site Reference ID/Investigator# 55992, Okayama, Japan|Site Reference ID/Investigator# 55995, Okayama, Japan|Site Reference ID/Investigator# 60390, Okayama, Japan|Site Reference ID/Investigator# 60527, Okayama, Japan|Site Reference ID/Investigator# 60529, Okayama, Japan|Site Reference ID/Investigator# 65127, Okayama, Japan|Site Reference ID/Investigator# 89822, Okayama, Japan|Site Reference ID/Investigator# 90398, Okayama, Japan|Site Reference ID/Investigator# 49097, Okinawa, Japan|Site Reference ID/Investigator# 55702, Okinawa, Japan|Site Reference ID/Investigator# 56072, Okinawa, Japan|Site Reference ID/Investigator# 56074, Okinawa, Japan|Site Reference ID/Investigator# 56075, Okinawa, Japan|Site Reference ID/Investigator# 56076, Okinawa, Japan|Site Reference ID/Investigator# 56078, Okinawa, Japan|Site Reference ID/Investigator# 56080, Okinawa, Japan|Site Reference ID/Investigator# 56081, Okinawa, Japan|Site Reference ID/Investigator# 60255, Okinawa, Japan|Site Reference ID/Investigator# 60268, Okinawa, Japan|Site Reference ID/Investigator# 60393, Okinawa, Japan|Site Reference ID/Investigator# 60420, Okinawa, Japan|Site Reference ID/Investigator# 60548, Okinawa, Japan|Site Reference ID/Investigator# 65136, Okinawa, Japan|Site Reference ID/Investigator# 65137, Okinawa, Japan|Site Reference ID/Investigator# 55819, Ome, Japan|Site Reference ID/Investigator# 79899, Omuta, Japan|Site Reference ID/Investigator# 79933, Omuta, Japan|Site Reference ID/Investigator# 89855, Omuta, Japan|Site Reference ID/Investigator# 48705, Osakasayama, Japan|Site Reference ID/Investigator# 48700, Osaka, Japan|Site Reference ID/Investigator# 48701, Osaka, Japan|Site Reference ID/Investigator# 48702, Osaka, Japan|Site Reference ID/Investigator# 48703, Osaka, Japan|Site Reference ID/Investigator# 48706, Osaka, Japan|Site Reference ID/Investigator# 49027, Osaka, Japan|Site Reference ID/Investigator# 49029, Osaka, Japan|Site Reference ID/Investigator# 49030, Osaka, Japan|Site Reference ID/Investigator# 49031, Osaka, Japan|Site Reference ID/Investigator# 49033, Osaka, Japan|Site Reference ID/Investigator# 49034, Osaka, Japan|Site Reference ID/Investigator# 49035, Osaka, Japan|Site Reference ID/Investigator# 49036, Osaka, Japan|Site Reference ID/Investigator# 49037, Osaka, Japan|Site Reference ID/Investigator# 55174, Osaka, Japan|Site Reference ID/Investigator# 55321, Osaka, Japan|Site Reference ID/Investigator# 55578, Osaka, Japan|Site Reference ID/Investigator# 55592, Osaka, Japan|Site Reference ID/Investigator# 55649, Osaka, Japan|Site Reference ID/Investigator# 55651, Osaka, Japan|Site Reference ID/Investigator# 55652, Osaka, Japan|Site Reference ID/Investigator# 55653, Osaka, Japan|Site Reference ID/Investigator# 55654, Osaka, Japan|Site Reference ID/Investigator# 55655, Osaka, Japan|Site Reference ID/Investigator# 55656, Osaka, Japan|Site Reference ID/Investigator# 55666, Osaka, Japan|Site Reference ID/Investigator# 55667, Osaka, Japan|Site Reference ID/Investigator# 55668, Osaka, Japan|Site Reference ID/Investigator# 55669, Osaka, Japan|Site Reference ID/Investigator# 55670, Osaka, Japan|Site Reference ID/Investigator# 55671, Osaka, Japan|Site Reference ID/Investigator# 55672, Osaka, Japan|Site Reference ID/Investigator# 55674, Osaka, Japan|Site Reference ID/Investigator# 55675, Osaka, Japan|Site Reference ID/Investigator# 55678, Osaka, Japan|Site Reference ID/Investigator# 55706, Osaka, Japan|Site Reference ID/Investigator# 55712, Osaka, Japan|Site Reference ID/Investigator# 55717, Osaka, Japan|Site Reference ID/Investigator# 60194, Osaka, Japan|Site Reference ID/Investigator# 60204, Osaka, Japan|Site Reference ID/Investigator# 60243, Osaka, Japan|Site Reference ID/Investigator# 60366, Osaka, Japan|Site Reference ID/Investigator# 60383, Osaka, Japan|Site Reference ID/Investigator# 60505, Osaka, Japan|Site Reference ID/Investigator# 60539, Osaka, Japan|Site Reference ID/Investigator# 60544, Osaka, Japan|Site Reference ID/Investigator# 60546, Osaka, Japan|Site Reference ID/Investigator# 60549, Osaka, Japan|Site Reference ID/Investigator# 60565, Osaka, Japan|Site Reference ID/Investigator# 65104, Osaka, Japan|Site Reference ID/Investigator# 65120, Osaka, Japan|Site Reference ID/Investigator# 65121, Osaka, Japan|Site Reference ID/Investigator# 67167, Osaka, Japan|Site Reference ID/Investigator# 67168, Osaka, Japan|Site Reference ID/Investigator# 79913, Osaka, Japan|Site Reference ID/Investigator# 89815, Osaka, Japan|Site Reference ID/Investigator# 90373, Osaka, Japan|Site Reference ID/Investigator# 48986, Osaki, Japan|Site Reference ID/Investigator# 60247, Ota-ku, Tokyo, Japan|Site Reference ID/Investigator# 49057, Otsu, Japan|Site Reference ID/Investigator# 55664, Otsu, Japan|Site Reference ID/Investigator# 55985, Otsu, Japan|Site Reference ID/Investigator# 60522, Otsu, Japan|Site Reference ID/Investigator# 89829, Sabae, Japan|Site Reference ID/Investigator# 48679, Sagamihara, Japan|Site Reference ID/Investigator# 55840, Sagamihara, Japan|Site Reference ID/Investigator# 49085, Saga, Japan|Site Reference ID/Investigator# 56045, Saga, Japan|Site Reference ID/Investigator# 56046, Saga, Japan|Site Reference ID/Investigator# 56047, Saga, Japan|Site Reference ID/Investigator# 56049, Saga, Japan|Site Reference ID/Investigator# 56050, Saga, Japan|Site Reference ID/Investigator# 56051, Saga, Japan|Site Reference ID/Investigator# 60396, Saga, Japan|Site Reference ID/Investigator# 60503, Saga, Japan|Site Reference ID/Investigator# 48673, Saitama, Japan|Site Reference ID/Investigator# 48674, Saitama, Japan|Site Reference ID/Investigator# 48676, Saitama, Japan|Site Reference ID/Investigator# 49014, Saitama, Japan|Site Reference ID/Investigator# 55323, Saitama, Japan|Site Reference ID/Investigator# 55606, Saitama, Japan|Site Reference ID/Investigator# 55833, Saitama, Japan|Site Reference ID/Investigator# 55834, Saitama, Japan|Site Reference ID/Investigator# 55835, Saitama, Japan|Site Reference ID/Investigator# 55836, Saitama, Japan|Site Reference ID/Investigator# 55838, Saitama, Japan|Site Reference ID/Investigator# 55839, Saitama, Japan|Site Reference ID/Investigator# 55845, Saitama, Japan|Site Reference ID/Investigator# 55846, Saitama, Japan|Site Reference ID/Investigator# 55847, Saitama, Japan|Site Reference ID/Investigator# 55848, Saitama, Japan|Site Reference ID/Investigator# 55849, Saitama, Japan|Site Reference ID/Investigator# 60197, Saitama, Japan|Site Reference ID/Investigator# 60419, Saitama, Japan|Site Reference ID/Investigator# 60526, Saitama, Japan|Site Reference ID/Investigator# 60534, Saitama, Japan|Site Reference ID/Investigator# 60541, Saitama, Japan|Site Reference ID/Investigator# 65118, Saitama, Japan|Site Reference ID/Investigator# 65149, Saitama, Japan|Site Reference ID/Investigator# 71472, Saitama, Japan|Site Reference ID/Investigator# 80221, Sakaide, Japan|Site Reference ID/Investigator# 89861, Sakaide, Japan|Site Reference ID/Investigator# 55308, Sakai, Japan|Site Reference ID/Investigator# 55676, Sakai, Japan|Site Reference ID/Investigator# 55677, Sakai, Japan|Site Reference ID/Investigator# 60512, Sakai, Japan|Site Reference ID/Investigator# 71469, Sakai, Japan|Site Reference ID/Investigator# 48666, Sakura, Japan|Site Reference ID/Investigator# 48993, Saku, Japan|Site Reference ID/Investigator# 56023, Sanuki, Japan|Site Reference ID/Investigator# 47382, Sapporo, Japan|Site Reference ID/Investigator# 48642, Sapporo, Japan|Site Reference ID/Investigator# 48787, Sapporo, Japan|Site Reference ID/Investigator# 48789, Sapporo, Japan|Site Reference ID/Investigator# 48790, Sapporo, Japan|Site Reference ID/Investigator# 55713, Sapporo, Japan|Site Reference ID/Investigator# 55868, Sapporo, Japan|Site Reference ID/Investigator# 55879, Sapporo, Japan|Site Reference ID/Investigator# 55884, Sapporo, Japan|Site Reference ID/Investigator# 79956, Sapporo, Japan|Site Reference ID/Investigator# 89816, Sapporo, Japan|Site Reference ID/Investigator# 90393, Sapporo, Japan|Site Reference ID/Investigator# 92733, Sapporo, Japan|Site Reference ID/Investigator# 92734, Sapporo, Japan|Site Reference ID/Investigator# 89833, Sasayama, Japan|Site Reference ID/Investigator# 48771, Sasebo, Japan|Site Reference ID/Investigator# 48982, Sendai, Japan|Site Reference ID/Investigator# 55175, Sendai, Japan|Site Reference ID/Investigator# 55176, Sendai, Japan|Site Reference ID/Investigator# 55919, Sendai, Japan|Site Reference ID/Investigator# 79895, Sendai, Japan|Site Reference ID/Investigator# 89824, Sendai, Japan|Site Reference ID/Investigator# 60516, Setouchi, Japan|Site Reference ID/Investigator# 60256, Seto, Japan|Site Reference ID/Investigator# 55662, Shiga, Japan|Site Reference ID/Investigator# 55982, Shiga, Japan|Site Reference ID/Investigator# 55986, Shiga, Japan|Site Reference ID/Investigator# 55987, Shiga, Japan|Site Reference ID/Investigator# 60200, Shiga, Japan|Site Reference ID/Investigator# 60250, Shiga, Japan|Site Reference ID/Investigator# 60409, Shiga, Japan|Site Reference ID/Investigator# 94895, Shimada, Japan|Site Reference ID/Investigator# 55721, Shimane, Japan|Site Reference ID/Investigator# 60209, Shimane, Japan|Site Reference ID/Investigator# 60218, Shimane, Japan|Site Reference ID/Investigator# 65128, Shimane, Japan|Site Reference ID/Investigator# 65145, Shimane, Japan|Site Reference ID/Investigator# 89830, Shimizu, Japan|Site Reference ID/Investigator# 55962, Shimotsuke-shi, Tochigi, Japan|Site Reference ID/Investigator# 48687, Shizuoka, Japan|Site Reference ID/Investigator# 49009, Shizuoka, Japan|Site Reference ID/Investigator# 49012, Shizuoka, Japan|Site Reference ID/Investigator# 55579, Shizuoka, Japan|Site Reference ID/Investigator# 55589, Shizuoka, Japan|Site Reference ID/Investigator# 55609, Shizuoka, Japan|Site Reference ID/Investigator# 55610, Shizuoka, Japan|Site Reference ID/Investigator# 55611, Shizuoka, Japan|Site Reference ID/Investigator# 55881, Shizuoka, Japan|Site Reference ID/Investigator# 55883, Shizuoka, Japan|Site Reference ID/Investigator# 60212, Shizuoka, Japan|Site Reference ID/Investigator# 60374, Shizuoka, Japan|Site Reference ID/Investigator# 60400, Shizuoka, Japan|Site Reference ID/Investigator# 60406, Shizuoka, Japan|Site Reference ID/Investigator# 60418, Shizuoka, Japan|Site Reference ID/Investigator# 65153, Shizuoka, Japan|Site Reference ID/Investigator# 89821, Shizuoka, Japan|Site Reference ID/Investigator# 48753, Shunan, Japan|Site Reference ID/Investigator# 55837, Soka, Japan|Site Reference ID/Investigator# 89854, Soka, Japan|Site Reference ID/Investigator# 55590, Suita, Japan|Site Reference ID/Investigator# 60365, Suita, Japan|Site Reference ID/Investigator# 68635, Suwa, Japan|Site Reference ID/Investigator# 90397, Suzuka, Japan|Site Reference ID/Investigator# 48698, Tajimi, Japan|Site Reference ID/Investigator# 48756, Takamatsu, Japan|Site Reference ID/Investigator# 55173, Takamatsu, Japan|Site Reference ID/Investigator# 55172, Takarazuka, Japan|Site Reference ID/Investigator# 89862, Takarazuka, Japan|Site Reference ID/Investigator# 60372, Takasaki, Japan|Site Reference ID/Investigator# 90395, Takasaki, Japan|Site Reference ID/Investigator# 49028, Takatsuki, Japan|Site Reference ID/Investigator# 55165, Takatsuki, Japan|Site Reference ID/Investigator# 55648, Takatsuki, Japan|Site Reference ID/Investigator# 55166, Tenri, Japan|Site Reference ID/Investigator# 89863, Tenri, Japan|Site Reference ID/Investigator# 55659, Tochigi, Japan|Site Reference ID/Investigator# 55961, Tochigi, Japan|Site Reference ID/Investigator# 60254, Tochigi, Japan|Site Reference ID/Investigator# 60265, Tochigi, Japan|Site Reference ID/Investigator# 60562, Tochigi, Japan|Site Reference ID/Investigator# 67170, Tochigi, Japan|Site Reference ID/Investigator# 68643, Tochigi, Japan|Site Reference ID/Investigator# 55628, Toki, Japan|Site Reference ID/Investigator# 49073, Tokushima, Japan|Site Reference ID/Investigator# 55314, Tokushima, Japan|Site Reference ID/Investigator# 55580, Tokushima, Japan|Site Reference ID/Investigator# 56028, Tokushima, Japan|Site Reference ID/Investigator# 56029, Tokushima, Japan|Site Reference ID/Investigator# 71465, Tokushima, Japan|Site Reference ID/Investigator# 48658, Tokyo, Japan|Site Reference ID/Investigator# 48659, Tokyo, Japan|Site Reference ID/Investigator# 48660, Tokyo, Japan|Site Reference ID/Investigator# 48661, Tokyo, Japan|Site Reference ID/Investigator# 48662, Tokyo, Japan|Site Reference ID/Investigator# 48663, Tokyo, Japan|Site Reference ID/Investigator# 48664, Tokyo, Japan|Site Reference ID/Investigator# 48665, Tokyo, Japan|Site Reference ID/Investigator# 48783, Tokyo, Japan|Site Reference ID/Investigator# 48992, Tokyo, Japan|Site Reference ID/Investigator# 48996, Tokyo, Japan|Site Reference ID/Investigator# 48997, Tokyo, Japan|Site Reference ID/Investigator# 48999, Tokyo, Japan|Site Reference ID/Investigator# 49003, Tokyo, Japan|Site Reference ID/Investigator# 49004, Tokyo, Japan|Site Reference ID/Investigator# 49005, Tokyo, Japan|Site Reference ID/Investigator# 49007, Tokyo, Japan|Site Reference ID/Investigator# 55168, Tokyo, Japan|Site Reference ID/Investigator# 55170, Tokyo, Japan|Site Reference ID/Investigator# 55191, Tokyo, Japan|Site Reference ID/Investigator# 55306, Tokyo, Japan|Site Reference ID/Investigator# 55318, Tokyo, Japan|Site Reference ID/Investigator# 55575, Tokyo, Japan|Site Reference ID/Investigator# 55576, Tokyo, Japan|Site Reference ID/Investigator# 55594, Tokyo, Japan|Site Reference ID/Investigator# 55595, Tokyo, Japan|Site Reference ID/Investigator# 55598, Tokyo, Japan|Site Reference ID/Investigator# 55604, Tokyo, Japan|Site Reference ID/Investigator# 55695, Tokyo, Japan|Site Reference ID/Investigator# 55698, Tokyo, Japan|Site Reference ID/Investigator# 55711, Tokyo, Japan|Site Reference ID/Investigator# 55714, Tokyo, Japan|Site Reference ID/Investigator# 55722, Tokyo, Japan|Site Reference ID/Investigator# 55784, Tokyo, Japan|Site Reference ID/Investigator# 55786, Tokyo, Japan|Site Reference ID/Investigator# 55787, Tokyo, Japan|Site Reference ID/Investigator# 55792, Tokyo, Japan|Site Reference ID/Investigator# 55795, Tokyo, Japan|Site Reference ID/Investigator# 55799, Tokyo, Japan|Site Reference ID/Investigator# 55854, Tokyo, Japan|Site Reference ID/Investigator# 55867, Tokyo, Japan|Site Reference ID/Investigator# 55925, Tokyo, Japan|Site Reference ID/Investigator# 55926, Tokyo, Japan|Site Reference ID/Investigator# 55927, Tokyo, Japan|Site Reference ID/Investigator# 55928, Tokyo, Japan|Site Reference ID/Investigator# 55933, Tokyo, Japan|Site Reference ID/Investigator# 55934, Tokyo, Japan|Site Reference ID/Investigator# 55935, Tokyo, Japan|Site Reference ID/Investigator# 55936, Tokyo, Japan|Site Reference ID/Investigator# 55937, Tokyo, Japan|Site Reference ID/Investigator# 55938, Tokyo, Japan|Site Reference ID/Investigator# 55939, Tokyo, Japan|Site Reference ID/Investigator# 55940, Tokyo, Japan|Site Reference ID/Investigator# 55941, Tokyo, Japan|Site Reference ID/Investigator# 55944, Tokyo, Japan|Site Reference ID/Investigator# 55945, Tokyo, Japan|Site Reference ID/Investigator# 60198, Tokyo, Japan|Site Reference ID/Investigator# 60245, Tokyo, Japan|Site Reference ID/Investigator# 60370, Tokyo, Japan|Site Reference ID/Investigator# 60392, Tokyo, Japan|Site Reference ID/Investigator# 60404, Tokyo, Japan|Site Reference ID/Investigator# 60417, Tokyo, Japan|Site Reference ID/Investigator# 60425, Tokyo, Japan|Site Reference ID/Investigator# 60511, Tokyo, Japan|Site Reference ID/Investigator# 60514, Tokyo, Japan|Site Reference ID/Investigator# 60536, Tokyo, Japan|Site Reference ID/Investigator# 60543, Tokyo, Japan|Site Reference ID/Investigator# 60547, Tokyo, Japan|Site Reference ID/Investigator# 65103, Tokyo, Japan|Site Reference ID/Investigator# 65106, Tokyo, Japan|Site Reference ID/Investigator# 65113, Tokyo, Japan|Site Reference ID/Investigator# 65114, Tokyo, Japan|Site Reference ID/Investigator# 65139, Tokyo, Japan|Site Reference ID/Investigator# 65142, Tokyo, Japan|Site Reference ID/Investigator# 68634, Tokyo, Japan|Site Reference ID/Investigator# 68642, Tokyo, Japan|Site Reference ID/Investigator# 71462, Tokyo, Japan|Site Reference ID/Investigator# 71464, Tokyo, Japan|Site Reference ID/Investigator# 80224, Tokyo, Japan|Site Reference ID/Investigator# 84096, Tokyo, Japan|Site Reference ID/Investigator# 89814, Tokyo, Japan|Site Reference ID/Investigator# 89857, Tokyo, Japan|Site Reference ID/Investigator# 89874, Tokyo, Japan|Site Reference ID/Investigator# 48791, Tomakomai, Japan|Site Reference ID/Investigator# 56073, Tomigusuku, Japan|Site Reference ID/Investigator# 48742, Tonami, Japan|Site Reference ID/Investigator# 79934, Tono, Japan|Site Reference ID/Investigator# 49075, Toon, Japan|Site Reference ID/Investigator# 67166, Toshigi, Japan|Site Reference ID/Investigator# 48750, Tottori, Japan|Site Reference ID/Investigator# 55658, Tottori, Japan|Site Reference ID/Investigator# 55993, Tottori, Japan|Site Reference ID/Investigator# 55994, Tottori, Japan|Site Reference ID/Investigator# 55996, Tottori, Japan|Site Reference ID/Investigator# 55999, Tottori, Japan|Site Reference ID/Investigator# 48743, Toyama, Japan|Site Reference ID/Investigator# 49049, Toyama, Japan|Site Reference ID/Investigator# 55171, Toyama, Japan|Site Reference ID/Investigator# 55309, Toyama, Japan|Site Reference ID/Investigator# 55760, Toyama, Japan|Site Reference ID/Investigator# 55762, Toyama, Japan|Site Reference ID/Investigator# 60373, Toyama, Japan|Site Reference ID/Investigator# 60395, Toyama, Japan|Site Reference ID/Investigator# 60405, Toyama, Japan|Site Reference ID/Investigator# 49010, Toyoake, Japan|Site Reference ID/Investigator# 49023, Toyohashi, Japan|Site Reference ID/Investigator# 94888, Toyokawa, Japan|Site Reference ID/Investigator# 55754, Toyooka, Japan|Site Reference ID/Investigator# 89838, Toyooka, Japan|Site Reference ID/Investigator# 48694, Toyota, Japan|Site Reference ID/Investigator# 49018, Toyota, Japan|Site Reference ID/Investigator# 55710, Toyota, Japan|Site Reference ID/Investigator# 65140, Toyota, Japan|Site Reference ID/Investigator# 68640, Tsuchiura, Japan|Site Reference ID/Investigator# 55956, Tsukuba, Japan|Site Reference ID/Investigator# 60397, Tsuruga, Japan|Site Reference ID/Investigator# 89859, Tsuruoka, Japan|Site Reference ID/Investigator# 55630, Tsu, Japan|Site Reference ID/Investigator# 55631, Tsu, Japan|Site Reference ID/Investigator# 89818, Tsu, Japan|Site Reference ID/Investigator# 55777, Uji, Japan|Site Reference ID/Investigator# 55167, Urayasu, Japan|Site Reference ID/Investigator# 89825, Usa, Japan|Site Reference ID/Investigator# 79879, Ushiku, Japan|Site Reference ID/Investigator# 55830, Utsunomiya, Japan|Site Reference ID/Investigator# 94890, Utsunomiya, Japan|Site Reference ID/Investigator# 49045, Wakayama, Japan|Site Reference ID/Investigator# 49050, Wakayama, Japan|Site Reference ID/Investigator# 55686, Wakayama, Japan|Site Reference ID/Investigator# 55687, Wakayama, Japan|Site Reference ID/Investigator# 55688, Wakayama, Japan|Site Reference ID/Investigator# 55689, Wakayama, Japan|Site Reference ID/Investigator# 55690, Wakayama, Japan|Site Reference ID/Investigator# 55696, Wakayama, Japan|Site Reference ID/Investigator# 60371, Wakayama, Japan|Site Reference ID/Investigator# 60391, Wakayama, Japan|Site Reference ID/Investigator# 60525, Wakayama, Japan|Site Reference ID/Investigator# 60551, Wakayama, Japan|Site Reference ID/Investigator# 65123, Wakayama, Japan|Site Reference ID/Investigator# 67155, Wakayama, Japan|Site Reference ID/Investigator# 48670, Yachiyo, Japan|Site Reference ID/Investigator# 55910, Yamagata, Japan|Site Reference ID/Investigator# 55911, Yamagata, Japan|Site Reference ID/Investigator# 55915, Yamagata, Japan|Site Reference ID/Investigator# 55916, Yamagata, Japan|Site Reference ID/Investigator# 60219, Yamagata, Japan|Site Reference ID/Investigator# 60267, Yamagata, Japan|Site Reference ID/Investigator# 60403, Yamagata, Japan|Site Reference ID/Investigator# 65154, Yamagata, Japan|Site Reference ID/Investigator# 94803, Yamagata, Japan|Site Reference ID/Investigator# 48752, Yamaguchi, Japan|Site Reference ID/Investigator# 48754, Yamaguchi, Japan|Site Reference ID/Investigator# 49065, Yamaguchi, Japan|Site Reference ID/Investigator# 49066, Yamaguchi, Japan|Site Reference ID/Investigator# 49067, Yamaguchi, Japan|Site Reference ID/Investigator# 55591, Yamaguchi, Japan|Site Reference ID/Investigator# 55700, Yamaguchi, Japan|Site Reference ID/Investigator# 56009, Yamaguchi, Japan|Site Reference ID/Investigator# 56012, Yamaguchi, Japan|Site Reference ID/Investigator# 56013, Yamaguchi, Japan|Site Reference ID/Investigator# 56015, Yamaguchi, Japan|Site Reference ID/Investigator# 60515, Yamaguchi, Japan|Site Reference ID/Investigator# 94891, Yamatokoriyama, Japan|Site Reference ID/Investigator# 55679, Yamatotakada, Japan|Site Reference ID/Investigator# 79896, Yanagawa, Japan|Site Reference ID/Investigator# 80217, Yanagawa, Japan|Site Reference ID/Investigator# 60202, Yatomi, Japan|Site Reference ID/Investigator# 79874, Yatsushiro, Japan|Site Reference ID/Investigator# 48699, Yokkaichi, Japan|Site Reference ID/Investigator# 48677, Yokohama, Japan|Site Reference ID/Investigator# 48678, Yokohama, Japan|Site Reference ID/Investigator# 55160, Yokohama, Japan|Site Reference ID/Investigator# 55310, Yokohama, Japan|Site Reference ID/Investigator# 55852, Yokohama, Japan|Site Reference ID/Investigator# 55856, Yokohama, Japan|Site Reference ID/Investigator# 55858, Yokohama, Japan|Site Reference ID/Investigator# 60399, Yokohama, Japan|Site Reference ID/Investigator# 60506, Yokohama, Japan|Site Reference ID/Investigator# 65152, Yokohama, Japan|Site Reference ID/Investigator# 79954, Yokohama, Japan|Site Reference ID/Investigator# 89832, Yokohama, Japan|Site Reference ID/Investigator# 90400, Yokohama, Japan|Site Reference ID/Investigator# 60424, Yokosuka, Japan|Site Reference ID/Investigator# 80218, Yokote, Japan|Site Reference ID/Investigator# 49058, Yonago, Japan|Site Reference ID/Investigator# 55709, Yonago, Japan|Site Reference ID/Investigator# 55998, Yonago, Japan|Site Reference ID/Investigator# 56057, Yufu, Japan",,"https://ClinicalTrials.gov/show/NCT01298648"
548,"NCT01297504","A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America",,"Completed","Has Results","Respiratory Syncytial Virus Infection",,"Characterization of Participants With Risk Factors for Respiratory Syncytial Virus (RSV) Infection|Distribution of Comorbidities in Study Participants|Number of Participants With Hospitalizations for Lower Respiratory Tract Infection and RSV|Characterization of Hospitalization Episodes Due to Lower Respiratory Tract Infection and RSV|Risk Factors for Hospitalization|Compliance to Prescribed Palivizumab|Mean Number of Doses of Palivizumab Administered","AbbVie (prior sponsor, Abbott)|Fundasamin (Argentina)|AbbVie","All","up to 2 Years   (Child)",,"464","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P10-129","February 2011","August 2013","August 2013","February 16, 2011","September 3, 2014","October 1, 2014","Site Reference ID/Investigator# 52185, Buenos Aires, Argentina|Site Reference ID/Investigator# 52182, Buenos Aires, Argentina|Site Reference ID/Investigator# 52183, Buenos Aires, Argentina|Site Reference ID/Investigator# 52184, Buenos Aires, Argentina|Site Reference ID/Investigator# 54426, Santiago, Chile|Site Reference ID/Investigator# 54427, Santiago, Chile|Site Reference ID/Investigator# 52732, Armenia, Colombia|Site Reference ID/Investigator# 52722, Barranquilla, Colombia|Site Reference ID/Investigator# 52726, Barranquilla, Colombia|Site Reference ID/Investigator# 52723, Bogota, Colombia|Site Reference ID/Investigator# 52725, Bogota, Colombia|Site Reference ID/Investigator# 52727, Bogota, Colombia|Site Reference ID/Investigator# 52729, Bogota, Colombia|Site Reference ID/Investigator# 63882, Bogota, Colombia|Site Reference ID/Investigator# 52735, Cali, Colombia|Site Reference ID/Investigator# 52731, Medellin, Colombia|Site Reference ID/Investigator# 52703, Quito, Ecuador|Site Reference ID/Investigator# 52704, Quito, Ecuador|Site Reference ID/Investigator# 52082, Guanajuato, Leon, Mexico|Site Reference ID/Investigator# 52084, Mexico City, DF, Mexico|Site Reference ID/Investigator# 52083, Nuevo Leon, Monterrey, Mexico|Site Reference ID/Investigator# 52243, Callao, Peru|Site Reference ID/Investigator# 52242, Lima, Peru|Site Reference ID/Investigator# 52246, Salto, Uruguay",,"https://ClinicalTrials.gov/show/NCT01297504"
549,"NCT01294371","Observational Program to Assess Routine Use of Add-back Therapy in Patients With Endometriosis in Russian Federation, Planned for 6-month Course of Lucrin Depot® (Leuprorelin)",,"Completed","Has Results","Genital Endometriosis",,"Percentage of Participants Administered Add-back Therapy During a 6-month Course of Leuprorelin Treatment|Percent Compliance to Treatment With Leuprorelin|Participants With Estrogen Deficiency Symptoms","AbbVie (prior sponsor, Abbott)|Almedis|AbbVie","Female","18 Years to 50 Years   (Adult)",,"391","Industry","Observational","Time Perspective: Prospective","P12-762","February 2011","May 2012","May 2012","February 11, 2011","July 22, 2013","July 22, 2013","Site Reference ID/Investigator# 51643, Chelyabinsk, Russian Federation|Site Reference ID/Investigator# 50563, Ekaterinburg, Russian Federation|Site Reference ID/Investigator# 50577, Irkutsk, Russian Federation|Site Reference ID/Investigator# 50561, Izhevsk, Russian Federation|Site Reference ID/Investigator# 50560, Kazan, Russian Federation|Site Reference ID/Investigator# 50570, Moscow, Russian Federation|Site Reference ID/Investigator# 50567, Moscow, Russian Federation|Site Reference ID/Investigator# 50565, Moscow, Russian Federation|Site Reference ID/Investigator# 50564, Moscow, Russian Federation|Site Reference ID/Investigator# 62184, Nizhniy Novgorod, Russian Federation|Site Reference ID/Investigator# 50558, Nizhny Novgorod, Russian Federation|Site Reference ID/Investigator# 50557, Orenburg, Russian Federation|Site Reference ID/Investigator# 50545, Perm, Russian Federation|Site Reference ID/Investigator# 53156, Perm, Russian Federation|Site Reference ID/Investigator# 50556, Samara, Russian Federation|Site Reference ID/Investigator# 50555, Saratov, Russian Federation|Site Reference ID/Investigator# 50547, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50548, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50549, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50551, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50552, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50554, Stavropol, Russian Federation|Site Reference ID/Investigator# 50580, Stavropol, Russian Federation|Site Reference ID/Investigator# 50579, Tumen, Russian Federation|Site Reference ID/Investigator# 50575, Vladivostok, Russian Federation|Site Reference ID/Investigator# 50562, Volzhskiy, Volgograd Region, Russian Federation|Site Reference ID/Investigator# 48866, Voronezh, Russian Federation|Site Reference ID/Investigator# 54502, Voronezh, Russian Federation",,"https://ClinicalTrials.gov/show/NCT01294371"
550,"NCT01282372","Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab",,"Completed","Has Results","Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis",,"Mean Change From Baseline in Work Time Missed Due to Health Problem|Mean Change From Baseline in Impairment While Working Due to Health Problem|Mean Change From Baseline in Overall Work Impairment Due to Health Problem|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem|Mean Change From Baseline in Work Time Missed Due to Health Problem by Disease Subgroups|Mean Change From Baseline in Impairment While Working Due to Health Problem by Disease Subgroups|Mean Change From Baseline in Overall Work Impairment Due to Health Problem by Disease Subgroups|Mean Change From Baseline in Overall Activity Impairment Due to Health Problem by Disease Subgroups|Mean Disease Activity Score 28 (DAS28)|Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) Score|Mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score|Mean Psoriatic Arthritis Response Criteria (PsARC) Score|Percentage of Participants With Tender Joint Count (TJC) and Swollen Joint Count (SJC) Greater Than Zero|Mean Erythrocyte Sedimentation Rate (ESR)|Mean Plasma Concentrations of C-Reactive Protein (CRP)|Mean Visual Analogue Scale (VAS) Score|Mean Sleep Disturbance Subscale Score","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"500","Industry","Observational","Time Perspective: Prospective","P12-179","March 2011","July 2014","July 2014","January 25, 2011","August 26, 2015","November 9, 2015",,,"https://ClinicalTrials.gov/show/NCT01282372"
551,"NCT01282203","Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevorane in Adult Patients Required General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on Cardiovascular System in Common Clinical Practice","SEVOPROTECTION","Completed","Has Results","Anesthesia, General",,"Time to Loss of Consciousness of Patients Administered Anesthesia|Time to Awakening of Patients|Time to Extubation of Patients|Anesthesiologists' Satisfaction With Using Sevorane for Induction and Maintenance Anesthesia|Patients' Overall Impression of Anesthesia With Sevorane|Systolic Blood Pressure|Diastolic Blood Pressure|Mean Arterial Pressure|Heart Rate|Presence of Deviations in Electrocardiogram Assessments During Anesthesia|Cardiac Troponin (if Available)|Creatine Kinase Myocardial Isoenzyme (if Available)|Correlation Between Anesthesiologists' Clinical Experience and Hemodynamic Parameters During Anesthesia|Correlation Between Anesthesiologists' Clinical Experience and Time to Extubation and Awakening|Anesthesiologists' Duration of Clinical Experience With Anesthesia","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"1122","Industry","Observational","Time Perspective: Prospective","P12-638","July 2011","November 2011","November 2011","January 24, 2011","January 7, 2013","March 4, 2013","Site Reference ID/Investigator# 51851, Almaty, Kazakhstan|Site Reference ID/Investigator# 54703, Almaty, Kazakhstan|Site Reference ID/Investigator# 51843, Astana, Kazakhstan|Site Reference ID/Investigator# 51844, Astana, Kazakhstan|Site Reference ID/Investigator# 54705, Astana, Kazakhstan|Site Reference ID/Investigator# 51842, Kokshetau, Kazakhstan|Site Reference ID/Investigator# 51847, Kostanay, Kazakhstan|Site Reference ID/Investigator# 64462, Kyzylorda, Kazakhstan|Site Reference ID/Investigator# 51845, Semey, Kazakhstan|Site Reference ID/Investigator# 51848, Shymkent, Kazakhstan|Site Reference ID/Investigator# 54704, Uralsk, Kazakhstan|Site Reference ID/Investigator# 44446, Zhezkazgan, Kazakhstan",,"https://ClinicalTrials.gov/show/NCT01282203"
552,"NCT01273597","Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands",,"Completed","Has Results","Kidney Failure, Chronic",,"Time (in Weeks) From Treatment Initiation to Achieving Maintenance Dose of Zemplar (Paricalcitol Injection)|Number of Participants Achieving Target Intact Parathyroid Hormone (iPTH) Levels at Month 6|Country-Specific Data on the Usage of Medication Affecting Calcium (Ca) Balance|Country-Specific Data on the Usage of Medication Affecting Phosphorus (P) Balance|Country-Specific Data on the Usage of Medication Affecting Secondary Hyperparathyroidism|Number of Participants With Hypercalcaemia During Preceding 6 Months of Conventional Vitamin D Therapy|Number of Participants With Hypercalcaemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment|Number of Participants With Hyperphosphataemia During Preceding Conventional Vitamin D Therapy|Number of Participants With Hyperphosphataemia During 6 Months of Selective Vitamin D Receptor Activator (Paricalcitol) Treatment","AbbVie (prior sponsor, Abbott)|Planimeter Ltd|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"60","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-644","January 2011","November 2011","November 2011","January 10, 2011","December 21, 2012","January 18, 2013","Site Reference ID/Investigator# 46593, Budapest, Hungary|Site Reference ID/Investigator# 46585, Budapest, Hungary|Site Reference ID/Investigator# 46594, Debrecen, Hungary|Site Reference ID/Investigator# 47722, Gyor, Hungary|Site Reference ID/Investigator# 46592, Karcag, Hungary|Site Reference ID/Investigator# 58644, Karcag, Hungary|Site Reference ID/Investigator# 46595, Miskolc, Hungary|Site Reference ID/Investigator# 46588, Nyiregyhaza, Hungary|Site Reference ID/Investigator# 46597, Pecs, Hungary|Site Reference ID/Investigator# 46590, Szombathely, Hungary|Site Reference ID/Investigator# 46591, Veszprem, Hungary",,"https://ClinicalTrials.gov/show/NCT01273597"
553,"NCT01273519","Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab",,"Completed","Has Results","Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis",,"Participant Assessment of Present Pain Intensity Recorded on a Visual Analogue Scale (VAS) at Baseline and Months 3, 6, 9, and 12|Physician Assessment of Present Pain Intensity Recorded on a Visual Analogue Scale (VAS) at Baseline and Months 3, 6, 9, and 12|Participant Assessment of Present Pain Intensity Recorded on a Likert Scale at Baseline and Month 12|Participant Assessment of Pain Intensity in the Past 3 Months Recorded on a Visual Analogue Scale (VAS) at Baseline and Months 3, 6, 9, and 12|Participant Assessment of Pain Intensity in the Past 3 Months Recorded on a Likert Scale at Baseline and Month 12|Participant Assessment of the Pattern of Pain Progression (Daytime/Nocturnal) in the Past 3 Months at Baseline and Month 12|Participant Assessment of the Pattern of Pain Progression (Sudden/Creeping) in the Past 3 Months at Baseline and Month 12|Participant Assessment of the Presence of Nocturnal Pain Progression in the Past 3 Months at Baseline and Month 12|Participant Assessment of the Presence of Distress Caused by Pain in the Last 3 Months Recorded on a Likert Scale at Baseline and Month 12|Mean Medical Outcomes Study Short Form 36 (SF-36) Summary of Scales at Baseline, and Months 3, 6, 9, and 12|Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) Scores at Baseline, and Months 3, 6, 9, and 12|Mean Rheumatoid Arthritis Disease Activity Index (RADAI) at Baseline, and Months 3, 6, 9, and 12|Mean Bath Ankylosing Spondylitis Functional Index (BASFI) Scores at Baseline, and Months 3, 6, 9, and 12|Mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for Participants With Ankylosing Spondylitis (AS) at Baseline, and Months 3, 6, 9, and 12|Mean Erythrocyte Sedimentation Rate (ESR) at Baseline, and Months 3, 6, 9, and 12|Mean C-reactive Protein (CRP) at Baseline, and Months 3, 6, 9, and 12","AbbVie (prior sponsor, Abbott)|Raffeiner GmbH|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"155","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-585","January 2011","January 2013","January 2013","January 10, 2011","February 24, 2014","March 26, 2014","Site Reference ID/Investigator# 52144, Bludenz, Austria|Site Reference ID/Investigator# 44915, Fuerstenfeld, Austria|Site Reference ID/Investigator# 44910, Gloggnitz, Austria|Site Reference ID/Investigator# 44914, Graz, Austria|Site Reference ID/Investigator# 52143, Innsbruck, Austria|Site Reference ID/Investigator# 44916, Klagenfurt, Austria|Site Reference ID/Investigator# 44911, Linz, Austria|Site Reference ID/Investigator# 44912, Linz, Austria|Site Reference ID/Investigator# 44913, Linz, Austria|Site Reference ID/Investigator# 44906, Neudorf, Austria|Site Reference ID/Investigator# 52145, Spitz, Austria|Site Reference ID/Investigator# 44909, St. Poelten, Austria|Site Reference ID/Investigator# 44908, Stockerau, Austria|Site Reference ID/Investigator# 67062, Vienna, Austria|Site Reference ID/Investigator# 57304, Voecklabruck, Austria",,"https://ClinicalTrials.gov/show/NCT01273519"
554,"NCT01265992","Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis","CAPITOL","Completed","Has Results","Secondary Hyperparathyroidism|Chronic Kidney Disease",,"Change From Baseline in Intact Parathyroid Hormone at 6 Months|Percentage of Participants With Intact Parathyroid Hormone Within K/DOQI Target Range at Baseline and 6 Months|Percentage of Participants With Elevated Serum-Phosphorus (s-P) Levels at Baseline and 6 Months|Percentage of Participants With Elevated Serum-Calcium (s-Ca) Levels at Baseline and 6 Months|Change From Baseline in Proteinuria|Percentage of Participants With a Reduction of Proteinuria of at Least 15% From Baseline|Change From Baseline in Quality of Life Assessed by the Kidney Disease Quality of Life-Short Form (KDQOL-SF)|Total Direct Costs of Care Associated With Secondary Hyperparathyroidism|Total Indirect Costs of Care Associated With Secondary Hyperparathyroidism|Number of Participants Using Concomitant Medications at Baseline","AbbVie (prior sponsor, Abbott)|Pharma Consulting Group AB|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"50","Industry","Observational","Time Perspective: Prospective","P12-270","February 2011","November 2012","November 2012","December 24, 2010","February 19, 2014","February 19, 2014","Site Reference ID/Investigator# 47723, Kalmar, Sweden|Site Reference ID/Investigator# 41084, Karlstad, Sweden|Site Reference ID/Investigator# 45190, Kristianstad, Sweden|Site Reference ID/Investigator# 41085, Linkoping, Sweden|Site Reference ID/Investigator# 41087, Norrkoping, Sweden|Site Reference ID/Investigator# 45188, Orebro, Sweden|Site Reference ID/Investigator# 41088, Skovde, Sweden|Site Reference ID/Investigator# 57782, Stockholm, Sweden|Site Reference ID/Investigator# 41089, Varnamo, Sweden|Site Reference ID/Investigator# 45191, Vasteras, Sweden",,"https://ClinicalTrials.gov/show/NCT01265992"
555,"NCT01265823","Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis",,"Completed","Has Results","Psoriasis","Biological: Adalimumab","Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 4|Percentage of Participants With Psoriasis Area and Severity Index (PASI)-75 Response at Week 16|Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 4|Percentage of Participants With a Dermatology Life Quality Index (DLQI) Score < 6 at Week 16|Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 4|Mean Score of Dermatology Life Quality Index (DLQI) at Baseline and Week 16|Dermatology Life Quality Index (DLQI) Categories at Week 4|Dermatology Life Quality Index (DLQI) Categories at Week 16|Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 4|Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-50, 90, 100 Responses at Week 16|Physician's Global Assessment (PGA) at Week 4|Physician's Global Assessment (PGA) at Week 16|Mean Lipid Profile, Triglycerides, and C-Reactive Protein (CRP) at Baseline and Week 16|Mean Homocysteine Levels at Baseline and Week 16|Percentage of Obese vs. Non-obese (Per Body Mass Index [BMI]) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16|Percentage of Obese vs. Non-obese (Per Waist-Hip Ratio) Participants Achieving a Psoriasis Area and Severity Index (PASI)-75 Response and a Total Dermatology Life Quality Index (DLQI) Score of <6 at Week 16|Serum Levels of Folic Acid at Baseline and Week 4|Serum Levels of Vitamin B6 at Baseline and Week 4|Serum Levels of Vitamin B12 at Baseline and Week 4|Serum Levels of Folic Acid at Baseline and Week 16|Serum Levels of Vitamin B6 at Baseline and Week 16|Serum Levels of Vitamin B12 at Baseline and Week 16","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W11-050","October 2010","February 2012","February 2012","December 23, 2010","March 11, 2013","March 11, 2013","Site Reference ID/Investigator# 50942, Circuito Comercial Satelite, Mexico|Site Reference ID/Investigator# 40964, Iztapalapa, Mexico|Site Reference ID/Investigator# 50943, Mexico City, Mexico|Site Reference ID/Investigator# 40965, Monterrey, Mexico|Site Reference ID/Investigator# 40962, Monterrey, Mexico|Site Reference ID/Investigator# 40662, Toluca de Lerdo, Mexico|Site Reference ID/Investigator# 41062, Toluca de Lerdo, Mexico|Site Reference ID/Investigator# 40963, Zapopan, Mexico",,"https://ClinicalTrials.gov/show/NCT01265823"
556,"NCT01255657","A Study of ABT-806 in Subjects With Advanced Solid Tumor Types",,"Completed","No Results Available","Advanced Solid Tumors","Drug: ABT-806","Safety (Number of subjects with adverse events and/or dose-limiting toxicities)|Pharmacokinetic profile (assay for ABT-806) Dose Escalation Cohort|Pharmacokinetic profile (assay for ABT-806) Expanded Safety Cohort|Pharmacokinetic profile (assay for Anti-drug Antibody) Dose Escalation Cohort|QT assessment|Infusion rate evaluation (Expanded Safety Cohort)|Pharmacokinetic profile (assay for Anti-drug Antibody) Expanded Safety Cohort","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","49","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-847","November 2010","November 2012","November 2012","December 7, 2010",,"November 21, 2017","Site Reference ID/Investigator# 54056, Baltimore, Maryland, United States|Site Reference ID/Investigator# 41931, Boston, Massachusetts, United States|Site Reference ID/Investigator# 43422, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01255657"
557,"NCT01251614","A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate",,"Completed","Has Results","Plaque Psoriasis","Biological: Adalimumab|Drug: Methotrexate|Biological: Placebo to Adalimumab|Drug: Placebo to Methotrexate","Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 75 Response at Week 16|Percentage of Participants Achieving a Physician's Global Assessment of Disease Activity (PGA) of ""Cleared"" (0) or ""Minimal"" (1) at Week 16|Percentage of Participants Who Achieved a PASI 90 Response at Week 16|Percentage of Participants Who Achieved a PASI 100 Response at Week 16|Change From Baseline in the Children's Dermatology Life Quality Index (CDLQI) Score at Week 16|Change From Baseline in the Pediatric Quality of Life Inventory (PedsQL) Score at Week 16|Percentage of Participants Achieving a PGA of ""Cleared"" (0) or ""Minimal"" (1) Upon Re-Treatment in Period C|Time to Loss of Disease Control for Participants Who Entered Period B|Percentage of Participants Achieving a PGA of ""Cleared"" (0) or ""Minimal"" (1) Over Time|Percentage of Participants Achieving a PGA of ""Cleared"" (0) Over Time|Percentage of Participants Who Achieved a PASI 50 Response Over Time|Percentage of Participants Who Achieved a PASI 75 Response Over Time|Percentage of Participants Who Achieved a PASI 90 Response Over Time|Percentage of Participants Who Achieved a PASI 100 Response Over Time|Percent Change From Baseline in PASI Score Over Time|Change From Baseline in CDLQI Over Time|Percentage of Participants With CDLQI = 0 Over Time|Time to PASI 50/75/90/100 Response in Period A|Change From Baseline in PedsQL Over Time|Change From Baseline in the Children's Depression Inventory: Short (CDI:S)","AbbVie (prior sponsor, Abbott)|AbbVie","All","4 Years to 17 Years   (Child)","Phase 3","114","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M04-717|2009-013072-52","December 2010","December 2013","February 2015","December 2, 2010","April 4, 2017","September 25, 2017",,,"https://ClinicalTrials.gov/show/NCT01251614"
558,"NCT01243671","A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease",,"Completed","Has Results","Intestinal Behçet's Disease","Biological: Adalimumab","Number of Participants With Marked Improvement at Week 24|Number of Participants With Marked Improvement at Week 52|Number of Participants With Complete Remission at Week 24 and Week 52|Number of Participants With a Global Assessment of Gastrointestinal Symptoms Grade 0 or ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52|Number of Participants With Endoscopic Improvement Grades 0, ≤1 and ≤2 at Week 24 and Week 52|Number of Participants With Abdominal Pain, Diarrhea and Other Gastrointestinal (GI) Symptoms Grade ≤1 and Improvement of ≥1 Grade at Week 24 and Week 52|Number of Participants With Resolution of Behçet's Disease Symptoms (Other Than Gastrointestinal Symptoms) at Week 24 and Week 52|Mean Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 24 and Week 52|Mean Change From Baseline in Short Form-36 (SF-36) Summary Scores at Week 24 and Week 52|Median Change From Baseline in C-Reactive Protein (CRP) at Week 24 and Week 52","AbbVie (prior sponsor, Abbott)|Eisai Co., Ltd.|AbbVie","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","20","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-509","October 2010","March 2012","June 2013","November 18, 2010","May 15, 2013","July 25, 2014","Site Reference ID/Investigator# 46738, Chikushino, Japan|Site Reference ID/Investigator# 46723, Kurume, Japan|Site Reference ID/Investigator# 46728, Nagoya-shi, Japan|Site Reference ID/Investigator# 46725, Nishinomiya-shi, Japan|Site Reference ID/Investigator# 46730, Osaka-shi, Japan|Site Reference ID/Investigator# 46722, Sagamihara-shi, Japan|Site Reference ID/Investigator# 46726, Sakura, Japan|Site Reference ID/Investigator# 59578, Sapporo-shi, Japan|Site Reference ID/Investigator# 46724, Takatsuki-shi, Japan|Site Reference ID/Investigator# 46729, Tokyo, Japan|Site Reference ID/Investigator# 46737, Tokyo, Japan|Site Reference ID/Investigator# 46733, Yokohama-shi, Japan",,"https://ClinicalTrials.gov/show/NCT01243671"
559,"NCT01235689","Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease","CALM","Completed","Has Results","Crohn's Disease","Biological: Adalimumab|Drug: Prednisone|Drug: Azathioprine","Percentage of Participants With Mucosal Healing and No Deep Ulcerations|Percentage of Participants in Deep Remission 48 Weeks After Randomization|Percentage of Participants in Biologic Remission 48 Weeks After Randomization|Percentage of Participants With Mucosal Healing 48 Weeks After Randomization|Percentage of Participants With Mucosal Healing and CDEIS < 4 in Every Segment 48 Weeks After Randomization|Percentage of Participants With Complete Mucosal Healing 48 Weeks After Randomization|Percentage of Participants With Endoscopic Response 48 Weeks After Randomization|Change From Baseline in CDEIS at 48 Weeks After Randomization|Change From Baseline in CDAI Over Time|Time to Crohn's Disease Flare|Time to Clinical Remission|Time to Steroid-free Remission|Percentage of Participants in Clinical Remission Over Time|Percentage of Participants in Steroid-free Remission Over Time|Time to All-cause Hospitalization|Time to Crohn's Disease-related Hospitalization or Hospitalization Due to Adverse Event Relating to Study Medication|Number of Major Crohn's Disease-related Surgeries After Randomization|Number of Crohn's Disease-related Hospitalizations After Randomization|Number of All-cause Hospitalizations After Randomization|Total Length of Stay in Hospital for All-cause Hospitalizations|Total Length of Stay in Hospital for Crohn's Disease-related Hospitalizations|Number of Crohn's Disease-related Surgical Procedures After Randomization|Time to Crohn's Disease-related Hospitalization Due to Emergency|Number of Crohn's Disease-related Hospitalizations Due to Emergency|Change in Crohn's Disease Behavior According to Montreal Classification|Change From Baseline in High Sensitivity C-Reactive Protein (Hs-CRP) Over Time|Change in Fecal Calprotectin From Baseline to 48 Weeks After Randomization|Total Dose of Prednisone|Change From Baseline in Quality of Life in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score|Change From Baseline in Work Productivity Activity Index - Crohn's Disease (WPAI:CD)|Change From Baseline in Patient Health Questionnaire - 9 (PHQ9)|Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score|Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary and Mental Component Summary Scores","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","252","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-271|2010-020137-10","February 11, 2011","November 3, 2016","January 3, 2017","November 5, 2010","December 7, 2017","January 16, 2018",,,"https://ClinicalTrials.gov/show/NCT01235689"
560,"NCT01224782","Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT)",,"Completed","Has Results","Chronic Kidney Disease|Secondary Hyperparathyroidism",,"Time to Achieve a > 30% Decrease From Baseline in Intact Parathyroid Hormone (iPTH) Values|Percentage of Participants With Calcium x Phosphorus Product (CxP) Values > 65 mg˄2/dL˄2 or 5.24 mmol˄2/L˄2|Percentage of Participants Who Achieved a > 30% Decrease From Baseline in Intact Parathyroid Hormone (iPTH)|Percentage of Participants With Hypercalcemia|Mean Weekly Dose of Zemplar (Paricalcitol)|Number of Participants With Adverse Events (AEs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"994","Industry","Observational",,"P12-269","October 2010","August 2013","August 2013","October 20, 2010","September 15, 2014","September 15, 2014","Site Reference ID/Investigator# 66544, Montana, Bulgaria|Site Reference ID/Investigator# 47685, Pleven, Bulgaria|Site Reference ID/Investigator# 66546, Plovdiv, Bulgaria|Site Reference ID/Investigator# 47683, Sofia, Bulgaria|Site Reference ID/Investigator# 66543, Sofia, Bulgaria|Site Reference ID/Investigator# 47684, Sofia, Bulgaria|Site Reference ID/Investigator# 66542, Sofia, Bulgaria|Site Reference ID/Investigator# 66545, Sofia, Bulgaria|Site Reference ID/Investigator# 47687, Varna, Bulgaria|Site Reference ID/Investigator# 43449, Beroun, Czech Republic|Site Reference ID/Investigator# 46744, Brno, Czech Republic|Site Reference ID/Investigator# 73353, Brno, Czech Republic|Site Reference ID/Investigator# 47690, Brno, Czech Republic|Site Reference ID/Investigator# 46742, Budejovice, Czech Republic|Site Reference ID/Investigator# 49542, Frydek-Mistek, Czech Republic|Site Reference ID/Investigator# 67442, Jilemnice, Czech Republic|Site Reference ID/Investigator# 67443, Jilemnice, Czech Republic|Site Reference ID/Investigator# 51003, Karlovy Vary, Czech Republic|Site Reference ID/Investigator# 51004, Marianske Lazne, Czech Republic|Site Reference ID/Investigator# 43522, Novy Jicin, Czech Republic|Site Reference ID/Investigator# 43523, Novy Jicin, Czech Republic|Site Reference ID/Investigator# 43524, Novy Jicin, Czech Republic|Site Reference ID/Investigator# 45483, Olomouc, Czech Republic|Site Reference ID/Investigator# 43453, Ostrava, Czech Republic|Site Reference ID/Investigator# 46743, Plzen, Czech Republic|Site Reference ID/Investigator# 51008, Prague 10, Czech Republic|Site Reference ID/Investigator# 47842, Prague 1, Czech Republic|Site Reference ID/Investigator# 68462, Prague 4, Czech Republic|Site Reference ID/Investigator# 51009, Prague 4, Czech Republic|Site Reference ID/Investigator# 51005, Prague 5, Czech Republic|Site Reference ID/Investigator# 51011, Prague 9, Czech Republic|Site Reference ID/Investigator# 48210, Prerov, Czech Republic|Site Reference ID/Investigator# 45487, Rakovnik, Czech Republic|Site Reference ID/Investigator# 51012, Slany, Czech Republic|Site Reference ID/Investigator# 51002, Sokolov, Czech Republic|Site Reference ID/Investigator# 43448, Trutnov, Czech Republic|Site Reference ID/Investigator# 45485, Vyskov, Czech Republic|Site Reference ID/Investigator# 42992, Bacau, Romania|Site Reference ID/Investigator# 42879, Bucharest, Romania|Site Reference ID/Investigator# 42880, Bucharest, Romania|Site Reference ID/Investigator# 42881, Bucharest, Romania|Site Reference ID/Investigator# 42882, Bucharest, Romania|Site Reference ID/Investigator# 42883, Bucharest, Romania|Site Reference ID/Investigator# 42963, Bucharest, Romania|Site Reference ID/Investigator# 42970, Bucharest, Romania|Site Reference ID/Investigator# 42877, Bucharest, Romania|Site Reference ID/Investigator# 42878, Bucharest, Romania|Site Reference ID/Investigator# 42973, Bucharest, Romania|Site Reference ID/Investigator# 42975, Bucharest, Romania|Site Reference ID/Investigator# 42976, Bucharest, Romania|Site Reference ID/Investigator# 42981, Cluj-Napoca, Romania|Site Reference ID/Investigator# 42982, Cluj-Napoca, Romania|Site Reference ID/Investigator# 42980, Cluj-Napoca, Romania|Site Reference ID/Investigator# 63623, Cluj-Napoca, Romania|Site Reference ID/Investigator# 43009, Constanta, Romania|Site Reference ID/Investigator# 43002, Craiova, Romania|Site Reference ID/Investigator# 43003, Craiova, Romania|Site Reference ID/Investigator# 43006, Craiova, Romania|Site Reference ID/Investigator# 42991, Iasi, Romania|Site Reference ID/Investigator# 42988, Iasi, Romania|Site Reference ID/Investigator# 42989, Iasi, Romania|Site Reference ID/Investigator# 42999, Oradea, Romania|Site Reference ID/Investigator# 43000, Oradea, Romania|Site Reference ID/Investigator# 42979, Ploiesti, Romania|Site Reference ID/Investigator# 42984, Targu Mures, Romania|Site Reference ID/Investigator# 42985, Targu Mures, Romania|Site Reference ID/Investigator# 42987, Targu Mures, Romania|Site Reference ID/Investigator# 42994, Timisoara, Romania|Site Reference ID/Investigator# 42995, Timisoara, Romania",,"https://ClinicalTrials.gov/show/NCT01224782"
561,"NCT01221298","A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)",,"Completed","Has Results","Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1","Drug: ABT-450|Drug: ABT-072|Drug: Ribavirin|Drug: Ritonavir","Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12|Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) < 1000 International Units Per Milliliter (IU/mL)|Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Below the Lower Limit of Quantitation (LLOQ) at Week 4|Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment|Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment|Time to Failure to Suppress or Rebound During Treatment|Time to Virologic Relapse Through 24 Weeks Post-treatment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M12-267","October 2010","May 2011","April 2012","October 15, 2010","January 8, 2015","January 8, 2015","Site Reference ID/Investigator# 41128, Los Angeles, California, United States|Site Reference ID/Investigator# 42262, Chicago, Illinois, United States|Site Reference ID/Investigator# 41127, San Antonio, Texas, United States|Site Reference ID/Investigator# 43182, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01221298"
562,"NCT01207115","A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee",,"Completed","No Results Available","Osteoarthritis of the Knee","Drug: ABT-652|Drug: Placebo|Drug: Naproxen","24-hour average pain score measured by Visual Analog Scale|Western Ontario and McMaster (WOMAC™ ) Osteoarthritis subscales, Pain, Physical Function and Stiffness scores|Subject's Global Assessment of Arthritis Status|Brief Pain Inventory|SF-36v2™ Health Status Survey","AbbVie (prior sponsor, Abbott)|AbbVie","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","322","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-889","September 2010","May 2011","May 2011","September 22, 2010",,"January 7, 2013","Site Reference ID/Investigator# 37220, Chandler, Arizona, United States|Site Reference ID/Investigator# 37223, Tempe, Arizona, United States|Site Reference ID/Investigator# 37215, Tucson, Arizona, United States|Site Reference ID/Investigator# 37221, Anaheim, California, United States|Site Reference ID/Investigator# 37222, Burbank, California, United States|Site Reference ID/Investigator# 35956, Chino, California, United States|Site Reference ID/Investigator# 37053, La Mesa, California, United States|Site Reference ID/Investigator# 37218, Lomita, California, United States|Site Reference ID/Investigator# 37227, Milford, Connecticut, United States|Site Reference ID/Investigator# 37229, Boynton Beach, Florida, United States|Site Reference ID/Investigator# 37209, Ocala, Florida, United States|Site Reference ID/Investigator# 37212, Plantation, Florida, United States|Site Reference ID/Investigator# 35961, South Miami, Florida, United States|Site Reference ID/Investigator# 37207, Valparaiso, Indiana, United States|Site Reference ID/Investigator# 37217, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 37228, St. Louis, Missouri, United States|Site Reference ID/Investigator# 35959, New York, New York, United States|Site Reference ID/Investigator# 37211, Salisbury, North Carolina, United States|Site Reference ID/Investigator# 37214, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 37205, Wyomissing, Pennsylvania, United States|Site Reference ID/Investigator# 37208, Austin, Texas, United States|Site Reference ID/Investigator# 37213, San Antonio, Texas, United States|Site Reference ID/Investigator# 35953, Richmond, Virginia, United States|Site Reference ID/Investigator# 41782, Brisbane, Australia|Site Reference ID/Investigator# 41779, Campsie, Sydney, Australia|Site Reference ID/Investigator# 41778, Clayton, Australia|Site Reference ID/Investigator# 41785, Fitzroy, Australia|Site Reference ID/Investigator# 41582, Kogarah, Australia|Site Reference ID/Investigator# 41776, Malvern East, Australia|Site Reference ID/Investigator# 41563, Montreal, Canada|Site Reference ID/Investigator# 41566, Newmarket, Canada|Site Reference ID/Investigator# 41565, Pointe-Claire, Canada|Site Reference ID/Investigator# 41562, Sainte-Foy, Quebec, Canada|Site Reference ID/Investigator# 41951, Santiago, Chile|Site Reference ID/Investigator# 37183, Caguas, Puerto Rico|Site Reference ID/Investigator# 37622, Ponce, Puerto Rico|Site Reference ID/Investigator# 35966, San Juan, Puerto Rico|Site Reference ID/Investigator# 37184, Trujillo Alto, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01207115"
563,"NCT01202565","Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice",,"Completed","Has Results","Moderate to Severe Plaque Psoriasis",,"Percent Change From Baseline in Nail Psoriasis Severity Index (NAPSI) to Month 12|Percent Change From Baseline in Psoriasis Scalp Severity Index (PSSI) to Month 12|Change From Baseline in Nail Psoriasis Severity Index (NAPSI)|Percentage of Participants Achieving a Good Clinical Response on Nail Psoriasis|Percentage of Participants Achieving Complete Clearing of Nails|Change From Baseline in Psoriasis Scalp Severity Index (PSSI)|Percentage of Participants Achieving Good Clinical Response on Scalp|Percentage of Participants Achieving Complete Clearing of Scalp|Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score|Change From Baseline in PASI Score|Percentage of Participants Achieving a PASI 90 Response|Percentage of Participants Achieving a PASI 75 Response|Percentage of Participants Achieving a PASI 50 Response|Percent Change From Baseline in Dermatology Life Quality Index (DLQI) Score|Change From Baseline in DLQI Score|Associations Between General Improvement in Psoriasis With Improvement in Nail Psoriasis|Associations Between General Improvement in Psoriasis With Improvement in Scalp Psoriasis|Associations Between Improvement in Quality of Life With Improvement in Nail Psoriasis|Associations Between Improvement in Quality of Life With Improvement in Scalp Psoriasis|Associations Between General Improvement in Psoriasis With Improvement in Quality of Life","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"506","Industry","Observational","Time Perspective: Prospective","P12-165","September 2010","July 2013","July 2013","September 16, 2010","August 7, 2014","August 7, 2014","Site Reference ID/Investigator# 63776, Chotoviny, Czech Republic|Site Reference ID/Investigator# 58083, Jihlava, Czech Republic|Site Reference ID/Investigator# 56762, Klimkovice, Czech Republic|Site Reference ID/Investigator# 56763, Klimkovice, Czech Republic|Site Reference ID/Investigator# 30742, Kostelec nad Ohri, Czech Republic|Site Reference ID/Investigator# 54503, Prague 10, Czech Republic|Site Reference ID/Investigator# 56542, Prague 2, Czech Republic|Site Reference ID/Investigator# 58084, Prague 8, Czech Republic|Site Reference ID/Investigator# 57562, Tallinn, Estonia|Site Reference ID/Investigator# 57563, Tallinn, Estonia|Site Reference ID/Investigator# 57564, Tallinn, Estonia|Site Reference ID/Investigator# 57567, Tartu, Estonia|Site Reference ID/Investigator# 30743, Budapest, Hungary|Site Reference ID/Investigator# 42506, Debrecen, Hungary|Site Reference ID/Investigator# 42507, Debrecen, Hungary|Site Reference ID/Investigator# 42508, Debrecen, Hungary|Site Reference ID/Investigator# 42509, Debrecen, Hungary|Site Reference ID/Investigator# 42510, Debrecen, Hungary|Site Reference ID/Investigator# 42514, Kaposvar, Hungary|Site Reference ID/Investigator# 42515, Kecskemet, Hungary|Site Reference ID/Investigator# 42516, Miskolc, Hungary|Site Reference ID/Investigator# 42511, Pecs, Hungary|Site Reference ID/Investigator# 42512, Pecs, Hungary|Site Reference ID/Investigator# 42513, Pecs, Hungary|Site Reference ID/Investigator# 44854, Pecs, Hungary|Site Reference ID/Investigator# 42502, Szeged, Hungary|Site Reference ID/Investigator# 42517, Szombathely, Hungary|Site Reference ID/Investigator# 30744, Afula, Israel|Site Reference ID/Investigator# 49888, Jerusalem, Israel|Site Reference ID/Investigator# 49886, Petach Tiqwa, Israel|Site Reference ID/Investigator# 49887, Ramat Gan, Israel|Site Reference ID/Investigator# 51783, Tel Aviv, Israel|Site Reference ID/Investigator# 46184, Alexandria, Romania|Site Reference ID/Investigator# 44580, Bucharest, Romania|Site Reference ID/Investigator# 44572, Bucharest, Romania|Site Reference ID/Investigator# 44575, Bucharest, Romania|Site Reference ID/Investigator# 44576, Bucharest, Romania|Site Reference ID/Investigator# 46185, Bucharest, Romania|Site Reference ID/Investigator# 44563, Bucharest, Romania|Site Reference ID/Investigator# 44564, Bucharest, Romania|Site Reference ID/Investigator# 44566, Bucharest, Romania|Site Reference ID/Investigator# 44567, Bucharest, Romania|Site Reference ID/Investigator# 44569, Bucharest, Romania|Site Reference ID/Investigator# 44571, Bucharest, Romania|Site Reference ID/Investigator# 30745, Cluj-Napoca, Romania|Site Reference ID/Investigator# 44561, Constanta, Romania|Site Reference ID/Investigator# 44562, Constanta, Romania|Site Reference ID/Investigator# 44557, Craiova, Romania|Site Reference ID/Investigator# 44558, Craiova, Romania|Site Reference ID/Investigator# 44559, Craiova, Romania|Site Reference ID/Investigator# 44560, Craiova, Romania|Site Reference ID/Investigator# 44547, Iasi, Romania|Site Reference ID/Investigator# 44548, Iasi, Romania|Site Reference ID/Investigator# 44549, Iasi, Romania|Site Reference ID/Investigator# 46183, Oradea, Romania|Site Reference ID/Investigator# 44555, Ploiesti, Romania|Site Reference ID/Investigator# 44554, Reghin, Romania|Site Reference ID/Investigator# 44550, Targu Mures, Romania|Site Reference ID/Investigator# 30746, Banska Bystrica, Slovakia|Site Reference ID/Investigator# 42521, Bratislava, Slovakia|Site Reference ID/Investigator# 42519, Kosice, Slovakia|Site Reference ID/Investigator# 42522, Martin, Slovakia|Site Reference ID/Investigator# 42518, Presov, Slovakia|Site Reference ID/Investigator# 30747, Ljubljana, Slovenia|Site Reference ID/Investigator# 44544, Ljubljana, Slovenia|Site Reference ID/Investigator# 44542, Maribor, Slovenia|Site Reference ID/Investigator# 47702, Sezana, Slovenia|Site Reference ID/Investigator# 64524, Donetsk, Ukraine|Site Reference ID/Investigator# 66642, Donetsk, Ukraine|Site Reference ID/Investigator# 62304, Kharkiv, Ukraine|Site Reference ID/Investigator# 56699, Kiev, Ukraine|Site Reference ID/Investigator# 55443, Lviv, Ukraine|Site Reference ID/Investigator# 70493, Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01202565"
564,"NCT01185301","Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)","CONCERTO","Completed","Has Results","Early Rheumatoid Arthritis","Biological: adalimumab|Drug: methotrexate","Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26|Percentage of Participants With DAS28(CRP) Remission at Week 26|Percentage of Participants With American College of Rheumatology (ACR) 20 Criteria Response at Week 26|Percentage of Participants With American College of Rheumatology (ACR) 50 Criteria Response at Week 26|Percentage of Participants With American College of Rheumatology (ACR) 70 Criteria Response at Week 26|Percentage of Participants With American College of Rheumatology (ACR) 90 Criteria Response at Week 26|Percentage of Participants With American College of Rheumatology (ACR) 100 Criteria Response at Week 26|Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 26|Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) ≤ -0.22 at Week 26|Change From Baseline in Modified Total Sharp Score (mTSS) at Week 26|Percentage of Participants With No Radiographic Progression at Week 26|Percentage of Participants With Simplified Disease Activity Index (SDAI) Remission at Week 26|Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission at Week 26","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","395","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-073|2010-019514-24","October 2010","September 2012","September 2012","August 19, 2010","November 15, 2013","November 15, 2013","Site Reference ID/Investigator# 38973, Huntsville, Alabama, United States|Site Reference ID/Investigator# 41962, Mesa, Arizona, United States|Site Reference ID/Investigator# 39260, Phoenix, Arizona, United States|Site Reference ID/Investigator# 45323, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 38912, Hemet, California, United States|Site Reference ID/Investigator# 39673, Victorville, California, United States|Site Reference ID/Investigator# 38909, Jacksonville, Florida, United States|Site Reference ID/Investigator# 40422, Miami, Florida, United States|Site Reference ID/Investigator# 38910, Sarasota, Florida, United States|Site Reference ID/Investigator# 44284, Atlanta, Georgia, United States|Site Reference ID/Investigator# 38907, Gainesville, Georgia, United States|Site Reference ID/Investigator# 38972, Lawrenceville, Georgia, United States|Site Reference ID/Investigator# 39670, Rock Island, Illinois, United States|Site Reference ID/Investigator# 42282, Springfield, Illinois, United States|Site Reference ID/Investigator# 38911, Wichita, Kansas, United States|Site Reference ID/Investigator# 39672, Covington, Louisiana, United States|Site Reference ID/Investigator# 42204, Omaha, Nebraska, United States|Site Reference ID/Investigator# 40651, Clifton, New Jersey, United States|Site Reference ID/Investigator# 41422, Freehold, New Jersey, United States|Site Reference ID/Investigator# 41424, Bronx, New York, United States|Site Reference ID/Investigator# 40463, Greenville, North Carolina, United States|Site Reference ID/Investigator# 42202, Columbus, Ohio, United States|Site Reference ID/Investigator# 44282, Norman, Oklahoma, United States|Site Reference ID/Investigator# 41423, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 38971, Charleston, South Carolina, United States|Site Reference ID/Investigator# 39666, Jackson, Tennessee, United States|Site Reference ID/Investigator# 39643, Dallas, Texas, United States|Site Reference ID/Investigator# 45325, Dallas, Texas, United States|Site Reference ID/Investigator# 52042, Houston, Texas, United States|Site Reference ID/Investigator# 40602, Seattle, Washington, United States|Site Reference ID/Investigator# 44924, Buenos Aires, Argentina|Site Reference ID/Investigator# 44926, Buenos Aires, Argentina|Site Reference ID/Investigator# 44925, Rosario, Santa Fe, Argentina|Site Reference ID/Investigator# 47302, San Juan, Argentina|Site Reference ID/Investigator# 44928, Graz, Austria|Site Reference ID/Investigator# 44930, Vienna, Austria|Site Reference ID/Investigator# 44927, Vienna, Austria|Site Reference ID/Investigator# 44934, Brussels, Belgium|Site Reference ID/Investigator# 44935, Genk, Belgium|Site Reference ID/Investigator# 44933, Gilly, Belgium|Site Reference ID/Investigator# 44932, Liege, Belgium|Site Reference ID/Investigator# 43783, Edmonton, Canada|Site Reference ID/Investigator# 43782, Winnipeg, Canada|Site Reference ID/Investigator# 44937, Brno, Czech Republic|Site Reference ID/Investigator# 48962, Ceske Budejovice, Czech Republic|Site Reference ID/Investigator# 44939, Ostrava, Czech Republic|Site Reference ID/Investigator# 44936, Prague 2, Czech Republic|Site Reference ID/Investigator# 44938, Uherske Hradiste, Czech Republic|Site Reference ID/Investigator# 48963, Zlin, Czech Republic|Site Reference ID/Investigator# 44945, Berlin-Buch, Germany|Site Reference ID/Investigator# 44941, Berlin, Germany|Site Reference ID/Investigator# 44942, Munich, Germany|Site Reference ID/Investigator# 44944, Ratingen, Germany|Site Reference ID/Investigator# 44943, Zerbst, Germany|Site Reference ID/Investigator# 44946, Bydgoszcz, Poland|Site Reference ID/Investigator# 44982, Lodz, Poland|Site Reference ID/Investigator# 46584, Torun, Poland|Site Reference ID/Investigator# 44984, Warsaw, Poland|Site Reference ID/Investigator# 44983, Warsaw, Poland|Site Reference ID/Investigator# 38975, Caguas, Puerto Rico|Site Reference ID/Investigator# 40122, San Juan, Puerto Rico|Site Reference ID/Investigator# 39693, San Juan, Puerto Rico|Site Reference ID/Investigator# 38916, San Juan, Puerto Rico|Site Reference ID/Investigator# 39692, Vega Baja, Puerto Rico|Site Reference ID/Investigator# 44947, A Coruna, Spain|Site Reference ID/Investigator# 44987, Elche (Alicante), Spain|Site Reference ID/Investigator# 44948, Oviedo (Asturias), Spain|Site Reference ID/Investigator# 47782, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01185301"
565,"NCT01185288","A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)","MUSICA","Completed","Has Results","Rheumatoid Arthritis","Biological: Adalimumab|Drug: Methotrexate","Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24|Percentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 24|Percentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 24|Percentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 24|Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤ -0.22 at Week 24|Percent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","309","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M12-071","September 2010","January 2013","January 2013","August 19, 2010","March 18, 2014","March 18, 2014","Site Reference ID/Investigator# 38982, Huntsville, Alabama, United States|Site Reference ID/Investigator# 38686, Tuscaloosa, Alabama, United States|Site Reference ID/Investigator# 42044, Mesa, Arizona, United States|Site Reference ID/Investigator# 37983, Phoenix, Arizona, United States|Site Reference ID/Investigator# 44823, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 37981, Hemet, California, United States|Site Reference ID/Investigator# 40208, Long Beach, California, United States|Site Reference ID/Investigator# 38423, Sacramento, California, United States|Site Reference ID/Investigator# 38204, Victorville, California, United States|Site Reference ID/Investigator# 40762, Walnut Creek, California, United States|Site Reference ID/Investigator# 43049, Danbury, Connecticut, United States|Site Reference ID/Investigator# 38687, Jacksonville, Florida, United States|Site Reference ID/Investigator# 40105, Miami, Florida, United States|Site Reference ID/Investigator# 38083, Sarasota, Florida, United States|Site Reference ID/Investigator# 38688, Lawrenceville, Georgia, United States|Site Reference ID/Investigator# 38689, Meridian, Idaho, United States|Site Reference ID/Investigator# 38085, Rock Island, Illinois, United States|Site Reference ID/Investigator# 40128, Springfield, Illinois, United States|Site Reference ID/Investigator# 38981, Bowling Green, Kentucky, United States|Site Reference ID/Investigator# 38086, Covington, Louisiana, United States|Site Reference ID/Investigator# 40125, Fall River, Massachusetts, United States|Site Reference ID/Investigator# 65490, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 40124, Clifton, New Jersey, United States|Site Reference ID/Investigator# 38978, Freehold, New Jersey, United States|Site Reference ID/Investigator# 40123, Voorhees, New Jersey, United States|Site Reference ID/Investigator# 38983, Bronx, New York, United States|Site Reference ID/Investigator# 38264, Smithtown, New York, United States|Site Reference ID/Investigator# 38263, Asheville, North Carolina, United States|Site Reference ID/Investigator# 38261, Greenville, North Carolina, United States|Site Reference ID/Investigator# 39024, Mayfield Village, Ohio, United States|Site Reference ID/Investigator# 40127, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 38202, Bend, Oregon, United States|Site Reference ID/Investigator# 39023, Eugene, Oregon, United States|Site Reference ID/Investigator# 38265, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 38082, Jackson, Tennessee, United States|Site Reference ID/Investigator# 37980, Dallas, Texas, United States|Site Reference ID/Investigator# 44888, Dallas, Texas, United States|Site Reference ID/Investigator# 43050, Houston, Texas, United States|Site Reference ID/Investigator# 43735, San Antonio, Texas, United States|Site Reference ID/Investigator# 44344, Richmond, Virginia, United States|Site Reference ID/Investigator# 40210, Seattle, Washington, United States|Site Reference ID/Investigator# 38084, Seattle, Washington, United States|Site Reference ID/Investigator# 38542, Seattle, Washington, United States|Site Reference ID/Investigator# 38424, Spokane, Washington, United States|Site Reference ID/Investigator# 38203, Tacoma, Washington, United States|Site Reference ID/Investigator# 38087, Franklin, Wisconsin, United States|Site Reference ID/Investigator# 60850, San Juan, Puerto Rico|Site Reference ID/Investigator# 38691, San Juan, Puerto Rico|Site Reference ID/Investigator# 60851, Vega Baja, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01185288"
566,"NCT01169987","Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life",,"Completed","Has Results","Psoriasis",,"Adalimumab Treatment Retention Status|Psoriasis Area and Severity Index (PASI): Mean Percentage Improvement From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status|PASI: Percentage Improvement Change Categories From Baseline for All Participants and Broken Down by Adalimumab Treatment Retention Status|Mean Percent Affected Body Surface Area (BSA) For All Participants and Broken Down by Adalimumab Treatment Retention Status|Physician's Global Assessment (PGA): Percentage of Participants in Regrouped PGA Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status|Dermatology Life Quality Index (DLQI): Mean Score for All Participants and Broken Down by Adalimumab Treatment Retention Status|DLQI: Percentage of Participants in DLQI Categories for All Participants and Broken Down by Adalimumab Treatment Retention Status|Work Productivity and Activity Impairment (WPAI) Questionnaire: Mean Percentage of Work Time Missed (Absenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status|WPAI Questionnaire: Mean Percentage of Impairment While Working Due to Psoriasis (Presenteeism) for All Participants and Broken Down by Adalimumab Treatment Retention Status|WPAI Questionnaire: Mean Percentage of Total Work Productivity Impairment (TWPI) Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status|WPAI Questionnaire: Mean Percentage of Activity Impairment Due to Psoriasis for All Participants and Broken Down by Adalimumab Treatment Retention Status","AbbVie (prior sponsor, Abbott)|Veeda Clinical Research|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"191","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-129","May 2010","March 2015","March 2015","July 27, 2010","June 14, 2016","July 13, 2016",,,"https://ClinicalTrials.gov/show/NCT01169987"
567,"NCT01166282","A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis",,"Completed","Has Results","Enthesitis Related Arthritis (ERA)","Biological: adalimumab|Biological: placebo for adalimumab","Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12|Number of Sites of Enthesitis: Change From Baseline to Week 12|Tender Joint Count (TJC72): Change From Baseline to Week 12|Swollen Joint Count (SJC68): Change From Baseline to Week 12|Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 30% Response (ACR Pedi30)|Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 50% Response (ACR Pedi50)|Percentage of Participants Achieving Pediatric American College of Rheumatology Pediatric 70% Response (ACR Pedi70)|Number of Participants With Adverse Events (AEs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","6 Years to 17 Years   (Child)","Phase 3","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-328|2009-017938-46","September 2010","November 2012","December 2015","July 21, 2010","June 21, 2016","June 27, 2016",,,"https://ClinicalTrials.gov/show/NCT01166282"
568,"NCT01163617","The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients",,"Completed","Has Results","Rheumatoid Arthritis","Device: Adalimumab delivered in current syringe|Device: Adalimumab delivered in Physiolis syringe|Device: Adalimumab delivered in current autoinjector|Device: Adalimumab delivered in Physiolis autoinjector","Participants' Overall Satisfaction With the Drug Administration Experience Using the Physiolis Syringe/Autoinjector in Comparison to the Current Syringe/Autoinjector|Injection Duration for the Physiolis Autoinjector at Room Temperature (20° to 27°C) and at Storage Temperature (2° to 8°C) Compared to the Current Autoinjector Ejection Time Specification of Not More Than 10 Seconds|Injection Duration for the Current Autoinjector Compared to the Physiolis Autoinjector|Injection Duration for the Current Autoinjector When Administered at Room Temperature (20° to 27°C) Versus the Storage Temperature (2° to 8°C)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","85","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","M12-088","May 2010","November 2010","November 2010","July 16, 2010","March 10, 2014","July 2, 2018","Site Reference ID/Investigator# 27144, Victorville, California, United States|Site Reference ID/Investigator# 27153, Tampa, Florida, United States|Site Reference ID/Investigator# 27150, Passaic, New Jersey, United States|Site Reference ID/Investigator# 27143, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 27145, Wyomissing, Pennsylvania, United States|Site Reference ID/Investigator# 27142, Charleston, South Carolina, United States|Site Reference ID/Investigator# 27151, Jackson, Tennessee, United States|Site Reference ID/Investigator# 27152, Dallas, Texas, United States|Site Reference ID/Investigator# 27147, Houston, Texas, United States|Site Reference ID/Investigator# 27155, Tyler, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01163617"
569,"NCT01163318","Special Investigation of Humira® (Adalimumab) on Long-term Treatment in Patients With Rheumatoid Arthritis",,"Completed","Has Results","Rheumatoid Arthritis",,"Incidence of Adverse Drug Reactions (ADRs)|Incidence of Infections and Malignant Tumors|Percentage of Participants With Disease Activity Score 28 - 4 Erythrocyte Sedimentation Rate (DAS28-4ESR) < 2.6 by Visit|Percentage of Participants With Modified Health Assessment Questionnaire (MHAQ) Score ≤ 0.5 by Visit","AbbVie (prior sponsor, Abbott)|AbbVie","All","15 Years and older   (Child, Adult, Older Adult)",,"552","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-070","December 2009","May 2014","May 2014","July 15, 2010","June 10, 2015","June 10, 2015",,,"https://ClinicalTrials.gov/show/NCT01163318"
570,"NCT01163292","Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467))",,"Completed","Has Results","Rheumatoid Arthritis",,"Disease Activity Score (DAS28)|Matrix Metalloprotease-3 (MMP-3)|Modified Total Sharp Score (mTSS) Change From Week 0 to Week 52|Health Assessment Questionnaire Disability Index (HAQ-DI)|Number of Participants With Adverse Events (AEs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years and older   (Adult, Older Adult)",,"220","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-069","March 2010","October 2012","October 2012","July 15, 2010","December 11, 2013","July 6, 2018","Site Reference ID/Investigator# 54680, Anjo, Japan|Site Reference ID/Investigator# 54677, Aomori, Japan|Site Reference ID/Investigator# 54516, Chiba, Japan|Site Reference ID/Investigator# 54660, Chiba, Japan|Site Reference ID/Investigator# 54683, Chiba, Japan|Site Reference ID/Investigator# 54521, Fukuoka, Japan|Site Reference ID/Investigator# 39854, Gifu, Japan|Site Reference ID/Investigator# 54666, Hamamatsu, Japan|Site Reference ID/Investigator# 54682, Hiroshima, Japan|Site Reference ID/Investigator# 54669, Hyogo, Japan|Site Reference ID/Investigator# 54674, Hyogo, Japan|Site Reference ID/Investigator# 54653, Ibaraki, Japan|Site Reference ID/Investigator# 54670, Kagoshima, Japan|Site Reference ID/Investigator# 54692, Kagoshima, Japan|Site Reference ID/Investigator# 54679, Kawagoe, Japan|Site Reference ID/Investigator# 59580, Kawagoe, Japan|Site Reference ID/Investigator# 54662, Kawasaki, Japan|Site Reference ID/Investigator# 54693, Kirishima, Japan|Site Reference ID/Investigator# 54671, Kitakyushu, Japan|Site Reference ID/Investigator# 54643, Kumamoto, Japan|Site Reference ID/Investigator# 59583, Kyoto, Japan|Site Reference ID/Investigator# 59582, Maebashi, Japan|Site Reference ID/Investigator# 39849, Matsumoto, Japan|Site Reference ID/Investigator# 54520, Matsuyama, Japan|Site Reference ID/Investigator# 54644, Miyazaki, Japan|Site Reference ID/Investigator# 54645, Morioka, Japan|Site Reference ID/Investigator# 54654, Nagano, Japan|Site Reference ID/Investigator# 54656, Nagaoka, Japan|Site Reference ID/Investigator# 63052, Nagasaki, Japan|Site Reference ID/Investigator# 54667, Nagoya, Japan|Site Reference ID/Investigator# 54673, Nagoya, Japan|Site Reference ID/Investigator# 54649, Nara, Japan|Site Reference ID/Investigator# 39844, Niigata, Japan|Site Reference ID/Investigator# 54675, Oita, Japan|Site Reference ID/Investigator# 39847, Okayama, Japan|Site Reference ID/Investigator# 54681, Okayama, Japan|Site Reference ID/Investigator# 39846, Osaka, Japan|Site Reference ID/Investigator# 54518, Osaka, Japan|Site Reference ID/Investigator# 54646, Rifu, Japan|Site Reference ID/Investigator# 54661, Sagamihara, Kanagawa, Japan|Site Reference ID/Investigator# 54514, Saitama, Japan|Site Reference ID/Investigator# 54689, Saitama, Japan|Site Reference ID/Investigator# 25922, Sapporo, Japan|Site Reference ID/Investigator# 39850, Sapporo, Japan|Site Reference ID/Investigator# 54651, Sapporo, Japan|Site Reference ID/Investigator# 54652, Sapporo, Japan|Site Reference ID/Investigator# 54522, Sasebo, Japan|Site Reference ID/Investigator# 54650, Setouchi, Japan|Site Reference ID/Investigator# 39851, Shimotsuke, Japan|Site Reference ID/Investigator# 39845, Shizuoka, Japan|Site Reference ID/Investigator# 54517, Shizuoka, Japan|Site Reference ID/Investigator# 59579, Takamatsu, Japan|Site Reference ID/Investigator# 54655, Takasaki, Japan|Site Reference ID/Investigator# 54519, Tenri, Japan|Site Reference ID/Investigator# 54515, Tokorozawa, Japan|Site Reference ID/Investigator# 39842, Tokyo, Japan|Site Reference ID/Investigator# 39852, Tokyo, Japan|Site Reference ID/Investigator# 39853, Tokyo, Japan|Site Reference ID/Investigator# 54647, Tokyo, Japan|Site Reference ID/Investigator# 54657, Tokyo, Japan|Site Reference ID/Investigator# 54658, Tokyo, Japan|Site Reference ID/Investigator# 54678, Tokyo, Japan|Site Reference ID/Investigator# 54688, Tokyo, Japan|Site Reference ID/Investigator# 59581, Tokyo, Japan|Site Reference ID/Investigator# 54672, Tomigusuku, Japan|Site Reference ID/Investigator# 54648, Toyama, Japan|Site Reference ID/Investigator# 54691, Toyama, Japan|Site Reference ID/Investigator# 54690, Toyoake, Japan|Site Reference ID/Investigator# 54676, Toyohashi, Japan|Site Reference ID/Investigator# 54668, Tsu, Japan|Site Reference ID/Investigator# 39843, Yokohama, Japan|Site Reference ID/Investigator# 54663, Yokohama, Japan|Site Reference ID/Investigator# 54664, Yokohama, Japan|Site Reference ID/Investigator# 54665, Yokohama, Japan|Site Reference ID/Investigator# 54659, Yotsukaido, Japan",,"https://ClinicalTrials.gov/show/NCT01163292"
571,"NCT01162421","A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis","RADAR","Completed","Has Results","Rheumatoid Arthritis","Biological: adalimumab|Drug: Methotrexate","Percentage of Participants With No Radiographic Progression at Month 12|Percentage of Participants With No Radiographic Progression at Month 6 and Month 24|Change From Baseline in mTSS at Months 6, 12 and 24|Percentage of Participants With Rapid Radiographic Progression at Month 12|Percentage of Participants With American College of Rheumatology 20% (ACR20) Response at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants With American College of Rheumatology 50% (ACR50) Response at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants With American College of Rheumatology 70% (ACR70) Response at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Swollen Joint Count 66 at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Swollen Joint Count 28 at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Tender Joint Count 68 at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Tender Joint Count 28 at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Physician's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Patient's Global Assessment of Disease Activity at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Patient's Global Assessment of Pain at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in CRP at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Disease Activity Score DAS28(CRP) at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants With DAS28(CRP) Remission at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants With DAS28(CRP) Low Disease Activity at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants With European League Against Rheumatism (EULAR) Good Response at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants With EULAR Moderate Response at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants With Flare-Up After Remission by Month 24|Change From Baseline in Disability Index of the Health Assessment Questionnaire (HAQ-DI) at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants Achieving Minimal Clinical Important Difference (MCID) in HAQ at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants Achieving HAQ < 0.5 at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale at Months 3, 6, 9, 12, 18 and 24|Percentage of Participants Achieving MCID in FACIT-Fatigue Scale at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Work Limitations Questionnaire (WLQ) at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in EuroQOL Questionnaire (EQ-5D) Index Score at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in EQ-5D VAS at Months 3, 6, 9, 12, 18 and 24|Change From Baseline in Beck Depression Inventory (BDI-II) Scores at Months 3, 6, 9, 12, 18 and 24|Likert Scale for Participant's Satisfaction With Care at Months 3, 6, 9, 12, 18 and 24|Health Care Resources Questionnaire (HCR): Medical Insurance at Baseline|HCR: Medical Insurance at Final Visit|HCR: Health Care for RA in the Past 4 Weeks at Baseline|HCR: Health Care for RA in the Past 4 Weeks at Final Visit|HCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Baseline|HCR: Out of Pocket Expenses Incurred for the Current Study Condition in the Past 4 Weeks at Final Visit","AbbVie (prior sponsor, Abbott)|Mount Sinai Hospital, Canada|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","77","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","W12-122","September 2010","July 2015","July 2015","July 14, 2010","November 1, 2016","November 1, 2016",,,"https://ClinicalTrials.gov/show/NCT01162421"
572,"NCT01159743","A Comparison of Body Fat Distribution in HIV-1 Infected Patients Receiving, Since the Beginning and for at Least Two Years, an Antiretroviral Therapy Based on Efavirenz or Lopinavir/Ritonavir Combined With Tenofovir + Emtricitabine or Lamivudine","LYNX","Completed","Has Results","HIV Infection",,"Total Limb Fat Mass|Distribution of Body Fat Mass|Lipodystrophy Severity Grading Scale (LSGS) Scores|Change Over Time in Body Fat Distribution","AbbVie (prior sponsor, Abbott)|Demométrica|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"346","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","P12-031","July 2010","September 2011","September 2011","July 9, 2010","October 30, 2012","January 24, 2013","Site Reference ID/Investigator# 39595, Alicante, Spain|Site Reference ID/Investigator# 39602, Barcelona, Spain|Site Reference ID/Investigator# 39605, Barcelona, Spain|Site Reference ID/Investigator# 39589, Barcelona, Spain|Site Reference ID/Investigator# 39601, Barcelona, Spain|Site Reference ID/Investigator# 39593, Barcelona, Spain|Site Reference ID/Investigator# 39603, Barcelona, Spain|Site Reference ID/Investigator# 39587, Bilbao, Spain|Site Reference ID/Investigator# 39596, Cabuenes-Gijon, Spain|Site Reference ID/Investigator# 39590, Granada, Spain|Site Reference ID/Investigator# 39604, La Laguna Teneriffe, Spain|Site Reference ID/Investigator# 39609, Logrono, Spain|Site Reference ID/Investigator# 39597, Madrid, Spain|Site Reference ID/Investigator# 39600, Madrid, Spain|Site Reference ID/Investigator# 39591, Madrid, Spain|Site Reference ID/Investigator# 24822, Madrid, Spain|Site Reference ID/Investigator# 39586, Madrid, Spain|Site Reference ID/Investigator# 39599, Madrid, Spain|Site Reference ID/Investigator# 39611, Madrid, Spain|Site Reference ID/Investigator# 39588, Malaga, Spain|Site Reference ID/Investigator# 39592, San Sebastian, Spain|Site Reference ID/Investigator# 39606, Seville, Spain|Site Reference ID/Investigator# 39598, Valencia, Spain|Site Reference ID/Investigator# 39612, Valencia, Spain|Site Reference ID/Investigator# 39607, Vigo, Spain|Site Reference ID/Investigator# 39610, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01159743"
573,"NCT01156532","Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy",,"Terminated","Has Results","Moderate to Severe Psoriasis",,"Percentage of Participants Reaching a Psoriasis Area and Severity Index 75 (PASI-75) Response|Percentage of Participants Reaching a Minimal Important Difference (MID) in the Dermatology Life Quality Index (DLQI) Score|European Quality of Life 5 Dimensions (EQ-5D) Index Score at Baseline and Week 16|Number of Participants With Serious Adverse Events (SAEs)|Adherence to Adalimumab Treatment|Mean Psoriasis Area and Severity Index (PASI) Score Over Time|Mean Dermatology Life Quality Index (DLQI) Score Over Time","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-261","November 2010","August 2013","August 2013","July 5, 2010","August 25, 2014","August 25, 2014","Site Reference ID/Investigator# 35783, Lima, Peru|Site Reference ID/Investigator# 56700, Lima, Peru|Site Reference ID/Investigator# 43147, Trujillo, Peru",,"https://ClinicalTrials.gov/show/NCT01156532"
574,"NCT01155570","Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation)",,"Completed","Has Results","Psoriasis",,"Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Drug Reactions (ADRs), Serious Adverse Drug Reactions (SADRs), Deaths, and Discontinuations Due to AEs|Physician's Global Assessment at Week 4|Physician's Global Assessment At Week 8|Physician's Global Assessment at Week 16|Physician's Global Assessment at Week 24|Psoriasis Area and Severity Index (PASI) at Week 16|Psoriasis Area and Severity Index (PASI) at Week 24|Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16|Percentage of Participants With Psoriasis Area and Severity Index 75 (PASI75) Response at Week 24|Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16|Percentage of Participants With Psoriasis Area and Severity Index 90 (PASI90) Response at Week 24|Dermatology Life Quality Index at Week 16|Dermatology Life Quality Index at Week 24|Pain Visual Analog Scale (VAS) at Week 4|Pain Visual Analog Scale (VAS) at Week 16|Pain Visual Analog Scale (VAS) at Week 24|Disease Activity Score 28-4, Erythrocyte Sedimentation Rate (DAS28-4 [ESR]) at Week 4|Disease Activity Score 28-4, Erythrocyte Sedimentation Rate (DAS28-4 [ESR]) at Week 16|Disease Activity Score 28-4, Erythrocyte Sedimentation Rate (DAS28-4 [ESR]) at Week 24|Disease Activity Score 28-4, C-reactive Protein (DAS28-4 [CRP]) at Week 4|Disease Activity Score 28-4, C-reactive Protein (DAS28-4 [CRP]) at Week 16|Disease Activity Score 28-4, C-reactive Protein (DAS28-4 [CRP]) at Week 24|Physician's Overall Response Rating At Week 24","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"752","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-077","February 2010","July 2012","July 2012","July 2, 2010","October 8, 2013","October 8, 2013","Site Reference ID/Investigator# 41606, Aichi, Japan|Site Reference ID/Investigator# 41769, Aichi, Japan|Site Reference ID/Investigator# 41810, Aichi, Japan|Site Reference ID/Investigator# 56131, Aichi, Japan|Site Reference ID/Investigator# 56251, Aichi, Japan|Site Reference ID/Investigator# 56252, Aichi, Japan|Site Reference ID/Investigator# 56254, Aichi, Japan|Site Reference ID/Investigator# 56340, Aichi, Japan|Site Reference ID/Investigator# 60016, Aichi, Japan|Site Reference ID/Investigator# 67150, Aichi, Japan|Site Reference ID/Investigator# 68627, Aichi, Japan|Site Reference ID/Investigator# 41327, Aizuwakamatsu, Japan|Site Reference ID/Investigator# 41820, Akita, Japan|Site Reference ID/Investigator# 41823, Akita, Japan|Site Reference ID/Investigator# 41684, Amagasaki, Japan|Site Reference ID/Investigator# 41851, Amagasaki, Japan|Site Reference ID/Investigator# 41305, Anjo, Japan|Site Reference ID/Investigator# 41822, Aomori, Japan|Site Reference ID/Investigator# 60012, Aomori, Japan|Site Reference ID/Investigator# 64811, Aomori, Japan|Site Reference ID/Investigator# 41800, Asahikawa, Japan|Site Reference ID/Investigator# 80887, Ashikaga, Japan|Site Reference ID/Investigator# 80879, Ayabe, Japan|Site Reference ID/Investigator# 41207, Bunkyo-ku, Tokyo, Japan|Site Reference ID/Investigator# 41247, Chiba, Japan|Site Reference ID/Investigator# 41258, Chiba, Japan|Site Reference ID/Investigator# 41260, Chiba, Japan|Site Reference ID/Investigator# 41263, Chiba, Japan|Site Reference ID/Investigator# 41485, Chiba, Japan|Site Reference ID/Investigator# 41821, Chiba, Japan|Site Reference ID/Investigator# 41927, Chiba, Japan|Site Reference ID/Investigator# 56127, Chiba, Japan|Site Reference ID/Investigator# 56224, Chiba, Japan|Site Reference ID/Investigator# 59995, Chiba, Japan|Site Reference ID/Investigator# 41893, Chuo, Japan|Site Reference ID/Investigator# 41721, Ehime, Japan|Site Reference ID/Investigator# 41724, Ehime, Japan|Site Reference ID/Investigator# 41727, Ehime, Japan|Site Reference ID/Investigator# 41696, Eiheiji, Japan|Site Reference ID/Investigator# 80873, Fujieda, Japan|Site Reference ID/Investigator# 41287, Fujisawa, Japan|Site Reference ID/Investigator# 41550, Fukui, Japan|Site Reference ID/Investigator# 41693, Fukui, Japan|Site Reference ID/Investigator# 41694, Fukui, Japan|Site Reference ID/Investigator# 41697, Fukui, Japan|Site Reference ID/Investigator# 41746, Fukui, Japan|Site Reference ID/Investigator# 41805, Fukui, Japan|Site Reference ID/Investigator# 41326, Fukuoka, Japan|Site Reference ID/Investigator# 41476, Fukuoka, Japan|Site Reference ID/Investigator# 41604, Fukuoka, Japan|Site Reference ID/Investigator# 41607, Fukuoka, Japan|Site Reference ID/Investigator# 41731, Fukuoka, Japan|Site Reference ID/Investigator# 41734, Fukuoka, Japan|Site Reference ID/Investigator# 41747, Fukuoka, Japan|Site Reference ID/Investigator# 41796, Fukuoka, Japan|Site Reference ID/Investigator# 41812, Fukuoka, Japan|Site Reference ID/Investigator# 56349, Fukuoka, Japan|Site Reference ID/Investigator# 56350, Fukuoka, Japan|Site Reference ID/Investigator# 59987, Fukuoka, Japan|Site Reference ID/Investigator# 59991, Fukuoka, Japan|Site Reference ID/Investigator# 41745, Fukushima, Japan|Site Reference ID/Investigator# 41757, Fukushima, Japan|Site Reference ID/Investigator# 41758, Fukushima, Japan|Site Reference ID/Investigator# 41818, Fukushima, Japan|Site Reference ID/Investigator# 41824, Fukushima, Japan|Site Reference ID/Investigator# 41825, Fukushima, Japan|Site Reference ID/Investigator# 56095, Fukushima, Japan|Site Reference ID/Investigator# 56242, Fukushima, Japan|Site Reference ID/Investigator# 56330, Fukushima, Japan|Site Reference ID/Investigator# 41301, Gifu, Japan|Site Reference ID/Investigator# 41302, Gifu, Japan|Site Reference ID/Investigator# 41306, Gifu, Japan|Site Reference ID/Investigator# 41309, Gifu, Japan|Site Reference ID/Investigator# 41322, Gifu, Japan|Site Reference ID/Investigator# 41774, Gifu, Japan|Site Reference ID/Investigator# 56103, Gifu, Japan|Site Reference ID/Investigator# 59989, Gifu, Japan|Site Reference ID/Investigator# 41830, Gunma, Japan|Site Reference ID/Investigator# 56122, Gunma, Japan|Site Reference ID/Investigator# 56123, Gunma, Japan|Site Reference ID/Investigator# 56207, Gunma, Japan|Site Reference ID/Investigator# 59986, Gunma, Japan|Site Reference ID/Investigator# 59997, Gunma, Japan|Site Reference ID/Investigator# 41828, Hakodate, Japan|Site Reference ID/Investigator# 41303, Hamamatsu, Japan|Site Reference ID/Investigator# 41304, Hamamatsu, Japan|Site Reference ID/Investigator# 59992, Hamamatsu, Japan|Site Reference ID/Investigator# 80895, Hamamatsu, Japan|Site Reference ID/Investigator# 56135, Hannan, Japan|Site Reference ID/Investigator# 56198, Higashihiroshima, Japan|Site Reference ID/Investigator# 41748, Himeji, Japan|Site Reference ID/Investigator# 41917, Himeji, Japan|Site Reference ID/Investigator# 41668, Hirakata, Japan|Site Reference ID/Investigator# 41915, Hirosaki, Japan|Site Reference ID/Investigator# 41712, Hiroshima, Japan|Site Reference ID/Investigator# 41713, Hiroshima, Japan|Site Reference ID/Investigator# 41714, Hiroshima, Japan|Site Reference ID/Investigator# 41715, Hiroshima, Japan|Site Reference ID/Investigator# 41716, Hiroshima, Japan|Site Reference ID/Investigator# 41717, Hiroshima, Japan|Site Reference ID/Investigator# 41753, Hiroshima, Japan|Site Reference ID/Investigator# 41773, Hiroshima, Japan|Site Reference ID/Investigator# 41833, Hiroshima, Japan|Site Reference ID/Investigator# 41835, Hiroshima, Japan|Site Reference ID/Investigator# 56196, Hiroshima, Japan|Site Reference ID/Investigator# 56197, Hiroshima, Japan|Site Reference ID/Investigator# 56346, Hiroshima, Japan|Site Reference ID/Investigator# 56347, Hiroshima, Japan|Site Reference ID/Investigator# 59988, Hiroshima, Japan|Site Reference ID/Investigator# 59999, Hiroshima, Japan|Site Reference ID/Investigator# 60013, Hiroshima, Japan|Site Reference ID/Investigator# 60017, Hiroshima, Japan|Site Reference ID/Investigator# 60018, Hiroshima, Japan|Site Reference ID/Investigator# 41827, Hokkaido, Japan|Site Reference ID/Investigator# 41829, Hokkaido, Japan|Site Reference ID/Investigator# 41832, Hokkaido, Japan|Site Reference ID/Investigator# 41837, Hokkaido, Japan|Site Reference ID/Investigator# 41838, Hokkaido, Japan|Site Reference ID/Investigator# 41842, Hokkaido, Japan|Site Reference ID/Investigator# 41844, Hokkaido, Japan|Site Reference ID/Investigator# 41847, Hokkaido, Japan|Site Reference ID/Investigator# 41852, Hokkaido, Japan|Site Reference ID/Investigator# 41929, Hokkaido, Japan|Site Reference ID/Investigator# 56109, Hokkaido, Japan|Site Reference ID/Investigator# 56206, Hokkaido, Japan|Site Reference ID/Investigator# 56327, Hokkaido, Japan|Site Reference ID/Investigator# 60014, Hokkaido, Japan|Site Reference ID/Investigator# 64802, Hokkaido, Japan|Site Reference ID/Investigator# 64813, Hokkaido, Japan|Site Reference ID/Investigator# 67144, Hokkaido, Japan|Site Reference ID/Investigator# 71456, Hokkaido, Japan|Site Reference ID/Investigator# 41481, Hyogo, Japan|Site Reference ID/Investigator# 41683, Hyogo, Japan|Site Reference ID/Investigator# 41687, Hyogo, Japan|Site Reference ID/Investigator# 41691, Hyogo, Japan|Site Reference ID/Investigator# 41750, Hyogo, Japan|Site Reference ID/Investigator# 41771, Hyogo, Japan|Site Reference ID/Investigator# 41846, Hyogo, Japan|Site Reference ID/Investigator# 56142, Hyogo, Japan|Site Reference ID/Investigator# 56143, Hyogo, Japan|Site Reference ID/Investigator# 56144, Hyogo, Japan|Site Reference ID/Investigator# 56146, Hyogo, Japan|Site Reference ID/Investigator# 56342, Hyogo, Japan|Site Reference ID/Investigator# 56343, Hyogo, Japan|Site Reference ID/Investigator# 60015, Hyogo, Japan|Site Reference ID/Investigator# 67149, Hyogo, Japan|Site Reference ID/Investigator# 41848, Ibaraki, Japan|Site Reference ID/Investigator# 41849, Ibaraki, Japan|Site Reference ID/Investigator# 41858, Ibaraki, Japan|Site Reference ID/Investigator# 41908, Ichikawa, Japan|Site Reference ID/Investigator# 41293, Ichinomiya, Japan|Site Reference ID/Investigator# 56229, Ichinomiya, Japan|Site Reference ID/Investigator# 56333, Ichinomiya, Japan|Site Reference ID/Investigator# 56137, Ikoma, Japan|Site Reference ID/Investigator# 56226, Inabe, Japan|Site Reference ID/Investigator# 56120, Inashiki, Japan|Site Reference ID/Investigator# 80893, Inzai, Japan|Site Reference ID/Investigator# 41740, Isahaya, Japan|Site Reference ID/Investigator# 56230, Isesaki, Japan|Site Reference ID/Investigator# 41330, Ishikawa, Japan|Site Reference ID/Investigator# 41543, Ishikawa, Japan|Site Reference ID/Investigator# 41695, Ishikawa, Japan|Site Reference ID/Investigator# 41920, Ishikawa, Japan|Site Reference ID/Investigator# 41889, Iwafune, Japan|Site Reference ID/Investigator# 56348, Iwakuni, Japan|Site Reference ID/Investigator# 80916, Iwakuni, Japan|Site Reference ID/Investigator# 41914, Iwate, Japan|Site Reference ID/Investigator# 59998, Iwate, Japan|Site Reference ID/Investigator# 41704, Izumo, Japan|Site Reference ID/Investigator# 41719, Izumo, Japan|Site Reference ID/Investigator# 56195, Izumo, Japan|Site Reference ID/Investigator# 41294, Izunokuni, Japan|Site Reference ID/Investigator# 41299, Izunokuni, Japan|Site Reference ID/Investigator# 41300, Izunokuni, Japan|Site Reference ID/Investigator# 60006, Joetsu, Japan|Site Reference ID/Investigator# 41720, Kagawa, Japan|Site Reference ID/Investigator# 41725, Kagawa, Japan|Site Reference ID/Investigator# 56200, Kagawa, Japan|Site Reference ID/Investigator# 56201, Kagawa, Japan|Site Reference ID/Investigator# 41737, Kagoshima, Japan|Site Reference ID/Investigator# 67145, Kagoshima, Japan|Site Reference ID/Investigator# 41283, Kanagawa, Japan|Site Reference ID/Investigator# 41284, Kanagawa, Japan|Site Reference ID/Investigator# 41451, Kanagawa, Japan|Site Reference ID/Investigator# 41452, Kanagawa, Japan|Site Reference ID/Investigator# 41815, Kanagawa, Japan|Site Reference ID/Investigator# 41854, Kanagawa, Japan|Site Reference ID/Investigator# 41856, Kanagawa, Japan|Site Reference ID/Investigator# 41862, Kanagawa, Japan|Site Reference ID/Investigator# 56098, Kanagawa, Japan|Site Reference ID/Investigator# 56250, Kanagawa, Japan|Site Reference ID/Investigator# 60011, Kanagawa, Japan|Site Reference ID/Investigator# 64805, Kanagawa, Japan|Site Reference ID/Investigator# 68629, Kanagawa, Japan|Site Reference ID/Investigator# 41699, Kanazawa, Japan|Site Reference ID/Investigator# 41762, Kariya, Japan|Site Reference ID/Investigator# 41461, Kashihara, Japan|Site Reference ID/Investigator# 41486, Kashiwa, Japan|Site Reference ID/Investigator# 41482, Kawagoe, Japan|Site Reference ID/Investigator# 41484, Kawagoe, Japan|Site Reference ID/Investigator# 41784, Kawagoe, Japan|Site Reference ID/Investigator# 41279, Kawasaki, Japan|Site Reference ID/Investigator# 41280, Kawasaki, Japan|Site Reference ID/Investigator# 41281, Kawasaki, Japan|Site Reference ID/Investigator# 41282, Kawasaki, Japan|Site Reference ID/Investigator# 71453, Kawasaki, Japan|Site Reference ID/Investigator# 80880, Kawasaki, Japan|Site Reference ID/Investigator# 41269, Kisarazu, Japan|Site Reference ID/Investigator# 41733, Kitakyushu, Japan|Site Reference ID/Investigator# 41735, Kitakyushu, Japan|Site Reference ID/Investigator# 68626, Kitakyushu, Japan|Site Reference ID/Investigator# 71454, Kitakyushu, Japan|Site Reference ID/Investigator# 80892, Kitakyushu, Japan|Site Reference ID/Investigator# 41471, Kobe, Japan|Site Reference ID/Investigator# 41472, Kobe, Japan|Site Reference ID/Investigator# 41544, Kobe, Japan|Site Reference ID/Investigator# 41686, Kobe, Japan|Site Reference ID/Investigator# 56090, Kobe, Japan|Site Reference ID/Investigator# 56145, Kobe, Japan|Site Reference ID/Investigator# 56264, Kobe, Japan|Site Reference ID/Investigator# 80874, Kobe, Japan|Site Reference ID/Investigator# 80883, Kobe, Japan|Site Reference ID/Investigator# 80914, Kobe, Japan|Site Reference ID/Investigator# 41480, Kochi, Japan|Site Reference ID/Investigator# 41548, Kochi, Japan|Site Reference ID/Investigator# 89493, Kofu, Japan|Site Reference ID/Investigator# 60003, Komaki, Japan|Site Reference ID/Investigator# 67153, Komoro, Japan|Site Reference ID/Investigator# 41817, Konan, Japan|Site Reference ID/Investigator# 41798, Koriyama, Japan|Site Reference ID/Investigator# 41819, Koriyama, Japan|Site Reference ID/Investigator# 41262, Koshigaya, Japan|Site Reference ID/Investigator# 56263, Kudamatsu, Japan|Site Reference ID/Investigator# 56087, Kumamoto, Japan|Site Reference ID/Investigator# 56351, Kumamoto, Japan|Site Reference ID/Investigator# 41467, Kurashiki, Japan|Site Reference ID/Investigator# 41903, Kurashiki, Japan|Site Reference ID/Investigator# 41904, Kurashiki, Japan|Site Reference ID/Investigator# 41926, Kurashiki, Japan|Site Reference ID/Investigator# 60001, Kurashiki, Japan|Site Reference ID/Investigator# 41718, Kure, Japan|Site Reference ID/Investigator# 41689, Kurobe, Japan|Site Reference ID/Investigator# 41460, Kurume, Japan|Site Reference ID/Investigator# 56202, Kurume, Japan|Site Reference ID/Investigator# 41839, Kushiro, Japan|Site Reference ID/Investigator# 41454, Kyoto, Japan|Site Reference ID/Investigator# 41698, Kyoto, Japan|Site Reference ID/Investigator# 41700, Kyoto, Japan|Site Reference ID/Investigator# 41705, Kyoto, Japan|Site Reference ID/Investigator# 41768, Kyoto, Japan|Site Reference ID/Investigator# 41801, Kyoto, Japan|Site Reference ID/Investigator# 41806, Kyoto, Japan|Site Reference ID/Investigator# 41905, Kyoto, Japan|Site Reference ID/Investigator# 41921, Kyoto, Japan|Site Reference ID/Investigator# 56193, Kyoto, Japan|Site Reference ID/Investigator# 56194, Kyoto, Japan|Site Reference ID/Investigator# 56259, Kyoto, Japan|Site Reference ID/Investigator# 56344, Kyoto, Japan|Site Reference ID/Investigator# 60005, Kyoto, Japan|Site Reference ID/Investigator# 64807, Kyoto, Japan|Site Reference ID/Investigator# 41831, Maebashi, Japan|Site Reference ID/Investigator# 41834, Maebashi, Japan|Site Reference ID/Investigator# 56121, Maebashi, Japan|Site Reference ID/Investigator# 67263, Maebashi, Japan|Site Reference ID/Investigator# 59994, Maizuru, Japan|Site Reference ID/Investigator# 41900, Matsumoto, Japan|Site Reference ID/Investigator# 41901, Matsumoto, Japan|Site Reference ID/Investigator# 41324, Matsuyama, Japan|Site Reference ID/Investigator# 41723, Matsuyama, Japan|Site Reference ID/Investigator# 41902, Matsuyama, Japan|Site Reference ID/Investigator# 41308, MIE, Japan|Site Reference ID/Investigator# 41749, Mie, Japan|Site Reference ID/Investigator# 56208, Mie, Japan|Site Reference ID/Investigator# 56255, Mie, Japan|Site Reference ID/Investigator# 59996, Mie, Japan|Site Reference ID/Investigator# 41608, Minato, Japan|Site Reference ID/Investigator# 41794, Minato, Japan|Site Reference ID/Investigator# 41760, Mito, Japan|Site Reference ID/Investigator# 41855, Miyagi, Japan|Site Reference ID/Investigator# 41859, Miyagi, Japan|Site Reference ID/Investigator# 41861, Miyagi, Japan|Site Reference ID/Investigator# 41865, Miyagi, Japan|Site Reference ID/Investigator# 41871, Miyagi, Japan|Site Reference ID/Investigator# 56111, Miyagi, Japan|Site Reference ID/Investigator# 56112, Miyagi, Japan|Site Reference ID/Investigator# 56329, Miyagi, Japan|Site Reference ID/Investigator# 41475, Miyazaki, Japan|Site Reference ID/Investigator# 41790, Miyazaki, Japan|Site Reference ID/Investigator# 41791, Miyazaki, Japan|Site Reference ID/Investigator# 41919, Miyazaki, Japan|Site Reference ID/Investigator# 60021, Miyazaki, Japan|Site Reference ID/Investigator# 41458, Morioka, Japan|Site Reference ID/Investigator# 41462, Nagakute, Japan|Site Reference ID/Investigator# 41545, Nagakute, Japan|Site Reference ID/Investigator# 41797, Nagano, Japan|Site Reference ID/Investigator# 41863, Nagano, Japan|Site Reference ID/Investigator# 41866, Nagano, Japan|Site Reference ID/Investigator# 41870, Nagano, Japan|Site Reference ID/Investigator# 56124, Nagano, Japan|Site Reference ID/Investigator# 64808, Nagaokakyo, Japan|Site Reference ID/Investigator# 41464, Nagasaki, Japan|Site Reference ID/Investigator# 41728, Nagasaki, Japan|Site Reference ID/Investigator# 41730, Nagasaki, Japan|Site Reference ID/Investigator# 41736, Nagasaki, Japan|Site Reference ID/Investigator# 41756, Nagasaki, Japan|Site Reference ID/Investigator# 41789, Nagasaki, Japan|Site Reference ID/Investigator# 41864, Nagasaki, Japan|Site Reference ID/Investigator# 41877, Nagasaki, Japan|Site Reference ID/Investigator# 41289, Nagoya, Japan|Site Reference ID/Investigator# 41290, Nagoya, Japan|Site Reference ID/Investigator# 41549, Nagoya, Japan|Site Reference ID/Investigator# 41744, Nagoya, Japan|Site Reference ID/Investigator# 41802, Nagoya, Japan|Site Reference ID/Investigator# 41909, Nagoya, Japan|Site Reference ID/Investigator# 41910, Nagoya, Japan|Site Reference ID/Investigator# 56130, Nagoya, Japan|Site Reference ID/Investigator# 41804, Nanao, Japan|Site Reference ID/Investigator# 41478, Nankoku, Japan|Site Reference ID/Investigator# 41710, Nara, Japan|Site Reference ID/Investigator# 56091, Nara, Japan|Site Reference ID/Investigator# 56227, Nara, Japan|Site Reference ID/Investigator# 59985, Nara, Japan|Site Reference ID/Investigator# 80896, Nayori, Japan|Site Reference ID/Investigator# 67152, Nigata, Japan|Site Reference ID/Investigator# 41793, Niigata, Japan|Site Reference ID/Investigator# 41873, Niigata, Japan|Site Reference ID/Investigator# 41879, Niigata, Japan|Site Reference ID/Investigator# 56326, Niigata, Japan|Site Reference ID/Investigator# 64812, Niigata, Japan|Site Reference ID/Investigator# 41741, Nishihara, Japan|Site Reference ID/Investigator# 41682, Nishinomiya, Japan|Site Reference ID/Investigator# 41690, Nishinomiya, Japan|Site Reference ID/Investigator# 80877, Nishio, Japan|Site Reference ID/Investigator# 67264, Nisshin, Japan|Site Reference ID/Investigator# 41841, Obihiro, Japan|Site Reference ID/Investigator# 41843, Obihiro, Japan|Site Reference ID/Investigator# 41857, Odawara, Japan|Site Reference ID/Investigator# 41766, Ogaki, Japan|Site Reference ID/Investigator# 41906, Oita, Japan|Site Reference ID/Investigator# 56203, Oita, Japan|Site Reference ID/Investigator# 80876, Okawa, Japan|Site Reference ID/Investigator# 41701, Okayama, Japan|Site Reference ID/Investigator# 41702, Okayama, Japan|Site Reference ID/Investigator# 41703, Okayama, Japan|Site Reference ID/Investigator# 41709, Okayama, Japan|Site Reference ID/Investigator# 41918, Okayama, Japan|Site Reference ID/Investigator# 60019, Okayama, Japan|Site Reference ID/Investigator# 64809, Okayama, Japan|Site Reference ID/Investigator# 41457, Osakasayama, Japan|Site Reference ID/Investigator# 41469, Osakasayama, Japan|Site Reference ID/Investigator# 41310, Osaka, Japan|Site Reference ID/Investigator# 41455, Osaka, Japan|Site Reference ID/Investigator# 41456, Osaka, Japan|Site Reference ID/Investigator# 41466, Osaka, Japan|Site Reference ID/Investigator# 41477, Osaka, Japan|Site Reference ID/Investigator# 41662, Osaka, Japan|Site Reference ID/Investigator# 41663, Osaka, Japan|Site Reference ID/Investigator# 41664, Osaka, Japan|Site Reference ID/Investigator# 41667, Osaka, Japan|Site Reference ID/Investigator# 41669, Osaka, Japan|Site Reference ID/Investigator# 41670, Osaka, Japan|Site Reference ID/Investigator# 41671, Osaka, Japan|Site Reference ID/Investigator# 41672, Osaka, Japan|Site Reference ID/Investigator# 41673, Osaka, Japan|Site Reference ID/Investigator# 41674, Osaka, Japan|Site Reference ID/Investigator# 41675, Osaka, Japan|Site Reference ID/Investigator# 41676, Osaka, Japan|Site Reference ID/Investigator# 41678, Osaka, Japan|Site Reference ID/Investigator# 41679, Osaka, Japan|Site Reference ID/Investigator# 41680, Osaka, Japan|Site Reference ID/Investigator# 41743, Osaka, Japan|Site Reference ID/Investigator# 41786, Osaka, Japan|Site Reference ID/Investigator# 41799, Osaka, Japan|Site Reference ID/Investigator# 41809, Osaka, Japan|Site Reference ID/Investigator# 41811, Osaka, Japan|Site Reference ID/Investigator# 41874, Osaka, Japan|Site Reference ID/Investigator# 41875, Osaka, Japan|Site Reference ID/Investigator# 41878, Osaka, Japan|Site Reference ID/Investigator# 56088, Osaka, Japan|Site Reference ID/Investigator# 56134, Osaka, Japan|Site Reference ID/Investigator# 56205, Osaka, Japan|Site Reference ID/Investigator# 56256, Osaka, Japan|Site Reference ID/Investigator# 56257, Osaka, Japan|Site Reference ID/Investigator# 56325, Osaka, Japan|Site Reference ID/Investigator# 56341, Osaka, Japan|Site Reference ID/Investigator# 59990, Osaka, Japan|Site Reference ID/Investigator# 67143, Osaka, Japan|Site Reference ID/Investigator# 67148, Osaka, Japan|Site Reference ID/Investigator# 67151, Osaka, Japan|Site Reference ID/Investigator# 80878, Osaka, Japan|Site Reference ID/Investigator# 80882, Osaka, Japan|Site Reference ID/Investigator# 80915, Osaka, Japan|Site Reference ID/Investigator# 41840, Osaki, Japan|Site Reference ID/Investigator# 41867, Osaki, Japan|Site Reference ID/Investigator# 41869, Osaki, Japan|Site Reference ID/Investigator# 56113, Osaki, Japan|Site Reference ID/Investigator# 41708, Otsu, Japan|Site Reference ID/Investigator# 56345, Otsu, Japan|Site Reference ID/Investigator# 80875, Rifu, Japan|Site Reference ID/Investigator# 41468, Sagamihara, Kanagawa, Japan|Site Reference ID/Investigator# 41323, Sagamihara, Japan|Site Reference ID/Investigator# 41729, Saga, Japan|Site Reference ID/Investigator# 41732, Saga, Japan|Site Reference ID/Investigator# 41876, Saga, Japan|Site Reference ID/Investigator# 41256, Saitama, Japan|Site Reference ID/Investigator# 41257, Saitama, Japan|Site Reference ID/Investigator# 41261, Saitama, Japan|Site Reference ID/Investigator# 41264, Saitama, Japan|Site Reference ID/Investigator# 41265, Saitama, Japan|Site Reference ID/Investigator# 41266, Saitama, Japan|Site Reference ID/Investigator# 41267, Saitama, Japan|Site Reference ID/Investigator# 41270, Saitama, Japan|Site Reference ID/Investigator# 41271, Saitama, Japan|Site Reference ID/Investigator# 41272, Saitama, Japan|Site Reference ID/Investigator# 41274, Saitama, Japan|Site Reference ID/Investigator# 41278, Saitama, Japan|Site Reference ID/Investigator# 41329, Saitama, Japan|Site Reference ID/Investigator# 56094, Saitama, Japan|Site Reference ID/Investigator# 56099, Saitama, Japan|Site Reference ID/Investigator# 56100, Saitama, Japan|Site Reference ID/Investigator# 56249, Saitama, Japan|Site Reference ID/Investigator# 60009, Saitama, Japan|Site Reference ID/Investigator# 64803, Saitama, Japan|Site Reference ID/Investigator# 64804, Saitama, Japan|Site Reference ID/Investigator# 64810, Saitama, Japan|Site Reference ID/Investigator# 41603, Sakai, Japan|Site Reference ID/Investigator# 56136, Sakai, Japan|Site Reference ID/Investigator# 41826, Sakura, Japan|Site Reference ID/Investigator# 41868, Saku, Japan|Site Reference ID/Investigator# 41763, Sapporo, Japan|Site Reference ID/Investigator# 41850, Sapporo, Japan|Site Reference ID/Investigator# 41853, Sapporo, Japan|Site Reference ID/Investigator# 56105, Sapporo, Japan|Site Reference ID/Investigator# 56107, Sapporo, Japan|Site Reference ID/Investigator# 56108, Sapporo, Japan|Site Reference ID/Investigator# 56209, Sapporo, Japan|Site Reference ID/Investigator# 80884, Sapporo, Japan|Site Reference ID/Investigator# 41739, Sasebo, Japan|Site Reference ID/Investigator# 41755, Sasebo, Japan|Site Reference ID/Investigator# 41605, Sendai, Japan|Site Reference ID/Investigator# 41813, Sendai, Japan|Site Reference ID/Investigator# 41814, Sendai, Japan|Site Reference ID/Investigator# 41930, Sendai, Japan|Site Reference ID/Investigator# 80889, Sendai, Japan|Site Reference ID/Investigator# 41546, Seto, Japan|Site Reference ID/Investigator# 41553, Shiga, Japan|Site Reference ID/Investigator# 41707, Shiga, Japan|Site Reference ID/Investigator# 41754, Shiga, Japan|Site Reference ID/Investigator# 41922, Shiga, Japan|Site Reference ID/Investigator# 59993, Shiga, Japan|Site Reference ID/Investigator# 60007, Shimane, Japan|Site Reference ID/Investigator# 41884, Shimotsuke, Japan|Site Reference ID/Investigator# 41885, Shimotsuke, Japan|Site Reference ID/Investigator# 41292, Shizuoka, Japan|Site Reference ID/Investigator# 41295, Shizuoka, Japan|Site Reference ID/Investigator# 41296, Shizuoka, Japan|Site Reference ID/Investigator# 41298, Shizuoka, Japan|Site Reference ID/Investigator# 41328, Shizuoka, Japan|Site Reference ID/Investigator# 41479, Shizuoka, Japan|Site Reference ID/Investigator# 41772, Shizuoka, Japan|Site Reference ID/Investigator# 41808, Shizuoka, Japan|Site Reference ID/Investigator# 41872, Shizuoka, Japan|Site Reference ID/Investigator# 41880, Shizuoka, Japan|Site Reference ID/Investigator# 41881, Shizuoka, Japan|Site Reference ID/Investigator# 56101, Shizuoka, Japan|Site Reference ID/Investigator# 56132, Shizuoka, Japan|Site Reference ID/Investigator# 56133, Shizuoka, Japan|Site Reference ID/Investigator# 56253, Shizuoka, Japan|Site Reference ID/Investigator# 56339, Shizuoka, Japan|Site Reference ID/Investigator# 68628, Shizuoka, Japan|Site Reference ID/Investigator# 41928, Shunan, Japan|Site Reference ID/Investigator# 80886, Soka, Japan|Site Reference ID/Investigator# 41551, Takamatsu, Japan|Site Reference ID/Investigator# 41552, Takamatsu, Japan|Site Reference ID/Investigator# 41761, Takamatsu, Japan|Site Reference ID/Investigator# 41836, Takasaki, Japan|Site Reference ID/Investigator# 41665, Takatsuki, Japan|Site Reference ID/Investigator# 41666, Takatsuki, Japan|Site Reference ID/Investigator# 41767, Takatsuki, Japan|Site Reference ID/Investigator# 56138, Tanabe, Japan|Site Reference ID/Investigator# 41465, Tenri, Japan|Site Reference ID/Investigator# 41752, Tenri, Japan|Site Reference ID/Investigator# 41803, Tokushima, Japan|Site Reference ID/Investigator# 56222, Tokushima, Japan|Site Reference ID/Investigator# 67146, Tokushima, Japan|Site Reference ID/Investigator# 26162, Tokyo, Japan|Site Reference ID/Investigator# 41206, Tokyo, Japan|Site Reference ID/Investigator# 41208, Tokyo, Japan|Site Reference ID/Investigator# 41209, Tokyo, Japan|Site Reference ID/Investigator# 41210, Tokyo, Japan|Site Reference ID/Investigator# 41211, Tokyo, Japan|Site Reference ID/Investigator# 41212, Tokyo, Japan|Site Reference ID/Investigator# 41213, Tokyo, Japan|Site Reference ID/Investigator# 41214, Tokyo, Japan|Site Reference ID/Investigator# 41222, Tokyo, Japan|Site Reference ID/Investigator# 41223, Tokyo, Japan|Site Reference ID/Investigator# 41224, Tokyo, Japan|Site Reference ID/Investigator# 41225, Tokyo, Japan|Site Reference ID/Investigator# 41226, Tokyo, Japan|Site Reference ID/Investigator# 41227, Tokyo, Japan|Site Reference ID/Investigator# 41228, Tokyo, Japan|Site Reference ID/Investigator# 41229, Tokyo, Japan|Site Reference ID/Investigator# 41230, Tokyo, Japan|Site Reference ID/Investigator# 41239, Tokyo, Japan|Site Reference ID/Investigator# 41240, Tokyo, Japan|Site Reference ID/Investigator# 41241, Tokyo, Japan|Site Reference ID/Investigator# 41242, Tokyo, Japan|Site Reference ID/Investigator# 41243, Tokyo, Japan|Site Reference ID/Investigator# 41244, Tokyo, Japan|Site Reference ID/Investigator# 41245, Tokyo, Japan|Site Reference ID/Investigator# 41246, Tokyo, Japan|Site Reference ID/Investigator# 41259, Tokyo, Japan|Site Reference ID/Investigator# 41268, Tokyo, Japan|Site Reference ID/Investigator# 41273, Tokyo, Japan|Site Reference ID/Investigator# 41443, Tokyo, Japan|Site Reference ID/Investigator# 41444, Tokyo, Japan|Site Reference ID/Investigator# 41445, Tokyo, Japan|Site Reference ID/Investigator# 41446, Tokyo, Japan|Site Reference ID/Investigator# 41447, Tokyo, Japan|Site Reference ID/Investigator# 41448, Tokyo, Japan|Site Reference ID/Investigator# 41449, Tokyo, Japan|Site Reference ID/Investigator# 41459, Tokyo, Japan|Site Reference ID/Investigator# 41470, Tokyo, Japan|Site Reference ID/Investigator# 41474, Tokyo, Japan|Site Reference ID/Investigator# 41547, Tokyo, Japan|Site Reference ID/Investigator# 41602, Tokyo, Japan|Site Reference ID/Investigator# 41610, Tokyo, Japan|Site Reference ID/Investigator# 41742, Tokyo, Japan|Site Reference ID/Investigator# 41764, Tokyo, Japan|Site Reference ID/Investigator# 41765, Tokyo, Japan|Site Reference ID/Investigator# 41792, Tokyo, Japan|Site Reference ID/Investigator# 41795, Tokyo, Japan|Site Reference ID/Investigator# 41882, Tokyo, Japan|Site Reference ID/Investigator# 41883, Tokyo, Japan|Site Reference ID/Investigator# 41886, Tokyo, Japan|Site Reference ID/Investigator# 41887, Tokyo, Japan|Site Reference ID/Investigator# 41888, Tokyo, Japan|Site Reference ID/Investigator# 41890, Tokyo, Japan|Site Reference ID/Investigator# 41891, Tokyo, Japan|Site Reference ID/Investigator# 41892, Tokyo, Japan|Site Reference ID/Investigator# 41896, Tokyo, Japan|Site Reference ID/Investigator# 41897, Tokyo, Japan|Site Reference ID/Investigator# 41907, Tokyo, Japan|Site Reference ID/Investigator# 41911, Tokyo, Japan|Site Reference ID/Investigator# 41912, Tokyo, Japan|Site Reference ID/Investigator# 41913, Tokyo, Japan|Site Reference ID/Investigator# 41924, Tokyo, Japan|Site Reference ID/Investigator# 41925, Tokyo, Japan|Site Reference ID/Investigator# 56092, Tokyo, Japan|Site Reference ID/Investigator# 56093, Tokyo, Japan|Site Reference ID/Investigator# 56102, Tokyo, Japan|Site Reference ID/Investigator# 56104, Tokyo, Japan|Site Reference ID/Investigator# 56125, Tokyo, Japan|Site Reference ID/Investigator# 56126, Tokyo, Japan|Site Reference ID/Investigator# 56211, Tokyo, Japan|Site Reference ID/Investigator# 56225, Tokyo, Japan|Site Reference ID/Investigator# 56243, Tokyo, Japan|Site Reference ID/Investigator# 56244, Tokyo, Japan|Site Reference ID/Investigator# 56245, Tokyo, Japan|Site Reference ID/Investigator# 56246, Tokyo, Japan|Site Reference ID/Investigator# 56247, Tokyo, Japan|Site Reference ID/Investigator# 56248, Tokyo, Japan|Site Reference ID/Investigator# 56331, Tokyo, Japan|Site Reference ID/Investigator# 60000, Tokyo, Japan|Site Reference ID/Investigator# 60002, Tokyo, Japan|Site Reference ID/Investigator# 60008, Tokyo, Japan|Site Reference ID/Investigator# 60020, Tokyo, Japan|Site Reference ID/Investigator# 80885, Tokyo, Japan|Site Reference ID/Investigator# 80888, Tokyo, Japan|Site Reference ID/Investigator# 41787, Tonami, Japan|Site Reference ID/Investigator# 67142, Toride, Japan|Site Reference ID/Investigator# 56262, Tottori, Japan|Site Reference ID/Investigator# 41325, Toyama, Japan|Site Reference ID/Investigator# 41609, Toyama, Japan|Site Reference ID/Investigator# 41685, Toyama, Japan|Site Reference ID/Investigator# 41688, Toyama, Japan|Site Reference ID/Investigator# 41692, Toyama, Japan|Site Reference ID/Investigator# 41783, Toyama, Japan|Site Reference ID/Investigator# 56097, Toyama, Japan|Site Reference ID/Investigator# 56192, Toyama, Japan|Site Reference ID/Investigator# 56258, Toyama, Japan|Site Reference ID/Investigator# 60004, Toyama, Japan|Site Reference ID/Investigator# 64806, Toyama, Japan|Site Reference ID/Investigator# 41288, Toyoake, Japan|Site Reference ID/Investigator# 60010, Toyoake, Japan|Site Reference ID/Investigator# 67147, Toyoake, Japan|Site Reference ID/Investigator# 41307, Toyohashi, Japan|Site Reference ID/Investigator# 41845, Toyooka, Japan|Site Reference ID/Investigator# 56228, Toyooka, Japan|Site Reference ID/Investigator# 56089, Toyota, Japan|Site Reference ID/Investigator# 56114, Tsukuba, Japan|Site Reference ID/Investigator# 56115, Tsukuba, Japan|Site Reference ID/Investigator# 56204, Tsuyama, Japan|Site Reference ID/Investigator# 56210, Uji, Japan|Site Reference ID/Investigator# 41453, Urayasu, Japan|Site Reference ID/Investigator# 41759, Urayasu, Japan|Site Reference ID/Investigator# 41807, Utazu, Japan|Site Reference ID/Investigator# 41923, Utazu, Japan|Site Reference ID/Investigator# 80913, Utsunomiya, Japan|Site Reference ID/Investigator# 41463, Wakayama, Japan|Site Reference ID/Investigator# 41677, Wakayama, Japan|Site Reference ID/Investigator# 41681, Wakayama, Japan|Site Reference ID/Investigator# 41770, Wakayama, Japan|Site Reference ID/Investigator# 80890, Yachiyo, Japan|Site Reference ID/Investigator# 80891, Yachiyo, Japan|Site Reference ID/Investigator# 80894, Yachiyo, Japan|Site Reference ID/Investigator# 41894, Yamagata, Japan|Site Reference ID/Investigator# 41895, Yamagata, Japan|Site Reference ID/Investigator# 41898, Yamagata, Japan|Site Reference ID/Investigator# 56110, Yamagata, Japan|Site Reference ID/Investigator# 56328, Yamagata, Japan|Site Reference ID/Investigator# 41711, Yamaguchi, Japan|Site Reference ID/Investigator# 41722, Yamaguchi, Japan|Site Reference ID/Investigator# 41726, Yamaguchi, Japan|Site Reference ID/Investigator# 56199, Yamaguchi, Japan|Site Reference ID/Investigator# 56223, Yamaguchi, Japan|Site Reference ID/Investigator# 41899, Yamanashi, Japan|Site Reference ID/Investigator# 41297, Yatomi, Japan|Site Reference ID/Investigator# 41275, Yokohama, Japan|Site Reference ID/Investigator# 41276, Yokohama, Japan|Site Reference ID/Investigator# 41277, Yokohama, Japan|Site Reference ID/Investigator# 41285, Yokohama, Japan|Site Reference ID/Investigator# 41286, Yokohama, Japan|Site Reference ID/Investigator# 41450, Yokohama, Japan|Site Reference ID/Investigator# 41860, Yokohama, Japan|Site Reference ID/Investigator# 41916, Yokohama, Japan|Site Reference ID/Investigator# 56128, Yokohama, Japan|Site Reference ID/Investigator# 56332, Yokohama, Japan|Site Reference ID/Investigator# 71459, Yokohama, Japan|Site Reference ID/Investigator# 80917, Yokohama, Japan|Site Reference ID/Investigator# 41291, Yokosuka, Japan|Site Reference ID/Investigator# 71458, Yokosuka, Japan|Site Reference ID/Investigator# 41706, Yonago, Japan|Site Reference ID/Investigator# 41738, Yufu, Japan",,"https://ClinicalTrials.gov/show/NCT01155570"
575,"NCT01155193","Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany",,"Completed","Has Results","Respiratory Syncytial Virus Infections",,"Percentage of Participants With RSV-associated Hospitalization|Diagnosis Documented at Hospital Discharge in Registries 02/03 - 06/07 and 07/08|Diagnosis Documented at Hospital Discharge in Registry 08/09 and 09/10 - 15/16|Presence of Complications During Hospitalization|Parental Cooperation in Registries 02/03 - 06/07 and 07/08|Parental Cooperation for Registry 08/09 and 09/10 - 15/16|Mean Number of Palivizumab Injections","AbbVie (prior sponsor, Abbott)|AbbVie","All","up to 24 Months   (Child)",,"30804","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P10-410","September 1, 2002","July 31, 2016","July 31, 2016","July 1, 2010","October 29, 2018","October 29, 2018",,,"https://ClinicalTrials.gov/show/NCT01155193"
576,"NCT01149291","A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitamin D Receptor Activator's for Prevention and Treatment of Secondary Hyperparathyroidism",,"Completed","No Results Available","Secondary Hyperparathyroidism|End Stage Renal Disease",,"To assess percentage change in iPTH (intact Parathyroid Hormone) level monthly among hemodialysis patients with SHPT (Secondary Hyperparathyroidism) receiving sVDRA (Selective Vitamin D Receptor Activator) therapy|Calcium, Phosphorus, ALP (Alkaline Phosphatase)|Albumin, hemoglobin and dialysis adequacy (KT/V)|hsCRP (High Sensitivity C-Reactive Protein)|Serious Adverse events|Mortality data","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"511","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P12-314","July 2011","December 2014","December 2014","June 23, 2010",,"January 12, 2015","Site Reference ID/Investigator# 37822, Antalya, Turkey|Site Reference ID/Investigator# 68286, Antalya, Turkey|Site Reference ID/Investigator# 40677, Antalya, Turkey|Site Reference ID/Investigator# 85153, Istanbul, Turkey|Site Reference ID/Investigator# 40672, Istanbul, Turkey|Site Reference ID/Investigator# 40674, Istanbul, Turkey|Site Reference ID/Investigator# 40678, Istanbul, Turkey|Site Reference ID/Investigator# 40686, Istanbul, Turkey|Site Reference ID/Investigator# 61585, Istanbul, Turkey|Site Reference ID/Investigator# 63764, Istanbul, Turkey|Site Reference ID/Investigator# 63765, Istanbul, Turkey|Site Reference ID/Investigator# 63766, Istanbul, Turkey|Site Reference ID/Investigator# 69973, İstanbul, Turkey|Site Reference ID/Investigator# 63763, Izmir, Turkey|Site Reference ID/Investigator# 48127, Izmir, Turkey|Site Reference ID/Investigator# 64444, Karaman, Turkey|Site Reference ID/Investigator# 40684, Kayseri, Turkey|Site Reference ID/Investigator# 48132, Konya, Turkey|Site Reference ID/Investigator# 68283, Kutahya, Turkey|Site Reference ID/Investigator# 68281, Mersin, Turkey|Site Reference ID/Investigator# 68282, Mersin, Turkey|Site Reference ID/Investigator# 69974, Mersin, Turkey",,"https://ClinicalTrials.gov/show/NCT01149291"
577,"NCT01138657","Efficacy and Safety of Adalimumab in Patients With Active Uveitis","VISUAL l","Completed","Has Results","Uveitis","Biological: Adalimumab|Drug: Prednisone|Drug: Placebo","Time to Treatment Failure on or After Week 6|Change in Anterior Chamber (AC) Cell Grade in Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit|Change in Vitreous Haze (VH) Grade in Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit|Change In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit|Time to Optical Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 6|Percent Change in Central Retinal Thickness in Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit|Change in Visual Functioning Questionnaire 25 (VFQ-25) Composite Score From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit|Change in VFQ-25 Distance Vision Subscore From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit|Change in VFQ-25 Near Vision Subscore From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit|Change in VFQ-25 Ocular Pain Subscore From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","239","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-877|2009-016095-68","August 2010","July 2014","August 2014","June 7, 2010","August 22, 2016","August 22, 2016",,,"https://ClinicalTrials.gov/show/NCT01138657"
578,"NCT01137526","Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-384|Drug: donepezil|Drug: placebo","Change from baseline to final observation in the Alzheimer's Disease Assessment Scale-Cognition portion (ADAS-cog) total score|Mini Mental Status Examination (MMSE) score at Baseline, Weeks 4, 8, and 12|Clinician's Interview Based Impression of Change-plus (CIBIC-plus) score at Baseline, Weeks 4, 8, and 12|Neuropsychiatric Inventory (NPI) score at Baseline, Weeks 4, 8, and 12|Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) score at Baseline, Weeks 4, 8, and 12","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M12-033|2009 017801-12","May 2010","July 2011","July 2011","June 4, 2010",,"January 29, 2013","Site Reference ID/Investigator# 40834, Ekaterinburg, Russian Federation|Site Reference ID/Investigator# 36304, Kazan, Russian Federation|Site Reference ID/Investigator# 36306, Kirov, Russian Federation|Site Reference ID/Investigator# 37944, Moscow, Russian Federation|Site Reference ID/Investigator# 26909, Saratov, Russian Federation|Site Reference ID/Investigator# 26904, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 26902, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 36305, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 38383, Yaroslavl, Russian Federation|Site Reference ID/Investigator# 45584, Belville, South Africa|Site Reference ID/Investigator# 47102, George, South Africa|Site Reference ID/Investigator# 45583, Johannesburg, South Africa|Site Reference ID/Investigator# 39855, Donetsk, Ukraine|Site Reference ID/Investigator# 26914, Kharkiv, Ukraine|Site Reference ID/Investigator# 26912, Kiev, Ukraine|Site Reference ID/Investigator# 40484, Lviv, Ukraine|Site Reference ID/Investigator# 27002, Poltava, Ukraine|Site Reference ID/Investigator# 39856, Poltava, Ukraine|Site Reference ID/Investigator# 40482, Simferopil, Ukraine|Site Reference ID/Investigator# 40483, Ternopil, Ukraine|Site Reference ID/Investigator# 35660, Vinnytsia, Ukraine|Site Reference ID/Investigator# 36327, Bath, United Kingdom|Site Reference ID/Investigator# 35657, Blackburn, United Kingdom|Site Reference ID/Investigator# 36330, Crowborough, United Kingdom|Site Reference ID/Investigator# 36326, Glasgow, United Kingdom|Site Reference ID/Investigator# 44123, Ivybridge, Devon, United Kingdom|Site Reference ID/Investigator# 35658, London, United Kingdom|Site Reference ID/Investigator# 35902, Northampton, United Kingdom|Site Reference ID/Investigator# 36328, Oxford, United Kingdom|Site Reference ID/Investigator# 36329, Peterborough, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01137526"
579,"NCT01134315","Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice",,"Terminated","Has Results","Secondary Hyperparathyroidism|End-Stage Renal Disease","Drug: Paricalcitol|Drug: Calcitriol","Percentage of Participants With at Least One Incidence of Hypercalcemia|Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs|Mean Baseline (BL) and Change From Baseline in Potassium, Sodium, Chloride, Bicarbonate at Final Visit (FV)|Mean Baseline (BL) and Change From Baseline in Calcium, Inorganic Phosphate (IP), Blood Urea Nitrogen (BUN), Creatinine at Final Visit (FV)|Mean Baseline and Change From Baseline in 25-Hydroxy Vitamin D3 at Final Visit (FV)|Mean Baseline and Change From Baseline in 1,25-Dihydroxy Vitamin D3 at Final Visit (FV)|Mean Baseline and Change From Baseline in Parathyroid Hormone at Final Visit (FV)|Mean Baseline and Change From Baseline in Albumin at Final Visit (FV)","AbbVie (prior sponsor, Abbott)|North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)|AbbVie","All","up to 16 Years   (Child)",,"61","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P12-053","June 2010","May 2012","May 2012","June 2, 2010","August 13, 2013","August 13, 2013","Site Reference ID/Investigator# 37082, Birmingham, Alabama, United States|Site Reference ID/Investigator# 26762, Gainesville, Florida, United States|Site Reference ID/Investigator# 28529, Orlando, Florida, United States|Site Reference ID/Investigator# 26748, Atlanta, Georgia, United States|Site Reference ID/Investigator# 37582, New Orleans, Louisiana, United States|Site Reference ID/Investigator# 39973, Baltimore, Maryland, United States|Site Reference ID/Investigator# 26769, Boston, Massachusetts, United States|Site Reference ID/Investigator# 26768, Detroit, Michigan, United States|Site Reference ID/Investigator# 26747, Kansas City, Missouri, United States|Site Reference ID/Investigator# 26749, Akron, Ohio, United States|Site Reference ID/Investigator# 26751, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 26765, Columbus, Ohio, United States|Site Reference ID/Investigator# 28528, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 26763, Portland, Oregon, United States|Site Reference ID/Investigator# 28526, Charlottesville, Virginia, United States|Site Reference ID/Investigator# 26758, Seattle, Washington, United States|Site Reference ID/Investigator# 40382, Madison, Wisconsin, United States|Site Reference ID/Investigator# 26759, Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT01134315"
580,"NCT01124838","Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis","Visual II","Completed","Has Results","Uveitis","Drug: Adalimumab|Drug: Prednisone|Drug: Placebo","Time to Treatment Failure on or After Week 2|Change in Anterior Chamber (AC) Cell Grade in Each Eye From Baseline to the Final/Early Termination Visit|Change in Vitreous Haze (VH) Grade in Each Eye From Baseline to the Final/Early Termination Visit|Change In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Baseline to the Final/Early Termination Visit|Time to Optimal Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 2|Percent Change in Central Retinal Thickness in Each Eye From Baseline to the Final/Early Termination Visit.|Change in Visual Functioning Questionnaire 25 (VFQ-25) Total Score From Baseline to the Final/Early Termination Visit|Change in VFQ-25 Subscore Distance Vision From Baseline to the Final/Early Termination Visit|Change in VFQ-25 Subscore Near Vision From Baseline to the Final/Early Termination Visit|Change in VFQ-25 Subscore Ocular Pain From Baseline to the Final/Early Termination Visit","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","261","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-880|2009-016008-22","August 2010","May 2015","May 2015","May 17, 2010","June 21, 2016","August 11, 2016",,,"https://ClinicalTrials.gov/show/NCT01124838"
581,"NCT01123876","Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor",,"Completed","No Results Available","Gastric Cancer","Drug: Veliparib","Determine the MTD and establish the recommended phase 2 dose of Veliparib in combination with two different FOLFIRI regimens that include a reduced regimen (150 mg/m2 irinotecan) and the standard regimen (180 mg/m2) in subjects with advanced solid tumors|To assess the safety and tolerability, pharmacokinetic profile of the combination at each of the FOLFIRI regimens.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-977","March 2010","January 2015","January 2015","May 14, 2010",,"June 6, 2018","Site Reference ID/Investigator# 24987, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 24985, Los Angeles, California, United States|Site Reference ID/Investigator# 26742, Los Angeles, California, United States|Site Reference ID/Investigator# 24986, Washington, District of Columbia, United States|Site Reference ID/Investigator# 24922, Durham, North Carolina, United States|Site Reference ID/Investigator# 24983, Nashville, Tennessee, United States|Site Reference ID/Investigator# 75713, Seoul, Korea, Republic of|Site Reference ID/Investigator# 75714, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01123876"
582,"NCT01117480","Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA","REACH","Completed","Has Results","Moderate-to-severe Rheumatoid Arthritis",,"Percentage of Participants That Achieved a Disease Activity Score 28 (DAS28) < 2.6|Mean Change From Baseline (Month 0) in Health Assessment Questionnaire (HAQ)|Mean Change From Baseline (Month 0) in Rheumatoid Arthritis Disease Activity Index (RADAI)","AbbVie (prior sponsor, Abbott)|University Health Network, Toronto|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"1013","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PMOS-CANA-04-01","July 2005","December 2014","December 2014","May 5, 2010","February 24, 2016","February 24, 2016",,,"https://ClinicalTrials.gov/show/NCT01117480"
583,"NCT01113957","A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer",,"Completed","No Results Available","Ovarian Cancer","Drug: ABT-888|Drug: pegylated liposomal doxorubicin|Drug: temozolomide","Objective response rate between the two treatment arms (ABT-888 + temozolomide versus the PLD) will be based on tumor measurements and CA-125 levels.|Evaluate progression free survival, time to progression, overall survival, 12-month survival rate, 6-month progression free survival rate, duration of response|Safety Assessments and tolerability (i.e. ECG, clinical laboratory tests, vital signs, AE assessments, physical exams, CT scans). See section 5 for detailed information.|Evaluate Quality of Life and performance status will be done through the use of FACT-O quality of fife questionnaire, EQ5D questionnaire and ECOG performance status.","AbbVie (prior sponsor, Abbott)|AbbVie","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-757|2009-015082-31","March 2010","June 2013","June 2013","April 30, 2010",,"June 6, 2018","Site Reference ID/Investigator# 25028, Duarte, California, United States|Site Reference ID/Investigator# 25024, Encino, California, United States|Site Reference ID/Investigator# 25034, Los Angeles, California, United States|Site Reference ID/Investigator# 25037, Newport Beach, California, United States|Site Reference ID/Investigator# 25030, Chicago, Illinois, United States|Site Reference ID/Investigator# 27837, Park Ridge, Illinois, United States|Site Reference ID/Investigator# 25039, Peoria, Illinois, United States|Site Reference ID/Investigator# 25038, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 25023, New York, New York, United States|Site Reference ID/Investigator# 25041, Chapel Hill, North Carolina, United States|Site Reference ID/Investigator# 25029, Hilliard, Ohio, United States|Site Reference ID/Investigator# 25543, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 25036, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 25042, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 25027, Houston, Texas, United States|Site Reference ID/Investigator# 25128, Adelaide, Australia|Site Reference ID/Investigator# 25130, Bedford Park, Australia|Site Reference ID/Investigator# 25131, East Melbourne, Australia|Site Reference ID/Investigator# 25133, Nedlands, Australia|Site Reference ID/Investigator# 25132, Randwick, Australia|Site Reference ID/Investigator# 25129, Westmead, Australia|Site Reference ID/Investigator# 25166, Edmonton, Canada|Site Reference ID/Investigator# 25162, Kelowna, Canada|Site Reference ID/Investigator# 25165, Laval, Canada|Site Reference ID/Investigator# 25135, Budapest, Hungary|Site Reference ID/Investigator# 25138, Haifa, Israel|Site Reference ID/Investigator# 25139, Tel Aviv, Israel|Site Reference ID/Investigator# 25141, Tel Hashomer, Israel|Site Reference ID/Investigator# 25402, Auckland, New Zealand|Site Reference ID/Investigator# 25145, Warsaw, Poland|Site Reference ID/Investigator# 25149, Northwood, United Kingdom|Site Reference ID/Investigator# 25154, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01113957"
584,"NCT01111240","Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice",,"Completed","Has Results","Psoriatic Arthritis",,"Mean Change From Baseline in Disease Activity Score (DAS)28|Mean Tender Joint Count (TJC) Over Time|Mean Swollen Joint Count (SJC) Over Time|Mean Percent Body Surface Area (BSA) Affected by Psoriasis Over Time|Mean Target Lesion Score (TLS) Over Time|Number of Participants With Adverse Events (AEs)|Number of Participants by Severity of Enthesitis Over Time|Number of Participants by Severity of Dactylitis Over Time|Number of Participants by Severity of Nail Psoriasis Levels Over Time|Mean Erythrocyte Sedimentation Rate (ESR) Over Time|Mean C-Reactive Protein (CRP) Levels Over Time|Patients Global Assessment of Disease Activity Over Time|Participants Assessment of Fatigue Over Time|Participants Assessment of Pain Over Time|Mean Funktionsfragebogen Hannover (FFbH) Questionnaire Scores Over Time|Percentage of Participants With Impairment in Daily Activities During the Last 4 Weeks of Each Visit|Mean Number of Days Missed From Work Due to Psoriatic Arthritis|Percentage of Participants With In-Patient Hospitalization|Percentage of Participants on Concomitant Systemic Rheumatic and Pain Relief Medication","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"4635","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HUM 05-3","August 2005","December 2013","December 2013","April 27, 2010","December 30, 2014","December 30, 2014","Site Reference ID/Investigator# 35035, Aachen, Germany|Site Reference ID/Investigator# 64288, Aachen, Germany|Site Reference ID/Investigator# 35509, Ahlen, Germany|Site Reference ID/Investigator# 53118, Ahrensburg, Germany|Site Reference ID/Investigator# 35042, Altenburg, Germany|Site Reference ID/Investigator# 35045, Altenholz, Germany|Site Reference ID/Investigator# 35048, Amberg, Germany|Site Reference ID/Investigator# 96243, Annaberg-Buchholz, Germany|Site Reference ID/Investigator# 53205, Arnstadt, Germany|Site Reference ID/Investigator# 53091, Artern, Germany|Site Reference ID/Investigator# 33348, Augsburg, Germany|Site Reference ID/Investigator# 33357, Bad Abbach, Germany|Site Reference ID/Investigator# 35085, Bad Aibling, Germany|Site Reference ID/Investigator# 57895, Bad Aibling, Germany|Site Reference ID/Investigator# 91097, Bad Bentheim, Germany|Site Reference ID/Investigator# 35524, Bad Bentheim, Germany|Site Reference ID/Investigator# 35572, Bad Bramstedt, Germany|Site Reference ID/Investigator# 64304, Bad Bramstedt, Germany|Site Reference ID/Investigator# 33371, Bad Endbach, Germany|Site Reference ID/Investigator# 53278, Bad Endbach, Germany|Site Reference ID/Investigator# 91084, Bad Homburg, Germany|Site Reference ID/Investigator# 33377, Bad Iburg, Germany|Site Reference ID/Investigator# 33381, Bad Iburg, Germany|Site Reference ID/Investigator# 53068, Bad Kissingen, Germany|Site Reference ID/Investigator# 33386, Bad Kreuznach, Germany|Site Reference ID/Investigator# 35574, Bad Kreuznach, Germany|Site Reference ID/Investigator# 33390, Bad Liebenwerda, Germany|Site Reference ID/Investigator# 33395, Bad Muender, Germany|Site Reference ID/Investigator# 96245, Bad Muender, Germany|Site Reference ID/Investigator# 91094, Bad Nauheim, Germany|Site Reference ID/Investigator# 35577, Bad Neuenahr, Germany|Site Reference ID/Investigator# 53181, Bad Neuenahr, Germany|Site Reference ID/Investigator# 57885, Bad Oeynhausen, Germany|Site Reference ID/Investigator# 33403, Bad Rappenau, Germany|Site Reference ID/Investigator# 53060, Bad Salzungen, Germany|Site Reference ID/Investigator# 91079, Bad Salzungen, Germany|Site Reference ID/Investigator# 53254, Bad Schlema, Germany|Site Reference ID/Investigator# 33416, Bad Staffelstein, Germany|Site Reference ID/Investigator# 33420, Bad Sulze, Germany|Site Reference ID/Investigator# 57890, Bad Toelz, Germany|Site Reference ID/Investigator# 33424, Baden-Baden, Germany|Site Reference ID/Investigator# 33428, Bamberg, Germany|Site Reference ID/Investigator# 33434, Bautzen, Germany|Site Reference ID/Investigator# 33437, Bautzen, Germany|Site Reference ID/Investigator# 53231, Bayreuth, Germany|Site Reference ID/Investigator# 33441, Bayreuth, Germany|Site Reference ID/Investigator# 33445, Bayreuth, Germany|Site Reference ID/Investigator# 68595, Bergen, Germany|Site Reference ID/Investigator# 34265, Berlin-Buch, Germany|Site Reference ID/Investigator# 64291, Berlin-Buch, Germany|Site Reference ID/Investigator# 53243, Berlin-Wannsee, Germany|Site Reference ID/Investigator# 57893, Berlin-Weissensee, Germany|Site Reference ID/Investigator# 33459, Berlin, Germany|Site Reference ID/Investigator# 35087, Berlin, Germany|Site Reference ID/Investigator# 53058, Berlin, Germany|Site Reference ID/Investigator# 53241, Berlin, Germany|Site Reference ID/Investigator# 53242, Berlin, Germany|Site Reference ID/Investigator# 33647, Berlin, Germany|Site Reference ID/Investigator# 57909, Berlin, Germany|Site Reference ID/Investigator# 53061, Berlin, Germany|Site Reference ID/Investigator# 53059, Berlin, Germany|Site Reference ID/Investigator# 68842, Berlin, Germany|Site Reference ID/Investigator# 33657, Berlin, Germany|Site Reference ID/Investigator# 53105, Berlin, Germany|Site Reference ID/Investigator# 98535, Berlin, Germany|Site Reference ID/Investigator# 34245, Berlin, Germany|Site Reference ID/Investigator# 33682, Berlin, Germany|Site Reference ID/Investigator# 68594, Berlin, Germany|Site Reference ID/Investigator# 34268, Berlin, Germany|Site Reference ID/Investigator# 33654, Berlin, Germany|Site Reference ID/Investigator# 64284, Berlin, Germany|Site Reference ID/Investigator# 35596, Berlin, Germany|Site Reference ID/Investigator# 35600, Berlin, Germany|Site Reference ID/Investigator# 53081, Berlin, Germany|Site Reference ID/Investigator# 53244, Berlin, Germany|Site Reference ID/Investigator# 91075, Berlin, Germany|Site Reference ID/Investigator# 64287, Berlin, Germany|Site Reference ID/Investigator# 34261, Berlin, Germany|Site Reference ID/Investigator# 33686, Berlin, Germany|Site Reference ID/Investigator# 64286, Berlin, Germany|Site Reference ID/Investigator# 52990, Berlin, Germany|Site Reference ID/Investigator# 52995, Berlin, Germany|Site Reference ID/Investigator# 35549, Berlin, Germany|Site Reference ID/Investigator# 53090, Berlin, Germany|Site Reference ID/Investigator# 35553, Berlin, Germany|Site Reference ID/Investigator# 35555, Bernau, Germany|Site Reference ID/Investigator# 53213, Bernsbach, Germany|Site Reference ID/Investigator# 34274, Beverungen, Germany|Site Reference ID/Investigator# 53085, Bietigheim-Bissingen, Germany|Site Reference ID/Investigator# 53268, Bietigheim-Bissingen, Germany|Site Reference ID/Investigator# 34284, Blankenburg/Hart, Germany|Site Reference ID/Investigator# 34287, Blaubeuren, Germany|Site Reference ID/Investigator# 34290, Bocholt, Germany|Site Reference ID/Investigator# 35640, Bochum, Germany|Site Reference ID/Investigator# 53196, Bochum, Germany|Site Reference ID/Investigator# 53179, Bochum, Germany|Site Reference ID/Investigator# 57908, Bochum, Germany|Site Reference ID/Investigator# 35643, Bogen, Germany|Site Reference ID/Investigator# 34301, Bonn, Germany|Site Reference ID/Investigator# 34295, Bonn, Germany|Site Reference ID/Investigator# 34306, Braunschweig, Germany|Site Reference ID/Investigator# 53234, Breitenbrunn, Germany|Site Reference ID/Investigator# 35608, Bremen, Germany|Site Reference ID/Investigator# 52987, Bremen, Germany|Site Reference ID/Investigator# 53107, Bremen, Germany|Site Reference ID/Investigator# 53247, Bremen, Germany|Site Reference ID/Investigator# 91073, Bremerhaven, Germany|Site Reference ID/Investigator# 68584, Burgstaedt, Germany|Site Reference ID/Investigator# 81599, Chemnitz, Germany|Site Reference ID/Investigator# 34698, Chemnitz, Germany|Site Reference ID/Investigator# 57902, Chemnitz, Germany|Site Reference ID/Investigator# 35094, Chemnitz, Germany|Site Reference ID/Investigator# 53262, Cologne, Germany|Site Reference ID/Investigator# 64298, Cologne, Germany|Site Reference ID/Investigator# 64293, Cologne, Germany|Site Reference ID/Investigator# 33988, Cologne, Germany|Site Reference ID/Investigator# 53193, Cologne, Germany|Site Reference ID/Investigator# 53071, Cologne, Germany|Site Reference ID/Investigator# 35236, Cologne, Germany|Site Reference ID/Investigator# 64300, Cologne, Germany|Site Reference ID/Investigator# 72857, Cologne, Germany|Site Reference ID/Investigator# 34710, Cottbus, Germany|Site Reference ID/Investigator# 53184, Cottbus, Germany|Site Reference ID/Investigator# 64303, Darmstadt, Germany|Site Reference ID/Investigator# 35620, Darmstadt, Germany|Site Reference ID/Investigator# 34724, Deggendorf, Germany|Site Reference ID/Investigator# 53209, Delmenhorst, Germany|Site Reference ID/Investigator# 53089, Delmenhorst, Germany|Site Reference ID/Investigator# 91077, Dinslaken, Germany|Site Reference ID/Investigator# 34741, Dortmund, Germany|Site Reference ID/Investigator# 35637, Dortmund, Germany|Site Reference ID/Investigator# 35633, Dortmund, Germany|Site Reference ID/Investigator# 57899, Dresden, Germany|Site Reference ID/Investigator# 35172, Dresden, Germany|Site Reference ID/Investigator# 34753, Dresden, Germany|Site Reference ID/Investigator# 53069, Dresden, Germany|Site Reference ID/Investigator# 34747, Dresden, Germany|Site Reference ID/Investigator# 34750, Dresden, Germany|Site Reference ID/Investigator# 34759, Dresden, Germany|Site Reference ID/Investigator# 68590, Dresden, Germany|Site Reference ID/Investigator# 53182, Dresden, Germany|Site Reference ID/Investigator# 91081, Dresden, Germany|Site Reference ID/Investigator# 68592, Dresden, Germany|Site Reference ID/Investigator# 57904, Dresden, Germany|Site Reference ID/Investigator# 53266, Dueren, Germany|Site Reference ID/Investigator# 34772, Duesseldorf, Germany|Site Reference ID/Investigator# 64302, Duesseldorf, Germany|Site Reference ID/Investigator# 34777, Duisburg, Germany|Site Reference ID/Investigator# 53072, Duisburg, Germany|Site Reference ID/Investigator# 98537, Duisburg, Germany|Site Reference ID/Investigator# 34783, Eberswalde, Germany|Site Reference ID/Investigator# 53194, Eberswalde, Germany|Site Reference ID/Investigator# 53065, Eisenach, Germany|Site Reference ID/Investigator# 72856, Eisenach, Germany|Site Reference ID/Investigator# 35181, Elmshorn, Germany|Site Reference ID/Investigator# 53114, Eppstein, Germany|Site Reference ID/Investigator# 53221, Erftstadt, Germany|Site Reference ID/Investigator# 53070, Erfurt, Germany|Site Reference ID/Investigator# 53258, Erfurt, Germany|Site Reference ID/Investigator# 53259, Erfurt, Germany|Site Reference ID/Investigator# 57900, Erfurt, Germany|Site Reference ID/Investigator# 34808, Erfurt, Germany|Site Reference ID/Investigator# 35095, Erfurt, Germany|Site Reference ID/Investigator# 57901, Erkrath, Germany|Site Reference ID/Investigator# 34820, Erlangen, Germany|Site Reference ID/Investigator# 57896, Erlangen, Germany|Site Reference ID/Investigator# 35195, Essen, Germany|Site Reference ID/Investigator# 35198, Essen, Germany|Site Reference ID/Investigator# 53219, Esslingen, Germany|Site Reference ID/Investigator# 35201, Feldafing, Germany|Site Reference ID/Investigator# 35204, Flensburg, Germany|Site Reference ID/Investigator# 34832, Forchheim, Germany|Site Reference ID/Investigator# 35209, Frankenberg, Germany|Site Reference ID/Investigator# 64283, Frankfurt, Germany|Site Reference ID/Investigator# 34839, Frankfurt, Germany|Site Reference ID/Investigator# 35212, Fraureuth, Germany|Site Reference ID/Investigator# 91078, Frechen, Germany|Site Reference ID/Investigator# 35218, Freiberg, Germany|Site Reference ID/Investigator# 34853, Freiburg, Germany|Site Reference ID/Investigator# 34856, Freiburg, Germany|Site Reference ID/Investigator# 34860, Freiburg, Germany|Site Reference ID/Investigator# 35100, Freystadt, Germany|Site Reference ID/Investigator# 35223, Friedrichroda, Germany|Site Reference ID/Investigator# 68843, Garching, Germany|Site Reference ID/Investigator# 34878, Gelsenkirchen, Germany|Site Reference ID/Investigator# 68591, Gelsenkirchen, Germany|Site Reference ID/Investigator# 34882, Gera, Germany|Site Reference ID/Investigator# 57907, Gera, Germany|Site Reference ID/Investigator# 64285, Gera, Germany|Site Reference ID/Investigator# 64294, Gera, Germany|Site Reference ID/Investigator# 57897, Gera, Germany|Site Reference ID/Investigator# 53222, Gera, Germany|Site Reference ID/Investigator# 34886, Giessen, Germany|Site Reference ID/Investigator# 52998, Goettingen, Germany|Site Reference ID/Investigator# 53116, Gornau, Germany|Site Reference ID/Investigator# 34895, Goslar, Germany|Site Reference ID/Investigator# 68589, Gotha, Germany|Site Reference ID/Investigator# 35493, Graefelfing, Germany|Site Reference ID/Investigator# 53224, Greifswald, Germany|Site Reference ID/Investigator# 57889, Greifswald, Germany|Site Reference ID/Investigator# 64289, Greifswald, Germany|Site Reference ID/Investigator# 34903, Greifswald, Germany|Site Reference ID/Investigator# 58122, Greifswald, Germany|Site Reference ID/Investigator# 53106, Gronau, Germany|Site Reference ID/Investigator# 91070, Grossenhain, Germany|Site Reference ID/Investigator# 34911, Guestrow, Germany|Site Reference ID/Investigator# 34936, Halle, Germany|Site Reference ID/Investigator# 34939, Halle, Germany|Site Reference ID/Investigator# 53067, Halle, Germany|Site Reference ID/Investigator# 53236, Halle, Germany|Site Reference ID/Investigator# 81601, Halle, Germany|Site Reference ID/Investigator# 34921, Halle, Germany|Site Reference ID/Investigator# 34943, Halle, Germany|Site Reference ID/Investigator# 34931, Halle, Germany|Site Reference ID/Investigator# 53063, Hamburg, Germany|Site Reference ID/Investigator# 53183, Hamburg, Germany|Site Reference ID/Investigator# 96237, Hamburg, Germany|Site Reference ID/Investigator# 34969, Hamburg, Germany|Site Reference ID/Investigator# 53073, Hamburg, Germany|Site Reference ID/Investigator# 34951, Hamburg, Germany|Site Reference ID/Investigator# 53276, Hamburg, Germany|Site Reference ID/Investigator# 34957, Hamburg, Germany|Site Reference ID/Investigator# 96242, Hamburg, Germany|Site Reference ID/Investigator# 35451, Hamburg, Germany|Site Reference ID/Investigator# 53198, Hamburg, Germany|Site Reference ID/Investigator# 35113, Hamburg, Germany|Site Reference ID/Investigator# 35006, Hamburg, Germany|Site Reference ID/Investigator# 53186, Hamburg, Germany|Site Reference ID/Investigator# 53212, Hamburg, Germany|Site Reference ID/Investigator# 53206, Hamburg, Germany|Site Reference ID/Investigator# 34960, Hamburg, Germany|Site Reference ID/Investigator# 53199, Hamburg, Germany|Site Reference ID/Investigator# 35448, Hamburg, Germany|Site Reference ID/Investigator# 34954, Hamburg, Germany|Site Reference ID/Investigator# 34997, Hamburg, Germany|Site Reference ID/Investigator# 34993, Hamburg, Germany|Site Reference ID/Investigator# 53098, Hamburg, Germany|Site Reference ID/Investigator# 53279, Hamburg, Germany|Site Reference ID/Investigator# 72854, Hamburg, Germany|Site Reference ID/Investigator# 34982, Hamburg, Germany|Site Reference ID/Investigator# 34985, Hamburg, Germany|Site Reference ID/Investigator# 35110, Hamburg, Germany|Site Reference ID/Investigator# 53066, Hamburg, Germany|Site Reference ID/Investigator# 53248, Hamburg, Germany|Site Reference ID/Investigator# 34973, Hamburg, Germany|Site Reference ID/Investigator# 35018, Hanau, Germany|Site Reference ID/Investigator# 64301, Hannover, Germany|Site Reference ID/Investigator# 33711, Hanover, Germany|Site Reference ID/Investigator# 53100, Hanover, Germany|Site Reference ID/Investigator# 68582, Hanover, Germany|Site Reference ID/Investigator# 53083, Hanover, Germany|Site Reference ID/Investigator# 53256, Harrislee, Germany|Site Reference ID/Investigator# 33797, Heidelberg, Germany|Site Reference ID/Investigator# 33804, Heidelberg, Germany|Site Reference ID/Investigator# 35118, Heidelberg, Germany|Site Reference ID/Investigator# 91083, Heidelberg, Germany|Site Reference ID/Investigator# 33800, Heidelberg, Germany|Site Reference ID/Investigator# 33807, Heidelberg, Germany|Site Reference ID/Investigator# 33817, Heilbad Heiligenstadt, Germany|Site Reference ID/Investigator# 53057, Heilbad Heiligenstadt, Germany|Site Reference ID/Investigator# 64297, Herne, Germany|Site Reference ID/Investigator# 57894, Herrsching, Germany|Site Reference ID/Investigator# 68586, Herten, Germany|Site Reference ID/Investigator# 53272, Hildburghausen, Germany|Site Reference ID/Investigator# 53080, Hilden, Germany|Site Reference ID/Investigator# 53097, Hildesheim, Germany|Site Reference ID/Investigator# 33841, Hofheim, Germany|Site Reference ID/Investigator# 33833, Hof, Germany|Site Reference ID/Investigator# 114015, Hohen Neuendorf, Germany|Site Reference ID/Investigator# 33844, Hohenfelde, Germany|Site Reference ID/Investigator# 53084, Holzkirchen, Germany|Site Reference ID/Investigator# 53092, Homburg, Germany|Site Reference ID/Investigator# 91085, Homburg, Germany|Site Reference ID/Investigator# 53109, Hoyerswerda, Germany|Site Reference ID/Investigator# 33857, Immenstadt, Germany|Site Reference ID/Investigator# 98538, Ingoldstadt, Germany|Site Reference ID/Investigator# 33934, Ingolstadt, Germany|Site Reference ID/Investigator# 53111, Ingolstadt, Germany|Site Reference ID/Investigator# 53053, Jena, Germany|Site Reference ID/Investigator# 53055, Jena, Germany|Site Reference ID/Investigator# 5305, Jena, Germany|Site Reference ID/Investigator# 33941, Juelich, Germany|Site Reference ID/Investigator# 33945, Kahla, Germany|Site Reference ID/Investigator# 35123, Kahla, Germany|Site Reference ID/Investigator# 33949, Kaiserslautern, Germany|Site Reference ID/Investigator# 52992, Kamenz, Germany|Site Reference ID/Investigator# 33960, Karlsruhe, Germany|Site Reference ID/Investigator# 35483, Karlstadt, Germany|Site Reference ID/Investigator# 53192, Kassel, Germany|Site Reference ID/Investigator# 33963, Kassel, Germany|Site Reference ID/Investigator# 33967, Katzhuette, Germany|Site Reference ID/Investigator# 53229, Kiel, Germany|Site Reference ID/Investigator# 72859, Kleinmachnow, Germany|Site Reference ID/Investigator# 53233, Koblenz, Germany|Site Reference ID/Investigator# 34001, Koenigs Wusterhausen, Germany|Site Reference ID/Investigator# 91076, Krefeld, Germany|Site Reference ID/Investigator# 91093, Krefeld, Germany|Site Reference ID/Investigator# 53108, Krefeld, Germany|Site Reference ID/Investigator# 34007, Kressbronn, Germany|Site Reference ID/Investigator# 34083, Kronach, Germany|Site Reference ID/Investigator# 53101, Kyritz, Germany|Site Reference ID/Investigator# 34004, Lahr, Germany|Site Reference ID/Investigator# 35244, Landau, Germany|Site Reference ID/Investigator# 64290, Langenfeld, Germany|Site Reference ID/Investigator# 53245, Leinefelde, Germany|Site Reference ID/Investigator# 53115, Leipzig, Germany|Site Reference ID/Investigator# 53087, Leipzig, Germany|Site Reference ID/Investigator# 34105, Leipzig, Germany|Site Reference ID/Investigator# 34108, Leipzig, Germany|Site Reference ID/Investigator# 53197, Leipzig, Germany|Site Reference ID/Investigator# 53052, Leipzig, Germany|Site Reference ID/Investigator# 53211, Leipzig, Germany|Site Reference ID/Investigator# 53088, Leverkusen, Germany|Site Reference ID/Investigator# 34122, Lichtenstein, Germany|Site Reference ID/Investigator# 53180, Lingen, Germany|Site Reference ID/Investigator# 35253, Lippstadt, Germany|Site Reference ID/Investigator# 96240, Loebau, Germany|Site Reference ID/Investigator# 35259, Ludwigsfelde, Germany|Site Reference ID/Investigator# 53195, Ludwigshafen, Germany|Site Reference ID/Investigator# 53249, Ludwigslust, Germany|Site Reference ID/Investigator# 53110, Luebeck, Germany|Site Reference ID/Investigator# 34135, Luebeck, Germany|Site Reference ID/Investigator# 53074, Luedenscheid, Germany|Site Reference ID/Investigator# 96239, Lueneburg, Germany|Site Reference ID/Investigator# 53000, Lutherstadt Eisleben, Germany|Site Reference ID/Investigator# 34146, Magdeburg, Germany|Site Reference ID/Investigator# 34149, Magdeburg, Germany|Site Reference ID/Investigator# 91082, Magdeburg, Germany|Site Reference ID/Investigator# 64292, Magdeburg, Germany|Site Reference ID/Investigator# 68583, Magdeburg, Germany|Site Reference ID/Investigator# 53230, Magdeburg, Germany|Site Reference ID/Investigator# 64305, Magdeburg, Germany|Site Reference ID/Investigator# 53075, Mainz, Germany|Site Reference ID/Investigator# 68593, Mainz, Germany|Site Reference ID/Investigator# 34179, Mannheim, Germany|Site Reference ID/Investigator# 34191, Marktredwitz, Germany|Site Reference ID/Investigator# 34195, Marl, Germany|Site Reference ID/Investigator# 34199, Meissen, Germany|Site Reference ID/Investigator# 53269, Melsungen, Germany|Site Reference ID/Investigator# 53078, Memmingen, Germany|Site Reference ID/Investigator# 35284, Menz, Germany|Site Reference ID/Investigator# 35286, Minden, Germany|Site Reference ID/Investigator# 34207, Mittelherwigsdorf, Germany|Site Reference ID/Investigator# 34217, Moenchengladbach, Germany|Site Reference ID/Investigator# 34212, Moenchengladbach, Germany|Site Reference ID/Investigator# 53095, Moenchengladbach, Germany|Site Reference ID/Investigator# 53261, Moenchengladbach, Germany|Site Reference ID/Investigator# 57883, Moenkeburg, Germany|Site Reference ID/Investigator# 34223, Muehlhausen, Germany|Site Reference ID/Investigator# 35291, Muelheim, Germany|Site Reference ID/Investigator# 53235, Muelheim, Germany|Site Reference ID/Investigator# 34228, Muellheim, Germany|Site Reference ID/Investigator# 53062, Muenster, Germany|Site Reference ID/Investigator# 68587, Muenster, Germany|Site Reference ID/Investigator# 34047, Muenster, Germany|Site Reference ID/Investigator# 53093, Muenster, Germany|Site Reference ID/Investigator# 91096, Muenster, Germany|Site Reference ID/Investigator# 64282, Munich, Germany|Site Reference ID/Investigator# 34039, Munich, Germany|Site Reference ID/Investigator# 57892, Munich, Germany|Site Reference ID/Investigator# 64295, Munich, Germany|Site Reference ID/Investigator# 35294, Munich, Germany|Site Reference ID/Investigator# 34234, Munich, Germany|Site Reference ID/Investigator# 91080, Munich, Germany|Site Reference ID/Investigator# 34042, Munich, Germany|Site Reference ID/Investigator# 53270, Munich, Germany|Site Reference ID/Investigator# 53246, Naila, Germany|Site Reference ID/Investigator# 53271, Nastaetten, Germany|Site Reference ID/Investigator# 35305, Naumburg, Germany|Site Reference ID/Investigator# 34051, Naunhof, Germany|Site Reference ID/Investigator# 34060, Neubrandenburg, Germany|Site Reference ID/Investigator# 34063, Neuburg, Germany|Site Reference ID/Investigator# 53220, Neunkirchen, Germany|Site Reference ID/Investigator# 35312, Neuss, Germany|Site Reference ID/Investigator# 34075, Neustadt, Germany|Site Reference ID/Investigator# 34079, Niefern-Oeschelbronn, Germany|Site Reference ID/Investigator# 34157, Nienburg, Germany|Site Reference ID/Investigator# 57891, Nienburg, Germany|Site Reference ID/Investigator# 52997, Nordhausen, Germany|Site Reference ID/Investigator# 52999, Nordhausen, Germany|Site Reference ID/Investigator# 53277, Nordhausen, Germany|Site Reference ID/Investigator# 53054, Nuremberg, Germany|Site Reference ID/Investigator# 68588, Nuremberg, Germany|Site Reference ID/Investigator# 53112, Nuremberg, Germany|Site Reference ID/Investigator# 96244, Oberhausen, Germany|Site Reference ID/Investigator# 34172, Oelsnitz, Germany|Site Reference ID/Investigator# 53104, Oelsnitz, Germany|Site Reference ID/Investigator# 34175, Offenburg, Germany|Site Reference ID/Investigator# 33491, Oldenburg, Germany|Site Reference ID/Investigator# 57886, Oldenburg, Germany|Site Reference ID/Investigator# 91067, Oschatz, Germany|Site Reference ID/Investigator# 53207, Osnabrueck, Germany|Site Reference ID/Investigator# 81600, Osnabrueck, Germany|Site Reference ID/Investigator# 53228, Ostseebad Damp, Germany|Site Reference ID/Investigator# 35334, Paderborn, Germany|Site Reference ID/Investigator# 33507, Parchim, Germany|Site Reference ID/Investigator# 35339, Passau, Germany|Site Reference ID/Investigator# 72858, Peitz, Germany|Site Reference ID/Investigator# 53096, Petershagen, Germany|Site Reference ID/Investigator# 53086, Pinneberg, Germany|Site Reference ID/Investigator# 53232, Pirna, Germany|Site Reference ID/Investigator# 33522, Planegg, Germany|Site Reference ID/Investigator# 33527, Plauen, Germany|Site Reference ID/Investigator# 96278, Plochingen, Germany|Site Reference ID/Investigator# 33469, Potsdam, Germany|Site Reference ID/Investigator# 33465, Potsdam, Germany|Site Reference ID/Investigator# 96236, Potsdam, Germany|Site Reference ID/Investigator# 53281, Potsdam, Germany|Site Reference ID/Investigator# 33475, Pruem, Germany|Site Reference ID/Investigator# 33478, Puettlingen, Germany|Site Reference ID/Investigator# 53257, Puettlingen, Germany|Site Reference ID/Investigator# 91120, Puettlingen, Germany|Site Reference ID/Investigator# 53094, Quedlinburg, Germany|Site Reference ID/Investigator# 53265, Querfurt, Germany|Site Reference ID/Investigator# 33483, Radebeul, Germany|Site Reference ID/Investigator# 35346, Radebeul, Germany|Site Reference ID/Investigator# 53280, Ratingen, Germany|Site Reference ID/Investigator# 57888, Ratingen, Germany|Site Reference ID/Investigator# 33487, Ratzeburg, Germany|Site Reference ID/Investigator# 33889, Regensburg, Germany|Site Reference ID/Investigator# 57912, Regensburg, Germany|Site Reference ID/Investigator# 57911, Regensburg, Germany|Site Reference ID/Investigator# 53264, Regensburg, Germany|Site Reference ID/Investigator# 33901, Rendsburg, Germany|Site Reference ID/Investigator# 52991, Ribnitz-Damgarten, Germany|Site Reference ID/Investigator# 53267, Riesa, Germany|Site Reference ID/Investigator# 33910, Riesa, Germany|Site Reference ID/Investigator# 33913, Rinteln, Germany|Site Reference ID/Investigator# 33922, Rostock, Germany|Site Reference ID/Investigator# 33926, Rostock, Germany|Site Reference ID/Investigator# 33930, Rothenburg, Germany|Site Reference ID/Investigator# 53113, Rudolstadt, Germany|Site Reference ID/Investigator# 35361, Ruedersdorf, Germany|Site Reference ID/Investigator# 34015, Saarbruecken, Germany|Site Reference ID/Investigator# 91071, Saarlouis, Germany|Site Reference ID/Investigator# 34022, Salzwedel, Germany|Site Reference ID/Investigator# 34026, Sande, Germany|Site Reference ID/Investigator# 53208, Schleiz, Germany|Site Reference ID/Investigator# 91074, Schlettau, Germany|Site Reference ID/Investigator# 33533, Schneeberg, Germany|Site Reference ID/Investigator# 33538, Schramberg, Germany|Site Reference ID/Investigator# 33541, Schutterwald, Germany|Site Reference ID/Investigator# 35370, Schwandorf, Germany|Site Reference ID/Investigator# 91072, Schwandorf, Germany|Site Reference ID/Investigator# 57905, Schwedt, Germany|Site Reference ID/Investigator# 72855, Schweina, Germany|Site Reference ID/Investigator# 33548, Schwerin, Germany|Site Reference ID/Investigator# 35375, Schwerin, Germany|Site Reference ID/Investigator# 33554, Schwerte, Germany|Site Reference ID/Investigator# 33558, Seesen, Germany|Site Reference ID/Investigator# 33566, Sinsheim, Germany|Site Reference ID/Investigator# 33571, Soltau, Germany|Site Reference ID/Investigator# 53255, Spelle, Germany|Site Reference ID/Investigator# 35382, St. Martin, Germany|Site Reference ID/Investigator# 33584, Stadtbergen, Germany|Site Reference ID/Investigator# 98539, Stolberg, Germany|Site Reference ID/Investigator# 53218, Storkow, Germany|Site Reference ID/Investigator# 53082, Straubing, Germany|Site Reference ID/Investigator# 33603, Stuttgart, Germany|Site Reference ID/Investigator# 33606, Stuttgart, Germany|Site Reference ID/Investigator# 33610, Stuttgart, Germany|Site Reference ID/Investigator# 33597, Stuttgart, Germany|Site Reference ID/Investigator# 53210, Suhl, Germany|Site Reference ID/Investigator# 53223, Suhl, Germany|Site Reference ID/Investigator# 35388, Suhl, Germany|Site Reference ID/Investigator# 33624, Torgelow, Germany|Site Reference ID/Investigator# 53077, Treuenbrietzen, Germany|Site Reference ID/Investigator# 57906, Treuenbrietzen, Germany|Site Reference ID/Investigator# 53200, Tuttlingen, Germany|Site Reference ID/Investigator# 57910, Ueberlingen-Nussdorf, Germany|Site Reference ID/Investigator# 33640, Ulm, Germany|Site Reference ID/Investigator# 33723, Ulm, Germany|Site Reference ID/Investigator# 81602, Unna, Germany|Site Reference ID/Investigator# 96241, Varel, Germany|Site Reference ID/Investigator# 98536, Verden, Germany|Site Reference ID/Investigator# 72860, Viersen, Germany|Site Reference ID/Investigator# 33736, Villingen-Schwenningen, Germany|Site Reference ID/Investigator# 33741, Waltrop, Germany|Site Reference ID/Investigator# 72853, Wasserburg, Germany|Site Reference ID/Investigator# 33748, Weener, Germany|Site Reference ID/Investigator# 33851, Welzow, Germany|Site Reference ID/Investigator# 35407, Wiesbaden, Germany|Site Reference ID/Investigator# 33764, Wiesbaden, Germany|Site Reference ID/Investigator# 52989, Wiesbaden, Germany|Site Reference ID/Investigator# 33771, Wilhelmshaven, Germany|Site Reference ID/Investigator# 53076, Winsen, Germany|Site Reference ID/Investigator# 33775, Wismar, Germany|Site Reference ID/Investigator# 33779, Wittlich, Germany|Site Reference ID/Investigator# 91095, Wittmund, Germany|Site Reference ID/Investigator# 96235, Wolfenbuettel, Germany|Site Reference ID/Investigator# 33717, Wuerzburg, Germany|Site Reference ID/Investigator# 57903, Wuerzburg, Germany|Site Reference ID/Investigator# 91068, Wuppertal, Germany|Site Reference ID/Investigator# 91069, Wuppertal, Germany|Site Reference ID/Investigator# 35419, Wuppertal, Germany|Site Reference ID/Investigator# 57884, Wurzen, Germany|Site Reference ID/Investigator# 53064, Zeitz, Germany|Site Reference ID/Investigator# 33863, Zerbst, Germany|Site Reference ID/Investigator# 33866, Zeven, Germany|Site Reference ID/Investigator# 64299, Zschopau, Germany|Site Reference ID/Investigator# 52996, Zwickau, Germany|Site Reference ID/Investigator# 33875, Zwickau, Germany|Site Reference ID/Investigator# 52993, Zwickau, Germany|Site Reference ID/Investigator# 53056, Zwickau, Germany|Site Reference ID/Investigator# 53102, Zwickau, Germany|Site Reference ID/Investigator# 52994, Zwickau, Germany|Site Reference ID/Investigator# 53226, Zwickau, Germany|Site Reference ID/Investigator# 53260, Zwickau, Germany|Site Reference ID/Investigator# 33879, Zwiesel, Germany",,"https://ClinicalTrials.gov/show/NCT01111240"
585,"NCT01110486","ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: ABT-348|Drug: ABT-348 and carboplatin|Drug: ABT-348 and docetaxel","Determine the safety profile (Adverse events by toxicity grade and relationship to study drug, serious adverse events, adverse events leading to discontinuation and relevant clinical laboratory abnormalities) of ABT-348 as monotherapy or in combination|Study the pharmacokinetic of ABT-348|Dose limiting toxicity determination|Evaluate safety at the recommended Phase 2 dose (RPTD) and schedule of ABT-348 as monotherapy, when in combination with carboplatin or in combination with docetaxel.|Evaluate preliminary efficacy data regarding objective response rate (ORR), time to progression (TTP), duration of overall response, and ECOG performance status of ABT-348 as monotherapy, when in combination with carboplatin or docetaxel.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","102","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-944","March 2010","September 2013","September 2013","April 26, 2010",,"November 6, 2013","Site Reference ID/Investigator# 26525, Chicago, Illinois, United States|Site Reference ID/Investigator# 26524, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01110486"
586,"NCT01110473","ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies",,"Completed","No Results Available","Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|B-cell Chronic Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Myelodysplasia","Drug: ABT-348|Drug: ABT-348 and azacitidine","Determine the safety profile (adverse events by toxicity grade and relationship to study drug, serious adverse events, adverse events leading to discontinuation and relevant clinical laboratory abnormalities) of ABT-348 as monotherapy or in combination|Study the pharmacokinetic interaction (plasma concentrations and pharmacokinetic parameter values) of ABT-348 as monotherapy and in combination|Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) of ABT-348 when administered as a monotherapy and in combination in subjects with advanced hematologic malignancies","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-943","April 2010","June 2013","June 2013","April 26, 2010",,"November 20, 2017","Site Reference ID/Investigator# 59324, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 26523, Atlanta, Georgia, United States|Site Reference ID/Investigator# 26522, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01110473"
587,"NCT01097655","Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet",,"Completed","Has Results","Human Immunodeficiency Virus",,"Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count|Change From Baseline in HIV-1 Ribonucleic Acid (RNA) Viral Load","AbbVie (prior sponsor, Abbott)|Veeda Clinical Research|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"3049","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P06-131","August 2006","January 2016","January 2016","April 2, 2010","May 23, 2017","May 23, 2017",,,"https://ClinicalTrials.gov/show/NCT01097655"
588,"NCT01095562","Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia",,"Completed","No Results Available","Cognitive Deficits in Schizophrenia","Drug: ABT-126|Drug: Placebo","Cognition: MCCB|Functioning: UPSA-2|Cognition: CANTAB|Symptom Severity: PANSS, NSA-16, CGI-S","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years to 55 Years   (Adult)","Phase 2","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-854","March 2010","August 2011","September 2011","March 30, 2010",,"June 6, 2018","Site Reference ID/Investigator# 26267, Cerritos, California, United States|Site Reference ID/Investigator# 45320, Costa Mesa, California, United States|Site Reference ID/Investigator# 27068, Escondido, California, United States|Site Reference ID/Investigator# 52568, Garden Grove, California, United States|Site Reference ID/Investigator# 26266, Granada Hills, California, United States|Site Reference ID/Investigator# 26388, Oceanside, California, United States|Site Reference ID/Investigator# 45315, San Bernardino, California, United States|Site Reference ID/Investigator# 26271, San Diego, California, United States|Site Reference ID/Investigator# 27045, Santa Ana, California, United States|Site Reference ID/Investigator# 45314, Santa Ana, California, United States|Site Reference ID/Investigator# 26264, Torrance, California, United States|Site Reference ID/Investigator# 27072, Tampa, Florida, United States|Site Reference ID/Investigator# 27043, Wichita, Kansas, United States|Site Reference ID/Investigator# 26395, Lake Charles, Louisiana, United States|Site Reference ID/Investigator# 26268, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 26392, Fresh Meadows, New York, United States|Site Reference ID/Investigator# 27073, New York, New York, United States|Site Reference ID/Investigator# 26262, Rochester, New York, United States|Site Reference ID/Investigator# 27071, Beachwood, Ohio, United States|Site Reference ID/Investigator# 36020, Media, Pennsylvania, United States|Site Reference ID/Investigator# 28063, Norristown, Pennsylvania, United States|Site Reference ID/Investigator# 27070, Sellersville, Pennsylvania, United States|Site Reference ID/Investigator# 27069, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT01095562"
589,"NCT01086033","A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece",,"Completed","Has Results","Rheumatoid Arthritis",,"Number of Participants With Adverse Events|Disease Activity Score (DAS) 28 Over Time|European League Against Rheumatism (EULAR) Response|Number of Participants With an American College of Rheumatology (ACR) 20 Response|Number of Participants With an American College of Rheumatology (ACR) 50 Response|Number of Participants With an American College of Rheumatology (ACR) 70 Response|Percentage of Participants Who Missed at Least One Dose of Humira","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"566","Industry","Observational","Time Perspective: Prospective","PMOS GREC 2004 06","May 2006","July 2012","July 2012","March 12, 2010","September 26, 2013","September 26, 2013","Site Reference ID/Investigator# 30116, A. Glyfada, Greece|Site Reference ID/Investigator# 47544, Ag. Dimitrios, Athens, Greece|Site Reference ID/Investigator# 47542, Ag. Paraskevi, Athens, Greece|Site Reference ID/Investigator# 29992, Agioi Anargyroi, Greece|Site Reference ID/Investigator# 29954, Agioi Anargyroi, Greece|Site Reference ID/Investigator# 29915, Alexandroupoli, Greece|Site Reference ID/Investigator# 30118, Arta, Greece|Site Reference ID/Investigator# 29989, Athens, Greece|Site Reference ID/Investigator# 29914, Athens, Greece|Site Reference ID/Investigator# 29950, Athens, Greece|Site Reference ID/Investigator# 5284, Athens, Greece|Site Reference ID/Investigator# 29944, Athens, Greece|Site Reference ID/Investigator# 30474, Athens, Greece|Site Reference ID/Investigator# 29953, Athens, Greece|Site Reference ID/Investigator# 30085, Athens, Greece|Site Reference ID/Investigator# 30472, Athens, Greece|Site Reference ID/Investigator# 30479, Athens, Greece|Site Reference ID/Investigator# 30480, Athens, Greece|Site Reference ID/Investigator# 29899, Athens, Greece|Site Reference ID/Investigator# 30178, Athens, Greece|Site Reference ID/Investigator# 30785, Athens, Greece|Site Reference ID/Investigator# 30788, Athens, Greece|Site Reference ID/Investigator# 30198, Chalkida, Greece|Site Reference ID/Investigator# 30008, Crete, Greece|Site Reference ID/Investigator# 30210, Crete, Greece|Site Reference ID/Investigator# 29828, Crete, Greece|Site Reference ID/Investigator# 30105, Drama, Greece|Site Reference ID/Investigator# 29820, Elefsina, Greece|Site Reference ID/Investigator# 30146, Ermoupolis Syros, Greece|Site Reference ID/Investigator# 30767, Heraklion Crete, Greece|Site Reference ID/Investigator# 30789, Holargos, Greece|Site Reference ID/Investigator# 30482, Ioannina, Greece|Site Reference ID/Investigator# 47322, Karditsa, Greece|Site Reference ID/Investigator# 29850, Katerini, Greece|Site Reference ID/Investigator# 30189, Kavala, Greece|Site Reference ID/Investigator# 30476, Kifisia, Greece|Site Reference ID/Investigator# 30004, Kozani, Greece|Site Reference ID/Investigator# 29993, Lamia, Greece|Site Reference ID/Investigator# 29988, Larisa, Greece|Site Reference ID/Investigator# 30770, Larissa, Greece|Site Reference ID/Investigator# 29922, Nikea, Greece|Site Reference ID/Investigator# 29972, Patras, Greece|Site Reference ID/Investigator# 29916, Patras, Greece|Site Reference ID/Investigator# 29827, Peristeri, Greece|Site Reference ID/Investigator# 29936, Pyrgos, Greece|Site Reference ID/Investigator# 30200, Rion, Patras, Greece|Site Reference ID/Investigator# 29900, Thessaloniki, Greece|Site Reference ID/Investigator# 30192, Thessaloniki, Greece|Site Reference ID/Investigator# 30165, Thessaloniki, Greece|Site Reference ID/Investigator# 30765, Thessaloniki, Greece|Site Reference ID/Investigator# 29845, Thessaloniki, Greece|Site Reference ID/Investigator# 30791, Thessaloniki, Greece|Site Reference ID/Investigator# 30792, Thessaloniki, Greece|Site Reference ID/Investigator# 47543, Thessaloniki, Greece|Site Reference ID/Investigator# 29924, Thessaloniki, Greece|Site Reference ID/Investigator# 30477, Thessaloniki, Greece|Site Reference ID/Investigator# 29947, Thessaloniki, Greece|Site Reference ID/Investigator# 30115, Trikala, Greece|Site Reference ID/Investigator# 30084, Veria, Greece|Site Reference ID/Investigator# 29968, Xanthi, Greece",,"https://ClinicalTrials.gov/show/NCT01086033"
590,"NCT01085422","A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Drug: ABT-888|Drug: temozolomide","Protein-specific antigen (PSA) test|Assessment of Efficacy|Assessment of Safety","AbbVie (prior sponsor, Abbott)|Prostate Cancer Clinical Trials Consortium|AbbVie","Male","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-070","April 2010","June 2011","June 2011","March 11, 2010",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01085422"
591,"NCT01083849","Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice","TOP","Completed","Has Results","Kidney Insufficiency|Secondary Hyperparathyroidism",,"Percentage of Participants Who Achieved Intact Parathyroid Hormone (iPTH) Levels Within the Target Range After 12 Months|Time to Achieve Target Range of Intact Parathyroid Hormone (iPTH) Levels Within the Target Range After 12 Months|Number of Participants With Hypercalcemia|Number of Participants With Hyperphosphatemia|Number of Participants With Elevated Calcium-Phosphorus Product|Mean Duration of Hospitalization by Visit|Mean Duration of Disability by Visit|Mean Intact Parathormone (iPTH) Levels by Visit|Mean Calcium-Phosphate Product Levels by Visit","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"761","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P10-681","March 2008","December 2013","December 2013","March 10, 2010","December 19, 2014","December 19, 2014","Site Reference ID/Investigator# 64522, Feldkirch, Austria|Site Reference ID/Investigator# 53506, Graz, Austria|Site Reference ID/Investigator# 53524, Graz, Austria|Site Reference ID/Investigator# 74733, Innsbruck, Austria|Site Reference ID/Investigator# 64523, Rottenmann, Austria|Site Reference ID/Investigator# 53525, Salzburg, Austria|Site Reference ID/Investigator# 53526, St. Poelten, Austria|Site Reference ID/Investigator# 69662, Steyr, Austria|Site Reference ID/Investigator# 53508, Vienna, Austria|Site Reference ID/Investigator# 53523, Vienna, Austria|Site Reference ID/Investigator# 53507, Vienna, Austria|Site Reference ID/Investigator# 28352, Aachen, Germany|Site Reference ID/Investigator# 28359, Alsfeld, Germany|Site Reference ID/Investigator# 28305, Arnstadt, Germany|Site Reference ID/Investigator# 28306, Aschersleben, Germany|Site Reference ID/Investigator# 28003, Augsburg, Germany|Site Reference ID/Investigator# 81613, Aurich, Germany|Site Reference ID/Investigator# 28017, Bad Bevensen, Germany|Site Reference ID/Investigator# 28301, Bad Nenndorf, Germany|Site Reference ID/Investigator# 28296, Balingen, Germany|Site Reference ID/Investigator# 28021, Berlin, Germany|Site Reference ID/Investigator# 28024, Berlin, Germany|Site Reference ID/Investigator# 28303, Berlin, Germany|Site Reference ID/Investigator# 54050, Berlin, Germany|Site Reference ID/Investigator# 28022, Bernburg, Germany|Site Reference ID/Investigator# 30862, Betzdorf, Germany|Site Reference ID/Investigator# 28007, Bielefeld, Germany|Site Reference ID/Investigator# 28304, Burg, Germany|Site Reference ID/Investigator# 28014, Coburg, Germany|Site Reference ID/Investigator# 28023, Cottbus, Germany|Site Reference ID/Investigator# 28134, Demmin, Germany|Site Reference ID/Investigator# 28037, Dresden, Germany|Site Reference ID/Investigator# 43903, Dresden, Germany|Site Reference ID/Investigator# 99777, Elmshorn, Germany|Site Reference ID/Investigator# 28284, Elsenfeld, Germany|Site Reference ID/Investigator# 124118, Emden, Germany|Site Reference ID/Investigator# 54054, Emsdetten, Germany|Site Reference ID/Investigator# 48864, Erfurt, Germany|Site Reference ID/Investigator# 72343, Erkelenz, Germany|Site Reference ID/Investigator# 28029, Eschweiler, Germany|Site Reference ID/Investigator# 28287, Friedrichroda, Germany|Site Reference ID/Investigator# 28276, Gera, Germany|Site Reference ID/Investigator# 28351, Halle, Germany|Site Reference ID/Investigator# 28280, Hamburg, Germany|Site Reference ID/Investigator# 48865, Hanover, Germany|Site Reference ID/Investigator# 28300, Heilbronn, Germany|Site Reference ID/Investigator# 28011, Herford, Germany|Site Reference ID/Investigator# 124119, Herne, Germany|Site Reference ID/Investigator# 28019, Herzberg, Germany|Site Reference ID/Investigator# 28135, Hildesheim, Germany|Site Reference ID/Investigator# 28286, Hoyerswerda, Germany|Site Reference ID/Investigator# 28353, Ilfeld, Germany|Site Reference ID/Investigator# 28044, Jena, Germany|Site Reference ID/Investigator# 48863, Kiel, Germany|Site Reference ID/Investigator# 28013, Lahr, Germany|Site Reference ID/Investigator# 28025, Loerrach, Germany|Site Reference ID/Investigator# 28290, Ludwigslust, Germany|Site Reference ID/Investigator# 10982, Magdeburg, Germany|Site Reference ID/Investigator# 28291, Malente, Germany|Site Reference ID/Investigator# 28036, Mannheim, Germany|Site Reference ID/Investigator# 28302, Marburg, Germany|Site Reference ID/Investigator# 54051, Minden, Germany|Site Reference ID/Investigator# 28278, Muellheim, Germany|Site Reference ID/Investigator# 99778, Munich, Germany|Site Reference ID/Investigator# 99776, Neumuenster, Germany|Site Reference ID/Investigator# 124120, Nordhorn, Germany|Site Reference ID/Investigator# 28275, Nordhorn, Germany|Site Reference ID/Investigator# 43904, Oberstdorf, Germany|Site Reference ID/Investigator# 28277, Osnabrueck, Germany|Site Reference ID/Investigator# 28297, Peine, Germany|Site Reference ID/Investigator# 28307, Pirmasens, Germany|Site Reference ID/Investigator# 28295, Potsdam, Germany|Site Reference ID/Investigator# 28294, Quedlinburg, Germany|Site Reference ID/Investigator# 48862, Rendsburg, Germany|Site Reference ID/Investigator# 28042, Ribnitz-Damgarten, Germany|Site Reference ID/Investigator# 28282, Rostock, Germany|Site Reference ID/Investigator# 28033, St. Wendel, Germany|Site Reference ID/Investigator# 54052, Stuttgart, Germany|Site Reference ID/Investigator# 28005, Stuttgart, Germany|Site Reference ID/Investigator# 28020, Viersen, Germany|Site Reference ID/Investigator# 28293, Villingen-Schwenningen, Germany|Site Reference ID/Investigator# 28018, Voelklingen, Germany|Site Reference ID/Investigator# 28298, Weissenfels, Germany|Site Reference ID/Investigator# 28292, Wetzlar, Germany|Site Reference ID/Investigator# 48882, Wiesbaden, Germany|Site Reference ID/Investigator# 28299, Wolfenbuettel, Germany|Site Reference ID/Investigator# 28279, Zwickau, Germany",,"https://ClinicalTrials.gov/show/NCT01083849"
592,"NCT01083680","Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine",,"Completed","Has Results","Crohn's Disease",,"Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) at Each Visit|Percentage of Full Analysis Set (FAS) Participants in Each CDAI Disease Classification Over Time|Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ) at Each Visit in FAS Participants|Percentage of Participants With Adverse Events (Excluding Serious Adverse Events)|4.Mean Harvey Bradshaw Index (HBI) in Full Analysis Set (FAS) Participants Over Time|Compliance With the Self-injection Via the Humira®-PEN","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"4107","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P10-278","May 2007","December 2015","December 2015","March 10, 2010","April 4, 2017","April 4, 2017",,,"https://ClinicalTrials.gov/show/NCT01083680"
593,"NCT01083186","Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience","PROTECT","Completed","Has Results","Chronic Kidney Failure|Secondary Hyperparathyroidism",,"Intact Parathormone (iPTH) Changes During the Study Time-Points for Overall Study Population|Intact Parathormone (iPTH) Changes During the Study Time-Points for Subpopulation of Renal Transplanted Participants|Median Time to Attain the First Lower Intact Parathormone (iPTH) Levels|Mean Duration of Effect Sustainability (Months)|Distribution of Participants by Achievement of Intact Parathormone (iPTH) Levels Within the Target Range|Number of Participants With Serum Calcium Level Abnormalities|Number of Participants With Serum Phosphorus Level Abnormalities|Change in Dipstick Albuminuria Grade From Baseline to Month 6|Change in Dipstick Albuminuria Grade From Baseline to Month 12|Glycosylated Hemoglobin A1c (HbA1c) Values Throughout the Study|Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs)|Distribution of Participants by Chronic Kidney Disease (CKD) Stage Throughout Study|Estimated Glomerular Filtration Rate (eGFR) Values Throughout the Study|Change From Baseline in Alanine Aminotransferase (ALT) Levels at Months 6 and 12|Change From Baseline in Aspartate Aminotransferase (AST) Levels at Months 6 and 12|Change From Baseline in Creatinine Levels at Months 6 and 12|Change From Baseline in Urea Levels at Months 6 and 12|Change From Baseline in Alkaline Phosphatase (ALP) Levels at Months 6 and 12|Change From Enrollment in Total Cholesterol Levels at Months 6 and 12|Change From Enrollment in Triglyceride Levels at Months 6 and 12|Change From Enrollment in Low Density Lipoprotein Cholesterol (LDL-C) Levels at Months 6 and 12|Change From Enrollment in High Density Lipoprotein Cholesterol (HDL-C) Levels at Months 6 and 12|Change From Baseline in C-Reactive Protein (CRP) Levels at Months 6 and 12|Homocysteine Values Throughout the Study","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Time Perspective: Prospective","P11-978","June 2009","January 2012","January 2012","March 9, 2010","March 7, 2013","March 12, 2013","Site Reference ID/Investigator# 47002, Arta, Greece|Site Reference ID/Investigator# 43772, Athens, Greece|Site Reference ID/Investigator# 27492, Athens, Greece|Site Reference ID/Investigator# 43769, Athens, Greece|Site Reference ID/Investigator# 38257, Athens, Greece|Site Reference ID/Investigator# 47003, Athens, Greece|Site Reference ID/Investigator# 27497, Athens, Greece|Site Reference ID/Investigator# 47004, Athens, Greece|Site Reference ID/Investigator# 27489, Athens, Greece|Site Reference ID/Investigator# 27495, Athens, Greece|Site Reference ID/Investigator# 43773, Athens, Greece|Site Reference ID/Investigator# 27498, Haidari, Athens, Greece|Site Reference ID/Investigator# 38259, Ioannina, Greece|Site Reference ID/Investigator# 22121, Larissa, Greece|Site Reference ID/Investigator# 43771, Larissa, Greece|Site Reference ID/Investigator# 43767, Maroussi Athens, Greece|Site Reference ID/Investigator# 27496, Nikaia, Greece|Site Reference ID/Investigator# 43768, North Ionia, Athens, Greece|Site Reference ID/Investigator# 27491, Piraeus, Greece|Site Reference ID/Investigator# 27494, Thessaloniki, Greece|Site Reference ID/Investigator# 27493, Thessaloniki, Greece|Site Reference ID/Investigator# 38255, Thessaloniki, Greece|Site Reference ID/Investigator# 43770, Thessaloniki, Greece|Site Reference ID/Investigator# 39839, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT01083186"
594,"NCT01083173","Surveillance of Kaletra in Korean Patients",,"Completed","Has Results","HIV-1 Infection",,"Number of Participants With Adverse Events|Number of Participants Who Interrupted or Discontinued Kaletra Treatment|Percentage of Participants With Viral Load Below 400 Copies/mL|Percentage of Participants With Viral Load Below 50 Copies/mL|Change From Baseline in Viral Load|Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Counts|Percentage of Participants With Confirmed Viral Resistance|Mean Time to Treatment Failure","AbbVie (prior sponsor, Abbott)|AbbVie","All","2 Years to 99 Years   (Child, Adult, Older Adult)",,"595","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P11-068","October 2009","October 2014","October 2014","March 9, 2010","February 22, 2016","February 22, 2016",,,"https://ClinicalTrials.gov/show/NCT01083173"
595,"NCT01083121","Surveillance of Humira Injection in Korean Patients",,"Completed","Has Results","Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis|Crohn's Disease|Psoriasis",,"Number of Participants With Adverse Events (AEs)|Physician's Global Assessment for Effectiveness","AbbVie (prior sponsor, Abbott)|Eisai Co., Ltd.|AbbVie","All","19 Years and older   (Adult, Older Adult)",,"1779","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P10-053","April 2007","June 2012","June 2012","March 9, 2010","August 20, 2013","August 21, 2013","Site Reference ID/Investigator# 29724, Ansan, Korea, Republic of|Site Reference ID/Investigator# 53586, Ansan, Korea, Republic of|Site Reference ID/Investigator# 29729, Bucheon, Korea, Republic of|Site Reference ID/Investigator# 29009, Bucheon, Korea, Republic of|Site Reference ID/Investigator# 29726, Busan, Korea, Republic of|Site Reference ID/Investigator# 29733, Busan, Korea, Republic of|Site Reference ID/Investigator# 28582, Busan, Korea, Republic of|Site Reference ID/Investigator# 5633, Busan, Korea, Republic of|Site Reference ID/Investigator# 28608, Cheonan, Korea, Republic of|Site Reference ID/Investigator# 28996, Cheonan, Korea, Republic of|Site Reference ID/Investigator# 29735, Daegu, Korea, Republic of|Site Reference ID/Investigator# 59287, Daegu, Korea, Republic of|Site Reference ID/Investigator# 29278, Daegu, Korea, Republic of|Site Reference ID/Investigator# 29279, Daegu, Korea, Republic of|Site Reference ID/Investigator# 29007, Daejeon, Korea, Republic of|Site Reference ID/Investigator# 29727, Daejeon, Korea, Republic of|Site Reference ID/Investigator# 29745, Daejeon, Korea, Republic of|Site Reference ID/Investigator# 48624, Daejeon, Korea, Republic of|Site Reference ID/Investigator# 29075, Goyang, Korea, Republic of|Site Reference ID/Investigator# 29042, Guri, Korea, Republic of|Site Reference ID/Investigator# 59285, Guri, Korea, Republic of|Site Reference ID/Investigator# 29731, Gwangju, Korea, Republic of|Site Reference ID/Investigator# 81693, Gwangju, Korea, Republic of|Site Reference ID/Investigator# 29732, Gwangju, Korea, Republic of|Site Reference ID/Investigator# 29737, Gwangju, Korea, Republic of|Site Reference ID/Investigator# 29742, Gwangju, Korea, Republic of|Site Reference ID/Investigator# 28611, Gyeongju, Korea, Republic of|Site Reference ID/Investigator# 29103, Iksan, Korea, Republic of|Site Reference ID/Investigator# 29010, Incheon, Korea, Republic of|Site Reference ID/Investigator# 28589, Jeju, Korea, Republic of|Site Reference ID/Investigator# 29080, Jeju, Korea, Republic of|Site Reference ID/Investigator# 29743, Jeollabuk-do, Korea, Republic of|Site Reference ID/Investigator# 29082, Jeonju, Korea, Republic of|Site Reference ID/Investigator# 29740, Jinju, Korea, Republic of|Site Reference ID/Investigator# 29172, Masan, Korea, Republic of|Site Reference ID/Investigator# 29436, Metropolitan city Daejon, Korea, Republic of|Site Reference ID/Investigator# 28970, Pohang, Korea, Republic of|Site Reference ID/Investigator# 29723, Seongnam, Korea, Republic of|Site Reference ID/Investigator# 29722, Seongnam, Korea, Republic of|Site Reference ID/Investigator# 29738, Seoul, Korea, Republic of|Site Reference ID/Investigator# 53584, Seoul, Korea, Republic of|Site Reference ID/Investigator# 59283, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29452, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29453, Seoul, Korea, Republic of|Site Reference ID/Investigator# 53583, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29728, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29734, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29721, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29029, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29736, Seoul, Korea, Republic of|Site Reference ID/Investigator# 59282, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29741, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29165, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29166, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29011, Seoul, Korea, Republic of|Site Reference ID/Investigator# 48623, Seoul, Korea, Republic of|Site Reference ID/Investigator# 63322, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29748, Seoul, Korea, Republic of|Site Reference ID/Investigator# 53582, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29076, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29034, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29434, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29435, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29744, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29041, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29012, Seoul, Korea, Republic of|Site Reference ID/Investigator# 66654, Seoul, Korea, Republic of|Site Reference ID/Investigator# 59284, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29035, Seoul, Korea, Republic of|Site Reference ID/Investigator# 59286, Seoul, Korea, Republic of|Site Reference ID/Investigator# 29746, Suwon-si, Korea, Republic of|Site Reference ID/Investigator# 53588, Suwon, Korea, Republic of|Site Reference ID/Investigator# 29739, Taegu, Korea, Republic of|Site Reference ID/Investigator# 29085, Uljeongbu, Korea, Republic of|Site Reference ID/Investigator# 28610, Ulsan, Korea, Republic of|Site Reference ID/Investigator# 29725, Ulsan, Korea, Republic of|Site Reference ID/Investigator# 29730, Wonju, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01083121"
596,"NCT01079182","Basic Documentation of Adalimumab (Humira) in Patients With Ankylosing Spondylitis (AS)",,"Completed","Has Results","Ankylosing Spondylitis",,"Mean Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score|Mean Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Score|Number of Participants With Drug-Related Adverse Events (AEs)|Mean Number of Involved Peripheral Joints|Percentage of Participants With Extraspinal Manifestations|Mean Erythrocyte Sedimentation Rate (ESR)|Mean Plasma Concentrations of C-Reactive Protein (CRP)|Mean Bath Ankylosing Spondylitis-Global (BAS-G) Score|Mean Global Assessment of Disease Activity Score|Mean Participant Fatigue Score|Mean Participant Pain Score|Percentage of Participants With Morning Stiffness|Mean Duration of Morning Stiffness|Percentage of Participants Achieving Assessment of SpondyloArthritis International Society (ASAS) Improvement Criteria|Percentage of Participants Achieving ASAS Partial Remission Criteria|Percentage of Participants With Impairment in Daily Activities During the Last 4 Weeks|Percentage of Participants Who Missed Work Days Due to Ankylosing Spondylitis (AS) in the Previous 12 Months|Mean Missed Work Days Due to Ankylosing Spondylitis in the Previous 12 Months|Percentage of Participants With In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months|Mean Days of In-Patient Hospitalization Due to Ankylosing Spondylitis in the Previous 12 Months|Percentage of Participants on Adalimumab Monotherapy|Percentage of Participants With Concomitant Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)|Percentage of Participants With Concomitant Pain Relief/Anti-Inflammatory Agents|Mean Equivalent Dose of Prednisolone","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"4681","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P10-147","January 2006","May 2014","May 2014","March 3, 2010","June 1, 2015","July 9, 2015",,,"https://ClinicalTrials.gov/show/NCT01079182"
597,"NCT01078597","A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA",,"Completed","No Results Available","Rheumatoid Arthritis",,"Anti-Cyclic Citrullinated Protein blood test results|Anti-Modified Citrullinated Vimentin blood test result|Rheumatoid Factor blood test result|Investigator Questionnaire assessing the impact (if any) of biomarker status on the management of the patient|C- Reactive Protein (CRP) & Erythrocyte Sedimentation Rate (ESR) blood test results|Swollen Joint Count|Tender Joint Count|Disease Activity Score (DAS)-28|Health Assessment Questionnaire Disability Index (HAQ-DI)|Visual Analogue Scale-Disease Activity (VAS-DA)|Visual Analogue Scale - Pain (VAS-Pain)|Visual Analogue Scale - General Health (VAS-GH)","AbbVie (prior sponsor, Abbott)|JSS Medical Research Inc.|Clinical Trial End-Point (CTEP) Ltd|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"35","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P11-983","September 2010","July 2013","July 2013","March 2, 2010",,"August 20, 2013","Site Reference ID/Investigator# 49402, Cork, Ireland|Site Reference ID/Investigator# 49403, Cork, Ireland|Site Reference ID/Investigator# 22307, Dublin 24, Ireland|Site Reference ID/Investigator# 72114, Dublin 4, Ireland",,"https://ClinicalTrials.gov/show/NCT01078597"
598,"NCT01078558","A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )","ProAct","Completed","Has Results","Rheumatoid Arthritis|Psoriatic Arthritis|Ankylosing Spondylitis",,"Change From Baseline in Physician's Assessment of Disease Activity Over Time|Change From Baseline in Tender Joints Over Time|Change From Baseline in Swollen Joints Over Time|Inflammatory Parameter: Change From Baseline in CRP Over Time|Inflammatory Parameter: Change From Baseline in ESR Over Time|Physical Function: Change From Baseline in HAQ% Over Time|Change From Baseline in DAS28 Over Time: RA Participants|DAS28 Category Over Time: RA Participants|BSA With PsA Over Time: PsA Participants|Change From Baseline in Patient's Numerical Rating Scale Over Time: Oligoarticular PsA Participants|Change From Baseline in Physician's Numerical Rating Scale Over Time: Oligoarticular PsA Participants|Change From Baseline in BASDAI Over Time: AS Participants|Number of Participants With Adverse Events (AEs) Serious AEs (SAEs), and AEs Leading to Study Drug Discontinuation","AbbVie (prior sponsor, Abbott)|Veeda Clinical Research|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"5940","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HUM04-28","May 13, 2004","January 11, 2018","January 11, 2018","March 2, 2010","July 5, 2019","July 5, 2019",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT01078558/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT01078558/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01078558"
599,"NCT01078402","EValuation of HumIRA® in Patients With Active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis in EASTern European Countries","EviraEAST","Completed","Has Results","Ankylosing Spondylitis (AS)|Psoriatic Arthritis (PsA|Rheumatoid Arthritis (RA",,"Clinical Outcome (Disease Activity Score [DAS28] Decrease ≥1.2) After 3 Months of Humira Therapy Relative to Baseline in Participants With RA|Clinical Outcome (Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] Decrease ≥50%) After 3 Months of Humira Therapy Relative to Baseline in Participants With PsA and AS|Physical Function: Mean Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Baseline, and After 4, 7 and 13 Months of Humira Therapy|Participant Acceptability of Self-injection at Month 13 (End of Study)|Compliance With the Humira Administration Schedule at Month 13 (End of Study)|Tolerability: Duration of Humira Therapy in Participants Who Discontinued Therapy|Tolerability: Overall Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"809","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P10-919","April 2009","November 2011","November 2011","March 2, 2010","February 7, 2013","February 12, 2013","Site Reference ID/Investigator# 43283, Opatija, Croatia|Site Reference ID/Investigator# 43282, Osijek, Croatia|Site Reference ID/Investigator# 43286, Rijeka, Croatia|Site Reference ID/Investigator# 43284, Split, Croatia|Site Reference ID/Investigator# 22405, Zagreb, Croatia|Site Reference ID/Investigator# 43285, Zagreb, Croatia|Site Reference ID/Investigator# 32641, Budapest, Hungary|Site Reference ID/Investigator# 32642, Budapest, Hungary|Site Reference ID/Investigator# 32676, Budapest, Hungary|Site Reference ID/Investigator# 32677, Budapest, Hungary|Site Reference ID/Investigator# 32679, Budapest, Hungary|Site Reference ID/Investigator# 32680, Budapest, Hungary|Site Reference ID/Investigator# 32681, Budapest, Hungary|Site Reference ID/Investigator# 32682, Budapest, Hungary|Site Reference ID/Investigator# 32685, Budapest, Hungary|Site Reference ID/Investigator# 32686, Budapest, Hungary|Site Reference ID/Investigator# 32687, Budapest, Hungary|Site Reference ID/Investigator# 32688, Budapest, Hungary|Site Reference ID/Investigator# 32689, Budapest, Hungary|Site Reference ID/Investigator# 32691, Budapest, Hungary|Site Reference ID/Investigator# 32692, Budapest, Hungary|Site Reference ID/Investigator# 32693, Budapest, Hungary|Site Reference ID/Investigator# 32633, Budapest, Hungary|Site Reference ID/Investigator# 32634, Budapest, Hungary|Site Reference ID/Investigator# 32635, Budapest, Hungary|Site Reference ID/Investigator# 32636, Budapest, Hungary|Site Reference ID/Investigator# 32638, Budapest, Hungary|Site Reference ID/Investigator# 32639, Budapest, Hungary|Site Reference ID/Investigator# 32640, Budapest, Hungary|Site Reference ID/Investigator# 32694, Budapest, Hungary|Site Reference ID/Investigator# 32695, Budapest, Hungary|Site Reference ID/Investigator# 32612, Debrecen, Hungary|Site Reference ID/Investigator# 32613, Debrecen, Hungary|Site Reference ID/Investigator# 32614, Debrecen, Hungary|Site Reference ID/Investigator# 32615, Debrecen, Hungary|Site Reference ID/Investigator# 32616, Debrecen, Hungary|Site Reference ID/Investigator# 32591, Debrecen, Hungary|Site Reference ID/Investigator# 32592, Debrecen, Hungary|Site Reference ID/Investigator# 32584, Esztergom, Hungary|Site Reference ID/Investigator# 32585, Esztergom, Hungary|Site Reference ID/Investigator# 32629, Gyor, Hungary|Site Reference ID/Investigator# 32630, Gyor, Hungary|Site Reference ID/Investigator# 32696, Gyula, Hungary|Site Reference ID/Investigator# 32697, Gyula, Hungary|Site Reference ID/Investigator# 32698, Gyula, Hungary|Site Reference ID/Investigator# 32699, Gyula, Hungary|Site Reference ID/Investigator# 32700, Gyula, Hungary|Site Reference ID/Investigator# 32701, Gyula, Hungary|Site Reference ID/Investigator# 32702, Gyula, Hungary|Site Reference ID/Investigator# 32703, Gyula, Hungary|Site Reference ID/Investigator# 32566, Heviz, Hungary|Site Reference ID/Investigator# 32580, Kecskemet, Hungary|Site Reference ID/Investigator# 32581, Kecskemet, Hungary|Site Reference ID/Investigator# 32582, Kistarcsa, Hungary|Site Reference ID/Investigator# 32583, Kistarcsa, Hungary|Site Reference ID/Investigator# 32624, Miskolc, Hungary|Site Reference ID/Investigator# 32625, Miskolc, Hungary|Site Reference ID/Investigator# 32626, Miskolc, Hungary|Site Reference ID/Investigator# 32586, Nyiregyhaza, Hungary|Site Reference ID/Investigator# 32588, Nyiregyhaza, Hungary|Site Reference ID/Investigator# 32589, Nyiregyhaza, Hungary|Site Reference ID/Investigator# 32590, Nyiregyhaza, Hungary|Site Reference ID/Investigator# 32704, Pecs, Hungary|Site Reference ID/Investigator# 32705, Pecs, Hungary|Site Reference ID/Investigator# 32709, Pecs, Hungary|Site Reference ID/Investigator# 32617, Szeged, Hungary|Site Reference ID/Investigator# 32618, Szeged, Hungary|Site Reference ID/Investigator# 32619, Szeged, Hungary|Site Reference ID/Investigator# 32627, Szekesfehervar, Hungary|Site Reference ID/Investigator# 32628, Szekesfehervar, Hungary|Site Reference ID/Investigator# 32594, Szolnok, Hungary|Site Reference ID/Investigator# 32595, Szolnok, Hungary|Site Reference ID/Investigator# 32620, Szombathely, Hungary|Site Reference ID/Investigator# 32622, Szombathely, Hungary|Site Reference ID/Investigator# 32711, Veszprem, Hungary|Site Reference ID/Investigator# 32712, Veszprem, Hungary|Site Reference ID/Investigator# 32713, Veszprem, Hungary|Site Reference ID/Investigator# 32079, Ashkelon, Israel|Site Reference ID/Investigator# 32082, Haifa, Israel|Site Reference ID/Investigator# 32080, Haifa, Israel|Site Reference ID/Investigator# 32081, Tel Hashomer, Israel|Site Reference ID/Investigator# 65468, Tel Hashomer, Israel|Site Reference ID/Investigator# 32078, Zrifin, Israel|Site Reference ID/Investigator# 32599, Bytom, Poland|Site Reference ID/Investigator# 43251, Krakow, Poland|Site Reference ID/Investigator# 32559, Krakow, Poland|Site Reference ID/Investigator# 32560, Krakow, Poland|Site Reference ID/Investigator# 43244, Krakow, Poland|Site Reference ID/Investigator# 43252, Krakow, Poland|Site Reference ID/Investigator# 43245, Poznan, Poland|Site Reference ID/Investigator# 43246, Poznan, Poland|Site Reference ID/Investigator# 32596, Sopot, Poland|Site Reference ID/Investigator# 32597, Sopot, Poland|Site Reference ID/Investigator# 43250, Wrocław, Poland|Site Reference ID/Investigator# 31675, Brasov, Romania|Site Reference ID/Investigator# 31678, Bucharest, Romania|Site Reference ID/Investigator# 32568, Bucharest, Romania|Site Reference ID/Investigator# 32569, Bucharest, Romania|Site Reference ID/Investigator# 32570, Bucharest, Romania|Site Reference ID/Investigator# 32571, Bucharest, Romania|Site Reference ID/Investigator# 32098, Bucharest, Romania|Site Reference ID/Investigator# 32099, Bucharest, Romania|Site Reference ID/Investigator# 32575, Bucharest, Romania|Site Reference ID/Investigator# 32576, Bucharest, Romania|Site Reference ID/Investigator# 32577, Bucharest, Romania|Site Reference ID/Investigator# 32578, Bucharest, Romania|Site Reference ID/Investigator# 31669, Bucharest, Romania|Site Reference ID/Investigator# 31670, Bucharest, Romania|Site Reference ID/Investigator# 31671, Bucharest, Romania|Site Reference ID/Investigator# 31672, Bucharest, Romania|Site Reference ID/Investigator# 32094, Bucharest, Romania|Site Reference ID/Investigator# 32090, Bucharest, Romania|Site Reference ID/Investigator# 32091, Bucharest, Romania|Site Reference ID/Investigator# 32100, Cluj-Napoca, Romania|Site Reference ID/Investigator# 32097, Cluj-Napoca, Romania|Site Reference ID/Investigator# 32101, Constanta, Romania|Site Reference ID/Investigator# 32103, Constanta, Romania|Site Reference ID/Investigator# 31673, Craiova, Romania|Site Reference ID/Investigator# 31674, Craiova, Romania|Site Reference ID/Investigator# 19163, Iasi, Romania|Site Reference ID/Investigator# 31668, Iasi, Romania|Site Reference ID/Investigator# 32114, Iasi, Romania|Site Reference ID/Investigator# 32115, Iasi, Romania|Site Reference ID/Investigator# 32116, Iasi, Romania|Site Reference ID/Investigator# 32117, Iasi, Romania|Site Reference ID/Investigator# 32118, Iasi, Romania|Site Reference ID/Investigator# 32119, Iasi, Romania|Site Reference ID/Investigator# 32112, Piatra Neamt, Romania|Site Reference ID/Investigator# 32572, Ploiesti, Romania|Site Reference ID/Investigator# 32573, Ploiesti, Romania|Site Reference ID/Investigator# 32574, Ploiesti, Romania|Site Reference ID/Investigator# 31676, Sf. Gheorghe jud. Covasna, Romania|Site Reference ID/Investigator# 32104, Targu Mures, Romania|Site Reference ID/Investigator# 32105, Targu Mures, Romania|Site Reference ID/Investigator# 32108, Timisoara, Romania|Site Reference ID/Investigator# 32113, Timisoara, Romania|Site Reference ID/Investigator# 19164, Banska Bystrica, Slovakia|Site Reference ID/Investigator# 43262, Bratislava, Slovakia|Site Reference ID/Investigator# 43263, Kosice, Slovakia|Site Reference ID/Investigator# 43242, Dnepropetrovsk, Ukraine|Site Reference ID/Investigator# 48364, Dnipropetrovsk, Ukraine|Site Reference ID/Investigator# 31693, Donetsk, Ukraine|Site Reference ID/Investigator# 31685, Donetsk, Ukraine|Site Reference ID/Investigator# 31690, Kharkov, Ukraine|Site Reference ID/Investigator# 31686, Kharkov, Ukraine|Site Reference ID/Investigator# 31679, Kiev, Ukraine|Site Reference ID/Investigator# 31680, Kiev, Ukraine|Site Reference ID/Investigator# 31684, Kiev, Ukraine|Site Reference ID/Investigator# 31682, Kiev, Ukraine|Site Reference ID/Investigator# 31683, Kiev, Ukraine|Site Reference ID/Investigator# 48363, Kiev, Ukraine|Site Reference ID/Investigator# 48365, Kryvyi Rih, Ukraine|Site Reference ID/Investigator# 48366, Lviv, Ukraine|Site Reference ID/Investigator# 48367, Lviv, Ukraine|Site Reference ID/Investigator# 48368, Lviv, Ukraine|Site Reference ID/Investigator# 31689, Odessa, Ukraine|Site Reference ID/Investigator# 31694, Simferopol, Ukraine|Site Reference ID/Investigator# 43243, Uzhgorod, Ukraine|Site Reference ID/Investigator# 48369, Uzhgorod, Ukraine|Site Reference ID/Investigator# 48370, Uzhgorod, Ukraine|Site Reference ID/Investigator# 31691, Vinnitsa, Ukraine|Site Reference ID/Investigator# 31692, Zaporogzhe, Ukraine|Site Reference ID/Investigator# 48371, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT01078402"
600,"NCT01078155","Evaluation of the Role of Adalimumab on Extraarticular Manifestation - Bone Metabolism and Bone Mineral Density in Patients With Active Rheumatoid Arthritis",,"Completed","Has Results","Rheumatoid Arthritis|Osteoporosis",,"Bone Mineral Density (BMD) of Spine and Hip by Dual-energy X-ray Absorptiometry (DEXA) at Baseline, Month 12, and Month 24|Spine and Hip T-score and Z-score by DEXA at Baseline, Month 12, and Month 24|Change in Bone Turnover Marker Osteocalcin (OC) From Baseline Through Month 3, Month 12, and Month 24|Change in Bone Turnover Marker C-terminal Type I Procollagen Peptide (CICP) From Baseline Through Month 3, Month 12, and Month 24|Change in Bone Turnover Marker C-telopeptide of Type I Collagen (CTX-I) From Baseline Through Month 3, Month 12, and Month 24|Mean Duration of Morning Stiffness at Baseline, Month 3, Month 12, and Month 24|Tender Joint Count at Baseline, Month 3, Month 12, and Month 24|Swollen Joint Count at Baseline, Month 3, Month 12, and Month 24|Disease Activity Score in 28 Joints (DAS28) at Baseline, Month 3, Month 12, Month 24|Visual Analogue Scale (VAS): Physician's Global Assessment of Disease Activity at Baseline, Month 3, Month 12, Month 24|Visual Analogue Scale (VAS): Subject's Global Assessment of Disease Activity at Baseline, Month 3, Month 12, Month 24|Visual Analogue Scale (VAS): Subject's Assessment of Pain at Baseline, Month 3, Month 12, Month 24|Erythrocyte Sedimentation Rate (ESR) at Baseline, Month 3, Month 12, Month 24","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"131","Industry","Observational","Time Perspective: Prospective","P10-733","March 2009","May 2014","May 2014","March 2, 2010","May 29, 2015","June 26, 2015",,,"https://ClinicalTrials.gov/show/NCT01078155"
601,"NCT01078090","Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice",,"Completed","Has Results","Rheumatoid Arthritis",,"Change From Baseline in Disease Activity Score (DAS) 28|Percentage of Participants in DAS28 Remission|Percentage of Participants With a Significant Therapeutic Response|Percentage of Participants With Low, Moderate and High Disease Activity|Erythrocyte Sedimentation Rate (ESR) Over Time|C-Reactive Protein (CRP) Levels Over Time|Tender Joint Count (TJC) Over Time|Swollen Joint Count (SJC) Over Time|Hannover Functional Questionnaire (FFbH) Over Time|Patients Global Assessment of Disease Activity Over Time|Participants Assessment of Pain Over Time|Participants Assessment of Fatigue Over Time|Percentage of Participants With Impairment in Daily Activities|Number of Days Missed From Work Due to Rheumatoid Arthritis|Percentage of Participants With In-patient Hospitalization|Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"5745","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","HUM 03-1","April 2003","March 2013","March 2013","March 2, 2010","April 23, 2014","May 8, 2014","Site Reference ID/Investigator# 35034, Aachen, Germany|Site Reference ID/Investigator# 35033, Aachen, Germany|Site Reference ID/Investigator# 53919, Achern, Germany|Site Reference ID/Investigator# 53883, Aichhalden, Germany|Site Reference ID/Investigator# 35041, Altenburg, Germany|Site Reference ID/Investigator# 35050, Amberg, Germany|Site Reference ID/Investigator# 53974, Amberg, Germany|Site Reference ID/Investigator# 33347, Augsburg, Germany|Site Reference ID/Investigator# 33356, Bad Abbach, Germany|Site Reference ID/Investigator# 33359, Bad Abbach, Germany|Site Reference ID/Investigator# 33362, Bad Aibling, Germany|Site Reference ID/Investigator# 35084, Bad Aibling, Germany|Site Reference ID/Investigator# 53968, Bad Aibling, Germany|Site Reference ID/Investigator# 53966, Bad Bellingen, Germany|Site Reference ID/Investigator# 35523, Bad Bentheim, Germany|Site Reference ID/Investigator# 35571, Bad Bramstedt, Germany|Site Reference ID/Investigator# 53903, Bad Bramstedt, Germany|Site Reference ID/Investigator# 53929, Bad Buchau, Germany|Site Reference ID/Investigator# 33370, Bad Endbach, Germany|Site Reference ID/Investigator# 33369, Bad Endbach, Germany|Site Reference ID/Investigator# 33380, Bad Iburg, Germany|Site Reference ID/Investigator# 33384, Bad Kissingen, Germany|Site Reference ID/Investigator# 33385, Bad Kreuznach, Germany|Site Reference ID/Investigator# 33389, Bad Liebenwerda, Germany|Site Reference ID/Investigator# 53942, Bad Mergentheim, Germany|Site Reference ID/Investigator# 33394, Bad Muender, Germany|Site Reference ID/Investigator# 33398, Bad Nauheim, Germany|Site Reference ID/Investigator# 33399, Bad Neuenahr, Germany|Site Reference ID/Investigator# 35576, Bad Neuenahr, Germany|Site Reference ID/Investigator# 53980, Bad Pyrmont, Germany|Site Reference ID/Investigator# 33402, Bad Rappenau, Germany|Site Reference ID/Investigator# 33410, Bad Soden-Salmuenster, Germany|Site Reference ID/Investigator# 33415, Bad Staffelstein, Germany|Site Reference ID/Investigator# 54804, Bad Toelz, Germany|Site Reference ID/Investigator# 33423, Baden-Baden, Germany|Site Reference ID/Investigator# 33427, Bamberg, Germany|Site Reference ID/Investigator# 33436, Bautzen, Germany|Site Reference ID/Investigator# 33440, Bayreuth, Germany|Site Reference ID/Investigator# 53978, Belm, Germany|Site Reference ID/Investigator# 33449, Bensheim, Germany|Site Reference ID/Investigator# 34264, Berlin-Buch, Germany|Site Reference ID/Investigator# 34250, Berlin-Wannsee, Germany|Site Reference ID/Investigator# 33646, Berlin, Germany|Site Reference ID/Investigator# 53902, Berlin, Germany|Site Reference ID/Investigator# 33662, Berlin, Germany|Site Reference ID/Investigator# 33695, Berlin, Germany|Site Reference ID/Investigator# 34243, Berlin, Germany|Site Reference ID/Investigator# 33681, Berlin, Germany|Site Reference ID/Investigator# 35599, Berlin, Germany|Site Reference ID/Investigator# 53959, Berlin, Germany|Site Reference ID/Investigator# 33688, Berlin, Germany|Site Reference ID/Investigator# 34260, Berlin, Germany|Site Reference ID/Investigator# 33685, Berlin, Germany|Site Reference ID/Investigator# 53948, Berlin, Germany|Site Reference ID/Investigator# 53939, Berlin, Germany|Site Reference ID/Investigator# 53971, Berlin, Germany|Site Reference ID/Investigator# 53933, Berlin, Germany|Site Reference ID/Investigator# 53884, Berlin, Germany|Site Reference ID/Investigator# 33672, Berlin, Germany|Site Reference ID/Investigator# 35552, Berlin, Germany|Site Reference ID/Investigator# 35554, Bernau, Germany|Site Reference ID/Investigator# 53899, Biberach, Germany|Site Reference ID/Investigator# 34279, Bielefeld, Germany|Site Reference ID/Investigator# 54810, Bielefeld, Germany|Site Reference ID/Investigator# 35559, Bietigheim-Bissingen, Germany|Site Reference ID/Investigator# 35560, Bietigheim-Bissingen, Germany|Site Reference ID/Investigator# 34283, Blankenburg/Hart, Germany|Site Reference ID/Investigator# 34286, Blaubeuren, Germany|Site Reference ID/Investigator# 34289, Bocholt, Germany|Site Reference ID/Investigator# 53946, Bocholt, Germany|Site Reference ID/Investigator# 35567, Bochum, Germany|Site Reference ID/Investigator# 35642, Bogen, Germany|Site Reference ID/Investigator# 34300, Bonn, Germany|Site Reference ID/Investigator# 53969, Bonn, Germany|Site Reference ID/Investigator# 35647, Bonn, Germany|Site Reference ID/Investigator# 35648, Bonn, Germany|Site Reference ID/Investigator# 34294, Bonn, Germany|Site Reference ID/Investigator# 34305, Braunschweig, Germany|Site Reference ID/Investigator# 34310, Braunschweig, Germany|Site Reference ID/Investigator# 35601, Breitenbrunn, Germany|Site Reference ID/Investigator# 35607, Bremen, Germany|Site Reference ID/Investigator# 53975, Bremen, Germany|Site Reference ID/Investigator# 53934, Buechen, Germany|Site Reference ID/Investigator# 34696, Celle, Germany|Site Reference ID/Investigator# 34700, Chemnitz, Germany|Site Reference ID/Investigator# 35092, Chemnitz, Germany|Site Reference ID/Investigator# 33990, Cologne, Germany|Site Reference ID/Investigator# 33987, Cologne, Germany|Site Reference ID/Investigator# 33996, Cologne, Germany|Site Reference ID/Investigator# 33993, Cologne, Germany|Site Reference ID/Investigator# 35238, Cologne, Germany|Site Reference ID/Investigator# 35617, Cottbus, Germany|Site Reference ID/Investigator# 53987, Cuxhaven, Germany|Site Reference ID/Investigator# 53889, Cuxhaven, Germany|Site Reference ID/Investigator# 35622, Darmstadt, Germany|Site Reference ID/Investigator# 53885, Delmenhorst, Germany|Site Reference ID/Investigator# 34726, Demmin, Germany|Site Reference ID/Investigator# 53932, Denkendorf, Germany|Site Reference ID/Investigator# 35636, Dortmund, Germany|Site Reference ID/Investigator# 35632, Dortmund, Germany|Site Reference ID/Investigator# 35171, Dresden, Germany|Site Reference ID/Investigator# 34762, Dresden, Germany|Site Reference ID/Investigator# 53958, Dresden, Germany|Site Reference ID/Investigator# 34749, Dresden, Germany|Site Reference ID/Investigator# 34763, Dresden, Germany|Site Reference ID/Investigator# 34771, Duesseldorf, Germany|Site Reference ID/Investigator# 34774, Duesseldorf, Germany|Site Reference ID/Investigator# 34776, Duisburg, Germany|Site Reference ID/Investigator# 53897, Duisburg, Germany|Site Reference ID/Investigator# 34779, Ebensfeld, Germany|Site Reference ID/Investigator# 34782, Eberswalde, Germany|Site Reference ID/Investigator# 54805, Eisenberg, Germany|Site Reference ID/Investigator# 35180, Elmshorn, Germany|Site Reference ID/Investigator# 34802, Erftstadt, Germany|Site Reference ID/Investigator# 34807, Erfurt, Germany|Site Reference ID/Investigator# 35097, Erfurt, Germany|Site Reference ID/Investigator# 35189, Erfurt, Germany|Site Reference ID/Investigator# 54811, Erlangen, Germany|Site Reference ID/Investigator# 34815, Erlangen, Germany|Site Reference ID/Investigator# 53925, Essen, Germany|Site Reference ID/Investigator# 34823, Essen, Germany|Site Reference ID/Investigator# 35194, Essen, Germany|Site Reference ID/Investigator# 53931, Essen, Germany|Site Reference ID/Investigator# 53945, Essen, Germany|Site Reference ID/Investigator# 34829, Esslingen, Germany|Site Reference ID/Investigator# 35200, Feldafing, Germany|Site Reference ID/Investigator# 35203, Flensburg, Germany|Site Reference ID/Investigator# 34831, Forchheim, Germany|Site Reference ID/Investigator# 34851, Frankfurt, Germany|Site Reference ID/Investigator# 34838, Frankfurt, Germany|Site Reference ID/Investigator# 35211, Fraureuth, Germany|Site Reference ID/Investigator# 35217, Freiberg, Germany|Site Reference ID/Investigator# 34852, Freiburg, Germany|Site Reference ID/Investigator# 34855, Freiburg, Germany|Site Reference ID/Investigator# 53926, Freiburg, Germany|Site Reference ID/Investigator# 34859, Freiburg, Germany|Site Reference ID/Investigator# 35099, Freystadt, Germany|Site Reference ID/Investigator# 53960, Friedberg, Germany|Site Reference ID/Investigator# 35222, Friedrichroda, Germany|Site Reference ID/Investigator# 53976, Geesthacht, Germany|Site Reference ID/Investigator# 53890, Geilenkirchen, Germany|Site Reference ID/Investigator# 34877, Gelsenkirchen, Germany|Site Reference ID/Investigator# 53909, Giessen, Germany|Site Reference ID/Investigator# 53922, Gladbeck, Germany|Site Reference ID/Investigator# 35231, Goettingen, Germany|Site Reference ID/Investigator# 65622, Goettingen, Germany|Site Reference ID/Investigator# 34894, Goslar, Germany|Site Reference ID/Investigator# 34902, Greifswald, Germany|Site Reference ID/Investigator# 34910, Guestrow, Germany|Site Reference ID/Investigator# 35501, Hagen, Germany|Site Reference ID/Investigator# 34924, Halle, Germany|Site Reference ID/Investigator# 34935, Halle, Germany|Site Reference ID/Investigator# 34938, Halle, Germany|Site Reference ID/Investigator# 34920, Halle, Germany|Site Reference ID/Investigator# 34942, Halle, Germany|Site Reference ID/Investigator# 33819, Halle, Germany|Site Reference ID/Investigator# 35442, Hamburg, Germany|Site Reference ID/Investigator# 53984, Hamburg, Germany|Site Reference ID/Investigator# 33367, Hamburg, Germany|Site Reference ID/Investigator# 53900, Hamburg, Germany|Site Reference ID/Investigator# 34956, Hamburg, Germany|Site Reference ID/Investigator# 34962, Hamburg, Germany|Site Reference ID/Investigator# 35450, Hamburg, Germany|Site Reference ID/Investigator# 35112, Hamburg, Germany|Site Reference ID/Investigator# 34946, Hamburg, Germany|Site Reference ID/Investigator# 35001, Hamburg, Germany|Site Reference ID/Investigator# 34959, Hamburg, Germany|Site Reference ID/Investigator# 34977, Hamburg, Germany|Site Reference ID/Investigator# 34965, Hamburg, Germany|Site Reference ID/Investigator# 54806, Hamburg, Germany|Site Reference ID/Investigator# 33578, Hamburg, Germany|Site Reference ID/Investigator# 34967, Hamburg, Germany|Site Reference ID/Investigator# 34989, Hamburg, Germany|Site Reference ID/Investigator# 34981, Hamburg, Germany|Site Reference ID/Investigator# 34984, Hamburg, Germany|Site Reference ID/Investigator# 34996, Hamburg, Germany|Site Reference ID/Investigator# 53953, Hamm, Germany|Site Reference ID/Investigator# 35017, Hanau, Germany|Site Reference ID/Investigator# 33788, Hannover, Germany|Site Reference ID/Investigator# 33713, Hanover, Germany|Site Reference ID/Investigator# 35032, Hanover, Germany|Site Reference ID/Investigator# 35021, Hanover, Germany|Site Reference ID/Investigator# 33790, Harrislee, Germany|Site Reference ID/Investigator# 65629, Haseluenne, Germany|Site Reference ID/Investigator# 33795, Hattingen, Germany|Site Reference ID/Investigator# 33796, Heidelberg, Germany|Site Reference ID/Investigator# 33806, Heidelberg, Germany|Site Reference ID/Investigator# 33811, Heidelberg, Germany|Site Reference ID/Investigator# 33816, Heilbad Heiligenstadt, Germany|Site Reference ID/Investigator# 53911, Herne, Germany|Site Reference ID/Investigator# 53910, Herne, Germany|Site Reference ID/Investigator# 65623, Herne, Germany|Site Reference ID/Investigator# 33823, Herrsching, Germany|Site Reference ID/Investigator# 33831, Hildesheim, Germany|Site Reference ID/Investigator# 33840, Hofheim, Germany|Site Reference ID/Investigator# 33836, Hof, Germany|Site Reference ID/Investigator# 33843, Hohenfelde, Germany|Site Reference ID/Investigator# 54807, Homburg, Germany|Site Reference ID/Investigator# 53985, Illingen, Germany|Site Reference ID/Investigator# 33933, Ingolstadt, Germany|Site Reference ID/Investigator# 53938, Jena, Germany|Site Reference ID/Investigator# 5323, Jena, Germany|Site Reference ID/Investigator# 33940, Juelich, Germany|Site Reference ID/Investigator# 33944, Kahla, Germany|Site Reference ID/Investigator# 35124, Kahla, Germany|Site Reference ID/Investigator# 33948, Kaiserslautern, Germany|Site Reference ID/Investigator# 53935, Kaltenkirchen, Germany|Site Reference ID/Investigator# 33397, Karlsruhe, Germany|Site Reference ID/Investigator# 33954, Karlsruhe, Germany|Site Reference ID/Investigator# 35482, Karlstadt, Germany|Site Reference ID/Investigator# 33962, Kassel, Germany|Site Reference ID/Investigator# 34000, Koenigs Wusterhausen, Germany|Site Reference ID/Investigator# 35239, Kolkwitz, Germany|Site Reference ID/Investigator# 34006, Kressbronn, Germany|Site Reference ID/Investigator# 34009, Kronach, Germany|Site Reference ID/Investigator# 34086, Kyritz, Germany|Site Reference ID/Investigator# 34003, Lahr, Germany|Site Reference ID/Investigator# 53937, Leipzig, Germany|Site Reference ID/Investigator# 65628, Leipzig, Germany|Site Reference ID/Investigator# 34107, Leipzig, Germany|Site Reference ID/Investigator# 34098, Leipzig, Germany|Site Reference ID/Investigator# 34119, Leverkusen, Germany|Site Reference ID/Investigator# 34121, Lichtenstein, Germany|Site Reference ID/Investigator# 35252, Lippstadt, Germany|Site Reference ID/Investigator# 53882, Lohne, Germany|Site Reference ID/Investigator# 53886, Ludwigsburg, Germany|Site Reference ID/Investigator# 35257, Ludwigsfelde, Germany|Site Reference ID/Investigator# 53906, Ludwigslust, Germany|Site Reference ID/Investigator# 34133, Luebeck, Germany|Site Reference ID/Investigator# 53943, Luedenscheid, Germany|Site Reference ID/Investigator# 33407, Lueneburg, Germany|Site Reference ID/Investigator# 53888, Lueneburg, Germany|Site Reference ID/Investigator# 34148, Magdeburg, Germany|Site Reference ID/Investigator# 53981, Magdeburg, Germany|Site Reference ID/Investigator# 53913, Magdeburg, Germany|Site Reference ID/Investigator# 53928, Mainz, Germany|Site Reference ID/Investigator# 65631, Mainz, Germany|Site Reference ID/Investigator# 34184, Mannheim, Germany|Site Reference ID/Investigator# 34194, Marl, Germany|Site Reference ID/Investigator# 35283, Menz, Germany|Site Reference ID/Investigator# 53896, Merxheim, Germany|Site Reference ID/Investigator# 33418, Minden, Germany|Site Reference ID/Investigator# 34206, Mittelherwigsdorf, Germany|Site Reference ID/Investigator# 34216, Moenchengladbach, Germany|Site Reference ID/Investigator# 53915, Moenchengladbach, Germany|Site Reference ID/Investigator# 34211, Moenchengladbach, Germany|Site Reference ID/Investigator# 34214, Moenchengladbach, Germany|Site Reference ID/Investigator# 34219, Moenkeberg, Germany|Site Reference ID/Investigator# 34222, Muehlhausen, Germany|Site Reference ID/Investigator# 34044, Muenster, Germany|Site Reference ID/Investigator# 53970, Muenster, Germany|Site Reference ID/Investigator# 34046, Muenster, Germany|Site Reference ID/Investigator# 53904, Munich, Germany|Site Reference ID/Investigator# 53956, Munich, Germany|Site Reference ID/Investigator# 34037, Munich, Germany|Site Reference ID/Investigator# 53962, Munich, Germany|Site Reference ID/Investigator# 53912, Munich, Germany|Site Reference ID/Investigator# 35296, Munich, Germany|Site Reference ID/Investigator# 53924, Munich, Germany|Site Reference ID/Investigator# 34041, Munich, Germany|Site Reference ID/Investigator# 34035, Munich, Germany|Site Reference ID/Investigator# 34050, Naunhof, Germany|Site Reference ID/Investigator# 34059, Neubrandenburg, Germany|Site Reference ID/Investigator# 34062, Neuburg, Germany|Site Reference ID/Investigator# 34980, Neunkirchen, Germany|Site Reference ID/Investigator# 35311, Neuss, Germany|Site Reference ID/Investigator# 34072, Neustadt, Germany|Site Reference ID/Investigator# 65630, Neuwied, Germany|Site Reference ID/Investigator# 82694, Niederbrombach, Germany|Site Reference ID/Investigator# 34078, Niefern-Oeschelbronn, Germany|Site Reference ID/Investigator# 34081, Nienburg, Germany|Site Reference ID/Investigator# 34082, Nienburg, Germany|Site Reference ID/Investigator# 53923, Nuremberg, Germany|Site Reference ID/Investigator# 34168, Oberguenzburg, Germany|Site Reference ID/Investigator# 34174, Offenburg, Germany|Site Reference ID/Investigator# 33490, Oldenburg, Germany|Site Reference ID/Investigator# 53950, Olsberg, Germany|Site Reference ID/Investigator# 33499, Osnabrueck, Germany|Site Reference ID/Investigator# 54803, Osnabrueck, Germany|Site Reference ID/Investigator# 34715, Ostseebad Damp, Germany|Site Reference ID/Investigator# 35333, Paderborn, Germany|Site Reference ID/Investigator# 33503, Papenburg, Germany|Site Reference ID/Investigator# 33506, Parchim, Germany|Site Reference ID/Investigator# 33509, Parsberg, Germany|Site Reference ID/Investigator# 35338, Passau, Germany|Site Reference ID/Investigator# 33511, Petershagen, Germany|Site Reference ID/Investigator# 33519, Pinneberg, Germany|Site Reference ID/Investigator# 33520, Pirna, Germany|Site Reference ID/Investigator# 33521, Planegg, Germany|Site Reference ID/Investigator# 33526, Plauen, Germany|Site Reference ID/Investigator# 33468, Potsdam, Germany|Site Reference ID/Investigator# 33464, Potsdam, Germany|Site Reference ID/Investigator# 53940, Pulheim, Germany|Site Reference ID/Investigator# 33482, Radebeul, Germany|Site Reference ID/Investigator# 53964, Raststatt, Germany|Site Reference ID/Investigator# 33485, Ratingen, Germany|Site Reference ID/Investigator# 35134, Ratingen, Germany|Site Reference ID/Investigator# 54812, Ratingen, Germany|Site Reference ID/Investigator# 33888, Regensburg, Germany|Site Reference ID/Investigator# 33891, Regensburg, Germany|Site Reference ID/Investigator# 33881, Regensburg, Germany|Site Reference ID/Investigator# 33884, Regensburg, Germany|Site Reference ID/Investigator# 53930, Regensburg, Germany|Site Reference ID/Investigator# 53986, Reichenbach, Germany|Site Reference ID/Investigator# 53957, Reken, Germany|Site Reference ID/Investigator# 53920, Remscheid, Germany|Site Reference ID/Investigator# 33900, Rendsburg, Germany|Site Reference ID/Investigator# 33903, Reutlingen, Germany|Site Reference ID/Investigator# 53982, Rheinfelden, Germany|Site Reference ID/Investigator# 53908, Rickenbach, Germany|Site Reference ID/Investigator# 33393, Riesa, Germany|Site Reference ID/Investigator# 33912, Rinteln, Germany|Site Reference ID/Investigator# 33921, Rostock, Germany|Site Reference ID/Investigator# 33929, Rothenburg, Germany|Site Reference ID/Investigator# 34014, Saarbruecken, Germany|Site Reference ID/Investigator# 34021, Salzwedel, Germany|Site Reference ID/Investigator# 53916, Schlangenbad, Germany|Site Reference ID/Investigator# 34030, Schneeberg, Germany|Site Reference ID/Investigator# 33550, Schwerin, Germany|Site Reference ID/Investigator# 35374, Schwerin, Germany|Site Reference ID/Investigator# 33553, Schwerte, Germany|Site Reference ID/Investigator# 33557, Seesen, Germany|Site Reference ID/Investigator# 53944, Siegen, Germany|Site Reference ID/Investigator# 33565, Sinsheim, Germany|Site Reference ID/Investigator# 53927, Solingen, Germany|Site Reference ID/Investigator# 33570, Soltau, Germany|Site Reference ID/Investigator# 33583, Stadtbergen, Germany|Site Reference ID/Investigator# 33586, Stadthagen, Germany|Site Reference ID/Investigator# 53936, Steinhagen, Germany|Site Reference ID/Investigator# 33602, Stuttgart, Germany|Site Reference ID/Investigator# 33609, Stuttgart, Germany|Site Reference ID/Investigator# 33596, Stuttgart, Germany|Site Reference ID/Investigator# 35387, Suhl, Germany|Site Reference ID/Investigator# 54808, Tarp, Germany|Site Reference ID/Investigator# 35433, Thum-Jahnsbach, Germany|Site Reference ID/Investigator# 53951, Tischenreuth, Germany|Site Reference ID/Investigator# 33623, Torgelow, Germany|Site Reference ID/Investigator# 33628, Treuenbrietzen, Germany|Site Reference ID/Investigator# 53907, Tuebingen, Germany|Site Reference ID/Investigator# 53893, Twistringen, Germany|Site Reference ID/Investigator# 33635, Ueberlingen-Nussdorf, Germany|Site Reference ID/Investigator# 53898, Uhlstaedt-Kirchhasel, Germany|Site Reference ID/Investigator# 33722, Ulm, Germany|Site Reference ID/Investigator# 65626, Ulm, Germany|Site Reference ID/Investigator# 33732, Verden, Germany|Site Reference ID/Investigator# 53965, Viersen, Germany|Site Reference ID/Investigator# 33735, Villingen-Schwenningen, Germany|Site Reference ID/Investigator# 53914, Vogelsang-Gommern, Germany|Site Reference ID/Investigator# 53952, Vreden, Germany|Site Reference ID/Investigator# 54809, Waldbronn, Germany|Site Reference ID/Investigator# 33740, Waltrop, Germany|Site Reference ID/Investigator# 33747, Weener, Germany|Site Reference ID/Investigator# 53891, Weiden i.d. Oberpfalz, Germany|Site Reference ID/Investigator# 53921, Weissenfels, Germany|Site Reference ID/Investigator# 33753, Welzow, Germany|Site Reference ID/Investigator# 35406, Wiesbaden, Germany|Site Reference ID/Investigator# 53941, Wiesbaden, Germany|Site Reference ID/Investigator# 33762, Wiesbaden, Germany|Site Reference ID/Investigator# 33770, Wilhelmshaven, Germany|Site Reference ID/Investigator# 53977, Winsen (Luhe), Germany|Site Reference ID/Investigator# 53954, Winsen, Germany|Site Reference ID/Investigator# 33778, Wittlich, Germany|Site Reference ID/Investigator# 33783, Wolfsburg, Germany|Site Reference ID/Investigator# 33716, Wuerzburg, Germany|Site Reference ID/Investigator# 53917, Wuppertal, Germany|Site Reference ID/Investigator# 35418, Wuppertal, Germany|Site Reference ID/Investigator# 33862, Zerbst, Germany|Site Reference ID/Investigator# 33865, Zeven, Germany|Site Reference ID/Investigator# 33870, Zwickau, Germany|Site Reference ID/Investigator# 33878, Zwiesel, Germany",,"https://ClinicalTrials.gov/show/NCT01078090"
602,"NCT01077700","Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia",,"Completed","No Results Available","Cognitive Deficits in Schizophrenia","Drug: ABT-288 Low Dose|Drug: Placebo|Drug: ABT-288 High Dose","Cognition: MCCB|Functioning: UPSA-2|Cognition: CANTAB|Symptom Severity: PANSS, NSA-16, CGI-S","AbbVie (prior sponsor, Abbott)|AbbVie","All","20 Years to 55 Years   (Adult)","Phase 2","214","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-503","March 2010","July 2011","July 2011","March 1, 2010",,"June 6, 2018","Site Reference ID/Investigator# 21662, Anaheim, California, United States|Site Reference ID/Investigator# 21683, Garden Grove, California, United States|Site Reference ID/Investigator# 21581, National City, California, United States|Site Reference ID/Investigator# 45310, Norwalk, California, United States|Site Reference ID/Investigator# 26400, Pasadena, California, United States|Site Reference ID/Investigator# 21584, Pico Rivera, California, United States|Site Reference ID/Investigator# 45312, Riverside, California, United States|Site Reference ID/Investigator# 45309, San Diego, California, United States|Site Reference ID/Investigator# 46603, Plantation, Florida, United States|Site Reference ID/Investigator# 21681, Chicago, Illinois, United States|Site Reference ID/Investigator# 26397, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 21761, Pittsfield, Massachusetts, United States|Site Reference ID/Investigator# 21591, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 26409, Brooklyn, New York, United States|Site Reference ID/Investigator# 21588, Cedarhurst, New York, United States|Site Reference ID/Investigator# 21589, Dayton, Ohio, United States|Site Reference ID/Investigator# 26407, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 21601, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 26399, Charleston, South Carolina, United States|Site Reference ID/Investigator# 21590, Austin, Texas, United States|Site Reference ID/Investigator# 21582, Austin, Texas, United States|Site Reference ID/Investigator# 26406, DeSoto, Texas, United States|Site Reference ID/Investigator# 26402, Houston, Texas, United States|Site Reference ID/Investigator# 27502, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01077700"
603,"NCT01077258","Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice",,"Completed","Has Results","Rheumatoid Arthritis",,"Change From Baseline in Disease Activity Score (DAS) 28|Percentage of Participants in DAS28 Remission|Percentage of Participants With a Significant Therapeutic Response|Percentage of Participants With Low, Moderate and High Disease Activity|Erythrocyte Sedimentation Rate (ESR) Over Time|C-Reactive Protein (CRP) Levels Over Time|Tender Joint Count (TJC) Over Time|Swollen Joint Count (SJC) Over Time|Hannover Functional Questionnaire (FFbH) Over Time|Patients Global Assessment of Disease Activity Over Time|Participants Assessment of Fatigue Over Time|Participants Assessment of Pain Over Time|Percentage of Participants With Impairment in Daily Activities|Number of Days Missed From Work Due to Rheumatoid Arthritis|Percentage of Participants With In-patient Hospitalization|Percentage of Participants on Concomitant Rheumatoid Arthritis and Pain Relief/Anti-inflammatory Medication","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"4208","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P10-448","April 2004","February 2013","February 2013","March 1, 2010","April 8, 2014","April 25, 2014","Site Reference ID/Investigator# 35036, Aachen, Germany|Site Reference ID/Investigator# 35510, Ahlen, Germany|Site Reference ID/Investigator# 35040, Ahrensburg, Germany|Site Reference ID/Investigator# 35043, Altenburg, Germany|Site Reference ID/Investigator# 35046, Altenholz, Germany|Site Reference ID/Investigator# 35049, Amberg, Germany|Site Reference ID/Investigator# 35057, Arnstadt, Germany|Site Reference ID/Investigator# 35520, Attendorn, Germany|Site Reference ID/Investigator# 33349, Augsburg, Germany|Site Reference ID/Investigator# 33358, Bad Abbach, Germany|Site Reference ID/Investigator# 33361, Bad Abbach, Germany|Site Reference ID/Investigator# 35142, Bad Aibling, Germany|Site Reference ID/Investigator# 35570, Bad Brambach, Germany|Site Reference ID/Investigator# 35573, Bad Bramstedt, Germany|Site Reference ID/Investigator# 33372, Bad Endbach, Germany|Site Reference ID/Investigator# 33378, Bad Iburg, Germany|Site Reference ID/Investigator# 33382, Bad Iburg, Germany|Site Reference ID/Investigator# 33387, Bad Kreuznach, Germany|Site Reference ID/Investigator# 35575, Bad Kreuznach, Germany|Site Reference ID/Investigator# 33391, Bad Liebenwerda, Germany|Site Reference ID/Investigator# 33396, Bad Muender, Germany|Site Reference ID/Investigator# 102216, Bad Nauheim, Germany|Site Reference ID/Investigator# 35578, Bad Neuenahr, Germany|Site Reference ID/Investigator# 33404, Bad Rappenau, Germany|Site Reference ID/Investigator# 51883, Bad Salzungen, Germany|Site Reference ID/Investigator# 33412, Bad Soden-Salmuenster, Germany|Site Reference ID/Investigator# 33425, Baden-Baden, Germany|Site Reference ID/Investigator# 33429, Bamberg, Germany|Site Reference ID/Investigator# 33438, Bautzen, Germany|Site Reference ID/Investigator# 33442, Bayreuth, Germany|Site Reference ID/Investigator# 33446, Bayreuth, Germany|Site Reference ID/Investigator# 34266, Berlin-Buch, Germany|Site Reference ID/Investigator# 34252, Berlin-Wannsee, Germany|Site Reference ID/Investigator# 33641, Berlin, Germany|Site Reference ID/Investigator# 35089, Berlin, Germany|Site Reference ID/Investigator# 33648, Berlin, Germany|Site Reference ID/Investigator# 33693, Berlin, Germany|Site Reference ID/Investigator# 33670, Berlin, Germany|Site Reference ID/Investigator# 33658, Berlin, Germany|Site Reference ID/Investigator# 33697, Berlin, Germany|Site Reference ID/Investigator# 34246, Berlin, Germany|Site Reference ID/Investigator# 33683, Berlin, Germany|Site Reference ID/Investigator# 34269, Berlin, Germany|Site Reference ID/Investigator# 35527, Berlin, Germany|Site Reference ID/Investigator# 35597, Berlin, Germany|Site Reference ID/Investigator# 33620, Berlin, Germany|Site Reference ID/Investigator# 33690, Berlin, Germany|Site Reference ID/Investigator# 33704, Berlin, Germany|Site Reference ID/Investigator# 33687, Berlin, Germany|Site Reference ID/Investigator# 33661, Berlin, Germany|Site Reference ID/Investigator# 35550, Berlin, Germany|Site Reference ID/Investigator# 33674, Berlin, Germany|Site Reference ID/Investigator# 35551, Berlin, Germany|Site Reference ID/Investigator# 34238, Berlin, Germany|Site Reference ID/Investigator# 35556, Bernau, Germany|Site Reference ID/Investigator# 34277, Biberach, Germany|Site Reference ID/Investigator# 35562, Binzen, Germany|Site Reference ID/Investigator# 34285, Blankenburg/Hart, Germany|Site Reference ID/Investigator# 34288, Blaubeuren, Germany|Site Reference ID/Investigator# 34291, Bocholt, Germany|Site Reference ID/Investigator# 35566, Bocholt, Germany|Site Reference ID/Investigator# 35641, Bochum, Germany|Site Reference ID/Investigator# 35644, Bogen, Germany|Site Reference ID/Investigator# 34302, Bonn, Germany|Site Reference ID/Investigator# 35646, Bonn, Germany|Site Reference ID/Investigator# 34296, Bonn, Germany|Site Reference ID/Investigator# 35652, Bottrop, Germany|Site Reference ID/Investigator# 34307, Braunschweig, Germany|Site Reference ID/Investigator# 35603, Breitenbrunn, Germany|Site Reference ID/Investigator# 35609, Bremen, Germany|Site Reference ID/Investigator# 35611, Celle, Germany|Site Reference ID/Investigator# 34699, Chemnitz, Germany|Site Reference ID/Investigator# 35093, Chemnitz, Germany|Site Reference ID/Investigator# 35615, Coesfeld, Germany|Site Reference ID/Investigator# 33989, Cologne, Germany|Site Reference ID/Investigator# 35237, Cologne, Germany|Site Reference ID/Investigator# 34708, Cottbus, Germany|Site Reference ID/Investigator# 34711, Cottbus, Germany|Site Reference ID/Investigator# 35621, Darmstadt, Germany|Site Reference ID/Investigator# 34725, Deggendorf, Germany|Site Reference ID/Investigator# 35631, Dessau-Rosslau, Germany|Site Reference ID/Investigator# 34742, Dortmund, Germany|Site Reference ID/Investigator# 35635, Dortmund, Germany|Site Reference ID/Investigator# 35634, Dortmund, Germany|Site Reference ID/Investigator# 35170, Dresden, Germany|Site Reference ID/Investigator# 34754, Dresden, Germany|Site Reference ID/Investigator# 34748, Dresden, Germany|Site Reference ID/Investigator# 34751, Dresden, Germany|Site Reference ID/Investigator# 34760, Dresden, Germany|Site Reference ID/Investigator# 34773, Duesseldorf, Germany|Site Reference ID/Investigator# 34768, Duesseldorf, Germany|Site Reference ID/Investigator# 34778, Duisburg, Germany|Site Reference ID/Investigator# 34784, Eberswalde, Germany|Site Reference ID/Investigator# 35184, Elmshorn, Germany|Site Reference ID/Investigator# 34809, Erfurt, Germany|Site Reference ID/Investigator# 35096, Erfurt, Germany|Site Reference ID/Investigator# 35191, Erfurt, Germany|Site Reference ID/Investigator# 34821, Erlangen, Germany|Site Reference ID/Investigator# 35196, Essen, Germany|Site Reference ID/Investigator# 35199, Essen, Germany|Site Reference ID/Investigator# 35202, Feldafing, Germany|Site Reference ID/Investigator# 35205, Flensburg, Germany|Site Reference ID/Investigator# 34833, Forchheim, Germany|Site Reference ID/Investigator# 35210, Frankenberg, Germany|Site Reference ID/Investigator# 34849, Frankfurt, Germany|Site Reference ID/Investigator# 34840, Frankfurt, Germany|Site Reference ID/Investigator# 34843, Frankfurt, Germany|Site Reference ID/Investigator# 35213, Fraureuth, Germany|Site Reference ID/Investigator# 35219, Freiberg, Germany|Site Reference ID/Investigator# 34854, Freiburg, Germany|Site Reference ID/Investigator# 35221, Freiburg, Germany|Site Reference ID/Investigator# 34861, Freiburg, Germany|Site Reference ID/Investigator# 35101, Freystadt, Germany|Site Reference ID/Investigator# 35224, Friedrichroda, Germany|Site Reference ID/Investigator# 34879, Gelsenkirchen, Germany|Site Reference ID/Investigator# 34883, Gera, Germany|Site Reference ID/Investigator# 34887, Giessen, Germany|Site Reference ID/Investigator# 35491, Gosheim, Germany|Site Reference ID/Investigator# 34896, Goslar, Germany|Site Reference ID/Investigator# 34901, Greifswald, Germany|Site Reference ID/Investigator# 35496, Greifswald, Germany|Site Reference ID/Investigator# 34904, Greifswald, Germany|Site Reference ID/Investigator# 102217, Gross Ammensleben, Germany|Site Reference ID/Investigator# 35498, Guben, Germany|Site Reference ID/Investigator# 34912, Guestrow, Germany|Site Reference ID/Investigator# 35503, Hagen, Germany|Site Reference ID/Investigator# 34937, Halle, Germany|Site Reference ID/Investigator# 34940, Halle, Germany|Site Reference ID/Investigator# 34922, Halle, Germany|Site Reference ID/Investigator# 34944, Halle, Germany|Site Reference ID/Investigator# 34932, Halle, Germany|Site Reference ID/Investigator# 35444, Hamburg, Germany|Site Reference ID/Investigator# 35441, Hamburg, Germany|Site Reference ID/Investigator# 34970, Hamburg, Germany|Site Reference ID/Investigator# 34952, Hamburg, Germany|Site Reference ID/Investigator# 34958, Hamburg, Germany|Site Reference ID/Investigator# 35452, Hamburg, Germany|Site Reference ID/Investigator# 35007, Hamburg, Germany|Site Reference ID/Investigator# 35000, Hamburg, Germany|Site Reference ID/Investigator# 34961, Hamburg, Germany|Site Reference ID/Investigator# 35449, Hamburg, Germany|Site Reference ID/Investigator# 34955, Hamburg, Germany|Site Reference ID/Investigator# 34998, Hamburg, Germany|Site Reference ID/Investigator# 34994, Hamburg, Germany|Site Reference ID/Investigator# 34983, Hamburg, Germany|Site Reference ID/Investigator# 34986, Hamburg, Germany|Site Reference ID/Investigator# 35111, Hamburg, Germany|Site Reference ID/Investigator# 34974, Hamburg, Germany|Site Reference ID/Investigator# 35019, Hanau, Germany|Site Reference ID/Investigator# 33712, Hanover, Germany|Site Reference ID/Investigator# 35025, Hanover, Germany|Site Reference ID/Investigator# 33792, Harrislee, Germany|Site Reference ID/Investigator# 35459, Haseluenne, Germany|Site Reference ID/Investigator# 102215, Heidelberg, Germany|Site Reference ID/Investigator# 33798, Heidelberg, Germany|Site Reference ID/Investigator# 35119, Heidelberg, Germany|Site Reference ID/Investigator# 33801, Heidelberg, Germany|Site Reference ID/Investigator# 33808, Heidelberg, Germany|Site Reference ID/Investigator# 35464, Heidenheim, Germany|Site Reference ID/Investigator# 33818, Heilbad Heiligenstadt, Germany|Site Reference ID/Investigator# 33825, Herrsching, Germany|Site Reference ID/Investigator# 33842, Hofheim, Germany|Site Reference ID/Investigator# 33834, Hof, Germany|Site Reference ID/Investigator# 33845, Hohenfelde, Germany|Site Reference ID/Investigator# 33855, Illertissen, Germany|Site Reference ID/Investigator# 33858, Immenstadt, Germany|Site Reference ID/Investigator# 35479, Ingolstadt, Germany|Site Reference ID/Investigator# 51882, Jena, Germany|Site Reference ID/Investigator# 33942, Juelich, Germany|Site Reference ID/Investigator# 33946, Kahla, Germany|Site Reference ID/Investigator# 35125, Kahla, Germany|Site Reference ID/Investigator# 33950, Kaiserslautern, Germany|Site Reference ID/Investigator# 33956, Karlsruhe, Germany|Site Reference ID/Investigator# 33961, Karlsruhe, Germany|Site Reference ID/Investigator# 33964, Kassel, Germany|Site Reference ID/Investigator# 34002, Koenigs Wusterhausen, Germany|Site Reference ID/Investigator# 34008, Kressbronn, Germany|Site Reference ID/Investigator# 34084, Kronach, Germany|Site Reference ID/Investigator# 34005, Lahr, Germany|Site Reference ID/Investigator# 35245, Landau, Germany|Site Reference ID/Investigator# 34112, Leipzig, Germany|Site Reference ID/Investigator# 34106, Leipzig, Germany|Site Reference ID/Investigator# 34109, Leipzig, Germany|Site Reference ID/Investigator# 34100, Leipzig, Germany|Site Reference ID/Investigator# 35254, Lippstadt, Germany|Site Reference ID/Investigator# 35306, Ludwigsfelde, Germany|Site Reference ID/Investigator# 35262, Ludwigshafen, Germany|Site Reference ID/Investigator# 34136, Luebeck, Germany|Site Reference ID/Investigator# 34139, Lueneburg, Germany|Site Reference ID/Investigator# 34147, Magdeburg, Germany|Site Reference ID/Investigator# 34150, Magdeburg, Germany|Site Reference ID/Investigator# 35276, Mainz, Germany|Site Reference ID/Investigator# 34192, Marktredwitz, Germany|Site Reference ID/Investigator# 34196, Marl, Germany|Site Reference ID/Investigator# 34200, Meissen, Germany|Site Reference ID/Investigator# 35285, Menz, Germany|Site Reference ID/Investigator# 35287, Minden, Germany|Site Reference ID/Investigator# 34208, Mittelherwigsdorf, Germany|Site Reference ID/Investigator# 34218, Moenchengladbach, Germany|Site Reference ID/Investigator# 34213, Moenchengladbach, Germany|Site Reference ID/Investigator# 34221, Moenkeberg, Germany|Site Reference ID/Investigator# 34224, Muehlhausen, Germany|Site Reference ID/Investigator# 35292, Muelheim, Germany|Site Reference ID/Investigator# 34229, Muellheim, Germany|Site Reference ID/Investigator# 34048, Muenster, Germany|Site Reference ID/Investigator# 34040, Munich, Germany|Site Reference ID/Investigator# 35295, Munich, Germany|Site Reference ID/Investigator# 34232, Munich, Germany|Site Reference ID/Investigator# 34235, Munich, Germany|Site Reference ID/Investigator# 35298, Munich, Germany|Site Reference ID/Investigator# 34043, Munich, Germany|Site Reference ID/Investigator# 34052, Naunhof, Germany|Site Reference ID/Investigator# 34061, Neubrandenburg, Germany|Site Reference ID/Investigator# 34064, Neuburg, Germany|Site Reference ID/Investigator# 34071, Neumuenster, Germany|Site Reference ID/Investigator# 35313, Neuss, Germany|Site Reference ID/Investigator# 34076, Neustadt, Germany|Site Reference ID/Investigator# 35321, Niederbrombach, Germany|Site Reference ID/Investigator# 34080, Niefern-Oeschelbronn, Germany|Site Reference ID/Investigator# 34158, Nienburg, Germany|Site Reference ID/Investigator# 34173, Oelsnitz, Germany|Site Reference ID/Investigator# 34176, Offenburg, Germany|Site Reference ID/Investigator# 33492, Oldenburg, Germany|Site Reference ID/Investigator# 34718, Ostseebad Damp, Germany|Site Reference ID/Investigator# 35335, Paderborn, Germany|Site Reference ID/Investigator# 33508, Parchim, Germany|Site Reference ID/Investigator# 35340, Passau, Germany|Site Reference ID/Investigator# 33517, Pfullendorf, Germany|Site Reference ID/Investigator# 67482, Pirna, Germany|Site Reference ID/Investigator# 33523, Planegg, Germany|Site Reference ID/Investigator# 33528, Plauen, Germany|Site Reference ID/Investigator# 33470, Potsdam, Germany|Site Reference ID/Investigator# 33466, Potsdam, Germany|Site Reference ID/Investigator# 33476, Pruem, Germany|Site Reference ID/Investigator# 33479, Puettlingen, Germany|Site Reference ID/Investigator# 33484, Radebeul, Germany|Site Reference ID/Investigator# 35347, Radebeul, Germany|Site Reference ID/Investigator# 35136, Ratingen, Germany|Site Reference ID/Investigator# 33488, Ratzeburg, Germany|Site Reference ID/Investigator# 33890, Regensburg, Germany|Site Reference ID/Investigator# 33883, Regensburg, Germany|Site Reference ID/Investigator# 33886, Regensburg, Germany|Site Reference ID/Investigator# 33897, Reken, Germany|Site Reference ID/Investigator# 33902, Rendsburg, Germany|Site Reference ID/Investigator# 33907, Rheine, Germany|Site Reference ID/Investigator# 35355, Rickenbach, Germany|Site Reference ID/Investigator# 33911, Riesa, Germany|Site Reference ID/Investigator# 33914, Rinteln, Germany|Site Reference ID/Investigator# 33923, Rostock, Germany|Site Reference ID/Investigator# 33927, Rostock, Germany|Site Reference ID/Investigator# 33931, Rothenburg, Germany|Site Reference ID/Investigator# 35362, Ruedersdorf, Germany|Site Reference ID/Investigator# 34016, Saarbruecken, Germany|Site Reference ID/Investigator# 34023, Salzwedel, Germany|Site Reference ID/Investigator# 34027, Sande, Germany|Site Reference ID/Investigator# 33534, Schneeberg, Germany|Site Reference ID/Investigator# 33539, Schramberg, Germany|Site Reference ID/Investigator# 33542, Schutterwald, Germany|Site Reference ID/Investigator# 35371, Schwandorf, Germany|Site Reference ID/Investigator# 33549, Schwerin, Germany|Site Reference ID/Investigator# 35376, Schwerin, Germany|Site Reference ID/Investigator# 33555, Schwerte, Germany|Site Reference ID/Investigator# 33559, Seesen, Germany|Site Reference ID/Investigator# 33563, Senden, Germany|Site Reference ID/Investigator# 35380, Singen, Germany|Site Reference ID/Investigator# 33567, Sinsheim, Germany|Site Reference ID/Investigator# 33572, Soltau, Germany|Site Reference ID/Investigator# 33577, Spremberg, Germany|Site Reference ID/Investigator# 35383, St. Martin, Germany|Site Reference ID/Investigator# 33588, Stadthagen, Germany|Site Reference ID/Investigator# 33592, Steinhagen, Germany|Site Reference ID/Investigator# 33604, Stuttgart, Germany|Site Reference ID/Investigator# 33607, Stuttgart, Germany|Site Reference ID/Investigator# 33611, Stuttgart, Germany|Site Reference ID/Investigator# 33598, Stuttgart, Germany|Site Reference ID/Investigator# 35389, Suhl, Germany|Site Reference ID/Investigator# 35391, Tegernau, Germany|Site Reference ID/Investigator# 33625, Torgelow, Germany|Site Reference ID/Investigator# 33637, Ueberlingen-Nussdorf, Germany|Site Reference ID/Investigator# 35395, Uffenheim, Germany|Site Reference ID/Investigator# 33721, Ulm, Germany|Site Reference ID/Investigator# 33724, Ulm, Germany|Site Reference ID/Investigator# 33734, Viersen, Germany|Site Reference ID/Investigator# 33737, Villingen-Schwenningen, Germany|Site Reference ID/Investigator# 35397, Voehringen, Germany|Site Reference ID/Investigator# 33742, Waltrop, Germany|Site Reference ID/Investigator# 33749, Weener, Germany|Site Reference ID/Investigator# 33751, Weissenfels, Germany|Site Reference ID/Investigator# 33852, Welzow, Germany|Site Reference ID/Investigator# 35404, Wiefelstede, Germany|Site Reference ID/Investigator# 33761, Wiesbaden, Germany|Site Reference ID/Investigator# 35408, Wiesbaden, Germany|Site Reference ID/Investigator# 33765, Wiesbaden, Germany|Site Reference ID/Investigator# 35413, Wiesbaden, Germany|Site Reference ID/Investigator# 33772, Wilhelmshaven, Germany|Site Reference ID/Investigator# 33780, Wittlich, Germany|Site Reference ID/Investigator# 33718, Wuerzburg, Germany|Site Reference ID/Investigator# 35420, Wuppertal, Germany|Site Reference ID/Investigator# 33864, Zerbst, Germany|Site Reference ID/Investigator# 33867, Zeven, Germany|Site Reference ID/Investigator# 33873, Zwickau, Germany|Site Reference ID/Investigator# 33876, Zwickau, Germany|Site Reference ID/Investigator# 33880, Zwiesel, Germany",,"https://ClinicalTrials.gov/show/NCT01077258"
604,"NCT01077232","Documentation of Humira in Psoriasis Patients in Routine Clinical Practice","LOTOS","Completed","No Results Available","Moderate to Severe Plaque Psoriasis",,"Changes in Psoriasis Area and Severity Index; number of patients with Psoriasis Area and Severity Index-75 reduction.|Changes in healthcare parameters: number of missed working days due to psoriasis; number of visits at the doctor's office; number and duration of hospitalizations, self-assessed workability.|Safety and tolerability assessed by analyzing serious and non-serous adverse events.|Global physician's assessment on Humira treatment.|Target Nail Psoriasis Severity Index (target NAPSI).|Itch Visual Analogue Scale (Itch VAS).|Safety and tolerability of Humira - treatment for patient groups with frequent concommitant diseases, especially diabetes type I and II, cardio-vascular and liver and kidney functional impairment and respective concommitant medication.|Palmoplantar Psoriasis Area Severity Index (pPASI).|Influence of body mass index and weight on efficacy measurement.|Patients' assessment on Humira treatment.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"5442","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P10-446","January 4, 2008","June 30, 2019","June 30, 2019","March 1, 2010",,"July 5, 2019","Universitaetsklinik Heidelberg /ID# 33810, Heidelberg, Baden-Wuerttemberg, Germany|Universitaetsklinik Heidelberg /ID# 50858, Heidelberg, Baden-Wuerttemberg, Germany|Universitatsklinikum Mannheim /ID# 166130, Mannheim, Baden-Wuerttemberg, Germany|Universitaetsklinikum Erlangen /ID# 34816, Erlangen, Bayern, Germany|Universitätsklinikum Frankfurt /ID# 53725, Frankfurt am Main, Hessen, Germany|Universitatsklinikum Munster /ID# 205840, Munster, Niedersachsen, Germany|Universitatsklinikum Munster /ID# 72018, Munster, Niedersachsen, Germany|Universitatsklinikum Munster /ID# 72022, Munster, Niedersachsen, Germany|Praxis M. Vilic /ID# 210108, Aachen, Nordrhein-Westfalen, Germany|Universitaetsklinikum Aachen /ID# 35037, Aachen, Nordrhein-Westfalen, Germany|Uniklinik Koln /ID# 166128, Köln, Nordrhein-Westfalen, Germany|Hautarztpraxis am Buddenturm /ID# 205094, Münster, Nordrhein-Westfalen, Germany|Praxis Dr. Büchner /ID# 204352, Dresden, Sachsen, Germany|Universitaetsklinikum Leipzig /ID# 53720, Leipzig, Sachsen, Germany|Praxis Dr. Reimann /ID# 142004, Pirna, Sachsen, Germany|Praxis N. Yenigün /ID# 206670, Kiel, Schleswig-Holstein, Germany|Univ Hosp Schleswig-Holstein /ID# 33981, Kiel, Schleswig-Holstein, Germany|Univ Hosp Schleswig-Holstein /ID# 35269, Kiel, Schleswig-Holstein, Germany|Medizinisches Versorgungszentrum DermaKiel GmbH /ID# 33972, Kiel, Schleswig-Holstein, Germany|Hoeller-Obrigkeit, Aachen, DE /ID# 60599, Aachen, Germany|Petri, Ahaus, DE /ID# 53712, Ahaus, Germany|Gewiss, Ahrensburg, DE /ID# 33431, Ahrensburg, Germany|Praxis Dr. Schuessler /ID# 149404, Alsfeld, Germany|Oster-Schmidt, Altenkirchen, D /ID# 126022, Altenkirchen, Germany|Weiss, Amberg, DE /ID# 60613, Amberg, Germany|Dietz, Ampfing, DE /ID# 50790, Ampfing, Germany|Bell, Andernach, DE /ID# 99815, Andernach, Germany|Schulz, Angermuende, DE /ID# 53719, Angermuende, Germany|Rebbien, Annaberg-Buchholz, DE /ID# 35052, Annaberg-buchholz, Germany|Thieme, Artern, DE /ID# 35518, Artern, Germany|Dr. Szlava Fuezesi, Achaffenbu /ID# 118537, Aschaffenburg, Germany|Theuring, Aschersleben, DE /ID# 35058, Aschersleben, Germany|Hums, Aue, DE /ID# 60601, AUE, Germany|Gerloff-Steiner, Aue, DE /ID# 53694, AUE, Germany|Schneider & Sedlmayr, Augsburg /ID# 33351, Augsburg, Germany|Lechner/Stuebich, Aurich, DE /ID# 33355, Aurich, Germany|Lechner/Stuebich, Aurich, DE /ID# 67967, Aurich, Germany|Brautzsch, Bad Berka, DE /ID# 33365, Bad Berka, Germany|Broschewitz/Hammer Bad Doberan /ID# 60596, Bad Doberan, Germany|Broschewitz/Hammer Bad Doberan /ID# 67948, Bad Doberan, Germany|Mauer, Bad Kreuznach, DE /ID# 126019, Bad Kreuznach, Germany|Schulz, Bad Muender, DE /ID# 48469, BAD Muender, Germany|SALUS-Klinik /ID# 33405, Bad Reichenhall, Germany|Praxis Dr. Bock /ID# 166127, Bad Rothenfelde, Germany|Houda, Bad Schlema, DE /ID# 35584, Bad Schlema, Germany|Moerstedt, Bad Woerishofen, DE /ID# 99844, BAD Woerishofen, Germany|Sozialstiftung Bamberg /ID# 33430, Bamberg, Germany|Stephan-Dahm, Bargteheide, DE /ID# 50861, Bargteheide, Germany|Dr. Roxana Homolka, Baunatal, /ID# 118539, Baunatal, Germany|Mirtschink, Bautzen, DE /ID# 50851, Bautzen, Germany|Graessel, Bayreuth, DE /ID# 35587, Bayreuth, Germany|Kinateder, Bayreuth, DE /ID# 33439, Bayreuth, Germany|Blaese & Walther, Bendorf, DE /ID# 50787, Bendorf, Germany|Pflieger-Bruss, Benndorf, DE /ID# 53713, Benndorf, Germany|Timmel/Timm/Vorwerk, Bergen /ID# 33451, Bergen, Germany|Wirtler, Bergisch Gladbach, DE /ID# 33452, Bergisch Gladbach, Germany|Charité Universitätsmedizin Campus Mitte /ID# 33457, Berlin, Germany|Hasert & Hasert, Berlin, DE /ID# 35531, Berlin, Germany|Kindler, Berlin, Germany /ID# 60604, Berlin, Germany|Klusmann, Berlin, DE /ID# 90974, Berlin, Germany|Spickermann, Berlin, DE /ID# 33675, Berlin, Germany|Praxis Dermatologie am Savigny /ID# 145783, Berlin, Germany|Herzler & Reupke, Berlin, DE /ID# 33705, Berlin, Germany|Boodstein, Berlin, Germany /ID# 48417, Berlin, Germany|Rothhaar, Berlin, DE /ID# 33644, Berlin, Germany|Simon, Berlin, DE /ID# 33678, Berlin, Germany|Steinhoff-Georgieva, Berlin,DE /ID# 60612, Berlin, Germany|Struss, Berlin, DE /ID# 33680, Berlin, Germany|Miller/Nerenheim, Berlin, DE /ID# 99842, Berlin, Germany|Praxis Dr. med. Meljanac /ID# 151477, Berlin, Germany|Praxis Dr. med. Meljanac /ID# 35594, Berlin, Germany|Jacob, Berlin, DE /ID# 48438, Berlin, Germany|Vivantes Klinikum Neukolln /ID# 34270, Berlin, Germany|Weihe/Stavermann, Berlin, DE /ID# 35547, Berlin, Germany|Gellrich, Berlin, DE /ID# 33691, Berlin, Germany|Schirmer, Berlin, DE /ID# 35534, Berlin, Germany|Skarabis/Skarabis, Berlin, DE /ID# 34241, Berlin, Germany|Kv Be /Id# 34253, Berlin, Germany|Praxis Dres. Eicholtz/Boerner /ID# 167676, Berlin, Germany|Wildfeuer, Berlin, DE /ID# 33694, Berlin, Germany|Kors, Berlin, DE /ID# 33649, Berlin, Germany|Zahn, Berlin, DE /ID# 35592, Berlin, Germany|Praxis Dr. Uhl /ID# 171308, Berlin, Germany|Dues/Manasterski, Berlin, DE /ID# 35538, Berlin, Germany|Miehe & Partner, Berlin, DE /ID# 166125, Berlin, Germany|Miehe & Partner, Berlin, DE /ID# 35544, Berlin, Germany|Baumann, Berlin, DE /ID# 60584, Berlin, Germany|Groene, Berlin, DE /ID# 60594, Berlin, Germany|Praxis Dr. Duhn /ID# 167672, Bernau Bei Berlin, Germany|Neumann, Bernau, DE /ID# 34271, Bernau, Germany|Biel, Bielefeld, DE /ID# 60586, Bielefeld, Germany|MVZ Otto-Brenner-Straße /ID# 167677, Bielefeld, Germany|Staedt Kliniken Bielefeld /ID# 35558, Bielefeld, Germany|Dabour & Dabour, Birkenwerder /ID# 34280, Birkenwerder, Germany|Wege & Kuehnast, Bitterfeld /ID# 34282, Bitterfeld, Germany|Praxis fuer Innere Medizin/Rhe /ID# 35564, Blaubeuren, Germany|Ruppert, Bocholt, DE /ID# 108918, Bocholt, Germany|Klinikum Ruhr Univ Bochum /ID# 35091, Bochum, Germany|GP Dr. Niesman & Dr. Othlingha /ID# 169694, Bochum, Germany|Ardabili/Niesmann, Bochum, DE /ID# 50784, Bochum, Germany|Universitaetsklinikum Bonn /ID# 34299, Bonn, Germany|Praxis Dr. Schift /ID# 141549, Borken, Germany|Barth, Borna, DE /ID# 35650, Borna, Germany|Barth, Borna, DE /ID# 67946, Borna, Germany|Alte Apotheke /ID# 48530, Bottrop, Germany|Flont-Schmeling, Bottrop, DE /ID# 48423, Bottrop, Germany|Karpinski, Bottrop, DE /ID# 34303, Bottrop, Germany|Tolzin, Brake, DE /ID# 50866, Brake, Germany|Praxis S. Osadtschy /ID# 161167, Brandenburg An Der Havel, Germany|Klee/Wolff, Brandenburg, DE /ID# 67960, Brandenburg, Germany|Atugoda, Braunschweig, DE /ID# 48509, Braunschweig, Germany|Gaedt, Braunschweig, DE /ID# 67954, Braunschweig, Germany|Koehn & Ramaker-Brunke, DE /ID# 34309, Braunschweig, Germany|Klinikverbund Bremen /ID# 171306, Bremen, Germany|Elsner, Bremen, DE /ID# 48422, Bremen, Germany|Derma am Diako /ID# 166131, Bremen, Germany|Hermann/Teichelmann, Bremen,DE /ID# 35605, Bremen, Germany|Altvater/Tauschke, Bremen, DE /ID# 34311, Bremen, Germany|Schwichtenberg, Bremen, DE /ID# 34312, Bremen, Germany|Friedmann, Bremerhaven, DE /ID# 67952, Bremerhaven, Germany|Heitmann, Bremerhaven, DE /ID# 148410, Bremerhaven, Germany|Streit, Buchholz, DE /ID# 53723, Buchholz I.D. Nordheide, Germany|Bessle, Buchholz, DE /ID# 60585, Buchholz, Germany|Praxis K. Neubert /ID# 149400, Burgstadt, Germany|Arensmeier-Gottschalkson, Burg /ID# 48508, Burg, Germany|Wagenpfeil, Burscheid, DE /ID# 99856, Burscheid, Germany|Elbe Klinikum Buxtehude /ID# 34694, Buxtehude, Germany|Praxis B. Jaeckel /ID# 145768, Chemnitz, Germany|Jaeckel & Partner, Chemnitz, D /ID# 34703, Chemnitz, Germany|Kuehn/Stengel, Chemnitz, DE /ID# 90978, Chemnitz, Germany|Praxis P. Hausler-Mehlhorn /ID# 149285, Chemnitz, Germany|Schneider, Chemnitz, DE /ID# 35613, Chemnitz, Germany|Hoffmann, Coburg, DE /ID# 34704, Coburg, Germany|Pappai, Coesfeld, DE /ID# 108917, Coesfeld, Germany|Karger/Rezazadegan, Cologne DE /ID# 60608, Cologne, Germany|Menge & Franckson, Cologne, DE /ID# 53708, Cologne, Germany|Haitas-Haase, Cologne, DE /ID# 53696, Cologne, Germany|Haase & Partner, Cologne, DE /ID# 53724, Cologne, Germany|Praxis Dres. Neuhaus/Sacha /ID# 149403, Cologne, Germany|Matias-Bako/Krickeberg,Cologne /ID# 90975, Cologne, Germany|Eichhorn, Cologne, DE /ID# 99818, Cologne, Germany|Krebs, Coswig, DE /ID# 48519, Coswig, Germany|Praxis S.-K. Strenzke /ID# 145781, Cottbus, Germany|Dr. Bernd Jantsch, Cottbus, DE /ID# 35618, Cottbus, Germany|Loessner, Cottbus, DE /ID# 34712, Cottbus, Germany|Dr. Susanne Jantsch,Cottbus,DE /ID# 35619, Cottbus, Germany|Klinikum Darmstadt GmbH /ID# 34720, Darmstadt, Germany|Buelow, Delmenhorst, DE /ID# 35626, Delmenhorst, Germany|Thelen, Delmenhorst, DE /ID# 35628, Delmenhorst, Germany|Heidlas, Dessau-Rosslau, DE /ID# 34730, Dessau-rosslau, Germany|Klinikum Lippe Detmold GmbH /ID# 34731, Detmold, Germany|Friedrich, Dieburg, DE /ID# 53693, Dieburg, Germany|Gerharz, Diez, DE /ID# 48432, Diez, Germany|Winter, Dinkelsbuehl, DE /ID# 34734, Dinkelsbuehl, Germany|Ghassem-Zadeh/Farashahi /ID# 138188, Dormagen, Germany|Thomas, Dorsten, DE /ID# 34736, Dorsten, Germany|Brinkmeier & Partner, Dortmund /ID# 138259, Dortmund, Germany|Brinkmeier & Partner, Dortmund /ID# 99847, Dortmund, Germany|Hautklinik Dortmund /ID# 72019, Dortmund, Germany|Hirschmueller, Dortmund, DE /ID# 34737, Dortmund, Germany|Bebnowski, Dortmund, DE /ID# 53684, Dortmund, Germany|Dick/Hubert/Mirkin, Dortmund /ID# 99843, Dortmund, Germany|Frolova, Dortmund, DE /ID# 51022, Dortmund, Germany|Frach/Hohaus, Dresden, DE /ID# 35166, Dresden, Germany|Frach/Hohaus, Dresden, DE /ID# 60600, Dresden, Germany|Gerlach, Dresden, DE /ID# 48433, Dresden, Germany|Praxis Dres. Pollack Schramm /ID# 149286, Dresden, Germany|Kuehn, Dresden, DE /ID# 34752, Dresden, Germany|Schamfuss, Dresden, DE /ID# 48468, Dresden, Germany|Richter-Huhn, Dresden, DE /ID# 35164, Dresden, Germany|Hass, Dresden, Germany /ID# 60597, Dresden, Germany|Meier, Dresden, DE /ID# 48452, Dresden, Germany|Universitaetklinikum Dresden /ID# 34764, Dresden, Germany|University Clinic Carl Gustav /ID# 99820, Dresden, Germany|Praxis Dr. Mayer /ID# 148243, Dresden, Germany|Scheibner, Dresden, DE /ID# 35162, Dresden, Germany|Oppers, Dresden, DE /ID# 126021, Dresden, Germany|Bockhorst & Dominicus, Duelmen /ID# 34765, Duelmen, Germany|Korge, Dueren, DE /ID# 35174, Dueren, Germany|Evangelisches Krankenhaus Dues /ID# 48419, Duesseldorf, Germany|Siebert, Duisburg, DE /ID# 34775, Duisburg, Germany|St. Barbara-Hospital /ID# 81302, Duisburg, Germany|Praxis. Y. Teoman /ID# 142005, Duisburg, Germany|Elsner, Duisburg, DE /ID# 99819, Duisburg, Germany|Saget & Riesopp, Duisburg, DE /ID# 35175, Duisburg, Germany|Praxis Dr. Lobert /ID# 145774, Duisburg, Germany|Berendt, Eberswalde, DE /ID# 35178, Eberswalde, Germany|Badura, Eilenburg, DE /ID# 35179, Eilenburg, Germany|Praxis Dr. Kues /ID# 145771, Einbeck, Germany|Dove, Eisenach, DE /ID# 48420, Eisenach, Germany|Reinhardt, Eisenach, DE /ID# 48465, Eisenach, Germany|Rast, Eisenhuettenstadt, DE /ID# 34789, Eisenhuettenstadt, Germany|Richter/Cyw, Eisenhuettenstadt /ID# 34790, Eisenhuettenstadt, Germany|Noack, Lutherstadt Eisleben,DE /ID# 48521, Eisleben, Germany|Schmid, Ellwangen, DE /ID# 34792, Ellwangen, Germany|Praxis Dr. Fitz /ID# 145767, Elmshorn, Germany|Hartl, Eltville, DE /ID# 34796, Eltville, Germany|Med X Aerzteteam GmbH /ID# 90977, Emden, Germany|Meinert, Emden, DE /ID# 34797, Emden, Germany|Maurer & Krebs-Posingies /ID# 34800, Emsdetten, Germany|Schurhammer-Fuhrmann, Endingen /ID# 67966, Endingen, Germany|Koenig, Erfurg, DE /ID# 99838, Erfurt, Germany|Nennstiel, Erfurt, DE /ID# 34804, Erfurt, Germany|Lichtenstein, Eschweiler, DE /ID# 50842, Eschweiler, Germany|Praxis Dres. Exner/Kanja /ID# 145769, Essen, Germany|Universitaetsklinikum Essen /ID# 34827, Essen, Germany|Universitaetsklinikum Essen /ID# 53718, Essen, Germany|Klundt, Essen, DE /ID# 138195, Essen, Germany|Praxis Dres. Beyer /ID# 141989, Essen, Germany|Praxis Dres. Beyer /ID# 90957, Essen, Germany|Praxis Dr. Porwollik /ID# 148244, Essen, Germany|Praxis Dres. Renner/Sohl /ID# 149289, Esslingen Am Neckar, Germany|Huerkamp, Euskirchen, DE /ID# 48517, Euskirchen, Germany|Swirski, Euskirchen, DE /ID# 81314, Euskirchen, Germany|Praxis Dres. Freitag/Knoell /ID# 167675, Falkensee, Germany|Jovic-Paris, Bad Neuenahr /ID# 48439, Fitzroy, Germany|Godt, Flensburg, DE /ID# 67957, Flensburg, Germany|Praxis T. Zimmermann /ID# 145784, Floeha, Germany|Eichinger, Frankenberg, DE /ID# 138260, Frankenberg/sa., Germany|Schoengen/Schwarzenbach, Frank /ID# 60610, Frankenthal, Germany|Schoengen/Schwarzenbach, Frank /ID# 60611, Frankenthal, Germany|Kaufmann, Frankfurt, DE /ID# 35098, Frankfurt, Germany|Hundgeburth, Frechen, DE /ID# 138192, Frechen, Germany|Kaemmerer, Freiberg, DE /ID# 138194, Freiberg, Germany|Trefzer, Freiburg im Breisgau, /ID# 126028, Freiburg, Germany|Kurzen, Freising, DE /ID# 67964, Freising, Germany|Schmidt, Fuerstenwalde, DE /ID# 34868, Fuerstenwalde, Germany|Gall, Fuerth, DE /ID# 48431, Fuerth, Germany|Teichler, Gaggenau, DE /ID# 99855, Gaggenau, Germany|Wolf, Garbsen, DE /ID# 99859, Garbsen, Germany|Praxis Dr. Billmann-Krutmann /ID# 149399, Geilenkirchen, Germany|Praxis Dres. Kobus / Wetz /ID# 169692, Gelsenkirchen, Germany|Praxis K. R. Koerber & Partner /ID# 151715, Gelsenkirchen, Germany|Wetz, Gelsenkirchen, DE /ID# 99858, Gelsenkirchen, Germany|Rotterdam, Gelsenkirchen, DE /ID# 50856, Gelsenkirchen, Germany|Praxis J. Teichmann & Partner /ID# 145775, Gelsenkirchen, Germany|Lange, Dietrich & Beyer, Gera /ID# 48449, Gera, Germany|Lange, Dietrich & Beyer, Gera /ID# 81274, Gera, Germany|Paul/Meyer, Gera, DE /ID# 54379, Gera, Germany|SRH Wald-Klinikum Gera GmbH /ID# 60602, Gera, Germany|Schnee, Gera, DE /ID# 81313, Gera, Germany|Estel, Gera, DE /ID# 35226, Gera, Germany|Loth, Gernsbach, DE /ID# 50844, Gernsbach, Germany|Gross/Braeu, Giessen, DE /ID# 34884, Giessen, Germany|Kloevekorn & Tepe, Gilching /ID# 118541, Gilching, Germany|Kloevekorn & Tepe, Gilching /ID# 48504, Gilching, Germany|Kloevekorn & Tepe, Gilching /ID# 48506, Gilching, Germany|Brinkmann & Partner, Gladbeck, /ID# 34889, Gladbeck, Germany|Brinkmann & Partner, Gladbeck, /ID# 53688, Gladbeck, Germany|Jahn, Glauchau, DE /ID# 35230, Glauchau, Germany|Hille, Goerlitz, DE /ID# 60598, Goerlitz, Germany|Cleffmann/Ranke, Goettingen DE /ID# 53689, Goettingen, Germany|Univ Medical Center Goettingen /ID# 35103, Goettingen, Germany|Kuckert, Graefenhainichen, DE /ID# 48520, Graefenhainichen, Germany|Kisslinger/Kisslinger, Grafena /ID# 34897, Grafenau, Germany|Herrmann, Greifswald, DE /ID# 72016, Greifswald, Germany|Manke, Grevesmuehlen, DE /ID# 34907, Grevesmuehlen, Germany|Wigbels, Gronau, DE /ID# 48505, Gronau, Germany|Grossmann, Grossenhain, DE /ID# 126016, Grossenhain, Germany|Westphal, Guestrow, DE /ID# 35500, Guestrow, Germany|Busse-Misic, Hagen, DE /ID# 34914, Hagen, Germany|Timtschenko, Hagen, DE /ID# 138203, Hagen, Germany|Stehl, Haiger, DE /ID# 126027, Haiger, Germany|Gstoettner, Halle, DE /ID# 48513, Halle, Germany|Hamm, Halle, DE /ID# 72015, Halle, Germany|Lutze, Halle, DE /ID# 34919, Halle, Germany|Reiss, Halle, DE /ID# 35507, Halle, Germany|Zarzour, Halle, DE /ID# 35505, Halle, Germany|Hetschko, Halle, DE /ID# 48437, Halle, Germany|Universitatsklinikum Halle /ID# 34941, Halle, Germany|Gagu-Koll, Hamburg, DE /ID# 48424, Hamburg, Germany|Univ Klinik Eppendorf Hamburg /ID# 35115, Hamburg, Germany|Univ Klinik Eppendorf Hamburg /ID# 48453, Hamburg, Germany|Dermatologikum Hamburg /ID# 35107, Hamburg, Germany|Wagner, Hamburg, DE /ID# 99857, Hamburg, Germany|Mengert/Nienstedt, Hamburg, DE /ID# 34995, Hamburg, Germany|Luetten, Hamburg, DE /ID# 50847, Hamburg, Germany|Kahle/Ohnemus, Hamburg, DE /ID# 148412, Hamburg, Germany|Praxis Dres. Harms/Hartmann /ID# 148249, Hamburg, Germany|Buerger, Hamburg, DE /ID# 34966, Hamburg, Germany|Montag, Hamburg, DE /ID# 35438, Hamburg, Germany|Buck, Hamburg, DE /ID# 34964, Hamburg, Germany|Dermatologisches Ambulatorium /ID# 35435, Hamburg, Germany|Dermatologisches Ambulatorium /ID# 35436, Hamburg, Germany|Kunze, Hamburg, DE /ID# 34949, Hamburg, Germany|Kuwert/Wendt/Schulz, Hamburg, /ID# 34991, Hamburg, Germany|Hautarztpraxis am Tibarg /ID# 35004, Hamburg, Germany|Schmolke, Hamburg, DE /ID# 67965, Hamburg, Germany|Wrage-Brors, Hamburg, DE /ID# 126030, Hamburg, Germany|Szabo, Hamm, DE /ID# 35015, Hamm, Germany|Weitzel, Hamm, DE /ID# 90982, Hamm, Germany|Klinikum Hanau gGmbH /ID# 35020, Hanau, Germany|Praxis U. Stein /ID# 171307, Hannover, Germany|Theuerkauf, Hanover, DE /ID# 35454, Hannover, Germany|Stein, Hanover, DE /ID# 35029, Hannover, Germany|Horstmann, Hanover, DE /ID# 35026, Hannover, Germany|Durani & Durani, Heidelberg,DE /ID# 48421, Heidelberg, Germany|Alheit, Heidenau, DE /ID# 50782, Heidenau, Germany|Pawlak, Heilbad Heiligenstadt, /ID# 138191, Heilbad Heiligenstadt, Germany|Pawlak, Heilbad Heiligenstadt, /ID# 35466, Heilbad Heiligenstadt, Germany|Arnold/Kaschubowski/Salzer/Wur /ID# 67971, Heilbronn, Germany|Arnold/Kaschubowski/Salzer/Wur /ID# 99837, Heilbronn, Germany|Schulte/Mainusch, Heiligenhaus /ID# 138202, Heiligenhaus, Germany|Postrach, Hennigsdorf, DE /ID# 35468, Hennigsdorf, Germany|Praxis G. Taesler /ID# 145782, Herrnhut, Germany|Allmacher, Hersbruck, DE /ID# 125998, Hersbruck, Germany|PsoriSol Hautklinik GmbH /ID# 169690, Hersbruck, Germany|Kroemer, Herten, DE /ID# 48448, Herten, Germany|Badacz, Heusenstamm, DE /ID# 125999, Heusenstamm, Germany|Biedenkapp, Heusenstamm, DE /ID# 81275, Heusenstamm, Germany|Stark & Stark, Hilden, DE /ID# 35470, Hilden, Germany|Klinken, Hilden, DE /ID# 33829, Hilden, Germany|Kubek, Hofgeismar, DE /ID# 67963, Hofgeismar, Germany|Praxis Dr. Brill /ID# 145764, Hofheim Am Taunus, Germany|Lenz, Hofheim, DE /ID# 33839, Hofheim, Germany|Reinecke, Holzminden, DE /ID# 48464, Holzminden, Germany|Franke, Homburg, DE /ID# 99821, Homburg, Germany|Univ Kliniken des Saarlandes /ID# 33848, Homburg, Germany|Nawka, Pistrosch, Hoyerswerda /ID# 81299, Hoyerswerda, Germany|Wolz/Bierbaum, Hoyerswerda, DE /ID# 48531, Hoyerswerda, Germany|Christoph, Ilmenau, DE /ID# 67949, Ilmenau, Germany|Lutz, Ingolstadt, DE /ID# 35477, Ingolstadt, Germany|Stockmeier, Ingoldstadt, DE /ID# 53722, Ingolstadt, Germany|Tuttner, Ingoldstadt, DE /ID# 53726, Ingolstadt, Germany|Gfesser, Ingolstadt, DE /ID# 81277, Ingolstadt, Germany|Pueschel, Ingolstadt, DE /ID# 33859, Ingolstadt, Germany|Universitaetsklinikum Jena /ID# 138198, Jena, Germany|Brilon & Zanker, Juelich, DE /ID# 33943, Juelich, Germany|Brilon & Zanker, Juelich, DE /ID# 60614, Juelich, Germany|Thomas & Heike Mauer,Kamenz,DE /ID# 35480, Kamenz, Germany|Gaehtgens, Kamen, DE /ID# 67955, Kamen, Germany|Dres. Bettinger & Kollegen /ID# 138185, Karlsruhe, Germany|Meyer-Rogge & Kollegen /ID# 72013, Karlsruhe, Germany|Meyer-Rogge & Kollegen /ID# 99841, Karlsruhe, Germany|Reitenbach-Blindt,Karlsruhe,DE /ID# 48466, Karlsruhe, Germany|Glutsch, Karlsruhe, DE /ID# 33953, Karlsruhe, Germany|Eichbauer, Karlsruhe, DE /ID# 126017, Karlsruhe, Germany|Eichbauer, Karlsruhe, DE /ID# 60592, Karlsruhe, Germany|Dunkel, Karlstadt, DE /ID# 50822, Karlstadt, Germany|Fueller, Kassel, DE /ID# 67953, Kassel, Germany|Medikum MVZ GmbH /ID# 148248, Kassel, Germany|Meyer & Baum, Kassel, DE /ID# 108916, Kassel, Germany|Meyer & Baum, Kassel, DE /ID# 50785, Kassel, Germany|Kreiselmaier, Kiel, DE /ID# 81298, Kiel, Germany|Klee/Radeck, Kleinmachnow, DE /ID# 33982, Kleinmachnow, Germany|Giesen, Kleve, DE /ID# 50825, Kleve, Germany|Grosse, Kleve, DE /ID# 33983, Kleve, Germany|Grossmann, Koblenz, DE /ID# 99835, Koblenz, Germany|Habermann, Koblenz, DE /ID# 35488, Koblenz, Germany|Blisse, Koenigs Wusterhausen, /ID# 33999, Koenigs Wusterhausen, Germany|Gruner, Koenigs Wusterhausen, /ID# 33998, Koenigs Wusterhausen, Germany|Hetzer/Schuster/Prothmann /ID# 138200, Krefeld, Germany|Hetzer/Schuster/Prothmann /ID# 50860, Krefeld, Germany|Gerhards, Krefeld, DE /ID# 108915, Krefeld, Germany|Sauer/Wolff/Kreiss, Krefeld, D /ID# 141546, Krefeld, Germany|Sauer/Wolff/Kreiss, Krefeld, D /ID# 35242, Krefeld, Germany|Sauer/Wolff/Kreiss, Krefeld, D /ID# 53705, Krefeld, Germany|Praxis Dres. Hartschuh/Sugar-B /ID# 167674, Krumbach, Germany|Sugar-Bunk, Krumbach, DE /ID# 34085, Krumbach, Germany|Dres. Jacobs & Kollegen /ID# 149402, Kulmbach, Germany|Schmidt, Kusel, DE /ID# 60609, Kusel, Germany|Fritz/Biwer/Scherer/Uhlig /ID# 149401, Landau, Germany|Huppmann, Landshut, DE /ID# 72017, Landshut, Germany|Jacoby, Landshut, DE /ID# 34089, Landshut, Germany|Janecka, Langenfeld, DE /ID# 34090, Langenfeld, Germany|Glockemann/Vennemann, Langenha /ID# 34091, Langenhagen, Germany|Glockemann/Vennemann, Langenha /ID# 53728, Langenhagen, Germany|Praxis. C. Nitzschner /ID# 142001, Langenselbold, Germany|Praxis Dr. Juttner /ID# 169691, Lauda-konigshofen, Germany|Riebel & Meckl & Goetz, Lauf /ID# 34093, Lauf, Germany|Schunter, Laupheim, DE /ID# 35247, Laupheim, Germany|Biedermann-Hahn, Lauterbach,DE /ID# 48416, Lauterbach, Germany|Wirbel, Lehrte, DE /ID# 53730, Lehrte, Germany|Noack-Wiemers, Leipzig, DE /ID# 35248, Leipzig, Germany|Gruenenwald, Leipzig, DE /ID# 60595, Leipzig, Germany|Neubauer, Leipzig, DE /ID# 34103, Leipzig, Germany|Adler, Lengenfeld, DE /ID# 34115, Lengenfeld, Germany|Ogger & Gueldner-Engelmann /ID# 48455, Leonberg, Germany|Onsa, Leverkusen, DE /ID# 90976, Leverkusen, Germany|Praxis Dr. Carl /ID# 148247, Lichtenfels, Germany|Dielmann, Limburg, DE /ID# 34124, Limburg, Germany|Vehring/Amann/Beier,Lingen,DE /ID# 35251, Lingen, Germany|Schuermeyer-Horst, Lippstadt, /ID# 34126, Lippstadt, Germany|Grodzki & Pier, Lippstadt, DE /ID# 34128, Lippstadt, Germany|Grodzki & Pier, Lippstadt, DE /ID# 48523, Lippstadt, Germany|Lochno, Loebau, DE /ID# 50843, Loebau, Germany|Hagemeier, Loehne, DE /ID# 35256, Loehne, Germany|Ifflaender, Luckenwalde, DE /ID# 50828, Luckenwalde, Germany|Schultz, Ludwigsfelde, DE /ID# 50859, Ludwigsfelde, Germany|Boehm & Boehm, Ludwigshafen /ID# 35263, Ludwigshafen, Germany|Wiest/Meng, Ludwigshafen, DE /ID# 138196, Ludwigshafen, Germany|Klinikum Stadt Ludwigshafen/Rh /ID# 34131, Ludwigshafen, Germany|Kreusch/Krengel/Mrowka, Luebec /ID# 148411, Luebeck, Germany|Thierfelder, Luebeck, DE /ID# 34132, Luebeck, Germany|Dlugosz-Wolf, Luedenscheid, DE /ID# 81276, Luedenscheid, Germany|Praxis Dr. Bause /ID# 167670, Luedenscheid, Germany|Praxis Ch. Nolting-Schraeer /ID# 141548, Luedinghausen, Germany|Birkner-Porath, Lueneburg, DE /ID# 90959, Lueneburg, Germany|Praxis C. Besser /ID# 141988, Lunen, Germany|Maerkische Kliniken GmbH /ID# 48512, Lüdenscheid, Germany|Bruecher, Magdeburg, DE /ID# 126000, Magdeburg, Germany|Grasshoff, Magdeburg, DE /ID# 34144, Magdeburg, Germany|Praxis Dr. Kuehne /ID# 145773, Magdeburg, Germany|Genseke/Krause, Magdeburg, DE /ID# 149288, Magdeburg, Germany|Kuchheuser, Magdeburg, DE /ID# 34143, Magdeburg, Germany|Otto von Guericke Universitaet /ID# 48435, Magdeburg, Germany|Otto von Guericke Universitaet /ID# 60588, Magdeburg, Germany|Drs Scholz/Sebastian/Schilling /ID# 35273, Mahlow, Germany|Univ Johannes Gutenberg /ID# 35662, Mainz, Germany|Knuechel, Mannheim, DE /ID# 48440, Mannheim, Germany|Richter & Schernitzky,Mannheim /ID# 34183, Mannheim, Germany|Fuchs, Markdorf, DE /ID# 90973, Markdorf, Germany|Schulze/Schulze, Markkleeberg, /ID# 34188, Markkleeberg, Germany|Maassen, Maxdorf, DE /ID# 34197, Maxdorf, Germany|Cymorek, Meinerzhagen, DE /ID# 48511, Meinerzhagen, Germany|Werner, Meissen, DE /ID# 81318, Meissen, Germany|Schwinn & Winkler,Memmingen,DE /ID# 35281, Memmingen, Germany|Moeller-Massling & Wippermann /ID# 48529, Menden, Germany|Klinikum Minden /ID# 34205, Minden, Germany|Boss, Minden, DE /ID# 145772, Minden, Germany|Kantner, Moenchengladbach, DE /ID# 99836, Moenchengladbach, Germany|Zentbeauty Gbr /ID# 72020, Moenchengladbach, Germany|Stroemer & Deden /ID# 48502, Moenchengladbach, Germany|Dorittke & Kardorff /ID# 35289, Moenchengladbach, Germany|Mang, Muehlhausen, DE /ID# 48451, Muehlhausen, Germany|Kaufmann, Muehlheim, DE /ID# 60603, Muehlheim, Germany|Nikodem-Koczwara, Muelheim, DE /ID# 53710, Muelheim, Germany|Schueller, Muelheim a.d. Ruhr /ID# 126025, Muelheim, Germany|Habenicht/Marth, Muenster, DE /ID# 138190, Muenster, Germany|Mueller, Muenster, DE /ID# 53709, Muenster, Germany|Husemann & Fischer, Munich, DE /ID# 53692, Munich, Germany|Malmusi, Munich, DE /ID# 48450, Munich, Germany|Anders-Ankerhold, Munich, DE /ID# 53682, Munich, Germany|Klinikum recht der Isar der TU /ID# 138208, Munich, Germany|Pfannenstiel, Munich, DE /ID# 126023, Munich, Germany|TU Uniklinik Munchen /ID# 202198, Munich, Germany|Gagel, Munich, DE /ID# 60593, Munich, Germany|Keilig, Munich, DE /ID# 53702, Munich, Germany|Quack, Munich, DE /ID# 53715, Munich, Germany|Lissner, Auerbach, DE /ID# 35061, Munster, Germany|Wilhelm, Naumburg, DE /ID# 67970, Naumburg, Germany|Paech, Neubrandenburg, DE /ID# 34057, Neubrandenburg, Germany|Bruckbauer, Neufahrn, DE /ID# 48418, Neufahrn, Germany|Franke, Neugersdorf, DE /ID# 138187, Neugersdorf, Germany|Meisel-Stosiek, Neumarkt, DE /ID# 34067, Neumarkt, Germany|Schwerbrock, Neumarkt, DE /ID# 34068, Neumarkt, Germany|Buettner & Meewes,Neumuenster /ID# 35310, Neumuenster, Germany|von Kobyletzki, Nuernberg, DE /ID# 35315, Neustadt, Germany|Sperling, Neustrelitz, DE /ID# 53721, Neustrelitz, Germany|Kloos & Loeser, Neuwied, DE /ID# 35318, Neuwied, Germany|Kloos & Loeser, Neuwied, DE /ID# 35319, Neuwied, Germany|Boeckers, Nieder-Olm, DE /ID# 138262, Nieder-olm, Germany|Mahlke, Norden, DE /ID# 99840, Norden, Germany|Krankenhaus Norderney /ID# 72021, Norderney, Germany|Praxis S. Zajac /ID# 148245, Norderstedt, Germany|Gutgesell, Norderstedt, DE /ID# 34159, Norderstedt, Germany|Niemeyer, Nordhausen, DE /ID# 35323, Nordhausen, Germany|Wienrich, Nordhausen, DE /ID# 126029, Nordhausen, Germany|Praxis Dr.S.Vogel- Kiener /ID# 167679, Nuernberg, Germany|Thuencher, Nuremberg, DE /ID# 34163, Nuremberg, Germany|Voelkel, Nuremberg, DE /ID# 34164, Nuremberg, Germany|Tuerk, Nuremberg, DE /ID# 67968, Nuremberg, Germany|Vogel/Walther, Nuremberg, DE /ID# 67969, Nuremberg, Germany|Alpagut & Alpagut & Meisel /ID# 35325, Nuremberg, Germany|HELIOS St. Elisabeth Klinik /ID# 138263, Oberhausen, Germany|Saleh, Oberhausen, DE /ID# 138201, Oberhausen, Germany|Rudolphi/Duckheim, Oberhausen, /ID# 34169, Oberhausen, Germany|Ponce de Poeschl, Oberschleiss /ID# 53714, Oberschleissheim, Germany|Hockmann, Oelde, DE /ID# 48515, Oelde, Germany|Wendrock-Shiga, Oelsnitz, DE /ID# 35328, Oelsnitz, Germany|Altmeyer, Oer-Erkenschwick, DE /ID# 50783, Oer-erkenschwick, Germany|Praxis Dr. Spreng /ID# 145780, Offenbach, Germany|Fechner/Addicks, Oldenburg, DE /ID# 60582, Oldenburg, Germany|Reinicke, Oldenburg, DE /ID# 126024, Oldenburg, Germany|Klinikum Oldenburg GmbH /ID# 50848, Oldenburg, Germany|Klinikum Oldenburg GmbH /ID# 50854, Oldenburg, Germany|MVZ Olpe I /ID# 167678, Olpe, Germany|Reipen, Olpe, DE /ID# 48524, Olpe, Germany|Fachklinik Bad Bentheim /ID# 35568, Ormond Beach, Germany|Praxis C. Bochenek /ID# 167671, Oschatz, Germany|Breitsprecher, Osnabrueck, DE /ID# 35330, Osnabrueck, Germany|Klinikum Osnabrueck GmbH /ID# 35332, Osnabrueck, Germany|Rosenbach, Osnabrueck, DE /ID# 33497, Osnabrueck, Germany|Hoppe, Pasewalk, DE /ID# 53699, Pasewalk, Germany|Kuehn, Peitz, DE /ID# 33510, Peitz, Germany|Baumann, Philippsburg, DE /ID# 33518, Philippsburg, Germany|Staender, Bad Bentheim, DE /ID# 35522, Phoenix, Germany|Itschert, Pinneberg, DE /ID# 67958, Pinneberg, Germany|Schmidt, Pirna, DE /ID# 48525, Pirna, Germany|Kallweit, Plettenberg, DE /ID# 53701, Plettenberg, Germany|Farzar/Kramer/Mohme, Porta /ID# 33530, Porta Westfalica, Germany|Farzar/Kramer/Mohme, Porta /ID# 99845, Porta Westfalica, Germany|Buehler/Radke, Potsdam, DE /ID# 33531, Potsdam, Germany|Hautarztpraxis am Stadthaus /ID# 141997, Potsdam, Germany|Hautarztpraxis am Stadthaus /ID# 149287, Potsdam, Germany|Asadullah/Gross, Potsdam, DE /ID# 72014, Potsdam, Germany|Luedcke, Potsdam, DE /ID# 33462, Potsdam, Germany|Praxis Dr. Barbu /ID# 156481, Potsdam, Germany|MARE Klinikum /ID# 33473, Preetz, Germany|Akst, Pruem, DE /ID# 33477, Pruem, Germany|John&Rupp-John, Puettlingen,DE /ID# 35342, Puettlingen, Germany|Kirchesch, Pulheim, DE /ID# 50830, Pulheim, Germany|Klin Christiane Erxleben GmbH /ID# 35344, Quedlinburg, Germany|Frank/Frank, Radebeul, DE /ID# 138186, Radebeul, Germany|Rozsondai, Radolfzell, DE /ID# 50857, Radolfzell, Germany|Gehse, Rastatt, DE /ID# 67956, Rastatt, Germany|Parker, Rastatt, DE /ID# 48522, Rastatt, Germany|Praxis Dres. Pierchalla & Part /ID# 151478, Recklinghausen, Germany|Klinikum Univ Regensburg /ID# 33894, Regensburg, Germany|Haueisen, Regensburg, DE /ID# 81296, Regensburg, Germany|Kluge & Ott, Rehau, DE /ID# 33895, Rehau, Germany|Weis, Reichenbach, DE /ID# 138204, Reichenbach, Germany|Kramer/Mortazawi, Remscheid /ID# 33898, Remscheid, Germany|Haut-und Allergie-Ambulatorium /ID# 148250, Rendsburg, Germany|Montag, Rheinbach, DE /ID# 99846, Rheinbach, Germany|Ludwig, Rheine, DE /ID# 50846, Rheine, Germany|Manuel, Rheinstetten, DE /ID# 33908, Rheinstetten, Germany|Maslen & Pavlovsky, Ribnitz /ID# 35353, Ribnitz-damgarten, Germany|Krausse, Riesa, DE /ID# 35357, Riesa, Germany|Krausch, Rinteln, DE /ID# 48447, Rinteln, Germany|Kleditzsch/Blank, Rostock, DE /ID# 60587, Rostock, Germany|Buttler, Rostock, DE /ID# 60590, Rostock, Germany|Hoene, Rostock, DE /ID# 48516, Rostock, Germany|Slucka, Rostock, DE /ID# 126026, Rostock, Germany|Goeldner, Rostock, DE /ID# 33919, Rostock, Germany|Bomke, Rostock, DE /ID# 99816, Rostock, Germany|Eisfelder, Rottweil, DE /ID# 34010, Rottweil, Germany|Prifert, Rudolstadt, DE /ID# 35359, Rudolstadt, Germany|Zapf, Rudolstadt, DE /ID# 34011, Rudolstadt, Germany|Hempel, Saalfeld, DE /ID# 34013, Saalfeld, Germany|Trennheuser % Hasselmann /ID# 34018, Saarlouis, Germany|Salzmann, St. Wendel, DE /ID# 33579, Saint Wendel, Germany|Spitzbarth, Sangerhausen, DE /ID# 34028, Sangerhausen, Germany|Broening, Schleiz, DE /ID# 35366, Schleiz, Germany|Durrant-Finn, Schmoelln, DE /ID# 67950, Schmoelln, Germany|Alscher, Schneeberg, DE /ID# 35368, Schneeberg, Germany|Gueldner, Schorndorf, DE /ID# 33536, Schorndorf, Germany|Frankerl, Schwandorf, DE /ID# 33543, Schwandorf, Germany|Mueller, Schwarzenberg, DE /ID# 138197, Schwarzenberg, Germany|Asklepios Klin Uckermark /ID# 35373, Schwedt, Germany|Huyke, Schweina, DE /ID# 138193, Schweina, Germany|Mehringer, Schweinfurt, DE /ID# 50850, Schweinfurt, Germany|Fraenken/Leksa, Schwelm, DE /ID# 33547, Schwelm, Germany|von Kiedrowski, Selters, DE /ID# 33560, Selters, Germany|David, Siegen, DE /ID# 148242, Siegen, Germany|David, Siegen, DE /ID# 99817, Siegen, Germany|Asefi, Simmern, DE /ID# 67945, Simmern, Germany|Albig, Singen, DE /ID# 33564, Singen, Germany|Wendler, Soemmerda, DE /ID# 138205, Soemmerda, Germany|Hagemann, Soest, DE /ID# 48514, Soest, Germany|Karl, Soest, DE /ID# 33569, Soest, Germany|Thiele, Soest, DE /ID# 33568, Soest, Germany|Wroblewska, Spaichingen, DE /ID# 34867, Spaichingen, Germany|Zobel, Spremberg, DE /ID# 50869, Spremberg, Germany|Blecher, Starnberg, DE /ID# 33589, Starnberg, Germany|Bange, Stassfurt, DE /ID# 48510, Stassfurt, Germany|Steinborn, Straubing, DE /ID# 33594, Straubing, Germany|Cavcic, Stuttgart, DE /ID# 126015, Stuttgart, Germany|Leitz, Stuttgart, DE /ID# 126018, Stuttgart, Germany|Leitz, Stuttgart, DE /ID# 72023, Stuttgart, Germany|Bauer, Stuttgart, DE /ID# 53683, Stuttgart, Germany|Flegl MD Stuttgart Germany /ID# 50824, Stuttgart, Germany|Praxis. Dr. Koehler /ID# 142000, Suhl, Germany|Krusche&Mai,Sulzbach-Rosenberg /ID# 33616, Sulzbach-rosenberg, Germany|Jager/Landwehr, Sulzbach, DE /ID# 33615, Sulzbach, Germany|Kirchhoff, Telgte, DE /ID# 50831, Telgte, Germany|Lueg, Teltow, DE /ID# 33617, Teltow, Germany|Cyrulies, Teterow, DE /ID# 33621, Teterow, Germany|Frank, Tirschenreuth, DE /ID# 33622, Tirschenreuth, Germany|Meyer, Tornesch, DE /ID# 33626, Tornesch, Germany|Pleier/Weidenbach, Traunstein, /ID# 33627, Traunstein, Germany|Brisch, Trier, DE /ID# 60589, Trier, Germany|Universitatsklinikum Tubingen /ID# 33631, Tuebingen, Germany|Universitatsklinikum Tubingen /ID# 81278, Tuebingen, Germany|Braun, Ueberlingen, DE /ID# 33638, Ueberlingen, Germany|Winkler-Gyulay, Unna, DE /ID# 48528, Unna, Germany|Giesenberg, Varel, DE /ID# 33728, Varel, Germany|Loetzsch, Varel, DE /ID# 50845, Varel, Germany|Jasnoch/Kock/Borrosch, Vechta, /ID# 145770, Vechta, Germany|Jasnoch/Kock/Borrosch, Vechta, /ID# 33730, Vechta, Germany|Jasnoch/Kock/Borrosch, Vechta, /ID# 60605, Vechta, Germany|Steiner, Viersen, DE /ID# 141547, Viersen, Germany|Steiner, Viersen, DE /ID# 99848, Viersen, Germany|Praxis Dr. Czech /ID# 145765, Villingen-schwenningen, Germany|Fischer, Vilshofen, DE /ID# 148252, Vilshofen, Germany|Fischer, Vilshofen, DE /ID# 50823, Vilshofen, Germany|Foss, Wadern, DE /ID# 33738, Wadern, Germany|Barnikol, Waltershausen, DE /ID# 35401, Waltershausen, Germany|Funke, Waltrop, DE /ID# 33739, Waltrop, Germany|Hoos, Wedel, DE /ID# 33745, Wedel, Germany|Billmann-Krutmann, Wegberg, DE /ID# 90958, Wegberg, Germany|Pausch, Weiden, DE /ID# 60606, Weiden, Germany|Reindl, Weimar, DE /ID# 60607, Weimar, Germany|Asklepios Krankenh Weissenfels /ID# 138206, Weissenfels, Germany|Fiedler, Weissenfels, DE /ID# 33752, Weissenfels, Germany|Pfennig, Werdau, DE /ID# 48459, Werdau, Germany|Roehrborn, Werl, DE /ID# 33754, Werl, Germany|Dr. Barbara Kempkes, Werne /ID# 118540, Werne, Germany|Jansen & Weersch, Wesel, DE /ID# 33756, Wesel, Germany|Schmeel, Wesseling, DE /ID# 81303, Wesseling, Germany|Uszynska-Jast, Wetter, DE /ID# 33758, Wetter, Germany|Kaempfer, Wetzlar, DE /ID# 33759, Wetzlar, Germany|Paul, Wetzlar, DE /ID# 50855, Wetzlar, Germany|Moeller, Wiesbaden, DE /ID# 50852, Wiesbaden, Germany|Hasselbusch, Wiesmoor, DE /ID# 33766, Wiesmoor, Germany|Buttgereit/Stiller, Wildau, DE /ID# 33767, Wildau, Germany|Hutschenreuther, Wilhelmshaven /ID# 33768, Wilhelmshaven, Germany|Gajda, Wilhelmshaven, DE /ID# 138261, Wilhelmshaven, Germany|Maronde, Winsen, DE /ID# 53707, Winsen (luhe), Germany|Dr. Martin Gruener, Wipperfuer /ID# 118538, Wipperfuerth, Germany|Merk, Lutherstadt Wittenberg, /ID# 126020, Wittenberg, Germany|Klein, Witten, DE /ID# 33777, Witten, Germany|Hoffmann, Witten, DE /ID# 35417, Witten, Germany|Suess, Wittlich, Germany /ID# 33629, Wittlich, Germany|Roos, Wittmund, DE /ID# 118542, Wittmund, Germany|Metz, Wittstock, DE /ID# 33781, Wittstock, Germany|Franz, Wolfenbuettel, DE /ID# 33782, Wolfenbuettel, Germany|Rowold, Wolfenbuettel, DE /ID# 48467, Wolfenbuettel, Germany|Rinke, Wolmirstedt, DE /ID# 48532, Wolmirstedt, Germany|Beilner-Tack, Wuerzburg, DE /ID# 67947, Wuerzburg, Germany|Schubert&Frank&Konrad&Eggert /ID# 33715, Wuerzburg, Germany|Schubert&Frank&Konrad&Eggert /ID# 48526, Wuerzburg, Germany|Schubert&Frank&Konrad&Eggert /ID# 67961, Wuerzburg, Germany|Hamm & Kinkelin, Wuerzburg, DE /ID# 33714, Wuerzburg, Germany|Fuge-Dierking, Wuppertal, DE /ID# 33720, Wuppertal, Germany|Gleissner/Sadlo, Wuppertal, DE /ID# 108919, Wuppertal, Germany|Gleissner/Sadlo, Wuppertal, DE /ID# 48434, Wuppertal, Germany|Huebinger, Wuppertal, DE /ID# 53700, Wuppertal, Germany|Praxis Dr. Schock-Skasa /ID# 148246, Wuppertal, Germany|Bartenberg, Wuppertal, DE /ID# 81273, Wuppertal, Germany|Albrecht, Wurzen, DE /ID# 35422, Wurzen, Germany|Franz-Reichel, Zehdenick, DE /ID# 33860, Zehdenick, Germany|Weber, Zeulenroda, DE /ID# 50867, Zeulenroda, Germany|Rudolph, Zschopau, DE /ID# 166129, Zschopau, Germany|Rudolph, Zschopau, DE /ID# 35424, Zschopau, Germany|Mischke, Zwickau, DE /ID# 35430, Zwickau, Germany|Heinrich Braun Klinik Zwickau /ID# 50849, Zwickau, Germany|Mende-Dietz, Zwickau, DE /ID# 35426, Zwickau, Germany|Praxis MVZ Gefaesszentrum Zwic /ID# 145766, Zwickau, Germany|Gebhardt, Zwickau, DE /ID# 35432, Zwickau, Germany|Junghaenel, Zwickau, DE /ID# 35428, Zwickau, Germany",,"https://ClinicalTrials.gov/show/NCT01077232"
605,"NCT01077128","Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab",,"Completed","Has Results","Psoriasis",,"Mean Change of Dermatology Life Quality Index (DLQI) Scores|Percentage of Patients Who Experienced an Improvement in Disease Severity as Determined by the Physician's Global Assessment of Disease Severity (PGA) Scores|Mean Change in the Dermatology Life Quality Index (DLQI) Score by Physician's Global Assessment of Disease Severity (PGA) Response Groups and by Geographical Region|Percentage of Patients Reporting ""No Problem"" on the European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D)|Mean Change From Baseline of European Quality of Life-5 Dimensions Health Questionnaire (EQ-5D) Visual Analogue Scale (VAS) Scores|Assessment of Long Term Use and Safety of Adalimumab as Prescribed by the Dermatologist in a Normal Clinical Setting and in Accordance With the Terms of the European Marketing Authorization","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Time Perspective: Prospective","P11-984","September 2009","September 2012","September 2012","February 26, 2010","February 21, 2014","February 21, 2014","Site Reference ID/Investigator# 43746, Agrinio, Greece|Site Reference ID/Investigator# 30197, Amaliada, Greece|Site Reference ID/Investigator# 30039, Argos, Greece|Site Reference ID/Investigator# 29903, Argyroupoli, Greece|Site Reference ID/Investigator# 29819, Athens, Greece|Site Reference ID/Investigator# 29949, Athens, Greece|Site Reference ID/Investigator# 30804, Athens, Greece|Site Reference ID/Investigator# 30806, Athens, Greece|Site Reference ID/Investigator# 38324, Athens, Greece|Site Reference ID/Investigator# 22385, Athens, Greece|Site Reference ID/Investigator# 29826, Athens, Greece|Site Reference ID/Investigator# 29966, Athens, Greece|Site Reference ID/Investigator# 29991, Athens, Greece|Site Reference ID/Investigator# 30106, Athens, Greece|Site Reference ID/Investigator# 30107, Athens, Greece|Site Reference ID/Investigator# 30181, Athens, Greece|Site Reference ID/Investigator# 30470, Athens, Greece|Site Reference ID/Investigator# 30086, Chania, Crete, Greece|Site Reference ID/Investigator# 43744, Chania, Crete, Greece|Site Reference ID/Investigator# 30794, Crete, Greece|Site Reference ID/Investigator# 29937, Crete, Greece|Site Reference ID/Investigator# 29959, Crete, Greece|Site Reference ID/Investigator# 29969, Crete, Greece|Site Reference ID/Investigator# 38334, Drama, Greece|Site Reference ID/Investigator# 30801, Florina, Greece|Site Reference ID/Investigator# 29919, Giannitsa, Greece|Site Reference ID/Investigator# 30202, Giannitsa, Greece|Site Reference ID/Investigator# 29970, Glyfada, Greece|Site Reference ID/Investigator# 30013, Glyfada, Greece|Site Reference ID/Investigator# 29823, Glyfada, Greece|Site Reference ID/Investigator# 30193, Halandri, Greece|Site Reference ID/Investigator# 30083, Kalamaria, Greece|Site Reference ID/Investigator# 30143, Kallithea, Greece|Site Reference ID/Investigator# 47262, Katerini, Greece|Site Reference ID/Investigator# 38329, Keratsini, Greece|Site Reference ID/Investigator# 30108, Kolonaki, Greece|Site Reference ID/Investigator# 30009, Kosmos, Greece|Site Reference ID/Investigator# 38323, Larissa, Greece|Site Reference ID/Investigator# 38340, Larissa, Greece|Site Reference ID/Investigator# 29822, Livadeia, Greece|Site Reference ID/Investigator# 30180, Makri, Greece|Site Reference ID/Investigator# 29834, Mitilini, Greece|Site Reference ID/Investigator# 30469, Mitilini, Greece|Site Reference ID/Investigator# 38326, N.Heraklion, Greece|Site Reference ID/Investigator# 30032, Neapoli, Greece|Site Reference ID/Investigator# 30104, Pagkrati, Greece|Site Reference ID/Investigator# 29817, Patras, Greece|Site Reference ID/Investigator# 29967, Peiraius, Greece|Site Reference ID/Investigator# 38327, Peristeri, Greece|Site Reference ID/Investigator# 30109, Petralona, Greece|Site Reference ID/Investigator# 29824, Smyrni, Greece|Site Reference ID/Investigator# 38325, Thessaloniki, Greece|Site Reference ID/Investigator# 30769, Thessaloniki, Greece|Site Reference ID/Investigator# 30170, Thessaloniki, Greece|Site Reference ID/Investigator# 38331, Thessaloniki, Greece|Site Reference ID/Investigator# 38332, Thessaloniki, Greece|Site Reference ID/Investigator# 38333, Thessaloniki, Greece|Site Reference ID/Investigator# 38335, Thessaloniki, Greece|Site Reference ID/Investigator# 38337, Thessaloniki, Greece|Site Reference ID/Investigator# 30203, Vari, Greece|Site Reference ID/Investigator# 29921, Volos, Greece",,"https://ClinicalTrials.gov/show/NCT01077128"
606,"NCT01076205","Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis","AGIL","Completed","Has Results","Rheumatoid Arthritis",,"Change From Baseline in Number of Missed Working Days Due to Sick Leave in the Past 6 Months|Percentage of Participants With > 5 Missed Working Days Due to Sick Leave in the Past 6 Months|Change From Baseline in Work Productivity and Activity Impairment: Absenteeism|Change From Baseline in Work Productivity and Activity Impairment: Presenteeism|Change From Baseline in Work Productivity and Activity Impairment: Total Work Productivity Impairment|Change From Baseline in Work Productivity and Activity Impairment: Total Activity Impairment|Change From Baseline in Work Activity Index (WAI)|Change From Baseline in Disease Activity Score - 28 Joints (DAS28)|Change From Baseline in Tender Joint Count|Change From Baseline in Swollen Joint Count|Change From Baseline in Erythrocyte Sedimentation Rate|Change From Baseline in C-reactive Protein|Change From Baseline in Health-Assessment Questionnaire-Disability Index (HAQ-DI)|EuroQol-5 Dimensions (EQ-5D) Scores|Change From Baseline in Euroqol Visual Analog Scale (VAS)|Number of Physician Visits in Past 6 Months|Number of Inpatient Hospitalizations in Past 6 Months|Duration of Inpatient Hospitalizations in Past 6 Months|Number of Days With Impairment of Non-Occupational Activities in Past 6 Months|Duration of Morning Stiffness|Participant's Assessment of Pain|Participant's Assessment of Fatigue|Percentage of Participants Taking Concomitant RA Medications|Patient Assessment of Adalimumab Therapy","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"7229","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","P11-973","January 12, 2009","September 14, 2017","September 14, 2017","February 26, 2010","February 7, 2019","February 7, 2019",,"""Study Protocol and Statistical Analysis Plan: original"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01076205/Prot_SAP_000.pdf|""Study Protocol: amendment"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT01076205/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01076205"
607,"NCT01076192","Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)","PROMISE","Completed","Has Results","Moderate-to-severe Chronic Plaque Psoriasis",,"Mean Change From Baseline in Psoriasis Area and Severity Index (PASI)|Percentage of Participants Achieving a Reduction in PASI Score of at Least 50% (PASI 50)|Percentage of Participants Achieving a Reduction in PASI Score of at Least 75% (PASI 75)|Percentage of Participants Achieving a Reduction in PASI Score of at Least 90% (PASI 90)|Percentage of Participants Achieving a Reduction in PASI Score of 100% (PASI 100)|Mean Change From Baseline in Body Surface Area (BSA) Affected|Percentage of Participants With Improvement From Baseline in Physician's Global Assessment (PGA)|Mean Change From Baseline in Dermatology Life Quality Index (DLQI)|Mean Change From Baseline in EuroQol Quality of Life Questionnaire (EQ-5D) Visual Analogue Scale (VAS)|Mean Change From Baseline in Percentage of Lost Productivity Assessed Using Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP)|Number of Participants With Adverse Events of Special Interest (AESIs)|Number of Participants With Serious Adverse Events (SAEs)","AbbVie (prior sponsor, Abbott)|IMS Health|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"547","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P11-067","February 2010","September 2014","September 2014","February 26, 2010","January 6, 2016","January 6, 2016",,,"https://ClinicalTrials.gov/show/NCT01076192"
608,"NCT01076179","Kaletra in Combination With Antiretroviral Agents","PROTEKT","Completed","Has Results","Human Immunodeficiency Virus",,"Prevalence of Adverse Events (Weeks 0-144), Per Event|Prevalence of Adverse Events (Weeks 0-144), Per Participant|Change From Baseline in Absolute Cluster of Differentiation 4 (CD4) Cell Count|Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, Modified Intent-to-Treat Analysis|Percentage of Participants Achieving Absolute CD4 Cell Count Increases From Baseline of ≥ 100 Cells/μL at All Time Points, As Treated Analysis|Time to CD4 Cell Count Increase From Baseline of ≥ 100/ Cells/μL|Number of Participants With Lopinavir (LPV) Resistance at Baseline|Number of Participants With LPV Resistance During Follow-Up|Number of Participants With Protease Inhibitor (PI) Resistance at Baseline|Number of Participants With PI Resistance During Follow-Up|Number of Participants With INI Resistance at Baseline|Number of Participants With INI Resistance During Follow-Up|Number of Participants With NNRTI Resistance at Baseline|Number of Participants With NNRTI Resistance During Follow-Up|Number of Participants With Nucleoside Analog Reverse-Transcriptase Inhibitor (NRTI) Resistance at Baseline|Number of Participants With NRTI Resistance During Follow-Up|Number of Participants With HIV-1 Coreceptor Tropism at Baseline|Number of Participants With HIV-1 Coreceptor Tropism During Follow-up","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"502","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P11-021","September 2008","January 2016","January 2016","February 26, 2010","May 19, 2017","May 19, 2017",,,"https://ClinicalTrials.gov/show/NCT01076179"
609,"NCT01075191","Kaletra: Therapy With Double Protease Inhibitors",,"Completed","Has Results","Human Immunodeficiency Virus",,"Percentage of Participants With Human Immunodeficiency Virus -1 Ribonucleic Acid (HIV-1 RNA) <50 Copies/mL|Change From Baseline in Absolute CD4 Cell Count|Change From Baseline in Relative CD4 Cell Count|Change From Baseline in Absolute CD8 Cell Count|Change From Baseline in Relative CD8 Cell Count|Change From Baseline in CD4/CD8 T-cell Ratio","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"65","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P05-103","January 2004","September 2011","September 2011","February 25, 2010","October 30, 2012","January 18, 2013","Site Reference ID/Investigator# 48283, Berlin, Germany|Site Reference ID/Investigator# 28131, Berlin, Germany|Site Reference ID/Investigator# 66422, Berlin, Germany|Site Reference ID/Investigator# 28123, Berlin, Germany|Site Reference ID/Investigator# 28109, Berlin, Germany|Site Reference ID/Investigator# 28115, Dortmund, Germany|Site Reference ID/Investigator# 28124, Frankfurt, Germany|Site Reference ID/Investigator# 28127, Frankfurt, Germany|Site Reference ID/Investigator# 28119, Frankfurt, Germany|Site Reference ID/Investigator# 5318, Krefeld, Germany|Site Reference ID/Investigator# 28112, Ludwigshafen, Germany|Site Reference ID/Investigator# 28111, Muenster, Germany|Site Reference ID/Investigator# 28129, Muenster, Germany|Site Reference ID/Investigator# 28118, Munich, Germany|Site Reference ID/Investigator# 28113, Munich, Germany|Site Reference ID/Investigator# 28133, Stuttgart, Germany|Site Reference ID/Investigator# 28126, Wuppertal, Germany",,"https://ClinicalTrials.gov/show/NCT01075191"
610,"NCT01074008","A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072","Champion2","Completed","Has Results","Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1","Drug: ABT-450|Drug: ABT-072|Drug: ABT-333|Drug: Ritonavir|Drug: Peginterferon alpha-2a|Drug: Ribavirin|Other: Placebo","Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment|Maximum Plasma Concentration (Cmax) of ABT-450|Time to Maximum Plasma Concentration (Tmax) of ABT-450|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450|Maximum Plasma Concentration (Cmax) of Ritonavir|Time to Maximum Plasma Concentration (Tmax) of Ritonavir|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir|Maximum Plasma Concentration (Cmax) of ABT-072|Time to Maximum Plasma Concentration (Tmax) of ABT-072|Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-072|Maximum Plasma Concentration (Cmax) of ABT-333|Time to Maximum Plasma Concentration (Tmax) of ABT-333|Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333|Percentage of Participants With Rapid Virologic Response (RVR) at Week 4|Percentage of Participants With Partial Early Virologic Response (EVR) at Week 12|Percentage of Participants With Complete Early Virologic Response (cEVR) at Week 12","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M11-602","March 2010","June 2011","January 2012","February 24, 2010","January 8, 2015","January 8, 2015","Site Reference ID/Investigator# 23392, Phoenix, Arizona, United States|Site Reference ID/Investigator# 23370, Anaheim, California, United States|Site Reference ID/Investigator# 23387, La Jolla, California, United States|Site Reference ID/Investigator# 23388, Los Angeles, California, United States|Site Reference ID/Investigator# 23371, Aurora, Colorado, United States|Site Reference ID/Investigator# 23369, Orlando, Florida, United States|Site Reference ID/Investigator# 26362, Orlando, Florida, United States|Site Reference ID/Investigator# 23373, Chicago, Illinois, United States|Site Reference ID/Investigator# 24908, Chicago, Illinois, United States|Site Reference ID/Investigator# 23381, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 23372, Baton Rouge, Louisiana, United States|Site Reference ID/Investigator# 24710, New Orleans, Louisiana, United States|Site Reference ID/Investigator# 23391, Baltimore, Maryland, United States|Site Reference ID/Investigator# 23377, Detroit, Michigan, United States|Site Reference ID/Investigator# 24909, St. Paul, Minnesota, United States|Site Reference ID/Investigator# 35842, New York, New York, United States|Site Reference ID/Investigator# 23379, New York, New York, United States|Site Reference ID/Investigator# 23375, Chapel Hill, North Carolina, United States|Site Reference ID/Investigator# 23385, Durham, North Carolina, United States|Site Reference ID/Investigator# 23376, Dallas, Texas, United States|Site Reference ID/Investigator# 24891, Houston, Texas, United States|Site Reference ID/Investigator# 23382, San Antonio, Texas, United States|Site Reference ID/Investigator# 24715, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 25463, Seattle, Washington, United States|Site Reference ID/Investigator# 23383, Madison, Wisconsin, United States|Site Reference ID/Investigator# 23363, Ponce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT01074008"
611,"NCT01073462","Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years",,"Completed","Has Results","Secondary Hyperparathyroidism|Chronic Kidney Disease Stage V|Cardiac Morbidity",,"Percentage of Participants Achieving an Intact Parathyroid Hormone (iPTH) Level Within the Target Range|Percentage of Participants With Hypercalcemia|Percentage of Participants With Hyperphosphatemia|Percentage of Participants With at Least a 30%-Reduction in iPTH Levels|Percentage of Participants With at Least 30%-Reduction in iPTH Levels in at Least Two Consecutive Measurements|Percentage of Participants With at Least One Concomitant Medication|Percentage of Participants Experiencing Hospitalization|Number of Participants With Cardiac Disease Progression","AbbVie (prior sponsor, Abbott)|Assign Data Management and Biostatistics GmbH|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"67","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","P10-680","December 2008","June 2013","June 2013","February 23, 2010","July 10, 2014","July 10, 2014","Site Reference ID/Investigator# 27447, Graz, Austria|Site Reference ID/Investigator# 49182, Graz, Austria|Site Reference ID/Investigator# 27483, Graz, Austria|Site Reference ID/Investigator# 52742, Graz, Austria|Site Reference ID/Investigator# 27487, Innsbruck, Austria|Site Reference ID/Investigator# 36983, Linz, Austria|Site Reference ID/Investigator# 27484, Linz, Austria|Site Reference ID/Investigator# 27485, Rottenmann, Austria|Site Reference ID/Investigator# 27446, Vienna, Austria|Site Reference ID/Investigator# 53469, Vienna, Austria|Site Reference ID/Investigator# 27482, Vienna, Austria|Site Reference ID/Investigator# 10981, Vienna, Austria",,"https://ClinicalTrials.gov/show/NCT01073462"
612,"NCT01064856","Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)",,"Completed","Has Results","Peripheral Spondyloarthritis","Biological: Adalimumab|Biological: Placebo","Percentage of Responders According to the Composite Peripheral SpA Response Criteria (PSpARC 40) at Week 12|Number of Participants With Adverse Events|Change From Baseline in Physician Global Assessment (PGA) of Disease Activity at Week 12|Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 12|Change From Baseline in Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S) Total at Week 12|Change From Baseline in Short Form-36 Health Status Survey™ Version 2 (SF-36™V2) Physical Component Score (PCS) at Week 12|Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 12|Change From Baseline in Leeds Enthesitis Index at Week 12|Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Score at Week 12|Change From Baseline in Dactylitis at Week 12|Change From Baseline in Tender Joint Count (TJC) at Week 12|Change From Baseline in Swollen Joint Count (SJC) at Week 12|Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-883|2009-014567-39","February 2010","August 2011","May 2014","February 9, 2010","November 25, 2016","November 25, 2016",,,"https://ClinicalTrials.gov/show/NCT01064856"
613,"NCT01063816","A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors",,"Completed","No Results Available","Advanced Solid Tumors","Drug: veliparib (ABT-888)|Drug: carboplatin|Drug: gemcitabine","Determine the maximum tolerated dose and recommended Phase 2 dose|Pharmacokinetics Area Under the Curve (AUC)|Safety assessment: Electrocardiogram|Safety assessment: Clinical Laboratory Tests|Physical exam including vital signs|Safety assessment: Adverse event assessments|Tumor assessment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","79","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-758","January 2010","August 2016","August 2016","February 5, 2010",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT01063816"
614,"NCT01038609","Hydrocodone/Acetaminophen for Acute Pain Following Bunionectomy",,"Completed","Has Results","Pain","Drug: Hydrocodone/Acetaminophen Extended Release|Drug: Acetaminophen|Drug: Morphine Extended Release|Drug: Placebo","Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analogue Scale (VAS)|TOTPAR (Total Pain Relief)|Participant's Global Assessment of Study Drug|Time to Perceptible and Meaningful Pain Relief|Participants With Adverse Events (AEs)|Number of Participants With Vital Signs Values Meeting Potentially Clinically Significant Criteria|Number of Participants With Chemistry Values Meeting Potentially Clinically Significant Criteria","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","M12-058","December 2009","May 2010","May 2010","December 24, 2009","March 7, 2014","April 8, 2014","Site Reference ID/Investigator# 26223, Peoria, Arizona, United States|Site Reference ID/Investigator# 26302, Austin, Texas, United States|Site Reference ID/Investigator# 26303, San Marcos, Texas, United States|Site Reference ID/Investigator# 26304, West Jordan, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01038609"
615,"NCT01020487","Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD)",,"Completed","Has Results","Chronic Kidney Disease Stage 3 and 4","Drug: Paricalcitol|Drug: Placebo","Part 1: Paricalcitol Maximum Observed Plasma Concentration (Cmax)|Part 1: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)|Part 2: Percentage of Participants Achieving Two Consecutive Reductions at Least 30% From Baseline in iPTH|Part 2: Percentage of Participants Achieving a Final iPTH Within KDOQI Target Ranges|Part 2: Change From Baseline in iPTH to Each Post-baseline Visit|Part 2: Percentage of Participants Achieving Final Calcium Levels Within KDOQI Target Ranges|Part 2: Percentage of Participants Achieving Final Phosphorus Levels Within KDOQI Target Ranges|Part 2: Change From Baseline in First Morning Void (FMV) Urinary Albumin to Creatinine Ratio (UACR)","AbbVie (prior sponsor, Abbott)|AbbVie","All","10 Years to 16 Years   (Child)","Phase 3","47","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-149|2010-019439-37","February 2010","May 2014","December 2014","November 24, 2009","March 29, 2017","July 2, 2018",,,"https://ClinicalTrials.gov/show/NCT01020487"
616,"NCT01018875","Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: ABT-288|Drug: donepezil|Drug: placebo","ADAS-cog: Alzheimer's Disease Assessment Scale - Cognition portion|MMSE: Mini Mental Status Exam|NPI: Neuropsychiatric Inventory|ADCS-ADL: Alzheimer's Disease Cooperative Study|CIBIC-Plus: Clinician Interview-Baed Impression of Change - plus","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-822|2009-010704-29","December 2009","February 2011","February 2011","November 24, 2009",,"June 6, 2018","Site Reference ID/Investigator# 22687, Kazan, Russian Federation|Site Reference ID/Investigator# 22636, Moscow, Russian Federation|Site Reference ID/Investigator# 23702, Moscow, Russian Federation|Site Reference ID/Investigator# 22689, Saratov, Russian Federation|Site Reference ID/Investigator# 22635, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22633, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22637, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22632, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22634, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 24563, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 22630, Dnipropetrovs'k, Ukraine|Site Reference ID/Investigator# 22625, Donetsk, Ukraine|Site Reference ID/Investigator# 22624, Glevakha, Ukraine|Site Reference ID/Investigator# 22629, Kharkiv, Ukraine|Site Reference ID/Investigator# 24565, Kherson, Ukraine|Site Reference ID/Investigator# 24566, Kiev, Ukraine|Site Reference ID/Investigator# 22622, Kiev, Ukraine|Site Reference ID/Investigator# 22623, Kiev, Ukraine|Site Reference ID/Investigator# 22628, Lugansk, Ukraine|Site Reference ID/Investigator# 43143, Odessa, Ukraine|Site Reference ID/Investigator# 22627, Poltava, Ukraine",,"https://ClinicalTrials.gov/show/NCT01018875"
617,"NCT01009073","A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects",,"Completed","No Results Available","Solid Tumors","Drug: ABT-263|Drug: erlotinib|Drug: irinotecan (3-week schedule)|Drug: irinotecan (weekly schedule)","Arm A|Arm B|Arm C","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M11-958","October 2009","June 2013","June 2013","November 6, 2009",,"November 20, 2017","Site Reference ID/Investigator# 37463, Santa Monica, California, United States|Site Reference ID/Investigator# 36342, Detroit, Michigan, United States|Site Reference ID/Investigator# 24046, San Antonio, Texas, United States|Site Reference ID/Investigator# 44917, Tacoma, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01009073"
618,"NCT00948909","Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease",,"Completed","No Results Available","Alzheimer's Disease","Drug: Placebo|Drug: ABT-126|Drug: donepezil","ADAS-Cog - Alzheimer's Disease Assessment Scale Cognition portion|MMSE, QoL-AD, CIBIC-plus, NPI, CSDD, ADAS-Cog (13 item) and ADCS-ADL. Note: Acronyms are fully defined in the area titled Detailed Description.","AbbVie (prior sponsor, Abbott)|AbbVie","All","55 Years to 90 Years   (Adult, Older Adult)","Phase 2","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-984|2009-011424-64","October 2009","November 2010","November 2010","July 29, 2009",,"January 31, 2013","Site Reference ID/Investigator# 19904, Fresno, California, United States|Site Reference ID/Investigator# 23025, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 19905, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 22944, Pleven, Bulgaria|Site Reference ID/Investigator# 22942, Plovdiv, Bulgaria|Site Reference ID/Investigator# 22945, Sofia, Bulgaria|Site Reference ID/Investigator# 22946, Sofia, Bulgaria|Site Reference ID/Investigator# 20276, Litomerice, Czech Republic|Site Reference ID/Investigator# 20273, Plzen, Czech Republic|Site Reference ID/Investigator# 20274, Prague 10, Czech Republic|Site Reference ID/Investigator# 20272, Prague 2, Czech Republic|Site Reference ID/Investigator# 20701, Prague 5, Czech Republic|Site Reference ID/Investigator# 23625, Bratislava, Slovakia|Site Reference ID/Investigator# 23624, Bratislava, Slovakia|Site Reference ID/Investigator# 23622, Michalovce, Slovakia|Site Reference ID/Investigator# 23942, Rimavska Sobota, Slovakia|Site Reference ID/Investigator# 20267, Belville, South Africa|Site Reference ID/Investigator# 20266, Cape Town, South Africa|Site Reference ID/Investigator# 20261, Durban, South Africa|Site Reference ID/Investigator# 21682, George, South Africa|Site Reference ID/Investigator# 20265, Johannesburg, South Africa|Site Reference ID/Investigator# 20271, Port Elizabeth, South Africa|Site Reference ID/Investigator# 20263, Richards Bay, South Africa|Site Reference ID/Investigator# 20187, Blackburn, United Kingdom|Site Reference ID/Investigator# 20183, Bradford, United Kingdom|Site Reference ID/Investigator# 20191, Crowborough, United Kingdom|Site Reference ID/Investigator# 20184, Glasgow, United Kingdom|Site Reference ID/Investigator# 20190, London, United Kingdom|Site Reference ID/Investigator# 20192, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00948909"
619,"NCT00939003","Study of Adalimumab in Patients With Axial Spondyloarthritis",,"Completed","Has Results","Axial Spondyloarthritis","Biological: Adalimumab|Biological: Placebo|Biological: Open-label Adalimumab","Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 40 Response|Number of Participants Achieving an Assessment of Spondyloarthritis International Society (ASAS) 20 Response|Number of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response|Change From Baseline in Short Form-36 (SF-36) Physical Component Summary Score|Number of Participants Achieving ASAS Partial Remission|Number of Participants Achieving an ASAS5/6 Response|Change From Baseline in Disability Index of Health Assessment Questionnaire Modified for the Spondyloarthropathies (HAQ-S)|Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP)|Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Score for Sacroiliac Joints|Change From Baseline in SPARCC MRI Score for the Spine","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","192","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-791|2009-010643-14","July 2009","February 2011","August 2013","July 14, 2009","March 6, 2012","September 9, 2014","Site Reference ID/Investigator# 21250, Birmingham, Alabama, United States|Site Reference ID/Investigator# 21249, Colorado Springs, Colorado, United States|Site Reference ID/Investigator# 21245, Denver, Colorado, United States|Site Reference ID/Investigator# 21246, Wheaton, Maryland, United States|Site Reference ID/Investigator# 26582, Duncansville, Pennsylvania, United States|Site Reference ID/Investigator# 21241, Wyomissing, Pennsylvania, United States|Site Reference ID/Investigator# 21243, Dallas, Texas, United States|Site Reference ID/Investigator# 21248, Houston, Texas, United States|Site Reference ID/Investigator# 21247, Seattle, Washington, United States|Site Reference ID/Investigator# 22342, Brisbane, Australia|Site Reference ID/Investigator# 21223, Kogarah, Australia|Site Reference ID/Investigator# 21222, Maroochydore, Australia|Site Reference ID/Investigator# 21225, Genk, Belgium|Site Reference ID/Investigator# 21224, Ghent, Belgium|Site Reference ID/Investigator# 26544, Gilly, Belgium|Site Reference ID/Investigator# 27382, Merksem, Belgium|Site Reference ID/Investigator# 21229, Edmonton, Canada|Site Reference ID/Investigator# 21226, Sainte-Foy, Quebec, Canada|Site Reference ID/Investigator# 21227, St. John's, Canada|Site Reference ID/Investigator# 21228, Toronto, Canada|Site Reference ID/Investigator# 21231, Brno, Czech Republic|Site Reference ID/Investigator# 26882, Pardubice, Czech Republic|Site Reference ID/Investigator# 21230, Prague 2, Czech Republic|Site Reference ID/Investigator# 26883, Uherske Hradiste, Czech Republic|Site Reference ID/Investigator# 21263, Boulogne Billancourt, France|Site Reference ID/Investigator# 21262, Chambray-les-Tour, France|Site Reference ID/Investigator# 21261, Orleans, France|Site Reference ID/Investigator# 22343, Paris Cedex 14, France|Site Reference ID/Investigator# 21266, Berlin, Germany|Site Reference ID/Investigator# 21267, Erlangen, Germany|Site Reference ID/Investigator# 21264, Herne, Germany|Site Reference ID/Investigator# 21265, Munich, Germany|Site Reference ID/Investigator# 21285, Amsterdam, Netherlands|Site Reference ID/Investigator# 21284, Leiden, Netherlands|Site Reference ID/Investigator# 21282, A Coruna, Spain|Site Reference ID/Investigator# 21283, Barcelona, Spain|Site Reference ID/Investigator# 21281, Cordoba, Spain|Site Reference ID/Investigator# 21289, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00939003"
620,"NCT00935311","Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction",,"Completed","Has Results","Pain","Drug: ABT-712 Extended-release|Drug: Hydrocodone/Acetaminophen Immediate-release|Drug: Placebo","Sum of Pain Intensity Difference (SPID) Using the Pain Intensity Visual Analog Scale (VAS)|TOTPAR (Total Pain Relief)|Time to First Rescue Medication|Participants With Adverse Events (AEs)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M11-063","June 2009","August 2009","August 2009","July 9, 2009","March 7, 2014","April 8, 2014","Site Reference ID/Investigator# 20745, Austin, Texas, United States|Site Reference ID/Investigator# 20743, San Marcos, Texas, United States|Site Reference ID/Investigator# 20744, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT00935311"
621,"NCT00920764","A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors",,"Completed","No Results Available","Chronic Kidney Disease|Diabetic Nephropathy","Drug: Placebo for Atrasentan 0.2 mg/mL solution|Drug: 0.25 mg Atrasentan QD|Drug: 0.75 mg Atrasentan QD|Drug: 1.75 mg Atrasentan QD","Mean change from baseline to each post-baseline observation on UACR over the course of treatment period versus standard of care|Proportion of subjects achieving at least a 25% reduction in final UACR levels from baseline|Proportion of subjects achieving at least a 40% reduction in final UACR levels from baseline|Change from baseline to the final value in UACR, estimated glomerular filtration rate (eGFR), Neutrophil Gelatinase-Associated Lipocalin (NGAL)|Change from baseline to each weekly measurement in NGAL","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","92","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-815","June 2009","April 2010","May 2010","June 15, 2009",,"June 6, 2018","Site Reference ID/Investigator# 19386, Tempe, Arizona, United States|Site Reference ID/Investigator# 25043, Azusa, California, United States|Site Reference ID/Investigator# 23308, Los Angeles, California, United States|Site Reference ID/Investigator# 25430, Los Angeles, California, United States|Site Reference ID/Investigator# 20421, San Diego, California, United States|Site Reference ID/Investigator# 22442, San Diego, California, United States|Site Reference ID/Investigator# 21061, Whittier, California, United States|Site Reference ID/Investigator# 16572, Yuba City, California, United States|Site Reference ID/Investigator# 26142, Coral Gables, Florida, United States|Site Reference ID/Investigator# 16567, Hudson, Florida, United States|Site Reference ID/Investigator# 16577, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 25242, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 16569, Rockville, Maryland, United States|Site Reference ID/Investigator# 16574, Omaha, Nebraska, United States|Site Reference ID/Investigator# 20221, Buffalo, New York, United States|Site Reference ID/Investigator# 16576, Greenville, North Carolina, United States|Site Reference ID/Investigator# 16573, Morehead City, North Carolina, United States|Site Reference ID/Investigator# 26143, Statesville, North Carolina, United States|Site Reference ID/Investigator# 19383, Bethlehem, Pennsylvania, United States|Site Reference ID/Investigator# 26365, Orangeburg, South Carolina, United States|Site Reference ID/Investigator# 16571, San Antonio, Texas, United States|Site Reference ID/Investigator# 16566, San Antonio, Texas, United States|Site Reference ID/Investigator# 19384, San Antonio, Texas, United States|Site Reference ID/Investigator# 24542, Fairfax, Virginia, United States|Site Reference ID/Investigator# 16564, Las Piedras, Puerto Rico|Site Reference ID/Investigator# 19381, Ponce, Puerto Rico|Site Reference ID/Investigator# 16563, San Juan, Puerto Rico|Site Reference ID/Investigator# 16562, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00920764"
622,"NCT00878449","A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer",,"Completed","No Results Available","Solid Tumors","Drug: ABT-263|Drug: etoposide/cisplatin","Assess the safety profile of ABT-263 when administered in combination with etoposide/cisplatin in subjects with Cancer.|Characterize the pharmacokinetics of ABT-263 when administered in combination with etoposide/cisplatin .|Determine the maximum tolerable dose (MTD) of ABT-263 when administered in combination with etoposide/cisplatin.|Determine the recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with etoposide/cisplatin.|Evaluate preliminary data regarding progression free survival (PFS).|Evaluate preliminary data regarding objective response rate (ORR).|Evaluate preliminary data regarding time to tumor progression (TTP).|Evaluate preliminary data regarding overall survival (OS).|Evaluate preliminary data regarding duration of overall response.|Evaluate preliminary data regarding Eastern Cooperative Oncology Group (ECOG) performance status.|Evaluate biomarkers","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","12","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-234","October 2009","July 2011","July 2011","April 9, 2009",,"June 6, 2018","Site Reference ID/Investigator# 13323, Chicago, Illinois, United States|Site Reference ID/Investigator# 12841, Maywood, Illinois, United States|Site Reference ID/Investigator# 12303, Baltimore, Maryland, United States|Site Reference ID/Investigator# 12305, Boston, Massachusetts, United States|Site Reference ID/Investigator# 20381, Boston, Massachusetts, United States|Site Reference ID/Investigator# 43505, Detroit, Michigan, United States|Site Reference ID/Investigator# 13322, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00878449"
623,"NCT00872196","A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies",,"Completed","No Results Available","Hepatitis C Virus Infection","Drug: ABT-072","Analysis of the prevalence of resistance of specific mutations over time will be summarized.|Analysis of the degree of phenotypic resistance (fold change in susceptibility of ABT-072 compared to wild-type virus) will also be summarized.|Summary of serious adverse events related to study procedures only.","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","5","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","M10-605","April 2009","April 2010","April 2010","March 31, 2009",,"April 1, 2013","Site Reference ID/Investigator# 18222, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00872196"
624,"NCT00868413","Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: ABT-263|Drug: FCR|Drug: BR","Assess the safety profile, characterize pharmacokinetics, and determine the MTD and recommended Phase 2 dose (RPTD) of ABT-263 when administered in combination with either FCR or BR in subjects with relapsed or refractory CLL.|Evaluate preliminary data regarding progression-free survival (PFS), tumor response rate and overall survival (OS) when ABT-263 is administered in combination with either FCR or BR.","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-458","November 2009","May 2013","May 2013","March 25, 2009",,"June 7, 2013","Site Reference ID/Investigator# 17841, La Jolla, California, United States|Site Reference ID/Investigator# 25899, Stanford, California, United States|Site Reference ID/Investigator# 21622, Baltimore, Maryland, United States|Site Reference ID/Investigator# 21621, Columbus, Ohio, United States|Site Reference ID/Investigator# 39613, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 17943, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00868413"
625,"NCT00853099","A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis",,"Completed","Has Results","Ulcerative Colitis","Biological: adalimumab|Drug: placebo","Percentage of Participants With Clinical Remission at 8 Weeks|Percentage of Participants With Clinical Remission at 52 Weeks|Percentage of Participants With Clinical Remission at 8, 32, and 52 Weeks|Percentage of Participants With a Clinical Response|Percentage of Participants With Mucosal Healing|Percentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1)|Percentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1)|Percentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1)|Percentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders|Number of Participants With Adverse Events up to Week 8|Number of Participants With Adverse Events up to Week 52|Number of Participants With Adverse Events During the Adalimumab Treatment Period","AbbVie (prior sponsor, Abbott)|Eisai Co., Ltd.|AbbVie","All","15 Years and older   (Child, Adult, Older Adult)","Phase 3","274","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-447","February 2009","May 2011","August 2013","March 2, 2009","November 27, 2012","September 5, 2014","Site Reference ID/Investigator# 47136, Asahikawa, Japan|Site Reference ID/Investigator# 47159, Chiba, Japan|Site Reference ID/Investigator# 47183, Chikushino, Japan|Site Reference ID/Investigator# 47135, Fukuoka-shi, Japan|Site Reference ID/Investigator# 47182, Fukuoka-shi, Japan|Site Reference ID/Investigator# 47124, Hamamatsu, Japan|Site Reference ID/Investigator# 47130, Hirakata-shi, Japan|Site Reference ID/Investigator# 47103, Hirosaki, Japan|Site Reference ID/Investigator# 47131, Hiroshima-shi, Japan|Site Reference ID/Investigator# 47178, Hiroshima, Japan|Site Reference ID/Investigator# 47179, Hiroshima, Japan|Site Reference ID/Investigator# 47176, Izumo, Japan|Site Reference ID/Investigator# 47226, Kagoshima, Japan|Site Reference ID/Investigator# 47123, Kanazawa-shi, Japan|Site Reference ID/Investigator# 47160, Kashiwa, Japan|Site Reference ID/Investigator# 47108, Kawagoe, Japan|Site Reference ID/Investigator# 47107, Koshigaya, Japan|Site Reference ID/Investigator# 47181, Kurume, Japan|Site Reference ID/Investigator# 47222, Kurume, Japan|Site Reference ID/Investigator# 47223, Kurume, Japan|Site Reference ID/Investigator# 47170, Kyoto-shi, Japan|Site Reference ID/Investigator# 47171, Kyoto-shi, Japan|Site Reference ID/Investigator# 47127, Kyoto, Japan|Site Reference ID/Investigator# 47172, Kyoto, Japan|Site Reference ID/Investigator# 47134, Matsuyama-shi, Japan|Site Reference ID/Investigator# 47225, Miyazaki, Japan|Site Reference ID/Investigator# 47138, Morioka-shi, Japan|Site Reference ID/Investigator# 47168, Nagakute-shi, Japan|Site Reference ID/Investigator# 47125, Nagoya-shi, Japan|Site Reference ID/Investigator# 47126, Nagoya-shi, Japan|Site Reference ID/Investigator# 47166, Nagoya-shi, Japan|Site Reference ID/Investigator# 47122, Niigata-shi, Japan|Site Reference ID/Investigator# 47227, Nishihara, Japan|Site Reference ID/Investigator# 47174, Nishinomiya-shi, Japan|Site Reference ID/Investigator# 47224, Oita, Japan|Site Reference ID/Investigator# 47177, Okayama-shi, Japan|Site Reference ID/Investigator# 47228, Okinawa, Japan|Site Reference ID/Investigator# 47128, Osaka-shi, Japan|Site Reference ID/Investigator# 47129, Osaka, Japan|Site Reference ID/Investigator# 47169, Otsu-shi, Japan|Site Reference ID/Investigator# 47118, Sagamihara-shi, Japan|Site Reference ID/Investigator# 47158, Saitama-shi, Japan|Site Reference ID/Investigator# 47109, Sakura, Japan|Site Reference ID/Investigator# 15853, Sapporo-shi, Japan|Site Reference ID/Investigator# 47137, Sapporo, Japan|Site Reference ID/Investigator# 47104, Sendai-shi, Japan|Site Reference ID/Investigator# 47147, Sendai-shi, Japan|Site Reference ID/Investigator# 47180, Susaki-shi, Japan|Site Reference ID/Investigator# 47133, Takamatsu, Japan|Site Reference ID/Investigator# 47173, Takatsuki-shi, Japan|Site Reference ID/Investigator# 47106, Tokorozawa-shi, Japan|Site Reference ID/Investigator# 47132, Tokushima, Japan|Site Reference ID/Investigator# 47110, Tokyo, Japan|Site Reference ID/Investigator# 47111, Tokyo, Japan|Site Reference ID/Investigator# 47112, Tokyo, Japan|Site Reference ID/Investigator# 47116, Tokyo, Japan|Site Reference ID/Investigator# 47117, Tokyo, Japan|Site Reference ID/Investigator# 47161, Tokyo, Japan|Site Reference ID/Investigator# 47164, Tokyo, Japan|Site Reference ID/Investigator# 47165, Toyama, Japan|Site Reference ID/Investigator# 47167, Toyoake, Japan|Site Reference ID/Investigator# 47105, Yamagata-shi, Japan|Site Reference ID/Investigator# 47175, Yamatotakada, Japan|Site Reference ID/Investigator# 47121, Yokohama-shi, Japan|Site Reference ID/Investigator# 47120, Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT00853099"
626,"NCT00851890","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",,"Completed","Has Results","Chronic Hepatitis C Virus Infection","Drug: ABT-333|Other: Placebo for ABT-333|Drug: Pegylated interferon|Drug: Ribavirin","Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Monotherapy Treatment|Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels Through Day 28|Maximum Plasma Concentration (Cmax) of ABT-333|Time to Maximum Plasma Concentration (Tmax) of ABT-333|Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post-dose (AUC12) of ABT-333|Serum Concentrations of Pegylated Interferon (pegIFN)|Plasma Concentrations of Ribavirin (RBV)|Number of Participants Having Treatment-emergent Adverse Events (AEs)|Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels Through Day 28 or Final Visit|Percentage of Participants With at Least a 2 log10 Maximal Decrease in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Treatment|Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels ≤ 25 IU/mL (the Lower Limit of Quantitation [LLOQ]) at Day 28 or Final Visit|Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels ≤ 10 IU/mL (Lower Limit of Detection [LLOD]) at Day 28 or Final Visit|Number of Participants With Resistance-Associated Variants in Non-structural Viral Protein 5B (NS5B) Through Day 28|Number of Participants With Maximal Phenotypic Resistance to ABT-333 >10 Fold Relative to Baseline Through Day 28","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-380","March 2009","July 2009","July 2009","February 26, 2009","January 8, 2015","July 2, 2018","Site Reference ID/Investigator# 16103, Anaheim, California, United States|Site Reference ID/Investigator# 16124, Los Angeles, California, United States|Site Reference ID/Investigator# 16102, Orlando, Florida, United States|Site Reference ID/Investigator# 16105, Baton Rouge, Louisiana, United States|Site Reference ID/Investigator# 16106, Chapel Hill, North Carolina, United States|Site Reference ID/Investigator# 16107, Dallas, Texas, United States|Site Reference ID/Investigator# 16123, San Antonio, Texas, United States|Site Reference ID/Investigator# 16182, Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00851890"
627,"NCT00808509","A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission","ADMIRE","Completed","Has Results","Arthritis, Rheumatoid","Biological: adalimumab|Drug: methotrexate","Percentage of Participants in Remission at Week 28|Percentage of Participants in Remission at Week 28 in the Full Analysis Set 2 (FAS2)|Percentage of Participants in Remission at Week 52|Percentage of Participants in Remission at Week 52 (FAS2)|Number of Participants With a Flare|Percentage of Participants With Response to Adalimumab Treatment (Return to Baseline DAS28 + ≤ 10%) After a Flare|Percentage of Participants With Response to Adalimumab Treatment (DAS28 <2.6 or DAS28 Decrease >1.2 Units) After a Flare|Health Assessment Questionnaire (HAQ) Total Score by Visit|European Quality of Life-5 Dimensions (EQ-5D) Mobility Score by Visit|European Quality of Life-5 Dimensions (EQ-5D) Self-care Score by Visit|European Quality of Life-5 Dimensions (EQ-5D) Usual Activities Score by Visit|European Quality of Life-5 Dimensions (EQ-5D) Pain/Discomfort Score by Visit|European Quality of Life-5 Dimensions (EQ-5D) Anxiety/Depression Score by Visit|European Quality of Life-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) by Visit|Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale by Visit|Work Instability Score (WIS) for RA: I'm Getting up Earlier Because of Arthritis|Work Instability Score (WIS) for RA: I Get Very Stiff at Work|Work Instability Score (WIS) for RA: I'm Finding my Job is About All I Can Manage|Work Instability Score (WIS) for RA: The Stress of my Job Makes my Arthritis Flare|Work Instability Score (WIS) for RA: I'm Finding Any Pressure on my Hands is a Problem|Work Instability Score (WIS) for RA: I Get Good Days and Bad Days at Work|Work Instability Score (WIS) for RA: I Can Get my Job Done, I'm Just a Lot Slower|Work Instability Score (WIS) for RA: If I Don't Reduce my Hours I May Have to Give up Work|Work Instability Score (WIS) for RA: I am Very Worried About my Ability to Keep Working|Work Instability Score (WIS) for RA: I Have Pain or Stiffness All the Time at Work|Work Instability Score (WIS) for RA: I Don't Have the Stamina to Work Like I Used to|Work Instability Score (WIS) for RA: I Have Used my Vacation so That I Don't Have to Take Sick Leave|Work Instability Score (WIS) for RA: I Push Myself to go to Work Because I Don't Want to Give in to the Arthritis|Work Instability Score (WIS) for RA: Sometimes I Can't Face Being at Work All Day|Work Instability Score (WIS) for RA: I Have to Say No to Certain Things at Work|Work Instability Score (WIS) for RA: I've Got to Watch How Much I do Certain Things at Work|Work Instability Score (WIS) for RA: I Have Great Difficulty Opening Some of the Doors at Work|Work Instability Score (WIS) for RA: I Have to Allow Myself Extra Time to do Some Jobs|Work Instability Score (WIS) for RA: It's Very Frustrating Because I Can't Always do Things at Work|Work Instability Score (WIS) for RA: I Feel I May Have to Give up Work|Work Instability Score (WIS) for RA: I Get on With the Work But Afterwards I Have a Lot of Pain|Work Instability Score (WIS) for RA: When I'm Feeling Tired All the Time Work is a Grind|Work Instability Score (WIS) for RA: I'd Like Another Job But I am Restricted to What I Can do|Work Productivity and Activity Impairment (WPAI): Currently Employed|Work Productivity and Activity Impairment (WPAI): Hours Missed From Work|Work Productivity and Activity Impairment (WPAI): Hours Missed From Work for Other Reasons|Work Productivity and Activity Impairment (WPAI): Hours Worked|Work Productivity and Activity Impairment (WPAI): Work Productivity|Work Productivity and Activity Impairment (WPAI): Daily Activities|Change From Baseline in Radiological Modified Total Sharp Score","AbbVie (prior sponsor, Abbott)|Pharma Consulting Group AB|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","W10-046|2008-004398-16","January 2009","September 2012","September 2012","December 16, 2008","November 20, 2013","December 16, 2013","Site Reference ID/Investigator# 22062, Linkoping, Sweden|Site Reference ID/Investigator# 14022, Lund, Sweden|Site Reference ID/Investigator# 14023, Malmo, Sweden|Site Reference ID/Investigator# 14301, Oskarstroem, Sweden|Site Reference ID/Investigator# 20241, Skoevde, Sweden|Site Reference ID/Investigator# 4918, Stockholm, Sweden|Site Reference ID/Investigator# 14021, Stockholm, Sweden|Site Reference ID/Investigator# 14302, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT00808509"
628,"NCT00804908","A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma",,"Completed","Has Results","Melanoma|Metastatic Melanoma|Skin Cancer","Drug: temozolomide|Drug: ABT-888|Other: Placebo","Progression-Free Survival (PFS): Time to Event|Overall Survival (OS): Time to Event|12-Month Overall Survival (OS) Rate|6-month Progression-Free Survival Rate|Objective Response Rate|Time to Disease Progression|Disease Control Rate|Time to Neurological/Brain Metastases Progression","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","346","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-440|2008-004941-27","February 2009","January 2016","January 2016","December 9, 2008","March 3, 2017","June 6, 2018",,,"https://ClinicalTrials.gov/show/NCT00804908"
629,"NCT00799877","Chronic Plaque Psoriasis (Ps) Registry",,"Active, not recruiting","No Results Available","Chronic Plaque Psoriasis",,"Incidence of Serious Adverse Events|Incidence of Adverse Events of Special Interest|Adverse Events that lead to permanent discontinuation of HUMIRA®|Health Care Utilization|Work Productivity and Activity Impairment Questionnaire: Specific Health Problem|Patient Global Assessment|Patient Health Question-9|Medical Outcomes Social Activities Scale|Patient reported outcome - Dermatology Life Quality Index|Census|Psoriasis Impact and Experience|Illness Cognition|Insurance Status|Rosenberg Self-Esteem Scale|Physician's Global Assessment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"6082","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","P10-023","September 26, 2008","September 15, 2022","September 15, 2022","December 1, 2008",,"March 25, 2019","Southview Medical Group, PC /ID# 20961, Birmingham, Alabama, United States|Total Skin and Beauty Derm Ctr /ID# 17156, Birmingham, Alabama, United States|Inverness Dermatology /ID# 76194, Birmingham, Alabama, United States|McLain Medical Associates, PC /ID# 18351, Birmingham, Alabama, United States|Deep South Dermatology, PC /ID# 40267, Daphne, Alabama, United States|Yates, Huntsville, AL /ID# 17130, Huntsville, Alabama, United States|Mobile Dermatology, P.C. /ID# 19783, Mobile, Alabama, United States|Arizona Advanced Dermatology /ID# 20512, Phoenix, Arizona, United States|Camelback Derm & Skin Surgery /ID# 18901, Phoenix, Arizona, United States|Alliance Dermatology and MOHs /ID# 17087, Phoenix, Arizona, United States|Affiliated Dermatology /ID# 18327, Scottsdale, Arizona, United States|Specialists in Dermatology /ID# 18864, Tucson, Arizona, United States|Johnson Dermatology Clinic /ID# 17088, Fort Smith, Arkansas, United States|Hull Dermatology, PA /ID# 17086, Rogers, Arkansas, United States|Elite MD Adv Derm Laser /ID# 28323, Danville, California, United States|Center for Dermatology Clin Res /ID# 20722, Fremont, California, United States|Associates in Research /ID# 17544, Fresno, California, United States|Dermatology and Dermatologic /ID# 17145, Garden Grove, California, United States|Guagenti, Glendale, CA /ID# 28263, Glendale, California, United States|Miremadi Dermatology /ID# 24323, La Jolla, California, United States|SCRIPPS Clinic /ID# 28147, La Mesa, California, United States|Dr. Abdallah Khourdaji /ID# 24307, Lodi, California, United States|Premiere Clinical Research,LLC /ID# 44719, Long Beach, California, United States|Kaiser Permanente LA Med Ctr /ID# 24334, Los Angeles, California, United States|Dermatology Res. Assoc., CA /ID# 17158, Los Angeles, California, United States|California Skin Institute /ID# 19769, Mountain View, California, United States|Derm Med Grp Oxnard/Camarillo /ID# 17102, Oxnard, California, United States|Univ California, San Francisco /ID# 28267, San Francisco, California, United States|Danesh, San Gabriel, CA /ID# 23068, San Gabriel, California, United States|Carson, San Jose, CA /ID# 17064, San Jose, California, United States|East Bay Psoriasis Trmnt Ctr /ID# 17081, San Ramon, California, United States|Skin Physicians & Surgeons Med /ID# 40265, Upland, California, United States|Adv Derm & Cosmetic Care /ID# 20511, Valencia, California, United States|Solano Dermatology Associates /ID# 20727, Vallejo, California, United States|Colorado Springs Derm Clinic /ID# 28165, Colorado Springs, Colorado, United States|Skin Care Specialists of CO /ID# 17142, Longmont, Colorado, United States|Notaro, Danbury, CT /ID# 40264, Danbury, Connecticut, United States|Panzer Dermatology & Cosmetic /ID# 17131, Newark, Delaware, United States|Panzer Dermatology & Cosmetic /ID# 17146, Newark, Delaware, United States|George Washington Univ Med /ID# 24270, Washington, District of Columbia, United States|Sullivan, Aventura, FL /ID# 17126, Aventura, Florida, United States|Florida Acad Dermatology Ctr /ID# 24273, Coral Gables, Florida, United States|Derm. Associates of the Palm /ID# 17137, Delray Beach, Florida, United States|Ft. Lauderdale Derm & Cosmetic /ID# 23071, Fort Lauderdale, Florida, United States|Hollywood Dermatology /ID# 17129, Hollywood, Florida, United States|Hollywood Dermatology /ID# 19771, Hollywood, Florida, United States|Suncoast Dermatology /ID# 23067, Lecanto, Florida, United States|Athenea Assoc Med Research /ID# 69768, Miami, Florida, United States|Assoc. in Med & Surg Derm /ID# 17523, Naples, Florida, United States|Cent Florida Dermatology Assoc /ID# 20508, Orlando, Florida, United States|Gulf Coast Dermatology /ID# 20724, Panama City, Florida, United States|Snyder, Pembroke Pines, FL /ID# 17122, Pembroke Pines, Florida, United States|Dermatology Research /ID# 17083, Pinellas Park, Florida, United States|Skin and Cancer Associates /ID# 20726, Plantation, Florida, United States|The Center for Skin Wellness /ID# 42005, Sarasota, Florida, United States|Water's Edge Dermatology /ID# 76114, Stuart, Florida, United States|Scannon, Tampa, Florida /ID# 28160, Tampa, Florida, United States|University of South Florida /ID# 38289, Tampa, Florida, United States|Ctr for Derm & Skin Surgery /ID# 28210, Tampa, Florida, United States|Geisinger Medical Center /ID# 17521, Tampa, Florida, United States|Coast Derm & Skin Cancer Ctr /ID# 40189, Venice, Florida, United States|ATL Derma, Vein & Res Ctr /ID# 20503, Alpharetta, Georgia, United States|Parker, Atlanta, GA /ID# 40190, Atlanta, Georgia, United States|Skin Cancer & Cosmetic Derm Ct /ID# 23313, Calhoun, Georgia, United States|East Metro Dermatology PC /ID# 20505, Conyers, Georgia, United States|Dermatologic Surgery Specialis /ID# 17149, Macon, Georgia, United States|NW GA Derm & Skin Cancer Spec /ID# 17089, Marietta, Georgia, United States|Paula Nelson MD & Associates /ID# 23076, Marietta, Georgia, United States|RI Dermatology & Cosmetic Ctr /ID# 40270, Newport, Georgia, United States|Skin Cancer & Cosmetic Derm /ID# 24305, Rome, Georgia, United States|Northwest Georgia Dermatology /ID# 28162, Rome, Georgia, United States|Atlanta Derm & Laser Surgery /ID# 28144, Tucker, Georgia, United States|Wray, Blackfoot, ID /ID# 24333, Blackfoot, Idaho, United States|Saltzer Medical Group /ID# 17144, Nampa, Idaho, United States|Olmstead, Twin Falls, ID /ID# 24325, Twin Falls, Idaho, United States|Pinski Dermatology /ID# 17147, Chicago, Illinois, United States|Northwestern University Feinberg School of Medicine /ID# 28169, Chicago, Illinois, United States|John H. Stroger, Jr. Hosp /ID# 40185, Chicago, Illinois, United States|Rush University Medical Center /ID# 47604, Chicago, Illinois, United States|Del Campo, Chicago, IL /ID# 19770, Chicago, Illinois, United States|Loyola University Medical Ctr /ID# 23065, Maywood, Illinois, United States|Arlington Dermatology /ID# 23062, Rolling Meadows, Illinois, United States|Schaumburg Dermatology, SC /ID# 38294, Schaumburg, Illinois, United States|DuPage Medical Group /ID# 18861, Wheaton, Illinois, United States|DuPage Medical Group /ID# 20507, Wheaton, Illinois, United States|Mercy Woodstock Medical Center /ID# 40186, Woodstock, Illinois, United States|Indiana University /ID# 37052, Indianapolis, Indiana, United States|Dawes Fretzin, LLC /ID# 17151, Indianapolis, Indiana, United States|Dawes Fretzin, LLC /ID# 17502, Indianapolis, Indiana, United States|Dermatology Associates of IN /ID# 24269, Indianapolis, Indiana, United States|The Dermatology Center PSC - New Albany /ID# 20501, New Albany, Indiana, United States|The Indiana Clinical Trials Center /ID# 17153, Plainfield, Indiana, United States|Great Plains Dermatology, P.A. /ID# 23079, Hays, Kansas, United States|Kansas City Dermatology PA /ID# 19764, Overland Park, Kansas, United States|Kansas Medical Clinic /ID# 28212, Topeka, Kansas, United States|Knuckles, Corbin, KY /ID# 17101, Corbin, Kentucky, United States|Anapolis Dermatology Center /ID# 24302, Annapolis, Maryland, United States|Glassman, Bethesda, MD /ID# 17069, Bethesda, Maryland, United States|Charles County Dermatology /ID# 18341, White Plains, Maryland, United States|Brigham Dermatology Associates /ID# 28207, Boston, Massachusetts, United States|Worcester Dermatology Assoc. /ID# 37048, Worcester, Massachusetts, United States|David Fivenson, MD, PLC /ID# 20504, Ann Arbor, Michigan, United States|Iacobelli, Clinton Twnshp, MI /ID# 38290, Clinton Township, Michigan, United States|Hamzavi Dermatology /ID# 25903, Fort Gratiot, Michigan, United States|Silverton Skin Institute /ID# 40196, Grand Blanc, Michigan, United States|Stawiski, Grand Rapids, MI /ID# 17124, Grand Rapids, Michigan, United States|Lakeshore Dermatology /ID# 24330, Norton Shores, Michigan, United States|Somerset Skin Centre /ID# 17157, Troy, Michigan, United States|Saint Louis University School of Medicine /ID# 28150, Saint Louis, Missouri, United States|Metro Hypertension and Kidney /ID# 40184, Saint Louis, Missouri, United States|Dermatology Associates, Inc. /ID# 23075, Saint Louis, Missouri, United States|Town Center Dermatology /ID# 28152, Wildwood, Missouri, United States|Assoc. Derm & Skin Cancer Clin /ID# 24303, Helena, Montana, United States|Center of Dermatology, P.C. /ID# 23078, Omaha, Nebraska, United States|Academic Dermatology of NV /ID# 20513, Henderson, Nevada, United States|Strimling, Las Vegas, NV /ID# 18332, Las Vegas, Nevada, United States|Woodson Dermatology /ID# 18333, Las Vegas, Nevada, United States|Riley, Reno, NV /ID# 36343, Reno, Nevada, United States|Dartmouth-Hitchcock Med Ctr /ID# 20502, Lebanon, New Hampshire, United States|Nashua Dermatology /ID# 18352, Nashua, New Hampshire, United States|Belleville Dermatology Center /ID# 17067, Belleville, New Jersey, United States|Psoriasis Treatment Ctr NJ /ID# 17148, East Windsor, New Jersey, United States|Fernandez-Obregon, Hoboken, NJ /ID# 23073, Hoboken, New Jersey, United States|Fulk, Morristown, TN /ID# 18344, Morristown, New Jersey, United States|UMDNJ R. W. Johnson Med School /ID# 24326, Somerset, New Jersey, United States|Derm Consultants of Summit /ID# 24308, Summit, New Jersey, United States|The Dermatology Group, PC /ID# 28158, Verona, New Jersey, United States|Marcus, Wyckoff, NJ /ID# 23074, Wyckoff, New Jersey, United States|Reflections Derm & Psoriasis /ID# 19781, Auburn, New York, United States|The Dermatology Center, PSC - Bayside NY /ID# 28170, Bayside, New York, United States|Montefiore Medical Center /ID# 24268, Bronx, New York, United States|Garden City Dermatology /ID# 42003, Garden City, New York, United States|Bruckstein, Lawrence, NY /ID# 17063, Lawrence, New York, United States|Scheinfeld, New York, NY /ID# 17136, New York, New York, United States|South Nassau Dermatology /ID# 17065, Oceanside, New York, United States|The Ctr for Derm at Lifetime /ID# 47603, Rochester, New York, United States|Dermedx Dermatology, PC /ID# 28163, Smithtown, New York, United States|Central Dermatology Center, PA /ID# 17070, Chapel Hill, North Carolina, United States|Dr. Aida Lugo-Somolinos /ID# 24309, Chapel Hill, North Carolina, United States|Fraser, Charlotte, NC /ID# 19772, Charlotte, North Carolina, United States|Duke Univ Med Ctr /ID# 24324, Durham, North Carolina, United States|Piedmont Dermatology Center /ID# 18326, Greensboro, North Carolina, United States|Carolina Skin Care, PA /ID# 19773, Pinehurst, North Carolina, United States|Andrus and Assoc Dermatology /ID# 20510, Raleigh, North Carolina, United States|Boice-Willis Clinic, P.A. /ID# 17125, Rocky Mount, North Carolina, United States|Crane, Wilmington, NC /ID# 17066, Wilmington, North Carolina, United States|Polley Clinic of Dermatology /ID# 18334, Wilson, North Carolina, United States|Piedmont Medical Research /ID# 17133, Winston-Salem, North Carolina, United States|Piedmont Medical Research /ID# 18329, Winston-Salem, North Carolina, United States|Hawkins, Akron, Ohio /ID# 28149, Akron, Ohio, United States|Summa Physicians Dermatology /ID# 37051, Akron, Ohio, United States|Oakview Dermatology, LLC /ID# 38298, Athens, Ohio, United States|The Ohio State University - Columbus /ID# 43150, Columbus, Ohio, United States|Allied Dermatology and Skin Surgery /ID# 28154, Fairlawn, Ohio, United States|Brodell Medical Inc. /ID# 24304, Warren, Ohio, United States|Univ Oklahoma HSC /ID# 28145, Oklahoma City, Oklahoma, United States|Tulsa Dermatology Clinic, Inc. /ID# 71675, Tulsa, Oklahoma, United States|Oregon Derm & Res. Ctr /ID# 24327, Portland, Oregon, United States|Oregon Health and Science University /ID# 28143, Portland, Oregon, United States|Altoona Ctr Clinical Res /ID# 17155, Duncansville, Pennsylvania, United States|University of Pittsburgh MC /ID# 17068, Pittsburgh, Pennsylvania, United States|Mikell, Beaufort, SC /ID# 17143, Beaufort, South Carolina, United States|Hampton, Charleston, NC /ID# 18865, Charleston, South Carolina, United States|Derm & Laser Ctr of Charleston /ID# 18353, Charleston, South Carolina, United States|Westside Dermatology, LLC /ID# 17541, Spartanburg, South Carolina, United States|MidSouth Dermatology /ID# 17128, Bartlett, Tennessee, United States|Dermatology Associates /ID# 42008, Kingsport, Tennessee, United States|Arlington Research Center, Inc /ID# 23063, Arlington, Texas, United States|Austin Dermatology Associates /ID# 38296, Austin, Texas, United States|Steiner Ranch Dermatology /ID# 20509, Austin, Texas, United States|Dermatology Treatment Center /ID# 17545, Dallas, Texas, United States|Aftergut, Dallas, TX /ID# 17041, Dallas, Texas, United States|Texas Dermatology Associates /ID# 28157, Dallas, Texas, United States|Schwartz,Harlingen,TX,US /ID# 20725, Harlingen, Texas, United States|Sonabend, Houston, TX /ID# 17123, Houston, Texas, United States|Desai, Houston, TX /ID# 28325, Houston, Texas, United States|Memorial Clinical Associates /ID# 17085, Houston, Texas, United States|West Houston Dermatology /ID# 18330, Houston, Texas, United States|Lehman Dermatology Clinic /ID# 17082, Lubbock, Texas, United States|TX Tech Univ Health Science /ID# 37050, Lubbock, Texas, United States|The Dermatology Inst of S. TX /ID# 38288, McAllen, Texas, United States|Dermatology Assoc San Antonio /ID# 17150, San Antonio, Texas, United States|Tucker, The Woodlands, Texas /ID# 38295, The Woodlands, Texas, United States|Aspen Dermatology, PLLC /ID# 38293, Spanish Fork, Utah, United States|Aspen Dermatology, PLLC /ID# 40183, Spanish Fork, Utah, United States|Aspen Dermatology, PLLC /ID# 40192, Spanish Fork, Utah, United States|Skin and Laser Surgery Center /ID# 40182, Tysons Corner, Virginia, United States|Dermatology & Laser Center NW /ID# 18324, Bellingham, Washington, United States|Dermatology Associates /ID# 18328, Seattle, Washington, United States|Dermatology Associates /ID# 19802, Seattle, Washington, United States|Premier Clinical Research /ID# 28168, Spokane, Washington, United States|Komorous, Tacoma, WA /ID# 42007, Tacoma, Washington, United States|Eastern Washington Dermatology /ID# 17542, Walla Walla, Washington, United States|Saoud, Bridgeport, WV /ID# 17135, Bridgeport, West Virginia, United States|Mountain State Clinical Resear /ID# 28146, Clarksburg, West Virginia, United States|Hardy County Medical /ID# 28264, Moorefield, West Virginia, United States|Dermatology Assoc of WI /ID# 28142, Appleton, Wisconsin, United States|Great Lakes Dermatology /ID# 17061, Pleasant Prairie, Wisconsin, United States|Aylesworth, Rhinelander, WI /ID# 18322, Rhinelander, Wisconsin, United States|University Hospital St. Polten /ID# 22842, St. Pölten, Niederoesterreich, Austria|Kepler Universitätsklinikum /ID# 27922, Linz, Oberoesterreich, Austria|Krankenanstalt Rudolfstiftung /ID# 20603, Vienna, Wien, Austria|Medizinische Universität Wien /ID# 18364, Vienna, Wien, Austria|LKH-Univ. Klinikum Graz /ID# 24263, Graz, Austria|Medical University Innsbruck /ID# 22844, Innsbruck, Austria|LKH Salzburg and Paracelsus /ID# 22843, Salzburg, Austria|Maier, Vienna, AT /ID# 27921, Vienna, Austria|Krankenhaus Hietzing /ID# 17183, Vienna, Austria|Klinikum Wels - Grieskirchen /ID# 17543, Wels, Austria|Kirk Barber Research, CA /ID# 24204, Calgary, Alberta, Canada|Stratica Medical /ID# 24266, Edmonton, Alberta, Canada|Guildford Derm. Specialists,CA /ID# 40199, Surrey, British Columbia, Canada|Univ British Columbia /ID# 24223, Vancouver, British Columbia, Canada|Winnipeg Clinic, Manitoba, CA /ID# 37046, Winnipeg, Manitoba, Canada|Durondel C.P. Inc. /ID# 28136, Moncton, New Brunswick, Canada|Karma Clinical Trials /ID# 37049, St. John's, Newfoundland and Labrador, Canada|Alpha Clinical Research Ctr. /ID# 20581, St. John's, Newfoundland and Labrador, Canada|Nexus Clinical Research /ID# 79198, St. John's, Newfoundland and Labrador, Canada|NewLab Clinical Research Inc. /ID# 18360, St. John's, Newfoundland and Labrador, Canada|Murray, Halifax, CA /ID# 24224, Halifax, Nova Scotia, Canada|Dermatrials Research /ID# 18363, Hamilton, Ontario, Canada|Guenther Derma Res Ctr, CA /ID# 79196, London, Ontario, Canada|Lynderm Research Inc. /ID# 18362, Markham, Ontario, Canada|Entralogix Clinical Research, /ID# 79194, Newmarket, Ontario, Canada|Entralogix Clinical Research, /ID# 79197, Newmarket, Ontario, Canada|Bank on Beauty /ID# 24205, Niagara Falls, Ontario, Canada|North Bay Dermatology Centre /ID# 28138, North Bay, Ontario, Canada|SKIN Centre for Dermatology /ID# 79195, Peterborough, Ontario, Canada|Yeung, Toronto, Canada /ID# 28141, Toronto, Ontario, Canada|K. Papp Clinical Research /ID# 28137, Waterloo, Ontario, Canada|XLR8 Medical Research /ID# 28140, Windsor, Ontario, Canada|Dr. Isabelle Delorme Inc. /ID# 79193, Drummondville, Quebec, Canada|Innovaderm Research Inc. /ID# 18866, Montreal, Quebec, Canada|Centre de Dermatologie Maizerets /ID# 20515, Quebec City, Quebec, Canada|Ctr Derma du QC Metropolitain /ID# 18361, Quebec City, Quebec, Canada|Dr. Beatrice Wang /ID# 18359, Westmount, Quebec, Canada|Fakultni Nemocnice Olomouc /ID# 27930, Olomouc, Olomoucky Kraj, Czechia|Fakultni Nemocnice Brno /ID# 27927, Brno, Czechia|Fakultni Nemocnice u SvateAnny /ID# 37062, Brno, Czechia|FN Hradec Kralove /ID# 40201, Hradec Kralove, Czechia|Univ Hosp, Plzen, CZ /ID# 27924, Plzen, Czechia|Vseobecna fakultni nemoc Praze /ID# 25907, Prague 2, Czechia|Vseobecna fakultni nemoc Praze /ID# 27933, Prague 2, Czechia|Vseobecna fakultni nemoc Praze /ID# 28269, Prague 2, Czechia|Masarykova Hospital /ID# 27923, Usti Nad Labem, Czechia|Bispebjerg Hospital /ID# 24271, Copenhagen NV, Hovedstaden, Denmark|Herlev Hospital /ID# 20602, Herlev, Hovedstaden, Denmark|Aarhus University Hospital /ID# 18357, Aarhus N, Midtjylland, Denmark|Hudklinik / Clinic Dermatology /ID# 20729, Herning, Denmark|Centre Hospitalier Lyon Sud /ID# 27940, Pierre Benite CEDEX, Auvergne-Rhone-Alpes, France|CHU Dupuytren /ID# 25904, Limoges CEDEX 1, Franche-Comte, France|Hopital Haut-Lévêque /ID# 27934, Pessac CEDEX, Gironde, France|CHRU Lille - Hôpital Claude Huriez /ID# 37063, Lille CEDEX, Hauts-de-France, France|CHU de la miletrie /ID# 25906, Poitiers, Poitou-Charentes, France|Charles Nicolle CHU Rouen /ID# 22845, Rouen CEDEX, Seine-Maritime, France|Service de Dermatologie /ID# 24202, Besancon, France|CHRU Tours - Hopital Trousseau /ID# 28271, Chambray Les Tours, France|Hopital Sainte Marguerite /ID# 28270, Marseille, France|Hopital Fournier /ID# 27938, Nancy, France|CHU de Nantes, Hotel Dieu -HME /ID# 27944, Nantes, France|CHU de Nice /ID# 27936, Nice, France|Hopital Saint-Louis /ID# 24203, Paris, France|Hopital Robert Debre /ID# 37064, Reims, France|Hopital Nord /ID# 27942, Saint Priest En Jarez, France|Universitaetsklinik Heidelberg /ID# 20601, Heidelberg, Baden-Wuerttemberg, Germany|Universitätsklinikum Frankfurt /ID# 19801, Frankfurt am Main, Hessen, Germany|Universitatsklinikum Munster /ID# 37066, Munster, Niedersachsen, Germany|Uniklinik Koln /ID# 27950, Köln, Nordrhein-Westfalen, Germany|Universitaetsklinikum Leipzig /ID# 20604, Leipzig, Sachsen, Germany|Univ Hosp Schleswig-Holstein /ID# 22846, Kiel, Schleswig-Holstein, Germany|Klinikum Ruhr Univ Bochum /ID# 40200, Bochum, Germany|Universitaetsklinikum Jena /ID# 19765, Jena, Germany|Univ Johannes Gutenberg /ID# 37067, Mainz, Germany|Tzaneio general hospital of Piraeus /ID# 28237, Piraeus, Attiki, Greece|Papageorgiou General Hospital Thessaloniki /ID# 28232, Nea Efkarpia, Thessaloniki, Greece|Hospital Errikos Ntynan /ID# 28272, Athens, Greece|Genl Hospital Andreas Syggros /ID# 22847, Athens, Greece|Genl Hospital Andreas Syggros /ID# 22848, Athens, Greece|Genl Hospital Andreas Syggros /ID# 25905, Athens, Greece|Naval Hospital of Crete /ID# 22849, Chania, Crete, Greece|General Hospital of Giannitsa /ID# 27951, Giannitsa, Greece|University General Hospital of Heraklion ""PA.G.N.I"" /ID# 27954, Heraklion, Greece|General Hospital of Katerini /ID# 27953, Katerini, Greece|Hosp Skin and Venereal Dis /ID# 37068, Thessaloniki, Greece|St Vincent's University Hosp /ID# 43149, Dublin, Ireland|Radboud Universitair Medisch Centrum /ID# 24265, Nijmegen, Gelderland, Netherlands|Academisch Medisch Centrum /ID# 22850, Amsterdam, Noord-Holland, Netherlands|Flebologisch Centrum Oosterwal /ID# 18349, Alkmaar, Netherlands|ZiekenhuisGroep Twente /ID# 18355, Almelo, Netherlands|Amphia Ziekenhuis /ID# 20461, Breda, Netherlands|Oosterschelde Ziekenhuis /ID# 20462, Goes, Netherlands|Spaarne Gasthuis /ID# 22851, Haarlem, Netherlands|Westfries Gasthuis /ID# 18354, Hoorn, Netherlands|Erasmus Medisch Centrum /ID# 24264, Rotterdam, Netherlands|Diaconessenhuis Voorburg /ID# 18868, Voorburg, Netherlands|Dr. Reinaldo Rosario Med Offic /ID# 24328, San Juan, Puerto Rico|Hospital Duran i Reynals /ID# 18348, L'Hospitalet de Llobregat, Barcelona, Spain|Hosp Univ Fundacion Alcorcon /ID# 20723, Alcorcon, Spain|Hospital General de Alicante /ID# 20730, Alicante, Spain|Hospital Clinic de Barcelona /ID# 19803, Barcelona, Spain|Hospital Univ Germans Trias I /ID# 17152, Barcelona, Spain|Capio Hospital Universitario S /ID# 19767, Barcelona, Spain|Hospital Univ de la Princesa /ID# 18867, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 18365, Madrid, Spain|HCU Lozano Blesa /ID# 19763, Zaragoza, Spain|Uppsala University Hospital /ID# 38283, Uppsala, Sweden|The Royal Free Hospital /ID# 40205, London, London, City Of, United Kingdom|Guy's and St Thomas' NHS Found /ID# 28273, London, London, City Of, United Kingdom|University Hospital of Wales /ID# 40204, Cardiff, United Kingdom|Aberdeen Royal Infirmary /ID# 37069, Foresterhill, United Kingdom|Glasgow Western Infirmary /ID# 27956, Glasgow, United Kingdom|Leeds General Infirmary /ID# 40202, Leeds, United Kingdom|Hope Hospital /ID# 40203, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00799877"
630,"NCT00788684","Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers",,"Active, not recruiting","No Results Available","CD20-Positive Lymphoid Malignancies|Chronic Lymphoid Leukemia|Hematological Malignancies|Non-Hodgkin's Lymphoma","Drug: rituximab|Drug: ABT-263","Extension Study: Continued assessment of the safety profile of ABT-263 when administered in combination with rituximab|Assess the safety profile and characterize the pharmacokinetics of ABT-263 when administered in combination with rituximab|Determination of dose limiting toxicity (DLT) and maximum tolerated dose (MTD) when ABT-263 is administered in combination with rituximab|Extension Study: Continued assessment of the preliminary progression-free survival (PFS), response rate, and duration of response.|Preliminary progression-free survival (PFS), response rate, and duration of response.","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-166","July 21, 2009","April 30, 2020","April 30, 2020","November 11, 2008",,"March 5, 2019","University Arizona Cancer Ctr /ID# 16721, Tucson, Arizona, United States|Stanford Univ School of Med /ID# 9782, Stanford, California, United States|Cleveland Clinic Foundation /ID# 9784, Cleveland, Ohio, United States|Univ of Wisconsin Hosp/Clinics /ID# 21701, Madison, Wisconsin, United States|Peter MacCallum Cancer Ctr /ID# 25067, Melbourne, Victoria, Australia|Royal Melbourne Hospital /ID# 9781, Parkville, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT00788684"
631,"NCT00775437","Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use",,"Completed","Has Results","Juvenile Idiopathic Arthritis","Drug: Adalimumab","Number of Participants With Treatment-Emergent Adverse Events (TEAEs)|Mean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24|Hemoglobin: Mean Change From Baseline to Each Visit|Hematocrit: Mean Change From Baseline to Each Visit|Red Blood Cell (RBC) Count: Mean Change From Baseline to Each Visit|Platelets: Mean Change From Baseline to Each Visit|White Blood Cell (WBC) Count: Mean Change From Baseline to Each Visit|Neutrophils: Mean Change From Baseline to Each Visit|Lymphocytes: Mean Change From Baseline to Each Visit|Monocytes: Mean Change From Baseline to Each Visit|Eosinophils: Mean Change From Baseline to Each Visit|Basophils: Mean Change From Baseline to Each Visit|Alanine Aminotransferase (SGPT/ALT): Mean Change From Baseline to Each Visit|Aspartate Aminotransferase (SGOT/AST): Mean Change From Baseline to Each Visit|Alkaline Phosphatase (ALP): Mean Change From Baseline to Each Visit|Creatine Phosphokinase: Mean Change From Baseline to Each Visit|Total Bilirubin: Mean Change From Baseline to Each Visit|Creatinine: Mean Change From Baseline to Each Visit|Uric Acid: Mean Change From Baseline to Each Visit|Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 30% Response (PedACR30)|Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 50% Response (PedACR50)|Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 70% Response (PedACR70)|Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 90% Response (PedACR90)|Physician's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit|Parent's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit|Disability Index of Child Health Assessment Questionnaire (DICHAQ): Mean Change From Baseline to Each Visit|Active Joint Counts (AJC73): Mean Change From Baseline to Each Visit|Limitation of Passive Motion (LOM69) Joint Count: Mean Change From Baseline to Each Visit|C-reactive Protein (CRP): Mean Change From Baseline to Each Visit|Tender Joint Count (TJC75): Mean Change From Baseline to Each Visit|Swollen Joint Count (SJC66): Mean Change From Baseline to Each Visit|Pain on Passive Motion (POM75) Joint Count: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Global Health Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Physical Functioning Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations/Emotional/Behavioral Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations - Physical Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Bodily Pain/Discomfort Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Behavior Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Global Behavior Item: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Mental Health Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Self Esteem Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) General Health Perceptions Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Change in Health Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Emotional Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Time Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Family Activities Category: Mean Change From Baseline to Each Visit|Child's Health Questionnaire Parent Form (CHQ-PF50) Family Cohesion Category: Mean Change From Baseline to Each Visit","AbbVie (prior sponsor, Abbott)|AbbVie","All","2 Years to 4 Years   (Child)","Phase 3","32","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-444|2009-013091-40","March 2009","March 2013","March 2013","October 20, 2008","January 26, 2016","January 26, 2016",,,"https://ClinicalTrials.gov/show/NCT00775437"
632,"NCT00763321","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)",,"Completed","Has Results","Chronic Low Back Pain","Drug: ABT-712|Drug: Placebo","Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)|Change From Double-blind (DB) Baseline to Final Assessment in Chronic Pain Sleep Inventory (CPSI)","AbbVie (prior sponsor, Abbott)|AbbVie","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 3","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-277","September 2008","April 2009","April 2009","September 30, 2008","December 23, 2013","February 6, 2014","Site Reference ID/Investigator# 10044, Huntsville, Alabama, United States|Site Reference ID/Investigator# 10070, Burbank, California, United States|Site Reference ID/Investigator# 10050, San Diego, California, United States|Site Reference ID/Investigator# 10060, Atlantis, Florida, United States|Site Reference ID/Investigator# 10069, Hollywood, Florida, United States|Site Reference ID/Investigator# 10045, Kissimmee, Florida, United States|Site Reference ID/Investigator# 10061, Tampa, Florida, United States|Site Reference ID/Investigator# 10054, Atlanta, Georgia, United States|Site Reference ID/Investigator# 10071, Marietta, Georgia, United States|Site Reference ID/Investigator# 13604, Chicago, Illinois, United States|Site Reference ID/Investigator# 10053, Evansville, Indiana, United States|Site Reference ID/Investigator# 10055, Newburgh, Indiana, United States|Site Reference ID/Investigator# 10043, Valparaiso, Indiana, United States|Site Reference ID/Investigator# 10072, Prairie Village, Kansas, United States|Site Reference ID/Investigator# 10041, Pasadena, Maryland, United States|Site Reference ID/Investigator# 10049, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 10062, Biloxi, Mississippi, United States|Site Reference ID/Investigator# 10066, Florissant, Missouri, United States|Site Reference ID/Investigator# 10073, St. Louis, Missouri, United States|Site Reference ID/Investigator# 10056, Omaha, Nebraska, United States|Site Reference ID/Investigator# 10075, Williamsville, New York, United States|Site Reference ID/Investigator# 10065, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 10067, Fargo, North Dakota, United States|Site Reference ID/Investigator# 10047, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 10052, Altoona, Pennsylvania, United States|Site Reference ID/Investigator# 10042, Bridgeville, Pennsylvania, United States|Site Reference ID/Investigator# 10063, Greer, South Carolina, United States|Site Reference ID/Investigator# 10046, Austin, Texas, United States|Site Reference ID/Investigator# 10058, Austin, Texas, United States|Site Reference ID/Investigator# 10059, Dallas, Texas, United States|Site Reference ID/Investigator# 10048, Chesapeake, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00763321"
633,"NCT00761150","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)",,"Completed","Has Results","Chronic Low Back Pain","Drug: ABT-712|Drug: Placebo","Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)|Change From Double-blind (DB) Baseline to Final Assessment in Chronic Pain Sleep Inventory (CPSI)","AbbVie (prior sponsor, Abbott)|AbbVie","All","21 Years to 75 Years   (Adult, Older Adult)","Phase 3","308","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-385","September 2008","March 2009","March 2009","September 29, 2008","December 23, 2013","February 7, 2014","Site Reference ID/Investigator# 10143, Tempe, Arizona, United States|Site Reference ID/Investigator# 10161, Tempe, Arizona, United States|Site Reference ID/Investigator# 10155, Tucson, Arizona, United States|Site Reference ID/Investigator# 10160, Anaheim, California, United States|Site Reference ID/Investigator# 10821, Lomita, California, United States|Site Reference ID/Investigator# 10152, Clearwater, Florida, United States|Site Reference ID/Investigator# 10157, DeLand, Florida, United States|Site Reference ID/Investigator# 10142, Oldsmar, Florida, United States|Site Reference ID/Investigator# 10147, Pembroke Pines, Florida, United States|Site Reference ID/Investigator# 13821, Plantation, Florida, United States|Site Reference ID/Investigator# 15821, Chicago, Illinois, United States|Site Reference ID/Investigator# 10136, Crestview Hills, Kentucky, United States|Site Reference ID/Investigator# 10822, New Orleans, Louisiana, United States|Site Reference ID/Investigator# 10140, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 10158, Brockton, Massachusetts, United States|Site Reference ID/Investigator# 13601, Fall River, Massachusetts, United States|Site Reference ID/Investigator# 10162, Wellesley Hills, Massachusetts, United States|Site Reference ID/Investigator# 10159, Omaha, Nebraska, United States|Site Reference ID/Investigator# 10126, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 10156, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 10148, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 10151, Kettering, Ohio, United States|Site Reference ID/Investigator# 10138, Marion, Ohio, United States|Site Reference ID/Investigator# 10150, Perrysburgh, Ohio, United States|Site Reference ID/Investigator# 10141, Dallas, Texas, United States|Site Reference ID/Investigator# 10149, El Paso, Texas, United States|Site Reference ID/Investigator# 10130, Fort Worth, Texas, United States|Site Reference ID/Investigator# 10163, Killeen, Texas, United States|Site Reference ID/Investigator# 13201, San Antonio, Texas, United States|Site Reference ID/Investigator# 10154, San Antonio, Texas, United States|Site Reference ID/Investigator# 10144, Roanoke, Virginia, United States|Site Reference ID/Investigator# 10113, Spokane, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00761150"
634,"NCT00742560","A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma",,"Completed","Has Results","Hematologic Cancer","Biological: elotuzumab|Drug: lenalidomide|Drug: dexamethasone oral|Drug: dexamethasone injection","Maximum Tolerated Dose (MTD) of Elotuzumab in Combination With Lenalidomide and Dexamethasone (Phase 1)|Objective Response Rate (ORR) According to the International Myeloma Working Group Uniform Response Criteria (Phase 2)|Objective Response Rate (ORR) According to the International Myeloma Working Group Uniform Response Criteria (Phase 1)|Number of Participants With Treatment-emergent Adverse Events (TEAEs)|Number of Participants With Infusion Reactions|Mean Serum Concentrations of Elotuzumab During Cycle 1|Maximum Serum Concentration (Cmax) of Elotuzumab|Area Under the Concentration-time Curve From 0 to Infinity (AUC0-inf) of Elotuzumab|Systemic Clearance (CL) of Elotuzumab|Volume of Distribution (V) of Elotuzumab|Serum Half-life (t1/2) of Elotuzumab|Duration of Response|Time to Progression (TTP)|Progression-free Survival (PFS)|Percentage of Participants With Treatment-emergent Anti-elotuzumab Antibody (ADA)|Plasma Cell Myeloma Cytogenetic Subtype","AbbVie (prior sponsor, Abbott)|Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","101","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HuLuc63-1703|2007-006677-83","August 2008","October 2016","October 2016","August 27, 2008","January 10, 2018","January 10, 2018",,,"https://ClinicalTrials.gov/show/NCT00742560"
635,"NCT00733187","Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869",,"Completed","No Results Available","Advanced Solid Tumors","Drug: ABT-869","Pharmacokinetic|ECG Evaluation|Adverse Events|Lab data and vital signs","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","34","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","M10-384","February 2009","June 2012","June 2012","August 12, 2008",,"November 21, 2017",,,"https://ClinicalTrials.gov/show/NCT00733187"
636,"NCT00726882","A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies",,"Completed","Has Results","HCV Infection","Procedure: Blood sample collection only|Drug: ABT-333","Persistence of Resistance-Associated Variants and Phenotypic Resistance|Number of Participants With Serious Adverse Events Related to Study Procedures","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","35","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)","M10-459","August 2008","May 2010","May 2010","August 1, 2008","January 8, 2015","January 8, 2015","Site Reference ID/Investigator# 17665, Anaheim, California, United States|Site Reference ID/Investigator# 17367, Los Angeles, California, United States|Site Reference ID/Investigator# 17672, Los Angeles, California, United States|Site Reference ID/Investigator# 10381, Orlando, Florida, United States|Site Reference ID/Investigator# 17667, Baton Rouge, Louisiana, United States|Site Reference ID/Investigator# 14461, San Antonio, Texas, United States|Site Reference ID/Investigator# 11141, Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00726882"
637,"NCT00716534","Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Advanced or Metastatic Non-Small Cell Lung Cancer","Drug: ABT-869|Drug: Placebo for ABT-869|Drug: Carboplatin|Drug: Paclitaxel","Progression Free Survival (PFS)|Overall survival, best response rate, time to tumor progression, objective response rate, best percent change in tumor size, duration of response|Survival Rate","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","145","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-301|2007-007107-32","June 2008","April 2012","April 2012","July 16, 2008",,"April 29, 2013","Site Reference ID/Investigator# 15850, Chandler, Arizona, United States|Site Reference ID/Investigator# 15846, Peoria, Arizona, United States|Site Reference ID/Investigator# 15841, Miami, Florida, United States|Site Reference ID/Investigator# 7179, Atlanta, Georgia, United States|Site Reference ID/Investigator# 15851, Lansing, Michigan, United States|Site Reference ID/Investigator# 15844, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 22443, Hackensack, New Jersey, United States|Site Reference ID/Investigator# 15848, Greensboro, North Carolina, United States|Site Reference ID/Investigator# 22444, Canton, Ohio, United States|Site Reference ID/Investigator# 15847, Cleveland, Ohio, United States|Site Reference ID/Investigator# 26842, Hershey, Pennsylvania, United States|Site Reference ID/Investigator# 13101, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 24122, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 19042, Bedford Park, Australia|Site Reference ID/Investigator# 23682, Cairns, Australia|Site Reference ID/Investigator# 21862, Lismore, Australia|Site Reference ID/Investigator# 19043, Woodville South, Australia|Site Reference ID/Investigator# 17703, Jau, Brazil|Site Reference ID/Investigator# 23522, Porto Alegre, Brazil|Site Reference ID/Investigator# 15601, Porto Alegre, Brazil|Site Reference ID/Investigator# 17704, Rio de Janeiro, Brazil|Site Reference ID/Investigator# 22684, Santo Andre, Brazil|Site Reference ID/Investigator# 17702, Sao Paulo, Brazil|Site Reference ID/Investigator# 23582, Sao Paulo, Brazil|Site Reference ID/Investigator# 18964, Kyjov, Czech Republic|Site Reference ID/Investigator# 22504, Nachod, Czech Republic|Site Reference ID/Investigator# 18963, Olomouc, Czech Republic|Site Reference ID/Investigator# 18962, Prague 2, Czech Republic|Site Reference ID/Investigator# 19022, Pribram V, Czech Republic|Site Reference ID/Investigator# 38003, Kazan, Russian Federation|Site Reference ID/Investigator# 38260, Kirov, Russian Federation|Site Reference ID/Investigator# 18064, Moscow, Russian Federation|Site Reference ID/Investigator# 18065, Moscow, Russian Federation|Site Reference ID/Investigator# 23312, Moscow, Russian Federation|Site Reference ID/Investigator# 18066, Moscow, Russian Federation|Site Reference ID/Investigator# 23562, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 18961, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00716534"
638,"NCT00710580","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","No Results Available","Moderate to Severe Plaque Psoriasis","Biological: ABT-874|Biological: etanercept|Drug: placebo","Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12","AbbVie (prior sponsor, Abbott)|Paragon Biomedical|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-315","July 2008","April 2009","April 2009","July 4, 2008",,"January 18, 2013","Site Reference ID/Investigator# 9984, Birmingham, Alabama, United States|Site Reference ID/Investigator# 10605, Birmingham, Alabama, United States|Site Reference ID/Investigator# 10001, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 10502, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 9985, Bakersfield, California, United States|Site Reference ID/Investigator# 10661, Irvine, California, United States|Site Reference ID/Investigator# 14701, Los Angeles, California, United States|Site Reference ID/Investigator# 9785, San Diego, California, United States|Site Reference ID/Investigator# 10662, Santa Monica, California, United States|Site Reference ID/Investigator# 10642, Vallejo, California, United States|Site Reference ID/Investigator# 10263, New Haven, Connecticut, United States|Site Reference ID/Investigator# 10503, Jacksonville, Florida, United States|Site Reference ID/Investigator# 10266, Miami, Florida, United States|Site Reference ID/Investigator# 9901, Miami, Florida, United States|Site Reference ID/Investigator# 10501, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 15201, Alpharetta, Georgia, United States|Site Reference ID/Investigator# 10762, Atlanta, Georgia, United States|Site Reference ID/Investigator# 10262, Newnan, Georgia, United States|Site Reference ID/Investigator# 9789, Snellville, Georgia, United States|Site Reference ID/Investigator# 10666, Maywood, Illinois, United States|Site Reference ID/Investigator# 15142, Plainfield, Indiana, United States|Site Reference ID/Investigator# 10265, Louisville, Kentucky, United States|Site Reference ID/Investigator# 15750, Owensboro, Kentucky, United States|Site Reference ID/Investigator# 9790, Owensboro, Kentucky, United States|Site Reference ID/Investigator# 9788, Fort Gratiot, Michigan, United States|Site Reference ID/Investigator# 10604, Grand Blanc, Michigan, United States|Site Reference ID/Investigator# 10541, Fridley, Minnesota, United States|Site Reference ID/Investigator# 10641, St. Louis, Missouri, United States|Site Reference ID/Investigator# 10606, Omaha, Nebraska, United States|Site Reference ID/Investigator# 10644, Omaha, Nebraska, United States|Site Reference ID/Investigator# 9786, Berlin, New Jersey, United States|Site Reference ID/Investigator# 10241, New York, New York, United States|Site Reference ID/Investigator# 9787, Rochester, New York, United States|Site Reference ID/Investigator# 9902, Hickory, North Carolina, United States|Site Reference ID/Investigator# 10581, Wilmington, North Carolina, United States|Site Reference ID/Investigator# 10504, Dayton, Ohio, United States|Site Reference ID/Investigator# 10643, Knoxville, Tennessee, United States|Site Reference ID/Investigator# 9981, Dallas, Texas, United States|Site Reference ID/Investigator# 10264, San Antonio, Texas, United States|Site Reference ID/Investigator# 9982, Webster, Texas, United States|Site Reference ID/Investigator# 10182, Seattle, Washington, United States|Site Reference ID/Investigator# 10321, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00710580"
639,"NCT00707889","Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer",,"Completed","No Results Available","Advanced Colorectal Cancer|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum","Drug: ABT-869|Drug: bevacizumab|Drug: oxaliplatin|Drug: folinic acid|Drug: fluorouracil","Progression-free survival|Overall survival|12-month overall survival rate|Objective response rate","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","159","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-300|2007-007081-38","October 2008","May 2012","May 2012","July 1, 2008",,"May 15, 2013","Site Reference ID/Investigator# 11341, Chapel Hill, North Carolina, United States|Site Reference ID/Investigator# 20801, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 8360, Nashville, Tennessee, United States|Site Reference ID/Investigator# 18581, Bedford Park, Australia|Site Reference ID/Investigator# 23443, Herston, Australia|Site Reference ID/Investigator# 18023, Bonheiden, Belgium|Site Reference ID/Investigator# 23646, Brussels, Belgium|Site Reference ID/Investigator# 18026, Leuven, Belgium|Site Reference ID/Investigator# 18022, Roeselare, Belgium|Site Reference ID/Investigator# 26662, Jau, Brazil|Site Reference ID/Investigator# 24245, Porto Alegre, Brazil|Site Reference ID/Investigator# 23265, Barrie, Canada|Site Reference ID/Investigator# 21083, Edmonton, Canada|Site Reference ID/Investigator# 22465, Ottawa, Canada|Site Reference ID/Investigator# 22141, Nachod, Czech Republic|Site Reference ID/Investigator# 22289, Heraklion, Greece|Site Reference ID/Investigator# 22286, Thessaloniki, Greece|Site Reference ID/Investigator# 22287, Thessaloniki, Greece|Site Reference ID/Investigator# 18281, Seoul, Korea, Republic of|Site Reference ID/Investigator# 18283, Seoul, Korea, Republic of|Site Reference ID/Investigator# 18282, Seoul, Korea, Republic of|Site Reference ID/Investigator# 20281, Wellington South, New Zealand|Site Reference ID/Investigator# 20141, Olsztyn, Poland|Site Reference ID/Investigator# 17946, Warsaw, Poland|Site Reference ID/Investigator# 38284, Warsaw, Poland|Site Reference ID/Investigator# 23908, Aveiro, Portugal|Site Reference ID/Investigator# 22324, Coimbra, Portugal|Site Reference ID/Investigator# 23724, Faro, Portugal|Site Reference ID/Investigator# 23964, Lisbon, Portugal|Site Reference ID/Investigator# 23303, Baia Mare, Romania|Site Reference ID/Investigator# 23302, Brasov, Romania|Site Reference ID/Investigator# 17962, Bucharest, Romania|Site Reference ID/Investigator# 17964, Bucharest, Romania|Site Reference ID/Investigator# 23304, Bucharest, Romania|Site Reference ID/Investigator# 17961, Cluj Napoca, Romania|Site Reference ID/Investigator# 23305, Craiova, Romania|Site Reference ID/Investigator# 24422, Moscow, Russian Federation|Site Reference ID/Investigator# 25063, Moscow, Russian Federation|Site Reference ID/Investigator# 25065, Moscow, Russian Federation|Site Reference ID/Investigator# 24423, Moscow, Russian Federation|Site Reference ID/Investigator# 22809, A Coruna, Spain|Site Reference ID/Investigator# 22807, Barcelona, Spain|Site Reference ID/Investigator# 22804, Madrid, Spain|Site Reference ID/Investigator# 22801, Madrid, Spain|Site Reference ID/Investigator# 22803, Pamplona Navarra, Spain|Site Reference ID/Investigator# 22800, Santander, Spain",,"https://ClinicalTrials.gov/show/NCT00707889"
640,"NCT00691964","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","No Results Available","Plaque Psoriasis","Biological: ABT-874|Biological: etanercept|Drug: placebo","Proportion of subjects who achieve a PGA of 0 or 1 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 12|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 12","AbbVie (prior sponsor, Abbott)|Paragon Biomedical|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","347","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-114","May 2008","March 2009","March 2009","June 6, 2008",,"January 21, 2013","Site Reference ID/Investigator# 8478, Tucson, Arizona, United States|Site Reference ID/Investigator# 8462, Fresno, California, United States|Site Reference ID/Investigator# 8454, Los Angeles, California, United States|Site Reference ID/Investigator# 8476, Denver, Colorado, United States|Site Reference ID/Investigator# 9641, Miami, Florida, United States|Site Reference ID/Investigator# 8463, Alpharetta, Georgia, United States|Site Reference ID/Investigator# 8479, Arlington Heights, Illinois, United States|Site Reference ID/Investigator# 8527, Schaumburg, Illinois, United States|Site Reference ID/Investigator# 9001, Skokie, Illinois, United States|Site Reference ID/Investigator# 8466, West Dundee, Illinois, United States|Site Reference ID/Investigator# 8467, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 8464, Boston, Massachusetts, United States|Site Reference ID/Investigator# 8459, St. Louis, Missouri, United States|Site Reference ID/Investigator# 8473, East Windsor, New Jersey, United States|Site Reference ID/Investigator# 8457, New Brunswick, New Jersey, United States|Site Reference ID/Investigator# 8447, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 8475, New York, New York, United States|Site Reference ID/Investigator# 8468, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 8460, Cleveland, Ohio, United States|Site Reference ID/Investigator# 9762, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 8480, Lake Oswego, Oregon, United States|Site Reference ID/Investigator# 8469, Portland, Oregon, United States|Site Reference ID/Investigator# 9566, Portland, Oregon, United States|Site Reference ID/Investigator# 9761, Hershey, Pennsylvania, United States|Site Reference ID/Investigator# 8471, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 8449, Johnston, Rhode Island, United States|Site Reference ID/Investigator# 8448, Providence, Rhode Island, United States|Site Reference ID/Investigator# 8456, Greer, South Carolina, United States|Site Reference ID/Investigator# 8458, Goodlettsville, Tennessee, United States|Site Reference ID/Investigator# 8461, Austin, Texas, United States|Site Reference ID/Investigator# 10542, Dallas, Texas, United States|Site Reference ID/Investigator# 8452, Houston, Texas, United States|Site Reference ID/Investigator# 8474, San Antonio, Texas, United States|Site Reference ID/Investigator# 8482, Tyler, Texas, United States|Site Reference ID/Investigator# 8472, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT00691964"
641,"NCT00686933","Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Attention-Deficit/Hyperactivity Disorder","Drug: ABT-089","CAARS:Inv|CGI-ADHD-S|CAARS:Self|BRIEF-A|AAQOL|WPAI|FTND","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 60 Years   (Adult)","Phase 2","117","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-425","May 2008","October 2008","October 2008","May 30, 2008",,"January 21, 2013","Site Reference ID/Investigator# 8315, Lafayette, California, United States|Site Reference ID/Investigator# 8306, Jacksonville, Florida, United States|Site Reference ID/Investigator# 8308, Orlando, Florida, United States|Site Reference ID/Investigator# 8314, Overland Park, Kansas, United States|Site Reference ID/Investigator# 8307, Farmington Hills, Michigan, United States|Site Reference ID/Investigator# 8318, Troy, Michigan, United States|Site Reference ID/Investigator# 8309, Eugene, Oregon, United States|Site Reference ID/Investigator# 8316, Portland, Oregon, United States|Site Reference ID/Investigator# 8310, Memphis, Tennessee, United States|Site Reference ID/Investigator# 8319, Virginia Beach, Virginia, United States|Site Reference ID/Investigator# 8305, Bellevue, Washington, United States|Site Reference ID/Investigator# 8320, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00686933"
642,"NCT00686374","Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806",,"Completed","Has Results","Crohn's Disease","Biological: Adalimumab","Number of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time|Number of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score Over Time|Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Remission Over Time|Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Response Over Time|Number of Participants in Steroid-free Pediatric Crohn's Disease Activity Index (PCDAI) Remission Over Time|Number of Participants in Steroid-free Crohn's Disease Activity Index (CDAI) Remission Over Time|Mean Change From Baseline in Pediatric Crohn's Disease Activity Index (PCDAI) Over Time|Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) Over Time","AbbVie (prior sponsor, Abbott)|AbbVie","All","7 Years to 18 Years   (Child, Adult)","Phase 3","100","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-807|2007-006494-90","May 1, 2008","April 4, 2017","April 4, 2017","May 29, 2008","April 20, 2018","July 2, 2018",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT00686374/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT00686374/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00686374"
643,"NCT00679731","A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: ABT-874|Drug: Methotrexate","Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 24|The proportion of subjects who achieve a PGA score of 0 or 1 at Week 24|Proportion of subjects who achieve a PASI 75 response relative to baseline at Week 52|The proportion of subjects who achieve a PGA score of 0 or 1 at Week 52|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 24|Changes from Baseline in the DLQI total score at Week 24|Proportion of subjects who achieve a PASI 100 response relative to baseline at Week 52|Changes from Baseline in the DLQI total score at Week 52","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","317","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-255|2007-004687-47","April 2008","November 2009","November 2009","May 19, 2008",,"January 29, 2013","Site Reference ID/Investigator# 9904, Graz, Austria|Site Reference ID/Investigator# 11001, Vienna, Austria|Site Reference ID/Investigator# 12763, Vienna, Austria|Site Reference ID/Investigator# 8022, Brussels, Belgium|Site Reference ID/Investigator# 13104, Barrie, Canada|Site Reference ID/Investigator# 13161, Halifax, Canada|Site Reference ID/Investigator# 11864, Hamilton, Canada|Site Reference ID/Investigator# 13223, Quebec City, Canada|Site Reference ID/Investigator# 13221, Waterloo, Canada|Site Reference ID/Investigator# 11381, Aarhus, Denmark|Site Reference ID/Investigator# 11841, Copenhagen NV, Denmark|Site Reference ID/Investigator# 8030, Helsinki, Finland|Site Reference ID/Investigator# 8033, Kuopio, Finland|Site Reference ID/Investigator# 8021, Lahti, Finland|Site Reference ID/Investigator# 8026, Turku, Finland|Site Reference ID/Investigator# 11661, Creteil, France|Site Reference ID/Investigator# 11504, Nice, France|Site Reference ID/Investigator# 11161, Paris, France|Site Reference ID/Investigator# 10963, Toulouse Cedex 9, France|Site Reference ID/Investigator# 8025, Berlin, Germany|Site Reference ID/Investigator# 8024, Frankfurt am Main, Germany|Site Reference ID/Investigator# 8032, Hamburg, Germany|Site Reference ID/Investigator# 8027, Kiel, Germany|Site Reference ID/Investigator# 8019, Muenster, Germany|Site Reference ID/Investigator# 8035, Munich, Germany|Site Reference ID/Investigator# 8023, Tuebingen, Germany|Site Reference ID/Investigator# 13422, Athens, Greece|Site Reference ID/Investigator# 13462, Athens, Greece|Site Reference ID/Investigator# 13461, Thessaloniki, Greece|Site Reference ID/Investigator# 12381, Milan, Italy|Site Reference ID/Investigator# 9583, Modena, Italy|Site Reference ID/Investigator# 8551, Rome, Italy|Site Reference ID/Investigator# 11701, Amsterdam, Netherlands|Site Reference ID/Investigator# 8363, Nijmegen, Netherlands|Site Reference ID/Investigator# 13481, Barcelona, Spain|Site Reference ID/Investigator# 10702, Madrid, Spain|Site Reference ID/Investigator# 13163, Seville, Spain|Site Reference ID/Investigator# 8362, Valencia, Spain|Site Reference ID/Investigator# 8185, Stockholm, Sweden|Site Reference ID/Investigator# 10203, Geneva 14, Switzerland|Site Reference ID/Investigator# 8020, Zurich, Switzerland|Site Reference ID/Investigator# 12401, Aberdeen, United Kingdom|Site Reference ID/Investigator# 8034, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00679731"
644,"NCT00667446","Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty",,"Completed","Has Results","Precocious|Leuprolide Acetate|Luteinizing Hormone (LH)|Gonadotrophin-releasing Hormone Agonist (GnRHa)|Tanner Staging|Depot Formulation|Suppression of LH|Central Precocious Puberty (CPP)|Gonadotrophin-releasing Hormone (GnRH)|Lupron|GnRH Analog|Pediatrics Central Precocious Puberty","Drug: Leuprolide Acetate 3 Month Depot","Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone|Percentage of Female Participants With Suppression of Basal Estradiol (Assay 1)|Percentage of Female Participants With Suppression of Basal Estradiol (Assay 2)|Percentage of Male Participants With Suppression of Basal Testosterone|Mean Peak-stimulated Luteinizing Hormone Concentration by Visit|Percentage of Female Participants With Suppression of the Physical Signs of Puberty (Breast Development)|Percentage of Male Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development)|Change From Baseline in Growth Rate|Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age","AbbVie (prior sponsor, Abbott)|AbbVie","All","Child, Adult, Older Adult","Phase 3","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L-CP07-177","December 2008","October 2012","January 2013","April 28, 2008","December 10, 2013","January 9, 2014","Site Reference ID/Investigator# 13521, Birmingham, Alabama, United States|Site Reference ID/Investigator# 14922, Long Beach, California, United States|Site Reference ID/Investigator# 26043, Los Angeles, California, United States|Site Reference ID/Investigator# 20802, San Diego, California, United States|Site Reference ID/Investigator# 22425, Greenwood Village, Colorado, United States|Site Reference ID/Investigator# 18181, Jacksonville, Florida, United States|Site Reference ID/Investigator# 26364, Pensacola, Florida, United States|Site Reference ID/Investigator# 26983, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 20821, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 23643, Minneapolis, Minnesota, United States|Site Reference ID/Investigator# 23502, St. Paul, Minnesota, United States|Site Reference ID/Investigator# 14121, Kansas City, Missouri, United States|Site Reference ID/Investigator# 23802, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 13324, Tulsa, Oklahoma, United States|Site Reference ID/Investigator# 16506, Hershey, Pennsylvania, United States|Site Reference ID/Investigator# 14024, Seattle, Washington, United States|Site Reference ID/Investigator# 23182, Bayamon, Puerto Rico|Site Reference ID/Investigator# 21721, Ponce, Puerto Rico|Site Reference ID/Investigator# 25908, Rio Piedras, Puerto Rico|Site Reference ID/Investigator# 23082, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00667446"
645,"NCT00660673","Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD",,"Active, not recruiting","No Results Available","Advanced Parkinson's Disease","Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump","Adverse Events|Long Term Safety and Maintenance of Efficacy","AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","All","30 Years to 99 Years   (Adult, Older Adult)","Phase 3","262","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S187.3.005|2008-001329-33","November 13, 2009","September 15, 2020","November 4, 2020","April 17, 2008",,"November 14, 2019","University of Alabama at Birmingham - Main /ID# 49941, Birmingham, Alabama, United States|The Research Ctr Southern CA /ID# 49928, Carlsbad, California, United States|Parkinson's and Movement /ID# 49915, Fountain Valley, California, United States|Usc /Id# 49913, Los Angeles, California, United States|Colorado Neurological Institut /ID# 49927, Englewood, Colorado, United States|MedStar Georgetown University Hospital /ID# 49931, Washington, District of Columbia, United States|Bradenton Research Center, Inc /ID# 49929, Bradenton, Florida, United States|Neurologic Consultants, PA /ID# 49918, Fort Lauderdale, Florida, United States|University of Florida /ID# 49935, Gainesville, Florida, United States|University of Florida /ID# 49922, Jacksonville, Florida, United States|Charlotte Neurological Service /ID# 49916, Port Charlotte, Florida, United States|University of South Florida /ID# 49919, Tampa, Florida, United States|Georgia Regents University /ID# 49938, Augusta, Georgia, United States|Northwestern University Feinberg School of Medicine /ID# 49944, Chicago, Illinois, United States|Rush University Medical Center /ID# 49930, Chicago, Illinois, United States|University of Kentucky Chandler Medical Center /ID# 49940, Lexington, Kentucky, United States|Louisiana State Univ HSC /ID# 49945, Shreveport, Louisiana, United States|Univ Maryland School Medicine /ID# 49934, Baltimore, Maryland, United States|Johns Hopkins University /ID# 49937, Baltimore, Maryland, United States|Washington University-School of Medicine /ID# 49933, Saint Louis, Missouri, United States|Univ Nebraska Med Ctr /ID# 49911, Omaha, Nebraska, United States|North Shore University Hospital /ID# 49932, New Hyde Park, New York, United States|Icahn School of Med Mt. Sinai /ID# 49942, New York, New York, United States|Weill Cornell Medicine /ID# 49943, New York, New York, United States|Raleigh Neurology Associates /ID# 49923, Raleigh, North Carolina, United States|Wake Forest Univ HS /ID# 49939, Winston-Salem, North Carolina, United States|University of Cincinnati /ID# 49914, Cincinnati, Ohio, United States|Cleveland Clinic Main Campus /ID# 76173, Cleveland, Ohio, United States|University of Vermont Medical Center /ID# 49912, Burlington, Vermont, United States|King County Public Hospital /ID# 49917, Kirkland, Washington, United States|Froedtert and Medical College /ID# 49924, Milwaukee, Wisconsin, United States|Westmead Hospital /ID# 50081, Westmead, New South Wales, Australia|Royal Adelaide Hospital /ID# 50083, Adelaide, South Australia, Australia|Austin Hospital /ID# 50082, Heidelberg, Victoria, Australia|Zeidler Ledcor Centre /ID# 78476, Edmonton, Alberta, Canada|Toronto Western Hospital /ID# 75913, Toronto, Ontario, Canada|CHUM - Notre-Dame Hospital /ID# 74513, Montréal, Quebec, Canada|Fakultni Nemocnice v Motole /ID# 50084, Prague 5, Praha 5, Czechia|Fakultni Nemocnice u SvateAnny /ID# 50085, Brno, Czechia|FN Hradec Kralove /ID# 50088, Hradec Kralove, Czechia|Multiscan s.r.o. /ID# 50087, Pardubice, Czechia|VFN Prague /ID# 50086, Prague, Czechia|Tel Aviv Sourasky Medical Ctr /ID# 50089, Tel Aviv-Yafo, Tel-Aviv, Israel|Waikato Hospital /ID# 50091, Hamilton, Waikato, New Zealand|Auckland City Hospital /ID# 50093, Auckland, New Zealand|Canterbury District Health Boa /ID# 50090, Christchurch, New Zealand|Wellington Hospital (Capital and Coast District Health Board) /ID# 50092, Wellington, New Zealand|Szpital Miejski Dr Jonschera /ID# 50096, Lodz, Poland|NZOZ Centrum Medyczne HCP /ID# 50094, Poznan, Poland|Ctr Hosp Univ Coimbra, EPE /ID# 50098, Coimbra, Portugal|Hospital de Santa Maria /ID# 50099, Lisbon, Portugal|Centro Hospitalar de Sao Joao, EPE /ID# 50101, Porto, Portugal|Ltd Liability Co Scientific Re /ID# 50104, Kazan, Tatarstan, Respublika, Russian Federation|State Inst Neurology RAMS /ID# 50102, Moscow, Russian Federation|Military Med Academy SM Kirov /ID# 50103, St. Petersburg, Russian Federation|St. Petersburg State Medical U /ID# 50107, St. Petersburg, Russian Federation|City Clinical Hospital #40 /ID# 50106, St. Petersburg, Russian Federation|King Chulalongkorn Mem Hosp /ID# 50108, Bangkok, Thailand|Siriraj Hospital /ID# 50109, Bangkok, Thailand|The Walton Centre /ID# 50003, Liverpool, United Kingdom|Nat Hosp Neurology & Surgery /ID# 50002, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00660673"
646,"NCT00660387","Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",,"Completed","Has Results","Advanced Parkinson's Disease","Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo Gel|Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube","Change From Baseline to Week 12 in Average Daily Normalized ""Off"" Time|Change From Baseline in Average Daily Normalized ""On"" Time Without Troublesome Dyskinesia at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Week 12|Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Week 12|Change From Baseline in UPDRS Part III Score at Week 12|Change From Baseline in EuroQual Quality of Life - 5 Dimensions (EQ-5D) Summary Index at Week 12|Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Week 12|Change From Baseline in Average Daily Normalized ""On"" Time With Troublesome Dyskinesia at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Questions 32, 33, and 34 at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Week 12|Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Week 12|Employment Impairment (EMP) I Status at Baseline|Employment Impairment (EMP) II Status at Week 12","AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","35","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S187.3.002|2007-003814-32","December 2009","October 2011","October 2011","April 17, 2008","January 16, 2015","January 16, 2015","Site Reference ID/Investigator# 45931, Birmingham, Alabama, United States|Site Reference ID/Investigator# 45910, Fountain Valley, California, United States|Site Reference ID/Investigator# 45925, Oceanside, California, United States|Site Reference ID/Investigator# 45912, Port Charlotte, Florida, United States|Site Reference ID/Investigator# 45935, Chicago, Illinois, United States|Site Reference ID/Investigator# 45930, Lexington, Kentucky, United States|Site Reference ID/Investigator# 45934, New York, New York, United States|Site Reference ID/Investigator# 45929, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 45908, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 45922, Cleveland, Ohio, United States|Site Reference ID/Investigator# 45915, Kirkland, Washington, United States|Site Reference ID/Investigator# 45904, Auckland, New Zealand|Site Reference ID/Investigator# 45902, Christchurch, New Zealand|Site Reference ID/Investigator# 45905, Hamilton, New Zealand",,"https://ClinicalTrials.gov/show/NCT00660387"
647,"NCT00649207","A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases",,"Completed","No Results Available","Brain Diseases|Brain Neoplasms|Central Nervous System Diseases|Neoplasm Metastasis|Nervous System Neoplasms","Drug: ABT-888|Radiation: Whole Brain Radiation Therapy","Determine the maximum tolerated dose of ABT-888 in combination with whole brain radiation therapy|Safety Assessment Physical and Neurological Exam|Safety Assessment Mini-Mental State Examination|Safety Assessment Laboratory testing","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1","80","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-128","March 2008","March 2013","March 2013","April 1, 2008",,"November 21, 2017","Site Reference ID/Investigator# 8334, Atlanta, Georgia, United States|Site Reference ID/Investigator# 52462, Chicago, Illinois, United States|Site Reference ID/Investigator# 24483, Kansas City, Kansas, United States|Site Reference ID/Investigator# 7180, Baltimore, Maryland, United States|Site Reference ID/Investigator# 19021, Detroit, Michigan, United States|Site Reference ID/Investigator# 6344, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 6653, Madison, Wisconsin, United States|Site Reference ID/Investigator# 18542, Toronto, Canada|Site Reference ID/Investigator# 46322, Ponce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00649207"
648,"NCT00648999","Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients",,"Completed","No Results Available","Human Immunodeficiency Virus","Drug: lopinavir/ritonavir","Quality of Life|CD4|Adverse Event Monitoring","AbbVie (prior sponsor, Abbott)|AbbVie","All","17 Years and older   (Child, Adult, Older Adult)","Phase 4","207","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXI-P01-02","November 2003","December 2006","December 2006","April 1, 2008",,"March 15, 2013","Site Ref # / Investigator 4049, Mexico City, Distrito Federal, Mexico|Site Ref # / Investigator 4050, Mexico City, Distrito Federal, Mexico|Site Ref # / Investigator 4051, Mexico City, Distrito Federal, Mexico|Site Ref # / Investigator 4077, Mexico City, Distrito Federal, Mexico|Site Ref # / Investigator 4056, Mexico City, Distrito Federal, Mexico|Site Ref # / Investigator 4074, Leon, Guanajauto, Mexico|Site Ref # / Investigator 4054, Morelia, Michoacan, Mexico|Site Ref # / Investigator 4072, Tepic, Nayarit, Mexico|Site Ref # / Investigator 4055, Culiacan, Sinaloa, Mexico|Site Ref # / Investigator 4075, Merida, Yucatan, Mexico|Site Ref # / Investigator 4073, Chihuahua, Mexico|Site Ref # / Investigator 4052, Oaxaca, Mexico|Site Ref # / Investigator 4053, Puebla, Mexico",,"https://ClinicalTrials.gov/show/NCT00648999"
649,"NCT00645177","Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer",,"Completed","No Results Available","Metastatic Breast Cancer","Drug: ABT-869|Drug: paclitaxel|Drug: Placebo for ABT-869","Progression-free survival|Overall survival","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","Female","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-265|2007-005905-23","July 2008","December 2009","December 2009","March 27, 2008",,"January 29, 2013","Site Reference ID/Investigator# 8352, San Francisco, California, United States|Site Reference ID/Investigator# 6920, Harvey, Illinois, United States|Site Reference ID/Investigator# 10181, Durango, DGO., Mexico",,"https://ClinicalTrials.gov/show/NCT00645177"
650,"NCT00640419","Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Attention-Deficit/Hyperactivity Disorder","Drug: ABT-089|Drug: placebo","ADHD-RS-IV (HV)|CSHQ|CGI-P|BRIEF|CGI-ADHD-S","AbbVie (prior sponsor, Abbott)|AbbVie","All","6 Years to 12 Years   (Child)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-345","March 2008","July 2008","July 2008","March 21, 2008",,"January 18, 2013","Site Reference ID/Investigator# 7536, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 7954, Bradenton, Florida, United States|Site Reference ID/Investigator# 7543, Jacksonville, Florida, United States|Site Reference ID/Investigator# 7542, Orlando, Florida, United States|Site Reference ID/Investigator# 7537, Libertyville, Illinois, United States|Site Reference ID/Investigator# 7561, Overland Park, Kansas, United States|Site Reference ID/Investigator# 7560, Troy, Michigan, United States|Site Reference ID/Investigator# 7559, Omaha, Nebraska, United States|Site Reference ID/Investigator# 7541, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7564, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 7538, Portland, Oregon, United States|Site Reference ID/Investigator# 7540, Memphis, Tennessee, United States|Site Reference ID/Investigator# 7544, Bellevue, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00640419"
651,"NCT00640185","Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Attention-Deficit/Hyperactivity Disorder","Drug: ABT-089|Drug: Placebo","CAARS: Inv Total Score|CAARS Inattentive and Hyperactive/Impulsivity Sub-scale scores, CAARS ADHD Index, CGI-ADHD-S, AISRS, CAARS:Self|TASS, AAQoL, WPAI|BRIEF-A, FTND|QSU-Brief, Number of Cigarettes smoked per day","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 60 Years   (Adult)","Phase 2","160","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M10-346","March 2008","August 2008","August 2008","March 21, 2008",,"January 18, 2013","Site Reference ID/Investigator# 7546, Lafayette, California, United States|Site Reference ID/Investigator# 7551, Jacksonville, Florida, United States|Site Reference ID/Investigator# 7553, Orlando, Florida, United States|Site Reference ID/Investigator# 7545, Overland Park, Kansas, United States|Site Reference ID/Investigator# 7552, Farmington Hills, Michigan, United States|Site Reference ID/Investigator# 7548, Troy, Michigan, United States|Site Reference ID/Investigator# 7554, Eugene, Oregon, United States|Site Reference ID/Investigator# 7547, Portland, Oregon, United States|Site Reference ID/Investigator# 7555, Memphis, Tennessee, United States|Site Reference ID/Investigator# 7549, Virginia Beach, Virginia, United States|Site Reference ID/Investigator# 7550, Bellevue, Washington, United States|Site Reference ID/Investigator# 7631, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00640185"
652,"NCT00635193","Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)",,"Completed","No Results Available","Ovarian Cancer, Primary Peritoneal Cancer","Drug: M200 (Volociximab)|Drug: Liposomal Doxorubicin","To evaluate the efficacy of volociximab in combination with liposomal doxorubicin in advanced epithelial ovarian cancer or primary peritoneal cancer. To evaluate the safety and tolerability of volociximab in combination with liposomal doxorubicin.","AbbVie (prior sponsor, Abbott)|Biogen|AbbVie","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","206OC202|2007-000509-31","July 2007","October 2008","October 2009","March 13, 2008",,"January 18, 2013","Site Reference ID/Investigator# 75281, Anaheim, California, United States|Site Reference ID/Investigator# 75275, Redondo Beach, California, United States|Site Reference ID/Investigator# 75296, Sunrise, Florida, United States|Site Reference ID/Investigator# 75299, Atlanta, Georgia, United States|Site Reference ID/Investigator# 75300, Savannah, Georgia, United States|Site Reference ID/Investigator# 75301, Hinsdale, Illinois, United States|Site Reference ID/Investigator# 75274, Baltimore, Maryland, United States|Site Reference ID/Investigator# 75294, Jackson City, Missouri, United States|Site Reference ID/Investigator# 75279, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 75295, Corpus Christi, Texas, United States|Site Reference ID/Investigator# 75280, Dallas, Texas, United States|Site Reference ID/Investigator# 75297, Danville, Virginia, United States|Site Reference ID/Investigator# 75298, Williamsburg, Virginia, United States|Site Reference ID/Investigator# 75278, Green Bay, Wisconsin, United States|Site Reference ID/Investigator# 75334, Toorak Gardens, Australia|Site Reference ID/Investigator# 75335, Woodville South, Australia|Site Reference ID/Investigator# 75337, Antwerp, Belgium|Site Reference ID/Investigator# 75336, Brussels, Belgium|Site Reference ID/Investigator# 75338, Leuven, Belgium|Site Reference ID/Investigator# 75415, Milan, Italy|Site Reference ID/Investigator# 75333, Milan, Italy|Site Reference ID/Investigator# 75344, Bialystok, Poland|Site Reference ID/Investigator# 75339, Krakow, Poland|Site Reference ID/Investigator# 75341, Lublin, Poland|Site Reference ID/Investigator# 75342, Poznan, Poland|Site Reference ID/Investigator# 75343, Poznan, Poland|Site Reference ID/Investigator# 75345, Szczecin, Poland|Site Reference ID/Investigator# 75340, Wroclaw, Poland|Site Reference ID/Investigator# 75346, Moscow, Russian Federation|Site Reference ID/Investigator# 75348, Moscow, Russian Federation|Site Reference ID/Investigator# 75347, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 75349, Barcelona, Spain|Site Reference ID/Investigator# 75351, Barcelona, Spain|Site Reference ID/Investigator# 75352, Barcelona, Spain|Site Reference ID/Investigator# 75350, Girona, Spain|Site Reference ID/Investigator# 75353, Madrid, Spain|Site Reference ID/Investigator# 75354, Stockholm, Sweden|Site Reference ID/Investigator# 75355, Umea, Sweden|Site Reference ID/Investigator# 75416, Bellinzona, Switzerland",,"https://ClinicalTrials.gov/show/NCT00635193"
653,"NCT00626002","Open Label Continuation Study in Moderate to Severe Psoriasis",,"Completed","No Results Available","Moderate to Severe Plaque Psoriasis","Drug: ABT-874","Proportion of subjects achieving PGA ""clear"" (0) or ""minimal"" (1) scores by visit.|Proportion of subjects achieving a > PASI 50 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit.|Proportion of subjects achieving a > PASI 75 clinical response that is defined as a reduction on PASI scores by at least 50% relative to Baseline, by visit.|AEs, serious adverse events (SAEs), laboratory data, ADA and vital signs will be assessed throughout the study","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","2301","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-016|2007-005955-40","February 2008","October 2011","October 2011","February 29, 2008",,"January 30, 2013","Site Reference ID/Investigator# 7496, Birmingham, Alabama, United States|Site Reference ID/Investigator# 8438, Birmingham, Alabama, United States|Site Reference ID/Investigator# 7522, Huntsville, Alabama, United States|Site Reference ID/Investigator# 7774, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 7435, Tucson, Arizona, United States|Site Reference ID/Investigator# 7933, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 7234, Bakersfield, California, United States|Site Reference ID/Investigator# 8249, Fresno, California, United States|Site Reference ID/Investigator# 7332, Irvine, California, United States|Site Reference ID/Investigator# 7239, Los Angeles, California, United States|Site Reference ID/Investigator# 8390, Oceanside, California, United States|Site Reference ID/Investigator# 7503, San Diego, California, United States|Site Reference ID/Investigator# 7520, San Diego, California, United States|Site Reference ID/Investigator# 7010, San Diego, California, United States|Site Reference ID/Investigator# 10962, San Francisco, California, United States|Site Reference ID/Investigator# 7334, Santa Monica, California, United States|Site Reference ID/Investigator# 7793, Vallejo, California, United States|Site Reference ID/Investigator# 7929, Denver, Colorado, United States|Site Reference ID/Investigator# 7436, Longmont, Colorado, United States|Site Reference ID/Investigator# 7521, New Haven, Connecticut, United States|Site Reference ID/Investigator# 7653, Doral, Florida, United States|Site Reference ID/Investigator# 8341, Jacksonville, Florida, United States|Site Reference ID/Investigator# 7716, Miami, Florida, United States|Site Reference ID/Investigator# 7657, Miami, Florida, United States|Site Reference ID/Investigator# 10841, South Miami, Florida, United States|Site Reference ID/Investigator# 7893, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 7331, Alpharetta, Georgia, United States|Site Reference ID/Investigator# 9743, Atlanta, Georgia, United States|Site Reference ID/Investigator# 7891, Newnan, Georgia, United States|Site Reference ID/Investigator# 7932, Snellville, Georgia, United States|Site Reference ID/Investigator# 8379, Arlington Heights, Illinois, United States|Site Reference ID/Investigator# 8798, Maywood, Illinois, United States|Site Reference ID/Investigator# 10703, Schaumburg, Illinois, United States|Site Reference ID/Investigator# 6950, Skokie, Illinois, United States|Site Reference ID/Investigator# 7892, West Dundee, Illinois, United States|Site Reference ID/Investigator# 6933, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 10422, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 16581, Plainfield, Indiana, United States|Site Reference ID/Investigator# 7992, Overland Park, Kansas, United States|Site Reference ID/Investigator# 17193, Henderson, Kentucky, United States|Site Reference ID/Investigator# 8528, Louisville, Kentucky, United States|Site Reference ID/Investigator# 9962, Owensboro, Kentucky, United States|Site Reference ID/Investigator# 8529, Andover, Massachusetts, United States|Site Reference ID/Investigator# 8149, Boston, Massachusetts, United States|Site Reference ID/Investigator# 9823, Detroit, Michigan, United States|Site Reference ID/Investigator# 7883, Fort Gratiot, Michigan, United States|Site Reference ID/Investigator# 7238, Grand Blanc, Michigan, United States|Site Reference ID/Investigator# 7656, Fridley, Minnesota, United States|Site Reference ID/Investigator# 6930, St. Louis, Missouri, United States|Site Reference ID/Investigator# 6949, St. Louis, Missouri, United States|Site Reference ID/Investigator# 7240, Omaha, Nebraska, United States|Site Reference ID/Investigator# 9567, Omaha, Nebraska, United States|Site Reference ID/Investigator# 7757, Berlin, New Jersey, United States|Site Reference ID/Investigator# 7330, East Windsor, New Jersey, United States|Site Reference ID/Investigator# 7882, New Brunswick, New Jersey, United States|Site Reference ID/Investigator# 7455, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 8078, Buffalo, New York, United States|Site Reference ID/Investigator# 8392, New York, New York, United States|Site Reference ID/Investigator# 8006, New York, New York, United States|Site Reference ID/Investigator# 7230, New York, New York, United States|Site Reference ID/Investigator# 10201, New York, New York, United States|Site Reference ID/Investigator# 8037, Rochester, New York, United States|Site Reference ID/Investigator# 7333, Stoney Brook, New York, United States|Site Reference ID/Investigator# 7434, Hickory, North Carolina, United States|Site Reference ID/Investigator# 8117, Wilmington, North Carolina, United States|Site Reference ID/Investigator# 9681, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 6945, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 23345, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7044, Cleveland, Ohio, United States|Site Reference ID/Investigator# 7899, Columbus, Ohio, United States|Site Reference ID/Investigator# 8389, Dayton, Ohio, United States|Site Reference ID/Investigator# 11181, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 6936, Lake Oswego, Oregon, United States|Site Reference ID/Investigator# 7703, Portland, Oregon, United States|Site Reference ID/Investigator# 6948, Portland, Oregon, United States|Site Reference ID/Investigator# 11424, Portland, Oregon, United States|Site Reference ID/Investigator# 8494, Hershey, Pennsylvania, United States|Site Reference ID/Investigator# 7930, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 6934, Johnston, Rhode Island, United States|Site Reference ID/Investigator# 6935, Providence, Rhode Island, United States|Site Reference ID/Investigator# 7785, Greer, South Carolina, United States|Site Reference ID/Investigator# 7497, Goodlettsville, Tennessee, United States|Site Reference ID/Investigator# 7388, Knoxville, Tennessee, United States|Site Reference ID/Investigator# 6931, Nashville, Tennessee, United States|Site Reference ID/Investigator# 7684, Arlington, Texas, United States|Site Reference ID/Investigator# 10842, Austin, Texas, United States|Site Reference ID/Investigator# 7498, Dallas, Texas, United States|Site Reference ID/Investigator# 6947, Dallas, Texas, United States|Site Reference ID/Investigator# 6944, Houston, Texas, United States|Site Reference ID/Investigator# 7758, San Antonio, Texas, United States|Site Reference ID/Investigator# 8108, San Antonio, Texas, United States|Site Reference ID/Investigator# 6937, Tyler, Texas, United States|Site Reference ID/Investigator# 7655, Webster, Texas, United States|Site Reference ID/Investigator# 10207, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 6946, Norfolk, Virginia, United States|Site Reference ID/Investigator# 6932, Seattle, Washington, United States|Site Reference ID/Investigator# 10306, Spokane, Washington, United States|Site Reference ID/Investigator# 7884, Milwaukee, Wisconsin, United States|Site Reference ID/Investigator# 16845, Graz, Austria|Site Reference ID/Investigator# 18183, Vienna, Austria|Site Reference ID/Investigator# 15761, Brussels, Belgium|Site Reference ID/Investigator# 7991, Barrie, Canada|Site Reference ID/Investigator# 8047, Calgary, Canada|Site Reference ID/Investigator# 7996, Edmonton, Canada|Site Reference ID/Investigator# 6996, Halifax, Canada|Site Reference ID/Investigator# 7236, Hamilton, Canada|Site Reference ID/Investigator# 6995, Laval, Canada|Site Reference ID/Investigator# 6998, London, Canada|Site Reference ID/Investigator# 7043, London, Canada|Site Reference ID/Investigator# 7329, Markham, Canada|Site Reference ID/Investigator# 6999, Montreal, Canada|Site Reference ID/Investigator# 7652, Montreal, Canada|Site Reference ID/Investigator# 7006, North Bay, Canada|Site Reference ID/Investigator# 8102, Ottawa, Canada|Site Reference ID/Investigator# 6993, Quebec City, Canada|Site Reference ID/Investigator# 8112, St. John's, Canada|Site Reference ID/Investigator# 7931, Surrey, Canada|Site Reference ID/Investigator# 8118, Vancouver, Canada|Site Reference ID/Investigator# 6997, Vancouver, Canada|Site Reference ID/Investigator# 6994, Waterloo, Canada|Site Reference ID/Investigator# 8111, Westmount, Canada|Site Reference ID/Investigator# 7005, Windsor, Canada|Site Reference ID/Investigator# 7979, Windsor, Canada|Site Reference ID/Investigator# 8348, Winnipeg, Canada|Site Reference ID/Investigator# 17781, Aarhus, Denmark|Site Reference ID/Investigator# 18041, Copenhagen NV, Denmark|Site Reference ID/Investigator# 18661, Helsinki, Finland|Site Reference ID/Investigator# 18701, Kuopio, Finland|Site Reference ID/Investigator# 14962, Lahti, Finland|Site Reference ID/Investigator# 19241, Turku, Finland|Site Reference ID/Investigator# 18502, Nice, France|Site Reference ID/Investigator# 16781, Paris Cedex 10, France|Site Reference ID/Investigator# 18506, Toulouse, Cedex 9, France|Site Reference ID/Investigator# 16281, Berlin, Germany|Site Reference ID/Investigator# 15664, Frankfurt am Main, Germany|Site Reference ID/Investigator# 15663, Hamburg, Germany|Site Reference ID/Investigator# 16381, Kiel, Germany|Site Reference ID/Investigator# 16161, Muenster, Germany|Site Reference ID/Investigator# 16143, Munich, Germany|Site Reference ID/Investigator# 17676, Tuebingen, Germany|Site Reference ID/Investigator# 16282, Athens, Greece|Site Reference ID/Investigator# 15921, Athens, Greece|Site Reference ID/Investigator# 15922, Thessaloniki, Greece|Site Reference ID/Investigator# 15401, Modena, Italy|Site Reference ID/Investigator# 14881, Rome, Italy|Site Reference ID/Investigator# 19322, Barcelona, Spain|Site Reference ID/Investigator# 15341, Madrid, Spain|Site Reference ID/Investigator# 16142, Stockholm, Sweden|Site Reference ID/Investigator# 17721, Geneva 14, Switzerland|Site Reference ID/Investigator# 16749, Zurich, Switzerland|Site Reference ID/Investigator# 19045, Aberdeen, United Kingdom|Site Reference ID/Investigator# 15422, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00626002"
654,"NCT00616772","Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood","FIRST","Completed","Has Results","Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia","Drug: ABT-335|Drug: Placebo|Other: Atorvastatin","Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)|Rate of Change in Mean of Maximal Posterior-wall Carotid Intima-media Thickness (cIMT)|Rate of Change in Composite of Mean of the Mean Posterior-wall Intima-media Thickness (IMT)|Rate of Change in Composite of Mean of Maximal Posterior-wall Intima-media Thickness (IMT)|Rate of Change in Composite of Mean of Maximal Posterior-wall and Anterior-wall Intima-media Thickness (IMT)","AbbVie (prior sponsor, Abbott)|AbbVie","All","45 Years and older   (Adult, Older Adult)","Phase 3","682","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-158","February 2008","September 2012","September 2012","February 15, 2008","January 20, 2014","July 2, 2018","Site Reference ID/Investigator# 6747, Chandler, Arizona, United States|Site Reference ID/Investigator# 7089, Gilbert, Arizona, United States|Site Reference ID/Investigator# 7097, Mesa, Arizona, United States|Site Reference ID/Investigator# 26394, Phoenix, Arizona, United States|Site Reference ID/Investigator# 6848, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 7059, Tempe, Arizona, United States|Site Reference ID/Investigator# 7094, Tempe, Arizona, United States|Site Reference ID/Investigator# 7098, Tempe, Arizona, United States|Site Reference ID/Investigator# 25082, Anaheim, California, United States|Site Reference ID/Investigator# 21347, Corona, California, United States|Site Reference ID/Investigator# 21483, Garden Grove, California, United States|Site Reference ID/Investigator# 21351, Huntington Beach, California, United States|Site Reference ID/Investigator# 21346, Laguna Hills, California, United States|Site Reference ID/Investigator# 21341, Long Beach, California, United States|Site Reference ID/Investigator# 21342, Norwalk, California, United States|Site Reference ID/Investigator# 21321, Santa Ana, California, United States|Site Reference ID/Investigator# 26242, Tustin, California, United States|Site Reference ID/Investigator# 15283, Arvada, Colorado, United States|Site Reference ID/Investigator# 7085, Aurora, Colorado, United States|Site Reference ID/Investigator# 6749, Denver, Colorado, United States|Site Reference ID/Investigator# 7077, Denver, Colorado, United States|Site Reference ID/Investigator# 7092, Golden, Colorado, United States|Site Reference ID/Investigator# 7722, Littleton, Colorado, United States|Site Reference ID/Investigator# 7721, Littleton, Colorado, United States|Site Reference ID/Investigator# 11925, Aventura, Florida, United States|Site Reference ID/Investigator# 15861, Boynton Beach, Florida, United States|Site Reference ID/Investigator# 14422, Deerfield Beach, Florida, United States|Site Reference ID/Investigator# 19281, Delray Beach, Florida, United States|Site Reference ID/Investigator# 20881, Hollywood, Florida, United States|Site Reference ID/Investigator# 20882, Kissimmee, Florida, United States|Site Reference ID/Investigator# 19321, Melbourne, Florida, United States|Site Reference ID/Investigator# 21353, Melbourne, Florida, United States|Site Reference ID/Investigator# 18503, Melbourne, Florida, United States|Site Reference ID/Investigator# 18841, Vero Beach, Florida, United States|Site Reference ID/Investigator# 19961, Vero Beach, Florida, United States|Site Reference ID/Investigator# 7166, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 6744, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 19301, Atlanta, Georgia, United States|Site Reference ID/Investigator# 7051, Atlanta, Georgia, United States|Site Reference ID/Investigator# 7109, Atlanta, Georgia, United States|Site Reference ID/Investigator# 7326, Dawsonville, Georgia, United States|Site Reference ID/Investigator# 7325, Decatur, Georgia, United States|Site Reference ID/Investigator# 7057, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 7101, Dunwoody, Georgia, United States|Site Reference ID/Investigator# 11324, Roswell, Georgia, United States|Site Reference ID/Investigator# 6741, Roswell, Georgia, United States|Site Reference ID/Investigator# 7103, Suwanee, Georgia, United States|Site Reference ID/Investigator# 10761, Addison, Illinois, United States|Site Reference ID/Investigator# 6748, Aurora, Illinois, United States|Site Reference ID/Investigator# 6742, Aurora, Illinois, United States|Site Reference ID/Investigator# 7128, Belleville, Illinois, United States|Site Reference ID/Investigator# 7069, Chicago, Illinois, United States|Site Reference ID/Investigator# 6849, Chicago, Illinois, United States|Site Reference ID/Investigator# 6867, Chicago, Illinois, United States|Site Reference ID/Investigator# 6751, Chicago, Illinois, United States|Site Reference ID/Investigator# 6847, Chicago, Illinois, United States|Site Reference ID/Investigator# 7049, Chicago, Illinois, United States|Site Reference ID/Investigator# 7093, Gurnee, Illinois, United States|Site Reference ID/Investigator# 6746, Hazel Crest, Illinois, United States|Site Reference ID/Investigator# 6743, Melrose Park, Illinois, United States|Site Reference ID/Investigator# 7090, Naperville, Illinois, United States|Site Reference ID/Investigator# 6750, Oak Brook, Illinois, United States|Site Reference ID/Investigator# 6788, Oak Park, Illinois, United States|Site Reference ID/Investigator# 6927, Vernon Hills, Illinois, United States|Site Reference ID/Investigator# 7076, Erlanger, Kentucky, United States|Site Reference ID/Investigator# 8103, Bloomington, Minnesota, United States|Site Reference ID/Investigator# 15121, Brooklyn Center, Minnesota, United States|Site Reference ID/Investigator# 7050, Edina, Minnesota, United States|Site Reference ID/Investigator# 7084, Edina, Minnesota, United States|Site Reference ID/Investigator# 6860, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 13182, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 14423, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 14541, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 6740, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 7053, Saint Louis, Missouri, United States|Site Reference ID/Investigator# 6784, Saint Peters, Missouri, United States|Site Reference ID/Investigator# 7063, Henderson, Nevada, United States|Site Reference ID/Investigator# 7070, Henderson, Nevada, United States|Site Reference ID/Investigator# 7106, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7518, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7119, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7129, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 7071, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7100, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 14321, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 21355, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7074, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7065, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 7075, Dayton, Ohio, United States|Site Reference ID/Investigator# 24802, Kettering, Ohio, United States|Site Reference ID/Investigator# 7068, Mason, Ohio, United States|Site Reference ID/Investigator# 7104, Bellaire, Texas, United States|Site Reference ID/Investigator# 7060, Carrollton, Texas, United States|Site Reference ID/Investigator# 15282, Dallas, Texas, United States|Site Reference ID/Investigator# 6745, Dallas, Texas, United States|Site Reference ID/Investigator# 7083, Dallas, Texas, United States|Site Reference ID/Investigator# 7127, Dallas, Texas, United States|Site Reference ID/Investigator# 7110, Dallas, Texas, United States|Site Reference ID/Investigator# 21356, Deer Park, Texas, United States|Site Reference ID/Investigator# 11923, Fort Worth, Texas, United States|Site Reference ID/Investigator# 7321, Houston, Texas, United States|Site Reference ID/Investigator# 21354, Houston, Texas, United States|Site Reference ID/Investigator# 21358, Houston, Texas, United States|Site Reference ID/Investigator# 26482, Houston, Texas, United States|Site Reference ID/Investigator# 7079, Houston, Texas, United States|Site Reference ID/Investigator# 7096, Houston, Texas, United States|Site Reference ID/Investigator# 7126, Houston, Texas, United States|Site Reference ID/Investigator# 8186, Houston, Texas, United States|Site Reference ID/Investigator# 11323, Houston, Texas, United States|Site Reference ID/Investigator# 7130, Houston, Texas, United States|Site Reference ID/Investigator# 11924, Irving, Texas, United States|Site Reference ID/Investigator# 13863, Irving, Texas, United States|Site Reference ID/Investigator# 7099, McKinney, Texas, United States|Site Reference ID/Investigator# 19121, New Braunfels, Texas, United States|Site Reference ID/Investigator# 26244, Pearland, Texas, United States|Site Reference ID/Investigator# 7105, Plano, Texas, United States|Site Reference ID/Investigator# 7061, San Antonio, Texas, United States|Site Reference ID/Investigator# 7320, San Antonio, Texas, United States|Site Reference ID/Investigator# 7914, San Antonio, Texas, United States|Site Reference ID/Investigator# 7058, San Antonio, Texas, United States|Site Reference ID/Investigator# 18402, San Antonio, Texas, United States|Site Reference ID/Investigator# 7052, San Antonio, Texas, United States|Site Reference ID/Investigator# 7062, San Antonio, Texas, United States|Site Reference ID/Investigator# 22947, San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00616772"
655,"NCT00573794","Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis",,"Completed","Has Results","Ulcerative Colitis","Biological: adalimumab","Partial Mayo Score: Change From Baseline Over Time|Mayo Score: Change From Baseline Over Time|Percentage of Participants With Remission Per Partial Mayo Score Over Time|Mayo Endoscopy Subscore: Change From Baseline Over Time|Mayo Rectal Bleeding Subscore: Change From Baseline Over Time|Mayo Physician's Global Assessment of Disease Severity Subscore: Change From Baseline Over Time|Mayo Stool Frequency Subscore: Change From Baseline Over Time|Inflammatory Bowel Disease Questionnaire (IBDQ): Change From Baseline Over Time|36-Item Short Form Health Survey Version 2 (SF-36) Mental Component Score: Change From Baseline Over Time|36-Item Short Form Health Survey Version 2 (SF-36) Physical Component Score: Change From Baseline Over Time|Work Productivity and Activity Impairment: General Health Version 2.0 (WPAI:GH) Work Time Missed Because of Ulcerative Colitis: Change From Baseline Over Time|WPAI:GH Impairment While Working: Change From Baseline Over Time|WPAI:GH Overall Work Impairment: Change From Baseline Over Time|WPAI:GH Activity Impairment: Change From Baseline Over Time|Colectomy Rate|Health Care Resource Utilization (HCRU): Cumulative Number of Unscheduled Utilizations|Number of Participants With Adverse Events|Hematology: Mean Change From Baseline to Final Values in Hemoglobin|Hematology: Mean Change From Baseline to Final Values in Hematocrit|Hematology: Mean Change From Baseline to Final Values in Red Blood Cell Count, Platelet Count, White Blood Cell Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, and Basophils|Clinical Chemistry: Mean Change From Baseline to Final Values in Alanine Aminotransferase, Aspartate Aminotransferase, and Alkaline Phosphatase|Clinical Chemistry: Mean Change From Baseline to Final Values in Total Bilirubin, Creatinine, and Uric Acid|Clinical Chemistry: Mean Change From Baseline to Final Values in Blood Urea Nitrogen, Inorganic Phosphate, Calcium, Sodium, Potassium, Glucose, Cholesterol, and Triglycerides|Clinical Chemistry: Mean Change From Baseline to Final Values in Albumin and Total Protein|Clinical Chemistry: Mean Change From Baseline to Final Values in High-sensitivity C-reactive Protein","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","592","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M10-223|2007-004157-28","November 28, 2007","December 2016","December 2016","December 14, 2007","December 19, 2017","February 20, 2018",,,"https://ClinicalTrials.gov/show/NCT00573794"
656,"NCT00570986","A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","No Results Available","Plaque Psoriasis","Drug: Placebo|Biological: ABT-874","PGA|PASI|DLQI|NAPSI|Safety parameters","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","1465","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M06-890","November 2007","June 2009","June 2009","December 11, 2007",,"February 8, 2013","Site Reference ID/Investigator# 6579, Birmingham, Alabama, United States|Site Reference ID/Investigator# 6697, Birmingham, Alabama, United States|Site Reference ID/Investigator# 7015, Huntsville, Alabama, United States|Site Reference ID/Investigator# 6728, Scottsdale, Arizona, United States|Site Reference ID/Investigator# 6584, Tucson, Arizona, United States|Site Reference ID/Investigator# 6696, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 6591, Bakersfield, California, United States|Site Reference ID/Investigator# 6710, Fresno, California, United States|Site Reference ID/Investigator# 7885, Irvine, California, United States|Site Reference ID/Investigator# 6872, Los Angeles, California, United States|Site Reference ID/Investigator# 7669, Oceanside, California, United States|Site Reference ID/Investigator# 6821, San Diego, California, United States|Site Reference ID/Investigator# 6832, San Diego, California, United States|Site Reference ID/Investigator# 7305, San Diego, California, United States|Site Reference ID/Investigator# 7990, San Francisco, California, United States|Site Reference ID/Investigator# 6711, Santa Monica, California, United States|Site Reference ID/Investigator# 8139, Torrance, California, United States|Site Reference ID/Investigator# 7167, Vallejo, California, United States|Site Reference ID/Investigator# 7302, Denver, Colorado, United States|Site Reference ID/Investigator# 6921, Longmont, Colorado, United States|Site Reference ID/Investigator# 6917, New Haven, Connecticut, United States|Site Reference ID/Investigator# 6707, Jacksonville, Florida, United States|Site Reference ID/Investigator# 7301, Miami, Florida, United States|Site Reference ID/Investigator# 7012, Miami, Florida, United States|Site Reference ID/Investigator# 6831, Miami, Florida, United States|Site Reference ID/Investigator# 7016, South Miami, Florida, United States|Site Reference ID/Investigator# 6590, West Palm Beach, Florida, United States|Site Reference ID/Investigator# 6582, Alpharetta, Georgia, United States|Site Reference ID/Investigator# 7450, Atlanta, Georgia, United States|Site Reference ID/Investigator# 6714, Newnan, Georgia, United States|Site Reference ID/Investigator# 6717, Snellville, Georgia, United States|Site Reference ID/Investigator# 7017, Arlington Heights, Illinois, United States|Site Reference ID/Investigator# 7877, Maywood, Illinois, United States|Site Reference ID/Investigator# 6704, Skokie, Illinois, United States|Site Reference ID/Investigator# 7292, West Dundee, Illinois, United States|Site Reference ID/Investigator# 6706, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 7646, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 7014, Overland Park, Kansas, United States|Site Reference ID/Investigator# 6873, Louisville, Kentucky, United States|Site Reference ID/Investigator# 7523, Owensboro, Kentucky, United States|Site Reference ID/Investigator# 6597, Andover, Massachusetts, United States|Site Reference ID/Investigator# 6703, Boston, Massachusetts, United States|Site Reference ID/Investigator# 7644, Detroit, Michigan, United States|Site Reference ID/Investigator# 6826, Fort Gratiot, Michigan, United States|Site Reference ID/Investigator# 7989, Grand Blanc, Michigan, United States|Site Reference ID/Investigator# 6581, Fridley, Minnesota, United States|Site Reference ID/Investigator# 7890, St. Louis, Missouri, United States|Site Reference ID/Investigator# 6709, St. Louis, Missouri, United States|Site Reference ID/Investigator# 7451, Omaha, Nebraska, United States|Site Reference ID/Investigator# 7299, Berlin, New Jersey, United States|Site Reference ID/Investigator# 6924, East Windsor, New Jersey, United States|Site Reference ID/Investigator# 6577, New Brunswick, New Jersey, United States|Site Reference ID/Investigator# 7030, Albuquerque, New Mexico, United States|Site Reference ID/Investigator# 7878, Buffalo, New York, United States|Site Reference ID/Investigator# 7876, New York, New York, United States|Site Reference ID/Investigator# 6599, New York, New York, United States|Site Reference ID/Investigator# 6895, New York, New York, United States|Site Reference ID/Investigator# 7637, New York, New York, United States|Site Reference ID/Investigator# 7504, Rochester, New York, United States|Site Reference ID/Investigator# 7018, Stoney Brook, New York, United States|Site Reference ID/Investigator# 6926, Hickory, North Carolina, United States|Site Reference ID/Investigator# 7293, Wilmington, North Carolina, United States|Site Reference ID/Investigator# 8251, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 6598, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 8082, Cleveland, Ohio, United States|Site Reference ID/Investigator# 7165, Columbus, Ohio, United States|Site Reference ID/Investigator# 7659, Dayton, Ohio, United States|Site Reference ID/Investigator# 6727, Lake Oswego, Oregon, United States|Site Reference ID/Investigator# 6894, Portland, Oregon, United States|Site Reference ID/Investigator# 6578, Portland, Oregon, United States|Site Reference ID/Investigator# 7295, Portland, Oregon, United States|Site Reference ID/Investigator# 7879, Hershey, Pennsylvania, United States|Site Reference ID/Investigator# 6712, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 6580, Johnston, Rhode Island, United States|Site Reference ID/Investigator# 6576, Providence, Rhode Island, United States|Site Reference ID/Investigator# 6589, Greer, South Carolina, United States|Site Reference ID/Investigator# 6586, Goodlettsville, Tennessee, United States|Site Reference ID/Investigator# 7668, Knoxville, Tennessee, United States|Site Reference ID/Investigator# 6915, Nashville, Tennessee, United States|Site Reference ID/Investigator# 6825, Arlington, Texas, United States|Site Reference ID/Investigator# 6762, Austin, Texas, United States|Site Reference ID/Investigator# 6822, Dallas, Texas, United States|Site Reference ID/Investigator# 7671, Dallas, Texas, United States|Site Reference ID/Investigator# 6705, Houston, Texas, United States|Site Reference ID/Investigator# 6708, San Antonio, Texas, United States|Site Reference ID/Investigator# 7081, San Antonio, Texas, United States|Site Reference ID/Investigator# 6912, Tyler, Texas, United States|Site Reference ID/Investigator# 7306, Webster, Texas, United States|Site Reference ID/Investigator# 8101, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 6807, Norfolk, Virginia, United States|Site Reference ID/Investigator# 6801, Seattle, Washington, United States|Site Reference ID/Investigator# 7519, Spokane, Washington, United States|Site Reference ID/Investigator# 7080, Milwaukee, Wisconsin, United States|Site Reference ID/Investigator# 7314, Barrie, Canada|Site Reference ID/Investigator# 7452, Calgary, Canada|Site Reference ID/Investigator# 6702, Edmonton, Canada|Site Reference ID/Investigator# 6716, Halifax, Canada|Site Reference ID/Investigator# 7309, Hamilton, Canada|Site Reference ID/Investigator# 6588, Laval, Canada|Site Reference ID/Investigator# 6715, London, Canada|Site Reference ID/Investigator# 7315, London, Canada|Site Reference ID/Investigator# 7636, Markham, Canada|Site Reference ID/Investigator# 6699, Montreal, Canada|Site Reference ID/Investigator# 7316, Montreal, Canada|Site Reference ID/Investigator# 7088, North Bay, Canada|Site Reference ID/Investigator# 7310, Ottawa, Canada|Site Reference ID/Investigator# 7311, Quebec City, Canada|Site Reference ID/Investigator# 7313, St. John's, Canada|Site Reference ID/Investigator# 7317, Surrey, Canada|Site Reference ID/Investigator# 7308, Vancouver, Canada|Site Reference ID/Investigator# 6713, Vancouver, Canada|Site Reference ID/Investigator# 7067, Waterloo, Canada|Site Reference ID/Investigator# 7312, Westmount, Canada|Site Reference ID/Investigator# 7087, Windsor, Canada|Site Reference ID/Investigator# 6805, Windsor, Canada|Site Reference ID/Investigator# 7638, Winnipeg, Canada",,"https://ClinicalTrials.gov/show/NCT00570986"
657,"NCT00548925","A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain",,"Completed","No Results Available","Diabetic Neuropathic Pain","Drug: ABT-894|Drug: placebo","Weekly mean of 24-hour average pain score|Pain improvement from Baseline to the final evaluation|Weekly mean of 24-hour worst pain severity; weekly average night pain and morning pain|Global assessments of study drug and pain status|Short-Form McGill Pain Questionnaire (SF-MPQ), Neuropathic Pain Scale (NPS)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M10-014|2007-001140-47","November 2007","December 2008","December 2008","October 24, 2007",,"January 21, 2013","Site Reference ID/Investigator# 6614, Spring Valley, California, United States|Site Reference ID/Investigator# 6617, Walnut Creek, California, United States|Site Reference ID/Investigator# 6356, Hollywood, Florida, United States|Site Reference ID/Investigator# 6615, Tampa, Florida, United States|Site Reference ID/Investigator# 6358, Wellington, Florida, United States|Site Reference ID/Investigator# 6609, St. Louis, Missouri, United States|Site Reference ID/Investigator# 7229, New Hyde Park, New York, United States|Site Reference ID/Investigator# 6618, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 6607, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 6575, Allentown, Pennsylvania, United States|Site Reference ID/Investigator# 8179, San Antonio, Texas, United States|Site Reference ID/Investigator# 6616, San Antonio, Texas, United States|Site Reference ID/Investigator# 5552, Hradec Kralove, Czech Republic|Site Reference ID/Investigator# 5554, Olomouc, Czech Republic|Site Reference ID/Investigator# 5553, Zlin, Czech Republic|Site Reference ID/Investigator# 9363, Corbeil Essonnes, France|Site Reference ID/Investigator# 5557, Limoges, France|Site Reference ID/Investigator# 6238, Nevers, France|Site Reference ID/Investigator# 6564, Bad Mergentheim, Germany|Site Reference ID/Investigator# 11201, Berlin, Germany|Site Reference ID/Investigator# 6234, Duesseldorf, Germany|Site Reference ID/Investigator# 11202, Mainz, Germany|Site Reference ID/Investigator# 7714, Munich, Germany|Site Reference ID/Investigator# 5549, L'Aquila, Italy|Site Reference ID/Investigator# 5558, Perugia, Italy|Site Reference ID/Investigator# 6475, Granada, Spain|Site Reference ID/Investigator# 7911, Sabadell, Barcelona, Spain|Site Reference ID/Investigator# 5555, Birmingham, United Kingdom|Site Reference ID/Investigator# 7133, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00548925"
658,"NCT00528697","A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Attention-Deficit/Hyperactivity Disorder","Drug: ABT-089|Drug: atomoxetine|Drug: placebo","ADHD-RS-IV (HV) - Administered by study doctor|Health Outcomes Measurements|Clinical Global Impression-ADHD-Severity Scale|Parent Rating Scales|Teacher Rating Scale","AbbVie (prior sponsor, Abbott)|AbbVie","All","6 Years to 12 Years   (Child)","Phase 2","278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M06-888","September 2007","April 2008","April 2008","September 12, 2007",,"January 29, 2013","Site Reference ID/Investigator# 5999, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 5979, El Centro, California, United States|Site Reference ID/Investigator# 5986, Boulder, Colorado, United States|Site Reference ID/Investigator# 5993, Bradenton, Florida, United States|Site Reference ID/Investigator# 5995, Jacksonville, Florida, United States|Site Reference ID/Investigator# 5977, Orlando, Florida, United States|Site Reference ID/Investigator# 5981, Northbrook, Illinois, United States|Site Reference ID/Investigator# 5982, Overland Park, Kansas, United States|Site Reference ID/Investigator# 5992, Omaha, Nebraska, United States|Site Reference ID/Investigator# 5997, Las Vegas, Nevada, United States|Site Reference ID/Investigator# 5987, Clementon, New Jersey, United States|Site Reference ID/Investigator# 5996, Eugene, Oregon, United States|Site Reference ID/Investigator# 5984, Portland, Oregon, United States|Site Reference ID/Investigator# 5980, Salem, Oregon, United States|Site Reference ID/Investigator# 5994, Charleston, South Carolina, United States|Site Reference ID/Investigator# 5976, Memphis, Tennessee, United States|Site Reference ID/Investigator# 6000, Austin, Texas, United States|Site Reference ID/Investigator# 5998, Herndon, Virginia, United States|Site Reference ID/Investigator# 5978, Bellevue, Washington, United States|Site Reference ID/Investigator# 5983, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00528697"
659,"NCT00524537","A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)",,"Completed","Has Results","Crohn's Disease",,"Number of Participants With Registry Treatment-Emergent Adverse Events (AEs)|Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Total Score: Change From Baseline to Each Visit|Physician's Global Assessment of Disease Activity (PGA): Change From Baseline to Each Visit|Work Productivity and Activity Impairment: Special Health Problem (WPAI:SHP): Change in Mean Percentage of Work Time Missed (Absenteeism) From Baseline to Each Visit|WPAI:SHP: Change in Mean Percentage of Impairment While Working (Presenteeism) Due to Crohn's Disease From Baseline to Each Visit|WPAI:SHP: Change in Mean Percentage of Overall Work Impairment Due to Crohn's Disease From Baseline to Each Visit|WPAI:SHP: Change in Mean Percentage of Activity Impairment Due to Crohn's Disease From Baseline to Each Visit|Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Physician's Office Due to CD at Each Study Visit|Healthcare Resource Utilization (HCRU): Mean Number Of Visits At Emergency Room Due to CD at Each Study Visit|Healthcare Resource Utilization (HCRU): Mean Number Of Admissions to Hospital Due to CD at Each Study Visit|Healthcare Resource Utilization (HCRU): Mean Total Days In Hospital Due to CD at Each Study Visit","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"5025","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P06-134","September 2007","December 2015","December 2015","September 3, 2007","January 24, 2017","January 24, 2017",,,"https://ClinicalTrials.gov/show/NCT00524537"
660,"NCT00517920","Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)",,"Completed","No Results Available","Advanced Hepatocellular Carcinoma","Drug: ABT-869","Progression-Free Rate|Objective Response Rate","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-879","September 2007","June 2011","June 2012","August 17, 2007",,"January 4, 2013","Site Reference ID/Investigator# 7726, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 7169, Toronto, Canada|Site Reference ID/Investigator# 5837, Vancouver, Canada|Site Reference ID/Investigator# 5235, Singapore, Singapore|Site Reference ID/Investigator# 5611, Singapore, Singapore|Site Reference ID/Investigator# 6265, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00517920"
661,"NCT00517790","Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-Small Cell Lung Cancer (NSCLC)","Drug: ABT-869 .25 mg/kg|Drug: ABT-869 0.10 mg/kg","Progression Free Rate (PFR)|Objective Response Rate","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-880|2007-005245-37","August 2007","June 2011","June 2012","August 17, 2007",,"April 5, 2013","Site Reference ID/Investigator# 7194, Fountain Valley, California, United States|Site Reference ID/Investigator# 5617, Los Angeles, California, United States|Site Reference ID/Investigator# 7934, Sacramento, California, United States|Site Reference ID/Investigator# 5646, Aurora, Colorado, United States|Site Reference ID/Investigator# 6627, Waterbury, Connecticut, United States|Site Reference ID/Investigator# 7868, Newark, Delaware, United States|Site Reference ID/Investigator# 7616, Port St. Lucie, Florida, United States|Site Reference ID/Investigator# 5648, Chicago, Illinois, United States|Site Reference ID/Investigator# 6739, Evanston, Illinois, United States|Site Reference ID/Investigator# 8100, Harvey, Illinois, United States|Site Reference ID/Investigator# 5269, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 6042, St. Louis, Missouri, United States|Site Reference ID/Investigator# 6680, East Orange, New Jersey, United States|Site Reference ID/Investigator# 5603, Voorhees, New Jersey, United States|Site Reference ID/Investigator# 5652, Buffalo, New York, United States|Site Reference ID/Investigator# 6184, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 6777, Greensboro, North Carolina, United States|Site Reference ID/Investigator# 5650, Memphis, Tennessee, United States|Site Reference ID/Investigator# 6040, Barrie, Canada|Site Reference ID/Investigator# 5275, Ottawa, Canada|Site Reference ID/Investigator# 6572, Toronto, Canada|Site Reference ID/Investigator# 7756, Marseille cedex 09, France|Site Reference ID/Investigator# 8068, Toulouse, France|Site Reference ID/Investigator# 8069, Villejuif, France|Site Reference ID/Investigator# 5660, Singapore, Singapore|Site Reference ID/Investigator# 5534, Singapore, Singapore|Site Reference ID/Investigator# 5663, Taichung, Taiwan|Site Reference ID/Investigator# 5640, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00517790"
662,"NCT00507936","Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain",,"Completed","No Results Available","Diabetic Neuralgia|Diabetic Neuropathies|Diabetic Neuropathy, Painful|Diabetic Polyneuropathy|Neuralgia, Diabetic","Drug: ABT-894|Drug: placebo|Drug: Duloxetine","Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP|Proportions of treatment responders; subjects who complete treatment period with 30% improvement|Mean of 24-hour worst pain severity, average of night pain, and average of morning pain measured by the 11-point Likert scale and from subject's daily diary|Brief Pain Inventory (BPI) (short form) including Pain Severity|Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M06-850|2007-001139-71","August 2007","October 2008","October 2008","July 27, 2007",,"January 23, 2013","Site Reference ID/Investigator# 5207, Mesa, Arizona, United States|Site Reference ID/Investigator# 6053, Phoenix, Arizona, United States|Site Reference ID/Investigator# 5206, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 7387, North Little Rock, Arkansas, United States|Site Reference ID/Investigator# 6052, Anaheim, California, United States|Site Reference ID/Investigator# 7064, Garden Grove, California, United States|Site Reference ID/Investigator# 8286, National City, California, United States|Site Reference ID/Investigator# 5276, Clearwater, Florida, United States|Site Reference ID/Investigator# 6781, Hialeah, Florida, United States|Site Reference ID/Investigator# 7514, Palm Beach Gardens, Florida, United States|Site Reference ID/Investigator# 8113, Tampa, Florida, United States|Site Reference ID/Investigator# 6047, Pasadena, Maryland, United States|Site Reference ID/Investigator# 5277, Brockton, Massachusetts, United States|Site Reference ID/Investigator# 6043, St. Louis, Missouri, United States|Site Reference ID/Investigator# 6044, St. Louis, Missouri, United States|Site Reference ID/Investigator# 7906, Omaha, Nebraska, United States|Site Reference ID/Investigator# 6045, New York, New York, United States|Site Reference ID/Investigator# 5946, New York, New York, United States|Site Reference ID/Investigator# 5216, New York, New York, United States|Site Reference ID/Investigator# 7483, New York, New York, United States|Site Reference ID/Investigator# 5947, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 6869, Cuyahoga Falls, Ohio, United States|Site Reference ID/Investigator# 5217, Portland, Oregon, United States|Site Reference ID/Investigator# 7699, Houston, Texas, United States|Site Reference ID/Investigator# 5836, San Antonio, Texas, United States|Site Reference ID/Investigator# 5899, San Antonio, Texas, United States|Site Reference ID/Investigator# 5950, San Antonio, Texas, United States|Site Reference ID/Investigator# 7187, San Antonio, Texas, United States|Site Reference ID/Investigator# 6054, Seattle, Washington, United States|Site Reference ID/Investigator# 8508, Kingston, Canada|Site Reference ID/Investigator# 8436, Laval, Canada|Site Reference ID/Investigator# 8481, Winnipeg, Canada|Site Reference ID/Investigator# 5258, Corbeil Essonnes, France|Site Reference ID/Investigator# 7696, Nanterre, France|Site Reference ID/Investigator# 5260, Narbonne, France|Site Reference ID/Investigator# 5171, Nevers, France|Site Reference ID/Investigator# 7115, Nimes, France|Site Reference ID/Investigator# 6763, Berlin, Germany|Site Reference ID/Investigator# 7117, Essen, Germany|Site Reference ID/Investigator# 5034, Frankfurt, Germany|Site Reference ID/Investigator# 6760, Heidelberg, Germany|Site Reference ID/Investigator# 6732, Mainz, Germany|Site Reference ID/Investigator# 5018, Milan, Italy|Site Reference ID/Investigator# 5006, Rome, Italy|Site Reference ID/Investigator# 8427, Guadalajara, Mexico|Site Reference ID/Investigator# 8497, Mexico D.F., Mexico|Site Reference ID/Investigator# 8125, Monterrey, N.L., Mexico|Site Reference ID/Investigator# 8120, Ponce, Puerto Rico|Site Reference ID/Investigator# 8121, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00507936"
663,"NCT00497146","The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4","PRIMO","Completed","Has Results","Chronic Kidney Disease|Left Ventricular Hypertrophy","Drug: paricalcitol|Drug: placebo","Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)|Change in Diastolic Mitral Annular Relaxation Velocity (E')|Change in Ratio of Peak E Wave Velocity to Lateral E Wave Velocity (E/E')|Change in E-wave Deceleration Time (DT)|Change in Isovolumetric Relaxation Time (IVRT)|Change in Left Atrial Volume|Change in Plasma Triiodothyronine (T3)|Change in Interleukin-6 (IL-6)|Change in Troponin-T|Change in B-type Natriuretic Peptide (BNP)|Change in High Sensitivity C-reactive Protein (hsCRP)|Change in Progression of Thoraco-abdominal Aortic Plaque Volume|Change in Progression of Thoraco-abdominal Aortic Wall Volume|Change in Progression of Aortic Compliance|Change in Progression of Left Ventricular End-systolic Volume Index|Change in Progression of Left Ventricular End-diastolic Volume Index|Change in Progression of Left Ventricular Ejection Fraction","AbbVie (prior sponsor, Abbott)|Massachusetts General Hospital|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","227","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","M10-030|2007-001689-34","February 2008","September 2010","March 2012","July 6, 2007","December 23, 2011","March 12, 2013","Site Reference ID/Investigator# 8062, Phoenix, Arizona, United States|Site Reference ID/Investigator# 8867, Tempe, Arizona, United States|Site Reference ID/Investigator# 8864, San Diego, California, United States|Site Reference ID/Investigator# 7257, San Dimas, California, United States|Site Reference ID/Investigator# 7727, Denver, Colorado, United States|Site Reference ID/Investigator# 8861, Miami, Florida, United States|Site Reference ID/Investigator# 7260, Orlando, Florida, United States|Site Reference ID/Investigator# 7725, Tampa, Florida, United States|Site Reference ID/Investigator# 7824, Tampa, Florida, United States|Site Reference ID/Investigator# 18882, Meridian, Idaho, United States|Site Reference ID/Investigator# 7823, Chicago, Illinois, United States|Site Reference ID/Investigator# 7249, Evergreen Park, Illinois, United States|Site Reference ID/Investigator# 7816, Bethesda, Maryland, United States|Site Reference ID/Investigator# 18881, Rockville, Maryland, United States|Site Reference ID/Investigator# 7817, Springfield, Massachusetts, United States|Site Reference ID/Investigator# 7245, Detroit, Michigan, United States|Site Reference ID/Investigator# 7248, Royal Oak, Michigan, United States|Site Reference ID/Investigator# 8868, Kansas City, Missouri, United States|Site Reference ID/Investigator# 7828, St. Louis, Missouri, United States|Site Reference ID/Investigator# 14442, Omaha, Nebraska, United States|Site Reference ID/Investigator# 6567, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 7262, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 7826, Allentown, Pennsylvania, United States|Site Reference ID/Investigator# 8865, Chattanooga, Tennessee, United States|Site Reference ID/Investigator# 7261, Houston, Texas, United States|Site Reference ID/Investigator# 8058, Houston, Texas, United States|Site Reference ID/Investigator# 7830, San Antonio, Texas, United States|Site Reference ID/Investigator# 7825, Murray, Utah, United States|Site Reference ID/Investigator# 8866, Provo, Utah, United States|Site Reference ID/Investigator# 7263, Fairfax, Virginia, United States|Site Reference ID/Investigator# 8493, Adelaide, Australia|Site Reference ID/Investigator# 8506, Liverpool, Australia|Site Reference ID/Investigator# 8507, Parkville, Australia|Site Reference ID/Investigator# 9581, Reservoir, Australia|Site Reference ID/Investigator# 9582, Richmond, Australia|Site Reference ID/Investigator# 8500, Westmead, Australia|Site Reference ID/Investigator# 8246, Prague 4, Czech Republic|Site Reference ID/Investigator# 8499, Prague 6, Czech Republic|Site Reference ID/Investigator# 8245, Prague, Czech Republic|Site Reference ID/Investigator# 6692, Dortmund, Germany|Site Reference ID/Investigator# 9723, Duesseldorf, Germany|Site Reference ID/Investigator# 6630, Luebeck, Germany|Site Reference ID/Investigator# 7268, Nettetal, Germany|Site Reference ID/Investigator# 6622, Wuerzburg, Germany|Site Reference ID/Investigator# 10626, Lido di Camaiore, Italy|Site Reference ID/Investigator# 8070, Naples, Italy|Site Reference ID/Investigator# 8060, Rome, Italy|Site Reference ID/Investigator# 8519, Lodz, Poland|Site Reference ID/Investigator# 7702, Humacao, Puerto Rico|Site Reference ID/Investigator# 7269, Ponce, Puerto Rico|Site Reference ID/Investigator# 7818, Rio Piedras, Puerto Rico|Site Reference ID/Investigator# 7270, San Juan, Puerto Rico|Site Reference ID/Investigator# 7712, San Juan, Puerto Rico|Site Reference ID/Investigator# 7266, Toa Baja, Puerto Rico|Site Reference ID/Investigator# 8881, Bucharest, Romania|Site Reference ID/Investigator# 8518, Bucharest, Romania|Site Reference ID/Investigator# 8514, Iasi, Romania|Site Reference ID/Investigator# 22682, Moscow, Russian Federation|Site Reference ID/Investigator# 8009, Moscow, Russian Federation|Site Reference ID/Investigator# 7251, Moscow, Russian Federation|Site Reference ID/Investigator# 7250, Moscow, Russian Federation|Site Reference ID/Investigator# 8883, Barcelona, Spain|Site Reference ID/Investigator# 8358, Barcelona, Spain|Site Reference ID/Investigator# 8355, Madrid, Spain|Site Reference ID/Investigator# 8356, Madrid, Spain|Site Reference ID/Investigator# 8882, Santander (Cantabria), Spain|Site Reference ID/Investigator# 8234, Hsin-Chuang City, Taiwan|Site Reference ID/Investigator# 8884, Taipei, Taiwan|Site Reference ID/Investigator# 8228, Taipei, Taiwan|Site Reference ID/Investigator# 8229, Taoyuan, Taiwan|Site Reference ID/Investigator# 8823, Coventry, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00497146"
664,"NCT00486538","Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib",,"Completed","No Results Available","Advanced Renal Cell Carcinoma","Drug: ABT-869","Objective Response Rate|Progression-free rate|Best response rate|Time to tumor progression|Progression free survival|Overall Survival","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","53","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-882","June 2007","June 2011","June 2012","June 14, 2007",,"January 4, 2013","Site Reference ID/Investigator# 7193, Sacramento, California, United States|Site Reference ID/Investigator# 5243, Washington, District of Columbia, United States|Site Reference ID/Investigator# 5384, Chicago, Illinois, United States|Site Reference ID/Investigator# 11662, Boston, Massachusetts, United States|Site Reference ID/Investigator# 11663, Boston, Massachusetts, United States|Site Reference ID/Investigator# 5379, Boston, Massachusetts, United States|Site Reference ID/Investigator# 5380, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 5249, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 6278, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 6269, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 7300, Charleston, South Carolina, United States|Site Reference ID/Investigator# 6796, Houston, Texas, United States|Site Reference ID/Investigator# 6566, Vancouver, Canada",,"https://ClinicalTrials.gov/show/NCT00486538"
665,"NCT00445198","A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies",,"Completed","No Results Available","Small Cell Lung Cancer|Small Cell Lung Carcinoma","Drug: ABT-263","Safety assessment|Dose limiting toxicity determination|Maximum tolerated dose determination|Pharmacokinetic profile evaluation|Extended safety assessment at the recommended Phase 2 dose|Preliminary efficacy assessment","AbbVie (prior sponsor, Abbott)|Genentech, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","86","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-822|2006-003298-28","April 2007","December 2010","December 2010","March 8, 2007",,"June 6, 2018","Site Reference ID/Investigator# 13605, Peoria, Arizona, United States|Site Reference ID/Investigator# 5261, Phoenix, Arizona, United States|Site Reference ID/Investigator# 11942, Los Angeles, California, United States|Site Reference ID/Investigator# 4718, Sacramento, California, United States|Site Reference ID/Investigator# 3755, Aurora, Colorado, United States|Site Reference ID/Investigator# 8324, Atlanta, Georgia, United States|Site Reference ID/Investigator# 2623, Chicago, Illinois, United States|Site Reference ID/Investigator# 2625, Baltimore, Maryland, United States|Site Reference ID/Investigator# 12343, Bethesda, Maryland, United States|Site Reference ID/Investigator# 11941, Boston, Massachusetts, United States|Site Reference ID/Investigator# 2626, Boston, Massachusetts, United States|Site Reference ID/Investigator# 4934, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 2624, Nashville, Tennessee, United States|Site Reference ID/Investigator# 6650, Tacoma, Washington, United States|Site Reference ID/Investigator# 7493, Edmonton, Canada|Site Reference ID/Investigator# 7635, Ottawa, Canada|Site Reference ID/Investigator# 18541, Leicester, United Kingdom|Site Reference ID/Investigator# 2622, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00445198"
666,"NCT00443391","A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)",,"Completed","No Results Available","Attention Deficit Hyperactivity Disorder","Drug: ABT-089","CAARS:INV|CGI-ADHD-S|AAQoL|WPAI|RUQ|FTND","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 60 Years   (Adult)","Phase 2","141","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-889","February 2007","October 2008","October 2008","March 6, 2007",,"January 18, 2013","Site Reference ID/Investigator# 6109, Mesa, Arizona, United States|Site Reference ID/Investigator# 6765, Mesa, Arizona, United States|Site Reference ID/Investigator# 6100, Lafayette, California, United States|Site Reference ID/Investigator# 6107, San Diego, California, United States|Site Reference ID/Investigator# 6112, Jacksonville, Florida, United States|Site Reference ID/Investigator# 6096, Maitland, Florida, United States|Site Reference ID/Investigator# 6105, Tampa, Florida, United States|Site Reference ID/Investigator# 6094, Smyrna, Georgia, United States|Site Reference ID/Investigator# 6111, Newton, Kansas, United States|Site Reference ID/Investigator# 6113, Farmington Hills, Michigan, United States|Site Reference ID/Investigator# 6110, Omaha, Nebraska, United States|Site Reference ID/Investigator# 6099, New York, New York, United States|Site Reference ID/Investigator# 6106, Chapel Hill, North Carolina, United States|Site Reference ID/Investigator# 6102, Portland, Oregon, United States|Site Reference ID/Investigator# 6097, Charleston, South Carolina, United States|Site Reference ID/Investigator# 6098, Memphis, Tennessee, United States|Site Reference ID/Investigator# 6103, Austin, Texas, United States|Site Reference ID/Investigator# 6104, Lake Jackson, Texas, United States|Site Reference ID/Investigator# 6095, Herndon, Virginia, United States|Site Reference ID/Investigator# 6092, Seattle, Washington, United States|Site Reference ID/Investigator# 6101, Middleton, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT00443391"
667,"NCT00406809","A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies",,"Completed","No Results Available","Chronic Lymphoid Leukemia|Lymphoid Malignancies|Non-Hodgkin's Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Peripheral T-cell Lymphoma","Drug: ABT-263","Phase 1a: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - intermittent dosing.|Phase 1b: Determine dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RPTD) and schedule - continuous dosing.|Phase 2a: Continued assessment of safety profile at the recommended Phase 2 dose (RPTD) and schedule - continuous dosing.|Phase 2a: Assessment of preliminary efficacy signals including biomarker assessment - continuous dosing.|Extension Study: Continued assessment of the safety profile of ABT-263|Extension Study: Continued assessment of the preliminary efficacy signals of ABT-263.|Phase 1a or Phase 1b safety assessment|Phase 1a, Phase 1b, or Phase 2a pharmacokinetic profile evaluation|Phase 1a effect of food on bioavailability","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","81","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M06-814","November 2006","October 2016","October 2016","December 4, 2006",,"November 6, 2017","Site Reference ID/Investigator# 4997, Los Angeles, California, United States|Site Reference ID/Investigator# 9104, Los Angeles, California, United States|Site Reference ID/Investigator# 2613, Bethesda, Maryland, United States|Site Reference ID/Investigator# 40243, Boston, Massachusetts, United States|Site Reference ID/Investigator# 4745, Boston, Massachusetts, United States|Site Reference ID/Investigator# 2628, Buffalo, New York, United States|Site Reference ID/Investigator# 23543, New York, New York, United States|Site Reference ID/Investigator# 2627, New York, New York, United States|Site Reference ID/Investigator# 2614, New York, New York, United States|Site Reference ID/Investigator# 5383, New York, New York, United States|Site Reference ID/Investigator# 12306, Rochester, New York, United States|Site Reference ID/Investigator# 8941, Edmonton, Canada",,"https://ClinicalTrials.gov/show/NCT00406809"
668,"NCT00401570","A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer",,"Completed","No Results Available","Pancreatic Cancer","Drug: Volociximab|Drug: Gemcitabine","The proportion of patients, in each dose cohort, with a confirmed tumor response|Duration of progression-free survival|Time to disease progression|Duration of overall survival|To evaluate the safety in of M200 in combination with gemcitabine|To evaluate the pharmacokinetics of M200|To evaluate the immunogenicity of M200","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M200-1205","March 2005","June 2008","June 2008","November 20, 2006",,"January 30, 2013","Site Reference ID/Investigator# 70538, Pittsburgh, Pennsylvania, United States|Site Reference ID/Investigator# 70537, Nashville, Tennessee, United States|Site Reference ID/Investigator# 70534, Glasgow, United Kingdom|Site Reference ID/Investigator# 70533, Leeds, United Kingdom|Site Reference ID/Investigator# 70536, Manchester, United Kingdom|Site Reference ID/Investigator# 70535, Northwood, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00401570"
669,"NCT00360568","Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects",,"Completed","Has Results","Dyskinesias|Parkinson's Disease|Severe Motor Fluctuations","Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube","Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs|Number of Participants With Device Complications|Number of Participants With Potentially Clinically Significant Values for Hematology Parameters|Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters|Number of Participants With Potentially Clinically Significant Vital Sign Parameters|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters|Number of Participants With Sleep Attacks at Baseline and Endpoint|Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and Post-baseline (PBL)|Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint|Number of Participants With Confirmed Cases of Melanoma|Number of Participants With Clinically Significant Neurological Examination Findings|Columbia-Suicide Severity Rating Scale (C-SSRS) Findings|Number of Participants Taking at Least 1 Concomitant Medication During the Study|Change From Baseline in Average Daily ""Off"" Time at Endpoint|Change From Baseline in Average Daily Normalized ""On"" Time With Troublesome Dyskinesia at Endpoint|Change From Baseline in Average Daily ""On"" Time Without Troublesome Dyskinesia at Month 12|Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint|Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint|Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint|Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint","AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","62","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S187.3.003|2006-000578-53","June 2009","October 2012","October 2012","August 4, 2006","January 16, 2015","January 16, 2015","Site Reference ID/Investigator# 45869, Birmingham, Alabama, United States|Site Reference ID/Investigator# 45834, Fountain Valley, California, United States|Site Reference ID/Investigator# 45854, Los Angeles, California, United States|Site Reference ID/Investigator# 45856, Oceanside, California, United States|Site Reference ID/Investigator# 45859, Washington, District of Columbia, United States|Site Reference ID/Investigator# 45857, Bradenton, Florida, United States|Site Reference ID/Investigator# 45863, Gainesville, Florida, United States|Site Reference ID/Investigator# 45836, Port Charlotte, Florida, United States|Site Reference ID/Investigator# 45874, Chicago, Illinois, United States|Site Reference ID/Investigator# 45868, Lexington, Kentucky, United States|Site Reference ID/Investigator# 45862, Baltimore, Maryland, United States|Site Reference ID/Investigator# 45861, St. Louis, Missouri, United States|Site Reference ID/Investigator# 45873, New York, New York, United States|Site Reference ID/Investigator# 45878, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 45850, Cleveland, Ohio, United States|Site Reference ID/Investigator# 45887, Burlington, Vermont, United States|Site Reference ID/Investigator# 45828, Bochum, Germany|Site Reference ID/Investigator# 45829, Bremerhaven, Germany|Site Reference ID/Investigator# 45825, Hanover, Germany|Site Reference ID/Investigator# 54402, Tuebingen, Germany|Site Reference ID/Investigator# 45884, Auckland, New Zealand|Site Reference ID/Investigator# 45885, Hamilton, New Zealand",,"https://ClinicalTrials.gov/show/NCT00360568"
670,"NCT00357994","Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",,"Completed","Has Results","Advanced Parkinson's Disease","Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo gel|Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube","Change From Baseline to Week 12 in Average Daily Normalized ""Off"" Time|Change From Baseline in Average Daily Normalized ""On"" Time Without Troublesome Dyskinesia at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Week 12|Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Week 12|Change From Baseline in UPDRS Part III Score at Week 12|Change From Baseline in EuroQual Quality of Life - 5 Dimensions (EQ-5D) Summary Index at Week 12|Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Week 12|Change From Baseline in Average Daily Normalized ""On"" Time With Troublesome Dyskinesia at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Week 12|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Questions 32, 33, and 34 at Week 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Week 12|Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Week 12|Employment Impairment (EMP) I Status at Baseline|Employment Impairment (EMP) II Status at Week 12","AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S187.3.001|2006-000577-29","January 2009","October 2011","October 2011","July 28, 2006","January 16, 2015","January 16, 2015","Site Reference ID/Investigator# 45719, Los Angeles, California, United States|Site Reference ID/Investigator# 45718, Englewood, Colorado, United States|Site Reference ID/Investigator# 45722, Washington, District of Columbia, United States|Site Reference ID/Investigator# 45721, Bradenton, Florida, United States|Site Reference ID/Investigator# 45705, Gainesville, Florida, United States|Site Reference ID/Investigator# 45740, Baltimore, Maryland, United States|Site Reference ID/Investigator# 45739, St. Louis, Missouri, United States|Site Reference ID/Investigator# 45703, Burlington, Vermont, United States|Site Reference ID/Investigator# 44970, Bochum, Germany|Site Reference ID/Investigator# 44971, Bremerhaven, Germany|Site Reference ID/Investigator# 44973, Dresden, Germany|Site Reference ID/Investigator# 44965, Hanover, Germany|Site Reference ID/Investigator# 44964, Kiel, Germany|Site Reference ID/Investigator# 44966, Marburg, Germany|Site Reference ID/Investigator# 44968, Tuebingen, Germany",,"https://ClinicalTrials.gov/show/NCT00357994"
671,"NCT00335153","Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease",,"Completed","Has Results","Advanced Parkinson's Disease","Drug: Levodopa-carbidopa intestinal gel|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: PEG tube|Device: J-tube","Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs|Number of Participants With Device Complications During the Nasojejunal (NJ) Test Period|Number of Participants With Device Complications During the Percutaneous Endoscopic Gastrostomy - With Jejunal Extension Tube (PEG-J) Surgery and Post-PEG Long Term Treatment Periods|Number of Participants With Potentially Clinically Significant Values for Hematology Parameters|Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters|Number of Participants With Potentially Clinically Significant Vital Sign Parameters|Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters|Number of Participants With Sleep Attacks at Baseline|Number of Participants With Sleep Attacks During the Post-PEG Long-Term Treatment Period|Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and During the Post-PEG Long-term Treatment (PPLT) Period|Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint|Number of Participants With Confirmed Cases of Melanoma|Number of Participants Taking at Least 1 Concomitant Medication During the Study|Change From Baseline in Average Daily ""Off"" Time at Endpoint|Change From Baseline in Average Daily Normalized ""On"" Time With Troublesome Dyskinesia at Endpoint|Change From Baseline in Average Daily ""On"" Time Without Troublesome Dyskinesia at Endpoint|Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Month 12|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint|Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint|Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint|Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint|Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint|Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint","AbbVie (prior sponsor, Abbott)|Quintiles, Inc.|AbbVie","All","30 Years and older   (Adult, Older Adult)","Phase 3","354","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S187.3.004|2006-005186-18","January 2008","June 2012","June 2012","June 9, 2006","January 16, 2015","January 16, 2015","Site Reference ID/Investigator# 50065, Birmingham, Alabama, United States|Site Reference ID/Investigator# 50059, Fountain Valley, California, United States|Site Reference ID/Investigator# 50048, Los Angeles, California, United States|Site Reference ID/Investigator# 50076, Oceanside, California, United States|Site Reference ID/Investigator# 50061, Englewood, Colorado, United States|Site Reference ID/Investigator# 50079, Washington, District of Columbia, United States|Site Reference ID/Investigator# 50077, Bradenton, Florida, United States|Site Reference ID/Investigator# 50060, Fort Lauderdale, Florida, United States|Site Reference ID/Investigator# 50049, Gainesville, Florida, United States|Site Reference ID/Investigator# 50047, Jacksonville, Florida, United States|Site Reference ID/Investigator# 50068, Port Charlotte, Florida, United States|Site Reference ID/Investigator# 50046, Tampa, Florida, United States|Site Reference ID/Investigator# 50062, Augusta, Georgia, United States|Site Reference ID/Investigator# 50050, Chicago, Illinois, United States|Site Reference ID/Investigator# 50078, Chicago, Illinois, United States|Site Reference ID/Investigator# 50064, Lexington, Kentucky, United States|Site Reference ID/Investigator# 50075, Shreveport, Louisiana, United States|Site Reference ID/Investigator# 50080, Baltimore, Maryland, United States|Site Reference ID/Investigator# 50074, Baltimore, Maryland, United States|Site Reference ID/Investigator# 50073, St. Louis, Missouri, United States|Site Reference ID/Investigator# 50042, Omaha, Nebraska, United States|Site Reference ID/Investigator# 50072, Manhasset, New York, United States|Site Reference ID/Investigator# 50067, New York, New York, United States|Site Reference ID/Investigator# 50066, New York, New York, United States|Site Reference ID/Investigator# 50069, Raleigh, North Carolina, United States|Site Reference ID/Investigator# 50063, Winston-Salem, North Carolina, United States|Site Reference ID/Investigator# 50043, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 50044, Cleveland, Ohio, United States|Site Reference ID/Investigator# 50058, Burlington, Vermont, United States|Site Reference ID/Investigator# 50045, Kirkland, Washington, United States|Site Reference ID/Investigator# 50070, Milwaukee, Wisconsin, United States|Site Reference ID/Investigator# 46429, Adelaide, Australia|Site Reference ID/Investigator# 46427, Heidelberg, Australia|Site Reference ID/Investigator# 46425, Westmead, Australia|Site Reference ID/Investigator# 54545, Edmonton, Canada|Site Reference ID/Investigator# 46433, Montreal, Canada|Site Reference ID/Investigator# 46434, Toronto, Canada|Site Reference ID/Investigator# 46436, Brno, Czech Republic|Site Reference ID/Investigator# 46438, Hradec Kralove, Czech Republic|Site Reference ID/Investigator# 46435, Pardubice, Czech Republic|Site Reference ID/Investigator# 46437, Prague 2, Czech Republic|Site Reference ID/Investigator# 46439, Prague 5, Czech Republic|Site Reference ID/Investigator# 48003, Lahti, Finland|Site Reference ID/Investigator# 48028, Berlin, Germany|Site Reference ID/Investigator# 48029, Berlin, Germany|Site Reference ID/Investigator# 48036, Freiburg, Germany|Site Reference ID/Investigator# 48034, Goettingen, Germany|Site Reference ID/Investigator# 48022, Hanau, Germany|Site Reference ID/Investigator# 48024, Hanover, Germany|Site Reference ID/Investigator# 48035, Mainz, Germany|Site Reference ID/Investigator# 49882, Tel Aviv, Israel|Site Reference ID/Investigator# 50131, Arcugnano, Italy|Site Reference ID/Investigator# 50132, Catania, Italy|Site Reference ID/Investigator# 50128, Genoa, Italy|Site Reference ID/Investigator# 50129, Lido di Camaiore, Italy|Site Reference ID/Investigator# 50130, Naples, Italy|Site Reference ID/Investigator# 50127, Rome, Italy|Site Reference ID/Investigator# 50138, Nijmegen, Netherlands|Site Reference ID/Investigator# 50126, Auckland, New Zealand|Site Reference ID/Investigator# 50123, Christchurch, New Zealand|Site Reference ID/Investigator# 50124, Hamilton, New Zealand|Site Reference ID/Investigator# 50125, Wellington, New Zealand|Site Reference ID/Investigator# 50140, Lodz, Poland|Site Reference ID/Investigator# 50139, Poznan, Poland|Site Reference ID/Investigator# 50136, Almada, Portugal|Site Reference ID/Investigator# 50134, Coimbra, Portugal|Site Reference ID/Investigator# 50135, Lisbon, Portugal|Site Reference ID/Investigator# 50137, Porto, Portugal|Site Reference ID/Investigator# 50143, Kazan, Russian Federation|Site Reference ID/Investigator# 50141, Moscow, Russian Federation|Site Reference ID/Investigator# 50145, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50142, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50147, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50146, St. Petersburg, Russian Federation|Site Reference ID/Investigator# 50154, Barcelona, Spain|Site Reference ID/Investigator# 50152, Barcelona, Spain|Site Reference ID/Investigator# 50202, Barcelona, Spain|Site Reference ID/Investigator# 50155, Barcelona, Spain|Site Reference ID/Investigator# 50153, Madrid, Spain|Site Reference ID/Investigator# 50150, Bangkok, Thailand|Site Reference ID/Investigator# 50151, Bangkok, Thailand|Site Reference ID/Investigator# 50149, Liverpool, United Kingdom|Site Reference ID/Investigator# 50148, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00335153"
672,"NCT00297089","A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Lung Cancer|NSCLC|Non-Small-Cell Lung Cancer","Drug: ABT-751|Drug: pemetrexed|Drug: placebo","Progression-free Survival|Overall Survival|Response Rate|Time-to-Progression (TTP)","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","M05-780|2006-002830-38","November 2006","January 2009","January 2009","February 28, 2006",,"January 31, 2013","Site Reference ID/Investigator# 3358, Fayetteville, Arkansas, United States|Site Reference ID/Investigator# 4102, Hot Springs, Arkansas, United States|Site Reference ID/Investigator# 2127, Greenbrae, California, United States|Site Reference ID/Investigator# 2417, Fort Collins, Colorado, United States|Site Reference ID/Investigator# 5690, Torrington, Connecticut, United States|Site Reference ID/Investigator# 2411, Fort Lauderdale, Florida, United States|Site Reference ID/Investigator# 3363, Lakeland, Florida, United States|Site Reference ID/Investigator# 3352, Port St. Lucie, Florida, United States|Site Reference ID/Investigator# 3807, Atlanta, Georgia, United States|Site Reference ID/Investigator# 3353, Chicago, Illinois, United States|Site Reference ID/Investigator# 3359, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 2416, Baltimore, Maryland, United States|Site Reference ID/Investigator# 2244, Baltimore, Maryland, United States|Site Reference ID/Investigator# 2401, Bethesda, Maryland, United States|Site Reference ID/Investigator# 3793, Peabody, Massachusetts, United States|Site Reference ID/Investigator# 3362, Worcester, Massachusetts, United States|Site Reference ID/Investigator# 2075, Kalamazoo, Michigan, United States|Site Reference ID/Investigator# 2418, Jefferson City, Missouri, United States|Site Reference ID/Investigator# 4170, St. Louis, Missouri, United States|Site Reference ID/Investigator# 3357, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 5098, Lake Success, New York, United States|Site Reference ID/Investigator# 2242, Huntersville, North Carolina, United States|Site Reference ID/Investigator# 2413, Columbus, Ohio, United States|Site Reference ID/Investigator# 3354, Bethelem, Pennsylvania, United States|Site Reference ID/Investigator# 6006, Philadelphia, Pennsylvania, United States|Site Reference ID/Investigator# 2414, Bristol, Tennessee, United States|Site Reference ID/Investigator# 2070, Tacoma, Washington, United States|Site Reference ID/Investigator# 4687, Brno, Czech Republic|Site Reference ID/Investigator# 3337, Brno, Czech Republic|Site Reference ID/Investigator# 4278, Kyjov, Czech Republic|Site Reference ID/Investigator# 3328, Novy Jicin, Czech Republic|Site Reference ID/Investigator# 3327, Olomouc, Czech Republic|Site Reference ID/Investigator# 3343, Ostrava-Poruba, Czech Republic|Site Reference ID/Investigator# 3344, Prague 2, Czech Republic|Site Reference ID/Investigator# 3342, Prague 4, Czech Republic|Site Reference ID/Investigator# 3411, Pribram, Czech Republic|Site Reference ID/Investigator# 3405, Heraklion, Greece|Site Reference ID/Investigator# 3403, Thessaloniki, Greece|Site Reference ID/Investigator# 3406, Thessaloniki, Greece|Site Reference ID/Investigator# 3331, Budapest, Hungary|Site Reference ID/Investigator# 3333, Miskolc, Hungary|Site Reference ID/Investigator# 3332, Szekesfehervar, Hungary|Site Reference ID/Investigator# 3409, Amsterdam, Netherlands|Site Reference ID/Investigator# 3319, Eindhoven, Netherlands|Site Reference ID/Investigator# 3341, Haraderwijk, Netherlands|Site Reference ID/Investigator# 3528, Hoorn, Netherlands|Site Reference ID/Investigator# 3400, Bratislava, Slovakia|Site Reference ID/Investigator# 3410, Martin, Slovakia",,"https://ClinicalTrials.gov/show/NCT00297089"
673,"NCT00292396","Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis",,"Completed","No Results Available","Psoriasis","Drug: Anti IL-12 monoclonal antibody/ABT-874|Drug: placebo","Proportion of subjects with clinical response relative to Baseline PASI score|Quality of Life Surveys|Clinical response indicators|Safety parameters|PGA Assessment","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","M05-736","November 2005","April 2008","April 2008","February 16, 2006",,"January 18, 2013","Site Reference ID/Investigator# 3351, San Diego, California, United States|Site Reference ID/Investigator# 3347, Alpharetta, Georgia, United States|Site Reference ID/Investigator# 3348, Skokie, Illinois, United States|Site Reference ID/Investigator# 993, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 990, Boston, Massachusetts, United States|Site Reference ID/Investigator# 3349, St. Louis, Missouri, United States|Site Reference ID/Investigator# 992, Cincinnati, Ohio, United States|Site Reference ID/Investigator# 991, Lake Oswego, Oregon, United States|Site Reference ID/Investigator# 3367, Portland, Oregon, United States|Site Reference ID/Investigator# 3346, Johnston, Rhode Island, United States|Site Reference ID/Investigator# 994, Nashville, Tennessee, United States|Site Reference ID/Investigator# 3350, Dallas, Texas, United States|Site Reference ID/Investigator# 796, Houston, Texas, United States|Site Reference ID/Investigator# 2081, Salt Lake City, Utah, United States|Site Reference ID/Investigator# 3366, Norfolk, Virginia, United States|Site Reference ID/Investigator# 989, Seattle, Washington, United States|Site Reference ID/Investigator# 3361, Halifax, Canada|Site Reference ID/Investigator# 985, Laval, Canada|Site Reference ID/Investigator# 987, London, Canada|Site Reference ID/Investigator# 3364, Montreal, Canada|Site Reference ID/Investigator# 794, North Bay, Canada|Site Reference ID/Investigator# 988, Quebec City, Canada|Site Reference ID/Investigator# 795, Waterloo, Canada|Site Reference ID/Investigator# 3360, Windsor, Canada",,"https://ClinicalTrials.gov/show/NCT00292396"
674,"NCT00234975","Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score",,"Completed","No Results Available","HIV Infection","Drug: Lopinavir/Ritonavir","Primary Outcome Measure|Secondary Outcome Measures","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PUER-02-003","October 2002","January 2008","January 2008","October 10, 2005",,"January 3, 2013","Site Reference ID/Investigator# 4118, Bayamon, Puerto Rico|Site Reference ID/Investigator# 4119, Bayamon, Puerto Rico|Site Reference ID/Investigator# 6298, Juana Diaz, Puerto Rico|Site Reference ID/Investigator# 6284, Las Piedras, Puerto Rico|Site Reference ID/Investigator# 4101, Mayaguez, Puerto Rico|Site Reference ID/Investigator# 4116, Playa de Ponce, Puerto Rico|Site Reference ID/Investigator# 4117, Ponce, Puerto Rico|Site Reference ID/Investigator# 4099, Ponce, Puerto Rico|Site Reference ID/Investigator# 4086, Rio Piedras, Puerto Rico|Site Reference ID/Investigator# 4080, San Juan, Puerto Rico|Site Reference ID/Investigator# 4100, Santurce, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00234975"
675,"NCT00195663","Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","PREMIER","Completed","Has Results","Early Rheumatoid Arthritis","Biological: Adalimumab|Drug: Methotrexate|Biological: Adalimumab placebo|Drug: Methotrexate placebo","Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52|Change From Baseline in Modified Total Sharp Score (mTSS) at Week 52|Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52|Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 104|Change From Baseline in Modified Total Sharp Score (mTSS) at Week 104|Number of Participants Who Achieved Clinical Remission, Defined as a Disease Activity 28 (DAS28) Score < 2.6 at Week 52|Change From Baseline in the Physical Component of the Short Form-36 Health Status Survey (SF-36) at Week 52|Number of Participants With Major Clinical Response After 104 Weeks of Treatment|Change From Baseline in the Mental Component of the Short Form-36 Health Status Survey (SF-36) at Week 52|Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Weeks 26 and 76|Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria During the Double-blind Phase|Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria During the Double-blind Phase|Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) During the Double-blind Treatment Phase|Number of Participants With Improvement in the HAQ-DI Score ≥ 0.3 During the Double-blind Treatment Phase|Change From Baseline in Health Utilities Index Mark 2 and Mark 3 (HUI 2/3) During the Double-blind Treatment Phase|Change From Baseline in the Short Form-36 Health Status Survey (SF-36) During the Double-blind Treatment Phase|Numeric American College of Rheumatology (ACR-N) During the Double-blind Treatment Phase|Change From Baseline in Disease Activity Score (DAS28) During the Double-blind Treatment Phase|Change From Baseline in Joint Erosion Score During the Double-blind Treatment Period|Change From Baseline in Joint Space Narrowing Score During the Double-blind Treatment Period|Number of Participants With No Worsening in Modified Total Sharp Score or Components During the Double-blind Treatment Phase|Number of Participants With No Erosions at Baseline and No New Erosions at Weeks 52 and 104|Number of Participants With Non-Involved Joints at Baseline and No Newly Involved Joints at Weeks 52 and 104|Number of Participants Meeting ACR20 Response Criteria Over 10 Years by Adalimumab Exposure|Number of Participants Meeting ACR50 Response Criteria Over 10 Years by Adalimumab Exposure|Number of Participants Meeting ACR70 Response Criteria Over 10 Years by Adalimumab Exposure|Change From Baseline in the Health Assessment Questionnaire - Disability Index (HAQ-DI) Over 10 Years by Adalimumab Exposure|Change From Baseline in DAS28 Over 10 Years by Adalimumab Exposure|Number of Participants With DAS28 < 2.6 and < 3.2 Over 10 Years by Adalimumab Exposure|Change From Baseline in Modified Total Sharp Score (mTSS) Over 10 Years|Number of Participants With No Radiographic Progression Over 10 Years|Composite Score of ACR50 Plus No Change in Modified Total Sharp Score|Number of Participants With a Major Clinical Response Over 10 Years by Adalimumab Exposure|Number of Participants With Improvement in HAQ-DI by 0.22 and 0.5 Units Over 10 Years by Adalimumab Exposure","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","799","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DE013","December 2000","April 2004","April 2012","September 20, 2005","February 25, 2010","July 12, 2013","Site Reference ID/Investigator# 322, Scottsdale, Arizona, United States|Site Ref # / Investigator 95957, La Jolla, California, United States|Site Reference ID/Investigator# 429, La Jolla, California, United States|Site Reference ID/Investigator# 2491, Los Angeles, California, United States|Site Reference ID/Investigator# 2500, Denver, Colorado, United States|Site Reference ID/Investigator# 762, Aventura, Florida, United States|Site Reference ID/Investigator# 328, Sarasota, Florida, United States|Site Reference ID/Investigator# 327, Tampa, Florida, United States|Site Reference ID/Investigator# 325, Zephyrhills, Florida, United States|Site Reference ID/Investigator# 302, Rockford, Illinois, United States|Site Reference ID/Investigator# 319, Cumberland, Maryland, United States|Site Ref # / Investigator 95960, Hagerstown, Maryland, United States|Site Reference ID/Investigator# 326, Wheaton, Maryland, United States|Site Reference ID/Investigator# 2533, Worcester, Massachusetts, United States|Site Reference ID/Investigator# 336, Lincoln, Nebraska, United States|Site Reference ID/Investigator# 318, Concord, New Hampshire, United States|Site Reference ID/Investigator# 488, Durham, North Carolina, United States|Site Reference ID/Investigator# 314, Dayton, Ohio, United States|Site Reference ID/Investigator# 761, Oklahoma City, Oklahoma, United States|Site Reference ID/Investigator# 757, Eugene, Oregon, United States|Site Reference ID/Investigator# 361, Lake Oswego, Oregon, United States|Site Reference ID/Investigator# 316, Bethlehem, Pennsylvania, United States|Site Reference ID/Investigator# 4649, Duncansville, Pennsylvania, United States|Site Ref # / Investigator 96122, Austin, Texas, United States|Site Reference ID/Investigator# 306, Austin, Texas, United States|Site Reference ID/Investigator# 313, Austin, Texas, United States|Site Reference ID/Investigator# 2437, Dallas, Texas, United States|Site Reference ID/Investigator# 2532, Houston, Texas, United States|Site Reference ID/Investigator# 758, Houston, Texas, United States|Site Reference ID/Investigator# 321, Spokane, Washington, United States|Site Reference ID/Investigator# 305, Yakima, Washington, United States|Site Reference ID/Investigator# 310, Brisbane, Australia|Site Reference ID/Investigator# 755, Camperdown, Australia|Site Reference ID/Investigator# 337, Clayton, Australia|Site Reference ID/Investigator# 331, Darlinghurst, Sydney, Australia|Site Reference ID/Investigator# 745, Kogarah, Australia|Site Reference ID/Investigator# 738, Maroochydore, Australia|Site Reference ID/Investigator# 335, New Lambton, Australia|Site Reference ID/Investigator# 737, Shenton Park, Australia|Site Reference ID/Investigator# 307, South Hobart, Australia|Site Reference ID/Investigator# 427, West Heidelberg, Australia|Site Reference ID/Investigator# 739, Woodville, Australia|Site Reference ID/Investigator# 344, Vienna, Austria|Site Reference ID/Investigator# 753, Brussels, Belgium|Site Reference ID/Investigator# 308, Brussels, Belgium|Site Reference ID/Investigator# 752, Brussels, Belgium|Site Reference ID/Investigator# 748, Diepenbeek, Belgium|Site Reference ID/Investigator# 6136, Ghent, Belgium|Site Ref # / Investigator 98256, Leuven, Belgium|Site Reference ID/Investigator# 333, Liege, Belgium|Site Ref # / Investigator 98199, North York, Ontario, Canada|Site Reference ID/Investigator# 4646, Edmonton, Canada|Site Reference ID/Investigator# 303, Hamilton, Canada|Site Reference ID/Investigator# 330, Hamilton, Canada|Site Reference ID/Investigator# 4634, Montreal, Canada|Site Reference ID/Investigator# 311, Montreal, Canada|Site Reference ID/Investigator# 309, Newmarket, Canada|Site Reference ID/Investigator# 304, Pointe-Claire, Canada|Site Reference ID/Investigator# 4633, Richmond, Canada|Site Reference ID/Investigator# 763, St. John's, Canada|Site Reference ID/Investigator# 4635, Toronto, Canada|Site Reference ID/Investigator# 490, Toronto, Canada|Site Reference ID/Investigator# 760, Victoria, Canada|Site Reference ID/Investigator# 4632, Winnipeg, Canada|Site Reference ID/Investigator# 754, Hradec Kralove, Czech Republic|Site Reference ID/Investigator# 332, Plzen, Czech Republic|Site Reference ID/Investigator# 734, Prague 2, Czech Republic|Site Ref # / Investigator 95878, Grasten, Denmark|Site Reference ID/Investigator# 6135, Heinola, Finland|Site Ref # / Investigator 6134, Helsinki, Finland|Site Reference ID/Investigator# 428, Bobigny, France|Site Reference ID/Investigator# 348, Montpellier Cedex 5, France|Site Reference ID/Investigator# 4650, Paris Cedex 14, France|Site Reference ID/Investigator# 3415, Pierre Benite, France|Site Reference ID/Investigator# 733, Rennes, France|Site Reference ID/Investigator# 346, Strasbourg, Cedex 1, France|Site Reference ID/Investigator# 3417, Berlin-Buch, Germany|Site Reference ID/Investigator# 4631, Berlin, Germany|Site Reference ID/Investigator# 759, Berlin, Germany|Site Reference ID/Investigator# 4630, Erlangen, Germany|Site Reference ID/Investigator# 347, Freiburg, Germany|Site Reference ID/Investigator# 742, Goerlitz, Germany|Site Reference ID/Investigator# 746, Leipzig, Germany|Site Ref # / Investigator 98125, Munich, Germany|Site Reference ID/Investigator# 339, Munich, Germany|Site Reference ID/Investigator# 744, Ratingen, Germany|Site Reference ID/Investigator# 338, Vogelsang-Gommern, Germany|Site Reference ID/Investigator# 740, Cork, Ireland|Site Reference ID/Investigator# 751, Dublin 4, Ireland|Site Ref # / Investigator 95719, Genoa, Italy|Site Reference ID/Investigator# 323, Naples, Italy|Site Reference ID/Investigator# 345, Udine, Italy|Site Reference ID/Investigator# 756, Verona, Italy|Site Reference ID/Investigator# 343, Groningen, Netherlands|Site Reference ID/Investigator# 6133, Leiden, Netherlands|Site Reference ID/Investigator# 317, Maastricht, Netherlands|Site Reference ID/Investigator# 315, Nijmegen, Netherlands|Site Ref # / Investigator 95800, Osla, Norway|Site Ref # / Investigator 95875, Osla, Norway|Site Reference ID/Investigator# 3426, Piestany, Slovakia|Site Ref # / Investigator 96121, Alicante, Spain|Site Reference ID/Investigator# 735, Alicante, Spain|Site Reference ID/Investigator# 1525, Barcelona, Spain|Site Reference ID/Investigator# 1528, Barcelona, Spain|Site Reference ID/Investigator# 750, Guadalajara, Spain|Site Reference ID/Investigator# 1526, Madrid, Spain|Site Reference ID/Investigator# 741, Madrid, Spain|Site Reference ID/Investigator# 390, Santiago de Compostela, Spain|Site Reference ID/Investigator# 749, Sevilla, Spain|Site Reference ID/Investigator# 728, Stockholm, Sweden|Site Reference ID/Investigator# 2565, Stockholm, Sweden|Site Reference ID/Investigator# 4638, Stockholm, Sweden|Site Ref # / Investigator 96126, Umea, Sweden|Site Reference ID/Investigator# 747, Uppsala, Sweden|Site Ref # / Investigator 96120, Vasteras, Sweden|Site Reference ID/Investigator# 736, Vasteras, Sweden|Site Reference ID/Investigator# 334, Lausanne, Switzerland|Site Ref # / Investigator 96116, Bangor, United Kingdom|Site Ref # / Investigator 95877, Cambridge, United Kingdom|Site Ref # / Investigator 98258, Hereford, United Kingdom|Site Ref # / Investigator 95795, Leeds, United Kingdom|Site Ref # / Investigator 95958, London, United Kingdom|Site Ref # / Investigator 98255, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00195663"
676,"NCT00141518","Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact","DAPHNE","Completed","Has Results","Advanced Idiopathic Parkinson's Disease","Drug: Levodopa-carbidopa intestinal gel (LCIG)|Device: CADD-Legacy® 1400 ambulatory infusion pump|Device: percutaneous endoscopic gastrostomy tube (PEG tube)|Device: jejunal extension tube (J-tube)","Unified Parkinson's Disease Rating Scale (UPDRS) Total Score, and UPDRS Subscores I, II, III, and IV at Baseline and Month 12|Euro QoL 5 Dimensions Quality of Life Instrument (EQ-5D) Descriptive Systems Summary Index Score at Baseline and Month 12|EQ-5D Visual Analog Scale (VAS) Score at Baseline and Month 12|Total Monthly Cost Per Participant, in Swedish Crowns (SEK) 2010|Monthly Drug Costs Per Participant, SEK 2010|Monthly Direct Medical Cost (Excluding Drug Costs) Per Participant, SEK 2010|Direct Monthly Non-medical Costs Per Participant, SEK 2010|Indirect Monthly Costs Per Participant (Only Applied to Participants Younger Than 65) by Study Month, SEK 2010|Modified Hoehn and Yahr Staging: Current Stage From Baseline to Month 36|Modified Hoehn and Yahr Staging: Best Stage From Baseline to Month 36|Modified Hoehn and Yahr Staging: Worst Stage From Baseline to Month 36|Schwab and England Scale: Best ""On"" Period Stage From Baseline to Month 36|Mini Mental Status Examination (MMSE) Total Scores From Baseline to Month 36|MMSE Orientation Subscale Scores From Baseline to Month 36|MMSE Registration Subscale Scores From Baseline to Month 36|MMSE Attention and Calculation Subscale Scores From Baseline to Month 36|MMSE Recall Subscale Scores From Baseline to Month 36|MMSE Language Subscale Scores From Baseline to Month 36|Montgomery-Åsberg Depression Rating Scale (MADRS) Total Scores From Baseline to Month 36|MADRS Reported Sadness Scores From Baseline to Month 36|MADRS Apparent Sadness Scores From Baseline to Month 36|MADRS Inner Tension Scores From Baseline to Month 36|MADRS Reduced Sleep Scores From Baseline to Month 36|MADRS Reduced Appetite Scores From Baseline to Month 36|MADRS Concentration Difficulties Scores From Baseline to Month 36|MADRS Lassitude Scores From Baseline to Month 36|MADRS Inability to Feel Scores From Baseline to Month 36|MADRS Pessimistic Thoughts Scores From Baseline to Month 36|MADRS Suicidal Thoughts Scores From Baseline to Month 36|Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index Scores From Baseline to Month 36|PDQ-39 Mobility Subscale Scores From Baseline to Month 36|PDQ-39 Activities of Daily Living Subscale Scores From Baseline to Month 36|PDQ-39 Emotional Well Being Subscale Scores From Baseline to Month 36|PDQ-39 Stigma Subscale Scores From Baseline to Month 36|PDQ-39 Social Support Subscale Scores From Baseline to Month 36|PDQ-39 Cognition Subscale Scores From Baseline to Month 36|PDQ-39 Communication Subscale Scores From Baseline to Month 36|PDQ-39 Bodily Discomfort Subscale Scores From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Walking) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Off Time) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (On Time) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Dyskinetic Time) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Off Magnitude) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Dyskinetic Magnitude) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Cramps) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Satisfied With Function) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Self-assessment) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Free Tapping - Speed) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Free Tapping - Accuracy) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Tapping, Increased Speed - Accuracy) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Speed) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Tapping, Random Chase - Accuracy) From Baseline to Month 36|Electronic Diary: Morning and Day Scores (Drawing Impairment [Wavelet Method]) From Baseline to Month 36","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","77","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S187.4.001|2005-002654-21","March 2006","March 2011","April 2011","September 1, 2005","July 18, 2016","July 18, 2016",,,"https://ClinicalTrials.gov/show/NCT00141518"
677,"NCT00086671","Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)",,"Completed","No Results Available","Multiple Sclerosis","Drug: ABT-874/Human monoclonal antibody against IL-12|Drug: Placebo","Comparison of the cumulative number of Gd enhanced (T1 weighted) lesions during the treatment phase|Safety and clinical laboratory parameters|vital signs|Magnetic Resonance Imaging endpoints","AbbVie (prior sponsor, Abbott)|AbbVie","All","18 Years to 60 Years   (Adult)","Phase 2","215","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","M03-654","April 2004","November 2006","November 2006","July 9, 2004",,"January 4, 2013","Site Reference ID/Investigator# 107, Phoenix, Arizona, United States|Site Reference ID/Investigator# 163, Sun City, Arizona, United States|Site Reference ID/Investigator# 156, Little Rock, Arkansas, United States|Site Reference ID/Investigator# 154, Irvine, California, United States|Site Reference ID/Investigator# 161, Laguna Hills, California, United States|Site Reference ID/Investigator# 84, Sacramento, California, United States|Site Reference ID/Investigator# 119, Boulder, Colorado, United States|Site Reference ID/Investigator# 111, Miami, Florida, United States|Site Reference ID/Investigator# 151, Tallahassee, Florida, United States|Site Reference ID/Investigator# 108, Atlanta, Georgia, United States|Site Reference ID/Investigator# 109, Atlanta, Georgia, United States|Site Reference ID/Investigator# 105, Northbrook, Illinois, United States|Site Reference ID/Investigator# 152, Indianapolis, Indiana, United States|Site Reference ID/Investigator# 258, Lenexa, Kansas, United States|Site Reference ID/Investigator# 261, Lexington, Kentucky, United States|Site Reference ID/Investigator# 116, Detroit, Michigan, United States|Site Reference ID/Investigator# 158, Traverse City, Michigan, United States|Site Reference ID/Investigator# 124, St. Louis, Missouri, United States|Site Reference ID/Investigator# 259, Henderson, Nevada, United States|Site Reference ID/Investigator# 153, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 110, Albany, New York, United States|Site Reference ID/Investigator# 117, Charlotte, North Carolina, United States|Site Reference ID/Investigator# 113, Columbus, Ohio, United States|Site Reference ID/Investigator# 157, Dayton, Ohio, United States|Site Reference ID/Investigator# 114, Allentown, Pennsylvania, United States|Site Reference ID/Investigator# 128, Houston, Texas, United States|Site Reference ID/Investigator# 155, Bennington, Vermont, United States|Site Reference ID/Investigator# 132, Greenfield Park, Canada|Site Reference ID/Investigator# 130, Halifax, Canada|Site Reference ID/Investigator# 82, Ottawa, Canada|Site Reference ID/Investigator# 169, Sherbrooke, Canada|Site Reference ID/Investigator# 134, Vancouver, Canada|Site Reference ID/Investigator# 149, Frankfurt, Germany|Site Reference ID/Investigator# 137, Breda, Netherlands|Site Reference ID/Investigator# 148, Nieuwegein, Netherlands|Site Reference ID/Investigator# 138, Nijmwegen, Netherlands|Site Reference ID/Investigator# 139, Sittard, Netherlands|Site Reference ID/Investigator# 159, Liverpool, United Kingdom|Site Reference ID/Investigator# 140, London, United Kingdom|Site Reference ID/Investigator# 142, Newcastle upon Tyne, United Kingdom|Site Reference ID/Investigator# 141, Nottingham, United Kingdom|Site Reference ID/Investigator# 144, Oxford, United Kingdom|Site Reference ID/Investigator# 143, Stoke on Trent, United Kingdom|Site Reference ID/Investigator# 160, Whitechapel, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00086671"
678,"NCT04196647","Guideline for Hometitration With Duodopa for Parkinson Patients",,"Recruiting","No Results Available","Parkinson Disease","Other: Home titration","Patient satisfaction|Hoehn Yahr staging of Parkinson's disease|Montreal Cognitive Assesment (MOCA)|Parkinsons Disease Questionnaire 39 (PD-Q39)|Unified Parkinsons Disease Rating Scale III (UPDRS)|Barthel-20 index|Non-Motor Symptom Scale (NMSS)","Rigshospitalet, Denmark|AbbVie","All","18 Years to 90 Years   (Adult, Older Adult)",,"10","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","15010036","March 1, 2017","December 31, 2020","June 30, 2021","December 12, 2019",,"December 12, 2019","Neurologisk klinik, Rigshospitalet Glostrup, Copenhagen, Glostrup, Denmark",,"https://ClinicalTrials.gov/show/NCT04196647"
679,"NCT04183608","A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab","CONTROL","Not yet recruiting","No Results Available","Ulcerative Colitis","Drug: Adalimumab|Diagnostic Test: Calprotectin|Other: e-Monitoring|Other: Therapy Education","Endoscopic Remission|Efficacy of adalimumab treatment on clinical remission (at Week 48)|Efficacy of adalimumab treatment on endoscopic Healing (at Week 48)|Efficacy of adalimumab treatment on endoscopic mucosal healing|Efficacy of adalimumab treatment on histological Healing (at Week 48)|Efficacy of adalimumab treatment on patient quality of life (at Week 48)|Patient satisfaction|Treatment compliance|Patient adhesion|Disability score evolution|Medico-economic analysis|Continuous Clinical Response (CCR)|Loss of clinical response|Number of visits in trial|Colectomies at Week 48|UC related Hospitalizations at Week 48","Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","238","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","GETAID-2018-01","December 2019","December 2022","April 2024","December 3, 2019",,"December 3, 2019","CHU Amiens- Picardie (site Sud), Amiens, France|CHU Caen Hôpital Côte de Nacre, Caen, France|CHU Estaing, Clermont-Ferrand, France|APHP - Hôpital Beaujon, Clichy, France|CH Colmar - Hôpital Pasteur, Colmar, France|CHRU Lille Hôpital Claude Huriez, Lille, France|APHM - Hôpital Nord, Marseille, France|GHI Le Raincy-Montfermeil, Montfermeil, France|CHU Montpellier - Hôpital Saint Eloi, Montpellier, France|CHU Nantes - Hôpital Hotel Dieu, Nantes, France|CHU Nice- Hopital l'Archet, Nice, France|Chu nimes - Hôpital Universitaire Caremeau, Nîmes, France|CHU Bordeaux - Hôpital Haut Lévêque, Pessac, France|CHU Lyon Sud, Pierre-Bénite, France|CHU Rennes Hôpital Pontchaillou, Rennes, France|CH Saint Etienne Hopital Nord, Saint-Priest-en-Jarez, France|CH Toulon - CHITS CH Sainte Musse, Toulon, France|CHU Toulouse - Hôpital Rangueil, Toulouse, France|CH Tourcoing - Hôpital Gustave Dron, Tourcoing, France|CHU Nancy - Hôpital de Brabois, Vandœuvre-lès-Nancy, France",,"https://ClinicalTrials.gov/show/NCT04183608"
680,"NCT03933735","A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma",,"Recruiting","No Results Available","Multiple Myeloma","Drug: TNB-383B","Number of subjects with Dose-limiting toxicities (DLT)|Number of subjects with adverse events (AEs) and/or serious adverse events (SAEs)|Maximum Observed Plasma Concentration of TNB-383B (Cmax)|Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast)|Apparent terminal half-life (t1/2) of TNB-383B.|Incidence of Anti-drug Antibody (ADA)|Titers of Anti-drug Antibody (ADA)|Anti-Myeloma Activity by Objective Response Rate (ORR)|Anti-Myeloma Activity by Duration of Objective Response (DOR)","Teneobio, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TNB383B.0001","June 24, 2019","March 2021","December 2021","May 1, 2019",,"January 22, 2020","UCSF, San Francisco, California, United States|Mayo Clinic-Rochester, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Carolinas Healthcare, Charlotte, North Carolina, United States|Wake Forest, Winston-Salem, North Carolina, United States|Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT03933735"
681,"NCT03844815","Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia",,"Not yet recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Decitabine|Drug: Venetoclax","The rate of dose limiting toxicity (DLT)|Levels of toxicity with combination regimen|Assessment of Overall Survival","University of Chicago|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB18-1498","April 10, 2020","June 10, 2022","June 10, 2024","February 18, 2019",,"October 9, 2019","University Of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03844815"
682,"NCT03757533","Health Coaching as a Tool for Improving Medication Adherence in Adult Patients With Crohn's Disease",,"Enrolling by invitation","No Results Available","Crohn Disease","Behavioral: Health Coaching|Other: Surveys","Medication Adherence MPR|Medication Adherence PDC","Vanderbilt University Medical Center|AbbVie","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","182030","June 11, 2019","July 2022","July 2022","November 29, 2018",,"July 2, 2019","Vanderbilt University Medical Center Inflammatory Bowel Disease Clinic, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03757533"
683,"NCT03710252","A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study","HEARTLAND","Completed","No Results Available","Chronic Hepatitis C","Drug: paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin","The primary analysis will be sustained virologic response 12 weeks after the last treatment dose (SVR12) for the all treated population.|Effect of baseline resistance variants on SVR12 (subgroups: all RAVs, different classes of RAVs)|Evaluate patient reported outcomes via the SF36v2 survey (subgroups: those who achieve SVR12 and those who do not)|Evaluate patient adherence (subgroups: those who achieve SVR12 and those who do not)","American Research Corporation|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TLI_IIS_01_2015","March 2016","September 2017","September 2017","October 18, 2018",,"October 18, 2018",,,"https://ClinicalTrials.gov/show/NCT03710252"
684,"NCT03693586","Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis",,"Recruiting","No Results Available","Chronic Hepatitis c|Vasculitis",,"seropositive for hepatitis C|confirmation of a hepatitis C case","Hospital General de Mexico|AbbVie","All","Child, Adult, Older Adult",,"1000","Other|Industry","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","DI/18/107/03/071","October 19, 2018","May 1, 2020","July 1, 2020","October 3, 2018",,"August 12, 2019","Hospital General de Mexico, Mexico City, Mexico",,"https://ClinicalTrials.gov/show/NCT03693586"
685,"NCT03637517","Malaria: Relative Bioavailability and Food Effect of DSM265",,"Completed","No Results Available","Healthy Volunteers","Drug: DSM265-TPGS 34% SDD, 400 mg fasted|Drug: DSM265-TPGS 34% SDD, 400 mg fed|Drug: DSM265 25% SDD, 400 mg fasted","Cmax|AUC|Tmax|β|C168","Medicines for Malaria Venture|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 1","42","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","MMV_DSM265_18_01|B19-227","October 3, 2018","November 19, 2018","November 19, 2018","August 20, 2018",,"February 20, 2019","AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03637517"
686,"NCT03567876","Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL",,"Recruiting","No Results Available","Lymphoma, Mantle-Cell","Drug: Venetoclax","Progression-free survival of the High Risk patients|Molecular response|Progression-free survival of all patients and different subgroups|Overall survival|Duration of responses|Proportion of complete remission in High Risk and Law Risk patients|Completed expected treatment schedule|Incidence of Treatment-Emergent Adverse Events","Fondazione Italiana Linfomi ONLUS|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FIL_V-RBAC","September 3, 2018","July 2020","July 2025","June 26, 2018",,"July 16, 2019","A.O. SS. Antonio e Biagio e Cesare Arrigo, SC Ematologia, Alessandria, Italy|Università Politecnica delle Marche, Clinica di Ematologia, Ancona, Italy|Centro Riferimento Oncologico, S.O.C. Oncologia Medica A, Aviano, Italy|IRCCS Istituto Tumori Giovanni Paolo II, UOC Ematologia, Bari, Italy|Policlinico S. Orsola-Malpighi, Istituto di Ematologia ""Seragnoli"", Bologna, Italy|Ospedale Centrale di Bolzano, Divisione di Ematologia e T.M.O., Bolzano, Italy|ASST Spedali Civili, Ematologia, Brescia, Italy|Ospedale Businco, Ematologia, Cagliari, Italy|Azienda Ospedaliera di Cosenza, UOC Ematologia, Cosenza, Italy|Azienda Ospedaliera S. Croce e Carle, SC Ematologia, Cuneo, Italy|Azienda Ospedaliera Universitaria Careggi, Unità funzionale di Ematologia, Firenze, Italy|Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Clinica Ematologica, Genova, Italy|Ospedale Policlinico San Martino S.S.R.L. - IRCCS per l'Oncologia, Ematologia, Genova, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Ematologia, Meldola, Italy|ASST Grande Ospedale Metropolitano Niguarda, SC Ematologia, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Ematologia, Milano, Italy|Istituto Scientifico San Raffaele, Unità Linfomi - Dipartimento Oncoematologia, Milano, Italy|Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Ematologia, Milano, Italy|AOU Maggiore della Carità di Novara, SCDU Ematologia, Novara, Italy|Azienda Ospedaliera Universitaria di Padova, Ematologia, Padova, Italy|A.O. Ospedali Riuniti Villa Sofia-Cervello, Divisione di Ematologia, Palermo, Italy|IRCCS Policlinico S. Matteo, Divisione di Ematologia, Pavia, Italy|Ospedale Guglielmo Da Saliceto, UO Ematologia, Piacenza, Italy|Ospedale delle Croci, Ematologia, Ravenna, Italy|Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Ematologia, Reggio Calabria, Italy|Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova, Ematologia, Reggio Emilia, Italy|Ospedale degli Infermi, UO Ematologia, Rimini, Italy|Policlinico Umberto I - Università ""La Sapienza"", Istituto Ematologia -Dipartimento di Biotecnologie Cellulari ed Ematologia, Roma, Italy|Università Cattolica S. Cuore, Ematologia, Roma, Italy|Istituto Clinico Humanitas, UO Ematologia, Rozzano, Italy|Casa Sollievo della Sofferenza, UO Ematologia, San Giovanni Rotondo, Italy|Azienda Ospedaliero Universitaria Senese, UOC Ematologia, Siena, Italy|A.O.U. Città della Salute e della Scienza di Torino, SC Ematologia Universitaria, Torino, Italy|A.O.U. Città della Salute e della Scienza di Torino, SC Ematologia, Torino, Italy|Ospedale Ca' Foncello, SC Ematologia, Treviso, Italy|Azienda Ospedaliera C. Panico, UOC Ematologia e Trapianto, Tricase, Italy|Azienda Sanitaria Universitaria Integrata di Udine, Clinica Ematologica, Udine, Italy|Ospedale di Circolo, UOC Ematologia, Varese, Italy|Azienda Ospedaliera Universitaria Integrata di Verona, UO Ematologia, Verona, Italy|Ospedale San Bortolo, Divisione di Ematologia, Vicenza, Italy",,"https://ClinicalTrials.gov/show/NCT03567876"
687,"NCT03485547","Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)",,"Recruiting","No Results Available","Blastic Plasmacytoid Dendritic Cell Neoplasm","Drug: Venetoclax","Dose Limiting Toxicity|Overall Response Rate|Complete Response|Partial Response|Overall Survival|Progression free survival","Dana-Farber Cancer Institute|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","26","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-045","August 23, 2018","April 30, 2021","April 30, 2025","April 2, 2018",,"October 18, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03485547"
688,"NCT03364725","Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study","ELIMINATEC","Unknown status","No Results Available","Hepatitis C|Addict Heroin","Drug: Glecaprevir-pibrentasvir","Cure rate of Hepatitis C Infection|Sobriety from Drug Use|Hepatitis C Reinfection Rate","Id Care|AbbVie","All","18 Years to 30 Years   (Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIS # 11-507","January 15, 2018","September 1, 2018","March 1, 2019","December 7, 2017",,"December 7, 2017","ID CARE, Hillsborough, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT03364725"
689,"NCT03319901","Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL",,"Recruiting","No Results Available","Leukemia","Drug: Venetoclax|Drug: Standard Chemotherapy","Maximum Tolerated Dose|To Evaluate The Safety of the Combination|Complete Response|Progression Free Survival|Overall Survival|Minimal Residual Disease|Disease Free Survival|Change in expression of BCL-2 family proteins: BCL-2|Change in expression of BCL-2 family proteins: BCL-XL|Change in expression of BCL-2 family proteins: MCL-1 (anti-apoptotic)|Change in expression of BCL-2 family proteins: BCL-2 homology 3 (BH3)|Change in expression of BCL-2 family proteins: BIM|Change in expression of BCL-2 family proteins: BID|Change in expression of BCL-2 family proteins: BAD|Change in expression of BCL-2 family proteins: NOXA|Change in expression of BCL-2 family proteins: PUMA|Change in expression of BCL-2 family proteins: HRK (pro-apoptotic)","Dana-Farber Cancer Institute|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-648","October 30, 2017","April 30, 2020","April 30, 2023","October 24, 2017",,"November 28, 2018","Dana Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03319901"
690,"NCT03288337","Impact of Hidradenitis Suppurativa on Quality of Life Functions",,"Recruiting","No Results Available","Hidradenitis Suppurativa|Quality of Life",,"Dermatology-related quality of life|Presence and severity of depression|Subject-reported subject health|Degree of enjoyment and satisfaction experienced by subjects in daily functioning.|Employment and economic productivity|Change in quality of life|Change in presence and severity of depression as measured using standardized Beck Depression Inventory|Change in subject-reported subject health|Change in degree of enjoyment and satisfaction experienced by subjects in various areas of daily functioning|Change in self-reported employment and economic productivity","Montefiore Medical Center|AbbVie","All","18 Years to 99 Years   (Adult, Older Adult)",,"400","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2014-3873","April 2015","August 2020","August 2020","September 20, 2017",,"January 2, 2020","Montefiore Medical Center, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT03288337"
691,"NCT03261102","TDM Guided Early Optimization of ADAL in Crohn's Disease",,"Recruiting","No Results Available","Crohn Disease|Drug Monitoring|Inflammatory Bowel Diseases","Biological: Adalimumab","Proportion of subjects who achieved remission|Proportion of subjects who achieved clinical response|Therapeutic drug monitoring|Proportion of steroid free subjects|Subjects well-being|Rates of complications","waqqas.afif|AbbVie|McGill University Health Centre/Research Institute of the McGill University Health Centre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MP-37-2017-2793","January 17, 2017","December 31, 2019","June 1, 2020","August 24, 2017",,"March 13, 2019","University of Calgary Medical Center (UCMC), Calgary, Alberta, Canada|The University of British Columbia, Vancouver, British Columbia, Canada|London Health Sciences Centre (LHSC) University Hospital, London, Ontario, Canada|The Ottawa Hospital, IBD Centre of Excellence, Ottawa, Ontario, Canada|McGill University Hospital Center (MUHC), Montréal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03261102"
692,"NCT03254121","Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response","HEPCASUS","Recruiting","No Results Available","Hepatocellular Carcinoma|Hepatitis C",,"Characterisation of genomic mutations of HCC, developed in HCV patients with SVR","Karolinska Institutet|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","SAleman","January 1, 2017","January 1, 2021","January 1, 2027","August 18, 2017",,"September 6, 2017","Karolinska Institutet, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03254121"
693,"NCT03217734","MAP Study: Methotrexate and Adalimumab in Psoriasis","MAP","Completed","No Results Available","Psoriasis","Biological: Adalimumab|Drug: Methotrexate|Drug: Placebo","PASI Change|ADA/Anti ADA Antibodies","Jeffrey J Crowley MD|AbbVie|Bakersfield Dermatology & Skin Cancer Medical Group","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","A16-241","April 10, 2017","December 31, 2018","December 31, 2018","July 14, 2017",,"July 9, 2019","Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, California, United States|Clinical Science Institute, Santa Monica, California, United States|DermAssociates, PC, Rockville, Maryland, United States|Modern Research Associates, PLLC, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03217734"
694,"NCT03155113","Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy",,"Active, not recruiting","No Results Available","Chronic Hepatitis C","Other: blood drawing","Immune T cell response","Azienda Ospedaliero-Universitaria di Parma|AbbVie","All","18 Years and older   (Adult, Older Adult)","Not Applicable","75","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","NR-DAA-HCV","August 30, 2017","October 2019","December 2019","May 16, 2017",,"July 5, 2019","Unit of Infectious Diseases and Hepatology, Parma, Italy",,"https://ClinicalTrials.gov/show/NCT03155113"
695,"NCT03097029","Use of Pancreatic Enzymes in Short Bowel Syndrome","SBS","Completed","No Results Available","Short Bowel Syndrome","Drug: Pancreatic Enzyme","Change in Coefficient of Fat Absorption|Change in the Coefficient of Nitrogen Absorption|Change in Stool bomb calorimetry","Children's Hospital of Philadelphia|AbbVie","All","4 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","15","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-013255","March 24, 2017","February 1, 2019","February 1, 2019","March 31, 2017",,"March 25, 2019","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03097029"
696,"NCT03063398","Post Acute Pancreatitis Pancreatic Exocrine Insufficiency","PAPPEI","Recruiting","No Results Available","Acute Pancreatitis","Diagnostic Test: No intervention, this is an observational study","Exocrine pancreatic insufficiency at 12 months","University of Pittsburgh|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"180","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRO16080320","June 21, 2017","April 2021","April 2021","February 24, 2017",,"December 18, 2019","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States|The Ohio State University, Columbus, Ohio, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03063398"
697,"NCT03052231","Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center","MOMMI3CFCM","Completed","No Results Available","Medication Adherence|Cystic Fibrosis","Device: caremessage","Number of Scheduled appointments attended|Knowledge of disease Questionnaire|FEV1 in LPM|Body mass index","Landon Pediatric Foundation|AbbVie","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","LandonPF","March 2016","February 2017","February 2017","February 14, 2017",,"May 7, 2019","Pediatric Diagnostic Center, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT03052231"
698,"NCT03050905","Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B",,"Completed","No Results Available","HCV Coinfection","Drug: VEKIRAX|Drug: EXVIERA","The percentage of patients achieving SVR12 (single last HCV RNA <12 IU/mL 12 weeks after the last actual dose of the ABBVIE regimen)|Safety: absolute and relative numbers of discontinuations, AE and SAEs (Number of Participants With Adverse Events That Are Related to Treatment).|Resistance Associated Substitute (RAS): The percentage of patients with the presence of RAS's- at baseline and at post-treatment weak 12.|Time of virologic failure using population sequencing; SVR12 rate|Time of virologic failure using population sequencing; presence of BL RAS's.","HaEmek Medical Center, Israel|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","7","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NINJA Study - 11227","June 22, 2017","November 16, 2017","November 28, 2018","February 13, 2017",,"August 9, 2019","Haemek medical center, Afula, Israel",,"https://ClinicalTrials.gov/show/NCT03050905"
699,"NCT03048721","Skin Tape Harvesting for Transcriptomics Analysis",,"Completed","No Results Available","Psoriasis","Procedure: Skin Tape Stripping|Procedure: Punch Biopsy","Fold Change of Human Beta Defensin2 (hBD2)|Fold Change of T-cell derived IL17A Inflammatory Cytokines|Fold Change of IFNG Inflammatory Cytokines","University of Michigan|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","15","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","Derm 684/HUM00115663|Derm 684","August 14, 2017","September 24, 2018","September 24, 2018","February 9, 2017",,"November 21, 2018","University of Michigan, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT03048721"
700,"NCT03023748","Intravenous Paricalcitol in Chronic Hemodialysis Patients",,"Unknown status","No Results Available","Endstage Renal Disease|Secondary Hyperparathyroidism","Drug: Intravenous Paricalcitol","Change in left ventricular mass index|Change in Coronary artery calcium score|Change in Aortic stiffness|Change in handgrip strength|Change in Serum albumin|Change in serum Calcium and phosphate|Change in Intact parathyroid hormone|Change in alkaline phosphatase","The University of Hong Kong|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW11-293","September 2011","December 2017","January 2018","January 18, 2017",,"January 18, 2017","Queen Mary Hospital and Tung Wah Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT03023748"
701,"NCT03003338","MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV",,"Unknown status","No Results Available","Hepatitis C, Chronic","Drug: OBV/PTV/r and DSV|Drug: Placebo to match OBV/PTV/r and DSV","Change in the Attention Test Battery Sum Score (Att Test Sum Score) at week 12 (12 weeks minus baseline)|Efficacy of treatment with OBV/PTV/r in combination with DSV for 12w in patients with chronic genotype 1b HCV infection as measured by the proportion of subjects with sustained viral response at FU 12 after discontinuation of therapy|Efficacy of treatment with OBV/PTV/r in combination with DSV for 12w in patients with chronic genotype 1b HCV infection as measured by the proportion of subjects with sustained viral response at FU 24 after discontinuation of therapy|Efficacy of treatment with OBV/PTV/r in combination with DSV for 12w in patients with chronic genotype 1b HCV infection as measured by the proportion of subjects with sustained viral response at FU48 after discontinuation of therapy|Change in FIS at Treatment week 12 after Treatment discontinuation|Change in FIS at Treatment at 12 weeks of follow-up after Treatment discontinuation|Change in FIS at Treatment at 24 weeks of follow-up after Treatment discontinuation|Change in FIS at Treatment at 48 weeks of follow-up after Treatment discontinuation|Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at Treatment week 12 after Treatment discontinuation|Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at 12 weeks follow-up after Treatment discontinuation|Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at 24 weeks follow-up after Treatment discontinuation|Change in Repeatable Battery for the Assessment of Neuropsychological Function (RBANS) total score at 48 weeks follow-up after Treatment discontinuation|Change in TAP Attention test scores at Treatment week 12 after Treatment discontinuation|Change in TAP Attention test scores at 12 weeks of follow-up after Treatment discontinuation|Change in TAP Attention test scores at 24 weeks of follow-up after Treatment discontinuation|Change in TAP Attention test scores at 48 weeks of follow-up after Treatment discontinuation|Change in word-figure Memory test scores for verbal and figural Memory function at Treatment week 12 after Treatment discontinuation|Change in word-figure Memory test scores for verbal and figural Memory function at 12 weeks of follow-up after Treatment discontinuation|Change in word-figure Memory test scores for verbal and figural Memory function at 24 weeks of follow-up after Treatment discontinuation|Change in word-figure Memory test scores for verbal and figural Memory function at 48 weeks of follow-up after Treatment discontinuation|Change in brain metabolite Levels after anti-viral Treatment|Change in brain metabolite Levels after 12 weeks follow-up|Change in brain metabolite Levels after 24 weeks follow-up|Change in brain metabolite Levels after 48 weeks follow-up|Change in the patients mood at Treatment week 12|Change in the patients mood at 12 weeks follow-up|Change in the patients mood at 24 weeks follow-up|Change in the patients mood at 48 weeks follow-up|Change in the Att Test Sum Score at 12 weeks of follow-up|Change in the Att Test Sum Score at 24 weeks of follow-up|Change in the Att Test Sum Score at 48 weeks of follow-up","Hannover Medical School|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MHH-HCV-NPM|2015-004556-22","May 2016","March 2018","December 2018","December 28, 2016",,"December 28, 2016","Hannover Medical School, Hannover, Germany",,"https://ClinicalTrials.gov/show/NCT03003338"
702,"NCT02985658","Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer",,"Available","No Results Available","Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation|Triple-Negative Breast Cancer","Drug: Veliparib|Drug: Cisplatin|Drug: Vinorelbine",,"University of Washington|AbbVie","Female","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access",,"9763",,,,"December 7, 2016",,"November 5, 2019","Seattle Cancer Care Allliance, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02985658"
703,"NCT02946034","Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C",,"Recruiting","No Results Available","Chronic Kidney Disease|Chronic Hepatitis C","Drug: Viekira Pak ± ribavirin|Drug: Mavyret","Reduction in biomarkers of CKD progression|Safety and Tolerability of Viekira Pak treatment in CKD patients|Efficacy of Viekira Pak treatment in CKD patients|Effect on patient quality of life","Massachusetts General Hospital|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016P001822","February 1, 2017","December 2019","December 2020","October 26, 2016",,"October 4, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT02946034"
704,"NCT02881567","Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab","SUSTAIN","Terminated","Has Results","Relapsing-Remitting Multiple Sclerosis (RRMS)","Drug: Daclizumab","Percentage of Participants Relapse-free at Month 6|Percentage of Participants Relapse-free at Month 12|Percentage of Participants Experiencing Relapse Requiring Hospitalization and/or Steroid Treatment at Month 12|Annualized Relapse Rate (ARR) at Month 12|Number of Participants With New Gadolinium-Enhanced (Gd+) and T1 Hypointense Lesions at Months 6 and 12|Number of Participants With New and Newly Enlarged T2 Hypointense Lesions at Months 6 and 12|Permanent Discontinuation Rate of Daclizumab at Month 12|Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Relevant Shifts in Laboratory Assessments","Biogen|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 3","41","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205MS305|2016-002820-10","April 18, 2017","September 12, 2018","September 12, 2018","August 29, 2016","September 24, 2019","September 27, 2019","Research Site, Tampa, Florida, United States|Research Site, Des Moines, Iowa, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Edmonton, Alberta, Canada|Research Site, Muenchen, Bayern, Germany|Research Site, Potsdam, Brandenburg, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Hamburg, Germany|Research Site, Pozzilli, Isernia, Italy|Research Site, Napoli, Italy|Research Site, Guaynabo, Puerto Rico","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02881567/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02881567/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02881567"
705,"NCT02874066","PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","PIVOTAL","Completed","Has Results","Hepatitis Viruses","Drug: PTV/r/OBV/DSV","Number of Participants With Sustained Virologic Response (SVR12)|Number of Participants With Treatment-emergent Adverse Event (AE)-Related Withdrawal Rate|Number of Participants With Sustained Virologic Response (SVR24)|Number of Participants With Rapid Virologic Response (RVR)|Number of Participants With End-of-treatment Virological Response (EOTVR)","National Taiwan University Hospital|AbbVie","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 4","46","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201606016MIPC","March 13, 2017","October 30, 2018","December 25, 2018","August 22, 2016","July 19, 2019","July 19, 2019","Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan|National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan|Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02874066/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02874066"
706,"NCT02856438","Early Patient Access Treatment Use Protocol CA204-220",,"Available","No Results Available","Multiple Myeloma","Drug: Elotuzumab|Drug: Lenalidomide|Drug: Dexamethasone",,"Bristol-Myers Squibb|AbbVie","All","20 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"CA204-220",,,,"August 4, 2016",,"December 13, 2017","Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Shibukawa-shi, Gunma, Japan|Local Institution, Osaka-shi, Osaka, Japan",,"https://ClinicalTrials.gov/show/NCT02856438"
707,"NCT02750384","Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects",,"Terminated","No Results Available","Healthy Volunteers|Bioavailability","Drug: DSM265 50% SDD granules|Drug: DSM265 25% SDD powder for suspension","DSM265 maximum observed plasma concentration (Cmax)|DSM265 time to Cmax (Tmax)|DSM265 observed concentration at 168 hours after dosing (C168)|DSM265 apparent terminal phase elimination rate constant (β)|DSM265 terminal elimination half-life (t1/2)|DSM265 area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUCt)|DSM265 area under the plasma concentration-time curve from time 0 to infinity (AUC∞)|safety evaluations","Medicines for Malaria Venture|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 1","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","B16-963|MMV_DSM265_16_01","May 2016","July 2016","July 2016","April 25, 2016",,"September 14, 2016","AbbVie Clinical Pharmacology Research Unit (ACPRU), Grayslake, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02750384"
708,"NCT02734173","Pilot HCV Direct Acting Antiviral Therapy and Metabolism","3D","Completed","No Results Available","Hepatitis C","Drug: ABT450r-ABT267-ABT333 +/- Ribavirin","Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin Hepatitis C Antiviral Therapy on Insulin Resistance|Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin Hepatitis C Antiviral Therapy Lipid Homeostasis","Ottawa Hospital Research Institute|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","24","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20150305-01H","July 2015","February 2017","May 31, 2017","April 12, 2016",,"August 13, 2019","The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02734173"
709,"NCT02726581","An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma","CheckMate 602","Active, not recruiting","No Results Available","Multiple Myeloma","Biological: Nivolumab|Biological: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone","Progression free survival (PFS) by investigator|Overall Survival (OS)|Time to objective response (TTR) by investigator|Duration of objective response (DOR) by investigator|Objective response rate (ORR) by investigator","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-602|2015-005699-21","April 21, 2016","March 15, 2020","December 8, 2022","April 1, 2016",,"January 14, 2020","Uab Comprehensive Cancer Center, Birmingham, Alabama, United States|Southern Cancer Center Pc, Mobile, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Compassionate Cancer Res Grp, Corona, California, United States|Compassionate Cancer Res Grp, Fountain Valley, California, United States|Scripps Health Dba Scripps Clinical Research Services, La Jolla, California, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ronald Reagan Ucla Medical Center, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Compassionate Cancer Res Grp, Riverside, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Poudre Valley Health Care, Fort Collins, Colorado, United States|St. Mary's Hospital Med Ctr, Grand Junction, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|University Cancer Institute, Boynton Beach, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Piedmont Cancer Institute, PC, Atlanta, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Indiana University Cancer Ctr, Indianapolis, Indiana, United States|St. Agnes Healthcare, Inc., Baltimore, Maryland, United States|Regional Cancer Care Associates, LLC, Bethesda, Maryland, United States|Department Of Medicine Division Of Hematology/Oncology, Worcester, Massachusetts, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St. Louis Cancer Care, Llp, Bridgeton, Missouri, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Hunterdon Hematology Oncology, Flemington, New Jersey, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|The Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States|The Valley Hospital, Paramus, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Broome Oncology LLC, Johnson City, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Mid Ohio Oncology Hematology, Columbus, Ohio, United States|University Of Oklahoma, Oklahoma City, Oklahoma, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Baylor Research Institute, Dallas, Texas, United States|Millennium Oncology, Houston, Texas, United States|CTRC at UTHSC San Antonio, San Antonio, Texas, United States|Scott And White Memorial Hosp, Temple, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Va Puget Sound Health Care System, Seattle, Washington, United States|Elisabethinen Hospital Dept of Medicine, Linz, Austria|Universitaetsklinik Salzburg, Salzburg, Austria|Akh, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Wilhelminenspital, Wien, Austria|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|MUHC - Glen Site, Montreal, Quebec, Canada|CIUSSS du Nord-de-l'ile-de-Montreal - Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Canada|Local Institution, Quebec, Canada|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika hematoonkologie, Ostrava-Poruba, Czechia|I. interni klinika - klinika hematologie 1. LF UK a VFN v Praze, Praha 2, Czechia|Local Institution, Aarhus, Denmark|Local Institution, Odense, Denmark|Charite Universitatsmedizin Berlin, Berlin, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Uniklinikum Duesseldorf, Duesseldorf, Germany|Universitaetsklink Schleswig-Holstein, Kiel, Germany|Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz, Germany|University Hopistal ULM Dept of Internal Medizin, Ulm, Germany|Alexandra General Hospital Of Athens, Athens, Greece|Local Institution, Beer Sheva, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola (FC), Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Auxilio Mutuo Cancer Center, San Juan, Puerto Rico|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pamplona, Spain|Local Institution, Salamanca, Spain|Local Institution, Stockholm, Sweden|Hopitaux Universitaires de Geneve, Geneve, Switzerland",,"https://ClinicalTrials.gov/show/NCT02726581"
710,"NCT02719613","Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Elotuzumab|Drug: Dexamethasone|Drug: Lenalidomide|Drug: Bortezomib","The number of subjects who received at least one dose of elotuzumab or backbone therapy (other study drugs) will be collected.|All serious adverse events (SAEs) and adverse events (AEs) will be collected.","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CA204-185|2016-000037-51","July 15, 2016","May 28, 2020","May 29, 2020","March 25, 2016",,"October 31, 2019","Arizona Clinical Research Center, Inc, Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|James R. Berenson, MD, Inc., Bakersfield, California, United States|Robert A. Moss, Md Facp, Inc., Fountain Valley, California, United States|Rocky Mountain Cancer Centers (Williams) - USOR, Denver, Colorado, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Texas Oncology, Dallas, Texas, United States|Local Institution, Toronto, Ontario, Canada|Local Institution, Halifax, Canada|Local Institution, Ancona, Italy|Local Institution, Firenze, Italy|Local Institution, Genova, Italy|Local Institution, Torino, Italy",,"https://ClinicalTrials.gov/show/NCT02719613"
711,"NCT02677324","Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia",,"Active, not recruiting","No Results Available","Waldenstrom Macroglobulinemia","Drug: ABT199","The Overall Response Rate (ORR) Of ABT-199 In Symptomatic WM Patients|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Rate Of Complete Response (CR),|Rate Of Very Good Partial Response (VGPR)|Rate Of Partial Response (PR)|Rate Of Minimal Response (MR)|Rate Of Stable Disease (SD)|Rate Of Progressive Disease (PD)|To evaluate the best response to ABT-199 by MYD88 and CXCR4 status|The 2-Year Progression-Free Survival (PFS)|The 4-Year Progression-Free Survival (PFS)|The 2-Year Overall Survival (OS)|The 4-Year Overall Survival (OS)|Median Duration Of Response","Dana-Farber Cancer Institute|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","33","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-491|A15-751","April 12, 2016","February 2020","February 2022","February 9, 2016",,"January 18, 2020","City of Hope National Medical Center, Duarte, California, United States|Stanford University, Palo Alto, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Weill Cornell Medical College, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT02677324"
712,"NCT02634541","Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis","PETSPA","Unknown status","No Results Available","Ankylosing Spondyloarthritis","Drug: Adalimumab|Other: PET/CT imaging","PET signals within groups|PET signals between groups","Helsinki University|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PETSPA|2015-000752-20","January 2016","December 2017","December 2017","December 18, 2015",,"February 23, 2017","Helsinki University Central Hospital, Helsinki, Finland|Päijät-Häme Central Hospital, Lahti, Finland",,"https://ClinicalTrials.gov/show/NCT02634541"
713,"NCT02634008","Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P","TARGET3D","Recruiting","No Results Available","Hepatitis C, Acute","Drug: Paritaprevir/ritonavir/ombitasvir|Drug: Dasabuvir|Drug: Ribavirin|Drug: Glecaprevir/pibrentasvir","Proportion of treated subjects (intention-to-treat (ITT) population) demonstrating undetectable hepatitis C virus (HCV) RNA at 12 weeks following treatment (SVR 12).|The proportion of treated subjects overall with ETR, SVR4 and SVR24 defined as undetectable HCV RNA at end of therapy, 4 weeks and 24 weeks post therapy, respectively.|Comparison of ETR, SVR4, SVR12 and SVR24 between those receiving 8 weeks treatment and those receiving 6 weeks treatment.|Comparison of adherence between those receiving 8 weeks treatment and those receiving 6 weeks treatment|Proportion with early treatment discontinuation|Proportion with adverse events (including serious adverse events)|Changes in laboratory parameters, including liver function tests (ALT, AST) and haematological indices (haemoglobin, neutrophil count, platelet count)|Emergence of resistance associated variants (RAVs)|HCV reinfection rate|Changes in sexual and injecting drug use behaviour at SVR 12 and end of follow up|Serum cytokine and ISG expression at baseline and week 4","Kirby Institute|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","90","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VHCRP1502","June 2016","June 2020","December 2022","December 17, 2015",,"August 8, 2019","St Vincent's Hospital, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Auckland City Hospital, Auckland, Grafton, New Zealand|Barts and London, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Guy's and St Thomas' Hospital, London, United Kingdom|Chelsea and Westminster Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02634008"
714,"NCT02539849","Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease",,"Completed","No Results Available","Crohn Disease","Dietary Supplement: FOS|Drug: Adalimumab","FOS increases counts of Faecalibacterium prausnitzii in faecal samples from Crohn's disease patients","Hospital Universitari Vall d'Hebron Research Institute|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","38","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ADA-FOS","December 2014","December 19, 2017","December 19, 2017","September 3, 2015",,"January 31, 2018","Hospital de Santiago, Santiago de Compostela, A Coruña, Spain|Hospital de Bellvitge, Hospitalet del Llobregat, Barcelona, Spain|Hospital Universitari vall d'Hebron, Barcelona, Spain|Hospital Josep Trueta, Girona, Spain|Hospital La Princesa, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02539849"
715,"NCT02478320","Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors",,"Active, not recruiting","No Results Available","Advanced Cancers","Drug: Ilorasertib","Response Rate of Ilorasertib (ABT-348) in Participants with Cancers Harboring CDKN2A Deletion or Mutation as Tumor Response|Toxicities of Ilorasertib (ABT-348)|Pharmacodynamics of Ilorasertib (ABT-348)","M.D. Anderson Cancer Center|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2014-0920|NCI-2015-01251","August 5, 2016","August 2022","August 2022","June 23, 2015",,"October 21, 2019","University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02478320"
716,"NCT02471118","Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)","OKINADA","Recruiting","No Results Available","Osteoarthritis, Knee","Drug: Adalimumab 40 mg|Drug: Placebo","Primary Endpoint: the percentage of subjects achieving an Osteoarthritis Research Society International/Outcome Measures in Rheumatology Clinical trials (OARSI/OMERACT) response at Week 16|Secondary endpoint Knee Injury and Osteoarthritis Outcome (KOOS) composite pain score at 16 weeks.|Secondary endpoint KOOS composite pain 20/50 response rates|Secondary Endpoint KOOS activities of daily living score|Secondary Endpoint KOOS symptoms score|Secondary Endpoint KOOS sport and recreation function score|Secondary Endpoint KOOS knee-related quality of life score|Secondary Endpoint Patient global assessment of disease status score|Secondary Endpoint Investigator global assessment of disease status score|Secondary Endpoint Physical assessment of Target Joint|Secondary Endpoint Expanded Target Joint Assessment score|Secondary Endpoint Average weekly consumption of analgesic medications","Canadian Research & Education in Arthritis|AbbVie","All","40 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IMM 11-0024","March 2015","March 2020","March 2020","June 15, 2015",,"July 23, 2019","Division of Rheumatology, University of Alberta Hospital, Edmonton, Alberta, Canada|Western University, London, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|A.M.I.R., Montréal, Quebec, Canada|GRMO Inc., Québec, Quebec, Canada|CHUS Hotel-Dieu, Sherbrooke, Quebec, Canada|Polmed Research Inc., Saskatoon, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT02471118"
717,"NCT02461745","Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs",,"Active, not recruiting","No Results Available","Hepatitis C, Chronic","Drug: ombitasvir, paritaprevir/r, dasabuvir + ribavirin|Drug: ombitasvir, paritaprevir/r, dasabuvir","Percentage of subjects achieving sustained virological response (SVR) at Week 12|Percentage of subjects achieving sustained virological response (SVR) at Week 4","Kaiser Permanente|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KPSC IRB 10568","June 2015","May 2017","July 2018","June 3, 2015",,"May 4, 2018","Kaiser Permanente Medical Center, Irvine, California, United States|Kaiser Permanente Medical Center, Los Angeles, California, United States|Kaiser Permanente Medical Center, San Diego, California, United States|Kaiser Permanente Medical Center, San Marcos, California, United States",,"https://ClinicalTrials.gov/show/NCT02461745"
718,"NCT02419560","Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL",,"Recruiting","No Results Available","Lymphoma, Mantle-Cell|Recurrent Lymphoma, Mantle-Cell","Drug: ABT-199 and Ibrutinib Combination","Incidence of Dose Limiting Toxicities|Incidence and Severity of Adverse Events|Overall Response Rate|Complete Response Rate|Progression-Free Survival|Overall Survival","Craig Portell, MD|AbbVie|University of Virginia","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17983|ABT199-MCL-UVA-001","April 2015","August 2018","December 2018","April 17, 2015",,"May 24, 2018","City of Hope, Duarte, California, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02419560"
719,"NCT02305953","Cytokines and Vascular Inflammation in Psoriasis",,"Completed","No Results Available","Vascular Inflammation|Psoriasis|Coronary Atherosclerosis",,"Correlation between serum cytokine levels (pg/mL) and TBR in the ascending aorta.|Correlation between a serum chemokine (S100A9 (pg/mL)) levels and TBR in the ascending aorta.","Innovaderm Research Inc.|AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)",,"96","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Inno-6037","October 2014","October 2014","October 2014","December 3, 2014",,"December 3, 2014","Lynderm Research, Markham, Ontario, Canada|Windsor Clinical Research Inc., Windsor, Ontario, Canada|Clinique Dre Isabelle Delorme, Drummondville, Quebec, Canada|Innovaderm Research, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02305953"
720,"NCT02272803","Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan",,"Active, not recruiting","Has Results","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone|Biological: Elotuzumab (BMS-901608)","Objective Response Rate (ORR) of Participants Treated With Elotuzumab + Lenalidomide/Dexamethasone (E-Ld)|Objective Response Rate (ORR) in All Treated Participants|Progression Free Survival (PFS) in Lenalidomide/Dexamethasone + Elotuzumab and Lenalidomide/Dexamethasone Therapy|PFS Rate at 1 Year","Bristol-Myers Squibb|AbbVie","All","20 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-116","January 22, 2015","February 9, 2017","December 31, 2020","October 23, 2014","March 22, 2018","December 20, 2019","Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Aomori-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kamogawa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Maebashi-shi, Gunma, Japan|Local Institution, Shibukawa-shi, Gunma, Japan|Local Institution, Fukuyama-shi, Hiroshima, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Kawagoe-shi, Saitama, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Utsunomiya-shi, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shibuya-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Tachikawa-shi, Tokyo, Japan|Local Institution, Kasama-shi, Japan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02272803/SAP_002.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT02272803/Prot_003.pdf","https://ClinicalTrials.gov/show/NCT02272803"
721,"NCT02255422","RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR",,"Completed","No Results Available","MItochondrial Myopathies","Drug: Omaveloxolone capsules, 2.5 mg|Drug: omaveloxolone capsules, 5 mg|Drug: omaveloxolone capsules, 10 mg|Drug: Placebo capsules|Drug: omaveloxolone capsules, 20 mg|Drug: omaveloxolone capsules, TBD mg|Drug: omaveloxolone capsules, 40 mg|Drug: omaveloxolone capsules, 80 mg|Drug: omaveloxolone capsules, 160 mg","Measure the change of peak workload (in watts/kg) during exercise testing|Measure the change in distance walked during a 6-minute walk test","Reata Pharmaceuticals, Inc.|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","53","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 408-C-1403","April 2015","November 2, 2017","November 30, 2017","October 2, 2014",,"July 19, 2018","UCLA, Los Angeles, California, United States|Mass General Hospital, Boston, Massachusetts, United States|Akron Children's Hospital, Akron, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Insitute for Exercise & Environmental Medicine, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Texas Medical School at Houston, Houston, Texas, United States|Neuromuscular Clinic, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT02255422"
722,"NCT02213289","PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression",,"Recruiting","No Results Available","Adenocarcinoma","Trastuzumab|ABT-806|TBD2|Ramucirumab|Nivolumab","Median Overall Survival|Safety and Feasibility of Baseline Biopsies|Safety and Feasibility of Conducting Serial Biopsies","University of Chicago|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","104","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB14-0141","January 20, 2015","February 1, 2020","February 1, 2022","August 11, 2014",,"May 1, 2019","University of Chicago, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02213289"
723,"NCT02187861","A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)",,"Completed","Has Results","Follicular Lymphoma","Drug: Venetoclax|Drug: Bendamustine|Drug: Rituximab","Percentage of Participants With Complete Metabolic Response (CMR) According to Independent Review Committee (IRC) as Per Lugano Classification, Using Positron Emission Tomography (PET) Scan at Primary Response Assessment (PRA)|Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at PRA|Percentage of Participants With CMR According to IRC as Per Lugano Classification, Using PET Scan at Year 1|Percentage of Participants With CMR According to Investigator as Per Lugano Classification, Using PET Scan at Year 1|Percentage of Participants With Complete Response (CR) According to IRC as Per Lugano Classification, Using Computed Tomography (CT) Scan|Percentage of Participants With CR According to Investigator as Per Lugano Classification, Using CT Scan|Percentage of Participants With Objective Response (OR) According to IRC as Per Lugano Classification, Using PET Scan|Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET Scan|Percentage of Participants With OR According to IRC as Per Lugano Classification, Using CT Scan|Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using CT Scan|Percentage of Participants With OR According to Investigator as Per Lugano Classification, Using PET or CT Scan|Duration of Response (DOR) According to Investigator as Per Lugano Classification, Using PET or CT Scan|Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan) or Death|Progression-Free Survival (PFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan|Percentage of Participants With Disease Progression (According to Investigator as Per Lugano Classification, Using PET or CT Scan), Death, or Start of a New Anti-lymphoma Therapy|Event-Free Survival (EFS) According to Investigator as Per Lugano Classification, Using PET or CT Scan|Percentage of Participants Who Died Due to Any Cause|Overall Survival (OS)|Apparent Clearance (CL) of Venetoclax|Apparent Volume of Distribution (Vd) of Venetoclax|Time to Maximum Plasma Concentration (Tmax) of Venetoclax|Maximum Plasma Concentration (Cmax) of Venetoclax|Area Under the Plasma Concentration-Time Curve From Time 0 to Last Observed Concentration (AUClast) of Venetoclax|Area Under the Plasma Concentration-Time Curve From Time 0 to 8 Hours Post Dose (AUC0-8h) of Venetoclax","Hoffmann-La Roche|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","163","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO29337|2014-000576-26","December 1, 2014","September 27, 2016","March 16, 2018","July 11, 2014","October 13, 2017","June 5, 2019","Southern Cancer Center, PC, Mobile, Alabama, United States|Arizona Cancer Center, Tucson, Arizona, United States|UCLA School of Medicine; Hematology/Oncology, Los Angeles, California, United States|Nothwest Georgia Oncology Centers P.C, Austell, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States|Primary Healthcare Associates SC - Harvey, Harvey, Illinois, United States|University of Kansas; Medical Center & Medical pavilion, Westwood, Kansas, United States|Sidney Kimmel Comp Cancer Ctr, Baltimore, Maryland, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|James P. Wilmot Cancer Center, Rochester, New York, United States|University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States|VCU Massey Cancer Center, Richmond, Virginia, United States|West Virginia Uni Med. Center - Robert Byrd Health Science, Morgantown, West Virginia, United States|Royal Prince Alfred Hospital; Medical Oncology, Camperdown, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Westmead Hospital; Haematology, Sydney, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Townsville General Hospital, Douglas, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Queen Elizabeth Hospital; Haematology, Woodville South, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Medical Centre, Clayton, Victoria, Australia|ZNA Stuivenberg, Antwerpen, Belgium|AZ Sint Jan, Brugge, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Kelowna, British Columbia, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|Hopital Maisonneuve- Rosemont; Oncology, Montreal, Quebec, Canada|Chum Hopital Notre Dame; Centre D'Oncologie, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Saskatoon Cancer Centre; Uni of Saskatoon Campus, Saskatoon, Saskatchewan, Canada|Institut de Cancerologie de l'Ouest, Angers, France|CHU Clermont Ferrand - Hôpital d'Estaing, Clermont Ferrand cedex 1, France|Hopital Henri Mondor, Creteil, France|CHU de Dijon - Hopital le Bocage, Dijon, France|Centre Jean Bernard, Le Mans, France|CHU Montpellier, Montpellier, France|Centre Hospitalier Lyon Sud; Hematolgie, Pierre Benite, France|Klinikum Chemnitz gGmbH; Klinik f. Innere Medizin III, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Germany|Universitätsklinik Essen; Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Essen, Germany|Universitätsklinikum Jena; Klinik für Innere Medizin II, Jena, Germany|Universitätsklinikum Köln; Klinik I für Innere Medizin, Koeln, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Med. Klinik I, Hämatologie/Onkologie, Lübeck, Germany|Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik, Mainz, Germany|Universitätsklinikum Ulm; Apotheke, Ulm, Germany|Universitätsklinikum Würzburg; Medizinische Klinik und Poliklinik II; Hämatologie / Onkologie, Würzburg, Germany|A.O. Universitaria Policlinico S.Orsola-Malpighi Di Bologna, Bologna, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Ospedale di Ravenna, Ravenna, Emilia-Romagna, Italy|Ospedale Infermi di Rimini, Rimini, Emilia-Romagna, Italy|Asst Papa Giovanni XXIII, Bergamo, Lombardia, Italy|Ospedale Niguarda Milano, Milano, Lombardia, Italy|Irccs Policlinico San Matteo; Divisione Di Ematologia, Pavia, Lombardia, Italy|Azienda Ospedale San Giovanni, Torino, Piemonte, Italy|Az. Osp. Di Careggi; Divisione Di Ematologia, Firenze, Toscana, Italy|Blackpool Victoria Hospital, Blackpool, United Kingdom|St James University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary; Dept. of Medical Oncology, Leicester, United Kingdom|University College London, Department of Haematology, London, United Kingdom|Royal Marsden Nhs Trust; Consultant Cancer Physician, London, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02187861"
724,"NCT02162472","Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis",,"Recruiting","No Results Available","Psoriasis",,"Videocapillaroscopy assessment in psoriasis","Northwestern University|AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)",,"30","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","STU78102","July 2015","December 2019","December 2019","June 12, 2014",,"September 23, 2019","Northwestern University, Department of Dermatology, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02162472"
725,"NCT02142959","RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE",,"Completed","No Results Available","Breast Cancer","Drug: Omaveloxolone Lotion 0.5%|Drug: Omaveloxolone Lotion 3%|Drug: Lotion vehicle/Placebo|Radiation: 3D conformal radiation therapy","Grading of skin changes following radiation therapy|Count of patients who experience a maximum radiation dermatitis grade of less than 2|Grading of radiation dermatitis following radiation therapy|Grading the duration of radiation dermatitis following radiation therapy","Reata Pharmaceuticals, Inc.|AbbVie","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","187","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","RTA 408-C-1306","June 2014","April 2015","April 2015","May 20, 2014",,"February 26, 2016","Ironwood Cancer and Research Centers, Mesa, Arizona, United States|St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Arizona Cancer Center, Scottsdale, Arizona, United States|University of Colorado Hospital, Dept. of Radiation Oncology, Aurora, Colorado, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|St. Vincent Anderson Regional Hospital Cancer Center, Anderson, Indiana, United States|Parkview Research Center, Fort Wayne, Indiana, United States|Radiation Oncology Associates - Parkview Research Center, Fort Wayne, Indiana, United States|Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States|Willis-Knighton Cancer Center, Shreveport, Louisiana, United States|University of Nebraska Medical Center - Eppley Cancer Center, Omaha, Nebraska, United States|CaroMont Health Comprehensive Cancer Center, Gastonia, North Carolina, United States|Sanford Health, Bismarck, North Dakota, United States|St. John Health System, Tulsa, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Hughes Cancer Center, East Stroudsburg, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|21st Century Oncology - Carolina Regional Cancer Center, Myrtle Beach, South Carolina, United States|Spartanburg Regional Medical Center - Gibbs Cancer Center, Spartanburg, South Carolina, United States|Sanford Research/USD, Sioux Falls, South Dakota, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Cancer Care Northwest, Spokane, Washington, United States|Mayo Clinic - LaCrosse, LaCrosse, Wisconsin, United States|Columbia St. Mary's, Milwaukee, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT02142959"
726,"NCT02128113","RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD",,"Completed","No Results Available","Corneal Endothelial Cell Loss|Ocular Pain|Ocular Inflammation|Cataract Surgery","Drug: Placebo|Drug: 0.5% Omaveloxolone Ophthalmic Suspension|Drug: 1% Omaveloxolone Ophthalmic Suspension","Count of corneal endothelial cells|Measure of inflammation|Measure of pain","Reata Pharmaceuticals, Inc.|AbbVie","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","304","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","RTA 408-C-1309","May 2014","February 2015","April 2015","May 1, 2014",,"February 26, 2016","Harvard Eye Associates, Laguna Hills, California, United States|Hull Eye Center, Lancaster, California, United States|Argus Research, Cape Coral, Florida, United States|Levenson Eye Associates, Jacksonville, Florida, United States|Chicago Cornea Consultants, Hoffman Estates, Illinois, United States|JacksonEye, Lake Villa, Illinois, United States|Discover Vision Centers, Leawood, Kansas, United States|Opthalmic Consultants of Boston, Waltham, Massachusetts, United States|Talamo Hatch Laser Eye Consultants, Waltham, Massachusetts, United States|Associated Eye Care, Stillwater, Minnesota, United States|Comprehensive Eye Care, Washington, Missouri, United States|Alterman, Modi and Wolter, Poughkeepsie, New York, United States|Cincinnati Eye Institute, Cincinnati, Ohio, United States|R & R Eye Research, San Antonio, Texas, United States|See Clearly Vision Group, McLean, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT02128113"
727,"NCT02065375","RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery",,"Completed","No Results Available","Inflammation and Pain Following Ocular Surgery","Drug: RTA 408 0.5% Ophthalmic Suspension|Drug: RTA 408 1.0% Ophthalmic Suspension|Drug: Placebo","Anterior Chamber Cell Count|Pain","Reata Pharmaceuticals, Inc.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","109","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 408-C-1307","February 2014","September 2014","September 2014","February 19, 2014",,"November 6, 2014","Garden Grove, California, United States|Fort Myers, Florida, United States|Kansas City, Missouri, United States|Elizabeth City, North Carolina, United States|Austin, Texas, United States|Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02065375"
728,"NCT02055820","A Safety and Pharmacokinetics (PK) Study of Venetoclax in Participants With Non-Hodgkin's Lymphoma",,"Completed","Has Results","Lymphoma, Non-Hodgkin","Drug: Venetoclax|Drug: Cyclophosphamide|Drug: Obinutuzumab|Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone","Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)|Percentage of Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)|Percentage of Participants With CR Defined by PET/CT Scan in Dual Expressor Diffuse Large B-Cell Lymphoma (DE-DLBCL) Participants Assessed by IRC|Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)|Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)|Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)|Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval|Prednisone Plasma PK: AUC|Prednisone Plasma PK: Tmax|Prednisone Plasma PK: Cmax|Rituximab PK: Cmax|Rituximab PK: Cmin Within the Dosing Interval|Obinutuzumab PK: Cmax|Cyclophosphamide PK: Cmax|Doxorubicin PK: Cmax|Vincristine PK: Cmax|Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Using the Modified Lugano Classification Assessed by IRC|Percentage of Participants Who Are Alive and Without Disease Progression at Month 12|Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification|Safety: Percentage of Participants With Adverse Events|Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy|Relative Dose Intensity of Venetoclax","Hoffmann-La Roche|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO27878|2013-003749-40","November 17, 2013","June 28, 2017","June 28, 2019","February 5, 2014","December 20, 2018","November 5, 2019","St. Jude Heritage Healthcare, Fullerton, California, United States|UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|The West Clinici, Saint Louis, Missouri, United States|Hackensack University Medical Center; WFAN - Imus Pediatric Center, Hackensack, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Uni of Rochester Medical Center; Wilmot Cancer Center, Pharmacy Department, Rochester, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Medizinische Universität Wien, Wien, Austria|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency, CSI, Kelowna, British Columbia, Canada|BC Cancer Agency Vancouver Centre - PARENT; BC Cancer Agency, Vancouver, British Columbia, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|CHU de Quebec - Hôpital de l' Enfant Jésus, Quebec, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK, Praha 2, Czechia|Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|Clinique Victor Hugo; Pharmacie, Le Mans, France|Hopital Claude Huriez - CHU Lille, Lille, France|Hopital Saint Eloi, Montpellier, France|CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation, Nantes, France|Hôpital Saint-Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre-Benite, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 09, France|Centre Henri Becquerel; Hematologie, Rouen, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, France|Semmelweis Egyetem, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Debreceni Egyetem; Belgyogyaszati Klinika Hematologiai Tanszek, Debrecen, Hungary|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Piemonte, Italy|Azienda Ospedaliera Vincenzo Cervello, Palermo, Sicilia, Italy|Azienda Ospedaliero Universitaria Pisana; U.O. Farmaceutica, Pisa, Toscana, Italy|Amsterdam UMC Location VUMC, Amsterdam, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Hospital del Mar, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|ICO l´Hospitalet - Hospital Duran i Reynals; Hematology, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02055820/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02055820/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02055820"
729,"NCT02035800","Bone Resorption, Osteoclastogenesis and Adalimumab","BROCAII","Recruiting","No Results Available","RheumatoId Arthritis","Drug: Adalimumab","Verify if the treatment with Adalimumab may be associated with a reduction in the number of osteoclasts.|Verify if this reduction may be associated with a better response to the treatment.|To verify reduction of osteoclasts may be associated with a better response to the treatment.","Université de Sherbrooke|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","120","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","IMM 11-0163","May 2013","December 2018","December 2019","January 14, 2014",,"May 8, 2018","CRC Étienne Le-Bel at CHUS, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT02035800"
730,"NCT02029729","RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER","DISCOVER","Completed","No Results Available","Metastatic or Incurable Non-small Cell Lung Cancer|Relapsed, Refractory Melanoma","Drug: omaveloxolone","Dose Determination","Reata Pharmaceuticals, Inc.|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","11","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RTA 408-C-1303","December 2013","October 2015","October 2015","January 8, 2014",,"January 29, 2016","H. Lee Moffitt Cancer Center (NSCLC), Tampa, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02029729"
731,"NCT02029716","RTA 408 Lotion in Healthy Volunteers",,"Completed","No Results Available","Healthy","Drug: RTA 408 Lotion 0.5%, 1%, 3%|Drug: Lotion vehicle/placebo","Skin changes or redness following topical application of RTA 408 lotion or lotion vehicle","Reata Pharmaceuticals, Inc.|AbbVie","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","109","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 408-C-1305","December 2013","April 2014","April 2014","January 8, 2014",,"November 5, 2014","Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT02029716"
732,"NCT02012764","The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?","CCP","Recruiting","No Results Available","Inflammatory Arthritis|Rheumatoid Arthritis",,"Anti-CCP Ab (+).|Anti-CCP positive developing I.A|Anti-CCP positive developing RA|Presenting complaints|Predictors for the development of an IA.|First degree familymembers who are anti-CCP Ab (+)","University of Leeds|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"4000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RR06/7674|06/Q1205/169","January 2007","January 2020","January 2020","December 16, 2013",,"October 31, 2019","Chapel Allerton Hospital : Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02012764"
733,"NCT02005471","A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)","MURANO","Active, not recruiting","Has Results","Chronic Lymphocytic Leukemia","Drug: Bendamustine|Drug: Venetoclax|Drug: Rituximab","Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death|Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines|Percentage of Participants With PD or Death as Assessed by the Independent Review Committee (IRC) Using Standard iwCLL Guidelines|PFS as Assessed by the IRC Using Standard iwCLL Guidelines|Percentage of Participants With PD or Death as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by Fluorescence In-situ Hybridization (FISH) Test|PFS as Assessed by the Investigator Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test|Percentage of Participants With PD or Death as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test|PFS as Assessed by the IRC Using Standard iwCLL Guidelines in Participants With 17p Deletion as Identified by FISH Test|Percentage of Participants With Best Overall Response of Complete Response (CR), CR With Incomplete Bone Marrow Recovery (CRi), Nodular Partial Response (nPR), or Partial Response (PR) as Assessed by the Investigator Using iwCLL Guidelines|Percentage of Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the IRC Using iwCLL Guidelines|Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the Investigator Using iwCLL Guidelines|Percentage of Participants With Overall Response of CR, Cri, nPR, or PR at End of Combination Treatment Visit as Assessed by the IRC Using iwCLL Guidelines|Percentage of Participants Who Died|Overall Survival (OS)|Percentage of Participants With PD/Relapse, Start of a New Anti-Chronic Lymphocytic Leukemia (CLL) Therapy, or Death as Assessed by the Investigator Using iwCLL Guidelines|Event-Free Survival (EFS) as Assessed by the Investigator Using iwCLL Guidelines|Percentage of Participants With PD or Death Among Participants With Best Overall Response of CR, CRi, nPR, or PR as Assessed by the Investigator Using iwCLL Guidelines|Duration of Responses (DOR) as Assessed by the Investigator Using iwCLL Guidelines|Percentage of Participants With Start of New Anti-CLL Treatment or Death as Assessed by the Investigator|Time to New Anti-CLL Treatment (TTNT) as Assessed by the Investigator|Percentage of Participants With Minimal Residual Disease (MRD) Negativity at the EoCTR Visit|Plasma Venetoclax Concentrations|Change From Baseline in Lymphocyte Subset Counts at Specified Time Points|Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Core Symptom Severity, Module Symptom Severity, and Interference Scores|Change From Baseline in HRQoL as Measured by European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scales Score and Global Health Status/Global Quality-of-Life (QoL) Scale Score|Change From Baseline in HRQoL as Measured by Quality of Life Questionnaire Associated CLL Module (QLQ-CLL16) Multi-Item Scales Score","Hoffmann-La Roche|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","389","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO28667|2013-002110-12","March 17, 2014","May 8, 2017","June 30, 2022","December 9, 2013","October 1, 2018","December 23, 2019","University of California San Diego Medical Center, La Jolla, California, United States|Henry Ford Health System, Detroit, Michigan, United States|Memorial Sloan Kettering Cancer Center; Clinical Trials Office, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Huntsman Cancer Institute; University of Utah, Salt Lake City, Utah, United States|The Canberra Hospital, Garran, Australian Capital Territory, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Frankston Hospital, Frankston, Victoria, Australia|Peter MacCallum Cancer Center, Melbourne, Victoria, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, Australia|Slade Health Pharmacy, Mount Waverley, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|The Perth Blood Institute, Nedlands, Western Australia, Australia|Medizinische Universität Innsbruck, Innsbruck, Austria|LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria|Medizinische Universität Wien, Wien, Austria|Wilhelminenspital der Stadt Wien, Wien, Austria|ZNA Stuivenberg, Antwerpen, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven; Maag, -darm en leverziekten/endoscopie - Endoscopy, Leuven, Belgium|CHU UCL Mont-Godinne, Mont-godinne, Belgium|AZ Delta (Campus Wilgenstraat), Roeselare, Belgium|Foothills Medical Centre; Centre Dept of Medical Clinical Neuroscience, Calgary, Alberta, Canada|Juravinski Cancer Clinic, Hamilton, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Saskatoon City Hospital;Saskatchewan Cancer Centre, Saskatoon, Saskatchewan, Canada|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Herlev Hospital, Herlev, Denmark|Rigshospitalet, København Ø, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Sygehus Lillebælt, Vejle, Vejle, Denmark|Hôpital Morvan, Brest, France|Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon, France|Hopital Claude Huriez - CHU Lille, Lille, France|Hopital Saint Eloi, Montpellier, France|CHU Nantes - Hôtel Dieu; Service Assistance Medicale à la Procreation, Nantes, France|Hopital Robert Debre, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|CHU Poitiers - Hopital La Miletrie, Poitiers, France|CHU de Rennes - Hopital de Pontchaillo, Rennes, France|Centre Henri Becquerel, Rouen, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|CHU Tours - Hôpital Bretonneau, Tours, France|Hôpital de Brabois Adultes, Vandoeuvre-les-nancy, France|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|Universitaetsklinikum Freiburg; Innere Medizin II, Gastroenterologie, Freiburg, Germany|Universitätsklinikum Tübingen, Tuebingen, Germany|Ogyi, Orszagos Gyogyszereszeti Intezet, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Pecs, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, Hungary|Azienda Ospedaliera Città della Salute e della Scienza di Torino; Radiology, Torino, Abruzzo, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Liguria, Italy|Asst Papa Giovanni XXIII; USC Farmacia, Bergamo, Lombardia, Italy|Ospedale San Raffaele, Milano, Lombardia, Italy|Asst Grande Ospedale Metropolitano Niguarda; SC Farmacia Ospedale, Milano, Lombardia, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Marche, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Puglia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Azienda Ospedaliera Di Padova, Padova, Veneto, Italy|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Konkuk University Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Amsterdam UMC Location VUMC, Amsterdam, Netherlands|Academisch Medisch Centrum; Opthamology, Amsterdam, Netherlands|Albert Schweitzer Ziekenhuis, Dordwijk; Internal Medicine, Hemato-Oncology, Dordrecht, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Leids Universitair Medisch Centrum; Cardiology, Leiden, Netherlands|Erasmus Medisch Centrum Rotterdam; Lokatie Daniel den Hoed, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|North Shore Hospital; Haematolgy, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Baxter Healthcare, Aukland, New Zealand|Christchurch Hospital NZ, Christchurch, New Zealand|SP ZOZ Zespol Szpitali Miejskich w Chorzowie, Chorzow, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Lublin, Poland|Szpital Wojewodzki w Opolu;Pododdz. Gastroenter., Pododdz. Hematologii, Opole, Poland|MTZ Clinical Research Sp. z o.o., Warszawa, Poland|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|FSBSI ""Russian Oncological Scientific Center n.a. N.N. Blokhin"", Moscow, Russian Federation|BHI of Omsk region Clinical Oncology Dispensary, Omsk, Russian Federation|SRI of Hematology and Transfusiology, St. Petersburg, Russian Federation|North-West Federal Medical Research Center n.a. V.A. Almazov, St. Petersburg, Russian Federation|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona; Hematology, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario de Salamanca, Salamanca, Spain|Skånes Universitetssjukhus, Lund, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|National Taiwan University Hospital, Taipei, Taiwan|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|The Christie, Manchester, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Singleton Hospital; Pharmacy Department, Swansea, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02005471/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/71/NCT02005471/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02005471"
734,"NCT01999192","Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis","986","Terminated","Has Results","Rheumatoid Arthritis","Drug: Tregalizumab|Drug: Placebo","The Proportion of Subjects Who Achieve an ACR20 at Week 12 Following Treatment With Tregalizumab + MTX Compared With Subjects Treated on Placebo + MTX|Proportions of Subjects With an ACR 20 Response.|Proportions of Subjects With an ACR 50 & 70 Response.|Proportions of Subjects With an Disease Activity Score DAS28 <2.6|Proportions of Subjects With Low Disease Activity DAS28 ≤3.2|ACR Score|Simple Disease Activity Index [SDAI] ≤11|Clinical Disease Activity Index [CDAI] ≤10|DAS28|EULAR Response|ACR Score Individual Components|DAS28 Score Individual Components","Biotest|AbbVie","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","321","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","986_TREAT 2b|2013-000114-38|BT986","October 2013","July 2015","July 2015","December 3, 2013","August 24, 2017","August 24, 2017","Study Site 07, Paradise Valley, Arizona, United States|Study Site 01, Springfield, Illinois, United States|Study Site 03, Lincoln, Nebraska, United States|Study Site 02, Clifton, New Jersey, United States|Study Site 04, North Charleston, South Carolina, United States|Study Site 05, Jackson, Tennessee, United States|Study Site 09, Houston, Texas, United States|Study Site 10, Katy, Texas, United States|Study Site 01, Plovdiv, Bulgaria|Study Site 06, Plovdiv, Bulgaria|Study Site 02, Sofia, Bulgaria|Study Site 04, Sofia, Bulgaria|Study Site 07, Sofia, Bulgaria|Study Site 05, Stara Zagora, Bulgaria|Study Site 03, Varna, Bulgaria|Study Site 02, Rimouski, Quebec, Canada|Study Site 01, St-Jérôme, Quebec, Canada|Study Site 03, Bruntal, Czechia|Study Site 05, Ostrava, Czechia|Study Site 01, Praha, Czechia|Study Site 04, Praha, Czechia|Study Site 08, Praha, Czechia|Study Site 09, Praha, Czechia|Study Site 02, Uherske Hradiste, Czechia|Study Site 07, Uherske Hradiste, Czechia|Study Site 06, Zlin, Czechia|Study Site 01, Tallinn, Estonia|Study Site 03, Berlin, Germany|Study Site 04, Frankfurt, Germany|Study Site 06, Muenchen, Germany|Study Site 02, Ratingen, Germany|Study Site 01, Zerbst, Germany|Study Site 03, Balatonfüred, Hungary|Study Site 02, Budapest, Hungary|Study Site 04, Budapest, Hungary|Study Site 05, Budapest, Hungary|Study Site 06, Gyula, Hungary|Study Site 01, Veszprem, Hungary|Study Site 01, Kaunas, Lithuania|Study Site 02, Vilnus, Lithuania|Study Site 05, Mexico, Distrito Federal, Mexico|Study Site 08, Mexico, Distrito Federal, Mexico|Study Site 06, Leon, Guanajuato, Mexico|Study Site 02, Chihuahua, Mexico|Study Site 03, Distrito Federal, Mexico|Study Site 08, Bialystok, Poland|Study Site 05, Bydgoszcz, Poland|Study Site 10, Elblag, Poland|Study Site 04, Gdynia, Poland|Study Site 02, Katowice, Poland|Study Site 03, Krakow, Poland|Study Site 06, Krakow, Poland|Study Site 09, Poznan, Poland|Study Site 01, Warszawa, Poland|Study Site 07, Warszawa, Poland|Study Site 08, Kemerovo, Russian Federation|Study Site 11, Kemerovo, Russian Federation|Study Site 04, Kursk, Russian Federation|Study Site 03, Moscow, Russian Federation|Study Site 07, Moscow, Russian Federation|Study Site 10, Moscow, Russian Federation|Study Site 05, Omsk, Russian Federation|Study Site 09, Saratov, Russian Federation|Study Site 06, Smolensk, Russian Federation|Study Site 01, Tomsk, Russian Federation|Study Site 02, Yaroslavl, Russian Federation|Study Site 01, Belgrade, Serbia|Study Site 02, Belgrade, Serbia|Study Site 04, Belgrade, Serbia|Study Site 03, Niska Banja, Serbia|Study Site 03, Bratislava, Slovakia|Study Site 04, Kosice - Saca, Slovakia|Study Site 05, Lucenec, Slovakia|Study Site 02, Povazska Bystrica, Slovakia|Study Site 01, Rimavska Sobota, Slovakia|Study Site 08, Donetsk, Ukraine|Study Site 01, Kharkiv, Ukraine|Study Site 02, Kharkiv, Ukraine|Study Site 03, Kyiv, Ukraine|Study Site 04, Kyiv, Ukraine|Study Site 05, Vinnytsia, Ukraine|Study Site 06, Vinnytsia, Ukraine|Study Site 07, Vinnytsia, Ukraine|Study Site 09, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01999192"
735,"NCT01929746","Daclizumab Japanese PK Study",,"Completed","No Results Available","Healthy","Biological: BIIB019 subcutaneous injection","Area under the concentration-time curve from time 0 to infinity (AUCinf)|Maximum observed concentration (Cmax)|Time to reach maximum observed concentration (Tmax)|Terminal elimination half-life (t1/2)|Apparent volume of distribution (Vd/F)|Apparent clearance (CL/F)|The number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs)","Biogen|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","205HV102|EUDRA CT NO: 2013‐002310‐12","October 2013","March 2014","March 2014","August 28, 2013",,"May 2, 2014","Research Site, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01929746"
736,"NCT01908478","Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer","VelGemRad","Active, not recruiting","No Results Available","Pancreatic Cancer","Drug: Veliparib|Drug: Gemcitabine|Radiation: Intensity modulated radiation therapy","Maximum-tolerated dose (MTD) of veliparib based on the incidence of dose-limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Assessment of objective response rates measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Evaluation of pre-treatment biopsy specimens for levels of various DNA repair proteins|Change in PAR [Poly(ADP-ribosyl)ation] levels in peripheral blood mononuclear cells","Cedars-Sinai Medical Center|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","34","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIS-ABT888-0002","October 2, 2013","July 14, 2017","July 2020","July 25, 2013",,"January 18, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT01908478"
737,"NCT01866592","Vascular Inflammation in Psoriasis - Extension Study","VIP-E","Completed","Has Results","Psoriasis|Cardiovascular Disease","Drug: Adalimumab","Change in Vascular Inflammation|Change in Cardiometabolic Biomarker - Total Cholesterol|Change in Cardiometabolic Biomarker - Cholesterol Efflux|Change in Cardiometabolic Biomarker - Low-density Lipoprotein Particle|Change in Cardiometabolic Biomarker - High-density Lipoprotein Particle|Change in Cardiometabolic Biomarker - Log Insulin|Change in Cardiometabolic Biomarker - Log Adiponectin|Change in Cardiometabolic Biomarker - Log Leptin|Change in Cardiometabolic Biomarker - Log C-reactive Protein|Change in Cardiometabolic Biomarker - Log Tumor Necrosis Factor-Alpha|Change in Cardiometabolic Biomarker - Log Interleukin 6|Change in Cardiometabolic Biomarker - GlycA|Change in Cardiometabolic Biomarkers: - Total Cholesterol|Psoriasis Activity (PASI and PGA)|Safety/Adverse Events|Change in Patient-Reported Quality of Life Outcomes-EuroQol EQ-5D|Change in Patient-Reported Quality of Life Outcomes - Dermatology Life Quality Index (DLQI)|Change in Patient-Reported Quality of Life Outcomes - MEDFICTS Dietary Assessment|Change in Patient-Reported Quality of Life Outcomes - International Physical Activity Questionnaire (IPAQ)","University of Pennsylvania|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","81","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","817552","April 2013","August 8, 2016","October 27, 2016","May 31, 2013","May 22, 2018","May 22, 2018","University of California, Davis Health System, Sacramento, California, United States|University of Colorado, Denver, Colorado, United States|National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States|Buffalo Medical Group, Buffalo, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Menter Dermatology Research Institute, Dallas, Texas, United States|Center for Clinical Studies, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT01866592"
738,"NCT01838512","Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)","PREAMBLE","Recruiting","No Results Available","Multiple Myeloma",,"Clinical effectiveness of IMiDs, proteasome inhibitors, and combination novel therapies (an IMiD plus a proteasome inhibitor) in relapsed/refractory MM in real-world clinical practice.|Examine PFS as a potential predictor of OS|Healthcare resource utilization and associated costs|Patient reported outcomes (health-related QoL and work productivity and activity)|Occurrence of secondary malignancies and AEs","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"1700","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CA204-008","June 13, 2012","June 13, 2024","June 13, 2024","April 24, 2013",,"September 27, 2018","Local Institution, Birmingham, Alabama, United States|Local Institute, Goodyear, Arizona, United States|Local Institution, Anaheim, California, United States|Local Institution, Corona, California, United States|Local Institute, Los Angeles, California, United States|Local Institute, Santa Rosa, California, United States|Local Institution, Brooksville, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institute, Valdosta, Georgia, United States|Local Institution, Skokie, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Local Institute, Sioux City, Iowa, United States|Local Institute, Louisville, Kentucky, United States|Local Institution, Lafayette, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institute, Southaven, Mississippi, United States|Local Institute, Kansas City, Missouri, United States|Local Institute, Saint Joseph, Missouri, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Springfield, Missouri, United States|Local Institute, Missoula, Montana, United States|Local Institute, Missoula, Montana, United States|Local Institute, Omaha, Nebraska, United States|Local Institute, Cary, North Carolina, United States|Local Institution, Gastonia, North Carolina, United States|Local Institute, Canton, Ohio, United States|Local Institute, Cleveland, Ohio, United States|Local Institute, Tulsa, Oklahoma, United States|Local Institute, Portland, Oregon, United States|Local Institute, Pottstown, Pennsylvania, United States|Local Institute, Charleston, South Carolina, United States|Local Institute, Knoxville, Tennessee, United States|Local Institution, Memphis, Tennessee, United States|Local Institute, Amarillo, Texas, United States|Local Institute, Corpus Christi, Texas, United States|Local Institute, Dallas, Texas, United States|Local Institute, Dallas, Texas, United States|Local Institute, Dallas, Texas, United States|Local Institute, San Antonio, Texas, United States|Local Institute, Sherman, Texas, United States|Local Institute, Seattle, Washington, United States|Local Institute, Spokane, Washington, United States|Local Institute, Yakima, Washington, United States|Local Institute, Yakima, Washington, United States|Local Institute, Toronto, Ontario, Canada|Local Institute, Weston, Ontario, Canada|Local Institute, Blois, France|Local Institute, Chalon sur Saone, France|Local Institute, La Roche sur Yon, France|Local Institute, Limoges, France|Local Institute, Meaux, France|Local Institute, Nantes, France|Local Institute, Rennes, France|Local Institute, Heidelberg, Baden-Württemberg, Germany|Local Institute, Hamm, Nordrhein-Westfalen, Germany|Local Institute, Aschaffenburg, Germany|Local Institute, Berlin, Germany|Local Institute, Dresden, Germany|Local Institute, Magdeburg, Germany|Local Institute, München, Germany|Local Institute, Rostock, Germany|Local Institute, Pesaro, Pesaro E Urbino, Italy|Local Institute, Ancona, Italy|Local Institute, Ancona, Italy|Local Institute, Cagliari, Italy|Local Institute, Firenze, Italy|Local Institute, Lecce, Italy|Local Institute, Milano, Italy|Local Institute, Napoli, Italy|Local Institute, Roma, Italy|Local Institution, Roma, Italy|Local Institute, Terni, Italy|Local Institute, Torino, Italy|Local Institute, Vicenza, Italy|Local Institute, Truro, Cornwall, United Kingdom|Local Institute, Leeds, United Kingdom|Local Institution, Liverpool, United Kingdom|Local Institute, Nottingham, United Kingdom|Local Institute, Stafford, United Kingdom|Local Institute, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01838512"
739,"NCT01797965","Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019","EXTEND","Terminated","Has Results","Relapsing-Remitting Multiple Sclerosis|Multiple Sclerosis","Drug: BIIB019 (Daclizumab)","Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)|Annualized Relapse Rate (ARR) in the 205MS303 Treatment Period|ARR in the 205MS301-303 Combined Study Period and 205MS301 Treatment Period|Number of Participants With Relapse in the 205MS303 Treatment Period|Number of Participants With Relapse in the 205MS301-303 Combined Study Period|Number of Participants With Sustained Disability Progression in the 205MS303 Treatment Period|Number of Participants With Sustained Disability Progression in the 205MS301-303 Combined Study Period|Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS303 Treatment Period|Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions in the 205MS301 Treatment Period|Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS303 Treatment Period|Number of Participants With Gadolinium-enhancing (Gd+) Lesions in the 205MS301 Treatment Period|Number of Participants With New T1 Hypointense Lesions in the 205MS303 Treatment Period|Number of Participants With New T1 Hypointense Lesions in the 205MS301 Treatment Period|Percent Change in Brain Volume From the 205MS303 Baseline|Percent Change in Brain Volume From 205MS301 Baseline|Total Volume of T2 Hyperintense Lesions in the 205MS303 Treatment Period|Change From Baseline in the Multiple Sclerosis Functional Composite (MSFC) Score in the 205MS303 Treatment Period|Change From 205MS301 Baseline in the MSFC Score in the 205MS301-303 Combined Study Period|Change From Baseline in the Expanded Disability Status Scale (EDSS) Score in the 205MS303 Treatment Period|Number of Participants Who Are Free From Disease Activity in the 205MS303 Treatment Period|Change From Baseline in the Multiple Sclerosis Impact Scale 29 (MSIS 29) Physical and Psychological Scores in the 205MS303 Treatment Period|Change From Baseline in Quality of Life as Assessed by the European Quality of Life, 5 Dimensions (EQ 5D) Health Scores in the 205MS303 Treatment Period|Change From Baseline in Quality of Life as Assessed by the European Quality of Life, Visual Analog Scale (EQ VAS) in the 205MS303 Treatment Period|Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS303 Treatment Period|Direct Health Resource Utilization (HRU): Number of Unscheduled Site Visits in the 205MS301 Treatment Period|Treatment Satisfaction as Assessed by the Participant in the 205MS303 Treatment Period|Health Related Productivity Questionnaire (HRPQ): Scheduled Work Hours in the 205MS303 Treatment Period|HRPQ: Number of Participants Where MS or Its Treatments Resulted in Missed Work in the 205MS303 Treatment Period|HRPQ: Hours of Work Missed Due to MS or Its Treatment in the 205MS303 Treatment Period|HRPQ: Percent Impact on Employment in the 205MS303 Treatment Period|HRPQ: Hours of Household Chores Planned to Perform in the 205MS303 Treatment Period|HRPQ: Number of Participants Where MS or Its Treatments Kept the Participant From Completing Chores in the 205MS303 Treatment Period|HRPQ: Hours Not Performing Household Chores Due to MS or Its Treatment in 205MS303 Treatment Period|HRPQ: Percent Impact on Performing Household Chores in the 205MS303 Treatment Period|Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Assessments in the 205MS303 Treatment Period|Local Tolerability as Assessed by Participant-reported Injection Site Pain VAS|Number of Participants in Local Tolerability Clinician Injection Site Assessment Categories|Number of Participants With Anti-BIIB019 Binding Antibodies (ADAbs) in the 205MS303 Treatment Period|Number of Participants With Anti-BIIB019 Neutralizing Antibodies (Nabs) in the 205MS303 Treatment Period|Change From 205MS303 Baseline in the Symbol Digit Modalities Test (SDMT) Score in the 205MS303 Treatment Period|Change From 205MS301 Baseline in the SDMT Score in the 205MS301-303 Combined Study Period|Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS303 Treatment Period|Change From Baseline in 3-Second Paced Auditory Serial Addition Test (PASAT 3) Score in the 205MS301-303 Combined Study Period","Biogen|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","1501","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205MS303|2012-003176-39","February 15, 2013","September 24, 2018","September 24, 2018","February 25, 2013","December 4, 2019","December 4, 2019","Research Site, Phoenix, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Centennial, Colorado, United States|Research Site, Naples, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Wellesley, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Latham, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Cordova, Tennessee, United States|Research Site, Franklin, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Round Rock, Texas, United States|Research Site, Henrico, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Auchenflower, Queensland, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Recife, Pernambuco, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Campinas, São Paulo, Brazil|Research Site, Ribeirão Preto, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, Vancouver, British Columbia, Canada|Research Site, Saint Johns, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Brno, Jihomoravský Kraj, Czechia|Research Site, Brno, Jihomoravský Kraj, Czechia|Research Site, Jihlava, Kray Vysocina, Czechia|Research Site, Ostrava, Moravskoslezský Kraj, Czechia|Research Site, Pardubice, Pardubický Kraj, Czechia|Research Site, Praha 10, Praha, Czechia|Research Site, Praha 2, Praha, Czechia|Research Site, Olomouc, Severomoravsky Kraj, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Praha 5, Czechia|Research Site, Teplice, Ústecký Kraj, Czechia|Research Site, Copenhagen, Denmark|Research Site, Glostrup, Denmark|Research Site, Odense C, Denmark|Research Site, Strasbourg, Bas-Rhin, France|Research Site, Marseille, Bouches-du-Rhône, France|Research Site, Caen, Calvados, France|Research Site, Bordeaux, Gironde, France|Research Site, Toulouse, Haute-Garonne, France|Research Site, Bobigny, Ile-de-France, France|Research Site, Nancy, Meurthe-et-Moselle, France|Research Site, Lille, Nord, France|Research Site, Amiens Cedex 1, France|Research Site, Paris, France|Research Site, Tbilisi, Georgia|Research Site, Bad Mergentheim, Baden-Württemberg, Germany|Research Site, Freiburg, Baden-Württemberg, Germany|Research Site, Bayreuth, Bayern, Germany|Research Site, Erlangen, Bayern, Germany|Research Site, München, Bayern, Germany|Research Site, Marburg, Hessen, Germany|Research Site, Rostock, Mecklenburg-Vorpommern, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Bamberg, Germany|Research Site, Athens, Attiki, Greece|Research Site, Thessaloniki, Macedonia, Greece|Research Site, Athens, Greece|Research Site, Thessaloniki, Greece|Research Site, Miskolc, Borsod-Abaúj-Zemplén, Hungary|Research Site, Kecskemét, Bács-Kiskun, Hungary|Research Site, Székesfehérvár, Fejer, Hungary|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Gurgaon, India|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Petah Tikva, Israel|Research Site, Safed, Israel|Research Site, Genova, Liguria, Italy|Research Site, Milano, Lombardia, Italy|Research Site, Padova, Veneto, Italy|Research Site, Catania, Italy|Research Site, Cefalù, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Distrito Federal, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Chisinau, Moldova, Republic of|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Lublin, Lubelskie, Poland|Research Site, Lodz, Lódzkie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Bialystok, Podlaskie, Poland|Research Site, Bialystok, Podlaskie, Poland|Research Site, Gdansk, Pomorskie, Poland|Research Site, Gdansk, Pomorskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Kielce, Swietokrzyskie, Poland|Research Site, Olsztyn, Warminsko-mazurskie, Poland|Research Site, Plewiska, Wielkopolskie, Poland|Research Site, Poznan, Wielkopolskie, Poland|Research Site, Poznan, Wielkopolskie, Poland|Research Site, Poznan, Wielkopolskie, Poland|Research Site, Szczecin, Zachodniopomorskie, Poland|Research Site, Szczecin, Zachodniopomorskie, Poland|Research Site, Gdansk, Poland|Research Site, Grudziadz, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Olsztyn, Poland|Research Site, Cluj- Napoca, Cluj, Romania|Research Site, Târgu Mures, Mures, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Yaroslavl, Yaroslavlr, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Badalona, Barcelona, Spain|Research Site, Cordoba, Córdoba, Spain|Research Site, Madrid, Madrid, Communidad Delaware, Spain|Research Site, Girona, Spain|Research Site, l'Hospitalet de Llobregat, Spain|Research Site, Sevilla, Spain|Research Site, Malmö, Skane, Sweden|Research Site, Stockholm, Sodermanlands Lan, Sweden|Research Site, Stockholm, Sodermanlands Lan, Sweden|Research Site, Göteborg, Vastra Gotalands Lan, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Basel-Stadt (de), Switzerland|Research Site, Chernivtsi, Chernivets'ka Oblast, Ukraine|Research Site, Dnipropetrovsk, Dnipropetrovs'ka Oblast', Ukraine|Research Site, Donetsk, Donets'ka Oblast', Ukraine|Research Site, Kharkiv, Kharkivs'ka Oblast', Ukraine|Research Site, Kyiv, Kyïv, Ukraine|Research Site, Kyiv, Kyïv, Ukraine|Research Site, Kyiv, Kyïv, Ukraine|Research Site, Odesa, Odes'ka Oblast, Ukraine|Research Site, Poltava, Poltavs'ka Oblast, Ukraine|Research Site, Vinnytsia, Vinnyts'ka Oblast', Ukraine|Research Site, Zaporizhzhia, Zaporiz'ka Oblast', Ukraine|Research Site, Zaporizhzhia, Zaporizhia Oblast, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Plymouth, Devon, United Kingdom|Research Site, Edinburgh, Edinburgh, City Of, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT01797965/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/65/NCT01797965/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01797965"
740,"NCT01789151","99m-Technetium- Glucosamine in Arthritis",,"No longer available","No Results Available","Rheumatoid Arthritis|Ankylosing Spondylitis","Device: Technetium labelled glucosamine",,"University of Sydney|AbbVie","All","18 Years to 90 Years   (Adult, Older Adult)",,,"Other|Industry","Expanded Access",,"Glucosamine|IMM 11-0091",,,,"February 11, 2013",,"October 31, 2016","Westmead Hospital, Sydney, New South Wales, Australia",,"https://ClinicalTrials.gov/show/NCT01789151"
741,"NCT01674413","Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)","CADHUM","Withdrawn","No Results Available","Crohn's Disease","Drug: Adalimumab|Drug: Adalimumab PRN|Drug: Placebo","Percent Time in Remission (PTIR) in PRNLOAD vs. Placebo arms|Percent Time in Remission MAINT vs. PRNLOAD|Percent Time in Remission MAINT vs. PBO|Strict Biologic Remission Rates|Subject acceptability|Subject preference|Equivalence of Percent Time in Remission|Comparison of Average CDAI|Comparison of average IBDQ|Comparison of average FCP|Comparison of average CRP|Comparison of Rates of Hospitalization|Comparison of Rates of Emergency Department visits|Comparison of Rates of Physician visits|Comparison of mg prednisone prescribed","Peter Higgins|AbbVie|University of Michigan","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Abbott IMM 10-0105","October 2013","March 2016","March 2016","August 28, 2012",,"May 24, 2017","University of Michigan Health System, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01674413"
742,"NCT01632150","Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma",,"Completed","Has Results","Relapsed and/or Refractory Multiple Myeloma","Biological: Elotuzumab|Biological: Thalidomide|Biological: Dexamethasone|Biological: Cyclophosphamide","Percentage of Participants Who Received Treatment Including Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events (AEs)|Percentage of All Participants Who Received Treatment Without Cyclophosphamide and Had Grade 3 or Higher Nonhematologic Adverse Events (AEs)|Percentage of All Participants Who Received Treatment Including Cyclophosphamide and Had 1 Dose Reduction or Discontinued Due to an Adverse Event|Percentage of All Participants Who Received Treatment Without Cyclophosphamide and Had 1 Dose Reduction or Discontinued Due to an Adverse Event","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","51","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-010|2011-005121-49","May 2012","October 2013","March 2016","July 2, 2012","February 26, 2016","April 14, 2017","Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, LaLaguna, S Cruz Tener, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Salamanca, Spain|Local Institution, Sevilla, Spain|Local Institution, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01632150"
743,"NCT01613014","ABT-436 for Alcohol Dependence",,"Completed","Has Results","Alcohol Dependence|Alcohol Abuse|Alcohol Use Disorders|Alcoholism","Drug: ABT-436|Drug: Matched Placebo - Sugar Pill","Weekly Percentage of Heaving Drinking Days","National Institute on Alcohol Abuse and Alcoholism (NIAAA)|AbbVie","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 2","150","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NCIG-004","February 2013","May 2015","July 2015","June 6, 2012","April 4, 2017","April 4, 2017","Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|Boston Medical Center, Quincy, Massachusetts, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Virginia, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01613014"
744,"NCT01478048","Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma",,"Completed","Has Results","Multiple Myeloma","Biological: Elotuzumab|Drug: Bortezomib|Drug: Dexamethasone","Median Investigator-Assessed Progression-free Survival (PFS) Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause - Randomized Participants|Number of Investigator-Assessed Progression-free Survival Events From Randomization to Date of First Tumor Progression or Death Due to Any Cause - All Randomized Participants|1 Year Progression-Free Survival Rate - Randomized Participants|Median Progression-free Survival Time (Months) From Randomization to Date of First Tumor Progression or Death Due to Any Cause, in Randomized Participants With at Least One FcγRIIIa V Allele|Investigator-Assessed Objective Response Rate (ORR) - All Randomized Participants|Investigator-Assessed Objective Response Rate in Randomized Participants With at Least One FcγRIIIa V Allele","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","185","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-009|2011-002695-16","November 30, 2011","May 30, 2014","April 21, 2017","November 23, 2011","January 26, 2016","May 21, 2018","Compassionate Cancer Res Grp, Corona, California, United States|Local Institution, Corona, California, United States|Local Institution, Long Beach, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Ucla Department Of Medicine, Los Angeles, California, United States|Medical Oncology Care Associates, Orange, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Kaiser Permanente Medical Center, Vallejo, California, United States|Local Institution, Vallejo, California, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Kaiser Permanente-Moanalua Medical Center, Honolulu, Hawaii, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Local Institution, Decatur, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Local Institution, Urbana, Illinois, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Local Institution, Hazard, Kentucky, United States|University Of Kentucky Markey Cancer Center, Lexington, Kentucky, United States|Pikeville Medical Center Leonard Lawson Cancer Center, Pikeville, Kentucky, United States|Cancer Center Of Acadiana, Lafayette, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|St. Agnes Hospital, Baltimore, Pennsylvania, United States|Cancer Care Associates, Bethlehem, Pennsylvania, United States|Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States|Penn State Hershey Cancer Inst, Hershey, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Local Institution, Greenville, South Carolina, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Local Institution, Fairfax, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Grenoble Cedex 9, France|Local Institution, Le Mans, France|Local Institution, Lille Cedex, France|Local Institution, Nantes, France|Local Institution, Paris 12, France|Local Institution, Toulouse, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Milano, Parma, Italy|Local Institution, Roma, Parma, Italy|Local Institution, Ancona, Italy|Local Institution, Bari, Italy|Local Institution, Bologna, Italy|Local Institution, Brescia, Italy|Local Institution, Firenze, Italy|Local Institution, Genova, Italy|Local Institution, Lecce, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Modena, Italy|Local Institution, Pescara, Italy|Local Institution, Ravenna, Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Rome, Italy|Local Institution, Torino, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Murcia, Spain|Local Institution, Salamanca, Spain|Local Institution, Santiago Compostela, Spain|Local Institution, Toledo, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01478048"
745,"NCT01441973","Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma",,"Completed","Has Results","Smoldering Multiple Myeloma","Biological: Elotuzumab (BMS-901608; HuLuc63)","Linear Regression of Maximal Percent Reduction in Serum Monoclonal (M) Protein on Baseline Percent CD56^Dim Cells in Bone Marrow|Number of Participants Who Died and With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Infusion Reactions|Number of Participants With Laboratory Test Results Meeting the Criteria for Grade 3-4 Abnormality|Number of Participants With a Dose- or Concentration-related Effect on QTcF Interval, PR Interval, QRS Interval, and Heart Rate|Progression Free Survival (PFS) Rate|Objective Response Rate (ORR)","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-011","December 28, 2011","May 30, 2014","January 17, 2017","September 28, 2011","January 29, 2016","January 23, 2018","Sharp Clinical Oncology Research, San Diego, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Va Connecticut Healthcare System, West Haven, Connecticut, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Mid Dakota Clinic, Pc, Bismarck, North Dakota, United States",,"https://ClinicalTrials.gov/show/NCT01441973"
746,"NCT01393964","Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function",,"Completed","Has Results","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone|Biological: Elotuzumab (BMS-901608; HuLuc63)","Geometric Mean Maximum Observed Serum Concentration (Cmax) of Elotuzumab Following Cycle 1, Day 1 Dose Administration - Grouping by Cockcroft-Gault Creatinine Clearance Method|Geometric Mean Area Under Serum Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration AUC(0-T) and From Time Zero Extrapolated to Infinite Time AUC(INF) of Elotuzumab Following Cycle 1, Day 1 - Grouping by C-G CrCl Method|Number of Participants With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Who Died|Number of Participants With Persistent Elotuzumab Anti-drug Antibodies (ADA) and Number of Participants ADA Positive at Cycle 2 Pre-dose.|Number of Participants With Worst Toxicity Grade Hematology Laboratory Tests|Number of Participants With Worst Toxicity Grade Renal and Liver Function Laboratory Tests|Number of Participants With Worst Toxicity Grade Chemistry Laboratory Tests","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-007","January 6, 2012","March 21, 2014","July 18, 2016","July 14, 2011","January 27, 2016","August 3, 2017","Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|University Of Maryland, Baltimore, Maryland, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Weill Cornell Medical College, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|The University Of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Va Puget Sound Health Care System, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT01393964"
747,"NCT01335399","Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma","ELOQUENT - 1","Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone|Biological: Elotuzumab (BMS-901608; HuLuc63)","Progression-free survival (PFS) - Time from randomization to date of first tumor progression or death due to any cause, provided death is not more than 10 weeks after the last tumor assessment.|Objective Response Rate - The percentage of patients who have a partial or complete response to study therapy.|Overall Survival - The period of time from study entry until the date of death or last known date alive.","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","750","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-006|2010-022445-20","May 18, 2011","November 10, 2019","September 1, 2020","April 14, 2011",,"August 26, 2019","Alabama Oncology, Birmingham, Alabama, United States|University Of South Alabama / Mitchell Cancer Institute, Mobile, Alabama, United States|Southern Cancer Center, Inc., Mobile, Alabama, United States|Ironwood Cancer And Research Centers, Pc, Chandler, Arizona, United States|Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Comprehensive Blood And Cancer Center, Bakersfield, California, United States|Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States|Compassionate Cancer Care Medical Group, Inc., Corona, California, United States|Compassionate Cancer Res Grp, Corona, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Medical Oncology Care Associates, Orange, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Washington Cancer Inst at MedStar Washington Hospital Ctr, Washington, District of Columbia, United States|Lynn Cancer Institute Center For Hematology-Oncology, Boca Raton, Florida, United States|Local Institution, Brooksville, Florida, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists, Llc, Jacksonville, Florida, United States|Local Institution, New Port Richey, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Kaiser Permanente Hawaii, Honolulu, Hawaii, United States|Rush University Medical Center, Chicago, Illinois, United States|The University Of Chicago, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Illinois Cancercare, PC, Peoria, Illinois, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Premier Healthcare, Llc, Bloomington, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Local Institution, Mishawaka, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Cancer Center Of Acadiana At Lafayette General, Lafayette, Louisiana, United States|Crescent City Research Consortium, LLC, Marrero, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Willis Knighton Cancer Center, Shreveport, Louisiana, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Harry & Jeanette Weinberg Cancer Institute, Baltimore, Maryland, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Columbia Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Local Institution, Lincoln, Nebraska, United States|University Of Nebraska Medical Center, Omaha, Nebraska, United States|Winthrop University Hospital, Mineola, New York, United States|Local Institution, New York, New York, United States|St. Luke'S Roosevelt Hospital Center, New York, New York, United States|St. Luke'S-Roosevelt Hosp. Ctr., New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Local Institution, Cleveland, Ohio, United States|Benson, Md, Don, Columbus, Ohio, United States|Mid Ohio Onc/Hema, Inc., Dba, Columbus, Ohio, United States|Signal Point Clinical Research Center, Llc, Middletown, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Cancer Care Associates, Bethlehem, Pennsylvania, United States|Alliance Cancer Specialists, Langhorne, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Musc Hollings Cancer Center, Charleston, South Carolina, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cancer Specialists Of South Texas, Pa, Corpus Christi, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Baylor College Of Medicine, Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Community Cancer Trials of Utah, Ogden, Utah, United States|Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States|Va Puget Sound Health Care System, Seattle, Washington, United States|Fred Hutchinson Cancer Research Ctr, Seattle, Washington, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Gundersen Clinic, Ltd, La Crosse, Wisconsin, United States|Dean Clinic-Hematology And Oncology, Madison, Wisconsin, United States|University Of Wisconsin Hospital And Clinics, Madison, Wisconsin, United States|Local Institution, Canberra, Australian Capital Territory, Australia|Local Institution, Albury, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Murdoch, Australia|Local Institution, Fadingerstra?e 1, Austria|Local Institution, Innsbruck, Austria|Local Institution, Rankweil, Austria|Local Institution, Wels, Austria|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Brussles, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Edegem-antwerp, Belgium|Local Institution, Gent, Belgium|Local Institution, La Louviere, Belgium|Local Institution, Leuven, Belgium|Local Institution, Liege, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Winnipeg, Manitoba, Canada|Local Institution, Saint John, New Brunswick, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montral, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Aschaffenburg, Germany|Local Institution, Berlin, Germany|Local Institution, Chemnitz, Germany|Local Institution, Dresden, Germany|Local Institution, Hamm, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Koln, Germany|Local Institution, Mainz, Germany|Local Institution, Munchen, Germany|Local Institution, Munster, Germany|Local Institution, Offenbach, Germany|Local Institution, Stuttgart, Germany|Local Institution, Tuebingen, Germany|Local Institution, Ulm, Germany|Local Institution, Athens, Greece|Local Institution, Athens, Greece|Local Institution, Ioannina, Greece|Local Institution, Larissa, Greece|Local Institution, Patras, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyor, Hungary|Local Institution, Szeged, Hungary|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Afula, Israel|Local Institution, Ashkelon, Israel|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Jerusalem, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Nahariya, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Rehovot, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zerifin, Israel|Local Institution, Ancona, Italy|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Firenze, Italy|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Palermo, Italy|Local Institution, Ravenna, Italy|Local Institution, Reggio Nell Emilia (RE), Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Bialystok, Poland|Local Institution, Chorzow, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Poznan, Poland|Local Institution, Szczecin, Poland|Local Institution, Warsaw, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Brasov, Romania|Local Institution, Bucaresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Lasi, Romania|Local Institution, Samara, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, La Laguna- Tenerife, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Salamanca, Spain|Local Institution, San Sebastian, Spain|Local Institution, Toledo, Spain|Local Institution, Bern, Switzerland|Local Institution, St Gallen, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Izmir, Bornova, Turkey|Local Institution, Ankara, Dikimevi, Turkey|Local Institution, Izmir, Inciralti, Turkey|Local Institution, Gaziantep, Turkey|Local Institution, Belfast, Antrim, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01335399"
748,"NCT01320293","Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.",,"Completed","Has Results","Psoriasis","Drug: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]","Percentage Change in Endothelial Function Compared to Baseline.|Changes in IL-6 Profile Compared to Baseline|Changes in Adiponectin Profile Compared to Baseline","University of North Carolina, Chapel Hill|AbbVie","All","18 Years to 55 Years   (Adult)","Not Applicable","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABBO-0001","March 2011","March 2015","March 2015","March 22, 2011","December 26, 2016","December 26, 2016","UNC Dermatology Clinical Trials Unit, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01320293"
749,"NCT01239797","Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma","ELOQUENT - 2","Active, not recruiting","Has Results","Lymphoma|Multiple Myeloma","Drug: Lenalidomide|Drug: Dexamethasone|Drug: Dexamethasone (Oral)|Drug: Dexamethasone (IV)|Biological: Elotuzumab (BMS-901608; HuLuc63)","Median Progression Free Survival (PFS)|Objective Response Rate (ORR)|Median Overall Survival (OS)|Change in Baseline of Brief Pain Inventory-Short Form (BPI-SF) Scores","Bristol-Myers Squibb|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","761","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-004|2010-020347-12","March 28, 2011","September 2, 2014","September 30, 2020","November 11, 2010","January 5, 2017","November 1, 2018","Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Local Institution, Berkeley, California, United States|Local Institution, Burbank, California, United States|Compassionate Cancer Res Grp, Corona, California, United States|Local Institution, Corona, California, United States|San Diego Pacific Oncology& Hematology Associates, Inc, Encinitas, California, United States|Local Institution, Greenbrae, California, United States|Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States|Medical Oncology Care Associates, Orange, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Local Institution, Vallejo, California, United States|Local Institution, Boca Raton, Florida, United States|Cancer Care Centers Of Florida, Brooksville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Local Institution, New Port Richey, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Titusville, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Georgia Health Science University, Augusta, Georgia, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Mishawaka, Indiana, United States|Local Institution, Iowa City, Iowa, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Louisville, Kentucky, United States|Pikeville Medical Center, Pikeville, Kentucky, United States|Cancer Center Of Acadiana At Lafayette General, Lafayette, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Local Institution, Shreveport, Louisiana, United States|Willis Knighton Cancer Center, Shreveport, Louisiana, United States|Dana Farber Cancer Inst, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Capitol Comprehensive Cancer Care Center, Jefferson City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Springfield, Missouri, United States|Local Institution, Las Vegas, Nevada, United States|NYU Clinical Cancer Center, New York, New York, United States|Local Institution, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Local Institution, Stony Brook, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Gaston Hematology & Oncology, Gastonia, North Carolina, United States|Local Institution, Bismarck, North Dakota, United States|University Of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Local Institution, Tulsa, Oklahoma, United States|Local Institution, Bethlehem, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Greenville, South Carolina, United States|Local Institution, Knoxville, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Cancer Specialists Of South Texas, Pa, Corpus Christi, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Hematology-Oncology Associates Of Fredricksburg, Inc, Fredericksburg, Virginia, United States|Local Institution, Seattle, Washington, United States|Va Puget Sound Health Care System, Seattle, Washington, United States|Gundersen Clinic, Ltd, La Crosse, Wisconsin, United States|University Of Wisconsin Hospital And Clinics, Madison, Wisconsin, United States|Medical College Of Wisconsin, Milwaukee, Wisconsin, United States|Local Institution, Albury, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Murdoch, Australia|Local Institution, Rankweil, Austria|Local Institution, Steyr, Austria|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Local Institution, Antwerpen, Belgium|Local Institution, Brugge, Belgium|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Brussles, Belgium|Local Institution, Edegem-antwerp, Belgium|Local Institution, La Louviere, Belgium|Local Institution, Liege, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Barrie, Ontario, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Montreal, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Copenhagen, Denmark|Local Institution, Odense C, Denmark|Local Institution, Vejle, Denmark|Local Institution, Blois, France|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, Clamart Cedex, France|Local Institution, La Roche Sur Yon, France|Local Institution, La Tronche, France|Local Institution, Lille, France|Local Institution, Limoges, France|Local Institution, Nantes, France|Local Institution, Paris 12, France|Local Institution, Pierre Benita, France|Local Institution, Toulouse, France|Local Institution, Tours Cedex, France|Local Institution, Vandoeuvre, France|Local Institution, Aschaffenburg, Germany|Local Institution, Berlin, Germany|Local Institution, Berlin, Germany|Local Institution, Chemnitz, Germany|Local Institution, Dresden, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamburg, Germany|Local Institution, Hamm, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Kiel, Germany|Local Institution, Koln, Germany|Local Institution, Marburg, Germany|Local Institution, Munchen, Germany|Local Institution, Munchen, Germany|Local Institution, Munster, Germany|Local Institution, Ravensburg, Germany|Local Institution, Tuebingen, Germany|Local Institution, Ulm, Germany|Local Institution, Wurzburg, Germany|Local Institution, Athens, Greece|Local Institution, Ioannina, Greece|Local Institution, Larissa, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyor, Hungary|Local Institution, Szeged, Hungary|Local Institution, Dublin, Ireland|Local Institution, Tullamore, Ireland|Local Institution, Afula, Israel|Local Institution, Ashkelon, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Rehovot, Israel|Local Institution, Zerifin, Israel|Local Institution, Ancona, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Firenze, Italy|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Monza, Italy|Local Institution, Napoli, Italy|Local Institution, Palermo, Italy|Local Institution, Ravenna, Italy|Local Institution, Rimini, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Maebashi-shi, Gunma, Japan|Local Institution, Shibukawa-shi, Gunma, Japan|Local Institution, Sapporo-city, Hokkaido, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shibuya-ku, Tokyo, Japan|Local Institution, Shinjuuku-ku, Tokyo, Japan|Local Institution, Kamogawa, Toyko, Japan|Local Institution, Chiba-shi, Japan|Local Institution, Fukuoka, Japan|Local Institution, Kyoto, Japan|Local Institution, Nagoya-shi, Japan|Local Institution, Niigata, Japan|Local Institution, Okayama, Japan|Local Institution, Toyohashi-shi, Japan|Local Institution, Bialystok, Poland|Local Institution, Chorzow, Poland|Local Institution, Lublin, Poland|Local Institution, Poznan, Poland|Local Institution, Warsaw, Poland|Local Institution, Warszawa, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Ponce, Puerto Rico|Local Institution, San Juan, Puerto Rico|Local Institution, Brasov, Romania|Local Institution, Bucaresti, Romania|Local Institution, Bucuresti, Romania|Local Institution, Lasi, Romania|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Murcia, Spain|Local Institution, Salamanca, Spain|Local Institution, Santiago De Comp-coruna, Spain|Local Institution, Toledo, Spain|Local Institution, Bern, Switzerland|Local Institution, Geneve 14, Switzerland|Local Institution, Izmir, Bornova, Turkey|Local Institution, Istanbul, Capa, Turkey|Local Institution, Izmir, Inciralti, Turkey|Local Institution, Ankara, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Airdrie, Lancashire, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Leeds, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01239797"
750,"NCT01064401","Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis","(DECIDE)","Completed","Has Results","Relapsing-Remitting Multiple Sclerosis","Biological: BIIB019 (Daclizumab High Yield Process)|Drug: Interferon beta-1a Placebo|Biological: Interferon beta-1a|Drug: Daclizumab High Yield Process Placebo","Adjusted Annualized Relapse Rate (ARR)|Adjusted Mean Number of New or Newly Enlarging T2 Hyperintense Lesions up to Week 96|Proportion of Participants With Sustained Disability Progression at 144 Weeks|Proportion of Participants Relapse-free at Week 144|Percentage of Participants With a ≥ 7.5 Point Worsening From Baseline in the Multiple Sclerosis Impact Scale (MSIS-29) Physical Impact Score at 96 Weeks","Biogen|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 3","1841","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","205MS301|2009-012500-11","May 2010","March 2014","July 2014","February 8, 2010","July 11, 2016","July 11, 2016","Research Site, Gilbert, Arizona, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Naples, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, St. Petersburg, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Evanston, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Springfield, Massachusetts, United States|Research Site, Worchester, Massachusetts, United States|Research Site, Clinton Township, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Buffalo, New York, United States|Research Site, Latham, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Medford, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Allentown, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburg, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Franklin, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Kirkland, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Godoy Cruz, Mendoza, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Auchenflower, Queensland, Australia|Research Site, Woodville, South Australia, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Heidelberg West, Victoria, Australia|Research Site, Belo Horizonte, Bahia, Brazil|Research Site, Brasilia, Distrito Federal, Brazil|Research Site, Recife, Pernambuco, Brazil|Research Site, Porto Alegre, Rio Grande, Brazil|Research Site, Sao Paulo, Rio Grande, Brazil|Research Site, Campinas, Sao Paulo, Brazil|Research Site, Ribeirão Preto, Sao Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Saint John, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Gatineau, Quebec, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montréal, Quebec, Canada|Research Site, Regina, Saskatchewan, Canada|Research Site, Brno, Jihocesky Kraj, Czech Republic|Research Site, Jihlava, Kraj Vysocina, Czech Republic|Research Site, Olomouc, Olomoucký kraj, Czech Republic|Research Site, Praha 10, Praha, Czech Republic|Research Site, Praha 2, Praha, Czech Republic|Research Site, Havirov, Severomoravksy Krav, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Copenhagen, Denmark|Research Site, Glostrup, Denmark|Research Site, Odense C, Denmark|Research Site, Århus, Denmark|Research Site, Tampere, Western Finalnd, Finland|Research Site, Helsinki, Finland|Research Site, Oulu, Finland|Research Site, Seinäjoki, Finland|Research Site, Turku, Finland|Research Site, Strasbourg, Alsace, France|Research Site, Caen Cedex 5, Basse-normandie, France|Research Site, Bobigny, Ile-de-france, France|Research Site, Paris Cedex 5, Ile-de-france, France|Research Site, Paris, Ile-de-france, France|Research Site, Amiens, Picardie, France|Research Site, Nice, Provence Alpes Cote D'azur, France|Research Site, Lyon, Rhone-alpes, France|Research Site, Bourdeaux, France|Research Site, Dijon, France|Research Site, Lille, France|Research Site, Lomme, France|Research Site, Marseille Cedex 9, France|Research Site, Nancy, France|Research Site, Toulouse Cedex 3, France|Research Site, Tbilisi, Georgia|Research Site, Freiburg, Baden-wuerttemberg, Germany|Research Site, Bad Mergentheim, Baden-Wurttemberg, Germany|Research Site, Bamberg, Bayern, Germany|Research Site, Bayreuth, Bayern, Germany|Research Site, München, Bayern, Germany|Research Site, Neuburg an der Donau, Bayern, Germany|Research Site, Marburg, Hessen, Germany|Research Site, Essen, Nordrhein Westfalen, Germany|Research Site, Koln, Nordrhein Westfalen, Germany|Research Site, Munster, Nordrhein-Westfalen, Germany|Research Site, Trier, Rheinland-Pfalz, Germany|Research Site, Dresden, Sachsen, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Tübingen, Germany|Research Site, Athens, Attica, Greece|Research Site, Heraklion, Crete, Greece|Research Site, Thessaloniki, Macedoni, Greece|Research Site, Székesfehérvár, Fejer, Hungary|Research Site, Gyor, Gyor-moson-sopron, Hungary|Research Site, Budapest, Hungary|Research Site, Esztergom, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Veszprém, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Delhi, Dwivdee, India|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, New Delhi, India|Research Site, Dublin, Ireland|Research Site, Ashkelon, Ashqelon, Israel|Research Site, Tzrifin, Beer Yaakov, Israel|Research Site, Petach Tikva, Petah Tiqwa, Israel|Research Site, Beer-Sheva, Israel|Research Site, Haifa, Israel|Research Site, Kfar Saba, Israel|Research Site, Tzfat, Israel|Research Site, Cefalù, PA, Italy|Research Site, Orbassano, Torino, Italy|Research Site, Bari, Italy|Research Site, Cagliari, Italy|Research Site, Catania, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Chisinau, Moldova, Republic of|Research Site, Lublin, Dolnoslaskie, Poland|Research Site, Bydgoszcz, Kujawsko-pomorskie, Poland|Research Site, Grudziadz, Kujawsko-pomorskie, Poland|Research Site, Lódz, Lodzkie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Bialystok, Podlaskie, Poland|Research Site, Gdansk, Pomorskie, Poland|Research Site, Katowice, Slaskie, Poland|Research Site, Kielce, Swietokrzycie, Poland|Research Site, Olsztyn, Warminsko-mazurskie, Poland|Research Site, Poznan, Wielkopolskie, Poland|Research Site, Szczecin, Zachodniopomorskie, Poland|Research Site, Bydgoszczas, Poland|Research Site, Plewiska, Poland|Research Site, Bucurest, Bucuresti, Romania|Research Site, Cluj-Napoca, Cluj, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Iasi, Romania|Research Site, Târgu Mures, Romania|Research Site, Kazan, Povolje-Tatarstan, Russian Federation|Research Site, Ekaterinburg, Ural, Russian Federation|Research Site, Yaroslavl, Yaroslavlr, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kemerovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tumen, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Kragujevac, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, L´Hospitalet de Llobregat, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Lugano, Switzerland|Research Site, Dnepropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyviv, Ukraine|Research Site, Odessa, Ukraine|Research Site, Poltava, Ukraine|Research Site, Vinnitsa, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, London, United Kingdom|Research Site, New Castle Upon Tyne, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01064401"
751,"NCT01051349","Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis","SELECTED","Completed","Has Results","Relapsing-Remitting Multiple Sclerosis","Biological: BIIB019 (Daclizumab)|Biological: trivalent seasonal influenza vaccine","Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs, Withdrawals Due to AEs|Area Under the Concentration-Time Curve Over the Dosing Interval (AUC0-t) After Dose 4 for Daclizumab|Number of Participants With New or Newly Enlarging T2 Hyperintense Lesions Compared to Baseline|Annual Change in Volume of New or Newly Enlarging T2 Hyperintense Lesions Compared to Baseline|Number of Participants With Total Number of New Gadolinium-enhancing Lesions|Annual Change in Number of T1 Hypointense Lesions|Annual Change in Volume of New Gadolinium-Enhancing Lesions|Annual Change in Volume of T1 Hypointense Lesions|Percent Change in Total Brain Volume|Number of Participants With Antibodies to DAC HYP|Annualized Relapse Rate (ARR)|Number of Participants With Sustained Disability Progression for 12 Weeks|Number of Participants With Sustained Disability Progression for 24 Weeks|Observed Maximum Concentration (Cmax) After Dose 4 for Daclizumab|Time to Reach Maximum Concentration (Tmax) for Daclizumab After Dose 4|Observed Minimum Concentration (Cmin) for Daclizumab After Dose 4|Participant-Reported Pain Visual Analog Scale (VAS) Score|Summary of Injection Site Assessment Performed by Clinician","Biogen|AbbVie","All","18 Years to 60 Years   (Adult)","Phase 2","410","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","205-MS-203|2009-015318-23","March 31, 2010","August 25, 2016","August 25, 2016","January 18, 2010","November 9, 2018","November 9, 2018","Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Prague, Czechia|Research Site, Teplice, Czechia|Research Site, Bayreuth, Germany|Research Site, Erlangen, Germany|Research Site, Marburg, Germany|Research Site, Rostock, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Siofok, Hungary|Research Site, Bangalore, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Rajasthan, India|Research Site, Bialystok, Poland|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Warszawa, Poland|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Yaroskavi, Russian Federation|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporizhia, Ukraine|Research Site, Zaporizhia, Ukraine|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01051349"
752,"NCT00870740","Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis","SELECTION","Completed","Has Results","Relapsing-Remitting Multiple Sclerosis","Biological: BIIB019 (Daclizumab High Yield Process)|Drug: Placebo","Number of Participants With Treatment-emergent Adverse Events (AEs)|Number of Participants With Abnormalities in Vital Signs|Number of Participants With Potentially Clinically Significant Hematology Laboratory Abnormalities|Number of Participants With Abnormalities in Blood Chemistry Laboratory Data|Number of Participants With Development of Anti-DAC Antibodies (ADAb) and Neutralizing Antibodies (NAb) Post-baseline|Adjusted Annualized Relapse Rate|Estimated Proportion of Participants With a Relapse|Mean Number of New Gadolinium-enhancing Lesions|Mean Number of New or Newly-enlarging T2 Hyperintense Lesions|Mean Volume of New T1 Hypointense Lesions|Mean Percentage Change From Baseline in Total Lesion Volume of T2 Hyperintense Lesions|Mean Percentage Change From Baseline in Total Volume of Non-gadolinium (Gd)-Enhancing T1 Hypointense Lesions|Rate of Percentage Change From Baseline in Mean Total Brain Volume","Biogen|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 2","517","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","205-MS-202|EUDRA CT No.: 2008-005559-46","February 2009","May 2012","October 2012","March 27, 2009","August 30, 2016","August 30, 2016","Research Site, Brno, Czech Republic|Research Site, Hraddec Kralove, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Bayreuth, Germany|Research Site, Erlangen, Germany|Research Site, Marburg, Germany|Research Site, Osnabruck, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Siofok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Andra-Pradeash, India|Research Site, Bangalore, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Visakhapatnam, India|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Warszawa, Poland|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Yaroskavl, Russian Federation|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporizhzhya, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, Devon, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00870740"
753,"NCT00390221","Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis","SELECT","Completed","Has Results","Relapsing-Remitting Multiple Sclerosis","Biological: BIIB019 (Daclizumab High Yield Process)|Drug: Placebo","Adjusted Annualized Relapse Rate Between Baseline and Week 52|Adjusted Mean Number of New Gadolinium (Gd)-Enhancing Lesions Between Week 8 and Week 24|Adjusted Mean Number of New or Newly-enlarging T2 Hyperintense Lesions at Week 52|Proportion of Participants Who Relapsed at Week 52|Mean Change From Baseline in Multiple Sclerosis Impact Scale (MSIS)-29 Physical Impact Score at Week 52","Biogen|AbbVie","All","18 Years to 55 Years   (Adult)","Phase 2","621","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","205-MS-201","February 2008","May 2011","August 2011","October 19, 2006","July 11, 2016","July 11, 2016","Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Teplice, Czech Republic|Research Site, Erlangen, Germany|Research Site, Marburg, Germany|Research Site, Osnabrueck, Germany|Research Site, Regensburg, Germany|Research Site, Rostock, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Esztergom, Hungary|Research Site, Gyor, Hungary|Research Site, Kecskemet, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Siofok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Andra-Pradeash, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Rajasthan, India|Research Site, Visakhapatnam, India|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Warsaw, Poland|Research Site, Warszawa, Poland|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Smolensk, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kiev, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporozhye, Ukraine|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00390221"
754,"NCT01685892","A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia",,"Completed","No Results Available","Lymphocytic Leukemia, Chronic","Drug: Obinutuzumab|Drug: Venetoclax","Percentage of Participants With Dose Limiting Toxicities (DLTs)|Maximum Tolerated Dose (MTD) of Venetoclax in Combination with Obinutuzumab|Percentage of Participants with Adverse Events|Percentage of Participants with Anti-Therapeutic Antibodies (ATAs) to Obinutuzumab|Area Under the Concentration-Time Curve (AUC) of Venetoclax|Time to Maximum Observed Plasma Concentration (Tmax) of Venetoclax|Maximal Plasma Concentration (Cmax) of Venetoclax|Minimum Plasma Concentration (Cmin) of Venetoclax|Cmax of Obinutuzumab|Cmin of Obinutuzumab|Percentage of Participants with Confirmed Complete Response (CR) as Determined by Standard CLL Response Criteria|Percentage of Participants with Objective Response (Partial Response [PR] or CR [Including Cytopenic CR] as Determined by Standard CLL Response Criteria|Duration of Objective Response as Determined by Standard CLL Response Criteria|Overall Survival|Progression-Free Survival as Determined by Standard CLL Response Criteria|Change from Baseline in Number of B-Cells|Change from Baseline in Number of T-Cells|Change from Baseline in Number of Natural Killer (NK) Cells|Change from Baseline in Serum Immunoglobulin Level","Genentech, Inc.|AbbVie (prior sponsor, Abbott)","All","18 Years and older   (Adult, Older Adult)","Phase 1","82","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GP28331|2012-002038-34","November 29, 2012","May 21, 2018","August 23, 2019","September 14, 2012",,"January 10, 2020","UCSD Moores Cancer Center, La Jolla, California, United States|Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Oncology Associates of Oregon, Springfield, Oregon, United States|SCRI-Tennessee Oncology, Nashville, Tennessee, United States|The Methodist Hospital Research Institute; Academic Office of Clinical Trials, Houston, Texas, United States|St James University Hospital, Leeds, United Kingdom|Leicester Royal Infirmary NHS Trust, Leicester, United Kingdom|Barts and The London School of Medicine and Dentistry; Queen Mary, University of London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01685892"
755,"NCT01671904","A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: Bendamustine|Drug: Obinutuzumab|Drug: Rituximab|Drug: Venetoclax","Number of Participants With Dose Limiting Toxicities (DLTs)|Plasma Concentrations of Venetoclax|Serum Concentrations of Rituximab|Serum Concentrations of Obinutuzumab|Plasma Concentrations of Bendamustine|Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 Guidelines|Duration of Response According to IWCLL 2008 Guidelines|Percentage of Participants with CR|Progression-Free Survival (PFS) According to IWCLL 2008 Guidelines|Overall Survival (OS)|Number of Participants With Adverse Events","Genentech, Inc.|AbbVie (prior sponsor, Abbott)","All","18 Years and older   (Adult, Older Adult)","Phase 1","84","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO28440|2012-002351-42","January 13, 2014","August 17, 2018","December 31, 2019","August 24, 2012",,"December 4, 2019","University of California San Diego Medical Center, La Jolla, California, United States|Ingalls Hospital; Cancer Clinical Trials, Harvey, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|North Star Lodge, Yakima, Washington, United States|Hopital Claude Huriez, Lille, France|Hopital Saint Eloi, Montpellier, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Centre Henri Becquerel, Rouen, France|Apotheke des Universitätsklinikums Freiburg, Freiburg, Germany|Universitatsklinik Koln, Köln, Germany|Klinikum Schwabing, München, Germany|Universtitätsklinikum Ulm; Klinik für Innere Medizin III, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT01671904"
756,"NCT01423539","A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)",,"Withdrawn","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: bendamustine|Drug: navitoclax|Drug: rituximab","Progression-free survival (time from randomization to progression, relapse or death of any cause)|Clinical response rates (complete response/partial response/stable disease)|Duration of response|Overall survival|Safety: Incidence of adverse events","Genentech, Inc.|AbbVie (prior sponsor, Abbott)","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GP27814","October 2011","February 2014","February 2014","August 26, 2011",,"November 2, 2016","Fountain Valley, California, United States|Hudson, Florida, United States|Lawrenceville, Georgia, United States|Centralia, Illinois, United States|Harvey, Illinois, United States|Terre Haute, Indiana, United States|Hazard, Kentucky, United States|Paducah, Kentucky, United States|Rockville, Maryland, United States|Jefferson City, Missouri, United States|Great Falls, Montana, United States|Newark, Ohio, United States|Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT01423539"
757,"NCT01087151","A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)",,"Completed","No Results Available","Chronic Lymphocytic Leukemia","Drug: ABT-263|Drug: rituximab","Progression-free survival|Overall response rate (ORR)|Duration of response|Complete response (CR) rate|Progression-free survival as assessed by a blinded, independent review|ORR as assessed by a blinded, independent review|Duration of response as assessed by a blinded, independent review|CR rate as assessed by a blinded, independent review|Overall survival (OS)","Genentech, Inc.|AbbVie (prior sponsor, Abbott)","All","18 Years and older   (Adult, Older Adult)","Phase 2","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABT4710n|2009-012152-24|GP00763","August 2010","June 2012","June 2012","March 16, 2010",,"November 2, 2016","Alhambra, California, United States|Antioch, California, United States|Berkeley, California, United States|Burbank, California, United States|Duarte, California, United States|Dublin, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Northridge, California, United States|Pleasant Hill, California, United States|San Leandro, California, United States|San Luis Obispo, California, United States|Santa Monica, California, United States|Fort Collins, Colorado, United States|Norwalk, Connecticut, United States|Bay Pines, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Decatur, Illinois, United States|Harvey, Illinois, United States|Tinley Park, Illinois, United States|Shreverport, Louisiana, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Bethesda, Maryland, United States|Randallstown, Maryland, United States|Lansing, Michigan, United States|Lansing, Michigan, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Las Vegas, Nevada, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Cherry Hill, New Jersey, United States|Farmington, New Mexico, United States|Oneida, New York, United States|Oswego, New York, United States|Syracuse, New York, United States|Middletown, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Corpus Christi, Texas, United States|Lubbock, Texas, United States|Lubbock, Texas, United States|Everett, Washington, United States|Randwick, New South Wales, Australia|Greenslopes, Queensland, Australia|Adelaide, South Australia, Australia|Kurralta Park, South Australia, Australia|Coburg, VIC, Victoria, Australia|Fitzroy, Victoria, Australia|Frankston, Victoria, Australia|Parkville, Victoria, Australia|Fremantle, Western Australia, Australia|Cachoeiro de Itapemirim, ES, Brazil|Belo Horizonte, MG, Brazil|Belo Horizonte, MG, Brazil|Rio de Janeiro, RJ, Brazil|Caxias do Sul, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Santo Andre, SP, Brazil|São Paulo, SP, Brazil|Brno, Czech Republic|Hradec Kralove, Czech Republic|Prague 2, Czech Republic|Lille, France|Pierre Benite, France|Afula, Israel|Petah Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Modena, Emilia-Romagna, Italy|Genova, Liguria, Italy|Cremona, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Rozzano, Lombardia, Italy|Torino, Piemonte, Italy|Chorzow, Poland|Gdansk, Poland|Warszawa, Poland|San Juan, Puerto Rico|Kazan, Russian Federation|Moscow, Russian Federation|Petrozavodsk, Russian Federation|Ryazan, Russian Federation|St. Petersburg, Russian Federation|Cherkassy, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankivsk, Ukraine|Khmelnitskyy, Ukraine|Kyiv, Ukraine|Lviv, Ukraine|Poltava, Ukraine|Zhytomir, Ukraine|Leicester, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01087151"
758,"NCT04042740","Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection","PURGE-C","Recruiting","No Results Available","Hepatitis C Infection|HIV Infection","Drug: Glecaprevir/Pibrentasvir (G/P)|Drug: Ribavirin (RBV)","Proportion of participants with sustained virologic response at 12 weeks post-treatment (SVR12)|Proportion of participants who experienced adverse events (AEs)|Number of participants who complete 4 weeks of treatment without discontinuation due to AEs|Proportion of participants with HCV RNA less than LLOQ (TD or TND)|Number of participants with HCV virologic failure","AIDS Clinical Trials Group|AbbVie|National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5380|38553","November 15, 2019","March 2, 2023","March 2, 2023","August 2, 2019",,"November 29, 2019","Ucsd, Avrc Crs (701), San Diego, California, United States|Massachusetts General Hospital ACTG CRS (101), Boston, Massachusetts, United States|Unc Aids Crs (3201), Chapel Hill, North Carolina, United States|The Miriam Hosp. ACTG CRS (2951), Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT04042740"
759,"NCT04010968","Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia","ERADIC","Recruiting","No Results Available","Intermediate Risk Chronic Lymphocytic Leukemia|Fit Patients|Risk-Adapted and MRD-Driven Strategy","Drug: venetoclax and ibrutinib (I+VEN)|Drug: FCR","Minimal residual disease (MRD) in bone marrow (BM) < 0.01% at month 27|Progression-free survival (PFS),|Complete response (CR) rate at month 9|Number of patients with bone marrow MRD < 0.01% at month 9|Complete response (CR) rate at month 27|Overall survival (OS)","French Innovative Leukemia Organisation|AbbVie|Janssen-Cilag Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FILOCLL08 - ERADIC","September 27, 2019","December 2023","June 2026","July 8, 2019",,"December 20, 2019","CH Annecy Genevois - Hématologie A3, Annecy, France|Ch Cote Basque, Bayonne, France|CH BLOIS, Blois, France|Hôpital Avicenne - Centre de Recherche Clinique, Bobigny, France|Institut Bergonie, Bordeaux, France|CHU Caen - IHBN - Hématologie Clinique, Caen, France|Hôpital Privé Sévigné, Cesson-Sévigné, France|CHU Estaing - Hématologie Clinique Adulte, Clermont-Ferrand, France|Centre Hospitalier Sud Francilien, Corbeil-essonnes, France|Chu Creteil, Créteil, France|GRENOBLE GHM - Institut Daniel Hollard, Grenoble, France|CHU Grenoble - Hématologie, Grenoble, France|CHD Vendée, La Roche-sur-Yon, France|Centre Hospitalier du Mans, Le Mans, France|Hôpital Saint Vincent de Paul, Lille, France|Centre Léon Bérard - Hématologie, Lyon, France|Institut Paoli Calmette, Marseille, France|Centre Hospitalier Regional Metz Thionville, Metz, France|Hôpital Saint Eloi, Montpellier, France|CHU Hôtel Dieu - Hématologie Clinique, Nantes, France|CHR ORLEANS - Hématologie, Orléans, France|Hôpital Pitié Salpétrière - Hématologie, Paris, France|Bordeaux Pessac, Pessac, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|Hôpital de la Milétrie - Hématologie et Thérapie Cellulaire, Poitiers, France|Chu Reims, Reims, France|CHU Pontchaillou - Hématologie Clinique BMT-HC, Rennes, France|Centre Henri Becquerel - Service Hématologie Clinique, Rouen, France|Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France|Hôpital Hautepierre - Hématologie, Strasbourg, France|IUCT ONCOPOLE - Hématologie, Toulouse, France|Hôpital Bretonneau - Hématologie et Thérapie Cellulaire, Tours, France|CHU Nancy Brabois, Vandœuvre-lès-Nancy, France|Hôpital André Mignot, Versailles, France",,"https://ClinicalTrials.gov/show/NCT04010968"
760,"NCT03709758","Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML",,"Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Venetoclax|Drug: Daunorubicin|Drug: Cytarabine","Maximum Tolerated Dose (Induction)|Maximum Tolerated Dose (Consolidation)|Complete Response Rate|Partial Response Rate|Minimal Residual Disease","Dana-Farber Cancer Institute|AbbVie|Genentech, Inc.","All","18 Years to 60 Years   (Adult)","Phase 1","64","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-351","October 15, 2018","June 1, 2023","June 1, 2025","October 17, 2018",,"June 24, 2019","Dana Farber Cancer Institute, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT03709758"
761,"NCT03379428","Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer",,"Recruiting","No Results Available","Breast Neoplasms|Malignant Neoplasm of Breast","Drug: Trastuzumab|Drug: Ibrutinib 560 mg|Drug: Ibrutinib 840 mg|Drug: Ibrutinib 420 mg","Phase I: Maximum Tolerated Dose|Phase II: Clinical Benefit Rate|Objective Response Rate|Median Overall Survival|Median Progression-free Survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of ibrutinib plus trastuzumab.|Pharmacokinetic Analysis for Ibrutinib (Phase I only)- Cmax|Pharmacokinetic Analysis for Ibrutinib (Phase I only)- Area under Curve","US Oncology Research|AbbVie|Pharmacyclics LLC.","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14059|14-05914-059","November 29, 2017","December 2019","December 2021","December 20, 2017",,"August 30, 2019","10 sites incl TX, WA, VA, and NV, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03379428"
762,"NCT03064815","The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies","SpACE","Completed","No Results Available","Spondyloarthropathy|Crohn Disease","Device: Videocapsule endoscopy|Procedure: colonoscopy|Diagnostic Test: PROMETHEUS® IBD sgi Diagnostic™|Diagnostic Test: Fecal calprotectin","Number of subjects with ankolysing spondylitis, with or without gastrointestinal symptoms, diagnosed with small bowel Crohn's disease via videocapsule endoscopy.|Number of subjects with ankolysing spondylitis diagnosed with small bowel Crohn's disease compared to same subjects serological biomarkers and colonoscopy results.|Number of subjects with ankolysing spondylitis diagnosed with small bowel Crohn's disease whose treatment changed as a result of the diagnosis of small bowel Crohn's disease.|Determine whether genetic polymorphisms or human leukocyte antigen haplotypes are associated with concurrent spondylarthropathies and inflammatory bowel disease.","McGill University Health Centre/Research Institute of the McGill University Health Centre|AbbVie|Prometheus Laboratories","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","67","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GEN-08-053","June 2009","March 2016","March 2016","February 27, 2017",,"August 19, 2019","Montreal General Hospital, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03064815"
763,"NCT03044795","Response to PARP Inhibitor Predicted by the RAD51 Assay","REPAIR","Withdrawn","No Results Available","Cancer","Drug: Veliparib","Part A: determine the value of the RAD51 assay in predicting response to veliparib|Part B: determine response to veliparib at eight weeks in novel patient groups with HR deficient tumors a","University Medical Center Groningen|AbbVie|Dutch Cancer Society","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201600942","November 2019","November 2020","November 2020","February 7, 2017",,"July 5, 2019",,,"https://ClinicalTrials.gov/show/NCT03044795"
764,"NCT04197141","Hypofractionated Whole-Pelvis Radiotherapy (WPRT) vs Conventionally-Fractionated WPRT in Prostate Cancer","HOPE","Not yet recruiting","No Results Available","Prostate Cancer","Radiation: Conventionally-fractionated WPRT|Radiation: Hypofractionated WPRT","Quality of Life (QOL) - late bowel function as measured by the EPIC- Bowel Summary|Quality of Life - acute urinary and sexual QOL as measured by the EPIC-26|Quality of Life - acute bowel toxicity as measured by the EPIC-Bowel Summary|Quality of Life - late bowel bother as measured by the EPIC- Bowel Summary|Quality of Life - late urinary and sexual QOL as measured by the EPIC-26|International Prostate Symptom Score (IPSS)|Toxicity - urinary, bowel, and sexual as measured by CTCAE version 4.0|Prostatic Specific Antigen (PSA) curve|Prostatic Specific Antigen (PSA) Nadir|Cost Effectiveness of Hypofractionated WPRT|Overall Survival|Biochemical Failure-Free Survival|Freedom from Local Failure|Freedom from Regional Failure|Androgen Deprivation Therapy Free Survival|Metastasis Free Survival|Prostate Cancer Free Survival","Lawson Health Research Institute|Canadian Association of Radiation Oncology|AbbVie","Male","18 Years and older   (Adult, Older Adult)","Phase 2","58","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOPE Trial","January 2020","March 2023","March 2027","December 12, 2019",,"December 12, 2019",,,"https://ClinicalTrials.gov/show/NCT04197141"
765,"NCT04161248","Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma",,"Not yet recruiting","No Results Available","Lymphoma, B-Cell","Drug: Venetoclax|Drug: RiTUXimab Injection|Drug: Rituximab SC|Drug: Gemcitabine|Drug: Dexamethasone|Drug: Cisplatin","Establish recommended Phase II dose of new combination therapy|Overall response rate using RECIL response criteria|Overall response rate using the Lugano response criteria|Severity of adverse events using CTCAE|Stem cell collection rate|Transplantation rate|Event-free survival|Overall Survival","Canadian Cancer Trials Group|Roche Pharma AG|AbbVie","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Early Phase 1","18","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LY18|ML40080|A17-190","December 2019","December 2023","July 2024","November 13, 2019",,"November 13, 2019",,,"https://ClinicalTrials.gov/show/NCT04161248"
766,"NCT04092179","Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers",,"Not yet recruiting","No Results Available","Acute Myeloid Leukemia|Relapsed Cancer|Refractory Cancer|IDH2 Gene Mutation","Drug: Enasidenib|Drug: Venetoclax","Overall response rate (ORR)|Dose Limiting Toxicity|Maximum tolerated dose or Recommended Phase 2 Dose|Duration of Response|Overall Survival|Event Free Survival","University Health Network, Toronto|Celgene|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","48","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-5939|ENAVEN-AML","December 2019","December 2022","June 2023","September 17, 2019",,"September 17, 2019","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04092179"
767,"NCT04070768","Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113",,"Recruiting","No Results Available","Acute Myeloid Leukemia","Drug: Gemtuzumab Ozogamicin|Drug: Venetoclax","Maximum Tolerated Dose (MTD) of Venetoclax when administered with GO|Overall response rate|Rate of Anti-leukemic activity|Relapse-free survival|Event-free Survival|overall survival","Big Ten Cancer Research Consortium|Pfizer|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 1","24","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BTCRC-AML17-113","September 6, 2019","October 2020","October 2021","August 28, 2019",,"November 13, 2019","Univeristy of Illinois, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04070768"
768,"NCT02255435","RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe",,"Active, not recruiting","No Results Available","Friedreich Ataxia","Drug: Omaveloxolone Capsules, 2.5 mg|Drug: Omaveloxolone Capsules, 5 mg|Drug: Omaveloxolone Capsules, 10 mg|Drug: Placebo|Drug: Omaveloxolone Capsules, 20 mg|Drug: Omaveloxolone Capsules, 40 mg|Drug: Omaveloxolone Capsules, 80 mg|Drug: Omaveloxolone Capsules, 160 mg|Drug: Omaveloxolone Capsules, 300 mg|Drug: Omaveloxolone Capsules, 150 mg","Measure the change in the modified Friedreich's ataxia rating scale (FARS)|Measure the change of peak workload (in watts/kg) during exercise testing","Reata Pharmaceuticals, Inc.|AbbVie|Friedreich's Ataxia Research Alliance","All","16 Years to 40 Years   (Child, Adult)","Phase 2","172","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RTA 408-C-1402","January 2015","October 3, 2019","December 2022","October 2, 2014",,"December 20, 2019","UCLA, Los Angeles, California, United States|University of Florida - Neurology, Gainesville, Florida, United States|USF Ataxia Research Center, Tampa, Florida, United States|Emory University Hospital - Neurology, Atlanta, Georgia, United States|University of Iowa Stead Family Children's Hospital, Iowa City, Iowa, United States|Ohio State University - Neurology, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Murdoch Childrens Research Institute, Parkville, Victoria, Australia|Medical University Innsbruck, Innsbruck, Austria|Neurological Institute Carlo Besta, Milan, Italy|University College of London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02255435"
769,"NCT02242942","A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia",,"Active, not recruiting","Has Results","Lymphocytic Leukemia, Chronic","Drug: Chlorambucil|Drug: Venetoclax|Drug: Obinutuzumab","Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria|Progression Free Survival (PFS) Based on Institutional Review Committee (IRC)-Assessments According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Criteria|Percentage of Participants With an Overall Response (OR) at Completion of Treatment, as Determined by the Investigator According to IWCLL Criteria|Percentage of Participants With a Complete Response Rate (CRR) at the Completion of Treatment Assessment as Determined by the Investigator According to IWCLL Criteria|Percentage of Participants With Minimal Residual Disease (MRD) Negativity in Peripheral Blood as Measured by Allele-Specific Oligonucleotide Polymerase Chain Reaction (ASO-PCR) at Completion of Treatment|Percentage of Participants With MRD Negativity in Bone Marrow as Measured by ASO-PCR at Completion of Treatment|Overall Survival (OS)|Percentage of Participants With MRD Negativity in Peripheral Blood as Measured by ASO-PCR at Completion of Combination Treatment Assessment|Percentage of Participants With MRD Negativity in Bone Marrow as Measured by ASO-PCR at Completion of Combination Treatment Assessment|Percentage of Participants With OR at Completion of Combination Treatment Response Assessment|Duration of Objective Response (DOR)|Percentage of Participants By Best Response Achieved (CR, CRi, PR, Stable Disease (SD), or PD)|Event-Free Survival|Time to Next Anti-Leukemic Treatment|Number of Participants With Adverse Events (AEs)|Percentage of Participants With CD19 + /CD5+ B Cells or CD14+ Monocytes|Percentage of Participants With Human-Anti-Human Antibodies|Percentage of Participants Recorded as Premature Study Withdrawals|Plasma Concentrations of Venetoclax|Serum Concentrations of Obinutuzumab|Change From Baseline in M.D. Anderson Symptom Inventory-CLL (MDASI-CLL) Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQC30)|Change From Baseline in EuroQol 5 Dimension Questionnaire (EQ-5D-3L)","Hoffmann-La Roche|AbbVie|German CLL Study Group","All","18 Years and older   (Adult, Older Adult)","Phase 3","445","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO25323|2014-001810-24|CLL14","December 31, 2014","August 17, 2018","September 1, 2020","September 17, 2014","October 1, 2019","October 1, 2019","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|City of Hope, Duarte, California, United States|San Diego Pacific Hematology Assocates, Encinitas, California, United States|cCare, Encinitas, California, United States|UC San Diego Health System, La Jolla, California, United States|Southwest Cancer Care, Poway, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Stony Brook Medical Center, New York, New York, United States|Joe Arrington Cancer Center, Lubbock, Texas, United States|CEMIC Saavedra, Buenos Aires, Argentina|Fundaleu; Haematology, Buenos Aires, Argentina|Hospital Italiano, Buenos Aires, Argentina|Royal Prince Alftred Hospital, Camperdown, NSW, New South Wales, Australia|The Northern Hospital, Epping, New South Wales, Australia|Gosford Hospital; Pathology, Gosford, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Tweed Hospital, Tweed Heads, New South Wales, Australia|Liz plummer Cancer Centre, Cairns, QLD, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia|Ashford Cancer Centre Research; Internal Medicine/Medical Oncology, Ashford, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre; Haematology, Melbourne, Victoria, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, Innsbruck, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie, Wien, Austria|Hanusch-Krankenhaus; Iii. Medizinische Abt., Wien, Austria|Wilhelminenspital; I. Medizinische Abt., Wien, Austria|Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, Brazil|Hospital das Clínicas de Porto Alegre, Porto Alegre, RS, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Hospital das Clínicas Faculdades Médicas de Ribeirão Preto, Ribeirao Preto, SP, Brazil|Instituto de Ensino e Pesquisa Sao Lucas - IEP, Sao Paulo, SP, Brazil|Hospital Sírio-Libanês, Sao Paulo, SP, Brazil|Hospital das Clinicas - FMUSP; Hematologia, Sao Paulo, SP, Brazil|Hospital Santa Marcelina;Oncologia, Sao Paulo, SP, Brazil|UMHAT Dr Georgi Stranski; Hematology, Pleven, Bulgaria|UMHAT "" Sveti Georgi"" Plovdiv - Clinic of Oncology and Hematology, Plovdiv, Bulgaria|University Hospital Sv.Georgi Clnic of Hematology; Hematology, Plovdiv, Bulgaria|Military Medical Academy; Hematology And Oncology, Sofia, Bulgaria|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology, Sofia, Bulgaria|MHAT Hristo Botev; First Internal Department, Vratsa, Bulgaria|Tom Baker Cancer Centre; Dept of Medicine, Calgary, Alberta, Canada|Queen Elizabeth II Health Sciences Centre; Oncology, Halifax, Nova Scotia, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Clinical Hospital Centre; Sestre Milosrdnice; Internal Medicine-Hematology, Vinogradska Cesta 29, Croatia|University Hospital Center Zagreb; Haematology Department, Zagreb, Croatia|University Hospital Merkur Clinic for Internal Medicine/ Hematology, Zagreb, Croatia|Aalborg Universitetshospital, Medicinerhuset, Hæmatologisk afdeling, Aalborg, Denmark|Herlev Hospital, Herlev, Denmark|Rigshospitalet, København Ø, Denmark|Odense Universitetshospital; Hæmatologisk Afdeling, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Sygehus Lillebælt, Vejle, Vejle, Denmark|North Estonia medical Centre; Hematology, Tallinn, Estonia|Tartu Uni Hospital; Hematology - Oncology Clinic, Tartu, Estonia|CHU Angers, Angers, France|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France|CH Fleyriat, Bourg en Bresse, France|Institut d'Hématologie de Basse Normandie, Caen, France|Chu Estaing; Hematologie Clinique Adultes, Clermont Ferrand, France|Hopital Henri Mondor, Creteil, France|CHU de Dijon - Hopital le Bocage, Dijon, France|CHU de Grenoble, Grenoble, France|Centre Jean Bernard, Le Mans, France|Clinique de la Sauvegarde, Lyon, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Hopital de la Conception, Marseille, France|Institut J Paolii Calmettes; Onco Hematologie 1, Marseille, France|Hôpital Saint Eloi; Service d'Hématologie et Oncologie Clinique - Recherche Clinique, Montpellier, France|Hopital Hotel Dieu Et Hme;Hopital De Jour, Nantes, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, France|Hopital Pontchaillou; Hematologie Clinique, Rennes, France|Centre Henri Becquerel; Hematologie, Rouen, France|CH de Toulon Hôpital Sainte Musse, Toulon, France|Institut Gustave Roussy - Hematologie, Villejuif, France|Uniklinik RWTH Aachen; Klinik IV; Klinik Hämatologie, Onkologie, Hämostaseologie und Stammz, Aachen, Germany|Gesundheitszentrum St. Marien GmbH; Med. II, Hämatologie/Onkologie, Amberg, Germany|Hämatologische/onkologische Gem.-Praxis Dres. Brudler/Heinrich/Bangerter, Augsburg, Augsburg, Germany|Klinikum Augsburg, Augsburg, Germany|Sozialstiftung Bamberg, Bamberg, Germany|Charite - Universitätsmedizin Berlin, Berlin, Germany|Charite - Campus Virchow-Klinikum, Berlin, Germany|ZAHO Bonn, Bonn, Germany|BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik und Poliklinik I, Dresden, Germany|St. Antonius-Hospital Eschweiler; Klinik für Hämatologie/Onkologie, Eschweiler, Germany|Universitätsklinikum Essen; Klinik für Hämatologie, Essen, Germany|Kliniken Essen Süd, Zentrum für Innere Medizin; Klinik f. Hämatologie, Essen, Germany|Klinik Esslingen; Klinik für Allgemeine Innere Medizin, Onkologie/Haematologie, Esslingen, Germany|Klinikum Frankfurt/Oder, Frankfurt/Oder, Germany|Onkologische Gemeinschaftspraxis am Bethanien Krankenhaus; Hämatologie und Onkologie, Frankfurt, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|Uniklinikum Freiburg, Freiburg, Germany|Hämatologische und Internistische Praxis Dr. Tessen, Goslar, Goslar, Germany|Universitätsmedizin Greifswald; Zentrum für Innere Medizin, Greifswald, Germany|Uni Göttingen, Georg-August-Universität; Klinik für Hämatologie und Medizinische Onkologie, Göttingen, Germany|Onkologische Schwerpunktpraxis Lerchenfeld, Hamburg, Hamburg, Germany|Evang. Krankenhaus Hamm, Hamm, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Stiftung Kathol. Krankenhaus Marienhospital Herne Klinik Mitte, Herne, Germany|Universitaetsklinikum des Saarlandes; medizinische Klinik und Poliklinik; Innere Medizin I, Homburg/Saar, Germany|Klinikum Idar-Oberstein, Medizinische Klinik I, Idar-Oberstein, Germany|Universitätsklinikum Jena; Klinik für Innere Medizin II, Jena, Germany|Westpfalz-Klinikum GmbH; Innere 1, Kaiserslautern, Germany|Gemeinschaftspraxis Dr. med Siegfried Siehl Dr. med Ulrike Söling, Kassel, Germany|UKSH Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Kiel, Germany|Praxisklinik für Hämatologie und Onkologie Koblenz, Koblenz, Germany|Uniklinik Köln, Köln, Germany|Tagesklinik Landshut; Hämatologie/Onkologie, Landshut, Germany|Caritas-Krankenhaus Lebach, Lebach, Germany|Studienzentrum UnterEms; Onkologische Schwerpunktpraxis Leer; Dr. med. Lothar Müller, Leer, Germany|Klinikum Leverkusen, Leverkusen, Germany|Evangelisches Krankenhaus Paul Gerhard Stift ; Abt. Allgem.-u. Gefäßchirurgie, Lutherstadt Wittenberg, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Uni. der Johannes Gutenberg-Universitaet Mainz; III. Medizinische Klinik und Poliklinik, Mainz, Germany|Klinikum rechts der Isar der Technischen Universität München, Munchen, Germany|Klinikum Schwäbisch Gmünd, Mutlangen, Germany|Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus; Medizinische Klinik I, Mönchengladbach, Germany|Klinikum Schwabing; Hämatologie, Onkologie, Immunologie, Palliativmedizin, München, Germany|Klinikum der Universitat Munchen, Campus Grobhadern;; Medizinische Klinik und Poliklinik III, München, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Gemeinschaftspraxis Dr. med. Holger Klaproth / Dr. med. Anca Astrid Cura, Neunkirchen/Saar, Germany|Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany|Praxis für Hämatologie und Onkologie, Porta Westfalica, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, Germany|Schwerpunktpraxis für Hämatologie und Onkologie Siegburg, Siegburg, Germany|Marienhospital, Stuttgart, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Universitätsklinikum Tübingen, Tuebingen, Germany|Universtitätsklinikum Ulm; Klinik für Innere Medizin III, Ulm, Germany|Medizinisches Versorgungszentrum Nuklearmedizin-Strahlentherapie-Onkologie, Weiden, Germany|Asklepios Klinik Weissenfels, Weißenfels, Germany|Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany|Arcispedale S. Anna; Sezione Di Ematologia, Ferrara, Emilia-Romagna, Italy|Ospedali Riuniti Papardo-Piemonte; Struttura Complessa Di Ematologia, Messina, Lazio, Italy|Uni Cattolica; Divisione Di Ematologia, Roma, Lazio, Italy|AOU Città della Salute e della Scienza di Torino - Presidio Le Molinette, Torino, Lazio, Italy|A.O. Universitaria S. Martino Di Genova; Ematologia 1, Genova, Liguria, Italy|Ospedale San Raffaele, Milano, Lombardia, Italy|Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello, Palermo, Sicilia, Italy|Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy|Ospedale dell' Angelo; U.O. Ematologia, Venezia Mestre, Veneto, Italy|Hospital General de Culiacan, Culiacan, Mexico|Hospital Universitario Dr. Jose E. Gonzalez; Haematology, Monterrey, Mexico|Auckland city hospital; Auckland Regional Cancer Centre and Blood Service, Auckland, New Zealand|Canterbury Health Laboratories; Haematology, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|Midcentral District Health Board, Palmerston North, New Zealand|Wellington Hospital, Wellington, New Zealand|Uniwersytecki Szpital Kliniczny w Białymstoku, Klinika Hematologii z Pododdziałem Chorob Naczyn, Bialystok, Poland|Samodzielny Public Zaklad, Chorzów, Poland|Wojewódzki Szpital Specjalistyczny im.MikołajaKopernika;KlinikaHematologiiUniwersytetuMedycznego, Lodz, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka; Oddział Chorób Wewnetrznych/Hematologiczny, Slupsk, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu; Klinika Hematologii, Wroclaw, Poland|Fundeni Clinical Inst. ; Hematology Dept, Bucharest, Romania|Institutul Regional de Oncologie Iasi; Clinica de Hematologie, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Targu-Mures; compartiment Hematologie, Targu-mures, Romania|Republican Clinical Oncologic Dispensary of Republic Of Tatarstan, Kazan, Russian Federation|Moscow State Budgetary Healthcare Institution, Moscow, Russian Federation|Regional Clinical Hospital N.A. Semashko; Hematology, Nizhny Novgorod, Russian Federation|Penza Regional Oncology Dispensary, Penza, Russian Federation|Clinical MSCh No1, Perm, Russian Federation|Rostov State Medical Uni ; Hematology, Rostov-na-donu, Russian Federation|SBEI of HPE ""Bashkir State Medical University"" of MoH RF, Ufa, Russian Federation|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario de Canarias;servicio de Hematologia, La Laguna, Tenerife, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitari Vall d'Hebron; Servicio de Hematologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Universitario de la Princesa; Servicio de Hematologia, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Universitario Puerta de Hierro; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Hematología, Toledo, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Hematologia, Valencia, Spain|Kantonsspital Aarau; Zentrum Für Onkologie, Hämatologie & Transfusionsmedizin, Aarau, Switzerland|Inselspital Bern; Hämatologie und Hämatologisches Zentrallabor, Bern, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|Luzerner Kantonsspital, Hämatologie, Luzern, Switzerland|Universitätsspital Zürich; Klinik für Hämatologie, Zürich, Switzerland|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Boston Pilgrim Hospital, Boston,Lincolnshire, United Kingdom|Western General Hospital; Department of Haematology, Edinburgh, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|University Hospital Southampton NHS Foundation Trust, Southhampton, United Kingdom|Torbay Hospital, Torquay, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02242942/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/42/NCT02242942/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02242942"
770,"NCT03955783","Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma|Acute Myeloid Leukemia|Non-Hodgkin's Lymphoma","Drug: Venetoclax|Drug: Selinexor","Maximum tolerated dose (escalation)|Overall response rate (expansion)|Progression free survival|Overall survival","Michael Byrne|Karyopharm Therapeutics Inc|AbbVie|Vanderbilt-Ingram Cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","78","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VICC HEM 1755|NCI-2019-02953","June 21, 2019","November 2020","November 2022","May 20, 2019",,"July 1, 2019","Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT03955783"
771,"NCT03751436","Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer",,"Recruiting","No Results Available","Castration Levels of Testosterone|Castration-Resistant Prostate Carcinoma|Metastatic Prostate Carcinoma|Metastatic Prostate Carcinoma in the Soft Tissue|Prostate Carcinoma Metastatic in the Bone|PSA Progression|Stage IV Prostate Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8","Drug: Enzalutamide|Drug: Venetoclax","Maximum tolerated dose (MTD) (Phase Ib)|Recommended phase 2 dose (RP2D) (Phase Ib)|Progression free survival (Phase II)|PSA50 (Phase II)|Circulating tumor cell (CTC) conversion in patients who enter the trial with unfavorable CTCs (five or more cells per 7.5 mL of blood) (Phase II)|Radiographic (r)PFS (Phase II)|Proportion of patients who remain radiographic progression free defined per PCWG3 (Phase II)|Overall response rate (ORR) (Phase II)|Duration of response (DOR) (Phase II)|Time to first skeletal-related event (SRE) (Phase II)|Time to clinical progression (Phase II)|Time to initiation of new systemic treatment for prostate cancer (Phase II)|Overall survival (Phase II)","Roswell Park Cancer Institute|National Cancer Institute (NCI)|AbbVie","Male","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","39","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I 63418|NCI-2018-02448|P30CA016056","June 7, 2019","June 7, 2022","June 7, 2023","November 23, 2018",,"December 3, 2019","Roswell Park Cancer Institute, Buffalo, New York, United States",,"https://ClinicalTrials.gov/show/NCT03751436"
772,"NCT02056184","Targeted Ultrasound in Rheumatoid Arthritis","TURA","Completed","No Results Available","Rheumatoid Arthritis|Targeted Ultrasound","Drug: Adalimumab","Proportion of patients in whom there is a decrease in Power Doppler (PD) at week 48 after randomisation.|Total PD score at week 48","University of Leeds|AbbVie|Theorem","All","18 Years and older   (Adult, Older Adult)","Phase 4","183","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","HG/1096|RR13/10787|2013-002777-22","December 2013","December 2017","July 2019","February 5, 2014",,"October 31, 2019","Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02056184"
773,"NCT01939977","Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.","PARIDOINAL","Completed","Has Results","Secondary Hyperparathyroidism Due to Renal Causes","Drug: Paricalcitol|Drug: Calcifediol","Percentage of Patients With iPTH Serum Concentration >110 pg/mL.|Change on iPTH Serum Concentration. Intention to Treat Analysis.|Percentage of Patients That Reach at Least a 30% iPTH Reduction at the End of the Study.|Percentage of Patients With iPTH Levels Between 70-110 pg/mL at the End of the Study. ITT.|Percentage of Patient With Presence of Calcifications on Protocol Renal Biopsies at 6 Months After Treatment in Each Treatment Group.|Patients That Suffered the Following Events: Acute Rejection, Acute Rejection Confirmed With Biopsy and/or Subclinic Rejection and/or Chronic Damage.|Change on Concentration of Bone Markers (Osteocalcin) at 6 Months After Transplantation on Each Treatment Group.|Percentage of Patients With Acute Rejection at 6 Months After Transplantation and Treatment on Each Treatment Group.|Percentage of Patients With Microalbuminuria on Months 1, 3 and 6 Post Transplantation.|Percentage of Patients on Each Stage of Renal Function on Months 1, 3 and 6 Post Transplantation.|Evolution of Speed of Pulse Wave From Month 1 to Month 6 Post Transplantation.|Percentage of Patients With Hypercalcemia on Each Treatment Group at 6 Months Post Transplantation.|Evolution of Anti-HLA Antibodies (PRA) From Basal to Month 6 Post-transplantation.|Frequency of Adverse Events or Serious Adverse Events That Occurs During the Study on Each Treatment Group.|Change on Concentration of Bone Markers (Alkaline Phosphatase) at 6 Months After Transplantation on Each Treatment Group.|Change on Concentration of Bone Markers (FGF-23) at 6 Months After Transplantation on Each Treatment Group","Fundación Senefro|AbbVie|Effice Servicios Para la Investigacion S.L.","All","18 Years and older   (Adult, Older Adult)","Phase 4","148","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACA-SPAI-11-24|2013-001326-25","January 2014","September 2015","December 2015","September 11, 2013","November 19, 2018","November 19, 2018","Hospital Universitari Germans Trias I Pujol de Badalona, Badalona, Barcelona, Spain|Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Del Mar, Barcelona, Spain|Fundació Puigvert-Iuna, Barcelona, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Puerta Del Mar, Cádiz, Spain|Hospital Reina Sofía, Córdoba, Spain|Complexo Hospitalario Universitario A Coruna, La Coruna, Spain|Complejo Hospitalario Universitario de Canarias, Las Palmas De Gran Canaria, Spain|Hospital Ramón Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Complejo Hospitalario Regional de Málaga, Málaga, Spain|Hospital Virgen Del Rocío, Sevilla, Spain|Hospital Universitari I Politècnic La Fe, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT01939977"
774,"NCT01744327","TL1A Expression in Psoriatic Skin",,"Unknown status","No Results Available","Psoriasis",,"Expression of TL1A in psoriatic skin","Bispebjerg Hospital|AbbVie|University of Copenhagen","All","18 Years and older   (Adult, Older Adult)",,"20","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","331536","December 2012","December 2013",,"December 6, 2012",,"May 29, 2013","Department of dermatology D40 , Bispebjerg Hospital, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT01744327"
775,"NCT03220841","Stricture Definition and Treatment (STRIDENT) Drug Therapy Study","STRIDENT","Active, not recruiting","No Results Available","Crohn Disease|Inflammatory Bowel Diseases|Stricture; Bowel","Drug: Adalimumab Injection|Drug: Thiopurine|Procedure: Endoscopic balloon dilatation","Improvement in obstructive symptoms.|Improvement in symptoms|Improvement in biochemical inflammatory parameters|Improvement in imaging parameters (Intestinal ultrasound)|Improvement in imaging parameters|Surgery|Improvement in patient reported outcomes (PROs)","St Vincent's Hospital Melbourne|Australasian Gastro Intestinal Research Foundation|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","78","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","StVincentsMelbourneSTRIDENT1","October 9, 2017","September 2020","September 2020","July 18, 2017",,"December 5, 2019","St. Vincent's Hospital Melbourne, Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT03220841"
776,"NCT03092375","Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects",,"Active, not recruiting","No Results Available","Hepatitis C|HCV","Drug: Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|Drug: Ribavirin 200Mg Tablet|Drug: Sofosbuvir 400Mg Tab","Compare percentage of non-cirrhotic participants achieving SVR 12 (Sustained Virologic Response at 12 weeks post treatment) after G/P 12 wks vs. G/P given for 16 weeks in non-cirrhotic tx-experienced GT1 HCV subjects|Compare percentage of cirrhotic participants achieving SVR 12 after G/P plus RBV for 12 wks vs. G/P for 16 Wks|Difference in efficacy (SVR 12) of G/P +/- RBV for 12 weeks (Arms A + C) versus G/P for 16 weeks (Arms B + D)|Difference in percentages of subjects with on-treatment virologic failure between 4 arms|Difference in percentages of subjects with post-treatment relapse between arms","University of Florida|University of North Carolina, Chapel Hill|AbbVie","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","217","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B16-439|OCR16260","April 20, 2017","December 28, 2018","January 31, 2020","March 27, 2017",,"August 22, 2019","Stanford University, Palo Alto, California, United States|University of California, San Francisco, San Francisco, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|MedStar Health Research Institute, Washington, District of Columbia, United States|UF Hepatology Research at CTRB, Gainesville, Florida, United States|UF Health Jacksonville-Gastroenterology Emerson, Jacksonville, Florida, United States|Schiff Center for Liver Diseases/University of Miami, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Atlanta Medical Center, Atlanta, Georgia, United States|Atlanta Gastro Associates, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|The Johns Hopkins Hospital/John G. Bartlett Specialty Practice, Baltimore, Maryland, United States|Digestive Disease Associates, PA, Catonsville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Univ. of Minnesota Health Clinics and Surgery Center, Inc., Minneapolis, Minnesota, United States|Southern Therapy and Advanced Research, Jackson, Mississippi, United States|Northwell Health - Sandra Atlaas Bass Center for Liver Diseases, Manhasset, New York, United States|NYU Langone Medical Center, New York, New York, United States|Weill Cornell Medicine, Hepatology, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Bon Secours Liver Institute of Virginia, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT03092375"
777,"NCT02654132","An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)",,"Active, not recruiting","Has Results","Multiple Myeloma","Drug: Elotuzumab|Drug: Pomalidomide|Drug: Dexamethasone","Progression-free Survival (PFS)|Objective Response Rate (ORR)|Overall Survival (OS)","Bristol-Myers Squibb|Celgene|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA204-125|2014-003282-19","March 16, 2016","January 17, 2018","December 1, 2020","January 13, 2016","June 3, 2019","December 26, 2019","Winship Cancer Institute, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Beth Israel Comprehensive Cancer Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Rochester General Hospital, Rochester, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|St Francis Hospital, Greenville, South Carolina, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Northern Utah Associates, Ogden, Utah, United States|University Of Washington, Seattle, Washington, United States|Local Institution, South Brisbane, Queensland, Australia|Local Institution, London, Ontario, Canada|CISSS de l'Outaouais, Gatineau, Quebec, Canada|CIUSSS de l'Est-de-L'Ile-de-Montreal - Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|Local Institution, Nantes Cedex 1, France|Local Institution, Paris Cedex 12, France|Local Institution, Pessac, France|Local Institution, Poitiers Cedex, France|Local Institution, Saint Pierre Cedex, France|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|St. Barbara-Klinik, Hamm, Germany|Universitasklinikum Heidelberg, Heidelberg, Germany|Universitasklinikum Schleswig-Holstein, Kiel, Germany|Klinikum Der Johannes Gutenberg Universitaet Mainz, Mainz, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Laiko University Hospital, Athens, Greece|Alexandra General Hospital Of Athens, Athens, Greece|Azienda Ospedaliero Universitaria Ospedali Riuniti Di Ancona, Ancona, Italy|A. O. U. Di Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Local Institution, Roma, Italy|Universita' La Sapienza, Roma, Italy|Azienda Ospedaliera Citta' Della Salute E Della Scienza Di Torino, Torino, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Shibuya-ku, Tokyo, Japan|Local Institution, Tachikawa-shi, Tokyo, Japan|Local Institution, Kasama-shi, Japan|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Maastrict, Netherlands|Local Institution, Utrecht, Netherlands|Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych, Chorzow, Poland|Local Institution, Lublin, Poland|Oddzial Hematologii i Transplantacji Szpiku, Poznan, Poland|Local Institution, Pamplona, Navarra, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02654132/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02654132/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02654132"
778,"NCT02526641","Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C",,"Active, not recruiting","No Results Available","Hepatitis C","Procedure: Functional Hepatic Nitrogen Clearance (FHNC)|Procedure: Galactose Elimination Capacity (GEC)|Procedure: Liver vein catheterization","Change in the hepatic venous pressure gradient determined by liver vein catheterization from baseline to 12 weeks|Change in the hepatic venous pressure gradient determined by liver vein catheterization from baseline to 1 year|Changes in the levels of the macrophage specific activation marker sCD163|Changes in metabolic liver function determined by the galactose elimination capacity (GEC) test|Changes in the functional hepatic nitrogen clearance (FHNC)","University of Aarhus|Aarhus University Hospital|AbbVie","All","30 Years to 70 Years   (Adult, Older Adult)",,"16","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HCV sCD163 AbbVie","August 2015","March 2019","September 2022","August 18, 2015",,"September 26, 2019","Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark",,"https://ClinicalTrials.gov/show/NCT02526641"
779,"NCT02401503","Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)",,"Active, not recruiting","No Results Available","Chronic Lymphocytic Leucemia","Drug: Bendamustine|Drug: GA101|Drug: ABT-199","Overall response rate (ORR)|Adverse Events (AEs) and adverse events of special interest (AESI)|Rate of minimal residual disease (MRD)","German CLL Study Group|Hoffmann-La Roche|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","66","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLL2-BAG|2014-000580-40","May 6, 2015","December 13, 2016","April 2020","March 27, 2015",,"October 17, 2018","German CLL Study Group, Cologne, Germany",,"https://ClinicalTrials.gov/show/NCT02401503"
780,"NCT01893996","Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease",,"Unknown status","No Results Available","Rheumatoid Arthritis|Cardiovascular Disease","Drug: Adalimumab|Drug: Placebo","Change in Endothelial Function|Change in vascular inflammation","University of California, San Francisco|American College of Rheumatology Research and Education Foundation|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","12-09816","July 2013","July 2017","December 2017","July 9, 2013",,"May 2, 2017","University of California San Francisco/San Francisco General Hospital, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT01893996"
781,"NCT01892228","Pilot Study of Immediate HIV Treatment in Guangxi, China",,"Unknown status","No Results Available","HIV|Acquired Immunodeficiency Syndrome","Behavioral: Immediate post-screening treatment education","mortality|ART treatment coverage","National Center for AIDS/STD Control and Prevention, China CDC|Guangxi Center for Disease Control and Prevention|AbbVie","All","Child, Adult, Older Adult","Not Applicable","1000","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Treat-All HIV Pilot","July 2012","July 2013","July 2015","July 4, 2013",,"May 12, 2015","Pubei Center for Disease Control, Pubei, Guangxi, China|Zhongshan Center for Disease Control, Zhongshan, China",,"https://ClinicalTrials.gov/show/NCT01892228"
782,"NCT01282086","Evaluation of Volatile Induction and Maintenance Anesthesia (VIMA) With Sevorane in Adult Patients Requiring General Anesthesia for Surgery in Terms of Quality of Anesthesia and Its Influence on the Cardiovascular System in Common Clinical Practice","SEVOPROTECTION","Completed","Has Results","Anesthesia, General",,"Time to Loss of Consciousness of Patients Administered Anesthesia|Time to Awakening of Patients|Time to Extubation of Patients|Anesthesiologists' Satisfaction With Using Sevorane for Induction and Maintenance Anesthesia|Patients' Overall Impression of the Anesthesia With Sevorane|Systolic Blood Pressure|Diastolic Blood Pressure|Mean Arterial Pressure|Heart Rate|Presence of Deviations in Electrocardiogram Assessments During Anesthesia|Cardiac Troponin (Troponin T) (if Available)|Creatine Kinase Myocardial Isoenzyme (if Available)|Correlation Between Anesthesiologists' Clinical Experience and Hemodynamic Parameters During Anesthesia|Correlation Between Anesthesiologists' Clinical Experience and Time to Extubation and Awakening","Abbott (Ukraine)|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"1365","Industry","Observational","Time Perspective: Prospective","P12-637","April 2011","December 2011","December 2011","January 24, 2011","February 4, 2013","February 4, 2013","Site Ref # / Investigator 49151, Dnipropetrovsk, Ukraine|Site Ref # / Investigator 49142, Kharkiv, Ukraine|Site Ref # / Investigator 52986, Kyiv, Ukraine|Site Ref # / Investigator 44445, Kyiv, Ukraine|Site Ref # / Investigator 49144, Kyiv, Ukraine|Site Ref # / Investigator 49145, Kyiv, Ukraine|Site Ref # / Investigator 49146, Lviv, Ukraine|Site Ref # / Investigator 49154, Mykolaiv, Ukraine|Site Ref # / Investigator 49148, Odesa, Ukraine|Site Ref # / Investigator 49152, Zaporizhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01282086"
783,"NCT02956382","Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma",,"Recruiting","No Results Available","Refractory Follicular Lymphoma|Relapsed Follicular Lymphoma","Drug: Ibrutinib|Drug: Venetoclax","Recommended Phase 2 dose|Response Rate|Pharmacokinetics of Ibrutinib|Pharmacokinetics of Venetoclax|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03","Georgetown University|AbbVie|Pharmacyclics LLC.|Hackensack Meridian Health","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","41","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2016-0014","March 1, 2017","November 2020","November 2021","November 6, 2016",,"December 23, 2019","Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT02956382"
784,"NCT02849704","Fat Malabsorption in Chronic Pancreatitis",,"Completed","Has Results","Chronic Pancreatitis","Drug: Creon36™","Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects|Coefficient of Fat Absorption: Difference in Mean % Dietary Fat Absorption Between Groups: Subjects With CP Compared to Healthy Subjects|Bomb Calorimetry: Difference in Mean Stool Energy Loss Between Groups: Subjects With CP Compared to Healthy Subjects|Bomb Calorimetry: Difference in Mean Energy Loss Between Groups: Subjects With CP Before and After Creon36™|Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Before and After Creon36™|Coefficient of Fat Absorption: Difference in Mean % Dietary Fat Absorption Between Groups: Subjects With CP Before and After Creon36™","Children's Hospital of Philadelphia|AbbVie|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Phoenix Indian Medical Center","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 2","48","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","16-013001","October 13, 2016","November 1, 2017","November 1, 2017","July 29, 2016","May 3, 2019","May 3, 2019","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT02849704/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02849704"
785,"NCT03874052","Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",,"Recruiting","No Results Available","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia","Drug: Ruxolitinib|Drug: Venetoclax","Dose limiting toxicities (DLT) of ruxolitinib and venetoclax in combination.|Composite complete remission rate|Clinical benefit rate (CBR)|Overall Survival at 12 months|Overall incidence of treatment-related and non-treatment related toxicity|Duration of response.|Event-free survival","OHSU Knight Cancer Institute|Incyte Corporation|AbbVie|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00018238|NCI-2019-03272","August 16, 2019","December 31, 2021","December 31, 2022","March 14, 2019",,"October 30, 2019","OHSU Knight Cancer Institute, Portland, Oregon, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03874052"
786,"NCT03061188","Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes",,"Active, not recruiting","No Results Available","Advanced Solid Neoplasm|Aggressive Non-Hodgkin Lymphoma|Recurrent Solid Neoplasm|Refractory Mantle Cell Lymphoma|T-Cell Non-Hodgkin Lymphoma|Unresectable Solid Neoplasm","Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study|Drug: Veliparib","Maximum Tolerated Dose (MTD)|Incidence of Adverse Events|ORR|Clinical Benefit Rate (CBR)|Progression Free Survival (PFS)|immune-related PFS (irPFS)|Overall Survival (OS)|Proportion of patients alive and progression free","Northwestern University|Bristol-Myers Squibb|AbbVie|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NU 16MH03|STU00204250|P30CA060553|NCI-2016-02018","May 23, 2017","September 2020","January 2021","February 23, 2017",,"August 9, 2019","Northwestern University, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT03061188"
787,"NCT02786537","Study of Oral Treatments for Hepatitis C","PRIORITIZE","Active, not recruiting","No Results Available","Chronic Hepatitis C","Drug: sofosbuvir/ledipasvir|Drug: ombitasvir/paritaprevir/ritonavir (Phase 1 only)|Drug: elbasvir/grazoprevir|Drug: Dasabuvir","Percentage of Patients who Achieve Undetectable Hepatitis C Virus (HCV) RNA 12 Weeks after completing HCV treatment|Number of patients who report missing pills (doses) (Voils' Medication Adherence Survey)|Number of patients with reduction in fibrosis 3 years (Liver Biopsy/Fibroscan) post treatment baseline|Percentage of patients who are HCV RNA undetectable (cured) 3 years post-treatment|Number of patients with decrease in HCV-associated symptoms (PROMIS measures) after HCV treatment initiation|Percentage of patients who have an increase in functional status (as reported on HCV-PRO questionnaire)|Number of participants with adverse events that caused treatment discontinuation","University of Florida|Patient-Centered Outcomes Research Institute|Merck Sharp & Dohme Corp.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 4","1676","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16-1234","June 2016","June 13, 2019","February 2022","June 1, 2016",,"July 5, 2019","Liver Wellness Center, Little Rock, Arkansas, United States|Stanford University, Palo Alto, California, United States|UCSD Medical Center, San Diego, California, United States|UCSF/Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, United States|Univ of California, San Francisco, San Francisco, California, United States|Yale University Digestive Diseases, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Howard University, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|University of Florida, Jacksonville, Jacksonville, Florida, United States|University of Miami/Schiff Center for Liver Diseases, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Internal Medicine Associates of Wellstar Atlanta Medical Center, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|John Hopkins University, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|GI Associates & Endoscopy Center, Flowood, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|University of Nebraska Medical Ctr, Omaha, Nebraska, United States|Southwest CARE Center, Santa Fe, New Mexico, United States|Mt. Sinai Beth Israel, New York, New York, United States|New York Langone Medical Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Mountain View Medical Center, Valatie, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Research Specialist of Texas, Houston, Texas, United States|Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia), Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT02786537"
788,"NCT02158507","Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",,"Active, not recruiting","No Results Available","Metastatic Triple Negative Breast Cancer","Drug: Combination of Veliparib + Lapatinib","Number of subjects experiencing study-related toxicities when taking Veliparib in Combination with Lapatinib|Number of subjects with objective response rate (ORR) at 4 years post baseline (Complete responses [CRs] plus partial responses [PRs]|Number of subjects with progression free survival (PFS) at 4 years after start of study.|DNA methylation and RNA transcriptome will be evaluated before and after therapy; baseline pattern will be compared with the post treatment pattern to identify markers of response or resistance.|Measure numbers of circulating tumor cells before and after therapy|Peak Plasma concentration of Veliparib and Palatinib when given in combination.|Measure level of the M30 before and after therapy","University of Alabama at Birmingham|Scariot Foundation|GlaxoSmithKline|AbbVie","Female","19 Years and older   (Adult, Older Adult)","Not Applicable","23","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","F131219003 (UAB 1372)|000504723","July 2014","December 31, 2020","December 31, 2020","June 9, 2014",,"January 9, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT02158507"
789,"NCT02048605","Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Patients With Parkinson's Disease","CBT","Active, not recruiting","No Results Available","Parkinson's Disease|Mild Cognitive Impairment","Behavioral: Psycho-social CBT based training|Behavioral: Unspecific group training","Schedule for the Evaluation of Individual Quality of Life-Direct Weighting (SeiQol-DW)|Scale for the assessment of management of daily living (Alltagsbewältigungsskala: A-B-S)","University Hospital, Basel, Switzerland|Parkinson Schweiz|Bangerter-Rhyner Foundation|AbbVie","All","45 Years to 95 Years   (Adult, Older Adult)","Not Applicable","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BSLTraining2","February 2014","January 2016","January 2021","January 29, 2014",,"September 18, 2019","University Hospital Basel, Basel, Switzerland",,"https://ClinicalTrials.gov/show/NCT02048605"
790,"NCT01828476","Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer",,"Terminated","Has Results","Prostate Cancer","Drug: Abiraterone|Drug: ABT-263|Drug: Hydroxychloroquine","Biochemical Response to ABT-263 and Abiraterone and to ABT-263 in Combination With Hydroxychloroquine and Abiraterone in Patients That Are Progressing on Abiraterone|Time to PSA Progression|Progression Free Survival|Measurable Tumor Response in Patients With Measurable Disease|Circulating Tumor Cells Pre-enrollment and During Therapy|Bcl-2 Family Protein Expression (Bcl-2, Bcl-XL, MCL-1) in Paraffin Blocks When Available by Immunohistochemistry|Biomarkers of Autophagy Modulation by EM; and LC3, and/or p62 by Immunoblotting in PBMC and Tumor Tissue When Available|Overall Survival","Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie","Male","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","081214|Pro2013002775|P30CA072720|NCI-2013-02403","June 2013","February 2016","March 3, 2016","April 10, 2013","March 31, 2017","May 4, 2017","Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT01828476"
791,"NCT03187873","Chamas for Change Validation",,"Unknown status","No Results Available","Pregnancy Related","Behavioral: Chama cha MamaToto","Skilled Delivery|Antenatal Care|Exclusive Breastfeeding|Contraception|Health Insurance","Moi University|University of Toronto|Indiana University|AbbVie|Grand Challenges Canada","All","up to 50 Years   (Child, Adult)","Not Applicable","3040","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","MoiU1","May 1, 2017","July 2018","December 2018","June 15, 2017",,"June 15, 2017","Trans-Nzoia MOH Health Centers, Kitale, Trans-Nzoia, Kenya",,"https://ClinicalTrials.gov/show/NCT03187873"
792,"NCT00908544","New Era Study: Treatment With Multi Drug Class (MDC) HAART in HIV Infected Patients","NewEra","Completed","Has Results","HIV Infections","Other: PHI-patients|Other: CHI-patients","Combined Endpoint Including HIV RNA and HIV DNA|Mean Change in HIV DNA in PBMC (Month 36 and Month 84)|Mean Change in HIV DNA in CD4+T Cells (Month 36 and Month 84)|HIV RNA <50 Copies/ml (Proportion)|Median Change in HIV DNA in PBMC Over Time|Median Change in HIV DNA in CD4+T Cells Over Time|Median Change in CD4+T Cells Over Time|Median Change in Relative CD4+T Cells Over Time|Median Change in CD4+/CD8+ Ratio Over Time|Median Change in CD8+T Cells Over Time|Median Change in CD8+CD38+T Cells Over Time|Absolute HIV DNA in PBMC|Absolute HIV DNA in CD4+T Cells|Absolute CD4+T Cells|Relative CD4+T Cells|CD4+/CD8+ Ratio|Absolute CD8+T Cells|Absolute CD8+CD38+T Cells","MUC Research GmbH|Merck Sharp & Dohme Corp.|AbbVie|Pfizer|German Center for Infection Research","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","47","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MUC_NewEra_3.3|2008-002070-35|4034932|08101|ID 8879|IISP #35576","May 15, 2009","April 3, 2018","May 2018","May 27, 2009","August 28, 2019","August 28, 2019","Onkology Karlsruhe, Karlsruhe, Baden-Wuerttemberg, Germany|Private Practice for Internal Medicine, Hematology and Oncology, Mannheim, Baden-Wuerttemberg, Germany|Private Practice Drs Ulmer/Frietsch/Mueller, Stuttgart, Baden-Wuerttemberg, Germany|Practice Dr. med. Lothar Schneider, Fürth, Bavaria, Germany|Private Practice Drs Pauli/Becker, Munich, Bavaria, Germany|MVZ Karlsplatz, Munich, Bavaria, Germany|University Munich University Hospital, Dept. of Infectious Diseases, Munich, Bavaria, Germany|ICH Study Center, Hamburg, Germany","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT00908544/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00908544"
793,"NCT02758665","Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL","CLL2-GiVe","Active, not recruiting","No Results Available","Leukemia, Lymphocytic, Chronic","Drug: ibrutinib|Drug: obinutuzumab|Drug: venetoclax","Complete response (CR) rate|PD-free rate|Overall Response rate|ORR|MRD levels|Progression-free survival (PFS)|Event-free survival (EFS)|Overall survival (OS)|Duration of response in patients with (clinical) CR/CRi, PR|Time to next CLL treatment (TTNT)|Treatment-free survival (TFS)|Subsequent Treatment for CLL|Safety Parameters (Type, frequency, and severity of adverse events (AEs) and adverse events of special interest (AESI) and their relationship to study Treatment)|Incidence of Richter's transformation","University of Ulm|German CLL Study Group|Roche Pharma AG|Janssen-Cilag Ltd.|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLL2-GIVe","September 2016","December 2020","March 2022","May 2, 2016",,"February 28, 2019","BAG Onkologische Gemeinschaftspraxis, Dresden, Germany|Universitätsklinikum Essen, Essen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Homburg / Saar, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Klinikum Schwabing, München, Germany|Unimedizin Rostock, Rostock, Germany|Universitätsklinikum Ulm, Ulm, Germany",,"https://ClinicalTrials.gov/show/NCT02758665"
794,"NCT01356758","Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents",,"Completed","No Results Available","Psoriasis|Atopic Dermatitis|Atherosclerosis","Drug: biological treatment","Change in coronary calcium score (CAC score)|Repeated Coronary CT Angiography (CCTA)|Cardiovascular risk markers|interleukines in blood|traditional cardiovascular risk factors","University of Aarhus|Aarhus University Hospital|Aage Bangs Fond|AbbVie|Region Midt Forskningsfond","All","18 Years and older   (Adult, Older Adult)",,"126","Other|Industry","Observational","Observational Model: Case Control|Time Perspective: Prospective","j-nr 20100249","March 2011","September 2015","November 2015","May 19, 2011",,"December 21, 2015","Dep. of Dermatology, Aarhus C, Denmark",,"https://ClinicalTrials.gov/show/NCT01356758"
795,"NCT01670240","Adalimumab in the Treatment of Chronic Pouchitis","ADAP","Completed","No Results Available","Ulcerative Colitis|Pouchitis","Drug: Adalimumab|Drug: Placebo","Clinical response on treatment with Adalimumab|Clinical improvement after 12 weeks of treatment|Clinical remission after 12 weeks|Endoscopic and histologic response after treatment with Adalimumab","Odense University Hospital|University of Southern Denmark|Hvidovre University Hospital|Aarhus University Hospital|AbbVie","All","18 Years and older   (Adult, Older Adult)","Phase 3","13","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2011-004268-31","August 2012","September 2015","January 2016","August 22, 2012",,"January 28, 2016","Odense University Hospital, Odense, Denmark",,"https://ClinicalTrials.gov/show/NCT01670240"
796,"NCT00114114","Dose-Response of Gonadal Steroids and Bone Turnover in Older Men",,"Completed","Has Results","Healthy Volunteers","Drug: Testosterone|Drug: Goserelin acetate","Percent Change in Bone Turnover Marker (Serum C-telopeptide, CTX)|Percentage Change in Body Composition: Fat Mass|Percentage Change in Thigh Muscle Area|Change in Erectile Function Symptoms|Change in Libido / Sexual Desire","Massachusetts General Hospital|National Institute on Aging (NIA)|Solvay Pharmaceuticals|AstraZeneca|AbbVie","Male","60 Years to 75 Years   (Adult, Older Adult)","Not Applicable","177","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","2003-P-001868|R01AG030545","September 2004","November 1, 2017","November 1, 2017","June 14, 2005","September 17, 2019","October 8, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT00114114/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00114114"
797,"NCT03088449","Personalising Anti-TNF Therapy in Crohns Disease (PANTS)","PANTS","Active, not recruiting","No Results Available","Crohn Disease",,"To measure the clinical, biological, genetic markers that define response to anti-TNF in patients with active Crohns disease|To measure the serious adverse events to Anti-TNF in Crohn's disease.|to measure the clinical, biochemical and genetic markers of durable clinical remission after anti-TNF withdrawal|To measure the clinical, biological and genetics marker for patients recruited and switched to biosimilar Infliximab (RemsimaTM and InflectraTM) including efficacy, safety and pharmacokinetics using a prospective open labelled study design.","Royal Devon and Exeter NHS Foundation Trust|Merck Sharp & Dohme Corp.|AbbVie|Pfizer|CORE|Napp Pharmaceuticals Limited","All","6 Years to 75 Years   (Child, Adult, Older Adult)",,"1750","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDE 1307805","March 2013","July 30, 2017","July 30, 2019","March 23, 2017",,"June 21, 2018","Royal Devon and Exeter Hospital NHS Foundation Trust, Exeter, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03088449"
798,"NCT03732703","Myeloma-Developing Regimens Using Genomics (MyDRUG)","MyDRUG","Recruiting","No Results Available","Relapsed Refractory Multiple Myeloma","Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomide|Drug: Enasidenib, dexamethasone, ixazomib, pomalidomide|Drug: Cobimetinib, dexamethasone, ixazomib, pomalidomide|Drug: Erdafitinib, dexamethasone, ixazomib, pomalidomide|Drug: Venetoclax, dexamethasone, ixazomib, pomalidomide|Drug: Daratumumab, dexamethasone, ixazomib, pomalidomide","Overall Response Rate - Actionable Genetic Alteration|Overall Response Rate - Non-Actionable Genetic Alteration","Multiple Myeloma Research Consortium|AbbVie|Celgene Corporation|Eli Lilly and Company|Genentech, Inc.|Janssen, LP|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","228","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MyDRUG (MMRC-085)","April 1, 2019","February 10, 2022","February 10, 2024","November 7, 2018",,"December 3, 2019","Mayo Clinic - Arizona, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Beth Israel Deaconess, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mayo Clinic - Minnesota, Rochester, Minnesota, United States|Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Ohio State University College of Medicine, Columbus, Ohio, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT03732703"
799,"NCT03498625","Crohn's Disease Endoscopic REmission Definition in an Objective Way","CREDO1","Recruiting","No Results Available","CD","Diagnostic Test: Colonoscopy","Building an objective definition of the depth or grade of endoscopic remission in relation to what is observed during endoscopy in CD patients presenting with clinical remission|Intra- and inter-observer variability of what is observed during endoscopy in CD|Intra- and inter-observer variability of depth and grade of endoscopic remission in CD","Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|AbbVie|Biogen|Celgene|Gilead Sciences|Roche Pharma AG|Takeda","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GETAID 2017-001|2017-003345-15","March 13, 2018","March 13, 2020","March 13, 2020","April 17, 2018",,"April 11, 2019","Leuven University Hospital, Leuven, Belgium|APHP- Hopital BEAUJON, Clichy, France",,"https://ClinicalTrials.gov/show/NCT03498625"
800,"NCT03487900","Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up","CREDO2","Recruiting","No Results Available","CD","Diagnostic Test: Colonoscopy","Sustained clinical remission at week 104|Sustained clinical remission at week 52|Sustained clinical remission at week 26|Time to disease flare based on biomarker measurement|Sustained clinical remission according to treatment group as an exploratory endpoint","Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|AbbVie|Biogen|Celgene|Gilead Sciences|Roche Pharma AG|Takeda","All","18 Years and older   (Adult, Older Adult)","Not Applicable","320","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","GETAID 2017-002|2017-003345-15","March 13, 2018","March 13, 2022","March 13, 2022","April 4, 2018",,"April 11, 2019","Leuven University Hospital, Leuven, Belgium|APHP- Hopital BEAUJON, Clichy, France",,"https://ClinicalTrials.gov/show/NCT03487900"
801,"NCT02415959","Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis",,"Completed","Has Results","Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis","Drug: Creon IR|Drug: Creon® (DR/GR)","Coefficient of Fat Absorption (CFA)|Coefficient of Nitrogen Absorption (CNA)|Stool Fat Content|Stool Weight","Abbott|AbbVie|LKF Laboratorium für Klinische Forschung GmbH|Analytical Biochemical Laboratory|Parexel|Datamap|Linical Co., Ltd.","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","70","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","PANC2002|2014-004519-35","March 2015","July 2015","July 2015","April 14, 2015","February 17, 2016","April 4, 2016","Dětská nemocnice FN Brno, Centrum pro cystickou fibrozu, Brno, Czech Republic|Klinika nemocí plicních a TBC, Brno, Czech Republic|Magyar Imre Kórház, Ajka, Hungary|Kenézy Gyula Kórház, Debrecen, Hungary|Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Tüdőgyógyintézet Törökbálint, Törökbálint, Hungary|Centrum Medyczne Karpacz S.A., Karpacz, Poland|Wojewódzki Szpital Specjalistyczny Im M Kopernika W Łodzi, Lodzi, Poland|Janusz Stankiewicz Sanatorium """"Cassia-Villa Medica, Rabka, Poland|Podkarpacki Ośrodek Pulmonologii i Alergologii, Rzeszów, Poland|ENEL-MED Szpital Centrum, Warszawa, Poland|Hospital Vall d ´Hebron, Barcelona, Spain|Hospital Universitario de La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Carlos Haya, Hospital Civil, Secretaria de Endocrinologia, Málaga, Spain|Hospital Universitario Virgen del Rocío, Hospital de la Mujer, Sevilla, Spain|Hospital La Fé Valencia, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02415959"
802,"NCT01641367","A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","MULTI-OCTAVE","Completed","Has Results","HIV-1 Infection","Drug: Darunavir|Drug: Etravirine|Drug: Emtricitabine/tenofovir disoproxil fumarate|Drug: Raltegravir|Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|Other: SOC adherence versus SOC+CPI adherence","Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks|Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks|Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks|Number of Weeks of Follow-up|Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study|Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study|Percent of Participants With Confirmed Virologic Failure by Week 48|Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing|Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing|Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48|Time From Study Entry/Randomization to Death|Percent of Participants Experiencing Death by Week 48|Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event|Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48|Time From Study Entry/Randomization to the First of Death or Hospitalization.|Percent of Participants With Death or Hospitalization by Week 48|Time From Study Entry/Randomization to Treatment Modification or Discontinuation.|Percent of Participants With Treatment Modification or Discontinuation by Week 48|Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity|Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48|Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS)|Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48|Time to First Dose Modification Due to Grade 3 or 4 Toxicity|Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48|Change From Baseline in CD4+ T-cell Count|Change From Baseline in Fasting Values of Total Cholesterol|Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol|Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol|Change From Baseline in Fasting Values of Triglycerides|Change From Baseline in Fasting Values of Glucose|Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 48 Weeks [CPI+SOC v SOC]|Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 24 Weeks [CPI+SOC v SOC]|Proportion of Participants With Plasma HIV-1 RNA ≤200 Copies/mL at 72 Weeks [CPI+SOC v SOC]|Number of Weeks of Follow-up [CPI+SOC v SOC]|Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]|Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study [CPI+SOC v SOC]|Percent of Participants With Confirmed Virologic Failure by Week 48 [CPI+SOC v SOC]|Time to Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]|Number of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing [CPI+SOC v SOC]|Percent of Participants With Confirmed Virologic Failure, Defined as First HIV-1 RNA ≥1000 Copies/mL at or After 24 Weeks on Study, With a New Resistance-associated Mutation Detected in Population-based Sequencing, by Week 48 [CPI+SOC v SOC]|Time From Study Entry/Randomization to Death [CPI+SOC v SOC]|Percent of Participants Experiencing Death by Week 48 [CPI+SOC v SOC]|Time From Study Entry/Randomization to the First of Death, an AIDS-defining Event or a Non-AIDS-defining Event [CPI+SOC v SOC]|Percent of Participants Experiencing Death, AIDS-defining Event or a Non-AIDS-defining Event by Week 48 [CPI+SOC v SOC]|Time From Study Entry/Randomization to the First of Death or Hospitalization [CPI+SOC v SOC]|Percent of Participants With Death or Hospitalization by Week 48 [CPI+SOC v SOC]|Time From Study Entry/Randomization to Treatment Modification or Discontinuation [CPI+SOC v SOC]|Percent of Participants With Treatment Modification or Discontinuation by Week 48 [CPI+SOC v SOC]|Time From Study Entry/Randomization to Treatment Modification or Discontinuation Due to Toxicity [CPI+SOC v SOC]|Percent of Participants With Treatment Modification or Discontinuation Due to Toxicity by Week 48 [CPI+SOC v SOC]|Time From Study Entry/Randomization to the Development of Immune Reconstitution Inflammatory Syndrome (IRIS) [CPI+SOC v SOC]|Percent of Participants That Developed Immune Reconstitution Inflammatory Syndrome (IRIS) by Week 48 [CPI+SOC v SOC]|Time to First Dose Modification Due to Grade 3 or 4 Toxicity [CPI+SOC v SOC]|Percent of Participants With a Dose Modification Due to Grade 3 or 4 Toxicity by Week 48 [CPI+SOC v SOC]|Change From Baseline in CD4+ T-cell Count [CPI+SOC v SOC]|Change From Baseline in Fasting Values of Total Cholesterol [CPI+SOC v SOC]|Change From Baseline in Fasting Values of High-density Lipoprotein Cholesterol [CPI+SOC v SOC]|Change From Baseline in Fasting Values of Calculated Low-density Lipoprotein Cholesterol [CPI+SOC v SOC]|Change From Baseline in Fasting Values of Triglycerides [CPI+SOC v SOC]|Change From Baseline in Fasting Values of Glucose [CPI+SOC v SOC]","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|AbbVie|Gilead Sciences|Janssen Pharmaceuticals|Merck Sharp & Dohme Corp.|Dimagi Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","545","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG A5288|1U01AI068636","February 22, 2013","November 23, 2016","December 31, 2018","July 16, 2012","February 20, 2018","March 15, 2019","Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, RS, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil|Les Centres GHESKIO CRS (30022), Port-au-Prince, Bicentaire, Haiti|GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port Au Prince, Haiti|BJ Medical College CRS (31441), Pune, Maharashtra, India|Chennai Antiviral Research and Treatment (CART) CRS (11701), Chennai, Taramani, India|AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret, Kenya|Kenya Medical Research Institute/Center for Disease Control (KEMRI/CDC) CRS (31460), Kisumu, Kenya|Malawi CRS (12001), Lilongwe, Malawi|San Miguel CRS (11302), San Miguel, Lima, Peru|Barranco CRS (11301), Lima, Peru|University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101), Johannesburg, Gauteng, South Africa|Family Clinical Research Unit (FAM-CUR) CRS (8950), Cape Town, West Cape, South Africa|Durban Adult HIV CRS (11201), Durban, South Africa|Soweto ACTG CRS (12301), Johannesburg, South Africa|31802 Thai Red Cross AIDS Research Centre (TRC-ARC) CRS, Bangkok, Patumwan, Thailand|31784 Chiang Mai University HIV Treatment CRS, Chiang Mai, Thailand|JCRC CRS, Kampala, Uganda|UZ-Parirenyatwa CRS (30313), Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT01641367"
803,"NCT01617018","Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis","PSOBIOTEQ","Recruiting","No Results Available","Psoriasis",,"Occurrence of skin cancer|Event-free survival; incidence of serious adverse events;effectiveness;therapeutic strategy,long-term safety(serious and non-serious adverse events,quality of life, rebounds after treatment discontinuation;maintenance of a therapeutic response over time","Assistance Publique - Hôpitaux de Paris|French Health Products Safety Agency|Société de Dermatologie Française|Janssen, LP|Pfizer|AbbVie|Merck Sharp & Dohme Corp.","All","18 Years and older   (Adult, Older Adult)",,"2636","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","AOM09195|N° IRB00006477","July 2012","July 2020","July 2020","June 12, 2012",,"November 18, 2019","Henri Mondor Hospital, Creteil, ILE DE France, France",,"https://ClinicalTrials.gov/show/NCT01617018"
804,"NCT03993847","CLassification of Axial SpondyloarthritiS Inception Cohort","CLASSIC","Recruiting","No Results Available","Spondyloarthritis",,"Physician diagnosis of axial spondyloarthritis at the final diagnostic evaluation.","Spondyloarthritis Research and Treatment Network|AbbVie|Amgen|Janssen Scientific Affairs, LLC|Eli Lilly and Company|Novartis Pharmaceuticals|Pfizer|UCB Pharma","All","18 Years and older   (Adult, Older Adult)",,"500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CLASSIC","December 4, 2019","January 2023","January 2024","June 21, 2019",,"December 20, 2019","UCSF Medical Center - Rheumatology Clinic, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT03993847"
805,"NCT03781726","Multi-center Study to Transplant Hepatitis-C Infected Kidneys","MYTHIC","Active, not recruiting","No Results Available","Renal Failure Chronic|Hepatitis C","Drug: glecaprevir/pibrentasvir treatment","Undetectable HCV|Percentage of subjects with on-treatment virologic failure|Percentage of subjects with post-treatment virologic relapse","Raymond Chung|AbbVie|University of Pennsylvania|Johns Hopkins University|University of Cincinnati|Weill Medical College of Cornell University|University of Michigan|Northwestern University|Massachusetts General Hospital","All","21 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018P003140","April 10, 2019","December 31, 2021","December 31, 2022","December 20, 2018",,"November 5, 2019","Northwestern Medicine, Chicago, Illinois, United States|John Hopkins, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Weill Cornell Medical Center, New York, New York, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT03781726"
806,"NCT02950051","Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation","GAIA","Active, not recruiting","No Results Available","Chronic Lymphocytic Leukemia","Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Rituximab|Drug: Bendamustine|Drug: Venetoclax|Biological: Obinutuzumab|Drug: Ibrutinib","Miminimal residual disease (MRD) negativity rate in peripheral blood (PB)|Progression free survival (PFS)|MRD negativity rate in PB|MRD levels in PB|MRD levels in bone marrow (BM)|PFS|Overall response rate (ORR)|Rate of complete responses (CR) / complete responses with incomplete bone marrow recovery(CRi)","German CLL Study Group|Janssen-Cilag Ltd.|Hoffmann-La Roche|AbbVie|Stichting Hemato-Oncologie voor Volwassenen Nederland|Nordic CLL Study Group (NCLLSG)|Swiss Group for Clinical Cancer Research|Cancer Trials Ireland|Israeli CLL Study Group","All","18 Years and older   (Adult, Older Adult)","Phase 3","926","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLL13|2015-004936-36","December 13, 2016","January 2023","January 2024","October 31, 2016",,"November 6, 2019","Medizinische Universitaet Wien, Wien, Austria|Hanusch Hospital, Wien, Austria|Wilhelminenspital, Wien, Austria|ZNA Stuivenberg, Antwerpen, Belgium|Algemeen Ziekenhuis St. Jan, Brugge, Belgium|Jan Yperman Ziekenhuis, Ieper, Belgium|UZ Gasthuisberg, Leuven, Belgium|AZ Delta, Roeselare, Belgium|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus, Denmark|Rigshospitalet/Copenhagen, Copenhagen, Denmark|Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark|University Hospital Herlev, Herlev, Denmark|Regionshospitalet Holstebro, Holstebro, Denmark|Odense Universitets Hospital, Odense, Denmark|Sjællands Universitetshospital, Roskilde, Denmark|Vejle Hospital, Vejle, Denmark|Helsinki University Hospital, Helsinki, Finland|Jyväskylä Central Hospital, Jyväskylä, Finland|Oulu University Hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|Gesundheitszentrum Klinikum St Marien, Amberg, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Helios-Klinikum Berlin, Berlin, Germany|ZAHO Bonn, Bonn, Germany|Ev. Diakonie-Krankenhaus gemeinnuetzige GmbH, Bremen, Germany|St. -Johannes-Hospital Dortmund, Dortmund, Germany|Gefos Dortmund mbH, Dortmund, Germany|BAG Dresden, Dresden, Germany|Universitaetsklinik Carl Gustav Carus, Dresden, Germany|Marien Hospital Düsseldorf GmbH, Düsseldorf, Germany|St. Georg Klinikum Eisenach GmbH, Eisenach, Germany|Helios Klinikum Erfurt, Erfurt, Germany|St. Antonius-Hospital, Eschweiler, Germany|Universitaetsklinikum Essen, Essen, Germany|Centrum fuer Haematologie und Onkologie Bethanien, Frankfurt, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|MVZ Onkologische Kooperation Harz, Drs. Tessen/Hoyer/Zahn, Goslar, Germany|Universitaetsmedizin Greifswald, Greifswald, Germany|Onkologische Schwerpunktpraxis Göttingen, Göttingen, Germany|Universitaetsmedizin Göttingen, Göttingen, Germany|UKE Hamburg, Hamburg, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|EVK Hamm, Hamm, Germany|MediProjekt GBR, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Marienhospital Herne, Herne, Germany|Onkologische Schwerpunktpraxis Des. Freier/Sievers, Hildesheim, Hildesheim, Germany|Universitaetsklinikum Jena, Jena, Germany|Westpfalz-Klinikum GmbH, Kaiserslautern, Germany|Städt. Klinikum Karlsruhe, Karlsruhe, Germany|Dres. Siehl / Soeling, Fachaerzte fuer Haematologie und Internistische Onkologie, Kassel, Kassel, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|InVO-Institut fuer Versorgungsforschung in der Onkologie GbR, Koblenz, Germany|University Hospital of Cologne, Köln, Germany|Tagesklinik Landshut, Dr. Vehling-Kaiser, Landshut, Germany|Gemeinschaftspraxis Haemato/ Onkologie Lebach, Lebach, Germany|Onkologische Schwerpunktpraxis Dr. Mueller, Leer, Leer, Germany|Klinikum Lippe GmbH, Lemgo, Germany|Gemeinschaftspraxis Haematologie und Onkologie, Magdeburg, Germany|Universitaetsklinikum Magdeburg, Magdeburg, Germany|Universitaetsklinik Mainz, Mainz, Germany|Mannheimer Onkologie Praxis, Mannheim, Germany|Institut fuer Versorgungsforschung Dr. med. M. Maasberger/ M. Schmitz/ Dr. med. M. T. Keller, Mayen, Germany|Stauferklinikum Schwaebisch-Gmuend, Mutlangen, Germany|Kliniken Maria Hilf GmbH, Mönchengladbach, Germany|MVZ MOP Elisenhof, München, Germany|Klinikum Schwabing, München, Germany|Ludwig-Maximilians-Universitaet Muenchen, München, Germany|Klinikum rechts der Isar, München, Germany|Haematologische/Onkologische Praxis Neunkirchen, Neunkirchen, Germany|Studiengesellschaft Onkologie Rhein Ruhr, Oberhausen, Germany|Gemeinschaftspraxis Dres. Ballo/Boeck, Offenbach, Germany|Klinik fuer Haematologie und Onkologie, Paderborn, Germany|Studienzentrum Onkologie Ravensburg, Ravensburg, Germany|Krankenhaus der Barmherzigen Brüder, Regensburg, Germany|OncoPro GbR, Regensburg, Germany|Universitätsmedizin Rostock, Rostock, Germany|Praxis für Hämatologie und Onkologie Dres. Jacobs/Daus/Schmits, Saarbrücken, Germany|Leopoldina-Krankenhaus, Schweinfurt, Germany|ZAHO-Rheinland, Siegburg, Germany|Marienhospital Stuttgart, Stuttgart, Germany|Robert-Bosch-Krankenhaus, Stuttgart, Germany|Universitaetsklinikum Tuebingen, Tübingen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|MVZ Weiden GmbH, Weiden, Germany|Haematologisch-Onkologische Schwerpunktpraxis Dres. Perker/Sandherr, Weilheim, Weilheim, Germany|Helios Klinikum Wuppertal, Wuppertal, Germany|Gemeinschaftspraxis Dr. Schlag/Dr. Schoettker, Würzburg, Germany|Universitaetsklinik Wuerzburg, Würzburg, Germany|Cork University Hospital, Cork, Ireland|Mater Misericordiae Hospital, Dublin, Ireland|St. James's Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|University Hospital Waterford, Waterford, Ireland|Bnai-Zion Medical. Il-Haifa, Haifa, Israel|Hadassah Ein Kerem, Jerusalem, Israel|Meir Medicail Center, Kfar-Saba, Israel|Rabin medical Center, Petach-Tikva, Israel|Kaplan Medical Center, Rechovot, Israel|Souraski Tel-Aviv Medical Center, Tel-Aviv, Israel|MC Alkmaar, Alkmaar, Netherlands|Meander Medisch Centrum, Amersfoort, Amersfoort, Netherlands|VUmc, Amsterdam, Amsterdam, Netherlands|NL-Amsterdam-AMC, Amsterdam, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|IJsselland Ziekenhuis, Capelle aan den Ijssel, Netherlands|Reinier de Graaf Gasthuis, Delft, Netherlands|Deventer ziekenhuizen, Deventer, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Dordrecht, Netherlands|Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Groene Hart Ziekenhuis, Gouda, Netherlands|UMCG, Groningen, Netherlands|Ziekenhuisgroep Twente Hengelo, Hengelo, Netherlands|Tergooi Ziekenhuis, Hilversum, Netherlands|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Medisch Centrum Leeuwarden Zuid, Leeuwarden, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Maastricht university medial Center, Maastricht, Netherlands|St. Antonius Ziekehuis, Nieuwegein, Netherlands|Radboud UMC, Nijmegen, Netherlands|Canisius-Wilhelmina ZH, Nijmegen, Netherlands|Maasstadziekenhuis, Rotterdam, Netherlands|Jeroen Bosch Ziekenhuis, s-Hertogenbosch, Netherlands|Antonius Ziekenhuis Sneek, Sneek, Netherlands|ZorgSaam Zeeuws Vlaanderen, Terneuzen, Netherlands|St. Elisabeth ZH, Tilburg, Netherlands|UMCU, Utrecht, Netherlands|VieCuri loc. Venlo, Venlo, Netherlands|Zaans Medisch Centrum, Zaandam, Netherlands|Isala, Zwolle, Netherlands|Soedra Aelvsborgs Sjukhus, Borås, Sweden|Falu lasarett, Falun, Sweden|Hallands hospital - Halmstad, Halmstad, Sweden|Universitetsjukhuset i Linkoeping, Linköping, Sweden|Sunderby Hospital, Luleå, Sweden|Skane University Hospital Lund, Lund, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Hallands hospital - Varberg, Varberg, Sweden|Universitetssjukhuset i Oerebro, Örebro, Sweden|Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden, Baden, Switzerland|Universitaetsspital Basel, Basel, Switzerland|IOSI, Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital Graubunden, Chur, Switzerland|Universitaire de Geneve, Genève, Switzerland|KSBL Liestal, Liestal, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|Spital Thurgau AG, Münsterlingen, Switzerland|Kantonsspital Olten, Olten, Switzerland|Kantonsspital St. Gallen, St Gallen, Switzerland|KS Winterthur, Winterthur, Switzerland|Stadtspital Triemli, Zürich, Switzerland|Universitaetsspital Zuerich, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT02950051"
807,"NCT00404989","Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women.","APR","Recruiting","No Results Available","HIV Infections|Hepatitis B",,,"Syneos Health|AbbVie|Apotex Inc.|Aurobindo Pharma Ltd|Boehringer Ingelheim|Bristol-Myers Squibb|Cipla Ltd.|Hoffmann-La Roche|Gilead Sciences|Hetero Labs Ltd.|Janssen Scientific Affairs, LLC|Lupin Pharmaceuticals, Inc.|Merck Sharp & Dohme Corp.|Mylan Laboratories|Novartis Pharmaceuticals|Prinston Pharmaceutical Inc.|Sandoz|Sigmapharm Laboratories|Lannett Company, Inc.|Strides Shasun Ltd.|Teva Pharmaceuticals USA|ViiV Healthcare|Alvogen Korea|Amneal Pharmaceuticals, LLC|Hikma Pharmaceuticals LLC|Accord Healthcare, Inc.|Macleods Pharmaceuticals, Ltd|Qilu Pharmaceutical Co., Ltd.|Celltrion","Female","12 Years to 60 Years   (Child, Adult)",,"1600","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","APR","January 1989","January 2099","January 2099","November 29, 2006",,"April 5, 2019","Registry Coordinating Center, Wilmington, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00404989"
808,"NCT01848028","PsoBest - The German Psoriasis Registry",,"Recruiting","No Results Available","Psoriasis|Psoriatic-arthritis",,"Psoriasis Area Severity Index (PASI)|Dermatology Life Quality Index (DLQI)","Universitätsklinikum Hamburg-Eppendorf|Berufsverband der Deutschen Dermatologen e.V. (BVDD)|Deutsche Dermatologische Gesellschaft e.V. (DDG)|AbbVie|Biogen|Janssen-Cilag G.m.b.H|medac GmbH|Merck Sharp & Dohme Corp.|Novartis Pharmaceuticals|Pfizer Deutschland GmbH|Serono GmbH (former collaborator)|PsoNet.eu|Celgene Corporation|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,"3500","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IVDP-085-07","January 2008","December 2025","July 2026","May 7, 2013",,"May 17, 2019","Nationwide group of dermatological centers, hospitals and medical offices, Hamburg, Germany",,"https://ClinicalTrials.gov/show/NCT01848028"
809,"NCT02922192","Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis",,"Unknown status","No Results Available","Rheumatoid Arthritis|Inflammatory Bowel Disease|Psoriasis|Psoriatic Arthritis|Ankylosing Spondylitis","Drug: TNF-α antagonists, non-TNFs, DMARD non-biologics","Incidence of hospitalization for serious infections","Biologics & Biosimilars Collective Intelligence Consortium|HealthCore, Inc.|Aetna, Inc.|University of Alabama; Rheumatologist and Healthcare Research|AbbVie|Amgen|Boehringer Ingelheim|Kaiser Permanente|Harvard Pilgrim Health Care|Merck Sharp & Dohme Corp.|Momenta Pharmaceuticals, Inc.|Pfizer|University of Pittsburgh","All","18 Years and older   (Adult, Older Adult)",,"100000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BBCIC-Anti-inflammatory","January 2006","September 2015","January 2017","October 4, 2016",,"October 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02922192"
810,"NCT02922179","Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics",,"Unknown status","No Results Available","Diabetes","Drug: Long- and intermediate- acting insulins","serious hypoglycemic events|Serious cardiac events","Biologics & Biosimilars Collective Intelligence Consortium|HealthCore, Inc.|Aetna, Inc.|University of Alabama; Rheumatologist and Healthcare Research|AbbVie|Amgen|Boehringer Ingelheim|Kaiser Permanente|Harvard Pilgrim Health Care|Merck Sharp & Dohme Corp.|Momenta Pharmaceuticals, Inc.|Pfizer|University of Pittsburgh","Female","18 Years and older   (Adult, Older Adult)",,"100000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","BBCIC Insulins","January 2011","September 2015","January 2017","October 4, 2016",,"October 7, 2016",,,"https://ClinicalTrials.gov/show/NCT02922179"
811,"NCT04084145","National Unified Renal Translation Research Enterprise - Chronic Kidney Disease","NURTuRE-CKD","Recruiting","No Results Available","Chronic Kidney Diseases",,"Number of participants with CKD progression|Number of participants who experience a major acute cardiovascular event|Number of participants who die from any cause|Number of participants who progress to end stage kidney disease (ESKD)|Number of participants who experience acute kidney injury (AKI)|Number of participants admitted to hospital with a new diagnosis of cardiac failure|Number of participants with an unplanned hospital admission|Number of participants admitted to hospital with an infection|Number of participants with a new diagnosis of cancer|Number of participants with a hip fracture|Number of participants with progression of chronic kidney disease (CKD) (KDIGO definition)","University of Nottingham|Kidney Cancer UK|UK Renal Registry|University of Bristol|University of Birmingham|University of Southampton|University of Geneva, Switzerland|NIHR National Biosample Centre|UCB Pharma Ltd|Evotec International GmbH|AbbVie","All","18 Years and older   (Adult, Older Adult)",,"3000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16091","July 27, 2016","December 31, 2032","December 31, 2032","September 10, 2019",,"September 19, 2019","Royal Derby Hospital, Derby, Derbyshire, United Kingdom|Salford Royal Hospital, Salford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT04084145/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04084145"
812,"NCT01277419","German Spondyloarthritis Inception Cohort","GESPIC","Recruiting","No Results Available","Ankylosing Spondylitis|Non-radiographic Axial Spondyloarthritis",,,"Charite University, Berlin, Germany|German Federal Ministry of Education and Research (BMBF): 2000-2007 and 2010-2019|2010-2019: AbbVie (Abbott)|Amgen|Centocor, Inc.|Schering-Plough|Wyeth is now a wholly owned subsidiary of Pfizer|Berlin Institute of Health|2019-current: Novartis","All","Child, Adult, Older Adult",,"1000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","GESPIC","July 2000","July 2030","July 2030","January 17, 2011",,"September 11, 2019","Charité - Universitätsmedizin Berlin, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT01277419"
